PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	HECHT, SS; CARMELLA, SG; MURPHY, SE; AKERKAR, S; BRUNNEMANN, KD; HOFFMANN, D				HECHT, SS; CARMELLA, SG; MURPHY, SE; AKERKAR, S; BRUNNEMANN, KD; HOFFMANN, D			A TOBACCO-SPECIFIC LUNG CARCINOGEN IN THE URINE OF MEN EXPOSED TO CIGARETTE-SMOKE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							N-NITROSAMINES; NICOTINE; CANCER	Background. Environmental tobacco smoke has been classified by the Environmental Protection Agency as a carcinogen causally associated with lung cancer in adults, but there have been no reports of lung carcinogens or their metabolites in the body fluids or tissues of nonsmokers exposed to environmental tobacco smoke. Methods. Five male nonsmokers were exposed to sidestream cigarette smoke generated by machine smoking of reference cigarettes tor 180 minutes on each of two days, six months apart. Sidestream smoke is the smoke that originates from the smoldering end of a cigarette between puffs. Twenty-four-hour urine samples were collected before and after exposure. The urine samples were analyzed for 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) and its glucuronide, which are metabolites of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), a powerful lung carcinogen in rodents. NNAL is also a lung carcinogen in rodents. Results. The urinary excretion of the metabolites increased after exposure to sidestream smoke in all the men. The mean (+/-SD) amount of NNAL and NNAL glucuronide was significantly higher after exposure than at base line (33.9+/-20.0 vs. 8.4+/-11.2 ng per 24 hours [127+/-74 vs. 31+/-41 pmol per day], P<0.001) and was correlated with urinary cotinine excretion (r = 0.89, P<0.001). The nicotine concentrations in the air to which the men were exposed were comparable to those in a heavily smoke-polluted bar. Conclusions. Nonsmokers exposed to sidestream cigarette smoke take up and metabolize a lung carcinogen, which provides experimental support for the proposal that environmental tobacco smoke can cause lung cancer.			HECHT, SS (corresponding author), AMER HLTH FDN,VALHALLA,NY 10595, USA.			Hecht, Stephen/0000-0001-7228-1356	PHS HHS [29580] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BRUNNEMANN KD, 1992, CARCINOGENESIS, V13, P2415, DOI 10.1093/carcin/13.12.2415; BRUNNEMANN KD, 1990, OCT P CORESTA S KALL, P100; BRUNNEMANN KD, 1993, IARC SCI PUBL, V109, P275; CARMELLA SG, 1993, CANCER RES, V53, P721; CASTONGUAY A, 1983, CANCER RES, V43, P1223; EATOUGH DJ, 1989, ENVIRON INT, V15, P19, DOI 10.1016/0160-4120(89)90005-6; FOILES PG, 1991, CHEM RES TOXICOL, V4, P364, DOI 10.1021/tx00021a017; FONTHAM ETH, 1991, CANCER EPIDEM BIOMAR, V1, P35; GUERIN MR, 1992, CHEM ENV TOBACCO SMO, P229; HALEY NJ, 1983, AM J PUBLIC HEALTH, V73, P1204, DOI 10.2105/AJPH.73.10.1204; HAMMOND SK, 1993, J NATL CANCER I, V85, P474, DOI 10.1093/jnci/85.6.474; HECHT SS, 1993, CARCINOGENESIS, V14, P229, DOI 10.1093/carcin/14.2.229; HECHT SS, 1988, CARCINOGENESIS, V9, P875, DOI 10.1093/carcin/9.6.875; HECHT SS, 1989, CANCER SURV, V8, P273; HECHT SS, 1991, ORIGINS OF HUMAN CANCER, P745; HOFFMANN D, 1985, CANCER RES, V45, P935; HOFFMANN D, 1990, HDB EXPT PHARM, V94, P63; MUSTONEN R, 1993, CARCINOGENESIS, V14, P151, DOI 10.1093/carcin/14.1.151; RIVENSON A, 1988, CANCER RES, V48, P6912; THOMPSON CV, 1989, ENVIRON SCI TECHNOL, V23, P429, DOI 10.1021/es00181a007; 1992, RESPIRATORY HLTH EFF, P1; 1992, RESPIRATORY HLTH EFF, P3	22	172	177	0	10	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 18	1993	329	21					1543	1546		10.1056/NEJM199311183292105	http://dx.doi.org/10.1056/NEJM199311183292105			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MG188	8413477	Bronze			2022-12-24	WOS:A1993MG18800005
J	JAYES, RL; ZIMMERMAN, JE; WAGNER, DP; DRAPER, EA; KNAUS, WA				JAYES, RL; ZIMMERMAN, JE; WAGNER, DP; DRAPER, EA; KNAUS, WA			DO-NOT-RESUSCITATE ORDERS IN INTENSIVE-CARE UNITS - CURRENT PRACTICES AND RECENT CHANGES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HOSPITAL CARDIOPULMONARY RESUSCITATION; ADVANCE DIRECTIVES; LIFE SUPPORT; SYSTEM; DNR; PREDICTION; MORTALITY; OUTCOMES; SEVERITY; FAILURE	Objectives.-To describe the characteristics of patients with do-not-resuscitate (DNR) orders and the frequency and timing of these orders in a representative sample of intensive care units (ICUs) and to compare practices from 1980 to 1990. Design.-Prospective inception cohort. Setting.-A total of 42 ICUs in 40 US hospitals with 200 or more beds; 26 randomly selected hospitals and 14 large, tertiary care hospitals that volunteered to be studied. Participants.-A consecutive sample of 17 440 ICU admissions from 1988 to 1990. Measurements.-Patient demographic characteristics, comorbid conditions, disease, and physiological abnormalities. Main Outcome Measures.-Frequency and timing of DN R orders; ICU resource use before and after DNR orders; and patients' hospital and ICU discharge status. Results.-Physicians wrote DNR orders for 1577 ICU admissions (9%) (hospital range, 1.5% to 22%). Patients with ICU DNR orders were older, more functionally impaired, had more comorbid illness, a higher severity of illness, and required the usp of more ICU resources compared with patients without DNR orders. Compared with data from a similar survey from 1979 to 1982, ICU DNR orders were more frequent in 1988 to 1990 (9% vs 5.4%; P<.001) and preceded 60% of all in-unit deaths compared with only 39% in 1979 to 1982 (P<.001). Do-not-resuscitate orders were written sooner (for 3.6% vs 2.0% of patients on day 1 in the ICU) and patients with DNR orders remained in the ICU longer in 1988 to 1990 (2.8 vs 1.4 days) than in 1979 to 1982, and had lower ICU and hospital mortality rates (64% vs 74%, P<.001; and 85% vs 94%, P<.001). Conclusions.-Over the last decade physicians and patients' families set limits earlier and more frequently in cases likely to have poor outcomes. We attribute this change to a greater dialogue about setting limits to care and a greater knowledge of treatment outcomes among physicians and families. These changes in practice preceded implementation of the Patient Self-determination Act, designed to ensure patient autonomy for decisions about life-sustaining therapy.	GEORGE WASHINGTON UNIV, MED CTR, ICU RES UNIT, 2300 K ST NW, WASHINGTON, DC 20037 USA; GEORGE WASHINGTON UNIV, MED CTR, DEPT MED, WASHINGTON, DC 20037 USA; GEORGE WASHINGTON UNIV, MED CTR, DEPT ANESTHESIOL, WASHINGTON, DC 20037 USA; APACHE MED SYST INC, WASHINGTON, DC USA	George Washington University; George Washington University; George Washington University			Knaus, William/AAX-2138-2020		AHRQ HHS [HSO 5787] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ANNAS GJ, 1991, NEW ENGL J MED, V324, P1210, DOI 10.1056/NEJM199104253241711; [Anonymous], 1974, JAMA-J AM MED ASSOC, V227, P864; [Anonymous], 1991, ANN INTERN MED, V115, P478; AREEN J, 1987, JAMA-J AM MED ASSOC, V258, P229, DOI 10.1001/jama.258.2.229; BEDELL SE, 1986, JAMA-J AM MED ASSOC, V256, P233, DOI 10.1001/jama.256.2.233; BONE RC, 1990, CHEST, V97, P949, DOI 10.1378/chest.97.4.949; CHANG RWS, 1989, LANCET, V2, P143; Cullen D J, 1974, Crit Care Med, V2, P57, DOI 10.1097/00003246-197403000-00001; DANIS M, 1991, NEW ENGL J MED, V324, P882, DOI 10.1056/NEJM199103283241304; DENARDO SJ, 1989, CRIT CARE MED, V17, P4, DOI 10.1097/00003246-198901000-00002; DONNELLY WJ, 1987, ARCH INTERN MED, V147, P37, DOI 10.1001/archinte.147.1.37; EVANS AL, 1985, JAMA-J AM MED ASSOC, V253, P2236, DOI 10.1001/jama.253.15.2236; FOWLER MDM, 1989, HEART LUNG, V18, P424; FRIED C, 1976, NEW ENGL J MED, V295, P390, DOI 10.1056/NEJM197608122950711; GRAY WA, 1991, NEW ENGL J MED, V325, P1393, DOI 10.1056/NEJM199111143252001; GRECO PJ, 1991, ANN INTERN MED, V115, P639, DOI 10.7326/0003-4819-115-8-639; HOLTZMAN J, 1992, CLIN RES, V40, pA584; JONSSON PV, 1988, ARCH INTERN MED, V148, P2373, DOI 10.1001/archinte.148.11.2373; KEENE AR, 1983, CRIT CARE MED, V11, P1, DOI 10.1097/00003246-198301000-00001; KNAUS WA, 1991, SCIENCE, V254, P389, DOI 10.1126/science.1925596; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KNAUS WA, 1981, JAMA-J AM MED ASSOC, V246, P2711, DOI 10.1001/jama.246.23.2711; KNAUS WA, 1985, ANN SURG, V202, P685, DOI 10.1097/00000658-198512000-00004; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; LIPTON HL, 1986, JAMA-J AM MED ASSOC, V256, P1164, DOI 10.1001/jama.256.9.1164; LO B, 1983, ARCH INTERN MED, V143, P1561, DOI 10.1001/archinte.143.8.1561; MCGRATH RB, 1987, ANN EMERG MED, V16, P1365, DOI 10.1016/S0196-0644(87)80420-1; MUPRHY DJ, 1990, J CLIN EPIDEMIOL S, V43, pR5; MURPHY DJ, 1990, JAMA-J AM MED ASSOC, V264, P2103, DOI 10.1001/jama.264.16.2103; MURPHY DJ, 1989, ANN INTERN MED, V111, P199, DOI 10.7326/0003-4819-111-3-199; NIEMANN JT, 1992, NEW ENGL J MED, V327, P1075; PINZANI M, 1987, INTENS CARE MED, V13, P148; RABKIN MT, 1976, NEW ENGL J MED, V295, P364, DOI 10.1056/NEJM197608122950705; RAPOPORT J, 1990, MED CARE, V28, P338, DOI 10.1097/00005650-199004000-00005; ROGERS WH, 1990, JAMA-J AM MED ASSOC, V264, P1989, DOI 10.1001/jama.264.15.1989; RUARK JE, 1988, NEW ENGL J MED, V318, P25, DOI 10.1056/NEJM198801073180106; SCHNEIDERMAN LJ, 1990, ANN INTERN MED, V112, P949, DOI 10.7326/0003-4819-112-12-949; SCHRAM RB, 1978, NEW ENGL J MED, V299, P875, DOI 10.1056/NEJM197810192991608; STERN SG, 1992, CRIT CARE MED, V20, P1263, DOI 10.1097/00003246-199209000-00013; TAFFET GE, 1988, JAMA-J AM MED ASSOC, V260, P2069, DOI 10.1001/jama.260.14.2069; WEBSTER GC, 1991, CAN J ANAESTH, V38, P553, DOI 10.1007/BF03008184; WOOG RH, 1987, ANAESTH INTENS CARE, V15, P193, DOI 10.1177/0310057X8701500213; YOUNGNER S J, 1985, Journal of the American Medical Association, V253, P54, DOI 10.1001/jama.253.1.54; YOUNGNER SJ, 1987, HASTINGS CENT REP, V17, P24, DOI 10.2307/3562438; ZIMMERMAN JE, 1986, JAMA-J AM MED ASSOC, V255, P351, DOI 10.1001/jama.255.3.351; ZIMMERMAN JE, 1989, CRIT CARE MED S, V17, pS169; 1991, JAMA-J AM MED ASSOC, V265, P1868; 1990, EFFECTIVE DNA POLICI; 1987, LIFE SUSTAINING TREA; 1992, CRIT CARE MED, V20, P320	50	107	110	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 10	1993	270	18					2213	2217		10.1001/jama.270.18.2213	http://dx.doi.org/10.1001/jama.270.18.2213			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ME816	8411606				2022-12-24	WOS:A1993ME81600034
J	MARTIN, JL; BARDWELL, JCA; KURIYAN, J				MARTIN, JL; BARDWELL, JCA; KURIYAN, J			CRYSTAL-STRUCTURE OF THE DSBA PROTEIN REQUIRED FOR DISULFIDE BOND FORMATION IN-VIVO	NATURE			English	Article							ESCHERICHIA-COLI GLUTAREDOXIN; MACROMOLECULAR STRUCTURES; 3-DIMENSIONAL STRUCTURE; DISULFIDE-ISOMERASE; THIOREDOXIN; RESOLUTION; IDENTIFICATION; CRYSTALLOGRAPHY; REFINEMENT; SEQUENCE	PROTEINS that contain disulphide bonds are often slow to fold in vitro because the oxidation and correct pairing of the cysteine residues is rate limiting1,2. The folding of such proteins is greatly accelerated in Escherichia coli by DsbA3,4, but the mechanism of this rate enhancement is not well understood. Here we report the crystal structure of oxidized DsbA and show that it resembles closely the ubiquitous redox protein thioredoxin5, despite very low sequence similarity. An important difference, however, is the presence of another domain which forms a cap over the thioredoxin-like active site of DsbA. The redox-active disulphide bond, which is responsible for the oxidation of substrates, is thus at a domain interface and is surrounded by grooves and exposed hydrophobic side chains. These features suggest that DsbA might act by binding to partially folded polypeptide chains before oxidation of cysteine residues.	ROCKEFELLER UNIV,NEW YORK,NY 10021; HOWARD HUGHES MED INST,NEW YORK,NY 10021; HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOLEC GENET,BOSTON,MA 02115	Rockefeller University; Howard Hughes Medical Institute; Harvard University; Harvard Medical School			Martin, Jennifer L./A-6039-2010	Martin, Jennifer L./0000-0002-9225-8863				BARDWELL JCA, 1993, P NATL ACAD SCI USA, V90, P1038, DOI 10.1073/pnas.90.3.1038; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BROWN LR, 1993, J MOL BIOL, V231, P800, DOI 10.1006/jmbi.1993.1327; Brunger A.T., 1992, X PLOR VERSION 3 1 M; CREIGHTON TE, 1984, METHOD ENZYMOL, V107, P305; DAILEY FE, 1993, P NATL ACAD SCI USA, V90, P1043, DOI 10.1073/pnas.90.3.1043; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; EKLUND H, 1992, J MOL BIOL, V228, P596, DOI 10.1016/0022-2836(92)90844-A; EKLUND H, 1991, PROTEINS, V11, P13, DOI 10.1002/prot.340110103; ELLIS LBM, 1992, BIOCHEMISTRY-US, V31, P4882, DOI 10.1021/bi00135a020; EPP O, 1983, EUR J BIOCHEM, V133, P51, DOI 10.1111/j.1432-1033.1983.tb07429.x; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; JI XH, 1992, BIOCHEMISTRY-US, V31, P10169, DOI 10.1021/bi00157a004; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAMITANI S, 1992, EMBO J, V11, P57, DOI 10.1002/j.1460-2075.1992.tb05027.x; KATTI SK, 1990, J MOL BIOL, V212, P167, DOI 10.1016/0022-2836(90)90313-B; KRAUSE G, 1991, J BIOL CHEM, V266, P9494; LOVEJOY B, 1993, SCIENCE, V259, P1288, DOI 10.1126/science.8446897; MARTIN JL, 1993, J MOL BIOL, V230, P1097, DOI 10.1006/jmbi.1993.1226; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; REINEMER P, 1991, EMBO J, V10, P1997, DOI 10.1002/j.1460-2075.1991.tb07729.x; SODANO P, 1991, J MOL BIOL, V221, P1311; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; THORNTON JM, 1981, J MOL BIOL, V151, P261, DOI 10.1016/0022-2836(81)90515-5; TOMB JF, 1992, P NATL ACAD SCI USA, V89, P10252, DOI 10.1073/pnas.89.21.10252; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WEISSMAN JS, 1992, CELL, V71, P841, DOI 10.1016/0092-8674(92)90559-U; WILSON KS, 1978, ACTA CRYSTALLOGR B, V34, P1599, DOI 10.1107/S0567740878006135; WUNDERLICH M, 1993, PROTEIN SCI, V2, P717, DOI 10.1002/pro.5560020503; WUNDERLICH M, IN PRESS J MOL BIOL; XIA TH, 1992, PROTEIN SCI, V1, P310; ZAPUN A, IN PRESS BIOCH; Zhang K. Y. J., 1990, ACTA CRYST A, VA46, P41	35	356	372	1	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 30	1993	365	6445					464	468		10.1038/365464a0	http://dx.doi.org/10.1038/365464a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LZ633	8413591				2022-12-24	WOS:A1993LZ63300064
J	STOGER, R; KUBICKA, P; LIU, CG; KAFRI, T; RAZIN, A; CEDAR, H; BARLOW, DP				STOGER, R; KUBICKA, P; LIU, CG; KAFRI, T; RAZIN, A; CEDAR, H; BARLOW, DP			MATERNAL-SPECIFIC METHYLATION OF THE IMPRINTED MOUSE IGF2R LOCUS IDENTIFIES THE EXPRESSED LOCUS AS CARRYING THE IMPRINTING SIGNAL	CELL			English	Article							MANNOSE 6-PHOSPHATE RECEPTOR; DNA METHYLATION; SEQUENCE-ANALYSIS; GENE-EXPRESSION; CELLS; INACTIVATION; TRANSGENE; MECHANISM; ISLANDS; CLONING	The mouse insulin-like growth factor type 2 receptor (Igf2r) is imprinted and expressed exclusively from the maternally inherited chromosome. To investigate whether methylation could function as the imprinting signal, we have cloned 130 kb from the Igf2r locus and searched for sequences methylated in a parental-specific manner. Two regions have been identified: region 1 contains the start of transcription and is methylated only on the silent paternal chromosome; region 2 is contained in an intron and is methylated only on the expressed maternal chromosome. Methylation of region 1 is acquired after fertilization, in contrast with the methylation of region 2, which is inherited from the female gamete. Methylation of region 2 may mark the maternal Igf2r locus in a manner that could act as an imprinting signal. These data suggest that the expressed locus carries a potential imprinting signal and imply that methylation is necessary for expression of the Igf2r gene.	HEBREW UNIV JERUSALEM,HADASSAH MED SCH,IL-91010 JERUSALEM,ISRAEL	Hebrew University of Jerusalem	STOGER, R (corresponding author), RES INST MOLEC PATHOL,DR BOHR GASSE 7,A-1030 VIENNA,AUSTRIA.			Stoger, Reinhard/0000-0002-2301-0805				ARTZT K, 1991, GENOME, V1, pS281; BARLOW DP, 1991, NATURE, V349, P84, DOI 10.1038/349084a0; BARTOLOMEI MS, 1991, NATURE, V351, P153, DOI 10.1038/351153a0; BEDDINGTON RSP, 1989, DEVELOPMENT, V105, P733; BEECHEY CV, 1990, MOUSE GENOME, V87, P64; BESTOR TH, 1990, PHILOS T ROY SOC B, V326, P179, DOI 10.1098/rstb.1990.0002; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BUSSLINGER M, 1981, CELL, V27, P289, DOI 10.1016/0092-8674(81)90412-8; CHAILLET JR, 1991, CELL, V66, P77, DOI 10.1016/0092-8674(91)90140-T; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CROUSE HV, 1960, GENETICS, V45, P1425; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOERFLER W, 1991, BIOL CHEM H-S, V372, P557; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FOREJT J, 1992, CELL, V70, P443, DOI 10.1016/0092-8674(92)90168-C; FRANK D, 1991, NATURE, V351, P239, DOI 10.1038/351239a0; HANSCOMBE O, 1991, GENE DEV, V5, P1387, DOI 10.1101/gad.5.8.1387; HERRMANN BG, 1987, METHOD ENZYMOL, V152, P180; HERRMANN BG, 1987, CELL, V48, P813, DOI 10.1016/0092-8674(87)90078-X; HOWLETT SK, 1991, DEVELOPMENT, V113, P119; JOHNSON DR, 1974, GENETICS, V76, P795; KAFRI T, 1992, GENE DEV, V6, P705, DOI 10.1101/gad.6.5.705; LAVIA P, 1987, EMBO J, V6, P2773, DOI 10.1002/j.1460-2075.1987.tb02572.x; LOBEL P, 1988, J BIOL CHEM, V263, P2563; LOCK LF, 1987, CELL, V48, P39, DOI 10.1016/0092-8674(87)90353-9; MACDONALD RJ, 1987, METHOD ENZYMOL, V152, P219; Maniatis T., 1982, MOL CLONING; MONK M, 1990, GENOMIC IMPRINTING D; OSHIMA A, 1988, J BIOL CHEM, V263, P2553; RAZIN A, 1991, MICROBIOL REV, V55, P451, DOI 10.1128/MMBR.55.3.451-458.1991; RIGGS AD, 1992, TRENDS GENET, V8, P169, DOI 10.1016/0168-9525(92)90219-T; SAJANTILA A, 1992, AM J HUM GENET, V50, P816; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Surani MA, 1991, CURR OPIN GENET DEV, V1, P241, DOI 10.1016/S0959-437X(05)80077-2; SURANI MA, 1988, DEVELOPMENT, V103, P171; SWAIN JL, 1987, CELL, V50, P719, DOI 10.1016/0092-8674(87)90330-8	39	527	539	0	24	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 9	1993	73	1					61	71		10.1016/0092-8674(93)90160-R	http://dx.doi.org/10.1016/0092-8674(93)90160-R			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KW753	8462104				2022-12-24	WOS:A1993KW75300008
J	MACDONALD, ME; AMBROSE, CM; DUYAO, MP; MYERS, RH; LIN, C; SRINIDHI, L; BARNES, G; TAYLOR, SA; JAMES, M; GROOT, N; MACFARLANE, H; JENKINS, B; ANDERSON, MA; WEXLER, NS; GUSELLA, JF; BATES, GP; BAXENDALE, S; HUMMERICH, H; KIRBY, S; NORTH, M; YOUNGMAN, S; MOTT, R; ZEHETNER, G; SEDLACEK, Z; POUSTKA, A; FRISCHAUF, AM; LEHRACH, H; BUCKLER, AJ; CHURCH, D; DOUCETTESTAMM, L; ODONOVAN, MC; RIBARAMIREZ, L; SHAH, M; STANTON, VP; STROBEL, SA; DRATHS, KM; WALES, JL; DERVAN, P; HOUSMAN, DE; ALTHERR, M; SHIANG, R; THOMPSON, L; FIELDER, T; WASMUTH, JJ; TAGLE, D; VALDES, J; ELMER, L; ALLARD, M; CASTILLA, L; SWAROOP, M; BLANCHARD, K; COLLINS, FS; SNELL, R; HOLLOWAY, T; GILLESPIE, K; DATSON, N; SHAW, D; HARPER, PS				MACDONALD, ME; AMBROSE, CM; DUYAO, MP; MYERS, RH; LIN, C; SRINIDHI, L; BARNES, G; TAYLOR, SA; JAMES, M; GROOT, N; MACFARLANE, H; JENKINS, B; ANDERSON, MA; WEXLER, NS; GUSELLA, JF; BATES, GP; BAXENDALE, S; HUMMERICH, H; KIRBY, S; NORTH, M; YOUNGMAN, S; MOTT, R; ZEHETNER, G; SEDLACEK, Z; POUSTKA, A; FRISCHAUF, AM; LEHRACH, H; BUCKLER, AJ; CHURCH, D; DOUCETTESTAMM, L; ODONOVAN, MC; RIBARAMIREZ, L; SHAH, M; STANTON, VP; STROBEL, SA; DRATHS, KM; WALES, JL; DERVAN, P; HOUSMAN, DE; ALTHERR, M; SHIANG, R; THOMPSON, L; FIELDER, T; WASMUTH, JJ; TAGLE, D; VALDES, J; ELMER, L; ALLARD, M; CASTILLA, L; SWAROOP, M; BLANCHARD, K; COLLINS, FS; SNELL, R; HOLLOWAY, T; GILLESPIE, K; DATSON, N; SHAW, D; HARPER, PS			A NOVEL GENE CONTAINING A TRINUCLEOTIDE REPEAT THAT IS EXPANDED AND UNSTABLE ON HUNTINGTONS-DISEASE CHROMOSOMES	CELL			English	Article							POLYMORPHIC DNA MARKER; LINKAGE DISEQUILIBRIUM; FRAGILE-X; REGION; LOCALIZATION; CONSTRUCTION; LOCATION; STRATEGY; COMPLEX; LOCUS	The Huntington's disease (HD) gene has been mapped in 4p16.3 but has eluded identification. We have used haplotype analysis of linkage disequilibrium to spotlight a small segment of 4p16.3 as the likely location of the defect. A new gene, IT15, isolated using cloned trapped exons from the target area contains a polymorphic trinucleotide repeat that is expanded and unstable on HD chromosomes. A (CAG)n repeat longer than the normal range was observed on HD chromosomes from all 75 disease families examined, comprising a variety of ethnic backgrounds and 4p16.3 haplotypes. The (CAG)n repeat appears to be located within the coding sequence of a predicted approximately 348 kd protein that is widely expressed but unrelated to any known gene. Thus, the HD mutation involves an unstable DNA segment, similar to those described in fragile X syndrome, spino-bulbar muscular atrophy, and myotonic dystrophy, acting in the context of a novel 4p16.3 gene to produce a dominant phenotype.	MASSACHUSETTS GEN HOSP, MOLEC NEUROGENET UNIT, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, DEPT GENET, BOSTON, MA 02114 USA; BOSTON UNIV, SCH MED, DEPT NEUROL, BOSTON, MA 02118 USA; HEREDITARY DIS FDN, SANTA MONICA, CA 90401 USA; IMPERIAL CANC RES FUND, GENOME ANAL LAB, LONDON WC2A 3PX, ENGLAND; MIT, CTR CANC RES, CAMBRIDGE, MA 02139 USA; CALTECH, DIV CHEM & CHEM ENGN, PASADENA, CA 91125 USA; UNIV CALIF IRVINE, DEPT BIOL CHEM, IRVINE, CA 92717 USA; UNIV MICHIGAN, DEPT INTERNAL MED & GENET, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, HOWARD HUGHES MED INST, ANN ARBOR, MI 48109 USA; UNIV WALES COLL MED, INST MED GENET, CARDIFF CF4 4XN, S GLAM, WALES	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Boston University; Cancer Research UK; The Genome Analysis Centre (TGAC); Massachusetts Institute of Technology (MIT); California Institute of Technology; University of California System; University of California Irvine; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; Cardiff University			Datson, Nicole A./O-8797-2014; Bates, Gillian P/E-1146-2012; O'Donovan, Michael C/P-7005-2018	Bates, Gillian P/0000-0002-4041-6305; O'Donovan, Michael C/0000-0001-7073-2379; Baxendale, Sarah/0000-0002-6760-9457; Datson, Nicole/0000-0003-2887-0238; Swaroop, Manju/0000-0002-0576-1664; Myers, Richard/0000-0002-8365-2674; Snell, Russell/0000-0002-8166-4014; Stanton, Vincent/0000-0002-2205-6000; Mott, Richard/0000-0002-1022-9330	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS025631, P50NS016367, R01NS022031, P01NS016367] Funding Source: NIH RePORTER; NINDS NIH HHS [NS25631, NS22031, NS16367] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Wellcome Trust(Wellcome TrustEuropean Commission)		ALLITTO BA, 1991, GENOMICS, V9, P104, DOI 10.1016/0888-7543(91)90226-5; ALTHERR MR, 1992, GENOMICS, V13, P1040, DOI 10.1016/0888-7543(92)90017-M; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AMBROSE C, 1992, MOL GENET, V1, P697; ANDERSON MA, 1984, IN VITRO CELL DEV B, V20, P856; ASHIZAWA T, 1991, LANCET, V338, P642, DOI 10.1016/0140-6736(91)90659-D; ASLANIDIS C, 1992, NATURE, V355, P548, DOI 10.1038/355548a0; BATES GP, 1990, AM J HUM GENET, V46, P762; BATES GP, 1991, AM J HUM GENET, V49, P7; BATES GP, 1992, NAT GENET, V1, P180, DOI 10.1038/ng0692-180; BAXENDALE S, 1991, NUCLEIC ACIDS RES, V19, P6651, DOI 10.1093/nar/19.23.6651; Biancalana V., 1992, Human Molecular Genetics, V1, P255, DOI 10.1093/hmg/1.4.255; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; BRUNNER HG, 1993, NEW ENGL J MED, V328, P476, DOI 10.1056/NEJM199302183280705; BUCAN M, 1990, GENOMICS, V6, P1; BUCKLER AJ, 1991, P NATL ACAD SCI USA, V88, P4005, DOI 10.1073/pnas.88.9.4005; BUXTON J, 1992, NATURE, V355, P547, DOI 10.1038/355547a0; CONNEALLY PM, 1989, GENOMICS, V5, P304, DOI 10.1016/0888-7543(89)90062-1; DEBOULLE K, 1993, NAT GENET, V3, P31, DOI 10.1038/ng0193-31; DOUCETTESTAMM LA, 1991, CELL MOL GENET, V17, P471; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; GUSELLA J, 1979, P NATL ACAD SCI USA, V76, P5239, DOI 10.1073/pnas.76.10.5239; Gusella J F, 1991, Adv Hum Genet, V20, P125; GUSELLA JF, 1983, NATURE, V306, P234, DOI 10.1038/306234a0; GUSELLA JF, 1989, FASEB J, V3, P2036, DOI 10.1096/fasebj.3.9.2568302; GUSELLA JF, 1984, SCIENCE, V225, P1320, DOI 10.1126/science.6089346; HARLEY HG, 1991, AM J HUM GENET, V49, P68; HARLEY HG, 1992, NATURE, V355, P545, DOI 10.1038/355545a0; HARLEY HG, 1992, LANCET, V339, P1125, DOI 10.1016/0140-6736(92)90729-M; Harper PS, 1991, HUNTINGTONS DISEASE; HARPER PS, 1992, J MED GENET, V89, P365; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; LEHRACH H., 1990, GENOME ANAL, P39; LIN CS, 1991, SOMAT CELL MOLEC GEN, V17, P481, DOI 10.1007/BF01233172; MACDONALD ME, 1989, J CLIN INVEST, V84, P1013, DOI 10.1172/JCI114222; MACDONALD ME, 1992, NAT GENET, V1, P99, DOI 10.1038/ng0592-99; MACDONALD ME, 1991, AM J HUM GENET, V49, P723; MACDONALD ME, 1989, NEURON, V3, P183, DOI 10.1016/0896-6273(89)90031-7; MAHADEVAN M, 1992, SCIENCE, V255, P1253, DOI 10.1126/science.1546325; MARTIN JB, 1986, NEW ENGL J MED, V315, P1267; MCCLATCHEY AI, 1992, HUM MOL GENET, V1, P521; MERRITT AD, 1969, PROGR NEUROGENETICS, P645; MYERS RH, 1989, AM J HUM GENET, V45, P615; NIZETIC D, 1991, P NATL ACAD SCI USA, V88, P3233, DOI 10.1073/pnas.88.8.3233; OUDET C, 1993, AM J HUM GENET, V52, P297; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; POHL TM, 1988, NUCLEIC ACIDS RES, V16, P9185, DOI 10.1093/nar/16.19.9185; PRITCHARD C, 1992, AM J HUM GENET, V50, P1218; RICHARDS RI, 1992, NAT GENET, V1, P257, DOI 10.1038/ng0792-257; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SNELL RG, 1989, J MED GENET, V26, P673, DOI 10.1136/jmg.26.11.673; SNELL RG, 1992, AM J HUM GENET, V51, P357; SUTHERS GK, 1992, J MED GENET, V29, P761, DOI 10.1136/jmg.29.11.761; TAYLOR SAM, 1992, NAT GENET, V2, P223, DOI 10.1038/ng1192-223; THEILMANN J, 1989, J MED GENET, V26, P676, DOI 10.1136/jmg.26.11.676; THOMPSON LM, 1991, GENOMICS, V11, P1133, DOI 10.1016/0888-7543(91)90041-C; TSILFIDIS C, 1992, NAT GENET, V1, P192, DOI 10.1038/ng0692-192; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; WEXLER NS, 1987, NATURE, V326, P194, DOI 10.1038/326194a0; WHALEY WL, 1991, SOMAT CELL MOLEC GEN, V17, P83, DOI 10.1007/BF01233207; YOUNGMAN S, 1992, GENOMICS, V14, P350, DOI 10.1016/S0888-7543(05)80225-3; YU S, 1992, AM J HUM GENET, V50, P968	64	5992	6169	12	469	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 26	1993	72	6					971	983		10.1016/0092-8674(93)90585-E	http://dx.doi.org/10.1016/0092-8674(93)90585-E			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KU175	8458085	Green Published			2022-12-24	WOS:A1993KU17500017
J	DEMENT, WC; MITLER, MM				DEMENT, WC; MITLER, MM			ITS TIME TO WAKE UP TO THE IMPORTANCE OF SLEEP DISORDERS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							SHIFT WORK; ACCIDENTS; INSOMNIA; PERFORMANCE; PHYSICIANS; ALERTNESS; DISEASE; ETHANOL; THERAPY; RISK		SCRIPPS CLIN & RES FDN,LA JOLLA,CA 92037	Scripps Research Institute	DEMENT, WC (corresponding author), STANFORD UNIV,CTR SLEEP DISORDERS,701 WELCH RD,SUITE 2226,PALO ALTO,CA 94304, USA.		Winwood, Peter/A-6363-2008					AKERSTEDT T, 1988, SLEEP, V11, P17, DOI 10.1093/sleep/11.1.17; ALDRICH CK, 1986, POSTGRAD MED, V80, P233, DOI 10.1080/00325481.1986.11699572; ALDRICH MS, 1989, SLEEP, V12, P487, DOI 10.1093/sleep/12.6.487; Bartels E C, 1965, Lahey Clin Found Bull, V14, P21; CARSKADON M A, 1990, Pediatrician, V17, P5; COLEMAN RM, 1986, SLEEP RES, V15, P265; DEMENT WC, 1991, 5TH ANN M ASS PROF S; Dement WC, 1978, SLEEP APNEA SYNDROME, P23; FORD DE, 1989, JAMA-J AM MED ASSOC, V262, P1479, DOI 10.1001/jama.262.11.1479; GILLIN JC, 1990, NEW ENGL J MED, V322, P239; GILLIN JC, 1992, POSTGRAD MED, V92, P157; JACQUES CHM, 1990, J FAM PRACTICE, V30, P223; JOHNSON LC, 1983, MIL MED, V148, P727; Kales A., 1984, EVALUATION TREATMENT; KNUTSSON A, 1986, LANCET, V2, P89; KOLLER M, 1983, INT ARCH OCC ENV HEA, V53, P59, DOI 10.1007/BF00406178; KRYGER MH, 1989, PRINCIPLES PRACTICE; LAUBER JK, 1988, SLEEP, V11, P503; LUMLEY M, 1987, SLEEP, V10, P306; MANHEIMER DI, 1973, AM J PSYCHIAT, V130, P1246, DOI 10.1176/ajp.130.11.1246; MELLINGER GD, 1985, ARCH GEN PSYCHIAT, V42, P225, DOI 10.1001/archpsyc.1985.01790260019002; MITLER MM, 1988, SLEEP, V11, P100, DOI 10.1093/sleep/11.1.100; MOOREEDE M, 1988, NOV P FED HIGHW ADM; PALOMAKI H, 1992, NEUROLOGY, V42, P75; Pollak C P, 1991, J Geriatr Psychiatry Neurol, V4, P204, DOI 10.1177/089198879100400405; ROEHRS T, 1989, PHARMACOL BIOCHEM BE, V34, P321, DOI 10.1016/0091-3057(89)90319-5; SCHEMO DJ, 1992, NY TIMES        0413; SEPPALA T, 1991, J INTERN MED, V229, P23, DOI 10.1111/j.1365-2796.1991.tb00301.x; WALSH JK, 1991, POSTGRAD MED, V90, P211; ZANINELLI A, 1991, INT J CARDIOL, V32, P347, DOI 10.1016/0167-5273(91)90297-3; 1992, NY TIMES        0411; 1989, TRANSPORTATION RELAT; 1991, SLEEP AM, P1; 1986, REPORT PRESIDENTIAL, P2; 1988, HEAD END COLLISION C; 1991, ACCIDENT FACTS 1991; 1991, OTABA463 OFF TECHN A; 1990, SAFETY STUDY FATIGUE, P1; 1988, OTASET382 OFF TECHN; 1990, INT CLASSIFICATION S	40	77	81	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 24	1993	269	12					1548	1550		10.1001/jama.269.12.1548	http://dx.doi.org/10.1001/jama.269.12.1548			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KR803	8445820				2022-12-24	WOS:A1993KR80300030
J	GABRIELLI, BG; ROY, LM; MALLER, JL				GABRIELLI, BG; ROY, LM; MALLER, JL			REQUIREMENT FOR CDK2 IN CYTOSTATIC FACTOR MEDIATED METAPHASE-II ARREST	SCIENCE			English	Article							MATURATION-PROMOTING FACTOR; PROTO-ONCOGENE PRODUCT; MEIOTIC MATURATION; XENOPUS EGGS; PROTOONCOGENE PRODUCT; MOSXE PROTOONCOGENE; CYTOPLASMIC FACTOR; CYCLIN-A; M-PHASE; OOCYTES	The unfertilized eggs of vertebrates are arrested in metaphase of meiosis II because of the activity of cytostatic factor (CSF). Xenopus CSF is thought to contain the product of the Mos proto-oncogene, but other proteins synthesized during meiosis II are also required for arrest induced by CSF. In Xenopus oocytes, ablation of synthesis of cyclin-dependent kinase 2 (Cdk2) during meiosis resulted in absence of the metaphase II block, even though the Mos(xe) protein kinase was fully active at metaphase. Introduction of purified Cdk2 restored metaphase II arrest, and increasing the amount of Cdk2 during meiosis I (when Mos(xe) is present) led to metaphase arrest at meiosis I. These data indicate that metaphase arrest is a result of cooperation between a proto-oncogene kinase and a cyclin-dependent kinase and illustrate the interaction of a cell growth regulator with a cell cycle control element.	UNIV COLORADO,SCH MED,DEPT PHARMACOL,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	GABRIELLI, BG (corresponding author), UNIV COLORADO,SCH MED,HOWARD HUGHES MED INST,DENVER,CO 80262, USA.		Gabrielli, Brian G/B-3655-2011	Gabrielli, Brian G/0000-0003-3933-1651	NCI NIH HHS [F32 CA0981] Funding Source: Medline; NIGMS NIH HHS [GM26743] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026743] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		DAAR I, 1991, J CELL BIOL, V114, P329, DOI 10.1083/jcb.114.2.329; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FREEMAN RS, 1990, J CELL BIOL, V111, P533, DOI 10.1083/jcb.111.2.533; GABRIELLI BG, 1992, J BIOL CHEM, V267, P1969; GABRIELLI BG, 1992, J BIOL CHEM, V267, P18040; GABRIELLI BG, UNPUB; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GERHART J, 1984, J CELL BIOL, V98, P1247, DOI 10.1083/jcb.98.4.1247; IZUMI T, 1991, MOL CELL BIOL, V11, P3860, DOI 10.1128/MCB.11.8.3860; KANKI JP, 1991, P NATL ACAD SCI USA, V88, P5794, DOI 10.1073/pnas.88.13.5794; KOBAYASHI H, 1991, J CELL BIOL, V114, P755, DOI 10.1083/jcb.114.4.755; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LORCA T, 1991, EMBO J, V10, P2087, DOI 10.1002/j.1460-2075.1991.tb07741.x; LORCA T, 1992, EMBO J, V11, P2381, DOI 10.1002/j.1460-2075.1992.tb05302.x; Maller JL, 1991, CURR OPIN CELL BIOL, V3, P269; MALLER JL, 1991, COLD SH Q B, V56, P533; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MASUI Y, 1980, CELL SURFACE MEDIATO, P235; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; NISHIZAWA M, 1992, EMBO J, V11, P2433, DOI 10.1002/j.1460-2075.1992.tb05308.x; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OKAZAKI K, 1992, EMBO J, V11, P2447, DOI 10.1002/j.1460-2075.1992.tb05309.x; PARIS J, 1990, DEV BIOL, V140, P221, DOI 10.1016/0012-1606(90)90070-Y; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; ROY L, UNPUB; ROY LM, 1991, J CELL BIOL, V113, P507, DOI 10.1083/jcb.113.3.507; ROY LM, 1990, CELL, V61, P825, DOI 10.1016/0092-8674(90)90192-H; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SLEIGHT SB, UNPUB; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WASSERMAN WJ, 1975, EXP CELL RES, V91, P381, DOI 10.1016/0014-4827(75)90118-4; WATANABE N, 1989, NATURE, V342, P505, DOI 10.1038/342505a0; WATANABE N, 1991, NATURE, V352, P247, DOI 10.1038/352247a0; YEW N, 1992, NATURE, V355, P649, DOI 10.1038/355649a0; ZHAO X, 1990, ONCOGENE, V5, P1727; ZHOU RP, 1991, SCIENCE, V251, P671, DOI 10.1126/science.1825142	40	77	78	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 19	1993	259	5102					1766	1769		10.1126/science.8456304	http://dx.doi.org/10.1126/science.8456304			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KT810	8456304				2022-12-24	WOS:A1993KT81000041
J	ANGERT, ER; CLEMENTS, KD; PACE, NR				ANGERT, ER; CLEMENTS, KD; PACE, NR			THE LARGEST BACTERIUM	NATURE			English	Article							RIBOSOMAL-RNA; GUT; SURGEONFISHES; ACANTHURIDAE; REEF; SEA; DNA	THE large, morphologically peculiar microorganism Epulopiscium fishelsoni1,2 inhabits the intestinal tract of Acanthurus nigrofuscus, a brown surgeonfish (family Acanthuridae) from the Red Sea. Similar microorganisms have been found in surgeonfish species from the Great Barrier Reef3. As these microorganisms have only been seen in surgeonfish and no free-living forms have been found, they are considered to be specific symbionts of surgeonfish, although the nature of the symbiosis is unclear1-4 . Initial reports considered them to be eukaryotic protists, based primarily on their size1-4, with individuals being larger than 600 mum by 80 mum. But their cellular morphology in the electron microscope is more like that of bacterial than eukaryotic cells1,2,5. To resolve the nature of these symbionts, we have isolated the genes encoding the small subunit ribosomal RNA from two morphotypes and used them in a phylogenetic analysis. In situ hybridization with oligonucleotide probes based on the cloned rRNA sequences confirmed the source of the rRNA genes. Our results identify the symbionts as members of the low-(G + C) Gram-positive group of bacteria. They are therefore the largest bacteria to be described so far.	INDIANA UNIV, DEPT BIOL, BLOOMINGTON, IN 47405 USA; JAMES COOK UNIV N QUEENSLAND, DEPT MARINE BIOL, TOWNSVILLE, QLD 4811, AUSTRALIA	Indiana University System; Indiana University Bloomington; James Cook University				Clements, Kendall/0000-0001-8512-5977				BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; BLAKEMORE RP, 1973, ARCH MIKROBIOL, V89, P273, DOI 10.1007/BF00408895; CLEMENTS KD, 1989, MAR BIOL, V102, P403, DOI 10.1007/BF00428493; CLEMENTS KD, 1991, J BACTERIOL, V173, P5359, DOI 10.1128/jb.173.17.5359-5362.1991; DELAPORTE B, 1964, ANN I PASTEUR PARIS, V107, P246; DELONG EF, 1989, SCIENCE, V243, P1360, DOI 10.1126/science.2466341; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; FISHELSON L, 1985, SCIENCE, V229, P49; JANNASCH HW, 1989, NATURE, V342, P834, DOI 10.1038/342834a0; MONTGOMERY WL, 1988, MAR ECOL PROG SER, V44, P7, DOI 10.3354/meps044007; MONTGOMERY WL, 1988, J PROTOZOOL, V35, P565, DOI 10.1111/j.1550-7408.1988.tb04153.x; OLSEN GJ, 1992, NUCLEIC ACIDS RES, V20, P2199, DOI 10.1093/nar/20.suppl.2199; OLSEN GJ, 1988, METHOD ENZYMOL, V164, P793; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 1989, MOL CLONING LAB MANU; WARD DM, 1992, ADV MICROB ECOL, V12, P219; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; [No title captured]	19	146	151	1	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 18	1993	362	6417					239	241		10.1038/362239a0	http://dx.doi.org/10.1038/362239a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KT026	8459849				2022-12-24	WOS:A1993KT02600054
J	EHLICH, A; SCHAAL, S; GU, H; KITAMURA, D; MULLER, W; RAJEWSKY, K				EHLICH, A; SCHAAL, S; GU, H; KITAMURA, D; MULLER, W; RAJEWSKY, K			IMMUNOGLOBULIN HEAVY AND LIGHT CHAIN GENES REARRANGE INDEPENDENTLY AT EARLY STAGES OF B-CELL DEVELOPMENT	CELL			English	Article							MOUSE BONE-MARROW; MICE; LINE; EXPRESSION; VH; PROLIFERATION; TRANSCRIPTION; REPERTOIRE; MATURATION; ACTIVATION	The compartment of mouse B cell progenitors can be resolved into five developmentally related fractions by multicolor flow cytometry. Using this system and employing mutant mice in which the membrane exon of the mu chain, the lambda5 gene, or the J(H) locus was inactivated by gene targeting, we found that expression of the pre-B cell receptor complex is necessary for the transition from the large CD43+ to the small CD43- pre-B cell stage. We report the occurrence of immunoglobulin heavy and light chain gene rearrangement at the stage of large B cell precursors. We show that neither the pre-B cell receptor complex nor any gene rearrangement in the heavy chain locus is required for the induction of K light chain gene rearrangement in early B cell progenitors.			EHLICH, A (corresponding author), UNIV COLOGNE,INST GENET,W-5000 COLOGNE 41,GERMANY.		Muller, Werner/B-9044-2008	Muller, Werner/0000-0002-1297-9725				ALT F, 1981, CELL, V27, P381, DOI 10.1016/0092-8674(81)90421-9; ALT FW, 1984, EMBO J, V3, P1209, DOI 10.1002/j.1460-2075.1984.tb01955.x; ALT FW, 1987, SCIENCE, V238, P1079, DOI 10.1126/science.3317825; BENATAR T, 1992, P NATL ACAD SCI USA, V89, P7615, DOI 10.1073/pnas.89.16.7615; BLACKWELL TK, 1989, EMBO J, V8, P735, DOI 10.1002/j.1460-2075.1989.tb03433.x; BURNET FM, 1959, CLONAL SELECTION THE; COFFMAN RL, 1983, J MOL CELL IMMUNOL, V1, P31; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; Forster I, 1989, Int Immunol, V1, P321, DOI 10.1093/intimm/1.4.321; GIGUERE V, 1985, EMBO J, V4, P2017, DOI 10.1002/j.1460-2075.1985.tb03886.x; Grutzmann R., 1981, THESIS U COLOGNE COL; GU H, 1991, CELL, V65, P47, DOI 10.1016/0092-8674(91)90406-O; GU H, 1991, J EXP MED, V173, P1357, DOI 10.1084/jem.173.6.1357; Hardy R. R., 1986, HDB EXPT IMMUNOLOGY; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HAYASHI SI, 1990, J EXP MED, V171, P1683, DOI 10.1084/jem.171.5.1683; HONJO T, 1985, ANNU REV BIOCHEM, V54, P803, DOI 10.1146/annurev.bi.54.070185.004103; ICHIHARA Y, 1989, EUR J IMMUNOL, V19, P1849, DOI 10.1002/eji.1830191014; IGLESIAS A, 1991, EMBO J, V10, P2147, DOI 10.1002/j.1460-2075.1991.tb07749.x; JOHO R, 1980, NATURE, V284, P179, DOI 10.1038/284179a0; KARASUYAMA H, 1990, J EXP MED, V172, P969, DOI 10.1084/jem.172.3.969; KITAMURA D, 1992, NATURE, V356, P154, DOI 10.1038/356154a0; KITAMURA D, 1992, CELL, V69, P823, DOI 10.1016/0092-8674(92)90293-L; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; KLEINFIELD R, 1986, NATURE, V322, P843, DOI 10.1038/322843a0; KOFLER R, 1992, IMMUNOL REV, V128, P5, DOI 10.1111/j.1600-065X.1992.tb00830.x; KRAWINKEL U, 1989, IMMUNOL TODAY, V10, P339, DOI 10.1016/0167-5699(89)90191-6; KUBAGAWA H, 1989, P NATL ACAD SCI USA, V86, P2356, DOI 10.1073/pnas.86.7.2356; LANDRETH KS, 1981, J IMMUNOL, V127, P2027; LEE G, 1989, J IMMUNOL, V142, P3875; LEWIS S, 1982, CELL, V30, P807, DOI 10.1016/0092-8674(82)90285-9; MALYNN BA, 1990, J EXP MED, V171, P843, DOI 10.1084/jem.171.3.843; MCCORMACK WT, 1989, GENE DEV, V3, P838, DOI 10.1101/gad.3.6.838; MELCHERS F, 1989, COLD SH Q B, V54, P183; MILTENYI S, 1990, CYTOMETRY, V11, P231, DOI 10.1002/cyto.990110203; OPSTELTEN D, 1983, J IMMUNOL, V131, P2635; OSMOND DG, 1991, CURR OPIN IMMUNOL, V3, P179, DOI 10.1016/0952-7915(91)90047-5; PARK YH, 1987, J EXP MED, V165, P444, DOI 10.1084/jem.165.2.444; PINK JRL, 1990, IMMUNOL REV, V115, P239, DOI 10.1111/j.1600-065X.1990.tb00794.x; RAJEWSKY K, 1992, NATURE, V359, P371, DOI 10.1038/359371b0; RATCLIFFE MJH, 1986, EUR J IMMUNOL, V16, P126; RETH M, 1987, EMBO J, V6, P3299, DOI 10.1002/j.1460-2075.1987.tb02649.x; RETH M, 1986, NATURE, V322, P840, DOI 10.1038/322840a0; RETH M, 1987, MOL GENETICS IMMUNOG, P111; RETH MG, 1985, NATURE, V317, P353, DOI 10.1038/317353a0; REYNAUD CA, 1989, CELL, V59, P171, DOI 10.1016/0092-8674(89)90879-9; SCHLISSEL MS, 1991, J EXP MED, V173, P711, DOI 10.1084/jem.173.3.711; SCHLISSEL MS, 1989, CELL, V58, P1001, DOI 10.1016/0092-8674(89)90951-3; SHAPIRO MA, 1987, J IMMUNOL, V139, P3834; TAKEMORI T, 1981, EUR J IMMUNOL, V11, P618, DOI 10.1002/eji.1830110806; TODA M, 1989, IMMUNOL LETT, V21, P311, DOI 10.1016/0165-2478(89)90025-4; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; TSUBATA T, 1991, CURR OPIN IMMUNOL, V3, P186, DOI 10.1016/0952-7915(91)90048-6; TSUBATA T, 1990, INT IMMUNOL, V172, P943; TSUKADA S, 1990, J IMMUNOL, V144, P4053; WALL R, 1986, P NATL ACAD SCI USA, V83, P295, DOI 10.1073/pnas.83.2.295; WEILL JC, 1986, P NATL ACAD SCI USA, V83, P3336, DOI 10.1073/pnas.83.10.3336; WEISS U, 1990, J EXP MED, V172, P1681, DOI 10.1084/jem.172.6.1681	58	289	301	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 12	1993	72	5					695	704		10.1016/0092-8674(93)90398-A	http://dx.doi.org/10.1016/0092-8674(93)90398-A			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KR436	8453664	Bronze			2022-12-24	WOS:A1993KR43600006
J	FORGE, A; LI, L; CORWIN, JT; NEVILL, G				FORGE, A; LI, L; CORWIN, JT; NEVILL, G			ULTRASTRUCTURAL EVIDENCE FOR HAIR CELL REGENERATION IN THE MAMMALIAN INNER-EAR	SCIENCE			English	Article							CHRONIC GENTAMICIN TREATMENT; ACOUSTIC TRAUMA; CHICK COCHLEA; STEREOCILIARY BUNDLES; ACTIN-FILAMENTS; GROWTH	It has long been thought that hair cell loss from the inner ears of mammals is irreversible. This report presents scanning electron micrographs and thin sections of the utricles from the inner ears of guinea pigs that show that, after hair cell loss caused by treatment with the aminoglycoside gentamicin, hair cells reappeared. Four weeks after the end of treatment, a large number of cells with immature hair bundles in multiple stages of development could be identified in the utricle. Thin sections showed that lost type 1 hair cells were replaced by cells with a morphology similar to that of type 2 hair cells. These results indicate an unexpected capacity for hair cell regeneration in vivo in the mature mammalian inner ear.	UNIV VIRGINIA, SCH MED, DEPT OTOLARYNGOL HEAD & NECK SURG, CHARLOTTESVILLE, VA 22908 USA	University of Virginia	FORGE, A (corresponding author), UCL, INST LARYNGOL & OTOL, 330-332 GRAYS INN RD, LONDON WC1X 8EE, ENGLAND.			Forge, Andrew/0000-0002-0995-0219	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BROWN AM, 1989, HEARING RES, V42, P143, DOI 10.1016/0378-5955(89)90140-8; CORWIN JT, 1988, SCIENCE, V240, P1772, DOI 10.1126/science.3381100; CORWIN JT, 1981, J COMP NEUROL, V201, P541, DOI 10.1002/cne.902010406; CORWIN JT, 1985, P NATL ACAD SCI USA, V82, P3911, DOI 10.1073/pnas.82.11.3911; CORWIN JT, 1983, J COMP NEUROL, V217, P342; CORWIN JT, 1986, BIOL CHANGE OTOLARYN, P291; COTANCHE DA, 1987, HEARING RES, V30, P181, DOI 10.1016/0378-5955(87)90135-3; COTANCHE DA, 1991, HEARING RES, V52, P379, DOI 10.1016/0378-5955(91)90027-7; CRUZ RM, 1987, ARCH OTOLARYNGOL, V113, P1058; DAVIES S, 1987, J MICROSC-OXFORD, V147, P89, DOI 10.1111/j.1365-2818.1987.tb02821.x; DECHESNE C, 1986, ACTA OTO-LARYNGOL, V101, P11, DOI 10.3109/00016488609108602; DEROSIER DJ, 1980, NATURE, V287, P291, DOI 10.1038/287291a0; FLOCK A, 1977, J CELL BIOL, V75, P339, DOI 10.1083/jcb.75.2.339; FORGE A, 1985, HEARING RES, V19, P171, DOI 10.1016/0378-5955(85)90121-2; FURNESS DN, 1989, HEARING RES, V38, P95, DOI 10.1016/0378-5955(89)90131-7; Manley GA., 1990, PERIPHERAL HEARING M; MICHAELS L, 1987, EAR NOSE THROAT HIST, P89; PICKLES JO, 1988, INTRO PHYSL HEARING, P298; POPPER AN, 1984, HEARING RES, V15, P133, DOI 10.1016/0378-5955(84)90044-3; RYALS BM, 1988, SCIENCE, V240, P1774, DOI 10.1126/science.3381101; TILNEY LG, 1986, DEV BIOL, V116, P100, DOI 10.1016/0012-1606(86)90047-3; WARCHOL ME, 1993, SCIENCE, V259, P1619, DOI 10.1126/science.8456285; WEISLEDER P, 1992, EXP NEUROL, V115, P2, DOI 10.1016/0014-4886(92)90211-8	23	410	433	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 12	1993	259	5101					1616	1619		10.1126/science.8456284	http://dx.doi.org/10.1126/science.8456284			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KR543	8456284				2022-12-24	WOS:A1993KR54300041
J	FLETCHER, AE; BEEVERS, DG; BULPITT, CJ; COLES, EC; DOLLERY, CT; LEDINGHAM, JG; PALMER, AJ; PETRIE, JC; WEBSTER, J				FLETCHER, AE; BEEVERS, DG; BULPITT, CJ; COLES, EC; DOLLERY, CT; LEDINGHAM, JG; PALMER, AJ; PETRIE, JC; WEBSTER, J			CANCER MORTALITY AND ATENOLOL TREATMENT	BRITISH MEDICAL JOURNAL			English	Article									HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DIV GERIATR MED,LONDON W12 0NN,ENGLAND; DUDLEY RD GEN HOSP,BIRMINGHAM B18 7QH,W MIDLANDS,ENGLAND; UNIV WALES COLL MED,DEPT COMPUTING & MED STAT,CARDIFF CF4 4XN,S GLAM,WALES; JOHN RADCLIFFE HOSP,DEPT MED,OXFORD OX3 9DU,ENGLAND; UNIV ABERDEEN,DEPT MED & THERAPEUT,CLIN PHARMACOL UNIT,ABERDEEN AB9 1FX,SCOTLAND	Imperial College London; Cardiff University; University of Oxford; University of Aberdeen								BEILIN LJ, 1974, BRIT MED J, V2, P212, DOI 10.1136/bmj.2.5912.212; BULPITT CJ, 1976, BMJ-BRIT MED J, V1, P677, DOI 10.1136/bmj.1.6011.677; COOPE J, 1986, BRIT MED J, V293, P1145, DOI 10.1136/bmj.293.6555.1145; 1992, BMJ, V304, P405	4	28	28	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 6	1993	306	6878					622	623		10.1136/bmj.306.6878.622	http://dx.doi.org/10.1136/bmj.306.6878.622			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KQ859	8461813	Bronze, Green Published			2022-12-24	WOS:A1993KQ85900021
J	EADY, EA; JONES, CE; TIPPER, JL; COVE, JH; CUNLIFFE, WJ; LAYTON, AM				EADY, EA; JONES, CE; TIPPER, JL; COVE, JH; CUNLIFFE, WJ; LAYTON, AM			ANTIBIOTIC-RESISTANT PROPIONIBACTERIA IN ACNE - NEED FOR POLICIES TO MODIFY ANTIBIOTIC USAGE	BRITISH MEDICAL JOURNAL			English	Article									GEN INFIRM,DEPT DERMATOL,LEEDS LS1 3EX,W YORKSHIRE,ENGLAND	Leeds General Infirmary	EADY, EA (corresponding author), UNIV LEEDS,DEPT MICROBIOL,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND.			Tipper, Joanne/0000-0002-8719-0323; Layton, Alison/0000-0003-0473-3319				CRAWFORD WW, 1978, J INVEST DERMATOL, V72, P187; CUNFLIFFE WJ, 1989, ACNE; EADY EA, 1989, BRIT J DERMATOL, V121, P51, DOI 10.1111/j.1365-2133.1989.tb01399.x; Leyden J J, 1976, Cutis, V17, P593; LEYDEN JJ, 1983, J AM ACAD DERMATOL, V8, P41, DOI 10.1016/S0190-9622(83)70005-8	5	113	119	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 27	1993	306	6877					555	556		10.1136/bmj.306.6877.555	http://dx.doi.org/10.1136/bmj.306.6877.555			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP886	8461769	Bronze, Green Published			2022-12-24	WOS:A1993KP88600021
J	LEW, DJ; MARINI, NJ; REED, SI				LEW, DJ; MARINI, NJ; REED, SI			A SUPPRESSOR OF CLN3 FOR SIZE CONTROL	CELL			English	Article							CEREVISIAE				LEW, DJ (corresponding author), SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA.							GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; LEW DJ, 1992, CELL, V69, P317, DOI 10.1016/0092-8674(92)90412-6; PILLUS L, 1989, CELL, V59, P637, DOI 10.1016/0092-8674(89)90009-3	3	4	4	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 26	1993	72	4					488	489		10.1016/0092-8674(93)90068-2	http://dx.doi.org/10.1016/0092-8674(93)90068-2			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KP165	8440017				2022-12-24	WOS:A1993KP16500004
J	PAFFENBARGER, RS; HYDE, RT; WING, AL; LEE, IM; JUNG, DL; KAMPERT, JB				PAFFENBARGER, RS; HYDE, RT; WING, AL; LEE, IM; JUNG, DL; KAMPERT, JB			THE ASSOCIATION OF CHANGES IN PHYSICAL-ACTIVITY LEVEL AND OTHER LIFE-STYLE CHARACTERISTICS WITH MORTALITY AMONG MEN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY HEART-DISEASE; ALL-CAUSE MORTALITY; RISK-FACTORS; LEISURE-TIME; COLLEGE ALUMNI; DEATH; ATTACK; RATES	Background. Recent trends toward increasing physical exercise, stopping cigarette smoking, and avoiding obesity may increase longevity. We analyzed changes in the lifestyles of Harvard College alumni and the associations of these changes with mortality. Methods. Men who were 45 to 84 years of age in 1977 and who had reported no life-threatening disease on questionnaires completed in 1962 or 1966 and again in 1977 were classified according to changes in lifestyle characteristics between the first and second questionnaires. We analyzed changes in their level of physical activity, cigarette smoking, blood pressure, and body weight, and the relation of these factors to mortality between 1977 and 1985. Results. Of the 10,269 men, 476 died during this period (which totaled 90,650 man-years of observation). Beginning moderately vigorous sports activity (at an intensity of 4.5 or more metabolic equivalents) was associated with a 23 percent lower risk of death (95 percent confidence interval, 4 to 42 percent; P = 0.015) than not taking up moderately vigorous sports. Quitting cigarette smoking was associated with a 41 percent lower risk (95 percent confidence interval, 20 to 57 percent; P = 0.001) than continuing smoking, but with a 23 percent higher risk than constant nonsmoking. Men with recently diagnosed hypertension had a lower risk of death than those with long-term hypertension (relative risk, 0.75; 95 percent confidence interval, 0.55 to 1.02; P = 0.057), as did men with consistently normal blood pressure (relative risk, 0.52; 95 percent confidence interval, 0.40 to 0.68; P < 0.001). Maintenance of lean body mass was associated with a lower mortality rate than long-term, recent, or previous obesity. The associations between changes in lifestyle and mortality were independent and were largely undiminished by age. Our findings on death from coronary heart disease mirrored those on death from all causes. Conclusions. Beginning moderately vigorous sports activity, quitting cigarette smoking, maintaining normal blood pressure, and avoiding obesity were separately associated with lower rates of death from all causes and from coronary heart disease among middle-aged and older men.	HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	PAFFENBARGER, RS (corresponding author), STANFORD UNIV, MED CTR,SCH MED,DEPT HLTH RES & POLICY, DIV EPIDEMIOL,HRP BLDG, RM 113, STANFORD, CA 94305 USA.		Lee, I-Min/ABD-5409-2021		NATIONAL CANCER INSTITUTE [R01CA044854] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034174] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 44854] Funding Source: Medline; NHLBI NIH HHS [R01 HL 34174] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AINSWORTH BE, 1993, MED SCI SPORT EXER, V25, P71, DOI 10.1249/00005768-199301000-00011; ARRAIZ GA, 1992, J CLIN EPIDEMIOL, V45, P419, DOI 10.1016/0895-4356(92)90043-M; BENFANTE RJ, 1989, J CLIN EPIDEMIOL, V42, P95, DOI 10.1016/0895-4356(89)90082-6; BLAIR SN, 1989, JAMA-J AM MED ASSOC, V262, P2395, DOI 10.1001/jama.262.17.2395; CASPERSEN CJ, 1991, AM J EPIDEMIOL, V133, P1078, DOI 10.1093/oxfordjournals.aje.a115821; CHAVE SPW, 1978, J EPIDEMIOL COMMUN H, V32, P239, DOI 10.1136/jech.32.4.239; FROME EL, 1983, BIOMETRICS, V39, P665, DOI 10.2307/2531094; KAPLAN GA, 1987, AM J PUBLIC HEALTH, V77, P307, DOI 10.2105/AJPH.77.3.307; KARVONEN MJ, 1989, ANN MED, V21, P3, DOI 10.3109/07853898909149175; LEE IM, 1992, AM J EPIDEMIOL, V135, P915, DOI 10.1093/oxfordjournals.aje.a116387; LEON AS, 1987, JAMA-J AM MED ASSOC, V258, P2388, DOI 10.1001/jama.258.17.2388; LINDSTED KD, 1991, J CLIN EPIDEMIOL, V44, P355, DOI 10.1016/0895-4356(91)90074-J; MANSON JE, 1992, NEW ENGL J MED, V326, P1406, DOI 10.1056/NEJM199205213262107; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; MORRIS JN, 1990, BRIT HEART J, V63, P325; MORRIS JN, IN PRESS MED SCI SPO; PAFFENBARGER RS, 1990, EXERCISE, FITNESS, AND HEALTH, P33; PAFFENBARGER RS, 1984, JAMA-J AM MED ASSOC, V252, P491, DOI 10.1001/jama.252.4.491; PAFFENBARGER RS, 1986, NEW ENGL J MED, V314, P605, DOI 10.1056/NEJM198603063141003; PAFFENBARGER RS, 1978, AM J EPIDEMIOL, V108, P12; PAFFENBARGER RS, 1966, AM J PUBLIC HEALTH N, V56, P962, DOI 10.2105/AJPH.56.6.962; PAFFENBARGER RS, 1978, AM J EPIDEMIOL, V108, P161, DOI 10.1093/oxfordjournals.aje.a112608; PAFFENBARGER RS, IN PRESS PHYSICAL AC; PEKKANEN J, 1987, LANCET, V1, P1473, DOI 10.1016/S0140-6736(87)92218-5; SALONEN JT, 1982, AM J EPIDEMIOL, V115, P526, DOI 10.1093/oxfordjournals.aje.a113334; SHAPER AG, 1991, BRIT HEART J, V66, P384; SLATTERY ML, 1989, CIRCULATION, V79, P304, DOI 10.1161/01.CIR.79.2.304; SYTKOWSKI PA, 1990, NEW ENGL J MED, V322, P1635, DOI 10.1056/NEJM199006073222304; WANNAMETHEE G, 1992, BRIT MED J, V304, P597, DOI 10.1136/bmj.304.6827.597; [No title captured]; 1986, NEW ENGL J MED, V315, P399	31	1336	1373	3	107	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 25	1993	328	8					538	545		10.1056/NEJM199302253280804	http://dx.doi.org/10.1056/NEJM199302253280804			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP053	8426621				2022-12-24	WOS:A1993KP05300004
J	MCDONALD, GB; HINDS, MS; FISHER, LD; SCHOCH, HG; WOLFORD, JL; BANAJI, M; HARDIN, BJ; SHULMAN, HM; CLIFT, RA				MCDONALD, GB; HINDS, MS; FISHER, LD; SCHOCH, HG; WOLFORD, JL; BANAJI, M; HARDIN, BJ; SHULMAN, HM; CLIFT, RA			VENOOCCLUSIVE DISEASE OF THE LIVER AND MULTIORGAN FAILURE AFTER BONE-MARROW TRANSPLANTATION - A COHORT STUDY OF 355 PATIENTS	ANNALS OF INTERNAL MEDICINE			English	Article						BONE MARROW TRANSPLANTATION; MULTIPLE ORGAN FAILURE; HEPATIC VENOOCCLUSIVE DISEASE; AMINOTRANSFERASES; VANCOMYCIN	TUMOR-NECROSIS-FACTOR; REGIMEN-RELATED TOXICITY; RESPIRATORY-DISTRESS SYNDROME; 2 IRRADIATION REGIMENS; VENOOCCLUSIVE DISEASE; VENOCCLUSIVE DISEASE; FACTOR-ALPHA; ENDOTHELIAL-CELLS; MYELOID-LEUKEMIA; RANDOMIZED TRIAL	Objective: To determine the incidence and clinical course of veno-occlusive disease of the liver (VOD) after bone marrow transplantation and to analyze risk factors for severe VOD. Design: Cohort study of 355 consecutive patients. Setting: A bone marrow transplantation center. Measurements: Each patient was prospectively evaluated for VOD, and many risk factors for severe VOD were analyzed using logistic regression models. The relation of VOD to renal and cardiopulmonary failure was analyzed using time-dependent proportional hazards models. Results: Veno-occlusive disease developed in 190 of 355 patients (54%; 95% CI, 48% to 59%): Fifty-four patients had severe VOD and 136 had mild or moderate VOD. Independent variables derived from a multivariate model for predicting severe VOD included elevated transaminase values before transplantation (relative risk, 4.6; P < 0.0001); vancomycin therapy during cytoreductive therapy (relative risk, 2.9; P = 0.003); cytoreductive therapy with a high-dose regimen (relative risk, 2.8; P = 0.01); acyclovir therapy before transplantation (relative risk, 4.8; P = 0.02); mismatched or unrelated donor marrow (relative risk, 2.4; P = 0.02); and previous radiation therapy to the abdomen (relative risk, 2.2; P = 0.04). Vancomycin therapy was a marker for persistent fever. Multiorgan failure was more frequent among patients with VOD and usually followed the onset of liver disease. Conclusions: Veno-occlusive disease, which developed in 54% of bone marrow transplant recipients, is frequently associated with renal and cardiopulmonary failure. Pretransplant transaminase elevations, use of high-dose cytoreductive therapy, and persistent fever during cytoreductive therapy are independent predictors of severe VOD.	UNIV WASHINGTON, SCH MED, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle	MCDONALD, GB (corresponding author), FRED HUTCHINSON CANC RES CTR, 1124 COLUMBIA ST, SEATTLE, WA 98104 USA.				NATIONAL CANCER INSTITUTE [P01CA018029, P30CA015704] Funding Source: NIH RePORTER; NCI NIH HHS [CA18029, CA15704] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDUS T, 1991, HEPATOLOGY, V13, P364, DOI 10.1016/0270-9139(91)92454-G; [Anonymous], 1991, J Infect Dis, V163, P951; AURER I, 1991, BONE MARROW TRANSPL, V7, P255; BEARMAN SI, 1989, J CLIN ONCOL, V7, P1288, DOI 10.1200/JCO.1989.7.9.1288; BEARMAN SI, 1988, J CLIN ONCOL, V6, P1562, DOI 10.1200/JCO.1988.6.10.1562; BEATTY PG, 1991, TRANSPLANTATION, V51, P443, DOI 10.1097/00007890-199102000-00034; BEVILACQUA MP, 1986, P NATL ACAD SCI USA, V83, P4533, DOI 10.1073/pnas.83.12.4533; BIANCO JA, 1991, BLOOD, V78, P1205; Birnbaum Z., 1974, RELIABILITY BIOMETRY, P441; CASTILLA A, 1991, NEW ENGL J MED, V324, P933, DOI 10.1056/NEJM199104043241401; CLIFT RA, 1990, BLOOD, V76, P1867; CLIFT RA, 1991, BLOOD, V77, P1660; ELMOUELHI M, 1986, HEPATOLOGY, V6, P450; ERIKSSON LS, 1990, HEPATOLOGY, V12, P1350, DOI 10.1002/hep.1840120616; ESSELL JH, 1992, BLOOD, V79, P2784; FAIONI EM, 1991, BLOOD S, V78, pA193; FOX ES, 1990, LAB INVEST, V63, P733; GALE RP, 1978, SCIENCE, V201, P937, DOI 10.1126/science.356266; GANEM G, 1988, INT J RADIAT ONCOL, V14, P879, DOI 10.1016/0360-3016(88)90009-0; GERLACH H, 1990, ANNU REV MED, V41, P15; GORDON B, 1991, BONE MARROW TRANSPL, V8, P497; GREVE JW, 1990, GASTROENTEROLOGY, V98, P478, DOI 10.1016/0016-5085(90)90841-N; GROCHOW LB, 1990, BLOOD, V75, P1723; GROCHOW LB, 1989, CANCER CHEMOTH PHARM, V25, P55, DOI 10.1007/BF00694339; HARPER PL, 1990, BONE MARROW TRANSPL, V5, P39; HASSAN M, 1991, CANCER CHEMOTH PHARM, V28, P130, DOI 10.1007/BF00689702; HILL HF, 1991, BLOOD, V78, pA243; HOLLER E, 1990, BLOOD, V75, P1011; ISHAWA T, 1986, TARGET ORGAN TOXICIT; JAATTELA M, 1991, LAB INVEST, V64, P724; JIRTLE RL, 1981, CANCER RES, V41, P3512; JOHNSON LK, 1982, ANAL QUANT CYTOL, V4, P188; JONES RJ, 1987, TRANSPLANTATION, V44, P778, DOI 10.1097/00007890-198712000-00011; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; LOCASCIULLI A, 1989, TRANSPLANTATION, V48, P68, DOI 10.1097/00007890-198907000-00016; LUCARELLI G, 1990, NEW ENGL J MED, V322, P417, DOI 10.1056/NEJM199002153220701; LUCARELLI G, 1987, NEW ENGL J MED, V316, P1050, DOI 10.1056/NEJM198704233161703; MATUSCHAK GM, 1987, J CRIT CARE, V2, P162, DOI 10.1016/0883-9441(87)90003-7; MATUSCHAK GM, 1988, CHEST, V94, P400, DOI 10.1378/chest.94.2.400; MCDONALD GB, 1984, HEPATOLOGY, V4, P116, DOI 10.1002/hep.1840040121; MCDONALD GB, 1985, TRANSPLANTATION, V39, P603, DOI 10.1097/00007890-198506000-00005; MEYERS JD, 1991, ANNU REV MED, V42, P179, DOI 10.1146/annurev.me.42.020191.001143; Mitchell J R, 1981, Semin Liver Dis, V1, P143, DOI 10.1055/s-2008-1040727; NASH RA, 1992, BLOOD, V80, P1838; NEVILL TJ, 1991, J CLIN ONCOL, V9, P1224, DOI 10.1200/JCO.1991.9.7.1224; OZKAYNAK MF, 1991, BONE MARROW TRANSPL, V7, P467; PINSKY MR, 1990, J CRIT CARE, V5, P108, DOI 10.1016/0883-9441(90)90056-F; RIO B, 1986, BLOOD, V67, P1773; ROBERTS DW, 1991, AM J PATHOL, V138, P359; SAKR MF, IN PRESS LIVER TRANS; SCOAZEC JY, 1991, HEPATOLOGY, V14, P789, DOI 10.1002/hep.1840140508; SCROBOHACI ML, 1991, THROMB RES, V63, P509, DOI 10.1016/0049-3848(91)90176-W; SHENEP JL, 1988, NEW ENGL J MED, V319, P1053, DOI 10.1056/NEJM198810203191604; SHULMAN HM, 1987, AM J PATHOL, V126, P114; SHULMAN HM, 1987, AM J PATHOL, V127, P549; SHULMAN HM, 1980, GASTROENTEROLOGY, V79, P1178; SOIFFER RJ, 1991, TRANSPLANTATION, V52, P1014, DOI 10.1097/00007890-199112000-00015; STORB R, 1986, NEW ENGL J MED, V314, P729, DOI 10.1056/NEJM198603203141201; TEBOEKHORST T, 1988, J HEPATOL, V7, P111, DOI 10.1016/S0168-8278(88)80514-2; Thomas E. D., 1990, BONE MARROW TRANSPLA; THOMAS ED, 1975, NEW ENGL J MED, V292, P832, DOI 10.1056/NEJM197504172921605; THOMAS ED, 1975, NEW ENGL J MED, V292, P895, DOI 10.1056/NEJM197504242921706; TILNEY NL, 1973, ANN SURG, V178, P117, DOI 10.1097/00000658-197308000-00001; TOX U, 1991, HEPATOLOGY, V14, pA220; TRABER PG, 1988, GASTROENTEROLOGY, V95, P1130, DOI 10.1016/0016-5085(88)90194-1; VANDERPOLL T, 1990, NEW ENGL J MED, V322, P1622, DOI 10.1056/NEJM199006073222302; VASSAL G, 1992, BLOOD, V79, P2475; VOLPES R, 1990, HEPATOLOGY, V12, P59, DOI 10.1002/hep.1840120110; VOLPES R, 1990, HEPATOLOGY, V12, P148, DOI 10.1002/hep.1840120123; VOLPES R, 1991, GASTROENTEROLOGY, V101, P200, DOI 10.1016/0016-5085(91)90478-4; WINGARD JR, 1989, BONE MARROW TRANSPL, V4, P685; WITHERSPOON RP, 1984, AM J HEMATOL, V17, P269, DOI 10.1002/ajh.2830170307; ZAGER RA, 1989, AM J KIDNEY DIS, V13, P210, DOI 10.1016/S0272-6386(89)80054-X; 1990, BMDP STATISTICAL SOF, V2, P1013	74	933	964	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1993	118	4					255	267		10.7326/0003-4819-118-4-199302150-00003	http://dx.doi.org/10.7326/0003-4819-118-4-199302150-00003			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KL457	8420443				2022-12-24	WOS:A1993KL45700003
J	BARKER, DJP; OSMOND, C; SIMMONDS, SJ; WIELD, GA				BARKER, DJP; OSMOND, C; SIMMONDS, SJ; WIELD, GA			THE RELATION OF SMALL HEAD CIRCUMFERENCE AND THINNESS AT BIRTH TO DEATH FROM CARDIOVASCULAR-DISEASE IN ADULT LIFE	BRITISH MEDICAL JOURNAL			English	Article							PLACENTAL SIZE; FETAL; WEIGHT	Objective-To determine how fetal growth is related to death from cardiovascular disease in adult life. Design-A follow up study of men born during 1907-24 whose birth weights, head circumferences, and other body measurements were recorded at birth. Setting-Sheffield, England. Subjects-1586 Men born in the Jessop Hospital. Main outcome measure-Death from cardiovascular disease. Results-Standardised mortality ratios for cardiovascular disease fell from 119 in men who weighed 5.5 pounds (2495 g) or less at birth to 74 in men who weighed more than 8.5 pounds (3856 g). The fall was significant for premature cardiovascular deaths up to 65 years of age (chi2=5.0, p=0.02). Standardised mortality ratios also fell with increasing head circumference (chi2=4.6, p=0.03) and increasing ponderal index (weight/length3) (chi2=3.8, p=0.05; for premature deaths chi2=6.0, p=0.01). They were not related to the duration of gestation. Among men for whom the ratio of placental weight to birth weight was in the highest fifths the standardised mortality ratio was 137. Conclusion-These findings show that reduced fetal growth is followed by increased mortality from cardiovascular disease. They suggest that reduction in growth begins early in gestation. They are further evidence that cardiovascular disease originates through programming of the body's structure, physiology, and metabolism by the environment during fetal life. Maternal nutrition may have an important influence on programming.			BARKER, DJP (corresponding author), SOUTHAMPTON GEN HOSP,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND.		Jansen, Heiko T./A-5770-2008	Jansen, Heiko T./0000-0003-0178-396X; Osmond, Clive/0000-0002-9054-4655	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Barker D J, 1992, Paediatr Perinat Epidemiol, V6, P35, DOI 10.1111/j.1365-3016.1992.tb00741.x; BARKER DJP, 1993, DIABETOLOGIA, V36, P62, DOI 10.1007/BF00399095; BARKER DJP, 1989, LANCET, V2, P577; BARKER DJP, 1992, BMJ-BRIT MED J, V304, P148, DOI 10.1136/bmj.304.6820.148; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; Barker DJP, 1992, FETAL INFANT ORIGINS; BEISCHER N A, 1970, Journal of Obstetrics and Gynaecology of the British Commonwealth, V77, P398; BERRY G, 1983, BIOMETRICS, V39, P173, DOI 10.2307/2530817; BLACKWELL NM, 1968, J NUTR, V97, P79; BUTLER NR, 1969, 2ND REPORT 1958 BRIT; DUBOS R, 1966, PEDIATRICS, V38, P789; FALL CHD, 1992, BRIT MED J, V304, P801, DOI 10.1136/bmj.304.6830.801; FARCHNEY GJ, 1987, AUSTR J BIOL SCI, V40, P365; Gardner M, 1984, ATLAS MORTALITY SELE; GODFREY KM, 1991, BRIT J OBSTET GYNAEC, V98, P886, DOI 10.1111/j.1471-0528.1991.tb13510.x; HAHN P, 1984, J NUTR, V114, P1231, DOI 10.1093/jn/114.7.1231; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; LAW CM, 1991, ARCH DIS CHILD, V66, P1291, DOI 10.1136/adc.66.11.1291; LUCAS A, 1991, CIBA F SYMP, V156, P38; MCCRABB GJ, 1991, BRIT J NUTR, V65, P157, DOI 10.1079/BJN19910077; PHIPPS K, 1993, IN PRESS DIABETOLOGI; ROBINSON SM, 1991, BRIT J OBSTET GYNAEC, V98, P1223, DOI 10.1111/j.1471-0528.1991.tb15393.x; WINICK M, 1966, J NUTR, V89, P300, DOI 10.1093/jn/89.3.300	23	544	557	1	13	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 13	1993	306	6875					422	426		10.1136/bmj.306.6875.422	http://dx.doi.org/10.1136/bmj.306.6875.422			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KM700	8461722	Bronze, Green Published			2022-12-24	WOS:A1993KM70000019
J	GLATT, CE; SNYDER, SH				GLATT, CE; SNYDER, SH			CLONING AND EXPRESSION OF AN ADENYLYL CYCLASE LOCALIZED TO THE CORPUS STRIATUM	NATURE			English	Article							MESSENGER-RNA; RAT-BRAIN; INSITU HYBRIDIZATION; LOCALIZATIONS	THE neurotransmitter dopamine acts through various receptor subtypes that are largely associated with enhancement or inhibition of adenylyl cyclases1,2. These dopamine-sensitive adenylyl cyclases are highly concentrated in the corpus striatum and associated limbic structures of the brain, where their levels exceed by orders of magnitude 3,4 those in other areas of the brain. Here we use in situ hybridization to show that messenger RNA for three of these adenylyl cyclases5-7 is not found in the corpus striatum. We have isolated and expressed a complementary DNA encoding new adenylyl cyclase whose selective concentration in the corpus striatum indicates that it may be responsible for the synaptic actions of dopamine.	JOHNS HOPKINS UNIV,SCH MED,DEPT PSYCHIAT,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PHARMACOL & MOLEC SCI,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University	GLATT, CE (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,725 N WOLFE ST,BALTIMORE,MD 21205, USA.							BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; Battey, 1986, BASIC METHODS MOL BI; DRINNAN S L, 1991, Molecular and Cellular Neuroscience, V2, P66, DOI 10.1016/1044-7431(91)90040-U; FEINSTEIN PG, 1991, P NATL ACAD SCI USA, V88, P10173, DOI 10.1073/pnas.88.22.10173; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; GEHLERT DR, 1985, EUR J PHARMACOL, V106, P223; GORMAN CM, 1992, DNA PROT ENG TECHN, V2, P3; Grandy D K, 1992, Curr Opin Neurobiol, V2, P275, DOI 10.1016/0959-4388(92)90115-2; ISHIKAWA Y, 1992, J BIOL CHEM, V267, P13553; KEBABIAN JW, 1979, NATURE, V277, P93, DOI 10.1038/277093a0; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; LARGENT BL, 1988, P NATL ACAD SCI USA, V85, P2864, DOI 10.1073/pnas.85.8.2864; LAURENZA A, 1989, TRENDS PHARMACOL SCI, V10, P442, DOI 10.1016/S0165-6147(89)80008-2; PREMONT RT, 1992, P NATL ACAD SCI USA, V89, P9809, DOI 10.1073/pnas.89.20.9809; PRITCHETT DB, 1988, SCIENCE, V242, P1306, DOI 10.1126/science.2848320; ROSS CA, 1989, P NATL ACAD SCI USA, V86, P2923, DOI 10.1073/pnas.86.8.2923; WORLEY PF, 1986, P NATL ACAD SCI USA, V83, P4053, DOI 10.1073/pnas.83.11.4053; XIA ZG, 1991, NEURON, V6, P431, DOI 10.1016/0896-6273(91)90251-T	18	182	185	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 11	1993	361	6412					536	538		10.1038/361536a0	http://dx.doi.org/10.1038/361536a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL714	8429907				2022-12-24	WOS:A1993KL71400060
J	SINGER, PT; SMALAS, A; CARTY, RP; MANGEL, WF; SWEET, RM				SINGER, PT; SMALAS, A; CARTY, RP; MANGEL, WF; SWEET, RM			THE HYDROLYTIC WATER MOLECULE IN TRYPSIN, REVEALED BY TIME-RESOLVED LAUE CRYSTALLOGRAPHY	SCIENCE			English	Article							CRYSTAL-STRUCTURE; RESOLUTION	Crystals of bovine trypsin were acylated at the reactive residue, serine 195, to form the transiently stable p-guanidinobenzoate. Hydrolysis of this species was triggered in the crystals by a jump in pH. The hydrolysis was monitored by three-dimensional Laue crystallography, resulting in three x-ray diffraction structures, all from the same crystal and each representing approximately 5 seconds of x-ray exposure. The structures were analyzed at a nominal resolution of 1.8 angstroms and were of sufficient quality to reproduce subtle features in the electron-density maps for each of the structures. Comparison of the structures before and after the pH jump reveals that a water molecule has positioned itself to attack the acyl group in the initial step of the hydrolysis of this transient intermediate.	BROOKHAVEN NATL LAB,DEPT BIOL,UPTON,NY 11973; ARGONNE NATL LAB,DEPT BIOL,ARGONNE,IL 60439; UNIV TROMSO,INST MATH & PHYS SCI,N-9000 TROMSO,NORWAY; SUNY HLTH SCI CTR,DEPT BIOCHEM,BROOKLYN,NY 11203	United States Department of Energy (DOE); Brookhaven National Laboratory; United States Department of Energy (DOE); Argonne National Laboratory; UiT The Arctic University of Tromso; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center			Smalås, Arne/C-4131-2016	Smalås, Arne/0000-0002-4651-9911				BARTUNIK HD, 1989, J MOL BIOL, V210, P813, DOI 10.1016/0022-2836(89)90110-1; BLOW DM, 1969, NATURE, V221, P337, DOI 10.1038/221337a0; BRUNGER AT, X PLOR; CHASE T, 1967, BIOCHEM BIOPH RES CO, V29, P508, DOI 10.1016/0006-291X(67)90513-X; HELLIWELL JR, 1989, J APPL CRYSTALLOGR, V22, P483, DOI 10.1107/S0021889889006564; HENDERSON R, 1970, Journal of Molecular Biology, V54, P341, DOI 10.1016/0022-2836(70)90434-1; LUZATTI V, 1952, ACTA CRYSTALLOGR, V5, P802; MANGEL WF, 1990, BIOCHEMISTRY-US, V29, P8351, DOI 10.1021/bi00488a022; SACK JS, 1988, J MOL GRAPHICS, V6, P24; SINGER P, UNPUB; SINGER PT, 1992, PHILOS T ROY SOC A, V340, P285, DOI 10.1098/rsta.1992.0067; SWEET RM, 1974, BIOCHEMISTRY-US, V13, P4212, DOI 10.1021/bi00717a024	12	98	99	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 29	1993	259	5095					669	673		10.1126/science.8430314	http://dx.doi.org/10.1126/science.8430314			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KJ688	8430314				2022-12-24	WOS:A1993KJ68800039
J	ABERG, A; NORDLUND, P; EKLUND, H				ABERG, A; NORDLUND, P; EKLUND, H			UNUSUAL CLUSTERING OF CARBOXYL SIDE-CHAINS IN THE CORE OF IRON-FREE RIBONUCLEOTIDE REDUCTASE	NATURE			English	Article							CONCANAVALIN-A	THE principal driving forces of protein folding are the burial of hydrophobic residues in the interior of proteins and the exposure of charged residues at the surface1. Charged residues are only occasionally found in the interior, where they form hydrogen bonds to oppositely charged residues or main-chain atoms2. Ribonucleotide reductase, a key enzyme in DNA synthesis, catalyses the de novo production of deoxyribonucleotide precursors. It is composed of two different dimeric proteins R1 and R2 (refs 3-5). R2 subunits contain buried iron-centres with each centre formed by two ferric ions coordinated by four carboxylates and two histidine ligands6. Iron-free R2, apoR2, is a precursor of active R2 and folds into a stable protein which is transformed into active R2 by ferrous ions and molecular oxygen. Here we show that the iron-free protein does not undergo any major structural changes compared with the iron-containing R2. The effect of this is a clustering of four carboxyl side chains in the interior of the subunit, in contrast to the normal distribution of charged residues in proteins.	LAB MOLEC BIOPHYS, OXFORD OX1 3QH, ENGLAND; SWEDISH UNIV AGR SCI, CTR BIOMED, DEPT MOLEC BIOL, S-75124 UPPSALA, SWEDEN	University of Oxford; Swedish University of Agricultural Sciences	ABERG, A (corresponding author), UNIV STOCKHOLM, DEPT MOLEC BIOL, S-10691 STOCKHOLM, SWEDEN.							ANDERSON BF, 1990, NATURE, V344, P784, DOI 10.1038/344784a0; ATKIN CL, 1973, J BIOL CHEM, V248, P7664; ATTA M, 1992, J BIOL CHEM, V267, P20682; BAJORATH J, 1989, NATURE, V337, P481, DOI 10.1038/337481a0; BAKER EN, 1984, PROG BIOPHYS MOL BIO, V44, P97, DOI 10.1016/0079-6107(84)90007-5; BLUM M, 1987, J APPL CRYSTALLOGR, V20, P235, DOI 10.1107/S0021889887086783; BrõndÚn CI., 1991, INTRO PROTEIN STRUCT; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; DAVIES D, 1989, A REV BIOPHYS CHEM, V19, P189; ERIKSSON S, 1989, ALLOSTERIC ENZYMES, P189; FONTECAVE M, 1992, ADV ENZYMOL, V65, P147; Honig B., 1992, CURR OPIN STRUC BIOL, V2, P40; JONES TA, 1985, METHOD ENZYMOL, V115, P157; JONES TA, 1990, CRYSTALLOGRAPHIC MOD, P189; NAR H, 1992, FEBS LETT, V306, P119, DOI 10.1016/0014-5793(92)80981-L; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; NORDLUND P, 1989, FEBS LETT, V258, P251, DOI 10.1016/0014-5793(89)81666-7; REEKE GN, 1978, P NATL ACAD SCI USA, V75, P2286, DOI 10.1073/pnas.75.5.2286; REES DC, 1983, P NATL ACAD SCI-BIOL, V80, P7151, DOI 10.1073/pnas.80.23.7151; SCHNEIDER G, 1983, P NATL ACAD SCI-BIOL, V80, P5289, DOI 10.1073/pnas.80.17.5289; SHOHAM M, 1979, J MOL BIOL, V131, P137, DOI 10.1016/0022-2836(79)90070-6; STROUD RM, 1990, BIOCHEMISTRY-US, V29, P11009, DOI 10.1021/bi00502a001; STUBBE JA, 1989, ANNU REV BIOCHEM, V58, P257; Stubbe J, 1991, CURR OPIN STRUC BIOL, V1, P788, DOI 10.1016/0959-440X(91)90180-2; Williams R.J.P., 1991, BIOL CHEM ELEMENTS	25	66	67	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 21	1993	361	6409					276	278		10.1038/361276a0	http://dx.doi.org/10.1038/361276a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KH614	8423856				2022-12-24	WOS:A1993KH61400066
J	SINGH, J; KLAR, AJS				SINGH, J; KLAR, AJS			DNA POLYMERASE-ALPHA IS ESSENTIAL FOR MATING-TYPE SWITCHING IN FISSION YEAST	NATURE			English	Article							SCHIZOSACCHAROMYCES-POMBE; REPLICATION; GENES; CELLS; INITIATION; ASYMMETRY; STRANDS; PATTERN; SITE; MAT1	IN the fission yeast Schizosaccharomyces pombe, the double-stranded chromosomal break (DSB) at the mating-type locus (mat1) initiates recombination during mating-type switching1-3 . A constant DSB level is maintained throughout the cell-cycle'. In the strand-segregation model for mating-type switching, it was postulated that if the DSB is generated during or soon after mat1 replication4, one of the chromatids could be repaired and switched during replication in the next cell cycle, while the other chromatid inherits the break3-6. Here we report a molecular characterization of swi7, one of the genes required for DSB formation. Surprisingly, a gene complementing the swi7 mutation maps to chromosome I and encodes S. pombe DNA polymerase-alpha. Disruption of this gene is lethal in both switching and non-switching strains, as expected. S. pombe DNA polymerase-alpha must therefore play a role in generating the DSB at mat1, suggesting that DSB formation is coupled with DNA replication.	NCI, FREDERICK CANC RES & DEV CTR, ABL BASIC RES PROGRAM,EUKARYOT GENE EXPRESS LAB, POB B,BLDG 539, FREDERICK, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick								ARCANGIOLI B, 1991, EMBO J, V10, P3025, DOI 10.1002/j.1460-2075.1991.tb07853.x; BEACH DH, 1983, NATURE, V305, P682, DOI 10.1038/305682a0; BEACH DH, 1984, EMBO J, V3, P603, DOI 10.1002/j.1460-2075.1984.tb01855.x; DAMAGNEZ V, 1991, MOL GEN GENET, V226, P182, DOI 10.1007/BF00273602; DEPAMPHILIS ML, 1988, CELL, V52, P635, DOI 10.1016/0092-8674(88)90398-4; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EDGAR LG, 1988, CELL, V53, P589, DOI 10.1016/0092-8674(88)90575-2; EGEL R, 1984, CURR GENET, V8, P205, DOI 10.1007/BF00417817; EGEL R, 1984, P NATL ACAD SCI-BIOL, V81, P3481, DOI 10.1073/pnas.81.11.3481; EGEL R, 1987, CURR GENET, V12, P429, DOI 10.1007/BF00434820; ENGELKE U, 1987, CURR GENET, V12, P535, DOI 10.1007/BF00419563; FAN JB, 1991, NUCLEIC ACIDS RES, V19, P6289, DOI 10.1093/nar/19.22.6289; GUTZ H, 1985, CURR GENET, V9, P325, DOI 10.1007/BF00421601; KLAR AJS, 1991, GENETICS, V127, P489; KLAR AJS, 1990, EMBO J, V9, P1407, DOI 10.1002/j.1460-2075.1990.tb08256.x; KLAR AJS, 1987, NATURE, V326, P466, DOI 10.1038/326466a0; MILLER AM, 1984, NATURE, V312, P247, DOI 10.1038/312247a0; MIYATA H, 1981, J GEN APPL MICROBIOL, V27, P365, DOI 10.2323/jgam.27.365; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Munz P, 1989, MOL BIOL FISSION YEA, P1; NIELSEN O, 1989, EMBO J, V8, P269, DOI 10.1002/j.1460-2075.1989.tb03373.x; PERKINS DD, 1949, GENETICS, V34, P607; RIVIER DH, 1992, SCIENCE, V256, P659, DOI 10.1126/science.1585179; RUSSELL P, 1989, MOL BIOL FISSION YEA, P244; Sambrook J., 1989, MOL CLONING LAB MANU; TSURIMOTO T, 1990, NATURE, V346, P534, DOI 10.1038/346534a0; WANG TSF, 1989, FASEB J, V3, P14, DOI 10.1096/fasebj.3.1.2642867; WRIGHT A, 1986, PLASMID, V15, P156, DOI 10.1016/0147-619X(86)90051-X	28	62	62	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 21	1993	361	6409					271	273		10.1038/361271a0	http://dx.doi.org/10.1038/361271a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KH614	8423854				2022-12-24	WOS:A1993KH61400064
J	GAUR, A; HASPEL, R; MAYER, JP; FATHMAN, CG				GAUR, A; HASPEL, R; MAYER, JP; FATHMAN, CG			REQUIREMENT FOR CD8+ CELLS IN T-CELL RECEPTOR PEPTIDE-INDUCED CLONAL UNRESPONSIVENESS	SCIENCE			English	Article							EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; LAMBDA-REPRESSOR; ANTIGEN RECEPTOR; DEGRADATION; IDENTIFICATION; IMMUNIZATION; ANTIBODIES; ELEMENT; USAGE	T cell receptor (TCR) vaccination in rats prevents the development of experimental allergic encephalomyelitis (EAE), an animal model of multiple sclerosis. The mechanism of this potential immunotherapy was examined by vaccinating mice with an immunogenic peptide fragment of the variable region of the TCR V(beta)8.2 gene. Another immunogen that usually induces an immune response mediated by V(beta)8.2+ T cells was subsequently inhibited because specific clonal unresponsiveness (anergy) had been induced. Depletion of CD8+ cells before TCR peptide vaccination blocked such inhibition. Thus, the clonal anergy was dependent on CD8+ T cells, and such immunoregulatory T cells may participate in the normal course of EAE.	STANFORD UNIV, MED CTR,SCH MED,DEPT MED,DIV IMMUNOL & RHEUMATOL, STANFORD, CA 94305 USA; IMMULOG PHARMACEUT CORP, PALO ALTO, CA 94304 USA	Stanford University				RUBERTI, Giovina/0000-0003-2367-9709	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027989] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039959] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 27989] Funding Source: Medline; NIDDK NIH HHS [DK 39959] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BONIFACINO JS, 1989, J CELL BIOL, V109, P73, DOI 10.1083/jcb.109.1.73; COHEN IR, 1989, COLD SPRING HARB SYM, V54, P879; DESQUENNECLARK L, 1991, P NATL ACAD SCI USA, V88, P7219, DOI 10.1073/pnas.88.16.7219; DIALYNAS DP, 1983, J IMMUNOL, V131, P2445; HASHIM GA, 1990, J IMMUNOL, V144, P4621; HOWELL MD, 1989, SCIENCE, V246, P668, DOI 10.1126/science.2814489; JIANG H, 1991, ANN NY ACAD SCI, V636, P28, DOI 10.1111/j.1749-6632.1991.tb33435.x; JIANG H, 1992, SCIENCE, V256, P1213, DOI 10.1126/science.256.5060.1213; KAPPLER JW, 1988, NATURE, V332, P35, DOI 10.1038/332035a0; KOH DR, 1992, SCIENCE, V256, P1210, DOI 10.1126/science.256.5060.1210; LAI MZ, 1988, J EXP MED, V168, P1081, DOI 10.1084/jem.168.3.1081; LAI MZ, 1990, J IMMUNOL, V144, P4851; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; MINAMI Y, 1987, P NATL ACAD SCI USA, V84, P2688, DOI 10.1073/pnas.84.9.2688; OFFNER H, 1991, SCIENCE, V251, P430, DOI 10.1126/science.1989076; RUBERTI G, 1991, J EXP MED, V174, P83, DOI 10.1084/jem.174.1.83; TSE DB, 1986, J MOL CELL IMMUNOL, V2, P315; VANDENBARK AA, 1989, NATURE, V341, P541, DOI 10.1038/341541a0; WILSON DB, 1989, IMMUNOL REV, V107, P159, DOI 10.1111/j.1600-065X.1989.tb00008.x; WISNIEWSKI HM, 1977, ANN NEUROL, V1, P144, DOI 10.1002/ana.410010207	21	119	123	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 1	1993	259	5091					91	94		10.1126/science.8418501	http://dx.doi.org/10.1126/science.8418501			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KE601	8418501				2022-12-24	WOS:A1993KE60100036
J	HUBBARD, A				HUBBARD, A			A TRAVELING-WAVE AMPLIFIER MODEL OF THE COCHLEA	SCIENCE			English	Article							BASILAR-MEMBRANE; MOSSBAUER TECHNIQUE; MECHANICS; CHINCHILLA; VIBRATION; EMISSIONS; BASE	A two-mode model of the cochlea that uses active intermode feedback has been developed that quantitatively accounts for the motion of the basilar membrane in response to single tones and qualitatively accounts for cochlear emission phenomena. In contrast to existing single-mode models, this model amplifies the mechanical traveling wave in spatially localized cochlear regions where an approximate match occurs between the traveling-wave velocities of each of the two traveling-wave lines or modes.	BOSTON UNIV, SCH MED, BOSTON, MA 02118 USA	Boston University	HUBBARD, A (corresponding author), BOSTON UNIV, COLL ENGN, BOSTON, MA 02215 USA.							ALLEN JB, 1992, J ACOUST SOC AM, V92, P178, DOI 10.1121/1.404281; AYASLI Y, 1984, IEEE T MICROW THEORY, V32, P290, DOI 10.1109/TMTT.1984.1132667; BROWNELL WE, 1985, SCIENCE, V227, P194, DOI 10.1126/science.3966153; CODY AR, 1992, HEARING RES, V62, P166, DOI 10.1016/0378-5955(92)90182-M; DEBOER E, 1983, J ACOUST SOC AM, V73, P567, DOI 10.1121/1.389002; DEBOER E, 1990, LECT NOTES BIOMATH, V87, P333; GINZTON EL, 1948, P IRE, V36, P956, DOI 10.1109/JRPROC.1948.231624; Guinan JJ, 1990, MECH BIOPHYSICS HEAR, P170; HUBBARD A, IN PRESS 16TH MIDW M; HUBBARD AE, 1983, SCIENCE, V222, P510, DOI 10.1126/science.6623090; IWASA KH, 1992, J ACOUST SOC AM, V92, P3169, DOI 10.1121/1.404194; KEMP DT, 1978, J ACOUST SOC AM, V64, P1386, DOI 10.1121/1.382104; KHANNA SM, 1982, SCIENCE, V215, P305, DOI 10.1126/science.7053580; Kiang NYS, 1965, DISCHARGE PATTERNS S; PETERSON LC, 1950, J ACOUST SOC AM, V22, P369, DOI 10.1121/1.1906615; RHODE WS, 1971, J ACOUST SOC AM, V49, P1218, DOI 10.1121/1.1912485; ROBLES L, 1986, J ACOUST SOC AM, V80, P1364, DOI 10.1121/1.394389; RUGGERO MA, 1990, J ACOUST SOC AM, V87, P1612, DOI 10.1121/1.399409; RUGGERO MA, 1991, HEARING RES, V51, P215, DOI 10.1016/0378-5955(91)90038-B; RUSSELL I, 1986, J PHYSIOL-LONDON, V284, P261; SELLICK PM, 1982, J ACOUST SOC AM, V72, P131, DOI 10.1121/1.387996; SHINE D, 1991, THESIS BOSTON U; von Bekesy G, 1928, PHYS Z, V29, P793; WILSON JP, 1980, HEARING RES, V2, P233, DOI 10.1016/0378-5955(80)90060-X; ZWEIG G, 1991, J ACOUST SOC AM, V89, P1229, DOI 10.1121/1.400653; ZWICKER E, 1979, BIOL CYBERN, V35, P243, DOI 10.1007/BF00344207	26	101	102	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 1	1993	259	5091					68	71		10.1126/science.8418496	http://dx.doi.org/10.1126/science.8418496			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KE601	8418496				2022-12-24	WOS:A1993KE60100029
J	ISOJARVI, JIT; LAATIKAINEN, TJ; PAKARINEN, AJ; JUNTUNEN, KTS; MYLLYLA, VV				ISOJARVI, JIT; LAATIKAINEN, TJ; PAKARINEN, AJ; JUNTUNEN, KTS; MYLLYLA, VV			POLYCYSTIC OVARIES AND HYPERANDROGENISM IN WOMEN TAKING VALPROATE FOR EPILEPSY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							REPRODUCTIVE ENDOCRINE DISORDERS; COMPLEX PARTIAL SEIZURES; TEMPORAL-LOBE ORIGIN; CARBAMAZEPINE THERAPY; PITUITARY-FUNCTION; HORMONES; SECRETION	Background. Reproductive endocrine disorders are more common among women with epilepsy than among normal women. These disorders have been attributed to epilepsy itself, but could be related to antiepileptic-drug therapy. Methods. We studied 238 women with epilepsy who were seen regularly at the Outpatient Department of the University Hospital, Oulu, Finland. Their mean age was 33 years (range, 18 to 45), and the mean duration of therapy was 9 years (range, 0 to 31). Twenty-nine (12 percent) were treated with valproate, 120 (50 percent) with carbamazepine, 12 (5 percent) with valproate and carbamazepine, and 62 (26 percent) with other medications; 15 (6 percent) were untreated. Vaginal ultrasonography was performed to determine ovarian size, and serum sex-hormone concentrations were measured in 41 women with epilepsy and menstrual disturbances, 57 women with epilepsy and regular menstrual cycles, and 51 normal women. Results. Menstrual disturbances were present in 13 of the women receiving valproate alone (45 percent), 3 of the women receiving valproate in combination with carbamazepine (25 percent), 23 of the women receiving carbamazepine (19 percent), and 8 of those receiving other medications (13 percent). Forty-three percent of the women receiving valproate had polycystic ovaries, and 17 percent had elevated serum testosterone concentrations without polycystic ovaries; 50 percent of the women receiving valproate and carbamazepine had polycystic ovaries, and 38 percent had elevated serum testosterone concentrations without polycystic ovaries. Eighty percent of the women treated with valproate before the age of 20 years had polycystic ovaries or hyperandrogenism. Conclusions. Menstrual disturbances, polycystic ovaries, and hyperandrogenism are often encountered in women taking valproate for epilepsy.	UNIV OULU, DEPT OBSTET & GYNECOL, SF-90220 OULU, FINLAND; UNIV OULU, DEPT CLIN CHEM, SF-90220 OULU, FINLAND	University of Oulu; University of Oulu	ISOJARVI, JIT (corresponding author), UNIV OULU, DEPT NEUROL, SF-90220 OULU, FINLAND.							ABEAL JL, 1991, CLIN ENDOCRINOL, V35, P477, DOI 10.1111/j.1365-2265.1991.tb00931.x; [Anonymous], 1981, Epilepsia, V22, P489; BILO L, 1988, EPILEPSIA, V29, P612, DOI 10.1111/j.1528-1157.1988.tb03770.x; ELIAS AN, 1982, AM J OBSTET GYNECOL, V144, P72, DOI 10.1016/0002-9378(82)90397-0; Everitt B.J., 1986, NEUROENDOCRINOLOGY, P472; HERZOG AG, 1986, ARCH NEUROL-CHICAGO, V43, P347, DOI 10.1001/archneur.1986.00520040035015; HERZOG AG, 1986, ARCH NEUROL-CHICAGO, V43, P341, DOI 10.1001/archneur.1986.00520040029014; ISOJARVI JIT, 1990, ARCH NEUROL-CHICAGO, V47, P670, DOI 10.1001/archneur.1990.00530060082023; ISOJARVI JIT, 1990, EPILEPSIA, V31, P438, DOI 10.1111/j.1528-1157.1990.tb05500.x; ISOJARVI JIT, 1991, EPILEPSY RES, V9, P139, DOI 10.1016/0920-1211(91)90025-B; KIDDY DS, 1990, CLIN ENDOCRINOL, V32, P213, DOI 10.1111/j.1365-2265.1990.tb00857.x; MARGRAF JW, 1981, NEUROLOGY S159, V31; MATTSON RH, 1992, NEW ENGL J MED, V327, P765, DOI 10.1056/NEJM199209103271104; MATTSON RH, 1983, EPILEPSY DIAGNOSIS M, P225; MELIS GB, 1986, ADV BIOCHEM PSYCHOPH, V42, P219; MOLAIE M, 1986, EPILEPSIA, V27, P724, DOI 10.1111/j.1528-1157.1986.tb03601.x; NOBELS F, 1992, FERTIL STERIL, V58, P655; POLSON DW, 1988, LANCET, V1, P870; PRITCHARD PB, 1983, ANN NEUROL, V14, P27, DOI 10.1002/ana.410140105; SWANSON M, 1981, J CLIN ULTRASOUND, V9, P219, DOI 10.1002/jcu.1870090504; TRIMBLE MR, 1984, ADV EPILEPTOL, P201; YEN SSC, 1980, CLIN ENDOCRINOL, V12, P177, DOI 10.1111/j.1365-2265.1980.tb02132.x	22	502	519	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 4	1993	329	19					1383	1388		10.1056/NEJM199311043291904	http://dx.doi.org/10.1056/NEJM199311043291904			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD949	8413434				2022-12-24	WOS:A1993MD94900004
J	FORTINI, ME; REBAY, I; CARON, LA; ARTAVANISTSAKONAS, S				FORTINI, ME; REBAY, I; CARON, LA; ARTAVANISTSAKONAS, S			AN ACTIVATED NOTCH RECEPTOR BLOCKS CELL-FATE COMMITMENT IN THE DEVELOPING DROSOPHILA EYE	NATURE			English	Article							SEVENLESS PROTEIN; TYROSINE KINASE; GENE-PRODUCT; LOCUS; MELANOGASTER; EXPRESSION; HOMOLOG; PHOTORECEPTOR; SEQUENCE; ENHANCER	THE Notch locus of Drosophila melanogaster encodes a 2,703-amino-acid transmembrane protein required for a variety of developmental processes, including neurogenesis, oogenesis and ommatidial assembly1,2. The Notch protein contains a large extracellular domain of 36 epidermal growth factor-like repeats as well as three Notch/Lin-12 repeats and an intracellular domain with 6 Cdc10/ankyrin repeats, motifs that are highly conserved in several vertebrate Notch homologues3-9. Truncation of the extracellular domain of the Drosophila Notch protein produces an activated receptor, as judged by its ability to cause phenotypes similar to gain-of-function alleles or duplications of the Notch locus10. Equivalent truncations of vertebrate Notch-related proteins have been associated with malignant neoplasms and other developmental abnormalities8,11-13. We present here an analysis of activated Notch function at single-cell resolution in the Drosophila compound eye. We find that overexpression of full-length Notch in defined cell types has no apparent effects but that overexpression of activated Notch in the same cells transiently blocks their proper cell-fate commitment, causing them either to adopt incorrect cell fates or to differentiate incompletely. Moreover, an activated Notch protein lacking the transmembrane domain is translocated to the nucleus, raising the possibility that Notch may participate directly in nuclear events.	YALE UNIV,DEPT BIOL,NEW HAVEN,CT 06536; YALE UNIV,HOWARD HUGHES MED INST,NEW HAVEN,CT 06536	Yale University; Howard Hughes Medical Institute; Yale University	FORTINI, ME (corresponding author), YALE UNIV,DEPT CELL BIOL,NEW HAVEN,CT 06536, USA.							ARTAVANISTSAKONAS S, 1991, TRENDS GENET, V7, P403, DOI 10.1016/0168-9525(91)90264-Q; BIER E, 1988, SCIENCE, V240, P913, DOI 10.1126/science.3129785; BOWTELL DDL, 1989, P NATL ACAD SCI USA, V86, P6245, DOI 10.1073/pnas.86.16.6245; CARTHEW RW, 1990, CELL, V63, P561, DOI 10.1016/0092-8674(90)90452-K; COFFMAN C, 1990, SCIENCE, V249, P1438, DOI 10.1126/science.2402639; COFFMAN CR, 1993, CELL, V73, P659, DOI 10.1016/0092-8674(93)90247-N; DELAMO FF, 1992, DEVELOPMENT, V115, P737; DELIDAKIS C, 1991, GENETICS, V129, P803; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; FEHON RG, 1991, J CELL BIOL, V113, P657, DOI 10.1083/jcb.113.3.657; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; FORTINI ME, 1990, GENE DEV, V4, P444, DOI 10.1101/gad.4.3.444; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; HEBERLEIN U, 1991, DEVELOPMENT, V112, P703; HEITZLER P, 1991, CELL, V64, P1083, DOI 10.1016/0092-8674(91)90263-X; JHAPPAN C, 1992, GENE DEV, V6, P345, DOI 10.1101/gad.6.3.345; KIDD S, 1986, MOL CELL BIOL, V6, P3094, DOI 10.1128/MCB.6.9.3094; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; REBAY I, 1993, CELL, V74, P319, DOI 10.1016/0092-8674(93)90423-N; REINKE R, 1988, CELL, V55, P321, DOI 10.1016/0092-8674(88)90055-4; ROBBINS J, 1992, J VIROL, V66, P2594, DOI 10.1128/JVI.66.4.2594-2599.1992; ROBINOW S, 1991, J NEUROBIOL, V22, P443, DOI 10.1002/neu.480220503; RUBIN GM, 1991, TRENDS GENET, V7, P372, DOI 10.1016/0168-9525(91)90258-R; SMOLLER D, 1990, GENE DEV, V4, P1688, DOI 10.1101/gad.4.10.1688; STIFANI S, 1992, NAT GENET, V2, P119, DOI 10.1038/ng1092-119; TOMLINSON A, 1987, CELL, V51, P143, DOI 10.1016/0092-8674(87)90019-5; TOMLINSON A, 1987, DEV BIOL, V123, P264, DOI 10.1016/0012-1606(87)90448-9; WEINMASTER G, 1991, DEVELOPMENT, V113, P199; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6	30	276	285	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 7	1993	365	6446					555	557		10.1038/365555a0	http://dx.doi.org/10.1038/365555a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MA661	8413612				2022-12-24	WOS:A1993MA66100057
J	BURNOL, AF; MARGOTTIN, F; HUET, J; ALMOUZNI, G; PRIOLEAU, MN; MECHALI, M; SENTENAC, A				BURNOL, AF; MARGOTTIN, F; HUET, J; ALMOUZNI, G; PRIOLEAU, MN; MECHALI, M; SENTENAC, A			TFIIIC RELIEVES REPRESSION OF U6 SNRNA TRANSCRIPTION BY CHROMATIN	NATURE			English	Article							RNA POLYMERASE-C; SACCHAROMYCES-CEREVISIAE; YEAST; DNA; GENE; INVITRO	THE U6 small nuclear (sn)RNA gene (SNR6) from the yeast Saccharomyces cerevisiae is transcribed by RNA polymerase III in vivo1. This gene is unusual in having a TATA box at position -30, and an essential B-block element located downstream of the T-rich termination signal2,3. The B block is one of the two intragenic promoter elements of transfer RNA genes that are recognized by transcription factor (TF)IIIC (ref. 4). But accurate in vitro transcription of yeast U6 snRNA gene by PolIII in a purified system requires only TFIIIB components, including the TATA-box binding protein TBP5. Here we report that, after nucleosome reconstitution or chromatin assembly, U6 snRNA synthesis becomes dependent on TFIIIC and on the integrity of the B-block element. This observation resolves an apparent paradox between in vitro and in vivo results concerning the necessity of the downstream B-block element3,5 and sheds light on a new role of TFIIIC in gene activation.	INST JACQUES MONOD,EMBRYOL MOLEC LAB,F-75251 PARIS,FRANCE	UDICE-French Research Universities; Universite Paris Cite	BURNOL, AF (corresponding author), CTR ETUD SACLAY,DEPT BIOL CELLULAIRE & MOLEC,SERV BIOCHIM & GENET MOLEC,F-91191 GIF SUR YVETTE,FRANCE.		Burnol, Anne-Francoise/P-2181-2017; Margottin-Goguet, Florence/F-9272-2013; Almouzni, Genevieve/ABG-1029-2021; , prioleau/S-6007-2019; Prioleau, Marie-Noelle/G-9824-2014	Margottin-Goguet, Florence/0000-0002-3124-6690; Almouzni, Genevieve/0000-0001-5570-0723; , prioleau/0000-0003-2585-4005; 				ALMOUZNI G, 1988, EMBO J, V7, P4355, DOI 10.1002/j.1460-2075.1988.tb03334.x; BORDONNE R, 1992, NUCLEIC ACIDS RES, V20, P479, DOI 10.1093/nar/20.3.479; BROW DA, 1988, NATURE, V334, P213, DOI 10.1038/334213a0; BROW DA, 1990, GENE DEV, V4, P1345, DOI 10.1101/gad.4.8.1345; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; GABRIELSEN OS, 1989, J BIOL CHEM, V264, P7505; GABRIELSEN OS, 1991, TRENDS BIOCHEM SCI, V16, P412, DOI 10.1016/0968-0004(91)90166-S; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; HUET J, 1992, NUCLEIC ACIDS RES, V20, P6451, DOI 10.1093/nar/20.24.6451; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; LASKEY RA, 1977, CELL, V10, P237, DOI 10.1016/0092-8674(77)90217-3; LASSAR AB, 1983, SCIENCE, V222, P740, DOI 10.1126/science.6356356; LAYBOURN PJ, 1991, SCIENCE, V254, P238, DOI 10.1126/science.1718039; MARGOTTIN F, 1991, SCIENCE, V251, P424, DOI 10.1126/science.1989075; MOENNE A, 1990, EMBO J, V9, P271, DOI 10.1002/j.1460-2075.1990.tb08105.x; MORSE RH, 1992, MOL CELL BIOL, V12, P4015, DOI 10.1128/MCB.12.9.4015; RIGGS DL, 1990, J BIOL CHEM, V265, P7596; STEIN A, 1979, J MOL BIOL, V130, P103, DOI 10.1016/0022-2836(79)90421-2; WOLFFE AP, 1991, CURR BIOL, V6, P366; ZIVANOVIC Y, 1990, J MOL BIOL, V214, P479, DOI 10.1016/0022-2836(90)90195-R	20	93	94	1	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 1	1993	362	6419					475	477		10.1038/362475a0	http://dx.doi.org/10.1038/362475a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KV424	8464480				2022-12-24	WOS:A1993KV42400092
J	LI, XX; FRANCESCHI, VR; OKITA, TW				LI, XX; FRANCESCHI, VR; OKITA, TW			SEGREGATION OF STORAGE PROTEIN MESSENGER-RNAS ON THE ROUGH ENDOPLASMIC-RETICULUM MEMBRANES OF RICE ENDOSPERM CELLS	CELL			English	Article							INSITU HYBRIDIZATION; MAIZE ENDOSPERM; LOCALIZATION; TRANSCRIPTS; EXPRESSION; PROLAMIN; ZEIN	Developing rice endosperm cells display two distinct rough endoplasmic reticula (ER), cisternal ER (C-ER) and protein body ER (PB-ER), the latter delimiting the prolamine protein bodies. These ER membranes are utilized for the simultaneous synthesis of glutelin and prolamine storage proteins, which are subsequently routed into separate protein bodies. We demonstrate by blot hybridization, and by visualization of the spatial distributions and densities of these transcripts in endosperm cells via high resolution in situ hybridization analysis, that prolamine transcripts are associated primarily with the PB-ER, while glutelin mRNAs are enriched on the C-ER. The results suggest that the initial targeting process of these storage proteins into distinct protein bodies is the segregation of their transcripts on the ER membranes.	WASHINGTON STATE UNIV,DEPT BOT,PULLMAN,WA 99164; WASHINGTON STATE UNIV,INST BIOL CHEM,PULLMAN,WA 99164	Washington State University; Washington State University	LI, XX (corresponding author), WASHINGTON STATE UNIV,DEPT GENET & CELL BIOL,PULLMAN,WA 99164, USA.			Okita, Tom/0000-0002-2246-0599				ABE S, 1991, PROTOPLASMA, V165, P139, DOI 10.1007/BF01322284; BINDER M, 1986, J CELL BIOL, V102, P1646, DOI 10.1083/jcb.102.5.1646; BONNEAU AM, 1985, J CELL BIOL, V100, P1209, DOI 10.1083/jcb.100.4.1209; CAMPOS N, 1989, NUCLEIC ACIDS RES, V17, P1573, DOI 10.1093/nar/17.4.1573; CHRISPEELS MJ, 1991, ANNU REV PLANT PHYS, V42, P21, DOI 10.1146/annurev.pp.42.060191.000321; DAVIS I, 1991, CELL, V67, P927, DOI 10.1016/0092-8674(91)90366-7; Fawcett D.W., 1981, CELL; Juliano B. O., 1972, RICE CHEM TECHNOLOGY, P16; KIM WT, 1988, PLANT PHYSIOL, V88, P649, DOI 10.1104/pp.88.3.649; KRISHNAN HB, 1986, PLANT PHYSIOL, V81, P748, DOI 10.1104/pp.81.3.748; KRISHNAN HB, 1986, PLANTA, V169, P471, DOI 10.1007/BF00392095; LARKINS BA, 1978, PLANT PHYSIOL, V62, P256, DOI 10.1104/pp.62.2.256; LAWRENCE JB, 1986, CELL, V45, P407, DOI 10.1016/0092-8674(86)90326-0; LI XX, 1990, EUR J CELL BIOL, V51, P9; Maniatis T., 1982, MOL CLONING; MASUMURA T, 1990, MOL GEN GENET, V221, P1, DOI 10.1007/BF00280360; MOWRY KL, 1992, SCIENCE, V255, P991, DOI 10.1126/science.1546297; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; OKITA TW, 1989, J BIOL CHEM, V264, P12573; ORNELLES DA, 1986, MOL CELL BIOL, V6, P1650, DOI 10.1128/MCB.6.5.1650; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; SHATTERS RG, 1991, BIOCHIM BIOPHYS ACTA, V1068, P179, DOI 10.1016/0005-2736(91)90208-P; SHORE GC, 1977, J CELL BIOL, V72, P726, DOI 10.1083/jcb.72.3.726; SHORE GC, 1977, BIOCHIM BIOPHYS ACTA, V472, P197, DOI 10.1016/0304-4157(77)90017-X; SINGER RH, 1989, J CELL BIOL, V108, P2343, DOI 10.1083/jcb.108.6.2343; WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cellbio.2.1.499; YAMAGATA H, 1986, PLANT CELL PHYSIOL, V27, P135; YAMAGATA H, 1986, PLANT CELL PHYSIOL, V27, P1419, DOI 10.1093/oxfordjournals.pcp.a077240; [No title captured]; [No title captured]; [No title captured]	32	122	133	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 26	1993	72	6					869	879		10.1016/0092-8674(93)90576-C	http://dx.doi.org/10.1016/0092-8674(93)90576-C			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KU175	8458081				2022-12-24	WOS:A1993KU17500008
J	CAVARELLI, J; REES, B; RUFF, M; THIERRY, JC; MORAS, D				CAVARELLI, J; REES, B; RUFF, M; THIERRY, JC; MORAS, D			YEAST TRANSFER RNA(ASP) RECOGNITION BY ITS COGNATE CLASS-II AMINOACYL-TRANSFER RNA-SYNTHETASE	NATURE			English	Article							ASPARAGINYL-TRANSFER-RNA; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; CRYSTALLOGRAPHIC REFINEMENT; 2.8-A RESOLUTION; SEQUENCE; IDENTITY; HOMOLOGIES; ATP	AMINOACYL-RNA synthetases can be divided into two classes according to structural features inferred from sequence alignments1-3. This classification correlates almost perfectly with the attachment of the amino acid to the 2'-OH (class I) or 3'-OH (class II) group of the terminal adenosine4-6. Six subgroups of higher homology can be inferred from sequence analysis7,8. The five aminoacyl-tRNA synthetases whose crystal structures are known (MetRS, TyrRS and GlnRS in class I, SerRS and AspRS in class II)9-13 belong to different subgroups. Two of them, GluRS and AspRS, have been cocrystallized with their cognate tRNA11,13. AspRS, like six other members of class II, is an alpha2 dimer. Yeast tRNA(Asp) exhibits five identity determinants: the three anticodon bases, the discriminator base G73 and the base pair G10-U25(14). We report here that the refined crystal structure of AspRS complexed with TRNA(Asp) at 2.9 angstrom resolution reveals three regions of contact, each involving a domain of AspRS and at least one identity determinant of tRNA(Asp). The mode of binding of the acceptor stem of tRNA(Asp) by AspRS can be generalized to class II aminoacyl-tRNA synthetases, whereas the deciphering of the anticodon, which involves a large conformational change of the loop and the formation of a bulge, is more specific to the aspartic system.	IBMC,BIOL STRUCT LAB,STRASBOURG,FRANCE				ruff, marc/J-3011-2013; Cavarelli, Jean/P-3566-2016	ruff, marc/0000-0001-5451-6377; Cavarelli, Jean/0000-0001-8620-8723				ANSELME J, 1989, GENE, V84, P481, DOI 10.1016/0378-1119(89)90524-6; BRICK P, 1989, J MOL BIOL, V208, P83, DOI 10.1016/0022-2836(89)90090-9; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; BRUNIE S, 1990, J MOL BIOL, V216, P411, DOI 10.1016/S0022-2836(05)80331-6; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CUSACK S, 1991, NUCLEIC ACIDS RES, V19, P3489, DOI 10.1093/nar/19.13.3489; CUSACK S, 1990, NATURE, V347, P249, DOI 10.1038/347249a0; ERIANI G, 1990, NUCLEIC ACIDS RES, V18, P7109, DOI 10.1093/nar/18.23.7109; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; ERIANI G, 1991, EUR J BIOCHEM, V200, P337, DOI 10.1111/j.1432-1033.1991.tb16190.x; FRASER TH, 1975, P NATL ACAD SCI USA, V72, P3044, DOI 10.1073/pnas.72.8.3044; GARCIA A, 1992, BIOCHEM BIOPH RES CO, V186, P956, DOI 10.1016/0006-291X(92)90839-D; HECHT SM, 1979, TRANSFER RNA STRUCTU, P345; HOU YM, 1988, NATURE, V333, P140, DOI 10.1038/333140a0; HOUNTONDJI C, 1986, BIOCHIMIE, V68, P1071, DOI 10.1016/S0300-9084(86)80181-X; HYNES TR, 1991, PROTEINS, V10, P92, DOI 10.1002/prot.340100203; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEVEQUE F, 1990, NUCLEIC ACIDS RES, V18, P305, DOI 10.1093/nar/18.2.305; MCCLAIN WH, 1988, SCIENCE, V241, P1804, DOI 10.1126/science.2459773; MORAS D, 1980, NATURE, V288, P669, DOI 10.1038/288669a0; MORAS D, 1992, TRENDS BIOCHEM SCI, V17, P159, DOI 10.1016/0968-0004(92)90326-5; PUTZ J, 1991, SCIENCE, V252, P1696, DOI 10.1126/science.2047878; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; SIXMA TK, 1992, NATURE, V355, P561, DOI 10.1038/355561a0; STEIN PE, 1992, NATURE, V355, P748, DOI 10.1038/355748a0; von der Haar F, 1976, Biochemistry, V15, P4131, DOI 10.1021/bi00663a034; WEBSTER T, 1984, SCIENCE, V226, P1315, DOI 10.1126/science.6390679; WESTHOF E, 1985, J MOL BIOL, V184, P119, DOI 10.1016/0022-2836(85)90048-8	29	274	276	1	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 11	1993	362	6416					181	184		10.1038/362181a0	http://dx.doi.org/10.1038/362181a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KR028	8450889				2022-12-24	WOS:A1993KR02800067
J	SPECTOR, TD; HALL, GM; MCCLOSKEY, EV; KANIS, JA				SPECTOR, TD; HALL, GM; MCCLOSKEY, EV; KANIS, JA			RISK OF VERTEBRAL FRACTURE IN WOMEN WITH RHEUMATOID-ARTHRITIS	BRITISH MEDICAL JOURNAL			English	Article									ST BARTHOLOMEWS HOSP,DEPT RHEUMATOL,LONDON EC1M 6BQ,ENGLAND; UNIV SHEFFIELD,SCH MED,DEPT HUMAN METAB & CLIN BIOCHEM,SHEFFIELD S10 2RX,S YORKSHIRE,ENGLAND	University of London; Queen Mary University London; University of Sheffield	SPECTOR, TD (corresponding author), ST THOMAS HOSP,DEPT RHEUMATOL,LONDON SE1 7EH,ENGLAND.		Spector, Tim D/F-6533-2012; McCloskey, Eugene/T-5197-2019; McCloskey, Eugene V/D-1065-2011	McCloskey, Eugene V/0000-0003-0177-8140	Arthritis Research UK [17489] Funding Source: Medline	Arthritis Research UK(Versus Arthritis)		COOPER C, 1990, OSTEOPOROSIS 1990, P1578; HOOYMAN JR, 1984, ARTHRITIS RHEUM-US, V27, P1353, DOI 10.1002/art.1780271205; LAAN FJM, 1992, ANN RHEUM DIS, V51, P826; MCCLOSKEY EV, IN PRESS OSTEROPOROS; RALSTON SH, 1990, BMJ-BRIT MED J, V300, P563, DOI 10.1136/bmj.300.6724.563	5	191	198	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 27	1993	306	6877					558	558		10.1136/bmj.306.6877.558	http://dx.doi.org/10.1136/bmj.306.6877.558			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP886	8461772	Bronze, Green Published			2022-12-24	WOS:A1993KP88600024
J	CARTER, KC; BOWMAN, D; CARRINGTON, W; FOGARTY, K; MCNEIL, JA; FAY, FS; LAWRENCE, JB				CARTER, KC; BOWMAN, D; CARRINGTON, W; FOGARTY, K; MCNEIL, JA; FAY, FS; LAWRENCE, JB			A 3-DIMENSIONAL VIEW OF PRECURSOR MESSENGER-RNA METABOLISM WITHIN THE MAMMALIAN NUCLEUS	SCIENCE			English	Article							INSITU HYBRIDIZATION; INTERPHASE NUCLEI; LOCALIZATION; RIBONUCLEOPROTEINS; ORGANIZATION; COMPONENTS; TRANSCRIPTION; SEQUENCES; ANTIGENS; REGIONS	A quantitative three-dimensional analysis of nuclear components involved in precursor messenger RNA metabolism was performed with a combination of fluorescence hybridization, immunofluorescence, and digital imaging microscopy. Polyadenylate [poly(A)] RNA-rich transcript domains were discrete, internal nuclear regions that formed a ventrally positioned horizontal array in monolayer cells. A dimmer, sometimes strand-like, poly(A) RNA signal was dispersed throughout the nucleoplasm. Spliceosome assembly factor SC-35 localized within the center of individual domains. These data support a nuclear model in which there is a specific topological arrangement of noncontiguous centers involved in precursor messenger RNA metabolism, from which RNA transport toward the nuclear envelope radiates.	UNIV MASSACHUSETTS, MED CTR, DEPT CELL BIOL, 55 LAKE AVE N, WORCESTER, MA 01655 USA; UNIV MASSACHUSETTS, MED CTR, DEPT PHYSIOL, WORCESTER, MA 01655 USA; UNIV MASSACHUSETTS, MED CTR, BIOMED IMAGING GRP, WORCESTER, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester				Lawrence, Jeanne/0000-0001-6572-3128	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [F32HG000026, K04HG000002, R01HG000251] Funding Source: NIH RePORTER; NHGRI NIH HHS [2RO1HG00251, 5K04HG00002, 1F32HG00026] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		BERMAN SA, 1990, SCIENCE, V247, P212, DOI 10.1126/science.1688472; Beyer A L, 1991, Semin Cell Biol, V2, P131; BEYER AL, 1981, CELL, V26, P155, DOI 10.1016/0092-8674(81)90299-3; BLOBEL G, 1985, P NATL ACAD SCI USA, V82, P8527, DOI 10.1073/pnas.82.24.8527; BRAKENHOFF GJ, 1989, J MICROSC-OXFORD, V153, P151, DOI 10.1111/j.1365-2818.1989.tb00555.x; CARMOFONSECA M, 1991, EMBO J, V10, P1863, DOI 10.1002/j.1460-2075.1991.tb07712.x; CARMOFONSECA M, 1991, EMBO J, V10, P195, DOI 10.1002/j.1460-2075.1991.tb07936.x; CARMOFONSECA M, 1992, J CELL BIOL, V117, P1, DOI 10.1083/jcb.117.1.1; CARRINGTON WA, 1990, P SOC PHOTO-OPT INS, V1205, P72, DOI 10.1117/12.17785; CARRINGTON WA, 1990, NONINVASIVE TECHNIQU, P53; CARTER KC, 1991, J CELL BIOL, V115, P1191, DOI 10.1083/jcb.115.5.1191; CARTER KC, UNPUB; COLEMAN J, UNPUB; ELLIOTT DJ, 1992, EMBO J, V11, P3731, DOI 10.1002/j.1460-2075.1992.tb05458.x; FAKAN S, 1986, J CELL BIOL, V103, P1153, DOI 10.1083/jcb.103.4.1153; Fakan S, 1980, Int Rev Cytol, V65, P255; FAKAN S, 1984, J CELL BIOL, V98, P358, DOI 10.1083/jcb.98.1.358; FAWCETT MD, 1981, CELL; FEY E G, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P127; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; GALL JG, 1989, P NATL ACAD SCI USA, V86, P6635, DOI 10.1073/pnas.86.17.6635; GALL JG, 1991, SCIENCE, V252, P1499, DOI 10.1126/science.1828621; HUANG S, 1992, P NATL ACAD SCI USA, V89, P305, DOI 10.1073/pnas.89.1.305; HUTCHISON N, 1985, CELL, V43, P471, DOI 10.1016/0092-8674(85)90177-1; JACKSON DA, 1991, BIOESSAYS, V13, P1, DOI 10.1002/bies.950130102; JOHNSON CV, 1991, METHOD CELL BIOL, V35, P73; KRYSTOSEK A, 1990, P NATL ACAD SCI USA, V87, P6560, DOI 10.1073/pnas.87.17.6560; LAWRENCE JB, 1988, CELL, V52, P51; LAWRENCE JB, 1989, CELL, V57, P493, DOI 10.1016/0092-8674(89)90924-0; LEWIN B, 1975, CELL, V4, P11, DOI 10.1016/0092-8674(75)90128-2; Maquat LE, 1991, CURR OPIN CELL BIOL, V3, P1004, DOI 10.1016/0955-0674(91)90121-E; NELSON WG, 1986, ANNU REV BIOPHYS BIO, V15, P457, DOI 10.1146/annurev.bb.15.060186.002325; NEVINS JR, 1983, ANNU REV BIOCHEM, V52, P441, DOI 10.1146/annurev.bi.52.070183.002301; Northway J.D., 1972, CLIN IMMUNOL IMMUNOP, V1, P140, DOI [10.1016/0090-1229(72)90013-X, DOI 10.1016/0090-1229(72)90013-X]; NYMAN U, 1986, J CELL BIOL, V102, P137, DOI 10.1083/jcb.102.1.137; PETTERSSON I, 1984, J BIOL CHEM, V259, P5907; PUCKETT L, 1977, J CELL PHYSIOL, V90, P521, DOI 10.1002/jcp.1040900315; RASKA I, 1991, EXP CELL RES, V195, P27, DOI 10.1016/0014-4827(91)90496-H; SCHEER U, 1990, BIOESSAYS, V12, P14, DOI 10.1002/bies.950120104; SINGER RH, 1986, BIOTECHNIQUES, V4, P230; SMALE ST, 1985, MOL CELL BIOL, V5, P352, DOI 10.1128/MCB.5.2.352; SPECTOR DL, 1983, BIOL CELL, V49, P1; SPECTOR DL, 1991, EMBO J, V10, P3467, DOI 10.1002/j.1460-2075.1991.tb04911.x; SPECTOR DL, 1990, P NATL ACAD SCI USA, V87, P147, DOI 10.1073/pnas.87.1.147; SPECTOR DL, 1992, MOL BIOL CELL, V3, P555, DOI 10.1091/mbc.3.5.555; WANG J, 1991, P NATL ACAD SCI USA, V88, P7391, DOI 10.1073/pnas.88.16.7391; XING YG, 1993, SCIENCE, V259, P1326, DOI 10.1126/science.8446901; XING YG, 1991, J CELL BIOL, V112, P1055, DOI 10.1083/jcb.112.6.1055; [No title captured]	49	296	301	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 26	1993	259	5099					1330	1335		10.1126/science.8446902	http://dx.doi.org/10.1126/science.8446902			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KN883	8446902				2022-12-24	WOS:A1993KN88300033
J	TAGLE, DA; SWAROOP, M; LOVETT, M; COLLINS, FS				TAGLE, DA; SWAROOP, M; LOVETT, M; COLLINS, FS			MAGNETIC BEAD CAPTURE OF EXPRESSED SEQUENCES ENCODED WITHIN LARGE GENOMIC SEGMENTS	NATURE			English	Article							TRANSCRIBED SEQUENCES; SELECTION; GENE; DNA		UNIV MICHIGAN,MED CTR,DEPT INTERNAL MED,ANN ARBOR,MI 48109; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235	University of Michigan System; University of Michigan; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	TAGLE, DA (corresponding author), UNIV MICHIGAN,MED CTR,DEPT HUMAN GENET,ANN ARBOR,MI 48109, USA.			Swaroop, Manju/0000-0002-0576-1664				ADAMS MD, 1992, SCIENCE, V355, P632; BATES GP, 1991, AM J HUM GENET, V49, P7; BATES GP, 1992, NAT GENET, V1, P180, DOI 10.1038/ng0692-180; Britten R., 1985, NUCLEIC ACID HYBRIDI, P3; Britten R J, 1974, Methods Enzymol, V29, P363; BUCKLER AJ, 1991, P NATL ACAD SCI USA, V88, P4005, DOI 10.1073/pnas.88.9.4005; COLLINS FS, 1992, NAT GENET, V1, P3, DOI 10.1038/ng0492-3; CORBO L, 1990, SCIENCE, V249, P652, DOI 10.1126/science.2382140; DUYK GM, 1990, P NATL ACAD SCI USA, V87, P8995, DOI 10.1073/pnas.87.22.8995; ELVIN P, 1990, NUCLEIC ACIDS RES, V18, P3913, DOI 10.1093/nar/18.13.3913; HAUKANES BI, 1993, BIO-TECHNOL, V11, P60, DOI 10.1038/nbt0193-60; Korn Bernhard, 1992, Human Molecular Genetics, V1, P235, DOI 10.1093/hmg/1.4.235; LIU P, 1989, SCIENCE, V246, P813, DOI 10.1126/science.2479099; LOVETT M, 1991, P NATL ACAD SCI USA, V88, P9628, DOI 10.1073/pnas.88.21.9628; MORGAN JG, 1992, NUCLEIC ACIDS RES, V20, P5173, DOI 10.1093/nar/20.19.5173; PARIMOO S, 1991, P NATL ACAD SCI USA, V88, P9623, DOI 10.1073/pnas.88.21.9623; SNELL RG, IN PRESS HUM MOL GEN; Tagle D. A., 1992, American Journal of Human Genetics, V51, pA22; TAYLOR SAM, 1992, NAT GENET, V2, P223, DOI 10.1038/ng1192-223; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; YOUNG BD, 1985, NUCLEIC ACID HYBRIDI, P47	21	84	95	1	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 25	1993	361	6414					751	753		10.1038/361751a0	http://dx.doi.org/10.1038/361751a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KN789	8441473	Green Published			2022-12-24	WOS:A1993KN78900065
J	HARTLEY, SB; COOKE, MP; FULCHER, DA; HARRIS, AW; CORY, S; BASTEN, A; GOODNOW, CC				HARTLEY, SB; COOKE, MP; FULCHER, DA; HARRIS, AW; CORY, S; BASTEN, A; GOODNOW, CC			ELIMINATION OF SELF-REACTIVE LYMPHOCYTES-B PROCEEDS IN 2 STAGES - ARRESTED DEVELOPMENT AND CELL-DEATH	CELL			English	Article							COMPLEMENT RECEPTOR TYPE-2; IMMUNOGLOBULIN MU-CHAIN; MOUSE BONE-MARROW; TRANSGENIC MICE; CLONAL DELETION; ANTIBODY-RESPONSES; T-CELLS; EXPRESSION; TOLERANCE; DIFFERENTIATION	In transgenic mice, self-reactive B lymphocytes are eliminated if they encounter membrane-bound self antigens during their development within the bone marrow. We show here that two separate and sequential events, arrested development and cell death, bring about B cell elimination. Developmental arrest is an early outcome of antigen binding in immature B cells, blocks acquisition of adhesion molecules and receptors important for B cell migration and activation, and is rapidly reversible by removal of antigen. Death of the arrested B cells occurs within 1 to 3 days and can be delayed by expression of a bcl-2 transgene, which results in escape of large numbers of self-reactive B cells from the bone marrow but fails to override the developmental arrest. These findings define a novel pathway for B cell elimination, involving an initial stage vulnerable to breakdown in autoimmune disease.	STANFORD UNIV, MED CTR,SCH MED,DEPT MICROBIOL & IMMUNOL, BECKMAN CTR, STANFORD, CA 94305 USA; UNIV SYDNEY, CENTENARY INST CANC MED & CELL BIOL, SYDNEY, NSW 2006, AUSTRALIA; ROYAL MELBOURNE HOSP, WALTER & ELIZA HALL INST MED RES, PARKVILLE, VIC 3050, AUSTRALIA	Stanford University; University of Sydney; Centenary Institute; Royal Melbourne Hospital; Walter & Eliza Hall Institute	HARTLEY, SB (corresponding author), STANFORD UNIV, MED CTR, SCH MED, HOWARD HUGHES MED INST, STANFORD, CA 94305 USA.		Goodnow, Christopher C/V-8108-2018; Cory, Suzanne/E-1642-2013	Goodnow, Christopher C/0000-0001-5296-6155; Cory, Suzanne/0000-0002-6818-3451	NCI NIH HHS [CA 43540] Funding Source: Medline; NIAID NIH HHS [AI-19512] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043540] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI019512] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHEARN JM, 1989, ADV IMMUNOL, V46, P183, DOI 10.1016/S0065-2776(08)60654-9; AUBRY JP, 1992, NATURE, V358, P505, DOI 10.1038/358505a0; BLACKMAN M, 1990, SCIENCE, V248, P1335, DOI 10.1126/science.1972592; BLATTNER FR, 1984, NATURE, V307, P417, DOI 10.1038/307417a0; BROMBACHER F, 1991, J EXP MED, V174, P1335, DOI 10.1084/jem.174.6.1335; CARTER RH, 1988, J IMMUNOL, V141, P457; CHEN SZ, 1990, BIOTECHNIQUES, V8, P32; CLARK EA, 1991, ANNU REV IMMUNOL, V9, P97; Conrad D H, 1991, Monogr Allergy, V29, P9; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; ERA T, 1991, EMBO J, V10, P337, DOI 10.1002/j.1460-2075.1991.tb07954.x; ERIKSON J, 1991, NATURE, V349, P331, DOI 10.1038/349331a0; FORD WL, 1975, PROG ALLERGY, V19, P1, DOI 10.1159/000313381; Forster I, 1989, Int Immunol, V1, P321, DOI 10.1093/intimm/1.4.321; GALLATIN WM, 1983, NATURE, V304, P30, DOI 10.1038/304030a0; GELFAND MC, 1974, J EXP MED, V139, P1125, DOI 10.1084/jem.139.5.1125; GLEICHMANN E, 1982, EUR J IMMUNOL, V12, P152, DOI 10.1002/eji.1830120210; GOODNOW CC, 1992, ANNU REV IMMUNOL, V10, P489, DOI 10.1146/annurev.iy.10.040192.002421; GOODNOW CC, 1989, NATURE, V342, P385, DOI 10.1038/342385a0; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; Gordon J, 1991, Monogr Allergy, V29, P156; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HARTLEY SB, 1991, NATURE, V353, P765, DOI 10.1038/353765a0; HEBELL T, 1991, SCIENCE, V254, P102, DOI 10.1126/science.1718035; KINOSHITA T, 1990, INT IMMUNOL, V2, P651, DOI 10.1093/intimm/2.7.651; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; KORSMEYER SJ, 1992, ANNU REV IMMUNOL, V10, P785, DOI 10.1146/annurev.immunol.10.1.785; LASKY LA, 1991, J CELL BIOCHEM, V45, P139, DOI 10.1002/jcb.240450204; Lawton A R 3rd, 1974, Contemp Top Immunobiol, V3, P193; MacLennan I C, 1989, Curr Top Pathol, V79, P37; MASON DY, 1992, INT IMMUNOL, V4, P163, DOI 10.1093/intimm/4.2.163; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; MURAKAMI M, 1992, NATURE, V357, P77, DOI 10.1038/357077a0; NEMAZEE D, 1989, P NATL ACAD SCI USA, V86, P8039, DOI 10.1073/pnas.86.20.8039; NEMAZEE DA, 1989, NATURE, V337, P562, DOI 10.1038/337562a0; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OKAMOTO M, 1992, J EXP MED, V175, P71, DOI 10.1084/jem.175.1.71; OSMOND DG, 1974, CELL IMMUNOL, V13, P132, DOI 10.1016/0008-8749(74)90233-0; PARKS DR, 1986, HDB EXPT IMMUNOLOGY, V1; PEPYS MB, 1974, J EXP MED, V140, P126, DOI 10.1084/jem.140.1.126; PICKER LJ, 1992, ANN REV IMMUNOL, V10; PLAYFAIR JH, 1973, NATURE-NEW BIOL, V243, P213, DOI 10.1038/newbio243213a0; RAJEWSKY K, 1992, CURR OPIN IMMUNOL, V4, P171, DOI 10.1016/0952-7915(92)90008-3; SCHWARTZ RH, 1989, CELL, V57, P1073, DOI 10.1016/0092-8674(89)90044-5; SHEN FW, 1981, MONOCLONAL ANTIBODIE, P25; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; SPRENT J, 1973, CELL IMMUNOL, V7, P40, DOI 10.1016/0008-8749(73)90181-0; SPRINGER T, 1978, EUR J IMMUNOL, V8, P539, DOI 10.1002/eji.1830080802; STAMENKOVIC I, 1991, CELL, V66, P1133, DOI 10.1016/0092-8674(91)90036-X; STRASSER A, 1990, CURR TOP MICROBIOL, V166, P175; STRASSER A, 1991, P NATL ACAD SCI USA, V88, P8661, DOI 10.1073/pnas.88.19.8661; SWAT W, 1991, NATURE, V351, P150, DOI 10.1038/351150a0; TIMENS W, 1989, EUR J IMMUNOL, V19, P2163, DOI 10.1002/eji.1830191129; VANKRIEKEN JHJM, 1989, HUM PATHOL, V20, P320, DOI 10.1016/0046-8177(89)90040-3; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WALDSCHMIDT TJ, 1991, INT IMMUNOL, V3, P305, DOI 10.1093/intimm/3.4.305; Weigle W O, 1973, Adv Immunol, V16, P61, DOI 10.1016/S0065-2776(08)60296-5; WIERSMA EJ, 1991, EUR J IMMUNOL, V21, P2501, DOI 10.1002/eji.1830211029; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YELLEN AJ, 1991, J IMMUNOL, V146, P1446	61	458	465	1	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 12	1993	72	3					325	335		10.1016/0092-8674(93)90111-3	http://dx.doi.org/10.1016/0092-8674(93)90111-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KM162	8431943				2022-12-24	WOS:A1993KM16200004
J	CROWLEY, TE; HOEY, T; LIU, JK; JAN, YN; JAN, LY; TJIAN, R				CROWLEY, TE; HOEY, T; LIU, JK; JAN, YN; JAN, LY; TJIAN, R			A NEW FACTOR RELATED TO TATA-BINDING PROTEIN HAS HIGHLY RESTRICTED EXPRESSION PATTERNS IN DROSOPHILA	NATURE			English	Article							RNA POLYMERASE-II; TRANSCRIPTIONAL ACTIVATION; NERVOUS-SYSTEM; INITIATION; COACTIVATORS; EMBRYOS	THE TATA-binding protein TBP is necessary for the transcription of eukaryotic genes. Multi-protein complexes formed by TBP and different TBP-associated factors are involved in the initiation of transcription by polymerases I and II, and probably ill as well1. During the formation of an active initiation complex, TBP makes specific contacts with other proteins, for example TFIIB and RNA polymerase II (refs 2-4). Here we describe the cloning and characterization of a Drosophila gene product with considerable sequence similarity to TBP and a highly restricted expression pattern in the embryo. This TBP-related factor is a DNA-binding protein but is not likely to be a basal transcription factor. Our results suggest that TBP-related factor is a sequence-specific transcription factor that shares the DNA-binding properties of TBP.	UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,BERKELEY,CA 94720; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143; UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of California System; University of California San Francisco; University of California System; University of California Berkeley				Jan, Yuh Nung/0000-0003-1367-6299; Jan, Lily/0000-0003-3938-8498				BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BIER E, 1990, GENE DEV, V4, P190, DOI 10.1101/gad.4.2.190; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; Gill Grace, 1992, Current Biology, V2, P565, DOI 10.1016/0960-9822(92)90046-D; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HORIKOSHI M, 1990, CELL, V61, P1171, DOI 10.1016/0092-8674(90)90681-4; HU SL, 1981, P NATL ACAD SCI-BIOL, V78, P820, DOI 10.1073/pnas.78.2.820; JACOBS JR, 1989, NEURON, V2, P1625; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; NASH HA, 1991, CELL, V67, P1037, DOI 10.1016/0092-8674(91)90280-C; PAPAZIAN DM, 1988, ANNU REV PHYSIOL, V50, P379; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REDDY P, 1991, CELL, V65, P349, DOI 10.1016/0092-8674(91)90168-X; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SCHULTZ MC, 1992, CELL, V69, P697, DOI 10.1016/0092-8674(92)90233-3; SINK H, 1991, DEVELOPMENT, V112, P307; STRUBIN M, 1992, CELL, V68, P721, DOI 10.1016/0092-8674(92)90147-5; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; WAMPLER SL, 1990, J BIOL CHEM, V265, P21223	26	104	106	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 11	1993	361	6412					557	561		10.1038/361557a0	http://dx.doi.org/10.1038/361557a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL714	8429912				2022-12-24	WOS:A1993KL71400068
J	QIAN, Z; GILBERT, ME; COLICOS, MA; KANDEL, ER; KUHL, D				QIAN, Z; GILBERT, ME; COLICOS, MA; KANDEL, ER; KUHL, D			TISSUE-PLASMINOGEN ACTIVATOR IS INDUCED AS AN IMMEDIATE EARLY GENE DURING SEIZURE, KINDLING AND LONG-TERM POTENTIATION	NATURE			English	Article							NERVE GROWTH-FACTOR; NEURITE OUTGROWTH; MESSENGER-RNA; EXPRESSION; HIPPOCAMPUS; RECEPTOR; PROTEIN; MEMORY; CELLS; RAT	THE requirement of protein and messenger RNA synthesis for long-term memory1,2 suggests that neural activity induced by learning initiates a cascade of gene expression3. Here we use differential screening to identify five immediate-early genes induced by neuronal activity. One of these is tissue-plasminogen activator (tPA), an extracellular serine protease, which is induced with different spatial patterns in the brain by three activity-dependent events: (1) convulsive seizure increases expression of tPA in the whole brain; (2) stimulation of the perforant path produces an epileptiform after-discharge that ultimately leads to kindling increases the levels of tPA throughout the hippocampus bilaterally; and (3) brief high-frequency stimulation of the perforant path that produces long-term potentiation (LTP) causes an NMDA (N-methyl-D-aspartate) receptor-mediated increase in the levels of tPA mRNA which is restricted to the granule cells of the ipsilateral dentate gyrus. As release of tPA is correlated with morphological differentiation4-6, the increased expression of tPA may play a role in the structural changes that accompany activity-dependent plasticity7-10.	COLUMBIA UNIV COLL PHYS & SURG,HOWARD HUGHES MED INST,NEW YORK,NY 10032; MANTECH ENVIRONM TECHNOL INC,RES TRIANGLE PK,NC 27709	Columbia University; Howard Hughes Medical Institute	QIAN, Z (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,CTR NEUROBIOL & BEHAV,722 W 168TH ST,NEW YORK,NY 10032, USA.		Kuhl, Dietmar/A-4689-2009	Kuhl, Dietmar/0000-0002-4772-6701				ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; BENARI Y, 1990, TRENDS NEUROSCI, V13, P312, DOI 10.1016/0166-2236(90)90135-W; BRADBURY A, 1991, P NATL ACAD SCI USA, V88, P3353, DOI 10.1073/pnas.88.8.3353; CARNEY DH, 1987, PROTEASES BIOL CONTR, P277; CAVAZOS JE, 1991, J NEUROSCI, V11, P2795; COLE AJ, 1989, NATURE, V340, P474, DOI 10.1038/340474a0; DAVIS HP, 1984, PSYCHOL BULL, V96, P518, DOI 10.1037/0033-2909.96.3.518; DRAGUNOW M, 1987, NATURE, V329, P441, DOI 10.1038/329441a0; FASELI MS, 1990, BRAIN RES, V521, P247; FLETCHER BS, 1991, J BIOL CHEM, V266, P14511; GEINISMAN Y, 1992, BRAIN RES, V569, P342; GERARD RD, 1989, ANNU REV PHYSIOL, V51, P245, DOI 10.1146/annurev.physiol.51.1.245; GILBERT ME, 1990, BRAIN RES, V519, P89, DOI 10.1016/0006-8993(90)90064-I; GOELET P, 1986, NATURE, V322, P419, DOI 10.1038/322419a0; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; HAJJAR KA, 1991, J BIOL CHEM, V266, P21962; KRYSTOSEK A, 1981, SCIENCE, V213, P1532, DOI 10.1126/science.7197054; MCNAMARA JO, 1980, PROG NEUROBIOL, V15, P139, DOI 10.1016/0301-0082(80)90006-4; MONARD D, 1988, TRENDS NEUROSCI, V11, P541, DOI 10.1016/0166-2236(88)90182-8; MONTAROLO PG, 1986, SCIENCE, V234, P1249, DOI 10.1126/science.3775383; MORGAN JI, 1987, SCIENCE, V237, P192, DOI 10.1126/science.3037702; NEUMAN T, 1989, J NEUROSCI RES, V23, P274, DOI 10.1002/jnr.490230305; PITTMAN RN, 1989, J NEUROSCI, V9, P4269; RACINE RJ, 1983, BRAIN RES, V260, P217, DOI 10.1016/0006-8993(83)90676-5; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P269, DOI 10.1016/0013-4694(72)90176-9; Sambrook J., 1989, MOL CLONING LAB MANU; SHAW G, 1986, CELL, V24, P151; WALLACE CS, 1991, LONG TERM POTENTIATI, P189; WISDEN W, 1990, NEURON, V4, P603, DOI 10.1016/0896-6273(90)90118-Y	29	648	662	1	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 4	1993	361	6411					453	457		10.1038/361453a0	http://dx.doi.org/10.1038/361453a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KK713	8429885				2022-12-24	WOS:A1993KK71300062
J	VANDERLINDEN, PWG; STRUYVENBERG, A; KRAAIJENHAGEN, RJ; HACK, CE; VANDERZWAN, JK				VANDERLINDEN, PWG; STRUYVENBERG, A; KRAAIJENHAGEN, RJ; HACK, CE; VANDERZWAN, JK			ANAPHYLACTIC SHOCK AFTER INSECT-STING CHALLENGE IN 138 PERSONS WITH A PREVIOUS INSECT-STING REACTION	ANNALS OF INTERNAL MEDICINE			English	Article						ANAPHYLAXIS; INSECT BITES AND STINGS; HYMENOPTERA; CATECHOLAMINES; ANGIOTENSINS	WASP VENOM; HISTAMINE; ANGIOTENSIN; HYPERSENSITIVITY; MECHANISMS; RESPONSES; PEPTIDES; PLASMA; HEART	Objective: To study the rate and severity of anaphylactic reaction in relation to plasma levels of cardiovascular mediators in persons with a history of insect-sting anaphylactic shock who were rechallenged with a sting by the same insect. Design: A cohort study with measurements before and after intentional sting challenge. Setting: Intensive care unit of an 830-bed general hospital, a national center of insect-sting anaphylaxis in The Netherlands. Patients: A total of 138 patients referred after a previous anaphylactic reaction to a Hymenoptera sting; and 8 volunteers. Measurements: Signs of anaphylaxis and plasma levels of catecholamines and angiotensins. Main Results: Only 39 of 138 (28%) of patients with a previous insect-sting anaphylactic reaction developed anaphylactic symptoms after sting challenge. Values of cardiovascular mediators and mean arterial pressure did not differ after the challenge from initial values in the volunteers or in the patients with a mild or no reaction after challenge. In the 17 patients with anaphylactic shock, mean arterial pressure decreased from 97 +/- 11 (mean t SD) to 65 +/- 17 mm Hg (P < 0.001), epinephrine levels rose from a median of 0.3 nmol/L (range, 0.2 to 2.3 nmol/L) to 2.5 nmol/L (0.2 to 35.7 nmol/L; P < 0.05), norepinephrine from 1.5 nmol/L (0.5 to 6.7) to 5.9 nmol/L (1.6 to 30.9 nmol/L; P < 0.01), and angiotensin 11 from 61 pmol/L (7 to 217 pmol/L) to 105 pmol/L (11 to 286 pmol/L; P < 0.01), all within 5 minutes after the onset of anaphylactic symptoms. The rise of these mediators correlated with the drop in blood pressure (P < 0.001). Dopamine and angiotensin I levels did not change in any participants. Conclusions: A recurrent insect-sting anaphylactic reaction occurred in only 28% of patients with a previous reaction. During this recurrent reaction, plasma levels of endogenous epinephrine, norepinephrine, and angiotensin II rose in relation to hypotension.	UNIV UTRECHT HOSP,3511 GV UTRECHT,NETHERLANDS; NETHERLANDS RED CROSS,BLOOD TRANSFUS SERV,CENT LAB,AMSTERDAM,NETHERLANDS	Utrecht University; Utrecht University Medical Center	VANDERLINDEN, PWG (corresponding author), EEMLAND HOSP,DEPT INTERNAL MED,UTRECHTSEWEG 160,3818 ES AMERSFOORT,NETHERLANDS.		Levi, Marcel/AAZ-8559-2020					ANDERSON MW, 1990, J ALLERGY CLIN IMMUN, V85, P856, DOI 10.1016/0091-6749(90)90068-F; BLAAUW PK, 1985, J ALLERGY CLIN IMMUN, V75, P566; BOCHNER BS, 1991, NEW ENGL J MED, V324, P1785, DOI 10.1056/NEJM199106203242506; BRISTOW MR, 1982, AM J CARDIOL, V49, P249, DOI 10.1016/0002-9149(82)90298-3; Fisher M, 1989, UPDATE INTENSIVE CAR, P309; FISHER MM, 1986, ANAESTH INTENS CARE, V14, P17, DOI 10.1177/0310057X8601400105; HELLER LJ, 1990, INT ARCH ALLER A IMM, V91, P285, DOI 10.1159/000235129; HERMANN K, 1988, CLIN CHEM, V34, P1046; HERMANN K, 1990, CLIN EXP ALLERGY, V20, P566; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; JOHNSON AR, 1977, J CLIN INVEST, V59, P684, DOI 10.1172/JCI108687; KALINER M, 1982, J ALLERGY CLIN IMMUN, V69, P283, DOI 10.1016/S0091-6749(82)80005-5; KAMPELMACHER MJ, 1987, CLIN ALLERGY, V17, P317, DOI 10.1111/j.1365-2222.1987.tb02021.x; KIFOR I, 1987, CIRC RES, V60, P422, DOI 10.1161/01.RES.60.3.422; LANDSBERG L, 1987, HARRISONS PRINCIPLES, P358; Levi R., 1988, HUMAN INFLAMMATORY D, P93; MUELLER HL, 1966, J ASTHMA RES, V3, P331; NAGARATNAM N, 1988, J ROY SOC MED, V81, P420, DOI 10.1177/014107688808100722; PAVEK K, 1982, KLIN WOCHENSCHR, V60, P941, DOI 10.1007/BF01716952; PETSAS AA, 1973, CHEST, V64, P66, DOI 10.1378/chest.64.1.66; PIPER PJ, 1967, NATURE, V213, P838, DOI 10.1038/213838a0; RAPER RF, 1988, LANCET, V1, P386; SAXENA PR, 1990, J CARDIOVASC PHARM, V15, pS17, DOI 10.1097/00005344-199001001-00004; SCHELLENBERG RR, 1991, J ALLERGY CLIN IMMUN, V87, P499, DOI 10.1016/0091-6749(91)90008-C; SCHWARTZ LB, 1989, J CLIN INVEST, V83, P1551, DOI 10.1172/JCI114051; SERAFIN WE, 1987, NEW ENGL J MED, V317, P30, DOI 10.1056/NEJM198707023170106; SMITH PL, 1980, J CLIN INVEST, V66, P1072, DOI 10.1172/JCI109936; TOOGOOD JH, 1988, J ALLERGY CLIN IMMUN, V81, P1, DOI 10.1016/0091-6749(88)90212-6; VANDERLINDEN PWG, 1992, J ALLERGY CLIN IMMUN, V90, P110, DOI 10.1016/S0091-6749(06)80017-5; VANDERLINDEN PWG, 1990, LANCET, V336, P904, DOI 10.1016/0140-6736(90)92272-J; VANDERZWAN JC, 1983, BRIT MED J, V287, P1329, DOI 10.1136/bmj.287.6402.1329; VANDERZWAN JK, 1992, J ALLERGY CLIN IMMUN, V89, P293; VANE JR, 1990, NEW ENGL J MED, V323, P27; WALDHAUSEN E, 1987, ANAESTHESIST, V36, P150; WASSERMAN SI, 1986, J ALLERGY CLIN IMMUN, V77, P663, DOI 10.1016/0091-6749(86)90405-7; ZAVECZ JH, 1977, CIRC RES, V40, P15, DOI 10.1161/01.RES.40.1.15; ZIMMERMAN BG, 1981, CLIN SCI, V60, P343, DOI 10.1042/cs0600343	37	72	74	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572	0003-4819			ANN INTERN MED	Ann. Intern. Med.	FEB 1	1993	118	3					161	168		10.7326/0003-4819-118-3-199302010-00001	http://dx.doi.org/10.7326/0003-4819-118-3-199302010-00001			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ439	8417633				2022-12-24	WOS:A1993KJ43900001
J	KAY, GF; PENNY, GD; PATEL, D; ASHWORTH, A; BROCKDORFF, N; RASTAN, S				KAY, GF; PENNY, GD; PATEL, D; ASHWORTH, A; BROCKDORFF, N; RASTAN, S			EXPRESSION OF XIST DURING MOUSE DEVELOPMENT SUGGESTS A ROLE IN THE INITIATION OF X-CHROMOSOME INACTIVATION	CELL			English	Article							CONTROLLING ELEMENTS; FEMALE MOUSE; GERM-LINE; PREFERENTIAL INACTIVATION; GENE-EXPRESSION; YOLK-SAC; EMBRYOS; DIFFERENTIATION; CELLS; INVITRO	The mouse Xist gene maps to the X inactivation center (Xic) region and is expressed exclusively from the inactive X chromosome. It is thus a candidate gene for the Xic. We show that the onset of Xist expression in mouse development precedes X chromosome inactivation and may therefore be a cause rather than merely a consequence of X inactivation. The earliest Xist expression in morulae and blastocysts is imprinted, resulting in specific expression of the paternal Xist allele. Imprinted Xist expression may thus be the cause of nonrandom inactivation of the paternal X in trophectoderm. Strong Xce alleles can act to reduce the effect of imprinted Xist expression in the trophectoderm. The imprint on Xist expression is lost shortly before gastrulation when random X inactivation occurs. Our data support a direct role for Xist in the initiation of X inactivation.	INST CANC RES,CHESTER BEATTY LABS,LONDON SW3 6JB,ENGLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	KAY, GF (corresponding author), CLIN RES CTR,MRC,COMPARAT BIOL SECT,HARROW HA1 3UJ,MIDDX,ENGLAND.		Kay, Graham F/A-4130-2011	Brockdorff, Neil/0000-0003-4838-2653				ADLER DA, 1977, NATURE, V267, P838, DOI 10.1038/267838a0; ASHWORTH A, 1991, NATURE, V351, P406, DOI 10.1038/351406a0; BORSANI G, 1991, NATURE, V351, P325, DOI 10.1038/351325a0; BROCKDORFF N, 1991, NATURE, V351, P329, DOI 10.1038/351329a0; BROCKDORFF N, 1992, CELL, V71, P515, DOI 10.1016/0092-8674(92)90519-I; BROWN CJ, 1991, NATURE, V349, P38, DOI 10.1038/349038a0; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; BROWN SW, 1973, P NATL ACAD SCI USA, V70, P195, DOI 10.1073/pnas.70.1.195; BUCHER T, 1985, GENET RES, V47, P43; Cattanach B. M., 1991, Mouse Genome, V89, P565; CATTANACH BM, 1981, GENET RES, V38, P57, DOI 10.1017/S0016672300020401; CATTANACH BM, 1969, GENET RES, V14, P233; CHAPMAN VM, 1976, NATURE, V259, P665, DOI 10.1038/259665a0; CHATOT CL, 1989, J REPROD FERTIL, V86, P679, DOI 10.1530/jrf.0.0860679; CHATOT CL, 1990, BIOL REPROD, V42, P432, DOI 10.1095/biolreprod42.3.432; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOPER DW, 1971, NATURE, V230, P292, DOI 10.1038/230292a0; EPSTEIN CJ, 1978, NATURE, V274, P500, DOI 10.1038/274500a0; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; GARTLER SM, 1975, EXP CELL RES, V91, P454, DOI 10.1016/0014-4827(75)90127-5; GOETZ P, 1984, J CELL SCI, V65, P249; GUETHHALLONET C, 1992, TRENDS GENET, V8, P274, DOI 10.1016/0168-9525(92)90134-P; HOGAN BLM, 1981, J EMBRYOL EXP MORPH, V62, P379; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; JOHNSTON PG, 1981, GENET RES, V37, P151, DOI 10.1017/S0016672300020127; KAY G, 1991, GENOMICS, V11, P651, DOI 10.1016/0888-7543(91)90072-M; KOOPMAN P, 1989, NATURE, V342, P940, DOI 10.1038/342940a0; KRATZER PG, 1981, P NATL ACAD SCI-BIOL, V78, P3093, DOI 10.1073/pnas.78.5.3093; KRATZER PG, 1978, NATURE, V274, P503, DOI 10.1038/274503a0; LEVAKSVA.B, 1969, EXPERIENTIA, V25, P1311, DOI 10.1007/BF01897519; LIFSCHYTZ E, 1972, P NATL ACAD SCI USA, V69, P182, DOI 10.1073/pnas.69.1.182; LYON MF, 1974, PROC R SOC SER B-BIO, V187, P243, DOI 10.1098/rspb.1974.0073; LYON MF, 1984, DIFFERENTIATION, V26, P63, DOI 10.1111/j.1432-0436.1984.tb01375.x; LYON MF, 1961, NATURE, V190, P373; LYON MF, 1989, GENETIC VARIANTS STA; MARTIN GR, 1975, P NATL ACAD SCI USA, V72, P1441, DOI 10.1073/pnas.72.4.1441; MCMAHON A, 1983, J EMBRYOL EXP MORPH, V74, P207; MCMAHON A, 1981, J EMBRYOL EXP MORPH, V64, P251; MONK M, 1981, J EMBRYOL EXP MORPH, V63, P75; MONK M, 1978, J EMBRYOL EXP MORPH, V46, P53; MONK M, 1979, NATURE, V281, P311, DOI 10.1038/281311a0; MONK M, 1977, NATURE, V270, P599, DOI 10.1038/270599a0; NICHOLS J, 1990, DEVELOPMENT, V110, P1341; RASTAN S, 1982, GENET RES, V40, P139, DOI 10.1017/S0016672300019017; RASTAN S, 1982, J EMBRYOL EXP MORPH, V71, P11; RASTAN S, 1983, J EMBRYOL EXP MORPH, V78, P1; RASTAN S, 1983, NATURE, V303, P635, DOI 10.1038/303635a0; RASTAN S, 1985, J EMBRYOL EXP MORPH, V90, P379; RASTAN S, 1990, GENET RES, V56, P99, DOI 10.1017/S0016672300035163; ROBERTSON EJ, 1983, COLD SPRING HARBOR C, V10, P647; SACHS L, 1954, ANN EUGENIC, V18, P255; SCHERER SE, 1988, NUCLEIC ACIDS RES, V16, P1593, DOI 10.1093/nar/16.4.1593; SOLARI AJ, 1974, INT REV CYTOL, V38, P273, DOI 10.1016/S0074-7696(08)60928-6; SUGAWARA O, 1985, CYTOGENET CELL GENET, V39, P210, DOI 10.1159/000132137; TAKAGI N, 1975, NATURE, V256, P640, DOI 10.1038/256640a0; TAKAGI N, 1982, CHROMOSOMA, V85, P275, DOI 10.1007/BF00294971; TAKAGI N, 1974, EXP CELL RES, V86, P127, DOI 10.1016/0014-4827(74)90657-0; TAKAGI N, 1978, CYTOGENET CELL GENET, V20, P240, DOI 10.1159/000130856; WEST JD, 1977, CELL, V12, P873, DOI 10.1016/0092-8674(77)90151-9; WILLISON K, 1987, TRENDS GENET, V3, P351, DOI 10.1016/0168-9525(87)90296-4	61	342	352	0	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 29	1993	72	2					171	182		10.1016/0092-8674(93)90658-D	http://dx.doi.org/10.1016/0092-8674(93)90658-D			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KK038	8425217				2022-12-24	WOS:A1993KK03800003
J	PRYOR, DB; SHAW, L; MCCANTS, CB; LEE, KL; MARK, DB; HARRELL, FE; MUHLBAIER, LH; CALIFF, RM				PRYOR, DB; SHAW, L; MCCANTS, CB; LEE, KL; MARK, DB; HARRELL, FE; MUHLBAIER, LH; CALIFF, RM			VALUE OF THE HISTORY AND PHYSICAL IN IDENTIFYING PATIENTS AT INCREASED RISK FOR CORONARY-ARTERY DISEASE	ANNALS OF INTERNAL MEDICINE			English	Article						CORONARY DISEASE; MEDICAL HISTORY TAKING; PHYSICAL EXAMINATION; HEART CATHETERIZATION	SURVIVAL; MODELS	Objective: To determine whether information from the physician's initial evaluation of patients with suspected coronary artery disease predicts coronary anatomy at catheterization and 3-year survival. Design: Prospective validation of regression model estimates in an outpatient cohort. Setting: University medical center. Patients: A total of 1030 consecutive outpatients referred for noninvasive testing for suspected coronary artery disease; 168 of these patients subsequently underwent catheterization within 90 days. Measurements: Information from the initial history, physical examination, electrocardiogram, and chest radiograph was used to predict coronary anatomy (the likelihood of any significant coronary disease, severe disease [left main or three-vessel], and significant left main disease) among 168 catheterized patients and to estimate 3-year survival among all patients. These estimates were compared with those based on treadmill testing. Cardiovascular testing charges were calculated for all patients. Results: Predicted coronary anatomy and survival closely corresponded to actual findings. Compared with the treadmill exercise test, initial evaluation was slightly better able to distinguish patients with or without any coronary disease and was similar in the ability to identify patients at increased risk for dying or with anatomically severe disease. Based on arbitrary definitions, 37% to 66% of patients were at low risk and responsible for 31% to 56% of the charges for cardiovascular testing. Conclusions: The physician's initial evaluation, despite the subjective nature of much of the information gathered, can be used to identify patients likely to benefit from further testing. The development of strategies for cost-conscious quality care must begin with the history, physical examination, and simple laboratory testing.			PRYOR, DB (corresponding author), DUKE UNIV, MED CTR, BOX 3531, DURHAM, NC 27710 USA.			Mark, Daniel/0000-0001-6340-8087	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS004873, R18HS005635] Funding Source: NIH RePORTER; AHRQ HHS [HS-04873, HS-05635, HS-06503] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BLUNDEN PB, 1989, AM ASS MED SYSTEMS I, P135; BOSWICK JM, 1987, 11TH P ANN S COMP AP, P162; CALIFF RM, 1989, JAMA-J AM MED ASSOC, V261, P2077, DOI 10.1001/jama.261.14.2077; COX DR, 1972, J R STAT SOC B, V34, P187; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Harrel F, 1986, SUGI SUPPLEMENTAL LI, P437; HARRELL FE, 1984, STAT MED, V3, P143, DOI 10.1002/sim.4780030207; HARRELL FE, 1982, JAMA-J AM MED ASSOC, V247, P2543, DOI 10.1001/jama.247.18.2543; HARRELL FE, 1988, SUGI SUPPLEMENTAL LI, V1, P15; HARRIS PJ, 1980, CIRCULATION, V62, P718, DOI 10.1161/01.CIR.62.4.718; HARRIS PJ, 1979, CIRCULATION, V60, P1259, DOI 10.1161/01.CIR.60.6.1259; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KONG DF, 1989, ARCH INTERN MED, V149, P1177, DOI 10.1001/archinte.149.5.1177; LEE JC, 1990, J AM COLL CARDIOL, V15, P378, DOI 10.1016/S0735-1097(10)80066-X; LEE KL, 1986, AM J MED, V80, P553, DOI 10.1016/0002-9343(86)90807-7; MARK DB, 1987, ANN INTERN MED, V106, P53, DOI 10.7326/0003-4819-106-1-53; MARK DB, 1987, ANN INTERN MED, V106, P793, DOI 10.7326/0003-4819-106-6-793; PRYOR DB, 1983, AM J MED, V75, P771, DOI 10.1016/0002-9343(83)90406-0; PRYOR DB, 1987, CIRCULATION, V76, P13; PRYOR DB, 1988, TRENDS CORONARY HEAR, P76; ROSATI RA, 1975, ARCH INTERN MED, V135, P1017, DOI 10.1001/archinte.135.8.1017; SOX HC, 1990, AM J MED, V89, P7, DOI 10.1016/0002-9343(90)90090-Z	22	388	396	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1993	118	2					81	90		10.7326/0003-4819-118-2-199301150-00001	http://dx.doi.org/10.7326/0003-4819-118-2-199301150-00001			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF918	8416322				2022-12-24	WOS:A1993KF91800001
J	CRICK, F; JONES, E				CRICK, F; JONES, E			BACKWARDNESS OF HUMAN NEUROANATOMY	NATURE			English	Editorial Material									UNIV CALIF IRVINE,DEPT ANAT & NEUROBIOL,IRVINE,CA 92715	University of California System; University of California Irvine	CRICK, F (corresponding author), SALK INST,POB 85800,SAN DIEGO,CA 92186, USA.							BURKHALTER A, 1989, P NATL ACAD SCI USA, V86, P1071, DOI 10.1073/pnas.86.3.1071; CLARK VP, 1992, CEREB CORTEX, V2, P417, DOI 10.1093/cercor/2.5.417; EDELMAN RR, 1990, DISCUSS NEUROSCI, V7, P11; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; GODEMENT P, 1987, DEVELOPMENT, V101, P697; HARI R, 1989, SCIENCE, V244, P432, DOI 10.1126/science.2655083; HEIMER L, 1989, NEUROANATOMICAL TRAC, V2; JONES EG, 1992, NEUROSCI METH, V44, P133; RAICHLE ME, 1990, COLD SPRING HARB SYM, V55, P983; Tank D. W., 1992, Current Biology, V2, P525, DOI 10.1016/0960-9822(92)90011-X; WONG DF, 1986, SCIENCE, V234, P1558, DOI 10.1126/science.2878495	11	154	161	0	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 14	1993	361	6408					109	110		10.1038/361109a0	http://dx.doi.org/10.1038/361109a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KG466	8421513				2022-12-24	WOS:A1993KG46600024
J	HOSTETLER, MD; DUNN, MI				HOSTETLER, MD; DUNN, MI			PERIOPERATIVE EVALUATION OF A PATIENT WITH ABDOMINAL AORTIC-ANEURYSM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							CORONARY-ARTERY DISEASE; VASCULAR-SURGERY; CARDIAC RISK; COMPLICATIONS; MANAGEMENT				HOSTETLER, MD (corresponding author), UNIV KANSAS,MED CTR,SCH MED,KANSAS CITY,KS 66103, USA.							[Anonymous], 1982, LANCET, V2, P1173; AROUS EJ, 1984, ARCH SURG-CHICAGO, V119, P780; BOUCHER CA, 1985, NEW ENGL J MED, V312, P389, DOI 10.1056/NEJM198502143120701; CAMPBELL JB, 1989, SOUTH MED J, V82, P458, DOI 10.1097/00007611-198904000-00013; CUTLER BS, 1991, AM J CARDIOL, V68, P593; EAGLE KA, 1989, ANN INTERN MED, V110, P859, DOI 10.7326/0003-4819-110-11-859; HERTZER NR, 1984, ANN SURG, V199, P223, DOI 10.1097/00000658-198402000-00016; LEPPO J, 1987, J AM COLL CARDIOL, V9, P269, DOI 10.1016/S0735-1097(87)80374-1; MCPHAIL NV, 1989, J VASC SURG, V10, P51, DOI 10.1067/mva.1989.vs0100051; ROGER VL, 1989, J AM COLL CARDIOL, V14, P1245, DOI 10.1016/0735-1097(89)90423-3	10	9	9	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 13	1993	269	2					295	295		10.1001/jama.269.2.295	http://dx.doi.org/10.1001/jama.269.2.295			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF405	8417248				2022-12-24	WOS:A1993KF40500037
J	UCKUN, FM; KERSEY, JH; HAAKE, R; WEISDORF, D; NESBIT, ME; RAMSAY, NKC				UCKUN, FM; KERSEY, JH; HAAKE, R; WEISDORF, D; NESBIT, ME; RAMSAY, NKC			PRETRANSPLANTATION BURDEN OF LEUKEMIC PROGENITOR CELLS AS A PREDICTOR OF RELAPSE AFTER BONE-MARROW TRANSPLANTATION FOR ACUTE LYMPHOBLASTIC-LEUKEMIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							REMISSION; 4-HYDROPEROXYCYCLOPHOSPHAMIDE; DISEASE	Background. We developed a test to discern small numbers of residual leukemic progenitor cells in the bone marrow of patients with acute lymphoblastic leukemia (ALL) in remission. Preliminary studies revealed that before undergoing bone marrow transplantation such patients differed in their burden of leukemic progenitor cells. These observations suggested that the burden of these cells might influence the risk of relapse after transplantation. Methods. The number of residual leukemic progenitor cells before bone marrow transplantation was determined for 83 patients with high-risk ALL. We combined multiparameter flow cytometry and cell sorting with assays for leukemic progenitor cells in a quantitative method for the detection of minimal residual disease. Results. The count of leukemic progenitor cells in bone marrow specimens from patients in remission varied markedly between patients, ranging from 0 to 12,546 cells per million mononuclear cells, or from 0 to 1.255 percent (median, 51 leukemic progenitor cells per million mononuclear cells, or 0.005 percent). Patients whose count of leukemic progenitor cells exceeded the median value had a higher likelihood of relapse than did patients with values below the median (relapse rate at one year, 100 percent vs. 41 percent; P<0.001). There was a statistically significant inverse relation between the leukemic progenitor-cell content of bone marrow before transplantation and the duration of remission after transplantation (P<0.001). The estimated risk of relapse for patients with greater-than-or-equal-to 51 leukemic progenitor cells per million mononuclear cells was more than 3.5 times the risk for patients with lower counts, after adjustment for the effects of other covariates (P = 0.005). Conclusions. The count of residual leukemic progenitor cells is a powerful predictor of relapse after autologous bone marrow transplantation, particularly among male patients. Its measurement may be useful for analyzing and improving the treatment of patients with high-risk ALL in remission.	UNIV MINNESOTA, HLTH SCI CTR, BONE MARROW TRANSPLANT PROGRAM, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, HLTH SCI CTR, DEPT PEDIAT, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, HLTH SCI CTR, DEPT THERAPEUT RADIOL RADIAT ONCOL, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, HLTH SCI CTR, DEPT MED, MINNEAPOLIS, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities				Uckun, Fatih M./0000-0001-9334-183X	NATIONAL CANCER INSTITUTE [P01CA021737, R29CA042111, R01CA042111, R01CA042633] Funding Source: NIH RePORTER; NCI NIH HHS [CA 21737, CA 42633, CA 42111] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CHAMPLIN R, 1989, BLOOD, V73, P2051; COX DR, 1972, J R STAT SOC B, V34, P187; ESTROV Z, 1986, NEW ENGL J MED, V315, P538, DOI 10.1056/NEJM198608283150902; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KERSEY JH, 1987, NEW ENGL J MED, V317, P461, DOI 10.1056/NEJM198708203170801; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MILLER CB, 1991, BLOOD, V78, P1125; NEGRIN RS, 1991, BLOOD, V78, P255; UCKUN FM, 1990, BLOOD, V76, P1723; UCKUN FM, 1992, BLOOD, V79, P1094; WRIGHT JJ, 1987, J CLIN ONCOL, V5, P735, DOI 10.1200/JCO.1987.5.5.735	11	92	92	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 28	1993	329	18					1296	1301		10.1056/NEJM199310283291802	http://dx.doi.org/10.1056/NEJM199310283291802			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD557	8413410				2022-12-24	WOS:A1993MD55700002
J	PARMA, J; DUPREZ, L; VANSANDE, J; COCHAUX, P; GERVY, C; MOCKEL, J; DUMONT, J; VASSART, G				PARMA, J; DUPREZ, L; VANSANDE, J; COCHAUX, P; GERVY, C; MOCKEL, J; DUMONT, J; VASSART, G			SOMATIC MUTATIONS IN THE THYROTROPIN RECEPTOR GENE CAUSE HYPERFUNCTIONING THYROID ADENOMAS	NATURE			English	Article							G-PROTEIN; TSH RECEPTOR; ALPHA-1B-ADRENERGIC RECEPTOR; CELL-PROLIFERATION; CYCLIC-AMP; AUTOANTIBODIES; NODULES; TUMORS; BINDING; REGION	THE pituitary hormone thyrotropin stimulates the function, expression of differentiation and growth of thyrocytes by cyclic AMP-dependent mechanisms1-3. Tissue hyperplasia and hyperthyroidism are therefore expected to result when activation of the adenylyl cyclase-cAMP cascade is unregulated. This is observed in several situations4,5, including when somatic mutations impair the GTPase activity of the G protein G(salpha) (refs 6, 7). Such a mechanism is probably responsible for the development of a minority, of monoclonal hyperfunctioning thyroid adenomas6,8,9. Here we identify somatic mutations in the carboxy-terminal portion of the third cytoplasmic loop of the thyrotropin receptor in three out of eleven hyperfunctioning thyroid adenomas. These mutations are restricted to tumour tissue and involve two different residues (aspartic acid at position 619 to glycine in two cases, and alanine at position 623 to isoleucine in one case). The mutant receptors confer constitutive activation of adenylyl cyclase when tested by transfection in COS cells. This shows that G-protein-coupled receptors are susceptible to constitutive activation by spontaneous somatic mutations10,11 and may thus behave as proto-oncogenes.	UNIV LIBRE BRUXELLES,FAC MED,SERV GENET MED,B-1070 BRUSSELS,BELGIUM	Universite Libre de Bruxelles	PARMA, J (corresponding author), UNIV LIBRE BRUXELLES,FAC MED,INST RECH INTERDISCIPLINAIRE,CAMPUS ERASME,808 ROUTE LENNIK,B-1070 BRUSSELS,BELGIUM.							ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; BERRIDGE MJ, 1983, BIOCHEM J, V212, P849, DOI 10.1042/bj2120849; Brooker G, 1979, Adv Cyclic Nucleotide Res, V10, P1; CHRISTOPHE D, 1989, MOL CELL ENDOCRINOL, V64, P5, DOI 10.1016/0303-7207(89)90060-9; DUMONT JE, 1989, TRENDS BIOCHEM SCI, V14, P67, DOI 10.1016/0968-0004(89)90046-7; DUMONT JE, 1992, PHYSIOL REV, V72, P667, DOI 10.1152/physrev.1992.72.3.667; DUMONT JE, 1989, METABOLIC BASIS INHE, P1843; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; KOSUGI S, 1992, J BIOL CHEM, V267, P24153; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LIBERT F, 1989, BIOCHEM BIOPH RES CO, V165, P1250, DOI 10.1016/0006-291X(89)92736-8; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; OSULLIVAN C, 1991, MOL CARCINOGEN, V4, P345, DOI 10.1002/mc.2940040503; ROBBINS LS, 1993, CELL, V72, P827, DOI 10.1016/0092-8674(93)90572-8; RUVKUN G, 1992, NATURE, V360, P711, DOI 10.1038/360711a0; Sambrook J., 1989, MOL CLONING LAB MANU; STROSBERG AD, 1991, EUR J BIOCHEM, V196, P1, DOI 10.1111/j.1432-1033.1991.tb15778.x; SUAREZ HG, 1991, ONCOGENE, V6, P677; THOMAS GA, 1989, AM J PATHOL, V134, P141; VANSANDE J, 1980, J CLIN ENDOCR METAB, V50, P776, DOI 10.1210/jcem-50-4-776; VANSANDE J, 1988, J CLIN ENDOCR METAB, V66, P570, DOI 10.1210/jcem-66-3-570; VASSART G, 1987, SCIENCE, V235, P683, DOI 10.1126/science.2880398; WEINSTEIN LS, 1991, NEW ENGL J MED, V325, P1688, DOI 10.1056/NEJM199112123252403; WEINTRAUB BD, 1981, ANN INTERN MED, V95, P339, DOI 10.7326/0003-4819-95-3-339; ZAKARIJA M, 1991, EXP CLIN ENDOCRINOL, V97, P165, DOI 10.1055/s-0029-1211057	26	824	862	0	25	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 14	1993	365	6447					649	651		10.1038/365649a0	http://dx.doi.org/10.1038/365649a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MB846	8413627				2022-12-24	WOS:A1993MB84600059
J	BREO, DL				BREO, DL			ALTERED FATES - COUNSELING FAMILIES WITH INHERITED BREAST-CANCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	15	15	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 21	1993	269	15					2017	2022		10.1001/jama.269.15.2017	http://dx.doi.org/10.1001/jama.269.15.2017			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KX215	8464136				2022-12-24	WOS:A1993KX21500036
J	DICKINSON, GM; MORHART, RE; KLIMAS, NG; BANDEA, CI; LARACUENTE, JM; BISNO, AL				DICKINSON, GM; MORHART, RE; KLIMAS, NG; BANDEA, CI; LARACUENTE, JM; BISNO, AL			ABSENCE OF HIV TRANSMISSION FROM AN INFECTED DENTIST TO HIS PATIENTS - AN EPIDEMIOLOGIC AND DNA-SEQUENCE ANALYSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BISEXUAL MEN; SURGEON; AIDS; COHORT	Objective.-To determine if a general dentist with human immunodeficiency virus (HIV) infection transmitted HIV to any of his patients. Design.-A cohort study in which all patients treated by a dentist who developed the acquired immunodeficiency syndrome (AIDS) were identified and attempts were made to contact all patients for HIV antibody testing. Setting.-A general dentistry clinic operated by the Department of Veterans Affairs in southeastern Florida. Participants.-All patients treated by a dentist during the 5 3/4 years before he developed AIDS were identified in a computerized registry of dental care. Main Outcome Measures.-Attempts were made to contact all living patients for counseling and HIV antibody testing. Living patients with newly identified HIV infection were interviewed, and DNA sequence analysis was performed to compare genetic relatedness of their HIV to that of the dentist. Death certificates were obtained for deceased patients, and the medical records of those with diagnoses suggestive of HIV disease or drug abuse and those dying under the age of 50 years were reviewed in detail. Results.-There were 1192 patients who had undergone 9267 procedures, of whom 124 were deceased. A review of the death certificates of the deceased patients identified five who had died with HIV infection, all of whom were either homosexuals or users of illicit intravenous drugs. We were able to locate 962 (92%) of the remaining 1048 patients, and 900 agreed to be tested. Infection with HIV was documented in five of the 900 patients, including four who had clear evidence of risk factors for acquiring HIV infection. One patient who had only a single evaluation by the dentist denied high-risk behavior. Comparative DNA sequence analysis demonstrated that the viruses from the dentist and these five patients were not closely related. Conclusion.-This study indicates that the risk for transmission of HIV from a general dentist to his patients is minimal in a setting in which universal precautions are strictly observed. Programs to ensure compliance with universal precautions would appear preferable to programs for widespread testing of dentists.	VET AFFAIRS MED CTR,DENT SERV,MIAMI,FL 33125; UNIV MIAMI,SCH MED,DEPT MED,MIAMI,FL 33152; CTR DIS CONTR & PREVENT,DIV HIV AIDS,ATLANTA,GA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Miami; Centers for Disease Control & Prevention - USA	DICKINSON, GM (corresponding author), VET AFFAIRS MED CTR,MED SERV 111-I,1201 NW 16TH ST,MIAMI,FL 33125, USA.							ARMSTRONG FP, 1987, MIL MED, V152, P414; BALFE P, 1990, J VIROL, V64, P6221, DOI 10.1128/JVI.64.12.6221-6233.1990; BURGER H, 1991, P NATL ACAD SCI USA, V88, P11236, DOI 10.1073/pnas.88.24.11236; CASTRO KG, 1988, JAMA-J AM MED ASSOC, V259, P1338, DOI 10.1001/jama.259.9.1338; CHAMBERLAND ME, 1992, ANN INTERN MED, V116, P871, DOI 10.7326/0003-4819-116-10-871; CICHUTEK K, 1991, AIDS, V5, P1185, DOI 10.1097/00002030-199110000-00005; CIESIELSKI C, 1992, ANN INTERN MED, V116, P798, DOI 10.7326/0003-4819-116-10-798; Comer R W, 1991, J Dent Educ, V55, P187; COMER RW, 1992, J AM DENT ASSOC, V123, P51, DOI 10.14219/jada.archive.1992.0219; DANILA RN, 1991, NEW ENGL J MED, V325, P1406, DOI 10.1056/NEJM199111143252003; LIFSON AR, 1990, AM J EPIDEMIOL, V131, P221, DOI 10.1093/oxfordjournals.aje.a115492; MISHU B, 1990, JAMA-J AM MED ASSOC, V264, P467, DOI 10.1001/jama.264.4.467; MYERS G, 1991, HUMAN RETROVIRUSES A; OU CY, 1992, SCIENCE, V256, P1165, DOI 10.1126/science.256.5060.1165; PORTER JD, 1990, LANCET, V335, P113, DOI 10.1016/0140-6736(90)90582-P; RUTHERFORD GW, 1990, BRIT MED J, V301, P1183, DOI 10.1136/bmj.301.6762.1183; SACKS JJ, 1985, NEW ENGL J MED, V313, P1017, DOI 10.1056/NEJM198510173131610; SACKS JJ, 1986, NEW ENGL J MED, V314, P1190; 1991, MMWR, V40, P377	19	46	46	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 14	1993	269	14					1802	1806		10.1001/jama.269.14.1802	http://dx.doi.org/10.1001/jama.269.14.1802			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW250	8459511				2022-12-24	WOS:A1993KW25000034
J	VONREYN, CF; GILBERT, TT; SHAW, FE; PARSONNET, KC; ABRAMSON, JE; SMITH, MG				VONREYN, CF; GILBERT, TT; SHAW, FE; PARSONNET, KC; ABRAMSON, JE; SMITH, MG			ABSENCE OF HIV TRANSMISSION FROM AN INFECTED ORTHOPEDIC SURGEON - A 13-YEAR LOOK-BACK STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH; AIDS	Objective.-To determine the risk of human immunodeficiency virus (HIV) transmission from an HIV-infected orthopedic surgeon to patients undergoing invasive procedures. Design.-Retrospective epidemiologic follow-up study. Participants.-A total of 2317 former patients on whom the orthopedic surgeon performed invasive procedures between January 1, 1978, and June 30, 1992. Main Outcome Measures.-HIV infection or death from an acquired immunodeficiency syndrome (AIDS)-defining tumor or opportunistic infection. Results.-An orthopedic surgeon voluntarily withdrew from practice after testing positive for HIV. Testing for HIV was performed on 1174 former patients, representing 50.7% of patients on whom the orthopedic surgeon performed invasive procedures during the 13.5-year period. Patients were tested from each year and from each category of invasive procedure. All patients were HIV-negative by enzyme-linked immunosorbent assay. Two former patients reported known HIV infection prior to surgery. Review of AIDS case registries and vital records failed to detect cases of HIV infection among former surgical patients. The estimated cost of the initial patient notification and testing was $158 500. The patient notification and testing were conducted while maintaining the confidentiality of the orthopedic surgeon who was an active participant in the planning and execution of the study. Conclusions.-The risk of HIV transmission from an HIV-infected surgeon who adheres to recommended infection control practices is extremely low. Notification and HIV testing of former patients in this setting is both disruptive and expensive and is not routinely recommended.	BROWN UNIV,SCH MED,DEPT FAMILY MED,PROVIDENCE,RI 02912; NEW HAMPSHIRE DEPT HLTH & HUMAN SERV,DIV PUBL HLTH SERV,CONCORD,NH	Brown University	VONREYN, CF (corresponding author), DARTMOUTH COLL,MED CTR,INFECT DIS SECT,1 MED CTR DR,LEBANON,NH 03756, USA.				PHS HHS [U62/CCU107221-01] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ARMSTRONG FP, 1987, MIL MED, V152, P414; BELL DM, 1991, AM J MED, V91, pS294, DOI 10.1016/0002-9343(91)90385-B; CHAMBERLAND ME, 1991, JAMA-J AM MED ASSOC, V266, P3459, DOI 10.1001/jama.266.24.3459; CIESIELSKI C, 1992, ANN INTERN MED, V116, P798, DOI 10.7326/0003-4819-116-10-798; DANILA RN, 1991, NEW ENGL J MED, V325, P1406, DOI 10.1056/NEJM199111143252003; DODD RY, 1992, NEW ENGL J MED, V327, P419, DOI 10.1056/NEJM199208063270610; HAMORY BH, 1992, 2ND ANN M SOC HOP EP, P34; HERSH BS, 1991, LANCET, V338, P645, DOI 10.1016/0140-6736(91)91230-R; MISHU B, 1990, JAMA-J AM MED ASSOC, V264, P467, DOI 10.1001/jama.264.4.467; POKROVSKY VV, 1992, 8TH INT C AIDS AMST; PORTER JD, 1990, LANCET, V335, P113, DOI 10.1016/0140-6736(90)90582-P; TOKARS JI, 1992, JAMA-J AM MED ASSOC, V267, P2899, DOI 10.1001/jama.267.21.2899; TOKARS JI, 1992, JAMA-J AM MED ASSOC, V268, P489, DOI 10.1001/jama.268.4.489; 1992, MMWR, V41, P575; 1987, MMWR, V36, pS3; 1992, MMWR, V41, P344; 1992, INFECT CONT HOSP EP, V13, P482	17	44	44	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 14	1993	269	14					1807	1811		10.1001/jama.269.14.1807	http://dx.doi.org/10.1001/jama.269.14.1807			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW250	8459512				2022-12-24	WOS:A1993KW25000035
J	STARZL, TE; DEMETRIS, AJ; TRUCCO, M; RICORDI, C; ILDSTAD, S; TERASAKI, PI; MURASE, N; KENDALL, RS; KOCOVA, M; RUDERT, WA; ZEEVI, A; VANTHIEL, D				STARZL, TE; DEMETRIS, AJ; TRUCCO, M; RICORDI, C; ILDSTAD, S; TERASAKI, PI; MURASE, N; KENDALL, RS; KOCOVA, M; RUDERT, WA; ZEEVI, A; VANTHIEL, D			CHIMERISM AFTER LIVER-TRANSPLANTATION FOR TYPE-IV GLYCOGEN-STORAGE-DISEASE AND TYPE-1 GAUCHERS-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FAMILIAL HYPERCHOLESTEROLEMIA; HOST-DISEASE; GRAFT; IMMUNOGENICITY; REPLACEMENT; RECIPIENT; CELLS	Background. Liver transplantation for type IV glycogen storage disease (branching-enzyme deficiency) results in the resorption of extrahepatic deposits of amylopectin, but the mechanism of resorption is not known. Methods. We studied two patients with type IV glycogen storage disease 37 and 91 months after liver transplantation and a third patient with lysosomal glucocerebrosidase deficiency (type 1 Gaucher's disease), in whom tissue glucocerebroside deposition had decreased 26 months after liver replacement, to determine whether the migration of cells from the allograft (microchimerism) could explain the improved metabolism of enzyme-deficient tissues in the recipient. Samples of blood and biopsy specimens of the skin, lymph nodes, heart, bone marrow, or intestine were examined immunocytochemically with the use of donor-specific monoclonal anti-HLA antibodies and the polymerase chain reaction, with preliminary amplification specific to donor alleles of the gene for the beta chain of HLA-DR molecules, followed by hybridization with allele-specific oligonucleotide probes. Results. Histopathological examination revealed that the cardiac deposits of amylopectin in the patients with glycogen storage disease and the lymph-node deposits of glucocerebroside in the patient with Gaucher's disease were dramatically reduced after transplantation. Immunocytochemical analysis showed cells containing the HLA phenotypes of the donor in the heart and skin of the patients with glycogen storage disease and in the lymph nodes, but not the skin, of the patient with Gaucher's disease. Polymerase-chain-reaction analysis demonstrated donor HLA-DR DNA in the heart of both patients with glycogen storage disease, in the skin of one of them, and in the skin, intestine, blood, and bone marrow of the patient with Gaucher's disease. Conclusions. Systemic microchimerism occurs after liver allotransplantation and can ameliorate pancellular enzyme deficiencies.	UNIV CALIF LOS ANGELES, TISSUE TYPING LAB, LOS ANGELES, CA USA; MARY BRIDGE CHILDRENS HOSP, TACOMA, WA USA; UNIV PITTSBURGH, HLTH SCI CTR, PITTSBURGH TRANSPLANT INST, PITTSBURGH, PA 15213 USA; UNIV PITTSBURGH, HLTH SCI CTR, DEPT PEDIAT, PITTSBURGH, PA 15213 USA; UNIV PITTSBURGH, HLTH SCI CTR, DEPT MED, PITTSBURGH, PA 15213 USA	University of California System; University of California Los Angeles; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	STARZL, TE (corresponding author), UNIV PITTSBURGH, HLTH SCI CTR, DEPT SURG, 3601 5TH AVE, 5C FALK CLIN, PITTSBURGH, PA 15213 USA.		RICORDI, CAMILLO/AAA-4740-2019	Ricordi, Camillo/0000-0001-8092-7153	NIDDK NIH HHS [R01 DK029961-19, DK-29961] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK029961, R01DK029961] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BILHEIMER DW, 1984, NEW ENGL J MED, V311, P1658, DOI 10.1056/NEJM198412273112603; BRADY RO, 1966, J CLIN INVEST, V45, P1112, DOI 10.1172/JCI105417; BROWN BI, 1966, P NATL ACAD SCI USA, V56, P725, DOI 10.1073/pnas.56.2.725; BURDICK JF, 1988, NEW ENGL J MED, V318, P689, DOI 10.1056/NEJM198803173181107; CALNE RY, 1969, NATURE, V223, P472, DOI 10.1038/223472a0; COMENZO RL, 1992, NEW ENGL J MED, V326, P867, DOI 10.1056/NEJM199203263261305; DALOZE P, 1977, AM J MED GENET, V1, P229, DOI 10.1002/ajmg.1320010209; DEMETRIS AJ, 1992, LANCET, V339, P1610, DOI 10.1016/0140-6736(92)91875-9; DESNICK RJ, 1972, SURGERY, V72, P203; DUCERF C, 1992, TRANSPLANTATION, V53, P1141; FERRY GD, 1991, J PEDIATR GASTR NUTR, V12, P376, DOI 10.1097/00005176-199104000-00016; GOUW ASH, 1987, TRANSPLANTATION, V43, P291, DOI 10.1097/00007890-198702000-00025; HOWELL RR, 1991, NEW ENGL J MED, V324, P55, DOI 10.1056/NEJM199101033240111; HSIA S, 1992, IN PRESS TRANSPLANTA; JONES EA, 1982, LIVER BIOL PATHOBIOL, P507; LECHLER RI, 1982, J EXP MED, V155, P31, DOI 10.1084/jem.155.1.31; NEUFELD EF, 1981, HARVEY LECT, V75, P41; PARKMAN R, 1986, SCIENCE, V232, P1373, DOI 10.1126/science.3520819; PORTER KA, 1969, EXPERIENCE HEPATIC T, P464; RAMSEY G, 1984, NEW ENGL J MED, V311, P1167, DOI 10.1056/NEJM198411013111807; RICORDI C, 1992, LANCET, V339, P1610, DOI 10.1016/0140-6736(92)91876-A; ROBERTS JP, 1991, HEPATOLOGY, V14, P274, DOI 10.1016/0270-9139(91)91415-W; SELBY R, 1991, NEW ENGL J MED, V324, P39, DOI 10.1056/NEJM199101033240107; STARZL TE, 1984, LANCET, V1, P1382; STARZL TE, 1992, LANCET, V339, P1579, DOI 10.1016/0140-6736(92)91840-5; STARZL TE, 1992, LANCET, V340, P876, DOI 10.1016/0140-6736(92)93286-V; STARZL TE, IN PRESS TRANSPLANT; STEINMAN RM, 1973, J EXP MED, V137, P1142, DOI 10.1084/jem.137.5.1142; STEINMAN RM, 1991, ANNU REV IMMUNOL, V9, P271, DOI 10.1146/annurev.iy.09.040191.001415	29	174	179	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 18	1993	328	11					745	749		10.1056/NEJM199303183281101	http://dx.doi.org/10.1056/NEJM199303183281101			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KR848	8437594	Green Accepted, Bronze			2022-12-24	WOS:A1993KR84800001
J	PETREK, JA; PETERS, M; CIRRINCIONE, C; RHODES, D; BAJORUNAS, D				PETREK, JA; PETERS, M; CIRRINCIONE, C; RHODES, D; BAJORUNAS, D			IS BODY-FAT TOPOGRAPHY A RISK FACTOR FOR BREAST-CANCER	ANNALS OF INTERNAL MEDICINE			English	Article						BREAST NEOPLASMS; BODY COMPOSITION; WAIST-TO-HIP RATIO; BODY MASS INDEX; ADIPOSE TISSUE	ADIPOSE-TISSUE DISTRIBUTION; POSTMENOPAUSAL WOMEN; ENDOMETRIAL CANCER; HEALTH RISKS; OBESITY; METABOLISM; EPIDEMIOLOGY; CARCINOMA; PATTERNS; DISEASE	Objective: To determine whether body fat distribution is associated with the onset of breast cancer. Design: Case-control study. Setting. Memorial Sloan-Kettering Cancer Center, New York, New York. Patients: Three hundred thirteen healthy, white women, born in the United States. Measurements: Waist and hip circumferences were measured on the day before diagnostic breast surgery, and an extensive risk assessment of clinical and family history data was done. After the results of diagnostic breast surgery were obtained, study participants were divided into three groups: women with breast cancer (n = 156); controls (n = 126) with benign tissue at biopsy and an average risk for breast cancer; and high-risk women (n = 31), defined as being at a risk for breast cancer development of 1% per year, based on rigorous histologic or clinical criteria. Results- The waist-to-hip ratios (WHR) were identical (mean +/- SD) in case patients (0.80 +/- 0.06), controls (0.80 +/- 0.06), and high-risk women (0.80 +/- 0.08). Further, no trend could be detected between increasing WHR and breast cancer risk; the estimated relative risk for cancer incidence in women with WHR greater than or equal to 0.81 was 0.78 (95% CI, 0.36 to 1.71), compared with women with WHR of less than 0.73. No difference in WHR was noted between the case patients and controls when analyzed separately according to menopausal status, age, absolute weight, or relative weight. Conclusion: In the women studied, body fat topography as defined by WHR was not associated with breast cancer development.			PETREK, JA (corresponding author), MEM SLOAN KETTERING CANC CTR, 1275 YORK AVE, NEW YORK, NY 10021 USA.			Rhodes, Deborah/0000-0003-4408-6451				ADAMSCAMPBELL LL, 1990, J NATL MED ASSOC, V82, P573; ASHWELL M, 1982, INT J OBESITY, V6, P143; BALLARDBARBASH R, 1990, J NATL CANCER I, V82, P286, DOI 10.1093/jnci/82.4.286; BEIJERINCK D, 1991, INT J OBESITY, V15, P89; Bjorntorp P, 1988, Acta Med Scand Suppl, V723, P121; BJORNTORP P, 1990, INFUSIONSTHERAPIE, V17, P24; Bouchard C, 1988, Acta Med Scand Suppl, V723, P135; BRAY GA, 1989, DM-DIS MON, V35, P451; CAMPAIGNE BN, 1990, MED SCI SPORT EXER, V22, P291; DENTONKELAAR I, 1990, INT J OBESITY, V14, P753; ELWOOD JM, 1977, J NATL CANCER I, V59, P1055, DOI 10.1093/jnci/59.4.1055; EVANS DJ, 1983, J CLIN ENDOCR METAB, V57, P304, DOI 10.1210/jcem-57-2-304; FOLSOM AR, 1989, AM J EPIDEMIOL, V130, P911, DOI 10.1093/oxfordjournals.aje.a115424; FOLSOM AR, 1990, AM J EPIDEMIOL, V131, P794, DOI 10.1093/oxfordjournals.aje.a115570; HAFFNER SM, 1988, CLIN RES, V36, pA482; HARTZ AJ, 1984, AM J EPIDEMIOL, V119, P71, DOI 10.1093/oxfordjournals.aje.a113727; KELLY PT, 1991, UNDERSTANDING BREAST, P29; KELSEY JL, 1991, CA-CANCER J CLIN, V41, P146, DOI 10.3322/canjclin.41.3.146; KELSEY JL, 1982, AM J EPIDEMIOL, V116, P333, DOI 10.1093/oxfordjournals.aje.a113417; KELSEY JL, 1983, BREAST GYNECOLOGIC C, P71; KILLINGER D W, 1987, Steroids, V50, P523, DOI 10.1016/0039-128X(87)90036-5; KIRSCHNER MA, 1990, J CLIN ENDOCR METAB, V70, P473, DOI 10.1210/jcem-70-2-473; KISSEBAH AH, 1982, J CLIN ENDOCR METAB, V54, P254, DOI 10.1210/jcem-54-2-254; KISSEBAH AH, 1989, DIABETES METAB REV, V5, P83, DOI 10.1002/dmr.5610050202; KISSEBAH AH, 1989, MED CLIN N AM, V73, P111, DOI 10.1016/S0025-7125(16)30695-2; KROTKIEWSKI M, 1978, J ENDOCRINOL INVEST, V1, P365, DOI 10.1007/BF03350985; LAPIDUS L, 1988, INT J OBESITY, V12, P361; Last JM, 1983, DICT EPIDEMIOLOGY; LEIBEL RL, 1989, ANNU REV NUTR, V9, P417, DOI 10.1146/annurev.nu.09.070189.002221; MILLER AB, 1991, BREAST DISEASES, V2, P119; OTTMAN R, 1983, LANCET, V2, P556; PAGE DL, 1991, B AM COLL SURG, V76, P16; Rebuffe-Scrive M., 1987, REC ADV OBES RES, V5, P82; REBUFFESCRIVE M, 1987, INT J OBESITY, V11, P347; SCHAPIRA DV, 1990, ANN INTERN MED, V112, P182, DOI 10.7326/0003-4819-112-3-182; SCHAPIRA DV, 1991, JAMA-J AM MED ASSOC, V266, P1808, DOI 10.1001/jama.266.13.1808; Seidell J C, 1988, Acta Med Scand Suppl, V723, P189; SEIDELL JC, 1989, AM J CLIN NUTR, V50, P269, DOI 10.1093/ajcn/50.2.269; SEIDELL JC, 1989, INFUSIONSTHERAPIE, V16, P276; SHIMOKATA H, 1989, J GERONTOL, V44, pM66, DOI 10.1093/geronj/44.2.M66; SONNICHSEN AC, 1990, ANN INTERN MED, V112, P882, DOI 10.7326/0003-4819-112-11-882_1; VERMEULEN A, 1969, J CLIN ENDOCR METAB, V29, P1470, DOI 10.1210/jcem-29-11-1470; WINCHESTER DP, 1986, B AM COLL SURG, V71, P29	43	36	37	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1993	118	5					356	362		10.7326/0003-4819-118-5-199303010-00006	http://dx.doi.org/10.7326/0003-4819-118-5-199303010-00006			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KN688	8430981				2022-12-24	WOS:A1993KN68800006
J	WALTERS, S; BRITTON, J; HODSON, ME				WALTERS, S; BRITTON, J; HODSON, ME			DEMOGRAPHIC AND SOCIAL CHARACTERISTICS OF ADULTS WITH CYSTIC-FIBROSIS IN THE UNITED-KINGDOM	BRITISH MEDICAL JOURNAL			English	Article								Objective-To obtain information about social and demographic characteristics and lifestyle of adult patients with cystic fibrosis, including those who do not attend major specialist clinics. Design-Confidential self completion postal questionnaire to adult patients with cystic fibrosis, asking about social and demographic characteristics, social class and occupation, employment, education, insurance and social security benefits, symptom severity, and medical care. Setting-National association for adults with cystic fibrosis. Subjects - 1052 adult members of the Association of Cystic Fibrosis Adults UK, accounting for 68% of those with cystic fibrosis in the United Kingdom population over 16 years of age and over 80% of those over 25 in June 1990. Results-The response rate was 82% (397 women, 423 men). Most adults with cystic fibrosis were found to be living fulfilling lives into adulthood. Significantly fewer men were married or cohabiting than women (110 (26%) men, 175 (44%) women). 420 (55%) responders were working, and of these 235 (56%) had less than two weeks' sick leave a year. Half of those not employed gave ill health as the reason. Revealing that they had cystic fibrosis at job interviews reduced likelihood of being employed for those with mild to moderate disease. People with cystic fibrosis had been less successful than the general population in achieving O level or equivalent qualifications, but more successful in achieving A level or higher qualifications. Achievement of any qualifications enhanced employment prospects irrespective of disease severity. Conclusion-Contrary to an image of chronic ill health and disability, a high proportion of adults with cystic fibrosis are living full and productive lives.	CITY HOSP NOTTINGHAM,NOTTINGHAM NG5 1PD,ENGLAND; NATL HEART & LUNG INST,LONDON SW3,ENGLAND	Nottingham University Hospital NHS Trust; Nottingham City Hospital; Imperial College London	WALTERS, S (corresponding author), UNIV BIRMINGHAM,INST PUBL & ENVIRONM HLTH,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND.		Britton, John R/G-9705-2011					ALLAN JL, MED J AUSTRALIA, V1, P600; Andersen DH, 1938, AM J DIS CHILD, V56, P344, DOI 10.1001/archpedi.1938.01980140114013; BRITTON JR, 1989, BRIT MED J, V298, P483, DOI 10.1136/bmj.298.6672.483; ELBORN JS, 1991, THORAX, V46, P881, DOI 10.1136/thx.46.12.881; Fanconi G UE, 1936, WIEN MED WOCHENSCHR, V86, P753; Hodson ME, 1983, CYSTIC FIBROSIS; ROBSON M, 1991, WORKING HEALTHIER LU, P65; 1989, SOCIAL TRENDS; 1989, WORKING PATIENTS; 1991, GENERAL HOUSEHOLD SU; 1988, BMJ, V297, P1599; 1991, CYSTIC FIBROSIS ADUL	12	33	33	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 27	1993	306	6877					549	552		10.1136/bmj.306.6877.549	http://dx.doi.org/10.1136/bmj.306.6877.549			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KP886	8461767	Green Published, Bronze			2022-12-24	WOS:A1993KP88600019
J	STRUHL, G; BASLER, K				STRUHL, G; BASLER, K			ORGANIZING ACTIVITY OF WINGLESS PROTEIN IN DROSOPHILA	CELL			English	Article							SEGMENT-POLARITY GENE; SITE-SPECIFIC RECOMBINATION; XENOPUS EMBRYOS; SPATIAL-DISTRIBUTION; REGULATORY ELEMENTS; ECTOPIC EXPRESSION; PATTERN-FORMATION; ENGRAILED GENE; IMAGINAL DISKS; BICOID PROTEIN	The adult appendages of Drosophila are formed from imaginal discs, sheets of epithelial cells that proliferate during larval development and differentiate during metamorphosis. wingless (wg, DWnt-1) protein, a putative signaling molecule, is expressed only in prospective ventral cells in each of the leg discs. To test the role of wg, we have generated randomly positioned clones of cells that express wg protein constitutively. Clones that arise in the prospective ventral portions of the leg discs develop normally. In contrast, dorsally situated clones give rise to ventrolateral patterns and exert a ventralizing influence on neighboring wild-type tissue. We propose that wg protein organizes leg pattern along the dorsoventral axis by conferring ventral positional information within the disc.			STRUHL, G (corresponding author), COLUMBIA UNIV COLL PHYS & SURG, HOWARD HUGHES MED INST, NEW YORK, NY 10032 USA.			Basler, Konrad/0000-0003-3534-1529				ARIAS AM, 1988, DEVELOPMENT, V103, P157; ARIAS AM, 1989, TRENDS GENET, V5, P262, DOI 10.1016/0168-9525(89)90099-1; BAKER NE, 1988, DEV BIOL, V125, P96, DOI 10.1016/0012-1606(88)90062-0; BAKER NE, 1987, EMBO J, V6, P1765, DOI 10.1002/j.1460-2075.1987.tb02429.x; BALCELLS L, 1988, EMBO J, V7, P3899, DOI 10.1002/j.1460-2075.1988.tb03276.x; BEJSOVEC A, 1991, DEVELOPMENT, V113, P471; BLAIR SS, 1992, DEVELOPMENT, V115, P21; BOHN H, 1972, ROUX ARCH DEV BIOL, V170, P354, DOI 10.1007/BF01380624; BOHN H, 1972, J EMBRYOL EXP MORPH, V28, P185; BOHN H, 1965, ROUX ARCH DEV BIOL, V156, P449; BOND BJ, 1986, MOL CELL BIOL, V6, P2080, DOI 10.1128/MCB.6.6.2080; BRADLEY RS, 1990, EMBO J, V9, P1569, DOI 10.1002/j.1460-2075.1990.tb08276.x; BROACH JR, 1980, CELL, V21, P501, DOI 10.1016/0092-8674(80)90487-0; BROWER DL, 1986, EMBO J, V5, P2649, DOI 10.1002/j.1460-2075.1986.tb04547.x; BRYANT SV, 1981, SCIENCE, V212, P993, DOI 10.1126/science.212.4498.993; BUSTURIA A, 1988, DEVELOPMENT, V104, P713; CHAKRABARTI A, 1992, DEVELOPMENT, V115, P355; CHAN LN, 1971, P NATL ACAD SCI USA, V68, P2217, DOI 10.1073/pnas.68.9.2217; CHRISTIAN JL, 1991, DEV BIOL, V143, P230, DOI 10.1016/0012-1606(91)90073-C; Dalcq A, 1938, FORM CAUSALITY EARLY; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; DRIEVER W, 1989, NATURE, V340, P363, DOI 10.1038/340363a0; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; EICHELE G, 1989, TRENDS GENET, V5, P246, DOI 10.1016/0168-9525(89)90096-6; FRENCH V, 1980, J EMBRYOL EXP MORPH, V59, P281; FRENCH V, 1981, PHILOS T R SOC B, V295, P601, DOI 10.1098/rstb.1981.0163; FRENCH V, 1976, SCIENCE, V193, P969, DOI 10.1126/science.948762; FRENCH V, 1978, J EMBRYOL EXP MORPH, V47, P53; GARCIABELLIDO A, 1973, NATURE-NEW BIOL, V245, P251, DOI 10.1038/newbio245251a0; GEYER PK, 1987, GENE DEV, V1, P996, DOI 10.1101/gad.1.9.996; GOLIC KG, 1989, CELL, V59, P499, DOI 10.1016/0092-8674(89)90033-0; GONZALEZ F, 1991, MECH DEVELOP, V35, P43, DOI 10.1016/0925-4773(91)90040-D; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; HAMA C, 1990, GENE DEV, V4, P1079, DOI 10.1101/gad.4.7.1079; HAMBURGER V, 1964, F EXPT EMBRYOLOGY, P146; HANNAH-ALAVA ALOHA, 1958, J MORPH, V103, P281, DOI 10.1002/jmor.1051030205; HARTLEY JL, 1980, NATURE, V286, P860, DOI 10.1038/286860a0; HEEMSKERK J, 1991, NATURE, V352, P404, DOI 10.1038/352404a0; HULSKAMP M, 1990, NATURE, V346, P577, DOI 10.1038/346577a0; IMMERGLUCK K, 1990, CELL, V62, P261, DOI 10.1016/0092-8674(90)90364-K; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; JACOBSON AG, 1988, DEVELOPMENT, V104, P341; JAYARAM M, 1985, P NATL ACAD SCI USA, V82, P5875, DOI 10.1073/pnas.82.17.5875; LAWRENCE PA, 1987, NATURE, V328, P440, DOI 10.1038/328440a0; LAWRENCE PA, 1982, EMBO J, V1, P827, DOI 10.1002/j.1460-2075.1982.tb01255.x; LAWRENCE PA, 1979, J EMBRYOL EXP MORPH, V51, P195; LAWRENCE PA, 1977, DEV BIOL, V56, P40, DOI 10.1016/0012-1606(77)90153-1; LAWRENCE PA, 1972, DEV SYSTEMS INSECTS, V2, P157; LIS JT, 1983, CELL, V35, P403, DOI 10.1016/0092-8674(83)90173-3; MCMAHON AP, 1992, TRENDS GENET, V8, P236, DOI 10.1016/0168-9525(92)90122-K; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; MORATA G, 1975, NATURE, V255, P614, DOI 10.1038/255614a0; NISHIDA Y, 1988, EMBO J, V7, P775, DOI 10.1002/j.1460-2075.1988.tb02875.x; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; PAPKOFF J, 1990, MOL CELL BIOL, V10, P2723, DOI 10.1128/MCB.10.6.2723; PAPKOFF J, 1987, MOL CELL BIOL, V7, P3978, DOI 10.1128/MCB.7.11.3978; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; PEIFER M, 1991, DEVELOPMENT, V111, P1029; PEIFER M, 1992, TRENDS GENET, V8, P243, DOI 10.1016/0168-9525(92)90394-J; RIDDIHOUGH G, 1991, GENE DEV, V5, P840, DOI 10.1101/gad.5.5.840; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; RODRIGUEZ I, 1990, EMBO J, V9, P3583, DOI 10.1002/j.1460-2075.1990.tb07569.x; ROMANI S, 1989, GENE DEV, V3, P997, DOI 10.1101/gad.3.7.997; ROSE SM, 1952, AM NAT, V86, P337, DOI 10.1086/281743; RUBIN GM, 1983, NUCLEIC ACIDS RES, V11, P6341, DOI 10.1093/nar/11.18.6341; Sander K, 1975, Ciba Found Symp, V0, P241; SCHALLER HC, 1981, P NATL ACAD SCI-BIOL, V78, P7000, DOI 10.1073/pnas.78.11.7000; SCHALLER HC, 1979, ROUX ARCH DEV BIOL, V186, P139, DOI 10.1007/BF00848175; SCHUBIGER G, 1971, DEV BIOL, V26, P277, DOI 10.1016/0012-1606(71)90127-8; SHARMA RP, 1976, DEV BIOL, V48, P461, DOI 10.1016/0012-1606(76)90108-1; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; Spemann H, 1924, ARCH MIKROSK ANAT EN, V100, P599, DOI 10.1007/BF02108133; Spemann H., 1938, EMBRYONIC DEV INDUCT; STEINER E, 1976, ROUX ARCH DEV BIOL, V178, P233; STRUHL G, 1992, CELL, V69, P237, DOI 10.1016/0092-8674(92)90405-2; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; STRUHL G, 1985, NATURE, V318, P677, DOI 10.1038/318677a0; THALLER C, 1987, NATURE, V327, P625, DOI 10.1038/327625a0; THEURKAUF WE, 1986, P NATL ACAD SCI USA, V83, P8477, DOI 10.1073/pnas.83.22.8477; TICKLE C, 1981, NATURE, V289, P295, DOI 10.1038/289295a0; TICKLE C, 1982, NATURE, V296, P564, DOI 10.1038/296564a0; TICKLE C, 1975, NATURE, V254, P199, DOI 10.1038/254199a0; TOMLINSON A, 1988, DEVELOPMENT, V104, P183; UDVARDY A, 1985, J MOL BIOL, V185, P341, DOI 10.1016/0022-2836(85)90408-5; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V	90	728	746	0	25	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 26	1993	72	4					527	540		10.1016/0092-8674(93)90072-X	http://dx.doi.org/10.1016/0092-8674(93)90072-X			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KP165	8440019	Green Accepted			2022-12-24	WOS:A1993KP16500008
J	BRADLEY, DM; PARSONS, EP; CLARKE, AJ				BRADLEY, DM; PARSONS, EP; CLARKE, AJ			EXPERIENCE WITH SCREENING NEWBORNS FOR DUCHENNE MUSCULAR-DYSTROPHY IN WALES	BRITISH MEDICAL JOURNAL			English	Article							CREATINE-KINASE; DIAGNOSIS; CDNA	Objectives-To assess the acceptability of screening newborn boys for Duchenne muscular dystrophy. Design-Screening is offered on the basis of informed consent in response to an information sheet entitled ''A new test for baby boys-Do you want it?'' The programme includes a prospective long term evaluation of family responses to early diagnosis and a comparison of their experiences and perceptions with those families who have undergone the later traditional clinical diagnosis. Setting-All maternity units throughout Wales. Samples obtained through screening programme for phenylketonuria and congenital hypothyroidism. Subjects-Those families whose son had a positive screening test. Main outcome measures-Creatine kinase activity. Venous blood test to confirm positive result. Molecular genetic mutation analysis. Muscle biopsy and dystrophin analysis. Qualitative measure of satisfaction among affected families. Results-34219 Boys have been screened and nine affected families have been identified. Eight families were very positive about the programme. Three chose not to complete the diagnostic process. Conclusion-The programme should continue to permit a full evaluation of the issues involved and should serve as a model for other initiatives within the community for genetic disease.			BRADLEY, DM (corresponding author), UNIV WALES COLL MED, INST MED GENET, HEATH PK, CARDIFF CF4 4XN, S GLAM, WALES.							DRUMMOND LM, 1978, LANCET, V1, P1258; GARDNERMEDWIN D, 1978, LANCET, V1, P1102; GREENBERG CR, 1992, J MED GENET, V29, P583, DOI 10.1136/jmg.29.8.583; JACOBS HK, 1989, INT CONGR SER, V848, P361; KOENIG M, 1987, CELL, V50, P509, DOI 10.1016/0092-8674(87)90504-6; PLANCHU H, 1987, ADV NEONATAL SCREENI, P371; PLAUCHU H, 1989, LANCET, V1, P669; SCHEUERBRANDT G, 1986, MUSCLE NERVE, V9, P11, DOI 10.1002/mus.880090103; SCHEUERBRANDT G, 1983, NEONATAL SCREENING, P352; SCHEUERBRANDT G, 1987, ADV NEONATAL SCREENI, P361; SKINNER R, 1982, J MED GENET, V19, P1, DOI 10.1136/jmg.19.1.1; SMITH RA, 1990, BRIT MED J, V300, P1112, DOI 10.1136/bmj.300.6732.1112; SMITH RA, 1989, ARCH DIS CHILD, V64, P1017, DOI 10.1136/adc.64.7.1017; UPADHYAYA M, 1990, CLIN GENET, V37, P456; WILLIAMS H, 1984, LANCET, V2, P645; ZELLWEGER H, 1975, PEDIATRICS, V55, P30	16	71	72	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 6	1993	306	6874					357	360		10.1136/bmj.306.6874.357	http://dx.doi.org/10.1136/bmj.306.6874.357			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KL715	8461680	Bronze, Green Published			2022-12-24	WOS:A1993KL71500017
J	CHUNG, HH; BENSON, DR; SCHULTZ, PG				CHUNG, HH; BENSON, DR; SCHULTZ, PG			PROBING THE STRUCTURE AND MECHANISM OF RAS PROTEIN WITH AN EXPANDED GENETIC-CODE	SCIENCE			English	Article							SITE-SPECIFIC INCORPORATION; UNNATURAL AMINO-ACIDS; TRIPHOSPHATE CONFORMATION; BIOCHEMICAL-PROPERTIES; CATALYTIC DOMAIN; GTP HYDROLYSIS; TRANSFER-RNAS; P21; PRODUCT; MUTANTS	Mutations in Ras protein at positions Gly12 and Gly13 (phosphate-binding loop L1) and at positions Ala59, Gly60, and Gln61 (loop L4) are commonly associated with oncogenic activation. The structural and catalytic roles of these residues were probed with a series of unnatural amino acids that have unusual main chain conformations, hydrogen bonding abilities, and steric features. The properties of wild-type and transforming Ras proteins previously thought to be uniquely associated with the structure of a single amino acid at these positions were retained by mutants that contained a variety of unnatural amino acids. This expanded set of functional mutants provides new insight into the role of loop L4 residues in switch function and suggests that loop L1 may participate in the activation of Ras protein by effector molecules.	UNIV CALIF BERKELEY, DEPT CHEM, BERKELEY, CA 94720 USA; LAWRENCE BERKELEY LAB, CTR ADV MAT, DIV MAT SCI, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory					NIGMS NIH HHS [F32 GM14165] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM014165] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAIN JD, 1991, BIOCHEMISTRY-US, V30, P5411, DOI 10.1021/bi00236a013; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BELOKON YN, 1988, J CHEM SOC PERK T 1, P2075, DOI 10.1039/p19880002075; BIRCHMEIER C, 1985, CELL, V43, P615, DOI 10.1016/0092-8674(85)90233-8; BOS JL, 1989, CANCER RES, V49, P4682; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; DEVOS AM, 1988, SCIENCE, V239, P888, DOI 10.1126/science.2448879; ELLMAN J, 1991, METHOD ENZYMOL, V202, P301; ELLMAN JA, 1992, SCIENCE, V255, P197, DOI 10.1126/science.1553546; ELLMAN JA, 1992, J AM CHEM SOC, V114, P7959, DOI 10.1021/ja00046a080; GAY NJ, 1983, NATURE, V301, P262, DOI 10.1038/301262a0; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; HAN JW, 1991, SCIENCE, V252, P576, DOI 10.1126/science.1902323; HOOZ J, 1968, CAN J CHEMISTRY, V46, P86, DOI 10.1139/v68-017; JOHN J, 1988, J BIOL CHEM, V263, P11792; KASIRO Y, 1978, BIOCHIM BIOPHYS ACTA, V95, P505; KRENGEL U, 1990, CELL, V62, P539, DOI 10.1016/0092-8674(90)90018-A; LOWRY TH, 1976, MECHANISM THEORY ORG; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MATSUEDA R, 1981, CHEM LETT, P737, DOI 10.1246/cl.1981.737; MENDEL D, 1991, J AM CHEM SOC, V113, P2758, DOI 10.1021/ja00007a063; MENDEL D, 1992, SCIENCE, V256, P1798, DOI 10.1126/science.1615324; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MIURA K, 1986, JPN J CANCER RES, V77, P45; NEAL SE, 1990, P NATL ACAD SCI USA, V87, P3562, DOI 10.1073/pnas.87.9.3562; NOREN CJ, 1990, NUCLEIC ACIDS RES, V18, P83, DOI 10.1093/nar/18.1.83; NOREN CJ, 1989, SCIENCE, V244, P182, DOI 10.1126/science.2649980; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PARTHASARATHY M, 1980, BIOPOLYMERS, V19, P1943; PRIVE GG, 1992, P NATL ACAD SCI USA, V89, P3649, DOI 10.1073/pnas.89.8.3649; RAE ID, 1979, INT J PEPT PROT RES, V13, P304; ROBERTSON SA, 1991, J AM CHEM SOC, V113, P2722, DOI 10.1021/ja00007a055; SCHLICHTING I, 1990, NATURE, V345, P309, DOI 10.1038/345309a0; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; SHIH TY, 1982, J BIOL CHEM, V257, P1767; SPANDIDOS D. A., 1989, RAS ONCOGENES; SUICH DJ, 1992, THESIS U CALIFORNIA; TONG L, 1989, SCIENCE, V245, P244, DOI 10.1126/science.2665078; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; WIBERG KB, 1987, J AM CHEM SOC, V109, P5935, DOI 10.1021/ja00254a006; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; YOKAYAMA S, UNPUB	45	126	182	3	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 5	1993	259	5096					806	809		10.1126/science.8430333	http://dx.doi.org/10.1126/science.8430333			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL110	8430333				2022-12-24	WOS:A1993KL11000031
J	CHATTHA, G; ARIEFF, AI; CUMMINGS, C; TIERNEY, LM				CHATTHA, G; ARIEFF, AI; CUMMINGS, C; TIERNEY, LM			LACTIC-ACIDOSIS COMPLICATING THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME	ANNALS OF INTERNAL MEDICINE			English	Note						ACIDOSIS, LACTIC; ACQUIRED IMMUNODEFICIENCY SYNDROME; ANOXIA; HUMAN IMMUNODEFICIENCY VIRUS; REYES SYNDROME		Lactic acidosis has been reported in patients with the acquired immunodeficiency syndrome (AIDS) only in association with tissue hypoxia. From 1989 to 1991, seven patients with human immunodeficiency virus (HIV) infection who had lactic acidosis without obvious cause were evaluated. Nine normovolemic patients without acidosis or hypoxia served as controls. Findings in the patients included the following: pH, 7.22 +/- 0.07; bicarbonate, 7.0 +/- 2.4 mmol/L and lactate, 14.3 +/- 2.6 mmol/L. Patients and controls did not differ regarding cardiac index, P(O2) oxygen extraction ratio, and systemic oxygen delivery or utilization. Four patients with AIDS died of overwhelming metabolic acidosis, but the three other patients were discharged from the hospital. Autopsy in the four patients who died showed no obvious cause for lactic acidosis. The normal oxygen delivery, utilization, and extraction suggest that increased hyperlactatemia occurred for reasons other than hypoxia. Thus, patients with AIDS but without hypoxia can develop severe lactic acidosis that is not necessarily fatal.	UNIV CALIF SAN FRANCISCO, SCH MED, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco								Aiyathurai J E, 1983, Ann Acad Med Singap, V12, P115; ANDRULIS DP, 1992, JAMA-J AM MED ASSOC, V267, P2482, DOI 10.1001/jama.267.18.2482; ARIEFF AI, 1987, AM J PHYSIOL, V253, pE271, DOI 10.1152/ajpendo.1987.253.3.E271; BERSIN RM, 1989, AM J MED, V87, P7, DOI 10.1016/S0002-9343(89)80476-0; COHEN RD, 1990, METABOLIC MOL BASIS, P981; GANZ W, 1971, AM J CARDIOL, V27, P392, DOI 10.1016/0002-9149(71)90436-X; GUTIERREZ G, 1992, CRIT CARE MED, V20, P451, DOI 10.1097/00003246-199204000-00004; MADIAS NE, 1986, KIDNEY INT, V29, P752, DOI 10.1038/ki.1986.62; MHIRI C, 1991, ANN NEUROL, V29, P606, DOI 10.1002/ana.410290607; PERETZ DI, 1965, ANN NY ACAD SCI, V119, P1133, DOI 10.1111/j.1749-6632.1965.tb47467.x	10	119	119	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1993	118	1					37	39		10.7326/0003-4819-118-1-199301010-00007	http://dx.doi.org/10.7326/0003-4819-118-1-199301010-00007			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KE605	8416156				2022-12-24	WOS:A1993KE60500007
J	LEVINSKY, NG				LEVINSKY, NG			THE ORGANIZATION OF MEDICAL-CARE - LESSONS FROM THE MEDICARE END-STAGE RENAL-DISEASE PROGRAM	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LIFE		BOSTON CITY HOSP, BOSTON, MA 02118 USA; UNIV HOSP BOSTON, BOSTON, MA 02118 USA	Boston Medical Center	LEVINSKY, NG (corresponding author), BOSTON UNIV, MED CTR, DEPT MED, 88 E NEWTON ST, BOSTON, MA 02118 USA.							AARON HJ, 1984, PAINFUL PRESCRIPTION; ABRAM HS, 1972, PSYCHIAT MED, V3, P51, DOI 10.2190/GKBB-DKN0-AD5M-RBBY; EVANS RW, 1981, JAMA-J AM MED ASSOC, V245, P487, DOI 10.1001/jama.245.5.487; EVANS RW, 1985, NEW ENGL J MED, V312, P553, DOI 10.1056/NEJM198502283120905; GAYLIN DS, 1993, JAMA-J AM MED ASSOC, V269, P603, DOI 10.1001/jama.269.5.603; HALPER T, 1985, MILBANK FUND Q, V63, P52, DOI 10.2307/3349898; MURRAY JS, 1962, T AM SOC ART INT ORG, V8, P315; NISSENSON AR, 1993, KIDNEY INT, V43, pS120; Reiser SJ., 1991, BIOMEDICAL POLITICS, P212; Rettig RA, 1991, BIOMEDICAL POLITICS, P176; RETTING RA, 1991, KIDNEY FAILURE FEDER; SANDERS D, 1968, UCLA LAW REV, V15, P357; SCHUPAK E, 1965, ANN INTERN MED, V62, P509, DOI 10.7326/0003-4819-62-3-509; SHERMAN RA, 1993, AM J KIDNEY DIS, V21, P632, DOI 10.1016/S0272-6386(12)80036-9; Tokars J I, 1993, ASAIO J, V39, P71, DOI 10.1097/00002480-199301000-00016; 1967, GPO933491 PUBL; 1992, USRDS SPECIAL STUDY	17	47	47	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 4	1993	329	19					1395	1399		10.1056/NEJM199311043291907	http://dx.doi.org/10.1056/NEJM199311043291907			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD949	8413437				2022-12-24	WOS:A1993MD94900007
J	KIM, JL; NIKOLOV, DB; BURLEY, SK				KIM, JL; NIKOLOV, DB; BURLEY, SK			CO-CRYSTAL STRUCTURE OF TBP RECOGNIZING THE MINOR-GROOVE OF A TATA ELEMENT	NATURE			English	Article							RNA POLYMERASE-II; NUCLEIC-ACID INTERACTION; BINDING-PROTEIN; TRANSCRIPTION FACTOR; TFIID BINDS; DNA; YEAST; COMPLEX; BOX; INITIATION	The three-dimensional structure of a TATA-box binding polypeptide complexed with the TATA element of the adenovirus major late promoter ha's been determined by X-ray crystallography at 2.25 angstrom resolution. Binding of the saddle-shaped protein induces a conformational change in the DNA, inducing sharp kinks at either end of the sequence TATAAAAG. Between the kinks, the right-handed double helix is smoothly curved and partially unwound, presenting a widened minor groove to TBP's concave, antiparallel beta-sheet. Side-chain/base interactions are restricted to the minor groove, and include hydrogen bonds, van der Waals contacts and phenylalanine-base stacking interactions.	ROCKEFELLER UNIV, MOLEC BIOPHYS LABS, 1230 YORK AVE, NEW YORK, NY 10021 USA	Rockefeller University				Burley, Stephen K./0000-0002-2487-9713				ARNDT KM, 1992, MOL CELL BIOL, V12, P2372, DOI 10.1128/MCB.12.5.2372; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BRUNGER AT, 1992, XPLOR MANUAL; BURATOWSKI S, 1992, SCIENCE, V255, P1130, DOI 10.1126/science.1546314; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; COLL M, 1989, BIOCHEMISTRY-US, V28, P310, DOI 10.1021/bi00427a042; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; DIGABRIELE AD, 1993, J MOL BIOL, V231, P1024, DOI 10.1006/jmbi.1993.1349; DREW HR, 1985, J MOL BIOL, V186, P773, DOI 10.1016/0022-2836(85)90396-1; FLORES O, 1988, J BIOL CHEM, V263, P10812; GREENBLATT J, 1991, CELL, V66, P1067, DOI 10.1016/0092-8674(91)90027-V; HAHN S, 1989, P NATL ACAD SCI USA, V86, P5718, DOI 10.1073/pnas.86.15.5718; HEGDE RS, 1992, NATURE, V359, P505, DOI 10.1038/359505a0; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HOOPES BC, 1992, J BIOL CHEM, V267, P11539; HORIKOSHI M, 1992, P NATL ACAD SCI USA, V89, P1060, DOI 10.1073/pnas.89.3.1060; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KOPKA ML, 1985, J MOL BIOL, V183, P553, DOI 10.1016/0022-2836(85)90171-8; LAVERY R, 1989, J BIOMOL STRUCT DYN, V6, P655, DOI 10.1080/07391102.1989.10507728; LEE DK, 1992, MOL CELL BIOL, V12, P5189, DOI 10.1128/MCB.12.11.5189; LEE DK, 1991, CELL, V67, P1241, DOI 10.1016/0092-8674(91)90300-N; LIEBERMAN PM, 1991, MOL CELL BIOL, V11, P63, DOI 10.1128/MCB.11.1.63; LORCH Y, 1993, MOL CELL BIOL, V13, P1872, DOI 10.1128/MCB.13.3.1872; MEISTERERNST M, 1990, P NATL ACAD SCI USA, V87, P9153, DOI 10.1073/pnas.87.23.9153; NELSON HCM, 1987, NATURE, V330, P221, DOI 10.1038/330221a0; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; ORNSTEIN RL, 1978, BIOPOLYMERS, V17, P2341, DOI 10.1002/bip.1978.360171005; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; Phillips SEV, 1991, CURR OPIN STRUC BIOL, V1, P89, DOI 10.1016/0959-440X(91)90016-M; PUGLISI JD, 1989, METHOD ENZYMOL, V180, P304; RAMACHANDRAN GN, 1963, J MOL BIOL, V7, P95, DOI 10.1016/S0022-2836(63)80023-6; REDDY P, 1991, CELL, V65, P349, DOI 10.1016/0092-8674(91)90168-X; RIGBY PWJ, 1993, CELL, V72, P7, DOI 10.1016/0092-8674(93)90042-O; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; SATCHWELL SC, 1986, J MOL BIOL, V191, P659, DOI 10.1016/0022-2836(86)90452-3; SCHULTZ MC, 1992, CELL, V69, P697, DOI 10.1016/0092-8674(92)90233-3; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SHARP PA, 1992, CELL, V68, P819, DOI 10.1016/0092-8674(92)90023-6; STARR DB, 1991, CELL, V67, P1231, DOI 10.1016/0092-8674(91)90299-E; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; STRUBIN M, 1992, CELL, V68, P721, DOI 10.1016/0092-8674(92)90147-5; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; Travers AA, 1991, CURR OPIN STRUC BIOL, V1, P114, DOI 10.1016/0959-440X(91)90019-P; WHITE RJ, 1992, TRENDS GENET, V8, P284, DOI 10.1016/0168-9525(92)90255-3; WOBBE CR, 1990, MOL CELL BIOL, V10, P3859, DOI 10.1128/MCB.10.8.3859; WOLBERGER C, 1993, CURR OPIN STRUC BIOL, V3, P3, DOI 10.1016/0959-440X(93)90194-P; WORKMAN JL, 1987, CELL, V51, P613, DOI 10.1016/0092-8674(87)90130-9; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; YAMAMOTO T, 1992, P NATL ACAD SCI USA, V89, P2844, DOI 10.1073/pnas.89.7.2844; ZAWEL L, 1992, Current Opinion in Cell Biology, V4, P488, DOI 10.1016/0955-0674(92)90016-6; ZENZIEGREGORY B, 1993, MOL CELL BIOL, V13, P3841, DOI 10.1128/MCB.13.7.3841; ZIFF EB, 1978, CELL, V15, P1463, DOI 10.1016/0092-8674(78)90070-3	56	1014	1025	1	57	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 7	1993	365	6446					520	527		10.1038/365520a0	http://dx.doi.org/10.1038/365520a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MA661	8413605				2022-12-24	WOS:A1993MA66100045
J	KAN, MK; WANG, F; XU, JM; CRABB, JW; HOU, JZ; MCKEEHAN, WL				KAN, MK; WANG, F; XU, JM; CRABB, JW; HOU, JZ; MCKEEHAN, WL			AN ESSENTIAL HEPARIN-BINDING DOMAIN IN THE FIBROBLAST GROWTH-FACTOR RECEPTOR KINASE	SCIENCE			English	Article							HIGH-AFFINITY RECEPTOR; SULFATE PROTEOGLYCAN; CELL-SURFACE; IDENTIFICATION; STIMULATION; CLONING	Heparin or heparin-like heparan sulfate proteoglycans are obligatory for activity of the heparin-binding fibroblast growth factor (FGF) family. Heparin interacts independently of FGF ligand with a specific sequence (K18K) in one of the immunoglobulin-like loops in the extracellular domain of the FGF receptor tyrosine kinase transmembrane glycoprotein. A synthetic peptide corresponding to K18K inhibited heparin and heparin-dependent FGF binding to the receptor. K18K and an antibody to K18K were antagonists of FGF-stimulated cell growth. Point mutations of lysine residues in the K18K sequence abrogated both heparin- and ligand-binding activities of the receptor kinase. The results indicate that the FGF receptor is a ternary complex of heparan sulfate proteoglycan, tyrosine kinase transmembrane glycoprotein, and ligand.	W ALTON JONES CELL SCI CTR INC,OLD BARN RD,LAKE PLACID,NY 12946									CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; HOU JZ, 1991, SCIENCE, V251, P665, DOI 10.1126/science.1846977; HOU JZ, 1992, J BIOL CHEM, V267, P17804; KAN M, 1988, J BIOL CHEM, V263, P11306; KAN M, 1991, METHOD ENZYMOL, V198, P158; KAN MK, 1990, IN VITRO CELL DEV B, V26, P1151; KIEFER MC, 1990, P NATL ACAD SCI USA, V87, P6985, DOI 10.1073/pnas.87.18.6985; MARYNEN P, 1989, J BIOL CHEM, V264, P7017; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; SAKAGUCHI K, 1991, J BIOL CHEM, V266, P7270; SAUNDERS S, 1989, J CELL BIOL, V108, P1547, DOI 10.1083/jcb.108.4.1547; XU JM, 1992, J BIOL CHEM, V267, P17792; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	13	479	494	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 26	1993	259	5103					1918	1921		10.1126/science.8456318	http://dx.doi.org/10.1126/science.8456318			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KU172	8456318				2022-12-24	WOS:A1993KU17200038
J	GERSTEIN, HC				GERSTEIN, HC			INCIDENCE OF POSTPARTUM THYROID-DYSFUNCTION IN PATIENTS WITH TYPE-I DIABETES-MELLITUS	ANNALS OF INTERNAL MEDICINE			English	Article						THYROID DISEASES; DIABETES-MELLITUS, INSULIN DEPENDENT; THYROIDITIS, AUTOIMMUNE; PUERPERIUM; GRAVES DISEASE	TERM FOLLOW-UP; CLINICAL COURSE; GRAVES-DISEASE; HYPERTHYROIDISM; HYPOTHYROIDISM; PREGNANCY; DELIVERY; HLA-DR4; ANTIGEN	Objective: To assess the incidence of postpartum thyroid dysfunction in women with type I diabetes. Design: Cohort study of consecutive patients, with clinical and biochemical assessments of thyroid dysfunction and glycemic control done during the first postpartum week and 3 and 6 months after delivery. Setting: University medical center providing obstetric care for more than 90% of the pregnant women in the region with type I diabetes. Patients: Fifty-one patients with type I diabetes who resided in the Hamilton, Ontario, catchment area and who delivered babies between May 1989 and June 1991, were not taking thyroid medication or thyroactive or immunosuppressive medications. Forty patients completed follow-up. Main Outcome Measures: Postpartum thyroid dysfunction was defined on the basis of thyroid function test results. Results: Postpartum thyroid dysfunction occurred in 10 of 40 patients (25%; 95% CI, 12.7% to 41.2%); postpartum thyroiditis developed in 9 patients and postpartum Graves disease developed in 1 patient during the first 6 months after delivery. The incidence could have varied between 19.6% and 41.2%, depending on whether none or all of the 11 nonparticipating eligible patients developed thyroid dysfunction. Glycemic control was not affected by thyroid dysfunction. Conclusions: Women with type I diabetes are at a high risk for symptomatic postpartum thyroid dysfunction and therefore may benefit from routine thyroid function screening at postpartum visits.	MCMASTER UNIV, HAMILTON L8S 4L8, ONTARIO, CANADA	McMaster University			Gerstein, Hertzel/ABB-8781-2020; Gerstein, Hertzel C/B-1235-2013	Gerstein, Hertzel/0000-0001-8072-2836; Gerstein, Hertzel C/0000-0001-8072-2836				AMINO N, 1982, J CLIN ENDOCR METAB, V55, P108, DOI 10.1210/jcem-55-1-108; BECH K, 1991, ACTA ENDOCRINOL-COP, V124, P534, DOI 10.1530/acta.0.1240534; BILLEWICZ WZ, 1969, Q J MED, V38, P255; CHIOVATO L, 1988, ENDOCRINOLOGY, V123, P1140, DOI 10.1210/endo-123-2-1140; CROOKS J, 1959, Q J MED, V28, P211; FUNG HYM, 1988, BRIT MED J, V296, P241, DOI 10.1136/bmj.296.6617.241; GERSTEIN HC, 1990, ARCH INTERN MED, V150, P1397, DOI 10.1001/archinte.150.7.1397; HASHIZUME K, 1991, NEW ENGL J MED, V324, P947, DOI 10.1056/NEJM199104043241403; HAYSLIP CC, 1988, AM J OBSTET GYNECOL, V159, P203, DOI 10.1016/0002-9378(88)90522-4; JANSSON R, 1985, J CLIN ENDOCR METAB, V60, P168, DOI 10.1210/jcem-60-1-168; JANSSON R, 1988, BAILLIERE CLIN ENDOC, V2, P619, DOI 10.1016/S0950-351X(88)80056-9; JANSSON R, 1984, J CLIN ENDOCR METAB, V58, P681, DOI 10.1210/jcem-58-4-681; LERVANG HH, 1987, ACTA MED SCAND, V222, P369; LERVANG HH, 1984, TISSUE ANTIGENS, V23, P250; LESHIN M, 1985, AM J MED SCI, V290, P77, DOI 10.1097/00000441-198508000-00007; MCKENNA MJ, 1990, DIABETES CARE, V13, P801, DOI 10.2337/diacare.13.7.801; NIKOLAI TF, 1987, ARCH INTERN MED, V147, P221, DOI 10.1001/archinte.147.2.221; NIKOLAI TF, 1989, AM J MED SCI, V297, P18, DOI 10.1097/00000441-198901000-00005; OTHMAN S, 1990, CLIN ENDOCRINOL, V32, P559, DOI 10.1111/j.1365-2265.1990.tb00898.x; POP VJM, 1991, NEW ENGL J MED, V324, P1815; ROBERTON HEW, 1948, BMJ-BRIT MED J, V2, P2275; TACHI J, 1988, J CLIN ENDOCR METAB, V66, P480, DOI 10.1210/jcem-66-3-480; WALFISH PG, 1985, CLIN ENDOCRINOL META, V14, P417, DOI 10.1016/S0300-595X(85)80041-4	23	65	69	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1993	118	6					419	423		10.7326/0003-4819-118-6-199303150-00004	http://dx.doi.org/10.7326/0003-4819-118-6-199303150-00004			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KR817	8439115				2022-12-24	WOS:A1993KR81700004
J	SHOICHET, BK; STROUD, RM; SANTI, DV; KUNTZ, ID; PERRY, KM				SHOICHET, BK; STROUD, RM; SANTI, DV; KUNTZ, ID; PERRY, KM			STRUCTURE-BASED DISCOVERY OF INHIBITORS OF THYMIDYLATE SYNTHASE	SCIENCE			English	Article							MULTIWIRE AREA DETECTOR; NUCLEIC-ACIDS; BINDING; REFINEMENT; PROTEINS; DESIGN; SYSTEM; SITE	A molecular docking computer program (DOCK) was used to screen the Fine Chemical Directory, a database of commercially available compounds, for molecules that are complementary to thymidylate synthase (TS), a chemotherapeutic target. Besides retrieving the substrate and several known inhibitors, DOCK proposed putative inhibitors previously unknown to bind to the enzyme. Three of these compounds inhibited Lactobacillus casei TS at submillimolar concentrations. One of these inhibitors, sulisobenzone, crystallized with TS in two configurations that differed from the DOCK-favored geometry: a counterion was bound in the substrate site, which resulted in a 6 to 9 angstrom displacement of the inhibitor. The structure of the complexes suggested another binding region in the active site that could be exploited. This region was probed with molecules sterically similar to sulisobenzone, which led to the identification of a family of phenolphthalein analogs that inhibit TS in the 1 to 30 micromolar range. These inhibitors do not resemble the substrates of the enzyme. A crystal structure of phenolphthalein with TS shows that it binds in the target site in a configuration that resembles the one suggested by DOCK.	UNIV CALIF SAN FRANCISCO, DEPT PHARMACEUT CHEM, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NIGMS NIH HHS [GM39553, GM31497, GM24485] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024485, R37GM024485, R01GM031497, R01GM039553] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APPELT K, 1991, J MED CHEM, V34, P1925, DOI 10.1021/jm00111a001; BLUM M, 1987, J APPL CRYSTALLOGR, V20, P235, DOI 10.1107/S0021889887086783; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHAMBERS JL, 1977, ACTA CRYSTALLOGR B, V33, P1824, DOI 10.1107/S0567740877007146; CHEN SC, 1989, INT J BIOCHEM, V21, P1217, DOI 10.1016/0020-711X(89)90006-2; CLIMIE S, 1990, P NATL ACAD SCI USA, V87, P633, DOI 10.1073/pnas.87.2.633; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; DESJARLAIS RL, 1988, J MED CHEM, V31, P722, DOI 10.1021/jm00399a006; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; FINERMOORE J, IN PRESS J MOL BIOL; FINERMOORE JS, 1990, BIOCHEMISTRY-US, V29, P6977, DOI 10.1021/bi00482a005; GASTEIGER J, 1980, TETRAHEDRON, V36, P3219, DOI 10.1016/0040-4020(80)80168-2; GILSON MK, 1988, J COMPUT CHEM, V9, P327, DOI 10.1002/jcc.540090407; GUNER OF, 1991, J CHEM INF COMP SCI, V31, P408, DOI 10.1021/ci00003a007; HARDY LW, 1987, SCIENCE, V235, P448, DOI 10.1126/science.3099389; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; JONES TR, 1981, EUR J CANCER, V17, P11, DOI 10.1016/0014-2964(81)90206-1; KALMAN TI, 1973, BIOCHEM BIOPH RES CO, V55, P210, DOI 10.1016/S0006-291X(73)80081-6; KAMB A, 1992, BIOCHEMISTRY-US, V31, P9883, DOI 10.1021/bi00156a005; KUNTZ ID, 1982, J MOL BIOL, V161, P269, DOI 10.1016/0022-2836(82)90153-X; MATTHEWS DA, 1990, J MOL BIOL, V214, P923, DOI 10.1016/0022-2836(90)90346-N; MENG EC, 1992, J COMPUT CHEM, V13, P505, DOI 10.1002/jcc.540130412; MONTFORT WR, 1990, BIOCHEMISTRY-US, V29, P6964, DOI 10.1021/bi00482a004; PINEDO HM, 1988, J CLIN ONCOL, V6, P1653, DOI 10.1200/JCO.1988.6.10.1653; RASHIN AA, 1990, J PHYS CHEM-US, V94, P1725, DOI 10.1021/j100368a005; REYES P, 1965, MOL PHARMACOL, V1, P14; SANTI DV, 1984, FOLATES PTERINS, V1, P345; SHOICHET BK, 1992, J COMPUT CHEM, V13, P380, DOI 10.1002/jcc.540130311; VARNEY MD, 1992, J MED CHEM, V35, P663, DOI 10.1021/jm00082a006; WAHBA AJ, 1961, J BIOL CHEM, V236, pPC11; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051	31	277	288	2	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 5	1993	259	5100					1445	1450		10.1126/science.8451640	http://dx.doi.org/10.1126/science.8451640			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KP978	8451640				2022-12-24	WOS:A1993KP97800034
J	KEKULE, AS; LAUER, U; WEISS, L; LUBER, B; HOFSCHNEIDER, PH				KEKULE, AS; LAUER, U; WEISS, L; LUBER, B; HOFSCHNEIDER, PH			HEPATITIS-B VIRUS TRANSACTIVATOR HBX USES A TUMOR PROMOTER SIGNALING PATHWAY	NATURE			English	Article							PROTEIN-KINASE-C; MAMMALIAN-CELLS; X-PROTEIN; POTENT INHIBITOR; GENE; DNA; EXPRESSION; PHOSPHATIDYLCHOLINE; HEPATOCYTES; ACTIVATION	THE hepatitis B virus (HBV) transactivator protein HBx is enigmatic in that it stimulates a striking variety of promoters which do not share a common cis-regulatory element1-5. As it does not bind to DNA6,7, it has been speculated that HBx acts indirectly through cellular pathways4,6-8. Under certain conditions HBx can have an oncogenic potential, which may be relevant for HBV-associated liver carcinogenesis9-11, but until now the mechanism for transactivation and cell transformation by HBx was unclear. We report here that HBx uses a complex signal transduction pathway for transactivation. An increase in the endogenous protein kinase C (PKC) activator sn-1,2-diacylglycerol and the subsequent activation of PKC give rise to activation of the transcription factor AP-1 (Jun-Fos). As a result, HBx transactivates through binding sites for AP-1 and other PKC-dependent transcription factors (AP-2, NF-kappaB), thereby explaining the as-yet incomprehensible variety of HBx-inducible genes. As the PKC signal cascade also mediates cell transformation by tumour-promoting agents, the mechanism presented here might account for the oncogenic potential of HBx.			KEKULE, AS (corresponding author), MAX PLANCK INST BIOCHEM,KLOPFERSPITZ 18A,W-8033 MARTINSRIED,GERMANY.							ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ASANO T, 1984, J PHARMACOL EXP THER, V231, P141; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BLUM HE, 1992, J VIROL, V66, P1223, DOI 10.1128/JVI.66.2.1223-1227.1992; BUSCHER M, 1988, ONCOGENE, V3, P301; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EXTON JH, 1990, J BIOL CHEM, V265, P1; FABBRO D, 1985, ARCH BIOCHEM BIOPHYS, V239, P102, DOI 10.1016/0003-9861(85)90816-1; FAKTOR O, 1990, ONCOGENE, V5, P867; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HOHNE M, 1990, EMBO J, V9, P1137, DOI 10.1002/j.1460-2075.1990.tb08220.x; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; LACAL JC, 1987, NATURE, V330, P269, DOI 10.1038/330269a0; LOOMIS CR, 1988, J BIOL CHEM, V263, P1682; LUCITO R, 1992, J VIROL, V66, P983, DOI 10.1128/JVI.66.2.983-991.1992; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; MULLER U, 1989, GENE DEV, V3, P1991, DOI 10.1101/gad.3.12a.1991; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PREISS J, 1986, J BIOL CHEM, V261, P8597; ROSSNER MT, 1992, J MED VIROL, V36, P101, DOI 10.1002/jmv.1890360207; SEIFER M, 1991, J HEPATOL, V13, pS61, DOI 10.1016/0168-8278(91)90026-8; SETO E, 1990, NATURE, V344, P72, DOI 10.1038/344072a0; SIDDIQUI A, 1987, P NATL ACAD SCI USA, V84, P2513, DOI 10.1073/pnas.84.8.2513; SONG JG, 1991, MOL CELL BIOL, V11, P4903, DOI 10.1128/MCB.11.10.4903; SPANDAU DF, 1988, J VIROL, V62, P427, DOI 10.1128/JVI.62.2.427-434.1988; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TOULLEC D, 1991, J BIOL CHEM, V266, P15571; TWU JS, 1987, J VIROL, V61, P3448, DOI 10.1128/JVI.61.11.3448-3453.1987; VANVELDHOVEN PP, 1987, ANAL BIOCHEM, V161, P45, DOI 10.1016/0003-2697(87)90649-X; WASYLYK C, 1987, CELL, V48, P525, DOI 10.1016/0092-8674(87)90203-0; WOLLERSHEIM M, 1988, VIRAL HEPATITIS LIVE, P334; WU JY, 1990, CELL, V63, P687, DOI 10.1016/0092-8674(90)90135-2; YAGINUMA K, 1987, P NATL ACAD SCI USA, V84, P2678, DOI 10.1073/pnas.84.9.2678; ZAHM P, 1988, ONCOGENE, V3, P169	41	358	369	1	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 25	1993	361	6414					742	745		10.1038/361742a0	http://dx.doi.org/10.1038/361742a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KN789	8441471				2022-12-24	WOS:A1993KN78900062
J	VISKIN, S; BELHASSEN, B; ROTH, A; REICHER, M; AVERBUCH, M; SHEPS, D; SHALABYE, E; LANIADO, S				VISKIN, S; BELHASSEN, B; ROTH, A; REICHER, M; AVERBUCH, M; SHEPS, D; SHALABYE, E; LANIADO, S			AMINOPHYLLINE FOR BRADYASYSTOLIC CARDIAC-ARREST REFRACTORY TO ATROPINE AND EPINEPHRINE	ANNALS OF INTERNAL MEDICINE			English	Note						AMINOPHYLLINE; CARDIAC ARREST; ASYSTOLE; BRADYARRHYTHMIAS	ATRIOVENTRICULAR-CONDUCTION; MYOCARDIAL-INFARCTION; ADENOSINE; ANTAGONISM; BLOCK	Endogenous adenosine, which accumulates during hypoxia and ischemia, may perpetuate asystole. Therefore, patients with cardiac arrest were prospectively studied to see if their immediate outcome could be improved with aminophylline, a competitive antagonist of adenosine. Fifteen consecutive patients with cardiac arrest due to asystole or to nonperfusing bradyarrhythmias, who failed to respond to intravenous atropine and epinephrine, were treated with aminophylline (rapid intravenous injection of 250 mg). Establishment of a stable heart rhythm with sufficient blood pressure to allow discontinuation of closed-chest cardiac massage was achieved in 11 of 15 (73%) patients. All these 11 patients were alive 60 minutes after resuscitation. One patient survived, without neurologic damage. We conclude that the immediate outcome of patients with asystole refractory to standard treatment may be improved with aminophylline. Further study is warranted to determine if earlier administration of aminophylline during cardiac arrest will improve long-term outcome.	TEL AVIV UNIV, SACKLER SCH MED, TEL AVIV, ISRAEL	Tel Aviv University; Sackler Faculty of Medicine	VISKIN, S (corresponding author), TEL AVIV MED CTR & SCH MED, DEPT CARDIOL, WEIZMAN ST 6, IL-64239 TEL AVIV, ISRAEL.							BELARDINELLI L, 1982, CIRC RES, V51, P569, DOI 10.1161/01.RES.51.5.569; BELARDINELLI L, 1989, PROG CARDIOVASC DIS, V32, P73, DOI 10.1016/0033-0620(89)90015-7; HORI M, 1991, CIRCULATION, V84, P828, DOI 10.1161/01.CIR.84.2.828; LERMAN BB, 1988, J CLIN INVEST, V82, P2127, DOI 10.1172/JCI113834; PARADIS NA, 1990, ANN EMERG MED, V19, P1288, DOI 10.1016/S0196-0644(05)82289-9; PELLEG A, 1990, AM J PHYSIOL, V258, pH1815, DOI 10.1152/ajpheart.1990.258.6.H1815; ROBERTS D, 1990, CHEST, V97, P413, DOI 10.1378/chest.97.2.413; STRASBERG B, 1991, AM J CARDIOL, V67, P527, DOI 10.1016/0002-9149(91)90016-E; VESTAL RE, 1983, CIRCULATION, V67, P162, DOI 10.1161/01.CIR.67.1.162; WESLEY RC, 1986, J AM COLL CARDIOL, V8, P1232, DOI 10.1016/S0735-1097(86)80406-5; 1992, JAMA-J AM MED ASSOC, V268, P2199	11	46	52	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1993	118	4					279	281		10.7326/0003-4819-118-4-199302150-00006	http://dx.doi.org/10.7326/0003-4819-118-4-199302150-00006			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KL457	8420445				2022-12-24	WOS:A1993KL45700006
J	MULLER, YA; SCHULZ, GE				MULLER, YA; SCHULZ, GE			STRUCTURE OF THE THIAMINE-DEPENDENT AND FLAVIN-DEPENDENT ENZYME PYRUVATE OXIDASE	SCIENCE			English	Article							MECHANISM; PROTEINS	Pyruvate oxidase from Lactobacillus plantarum is a tetrameric enzyme that decarboxylates pyruvate, producing hydrogen peroxide and the energy-storage metabolite acetylphosphate. Structure determination at 2.1 angstroms showed that the cofactors thiamine pyrophosphate (TPP) and flavin adenine dinucleotide (FAD) are bound at the carboxyl termini of six-stranded parallel beta sheets. The pyrophosphate moiety of TPP is bound to a metal ion and to a betaalphaalphabeta unit corresponding to an established sequence fingerprint. The spatial arrangement of TPP and FAD suggests that the oxidation of the oxyethyl intermediate does not occur by hydride displacement but rather by a two-step transfer of two electrons.	UNIV FREIBURG,INST ORGAN CHEM & BIOCHEM,W-7800 FREIBURG,GERMANY	University of Freiburg			Muller, Yves A/R-5397-2016	Muller, Yves A/0000-0003-0519-8928				BLAKE R, 1982, J BIOL CHEM, V257, P9605; BRICOGNE G, 1976, ACTA CRYSTALLOGR A, V32, P832, DOI 10.1107/S0567739476001691; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; GOETZ F, 1991, P286; GREEN JBA, 1989, FEBS LETT, V246, P1, DOI 10.1016/0014-5793(89)80241-8; HAWKINS CF, 1989, FEBS LETT, V255, P77, DOI 10.1016/0014-5793(89)81064-6; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KARPLUS PA, 1987, J MOL BIOL, V195, P701, DOI 10.1016/0022-2836(87)90191-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LINDQVIST Y, 1992, EMBO J, V11, P2373, DOI 10.1002/j.1460-2075.1992.tb05301.x; RAO ST, 1973, J MOL BIOL, V76, P241, DOI 10.1016/0022-2836(73)90388-4; RAWN DJ, 1983, BIOCHEMISTRY-US, P414; RISSE B, IN PRESS PROTEIN SCI; SCHELLENBERGER A, 1990, CHEM BER, V123, P1489, DOI 10.1002/cber.19901230709; SCHREUDER HA, 1990, BIOCHEMISTRY-US, V29, P3101, DOI 10.1021/bi00464a029; SCHULZ GE, 1992, CURR OPIN STRUC BIOL, V2, P61; SUNDSTROM M, 1992, FEBS LETT, V313, P229, DOI 10.1016/0014-5793(92)81197-T; WIERENGA RK, 1985, BIOCHEMISTRY-US, V24, P1346, DOI 10.1021/bi00327a012	18	217	222	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 12	1993	259	5097					965	967		10.1126/science.8438155	http://dx.doi.org/10.1126/science.8438155			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL800	8438155				2022-12-24	WOS:A1993KL80000041
J	TAPPERO, JW; MOHLEBOETANI, J; KOEHLER, JE; SWAMINATHAN, B; BERGER, TG; LEBOIT, PE; SMITH, LL; WENGER, JD; PINNER, RW; KEMPER, CA; REINGOLD, AL				TAPPERO, JW; MOHLEBOETANI, J; KOEHLER, JE; SWAMINATHAN, B; BERGER, TG; LEBOIT, PE; SMITH, LL; WENGER, JD; PINNER, RW; KEMPER, CA; REINGOLD, AL			THE EPIDEMIOLOGY OF BACILLARY ANGIOMATOSIS AND BACILLARY PELIOSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CAT-SCRATCH DISEASE; ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS-RELATED COMPLEX; EPITHELIOID ANGIOMATOSIS; INFECTION; PATHOGENS; AGENT	Objective.-To determine environmental risk factors for bacillary angiomatosis-bacillary peliosis (BAP), and to confirm infection with Rochalimaea species. Design.-Case-control study. Setting.-Community and university hospitals and clinics. Patients.-Case patients (N=48) had biopsy-confirmed BAP. Controls (N=94) were matched to patients by institution and by human immunodeficiency virus (HIV) serological status. Main Outcome Measures.-Clinical information was obtained from medical records. Subjects were queried about environmental exposures. Univariate odds ratios (ORs) with 95% confidence intervals (CIs) were determined. Bivariate analyses were performed on variables associated with disease by univariate analysis. DNA from 22 available case-patient tissues and from 22 control tissues was amplified with the polymerase chain reaction (PCR) using primers designed to detect Rochalimaea species. Results.-We identified five HIV-negative, immunocompetent case patients; one HIV-negative, immunodeficient case patient; and 42 HIV-positive case patients. There were no significant differences between case patients and controls by race, sex, age, or risk factors for HIV infection. Owning a cat (OR, 2.8; CI, 1.4 to 5.8) and history of a recent cat lick (OR, 1.95; CI, 1.0 to 3.8), cat scratch (OR, 3.7; CI, 1.7 to 8.0), or cat bite (OR, 3.9; CI, 1.8 to 8.9) were associated with disease in the univariate analysis. In bivariate analyses, only the variables representing traumatic contact with a cat (bite or scratch) remained associated with disease. No other environmental exposure was associated with disease. The PCR amplified a DNA fragment of the size expected for Rochalimaea species in all 22 case-patient tissue specimens. Conclusions.-These data suggest that BAP is a new zoonosis associated with both traumatic exposure to cats and infection with Rochalimaea species or a closely related organism.	UNIV CALIF SAN FRANCISCO,DEPT DERMATOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED & LAB MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PATHOL,SAN FRANCISCO,CA 94143; CTR DIS CONTROL,MYCOT DIS BRANCH,ATLANTA,GA 30333; STANFORD UNIV,MED CTR,DIV INFECT DIS,STANFORD,CA 94305; SANTA CLARA VALLEY MED CTR,SAN JOSE,CA 95128; UNIV CALIF BERKELEY,SCH PUBL HLTH,EPIDEMIOL PROGRAM,BERKELEY,CA 94720	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Centers for Disease Control & Prevention - USA; Stanford University; Santa Clara Valley Medical Center; University of California System; University of California Berkeley	TAPPERO, JW (corresponding author), CTR DIS CONTROL,NATL CTR INFECT DIS,DIV BACTERIAL & MYCOT DIS,ATLANTA,GA 30333, USA.		Mohle-Boetani, Janet/AAH-4221-2019		NIAMS NIH HHS [AR07175-15] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007175] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AZAD AF, 1992, P NATL ACAD SCI USA, V89, P43, DOI 10.1073/pnas.89.1.43; BERGER TG, 1989, ARCH DERMATOL, V125, P1543, DOI 10.1001/archderm.125.11.1543; BRENNER DJ, 1991, J CLIN MICROBIOL, V29, P2450, DOI 10.1128/JCM.29.11.2450-2460.1991; CARITHERS HA, 1985, AM J DIS CHILD, V139, P1124, DOI 10.1001/archpedi.1985.02140130062031; CHAN JKC, 1991, AM J SURG PATHOL, V15, P430, DOI 10.1097/00000478-199105000-00002; COCKERELL CJ, 1987, LANCET, V2, P654; Dean A. G., 1990, EPI INFO VERSION 5 W; ENGLISH CK, 1988, JAMA-J AM MED ASSOC, V259, P1347, DOI 10.1001/jama.259.9.1347; HELLER MJ, 1991, BIOTECHNIQUES, V11, P372; Hertig Marshall, 1942, AMER JOUR TROP MED SUPPL, V22, P1; KEMPER CA, 1990, AM J MED, V89, P216, DOI 10.1016/0002-9343(90)90301-S; KOEHLER JE, 1988, ANN INTERN MED, V109, P449, DOI 10.7326/0003-4819-109-6-449; KOEHLER JE, 1992, NEW ENGL J MED, V327, P1625, DOI 10.1056/NEJM199212033272303; LEBOIT PE, 1988, LANCET, V1, P960; LUCEY D, 1992, CLIN INFECT DIS, V14, P683, DOI 10.1093/clinids/14.3.683; OCONNOR SP, 1991, J CLIN MICROBIOL, V29, P2144, DOI 10.1128/JCM.29.10.2144-2150.1991; PERKINS BA, 1992, NEW ENGL J MED, V327, P1599, DOI 10.1056/NEJM199211263272215; PERKOCHA LA, 1990, NEW ENGL J MED, V323, P1581, DOI 10.1056/NEJM199012063232302; REGNERY RL, 1992, LANCET, V339, P1443, DOI 10.1016/0140-6736(92)92032-B; REGNERY RL, 1992, J CLIN MICROBIOL, V30, P265, DOI 10.1128/JCM.30.2.265-274.1992; RELMAN DA, 1992, MOL MICROBIOL, V6, P1801, DOI 10.1111/j.1365-2958.1992.tb01352.x; RELMAN DA, 1990, NEW ENGL J MED, V323, P1573, DOI 10.1056/NEJM199012063232301; SLATER LN, 1990, NEW ENGL J MED, V323, P1587, DOI 10.1056/NEJM199012063232303; SPACH DH, 1992, ANN INTERN MED, V116, P740, DOI 10.7326/0003-4819-116-9-740; SPENCER L, 1992, J AM VET MED ASSOC, V201, P1669; Spink WW, 1956, NATURE BRUCELLOSIS; STOLER MH, 1983, AM J CLIN PATHOL, V80, P714, DOI 10.1093/ajcp/80.5.714; STRONG RP, 1918, TRENCH FEVER REPORT; TAPPERO JW, 1991, JAMA-J AM MED ASSOC, V266, P1938, DOI 10.1001/jama.1991.03470140050020; TAPPERO JW, 1991, 7TH INT C AIDS FLOR, V1, P340; TAPPERO JW, 1960, AM J MED, V28, P504; WEAR DJ, 1983, SCIENCE, V221, P1403, DOI 10.1126/science.6612349; WEISBURG WG, 1985, SCIENCE, V230, P556, DOI 10.1126/science.3931222; WELCH DF, 1992, J CLIN MICROBIOL, V30, P275, DOI 10.1128/JCM.30.2.275-280.1992; WRIGHT DK, 1990, PCR PROTOCOLS GUIDE, P153; 1992, SAS RELEASE 6 07	36	165	172	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 10	1993	269	6					770	775		10.1001/jama.269.6.770	http://dx.doi.org/10.1001/jama.269.6.770			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK544	8423659				2022-12-24	WOS:A1993KK54400030
J	HARKNESS, MR; MCDERMOTT, JB; ABRAMOWICZ, DA; SALVO, JJ; FLANAGAN, WP; STEPHENS, ML; MONDELLO, FJ; MAY, RJ; LOBOS, JH; CARROLL, KM; BRENNAN, MJ; BRACCO, AA; FISH, KM; WARNER, GL; WILSON, PR; DIETRICH, DK; LIN, DT; MORGAN, CB; GATELY, WL				HARKNESS, MR; MCDERMOTT, JB; ABRAMOWICZ, DA; SALVO, JJ; FLANAGAN, WP; STEPHENS, ML; MONDELLO, FJ; MAY, RJ; LOBOS, JH; CARROLL, KM; BRENNAN, MJ; BRACCO, AA; FISH, KM; WARNER, GL; WILSON, PR; DIETRICH, DK; LIN, DT; MORGAN, CB; GATELY, WL			INSITU STIMULATION OF AEROBIC PCB BIODEGRADATION IN HUDSON RIVER SEDIMENTS	SCIENCE			English	Article							POLYCHLORINATED BIPHENYL METABOLISM; ALCALIGENES-EUTROPHUS H850; ANAEROBIC MICROORGANISMS; DEGRADATION; DECHLORINATION; SORPTION; HYDROCARBONS; STRAINS; SOILS	A 73-day field study of in situ aerobic biodegradation of polychlorinated biphenyls (PCBs) in the Hudson River shows that indigenous aerobic microorganisms can degrade the lightly chlorinated PCBs present in these sediments. Addition of inorganic nutrients, biphenyl, and oxygen enhanced PCB biodegradation, as indicated both by a 37 to 55 percent loss of PCBs and by the production of chlorobenzoates, intermediates in the PCB biodegradation pathway. Repeated inoculation with a purified PCB-degrading bacterium failed to improve biodegradative activity. Biodegradation was also observed under mixed but unamended conditions, which suggests that this process may occur commonly in river sediments, with implications for PCB fate models and risk assessments.	GE,CTR CORP RES & DEV,SCHENECTADY,NY 12301	General Electric								ABRAMOWICZ DA, 1990, CRIT REV BIOTECHNOL, V10, P241, DOI 10.3109/07388559009038210; ABRAMOWICZ DA, 1992, 1991 IN SITU HUDSON; AHMED M, 1973, CAN J MICROBIOL, V19, P47, DOI 10.1139/m73-007; ATLAS RM, 1981, MICROBIOL REV, V45, P180, DOI 10.1128/MMBR.45.1.180-209.1981; BEDARD DL, 1990, ADV AP BIOT, V4, P369; BEDARD DL, 1990, MICROBIAL ECOL, V20, P87, DOI 10.1007/BF02543870; BEDARD DL, 1987, APPL ENVIRON MICROB, V53, P1094, DOI 10.1128/AEM.53.5.1094-1102.1987; BEDARD DL, 1986, APPL ENVIRON MICROB, V51, P761, DOI 10.1128/AEM.51.4.761-768.1986; BEDARD DL, 1987, APPL ENVIRON MICROB, V53, P1103, DOI 10.1128/AEM.53.5.1103-1112.1987; BROWN JF, 1990, ENVIRON TOXICOL CHEM, V9, P1215, DOI 10.1002/etc.5620091001; BROWN JF, 1987, ENVIRON TOXICOL CHEM, V6, P579, DOI 10.1897/1552-8618(1987)6[579:EDOP]2.0.CO;2; BROWN JF, 1987, SCIENCE, V236, P709, DOI 10.1126/science.236.4802.709; Clesceri LS, 1989, STANDARD METHODS EXA; CLIFTON MJ, 1986, J APPL ELECTROCHEM, V16, P812, DOI 10.1007/BF01006526; Coates JT, 1986, J CONTAM HYDROL, V1, P191; DUNNIVANT FM, 1988, THESIS CLEMSON U; FISCHER R, 1988, FRESEN Z ANAL CHEM, V332, P441, DOI 10.1007/BF00499265; FLANAGAN WP, UNPUB; FOCHT DD, 1985, APPL ENVIRON MICROB, V50, P1058, DOI 10.1128/AEM.50.4.1058-1063.1985; FURUKAWA K, 1978, AGR BIOL CHEM TOKYO, V42, P543, DOI 10.1080/00021369.1978.10863017; FURUKAWA K, 1982, BIODEGRADATION DETOX, P33; HATZIKONSTANTINOU H, 1978, BIOCHEM J, V174, P893, DOI 10.1042/bj1740893; HERNANDEZ BS, 1991, APPL ENVIRON MICROB, V57, P3361, DOI 10.1128/AEM.57.11.3361-3366.1991; HICKEY WJ, 1990, APPL ENVIRON MICROB, V56, P3842, DOI 10.1128/AEM.56.12.3842-3850.1990; Karickhoff S.W., 1980, CONTAMINANTS SEDIMEN, P193; KARICKHOFF SW, 1985, ENVIRON TOXICOL CHEM, V4, P469; KAWAHARA FK, 1968, ANAL CHEM, V40, P2073, DOI 10.1021/ac60269a044; LAKE JL, 1992, MAR ENVIRON RES, V33, P31, DOI 10.1016/0141-1136(92)90004-6; LARSSON P, 1992, ENVIRON SCI TECHNOL, V26, P346, DOI 10.1021/es00026a016; MADSEN EL, 1991, ENVIRON SCI TECHNOL, V25, P1663, DOI 10.1021/es00022a001; MEANS JC, 1980, ENVIRON SCI TECHNOL, V14, P1524, DOI 10.1021/es60172a005; MONDELLO FJ, 1989, J BACTERIOL, V171, P1725, DOI 10.1128/jb.171.3.1725-1732.1989; PIGNATELLO JJ, 1990, ENVIRON TOXICOL CHEM, V9, P1107, DOI 10.1002/etc.5620090901; Pourbaix M, 1974, ATLAS ELECTROCHEMICA, P309; PRITCHARD PH, 1991, ENVIRON SCI TECHNOL, V25, P372, DOI 10.1021/es00015a002; QUENSEN JF, 1988, SCIENCE, V242, P752, DOI 10.1126/science.242.4879.752; Sediak DL, 1991, ENVIRON SCI TECHNOL, V25, P1419; SUNDSTROM G, 1976, CHEMOSPHERE, V5, P267, DOI 10.1016/0045-6535(76)90002-3; VANDORT HM, 1991, APPL ENVIRON MICROB, V57, P1576, DOI 10.1128/AEM.57.5.1576-1578.1991	39	148	157	2	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 22	1993	259	5094					503	507		10.1126/science.8424172	http://dx.doi.org/10.1126/science.8424172			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KJ079	8424172				2022-12-24	WOS:A1993KJ07900031
J	OSMOND, DH; PADIAN, NS; SHEPPARD, HW; GLASS, S; SHIBOSKI, SC; REINGOLD, A				OSMOND, DH; PADIAN, NS; SHEPPARD, HW; GLASS, S; SHIBOSKI, SC; REINGOLD, A			RISK-FACTORS FOR HEPATITIS-C VIRUS SEROPOSITIVITY IN HETEROSEXUAL COUPLES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NON-B-HEPATITIS; HUMAN-IMMUNODEFICIENCY-VIRUS; NON-A-HEPATITIS; SEXUAL TRANSMISSION; UNITED-STATES; DRUG-USERS; ANTIBODIES; HEMOPHILIACS; PREVALENCE; INFECTION	Objectives.-To determine the risk of heterosexual transmission of hepatitis C virus (HCV) and to identify other risk factors for HCV seropositivity in heterosexual couples. Design.-Retrospective cross-sectional study comparing HCV-seropositive and HCV-seronegative heterosexual men and women. Setting.-Couples recruited from the community and screened for participation in a study of the heterosexual transmission of human immunodeficiency virus. Participants.-A total of 340 subjects, 170 men and 170 women in sexual partnerships, aged 18 through 61 years. Main Outcome Measure.-Seropositivity for HCV antibodies. Results.-Overall, 31 (18%) of the 170 women and 56 (33%) of the 170 men were positive by a four-antigen HCV immunoblot. Injection drug use and hemophilia were strongly associated with HCV seropositivity. Sixty-four percent of injection drug users were positive (odds ratio [OR], 27.0; 95% confidence interval [CI], 13.4 to 56.1; P<.0001), as were all four hemophiliacs in the study. History of blood transfusion was significantly associated with HCV seropositivity (OR, 2.7; 95% CI, 1.1 to 7.0; P=.02). Positivity for HCV was not associated with measures of sexual behavior within couples or with numbers of other sexual partners, history of sexually transmitted diseases, or human immunodeficiency virus seropositivity. However, two of the 31 women without parenteral risk but with a long-term HCV-positive male partner were HCV seropositive compared with none of 81 women with an HCV-negative male partner (P=.07). Conclusions.-These results provide little evidence of HCV sexual transmission but are consistent with infrequent sexual transmission. They corroborate the importance of injection drug use and transfusion of blood or blood products in transmitting HCV and underscore the importance of ascertaining parenteral exposures when examining sexual transmission of HCV.	UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA 94143; CALIF DEPT HLTH SERV,VIRAL & RICKETTSIAL DIS LAB,BERKELEY,CA; UNIV CALIF BERKELEY,SCH PUBL HLTH,BERKELEY,CA 94720	University of California System; University of California San Francisco; California Department of Health Care Services; University of California System; University of California Berkeley	OSMOND, DH (corresponding author), SAN FRANCISCO GEN HOSP,DIV EPIDEMIOL,WARD 95 995 POTRERO AVE,SAN FRANCISCO,CA 94110, USA.							ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; ALTER MJ, 1989, NEW ENGL J MED, V321, P1538, DOI 10.1056/NEJM198911303212208; ALTER MJ, 1982, J INFECT DIS, V145, P886, DOI 10.1093/infdis/145.6.886; ALTER MJ, 1990, JAMA-J AM MED ASSOC, V264, P2231, DOI 10.1001/jama.264.17.2231; ALTER MJ, 1987, AM J EPIDEMIOL, V125, P132; BENAMOUZIG R, 1990, ANN INTERN MED, V113, P638, DOI 10.7326/0003-4819-113-8-638_1; BLOSSER JW, 1991, 3RD INT S HCV STRASB; CARLSON JR, 1985, JAMA-J AM MED ASSOC, V253, P3405, DOI 10.1001/jama.253.23.3405; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; DEPALMA M, 1991, 3RD INT S HCV STRASB; ESTEBAN JI, 1990, NEW ENGL J MED, V323, P1107, DOI 10.1056/NEJM199010183231605; EVANS CS, 1991, 3RD INT S HCV STRASB; EVERHART JE, 1990, ANN INTERN MED, V112, P544, DOI 10.7326/0003-4819-112-7-544; EYSTER ME, 1991, ANN INTERN MED, V115, P764, DOI 10.7326/0003-4819-115-10-764; FARCI P, 1991, NEW ENGL J MED, V325, P98, DOI 10.1056/NEJM199107113250205; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; MAZZOTTA F, 1991, 3RD INT S HCV STRASB; MELBYE M, 1990, BRIT MED J, V301, P210, DOI 10.1136/bmj.301.6745.210; MORTIMER PP, 1989, LANCET, V2, P798; MOSELEY JW, 1990, JAMA-J AM MED ASSOC, V263, P77; NELSON KE, 1991, 3RD INT S HCV STRASB; PACHUCKI CT, 1991, J INFECT DIS, V164, P820, DOI 10.1093/infdis/164.4.820; PADIAN N, 1987, JAMA-J AM MED ASSOC, V258, P788, DOI 10.1001/jama.258.6.788; PADIAN NS, 1991, JAMA-J AM MED ASSOC, V266, P1664; RUMI MG, 1990, ANN INTERN MED, V112, P379, DOI 10.7326/0003-4819-112-5-379; Schlesselman J. J, 1982, CASE CONTROL STUDIES, P207; SIMMONDS P, 1990, LANCET, V336, P1469, DOI 10.1016/0140-6736(90)93179-S; TEDDER RS, 1991, BRIT MED J, V302, P1302; TOR J, 1990, BRIT MED J, V301, P1130, DOI 10.1136/bmj.301.6761.1130; VANDERPOEL CL, 1990, LANCET, V335, P558, DOI 10.1016/0140-6736(90)90347-8; VANDERPOEL CL, 1991, LANCET, V337, P317, DOI 10.1016/0140-6736(91)90942-I; WEINER AJ, 1990, LANCET, V335, P1, DOI 10.1016/0140-6736(90)90134-Q; 1987, SAS STAT GUIDE PERSO; 1989, EGRET USERS MANUAL 3, P43	34	150	149	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 20	1993	269	3					361	365		10.1001/jama.269.3.361	http://dx.doi.org/10.1001/jama.269.3.361			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG381	8418342				2022-12-24	WOS:A1993KG38100027
J	BENHAR, I; ENGELBERGKULKA, H				BENHAR, I; ENGELBERGKULKA, H			FRAMESHIFTING IN THE EXPRESSION OF THE ESCHERICHIA-COLI TRPR GENE OCCURS BY THE BYPASSING OF A SEGMENT OF ITS CODING SEQUENCE	CELL			English	Article							POLYMERASE-III HOLOENZYME; CHAIN RELEASE FACTORS; ESCHERICHIA-COLI; GAMMA-SUBUNIT; STRUCTURAL GENE; MESSENGER-RNA; PROTEIN; PEPTIDE; REPRESSOR; YEAST	The E. coli trpR gene encodes the 108 amino acid long trp repressor. We have previously shown that a +1 frameshifting event occurs during the expression of trpR. Here we show that the transition from the 0 to the +1 frame of trpR occurs by the bypassing of a 55 nt long segment of the trpR+1-lacZ mRNA. This bypassing event is not pretranslational, and it probably takes place during translation. Two adjacent elements are required: a specific sequence of trpR, which must be preceded by a nonspecific 5' end longer than 10 translatable codons. Unique to trpR-lacZ bypassing is that the 55 nt long region must be translated in frame 0 to enable bypassing into the +1 frame. Translational bypassing as a newly discovered mechanism of gene expression is discussed, and the possible existence of translational introns is suggested.			BENHAR, I (corresponding author), HEBREW UNIV JERUSALEM,HADASSAH MED SCH,DEPT MOLEC BIOL,IL-91010 JERUSALEM,ISRAEL.			Benhar, Itai/0000-0002-0824-7177				ATKINS JF, 1990, CELL, V62, P413, DOI 10.1016/0092-8674(90)90007-2; BARRY G, 1980, P NATL ACAD SCI-BIOL, V77, P3331, DOI 10.1073/pnas.77.6.3331; BELCOURT MF, 1990, CELL, V62, P339, DOI 10.1016/0092-8674(90)90371-K; BENHAR I, 1992, MOL MICROBIOL, V6, P2777, DOI 10.1111/j.1365-2958.1992.tb01457.x; BENHAR I, 1991, GENE, V103, P79, DOI 10.1016/0378-1119(91)90394-Q; BENHAR I, 1990, POSTTRANSCRIPTIONAL, P591; BLINKOWA AL, 1990, NUCLEIC ACIDS RES, V18, P1725, DOI 10.1093/nar/18.7.1725; BOGOSIAN G, 1981, J MOL BIOL, V149, P821, DOI 10.1016/0022-2836(81)90361-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASADABAN MJ, 1980, J BACTERIOL, V143, P971, DOI 10.1128/JB.143.2.971-980.1980; CRAIGEN WJ, 1987, CELL, V50, P1, DOI 10.1016/0092-8674(87)90652-0; CRAIGEN WJ, 1987, BIOCHIMIE, V69, P1031, DOI 10.1016/0300-9084(87)90003-4; CRAIGEN WJ, 1986, NATURE, V322, P273, DOI 10.1038/322273a0; CRAIGEN WJ, 1985, P NATL ACAD SCI USA, V82, P3616, DOI 10.1073/pnas.82.11.3616; ENGELBERGKULKA H, 1988, TRENDS BIOCHEM SCI, V13, P419, DOI 10.1016/0968-0004(88)90209-5; FLOWER AM, 1990, P NATL ACAD SCI USA, V87, P3713, DOI 10.1073/pnas.87.10.3713; GIMBLE P, 1992, NATURE, V357, P301; GROVE CL, 1987, J BACTERIOL, V169, P2158, DOI 10.1128/jb.169.5.2158-2164.1987; GUNSALUS RP, 1980, P NATL ACAD SCI-BIOL, V77, P7117, DOI 10.1073/pnas.77.12.7117; HEATWOLE VM, 1991, J BACTERIOL, V173, P3601, DOI 10.1128/jb.173.11.3601-3604.1991; HUANG WM, 1988, SCIENCE, V239, P1005, DOI 10.1126/science.2830666; KANE PM, 1990, SCIENCE, V250, P651, DOI 10.1126/science.2146742; KANG C, 1985, J MOL BIOL, V181, P241, DOI 10.1016/0022-2836(85)90088-9; Maniatis T., 1982, MOL CLONING; Miller J.H., 1972, EXPT MOL GENETICS; OCONNOR M, 1989, EMBO J, V8, P4315, DOI 10.1002/j.1460-2075.1989.tb08618.x; PARKER J, 1989, MICROBIOL REV, V53, P273, DOI 10.1128/MMBR.53.3.273-298.1989; PIKIELNY CW, 1985, CELL, V41, P119, DOI 10.1016/0092-8674(85)90066-2; ROEDER W, 1979, MOL GEN GENET, V176, P361, DOI 10.1007/BF00333098; ROSE JK, 1973, NATURE-NEW BIOL, V245, P133, DOI 10.1038/newbio245133a0; SARSERO JP, 1991, J BACTERIOL, V173, P4133, DOI 10.1128/jb.173.13.4133-4143.1991; TSUCHIHASHI Z, 1990, P NATL ACAD SCI USA, V87, P2516, DOI 10.1073/pnas.87.7.2516; VARMUS H, 1988, SCIENCE, V240, P1427, DOI 10.1126/science.3287617; WEISS RB, 1990, CELL, V62, P117, DOI 10.1016/0092-8674(90)90245-A; WEISS RB, 1987, COLD SPRING HARB SYM, V52, P687, DOI 10.1101/SQB.1987.052.01.078; WONG SC, 1990, J BACTERIOL, V172, P630, DOI 10.1128/jb.172.2.630-642.1990; YANOFSKY C, 1987, ESCHERICHIA COLI SAL, P1453; ZURAWSKI G, 1981, J MOL BIOL, V145, P47, DOI 10.1016/0022-2836(81)90334-X	38	40	40	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 15	1993	72	1					121	130		10.1016/0092-8674(93)90056-V	http://dx.doi.org/10.1016/0092-8674(93)90056-V			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KG955	8422674				2022-12-24	WOS:A1993KG95500016
J	GORMAN, M; KURODA, MI; BAKER, BS				GORMAN, M; KURODA, MI; BAKER, BS			REGULATION OF THE SEX-SPECIFIC BINDING OF THE MALELESS DOSAGE COMPENSATION PROTEIN TO THE MALE X-CHROMOSOME IN DROSOPHILA	CELL			English	Article							FEMALE-SPECIFIC LETHAL; SACCHAROMYCES-CEREVISIAE; TRANSFORMER GENE; SPLICE SITE; MELANOGASTER; EXPRESSION; RNA; DIFFERENTIATION; SNF5; PRODUCT	In Drosophila, the single male X chromosome is transcribed at twice the rate of a single female X chromosome. This hypertranscription requires the functions of at least four autosomal male-specific lethal genes (msls) and is under the control of the Sex-lethal (Sxl) gene. One of the msls, the maleless (mle) gene, encodes a protein that is associated with the male X chromosome. To investigate how dosage compensation is regulated, we have determined whether Sxl and the other msls are required for mle X chromosome binding. We have found that in females, Sxl functions to prevent mle from binding to the two X chromosomes. Additionally, we have found that mle X chromosome binding requires wild-type msl1, msl2, and msl3 functions. These data support a model whereby the activity of the mle protein is regulated through its association with one or more of the other msl proteins.	BAYLOR COLL MED, DEPT CELL BIOL, HOUSTON, TX 77030 USA	Baylor College of Medicine	GORMAN, M (corresponding author), STANFORD UNIV, DEPT BIOL SCI, STANFORD, CA 94305 USA.							ABRAMS E, 1986, MOL CELL BIOL, V6, P3643, DOI 10.1128/MCB.6.11.3643; BAKER BS, 1983, ANNU REV GENET, V17, P345, DOI 10.1146/annurev.ge.17.120183.002021; BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BELL LR, 1991, CELL, V65, P229, DOI 10.1016/0092-8674(91)90157-T; BELL LR, 1988, CELL, V55, P1037, DOI 10.1016/0092-8674(88)90248-6; BELOTE JM, 1980, NATURE, V285, P573, DOI 10.1038/285573a0; BELOTE JM, 1980, GENETICS, V96, P165; BIRCHLER JA, 1982, GENETICS, V102, P525; BOGGS RT, 1987, CELL, V50, P739, DOI 10.1016/0092-8674(87)90332-1; BOPP D, 1991, GENE DEV, V5, P403, DOI 10.1101/gad.5.3.403; BREEN TR, 1986, GENETICS, V112, P483; CLINE TW, 1986, GENETICS, V113, P641; CLINE TW, 1978, GENETICS, V90, P683; CLINE TW, 1984, GENETICS, V107, P231; CLINE TW, 1980, GENETICS, V96, P903; CLINE TW, 1983, DEV BIOL, V95, P260, DOI 10.1016/0012-1606(83)90027-1; CLINE TW, 1979, DEV BIOL, V72, P266, DOI 10.1016/0012-1606(79)90117-9; CLINE TW, 1985, ORIGIN EVOLUTION SEX, P301; CLINE TW, 1982, GENETICS S, V100, P13; CLINE TW, 1988, EVOLUTIONARY MECHANI, P23; CLINE TW, 1986, GENETICS, V114, P345; DAVIS JL, 1992, MOL CELL BIOL, V12, P1879, DOI 10.1128/MCB.12.4.1879; DOBZHANSKY T, 1957, CHROMOSOMA, V8, P691; ESTRUCH F, 1990, MOL CELL BIOL, V10, P2544, DOI 10.1128/MCB.10.6.2544; FUKUNAGA A, 1975, GENETICS, V81, P135; GANGULY R, 1985, GENE, V35, P91, DOI 10.1016/0378-1119(85)90161-1; GERGEN JP, 1987, GENETICS, V117, P477; GOLUBOVSKY MD, 1972, DROS INF SERV, V49, P117; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; HAPPEL AM, 1991, GENETICS, V128, P69; HODGKIN J, 1990, NATURE, V344, P721, DOI 10.1038/344721a0; HOLMQUIST G, 1972, CHROMOSOMA, V36, P413, DOI 10.1007/BF00336796; INOUE K, 1990, NATURE, V344, P461, DOI 10.1038/344461a0; JAFFE E, 1986, TRENDS GENET, V2, P316, DOI 10.1016/0168-9525(86)90287-8; KURODA MI, 1991, CELL, V66, P935, DOI 10.1016/0092-8674(91)90439-6; LAURENT BC, 1990, MOL CELL BIOL, V10, P5616, DOI 10.1128/MCB.10.11.5616; LAURENT BC, 1991, P NATL ACAD SCI USA, V88, P2687, DOI 10.1073/pnas.88.7.2687; LAURENT BC, 1992, MOL CELL BIOL, V12, P1893, DOI 10.1128/MCB.12.4.1893; LINDSLEY DL, 1992, GENOME DORSOPHILA ME; LUCCHESI JC, 1981, CHROMOSOMA, V82, P217, DOI 10.1007/BF00286106; LUCCHESI JC, 1987, ADV GENET, V24, P371, DOI 10.1016/S0065-2660(08)60013-9; LUCCHESI JC, 1982, GENETICS, V100, P42; MCKEOWN M, 1988, CELL, V53, P887, DOI 10.1016/S0092-8674(88)90369-8; MUKHERJEE AS, 1965, NATURE, V207, P785, DOI 10.1038/207785a0; MUKHERJEE AS, 1966, NUCLEUS CALCUTTA, V9, P83; MULLER HJ, 1960, GENETICS, V45, P1001; NAGOSHI RN, 1988, CELL, V53, P229, DOI 10.1016/0092-8674(88)90384-4; NEIGEBORN L, 1984, GENETICS, V108, P845; OKUNO T, 1984, JPN J GENET, V59, P237, DOI 10.1266/jjg.59.237; OTTER T, 1987, ANAL BIOCHEM, V162, P370, DOI 10.1016/0003-2697(87)90406-4; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; SANCHEZ L, 1982, ROUX ARCH DEV BIOL, V186, P235; SKRIPSKY T, 1982, DEV BIOL, V94, P153, DOI 10.1016/0012-1606(82)90078-1; SOSNOWSKI BA, 1989, CELL, V58, P449, DOI 10.1016/0092-8674(89)90426-1; Steinmann-Zwicky M, 1990, Adv Genet, V27, P189; TRAVERS AA, 1992, CELL, V69, P573, DOI 10.1016/0092-8674(92)90218-2; TURNER BM, 1992, CELL, V69, P375, DOI 10.1016/0092-8674(92)90417-B; UCHIDA S, 1981, JPN J GENET, V56, P523, DOI 10.1266/jjg.56.523; UENOYAMA T, 1982, GENETICS, V102, P233	59	85	85	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 15	1993	72	1					39	49		10.1016/0092-8674(93)90048-U	http://dx.doi.org/10.1016/0092-8674(93)90048-U			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KG955	8422681				2022-12-24	WOS:A1993KG95500008
J	RUSTICI, A; VELUCCHI, M; FAGGIONI, R; SIRONI, M; GHEZZI, P; QUATAERT, S; GREEN, B; PORRO, M				RUSTICI, A; VELUCCHI, M; FAGGIONI, R; SIRONI, M; GHEZZI, P; QUATAERT, S; GREEN, B; PORRO, M			MOLECULAR MAPPING AND DETOXIFICATION OF THE LIPID-A BINDING-SITE BY SYNTHETIC PEPTIDES	SCIENCE			English	Article							TUMOR-NECROSIS-FACTOR; BORDETELLA-PERTUSSIS ENDOTOXIN; POLYMYXIN-B; HUMAN-MONOCYTES; SEPTIC SHOCK; FACTOR-ALPHA; LIPOPOLYSACCHARIDE; INTERLEUKIN-1; EXPRESSION; ANTIBODIES	Endotoxin [lipopolysaccharide (LPS)], the major antigen of the outer membrane of Gram-negative bacteria, consists of a variable-size carbohydrate chain that is covalently linked to N,O-acylated beta-1,6-D-glucosamine disaccharide 1,4'-bisphosphate (lipid A). The toxic activity of LPS resides in the lipid A structure. The structural features of synthetic peptides that bind to lipid A with high affinity, detoxify LPS in vitro, and prevent LPS-induced cytokine release and lethality in vivo were defined. The binding thermodynamics were comparable to that of an antigen-antibody reaction. Such synthetic peptides may provide a strategy for prophylaxis and treatment of LPS-mediated diseases.	RAPOLANO TERME,BIOSYNTH RES LABS,I-53040 SIENA,ITALY; LEDERLE PRAXIS BIOL,ROCHESTER,NY 14623; MARIO NEGRI INST PHARMACOL RES,I-20157 MILAN,ITALY	Istituto di Ricerche Farmacologiche Mario Negri IRCCS			sironi, marina/AAB-5757-2020	sironi, marina/0000-0002-3342-1149; Ghezzi, Pietro/0000-0003-0911-8358				AGGARWAL BB, 1985, J BIOL CHEM, V260, P2345; ARNDT B, 1991, IMMUNOBIOLOGY PROTEI, V6, P129; Atherton E., 1981, J CHEM SOC P1, V1, P538; BERZOFSKY JA, 1978, CLIN CHEM, V24, P419; BROWN SE, 1984, J IMMUNOL METHODS, V72, P41, DOI 10.1016/0022-1759(84)90431-9; CAROFF M, 1983, CARBOHYD RES, V114, P95, DOI 10.1016/0008-6215(83)88176-2; CAROFF M, 1986, INFECT IMMUN, V54, P465, DOI 10.1128/IAI.54.2.465-471.1986; CAROFF M, 1988, CARBOHYD RES, V175, P273, DOI 10.1016/0008-6215(88)84149-1; CAVAILLON JM, 1986, MOL IMMUNOL, V23, P965, DOI 10.1016/0161-5890(86)90127-6; CRAIG WA, 1974, INFECT IMMUN, V10, P287, DOI 10.1128/IAI.10.2.287-292.1974; CYGLER M, 1991, SCIENCE, V253, P442, DOI 10.1126/science.1713710; DINARELLO CA, 1991, J INFECT DIS, V163, P1177, DOI 10.1093/infdis/163.6.1177; DINARELLO CA, 1983, AGENTS ACTIONS, V13, P470, DOI 10.1007/BF02176419; HABEEB AFS, 1966, ANAL BIOCHEM, V14, P328, DOI 10.1016/0003-2697(66)90275-2; KOTANI S, 1985, INFECT IMMUN, V49, P225, DOI 10.1128/IAI.49.1.225-237.1985; LOPPNOW H, 1990, INFECT IMMUN, V58, P3743, DOI 10.1128/IAI.58.11.3743-3750.1990; MORRISON DC, 1976, IMMUNOCHEMISTRY, V13, P813, DOI 10.1016/0019-2791(76)90181-6; NESTEL FP, 1992, J EXP MED, V175, P405, DOI 10.1084/jem.175.2.405; POMERANTZ RJ, 1990, J EXP MED, V172, P253, DOI 10.1084/jem.172.1.253; PORRO M, 1986, MOL IMMUNOL, V23, P385, DOI 10.1016/0161-5890(86)90136-7; PORRO M, 1985, MOL IMMUNOL, V22, P907, DOI 10.1016/0161-5890(85)90077-X; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; RIFKIND D, 1967, J BACTERIOL, V93, P1463, DOI 10.1128/JB.93.4.1463-1464.1967; SHIMOZATO T, 1990, INFECT IMMUN, V58, P1384, DOI 10.1128/IAI.58.5.1384-1390.1990; SIRONI M, 1989, J IMMUNOL, V142, P549; SPEAR GT, 1984, J IMMUNOL METHODS, V73, P321, DOI 10.1016/0022-1759(84)90407-1; STOKES DC, 1989, J INFECT DIS, V160, P52, DOI 10.1093/infdis/160.1.52; ULICH TR, 1989, AM J PATHOL, V134, P11; WADE D, 1990, P NATL ACAD SCI USA, V87, P4761, DOI 10.1073/pnas.87.12.4761; WESTPHAL O, 1952, Z NATURFORSCH B, V7, P148, DOI 10.1515/znb-1952-0303; WRIGHT SD, 1991, SCIENCE, V252, P1321, DOI 10.1126/science.252.5010.1321-a; YOCKOCHI T, 1990, J IMMUNOL, V144, P3106; ZIEGLER EJ, 1991, NEW ENGL J MED, V324, P429, DOI 10.1056/NEJM199102143240701; 1985, US PHARMACOPEIA, V21	34	143	169	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 15	1993	259	5093					361	365		10.1126/science.8420003	http://dx.doi.org/10.1126/science.8420003			5	Multidisciplinary Sciences	Index Chemicus (IC); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KG624	8420003				2022-12-24	WOS:A1993KG62400032
J	ADAMS, WG; DEAVER, KA; COCHI, SL; PLIKAYTIS, BD; ZELL, ER; BROOME, CV; WENGER, JD				ADAMS, WG; DEAVER, KA; COCHI, SL; PLIKAYTIS, BD; ZELL, ER; BROOME, CV; WENGER, JD			DECLINE OF CHILDHOOD HAEMOPHILUS-INFLUENZAE TYPE-B (HIB) DISEASE IN THE HIB VACCINE ERA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CAPSULAR POLYSACCHARIDE VACCINE; UNITED-STATES CHILDREN; BACTERIAL-MENINGITIS; CONJUGATE VACCINE; EFFICACY; SURVEILLANCE; AGE	Objective.-Effective Haemophilus influenzae type b (Hib) conjugate vaccines were first licensed for use in US children at least 18 months old in December 1987 and for infants at least 2 months old in October 1990. We evaluated trends in Hib disease associated with licensure of Hib conjugate vaccines. Design.-Data from two sources, an intensive laboratory-based active surveillance system and the National Bacterial Meningitis Reporting System (NBMRS), were used separately to evaluate disease incidence. Data from vaccine manufacturers on Hib vaccine doses distributed in the United States were compared with trends in Hib disease incidence. Results.-The age-specific incidence of Hib disease among children less than 5 years old decreased by 71 % from 37 per 100 000 persons in 1989 to 11 per 100 000 persons in 1991 (active surveillance data). Haemophilus influenzae meningitis incidence decreased by 82% between 1985 and 1991 (NBMRS data). Increases in doses of Hib vaccine distributed in the United States coincided with steep declines in Hib disease. Both surveillance systems showed decreased rates of Hib disease in infants less than 1 year old before vaccine was licensed for use in this age group. Haemophilus influenzae type b disease incidence in persons at least 12 years old and pneumococcal meningitis incidence in children less than 5 years old did not change substantially during the same period; therefore, decreased Hib disease in children less than 5 years old is not likely to be explained solely by changes in surveillance sensitivity or decreases in bacterial disease due to changes in medical practice. Conclusion.-Our data suggest that conjugate vaccines have already had a marked impact on the incidence of Hib disease in the United States, preventing an estimated 10000 to 16000 cases of Hib disease in 1991. The decline of disease in infants less than 1 year old before licensure for this age group warrants further investigation.	CTR DIS CONTROL & PREVENT,NATL CTR PREVENT SERV,BIOSTAT & INFORMAT MANAGEMENT BRANCH,ATLANTA,GA; CTR DIS CONTROL & PREVENT,NATL CTR PREVENT DIS,DIV IMMUNIZAT,ATLANTA,GA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	ADAMS, WG (corresponding author), NATL CTR INFECT DIS,DIV BACTERIAL & MYCOT DIS,MENINGITIS & SPECIAL PATHOGENS BRANCH,ATLANTA,GA 30333, USA.			Adams, William/0000-0002-5330-0010				BLACK SB, 1991, PEDIATR INFECT DIS J, V10, P97, DOI 10.1097/00006454-199102000-00004; COCHI SL, 1985, JAMA-J AM MED ASSOC, V253, P521, DOI 10.1001/jama.253.4.521; CUTTS FT, 1992, JAMA-J AM MED ASSOC, V267, P1952, DOI 10.1001/jama.267.14.1952; DEAN AG, 1990, EPIINFO VERSION 5 WO; GREENBERG DP, 1991, JAMA-J AM MED ASSOC, V265, P987, DOI 10.1001/jama.265.8.987; LEPEL MH, 1988, NEW ENGL J MED, V319, P964; LOUGHLIN AM, 1992, PEDIATR INFECT DIS J, V11, P374, DOI 10.1097/00006454-199205000-00007; OSTERHOLM MT, 1991, 31ST INT C ANT AG CH; PELTOLA H, 1984, NEW ENGL J MED, V310, P1561, DOI 10.1056/NEJM198406143102404; PELTOLA H, 1977, PEDIATRICS, V60, P730; SANTOSHAM M, 1991, NEW ENGL J MED, V324, P1767, DOI 10.1056/NEJM199106203242503; SCHLECH WF, 1985, JAMA-J AM MED ASSOC, V253, P1749, DOI 10.1001/jama.253.12.1749; SELL SH, 1983, PEDIATR INFECT DIS J, V2, P90, DOI 10.1097/00006454-198303000-00003; SHAPIRO ED, 1991, EPIDEMIOL REV, V13, P113, DOI 10.1093/oxfordjournals.epirev.a036066; TAKALA AK, 1991, J INFECT DIS, V164, P982, DOI 10.1093/infdis/164.5.982; WENGER JD, 1991, LANCET, V338, P395; WENGER JD, 1990, J INFECT DIS, V162, P1316, DOI 10.1093/infdis/162.6.1316; 1985, MMWR, V34, P201; 1990, MMWR, V39, P232; 1989, MMWR, V38, P32; 1989, MMWR, V38, P14; 1991, MMWR, V40, P1; 1991, PEDIATRICS, V88, P169; 1992, 93 US DEP HLTH HUM S, P4; 1988, MMWR, V37, P13; 1991, JAMA-J AM MED ASSOC, V266, P1547; 1985, NEW VACCINE DEV ESTA; 1990, MMWR, V39, P698	28	534	546	0	21	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 13	1993	269	2					221	226		10.1001/jama.269.2.221	http://dx.doi.org/10.1001/jama.269.2.221			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF405	8417239				2022-12-24	WOS:A1993KF40500027
J	PERRING, TM; COOPER, AD; RODRIGUEZ, RJ; FARRAR, CA; BELLOWS, TS				PERRING, TM; COOPER, AD; RODRIGUEZ, RJ; FARRAR, CA; BELLOWS, TS			IDENTIFICATION OF A WHITEFLY SPECIES BY GENOMIC AND BEHAVIORAL-STUDIES	SCIENCE			English	Article							BEMISIA-TABACI	An introduced whitefly species, responsible for over a half billion dollars in damage to U.S. agricultural production in 1991, is morphologically indistinguishable from Bemisia tabaci (Gennadius). However, with the use of polymerase chain reaction-based DNA differentiation tests, allozymic frequency analyses, crossing experiments, and mating behavior studies, the introduced whitefly is found to be a distinct species. Recognition of this new species, the silverleaf whitefly, is critical in the search for management options.	UNIV CALIF RIVERSIDE,DEPT PLANT PATHOL,RIVERSIDE,CA 92521	University of California System; University of California Riverside	PERRING, TM (corresponding author), UNIV CALIF RIVERSIDE,DEPT ENTOMOL,RIVERSIDE,CA 92521, USA.							AYALA FJ, 1985, POPULATION EVOLUTION; BETHKE JA, 1991, ANN ENTOMOL SOC AM, V84, P401; BHARATHAN N, 1990, PLANT PATHOL, V39, P530, DOI 10.1111/j.1365-3059.1990.tb02530.x; BREADY E, 1991, TEX VEG ASS PESTIC R, V1, P1; BROWN JK, 1992, PLANT DIS, V76, P220, DOI 10.1094/PD-76-0220; Byrne Daragh, COMMUNICATION; BYRNE DN, 1991, ANNU REV ENTOMOL, V36, P431, DOI 10.1146/annurev.en.36.010191.002243; BYRNE DN, 1990, WHITEFLIES : THEIR BIONOMICS, PEST STATUS AND MANAGEMENT, P227; BYRNE DN, 1990, J INSECT PHYSIOL, V36, P433, DOI 10.1016/0022-1910(90)90061-J; Cock M.J.W., 1986, BEMISIA TABACI LIT S; COHEN S, 1992, PHYTOPATHOLOGY, V82, P86, DOI 10.1094/Phyto-82-86; COSTA HS, 1991, ENTOMOL EXP APPL, V61, P211, DOI 10.1007/BF00187724; CULOTTA E, 1991, SCIENCE, V254, P1445, DOI 10.1126/science.254.5037.1445; DIEHL SR, 1984, ANNU REV ENTOMOL, V29, P471, DOI 10.1146/annurev.en.29.010184.002351; EPPLEN J, 1989, J HERED, V79, P409; FAUST RM, 1992, C REPORT 5 YEAR NATI; Gennadius P., 1889, ELLENIKE GEORGIA, V5, P1; GILL RJ, 1992, PAN-PAC ENTOMOL, V68, P144; Greathead D. J., 1981, Biocontrol News and Information, V2, P7; GUPTA M, 1991, INT SOC PLANT BIOL; LI TY, 1989, ENVIRON ENTOMOL, V18, P800, DOI 10.1093/ee/18.5.800; Mound L. A., 1963, Proceedings of the Royal Entomological Society of London (A), V38, P171; Mound L.A., 1983, P305; Mound L.A., 1978, WHITEFLY WORLD; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; Nei M., 1976, P723; OWEN J L, 1991, Animal Biotechnology, V2, P107, DOI 10.1080/10495399109525753; Perring T. M., 1991, California Agriculture, V45, P10; PERRING TM, 1992, J ECON ENTOMOL, V85, P1278, DOI 10.1093/jee/85.4.1278; POWELL DA, 1992, ENVIRON ENTOMOL, V21, P359, DOI 10.1093/ee/21.2.359; Price J.F., 1987, GREENHOUSE GROWER, V35, P55; QUAINTANCE AL, 1900, TECH SER BUR ENTOMOL, V8, P9; RODRIGUEZ RJ, 1991, EXP MYCOL, V15, P232, DOI 10.1016/0147-5975(91)90025-9; Russell L.M, 1975, Co-operative Economic Insect Report, V25, P229; Sambrook J., 1989, MOL CLONING LAB MANU; SCHUSTER DI, COMMUNICATION; WEISING K, 1989, NUCLEIC ACIDS RES, V17, P10128, DOI 10.1093/nar/17.23.10128	37	382	475	0	49	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 1	1993	259	5091					74	77		10.1126/science.8418497	http://dx.doi.org/10.1126/science.8418497			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KE601	8418497				2022-12-24	WOS:A1993KE60100031
J	GROVER, SA; BARKUN, AN; SACKETT, DL				GROVER, SA; BARKUN, AN; SACKETT, DL			DOES THIS PATIENT HAVE SPLENOMEGALY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SPLENIC ENLARGEMENT; SPLEEN SIZE; LIVER; PREDICTION		MONTREAL GEN HOSP,DIV GASTROENTEROL,MONTREAL H3G 1A4,QUEBEC,CANADA; MONTREAL GEN HOSP,DIV CLIN EPIDEMIOL,MONTREAL H3G 1A4,QUEBEC,CANADA; MCGILL UNIV,DEPT MED,MONTREAL H3A 2T5,QUEBEC,CANADA; MCGILL UNIV,DEPT EPIDEMIOL & BIOSTAT,MONTREAL H3A 2T5,QUEBEC,CANADA; MCMASTER UNIV,DEPT MED,DIV GEN INTERNAL MED,HAMILTON L8S 4L8,ONTARIO,CANADA; MCMASTER UNIV,DEPT CLIN EPIDEMIOL & BIOSTAT,HAMILTON L8S 4L8,ONTARIO,CANADA; HENDERSON GEN HOSP,HAMILTON L8V 1C3,ONTARIO,CANADA	McGill University; McGill University; McGill University; McGill University; McMaster University; McMaster University; McMaster University	GROVER, SA (corresponding author), MONTREAL GEN HOSP,DIV GEN INTERNAL MED,1650 AVE CEDAR,MONTREAL H3G 1A4,QUEBEC,CANADA.							BARKUN AN, 1989, AM J MED, V87, P562; BARKUN AN, 1991, AM J MED, V91, P512, DOI 10.1016/0002-9343(91)90188-4; BERRIS B, 1966, CAN MED ASSOC J, V95, P1318; BLENDIS LM, 1970, BMJ-BRIT MED J, V1, P727, DOI 10.1136/bmj.1.5698.727; CASTELL DO, 1967, ANN INTERN MED, V67, P1265, DOI 10.7326/0003-4819-67-6-1265; EBAUGH FG, 1979, ANN INTERN MED, V90, P130, DOI 10.7326/0003-4819-90-1-130_2; ESPINOZA P, 1987, DIGEST DIS SCI, V32, P244, DOI 10.1007/BF01297048; HALPERN S, 1974, ARCH INTERN MED, V134, P123, DOI 10.1001/archinte.134.1.123; INGEBERG S, 1983, ACTA HAEMATOL-BASEL, V69, P243, DOI 10.1159/000206899; KOGA T, 1975, RADIOLOGY, V115, P157, DOI 10.1148/115.1.157; LARSON SM, 1971, J NUCL MED, V12, P123; MCINTYRE OR, 1967, ANN INTERN MED, V66, P301, DOI 10.7326/0003-4819-66-2-301; MYERS J, 1974, ARCH PATHOL, V98, P33; NIEDERAU C, 1983, RADIOLOGY, V149, P537, DOI 10.1148/radiology.149.2.6622701; NIXON RK, 1954, NEW ENGL J MED, V250, P166, DOI 10.1056/NEJM195401282500407; RIEMENSCHNEIDER PA, 1965, AMER J ROENTGENOL RA, V94, P462; SHAW MT, 1973, LANCET, V1, P317; SULLIVAN S, 1976, BRIT MED J, V2, P1043, DOI 10.1136/bmj.2.6043.1043; TALBOTT JE, 1970, BIOGRAPHICAL HIST ME, P594; WESTIN J, 1972, ACTA MED SCAND, V191, P263; ZHANG B, 1987, J CLIN PATHOL, V40, P508, DOI 10.1136/jcp.40.5.508	21	51	51	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 10	1993	270	18					2218	2221		10.1001/jama.270.18.2218	http://dx.doi.org/10.1001/jama.270.18.2218			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ME816	8411607				2022-12-24	WOS:A1993ME81600035
J	KUNDROTAS, L				KUNDROTAS, L			STING OF THE FIRE ANT (SOLENOPSIS)	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											KUNDROTAS, L (corresponding author), WILFORD HALL USAF MED CTR,LACKLAND AFB,TX 78236, USA.								0	6	6	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 28	1993	329	18					1317	1317						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD557	8413412				2022-12-24	WOS:A1993MD55700006
J	MOORE, EDW; ETTER, EF; PHILIPSON, KD; CARRINGTON, WA; FOGARTY, KE; LIFSHITZ, LM; FAY, FS				MOORE, EDW; ETTER, EF; PHILIPSON, KD; CARRINGTON, WA; FOGARTY, KE; LIFSHITZ, LM; FAY, FS			COUPLING OF THE NA+/CA2+ EXCHANGER, NA+/K+ PUMP AND SARCOPLASMIC-RETICULUM IN SMOOTH-MUSCLE	NATURE			English	Article							SODIUM CALCIUM EXCHANGE; ENDOPLASMIC-RETICULUM; CELLS; ACTIVATION; RELEASE; CALSEQUESTRIN; CONTRACTION; MECHANISM; PROTEIN	THE Na+/Ca2+ exchanger, driven by a transmembrane Na+ gradient, plays a key role in regulating Ca2+ concentration in many cells1,2. Although the exchanger influences Ca2+ concentration, its activity in smooth muscle appears to be closely coupled to Ca2+ availability from intracellular stores3. This linkage might result if the exchanger were positioned close to Ca2+ storage sites within the sarcoplasmic reticulum. To test this hypothesis we have developed methods to assess the relative three-dimensional distribution of proteins involved in Na+/K+ pumping, Na+/Ca2+ exchange, Ca2+ storage within the sarcoplasmic reticulum, and attachment of contractile filaments to the membrane in smooth muscle. Here we report that the Na+/Ca2+ exchanger is largely co-distributed with the Na+/K+ pump on unique regions, of the plasma membrane in register with, and close to, calsequestrin-containing regions of the sarcoplasmic reticulum in sites distinct from the sites where contractile filaments attach to the membrane. This molecular organization suggests that the plasma membrane is divided into at least two functional domains, and appear to provide a mechanism for the strong linkage seen in smooth muscle between Na+/K+ pumping and Na+/Ca2+ exchange, and between Na+/Ca2+ exchange and Ca2+ release from the sarcoplasmic reticulum4-7.	UNIV MASSACHUSETTS, SCH MED, BIOMED IMAGING GRP, WORCESTER, MA 01605 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT MED, CARDIOVASC RES LAB, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT PHYSIOL, CARDIOVASC RES LAB, LOS ANGELES, CA 90024 USA	University of Massachusetts System; University of Massachusetts Worcester; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	MOORE, EDW (corresponding author), UNIV MASSACHUSETTS, SCH MED, PROGRAM MOLEC MED, WORCESTER, MA 01605 USA.			Moore, Edwin DW/0000-0001-7519-5592				ASHIDA T, 1987, J PHYSIOL-LONDON, V392, P617, DOI 10.1113/jphysiol.1987.sp016800; BIRD GS, 1991, NATURE, V352, P162, DOI 10.1038/352162a0; BRADING AF, 1980, BRIT J PHARMACOL, V70, P229, DOI 10.1111/j.1476-5381.1980.tb07928.x; CARRINGTON WA, 1990, SPIE P, V1205, P72; CARRINGTON WA, 1990, MODERN CELL BIOL, V9, P53; ETTER E F, 1989, Journal of Cell Biology, V109, p169A; FAMBROUGH DM, 1988, TRENDS NEUROSCI, V11, P325, DOI 10.1016/0166-2236(88)90096-3; FAY F S, 1992, Biophysical Journal, V61, pA389; FAY FS, 1989, J MICROSC-OXFORD, V153, P133, DOI 10.1111/j.1365-2818.1989.tb00554.x; FAY FS, 1982, METHOD ENZYMOL, V85, P284; GABELLA G, 1973, PHILOS T R SOC B, V265, P7, DOI 10.1098/rstb.1973.0004; GABELLA G, 1978, CELL TISSUE RES, V190, P255; GEIGER B, 1979, CELL, V18, P193, DOI 10.1016/0092-8674(79)90368-4; GIRARDET M, 1983, BIOCHEMISTRY-US, V22, P2296, DOI 10.1021/bi00278a037; HILGEMANN DW, 1991, NATURE, V352, P715, DOI 10.1038/352715a0; HOROWITZ B, 1990, J BIOL CHEM, V265, P4189; LEBLANC N, 1990, SCIENCE, V248, P372, DOI 10.1126/science.2158146; LIFSHITZ LM, 1992, SOC PHOTOOPT INSTR E, V1808, P521; LYNCH RM, 1991, J CELL BIOL, V112, P385, DOI 10.1083/jcb.112.3.385; MAHONY L, 1986, J BIOL CHEM, V261, P5257; MILNER RE, 1991, J BIOL CHEM, V266, P7155; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; NIGGLI E, 1990, SCIENCE, V250, P565, DOI 10.1126/science.2173135; REUTER H, 1973, PHILOS T R SOC B, V265, P87, DOI 10.1098/rstb.1973.0011; REUTER H, 1991, NATURE, V349, P567, DOI 10.1038/349567a0; SCHEID CR, 1979, NATURE, V277, P32, DOI 10.1038/277032a0; SOMLYO AP, 1971, J CELL BIOL, V51, P722, DOI 10.1083/jcb.51.3.722; STEHNOBITTEL L, 1992, J PHYSIOL-LONDON, V451, P49, DOI 10.1113/jphysiol.1992.sp019153; VANBREEMEN C, 1977, J PHYSIOL-LONDON, V272, P317, DOI 10.1113/jphysiol.1977.sp012046; VILLA A, 1993, J CELL BIOL, V121, P1041, DOI 10.1083/jcb.121.5.1041; WILLIAMS DA, 1986, AM J PHYSIOL, V250, pC779, DOI 10.1152/ajpcell.1986.250.5.C779; WUYTACK F, 1987, BIOCHIM BIOPHYS ACTA, V899, P151, DOI 10.1016/0005-2736(87)90395-6	32	203	203	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 14	1993	365	6447					657	660		10.1038/365657a0	http://dx.doi.org/10.1038/365657a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MB846	8413629				2022-12-24	WOS:A1993MB84600062
J	MOORE, MS; BLOBEL, G				MOORE, MS; BLOBEL, G			THE GTP-BINDING PROTEIN RAN/TC4 IS REQUIRED FOR PROTEIN IMPORT INTO THE NUCLEUS	NATURE			English	Article							PREMATURE CHROMOSOME CONDENSATION; SACCHAROMYCES-CEREVISIAE; GENE RCC1; REGULATOR; INHIBITION; CELLS; DNA; TRANSLOCATION; MUTATION; MITOSIS	Two cytosolic fractions (A and B) from Xenopus oocytes are sufficient to support protein import into the nuclei of digitonin-permeabilized cells1. Fraction A recognizes the nuclear localization sequence (NLS) and binds the import substrate to the nuclear envelope, whereas fraction B mediates the subsequent passage of the bound substrate into the nucleus. Here we report that two interacting components are required for full fraction-B activity, purify one of these components to homogeneity, and show that it is the highly abundant GTP-binding protein Ran (Ras-related nuclear protein)/TC4.			MOORE, MS (corresponding author), ROCKEFELLER UNIV,HOWARD HUGHES MED INST,CELL BIOL LAB,1230 YORK AVE,NEW YORK,NY 10021, USA.							ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; AEBI M, 1990, MOL GEN GENET, V224, P72, DOI 10.1007/BF00259453; AMBERG DC, 1993, EMBO J, V12, P233, DOI 10.1002/j.1460-2075.1993.tb05649.x; BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; BISCHOFF FR, 1991, P NATL ACAD SCI USA, V88, P10830, DOI 10.1073/pnas.88.23.10830; BISCHOFF FR, 1990, P NATL ACAD SCI USA, V87, P8617, DOI 10.1073/pnas.87.21.8617; CLARK KL, 1989, MOL CELL BIOL, V9, P2682, DOI 10.1128/MCB.9.6.2682; CONNOLLY T, 1986, J CELL BIOL, V103, P2253, DOI 10.1083/jcb.103.6.2253; DASSO M, 1993, TRENDS BIOCHEM SCI, V18, P96, DOI 10.1016/0968-0004(93)90161-F; DASSO M, 1992, MOL CELL BIOL, V12, P3337, DOI 10.1128/MCB.12.8.3337; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; FINLAY DR, 1987, J CELL BIOL, V104, P189, DOI 10.1083/jcb.104.2.189; FORRESTER W, 1992, GENE DEV, V2, P754; IMAMOTO N, 1992, J CELL BIOL, V119, P1047, DOI 10.1083/jcb.119.5.1047; MATSUMOTO T, 1991, CELL, V66, P347, DOI 10.1016/0092-8674(91)90624-8; MOORE MS, 1992, CELL, V69, P939, DOI 10.1016/0092-8674(92)90613-H; NISHIMOTO T, 1978, CELL, V15, P475, DOI 10.1016/0092-8674(78)90017-X; OHTSUBO M, 1989, J CELL BIOL, V109, P1389, DOI 10.1083/jcb.109.4.1389; OHTSUBO M, 1991, EMBO J, V10, P1265, DOI 10.1002/j.1460-2075.1991.tb08068.x; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; REN MD, 1993, J CELL BIOL, V120, P313, DOI 10.1083/jcb.120.2.313; SHI YG, 1992, MOL CELL BIOL, V12, P2186, DOI 10.1128/MCB.12.5.2186; UCHIDA S, 1990, MOL CELL BIOL, V10, P577, DOI 10.1128/MCB.10.2.577; VIJAYRAGHAVAN U, 1989, GENE DEV, V3, P1206, DOI 10.1101/gad.3.8.1206; YONEDA Y, 1987, EXP CELL RES, V173, P586, DOI 10.1016/0014-4827(87)90297-7	26	689	694	0	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 14	1993	365	6447					661	663		10.1038/365661a0	http://dx.doi.org/10.1038/365661a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MB846	8413630				2022-12-24	WOS:A1993MB84600063
J	SEKIDO, N; MUKAIDA, N; HARADA, A; NAKANISHI, I; WATANABE, Y; MATSUSHIMA, K				SEKIDO, N; MUKAIDA, N; HARADA, A; NAKANISHI, I; WATANABE, Y; MATSUSHIMA, K			PREVENTION OF LUNG REPERFUSION INJURY IN RABBITS BY A MONOCLONAL-ANTIBODY AGAINST INTERLEUKIN-8	NATURE			English	Article							ISCHEMIA-REPERFUSION; VASCULAR INJURY; LYMPHOCYTES-T; NEUTROPHIL; LEUKOTRIENE-B4; PURIFICATION; DEPLETION; PEPTIDE; BINDING; MODEL	RE-ESTABLISHING blood flow to ischaemic tissues causes greater injury than that induced during the ischaemic period1,2. This type of tissue injury, reperfusion injury, is involved in frostbite, multiple organ failure after hypovolaemia and in myocardial infarction1. Depletion of neutrophils alleviates reperfusion injury, implying a causal role of neutrophil infiltration3,4. Among members of the recently discovered family of chemotactic cytokines (chemokines)5-8, interleukin-8 (IL-8)5,9-13 is a major neutrophil chemotactic and activating factor produced by various types of human cells. We investigated its pathophysiological role in a rabbit model of a lung reperfusion injury. Reperfusion of ischaemic lung caused neutrophil infiltration and destruction of pulmonary structure, as well as local production of IL-8. Furthermore, the administration of a neutralizing monoclonal antibody against IL-8 prevented neutrophil infiltration and tissue injury, proving a causal role of locally produced IL-8 in this model.	KANAZAWA UNIV,SCH MED,CANC RES INST,DEPT PHARMACOL,13-1 TAKARA MACHI,KANAZAWA,ISHIKAWA 920,JAPAN; KANAZAWA UNIV,SCH MED,DEPT PATHOL 1,KANAZAWA,ISHIKAWA 920,JAPAN; KANAZAWA UNIV,SCH MED,DEPT HYG,KANAZAWA,ISHIKAWA 920,JAPAN; KANAZAWA UNIV,SCH MED,DEPT SURG 1,KANAZAWA,ISHIKAWA 920,JAPAN	Kanazawa University; Kanazawa University; Kanazawa University; Kanazawa University			Mukaida, Naofumi/D-7623-2011	Mukaida, Naofumi/0000-0002-4193-1851				ABE Y, IN PRESS BR HEART J; DEFORGE LE, 1992, J CLIN INVEST, V90, P2123, DOI 10.1172/JCI116097; DETMERS PA, 1990, J EXP MED, V171, P1155, DOI 10.1084/jem.171.4.1155; EGAN JW, 1989, PROSTAGLANDINS, V37, P597, DOI 10.1016/0090-6980(89)90075-0; FURIE MB, 1984, J CELL BIOL, V98, P1033, DOI 10.1083/jcb.98.3.1033; GIMBRONE MA, 1989, SCIENCE, V246, P1601, DOI 10.1126/science.2688092; GRANGER DN, 1988, AM J PHYSIOL, V255, pH1269, DOI 10.1152/ajpheart.1988.255.6.H1269; GUESDON JL, 1979, J HISTOCHEM CYTOCHEM, V27, P1131, DOI 10.1177/27.8.90074; HILL J, 1992, SURGERY, V112, P166; HORGAN MJ, 1990, AM J PHYSIOL, V259, pL315, DOI 10.1152/ajplung.1990.259.4.L315; HUBER AR, 1991, SCIENCE, V254, P99, DOI 10.1126/science.1718038; KLAUSNER JM, 1989, AM J PHYSIOL, V256, pF794, DOI 10.1152/ajprenal.1989.256.5.F794; KO YC, 1992, J IMMUNOL METHODS, V149, P227, DOI 10.1016/0022-1759(92)90254-Q; KORTHUIS RJ, 1988, AM J PHYSIOL, V254, pH823, DOI 10.1152/ajpheart.1988.254.5.H823; LARSEN CG, 1989, SCIENCE, V243, P1464, DOI 10.1126/science.2648569; LEFER AM, 1991, BRIT J PHARMACOL, V103, P1153, DOI 10.1111/j.1476-5381.1991.tb12316.x; LEHR HA, 1991, J CLIN INVEST, V87, P2036, DOI 10.1172/JCI115233; LUSCINSKAS FW, 1992, J IMMUNOL, V149, P2163; MENTIKO AP, 1992, J CLIN INVEST, V90, P791; OGATA K, 1983, J IMMUNOL METHODS, V65, P75, DOI 10.1016/0022-1759(83)90305-8; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; ROMSON JL, 1983, CIRCULATION, V67, P1016, DOI 10.1161/01.CIR.67.5.1016; ROT A, 1992, IMMUNOL TODAY, V13, P291, DOI 10.1016/0167-5699(92)90039-A; SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0; SCHRODER JM, 1987, J IMMUNOL, V139, P3474; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; THELEN M, 1988, FASEB J, V2, P2702, DOI 10.1096/fasebj.2.11.2840318; WELBOURN CRB, 1991, BRIT J SURG, V78, P651, DOI 10.1002/bjs.1800780607; WELBOURN R, 1990, J IMMUNOL, V145, P1906; YOSHIMURA T, 1987, P NATL ACAD SCI USA, V84, P9233, DOI 10.1073/pnas.84.24.9233; ZIMMERMAN BJ, 1990, GASTROENTEROLOGY, V99, P1358, DOI 10.1016/0016-5085(90)91162-Y	31	465	559	1	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 14	1993	365	6447					654	657		10.1038/365654a0	http://dx.doi.org/10.1038/365654a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MB846	8413628				2022-12-24	WOS:A1993MB84600061
J	LAM, KSL; SHAM, MMK; TAM, SCF; NG, MMT; MA, HTG				LAM, KSL; SHAM, MMK; TAM, SCF; NG, MMT; MA, HTG			HYPOPITUITARISM AFTER TUBERCULOUS MENINGITIS IN CHILDHOOD	ANNALS OF INTERNAL MEDICINE			English	Article						HYPOPITUITARISM; TUBERCULOSIS, MENINGEAL; HYPOTHALAMOHYPOPHYSEAL SYSTEM; SOMATOTROPIN; GONADOTROPINS	GROWTH-HORMONE DEFICIENCY; CRANIAL IRRADIATION; PITUITARY	Objective: To study the prevalence and pathogenesis of hypopituitarism following tuberculous meningitis in childhood. Design: A retrospective cross-sectional study. Setting: A university teaching hospital and a tuberculosis referral center. Patients: Forty-nine patients, aged 23.4 +/- 6.0 years (mean +/- SD), who had tuberculous meningitis in childhood (age at diagnosis, 5.9 +/- 5.0 years) were studied. Measurements: A detailed assessment of hypothalamic-pituitary function, including conventional stimulation tests and responses to four hypothalamic releasing hormones, was done. Magnetic resonance imaging of the hypothalamic-pituitary region was performed in patients with abnormal endocrine function. Results: Ten patients were found to have abnormal pituitary function: Seven had growth hormone deficiency, four of whom also had gonadotropin deficiency; the other three had gonadotropin deficiency, corticotropin deficiency, and mild hyperprolactinemia, respectively; none had diabetes insipidus. Among those with growth hormone deficiency, a significant correlation (r = 0.749, P < 0.05) was found between the height standard deviation score and the age at diagnosis of tuberculous meningitis. Growth hormone, corticotropin, and gonadotropin responses to growth hormone releasing hormone, corticotropin releasing hormone, and gonadotropin releasing hormone, respectively, suggested a hypothalamic defect in five patients. Magnetic resonance imaging scans of the hypothalamic-pituitary region were abnormal in five patients. Conclusions: Hypopituitarism was documented in 20% of a small subset of patients years after recovery from tuberculous meningitis in childhood. The cause appears to be tuberculous lesions affecting the hypothalamus, pituitary stalk and, directly or indirectly, the pituitary itself. Early recognition and treatment can be beneficial.	RUTTONJE HOSP, HONG KONG, HONG KONG		LAM, KSL (corresponding author), UNIV HONG KONG, QUEEN MARY HOSP, DEPT MED, POKFULAM RD, HONG KONG, HONG KONG.		/C-4315-2009	/0000-0001-5757-541X				BHARUCHA NE, 1991, NEUROLOGY CLIN PRACT, P1925; GARG SK, 1987, TROP GEOGR MED, V39, P296; HALL R, 1980, FUNDAMENTALS CLIN EN, P37; HASLAM RHA, 1969, AM J DIS CHILD, V118, P903, DOI 10.1001/archpedi.1969.02100040905017; HERBER SM, 1986, ARCH DIS CHILD, V61, P110, DOI 10.1136/adc.61.2.110; LAM KSL, 1991, Q J MED, V78, P165; LAM KSL, 1986, CLIN ENDOCRINOL, V24, P643, DOI 10.1111/j.1365-2265.1986.tb01660.x; LAM KSL, 1987, J CLIN ENDOCR METAB, V64, P418, DOI 10.1210/jcem-64-3-418; MILNER RDG, 1982, ARCH DIS CHILD, V57, P944, DOI 10.1136/adc.57.12.944; SCHRIOCK EA, 1984, J CLIN ENDOCR METAB, V58, P1043, DOI 10.1210/jcem-58-6-1043; STACPOOLE PW, 1982, MEDICINE, V61, P13, DOI 10.1097/00005792-198201000-00002; STEWART PM, 1988, LANCET, V1, P1208; TANDON PN, 1978, HDB CLIN NEUROLOGY I, P193; TSUKADA T, 1984, J CLIN ENDOCR METAB, V58, P758, DOI 10.1210/jcem-58-4-758; WASS JAH, 1989, ENDOCRINOLOGY, P492; WASZHOCKERT O, 1962, ACTA PAEDIAT S141, V51, P26	16	24	25	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1993	118	9					701	706		10.7326/0003-4819-118-9-199305010-00007	http://dx.doi.org/10.7326/0003-4819-118-9-199305010-00007			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY502	8460856				2022-12-24	WOS:A1993KY50200007
J	BLACK, WC; WELCH, HG				BLACK, WC; WELCH, HG			ADVANCES IN DIAGNOSTIC-IMAGING AND OVERESTIMATIONS OF DISEASE PREVALENCE AND THE BENEFITS OF THERAPY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LUNG-CANCER DETECTION; ABDOMINAL AORTIC-ANEURYSMS; DIGITAL RECTAL EXAMINATION; RENAL-CELL CARCINOMA; BREAST-CANCER; PHYSICAL-EXAMINATION; PROSTATE-CANCER; FOLLOW-UP; POPULATION; TRIAL		DARTMOUTH HITCHCOCK MED CTR,DEPT RADIOL,LEBANON,NH; VET AFFAIRS HOSP,MED SERV,WHITE RIVER JCT,VT	Dartmouth College	BLACK, WC (corresponding author), DARTMOUTH COLL SCH MED,CTR EVALUAT CLIN SCI,318 STRAUSENBURGH HALL,HANOVER,NH 03755, USA.			Welch, H. Gilbert/0000-0002-3448-1207				ANDERSSON I, 1988, BRIT MED J, V297, P943, DOI 10.1136/bmj.297.6654.943; BAILAR JC, 1986, NEW ENGL J MED, V314, P1226, DOI 10.1056/NEJM198605083141905; BLACK WC, 1990, AM J ROENTGENOL, V155, P625, DOI 10.2214/ajr.155.3.2117366; BLACK WC, 1990, MED DECIS MAKING, V10, P226; BODEN SD, 1990, J BONE JOINT SURG AM, V72A, P403, DOI 10.2106/00004623-199072030-00013; BOSNIAK MA, 1991, RADIOLOGY, V181, P289; BOTTIGER L. E., 1964, ACTA CHIR SCAND, V127, P158; COLE P, 1980, JNCI-J NATL CANCER I, V64, P1263; COONER WH, 1990, J UROLOGY, V143, P1146, DOI 10.1016/S0022-5347(17)40211-4; FEINLEIB M, 1969, ARCH ENVIRON HEALTH, V19, P412, DOI 10.1080/00039896.1969.10666863; FEINSTEIN AR, 1985, NEW ENGL J MED, V312, P1604, DOI 10.1056/NEJM198506203122504; FEINSTEIN AR, 1985, CLIN EPIDEMIOLOGY AR, P597; FELDMAN AR, 1986, NEW ENGL J MED, V315, P1394, DOI 10.1056/NEJM198611273152206; FLEHINGER BJ, 1984, AM REV RESPIR DIS, V130, P555; FONTANA RS, 1984, AM REV RESPIR DIS, V130, P561; FROST JK, 1984, AM REV RESPIR DIS, V130, P549; GRAUNT J, 1988, WORLD MATH, V3, P1399; GRINNELL R S, 1958, Int Abstr Surg, V106, P519; HARACH HR, 1985, CANCER-AM CANCER SOC, V56, P531, DOI 10.1002/1097-0142(19850801)56:3<531::AID-CNCR2820560321>3.0.CO;2-3; HEALY ME, 1987, RADIOLOGY, V165, P619, DOI 10.1148/radiology.165.3.3317496; HELLSTEN S, 1981, SCAND J UROL NEPHROL, V15, P269, DOI 10.3109/00365598109179615; HICKS MJ, 1979, JAMA-J AM MED ASSOC, V242, P2080, DOI 10.1001/jama.242.19.2080; HOPPER KD, 1991, INVEST RADIOL, V26, P939, DOI 10.1097/00004424-199111000-00004; HUISMAN MV, 1989, CHEST, V95, P498, DOI 10.1378/chest.95.3.498; KOPANS DB, 1992, AM J ROENTGENOL, V158, P521, DOI 10.2214/ajr.158.3.1310825; KORNICK J, 1990, RADIOLOGY, V177, P463, DOI 10.1148/radiology.177.2.2217786; KUBIK A, 1986, CANCER-AM CANCER SOC, V57, P2427, DOI 10.1002/1097-0142(19860615)57:12<2427::AID-CNCR2820571230>3.0.CO;2-M; KUBIK A, 1990, INT J CANCER, V45, P26, DOI 10.1002/ijc.2910450107; LEDERLE FA, 1988, ARCH INTERN MED, V148, P1753, DOI 10.1001/archinte.148.8.1753; LEE F, 1988, RADIOLOGY, V168, P389, DOI 10.1148/radiology.168.2.3293108; LINVER MN, 1992, RADIOLOGY, V184, P39, DOI 10.1148/radiology.184.1.1609100; LINVER MN, 1992, RADIOLOGY, V184, P878; Mandelbrot B. B., 1983, FRACTAL GEOMETRY NAT, P116; MARTINI N, 1986, CHEST, V89, pS325, DOI 10.1378/chest.89.4_Supplement.325S; MELTON LJ, 1984, AM J EPIDEMIOL, V120, P379, DOI 10.1093/oxfordjournals.aje.a113902; MEYER JE, 1990, JAMA-J AM MED ASSOC, V263, P2341, DOI 10.1001/jama.263.17.2341; MILLER AB, 1991, BREAST, P419; MOLD JW, 1986, NEW ENGL J MED, V314, P512, DOI 10.1056/NEJM198602203140809; MONTIE JE, 1989, CANCER, V63, P381, DOI 10.1002/1097-0142(19890115)63:2<381::AID-CNCR2820630230>3.0.CO;2-O; MORRISON AS, 1985, MONOGRAPHS EPIDEMIOL, V7, P22; NIELSEN M, 1987, BRIT J CANCER, V56, P814, DOI 10.1038/bjc.1987.296; REINIG JW, 1987, RADIOLOGY, V162, P43, DOI 10.1148/radiology.162.1.3786786; SACKS H, 1982, AM J MED, V72, P233, DOI 10.1016/0002-9343(82)90815-4; SANDERSON DR, 1986, CHEST, V89, pS324, DOI 10.1378/chest.89.4_Supplement.324S; SCOTT RAP, 1991, BRIT J SURG, V78, P1122, DOI 10.1002/bjs.1800780929; SEIDMAN H, 1985, CA-CANCER J CLIN, V35, P36, DOI 10.3322/canjclin.35.1.36; SHAPIRO S, 1977, CANCER, V39, P2772, DOI 10.1002/1097-0142(197706)39:6<2772::AID-CNCR2820390665>3.0.CO;2-K; SICKLES EA, 1990, RADIOLOGY, V175, P323, DOI 10.1148/radiology.175.2.2326455; SICKLES EA, 1991, RADIOLOGY, V179, P463, DOI 10.1148/radiology.179.2.2014293; SMITH SJ, 1989, RADIOLOGY, V170, P699, DOI 10.1148/radiology.170.3.2644658; STACEYCLEAR A, 1992, LANCET, V340, P991; TOCKMAN MS, 1986, CHEST, V89, pS324, DOI 10.1378/chest.89.4_Supplement.324S-a; VACCARO JP, 1990, RADIOLOGY, V175, P645, DOI 10.1148/radiology.175.3.2188294; WHITE E, 1990, J NATL CANCER I, V82, P1524; XIPELL JM, 1971, J UROLOGY, V106, P503, DOI 10.1016/S0022-5347(17)61327-2; 1986, DHHS PHS881114 PUBL; 1988, DORLANDS ILLUSTRATED, P261	57	430	437	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 29	1993	328	17					1237	1243		10.1056/NEJM199304293281706	http://dx.doi.org/10.1056/NEJM199304293281706			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ061	8464435				2022-12-24	WOS:A1993KZ06100006
J	MARKELLO, TC; BERNARDINI, IM; GAHL, WA				MARKELLO, TC; BERNARDINI, IM; GAHL, WA			IMPROVED RENAL-FUNCTION IN CHILDREN WITH CYSTINOSIS TREATED WITH CYSTEAMINE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NEPHROPATHIC CYSTINOSIS; SERUM CREATININE; COMPLICATIONS; INSUFFICIENCY; PATIENT; AGE	Background. The lysosomal storage disease cystinosis results in renal failure at approximately 10 years of age. Although oral cysteamine therapy is recognized to preserve kidney function, the extent of renal benefit has not been determined. Methods. Between 1960 and 1992, we determined 24-hour creatinine clearances in 76 children with cystinosis during 1081 admissions to the National Institutes of Health. Seventeen children were considered to have received adequate treatment with cysteamine, since they had depletion of cystine from leukocytes and began therapy before the age of 2 years; treatment lasted a mean of 7.1 years. Thirty-two children were considered to have received partial treatment, since they had poor compliance with therapy or began treatment after the age of 2; treatment lasted a mean of 4.5 years. Twenty-seven children were followed in the era before cysteamine therapy and thus never received cysteamine. Results. Of the 27 children who never received cysteamine, 16 were followed at the National Institutes of Health until renal failure occurred: their mean (+/-SD) creatinine clearance was 8.0+/-4.8 ml per minute per 1.73 m2 of body-surface area at a mean age of 8.3+/-1.9 years. Of the 17 children who received adequate treatment, none had renal failure; their mean creatinine clearance was 57+/-20 ml per minute per 1.73 m2 at 8.3+/-3.8 years of age. The mean creatinine clearance of the children who received partial or adequate treatment with cysteamine increased with age up to the age of five years and then declined linearly with age at a normal rate. For the children who received adequate treatment, the mean creatinine clearance was predicted to reach 0 ml per minute per 1.73 m2 at the age of 74 years, as compared with 20 years of age for the children who received partial treatment. With no therapy, the mean creatinine clearance reaches 0 ml per minute per 1.73 m2 at 10 years of age. Conclusions. Children with cystinosis who are treated early and adequately with cysteamine have renal function that increases during the first five years of life and then declines at a normal rate. Patients with poorer compliance and those who are treated at an older age do less well.	NICHHD, HUMAN GENET BRANCH,HUMAN BIOL CHEM & GENET SECT, BLDG 10,RM 9S-242, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)								ANDERSSON HC, 1992, J PEDIATR-US, V120, P716, DOI 10.1016/S0022-3476(05)80233-1; BEHRMAN RE, 1987, NELSON TXB PEDIATRIC, P1542; Brodehl J, 1973, Clin Nephrol, V1, P149; CLARK KF, 1992, CLIN RES, V40, pA113; FINK JK, 1989, ARCH NEUROL-CHICAGO, V46, P543, DOI 10.1001/archneur.1989.00520410077027; FIVUSH B, 1988, J PEDIATR-US, V112, P49, DOI 10.1016/S0022-3476(88)80119-7; FIVUSH B, 1987, AM J DIS CHILD, V141, P1087, DOI 10.1001/archpedi.1987.04460100065027; Gahl W A, 1986, Adv Pediatr, V33, P95; GAHL WA, 1990, PEDIATR NEPHROL, V4, P129, DOI 10.1007/BF00858823; GAHL WA, 1987, NEW ENGL J MED, V316, P971, DOI 10.1056/NEJM198704163161602; GAHL WA, 1982, J BIOL CHEM, V257, P9570; GAHL WA, 1987, PEDIATR NEPHROL, V1, P260, DOI 10.1007/BF00849221; GAHL WA, 1988, NEW ENGL J MED, V319, P1461, DOI 10.1056/NEJM198812013192206; GAHL WA, 1982, SCIENCE, V217, P1263, DOI 10.1126/science.7112129; GAHL WA, 1989, METABOLIC BASIS INHE, V2, P2619; GRETZ N, 1982, P EUR DIAL TRANS, V19, P582; HEINEGAR.D, 1973, CLIN CHIM ACTA, V43, P305, DOI 10.1016/0009-8981(73)90466-X; JONAS AJ, 1987, AM J MED, V83, P966, DOI 10.1016/0002-9343(87)90661-9; JONAS AJ, 1982, J BIOL CHEM, V257, P13185; JONES RH, 1991, BIOMETRICS, V47, P161, DOI 10.2307/2532504; KAISERKUPFER MI, 1987, NEW ENGL J MED, V316, P775, DOI 10.1056/NEJM198703263161304; KAISERKUPFER MI, 1990, ARCH OPHTHALMOL-CHIC, V108, P689, DOI 10.1001/archopht.1990.01070070075038; KAISERKUPFER MI, 1986, ARCH OPHTHALMOL-CHIC, V104, P706, DOI 10.1001/archopht.1986.01050170096030; KRASNEWICH DM, 1991, ENDOCRINOLOGIST, V1, P111; ROWE JW, 1976, J GERONTOL, V31, P155, DOI 10.1093/geronj/31.2.155; SCHWARTZ GJ, 1976, PEDIATRICS, V58, P259; SMOLIN LA, 1988, PEDIATR RES, V23, P616, DOI 10.1203/00006450-198806000-00018; SONIES BC, 1990, NEW ENGL J MED, V323, P565, DOI 10.1056/NEJM199008303230903; THOENE JG, 1976, J CLIN INVEST, V58, P180, DOI 10.1172/JCI108448; WINBERG J, 1959, Acta Paediatr, V48, P443	30	209	221	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 22	1993	328	16					1157	1162		10.1056/NEJM199304223281604	http://dx.doi.org/10.1056/NEJM199304223281604			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY447	8455682				2022-12-24	WOS:A1993KY44700004
J	BAYERDORFFER, E; MANNES, GA; RICHTER, WO; OCHSENKUHN, T; SEEHOLZER, G; KOPCKE, W; WIEBECKE, B; PAUMGARTNER, G				BAYERDORFFER, E; MANNES, GA; RICHTER, WO; OCHSENKUHN, T; SEEHOLZER, G; KOPCKE, W; WIEBECKE, B; PAUMGARTNER, G			DECREASED HIGH-DENSITY-LIPOPROTEIN CHOLESTEROL AND INCREASED LOW-DENSITY CHOLESTEROL LEVELS IN PATIENTS WITH COLORECTAL ADENOMAS	ANNALS OF INTERNAL MEDICINE			English	Article						LIPOPROTEINS, HDL CHOLESTEROL; LIPOPROTEINS, LDL CHOLESTEROL; LIPOPROTEINS, VLDL CHOLESTEROL; ADENOMA; COLORECTAL NEOPLASMS	CORONARY HEART-DISEASE; LARGE-BOWEL CANCER; SERUM-CHOLESTEROL; COLON CANCER; PLASMA TRIGLYCERIDE; HAWAIIAN-JAPANESE; RISK FACTOR; BILE-ACIDS; MORTALITY; RECTUM	Objective: To study the relation between serum lipoprotein levels and the frequency of colorectal adenomas, the benign precursors of colorectal cancer. Design: Cross-sectional. Setting: University hospital in Germany. Patients: The study included 822 of 1124 consecutive patients who underwent colonoscopy at our institution (302 patients were excluded because of malignant disease, chronic inflammatory bowel disease, familial polyposis, partial colectomy, or other chronic diseases). Of the 822 study patients, 194 had colorectal adenoma. Measurements: Serum cholesterol fractions (high-density lipoprotein [HDL], low-density lipoprotein [LDL], and very low-density lipoprotein [VLDL]) and presence or absence of adenomas; univariate and logistic regression analyses were carried out to evaluate the association between serum HDL, LDL, and VLDL cholesterol levels and the frequency of colorectal adenoma. Results: Univariate analysis of the total patient group showed that the HDL cholesterol level was inversely related to the frequency of colorectal adenoma (odds ratio, 0.36; 95% Cl, 0.21 to 0.62) and that LDL and VLDL cholesterol levels were positively associated with adenoma frequency (odds ratio, 2.31 [Cl, 1.36 to 3.92] and 1.72 [Cl, 1.03 to 2.86], respectively). Univariate analysis of the subgroup of 89 patients with high-risk adenomas showed an inverse association between such adenomas and HDL cholesterol (odds ratio, 0.37; Cl, 0.18 to 0.76). A logistic regression analysis that included age and body mass index showed an association between lipoprotein levels and the presence of adenomas. The relative strength (in descending order) of these associations was as follows: HDL, LDL, VLDL, and total serum cholesterol. A logistic regression analysis of patients with high-risk adenoma showed a significant association between such adenomas and the HDL cholesterol level. Conclusions: Patients with colorectal adenomas have lower HDL cholesterol levels and higher LDL and VLDL cholesterol levels; these lipoproteins may have prognostic significance for the development of colorectal adenomas.	UNIV MUNICH, KLINIKUM GROSSHADERN, INST PATHOL, W-8000 MUNICH 2, GERMANY	University of Munich	BAYERDORFFER, E (corresponding author), UNIV MUNICH, KLINIKUM GROSSHADERN, DEPT MED 2, MARCHIONINISTR 15, W-8000 MUNICH 70, GERMANY.							[Anonymous], 1982, JAMA-J AM MED ASSOC, V248, P2853; ARMSTRONG B, 1975, INT J CANCER, V15, P617, DOI 10.1002/ijc.2910150411; AUSTIN MA, 1988, JAMA-J AM MED ASSOC, V260, P1917; AUSTIN MA, 1989, AM J EPIDEMIOL, V129, P249, DOI 10.1093/oxfordjournals.aje.a115130; BRUNZELL JD, 1989, NEW ENGL J MED, V320, P1273, DOI 10.1056/NEJM198905113201910; BULL AW, 1983, CARCINOGENESIS, V4, P207, DOI 10.1093/carcin/4.2.207; CAMBIEN F, 1980, AM J EPIDEMIOL, V112, P388, DOI 10.1093/oxfordjournals.aje.a113004; Correa P, 1978, Major Probl Pathol, V10, P126; CUMMINGS JH, 1978, J CLIN INVEST, V61, P953, DOI 10.1172/JCI109020; DAY DW, 1978, MAJOR PROBLEMS PATHO, V10, P126; DESCHNER EE, 1982, AM J GASTROENTEROL, V77, P207; DESCHNER EE, 1981, DIGESTION, V21, P290, DOI 10.1159/000198579; DYER AR, 1981, J CHRON DIS, V34, P249, DOI 10.1016/0021-9681(81)90030-8; ENSTROM JE, 1975, BRIT J CANCER, V32, P432, DOI 10.1038/bjc.1975.244; FREEDMAN DS, 1988, AM J EPIDEMIOL, V127, P1118, DOI 10.1093/oxfordjournals.aje.a114906; GARCIAPALMIERI MR, 1981, AM J EPIDEMIOL, V114, P29, DOI 10.1093/oxfordjournals.aje.a113171; GOLDBOURT U, 1985, BMJ-BRIT MED J, V290, P1239, DOI 10.1136/bmj.290.6477.1239; HAENSZEL W, 1968, JNCI-J NATL CANCER I, V40, P43; HAENSZEL W, 1971, CANCER, V28, P14, DOI 10.1002/1097-0142(197107)28:1<14::AID-CNCR2820280105>3.0.CO;2-I; HAENSZEL W, 1973, J NATL CANCER I, V51, P1765, DOI 10.1093/jnci/51.6.1765; HERMANEK P, 1983, ENDOSCOPY, V15, P16, DOI 10.1055/s-2007-1018598; HILL MJ, 1975, CANCER RES, V35, P3398; HOLTZMAN EJ, 1987, NEW ENGL J MED, V317, P114; HOWELL MA, 1975, J CHRON DIS, V28, P67, DOI 10.1016/0021-9681(75)90063-6; ISLES CG, 1989, BMJ-BRIT MED J, V298, P920, DOI 10.1136/bmj.298.6678.920; JAIN M, 1980, INT J CANCER, V26, P757, DOI 10.1002/ijc.2910260609; KAGAN A, 1981, AM J EPIDEMIOL, V114, P11, DOI 10.1093/oxfordjournals.aje.a113157; KANNEL WB, 1971, ANN INTERN MED, V74, P1, DOI 10.7326/0003-4819-74-1-1; KEYS A, 1970, CIRCULATION S4, V41; KJELSBERG MO, 1982, JAMA-J AM MED ASSOC, V248, P1465; MANNES GA, 1986, NEW ENGL J MED, V315, P1634, DOI 10.1056/NEJM198612253152602; MILLER SR, 1981, JNCI-J NATL CANCER I, V67, P297; Morson B, 1976, HISTOLOGICAL TYPING; MUTO T, 1975, CANCER, V36, P2251, DOI 10.1002/cncr.2820360944; NARISAWA T, 1974, JNCI-J NATL CANCER I, V53, P1093, DOI 10.1093/jnci/53.4.1093; PETERSSON B, 1984, BRIT MED J, V288, P1264, DOI 10.1136/bmj.288.6426.1264; PHILLIPS RL, 1975, CANCER RES, V35, P3513; ROSE G, 1974, LANCET, V1, P181, DOI 10.1016/S0140-6736(74)92492-1; ROSE G, 1980, LANCET, V1, P523; SCHATZKIN A, 1987, LANCET, V2, P298; SHERWIN RW, 1987, JAMA-J AM MED ASSOC, V257, P943; SNIDERMAN A, 1980, P NATL ACAD SCI-BIOL, V77, P604, DOI 10.1073/pnas.77.1.604; STEMMERMANN GN, 1981, J NATL CANCER I, V67, P1179; THOMAS CB, 1982, JOHNS HOPKINS MED J, V150, P89; TORNBERG SA, 1986, NEW ENGL J MED, V315, P1629, DOI 10.1056/NEJM198612253152601; WESTLUND K, 1972, SCAND J CLIN LAB INV, V30, P1; WILLIAMS RR, 1981, JAMA-J AM MED ASSOC, V245, P247, DOI 10.1001/jama.245.3.247; WILSON PWF, 1988, ARTERIOSCLEROSIS, V8, P737, DOI 10.1161/01.ATV.8.6.737; WYNDER EL, 1975, CANCER RES, V35, P3388; YAARI S, 1981, LANCET, V1, P1011; 1981, JAMA-J AM MED ASSOC, V246, P731	51	72	73	2	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1993	118	7					481	487		10.7326/0003-4819-118-7-199304010-00001	http://dx.doi.org/10.7326/0003-4819-118-7-199304010-00001			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KU079	8442619				2022-12-24	WOS:A1993KU07900001
J	MCKIM, KS; JANG, JK; THEURKAUF, WE; HAWLEY, RS				MCKIM, KS; JANG, JK; THEURKAUF, WE; HAWLEY, RS			MECHANICAL BASIS OF MEIOTIC METAPHASE ARREST	NATURE			English	Article							DROSOPHILA-MELANOGASTER; SEGREGATION	CONTROL of the metaphase to anaphase transition is a central component of cell-cycle regulation. Arrest at either metaphase I or II before fertilization is a common component of oogenesis in many organisms1. In Drosophila melanogaster females, this arrest occurs at meiosis I with the chiasmate bivalents tightly massed at the metaphase plate and the nonexchange chromosomes positioned between the plate and the poles on long tapered spindles2. Meiosis resumes only after passage through the oviduct 3,4. Thus, metaphase arrest defines an important checkpoint in the meiotic cell cycle'. We report here that this arrest results from the balancing of chiasmate bivalents at the metaphase plate. Two meiotic mutations, mei-9b and mei-218a4, both of which greatly reduce the frequency of chiasma formation, bypass the metaphase block and allow stage 14 oocytes to finish both meiotic divisions without arrest. We conclude that metaphase arrest results from the balancing of kinetochore forces due to chiasmata.	UNIV CALIF DAVIS,DEPT GENET,DAVIS,CA 95616; SUNY STONY BROOK,DEPT BIOCHEM & CELL BIOL,STONY BROOK,NY 11794	University of California System; University of California Davis; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook				Theurkauf, William/0000-0001-7342-1912; Hawley, R. Scott/0000-0002-6478-0494				Baker BS, 1976, GENETICS BIOL DROS B, P351; CARPENTER AT, 1974, GENETICS, V76, P453; CARPENTER ATC, 1979, CHROMOSOMA, V75, P259, DOI 10.1007/BF00293472; CARPENTER ATC, 1984, COLD SPRING HARB SYM, V49, P23, DOI 10.1101/SQB.1984.049.01.005; CARPENTER ATC, 1972, GENETICS, V71, P255; Hawley R.S., 1988, GENETIC RECOMBINATIO, P497; King R. C., 1970, OVARIAN DEV DROSOPHI; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; NICKLAS RB, 1974, GENETICS, V78, P205; PURO J, 1977, CHROMOSOMA, V63, P273, DOI 10.1007/BF00327454; Sonnenblick BP, 1965, BIOLOGY DROSOPHILA, P62; THEURKAUF WE, 1992, J CELL BIOL, V116, P1167, DOI 10.1083/jcb.116.5.1167; ZHANG P, 1990, GENETICS, V125, P115	14	70	70	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 25	1993	362	6418					364	366		10.1038/362364a0	http://dx.doi.org/10.1038/362364a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KU176	8455723				2022-12-24	WOS:A1993KU17600068
J	RANSOHOFF, DF; LANG, CA				RANSOHOFF, DF; LANG, CA			SIGMOIDOSCOPIC SCREENING IN THE 1990S	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COLORECTAL-CANCER; SURVEILLANCE; COLONOSCOPY; POLYPS		COLORADO PERMANENTE MED GRP,DENVER,CO; UNIV COLORADO,DEPT MED,DENVER,CO 80202	Permanente Medical Groups; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	RANSOHOFF, DF (corresponding author), UNIV N CAROLINA,SCH MED,DEPT MED,CB 7105,CHAPEL HILL,NC 27599, USA.							ACHKAR E, 1988, ANN INTERN MED, V109, P880, DOI 10.7326/0003-4819-109-11-880; AHLQUIST DA, 1993, JAMA-J AM MED ASSOC, V269, P1262, DOI 10.1001/jama.269.10.1262; ATKIN WS, 1992, NEW ENGL J MED, V326, P658, DOI 10.1056/NEJM199203053261002; BOLAND CR, 1989, GASTROINTESTINAL DIS, P1483; CANNONALBRIGHT LA, 1988, NEW ENGL J MED, V319, P533, DOI 10.1056/NEJM198809013190902; FLEISCHER DE, 1989, JAMA-J AM MED ASSOC, V261, P580, DOI 10.1001/jama.261.4.580; LEVIN B, 1992, CA-CANCER J CLIN, V42, P296, DOI 10.3322/canjclin.42.5.296; LIEBERMAN DA, 1991, AM J GASTROENTEROL, V86, P946; LILLARD LA, 1986, RAND JR3266HCFA PUBL; LIMBERG B, 1992, NEW ENGL J MED, V327, P65, DOI 10.1056/NEJM199207093270201; LUK GD, 1990, CURRENT THERAPY GAST, P387; MACCARTY RL, 1992, MAYO CLIN PROC, V67, P253, DOI 10.1016/S0025-6196(12)60102-5; NEUGUT AI, 1988, GASTROENTEROLOGY, V95, P492, DOI 10.1016/0016-5085(88)90511-2; NEWCOMB PA, 1992, JNCI-J NATL CANCER I, V84, P1572, DOI 10.1093/jnci/84.20.1572; OW CL, 1989, J GEN INTERN MED, V4, P209, DOI 10.1007/BF02599525; RANSOHOFF DF, 1991, NEW ENGL J MED, V325, P37; RANSOHOFF DF, 1991, ANN INTERN MED, V114, P177, DOI 10.7326/0003-4819-114-3-177; RANSOHOFF DF, IN PRESS DIGESTIVE D; REX DK, 1991, GASTROENTEROLOGY, V100, P64, DOI 10.1016/0016-5085(91)90583-7; SCHAPIRO M, 1984, DIGEST DIS SCI, V29, P159, DOI 10.1007/BF01317058; SELBY JV, 1989, JAMA-J AM MED ASSOC, V261, P595; SELBY JV, 1992, NEW ENGL J MED, V326, P653, DOI 10.1056/NEJM199203053261001; SELBY JV, 1993, ANN INTERN MED, V118, P1294; SILVERBERG E, 1990, CA-CANCER J CLIN, V40, P9, DOI 10.3322/canjclin.40.1.9; SPIRO HM, 1988, MT SINAI J MED, V55, P251; STJOHN DGB, IN PRESS ANN INTERN; WEISS NS, 1983, AM J EPIDEMIOL, V118, P457; 1989, SUMMARY CURRENT GUID; 1990, SCREENING COLORECTAL; 1987, WORKING GUIDELINES E; 1989, BLUE SHEET      1018, P3	31	78	78	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 10	1993	269	10					1278	1281		10.1001/jama.269.10.1278	http://dx.doi.org/10.1001/jama.269.10.1278			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP885	8437306				2022-12-24	WOS:A1993KP88500027
J	PRINGLE, M; STEWARTEVANS, C; COUPLAND, C; WILLIAMS, I; ALLISON, S; STERLAND, J				PRINGLE, M; STEWARTEVANS, C; COUPLAND, C; WILLIAMS, I; ALLISON, S; STERLAND, J			INFLUENCES ON CONTROL IN DIABETES-MELLITUS - PATIENT, DOCTOR, PRACTICE, OR DELIVERY OF CARE	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE; MANAGEMENT; PREVALENCE; KNOWLEDGE; LONDON	Objective-To assess patient, doctor, practice, and process of care variables for their effect on glycaemic control in diabetes mellitus, and to quantify their relative effects. Design-Search of general practice medical records, patient questionnaires and examination, doctor questionnaire, videotaping and analysis of consultations, and practice questionnaire. Setting- 12 practices with 32 participating general practitioners in Nottinghamshire. Subjects-318 patients randomly selected from those with diabetes in each practice, 10 for each participating doctor. Main outcome measure-Glycaemic control as measured by random glycated haemoglobin A1c estimation (random haemoglobin A1 measurement). Results-Glycaemic control was significantly related to the disease process as measured by years since diagnosis, treatment group, and number of diabetes related clinical events. Females had significantly worse control than males. Other patient factors, such as age, social class, lifestyle, attitudes, satisfaction, and knowledge, had no association with glycaemic control. Of all the doctor factors examined, only doctors who professed a special interest in diabetes achieved significantly better glycaemic control. Bigger and better equipped practices and those with a diabetic miniclinic had patients with significantly better glycaemic control, as did those with access to dietetic advice. Patients attending hospital clinics had worse glycaemic control, but this seemed to be attributable to the case mix and practice characteristics. Shared care did not contribute to the multiple linear regression model. Conclusion-Glycaemic control among diabetic patients in the community is related to such factors as treatment group, sex, and years since diagnosis; it is also related to the organisation and process of care. The findings support concentrating diabetic care on partners with special interests in diabetes in well equipped practices with adequate dietetic support.	UNIV NOTTINGHAM HOSP,QUEENS MED CTR,SCH MED,DEPT PUBL HLTH MED & EPIDEMIOL,NOTTINGHAM NG7 2UH,ENGLAND; UNIV NOTTINGHAM HOSP,QUEENS MED CTR,SCH MED,DEPT MED,NOTTINGHAM NG7 2UH,ENGLAND	University of Nottingham; University of Nottingham	PRINGLE, M (corresponding author), UNIV NOTTINGHAM HOSP,QUEENS MED CTR,SCH MED,DEPT GEN PRACTICE,NOTTINGHAM NG7 2UH,ENGLAND.			Coupland, Carol/0000-0002-2327-3306				BASDEVANT A, 1982, DIABETOLOGIA, V22, P309; Bradley C, 1984, Diabet Med, V1, P213; BRADLEY C, 1986, DIABETES ANN; BURROWS PJ, 1987, J ROY COLL GEN PRACT, V37, P65; CAHILL GF, 1976, NEW ENGL J MED, V294, P1004, DOI 10.1056/NEJM197604292941811; CHESOVER D, 1991, BRIT J GEN PRACT, V41, P282; FOULKES A, 1989, J ROY COLL GEN PRACT, V39, P444; GATLING W, 1985, J R COLL PHYSICIANS, V4, P248; GIBBINS RL, 1988, BRIT MED J, V297, P187, DOI 10.1136/bmj.297.6642.187; HAYES TM, 1984, BRIT MED J, V289, P728, DOI 10.1136/bmj.289.6447.728; HESS GE, 1983, DIABETES CARE, V6, P591, DOI 10.2337/diacare.6.6.591; HOLMAN RR, 1983, LANCET, V1, P204; KINMONTH AL, 1989, FAM PRACT, V6, P193, DOI 10.1093/fampra/6.3.193; MATHER HM, 1985, BRIT MED J, V291, P1081, DOI 10.1136/bmj.291.6502.1081; MCCANCE DR, 1989, LANCET, V2, P824; NEIL HAW, 1987, DIABETIC MED, V4, P539, DOI 10.1111/j.1464-5491.1987.tb00926.x; Pendleton D., 1984, CONSULTATION APPROAC; PICKUP J, 1988, BMJ-BRIT MED J, V297, P929, DOI 10.1136/bmj.297.6654.929; PRINGLE M, 1990, BRIT J GEN PRACT, V40, P455; RASKIN P, 1986, ANN INTERN MED, V105, P254, DOI 10.7326/0003-4819-105-2-254; ROBINSON N, 1985, J PSYCHOSOM RES, V29, P583, DOI 10.1016/0022-3999(85)90067-4; RUTTEN G, 1990, FAM PRACT, V7, P273, DOI 10.1093/fampra/7.4.273; SINGH BM, 1984, BRIT MED J, V289, P726, DOI 10.1136/bmj.289.6447.726; THORN PA, 1982, BRIT MED J, V285, P787, DOI 10.1136/bmj.285.6344.787; WATKINS PJ, 1983, BRIT MED J, V286, P269, DOI 10.1136/bmj.286.6361.269; WEINBERGER M, 1984, SOC SCI MED, V19, P965, DOI 10.1016/0277-9536(84)90326-5; Wilkes E, 1980, J R Coll Gen Pract, V30, P199; Wood J, 1990, Health Trends, V22, P39; YUDKIN JS, 1980, J EPIDEMIOL COMMUN H, V34, P277, DOI 10.1136/jech.34.4.277; 1986, ADM MANUAL 16 PERSON	30	128	130	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 6	1993	306	6878					630	634		10.1136/bmj.306.6878.630	http://dx.doi.org/10.1136/bmj.306.6878.630			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KQ859	8461816	Bronze, Green Published			2022-12-24	WOS:A1993KQ85900024
J	LINSKENS, M; TYERS, M; FUTCHER, B				LINSKENS, M; TYERS, M; FUTCHER, B			CLN3 FUNCTIONS IN BOTH DAUGHTER AND MOTHER CELLS OF SACCHAROMYCES-CEREVISIAE	CELL			English	Article											LINSKENS, M (corresponding author), COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724, USA.		Tyers, Michael/ABE-3194-2021					CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; LEW DJ, 1992, CELL, V69, P317, DOI 10.1016/0092-8674(92)90412-6; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x	3	5	5	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 26	1993	72	4					487	488		10.1016/0092-8674(93)90067-Z	http://dx.doi.org/10.1016/0092-8674(93)90067-Z			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KP165	8440016	Green Published			2022-12-24	WOS:A1993KP16500003
J	BELONGIA, EA; OSTERHOLM, MT; SOLER, JT; AMMEND, DA; BRAUN, JE; MACDONALD, KL				BELONGIA, EA; OSTERHOLM, MT; SOLER, JT; AMMEND, DA; BRAUN, JE; MACDONALD, KL			TRANSMISSION OF ESCHERICHIA-COLI O157-H7 INFECTION IN MINNESOTA CHILD DAY-CARE FACILITIES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEMOLYTIC-UREMIC SYNDROME; HEMORRHAGIC COLITIS; WASHINGTON-STATE; O157-H7; OUTBREAK; EPIDEMIOLOGY; DIARRHEA; SHIGELLOSIS; SEROTYPE	Objective.-Escherichia coli O157:H7 infection can cause hemorrhagic colitis and hemolytic uremic syndrome. Since 1988 the Minnesota Department of Health has carried out surveillance for this infection. To assess the occurrence of person-to-person transmission within day-care facilities, we investigated facilities where an infected child attended after onset of symptoms. Design.-Parents of children less than 5 years old with E coli O157:H7 infection were interviewed from July 1988 through December 1989. If the child attended day care after onset, stool cultures were obtained from other children in attendance and their parents were interviewed. If there was presumptive evidence of ongoing E coli O157:H7 transmission in a facility, all preschool children were excluded from attending day-care facilities until two consecutive stool cultures were negative. Results.-Sixty-eight cases of E coli O157:H7 infection were identified in Minnesota during the 18-month period, including 29 cases identified through investigations at nine day-care facilities. There was evidence of person-to-person transmission in all nine facilities. The median number of infected children per facility was two (range, two to 18), and the median attack rate was 22% (range, 3% to 38%). The median age of the primary case at each facility was 26 months (range, 12 to 59 months). There was no evidence of further transmission at facilities where children were temporarily excluded until two consecutive stool cultures were negative. Conclusion.-Person-to-person transmission of E coli O157:H7 is common when infected preschool children attend day care while symptomatic. The number of unrecognized day-care outbreaks in the United States may be substantial due to the lack of routine testing for this pathogen in stool cultures, the absence of public health surveillance in many regions, and incomplete follow-up of infected children. Temporary exclusion of all children was an effective control strategy in this population, but additional investigations are needed to determine the optimal intervention.	HENNEPIN CTY COMMUNITY HLTH DEPT, MINNEAPOLIS, MN USA; CTR DIS CONTROL & PREVENT, EPIDEMIOL PROGRAM OFF, DIV FIELD EPIDEMIOL, ACUTE DIS EPIDEMIOL SECT, ATLANTA, GA USA	Centers for Disease Control & Prevention - USA	BELONGIA, EA (corresponding author), MINNESOTA DEPT HLTH, ACUTE DIS EPIDEMIOL SECT, 717 SE DELAWARE ST, BOX 9441, MINNEAPOLIS, MN 55440 USA.			Belongia, Edward/0000-0001-7478-0415				BELONGIA EA, 1991, J INFECT DIS, V164, P338, DOI 10.1093/infdis/164.2.338; CLEARY TG, 1988, PEDIATR CLIN N AM, V35, P485; Ewing WH, 1986, IDENTIFICATION ENTER; GOODMAN RA, 1984, PEDIATRICS, V74, P134; HASKINS R, 1989, B NEW YORK ACAD MED, V65, P319; HOFFMAN RE, 1990, AM J DIS CHILD, V144, P219, DOI 10.1001/archpedi.1990.02150260099038; KARMALI MA, 1988, LANCET, V1, P526; KARMALI MA, 1985, J INFECT DIS, V151, P775, DOI 10.1093/infdis/151.5.775; LERMAN Y, 1992, J CLIN MICROBIOL, V30, P520, DOI 10.1128/JCM.30.2.520-521.1992; LOPEZ EL, 1991, PEDIATR INFECT DIS J, V10, P20, DOI 10.1097/00006454-199101000-00005; MACDONALD KL, 1988, JAMA-J AM MED ASSOC, V259, P3567, DOI 10.1001/jama.259.24.3567; MARCH SB, 1986, J CLIN MICROBIOL, V23, P869, DOI 10.1128/JCM.23.5.869-872.1986; MARTIN DL, 1990, NEW ENGL J MED, V323, P1161, DOI 10.1056/NEJM199010253231703; MARTIN ML, 1986, LANCET, V2, P1043; Ostroff S M, 1991, MMWR CDC Surveill Summ, V40, P1; OSTROFF SM, 1990, AM J EPIDEMIOL, V132, P239, DOI 10.1093/oxfordjournals.aje.a115653; OSTROFF SM, 1989, JAMA-J AM MED ASSOC, V262, P355, DOI 10.1001/jama.262.3.355; PAVIA AT, 1990, J PEDIATR-US, V116, P544, DOI 10.1016/S0022-3476(05)81600-2; PICKERING LK, 1986, REV INFECT DIS, V8, P539; RILEY LW, 1983, NEW ENGL J MED, V308, P681, DOI 10.1056/NEJM198303243081203; ROGERS MF, 1986, AM J EPIDEMIOL, V123, P137, DOI 10.1093/oxfordjournals.aje.a114207; RYAN CA, 1986, J INFECT DIS, V154, P631, DOI 10.1093/infdis/154.4.631; SPIKA JS, 1986, J PEDIATR-US, V109, P287, DOI 10.1016/S0022-3476(86)80386-9; TARR PI, 1990, J INFECT DIS, V162, P553, DOI 10.1093/infdis/162.2.553; TARR PI, 1987, PEDIATRICS, V80, P41; TAUXE RV, 1986, AM J PUBLIC HEALTH, V76, P627, DOI 10.2105/AJPH.76.6.627; WELLS JG, 1983, J CLIN MICROBIOL, V18, P512, DOI 10.1128/JCM.18.3.512-520.1983; 1987, CDWR, V13, P5	28	189	194	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 17	1993	269	7					883	888		10.1001/jama.269.7.883	http://dx.doi.org/10.1001/jama.269.7.883			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KL474	8426447				2022-12-24	WOS:A1993KL47400026
J	NICOLELIS, MAL; LIN, RCS; WOODWARD, DJ; CHAPIN, JK				NICOLELIS, MAL; LIN, RCS; WOODWARD, DJ; CHAPIN, JK			INDUCTION OF IMMEDIATE SPATIOTEMPORAL CHANGES IN THALAMIC NETWORKS BY PERIPHERAL BLOCK OF ASCENDING CUTANEOUS INFORMATION	NATURE			English	Article							ADULT FLYING-FOX; SOMATOSENSORY CORTEX; DIGIT DENERVATION; RECEPTIVE-FIELDS; RAT; DEAFFERENTATION; MONKEYS; REORGANIZATION; PLASTICITY; RESPONSES	PERIPHERAL sensory deprivation induces reorganization within the somatosensory cortex of adult animals1-6. Although most studies have focused on the somatosensory cortex1-6, changes at subcortical levels (for example the thalamus) could also play a fundamental role in sensory plasticity7-11. To investigate this, we made chronic simultaneous recordings of large numbers of single neurons across the ventral posterior medial thalamus (VPM) in adult rats. This allowed a continuous and quantitative evaluation of the receptive fields of the same sample of single VPM neurons per animal, before and after sensory deprivation. Local anaesthesia in the face induced an immediate and reversible reorganization of a large portion of the VPM map. This differentially affected the short latency (4-6 ms) responses (SLRs) and long latency (15-25 ms) responses (LLRs) of single VPM neurons. The SLRs and LLRs normally define spatiotemporally complex receptive fields in the VPM12. Here we report that 73% of single neurons whose original receptive fields included the anaesthetized zone showed immediate unmasking of SLRs in response to stimulation of adjacent cutaneous regions, and/or loss of SLRs with preservation or enhancement of LLRs in response to stimulation of regions just surrounding the anaesthetized zone. This thalamic reorganization demonstrates that peripheral sensory deprivation may induce immediate plastic changes at multiple levels of the somatosensory system. Further, its spatiotemporally complex character suggests a disruption of the normal dynamic equilibrium between multiple ascending and descending influences on the VPM.	UNIV SAO PAULO,DEPT PATHOL,BR-01246 SAO PAULO,BRAZIL; WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT PHYSIOL & PHARMACOL,WINSTON SALEM,NC 27103	Universidade de Sao Paulo; Wake Forest University; Wake Forest Baptist Medical Center	NICOLELIS, MAL (corresponding author), HAHNEMANN UNIV,DEPT PHYSIOL & BIOPHYS,BROAD & VINE ST,PHILADELPHIA,PA 19102, USA.							CALFORD MB, 1988, NATURE, V332, P446, DOI 10.1038/332446a0; CALFORD MB, 1991, J NEUROPHYSIOL, V65, P178, DOI 10.1152/jn.1991.65.2.178; CALFORD MB, 1991, SOMATOSENS MOT RES, V8, P249, DOI 10.3109/08990229109144748; CHMIELOWSKA J, 1989, J COMP NEUROL, V285, P325, DOI 10.1002/cne.902850304; GARRAGHTY PE, 1992, NEUROREPORT, V2, P747; KAAS JH, 1991, ANNU REV NEUROSCI, V14, P137, DOI 10.1146/annurev.neuro.14.1.137; MERZENICH MM, 1983, NEUROSCIENCE, V10, P639, DOI 10.1016/0306-4522(83)90208-7; MERZENICH MM, 1983, NEUROSCIENCE, V8, P33, DOI 10.1016/0306-4522(83)90024-6; Nakahama H, 1966, Prog Brain Res, V21, P180; NICOLELIS MAL, 1991, BRAIN RES, V561, P344, DOI 10.1016/0006-8993(91)91614-7; NICOLELIS MAL, IN PRESS P NATN ACAD; PESCHANSKI M, 1983, BRAIN RES, V278, P240, DOI 10.1016/0006-8993(83)90245-7; PONS TP, 1991, SCIENCE, V252, P1857, DOI 10.1126/science.1843843; RAUSELL E, 1992, P NATL ACAD SCI USA, V89, P2571, DOI 10.1073/pnas.89.7.2571; RHOADES RW, 1987, J NEUROPHYSIOL, V57, P1577, DOI 10.1152/jn.1987.57.5.1577; WAITE PME, 1973, J PHYSIOL-LONDON, V228, P541, DOI 10.1113/jphysiol.1973.sp010099; WALL PD, 1971, NATURE, V232, P542, DOI 10.1038/232542a0	17	185	196	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 11	1993	361	6412					533	536		10.1038/361533a0	http://dx.doi.org/10.1038/361533a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL714	8429906				2022-12-24	WOS:A1993KL71400059
J	DIZHOOR, AM; CHEN, CK; OLSHEVSKAYA, E; SINELNIKOVA, VV; PHILLIPOV, P; HURLEY, JB				DIZHOOR, AM; CHEN, CK; OLSHEVSKAYA, E; SINELNIKOVA, VV; PHILLIPOV, P; HURLEY, JB			ROLE OF THE ACYLATED AMINO TERMINUS OF RECOVERIN IN CA2+-DEPENDENT MEMBRANE INTERACTION	SCIENCE			English	Article							ROD OUTER SEGMENTS; FREE CALCIUM-CONCENTRATION; BINDING PROTEIN; GUANYLATE-CYCLASE; PLASMA-MEMBRANE; MYRISTOYLATION; SUBUNITS; KINASE	Recoverin, a calcium ion (Ca2+)-binding protein of vertebrate photoreceptors, binds to photoreceptor membranes when the Ca2+ concentration is greater than 1 micromolar. This interaction requires a fatty acyl residue covalently linked to the recoverin amino (NH2)-terminus. Removal of the acyl residue, either by proteolytic cleavage of the NH2-terminus or by production of nonacylated recoverin, prevented recoverin from binding to membranes. The acylated recoverin NH2-terminus could be cleaved by trypsin only when Ca2+ was bound to recoverin. These results suggest that the hydrophobic NH2-terminus is constrained in Ca2+-free recoverin and liberated by Ca2+ binding. The hydrophobic acyl moiety of recoverin may interact with the membrane only when recoverin binds Ca2+.	UNIV WASHINGTON, DEPT BIOCHEM, SEATTLE, WA 98195 USA; MOSCOW MV LOMONOSOV STATE UNIV, INST PHYSICOCHEM BIOL, MOSCOW 119899, RUSSIA; UNIV WASHINGTON, HOWARD HUGHES MED INST, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle; Lomonosov Moscow State University; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle			Philippov, Pavel P/A-8939-2012	Dizhoor, Alexander/0000-0001-6770-9186	NATIONAL EYE INSTITUTE [R01EY006641] Funding Source: NIH RePORTER; NEI NIH HHS [EYO6641, R01 EY006641] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BRYANT M, 1990, P NATL ACAD SCI USA, V87, P523, DOI 10.1073/pnas.87.2.523; BUSS JE, 1987, P NATL ACAD SCI USA, V84, P7493, DOI 10.1073/pnas.84.21.7493; CARR SA, 1982, P NATL ACAD SCI-BIOL, V79, P6128, DOI 10.1073/pnas.79.20.6128; CHOW M, 1987, NATURE, V327, P482, DOI 10.1038/327482a0; DIZHOOR AM, 1992, J BIOL CHEM, V267, P16033; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; DIZHOOR AM, UNPUB; GORDON JI, 1991, J BIOL CHEM, V266, P8647; HURLEY JB, 1992, J BIOENERG BIOMEMBR, V24, P219, DOI 10.1007/BF00762680; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KAUPP UB, 1992, ANN REV PHYS, V54, P15; KAWAMURA S, 1991, NATURE, V349, P420, DOI 10.1038/349420a0; KAWAMURA S, 1992, BIOCHEM BIOPH RES CO, V186, P411, DOI 10.1016/S0006-291X(05)80823-X; KOKAME K, 1992, NATURE, V359, P749, DOI 10.1038/359749a0; KORENBROT JI, 1989, VISION RES, V29, P939, DOI 10.1016/0042-6989(89)90108-9; LAMBRECHT HG, 1991, EMBO J, V10, P793, DOI 10.1002/j.1460-2075.1991.tb08011.x; LINDER ME, 1991, J BIOL CHEM, V266, P4654; MCNAUGHTON PA, 1986, NATURE, V322, P261, DOI 10.1038/322261a0; NEUBERT TA, 1992, J BIOL CHEM, V267, P18274; POLANS AS, 1991, J CELL BIOL, V112, P981, DOI 10.1083/jcb.112.5.981; RATTO GM, 1988, J NEUROSCI, V8, P3240; RAY S, 1992, P NATL ACAD SCI USA, V89, P5705, DOI 10.1073/pnas.89.13.5705; RESH MD, 1990, NATURE, V346, P84, DOI 10.1038/346084a0; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; STRYER L, 1991, J BIOL CHEM, V266, P10711; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; TSIEN R, 1989, METHOD ENZYMOL, V172, P230; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569	29	177	181	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 5	1993	259	5096					829	832		10.1126/science.8430337	http://dx.doi.org/10.1126/science.8430337			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL110	8430337				2022-12-24	WOS:A1993KL11000038
J	HEALY, B				HEALY, B			THE PACE OF HUMAN GENE-TRANSFER RESEARCH QUICKENS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											HEALY, B (corresponding author), NIH,BETHESDA,MD 20892, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 3	1993	269	5					567	567						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ444	8421352				2022-12-24	WOS:A1993KJ44400005
J	GILBERT, RE; TOOKEY, PA; CUBITT, WD; ADES, AE; MASTERS, J; PECKHAM, CS				GILBERT, RE; TOOKEY, PA; CUBITT, WD; ADES, AE; MASTERS, J; PECKHAM, CS			PREVALENCE OF TOXOPLASMA IGG AMONG PREGNANT-WOMEN IN WEST LONDON ACCORDING TO COUNTRY OF BIRTH AND ETHNIC-GROUP	BRITISH MEDICAL JOURNAL			English	Article									HOSP SICK CHILDREN,DEPT VIROL,LONDON WC1N 3JH,ENGLAND	University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust	GILBERT, RE (corresponding author), INST CHILD HLTH,EPIDEMIOL & BIOSTAT UNIT,LONDON WC1N 1EH,ENGLAND.		Tookey, Pat A/G-2732-2010	Tookey, Pat A/0000-0001-6258-0387; Gilbert, Ruth/0000-0001-9347-2709				ADES AE, 1992, EPIDEMIOL INFECT, V108, P367, DOI 10.1017/S0950268800049839; CUBITT WD, 1992, J CLIN PATHOL, V45, P435, DOI 10.1136/jcp.45.5.435; FORSGREN M, 1991, LANCET, V337, P1413, DOI 10.1016/0140-6736(91)93095-Q; REMINGTON JS, 1990, INFECT DIS, P90; WALKER J, 1992, EPIDEMIOL INFECT, V108, P99, DOI 10.1017/S0950268800049542	5	22	23	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 16	1993	306	6871					185	185		10.1136/bmj.306.6871.185	http://dx.doi.org/10.1136/bmj.306.6871.185			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KH513	8443482	Bronze, Green Published			2022-12-24	WOS:A1993KH51300023
J	HAIN, R; REIF, HJ; KRAUSE, E; LANGEBARTELS, R; KINDL, H; VORNAM, B; WIESE, W; SCHMELZER, E; SCHREIER, PH; STOCKER, RH; STENZEL, K				HAIN, R; REIF, HJ; KRAUSE, E; LANGEBARTELS, R; KINDL, H; VORNAM, B; WIESE, W; SCHMELZER, E; SCHREIER, PH; STOCKER, RH; STENZEL, K			DISEASE RESISTANCE RESULTS FROM FOREIGN PHYTOALEXIN EXPRESSION IN A NOVEL PLANT	NATURE			English	Article							STILBENE SYNTHASE; RESVERATROL; GENE; GRAPEVINES; BOTRYTIS; VITIS	ALTHOUGH phytoalexins1,2 have long been inferred to be important in the defence of plants against fungal infection1,2, there are few reports showing that they provide resistance to infection. Several plants, including grapevine, synthesize the stilbene-type phytoalexin resveratrol3-7 when attacked by pathogens. Stilbenes with fungicidal potential are formed in several unrelated plant species, such as peanut (Arachis hypogaea), grapevine (Vitis vinifera) and pine (Pinus sylvestris)3,5,11-15. Stilbene biosynthesis only specifically requires the presence of stilbene synthase 6,9. Furthermore, the precursor molecules for the formation of hydroxystilbenes are malonyl-CoA and p-coumaroyl-CoA, both present in plants9. To investigate the potential of stilbene biosynthetic genes in a strategy of engineering pathogen resistance, we isolated stilbene synthase genes from grapevine, where they are expressed at a high level, and transferred them into tobacco10. We report here that regenerated tobacco plants containing these genes are more resistant to infection by Botrytis cinerea. This is, to our knowledge, the first report of increased disease resistance in transgenic plants based on an additional foreign phytoalexin.	UNIV MARBURG,FACHBEREICH CHEM,W-3550 MARBURG,GERMANY; MAX PLANCK INST ZUCHTUNGSFORSCH,W-5000 COLOGNE 30,GERMANY	Philipps University Marburg; Max Planck Society	HAIN, R (corresponding author), BAYER AG,PF-E-FU,INST BIOTECHNOL,W-5090 LEVERKUSEN 1,GERMANY.							BEDBROOK J, 1981, PLANT MOL BIOL NEWSL, V2, P24; Cuypers B., 1988, Molecular Plant-Microbe Interactions, V1, P157, DOI 10.1094/MPMI-1-157; DERCKS W, 1989, PHYSIOL MOL PLANT P, V34, P189, DOI 10.1016/0885-5765(89)90043-X; EBEL J, 1986, ANNU REV PHYTOPATHOL, V24, P235; FRISCHAUF AM, 1983, J MOL BIOL, V170, P827, DOI 10.1016/S0022-2836(83)80190-9; Gorham J., 1980, Progress in phytochemistry. Volume 6., P203; HAIN R, 1990, PLANT MOL BIOL, V15, P325, DOI 10.1007/BF00036918; HAIN R, 1985, MOL GEN GENET, V199, P161, DOI 10.1007/BF00330254; INGHAM J, 1972, BOT REV, V38, P3432; INGHAM JL, 1976, PHYTOCHEMISTRY, V15, P1791, DOI 10.1016/S0031-9422(00)97494-6; LANGCAKE P, 1976, PHYSIOL PLANT PATHOL, V9, P77, DOI 10.1016/0048-4059(76)90077-1; LANGCAKE P, 1977, PHYTOCHEMISTRY, V16, P1193, DOI 10.1016/S0031-9422(00)94358-9; LANGCAKE P, 1977, EXPERIENTIA, V33, P151, DOI 10.1007/BF02124034; LINSMAIER EM, 1965, PHYSIOL PLANTARUM, V18, P100, DOI 10.1111/j.1399-3054.1965.tb06874.x; MELCHIOR F, 1991, ARCH BIOCHEM BIOPHYS, V288, P552, DOI 10.1016/0003-9861(91)90234-A; PONT V, 1990, J PHYTOPATHOL, V130, P1, DOI 10.1111/j.1439-0434.1990.tb01147.x; SCHAFER W, 1989, SCIENCE, V246, P247, DOI 10.1126/science.246.4927.247; SCHMELZER E, 1989, PLANT CELL, V1, P993, DOI 10.1105/tpc.1.10.993; SCHOPPNER A, 1979, FEBS LETT, V108, P345; SCHRODER G, 1988, EUR J BIOCHEM, V172, P161, DOI 10.1111/j.1432-1033.1988.tb13868.x; STEIN U, 1985, VITIS, V24, P75; TEGTMEIER KJ, 1982, PHYTOPATHOLOGY, V72, P608, DOI 10.1094/Phyto-72-608	22	464	554	3	69	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 14	1993	361	6408					153	156		10.1038/361153a0	http://dx.doi.org/10.1038/361153a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KG466	8421520				2022-12-24	WOS:A1993KG46600059
J	GOSTIN, LO				GOSTIN, LO			CONTROLLING THE RESURGENT TUBERCULOSIS EPIDEMIC - A 50-STATE SURVEY OF TB STATUTES AND PROPOSALS FOR REFORM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; INFECTION; ISSUES; AIDS				GOSTIN, LO (corresponding author), AMER SOC LAW MED & ETH,OFF EXECUT DIRECTOR,765 COMMONWEALTH AVE,16TH FLOOR,BOSTON,MA 02215, USA.							BARNES M, 1992, COMMUNICATION   1116; BARNES PF, 1991, NEW ENGL J MED, V324, P1644, DOI 10.1056/NEJM199106063242307; Bayer R., 1991, PRIVATE ACTS SOCIAL; Bayer Ronald, 1992, TUBERCULOSIS REVIVAL; BRAKEL SJ, 1985, MENTALLY DISABLED LA; BRAUN MM, 1989, JAMA-J AM MED ASSOC, V261, P393, DOI 10.1001/jama.261.3.393; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; Burris Scott, 1985, Yale Law Policy Rev, V3, P479; COWLEY G, 1992, NEWSWEEK        0316, P53; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; EDGAR H, 1990, AM J LAW MED, V16, P155; GOLDSMITH MF, 1990, JAMA-J AM MED ASSOC, V264, P165, DOI 10.1001/jama.264.2.165; GOLDSMITH MF, 1992, JAMA-J AM MED ASSOC, V268, P174, DOI 10.1001/jama.268.2.174; Gostin L. O., 1987, AM J LAW MED, V12, P461; GOSTIN LO, 1992, HEALTH AFFAIR, V11, P248, DOI 10.1377/hlthaff.11.3.248; NOLAN CM, 1991, AM REV RESPIR DIS, V143, P257, DOI 10.1164/ajrccm/143.2.257; PARMET WE, 1989, J HEALTH POLIT POLIC, V14, P741, DOI 10.1215/03616878-14-4-741; RIEDER HL, 1989, EPIDEMIOL REV, V11, P79, DOI 10.1093/oxfordjournals.epirev.a036046; SHERMAN R, 1992, NATL LAW J, V14, P32; SHERMAN R, 1992, NATL LAW J, V14, P1; SKOLNICK A, 1989, JAMA-J AM MED ASSOC, V262, P3249, DOI 10.1001/jama.262.23.3249; SMALL PM, 1991, AM REV RESPIR DIS, V144, P745; SNIDER DE, 1989, JAMA-J AM MED ASSOC, V261, P436, DOI 10.1001/jama.261.3.436; SNIDER DE, 1992, NEW ENGL J MED, V326, P703, DOI 10.1056/NEJM199203053261011; 1991, MMWR, V40, P649; 1992, TUBERCULOSIS CONTROL; 1992, NATIONAL ACTION PLAN; 1986, TREATMENT TUBERCULOS; 1992, NIOSH RECOMMENDED GU; 1992, MMWR SRR5, V41, P1; 1990, MMWR, V39, P718; 1991, MMWR, V40, P585; 1989, MMWR SS3, V38, P1; 1992, MMWR SRR10, V41, P1; 1991, MMWR, V40, P869; 1990, MMWR SRR18, V39, P1; 1991, TUBERCULOSIS STATIST; 1989, OHIO ST LAW J, V49, P1017; 1990, MMWR SRR10, V39, P7	39	63	63	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 13	1993	269	2					255	261		10.1001/jama.269.2.255	http://dx.doi.org/10.1001/jama.269.2.255			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF405	8417246				2022-12-24	WOS:A1993KF40500034
J	KAY, AB				KAY, AB			ALTERNATIVE ALLERGY AND THE GENERAL MEDICAL COUNCIL	BRITISH MEDICAL JOURNAL			English	Article								In July 1992 Dr Keith Mumby, a clinical ecologist, appeared before the professional conduct committee of the General Medical Council on five charges to do with his practice of clinical ecology. He was found guilty of two of the charges-touting for publicity and failing to give a patient adequate medical attention-and admonished. The GMC failed, however, to address the issue of the nature of Mumby's treatments-Clinical ecology itself. This is based on the idea that some patients are unusually susceptible to their environment, the diagnosis and treatment are based on an unstandardised provocation-neutralisation test. A variety of medical bodies have failed to find scientific foundation for the technique. The GMC's policy on advertising services to patients is inconsistent, and in this case it has shown a regrettable reluctance to deal with the issue of treatments that are not scientifically validated.			KAY, AB (corresponding author), NAT HEART & LUNG INST,DEPT ALLERGY & CLIN IMMUNOL,LONDON SW3 6LY,ENGLAND.							JEWETT DL, 1990, NEW ENGL J MED, V323, P429, DOI 10.1056/NEJM199008163230701; MILLER JB, 1972, FOOD ALLERGY PROVOCA, P7; RAWLINS MD, 1988, REGULATORY CONTROL S, P147; WATSON J, 1991, MIRACLE ALLERGY CURE; WOOD B, 1992, KEEP TAKING TABLOIDS; 1992, ALLERGY CONVENTIONAL; 1986, J ALLERGY CLIN IMMUN, V78, P269; 1989, ANN INTERN MED, V111, P168; 1986, W J MED, V144, P239; 1986, BMJ, V293, P948; 1983, FED REGISTER, V48, P37716	11	18	18	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 9	1993	306	6870					122	124		10.1136/bmj.306.6870.122	http://dx.doi.org/10.1136/bmj.306.6870.122			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG465	8435610	Green Published, Bronze			2022-12-24	WOS:A1993KG46500028
J	JIA, ZC; VANDONSELAAR, M; QUAIL, JW; DELBAERE, LTJ				JIA, ZC; VANDONSELAAR, M; QUAIL, JW; DELBAERE, LTJ			ACTIVE-CENTER TORSION-ANGLE STRAIN REVEALED IN 1.6 ANGSTROM-RESOLUTION STRUCTURE OF HISTIDINE-CONTAINING PHOSPHOCARRIER PROTEIN	NATURE			English	Article							ESCHERICHIA-COLI; MACROMOLECULAR CRYSTALLOGRAPHY; PHOSPHOTRANSFERASE SYSTEM; TERTIARY STRUCTURE; HPR; H-1-NMR; PHOSPHOENOLPYRUVATE; ASSIGNMENTS; RESONANCE; SECONDARY	THE histidine-containing phosphocarrier protein (HPr) is a central component of the phosphoenolpyruvate: sugar phosphotransferase system that transports carbohydrates across the cell membrane of bacteria1. A typical phosphotransfer sequence is phosphoenolpyruvate --> enzyme I --> HPr --> enzyme II/III(sugar) -->. This is thermodynamically favourable owing to the participation of the high-energy phosphoenolpyruvate. We report here the structure of HPr from Streptococcus faecalis determined at 1.6 angstrom resolution. Remarkable disallowed Ramachandran torsion angles at the active centre, revealed by the X-ray structure, demonstrate a unique example of torsion-angle strain that is probably directly involved in protein function. During phosphorylation, the active-centre torsion-angle strain should facilitate the phosphotransfer reaction by lowering the activation-energy barrier. A recently reported Bacillus subtilis HPr structure2, which represents the phosphorylated state of HPr with no torsion-angle strain, provides direct evidence supporting our hypothesis that torsion-angle strain plays a direct part in the function of HPr. An HPr phosphotransfer cycling mechanism is proposed, based primarily on the structures of HPr and other phosphotransferase system proteins.	UNIV SASKATCHEWAN,DEPT BIOCHEM,SASKATOON S7N 0W0,SASKATCHEWAN,CANADA	University of Saskatchewan	JIA, ZC (corresponding author), UNIV SASKATCHEWAN,DEPT CHEM,SASKATOON S7N 0W0,SASKATCHEWAN,CANADA.							AQVIST J, 1991, P NATL ACAD SCI USA, V88, P2026, DOI 10.1073/pnas.88.5.2026; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; DICKERSO.RE, 1968, ACTA CRYSTALL B-STRU, VB 24, P997, DOI 10.1107/S0567740868003626; ELKABBANI OAL, 1987, J BIOL CHEM, V262, P12926; EVANS SV, IN PRESS J MOL GRAPH; FERSHT AR, 1985, NATURE, V314, P235, DOI 10.1038/314235a0; HAMMEN PK, 1991, BIOCHEMISTRY-US, V30, P11842, DOI 10.1021/bi00115a014; HERZBERG O, 1991, PROTEINS, V11, P223, DOI 10.1002/prot.340110307; HERZBERG O, 1992, P NATL ACAD SCI USA, V89, P2499, DOI 10.1073/pnas.89.6.2499; HOL WGJ, 1985, PROG BIOPHYS MOL BIO, V45, P149, DOI 10.1016/0079-6107(85)90001-X; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KALBITZER HR, 1991, BIOCHEMISTRY-US, V30, P11186, DOI 10.1021/bi00110a024; KALBITZER HR, 1982, BIOCHEMISTRY-US, V21, P2879, DOI 10.1021/bi00541a012; KLEVIT RE, 1986, BIOCHEMISTRY-US, V25, P7774, DOI 10.1021/bi00371a073; LIAO D, 1991, BIOCHEMISTRY-US, V90, P9583; MEADOW ND, 1990, REV BIOCH, V59, P495; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; RAMAKRISHNAN C, 1965, BIOPHYS J, V5, P909, DOI 10.1016/S0006-3495(65)86759-5; SHARMA S, 1991, P NATL ACAD SCI USA, V88, P4877, DOI 10.1073/pnas.88.11.4877; STONE MJ, 1992, BIOCHEMISTRY-US, V31, P4394, DOI 10.1021/bi00133a003; VANDIJK AA, 1990, BIOCHEMISTRY-US, V29, P8164, DOI 10.1021/bi00487a026; VANNULAND NAJ, 1992, EUR J BIOCHEM, V203, P483; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WITTEKIND M, 1990, BIOCHEMISTRY-US, V29, P7191, DOI 10.1021/bi00483a006; WORTHYLAKE D, 1991, P NATL ACAD SCI USA, V88, P10382, DOI 10.1073/pnas.88.23.10382	25	62	64	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 7	1993	361	6407					94	97		10.1038/361094a0	http://dx.doi.org/10.1038/361094a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KF718	8421502				2022-12-24	WOS:A1993KF71800058
J	PFLUGL, G; KALLEN, J; SCHIRMER, T; JANSONIUS, JN; ZURINI, MGM; WALKINSHAW, MD				PFLUGL, G; KALLEN, J; SCHIRMER, T; JANSONIUS, JN; ZURINI, MGM; WALKINSHAW, MD			X-RAY STRUCTURE OF A DECAMERIC CYCLOPHILIN CYCLOSPORINE CRYSTAL COMPLEX	NATURE			English	Article							BINDING; PROTEIN; ISOMERASE	HUMAN cyclophilin A (CypA), a ubiquitous intracellular protein of 165 amino acids, is the major receptor for the cyclic undecapeptide immunosuppressant drug cyclosporin A (CsA)1,2, which pre vents allograft rejection after transplant surgery3,4 and is efficacious in the field of autoimmune diseases5. CsA prevents T-cell proliferation by blocking the calcium-activated pathway leading to interleukin-2 transcription. Besides their ability to bind CsA, the cyclophilin isoforms6-8 also have peptidyl-prolyl isomerase activity9-11 and enhance the rate of protein folding12,13. The macrolide FK506 acts similarly to CsA and its cognate receptor FKBP also has peptidyl-prolyl isomerase activity14. Inhibition of this enzymatic activity alone is not sufficient to achieve immunosuppression15,16. A direct molecular interaction between the drug-immunophilin complex (CsA-CypA, or FK506-FKBP) and the phosphatase calcineurin, is responsible for modulating the T-cell receptor signal transduction pathway17,18. Here we describe the crystal structure of a decameric CypA-CsA complex. The crystallographic asymmetric unit is composed of a pentamer of 1 : 1 cyclophilin-cyclosporin complexes of rather exact non-crystallographic fivefold symmetry. The 2.8 angstrom electron density map is of high quality. The five independent cyclosporin molecules are clearly identifiable, providing an unambiguous picture of the detailed interactions between a peptide drug and its receptor. It broadly confirms the results of previous NMR, X-ray and modelling studies, but provides further important structural details which will be of use in the design of drugs that are analogues of CsA.	SANDOZ PHARMA AG,PRECLIN RES,CH-4002 BASEL,SWITZERLAND; UNIV BASEL,BIOCTR,CH-4056 BASEL,SWITZERLAND	Novartis; Sandoz; University of Basel			walkinshaw, malcolm/AAB-7497-2019	walkinshaw, malcolm/0000-0001-5955-9325				BOREL JF, 1989, PHARMACOL REV, V41, P259; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CALNE RY, 1978, LANCET, V2, P1323; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; FESIK SW, 1991, BIOCHEMISTRY-US, V30, P6574, DOI 10.1021/bi00240a030; FESIK SW, 1992, J AM CHEM SOC, V114, P3165, DOI 10.1021/ja00034a087; FEUTREN G, 1992, TRANSPLANT P, V24, P55; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FRANSSON C, 1992, FEBS LETT, V296, P90, DOI 10.1016/0014-5793(92)80410-I; FRIEDMAN J, 1991, CELL, V66, P799, DOI 10.1016/0092-8674(91)90123-G; GALLION S, 1992, PROTEIN ENG, V5, P391, DOI 10.1093/protein/5.5.391; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HARDING MW, 1986, J BIOL CHEM, V261, P8547; HARRISON RK, 1992, J AM CHEM SOC, V114, P3464, DOI 10.1021/ja00035a046; KALLEN J, 1992, FEBS LETT, V300, P286, DOI 10.1016/0014-5793(92)80865-E; KALLEN J, 1991, NATURE, V353, P276, DOI 10.1038/353276a0; KE HM, 1991, P NATL ACAD SCI USA, V88, P9483, DOI 10.1073/pnas.88.21.9483; KOFRON JL, 1991, BIOCHEMISTRY-US, V30, P6127, DOI 10.1021/bi00239a007; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LINDQVIST Y, 1989, J MOL BIOL, V209, P151, DOI 10.1016/0022-2836(89)90178-2; MYLES DAA, 1990, J MOL BIOL, V216, P491, DOI 10.1016/0022-2836(90)90373-T; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; PRICE ER, 1991, P NATL ACAD SCI USA, V88, P1903, DOI 10.1073/pnas.88.5.1903; ROSEN MK, 1992, ANGEW CHEM, V104, P413; SCHONBRUNNER ER, 1991, J BIOL CHEM, V266, P3630; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SIGAL NH, 1991, J EXP MED, V173, P619, DOI 10.1084/jem.173.3.619; SPITZFADEN C, 1992, FEBS LETT, V300, P291, DOI 10.1016/0014-5793(92)80866-F; SWANSON SKH, 1992, P NATL ACAD SCI USA, V89, P3741, DOI 10.1073/pnas.89.9.3741; TAI PKK, 1992, SCIENCE, V256, P1315, DOI 10.1126/science.1376003; WEBER C, 1991, BIOCHEMISTRY-US, V30, P6563, DOI 10.1021/bi00240a029; WOOD SP, 1988, J MOL BIOL, V202, P169, DOI 10.1016/0022-2836(88)90529-3; ZURINI M, 1990, FEBS LETT, V276, P63, DOI 10.1016/0014-5793(90)80507-F	33	195	202	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 7	1993	361	6407					91	94		10.1038/361091a0	http://dx.doi.org/10.1038/361091a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KF718	8421501				2022-12-24	WOS:A1993KF71800057
J	TANG, AM; AMAGAI, M; GRANGER, LG; STANLEY, JR; UDEY, MC				TANG, AM; AMAGAI, M; GRANGER, LG; STANLEY, JR; UDEY, MC			ADHESION OF EPIDERMAL LANGERHANS CELLS TO KERATINOCYTES MEDIATED BY E-CADHERIN	NATURE			English	Article							DENDRITIC CELLS; BONE-MARROW; MOLECULES; FAMILY; EXPRESSION; DIFFERENTIATION; GLYCOPROTEIN; DESMOCOLLINS; DESMOGLEIN; MEMBER	LANGERHANS cells (LC) are the principal accessory cells present in epidermis1. Because LC have limited capacity for self-renewal2, epidermis is continually repopulated by as-yet uncharacterized bone marrow-derived LC progenitors3,4. In addition, although LC persist in epidermis for extended periods, LC are induced to migrate from skin to regional lymph nodes after antigen exposure5. To begin to elucidate mechanisms involved in LC trafficking, we characterized LC-keratinocyte (KC) interactions. Here we report that fresh murine LC express cadherins, and that LC adhere to KC in vitro through E-cadherin. Cultured LC (which may bear a phenotypic and functional relationship to LC that have migrated to lymph nodes6,7) express lower levels of E-cadherin and exhibit decreased affinity for KC. These results suggest that expression of E-cadherin by LC promotes persistence of these cells in epidermis, and that cadherins may play important and unanticipated roles in interactions between leukocytes and epithelia.	NCI,DERMATOL BRANCH,BETHESDA,MD 20892; NCI,EXPTL IMMUNOL BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Amagai, Masayuki/K-5325-2013	Amagai, Masayuki/0000-0003-3314-7052				AMAGAI M, 1991, CELL, V67, P869, DOI 10.1016/0092-8674(91)90360-B; BREATHNACH SM, 1991, EPIDERMAL LANGERHANS, P23; COLLINS JE, 1991, J CELL BIOL, V113, P381, DOI 10.1083/jcb.113.2.381; DONALIES M, 1991, P NATL ACAD SCI USA, V88, P8024, DOI 10.1073/pnas.88.18.8024; FRELINGER JG, 1979, NATURE, V282, P321, DOI 10.1038/282321a0; GOODWIN L, 1990, BIOCHEM BIOPH RES CO, V173, P1224, DOI 10.1016/S0006-291X(05)80917-9; HAUSER C, 1989, EUR J IMMUNOL, V19, P245, DOI 10.1002/eji.1830190205; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; KATZ SI, 1979, NATURE, V282, P324, DOI 10.1038/282324a0; KOCH PJ, 1990, EUR J CELL BIOL, V53, P1; KRIPKE ML, 1990, J IMMUNOL, V145, P2833; MECHANIC S, 1991, P NATL ACAD SCI USA, V88, P4476, DOI 10.1073/pnas.88.10.4476; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; NOSE A, 1990, CELL, V61, P147, DOI 10.1016/0092-8674(90)90222-Z; NOSE A, 1986, J CELL BIOL, V103, P2649, DOI 10.1083/jcb.103.6.2649; NOSE A, 1988, CELL, V54, P993, DOI 10.1016/0092-8674(88)90114-6; RASANEN L, 1986, J INVEST DERMATOL, V86, P9, DOI 10.1111/1523-1747.ep12283693; RINGWALD M, 1991, NUCLEIC ACIDS RES, V19, P6533, DOI 10.1093/nar/19.23.6533; ROMANI N, 1989, J INVEST DERMATOL, V93, P600, DOI 10.1111/1523-1747.ep12319727; SCHULER G, 1985, J EXP MED, V161, P526, DOI 10.1084/jem.161.3.526; SHIRAYOSHI Y, 1986, CELL STRUCT FUNCT, V11, P245, DOI 10.1247/csf.11.245; STINGL G, 1978, J IMMUNOL, V121, P2005; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TAKEICHI M, 1990, REV BIOCH, V59, P237; TANG AM, 1991, J IMMUNOL, V146, P3347; TANG AM, 1992, EUR J IMMUNOL, V22, P581, DOI 10.1002/eji.1830220242; WITSELL AL, 1990, BIOTECHNIQUES, V9, P318; YOSHIDANORO C, 1984, DEV BIOL, V101, P19, DOI 10.1016/0012-1606(84)90112-X; YUSPA SH, 1985, METHODS SKIN RES, P213	29	405	411	1	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 7	1993	361	6407					82	85		10.1038/361082a0	http://dx.doi.org/10.1038/361082a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KF718	8421498				2022-12-24	WOS:A1993KF71800054
J	WALLACE, MR; ROSSETTI, RJ; OLSON, PE				WALLACE, MR; ROSSETTI, RJ; OLSON, PE			CATS AND TOXOPLASMOSIS RISK IN HIV-INFECTED ADULTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							ENCEPHALITIS; PREVALENCE; GONDII; AIDS	Objective.-To establish the prevalence and incidence of toxoplasmosis in an adult human immunodeficiency virus (HIV) population, and to determine if cat ownership contributes to the risk of toxoplasmosis. Design.-Retrospective record and laboratory review, coupled with a patient survey. Setting.-A tertiary-care military hospital HIV program. Patients.-A total of 723 HIV-infected adults, all former or current US military personnel. Main Outcome Measures.-Prevalence and incidence of serologic evidence of toxoplasmosis infection. Results.-A total of 723 HIV-infected patients had serial Toxoplasma IgG antibody determinations. Seventy patients (9.7%) were positive on their initial screen; the seronegative patients were tested annually for 1 to 5 years (mean duration of follow-up, 2.1 years). Only 13 patients (2.0%) who were initially seronegative acquired antibodies to Toxoplasma gondii. None of the patients who seroconverted developed clinical disease. A pet history was available on 12 of 13 patients who seroconverted; only one (8.3%) had owned or lived in a household with a cat during the period of seroconversion. The calculated attributable risk of cat ownership/exposure for toxoplasmosis seroconversion in this population is -2.9 per 100 persons annually. Conclusion.-Toxoplasma antibody seroconversion in an adult HIV-infected population is unusual and appears unrelated to cat ownership or exposure.	USN HOSP,DEPT CLIN INVEST,SAN DIEGO,CA 92134	United States Department of Defense; United States Navy	WALLACE, MR (corresponding author), USN HOSP,DEPT INTERNAL MED,DIV INFECT DIS,SAN DIEGO,CA 92134, USA.							BEACH PG, 1979, J INFECT DIS, V140, P780, DOI 10.1093/infdis/140.5.780; DANNEMANN BR, 1989, HOSP PRACT, V24, P139; FELDMAN HA, 1965, AM J EPIDEMIOL, V81, P385, DOI 10.1093/oxfordjournals.aje.a120524; GRANT IH, 1990, AIDS, V4, P519, DOI 10.1097/00002030-199006000-00004; Israelski D M, 1988, Infect Dis Clin North Am, V2, P429; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P292; LAST JM, 1988, DICT EPIDEMIOLOGY, P170; LUFT BJ, 1990, AIDS, V4, P593, DOI 10.1097/00002030-199006000-00018; McCabe R. E., 1990, Principles and practice of infectious diseases., P2090; PETERSON DR, 1972, AM J EPIDEMIOL, V96, P215, DOI 10.1093/oxfordjournals.aje.a121450; STRAYPEDERSEN B, 1975, SCAND J INFECT DIS, V11, P159; TEUTSCH SM, 1979, NEW ENGL J MED, V300, P695, DOI 10.1056/NEJM197903293001302; ULMANEN I, 1975, SCAND J INFECT DIS, V7, P67, DOI 10.3109/inf.1975.7.issue-1.12	13	66	67	1	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 6	1993	269	1					76	77		10.1001/jama.269.1.76	http://dx.doi.org/10.1001/jama.269.1.76			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF026	8416410				2022-12-24	WOS:A1993KF02600031
J	BANDTLOW, CE; SCHMIDT, MF; HASSINGER, TD; SCHWAB, ME; KATER, SB				BANDTLOW, CE; SCHMIDT, MF; HASSINGER, TD; SCHWAB, ME; KATER, SB			ROLE OF INTRACELLULAR CALCIUM IN NI-35-EVOKED COLLAPSE OF NEURONAL GROWTH CONES	SCIENCE			English	Article							CENTRAL NERVOUS-SYSTEM; CELL-ADHESION MOLECULES; NEURITE GROWTH; NEUROTROPHIC FACTORS; INOSITOL PHOSPHATES; NEURAL DEVELOPMENT; MYELIN; HOMEOSTASIS; ACTIVATION; RECEPTORS	A myelin-associated protein from the central nervous system, the neurite growth inhibitor NI-35, inhibits regeneration of lesioned neuronal fiber tracts in vivo and growth of neurites in vitro. Growth cones of cultured rat dorsal root ganglion neurons arrested their growth and collapsed when exposed to liposomes containing NI-35. Before morphological changes, the concentration of free intracellular calcium ([Ca2+]i) showed a rapid and large increase.in growth cones exposed to liposomes containing NI-35. Neither an increase in [Ca2+]i nor collapse of growth cones was detected in the presence of antibodies to NI-35. Dantrolene, an inhibitor of calcium release from caffeine-sensitive intracellular calcium stores, protected growth cones from collapse evoked by NI-35. Depletion of these caffeine-sensitive intracellular calcium stores prevented the increase in [Ca2+]i evoked by NI-35. The NI-35-evoked cascade of intracellular messengers that mediates collapse of growth cones includes the crucial step of calcium release from intracellular stores.	COLORADO STATE UNIV,DEPT ANAT & NEUROBIOL,PROGRAM NEURONAL GROWTH & DEV,FT COLLINS,CO 80523	Colorado State University	BANDTLOW, CE (corresponding author), UNIV ZURICH,BRAIN RES INST,CH-8029 ZURICH,SWITZERLAND.		Schwab, Martin E/B-6818-2016; Schmidt, Marc/B-1597-2008		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS028323, R01NS024683] Funding Source: NIH RePORTER; NINDS NIH HHS [NS28323, NS24683] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANTONICEK H, 1988, J NEUROSCI, V8, P2961; BANDTLOW CE, 1990, J NEUROSCI, V10, P3937; BENHAM CD, 1987, NATURE, V328, P275, DOI 10.1038/328275a0; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BRIDGMAN PC, 1989, J CELL BIOL, V108, P95, DOI 10.1083/jcb.108.1.95; BRUNNER J, 1978, J BIOL CHEM, V235, P7538; CADELLI D, 1991, EUR J NEUROSCI, V3, P825, DOI 10.1111/j.1460-9568.1991.tb00093.x; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.biochem.56.1.395; CARONI P, 1988, NEURON, V1, P85, DOI 10.1016/0896-6273(88)90212-7; CARONI P, 1988, J CELL BIOL, V106, P1281, DOI 10.1083/jcb.106.4.1281; COHAN CS, 1987, J NEUROSCI, V7, P3588; CONNOR JA, 1986, P NATL ACAD SCI USA, V83, P6179, DOI 10.1073/pnas.83.16.6179; COX EC, 1990, NEURON, V2, P31; DAVIES JA, 1990, NEURON, V2, P11; DESMEDT JE, 1977, J PHYSIOL-LONDON, V265, P565, DOI 10.1113/jphysiol.1977.sp011731; DOHERTY P, 1991, CELL, V67, P21, DOI 10.1016/0092-8674(91)90569-K; FICHARD A, 1991, DEV BIOL, V148, P1, DOI 10.1016/0012-1606(91)90312-Q; GOLDBERG DJ, 1988, J NEUROSCI, V8, P2596; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAGIWARA S, 1981, ANNU REV NEUROSCI, V4, P69, DOI 10.1146/annurev.ne.04.030181.000441; HAYDON PG, 1984, SCIENCE, V226, P561, DOI 10.1126/science.6093252; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; JESSELL TM, 1988, NEURON, V1, P3, DOI 10.1016/0896-6273(88)90204-8; JOHNSON P, 1990, INT J BIOCHEM, V22, P811, DOI 10.1016/0020-711X(90)90284-A; KATER SB, 1991, J NEUROSCI, V11, P891; KATER SB, 1988, TRENDS NEUROSCI, V11, P315, DOI 10.1016/0166-2236(88)90094-X; KUBA K, 1980, J PHYSIOL-LONDON, V298, P251, DOI 10.1113/jphysiol.1980.sp013079; LANKFORD KL, 1989, J CELL BIOL, V109, P1229, DOI 10.1083/jcb.109.3.1229; LANKFORD KL, 1988, P NATL ACAD SCI USA, V85, P2839, DOI 10.1073/pnas.85.8.2839; LIBSCOMBE D, 1988, NEURON, V1, P355; LIPTON SA, 1989, TRENDS NEUROSCI, V12, P265, DOI 10.1016/0166-2236(89)90026-X; LUECKHOFF A, 1992, NATURE, V355, P356; MCBURNEY RN, 1987, TRENDS NEUROSCI, V10, P164, DOI 10.1016/0166-2236(87)90042-7; MCKEON RJ, 1991, J NEUROSCI, V11, P3398; MELDOLESI J, 1991, TRENDS PHARMACOL SCI, V12, P289, DOI 10.1016/0165-6147(91)90577-F; MILLER RJ, 1988, TRENDS NEUROSCI, V11, P415, DOI 10.1016/0166-2236(88)90191-9; MILLS LR, 1990, NEURON, V4, P149, DOI 10.1016/0896-6273(90)90451-K; NEERING JR, 1984, NATURE, V309, P158; PALADE P, 1989, MOL PHARMACOL, V36, P673; PFEIFFER DR, 1978, ANN NY ACAD SCI, V307, P403; POLOTORAK M, 1987, J CELL BIOL, V105, P1893; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; QUARLES RH, 1984, DEV NEUROSCI-BASEL, V6, P285; RAPER JA, 1990, NEURON, V2, P21; REHDER V, UNPUB; REICHARDT LF, 1991, ANNU REV NEUROSCI, V14, P531, DOI 10.1146/annurev.neuro.14.1.531; SADOUL R, 1983, NATURE, V304, P347, DOI 10.1038/304347a0; SCHLIWA M, 1981, P NATL ACAD SCI-BIOL, V78, P1037, DOI 10.1073/pnas.78.2.1037; SCHMIDT M F, 1991, Society for Neuroscience Abstracts, V17, P927; SCHNELL L, 1990, NATURE, V343, P269, DOI 10.1038/343269a0; SCHUCH U, 1989, NEURON, V3, P13, DOI 10.1016/0896-6273(89)90111-6; SCHWAB ME, 1985, J NEUROSCI, V5, P2415; SILVER RA, 1990, NATURE, V343, P751, DOI 10.1038/343751a0; SNOW DM, 1991, DEVELOPMENT, V113, P1437; SOMMER I, 1981, DEV BIOL, V83, P311, DOI 10.1016/0012-1606(81)90477-2; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TAYLOR CW, 1990, TRENDS PHARMACOL SCI, V11, P271; THOENEN H, 1991, TRENDS NEUROSCI, V14, P165, DOI 10.1016/0166-2236(91)90097-E; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; YAMAMOTO H, 1983, J NEUROCHEM, V41, P1119, DOI 10.1111/j.1471-4159.1983.tb09060.x; YANG XH, 1991, CELL, V67, P661, DOI 10.1016/0092-8674(91)90062-4	61	244	251	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 1	1993	259	5091					80	83		10.1126/science.8418499	http://dx.doi.org/10.1126/science.8418499			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KE601	8418499				2022-12-24	WOS:A1993KE60100033
J	GROVES, AK; BARNETT, SC; FRANKLIN, RJM; CRANG, AJ; MAYER, M; BLAKEMORE, WF; NOBLE, M				GROVES, AK; BARNETT, SC; FRANKLIN, RJM; CRANG, AJ; MAYER, M; BLAKEMORE, WF; NOBLE, M			REPAIR OF DEMYELINATED LESIONS BY TRANSPLANTATION OF PURIFIED 0-2A PROGENITOR CELLS	NATURE			English	Article							RAT SPINAL-CORD; MYELIN-DEFICIENT RAT; SCHWANN-CELLS; TYPE-1 ASTROCYTES; GROWTH-HORMONE; NERVOUS-SYSTEM; OLIGODENDROCYTES; DIFFERENTIATION; GALACTOCEREBROSIDE; INJECTION	THE transplantation of well defined populations of precursor cells offers a means of repairing damaged tissue and of delivering therapeutic compounds to sites of injury or degeneration. For example, a functional immune system can be reconstituted by transplantation of purified haematopoietic stem cells1, and transplanted skeletal myoblasts and keratinocytes can participate in the formation of normal tissue in host animals2-4. Cell transplantation in the central nervous system (CNS) has been proposed as a means of correcting neuronal dysfunction in diseases associated with neuronal loss5-7; it might also rectify glial cell dysfunction, with transplanted oligodendrocyte precursor cells eventually allowing repair of demyelinating damage in the CNS. Here we use co-operating growth factors to expand purified populations of oligodendrocyte type-2 astrocyte (O-2A) progenitor cells for several weeks in vitro. When injected into demyelinating lesions in spinal cords of adult rats, created in such a way as to preclude host-mediated remyelination, these expanded populations are capable of producing extensive remyelination. In addition, transplantation of O-2A progenitor cells genetically modified to express the bacterial beta-galactosidase gene gives rise to beta-galactosidase-positive oligodendrocytes which remyelinate demyelinated axons within the lesion. These results offer a viable strategy for the manipulation of neural precursor cells which is compatible with attempts to repair damaged CNS tissue by precursor transplantation.	UNIV CAMBRIDGE,MRC,CAMBRIDGE CTR BRAIN REPAIR,CAMBRIDGE CB3 0ES,ENGLAND; LUDWIG INST CANC RES,CELLULAR NEUROBIOL LAB,LONDON W1P 8BT,ENGLAND; CRC BEATSON LABS,DEPT MED ONCOL & NEUROBIOL,GLASGOW G61 1BD,SCOTLAND; UNIV CAMBRIDGE,DEPT CLIN VET MED,CAMBRIDGE CB3 0ES,ENGLAND	University of Cambridge; Ludwig Institute for Cancer Research; Beatson Institute; University of Cambridge			Messier, Claude/A-2322-2008	Messier, Claude/0000-0002-4791-1763; Franklin, Robin/0000-0001-6522-2104; Groves, Andrew/0000-0002-0784-7998	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; BLAKEMORE WF, 1989, J NEUROCYTOL, V18, P519, DOI 10.1007/BF01474547; BLAKEMORE WF, 1988, DEV NEUROSCI-BASEL, V10, P1, DOI 10.1159/000111949; BOGLER O, 1990, P NATL ACAD SCI USA, V87, P6368, DOI 10.1073/pnas.87.16.6368; CRANG AJ, 1992, J NEUROIMMUNOL, V40, P243, DOI 10.1016/0165-5728(92)90140-G; DHAWAN J, 1991, SCIENCE, V254, P1509, DOI 10.1126/science.1962213; DUNCAN ID, 1988, J NEUROCYTOL, V17, P351, DOI 10.1007/BF01187857; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FRANKLIN RJM, 1991, ACTA NEUROPATHOL, V81, P686, DOI 10.1007/BF00296381; FRANKLIN RJM, 1991, J NEUROCYTOL, V20, P420, DOI 10.1007/BF01355538; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRANSMULLER A, 1991, GLIA, V4, P580; GUMPEL M, 1983, NEUROSCI LETT, V37, P307, DOI 10.1016/0304-3940(83)90449-4; GUSSONI E, 1992, NATURE, V356, P435, DOI 10.1038/356435a0; LINDVALL O, 1990, SCIENCE, V247, P574, DOI 10.1126/science.2105529; MAYER MM, IN PRESS; MORGAN JR, 1987, SCIENCE, V237, P1476; PRICE J, 1987, P NATL ACAD SCI USA, V84, P156, DOI 10.1073/pnas.84.1.156; RAFF MC, 1983, NATURE, V303, P390, DOI 10.1038/303390a0; RAFF MC, 1978, NATURE, V274, P813, DOI 10.1038/274813a0; RANSCHT B, 1982, P NATL ACAD SCI-BIOL, V79, P2709, DOI 10.1073/pnas.79.8.2709; RENFRANZ PJ, 1991, CELL, V66, P713, DOI 10.1016/0092-8674(91)90116-G; ROSENBLUTH J, 1990, J NEUROCYTOL, V19, P718, DOI 10.1007/BF01188040; SNYDER EY, 1992, CELL, V68, P33, DOI 10.1016/0092-8674(92)90204-P; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; WARRINGTON AE, 1993, J NEUROSCI RES, V34, P1, DOI 10.1002/jnr.490340102; WILLIAMS BP, 1991, NEURON, V7, P685, DOI 10.1016/0896-6273(91)90381-9	27	322	340	1	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 1	1993	362	6419					453	455		10.1038/362453a0	http://dx.doi.org/10.1038/362453a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KV424	8464477				2022-12-24	WOS:A1993KV42400085
J	HULLEY, SB; NEWMAN, TB; GRADY, D; GARBER, AM; BARON, RB; BROWNER, WS				HULLEY, SB; NEWMAN, TB; GRADY, D; GARBER, AM; BARON, RB; BROWNER, WS			SHOULD WE BE MEASURING BLOOD CHOLESTEROL LEVELS IN YOUNG-ADULTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; SECONDARY PREVENTION; COST-EFFECTIVENESS; MYOCARDIAL-INFARCTION; LOWERING CHOLESTEROL; LIFE EXPECTANCY; MORTALITY; TRIALS; RISK; REDUCTION	Should we measure blood cholesterol levels in all adults, or only in those at high risk of coronary heart disease (CHD)? Most men under the age of 35 years and women under the age of 45 years-roughly half the adult population-are at very low short-term risk of CHD. One consequence is that drug treatment to lower high blood cholesterol levels in the average young adult is an extremely expensive means of prolonging life; the estimated $1 million to $10 million per year of life is 100 to 1000 times the cost of other approaches. Individualized dietary treatment is somewhat cheaper but relatively ineffective. Another consequence of the low CHD risk in young adults is the greater likelihood that intervention may have harmful effects that outweigh the benefits. Meta-analyses of primary prevention trials in middle-aged men reveal an increase in non-CHD deaths among those randomized to cholesterol interventions, an unexpected finding that is more substantial than the decrease in CHD deaths. This raises the possibility that one or more of the cholesterol interventions could have very serious adverse effects among young adults, whose risk of non-CHD death is normally 100 times their risk of CHD death. We conclude that the policy of screening and treating high blood cholesterol levels in young adults is neither cost-effective,nor does it satisfy ethical standards requiring strong evidence that preventive interventions do more good than harm. Fortunately, cholesterol screening in young adults is also not necessary: most CHD events associated with high blood cholesterol levels in this population will not occur for decades and can be prevented by treatment that is begun in middle age. Cholesterol screening and treatment in young adults should be limited to individuals with known coronary disease or other unusual factors that place them at high short-term risk of CHD death.	UNIV CALIF SAN FRANCISCO,SCH MED,DEPT MED,DIV GEN INTERNAL MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT LAB MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT PEDIAT,DIV GEN PEDIAT,SAN FRANCISCO,CA 94143; DEPT VET AFFAIRS MED CTR,DEPT MED,GEN INTERNAL MED SECT,SAN FRANCISCO,CA; DEPT VET AFFAIRS MED CTR,PALO ALTO,CA; STANFORD UNIV,DEPT MED,DIV GEN INTERNAL MED,STANFORD,CA 94305	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Stanford University	HULLEY, SB (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,DEPT EPIDEMIOL & BIOSTAT,DIV CLIN EPIDEMIOL,BOX 0886,SAN FRANCISCO,CA 94143, USA.		Garber, Alan M/F-1476-2010		NHLBI NIH HHS [HL-46297] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046297] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRETT AS, 1989, NEW ENGL J MED, V321, P676, DOI 10.1056/NEJM198909073211009; BROWN MA, 1989, ENERG BUILDINGS, V13, P51, DOI 10.1016/0378-7788(89)90017-0; CRIQUI MH, 1991, ANN INTERN MED, V115, P973, DOI 10.7326/0003-4819-115-12-973; DAVIS CE, 1990, JAMA-J AM MED ASSOC, V264, P3044, DOI 10.1001/jama.264.23.3044; DUFFY MA, 1993, PHYSICIANS DESK REFE; ENGELBERG H, 1992, LANCET, V339, P727, DOI 10.1016/0140-6736(92)90609-7; GOLDMAN L, 1991, JAMA-J AM MED ASSOC, V265, P1145, DOI 10.1001/jama.265.9.1145; GOLDMAN L, 1992, CIRCULATION, V85, P1930; HOLME I, 1990, CIRCULATION, V82, P1916, DOI 10.1161/01.CIR.82.6.1916; HULLEY SB, 1992, CIRCULATION, V86, P1026, DOI 10.1161/01.CIR.86.3.1026; HULLEY SB, 1980, NEW ENGL J MED, V302, P1383, DOI 10.1056/NEJM198006193022503; JACOBS D, 1992, CIRCULATION, V86, P1046, DOI 10.1161/01.CIR.86.3.1046; JACOBS DR, IN PRESS ANN REV PUB; KAPLAN JR, 1991, PSYCHOSOM MED, V53, P634, DOI 10.1097/00006842-199111000-00005; KLAG MJ, 1993, NEW ENGL J MED, V328, P313, DOI 10.1056/NEJM199302043280504; KRAHN M, 1991, ANN INTERN MED, V115, P248, DOI 10.7326/0003-4819-115-4-248; KRISTIANSEN IS, 1991, BRIT MED J, V302, P1119, DOI 10.1136/bmj.302.6785.1119; MASON RP, 1991, J MOL CELL CARDIOL, V23, P1339, DOI 10.1016/0022-2828(91)90091-Y; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; NEATON JD, 1992, ARCH INTERN MED, V152, P1490, DOI 10.1001/archinte.152.7.1490; NEWMAN TB, 1992, JAMA-J AM MED ASSOC, V267, P100, DOI 10.1001/jama.267.1.100; NEWMAN TB, 1990, JAMA-J AM MED ASSOC, V264, P3039, DOI 10.1001/jama.264.23.3039; NEWMAN TB, 1993, NEW ENGL J MED, V328, P139; OLIVER MF, 1992, BMJ-BRIT MED J, V304, P393, DOI 10.1136/bmj.304.6824.393; OSTER G, 1987, JAMA-J AM MED ASSOC, V258, P2381, DOI 10.1001/jama.258.17.2381; PEKKANEN J, 1990, NEW ENGL J MED, V322, P1700, DOI 10.1056/NEJM199006143222403; RAMSAY LE, 1991, BMJ-BRIT MED J, V303, P953, DOI 10.1136/bmj.303.6808.953; RAVNSKOV U, 1992, BMJ-BRIT MED J, V305, P15, DOI 10.1136/bmj.305.6844.15; ROSSOUW JE, 1990, NEW ENGL J MED, V323, P1112, DOI 10.1056/NEJM199010183231606; ROSSOUW JE, 1991, NEW ENGL J MED, V325, P1813; Sackett DL, 1991, CLIN EPIDEMIOLOGY BA, P163; SIEGEL D, 1988, ANN INTERN MED, V109, P213, DOI 10.7326/0003-4819-109-3-213; SILBERBERG JS, 1991, MED J AUSTRALIA, V155, P665, DOI 10.5694/j.1326-5377.1991.tb93956.x; SMITH GD, 1992, BRIT MED J, V304, P913, DOI 10.1136/bmj.304.6831.913-a; TAYLOR WC, 1987, ANN INTERN MED, V106, P605, DOI 10.7326/0003-4819-106-4-605; TSEVAT J, 1991, CIRCULATION, V83, P1194, DOI 10.1161/01.CIR.83.4.1194; Weinstein M C, 1981, Med Decis Making, V1, P309, DOI 10.1177/0272989X8100100403; YUSUF S, 1987, ATHEROSCLEROSIS, P389; 1990, J CLIN EPIDEMIOL, V43, P1029; 1970, JAMA-J AM MED ASSOC, V214, P1303; 1988, ARCH INTERN MED, V148, P36; 1984, JAMA-J AM MED ASSOC, V251, P365; 1990, STATISTICAL ABSTRACT; 1972, JAMA-J AM MED ASSOC, V220, P996; 1991, VITAL STATISTICS US, V2	45	74	74	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 17	1993	269	11					1416	1419		10.1001/jama.269.11.1416	http://dx.doi.org/10.1001/jama.269.11.1416			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KQ857	8441219				2022-12-24	WOS:A1993KQ85700038
J	DAVENPORT, RW; DOU, P; REHDER, V; KATER, SB				DAVENPORT, RW; DOU, P; REHDER, V; KATER, SB			A SENSORY ROLE FOR NEURONAL GROWTH CONE FILOPODIA	NATURE			English	Article							CALCIUM; GENERATION; CONTACTS; AXONS; DEGENERATION; MORPHOLOGY; SEROTONIN; TARGETS; PATHWAY; CULTURE	THE dynamic nature of neuronal growth cone filopodia led to the suggestion that the primary function of filopodia is to sample their immediate environment1-3, responding to and transducing environmental signals that affect growth cone behaviour4-6 and shape7-11. Filopodia seem well suited to serve as antenna-like sensors, their broad span allows sampling of information over a greatly enhanced radius, and forward-projecting filopodia encounter potential cues in the molecular terrain long before the advancing growth cone itself12. Filopodia in culture can serve structural roles13, exert mechanical tension14-16 and selectively adhere to their surrounding17-20. Whether or not filopodia have a general sensory role has not been tested directly, largely because of their small size, which limits an electrophysiological approach, and their integral relationship with the parent growth cone, which prevents resolution of their different functions. Here we use surgical procedures to isolate individual filopodia from their parent growth cone and, by monitoring their morphology and calcium second messenger systems, we show that neuronal growth cone filopodia contain signal transduction mechanisms that allow autonomous responses and the transmission of distant environmental information to their parent growth cone.	COLORADO STATE UNIV,DEPT ANAT & NEUROBIOL,PROGRAM NEURONAL GROWTH & DEV,FT COLLINS,CO 80523	Colorado State University								BANDTLOW C, 1990, J NEUROSCI, V10, P3837, DOI 10.1523/JNEUROSCI.10-12-03837.1990; BEDLACK RS, 1992, NEURON, V9, P393, DOI 10.1016/0896-6273(92)90178-G; BONHOEFFER F, 1984, TRENDS NEUROSCI, V7, P378, DOI 10.1016/S0166-2236(84)80060-0; BOVOLENTA P, 1987, J NEUROSCI, V7, P1447; BRAY D, 1973, NATURE, V244, P93, DOI 10.1038/244093a0; BRAY D, 1979, J CELL SCI, V37, P391; COHAN CS, 1987, J NEUROSCI, V7, P3588; DAVENPORT RW, 1992, NEURON, V9, P405, DOI 10.1016/0896-6273(92)90179-H; EISEN JS, 1986, NATURE, V320, P269, DOI 10.1038/320269a0; GOLDBERG DJ, 1986, J CELL BIOL, V103, P1921, DOI 10.1083/jcb.103.5.1921; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUNDERSEN RW, 1988, J NEUROSCI RES, V21, P298, DOI 10.1002/jnr.490210222; HAMMARBACK JA, 1986, DEV BIOL, V117, P655, DOI 10.1016/0012-1606(86)90334-9; HAYDON PG, 1988, NEURON, V1, P919, DOI 10.1016/0896-6273(88)90149-3; HAYDON PG, 1984, SCIENCE, V226, P561, DOI 10.1126/science.6093252; HEIDEMANN SR, 1990, J CELL BIOL, V111, P1949, DOI 10.1083/jcb.111.5.1949; HOLT CE, 1989, J NEUROSCI, V9, P3123; LETOURNEAU PC, 1989, DEVELOPMENT, V105, P505; LETOURNEAU PC, 1991, NERVE GROWTH CONE, P1; LIPSCOMBE D, 1988, P NATL ACAD SCI USA, V85, P2398, DOI 10.1073/pnas.85.7.2398; MATTSON MP, 1988, J NEUROSCI, V8, P2087; MATTSON MP, 1989, BRAIN RES, V478, P337, DOI 10.1016/0006-8993(89)91514-X; MCCOBB DP, 1988, NEURON, V1, P377, DOI 10.1016/0896-6273(88)90187-0; MILLS LR, 1990, NEURON, V4, P149, DOI 10.1016/0896-6273(90)90451-K; NAKAI J, 1959, Z ZELLFORSCH MIK ANA, V51, P108, DOI 10.1007/BF00345083; OCONNOR TP, 1990, J NEUROSCI, V10, P3935, DOI 10.1523/JNEUROSCI.10-12-03935.1990; REHDER V, 1992, J NEUROSCI, V12, P3175, DOI 10.1523/JNEUROSCI.12-08-03175.1992; SILVER RA, 1990, NATURE, V343, P751, DOI 10.1038/343751a0; SPERRY RW, 1963, P NATL ACAD SCI USA, V50, P703, DOI 10.1073/pnas.50.4.703; TAGHERT PH, 1982, DEV BIOL, V94, P391, DOI 10.1016/0012-1606(82)90356-6; TESSIERLAVIGNE M, 1991, TRENDS NEUROSCI, V14, P303, DOI 10.1016/0166-2236(91)90142-H; TOSNEY KW, 1985, J NEUROSCI, V5, P2345; UTO A, 1991, CELL CALCIUM, V12, P29, DOI 10.1016/0143-4160(91)90082-P; WONG RG, 1981, J NEUROSCI, V1, P1008	34	183	185	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 25	1993	361	6414					721	724		10.1038/361721a0	http://dx.doi.org/10.1038/361721a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KN789	8441465				2022-12-24	WOS:A1993KN78900055
J	IGLEHART, JK				IGLEHART, JK			THE AMERICAN HEALTH-CARE SYSTEM - THE END STAGE RENAL-DISEASE PROGRAM	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							HEMODIALYSIS; MORTALITY; DIALYSIS											ANGELL M, 1991, NEW ENGL J MED, V324, P1498, DOI 10.1056/NEJM199105233242110; BRUNNER FP, 1992, KIDNEY INT, V42, pS4; COOPER H, 1992, WALL STREET J   1005, pB8; EGGERS PW, 1990, DHHS PHS901214 PUBL, P121; GREER JW, 1992, MEDICARE PAYMENT REC; HELD PJ, 1990, AM J KIDNEY DIS, V15, P441, DOI 10.1016/S0272-6386(12)70362-1; HELD PJ, 1991, JAMA-J AM MED ASSOC, V265, P871, DOI 10.1001/jama.265.7.871; HELD PJ, 1992, KIDNEY INT, V42, pS16; HULL AR, 1990, AM J KIDNEY DIS, V15, P375, DOI 10.1016/S0272-6386(12)70354-2; IGLEHART JK, 1992, NEW ENGL J MED, V326, P962, DOI 10.1056/NEJM199204023261426; IGLEHART JK, 1992, NEW ENGL J MED, V326, P1715, DOI 10.1056/NEJM199206183262526; IGLEHART JK, 1992, NEW ENGL J MED, V327, P742, DOI 10.1056/NEJM199209033271029; KASSIRER JP, 1992, NEW ENGL J MED, V326, P945, DOI 10.1056/NEJM199204023261408; MCCLELLAN WM, 1992, ANN INTERN MED, V117, P332, DOI 10.7326/0003-4819-117-4-332; POWE NR, 1992, JAMA-J AM MED ASSOC, V268, P1434, DOI 10.1001/jama.268.11.1434; PRICE CA, 1992, NEPHROLOGY NEWS  FEB, P18; Rettig RA, 1991, BIOMEDICAL POLITICS, P176; Rettig RA, 1991, KIDNEY FAILURE FEDER; VONALBERTINI B, 1991, AM J NEPHROL, V11, P169, DOI 10.1159/000168298; 1992, C9204 C REP; 1992, 1992 GREEN BOOK; 1980, HLTH CARE FINANCING; 1992, GAOHRD9331 GEN ACC O	23	60	63	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 4	1993	328	5					366	371		10.1056/NEJM199302043280528	http://dx.doi.org/10.1056/NEJM199302043280528			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK247	8419833				2022-12-24	WOS:A1993KK24700029
J	MCLEAN, AD; STONEBRIDGE, PA; BRADBURY, AW; RAINEY, JB; MACLEOD, DAD				MCLEAN, AD; STONEBRIDGE, PA; BRADBURY, AW; RAINEY, JB; MACLEOD, DAD			TIME OF PRESENTATION, TIME OF OPERATION, AND UNNECESSARY APPENDECTOMY	BRITISH MEDICAL JOURNAL			English	Article							APPENDICITIS		ST JOHNS HOSP,DEPT SURG,LIVINGSTON EH54 6PP,W LOTHIAN,SCOTLAND									CAMPLING EA, 1992, REPORT NATIONAL CONF; HOFFMANN J, 1989, BRIT J SURG, V76, P774, DOI 10.1002/bjs.1800760803; JACOB ET, 1975, LANCET, V2, P1032; MALT RA, 1986, NEW ENGL J MED, V315, P1546, DOI 10.1056/NEJM198612113152409; 1987, LANCET, V24, P198	5	16	16	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 30	1993	306	6873					307	307		10.1136/bmj.306.6873.307	http://dx.doi.org/10.1136/bmj.306.6873.307			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK718	8461650	Green Published, Bronze			2022-12-24	WOS:A1993KK71800022
J	AMATI, B; BROOKS, MW; LEVY, N; LITTLEWOOD, TD; EVAN, GI; LAND, H				AMATI, B; BROOKS, MW; LEVY, N; LITTLEWOOD, TD; EVAN, GI; LAND, H			ONCOGENIC ACTIVITY OF THE C-MYC PROTEIN REQUIRES DIMERIZATION WITH MAX	CELL			English	Article							LOOP-HELIX PROTEIN; LEUCINE ZIPPER PROTEINS; DNA-BINDING; ACTIVATES TRANSCRIPTION; COILED-COIL; BASIC REGION; CELLS; GENE; EXPRESSION; DOMAINS	c-Myc (Myc) and Max proteins dimerize and bind DNA through basic-helix-loop-helix-leucine zipper motifs (b-HLH-LZ). Using a genetic approach, we demonstrate that binding to Max is essential for Myc transforming activity and that Myc homodimers are inactive. Mutants of Myc and Max that bind efficiently to each other but not to their wild-type partners were generated by either exchanging the HLH-LZ domains or reciprocally modifying LZ dimerization specificities. While transformation defective on their own, complementary mutants restore Myc transforming activity when coexpressed in cells. The HLH-LZ exchange mutants also have dominant negative activity on wild-type Myc function. In addition, wild-type max antagonizes myc function in a dose-dependent manner, presumably through competition of Max-Max and Myc-Max dimers for common target DNA sites. Therefore, Max can function as both suppressor and activator of Myc. A general model for the role of Myc and Max in growth control is discussed.	IMPERIAL CANC RES FUND, BIOCHEM CELL NUCLEUS LAB, LONDON WC2A 3PX, ENGLAND	Cancer Research UK	AMATI, B (corresponding author), IMPERIAL CANC RES FUND, GROWTH CONTROL & DEV LAB, LINCOLNS INN FIELDS, LONDON WC2A 3PX, ENGLAND.		Amati, Bruno/AAM-3418-2020	Levy-Strumpf, Naomi/0000-0002-5454-8800; Amati, Bruno/0000-0002-2958-1799				AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; BECKMANN H, 1991, GENE DEV, V5, P1057, DOI 10.1101/gad.5.6.1057; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BERBERICH S, 1992, ONCOGENE, V7, P775; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P5675, DOI 10.1073/pnas.88.13.5675; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; DANG CV, 1991, MOL CELL BIOL, V11, P954, DOI 10.1128/MCB.11.2.954; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DEAN M, 1986, J BIOL CHEM, V261, P9161; DROLET DW, 1991, GENE DEV, V5, P1739, DOI 10.1101/gad.5.10.1739; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FISHER F, 1991, ONCOGENE, V6, P1099; FREYTAG SO, 1990, CELL GROWTH DIFFER, V1, P339; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; GRIEP AE, 1988, P NATL ACAD SCI USA, V85, P6806, DOI 10.1073/pnas.85.18.6806; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; HARLOW E, 1988, ANTIBODIES; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KERKHOFF E, 1991, P NATL ACAD SCI USA, V88, P4323, DOI 10.1073/pnas.88.10.4323; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LAMB P, 1991, TRENDS BIOCHEM SCI, V16, P417, DOI 10.1016/0968-0004(91)90167-T; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LITTLEWOOD TD, 1992, ONCOGENE, V7, P1783; LOKE SL, 1988, CURR TOP MICROBIOL, V141, P282; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; LUSCHER B, 1988, MOL CELL BIOL, V8, P2504; MAKELA TP, 1992, SCIENCE, V256, P373, DOI 10.1126/science.256.5055.373; MCLACHLAN AD, 1975, J MOL BIOL, V98, P293, DOI 10.1016/S0022-2836(75)80119-7; MOORE JP, 1987, ONCOGENE RES, V2, P65; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; MUKHERJEE B, 1992, GENE DEV, V6, P1480, DOI 10.1101/gad.6.8.1480; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NEUBERG M, 1989, NATURE, V338, P589, DOI 10.1038/338589a0; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; Penn L J, 1990, Semin Cancer Biol, V1, P69; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; PENN LJZ, 1990, MOL CELL BIOL, V10, P4961, DOI 10.1128/MCB.10.9.4961; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; ROUSSEL MF, 1991, NATURE, V353, P361, DOI 10.1038/353361a0; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722; WATERS CM, 1991, ONCOGENE, V6, P797; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x	66	479	485	1	19	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 29	1993	72	2					233	245		10.1016/0092-8674(93)90663-B	http://dx.doi.org/10.1016/0092-8674(93)90663-B			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KK038	8425220				2022-12-24	WOS:A1993KK03800008
J	MACLEOD, DIA; HE, S				MACLEOD, DIA; HE, S			VISIBLE FLICKER FROM INVISIBLE PATTERNS	NATURE			English	Article							MONKEY MACACA-FASCICULARIS; SENSITIVITY; ADAPTATION; VISION; CONES	USING a laser interferometer we can create grating patterns of high optical contrast (interference fringes) directly on the retina1-3. With coarse fringe patterns, the alternating light and dark bars of the pattern can be seen, but the bars of the finest fringes are not subjectively resolved. We report here that when we rapidly modulate the contrast of a fine fringe pattern (keeping overall luminance constant), observers experience flicker, even if the fringes are too finely spaced to be perceived as a grating. For this flicker to be seen, the pattern needs to be resolvable by the photoreceptors themselves, but not necessarily by later stages of visual processing. It can be explained if, in man, signals associated with individual cone receptors do not depend linearly on light intensity, but instead are scaled by a fast sensitivity-regulating or light-adaptation mechanism. Contrast-modulation flicker is not demonstrable in rod vision; rod vision therefore lacks such a local adaptation process.			MACLEOD, DIA (corresponding author), UNIV CALIF SAN DIEGO,DEPT PSYCHOL,LA JOLLA,CA 92093, USA.							BAYLOR DA, 1984, J PHYSIOL-LONDON, V357, P575, DOI 10.1113/jphysiol.1984.sp015518; BOYNTON RM, 1970, SCIENCE, V170, P1423, DOI 10.1126/science.170.3965.1423; BURTON GJ, 1973, VISION RES, V13, P1211, DOI 10.1016/0042-6989(73)90198-3; CAMPBELL FW, 1965, J PHYSIOL-LONDON, V414, P89; KELLY DH, 1971, J OPT SOC AM, V61, P537, DOI 10.1364/JOSA.61.000537; MACLEOD DIA, 1989, VISION RES, V29, P965, DOI 10.1016/0042-6989(89)90111-9; MACLEOD DIA, 1992, VISION RES, V32, P347, DOI 10.1016/0042-6989(92)90144-8; MACLEOD DIA, 1992, INVEST OPHTH VIS SCI, V33, P1136; MILLER WH, 1983, VISION RES, V23, P1365, DOI 10.1016/0042-6989(83)90147-5; Polyak S. L., 1941, RETINA-J RET VIT DIS; RUSHTON WAH, 1965, PROC R SOC SER B-BIO, V162, P20, DOI 10.1098/rspb.1965.0024; SCHNAPF JL, 1990, J PHYSIOL-LONDON, V427, P681, DOI 10.1113/jphysiol.1990.sp018193; TRANCHINA D, 1988, VISUAL NEUROSCI, V1, P339, DOI 10.1017/S0952523800004119; WILLIAMS DR, 1985, VISION RES, V25, P195, DOI 10.1016/0042-6989(85)90113-0	14	40	40	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 21	1993	361	6409					256	258		10.1038/361256a0	http://dx.doi.org/10.1038/361256a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KH614	8423852				2022-12-24	WOS:A1993KH61400058
J	SKOOG, I; NILSSON, L; PALMERTZ, B; ANDREASSON, LA; SVANBORG, A				SKOOG, I; NILSSON, L; PALMERTZ, B; ANDREASSON, LA; SVANBORG, A			A POPULATION-BASED STUDY OF DEMENTIA IN 85-YEAR-OLDS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ALZHEIMERS-DISEASE; VASCULAR DEMENTIA; DIFFERENTIAL-DIAGNOSIS; CLINICAL-DIAGNOSIS; PREVALENCE; DISORDERS; COMMUNITY; PEOPLE	Background. The aim of this study was to investigate the causes, severity, and prevalence of dementia in a representative sample of 494 85-year-olds living in Gothenburg, Sweden. Methods. The study included a psychiatric interview, neuropsychological and physical examinations, comprehensive laboratory tests, electrocardiography, chest radiography, computed tomography (CT) of the head, and analysis of cerebrospinal fluid. A person close to each subject was also interviewed. Dementia was defined according to the criteria proposed in the Diagnostic and Statistical Manual of Mental Disorders (third edition, revised), Alzheimer's disease according to the criteria of the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association, and vascular dementia according to recently proposed criteria that incorporate information from CT scanning and the patient's neurologic history. Results. The prevalence of dementia was 29.8 percent (147 subjects). The condition was mild in 8.3 percent, moderate in 10.3 percent, and severe in 11.1 percent. There were no significant sex-related differences in prevalence or severity. Of the subjects with dementia, 43.5 percent had Alzheimer's disease, 46.9 percent had vascular dementia (multi-infarct dementia in 34.6 percent, dementia related to cerebral hypoperfusion in 4.1 percent, and mixed dementia in 8.2 percent), and 9.5 percent had dementia due to other causes. The three-year mortality rate was 23.1 percent in the subjects without dementia, 42.2 percent in the patients with Alzheimer's disease, and 66.7 percent in the patients with vascular dementia. Infarcts detected by CT scanning were significantly more common in the subjects with dementia than in those without it (27.9 percent vs. 12.6 percent). Conclusions. Dementia was present in nearly a third of unselected 85-year-olds in Sweden. Almost half these subjects appeared to have vascular dementia, which may currently be more amenable to prevention or treatment than Alzheimer's disease.	OSTRA HOSP, DEPT RADIOL, S-41685 GOTHENBURG, SWEDEN; UNIV ILLINOIS, DEPT MED, GERIATR MED SECT, CHICAGO, IL 60680 USA	Sahlgrenska University Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	SKOOG, I (corresponding author), SAHLGRENS UNIV HOSP, DEPT PSYCHIAT, S-41345 GOTHENBURG, SWEDEN.							ASBERG M, 1978, ACTA PSYCHIAT SCAND, P5; BONITA R, 1992, LANCET, V339, P342, DOI 10.1016/0140-6736(92)91658-U; BRUN A, 1990, CLIN SCI GERIATRICS, P1; BRUST JCM, 1988, ARCH NEUROL-CHICAGO, V45, P799, DOI 10.1001/archneur.1988.00520310117026; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; Cox DR, 1974, THEORETICAL STATISTI; CUMMINGS JL, 1987, PSYCHOSOMATICS, V28, P117, DOI 10.1016/S0033-3182(87)72553-5; DELSER T, 1990, J NEUROL SCI, V96, P1, DOI 10.1016/0022-510X(90)90052-O; ERKINJUNTTI T, 1987, ACTA NEUROL SCAND, V76, P433, DOI 10.1111/j.1600-0404.1987.tb03599.x; ERKINJUNTTI T, 1988, J NEUROL NEUROSUR PS, V51, P1037, DOI 10.1136/jnnp.51.8.1037; EVANS DA, 1989, JAMA-J AM MED ASSOC, V262, P2551, DOI 10.1001/jama.262.18.2551; FOLSTEIN M, 1985, J AM GERIATR SOC, V33, P228, DOI 10.1111/j.1532-5415.1985.tb07109.x; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Glatt S, 1984, Annu Rev Gerontol Geriatr, V4, P61; HACHINSKI V, 1992, LANCET, V340, P645; HACHINSKI VC, 1975, ARCH NEUROL-CHICAGO, V32, P632, DOI 10.1001/archneur.1975.00490510088009; HACHINSKI VC, 1990, CAN MED ASSOC J, V142, P107; HARSCH HH, 1988, ARCH NEUROL-CHICAGO, V45, P375, DOI 10.1001/archneur.1988.00520280017010; HENDERSON AS, 1987, PSYCHOL MED, V17, P549, DOI 10.1017/S0033291700025800; JELLINGER K, 1990, J NEUROL SCI, V95, P239, DOI 10.1016/0022-510X(90)90072-U; JORM AF, 1987, ACTA PSYCHIAT SCAND, V76, P465, DOI 10.1111/j.1600-0447.1987.tb02906.x; JORM AF, 1990, EPIDEMIOLOGY ALZHEIM; KATZMAN R, 1986, NEW ENGL J MED, V314, P964, DOI 10.1056/NEJM198604103141506; KHACHATURIAN ZS, 1985, ARCH NEUROL-CHICAGO, V42, P1097, DOI 10.1001/archneur.1985.04060100083029; LARSON EB, 1985, J GERONTOL, V40, P536, DOI 10.1093/geronj/40.5.536; LIVINGSTON G, 1990, PSYCHOL MED, V20, P881, DOI 10.1017/S0033291700036588; LOEB C, 1990, DEMENTIA, V1, P175; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MCLEAN S, 1987, AUST NZ J PSYCHIAT, V21, P142, DOI 10.3109/00048678709160910; MORTIMER JA, 1981, EPIDEMIOLOGY DEMENTI, P173; NILSSON LV, 1984, ACTA PSYCHIAT SCAND, V69, P519, DOI 10.1111/j.1600-0447.1984.tb02526.x; OBRIEN MD, 1988, ARCH NEUROL-CHICAGO, V45, P797, DOI 10.1001/archneur.1988.00520310115025; RINDER L, 1975, ACTA MED SCAND, V198, P397, DOI 10.1111/j.0954-6820.1975.tb19563.x; ROCCA WA, 1990, NEUROLOGY, V40, P626, DOI 10.1212/WNL.40.4.626; ROTH M, 1981, EPIDEMIOLOGY DEMENTI, P24; SVANBORG A, 1977, ACTA MED SCAND, P5; TOMLINSON BE, 1970, J NEUROL SCI, V11, P205, DOI 10.1016/0022-510X(70)90063-8; UEMURA K, 1988, EUR HEART J, V9, P1; WALLIN A, 1991, ALZ DIS ASSOC DIS, V5, P91, DOI 10.1097/00002093-199100520-00006; 1987, DIAGNOSTIC STATISTIC	40	606	614	1	22	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 21	1993	328	3					153	158		10.1056/NEJM199301213280301	http://dx.doi.org/10.1056/NEJM199301213280301			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG625	8417380				2022-12-24	WOS:A1993KG62500001
J	RABINDRAN, SK; HAROUN, RI; CLOS, J; WISNIEWSKI, J; WU, C				RABINDRAN, SK; HAROUN, RI; CLOS, J; WISNIEWSKI, J; WU, C			REGULATION OF HEAT-SHOCK FACTOR TRIMER FORMATION - ROLE OF A CONSERVED LEUCINE ZIPPER	SCIENCE			English	Article							DNA-BINDING; TRANSCRIPTION FACTOR; ACTIVATION; CLONING; GENE	The human and Drosophila heat shock transcription factors (HSFs) are multi-zipper proteins with high-affinity binding to DNA that is regulated by heat shock-induced trimerization. Formation of HSF trimers is dependent on hydrophobic heptad repeats located in the amino-terminal region of the protein. Two subregions at the carboxyl-terminal end of human HSF1 were identified that maintain the monomeric form of the protein under normal conditions. One of these contains a leucine zipper motif that is conserved between vertebrate and insect HSFs. These results suggest that the carboxyl-terminal zipper may suppress formation of trimers by the amino-terminal HSF zipper elements by means of intramolecular coiled-coil interactions that are sensitive to heat shock.	NCI,BIOCHEM LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								ABRAVAYA K, 1992, GENE DEV, V6, P1153, DOI 10.1101/gad.6.7.1153; AMIN J, 1988, MOL CELL BIOL, V8, P3761, DOI 10.1128/MCB.8.9.3761; BALER R, 1992, J CELL BIOL, V117, P1151, DOI 10.1083/jcb.117.6.1151; CLOS J, 1990, CELL, V63, P1085, DOI 10.1016/0092-8674(90)90511-C; CLOS J, UNPUB; CRAIG EA, 1985, CRC CR REV BIOCH MOL, V18, P239, DOI 10.3109/10409238509085135; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; JAKOBSEN BK, 1991, EMBO J, V10, P369, DOI 10.1002/j.1460-2075.1991.tb07958.x; JAKOBSEN BK, 1988, MOL CELL BIOL, V8, P5040, DOI 10.1128/MCB.8.11.5040; LARSON JS, 1988, NATURE, V335, P372, DOI 10.1038/335372a0; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; LIS JT, IN PRESS TRANSCRIPTI; Morimoto RI, 1990, STRESS PROTEINS BIOL; NOVER L, 1984, BIOL ZBL, V103, P357; PELHAM HRB, 1982, CELL, V30, P517, DOI 10.1016/0092-8674(82)90249-5; PERISIC O, 1989, CELL, V59, P797, DOI 10.1016/0092-8674(89)90603-X; PETERANDERL R, IN PRESS BIOCHEMISTR; RABINDRAN SK, 1991, P NATL ACAD SCI USA, V88, P6906, DOI 10.1073/pnas.88.16.6906; RABINDRAN SK, UNPUB; SARGE KD, 1991, GENE DEV, V5, P1902, DOI 10.1101/gad.5.10.1902; SCHARF KD, 1990, EMBO J, V9, P4495, DOI 10.1002/j.1460-2075.1990.tb07900.x; SCHUETZ TJ, 1991, P NATL ACAD SCI USA, V88, P6911, DOI 10.1073/pnas.88.16.6911; SORGER PK, 1990, CELL, V62, P793, DOI 10.1016/0092-8674(90)90123-V; SORGER PK, 1991, CELL, V65, P363, DOI 10.1016/0092-8674(91)90452-5; SORGER PK, 1989, CELL, V59, P807, DOI 10.1016/0092-8674(89)90604-1; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; SZENTGYORGYI C, 1987, J MOL BIOL, V193, P71, DOI 10.1016/0022-2836(87)90628-0; WESTWOOD JT, 1991, NATURE, V353, P822, DOI 10.1038/353822a0; WESTWOOD JT, UNPUB HYDRODYNAMIC S; WIEDERRECHT G, 1988, CELL, V54, P841, DOI 10.1016/S0092-8674(88)91197-X; WU C, 1990, STRESS PROTEINS BIOL, P429; XIAO H, 1988, SCIENCE, V239, P1139, DOI 10.1126/science.3125608; ZIMARINO V, 1990, MOL CELL BIOL, V10, P752, DOI 10.1128/MCB.10.2.752; ZIMARINO V, 1987, NATURE, V327, P727, DOI 10.1038/327727a0	38	410	434	2	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 8	1993	259	5092					230	234		10.1126/science.8421783	http://dx.doi.org/10.1126/science.8421783			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KF719	8421783				2022-12-24	WOS:A1993KF71900032
J	TROJAN, J; JOHNSON, TR; RUDIN, SD; ILAN, J; TYKOCINSKI, ML; ILAN, J				TROJAN, J; JOHNSON, TR; RUDIN, SD; ILAN, J; TYKOCINSKI, ML; ILAN, J			TREATMENT AND PREVENTION OF RAT GLIOBLASTOMA BY IMMUNOGENIC C6 CELLS EXPRESSING ANTISENSE INSULIN-LIKE GROWTH FACTOR-I RNA	SCIENCE			English	Article							FACTOR IGF RECEPTORS; BREAST-CANCER; WILMS-TUMORS; GENE; LINES	Rat C6 glioma cells express insulin-like growth factor I (IGF-I) and form rapidly growing tumors in syngeneic animals. When transfected with an episome-based vector encoding antisense IGF-I complementary DNA, these cells lost tumorigenicity. Subcutaneous injection of IGF-I antisense-transfected C6 cells into rats prevented formation of both subcutaneous tumors and brain tumors induced by nontransfected C6 cells. The antisense-transfected cells also caused regression of established brain glioblastomas when injected at a point distal to the tumor. These antitumor effects result from a glioma-specific immune response involving CD8+ lymphocytes. Antisense blocking of IGF-I expression may reverse a phenotype that allows C6 glioma cells to evade the immune system.	CASE WESTERN RESERVE UNIV,DEPT REPROD BIOL,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,DEPT ANAT,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,DEV GENET & MOLEC BIOL LAB,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,CTR CANC,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,INST PATHOL,CLEVELAND,OH 44106; INSERM,F-75005 PARIS,FRANCE	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Institut National de la Sante et de la Recherche Medicale (Inserm)					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD025004, R01HD018271] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA043703] Funding Source: NIH RePORTER; NCI NIH HHS [CA-43703] Funding Source: Medline; NICHD NIH HHS [HD-18271, HD-25004] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANTONIADES HN, 1992, INT J CANCER, V50, P215, DOI 10.1002/ijc.2910500210; BENDA P, 1968, SCIENCE, V161, P370, DOI 10.1126/science.161.3839.370; BLATT J, 1984, BIOCHEM BIOPH RES CO, V123, P373, DOI 10.1016/0006-291X(84)90423-6; BOEHM KD, 1989, P NATL ACAD SCI USA, V86, P656, DOI 10.1073/pnas.86.2.656; BREWER Y, 1990, P ANN M AM ASS CANCE, V31, pA247; BRUNNER N, 1990, Breast Cancer Research and Treatment, V16, P148; COLOUSCOU JM, 1987, INT J CANCER, V40, P646; CULVER KW, 1992, SCIENCE, V256, P1550, DOI 10.1126/science.1317968; DRUCKREY H, 1965, Z KREBSFORSCH KLIN O, V66, P389, DOI 10.1007/BF00525737; FEARON ER, 1988, CANCER RES, V48, P2975; FEARON ER, 1990, CELL, V60, P397, DOI 10.1016/0092-8674(90)90591-2; FOEKENS JA, 1989, CANCER, V63, P2139, DOI 10.1002/1097-0142(19890601)63:11<2139::AID-CNCR2820631112>3.0.CO;2-D; FU XX, 1988, J VIROL, V62, P3422, DOI 10.1128/JVI.62.9.3422-3430.1988; GANSLER T, 1988, AM J PATHOL, V130, P431; HALL TC, 1988, P AM ASSOC CANC RES, V29, pA802; HAMBOR JE, 1988, P NATL ACAD SCI USA, V85, P4010, DOI 10.1073/pnas.85.11.4010; HELDIN CH, 1989, EUR J BIOCHEM, V184, P487, DOI 10.1111/j.1432-1033.1989.tb15041.x; HEWETT HB, 1976, BRIT J CANCER, V33, P241; HUFF KK, 1986, CANCER RES, V46, P4613; JING NH, 1991, IN VITRO CELL DEV B, V27, P864; MACAULAY VM, 1990, CANCER RES, V50, P2511; MINUTO F, 1988, CANCER RES, V48, P3716; RECHLER MM, 1985, ANNU REV PHYSIOL, V47, P425; ROHOLL PJM, 1990, HISTOPATHOLOGY, V16, P455; SCHUBERT D, 1974, NATURE, V249, P224, DOI 10.1038/249224a0; SHOOTER EM, 1991, MODERN CONCEPTS INSU, P297; STUART GW, 1984, P NATL ACAD SCI-BIOL, V81, P7318, DOI 10.1073/pnas.81.23.7318; TROJAN J, 1992, P NATL ACAD SCI USA, V89, P4874, DOI 10.1073/pnas.89.11.4874; TROJAN J, 1984, DEV NEUROSCI-BASEL, V6, P251; TROJAN J, UNPUB; WILLIAMS DW, 1989, MOL CELL ENDOCRINOL, V61, P139, DOI 10.1016/0303-7207(89)90199-8; YANG DY, 1991, CARCINOGENESIS, V12, P1983	32	338	374	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 1	1993	259	5091					94	97		10.1126/science.8418502	http://dx.doi.org/10.1126/science.8418502			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KE601	8418502				2022-12-24	WOS:A1993KE60100037
J	LOWEY, S; WALLER, GS; TRYBUS, KM				LOWEY, S; WALLER, GS; TRYBUS, KM			SKELETAL-MUSCLE MYOSIN LIGHT-CHAINS ARE ESSENTIAL FOR PHYSIOLOGICAL SPEEDS OF SHORTENING	NATURE			English	Article							SCALLOP MYOSIN; HEAVY-CHAINS; ACTIN; SUBFRAGMENT-1; MICROSCOPY; ANTIBODIES; VELOCITY; BINDING; INVITRO; FIBERS	IN muscle each myosin head contains a regulatory light chain (LC2) that is wrapped around the head/rod junction, and an alkali light chain that is distal to LC2 (ref. 1). The role of these light chains in vertebrate skeletal muscle myosin has remained obscure2,3. Here we prepare heavy chains that are free of both light chains in order to determine by a motility assay4 whether the light chains are necessary for movement. We find that removal of light chains from myosin reduces the velocity of actin filaments from 8.8 mum s-1 to 0.8 mum s-1 without significantly decreasing the ATPase activity. Reconstitution of myosin with LC2 or alkali light chain increases filament velocity to intermediate rates, and readdition of both classes of light chains fully restores the original sliding velocity. We conclude that even though the light chains are not essential for enzymatic activity, light-chain/heavy-chain interactions play an important part in the conversion of chemical energy into movement.			LOWEY, S (corresponding author), BRANDEIS UNIV,ROSENSTIEL BASIC MED SCI RES CTR,WALTHAM,MA 02254, USA.							FLICKER PF, 1983, J MOL BIOL, V169, P723, DOI 10.1016/S0022-2836(83)80167-3; HOFMANN PA, 1990, J GEN PHYSIOL, V95, P477, DOI 10.1085/jgp.95.3.477; HUXLEY HE, 1985, J MUSCLE RES CELL M, V6, P153, DOI 10.1007/BF00713057; KATOH T, 1989, J CELL BIOL, V109, P1549, DOI 10.1083/jcb.109.4.1549; KWON H, 1990, P NATL ACAD SCI USA, V87, P4771, DOI 10.1073/pnas.87.12.4771; LOWEY S, IN PRESS J BIOL CHEM; MOSS RL, 1982, J BIOL CHEM, V257, P8588; PASTRALANDIS SC, 1986, J BIOL CHEM, V261, P4811; POLLENZ RS, 1992, CELL, V69, P951, DOI 10.1016/0092-8674(92)90614-I; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; SIVARAMAKRISHNAN M, 1982, J BIOL CHEM, V257, P1102; TOYOSHIMA YY, 1987, NATURE, V328, P536, DOI 10.1038/328536a0; TRYBUS KM, 1993, J BIOL CHEM, V268, P4412; VIBERT P, 1988, J MUSCLE RES CELL M, V9, P296, DOI 10.1007/BF01773873; WAGNER PD, 1981, NATURE, V292, P560, DOI 10.1038/292560a0; WAGNER PD, 1977, J MOL BIOL, V109, P455, DOI 10.1016/S0022-2836(77)80023-5; WARSHAW DM, 1990, J CELL BIOL, V111, P453, DOI 10.1083/jcb.111.2.453; WINKELMANN DA, 1983, CELL, V34, P295, DOI 10.1016/0092-8674(83)90160-5; WORK SS, 1992, ANAL BIOCHEM, V202, P275, DOI 10.1016/0003-2697(92)90106-H	19	280	284	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 30	1993	365	6445					454	456		10.1038/365454a0	http://dx.doi.org/10.1038/365454a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LZ633	8413589				2022-12-24	WOS:A1993LZ63300060
J	NISHIMI, RY				NISHIMI, RY			CYSTIC-FIBROSIS AND DNA TESTS - THE IMPLICATIONS OF CARRIER SCREENING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	5	5	1	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 21	1993	269	15					1921	1921		10.1001/jama.269.15.1921	http://dx.doi.org/10.1001/jama.269.15.1921			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KX215	8464112	Green Submitted			2022-12-24	WOS:A1993KX21500004
J	HAUSER, P; ZAMETKIN, AJ; MARTINEZ, P; VITIELLO, B; MATOCHIK, JA; MIXSON, AJ; WEINTRAUB, BD				HAUSER, P; ZAMETKIN, AJ; MARTINEZ, P; VITIELLO, B; MATOCHIK, JA; MIXSON, AJ; WEINTRAUB, BD			ATTENTION-DEFICIT HYPERACTIVITY DISORDER IN PEOPLE WITH GENERALIZED RESISTANCE TO THYROID-HORMONE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ERBA-BETA GENE; RECEPTOR; KINDREDS; BINDING; BRAIN; TRIIODOTHYRONINE; INTERVIEW; MUTATION; CHILDREN; PROTEIN	Background. Attention deficit-hyperactivity disorder is a well-recognized psychiatric disorder of childhood. Its cause is unknown, but there is evidence of a familial predisposition. Symptoms suggestive of this disorder have been reported in subjects with generalized resistance to thyroid hormone, a disease caused by mutations in the thyroid receptor-beta gene and characterized by reduced responsiveness of peripheral and pituitary tissues to the actions of thyroid hormone. We systematically evaluated the presence and severity of attention deficit-hyperactivity disorder in 18 families with a history of generalized resistance to thyroid hormone. Methods. We studied 49 affected and 55 unaffected family members; 52 were adults, and 52 were children. All subjects were evaluated with structured psychiatric questionnaires by interviewers who were unaware of the medical diagnosis. The number of symptoms of attention deficit-hyperactivity disorder was calculated for each subject. Results. Among the adults, 11 of 22 subjects with generalized resistance to thyroid hormone (50 percent) and 2 of 30 unaffected subjects (7 percent) had met the criteria for attention deficit-hyperactivity disorder as children (P less-than-or-equal-to 0.001). Among the children, 19 of 27 subjects resistant to thyroid hormone (70 percent) and 5 of 25 unaffected subjects (20 percent) met the criteria for the disorder (P<0.001). The odds of having attention deficit-hyperactivity disorder were 3.2 times higher for affected male subjects than for affected female subjects and 2.7 times higher for unaffected male subjects than for unaffected female subjects. The mean symptom score was 2.5 times higher in the affected group than in the unaffected group (7.0 vs. 2.8, P<0.001). The frequency of other psychiatric diagnoses was similar in the two groups. Conclusions. In our study sample, attention deficit-hyperactivity disorder is strongly associated with generalized resistance to thyroid hormone.	NIMH,CEREBRAL METAB LAB,CLIN BRAIN IMAGING SECT,BETHESDA,MD 20892; NIMH,DEV PSYCHOL LAB,BETHESDA,MD 20892; NIMH,DIV BASIC BRAIN & BEHAV SCI,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	HAUSER, P (corresponding author), NIDDKD,MOLEC & CELLULAR ENDOCRINOL BRANCH,RM 8D-14,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.		Vitiello, Benedetto/AAC-1758-2022; Mixson, Archibald/Q-5659-2019					ANDERSON JC, 1987, ARCH GEN PSYCHIAT, V44, P69; BERNAL J, 1984, ENDOCRINOLOGY, V114, P677, DOI 10.1210/endo-114-2-677; BIEDERMAN J, 1991, AM J PSYCHIAT, V148, P564; BIEDERMAN J, 1990, J AM ACAD CHILD PSY, V29, P526, DOI 10.1097/00004583-199007000-00004; CHATTERJEE VKK, 1991, J CLIN INVEST, V87, P1977; DUSSAULT JH, 1987, ANNU REV PHYSIOL, V49, P321, DOI 10.1146/annurev.ph.49.030187.001541; ENDICOTT J, 1978, ARCH GEN PSYCHIAT, V35, P837; FARSETTI A, 1991, J BIOL CHEM, V266, P23226; FARSETTI A, 1992, J BIOL CHEM, V267, P17478; GAREAU JLP, 1988, NUCLEIC ACIDS RES, V16, P1223, DOI 10.1093/nar/16.3.1223; HERJANIC B, 1982, J ABNORM CHILD PSYCH, V10, P307, DOI 10.1007/BF00912324; HODIN RA, 1989, SCIENCE, V244, P76, DOI 10.1126/science.2539642; JADRESIC DP, 1990, J PSYCHOSOM RES, V34, P603, DOI 10.1016/0022-3999(90)90104-C; MAGNER JA, 1986, J ENDOCRINOL INVEST, V9, P459, DOI 10.1007/BF03346968; MEIER CA, 1992, MOL ENDOCRINOL, V6, P248, DOI 10.1210/me.6.2.248; MIXSON AJ, 1992, J CLIN ENDOCR METAB, V75, P1039, DOI 10.1210/jc.75.4.1039; PARRILLA R, 1991, J CLIN INVEST, V88, P2123, DOI 10.1172/JCI115542; PIPAON C, 1992, J BIOL CHEM, V267, P21, DOI 10.1016/S0021-9258(18)48449-9; Reeve E, 1991, RITALIN THEORY PATIE, P289; REFETOFF S, 1972, METABOLISM, V21, P723, DOI 10.1016/0026-0495(72)90121-7; REFETOFF S, 1990, THYROID TODAY, V13, P1; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; Shenker A, 1992, Adv Pediatr, V39, P337; STRAIT KA, 1990, J BIOL CHEM, V265, P10514; TAKEDA K, 1992, J CLIN ENDOCR METAB, V74, P712, DOI 10.1210/jc.74.4.712; USALA SJ, 1991, J CLIN ENDOCR METAB, V72, P32, DOI 10.1210/jcem-72-1-32; USALA SJ, 1990, J CLIN INVEST, V85, P93, DOI 10.1172/JCI114438; USALA SJ, 1988, MOL ENDOCRINOL, V2, P1217, DOI 10.1210/mend-2-12-1217; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; ZAMETKIN AJ, 1987, J AM ACAD CHILD PSY, V26, P676, DOI 10.1097/00004583-198709000-00011; ZAMETKIN AJ, 1988, J AM ACAD CHILD ADOL, V27, P338; 1987, DIAGNOSTIC STATISTIC	32	242	246	0	10	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 8	1993	328	14					997	1001		10.1056/NEJM199304083281403	http://dx.doi.org/10.1056/NEJM199304083281403			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KW282	8450877	Green Published			2022-12-24	WOS:A1993KW28200003
J	DALTON, DK; PITTSMEEK, S; KESHAV, S; FIGARI, IS; BRADLEY, A; STEWART, TA				DALTON, DK; PITTSMEEK, S; KESHAV, S; FIGARI, IS; BRADLEY, A; STEWART, TA			MULTIPLE DEFECTS OF IMMUNE CELL-FUNCTION IN MICE WITH DISRUPTED INTERFERON-GAMMA GENES	SCIENCE			English	Article							NATURAL-KILLER CELLS; MACROPHAGE ACTIVATION; CYTO-TOXICITY; IFN-GAMMA; MOUSE; EXPRESSION; INDUCTION; PROLIFERATION; LYMPHOKINE; CYTOKINES	Interferon-gamma (IFN-gamma) is a pleiotrophic cytokine with immunomodulatory effects on a variety of immune cells. Mice with a targeted disruption of the IFN-gamma gene were generated. These mice developed normally and were healthy in the absence of pathogens. However, mice deficient in IFN-gamma had impaired production of macrophage antimicrobial products and reduced expression of macrophage major histocompatibility complex class II antigens. IFN-gamma-deficient mice were killed by a sublethal dose of the intracellular pathogen Mycobacterium bovis. Splenocytes exhibited uncontrolled proliferation in response to mitogen and alloantigen. After a mixed lymphocyte reaction, T cell cytolytic activity was enhanced against allogeneic target cells. Resting splenic natural killer cell activity was reduced in IFN-gamma-deficient mice. Thus, IFN-gamma is essential for the function of several cell types of the murine immune system.	BAYLOR COLL MED,INST MOLEC GENET,HOUSTON,TX 77030; UNIV OXFORD,SIR WILLIAM DUNN SCH PATHOL,OXFORD OX1 3RE,ENGLAND; GENENTECH INC,S SAN FRANCISCO,CA 94080	Baylor College of Medicine; University of Oxford; Roche Holding; Genentech			Dalton, Dyana/D-2460-2009	Bradley, Allan/0000-0002-2349-8839; Keshav, Satish/0000-0003-0508-8665				BANCROFT GJ, 1989, J IMMUNOL, V143, P127; BENOIST C, 1990, ANNU REV IMMUNOL, V8, P681, DOI 10.1146/annurev.immunol.8.1.681; BRENNAN GL, 1983, BIOTECHNIQUES, V1, P78; BUCHMEIER NA, 1985, P NATL ACAD SCI USA, V82, P7404, DOI 10.1073/pnas.82.21.7404; BUCY RP, 1988, J IMMUNOL, V140, P1148; CRAWFORD RM, 1987, J IMMUNOL, V139, P135; DALTON DA, UNPUB; DING AH, 1988, J IMMUNOL, V141, P2407; DJEU JY, 1982, J EXP MED, V156, P1222, DOI 10.1084/jem.156.4.1222; DJEU JY, 1979, J IMMUNOL, V122, P175; EZEKOWITZ RAB, 1981, J EXP MED, V154, P60, DOI 10.1084/jem.154.1.60; GAJEWSKI TF, 1988, J IMMUNOL, V140, P4245; GIDLUND M, 1978, NATURE, V273, P759, DOI 10.1038/273759a0; GIOVARELLI M, 1988, J IMMUNOL, V141, P2831; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; HANDA K, 1983, J IMMUNOL, V130, P988; KESHAV S, 1991, J EXP MED, V174, P1049, DOI 10.1084/jem.174.5.1049; KIESSLING R, 1975, EUR J IMMUNOL, V5, P112, DOI 10.1002/eji.1830050208; KIRCHNER H, 1979, EUR J IMMUNOL, V9, P824, DOI 10.1002/eji.1830091015; KOO GC, 1984, HYBRIDOMA, V3, P301, DOI 10.1089/hyb.1984.3.301; LIEW FY, 1991, IMMUNOPARASITOL TOD, pA17, DOI 10.1016/S0167-5699(05)80006-4; LIU Y, 1990, Journal of Experimental Medicine, V172, P1735, DOI 10.1084/jem.172.6.1735; MACKANESS GB, 1962, J EXP MED, V116, P381, DOI 10.1084/jem.116.3.381; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MORRISSEY PJ, 1987, J IMMUNOL, V139, P1113; MURRAY HW, 1980, J EXP MED, V152, P1596, DOI 10.1084/jem.152.6.1596; NATHAN CF, 1984, J EXP MED, V160, P600, DOI 10.1084/jem.160.2.600; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; PERUSSIA B, 1980, J IMMUNOL, V125, P1589; RANGES GE, 1987, J EXP MED, V166, P991, DOI 10.1084/jem.166.4.991; REED SG, 1987, J EXP MED, V166, P1734, DOI 10.1084/jem.166.6.1734; SCHREIBER R, 1991, CURRENT PROTOCOLS IM, V1, pCH6; SCHREIBER RD, 1985, J IMMUNOL, V134, P1609; SCHREIBER RD, 1985, LYMPHOKINES, V11, P87; STEIN M, 1991, CYTOKINES PRACTICAL, P245; TRINCHIERI G, 1985, IMMUNOL TODAY, V6, P131, DOI 10.1016/0167-5699(85)90080-5; VILCEK J, 1985, LYMPHOKINES, V11, P1; WALLICK SC, 1990, J EXP MED, V172, P1777, DOI 10.1084/jem.172.6.1777; WEIGENT DA, 1983, INFECT IMMUN, V41, P992, DOI 10.1128/IAI.41.3.992-997.1983; WELSH RM, 1978, J IMMUNOL, V121, P1631	40	1503	1545	1	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 19	1993	259	5102					1739	1742		10.1126/science.8456300	http://dx.doi.org/10.1126/science.8456300			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KT810	8456300				2022-12-24	WOS:A1993KT81000033
J	PERNEGER, TV; KLAG, MJ; FELDMAN, HI; WHELTON, PK				PERNEGER, TV; KLAG, MJ; FELDMAN, HI; WHELTON, PK			PROJECTIONS OF HYPERTENSION-RELATED RENAL-DISEASE IN MIDDLE-AGED RESIDENTS OF THE UNITED-STATES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BLOOD-PRESSURE; ANTIHYPERTENSIVE TREATMENT; DECLINE; ASSOCIATION; PREVALENCE; MORTALITY; STROKE; HEALTH; RISK	Objective.-To establish nationwide projections for hypertension-related renal disease among middle-aged residents of the United States and compare disease burden in demographic subgroups. Design.-Integrated analysis of data from the US Census, the National Health and Nutrition Examination Survey of 1976 through 1980 (NHANES II), the 1971 through 1975 NHANES I Epidemiologic Follow-up Study, the Hypertension Detection and Follow-up Program trial, and the US Renal Data System. Population.-African-American and white residents of the United States, aged 30 to 69 years. Main Outcome Measures.-Incidence rates and counts of hypertension, hypertension-related hypercreatinemia, and hypertension-related end-stage renal disease (ESRD). Results.-Each year, approximately 1.8 million middle-aged Americans develop hypertension, 140000 develop hypertension-related hypercreatinemia, and 5300 develop hypertension-related ESRD. African Americans are at increased risk for hypertension (relative risk [RR], 1.6; population-attributable risk [PAR], 5%), hypercreatinemia if hypertensive (RR, 2.4; PAR, 18%), ESRD if hypertensive with hypercreatinemia (RR, 2.7; PAR, 32%), and hypertension-related ESRD overall (RR, 8.0; PAR, 44%). Compared with women, men are at increased risk for hypertension (RR, 1.3; PAR, 13%) and hypertension-related ESRD (RR, 1.6; PAR, 23%). Most cases of hypercreatinemia in hypertensives (73%) occur among those with mild hypertension. Conclusions.-Progression to ESRD is rare in persons with hypertension-related renal disease, and factors other than blood pressure probably play an important role. A large proportion of hypertension-related renal disease cases occur among population subgroups considered to be at low risk. Interventions that favorably influence factors associated with the progression of hypertension-related renal disease in African Americans, in men, and in persons with mild hypertension, hold the greatest potential for reducing the population burden of hypertension-related ESRD.	JOHNS HOPKINS UNIV, WELCH CTR PREVENT EPIDEMIOL & CLIN RES, BALTIMORE, MD 21218 USA; JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT HLTH POLICY & MANAGEMENT, BALTIMORE, MD 21218 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT MED, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT EPIDEMIOL, BALTIMORE, MD 21218 USA; UNIV PENN, MED CTR, CTR CLIN EPIDEMIOL & BIOSTAT, PHILADELPHIA, PA 19104 USA; UNIV GENEVA, INST SOCIAL & PREVENT MED, CH-1211 GENEVA 4, SWITZERLAND	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; University of Pennsylvania; University of Geneva					NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000722] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00035, 5MOIRR00722] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		CAMPESE VM, 1991, SEMIN NEPHROL, V11, P549; CORNONIHUNTLEY J, 1989, ARCH INTERN MED, V149, P780, DOI 10.1001/archinte.149.4.780; DRIZD T, 1986, VITAL HLTH STAT, V11; FELDMAN HI, 1992, AM J KIDNEY DIS, V19, P397, DOI 10.1016/S0272-6386(12)80945-0; FREEMAN J, 1980, AM J EPIDEMIOL, V112, P707, DOI 10.1093/oxfordjournals.aje.a113043; HOY W, 1988, AM J KIDNEY DIS, V12, P454, DOI 10.1016/S0272-6386(88)80046-5; KLAG MJ, 1989, STROKE, V20, P14, DOI 10.1161/01.STR.20.1.14; KLAG MJ, 1990, HYPERTENSION, V16, P700, DOI 10.1161/01.HYP.16.6.700; LINDEMAN RD, 1984, KIDNEY INT, V26, P861, DOI 10.1038/ki.1984.229; LUKE RG, 1991, HYPERTENSION, V18, P139; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MCCLELLAN W, 1988, AM J KIDNEY DIS, V12, P285, DOI 10.1016/S0272-6386(88)80221-X; PARVING HH, 1983, LANCET, V1, P1175; PERNEGER TV, 1993, JAMA-J AM MED ASSOC, V269, P488, DOI 10.1001/jama.269.4.488; ROCCELLA EJ, 1985, HYPERTENSION, V7, P457; ROCCELLA EJ, 1991, ARCH INTERN MED, V151, P1280; ROSANSKY SJ, 1990, ARCH INTERN MED, V150, P2073, DOI 10.1001/archinte.150.10.2073; ROSE G, 1981, BMJ-BRIT MED J, V282, P1847, DOI 10.1136/bmj.282.6279.1847; SHULMAN N B, 1989, Hypertension (Dallas), V13, pI80; TUOMILEHTO J, 1986, BRIT MED J, V293, P1068, DOI 10.1136/bmj.293.6554.1068; WALKER WG, 1992, JAMA-J AM MED ASSOC, V268, P3085, DOI 10.1001/jama.268.21.3085; WALTER SD, 1976, BIOMETRICS, V32, P829, DOI 10.2307/2529268; WEISSTUCH JM, 1992, KIDNEY INT, V41, pS33; WHELTON PK, 1992, J HYPERTENS, V10, pS77; WHELTON PK, 1984, J HYPERTENSION S2, V2, P3; WHELTON PK, 1989, HYPERTENSION S1, V13, P19, DOI DOI 10.1161/HYPERTENSIONAHA.113.02250; WHITTLE JC, 1991, ARCH INTERN MED, V151, P1359, DOI 10.1001/archinte.151.7.1359; WILLIAMS OD, 1989, AM J EPIDEMIOL, V129, P687, DOI 10.1093/oxfordjournals.aje.a115184; 1990, CURRENT POPULATION P, V25; 1991, USRDS1991 NIH NAT I	30	75	78	1	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 10	1993	269	10					1272	1277		10.1001/jama.269.10.1272	http://dx.doi.org/10.1001/jama.269.10.1272			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP885	8437305				2022-12-24	WOS:A1993KP88500026
J	SAMUELS, MP; POETS, CF; NOYES, JP; HARTMANN, H; HEWERTSON, J; SOUTHALL, DP				SAMUELS, MP; POETS, CF; NOYES, JP; HARTMANN, H; HEWERTSON, J; SOUTHALL, DP			DIAGNOSIS AND MANAGEMENT AFTER LIFE THREATENING EVENTS IN INFANTS AND YOUNG-CHILDREN WHO RECEIVED CARDIOPULMONARY-RESUSCITATION	BRITISH MEDICAL JOURNAL			English	Article							SEVERE ARTERIAL HYPOXEMIA; BLOOD-TRANSFUSION; PARTIAL SEIZURES; SUDDEN-DEATH; APNEA; OBSTRUCTION; EPISODES	Objective-To determine the mechanisms and thereby appropriate management for apparent life threatening events treated with cardiopulmonary resuscitation in infants and young children. Design-Prospective clinical and physiological study. Setting-Royal Brompton Hospital or in patients' homes, or both. Subjects-157 Patients referred at median age 2.8 months (range 1 week to 96 months), 111 (71%) had recurrent events, 44 were born preterm, 19 were siblings of infants who had died suddenly and unexpectedly, and 18 were over 12 months old. Interventions-Multichannel physiological recordings, including oxygenation, in hospital (n=150) and at home (n=61). Additional recordings with electroencephalogram, video, or other respiratory measures were used to confirm diagnoses. Management involved monitoring of oxygen at home, additional inspired oxygen, anticonvulsant treatment, or child protection procedures. Main outcome measures-Abnormalities on recordings compared to published normal data and their correlation with clinical events; sudden death. Results-53 of 150 patients had abnormalities of oxygenation on hospital recordings, 28 of whom had an accompanying clinical event. Home recordings produced physiological data from 34 of 61 patients during subsequent clinical events. Final diagnoses were reached in 77 patients: deliberate suffocation by a parent (18), hypoxaemia induced by epileptic seizure (10), fabricated history and data (Munchausen syndrome by proxy; seven), acute hypoxaemia of probable respiratory origin (40), and changes in peripheral perfusion and skin colour without hypoxaemia (two). Four patients died: three suddenly and unexpectedly (none on home oxygen monitors) and one from pneumonia. Conclusions-Identification of mechanisms is essential to the appropriate management of infants with apparent fife threatening events.			SAMUELS, MP (corresponding author), UNIV KEELE,N STAFFORDSHIRE HOSP CTR,ACAD DEPT PAEDIAT,STOKE ON TRENT ST4 6QG,ENGLAND.							ABRAHAM NG, 1990, PEDIATR PULM, V8, P259, DOI 10.1002/ppul.1950080409; BROWN DC, 1991, ARCH DIS CHILD, V66, P986, DOI 10.1136/adc.66.8.986; DEMAIO JG, 1989, J PEDIATR-US, V114, P1039, DOI 10.1016/S0022-3476(89)80459-7; HOLOWACH J, 1963, NEW ENGL J MED, V268, P21, DOI 10.1056/NEJM196301032680105; JAMES LS, 1957, J PEDIATR-US, V51, P5, DOI 10.1016/S0022-3476(57)80274-1; JOSHI A, 1987, PEDIATRICS, V80, P79; KEETON BR, 1977, BRIT MED J, V2, P600, DOI 10.1136/bmj.2.6087.600; Little G., 1987, PEDIATRICS, V79, P292; OREN J, 1986, PEDIATRICS, V77, P495; POETS CF, 1992, PEDIATRICS, V90, P385; POETS CF, 1991, ARCH DIS CHILD, V66, P676, DOI 10.1136/adc.66.6.676; POETS CF, 1992, ACTA PAEDIATR, V81, P319, DOI 10.1111/j.1651-2227.1992.tb12234.x; POETS CF, 1992, ACTA PAEDIATR, V81, P536, DOI 10.1111/j.1651-2227.1992.tb12290.x; POETS CF, 1992, J PEDIATR-US, V120, P447, DOI 10.1016/S0022-3476(05)80919-9; POETS CF, 1992, PEDIATR PULM, V14, P257; SAMUELS MP, 1991, ARCH DIS CHILD, V66, P257, DOI 10.1136/adc.66.2.257; SAMUELS MP, 1992, ACTA PAEDIATR, V81, P875, DOI 10.1111/j.1651-2227.1992.tb12127.x; SAMUELS MP, 1992, BRIT J HOSP MED, V47, P759; SAMUELS MP, 1992, ARCH DIS CHILD, V67, P162, DOI 10.1136/adc.67.2.162; SMITH PEM, 1989, ELECTROEN CLIN NEURO, V72, P207, DOI 10.1016/0013-4694(89)90245-9; SOUTHALL DP, 1988, ARCH DIS CHILD, V63, P598, DOI 10.1136/adc.63.6.598; SOUTHALL DP, 1987, DEV MED CHILD NEUROL, V29, P784; SOUTHALL DP, 1990, ARCH DIS CHILD, V65, P953, DOI 10.1136/adc.65.9.953; SOUTHALL DP, 1989, EUR J PEDIATR, V148, P353, DOI 10.1007/BF00444133; SOUTHALL DP, 1989, MATERN CHILD HLTH J, V14, P210; STEBBENS VA, 1991, ARCH DIS CHILD, V66, P569, DOI 10.1136/adc.66.5.569; TAYUYBOCO JS, 1989, J PEDIATR-US, V115, P456, DOI 10.1016/S0022-3476(89)80855-8; UPTON CJ, 1992, ARCH DIS CHILD-FETAL, V67, P419, DOI 10.1136/adc.67.4_Spec_No.419	28	54	58	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 20	1993	306	6876					489	492		10.1136/bmj.306.6876.489	http://dx.doi.org/10.1136/bmj.306.6876.489			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KN786	8448459	Green Published, Bronze			2022-12-24	WOS:A1993KN78600018
J	SONNICHSEN, FD; SYKES, BD; CHAO, H; DAVIES, PL				SONNICHSEN, FD; SYKES, BD; CHAO, H; DAVIES, PL			THE NONHELICAL STRUCTURE OF ANTIFREEZE PROTEIN TYPE-III	SCIENCE			English	Article							MACROZOARCES-AMERICANUS; POLAR FISHES; OCEAN POUT; PEPTIDES; GLYCOPEPTIDES; POLYPEPTIDE; ADSORPTION; INHIBITION; DIVERSITY; SURFACE	Antifreeze proteins (AFPs) are present in the blood of some marine fishes and inhibit the growth of ice crystals at subzero temperatures by adsorption to the ice lattice. The solution structure of a Type III AFP was determined by two-dimensional nuclear magnetic resonance spectroscopy. These measurements indicate that this 66-residue protein has an unusual fold in which eight beta strands form two sheets of three antiparallel strands and one sheet of two antiparallel strands, and the triple-stranded sheets are packed orthogonally into a beta sandwich. This structure is completely different from the amphipathic, helical structure observed for Type I AFPs.	UNIV ALBERTA,CTR EXCELLENCE,PROT ENGN NETWORK,EDMONTON T6G 2S2,AB,CANADA; UNIV ALBERTA,DEPT BIOCHEM,EDMONTON T6G 2S2,AB,CANADA; QUEENS UNIV,DEPT BIOCHEM,KINGSTON K7L 3N6,ONTARIO,CANADA	University of Alberta; University of Alberta; Queens University - Canada			Sönnichsen, Frank D/D-8408-2011	Sönnichsen, Frank D/0000-0002-4539-3755				ANANTHANARAYANAN VS, 1986, BIOCHIM BIOPHYS ACTA, V870, P154, DOI 10.1016/0167-4838(86)90019-1; CHOTHIA C, 1990, ANNU REV BIOCHEM, V59, P1007, DOI 10.1146/annurev.bi.59.070190.005043; CHOTHIA C, 1982, BIOCHEMISTRY-US, V21, P3955, DOI 10.1021/bi00260a009; CHOU KC, 1992, J MOL BIOL, V223, P509, DOI 10.1016/0022-2836(92)90666-8; DAVIES PL, 1990, FASEB J, V4, P2460, DOI 10.1096/fasebj.4.8.2185972; DEVRIES AL, 1984, PHILOS T R SOC B, V304, P575; DEVRIES AL, 1983, ANNU REV PHYSIOL, V45, P245, DOI 10.1146/annurev.ph.45.030183.001333; Feeney R E, 1978, Adv Protein Chem, V32, P191, DOI 10.1016/S0065-3233(08)60576-8; HAVEL TF, 1991, PROG BIOPHYS MOL BIO, V56, P45; HAYES PH, 1989, J BIOL CHEM, V264, P18761; HEW CL, 1988, J BIOL CHEM, V263, P12049; HEW CL, 1992, EUR J BIOCHEM, V203, P33, DOI 10.1111/j.1432-1033.1992.tb19824.x; KNIGHT CA, 1991, BIOPHYS J, V59, P409, DOI 10.1016/S0006-3495(91)82234-2; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MILLER S, 1987, J MOL BIOL, V196, P641, DOI 10.1016/0022-2836(87)90038-6; OTTING G, 1991, SCIENCE, V254, P974, DOI 10.1126/science.1948083; RAYMOND JA, 1977, P NATL ACAD SCI USA, V74, P2589, DOI 10.1073/pnas.74.6.2589; SLAUGHTER D, 1981, J BIOL CHEM, V256, P2022; SONNICHSEN FD, UNPUB; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; WEN DY, 1992, J BIOL CHEM, V267, P14102; Wuthrich K., 1986, NMR PROTEINS NUCL AC; YANG DSC, 1988, NATURE, V333, P232, DOI 10.1038/333232a0	24	98	102	1	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 19	1993	259	5098					1154	1157		10.1126/science.8438165	http://dx.doi.org/10.1126/science.8438165			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KM917	8438165				2022-12-24	WOS:A1993KM91700037
J	ONEK, LU				ONEK, LU			THE EAR	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 17	1993	269	7					918	918						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KL474	8426453				2022-12-24	WOS:A1993KL47400034
J	HURLEY, JH; FABER, HR; WORTHYLAKE, D; MEADOW, ND; ROSEMAN, S; PETTIGREW, DW; REMINGTON, SJ				HURLEY, JH; FABER, HR; WORTHYLAKE, D; MEADOW, ND; ROSEMAN, S; PETTIGREW, DW; REMINGTON, SJ			STRUCTURE OF THE REGULATORY COMPLEX OF ESCHERICHIA-COLI III(GLC) WITH GLYCEROL KINASE	SCIENCE			English	Article							BACTERIAL PHOSPHOTRANSFERASE SYSTEM; PHOSPHOCARRIER PROTEIN-IIIGLC; SIGNAL-TRANSDUCING PROTEIN; SHOCK COGNATE PROTEIN; 3-DIMENSIONAL STRUCTURE; SALMONELLA-TYPHIMURIUM; ISOCITRATE DEHYDROGENASE; SECONDARY STRUCTURE; ATPASE FRAGMENT; SUGAR-TRANSPORT	The phosphocarrier protein III(Glc) is an integral component of the bacterial phosphotransferase (PTS) system. Unphosphorylated III(Glc) inhibits non-PTS carbohydrate transport systems by binding to diverse target proteins. The crystal structure at 2.6 angstrom resolution of one of the targets, glycerol kinase (GK), in complex with unphosphorylated III(Glc), glycerol, and adenosine diphosphate was determined. GK contains a region that is topologically identical to the adenosine triphosphate binding domains of hexokinase, the 70-kD heat shock cognate, and actin. III(Glc) binds far from the catalytic site of GK, indicating that long-range conformational changes mediate the inhibition of GK by III(Glc). GK and III(Glc) are bound by hydrophobic and electrostatic interactions, with only one hydrogen bond involving an uncharged group. The phosphorylation site of III(Glc), His90, is buried in a hydrophobic environment formed by the active site region of III(Glc) and a 3(10) helix of GK, suggesting that phosphorylation prevents III(Glc) binding to GK by directly disrupting protein-protein interactions.	UNIV OREGON, DEPT PHYS, EUGENE, OR 97403 USA; UNIV OREGON, INST MOLEC BIOL, EUGENE, OR 97403 USA; JOHNS HOPKINS UNIV, DEPT BIOL, BALTIMORE, MD 21218 USA; JOHNS HOPKINS UNIV, MCCOLLUM PRATT INST, BALTIMORE, MD 21218 USA; TEXAS A&M UNIV SYST, DEPT BIOCHEM & BIOPHYS, COLL STN, TX 77843 USA	University of Oregon; University of Oregon; Johns Hopkins University; Johns Hopkins University; Texas A&M University System; Texas A&M University College Station					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042618, R37GM038759] Funding Source: NIH RePORTER; NIGMS NIH HHS [5-R37 GM38759, GM 42618-01A1] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON CM, 1978, J MOL BIOL, V123, P207, DOI 10.1016/0022-2836(78)90321-2; BENNETT WS, 1980, J MOL BIOL, V140, P183, DOI 10.1016/0022-2836(80)90102-3; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BRUNGER AT, 1989, ACTA CRYSTALLOGR A, V45, P50, DOI 10.1107/S0108767388009195; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CLORE GM, 1989, J BIOL CHEM, V264, P18907; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; DEAN AM, 1990, SCIENCE, V249, P1044, DOI 10.1126/science.2204110; DERIEL JK, 1978, BIOCHEMISTRY-US, V17, P5146, DOI 10.1021/bi00617a012; DERIEL JK, 1978, BIOCHEMISTRY-US, V17, P5134, DOI 10.1021/bi00617a010; FABER HR, 1989, J MOL BIOL, V207, P637, DOI 10.1016/0022-2836(89)90473-7; FLAHERTY KM, 1991, P NATL ACAD SCI USA, V88, P5041, DOI 10.1073/pnas.88.11.5041; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FROHLICH KU, 1985, GENE, V36, P105, DOI 10.1016/0378-1119(85)90074-5; HAMLIN R, 1985, METHOD ENZYMOL, V114, P416; HERZBERG O, 1992, P NATL ACAD SCI USA, V89, P2499, DOI 10.1073/pnas.89.6.2499; HOEFFKEN HW, 1988, J MOL BIOL, V204, P417, DOI 10.1016/0022-2836(88)90586-4; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; HURLEY JH, 1989, P NATL ACAD SCI USA, V86, P8635, DOI 10.1073/pnas.86.22.8635; HURLEY JH, 1990, SCIENCE, V249, P1012, DOI 10.1126/science.2204109; HURLEY JH, 1990, J BIOL CHEM, V265, P3599; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; JANIN J, 1990, J BIOL CHEM, V265, P16027; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KLEVIT RE, 1986, BIOCHEMISTRY-US, V25, P7774, DOI 10.1021/bi00371a073; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LIAO DI, 1991, BIOCHEMISTRY-US, V30, P9583, DOI 10.1021/bi00104a004; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MEADOW ND, 1982, J BIOL CHEM, V257, P4526; MEADOW ND, 1990, ANNU REV BIOCHEM, V59, P497, DOI 10.1146/annurev.biochem.59.1.497; MEADOW ND, 1986, J BIOL CHEM, V261, P3504; NOVOTNY MJ, 1985, J BACTERIOL, V162, P810, DOI 10.1128/JB.162.2.810-816.1985; PELTON JG, 1991, P NATL ACAD SCI USA, V88, P3479, DOI 10.1073/pnas.88.8.3479; PELTON JG, 1992, BIOCHEMISTRY-US, V31, P5215, DOI 10.1021/bi00137a017; PELTON JG, 1991, BIOCHEMISTRY-US, V30, P10043, DOI 10.1021/bi00105a032; PELTON JG, IN PRESS PROTEIN SCI; PETTIGREW DW, UNPUB; POSTMA PW, 1985, MICROBIOL REV, V49, P232, DOI 10.1128/MMBR.49.3.232-269.1985; POSTMA PW, 1984, J BACTERIOL, V158, P351, DOI 10.1128/JB.158.1.351-353.1984; PRESPER KA, 1989, P NATL ACAD SCI USA, V86, P4052, DOI 10.1073/pnas.86.11.4052; REIZER J, 1992, J BIOL CHEM, V267, P9158; ROSEMAN S, 1990, J BIOL CHEM, V265, P2993; ROSSMANN MG, 1979, J APPL CRYSTALLOGR, V12, P225, DOI 10.1107/S0021889879012218; SAIER MH, 1989, MICROBIOL REV, V53, P109, DOI 10.1128/MMBR.53.1.109-120.1989; SCHMID MF, 1981, ACTA CRYSTALLOGR A, V37, P701, DOI 10.1107/S0567739481001587; STCHARLES R, 1989, J BIOL CHEM, V264, P2092; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; THORNER JW, 1973, J BIOL CHEM, V248, P3922; VALEGARD K, 1990, NATURE, V345, P36, DOI 10.1038/345036a0; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WORTHYLAKE D, 1991, P NATL ACAD SCI USA, V88, P10382, DOI 10.1073/pnas.88.23.10382	52	215	219	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 29	1993	259	5095					673	677		10.1126/science.8430315	http://dx.doi.org/10.1126/science.8430315			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KJ688	8430315				2022-12-24	WOS:A1993KJ68800040
J	JANES, CH; LINDOR, KD				JANES, CH; LINDOR, KD			OUTCOME OF PATIENTS HOSPITALIZED FOR COMPLICATIONS AFTER OUTPATIENT LIVER-BIOPSY	ANNALS OF INTERNAL MEDICINE			English	Article						BIOPSY, NEEDLE; AMBULATORY SURGERY; AMBULATORY CARE; LIVER DISEASES; HOSPITALIZATION		Objective: To determine the safety of outpatient liver biopsies by analyzing the outcome of patients hospitalized for complications. Design: Retrospective review. Setting: Large clinic referral center. Patients: All patients admitted after outpatient liver biopsy at the Mayo Clinic from 1 April 1989 to 1 April 1991. Results: During this period, 405 outpatients underwent biopsy. Of the 405 patients, 13 (3.2%) were admitted with complications after biopsy. Five patients (38%) were admitted with persistent localized pain, five (38%) with orthostatic hypotension, one (8%) with both pain and hypotension, one (8%) with peritoneal signs, and one (8%) with lightheadedness but no orthostatic changes. All complications were noted within 3 hours after the biopsy. Bleeding, potentially the most serious complication, was radiographically defined in 5 of the 13 patients (38%) admitted. Only two patients, however, required blood transfusions. No patient required invasive management such as surgery or chest tube placement. The average length of the hospital stay was 1.5 days. Conclusion: Complications after outpatient liver biopsy occur early and rarely require invasive management. Outpatient liver biopsy is safe when done on carefully selected patients in a setting that provides close observation for at least 3 hours after liver biopsy.	MAYO CLIN & MAYO FDN, 200 1ST ST SW, ROCHESTER, MN 55905 USA	Mayo Clinic								HEGARTY JE, 1984, BRIT MED J, V288, P1254, DOI 10.1136/bmj.288.6426.1254; JACOBS WH, 1989, DIGEST DIS SCI, V34, P322, DOI 10.1007/BF01536249; KNAUER CM, 1978, GASTROENTEROLOGY, V74, P101; MCGILL DB, 1990, GASTROENTEROLOGY, V99, P1396, DOI 10.1016/0016-5085(90)91167-5; PERRAULT J, 1978, GASTROENTEROLOGY, V74, P103; PICCININO F, 1986, J HEPATOL, V2, P165, DOI 10.1016/S0168-8278(86)80075-7; TERRY R, 1952, BRIT MED J, V1, P1102, DOI 10.1136/bmj.1.4768.1102; ZAMCHECK N, 1953, NEW ENGL J MED, V249, P1062, DOI 10.1056/NEJM195312242492605; 1990, MEDICARE NATIONAL DA	9	237	245	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1993	118	2					96	98		10.7326/0003-4819-118-2-199301150-00003	http://dx.doi.org/10.7326/0003-4819-118-2-199301150-00003			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF918	8416324				2022-12-24	WOS:A1993KF91800003
J	LEHMAN, N; JOYCE, GF				LEHMAN, N; JOYCE, GF			EVOLUTION INVITRO OF AN RNA ENZYME WITH ALTERED METAL DEPENDENCE	NATURE			English	Article							GROUP-I INTRONS; SECONDARY STRUCTURE; CATALYTIC RNA; ACTIVE-SITE; TETRAHYMENA; REQUIREMENTS; AMPLIFICATION; RIBOZYME	THE Tetrahymena group I ribozyme catalyses a sequence-specific phosphodiester cleavage reaction on an external RNA oligonucleotide substrate in the presence of a divalent metal cation cofactor1. This reaction proceeds readily with either Mg2+ or Mn2+, but no detectable reaction has been reported when other divalent cations are used as the sole cofactor2-5. Cations such as Ca2+, Sr2+ and Ba2+ can stabilize the correct folded conformation of the ribozyme, thereby partially alleviating the Mg2+ or Mn2+ requirement2. But catalysis by the ribozyme involves coordination of either Mg2+ or Mn2+ at the active site, resulting in an overall requirement for one of these two cations5. Here we use an in vitro evolution process6,7 to obtain variants of the Tetrahymena ribozyme that are capable of cleaving an RNA substrate in reaction mixtures containing Ca2+ as the divalent cation. These findings extend the range of different chemical environments available to RNA enzymes and illustrate the power of in vitro evolution in generating macromolecular catalysts with desired properties.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute	LEHMAN, N (corresponding author), SCRIPPS RES INST, DEPT CHEM, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.		Lehman, Niles/ABF-7609-2021; Lehman, Niles/A-3434-2008	Lehman, Niles/0000-0002-9056-6600; 				BEAUDRY AA, 1992, SCIENCE, V257, P635, DOI 10.1126/science.1496376; BEAUDRY AA, 1990, BIOCHEMISTRY-US, V29, P6534, DOI 10.1021/bi00479a027; BURKE JM, 1988, GENE, V73, P273, DOI 10.1016/0378-1119(88)90493-3; CECH TR, 1988, GENE, V73, P259, DOI 10.1016/0378-1119(88)90492-1; CELANDER DW, 1991, SCIENCE, V251, P401, DOI 10.1126/science.1989074; COUTURE S, 1990, J MOL BIOL, V215, P345, DOI 10.1016/S0022-2836(05)80356-0; DAVIES RW, 1982, NATURE, V300, P719, DOI 10.1038/300719a0; Fisher R. A., 1930, GENETICAL THEORY NAT, DOI 10.5962/bhl.title.27468; GROSSHANS CA, 1989, BIOCHEMISTRY-US, V28, P6888, DOI 10.1021/bi00443a017; GUATELLI JC, 1990, P NATL ACAD SCI USA, V87, P1874, DOI 10.1073/pnas.87.5.1874; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10159, DOI 10.1021/bi00496a003; JOYCE GF, 1989, GENE, V82, P83, DOI 10.1016/0378-1119(89)90033-4; JOYCE GF, 1992, ANTISENSE RNA DNA, P353; MICHEL F, 1982, BIOCHIMIE, V64, P867, DOI 10.1016/S0300-9084(82)80349-0; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MICHEL F, 1983, EMBO J, V2, P33, DOI 10.1002/j.1460-2075.1983.tb01376.x; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; PICCIRILLI JA, 1993, NATURE, V361, P85, DOI 10.1038/361085a0; PRICE JV, 1985, NUCLEIC ACIDS RES, V13, P1871, DOI 10.1093/nar/13.6.1871; PYLE AM, 1990, P NATL ACAD SCI USA, V87, P8187, DOI 10.1073/pnas.87.21.8187; SZOSTAK JW, 1986, NATURE, V322, P83, DOI 10.1038/322083a0; ZAUG AJ, 1986, SCIENCE, V231, P470, DOI 10.1126/science.3941911	22	163	187	1	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 14	1993	361	6408					182	185		10.1038/361182a0	http://dx.doi.org/10.1038/361182a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KG466	8421526				2022-12-24	WOS:A1993KG46600069
J	ZHANG, JY; TEMIN, HM				ZHANG, JY; TEMIN, HM			RATE AND MECHANISM OF NONHOMOLOGOUS RECOMBINATION DURING A SINGLE CYCLE OF RETROVIRAL REPLICATION	SCIENCE			English	Article							VIRUS; DNA; VECTORS; RNA; TRANSDUCTION; CELLS; CONSTRUCTION; SEQUENCE; CLONING; GENOMES	Oncogenes discovered in retroviruses such as Rous sarcoma virus were generated by transduction of cellular proto-oncogenes into the viral genome. Several different kinds of junctions between the viral and proto-oncogene sequences have been found in different viruses. A system of retrovirus vectors and a protocol that mimicked this transduction during a single cycle of retrovirus replication was developed. The transduction involved the formation of a chimeric viral-cellular RNA, strand switching of the reverse transcription growing point from an infectious retrovirus to the chimeric RNA, and often a subsequent deletion during the rest of viral DNA synthesis. A short region of sequence identity was frequently used for the strand switching. The rate of this process was about 0.1 to 1 percent of the rate of homologous retroviral recombination.	UNIV WISCONSIN,MCARDLE LAB CANC RES,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison					NATIONAL CANCER INSTITUTE [P01CA022443, P30CA007175] Funding Source: NIH RePORTER; NCI NIH HHS [CA-07175, CA-22443] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		COFFIN JM, 1979, J GEN VIROL, V42, P1, DOI 10.1099/0022-1317-42-1-1; DORNBURG R, 1988, MOL CELL BIOL, V8, P2328, DOI 10.1128/MCB.8.6.2328; DOUGHERTY JP, 1986, MOL CELL BIOL, V6, P4387, DOI 10.1128/MCB.6.12.4387; EMBRETSON JE, 1987, J VIROL, V61, P3454, DOI 10.1128/JVI.61.11.3454-3462.1987; GOODRICH DW, 1988, P NATL ACAD SCI USA, V85, P3733, DOI 10.1073/pnas.85.11.3733; GOODRICH DW, 1990, P NATL ACAD SCI USA, V87, P3604, DOI 10.1073/pnas.87.9.3604; HU WS, 1990, P NATL ACAD SCI USA, V87, P1556, DOI 10.1073/pnas.87.4.1556; HU WS, IN PRESS REVERSE TRA; HUANG CC, 1985, J MOL BIOL, V181, P175, DOI 10.1016/0022-2836(85)90083-X; JUNGHANS RP, 1982, CELL, V30, P53, DOI 10.1016/0092-8674(82)90011-3; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; MILLER AD, 1991, J VIROL, V65, P2220, DOI 10.1128/JVI.65.5.2220-2224.1991; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; MURNANE JP, 1990, NUCLEIC ACIDS RES, V18, P2733, DOI 10.1093/nar/18.9.2733; OLSON P, 1992, J VIROL, V66, P1336, DOI 10.1128/JVI.66.3.1336-1343.1992; PATHAK VK, 1990, P NATL ACAD SCI USA, V87, P6024, DOI 10.1073/pnas.87.16.6024; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RAPP UR, 1988, HDB ONCOGENES, P213; STUHLMANN H, 1990, J VIROL, V64, P5783, DOI 10.1128/JVI.64.12.5783-5796.1990; SWAIN A, 1992, SCIENCE, V255, P841, DOI 10.1126/science.1371365; TEMIN HM, 1984, CANCER SURV, V3, P229; TEMIN HM, 1989, BIOCHEM INT, V18, P1; WANG JYJ, 1984, CELL, V36, P349; WATANABE S, 1983, MOL CELL BIOL, V3, P2241, DOI 10.1128/MCB.3.12.2241; ZHANG J, IN PRESS J VIROL; ZHANG J, UNPUB	27	139	144	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 8	1993	259	5092					234	238		10.1126/science.8421784	http://dx.doi.org/10.1126/science.8421784			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KF719	8421784				2022-12-24	WOS:A1993KF71900033
J	ROGERS, AS; FROGGATT, JW; TOWNSEND, T; GORDON, T; BROWN, AJL; HOLMES, EC; ZHANG, LQ; MOSES, H				ROGERS, AS; FROGGATT, JW; TOWNSEND, T; GORDON, T; BROWN, AJL; HOLMES, EC; ZHANG, LQ; MOSES, H			INVESTIGATION OF POTENTIAL HIV TRANSMISSION TO THE PATIENTS OF AN HIV-INFECTED SURGEON	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INDIVIDUALS; AIDS	Objective.-To ascertain if a surgeon infected with the human immunodeficiency virus (HIV) transmitted HIV to patients during invasive surgical procedures. Design.-Survey of patients and acquired immunodeficiency syndrome (AIDS) case registries, and laboratory analysis of nucleotide sequence data. Setting.-One surgeon's private and institutional practices within one academic referral hospital. Patients.-A total of 1131 persons identified in hospital databases who under-went invasive surgical procedures from 1984 through 1990 and for whom the surgeon was listed as the admitting or operating surgeon. Measurement.-Patients presumed to be living were surveyed by mailed questionnaire. The AIDS case registries were reviewed for all patients having undergone invasive procedures and death certificates were obtained. Person-hours of surgery during which exposure might have occurred were calculated for surgical procedures. Results.-Of 1131 patients, 101 were dead, 119 had no address, 413 had test results known, and 498 did not respond to the questionnaire. No study patient name was found in reported AIDS case registries. One newly detected, HIV-seropositive patient was determined (through nucleotide sequencing) to have been most probably infected in 1985 during a transfusion. There was no HIV transmission in 369 person-hours of surgical exposure, indicating that HIV transmission to patients is unlikely to occur more frequently than once per 1000 person-hours of surgical exposure. Conclusions.-If study validity and resources permit, investigation of publicly disclosed, HIV-infected health care workers whose practices involve invasive procedures should be pursued. The risk of HIV transmission during surgery may be so small that it will be quantified only by pooling data from multiple, methodologically similar investigations.	MARYLAND DEPT HLTH & MENTAL HYG,AIDS ADM,BALTIMORE,MD 21201; JOHNS HOPKINS UNIV,SCH MED,BALTIMORE,MD 21205; UNIV EDINBURGH,DEPT BIOL SCI,EDINBURGH EH8 9YL,MIDLOTHIAN,SCOTLAND; JOHNS HOPKINS UNIV HOSP,BALTIMORE,MD 21205	Maryland Department of Health & Mental Hygiene; Johns Hopkins University; University of Edinburgh; Johns Hopkins University; Johns Hopkins Medicine			Gordon, Toby/AAG-1436-2019; Brown, Andrew Leigh/ABF-8269-2020; Holmes, Edward/GVR-9499-2022; Leigh Brown, Andrew/F-3802-2010	Brown, Andrew Leigh/0000-0002-5700-3128; Leigh Brown, Andrew/0000-0002-5700-3128; Holmes, Edward/0000-0001-9596-3552	PHS HHS [U62/CCU307194-01] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ARMSTRONG FP, 1987, MIL MED, V152, P414; BELL DM, 1991, 7TH INT C AIDS FLOR; CHAMBERLAND ME, 1992, ANN INTERN MED, V116, P871, DOI 10.7326/0003-4819-116-10-871; CIESIELSKI C, 1992, ANN INTERN MED, V116, P798, DOI 10.7326/0003-4819-116-10-798; Comer R W, 1991, J Dent Educ, V55, P187; DANILA RN, 1991, NEW ENGL J MED, V325, P1406, DOI 10.1056/NEJM199111143252003; FELSENSTEIN J, 1991, PHYLIP 3 4 MANUAL; HOLMES EC, IN PRESS J INFECT DI; LOWENFELS A, 1991, 7TH INT C AIDS FLOR; MISHU B, 1990, JAMA-J AM MED ASSOC, V264, P467, DOI 10.1001/jama.264.4.467; PORTER JD, 1990, LANCET, V335, P113, DOI 10.1016/0140-6736(90)90582-P; SACKS JJ, 1985, NEW ENGL J MED, V313, P1017, DOI 10.1056/NEJM198510173131610; SIMMONDS P, 1990, J VIROL, V64, P864, DOI 10.1128/JVI.64.2.864-872.1990; STAVER S, 1990, AM MED NEWS     1228, P3; URY HK, 1980, BIOMETRICS, V36, P347, DOI 10.2307/2529991; ZHANG LQ, 1991, AIDS, V5, P675, DOI 10.1097/00002030-199106000-00006; 1986, MMWR, V35, P237; 1987, SAS RELEASE 6 04; 1991, MMWR, V40, P33; 1988, J AM DENT ASSOC, V116, P248; 1991, AIDS ALERT, V6, P1; 1991, MMWR, V40, P1; 1988, J AM DENT ASSOC, V116, P241; 1992, MMWR, V41, P344; 1989, AM J INFECT CONTROL, V17, pA24; 1990, INFECT CONT HOSP EP, V11, P647; 1986, MMWR, V35, P221; 1990, MMWR, V39, P489; 1991, MMWR, V40, P377; 1991, MMWR, V40, P21	30	44	44	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 14	1993	269	14					1795	1801		10.1001/jama.269.14.1795	http://dx.doi.org/10.1001/jama.269.14.1795			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW250	8459510				2022-12-24	WOS:A1993KW25000033
J	GOGUEL, V; ROSBASH, M				GOGUEL, V; ROSBASH, M			SPLICE SITE CHOICE AND SPLICING EFFICIENCY ARE POSITIVELY INFLUENCED BY PREMESSENGER RNA INTRAMOLECULAR BASE-PAIRING IN YEAST	CELL			English	Article							SECONDARY STRUCTURE; RIBOSOMAL PROTEIN-51; BETA-GLOBIN; U1 SNRNP; SEQUENCES; SELECTION; GENE; INVITRO; INTRON; EXON	Many of the mechanisms that govern splice site selection and splice site partner assignment during pre-mRNA splicing are obscure. To address this problem, we analyzed the splicing of transcripts containing chimeric introns or splice site duplications derived from two natural yeast genes. Our experiments indicate that there are strong context effects that influence splicing efficiency and relative splice site strength. Cis-competition experiments showed that the context effects are not only local, as the source of the 3' splice site region influences 5' splice site selection and the source of the 5' splice site affects 3' splice site selection. A significant fraction of the long-range context effect appears to be due to base pairing between two intronic regions near the 5' splice site and branchpoint, an interaction that positively affects splicing efficiency as well as splice site selection.	ECOLE NORM SUPER,GENET MOLEC LAB,F-75230 PARIS 05,FRANCE	UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)	GOGUEL, V (corresponding author), BRANDEIS UNIV,HOWARD HUGHES MED INST,DEPT BIOL,WALTHAM,MA 02254, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023549] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-23549] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOVICH N, 1984, MOL CELL BIOL, V4, P1871, DOI 10.1128/MCB.4.9.1871; ABOVICH N, 1988, THESIS BRANDEIS U WA; AEBI M, 1986, CELL, V47, P555, DOI 10.1016/0092-8674(86)90620-3; BEYER AL, 1988, GENE DEV, V2, P754, DOI 10.1101/gad.2.6.754; CHU G, 1981, NATURE, V289, P378, DOI 10.1038/289378a0; DESHLER JO, 1991, GENE DEV, V5, P1252, DOI 10.1101/gad.5.7.1252; DORVAL BC, 1991, SCIENCE, V252, P1823, DOI 10.1126/science.2063195; ENG FJ, 1991, CELL, V65, P797, DOI 10.1016/0092-8674(91)90387-E; ENGEBRECHT J, 1991, CELL, V66, P1257, DOI 10.1016/0092-8674(91)90047-3; EPERON LP, 1988, CELL, V54, P393, DOI 10.1016/0092-8674(88)90202-4; EPERON LP, 1986, NATURE, V324, P280, DOI 10.1038/324280a0; FURDON PJ, 1988, MOL CELL BIOL, V8, P860, DOI 10.1128/MCB.8.2.860; GALLEGO ME, 1990, MOL CELL BIOL, V10, P2133, DOI 10.1128/MCB.10.5.2133; GOGUEL V, 1991, GENE DEV, V5, P1430, DOI 10.1101/gad.5.8.1430; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; LEAR AL, 1990, J MOL BIOL, V211, P103, DOI 10.1016/0022-2836(90)90014-D; LEGRAIN P, 1989, CELL, V57, P573, DOI 10.1016/0092-8674(89)90127-X; LEMAIRE MF, 1990, MOL CELL BIOL, V10, P6059, DOI 10.1128/MCB.10.11.6059; LIAO XL, 1990, GENE DEV, V4, P1766, DOI 10.1101/gad.4.10.1766; LIBRI D, 1991, SCIENCE, V252, P1842, DOI 10.1126/science.2063196; MAYEDA A, 1988, MOL CELL BIOL, V8, P4484, DOI 10.1128/MCB.8.10.4484; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; MILLER AM, 1984, EMBO J, V3, P1061, DOI 10.1002/j.1460-2075.1984.tb01927.x; MOLENAAR CMT, 1984, NUCLEIC ACIDS RES, V12, P7345, DOI 10.1093/nar/12.19.7345; MUNROE SH, 1992, P NATL ACAD SCI USA, V89, P895, DOI 10.1073/pnas.89.3.895; NELSON KK, 1988, GENE DEV, V2, P319, DOI 10.1101/gad.2.3.319; NEWMAN A, 1987, EMBO J, V6, P3833, DOI 10.1002/j.1460-2075.1987.tb02720.x; OHSHIMA Y, 1987, J MOL BIOL, V195, P247, DOI 10.1016/0022-2836(87)90647-4; Parker R, 1987, MOL BIOL RNA NEW PER, P133; PIKIELNY CW, 1985, CELL, V41, P119, DOI 10.1016/0092-8674(85)90066-2; REED R, 1986, CELL, V46, P681, DOI 10.1016/0092-8674(86)90343-0; RYMOND BC, 1992, MOL CELLULAR BIOL YE, V2; Sambrook J., 1989, MOL CLONING LAB MANU; SERAPHIN B, 1989, GENE, V82, P145, DOI 10.1016/0378-1119(89)90039-5; SOLNICK D, 1987, MOL CELL BIOL, V7, P3194, DOI 10.1128/MCB.7.9.3194; TEEM JL, 1983, P NATL ACAD SCI-BIOL, V80, P4403, DOI 10.1073/pnas.80.14.4403; ULFENDAHL PJ, 1989, NUCLEIC ACIDS RES, V17, P925, DOI 10.1093/nar/17.3.925; WAIGMANN E, 1992, NUCLEIC ACIDS RES, V20, P75, DOI 10.1093/nar/20.1.75; WOOLFORD JL, 1989, YEAST, V5, P439, DOI 10.1002/yea.320050604	41	90	90	1	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 26	1993	72	6					893	901		10.1016/0092-8674(93)90578-E	http://dx.doi.org/10.1016/0092-8674(93)90578-E			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KU175	8458083				2022-12-24	WOS:A1993KU17500010
J	PAULESU, E; FRITH, CD; FRACKOWIAK, RSJ				PAULESU, E; FRITH, CD; FRACKOWIAK, RSJ			THE NEURAL CORRELATES OF THE VERBAL COMPONENT OF WORKING MEMORY	NATURE			English	Article							SHORT-TERM-MEMORY; PET IMAGES; SPEECH; COMPREHENSION; STORE	BY repeating words 'in our head', verbal material (such as telephone numbers) can be kept in working memory1 almost indefinitely. This 'articulatory loop' includes a subvocal rehearsal system2-6 and a phonological store3,6-10. Little is known about neural correlates of this model of verbal short-term memory. We therefore measured regional cerebral blood flow, an index of neuronal activity, in volunteers performing a task engaging both components of the articulatory loop (short-term memory for letters)5-10 and a task which engages only the subvocal rehearsal system (rhyming judgement for letters)4,11. Stimuli were presented visually and the subjects did not speak. We report here that comparisons of distribution of cerebral blood flow in these conditions localized the phonological store to the left supramarginal gyrus whereas the subvocal rehearsal system was associated with Broca's area. This is, to our knowledge, the first demonstration of the normal anatomy of the components of the 'articulatory loop'.	HAMMERSMITH HOSP, MRC, CYCLOTRON UNIT, DUCANE RD, LONDON W12 0HS, ENGLAND; IST SCI SAN RAFFAELE, I-20132 MILAN, ITALY; UCL, DEPT PSYCHOL, LONDON WC1E 6TB, ENGLAND	Imperial College London; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of London; University College London			Frackowiak, Richard S/I-1809-2013; Frackowiak, Richard/H-4383-2011; Frith, Chris D/A-2171-2009; PAULESU, ERALDO/C-2737-2017	Frackowiak, Richard/0000-0002-3151-822X; Frith, Chris D/0000-0002-8665-0690; PAULESU, ERALDO/0000-0002-9224-754X				BADDELEY A, 1984, Q J EXP PSYCHOL-A, V36, P233, DOI 10.1080/14640748408402157; BADDELEY A, 1985, J MEM LANG, V24, P490, DOI 10.1016/0749-596X(85)90041-5; BADDELEY AD, 1975, J VERB LEARN VERB BE, V14, P575, DOI 10.1016/S0022-5371(75)80045-4; Baddeley A, 2010, CURR BIOL, V20, pR136, DOI 10.1016/j.cub.2009.12.014; BESNER D, 1987, Q J EXP PSYCHOL-A, V39, P467, DOI 10.1080/14640748708401799; Burani C., 1991, EUR J COGN PSYCHOL, V3, P379, DOI [10.1080/09541449108406235, DOI 10.1080/09541449108406235]; DAMASIO AR, 1983, NEUROLOGY, V33, P1573, DOI 10.1212/WNL.33.12.1573; DEMONET JF, 1992, BRAIN, V115, P1753, DOI 10.1093/brain/115.6.1753; FOX PT, 1989, J NUCL MED, V30, P141; FRISTON KJ, 1990, J CEREBR BLOOD F MET, V10, P458, DOI 10.1038/jcbfm.1990.88; FRISTON KJ, 1991, J CEREBR BLOOD F MET, V11, P690, DOI 10.1038/jcbfm.1991.122; FRISTON KJ, 1989, J CEREBR BLOOD F MET, V9, P690, DOI 10.1038/jcbfm.1989.97; SALAME P, 1982, J VERB LEARN VERB BE, V21, P150, DOI 10.1016/S0022-5371(82)90521-7; SHALLICE T, 1977, NEUROPSYCHOLOGIA, V15, P729, DOI 10.1016/0028-3932(77)90002-1; Shallice T., 1990, NEUROPSYCHOLOGICAL I, P11, DOI [10.1017/CBO9780511665547.003, DOI 10.1017/CBO9780511665547.003]; SPINKS TJ, 1992, PHYS MED BIOL, V37, P1637, DOI 10.1088/0031-9155/37/8/002; Talairach I., 1988, COPLANAR STEREOTACTI; TOWNSEND DW, 1991, IEEE T MED IMAGING, V10, P505, DOI 10.1109/42.108584; VALLAR G, 1984, COGNITIVE NEUROPSYCH, V1, P121, DOI 10.1080/02643298408252018; VALLAR G, 1984, J VERB LEARN VERB BE, V23, P151, DOI 10.1016/S0022-5371(84)90104-X; VALLAR G, 1987, COGNITIVE NEUROPSYCH, V4, P55, DOI 10.1080/02643298708252035; WARRINGTON EK, 1969, BRAIN, V92, P885, DOI 10.1093/brain/92.4.885; WISE R, 1991, BRAIN, V114, P1803, DOI 10.1093/brain/114.4.1803; ZATORRE RJ, 1992, SCIENCE, V256, P846, DOI 10.1126/science.1589767	24	1771	1794	0	122	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAR 25	1993	362	6418					342	345		10.1038/362342a0	http://dx.doi.org/10.1038/362342a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KU176	8455719				2022-12-24	WOS:A1993KU17600060
J	MADDOCK, JR; SHAPIRO, L				MADDOCK, JR; SHAPIRO, L			POLAR LOCATION OF THE CHEMORECEPTOR COMPLEX IN THE ESCHERICHIA-COLI CELL	SCIENCE			English	Article							BACTERIAL CHEMOTAXIS; SIGNAL TRANSDUCTION; PROTEIN-PHOSPHORYLATION; GENETIC-EVIDENCE; LOCALIZATION; DIVISION; YEAST; MICROSCOPY; MECHANISM; RECEPTOR	The eukaryotic cell exhibits compartmentalization of functions to various membrane-bound organelles and to specific domains within each membrane. The spatial distribution of the membrane chemoreceptors and associated cytoplasmic chemotaxis proteins in Escherichia coli were examined as a prototypic functional aggregate in bacterial cells. Bacterial chemotaxis involves a phospho-relay system brought about by ligand association with a membrane receptor, culminating in a switch in the direction of flagellar rotation. The transduction of the chemotaxis signal is initiated by a chemoreceptor-CheW-CheA ternary complex at the inner membrane. These ternary complexes aggregate predominantly at the cell poles. Polar localization of the cytoplasmic CheA and CheW proteins is dependent on membrane-bound chemoreceptor. Chemoreceptors are not confined to the cell poles in strains lacking both CheA and CheW. The chemoreceptor-CheW binary complex is polarly localized in the absence of CheA, whereas the chemoreceptor-CheA binary complex is not confined to the cell poles in strains lacking CheW. The subcellular localization of the chemotaxis proteins may reflect a general mechanism by which the bacterial cell sequesters different regions of the cell for specialized functions.			MADDOCK, JR (corresponding author), STANFORD UNIV, MED CTR, SCH MED, BECKMAN CTR, DEPT DEV BIOL, STANFORD, CA 94305 USA.				NIGMS NIH HHS [GM32506, GM13929] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM032506, F32GM013929, R01GM032506] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEY MRK, 1992, GENE DEV, V6, P825, DOI 10.1101/gad.6.5.825; ALLEY MRK, 1993, SCIENCE, V259, P1754, DOI 10.1126/science.8456303; BARAK R, 1992, BIOCHEMISTRY-US, V31, P1821, DOI 10.1021/bi00121a034; BERG HC, 1977, BIOPHYS J, V20, P193, DOI 10.1016/S0006-3495(77)85544-6; BI E, 1991, NATURE, V354, P161, DOI 10.1038/354161a0; BOOS W, 1981, ARCH MICROBIOL, V129, P240, DOI 10.1007/BF00425258; BORKOVICH KA, 1989, P NATL ACAD SCI USA, V86, P1208, DOI 10.1073/pnas.86.4.1208; BORKOVICH KA, 1990, CELL, V63, P1339, DOI 10.1016/0092-8674(90)90429-I; BOURRET RB, 1990, P NATL ACAD SCI USA, V87, P41, DOI 10.1073/pnas.87.1.41; COOK WR, 1987, P NATL ACAD SCI USA, V84, P7144, DOI 10.1073/pnas.84.20.7144; DIETZEL I, 1978, ARCH MICROBIOL, V118, P207, DOI 10.1007/BF00415731; DREWS G, 1990, PROKARYOTIC STRUCTUR, P249; DRUBIN DG, 1991, CELL, V65, P1093, DOI 10.1016/0092-8674(91)90001-F; ENGSTROM P, 1982, BIOCHIM BIOPHYS ACTA, V686, P19, DOI 10.1016/0005-2736(82)90147-X; GEGNER JA, 1992, CELL, V70, P975, DOI 10.1016/0092-8674(92)90247-A; GOLLOP N, 1991, RES MICROBIOL, V142, P301, DOI 10.1016/0923-2508(91)90045-C; Harlow E., 1988, ANTIBODIES LABORATOR, P633; HESS JF, 1988, CELL, V53, P79, DOI 10.1016/0092-8674(88)90489-8; HESS JF, 1987, P NATL ACAD SCI USA, V84, P7609, DOI 10.1073/pnas.84.21.7609; LIU JD, 1991, J BACTERIOL, V173, P4941, DOI 10.1128/jb.173.16.4941-4951.1991; MACALISTER TJ, 1983, P NATL ACAD SCI-BIOL, V80, P1372, DOI 10.1073/pnas.80.5.1372; MACNAB RM, 1972, P NATL ACAD SCI USA, V69, P2509, DOI 10.1073/pnas.69.9.2509; MANSON MD, 1985, J BIOL CHEM, V260, P9727; MCNALLY DF, 1991, P NATL ACAD SCI USA, V88, P6269, DOI 10.1073/pnas.88.14.6269; MILBURN MV, 1991, SCIENCE, V254, P1342, DOI 10.1126/science.1660187; MILLER JH, 1977, EXPT MOL GENETICS, P432; MILLIGAN DL, 1991, SCIENCE, V254, P1651, DOI 10.1126/science.1661030; NINFA EG, 1991, J BIOL CHEM, V266, P9764; OOSAWA K, 1988, J BACTERIOL, V170, P2521, DOI 10.1128/jb.170.6.2521-2526.1988; PARKINSON JS, 1983, J BACTERIOL, V155, P265, DOI 10.1128/JB.155.1.265-274.1983; PRINGLE JR, 1989, METHOD CELL BIOL, V31, P357; RIDGWAY HF, 1977, J BACTERIOL, V132, P657, DOI 10.1128/JB.132.2.657-665.1977; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; ROMAN SJ, 1992, J BACTERIOL, V174, P6247, DOI 10.1128/JB.174.19.6247-6255.1992; SEGALL JE, 1982, NATURE, V296, P855, DOI 10.1038/296855a0; SEGALL JE, 1986, P NATL ACAD SCI USA, V83, P8987, DOI 10.1073/pnas.83.23.8987; SEGALL JE, 1985, J BACTERIOL, V161, P51, DOI 10.1128/JB.161.1.51-59.1985; STEWART RC, 1990, J BACTERIOL, V172, P3388, DOI 10.1128/jb.172.6.3388-3399.1990; WALTER RJ, 1980, NATURE, V286, P724, DOI 10.1038/286724a0; WEINBAUM DL, 1980, NATURE, V286, P725, DOI 10.1038/286725a0; WIEGEL FW, 1983, PHYS REP, V95, P283, DOI 10.1016/0370-1573(83)90078-9; WRIGHT R, 1989, METHOD CELL BIOL, V31, P473; YAMAGUCHI S, 1986, J BACTERIOL, V168, P1172, DOI 10.1128/jb.168.3.1172-1179.1986	43	618	624	0	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 19	1993	259	5102					1717	1723						7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KT810	8456299				2022-12-24	WOS:A1993KT81000027
J	FROGUEL, P; ZOUALI, H; VIONNET, N; VELHO, G; VAXILLAIRE, M; SUN, F; LESAGE, S; STOFFEL, M; TAKEDA, J; PASSA, P; PERMUTT, MA; BECKMANN, JS; BELL, GI; COHEN, D				FROGUEL, P; ZOUALI, H; VIONNET, N; VELHO, G; VAXILLAIRE, M; SUN, F; LESAGE, S; STOFFEL, M; TAKEDA, J; PASSA, P; PERMUTT, MA; BECKMANN, JS; BELL, GI; COHEN, D			FAMILIAL HYPERGLYCEMIA DUE TO MUTATIONS IN GLUCOKINASE - DEFINITION OF A SUBTYPE OF DIABETES-MELLITUS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DNA; GENE; AMPLIFICATION; POLYMERASE	Background and Methods. Non-insulin-dependent diabetes mellitus (NIDDM) is a genetically heterogeneous disorder. Maturity-onset diabetes of the young, a form of NIDDM with an early age of onset and autosomal dominant inheritance, can result from mutations in glucokinase, a key enzyme of glucose metabolism in beta cells and the liver. We studied 32 French families with maturity-onset diabetes of the young as well as 21 families with late-onset NIDDM to determine the frequency and clinical features of mutations of glucokinase. Fasting plasma glucose concentrations and oral glucose-tolerance tests were used to determine metabolic status. DNA was isolated from lymphocytes, and DNA polymorphisms in the glucokinase gene were tested for linkage with diabetes. Individual exons of the glucokinase gene from one affected member in each family were amplified by the polymerase chain reaction and screened for mutations by analysis of the conformation-dependent polymorphisms of single-stranded DNA and by DNA sequencing. Results. We found substantial evidence of linkage between the glucokinase locus and maturity-onset diabetes of the young but not between this locus and late-onset NIDDM. Sixteen mutations were identified in 18 of the 32 families with maturity-onset diabetes of the young, but none were found in families with late-onset NIDDM. They included 1 0 mutations that resulted in an amino acid substitution, 3 that resulted in the synthesis of a truncated protein, and 3 that affected RNA processing. The affected subjects with glucokinase mutations usually had mild hyperglycemia that began during childhood, whereas in subjects with maturity-onset diabetes of the young not due to glucokinase mutations, hyperglycemia usually appeared after puberty. Conclusions. Mutations in glucokinase are the primary cause of hyperglycemia in a substantial fraction of French patients with maturity-onset diabetes of the young and result in a relatively mild form of NIDDM that can be diagnosed in childhood.	HOP ST LOUIS,SERV ENDOCRINOL,F-75010 PARIS,FRANCE; WASHINGTON UNIV,SCH MED,DIV METAB,ST LOUIS,MO 63110; UNIV CHICAGO,HOWARD HUGHES MED INST,CHICAGO,IL 60637; UNIV CHICAGO,DEPT BIOCHEM & MOLEC BIOL,CHICAGO,IL 60637; UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Washington University (WUSTL); Howard Hughes Medical Institute; University of Chicago; University of Chicago; University of Chicago	FROGUEL, P (corresponding author), CTR ETUD POLYMORPHISME HUMAIN,27 RUE JULIETTE DODU,F-75010 PARIS,FRANCE.		Beckmann, Jacques S/A-9772-2008; FROGUEL, Philippe/O-6799-2017; Velho, Gilberto/Q-6724-2017; Vionnet, Nathalie/N-6302-2017	Beckmann, Jacques S/0000-0002-9741-1900; FROGUEL, Philippe/0000-0003-2972-0784; Velho, Gilberto/0000-0001-8811-363X; Stoffel, Markus/0000-0003-1304-5817	NIDDK NIH HHS [DK-20595, DK-44840, DK-16746] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020595, R01DK016746, P01DK044840, R37DK016746] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALLINGER SW, 1992, NAT GENET, V1, P11, DOI 10.1038/ng0492-11; BELL GI, 1991, P NATL ACAD SCI USA, V88, P1484, DOI 10.1073/pnas.88.4.1484; CHIU KC, 1992, DIABETES, V41, P843, DOI 10.2337/diabetes.41.7.843; CHIU KC, 1992, DIABETOLOGIA, V35, P632, DOI 10.1007/BF00400254; COOPER DN, 1990, HUM GENET, V85, P55; FAJANS SS, 1990, DIABETES CARE, V13, P49, DOI 10.2337/diacare.13.1.49; FAJANS SS, 1990, DIABETES CARE, V13, P910; FROGUEL P, 1992, NATURE, V356, P162, DOI 10.1038/356162a0; FROGUEL P, 1991, DIABETOLOGIA, V34, P685, DOI 10.1007/BF00401001; HATTERSLEY AT, 1992, LANCET, V339, P1307, DOI 10.1016/0140-6736(92)91958-B; KOBBERLING J, 1982, SERONO S, V47, P201; LATHROP GM, 1984, AM J HUM GENET, V36, P460; LESTRADET H, 1989, ARCH FR PEDIATR, V46, P19; MAGNUSON MA, 1990, DIABETES, V39, P523, DOI 10.2337/diabetes.39.5.523; MATSCHINSKY FM, 1990, DIABETES, V39, P647, DOI 10.2337/diabetes.39.6.647; MEGLASSON MD, 1984, AM J PHYSIOL, V246, pE1, DOI 10.1152/ajpendo.1984.246.1.E1; NEWTON CR, 1989, NUCLEIC ACIDS RES, V17, P2503, DOI 10.1093/nar/17.7.2503; ORAHILLY S, 1988, DIABETOLOGIA, V31, P407, DOI 10.1007/BF00271584; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; Ott J., 1991, ANAL HUMAN GENETIC L; RICH SS, 1990, DIABETES, V39, P1315, DOI 10.2337/diabetes.39.11.1315; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; STEINER DF, 1990, DIABETES CARE, V13, P600, DOI 10.2337/diacare.13.6.600; STOFFEL M, 1992, P NATL ACAD SCI USA, V89, P7698, DOI 10.1073/pnas.89.16.7698; TAYLOR SI, 1991, J CLIN ENDOCR METAB, V73, P1158, DOI 10.1210/jcem-73-6-1158; TCHOBROUTSKY G, 1991, DIABETOLOGIA, V34, P67, DOI 10.1007/BF00500374; VELHO G, 1992, LANCET, V340, P444, DOI 10.1016/0140-6736(92)91768-4; VIONNET N, 1992, NATURE, V356, P721, DOI 10.1038/356721a0; 1980, WHO TECH REP SER, V646, P1	31	658	697	0	12	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 11	1993	328	10					697	702		10.1056/NEJM199303113281005	http://dx.doi.org/10.1056/NEJM199303113281005			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KQ861	8433729				2022-12-24	WOS:A1993KQ86100005
J	LEE, J; ISHIHARA, A; THERIOT, JA; JACOBSON, K				LEE, J; ISHIHARA, A; THERIOT, JA; JACOBSON, K			PRINCIPLES OF LOCOMOTION FOR SIMPLE-SHAPED CELLS	NATURE			English	Article							NEURONAL GROWTH CONE; LEADING-EDGE; FLOW; MICROFILAMENT; MICROTUBULES; ORGANIZATION; FIBROBLASTS; MOVEMENT; CULTURE; INVITRO	MOVING cells display a variety of shapes and modes of locomotion1, but it is not clear how motility at the molecular level relates to the locomotion of a whole cell, a problem compounded in studies of cells with complex shapes2-5. A striking feature of fish epidermal keratocyte locomotion is its apparent simplicity6. Here we present a kinematic description of locomotion which is consistent with the semicircular shape and persistent 'gliding' motion of fish epidermal keratocytes. We propose that extension of the front and retraction of the rear of these cells occurs perpendicularly to the cell edge, and that a graded distribution of extension and retraction rates along the cell margin maintains cell shape and size during locomotion. Evidence for this description is provided by the predicted circumferential motion of lamellar features and the curvature of 'photo-marked' lines within specific molecular components of moving keratocytes. Our description relates the dynamics of molecular assemblies to the movement of a whole cell.	UNIV N CAROLINA,LINEBERGER CANC RES CTR,CHAPEL HILL,NC 27599; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOPHYS,SAN FRANCISCO,CA 94143	University of North Carolina; University of North Carolina Chapel Hill; University of California System; University of California San Francisco; University of California System; University of California San Francisco	LEE, J (corresponding author), UNIV N CAROLINA,DEPT CELL BIOL & ANAT,CHAPEL HILL,NC 27599, USA.		Theriot, Julie/HHN-2034-2022	Theriot, Julie/0000-0002-2334-2535				BEREITERHAHN J, 1981, J CELL SCI, V52, P289; BRAY D, 1988, SCIENCE, V239, P883, DOI 10.1126/science.3277283; BRAY D, 1985, J NEUROSCI, V5, P3204; DEBIOSFLEURYCHE.A, 1989, BLOOD CELLS, V15, P334; DIPASQUALE A, 1975, EXP CELL RES, V95, P425, DOI 10.1016/0014-4827(75)90568-6; DUNN GA, 1987, J CELL SCI S, V8, P81; Dunn GA, 1980, CELL ADHESION MOTILI, P409; EUTENEUER U, 1984, NATURE, V310, P58, DOI 10.1038/310058a0; EVANS E, 1990, BIOMECHANICS ACTIVE, P185; FORSCHER P, 1988, J CELL BIOL, V107, P1505, DOI 10.1083/jcb.107.4.1505; GUDIMA GO, 1988, J CELL SCI, V89, P225; KOLEGA J, 1986, J CELL BIOL, V102, P1400, DOI 10.1083/jcb.102.4.1400; KOLEGA J, 1981, J CELL SCI, V49, P15; KUCIK DF, 1989, NATURE, V340, P315, DOI 10.1038/340315a0; LEE J, 1990, SCIENCE, V247, P1229, DOI 10.1126/science.2315695; RINNERTHALER G, 1991, J STRUCT BIOL, V106, P1, DOI 10.1016/1047-8477(91)90058-5; ROBERTS TM, 1991, CELL MOTIL CYTOSKEL, V20, P228, DOI 10.1002/cm.970200306; SYMONS MH, 1991, J CELL BIOL, V114, P503, DOI 10.1083/jcb.114.3.503; THERIOT JA, 1991, NATURE, V352, P126, DOI 10.1038/352126a0; TRINKAUS JP, 1984, CELLS ORGANS FORCES, P179; WANG YL, 1985, J CELL BIOL, V101, P597, DOI 10.1083/jcb.101.2.597	21	188	190	0	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 11	1993	362	6416					167	171		10.1038/362167a0	http://dx.doi.org/10.1038/362167a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KR028	8450887				2022-12-24	WOS:A1993KR02800063
J	NISHIMOTO, I; OKAMOTO, T; MATSUURA, Y; TAKAHASHI, S; OKAMOTO, T; MURAYAMA, Y; OGATA, E				NISHIMOTO, I; OKAMOTO, T; MATSUURA, Y; TAKAHASHI, S; OKAMOTO, T; MURAYAMA, Y; OGATA, E			ALZHEIMER AMYLOID PROTEIN-PRECURSOR COMPLEXES WITH BRAIN GTP-BINDING PROTEIN-G(O)	NATURE			English	Article							GROWTH FACTOR-II; PERTUSSIS-TOXIN; DISEASE; RECEPTOR; EXPRESSION; G0; FRAGMENT; PEPTIDE; GAP-43	THE most characteristic change in progressive dementia of Alzheimer's type is a tissue deposit of amyloid beta/A4 protein1, which is derived from its precursor protein APP (ref. 2). Structural alterations of APP are implicated in the pathogenesis of Alzheimer's disease, but it is not known how they cause the disease. Although APP has a receptor-like architecture 2-5, is located on the neuronal surface6, and has a conserved cytoplasmic domain7, no receptor function has been demonstrated for APP. Here we report that APP forms a complex with G(o), a major GTP-binding protein in brain. The cytoplasmic APP sequence His 657-Lys 676 shows a specific G(o)-activating function and is necessary for complex formation. G(o) protein treated with GTP-gammaS lost the ability to associate with APP. This suggests that APP is a receptor coupled to G(o) and that abnormal APP-G(o) signalling is involved in the Alzheimer's disease process.	UNIV TOKYO,SCH MED,DEPT INTERNAL MED 4,LIFE SCI LAB,BUNKYO KU,TOKYO 112,JAPAN; NATL INST HLTH,DEPT VIROL 2,HEPATITIS VIRUSES LAB,SHINJUKU KU,TOKYO 160,JAPAN; SAPPORO MED COLL,DEPT PATHOL,CHUO KU,SAPPORO,HOKKAIDO 060,JAPAN	University of Tokyo; Sapporo Medical University								ABRAHAM CR, 1989, BIO-TECHNOL, V7, P147, DOI 10.1038/nbt0289-147; BIRNBAUMER L, 1983, EUR J BIOCHEM, V136, P107, DOI 10.1111/j.1432-1033.1983.tb07712.x; DYRKS T, 1988, EMBO J, V7, P949, DOI 10.1002/j.1460-2075.1988.tb02900.x; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GRANNEMAN JG, 1990, J NEUROCHEM, V54, P1995, DOI 10.1111/j.1471-4159.1990.tb04903.x; GUILLEN A, 1990, EMBO J, V9, P1449, DOI 10.1002/j.1460-2075.1990.tb08261.x; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; KAMETANI F, 1989, BIOMED RES-TOKYO, V10, P179, DOI 10.2220/biomedres.10.179; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KATADA T, 1987, FEBS LETT, V213, P353, DOI 10.1016/0014-5793(87)81521-1; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MORISHITA R, 1988, EUR J BIOCHEM, V174, P87, DOI 10.1111/j.1432-1033.1988.tb14066.x; NISHIMOTO I, 1989, J BIOL CHEM, V264, P14029; OKAMOTO T, 1991, J BIOL CHEM, V266, P1085; OKAMOTO T, 1990, CELL, V62, P709, DOI 10.1016/0092-8674(90)90116-V; OKAMOTO T, 1991, P NATL ACAD SCI USA, V88, P8020, DOI 10.1073/pnas.88.18.8020; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; SELKOE DJ, 1989, CELL, V58, P611, DOI 10.1016/0092-8674(89)90093-7; SHIVERS BD, 1988, EMBO J, V7, P1365, DOI 10.1002/j.1460-2075.1988.tb02952.x; STRITTMATTER SM, 1991, J BIOL CHEM, V266, P22465; STRITTMATTER SM, 1991, BIOESSAYS, V13, P127, DOI 10.1002/bies.950130306; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; SUMMERS MD, 1987, TEX AGR EXP STN B, P1555; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; YAMADA T, 1987, BIOCHEM BIOPH RES CO, V149, P665, DOI 10.1016/0006-291X(87)90419-0; YANKNER BA, 1989, SCIENCE, V245, P417, DOI 10.1126/science.2474201	27	389	401	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 4	1993	362	6415					75	79		10.1038/362075a0	http://dx.doi.org/10.1038/362075a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KP976	8446172				2022-12-24	WOS:A1993KP97600065
J	ANNAS, GJ				ANNAS, GJ			CONTROL OF TUBERCULOSIS - THE LAW AND THE PUBLICS HEALTH	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material														Annas, George/0000-0001-5836-7831				Bayer Ronald, 1992, TUBERCULOSIS REVIVAL; BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; CALIFANO J, 1992, WASHINGTON POST 1221, pA21; Dubos R, 1952, WHITE PLAGUE TUBERCU; FRIEDEN TR, 1993, NEW ENGL J MED, V328, P521, DOI 10.1056/NEJM199302253280801; GOBLE M, 1993, NEW ENGL J MED, V328, P527, DOI 10.1056/NEJM199302253280802; GOSTIN LO, 1993, JAMA-J AM MED ASSOC, V269, P255, DOI 10.1001/jama.269.2.255; HINGSON R, 1981, SICKNESS HLTH SOCIAL, P142; ISEMAN MD, 1993, NEW ENGL J MED, V328, P576, DOI 10.1056/NEJM199302253280811; Lederberg J., 1992, EMERGING INFECTIONS; MAHON W, 1992, DEV SYSTEM TB PREVEN; SKOLNICK AA, 1992, JAMA-J AM MED ASSOC, V268, P3177, DOI 10.1001/jama.268.22.3177; 1992, MMWR MORB MORTAL WKL, V41; 1992, RECOMMENDATIONS MASS	14	64	66	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 25	1993	328	8					585	588		10.1056/NEJM199302253280825	http://dx.doi.org/10.1056/NEJM199302253280825			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP053	8426636	Green Published			2022-12-24	WOS:A1993KP05300028
J	FRISCH, M; MELBYE, M; MOLLER, H				FRISCH, M; MELBYE, M; MOLLER, H			TRENDS IN INCIDENCE OF ANAL CANCER IN DENMARK	BMJ-BRITISH MEDICAL JOURNAL			English	Article							INTRAEPITHELIAL NEOPLASIA; PAPILLOMAVIRUS INFECTION; HOMOSEXUAL MEN; MARITAL-STATUS; DISEASE; IMMUNODEFICIENCY; ASSOCIATION; CARCINOMA; RISK	Objective-To study long term trends in incidence of anal cancer in a well monitored, unselected population. Design-Descriptive epidemiological study based on data from the Danish Cancer Registry. Setting-Denmark, 1943-87. Main outcome measures-Time related changes in anal cancer incidence according to sex, age, birth cohort, urban or rural residence, and marital status. Results-The incidence of anal cancer remained fairly constant in the period 1943-57 and was similar for men and women, but it increased 1.5-fold among men and nearly tripled among women thereafter. Among men the incidence increased from 0.25 per 100000 population (world standardised) in 1958-62 to 0.38 in 1983-7 (p=0.01) and among women from 0.28 to 0.74 (p<0.01). The greatest increase was among residents of the capital (Copenhagen). During 1943-87 age specific trends increased in young and middle aged men and in all age groups among women. Men with anal cancer were significantly more likely throughout the study period to be unmarried than were patients with cancer of the colon (adjusted odds ratio 2.7; 95% confidence interval 2.0 to 3.6) and stomach (2.1; 1.5 to 2.8), but no association with marital status was found among women. Conclusions-The distribution and incidence of anal cancer have changed appreciably since around 1960, especially among women, which indicates important aetiological changes. Changes in sexual behaviour may have facilitated the spread of a transmittable agent of aetiological importance. It has recently been suggested that cigarette smoking promotes anal cancer, and this finds indirect support in the synchronism between changes in anal cancer incidence and heavy smoking behaviour. Factors associated with homosexuality are likely to explain some of the cases among men.	DANISH CANC SOC, RES CTR, DIV CANC EPIDEMIOL, COPENHAGEN, DENMARK	Danish Cancer Society	FRISCH, M (corresponding author), STATE SERUM INST, EPIDEMIOL RES UNIT, ARTILLERIVEJ 5, DK-2300 COPENHAGEN S, DENMARK.		Frisch, Morten/E-9206-2016	Frisch, Morten/0000-0002-3864-8860; melbye, mads/0000-0001-8264-6785; Moller, Henrik/0000-0001-8200-5929				Austin D F, 1982, Natl Cancer Inst Monogr, V62, P89; BECKMANN AM, 1989, INT J CANCER, V43, P1042, DOI 10.1002/ijc.2910430615; BIGGAR RJ, 1989, INT J CANCER, V43, P979, DOI 10.1002/ijc.2910430605; BLOHME I, 1985, TRANSPLANTATION, V39, P23; CAUSSY D, 1990, INT J CANCER, V46, P214, DOI 10.1002/ijc.2910460212; Daling J R, 1992, IARC Sci Publ, P223; DALING JR, 1982, JAMA-J AM MED ASSOC, V247, P1988; DALING JR, 1992, AM J EPIDEMIOL, V135, P180, DOI 10.1093/oxfordjournals.aje.a116270; DALING JR, 1987, NEW ENGL J MED, V317, P973, DOI 10.1056/NEJM198710153171601; GOLDMAN S, 1989, ACTA CHIR SCAND, V155, P191; HAUSEN HZ, 1989, CANCER RES, V49, P4677; HEVER D, 1989, 5TH INT C AIDS MONTR; HOLLY EA, 1989, JNCI, V81, P726; HOLMES F, 1988, GASTROENTEROLOGY, V95, P107, DOI 10.1016/0016-5085(88)90297-1; MELBYE M, 1992, AM J EPIDEMIOL, V135, P593, DOI 10.1093/oxfordjournals.aje.a116338; MELBYE M, 1984, BRIT MED J, V289, P573, DOI 10.1136/bmj.289.6445.573; MELBYE M, 1991, LANCET, V338, P657, DOI 10.1016/0140-6736(91)91233-K; MELBYE M, 1990, INT J CANCER, V46, P203, DOI 10.1002/ijc.2910460210; OSLER M, 1992, INT J EPIDEMIOL, V21, P862, DOI 10.1093/ije/21.5.862; PALEFSKY JM, 1990, JAMA-J AM MED ASSOC, V263, P2911, DOI 10.1001/jama.263.21.2911; PALEFSKY JM, 1991, CANCER RES, V51, P1014; PENN I, 1986, CANCER-AM CANCER SOC, V58, P611, DOI 10.1002/1097-0142(19860801)58:3<611::AID-CNCR2820580303>3.0.CO;2-M; PETERS RK, 1983, BRIT J CANCER, V48, P629, DOI 10.1038/bjc.1983.244; RABKIN CS, 1992, AM J EPIDEMIOL, V136, P54, DOI 10.1093/oxfordjournals.aje.a116420; SCHOLEFIELD JH, 1990, BRIT J CANCER, V62, P286, DOI 10.1038/bjc.1990.279; Smith P., 1987, CANC INCIDENCE 5 CON, V88, P790; Storm H H, 1991, IARC Sci Publ, P220; Wagner G, 1991, IARC Sci Publ, P3; WEXNER SD, 1987, DIS COLON RECTUM, V30, P942, DOI 10.1007/BF02554281; 1989, SAS STAT USERS GUIDE, V2, P1325	30	133	135	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 13	1993	306	6875					419	422		10.1136/bmj.306.6875.419	http://dx.doi.org/10.1136/bmj.306.6875.419			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KM700	8461721	Green Published, Bronze			2022-12-24	WOS:A1993KM70000018
J	SOMERS, VK; DYKEN, ME; MARK, AL; ABBOUD, FM				SOMERS, VK; DYKEN, ME; MARK, AL; ABBOUD, FM			SYMPATHETIC-NERVE ACTIVITY DURING SLEEP IN NORMAL SUBJECTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SUDDEN CARDIAC DEATH; CIRCADIAN VARIATION; MYOCARDIAL-INFARCTION; ARTERIAL-PRESSURE; MORNING INCREASE; BLOOD-PRESSURE; ONSET; FREQUENCY; OUTFLOW; MUSCLE	Background. The early hours of the morning after awakening are associated with an increased frequency of events such as myocardial infarction and ischemic stroke. The triggering mechanisms for these events are not clear. We investigated whether autonomic changes occurring during sleep, particularly rapid-eye-movement (REM) sleep, contribute to the initiation of such events. Methods. We measured blood pressure, heart rate, and sympathetic-nerve activity (using microneurography, which provides direct measurements of efferent sympathetic-nerve activity related to muscle blood vessels) in eight normal subjects while they were awake and while in the five stages of sleep. Results. The mean (+/-SE)amplitude of bursts of sympathetic-nerve activity and levels of blood pressure and heart rate declined significantly (P<0.001), from 100+/-9 percent, 90+/-4 mm Hg, and 64+/-2 beats per minute, respectively, during wakefulness to 41+/-9 percent, 80+/-4 mm Hg, and 59+/-2 beats per minute, respectively, during stage 4 ot non-REM sleep. Arousal stimuli during stage 2 sleep elicited high-amplitude deflections on the electroencephalogram (called ''K complexes''), which were frequently associated with bursts of sympathetic-nerve activity and transient increases in blood pressure. During REM sleep, sympathetic-nerve activity increased significantly (to 215+/-11 percent; P<0.001) and the blood pressure and heart rate returned to levels similar to those during wakefulness. Momentary restorations of muscle tone during REM sleep (REM twitches) were associated with cessation of sympathetic-nerve discharge and surges in blood pressure. Conclusions. REM sleep is associated with profound sympathetic activation in normal subjects, possibly linked to changes in muscle tone. The hemodynamic and sympathetic changes during REM sleep could play a part in triggering ischemic events in patients with vascular disease.	UNIV IOWA,COLL MED,DEPT NEUROL,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT MED,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,CTR CARDIOVASC,IOWA CITY,IA 52242	University of Iowa; University of Iowa; University of Iowa; University of Iowa				Abboud, Francois/0000-0002-7284-9148; Dyken, Mark/0000-0002-6252-581X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL024962, R01HL024962] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-24962, HL-14388] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACCELLI G, 1974, CIRC RES, V35, P625, DOI 10.1161/01.RES.35.4.625; COCCAGNA G, 1971, ELECTROEN CLIN NEURO, V31, P277, DOI 10.1016/0013-4694(71)90098-8; CONWAY J, 1983, HYPERTENSION, V5, P746, DOI 10.1161/01.HYP.5.5.746; DEMENT W, 1957, ELECTROEN CLIN NEURO, V9, P673, DOI 10.1016/0013-4694(57)90088-3; FAGIUS J, 1985, BRAIN, V108, P423, DOI 10.1093/brain/108.2.423; FURLAN R, 1989, J HYPERTENS, V7, pS30, DOI 10.1097/00004872-198900076-00012; FURLAN R, 1990, CIRCULATION, V81, P537, DOI 10.1161/01.CIR.81.2.537; GEORGE CF, 1985, CLIN CHEST MED, V6, P595; HORNYAK M, 1991, BRAIN, V114, P1281, DOI 10.1093/brain/114.3.1281; Kelly D. D., 1991, PRINCIPLES NEURAL SC, P792; KHATRI IM, 1967, J APPL PHYSIOL, V22, P867, DOI 10.1152/jappl.1967.22.5.867; KING MJ, 1973, AM J MED SCI, V265, P419, DOI 10.1097/00000441-197305000-00009; KIRBY DA, 1989, PHYSIOL BEHAV, V45, P1017, DOI 10.1016/0031-9384(89)90231-X; MANCIA G, 1971, AM J PHYSIOL, V220, P1086, DOI 10.1152/ajplegacy.1971.220.4.1086; MANCIA G, 1980, RES TOPICS PHYSL, V3, P2; MARK AL, 1985, CIRC RES, V57, P461, DOI 10.1161/01.RES.57.3.461; MARK AL, 1990, J HYPERTENS, V8, pS67; MARLER JR, 1989, STROKE, V20, P473, DOI 10.1161/01.STR.20.4.473; MION D, 1988, J HYPERTENS, V6, pS74, DOI 10.1097/00004872-198812040-00019; MULLER JE, 1987, CIRCULATION, V75, P131, DOI 10.1161/01.CIR.75.1.131; MULLER JE, 1985, NEW ENGL J MED, V313, P1315, DOI 10.1056/NEJM198511213132103; MULLER JE, 1989, CIRCULATION, V79, P733, DOI 10.1161/01.CIR.79.4.733; NOWLIN JB, 1965, ANN INTERN MED, V63, P1040, DOI 10.7326/0003-4819-63-6-1040; OKADA H, 1991, NEUROLOGY, V41, P1961, DOI 10.1212/WNL.41.12.1961; PAGANI M, 1988, HYPERTENSION, V12, P600, DOI 10.1161/01.HYP.12.6.600; PARATI G, 1989, HYPERTENSION, V13, P647, DOI 10.1161/01.HYP.13.6.647; RECHTSTAFFEN A, 1968, MANUAL STANDARDIZED; REIS DJ, 1969, AM J PHYSIOL, V217, P541, DOI 10.1152/ajplegacy.1969.217.2.541; SMYTH HS, 1969, CIRC RES, V24, P109, DOI 10.1161/01.RES.24.1.109; SNEDECOR GW, 1980, STATISTICAL METHODS, P265; SNYDER F, 1964, J APPL PHYSIOL, V19, P417, DOI 10.1152/jappl.1964.19.3.417; STJERNBERG L, 1986, BRAIN, V109, P695, DOI 10.1093/brain/109.4.695; TOFLER GH, 1987, NEW ENGL J MED, V316, P1514, DOI 10.1056/NEJM198706113162405; Wesseling K.H., 1986, BIOLOGICAL PSYCHOL F, P355, DOI [10.1007/978-3-642-71234-0_22, DOI 10.1007/978-3-642-71234-0_22]; [No title captured]	35	1055	1084	1	46	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 4	1993	328	5					303	307		10.1056/NEJM199302043280502	http://dx.doi.org/10.1056/NEJM199302043280502			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK247	8419815	Bronze			2022-12-24	WOS:A1993KK24700002
J	PANTON, R				PANTON, R			THE FUTURE OF FHSAS .5. FHSAS AND PRESCRIBING	BRITISH MEDICAL JOURNAL			English	Article											PANTON, R (corresponding author), UNIV KEELE,DEPT PHARM POLICY & PRACTICE,KEELE ST5 5BG,STAFFS,ENGLAND.							BAKER JA, 1988, BRIT MED J, V297, P465, DOI 10.1136/bmj.297.6646.465; BRADLEY CP, 1992, BRIT MED J, V304, P294, DOI 10.1136/bmj.304.6822.294; KESSLER A, 1992, CHEM DRUGGIST, V236, P605; NEWTONSYMS FAO, 1988, PHARM J, V294, pR2; PARR C, 1992, PHARM J, V248, P616; 1992, DETERMINING DRUG INF; 1992, LANCET, V340, P341; 1992, STATISTICAL B GENERA; 1990, IMPROVING PRESCRIBIN; 1992, PHARM CARE FUTURE CO; 1991, PHARMACEUTICALS CONS; 1992, IMPEDIMENTS PARALLEL; 1992, EXCESSIVE PRESCRIBIN	13	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 30	1993	306	6873					310	314		10.1136/bmj.306.6873.310	http://dx.doi.org/10.1136/bmj.306.6873.310			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK718	8461652	Green Published, Bronze			2022-12-24	WOS:A1993KK71800024
J	DIETZ, HC; VALLE, D; FRANCOMANO, CA; KENDZIOR, RJ; PYERITZ, RE; CUTTING, GR				DIETZ, HC; VALLE, D; FRANCOMANO, CA; KENDZIOR, RJ; PYERITZ, RE; CUTTING, GR			THE SKIPPING OF CONSTITUTIVE EXONS INVIVO INDUCED BY NONSENSE MUTATIONS	SCIENCE			English	Article							PRE-MESSENGER RNA; MARFAN-SYNDROME; SPLICE-SITE; GENE; SEQUENCES; INTRON; IDENTIFICATION; TRANSCRIPTS; PRECURSORS; FIBRILLIN	Nonsense mutations create a premature signal for the termination of translation of messenger RNA. Such mutations have been observed to cause a severe reduction in the amount of mutant allele transcript or to generate a peptide truncated at the carboxyl end. Analysis of fibrillin transcript from a patient with Marfan syndrome revealed the skipping of a constitutive exon containing a nonsense mutation. Similar results were observed for two nonsense mutations in the gene encoding ornithine delta-aminotransferase from patients with gyrate atrophy. All genomic DNA sequences flanking these exons that are known to influence RNA splicing were unaltered, which suggests that nonsense mutations can after splice site selection in vivo.	JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205	Johns Hopkins University	DIETZ, HC (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT,HOWARD HUGHES MED INST,BALTIMORE,MD 21205, USA.		Pyeritz, Reed/A-1364-2010		NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000722] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P01HG000373] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00722] Funding Source: Medline; NHGRI NIH HHS [HG-00373] Funding Source: Medline; NIAMS NIH HHS [AR-41135] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BELL LR, 1988, CELL, V55, P1037, DOI 10.1016/0092-8674(88)90248-6; BOND RW, 1990, P NATL ACAD SCI USA, V87, P8771, DOI 10.1073/pnas.87.22.8771; CHAIN AC, 1991, MOL CELL BIOL, V11, P1538, DOI 10.1128/MCB.11.3.1538; COOPER TA, 1992, J BIOL CHEM, V267, P5330; DIETZ H, UNPUB; DIETZ HC, 1992, J CLIN INVEST, V89, P1674, DOI 10.1172/JCI115766; DIETZ HC, 1991, NATURE, V352, P337, DOI 10.1038/352337a0; DIETZ HC, IN PRESS HUM MUTAT; DOMENJOUD L, 1991, MOL CELL BIOL, V11, P4581, DOI 10.1128/MCB.11.9.4581; GOWER HJ, 1988, CELL, V55, P955, DOI 10.1016/0092-8674(88)90241-3; HAMPSON RK, 1989, MOL CELL BIOL, V9, P1604, DOI 10.1128/MCB.9.4.1604; LIBRI D, 1990, MOL CELL BIOL, V10, P5036, DOI 10.1128/MCB.10.10.5036; MANIATIS T, 1987, NATURE, V325, P673, DOI 10.1038/325673a0; MARDON HJ, 1987, NUCLEIC ACIDS RES, V15, P7725, DOI 10.1093/nar/15.19.7725; MASLEN CL, 1991, NATURE, V352, P334, DOI 10.1038/352334a0; MATSUO M, 1991, J CLIN INVEST, V87, P2127, DOI 10.1172/JCI115244; MICHAUD J, 1992, GENOMICS, V13, P389, DOI 10.1016/0888-7543(92)90258-T; MITCHELL GA, 1988, J BIOL CHEM, V263, P14288; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NAEGER LK, 1992, GENE DEV, V6, P1107, DOI 10.1101/gad.6.6.1107; OSHIMA Y, 1987, J MOL BIOL, V195, P247; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; REED R, 1986, CELL, V46, P681, DOI 10.1016/0092-8674(86)90343-0; RICKETTS MH, 1987, P NATL ACAD SCI USA, V84, P3181, DOI 10.1073/pnas.84.10.3181; RUSKIN B, 1984, CELL, V38, P317, DOI 10.1016/0092-8674(84)90553-1; SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499; SHARP PA, 1987, SCIENCE, V235, P766, DOI 10.1126/science.3544217; SOMASEKHAR MB, 1985, NUCLEIC ACIDS RES, V13, P5591, DOI 10.1093/nar/13.15.5591; TSAI AYM, 1989, MOL CELL BIOL, V9, P4550, DOI 10.1128/MCB.9.10.4550; URLAUB G, 1989, MOL CELL BIOL, V9, P2868, DOI 10.1128/MCB.9.7.2868; VALLE D, UNPUB; WAKAMATSU N, 1992, J BIOL CHEM, V267, P2406	32	405	414	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 29	1993	259	5095					680	683		10.1126/science.8430317	http://dx.doi.org/10.1126/science.8430317			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KJ688	8430317				2022-12-24	WOS:A1993KJ68800042
J	MATHIAS, S; YOUNES, A; KAN, CC; ORLOW, I; JOSEPH, C; KOLESNICK, RN				MATHIAS, S; YOUNES, A; KAN, CC; ORLOW, I; JOSEPH, C; KOLESNICK, RN			ACTIVATION OF THE SPHINGOMYELIN SIGNALING PATHWAY IN INTACT EL4 CELLS AND IN A CELL-FREE SYSTEM BY IL-1-BETA	SCIENCE			English	Article							PROTEIN-KINASE-C; GROWTH-FACTOR RECEPTOR; GH3 PITUITARY-CELLS; NECROSIS-FACTOR-ALPHA; PHORBOL ESTERS; IL-1 RECEPTOR; INTERLEUKIN-1 RECEPTOR; PLASMA-MEMBRANE; THYMOMA CELLS; GTP-BINDING	The mechanism of interleukin-1 (IL-1) signaling is unknown. Tumor necrosis factor-alpha uses a signal transduction pathway that involves sphingomyelin hydrolysis to ceramide and stimulation of a ceramide-activated protein kinase. In intact EL4 thymoma cells, IL-1beta similarly stimulated a rapid decrease of sphingomyelin and an elevation of ceramide, and enhanced ceramide-activated protein kinase activity. This cascade was also activated by IL-1beta in a cell-free system, demonstrating tight coupling to the receptor. Exogenous sphingomyelinase, but not phospholipases A2, C, or D, in combination with phorbol ester replaced IL-1beta to stimulate IL-2 secretion. Thus, IL-1beta signals through the sphingomyelin pathway.	MEM SLOAN KETTERING CANC CTR,SLOAN KETTERING INST,SIGNAL TRANSDUCT LAB,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center					NATIONAL CANCER INSTITUTE [R01CA042385] Funding Source: NIH RePORTER; NCI NIH HHS [R0-1-CA-42385] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AITKEN A, 1984, BIOCHIM BIOPHYS ACTA, V790, P288, DOI 10.1016/0167-4838(84)90034-7; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; BALLESTER R, 1985, J BIOL CHEM, V260, P5194; BALLOU LR, 1992, J BIOL CHEM, V267, P20044; BIRD TA, 1989, J IMMUNOL, V142, P126; BIRD TA, 1991, J BIOL CHEM, V266, P22661; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; CHATTERJEE S, 1989, J BIOL CHEM, V264, P12554; CHEDID M, 1989, J IMMUNOL, V142, P4301; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; DAS DVM, 1984, BIOCHIM BIOPHYS ACTA, V777, P339; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; DORNAND J, 1987, IMMUNOL LETT, V16, P101, DOI 10.1016/0165-2478(87)90115-5; DORNAND J, 1992, J CELL PHYSIOL, V151, P71, DOI 10.1002/jcp.1041510112; DOWER SK, 1985, J EXP MED, V162, P501, DOI 10.1084/jem.162.2.501; DRESSLER KA, 1990, J BIOL CHEM, V265, P14917; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; FARRAR JJ, 1980, J IMMUNOL, V125, P2555; GOLDKORN T, 1991, J BIOL CHEM, V266, P16092; GUY GR, 1991, J BIOL CHEM, V266, P14343; JOSEPH CK, 1992, J BIOL CHEM, V267, P1327; KIM MY, 1991, J BIOL CHEM, V266, P484; Kolesnick Richard, 1992, Trends in Cell Biology, V2, P232, DOI 10.1016/0962-8924(92)90310-J; KOLESNICK RN, 1987, J BIOL CHEM, V262, P9204; KOLESNICK RN, 1987, J BIOL CHEM, V262, P16759; KOLESNICK RN, 1988, J BIOL CHEM, V263, P6534; LEWIS C, 1990, EUR J IMMUNOL, V20, P207, DOI 10.1002/eji.1830200130; LOWENTHAL JW, 1986, J IMMUNOL, V137, P1226; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; MCINTYRE KW, 1991, J EXP MED, V173, P931, DOI 10.1084/jem.173.4.931; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; MCMANNIS JD, 1985, P NATL ACAD SCI USA, V82, P1513, DOI 10.1073/pnas.82.5.1513; MUNOZ E, 1990, J IMMUNOL, V144, P964; NETA R, 1992, TUMOR NECROSIS FACTO, P499; NISHIZUKA Y, 1989, JAMA-J AM MED ASSOC, V262, P1826, DOI 10.1001/jama.262.13.1826; NORTHWOOD IC, 1991, J BIOL CHEM, V266, P15266; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; ONEILL LAJ, 1990, J BIOL CHEM, V265, P3146; ONEILL LAJ, 1990, IMMUNOL TODAY, V11, P392, DOI 10.1016/0167-5699(90)90155-3; PREISS J, 1986, J BIOL CHEM, V261, P8597; RANGNEKAR VM, 1988, J BIOL CHEM, V263, P16408; RAO BG, 1976, J LIPID RES, V17, P506; REBECCHI MJ, 1983, J BIOL CHEM, V258, P227; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; SHIRAKAWA F, 1988, P NATL ACAD SCI USA, V85, P8201, DOI 10.1073/pnas.85.21.8201; SIMS JE, 1989, P NATL ACAD SCI USA, V86, P8946, DOI 10.1073/pnas.86.22.8946; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; VONHOEGEN I, 1989, EUR J IMMUNOL, V19, P329; WHITEHEAD TP, 1983, NATURE, V305, P158, DOI 10.1038/305158a0; YODOI J, 1985, J IMMUNOL, V134, P1623; ZHANG YH, 1988, P NATL ACAD SCI USA, V85, P6802, DOI 10.1073/pnas.85.18.6802	52	429	440	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 22	1993	259	5094					519	522		10.1126/science.8424175	http://dx.doi.org/10.1126/science.8424175			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KJ079	8424175				2022-12-24	WOS:A1993KJ07900036
J	LEESE, GP; AHMED, S; NEWTON, RW; JUNG, RT; ELLINGFORD, A; BAINES, P; ROXBURGH, S; COLEIRO, J				LEESE, GP; AHMED, S; NEWTON, RW; JUNG, RT; ELLINGFORD, A; BAINES, P; ROXBURGH, S; COLEIRO, J			USE OF MOBILE SCREENING UNIT FOR DIABETIC-RETINOPATHY IN RURAL AND URBAN AREAS	BRITISH MEDICAL JOURNAL			English	Article							PHOTOGRAPHY; COMMUNITY; CARE	Objectives-To compare the effectiveness of a mobile screening unit with a non-mydriatic polaroid camera in detecting diabetic retinopathy in rural and urban areas. To estimate the cost of the service. Design-Prospective data collection over two years of screening for diabetic retinopathy throughout Tayside. Setting-Tayside region, population 390 000, area 7770 km2. Subjects-961 patients in rural areas and 1225 in urban areas who presented for screening. Main outcome measures-Presence of diabetic retinopathy, need for laser photocoagulation, age, duration of diabetes, and diabetic treatment. Results-Compared with diabetic patients in urban areas, those in rural areas were less likely to attend a hospital based diabetic clinic (46% (442) v 86% (1054), p < 0.001); less likely to be receiving insulin (260 (27%) v 416 (34%), p < 0.001 and also after correction for differences in age distribution); more likely to have advanced (maculopathy or proliferative retinopathy) diabetic retinopathy (13% (122) v 7% (89), p < 0.001); and more likely to require urgent laser photocoagulation for previously unrecognised retinopathy (1.4% (13) v 0.5% (6), p < 0.02). The screening programme cost 10 Pound per patient screened and 1000 Pound per patient requiring laser treatment. Conclusion-The mobile diabetic eye screening programme detected a greater prevalence of advanced retinopathy in diabetic patients living in rural areas. Patients in rural areas were also more likely to need urgent laser photocoagulation. Present screening procedures seem to be less effective in rural areas and rural patients may benefit more from mobile screening units than urban patients.	UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT OPHTHALMOL,DUNDEE DD1 9SY,SCOTLAND; UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT COMMUNITY MED,DUNDEE DD1 9SY,SCOTLAND	University of Dundee; University of Dundee	LEESE, GP (corresponding author), UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT MED,DUNDEE DD1 9SY,SCOTLAND.							Carstairs V., 1991, DEPRIVATION HLTH SCO; CHALLEN AH, 1990, PRACTICAL DIABETES, V7, P26; DORNAN C, 1983, J ROY COLL GEN PRACT, V33, P151; HAYES TM, 1984, BRIT MED J, V289, P728, DOI 10.1136/bmj.289.6447.728; HIGGS ER, 1991, DIABETIC MED, V8, P551, DOI 10.1111/j.1464-5491.1991.tb01650.x; HIGGS ER, 1987, DIABETIC MED, V4, pA577; HILL RD, 1976, BRIT MED J, V1, P1137, DOI 10.1136/bmj.1.6018.1137; HOUGHTON G, 1990, PRAC DIAB, V7, P174; JONES RB, 1989, DIABETIC MED, V6, P262, DOI 10.1111/j.1464-5491.1989.tb01158.x; KOHNER EM, 1987, DIABETES S1, V36, pA42; LEESE GP, 1992, DIABETIC MED, V9, P459, DOI 10.1111/j.1464-5491.1992.tb01817.x; NATHAN DM, 1991, DIABETES CARE, V14, P26, DOI 10.2337/diacare.14.1.26; REITH S, 1985, LONDON UPDATE, V10, P24; ROGERS D, 1990, DIABETIC MED, V7, P165, DOI 10.1111/j.1464-5491.1990.tb01353.x; SCULPHER MJ, 1991, DIABETIC MED, V8, P644, DOI 10.1111/j.1464-5491.1991.tb01671.x; Snedecor G.W., 1980, STAT METHODS, V7; SPATHIS GS, 1986, DIABETIC MED, V3, P131, DOI 10.1111/j.1464-5491.1986.tb00723.x; Tattersall R, 1986, Diabet Med, V3, P166; TAYLOR R, 1990, BRIT MED J, V301, P1243, DOI 10.1136/bmj.301.6763.1243; WAREHAM N, 1990, DIABETIC MED S2, V7, pA32; WHITFORD DL, 1989, PRACT DIABET, V6, P114; WILLIAMS R, 1986, BRIT MED J, V293, P1140, DOI 10.1136/bmj.293.6555.1140; YUDKIN JS, 1980, J EPIDEMIOL COMMUN H, V34, P277, DOI 10.1136/jech.34.4.277	23	61	61	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 16	1993	306	6871					187	189		10.1136/bmj.306.6871.187	http://dx.doi.org/10.1136/bmj.306.6871.187			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KH513	8443485	Green Published, Bronze			2022-12-24	WOS:A1993KH51300027
J	MICHEL, S; GEUSZ, ME; ZARITSKY, JJ; BLOCK, GD				MICHEL, S; GEUSZ, ME; ZARITSKY, JJ; BLOCK, GD			CIRCADIAN-RHYTHM IN MEMBRANE CONDUCTANCE EXPRESSED IN ISOLATED NEURONS	SCIENCE			English	Article							CHICK PINEAL CELLS; CELLULAR ANALYSIS; PACEMAKER SYSTEM; BULLA; EYE; LIGHT; LOCALIZATION; OSCILLATION; RELEASE; APLYSIA	Although isolated neurons can generate rhythmic activity, they have not yet been shown to generate rhythms with a period in the circadian range (near 24 hours). The eye of the mollusk Bulla gouldiana expresses a circadian rhythm in optic nerve impulses that is generated by electrically coupled cells known as basal retinal neurons (BRNs). Daily fluctuations in the membrane potential of the BRNs appear to be driven by a rhythm in membrane conductance. Isolated BRNs exhibited spontaneous conductance changes similar to those observed in the intact retina. Membrane conductance was high in the late subjective night and decreased approximately twofold near projected dawn during at least two circadian cycles in culture. The persistence of daily conductance changes in isolated BRNs indicates that individual neurons can function as circadian pacemakers.	UNIV VIRGINIA, DEPT BIOL, NATL SCI FDN, CTR BIOL TIMING, CHARLOTTESVILLE, VA 22901 USA	National Science Foundation (NSF); NSF - Center for Biological Timing; University of Virginia					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS008806, R01NS015264] Funding Source: NIH RePORTER; NINDS NIH HHS [NS15264, NS08806] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BLOCK GD, 1983, BRAIN RES, V265, P134, DOI 10.1016/0006-8993(83)91343-4; BLOCK GD, 1981, J COMP PHYSIOL, V142, P403, DOI 10.1007/BF00605452; BLOCK GD, 1982, SCIENCE, V217, P155, DOI 10.1126/science.217.4555.155; BLOCK GD, 1984, J COMP PHYSIOL, V155, P387, DOI 10.1007/BF00610592; DEGUCHI T, 1979, NATURE, V282, P94, DOI 10.1038/282094a0; ESKIN A, 1979, FED PROC, V38, P2573; ESKIN A, 1977, COMP BIOCHEM PHYS A, V57, P443, DOI 10.1016/0300-9629(77)90143-8; GEUSZ ME, 1991, J COMP PHYSIOL A, V168, P565, DOI 10.1007/BF00215078; GEUSZ ME, 1992, J BIOL RHYTHM, V7, P255, DOI 10.1177/074873049200700306; JACKLET JW, 1983, J NEUROCYTOL, V12, P673, DOI 10.1007/BF01181530; JACKLET JW, 1969, SCIENCE, V164, P562, DOI 10.1126/science.164.3879.562; JACKLET JW, 1989, NEURONAL CELLULAR OS, P483; KHALSA S B S, 1991, Society for Neuroscience Abstracts, V17, P1240; MCMAHON DG, 1984, J COMP PHYSIOL, V155, P379, DOI 10.1007/BF00610591; MCMAHON DG, 1987, J COMP PHYSIOL A, V161, P335, DOI 10.1007/BF00603959; MCMAHON DG, 1986, THESIS U VIRGINIA; MURAKAMI N, 1991, BRAIN RES, V545, P347, DOI 10.1016/0006-8993(91)91312-O; RALPH MR, 1990, J COMP PHYSIOL A, V166, P589; ROBERTSON LM, 1988, J NEUROSCI, V8, P12; TAKAHASHI JS, 1989, RECENT PROG HORM RES, V45, P279; TUREK FW, 1985, ANNU REV PHYSIOL, V47, P49, DOI 10.1146/annurev.ph.47.030185.000405; ZATZ M, 1988, BRAIN RES, V438, P199, DOI 10.1016/0006-8993(88)91339-X	22	177	178	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 8	1993	259	5092					239	241		10.1126/science.8421785	http://dx.doi.org/10.1126/science.8421785			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KF719	8421785	Green Submitted			2022-12-24	WOS:A1993KF71900034
J	WILLIAMS, N; CHELL, J; KAPILA, L				WILLIAMS, N; CHELL, J; KAPILA, L			WHY ARE CHILDREN REFERRED FOR CIRCUMCISION	BRITISH MEDICAL JOURNAL			English	Article									UNIV NOTTINGHAM HOSP,QUEENS MED CTR,DEPT PAEDIAT SURG,NOTTINGHAM NG7 2UH,ENGLAND	University of Nottingham								ESCALA JM, 1989, BRIT J UROL, V63, P196, DOI 10.1111/j.1464-410X.1989.tb05164.x; GAIRDNER D, 1949, BMJ-BRIT MED J, V2, P1433, DOI 10.1136/bmj.2.4642.1433; MCKINLEY GA, 1988, BRIT MED J, V297, P590; RICKWOOD AMK, 1989, ANN ROY COLL SURG, V71, P275; STRINGER MD, 1991, BRIT MED J, V302, P292, DOI 10.1136/bmj.302.6771.292-a	5	25	25	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 2	1993	306	6869					28	28		10.1136/bmj.306.6869.28	http://dx.doi.org/10.1136/bmj.306.6869.28			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KE984	8435573	Green Published, Bronze			2022-12-24	WOS:A1993KE98400022
J	SVOBODA, K; SCHMIDT, CF; SCHNAPP, BJ; BLOCK, SM				SVOBODA, K; SCHMIDT, CF; SCHNAPP, BJ; BLOCK, SM			DIRECT OBSERVATION OF KINESIN STEPPING BY OPTICAL TRAPPING INTERFEROMETRY	NATURE			English	Article							FORCE GENERATION; INVITRO; MICROTUBULES; MOVEMENT; MOLECULES; ASSAY; SIZE; DISPLACEMENT; ORGANELLE; DENSITIES	Do biological motors move with regular steps? To address this question, we constructed instrumentation with the spatial and temporal sensitivity to resolve movement on a molecular scale. We deposited silica beads carrying single molecules of the motor protein kinesin on microtubules using optical tweezers and analysed their motion under controlled loads by interferometry. We find that kinesin moves with 8-nm steps.	ROWLAND INST SCI INC, 100 EDWIN LAND BLVD, CAMBRIDGE, MA 02142 USA; HARVARD UNIV, COMM BIOPHYS, CAMBRIDGE, MA 02138 USA; HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA	Harvard University; Harvard University; Harvard Medical School			Schmidt, Christoph F/G-3787-2011	Schmidt, Christoph F/0000-0003-2864-6973				AMOS LA, 1974, J CELL SCI, V14, P523; ASHKIN A, 1986, OPT LETT, V11, P288, DOI 10.1364/OL.11.000288; ASHKIN A, 1990, NATURE, V348, P346, DOI 10.1038/348346a0; BAGSHAW CR, 1982, MUSCLE CONTRACTION; Block S, 1990, NONINVASIVE TECHNIQU, V9, P375; BLOCK SM, 1989, NATURE, V338, P514, DOI 10.1038/338514a0; BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; BURTON K, 1992, J MUSCLE RES CELL M, V13, P590, DOI 10.1007/BF01738249; COOKE R, 1986, CRIT REV BIOCHEM MOL, V21, P53, DOI 10.3109/10409238609113609; DENK W, 1990, APPL OPTICS, V29, P2382, DOI 10.1364/AO.29.002382; GALLAGHER NC, 1981, IEEE T ACOUST SPEECH, V29, P1136, DOI 10.1109/TASSP.1981.1163708; GELLES J, 1988, NATURE, V331, P450, DOI 10.1038/331450a0; GILBERT SP, 1993, BIOCHEMISTRY-US, V32, P4677, DOI 10.1021/bi00068a028; GITTES F, 1993, J CELL BIOL, V120, P923, DOI 10.1083/jcb.120.4.923; Glatter O, 1982, SMALL ANGLE XRAY SCA; HACKNEY DD, 1988, P NATL ACAD SCI USA, V85, P6314, DOI 10.1073/pnas.85.17.6314; Happel J, 1991, LOW REYNOLDS NUMBER, P322; HARADA Y, 1990, J MOL BIOL, V216, P49, DOI 10.1016/S0022-2836(05)80060-9; HARRISON BC, 1993, NATURE, V362, P73, DOI 10.1038/362073a0; HIGUCHI H, 1991, NATURE, V352, P352, DOI 10.1038/352352a0; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; HUXLEY HE, 1969, SCIENCE, V164, P1356, DOI 10.1126/science.164.3886.1356; ISHIJIMA A, 1991, NATURE, V352, P301, DOI 10.1038/352301a0; KAMIMURA S, 1992, J CELL BIOL, V116, P1443, DOI 10.1083/jcb.116.6.1443; KAMIMURA S, 1992, J CELL BIOL, V118, P865, DOI 10.1083/jcb.118.4.865; KAMIMURA S, 1987, APPL OPTICS, V26, P3425, DOI 10.1364/AO.26.003425; KRON SJ, 1986, P NATL ACAD SCI USA, V83, P6272, DOI 10.1073/pnas.83.17.6272; KUO SC, 1991, J CELL SCI, P135; KUO SC, 1993, SCIENCE, V260, P232, DOI 10.1126/science.8469975; KUZNETSOV SA, 1986, P NATL ACAD SCI USA, V83, P8530, DOI 10.1073/pnas.83.22.8530; Oosawa F, 1986, Adv Biophys, V22, P151, DOI 10.1016/0065-227X(86)90005-5; RAY S, 1993, J CELL BIOL, V121, P1083, DOI 10.1083/jcb.121.5.1083; SAKMANN B, 1983, SINGLE CHANNEL RECOR; SCHNAPP BJ, 1986, METHOD ENZYMOL, V134, P561; SCHNAPP BJ, 1989, P NATL ACAD SCI USA, V86, P1548, DOI 10.1073/pnas.86.5.1548; SCHNAPP BJ, 1990, P NATL ACAD SCI USA, V87, P10053, DOI 10.1073/pnas.87.24.10053; SIMMONS R M, 1992, Current Biology, V2, P373, DOI 10.1016/0960-9822(92)90074-K; SIMMONS RM, 1993, ADV EXP MED BIOL, V332, P331; SONG YH, 1993, P NATL ACAD SCI USA, V90, P1671, DOI 10.1073/pnas.90.5.1671; SPUDICH JA, 1990, NATURE, V348, P284, DOI 10.1038/348284a0; Squire J, 1981, STRUCTURAL BASIS MUS; TOYOSHIMA YY, 1990, P NATL ACAD SCI USA, V87, P7130, DOI 10.1073/pnas.87.18.7130; UYEDA TQP, 1991, NATURE, V352, P307, DOI 10.1038/352307a0; UYEDA TQP, 1990, J MOL BIOL, V214, P699, DOI 10.1016/0022-2836(90)90287-V; VALE RD, 1985, CELL, V40, P559, DOI 10.1016/0092-8674(85)90204-1; WANG CW, 1954, SELECTED PAPERS NOIS, P113; WEINGARTEN MD, 1974, BIOCHEMISTRY-US, V13, P5529, DOI 10.1021/bi00724a012; YANAGIDA T, 1985, NATURE, V316, P366, DOI 10.1038/316366a0; YANG JT, 1990, SCIENCE, V249, P42, DOI 10.1126/science.2142332	49	1530	1575	9	401	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 21	1993	365	6448					721	727		10.1038/365721a0	http://dx.doi.org/10.1038/365721a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MC812	8413650				2022-12-24	WOS:A1993MC81200052
J	ALLEY, MRK; MADDOCK, JR; SHAPIRO, L				ALLEY, MRK; MADDOCK, JR; SHAPIRO, L			REQUIREMENT OF THE CARBOXYL TERMINUS OF A BACTERIAL CHEMORECEPTOR FOR ITS TARGETED PROTEOLYSIS	SCIENCE			English	Article							CAULOBACTER-CRESCENTUS; ESCHERICHIA-COLI; PROTEINS; CELLS	The bacterium Caulobacter crescentus yields two different progeny at each cell division; a chemotactically competent swarmer cell and a sessile stalked cell. The chemotaxis proteins are synthesized in the predivisional cell and then partition only to the swarmer cell upon division. The chemoreceptors that were newly synthesized were located at the nascent swarmer pole of the predivisional cell, an indication that asymmetry was established prior to cell division. When the swarmer cell differentiated into a stalked cell, the chemoreceptor was specifically degraded by virtue of an amino acid sequence located at its carboxyl terminus. Thus, a temporally and spatially restricted proteolytic event was a component of this differentiation process.	STANFORD UNIV,MED CTR,SCH MED,BECKMAN CTR,DEPT DEV BIOL,STANFORD,CA 94305	Stanford University					NIGMS NIH HHS [GM32506, GM13929] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM013929, R37GM032506, R01GM032506] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEY MRK, 1991, GENETICS, V129, P333; ALLEY MRK, 1992, GENE DEV, V6, P825, DOI 10.1101/gad.6.5.825; ALLEY MRK, UNPUB; BOYD A, 1983, NATURE, V301, P623, DOI 10.1038/301623a0; EVINGER M, 1977, J BACTERIOL, V132, P294, DOI 10.1128/JB.132.1.294-301.1977; FREDERIKSE P, UNPUB; GILL R, COMMUNICATION; GOMES SL, 1984, J MOL BIOL, V178, P551, DOI 10.1016/0022-2836(84)90238-9; HAMMERTON RW, 1991, SCIENCE, V254, P847, DOI 10.1126/science.1658934; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; JOHNSON RC, 1977, GENETICS, V86, P25; KRIKOS A, 1983, CELL, V33, P615, DOI 10.1016/0092-8674(83)90442-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MADDOCK J, UNPUB; MADDOCK JR, 1993, SCIENCE, V259, P1717; PARKINSON JS, COMMUNICATION; REUTER SH, 1987, J MOL BIOL, V194, P653, DOI 10.1016/0022-2836(87)90242-7; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WOLLNER DA, 1992, J CELL BIOL, V116, P889, DOI 10.1083/jcb.116.4.889	20	107	108	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 19	1993	259	5102					1754	1757		10.1126/science.8456303	http://dx.doi.org/10.1126/science.8456303			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KT810	8456303				2022-12-24	WOS:A1993KT81000037
J	ULMER, JB; DONNELLY, JJ; PARKER, SE; RHODES, GH; FELGNER, PL; DWARKI, VJ; GROMKOWSKI, SH; DECK, RR; DEWITT, CM; FRIEDMAN, A; HAWE, LA; LEANDER, KR; MARTINEZ, D; PERRY, HC; SHIVER, JW; MONTGOMERY, DL; LIU, MA				ULMER, JB; DONNELLY, JJ; PARKER, SE; RHODES, GH; FELGNER, PL; DWARKI, VJ; GROMKOWSKI, SH; DECK, RR; DEWITT, CM; FRIEDMAN, A; HAWE, LA; LEANDER, KR; MARTINEZ, D; PERRY, HC; SHIVER, JW; MONTGOMERY, DL; LIU, MA			HETEROLOGOUS PROTECTION AGAINST INFLUENZA BY INJECTION OF DNA ENCODING A VIRAL PROTEIN	SCIENCE			English	Article							TOXIC LYMPHOCYTES-T; A VIRUS NUCLEOPROTEIN; ANTIGEN PRESENTATION; SYNTHETIC PEPTIDES; MAMMALIAN-CELLS; TARGET-CELLS; INVIVO; EXPRESSION; GENE; VACCINIA	Cytotoxic T lymphocytes (CTLs) specific for conserved viral antigens can respond to different strains of virus, in contrast to antibodies, which are generally strain-specific. The generation of such CTLs in vivo usually requires endogenous expression of the antigen, as occurs in the case of virus infection. To generate a viral antigen for presentation to the immune system without the limitations of direct peptide delivery or viral vectors, plasmid DNA encoding influenza A nucleoprotein was injected into the quadriceps of BALB/c mice. This resulted in the generation of nucleoprotein-specific CTLs and protection from a subsequent challenge with a heterologous strain of influenza A virus, as measured by decreased viral lung titers, inhibition of mass loss, and increased survival.	MERCK RES LABS, DEPT CANC RES, West Point, PA 19486 USA; VICAL, SAN DIEGO, CA 92121 USA	Merck & Company								ACSADI G, 1991, NATURE, V352, P815, DOI 10.1038/352815a0; ALDOVINI A, 1991, NATURE, V351, P479, DOI 10.1038/351479a0; BASTIN J, 1987, J EXP MED, V165, P1508, DOI 10.1084/jem.165.6.1508; BENNINK JR, 1984, NATURE, V311, P578, DOI 10.1038/311578a0; BENNINK JR, 1990, CURR TOP MICROBIOL, V163, P153; CARBONE FR, 1989, J EXP MED, V169, P603, DOI 10.1084/jem.169.3.603; CHAPMAN BS, 1991, NUCLEIC ACIDS RES, V19, P3979, DOI 10.1093/nar/19.14.3979; COLLINS DS, 1992, J IMMUNOL, V148, P3336; COONEY EL, 1991, LANCET, V337, P567, DOI 10.1016/0140-6736(91)91636-9; DERES K, 1989, NATURE, V342, P561, DOI 10.1038/342561a0; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DONNELLY JJ, 1990, J IMMUNOL, V145, P3071; DONNELLY JJ, UNPUB; GAMMELIN M, 1989, VIROLOGY, V170, P71, DOI 10.1016/0042-6822(89)90353-X; GARDNER I, 1974, EUR J IMMUNOL, V4, P68, DOI 10.1002/eji.1830040203; GERMAIN RN, 1991, NATURE, V353, P605, DOI 10.1038/353605a0; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GORMAN OT, 1991, J VIROL, V65, P3704, DOI 10.1128/JVI.65.7.3704-3714.1991; GRAY D, 1991, J EXP MED, V174, P969, DOI 10.1084/jem.174.5.969; HAHN CS, 1992, P NATL ACAD SCI USA, V89, P2679, DOI 10.1073/pnas.89.7.2679; HANSEN E, 1991, FEBS LETT, V290, P73, DOI 10.1016/0014-5793(91)81229-2; HAWE LA, UNPUB; JIAO SS, 1992, HUM GENE THER, V3, P21, DOI 10.1089/hum.1992.3.1-21; KITSIS RN, 1991, P NATL ACAD SCI USA, V88, P4138, DOI 10.1073/pnas.88.10.4138; LIN H, 1990, CIRCULATION, V82, P2217, DOI 10.1161/01.CIR.82.6.2217; LIN YL, 1981, J EXP MED, V154, P225, DOI 10.1084/jem.154.2.225; MASCOLA L, 1989, ARCH INTERN MED, V149, P1569, DOI 10.1001/archinte.149.7.1569; MBAWUIKE I, COMMUNICATION; MCMICHAEL AJ, 1986, J GEN VIROL, V67, P719, DOI 10.1099/0022-1317-67-4-719; MCMICHAEL AJ, 1983, NEW ENGL J MED, V309, P13, DOI 10.1056/NEJM198307073090103; MILLER AD, 1992, CURR TOP MICROBIOL, V158, P1; MORAN TM, 1991, J IMMUNOL, V146, P321; NEWMAN MJ, 1992, J IMMUNOL, V148, P2357; NUCHTERN JG, 1989, NATURE, V339, P223, DOI 10.1038/339223a0; OEHEN S, 1992, J EXP MED, V176, P1273, DOI 10.1084/jem.176.5.1273; PARKER SC, UNPUB; REDFIELD RR, 1987, NEW ENGL J MED, V316, P673, DOI 10.1056/NEJM198703123161106; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; Sambrook J., 1989, MOL CLONING LAB MANU; SCHAFER R, 1992, J IMMUNOL, V149, P53; SCHULMAN JL, 1963, J EXP MED, V118, P257, DOI 10.1084/jem.118.2.257; SCOTT GH, 1976, INFECT IMMUN, V13, P696, DOI 10.1128/IAI.13.3.696-703.1976; STOVER CK, 1991, NATURE, V351, P456, DOI 10.1038/351456a0; TAKAHASHI H, 1990, NATURE, V344, P873, DOI 10.1038/344873a0; TANAKA K, 1988, ANNU REV IMMUNOL, V6, P359; TANG DC, 1992, NATURE, V356, P152, DOI 10.1038/356152a0; TAYLOR PM, 1986, IMMUNOLOGY, V58, P417; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; VIEIRA P, 1990, INT IMMUNOL, V2, P487, DOI 10.1093/intimm/2.6.487; WHANG Y, 1987, J VIROL, V61, P1796, DOI 10.1128/JVI.61.6.1796-1807.1987; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; Wolff Jon A., 1992, Human Molecular Genetics, V1, P363, DOI 10.1093/hmg/1.6.363; YAP KL, 1978, NATURE, V273, P238, DOI 10.1038/273238a0; YETTER RA, 1980, INFECT IMMUN, V29, P654; YEWDELL JW, 1985, P NATL ACAD SCI USA, V82, P1785, DOI 10.1073/pnas.82.6.1785; YEWDELL JW, 1989, SCIENCE, V244, P1072, DOI 10.1126/science.2471266; YOUNG JF, 1983, ORIGIN PANDEMIC INFL, P129; ZINKERNAGEL RM, 1975, J EXP MED, V141, P1427, DOI 10.1084/jem.141.6.1427	60	2020	2475	1	174	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 19	1993	259	5102					1745	1749		10.1126/science.8456302	http://dx.doi.org/10.1126/science.8456302			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KT810	8456302				2022-12-24	WOS:A1993KT81000035
J	BOURS, V; FRANZOSO, G; AZARENKO, V; PARK, S; KANNO, T; BROWN, K; SIEBENLIST, U				BOURS, V; FRANZOSO, G; AZARENKO, V; PARK, S; KANNO, T; BROWN, K; SIEBENLIST, U			THE ONCOPROTEIN BCL-3 DIRECTLY TRANSACTIVATES THROUGH KAPPA-B MOTIFS VIA ASSOCIATION WITH DNA-BINDING P50B HOMODIMERS	CELL			English	Article							V-REL ONCOGENE; RECEPTOR-ALPHA GENE; CELL-CYCLE CONTROL; RETICULOENDOTHELIOSIS VIRUS; TRANSCRIPTION FACTOR; PROTO-ONCOGENE; C-REL; P65 SUBUNIT; CHLORAMPHENICOL ACETYLTRANSFERASE; 65-KD SUBUNIT	Bcl-3 is an IkappaB-related protein with ankyrin repeat motifs. Its gene is located at a site of recurrent translocations in a subset of B cell chronic lymphocytic leukemias. Bcl-3 associates tightly with p50B (NFKB2, p52) homodimers in cells, and together these proteins form a ternary complex with DNA at kappaB sites. Such an association functionally leads to a novel and potent form of transactivation through the kappaB motif: the tethering of Bcl-3 to DNA via the p50B homodimers allows Bcl-3 to transactivate directly, while p50B homodimers alone cannot. Transactivation mediated by Bcl-3 requires two cooperating domains located amino- and carboxy-terminal to the ankyrin domain. Bcl-3 is localized to the nucleus, and a Bcl-3-p50B complex is detected in certain lymphoid cells. Our data reveal a novel role for Bcl-3, distinct from that of the inhibitor IkappaB. The results have implications for tumorigenesis.	NIAID,IMMUNOREGULAT LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			Franzoso, Guido/GRR-8628-2022	Franzoso, Guido/0000-0002-0778-988X				BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BALLARD DW, 1992, P NATL ACAD SCI USA, V89, P1875, DOI 10.1073/pnas.89.5.1875; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BHATIA K, 1991, ONCOGENE, V6, P1569; BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; BOHNLEIN E, 1988, CELL, V53, P827, DOI 10.1016/0092-8674(88)90099-2; BOHNLEIN E, 1989, J BIOL CHEM, V264, P8475; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BRESSLER P, 1993, J VIROL, V67, P288, DOI 10.1128/JVI.67.1.288-293.1993; BROWNELL E, 1989, ONCOGENE, V4, P935; COHEN L, 1992, J CELL PHYSIOL, V152, P10, DOI 10.1002/jcp.1041520103; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DAVIS N, 1990, J VIROL, V64, P584, DOI 10.1128/JVI.64.2.584-591.1990; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GEISLER R, 1992, CELL, V71, P613, DOI 10.1016/0092-8674(92)90595-4; GELINAS C, 1988, ONCOGENE, V3, P349; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMORE TD, 1991, TRENDS GENET, V7, P318, DOI 10.1016/0168-9525(91)90200-A; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GRILLI M, 1993, INT REV CYTOL, V148, P1; HANNINK M, 1989, MOL CELL BIOL, V9, P4323, DOI 10.1128/MCB.9.10.4323; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; HISSE C, 1991, CELL, V65, P1191; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; INOUE JI, 1992, P NATL ACAD SCI USA, V89, P4333, DOI 10.1073/pnas.89.10.4333; ISRAEL DI, 1989, NUCLEIC ACIDS RES, V17, P4589, DOI 10.1093/nar/17.12.4589; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KANG SM, 1992, SCIENCE, V256, P1452, DOI 10.1126/science.1604322; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; KERR LD, 1992, GENE DEV, V6, P2352, DOI 10.1101/gad.6.12a.2352; KIDD S, 1992, CELL, V71, P623, DOI 10.1016/0092-8674(92)90596-5; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KRETZSCHMAR M, 1992, GENE DEV, V6, P761, DOI 10.1101/gad.6.5.761; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; LIOU HC, 1992, EMBO J, V11, P3003, DOI 10.1002/j.1460-2075.1992.tb05370.x; LOGEAT F, 1991, EMBO J, V10, P1827, DOI 10.1002/j.1460-2075.1991.tb07708.x; LU D, 1991, ONCOGENE, V6, P1235; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MERCURIO F, 1992, DNA CELL BIOL, V11, P523, DOI 10.1089/dna.1992.11.523; MEYER R, 1991, P NATL ACAD SCI USA, V88, P966, DOI 10.1073/pnas.88.3.966; MOORE BE, 1988, VIROLOGY, V162, P377, DOI 10.1016/0042-6822(88)90478-3; MOORE BE, 1988, MUTAT RES, V195, P79, DOI 10.1016/0165-1110(88)90016-4; MORIN PJ, 1992, NUCLEIC ACIDS RES, V20, P2453, DOI 10.1093/nar/20.10.2453; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NARAYANAN R, 1992, SCIENCE, V256, P367, DOI 10.1126/science.256.5055.367; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RIVIERE Y, 1991, NATURE, V350, P625, DOI 10.1038/350625a0; RUBEN SM, 1992, GENE DEV, V6, P745, DOI 10.1101/gad.6.5.745; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHIMIZU H, 1990, MOL CELL BIOL, V10, P561, DOI 10.1128/MCB.10.2.561; STEPHENS RM, 1983, P NATL ACAD SCI-BIOL, V80, P6229, DOI 10.1073/pnas.80.20.6229; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; SYLLA BS, 1986, MOL CELL BIOL, V6, P4709, DOI 10.1128/MCB.6.12.4709; TEWARI M, 1992, MOL CELL BIOL, V12, P2898, DOI 10.1128/MCB.12.6.2898; URBAN MB, 1990, GENE DEV, V4, P1975, DOI 10.1101/gad.4.11.1975; URBAN MB, 1991, EMBO J, V10, P1817, DOI 10.1002/j.1460-2075.1991.tb07707.x; VANKRIEKEN JHJM, 1990, LEUKEMIA, V4, P811; WALKER WH, 1992, J VIROL, V66, P5018, DOI 10.1128/JVI.66.8.5018-5029.1992; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984; WULCZYN FG, 1992, NATURE, V358, P597, DOI 10.1038/358597a0; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x	79	400	419	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 12	1993	72	5					729	739		10.1016/0092-8674(93)90401-B	http://dx.doi.org/10.1016/0092-8674(93)90401-B			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KR436	8453667	Bronze			2022-12-24	WOS:A1993KR43600009
J	CASANOVA, J; STRUHL, G				CASANOVA, J; STRUHL, G			THE TORSO RECEPTOR LOCALIZES AS WELL AS TRANSDUCES THE SPATIAL SIGNAL SPECIFYING TERMINAL BODY PATTERN IN DROSOPHILA	NATURE			English	Article							TYROSINE KINASE; VULVAR INDUCTION; GENE TORSO; EMBRYO; EXPRESSION; MUTATIONS; ELEMENTS; ANLAGEN; ENCODES; LET-23	SPECIFICATION of the end portions of the Drosophila body depends on the torso (tor) protein, a receptor tyrosine kinase that accumulates uniformly along the entire surface of the embryo but is activated only in the vicinity of the poles1-6. Several genes are normally required for activating tor and appear to define a system in which a gene product tethered to the extracellular vitelline membrane at each end of the egg provides a local source for an extracellular tor ligand2,5-7. This ligand would have to diffuse from the membrane to the cell surface of the embryo without losing its spatial localization. Here we report that the failure to accumulate tor protein at one or both poles leads to spatially inappropriate activity of more centrally located receptor. This ectopic activity depends on the same gene functions normally required for activating tor; thus we infer that it reflects inappropriate diffusion of the ligand to more central regions of the body. We conclude that the receptor not only transduces the spatial signal imparted by the tor ligand, but also ensures its correct localization by sequestering the ligand. Ligand trapping by receptor, may also localize spatial signals in other patterning systems, including specification of the dorsal-ventral axis in Drosophila and of vulval cell fates in Caenorhabditis elegans.	CSIC,CTR INVESTIGACIO & DESENVOLUPAMENT,E-08034 BARCELONA,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC)	CASANOVA, J (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,HOWARD HUGHES MED INST,701 W 168TH ST,NEW YORK,NY 10032, USA.		Casanova, Jordi/L-5181-2014	Casanova, Jordi/0000-0001-6121-8589				AROIAN RV, 1991, GENETICS, V128, P251; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; CASANOVA J, 1989, GENE DEV, V3, P2025, DOI 10.1101/gad.3.12b.2025; CASANOVA J, 1991, MECH DEVELOP, V36, P41, DOI 10.1016/0925-4773(91)90070-M; HILL RJ, 1992, NATURE, V358, P470, DOI 10.1038/358470a0; HOCH M, 1990, EMBO J, V9, P2587, DOI 10.1002/j.1460-2075.1990.tb07440.x; KLINGLER M, 1988, NATURE, V335, P275, DOI 10.1038/335275a0; RAY RP, 1991, DEVELOPMENT, V113, P35; SCHUEPBACH T, 1986, Wilhelm Roux's Archives of Developmental Biology, V195, P302; SCHUPBACH T, 1989, GENETICS, V121, P101; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; STEIN D, 1991, CELL, V65, P725, DOI 10.1016/0092-8674(91)90381-8; STEVENS LM, 1990, NATURE, V346, P660, DOI 10.1038/346660a0; STRECKER TR, 1989, SCIENCE, V243, P1062, DOI 10.1126/science.2922596; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; WEIGEL D, 1990, SCIENCE, V248, P495, DOI 10.1126/science.2158673; WHARTON RP, 1991, CELL, V67, P955, DOI 10.1016/0092-8674(91)90368-9	17	81	82	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 11	1993	362	6416					152	155		10.1038/362152a0	http://dx.doi.org/10.1038/362152a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KR028	8450886				2022-12-24	WOS:A1993KR02800058
J	SMITH, WC; KNECHT, AK; WU, M; HARLAND, RM				SMITH, WC; KNECHT, AK; WU, M; HARLAND, RM			SECRETED NOGGIN PROTEIN MIMICS THE SPEMANN ORGANIZER IN DORSALIZING XENOPUS MESODERM	NATURE			English	Article							MESSENGER-RNA; INSITU HYBRIDIZATION; LAEVIS EMBRYOS; LOCALIZATION; EXPRESSION; AXIS	A DORSALIZING signal acts during gastrulation to change the specification of lateral mesodermal tissues from ventral (blood, mesenchyme) to more dorsal fates (muscle, heart, pronephros)1-3. This signal, from Spemann's organizer, cannot be mimicked by the mesoderm inducers activin and fibroblast growth factor2. The gene noggin is expressed in the organizer 4, and could be the dorsalizing signal. Here we show that soluble noggin protein added to ventral marginal zones during gastrulation induces muscle, but that activin does not. Dorsal pattern can be partially rescued in ventralized embryos by injection of a plasmid that expresses noggin during gastrulation. The results suggest that the noggin product may be the dorsalizing signal from the organizer.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,DIV BIOCHEM & MOLEC BIOL,401 BARKER HALL,BERKELEY,CA 94720	University of California System; University of California Berkeley								AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; BOLCE ME, 1992, DEVELOPMENT, V115, P681; CHRISTIAN JL, IN PRESS GENES DEV; CONDIE BG, 1987, DEVELOPMENT, V101, P93; DALE L, 1987, DEVELOPMENT, V100, P279; DWORKINRASTL E, 1986, J EMBRYOL EXP MORPH, V91, P153; HARLAND R, 1988, DEVELOPMENT, V102, P837; HEMMATIBRIVANLOU A, 1990, DEVELOPMENT, V110, P325; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; LETTICE LA, 1993, DEVELOPMENT, V117, P263; MOHUN TJ, 1984, NATURE, V311, P716, DOI 10.1038/311716a0; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; PENG HB, 1991, METHOD CELL BIOL, V36, P661; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; STEWART RM, 1990, DEVELOPMENT, V109, P363; VIZE PD, 1991, METHOD CELL BIOL, V36, P361	20	326	336	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 11	1993	361	6412					547	549		10.1038/361547a0	http://dx.doi.org/10.1038/361547a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL714	8429909				2022-12-24	WOS:A1993KL71400064
J	ENQUIST, M; ARAK, A				ENQUIST, M; ARAK, A			SELECTION OF EXAGGERATED MALE TRAITS BY FEMALE AESTHETIC SENSES	NATURE			English	Article							SEXUAL SELECTION; PREFERENCES; EVOLUTION	DARWIN1 suggested that many apparently deleterious secondary sexual characters in males, such as bright colours, elaborate ornaments and conspicuous displays, evolved as a result of female choice. Darwin never tried to explain the crucial agent of selection, that females have preferences for exaggerated male traits. Rather, he took it for granted that females of many species possess a 'sense of the beautiful', akin to the aesthetic sense in humans. The question of why such preferences evolve remains a controversial issue2,3 . Here we report that mechanisms concerned with signal recognition possess inevitable biases in response that act as important agents of selection on signal form. The existence of such biases may be sufficient to explain the evolution of exaggerated male secondary sexual traits, and elaborate signals in general.			ENQUIST, M (corresponding author), UNIV STOCKHOLM,DEPT ZOOL,S-10691 STOCKHOLM,SWEDEN.							BASOLO AL, 1990, SCIENCE, V250, P808, DOI 10.1126/science.250.4982.808; BASOLO AL, 1991, SCIENCE, V253, P1426, DOI 10.1126/science.253.5026.1426-b; Caudill M, 1990, NATURALLY INTELLIGEN; Darwin C., 1871, P423; EBERHART RC, 1990, NEURAL NETWORK PC TO; HUXLEY J, 1966, PHILOS T ROY SOC B, V251, P249, DOI 10.1098/rstb.1966.0010; KIRKPATRICK M, 1991, NATURE, V350, P33, DOI 10.1038/350033a0; LANDE R, 1981, P NATL ACAD SCI-BIOL, V78, P3721, DOI 10.1073/pnas.78.6.3721; RYAN MJ, 1990, NATURE, V343, P66, DOI 10.1038/343066a0; RYAN MJ, 1991, OXFORD SURVEYS EVOLU, V7, P156; SMITH JM, 1991, TRENDS ECOL EVOL, V6, P146, DOI 10.1016/0169-5347(91)90055-3; Spence KW, 1937, PSYCHOL REV, V44, P430, DOI 10.1037/h0062885; Tinbergen N., 1948, Wilson Bulletin, V60, P6	13	148	151	0	49	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 4	1993	361	6411					446	448		10.1038/361446a0	http://dx.doi.org/10.1038/361446a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	Science & Technology - Other Topics	KK713	8429883				2022-12-24	WOS:A1993KK71300059
J	JANDA, KD; SHEVLIN, CG; LERNER, RA				JANDA, KD; SHEVLIN, CG; LERNER, RA			ANTIBODY CATALYSIS OF A DISFAVORED CHEMICAL TRANSFORMATION	SCIENCE			English	Article							POLYETHER ANTIBIOTICS; STEREOCONTROLLED SYNTHESIS; TETRAHYDROPYRAN SYSTEMS; EPOXIDE OPENINGS; CONSTRUCTION; CYCLIZATION; STRATEGY; MONENSIN; SPECIFICITY; ACTIVATION	Organic reactions are often limited by stereoelectronic constrains that appear along the reaction coordinate. An antibody has been generated that overcomes these constraints and catalyzes a highly disfavored chemical transformation. The antibody facilitates the difficult 6-endo-tet ring closure of an epoxy-alcohol to form a tetrahydropyran. The catalyzed process is in formal violation of what has become known as Baldwin's rules for ring-closure reactions. In addition to controlling the regiochemistry of the disfavored cyclization reaction, these catalytic antibodies resolve enantiomeric substrates to afford a stereochemically pure product. The principles demonstrated in this study may be applicable to other disfavored chemical processes.	SCRIPPS RES INST, DEPT CHEM, LA JOLLA, CA 92037 USA	Scripps Research Institute	JANDA, KD (corresponding author), SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA.							ASHLEY JA, IN PRESS J ORG CHEM; BALDWIN JE, 1976, J CHEM SOC CHEM COMM, P734, DOI 10.1039/c39760000734; BALDWIN JE, 1982, TETRAHEDRON, V19, P2929; BALDWIN JE, 1977, J CHEM SOC CHEM COMM, P253; BARTLETT PA, 1986, J ORG CHEM, V51, P2230, DOI 10.1021/jo00362a014; BEAK P, 1992, ACCOUNTS CHEM RES, V25, P215, DOI 10.1021/ar00017a002; BOIVIN TLB, 1987, TETRAHEDRON, V43, P3309, DOI 10.1016/S0040-4020(01)81626-4; CRUICKSHANK PA, 1969, J ORG CHEM, V34, P4060, DOI 10.1021/jo01264a066; DANISHEFSKY S, 1974, J AM CHEM SOC, V96, P1256, DOI 10.1021/ja00811a068; DANISHEFSKY SJ, 1987, J AM CHEM SOC, V109, P1572, DOI 10.1021/ja00239a049; DOLLE RE, 1985, J AM CHEM SOC, V107, P1691, DOI 10.1021/ja00292a038; Engvall E, 1980, Methods Enzymol, V70, P419; FUKUYAMA T, 1979, J AM CHEM SOC, V101, P260, DOI 10.1021/ja00495a065; FUKUYAMA T, 1979, J AM CHEM SOC, V101, P262, DOI 10.1021/ja00495a066; HOGG DR, 1970, J CHEM SOC C, P2142, DOI 10.1039/j39700002142; HOYE TR, 1985, J AM CHEM SOC, V107, P5312, DOI 10.1021/ja00304a068; HOYE TR, 1987, J AM CHEM SOC, V109, P6196, DOI 10.1021/ja00254a056; JANDA KD, 1991, J AM CHEM SOC, V113, P5427, DOI 10.1021/ja00014a039; JANDA KD, 1990, J AM CHEM SOC, V112, P1274, DOI 10.1021/ja00159a074; JANDA KD, 1991, TETRAHEDRON, V47, P2503, DOI 10.1016/S0040-4020(01)81784-1; JANDA KD, 1988, SCIENCE, V241, P1188, DOI 10.1126/science.3413482; JANDA KD, 1990, BIOTECHNOL PROGR, V6, P178, DOI 10.1021/bp00003a002; JANDA KD, 1987, 198TH NAT M AM CHEM; KLUMPP GW, 1982, REACTIVITY ORGANIC C; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KOLB HC, IN PRESS TETRAHEDRON; KOZIKOWSKI AP, 1985, J ORG CHEM, V50, P3017, DOI 10.1021/jo00216a049; LEWIS C, 1991, SCIENCE, V253, P1019, DOI 10.1126/science.1887215; MARCH J, 1985, ADV ORG CHEM, P187; MOORE JW, 1981, KINETICS MECHANISM; NAKATA T, 1978, J AM CHEM SOC, V100, P2933, DOI 10.1021/ja00477a081; NICOLAOU KC, 1985, J CHEM SOC CHEM COMM, P1359, DOI 10.1039/c39850001359; NICOLAOU KC, 1989, J AM CHEM SOC, V111, P5330, DOI 10.1021/ja00196a043; NICOLAOU KC, 1989, J AM CHEM SOC, V111, P5355; OVERMAN LE, 1986, J AM CHEM SOC, V108, P3516, DOI 10.1021/ja00272a062; PAQUETTE LA, 1981, TETRAHEDRON LETT, V22, P291, DOI 10.1016/0040-4039(81)80078-0; PATERSON I, 1987, TETRAHEDRON LETT, V28, P5205, DOI 10.1016/S0040-4039(00)95630-2; POLLACK SJ, 1989, J AM CHEM SOC, V111, P5961, DOI 10.1021/ja00197a078; PRESSMAN D, 1953, J AM CHEM SOC, V75, P686, DOI 10.1021/ja01099a052; PRESSMAN D, 1946, J AM CHEM SOC, V68, P250, DOI 10.1021/ja01206a031; RAO AS, 1983, TETRAHEDRON, V39, P2323, DOI 10.1016/S0040-4020(01)91961-1; RUSSELL ST, 1986, J CHEM SOC CHEM COMM, P351; SCHMID G, 1979, J AM CHEM SOC, V101, P259, DOI 10.1021/ja00495a064; SCHREIBER SL, 1986, J AM CHEM SOC, V108, P2106, DOI 10.1021/ja00268a070; SCHULTZ WJ, 1980, J AM CHEM SOC, V102, P7981, DOI 10.1021/ja00547a049; SHARPLESS KB, 1992, J ORG CHEM, V57, P2768, DOI 10.1021/jo00036a003; SHOKAT KM, 1989, NATURE, V338, P269, DOI 10.1038/338269a0; STILL WC, 1986, J AM CHEM SOC, V108, P2105, DOI 10.1021/ja00268a069; STORK G, 1974, J AM CHEM SOC, V96, P5268, DOI 10.1021/ja00823a052; TAWFIK DS, 1990, BIOCHEMISTRY-US, V29, P9916, DOI 10.1021/bi00494a023; Tenud L., 1970, HELV CHIM ACTA, V53, P2059, DOI [10.1002/hlca.19700530816, DOI 10.1002/HLCA.19700530816]; TIETZE LF, 1981, TETRAHEDRON LETT, V22, P219, DOI 10.1016/0040-4039(81)80059-7; UNO T, 1992, J AM CHEM SOC, V114, P6573, DOI 10.1021/ja00042a055; WATT RM, 1980, MOL IMMUNOL, V17, P1237, DOI 10.1016/0161-5890(80)90020-6; WUTS PGM, 1984, J ORG CHEM, V49, P2582, DOI 10.1021/jo00188a014; [No title captured]	56	156	159	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 22	1993	259	5094					490	493		10.1126/science.8424171	http://dx.doi.org/10.1126/science.8424171			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC); Current Chemical Reactions (CCR-EXPANDED)	Science & Technology - Other Topics	KJ079	8424171				2022-12-24	WOS:A1993KJ07900026
J	NIGHTINGALE, SL				NIGHTINGALE, SL			PUBLIC WARNING ABOUT HERBAL PRODUCT CHAPARRAL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 20	1993	269	3					328	328						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG381	8418328				2022-12-24	WOS:A1993KG38100004
J	SUH, WC; ROSS, W; RECORD, MT				SUH, WC; ROSS, W; RECORD, MT			2 OPEN COMPLEXES AND A REQUIREMENT FOR MG2+ TO OPEN THE LAMBDA-P(R) TRANSCRIPTION START SITE	SCIENCE			English	Article							COLI RNA-POLYMERASE; LAC UV5 PROMOTER; SINGLE-STRANDED REGIONS; ESCHERICHIA-COLI; MECHANISM INVIVO; PR PROMOTER; DNA; ACTIVATION; KINETICS	Potassium permanganate (KMnO4) footprinting in the absence and presence of magnesium (Mg2+) at the lambdaP(R) promoter identified two different open complexes with Escherichia coli Esigma70 RNA polymerase (designated RP(o1) and RP(o2). The single-stranded region in RP(o1), (formed in the absence of Mg2+) was at most 12 bases long, whereas that in RP(o2) (formed in the presence of Mg2+) spanned at least 14 bases. Only in RP(o2) did the single-stranded region extend to the start point of transcription (+1, +2). These results provide a structural basis for the requirement for uptake of Mg2+ in the formation of RP(o2) from RP(o1), as deduced from kinetic studies at this promoter.	UNIV WISCONSIN,DEPT CHEM,MADISON,WI 53706; UNIV WISCONSIN,DEPT BIOCHEM,MADISON,WI 53706; UNIV WISCONSIN,DEPT BACTERIOL,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison					NIGMS NIH HHS [GM23467, GM37048] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023467, R37GM037048, R01GM037048, R37GM023467] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALATOSSAVA T, 1985, J BACTERIOL, V162, P413, DOI 10.1128/JB.162.1.413-419.1985; BOROWIEC JA, 1987, J MOL BIOL, V196, P101, DOI 10.1016/0022-2836(87)90513-4; BUC H, 1985, BIOCHEMISTRY-US, V24, P2712, DOI 10.1021/bi00332a018; BUC H, 1989, NUCLEIC ACIDS MOL BI, V1, P186; BUCKLE M, 1989, BIOCHEMISTRY-US, V28, P4388, DOI 10.1021/bi00436a040; COWING DW, 1989, J MOL BIOL, V210, P521, DOI 10.1016/0022-2836(89)90128-9; HAYATSU H, 1967, BIOCHEM BIOPH RES CO, V29, P556, DOI 10.1016/0006-291X(67)90521-9; KAINZ M, 1992, SCIENCE, V255, P838, DOI 10.1126/science.1536008; KIRKEGAARD K, 1983, P NATL ACAD SCI-BIOL, V80, P2544, DOI 10.1073/pnas.80.9.2544; KLADDE MP, IN PRESS J MOL BIOL; KOREN R, 1977, BIOCHEMISTRY-US, V16, P241, DOI 10.1021/bi00621a013; LEIRMO S, 1990, NUCLEIC ACIDS MOL BI, V4, P123; LUSK JE, 1968, J BIOL CHEM, V243, P2618; NEWLANDS JT, 1991, J MOL BIOL, V220, P569, DOI 10.1016/0022-2836(91)90101-B; OHALLORAN TV, 1989, CELL, V56, P119, DOI 10.1016/0092-8674(89)90990-2; RECORD MT, 1991, METHOD ENZYMOL, V208, P291; ROE JH, 1985, BIOCHEMISTRY-US, V24, P4721, DOI 10.1021/bi00339a002; ROE JH, 1984, J MOL BIOL, V176, P495, DOI 10.1016/0022-2836(84)90174-8; ROE JH, 1985, J MOL BIOL, V184, P444; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASSEDWIGHT S, 1989, J BIOL CHEM, V264, P8074; SASSEDWIGHT S, 1988, P NATL ACAD SCI USA, V85, P8934, DOI 10.1073/pnas.85.23.8934; SCHICKOR P, 1990, EMBO J, V9, P2215, DOI 10.1002/j.1460-2075.1990.tb07391.x; SIEBENLIST U, 1979, NATURE, V279, P651, DOI 10.1038/279651a0; SIEBENLIST U, 1980, CELL, V20, P269, DOI 10.1016/0092-8674(80)90613-3; SPASSKY A, 1985, BIOCHEMISTRY-US, V24, P2723, DOI 10.1021/bi00332a019; SUH WC, 1992, BIOCHEMISTRY-US, V31, P7815, DOI 10.1021/bi00149a011; WANG WD, 1992, SCIENCE, V255, P450, DOI 10.1126/science.1310361; WU CW, 1969, BIOCHEMISTRY-US, V8, P4458, DOI 10.1021/bi00839a035; ZWIEB C, IN PRESS MOL BIOL	30	95	96	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 15	1993	259	5093					358	361		10.1126/science.8420002	http://dx.doi.org/10.1126/science.8420002			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KG624	8420002				2022-12-24	WOS:A1993KG62400031
J	CHALFIN, DB; HOLBEIN, MEB; FEIN, AM; CARLON, GC				CHALFIN, DB; HOLBEIN, MEB; FEIN, AM; CARLON, GC			COST-EFFECTIVENESS OF MONOCLONAL-ANTIBODIES TO GRAM-NEGATIVE ENDOTOXIN IN THE TREATMENT OF GRAM-NEGATIVE SEPSIS IN ICU PATIENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DIAGNOSIS-RELATED GROUPS; CRITICALLY ILL PATIENTS; INTENSIVE-CARE; PROSPECTIVE PAYMENT; BACTEREMIA; CHARGES; IMPACT; HEALTH; SHOCK; TRIAL	Objective-To evaluate the fiscal impact and the cost-effectiveness of monoclonal antibodies against gram-negative endotoxin (MAbGNE) in the treatment of presumed gram-negative sepsis. Design.-A decision analysis model was developed from (1) data from two phase ill trials that studied the E5 or HA-1A MAbGNE, and (2) financial data from 1405 septic patients who required intensive care at a large tertiary hospital. Setting.-Intensive care unit (ICU) patients with presumed gram-negative sepsis. Patients.-The E5 trial evaluated 468 patients, and the HA-1A study enrolled 543 patients with presumed gram-negative sepsis. Interventions.-The addition of MAbGNE to standard regimens or standard regimens alone. Main Outcome Measures.-Total expected charges and the expected probability of survival were determined for each option. Cost-effectiveness and marginal cost-effectiveness ratios were also derived. Multiple sensitivity and Monte Carlo analyses were performed to test the underlying assumptions. Results.-MAbGNE therapy always resulted in higher expected charges; however, these differences were less than its acquisition cost by $870. The cost-effectiveness ratio for MAbGNE, for $2000 and $4000 acquisition costs, was $71 674 and $74 900 per probability of survival, respectively. Sensitivity analysis showed that cost-effectiveness was most affected by diagnostic accuracy, patient selection, and acquisition cost. Monte Carlo analysis showed that MAbGNE was more costly for 71 % of simulations, yet the most efficacious option for 79% of simulations. Conclusions.-From the perspective of acute care institutions, MAbGNE is expensive and cannot be justified on a cost-saving basis. However, it may be cost-effective throughout a reasonable range of assumptions.	WINTHROP UNIV HOSP,PULM RES INST,MINEOLA,NY; PRESBYTERIAN MED CTR,DEPT INTERNAL MED,DALLAS,TX; SUNY STONY BROOK,HLTH SCI CTR,SURG INTENS CARE UNIT,STONY BROOK,NY 11794; SUNY STONY BROOK,HLTH SCI CTR,DIV PULM & CRIT CARE MED,STONY BROOK,NY 11794; CORNELL UNIV,MED CTR,COLL MED,CRIT CARE MED SERV,NEW YORK,NY 10021; CORNELL UNIV,MED CTR,COLL MED,DEPT ANESTHESIOL,NEW YORK,NY 10021	Winthrop University Hospital; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Cornell University; Cornell University	CHALFIN, DB (corresponding author), WINTHROP UNIV HOSP,DIV PULM & CRIT CARE MED,222 STN PLAZA N,SUITE 400,MINEOLA,NY 11501, USA.							AHMAD M, 1988, CHEST, V93, P176, DOI 10.1378/chest.93.1.176; BECK JR, 1982, AM J MED, V73, P883, DOI 10.1016/0002-9343(82)90786-0; BECK JR, 1983, MED DECIS MAKING, V3, P419, DOI 10.1177/0272989X8300300403; BEKES C, 1988, CRIT CARE MED, V16, P478, DOI 10.1097/00003246-198805000-00003; BOGARD WC, 1987, INFECT IMMUN, V55, P899, DOI 10.1128/IAI.55.4.899-908.1987; BONE RC, 1989, CRIT CARE MED, V17, P389, DOI 10.1097/00003246-198905000-00002; BONE RC, 1991, ARCH INTERN MED, V151, P1061, DOI 10.1001/archinte.151.6.1061; BUTLER PW, 1985, CHEST, V87, P228; CERRA FB, 1990, HOSP PRACT, V25, P169; CHALFIN DB, 1989, CRIT CARE MED S, V17, pS86; CULLEN DJ, 1976, NEW ENGL J MED, V294, P982, DOI 10.1056/NEJM197604292941805; CULLEN DJ, 1977, ANESTHESIOLOGY, V47, P203, DOI 10.1097/00000542-197708000-00011; CUNNION RE, 1992, CRIT CARE MED, V20, P721, DOI 10.1097/00003246-199206000-00001; DEGROOT MH, 1986, PROBABILITY STATISTI; Doubilet P, 1985, Med Decis Making, V5, P157, DOI 10.1177/0272989X8500500205; ENGLEBERG NC, 1984, NEW ENGL J MED, V311, P892, DOI 10.1056/NEJM198410043111406; FINEBERG HV, 1984, NEW ENGL J MED, V310, P1301, DOI 10.1056/NEJM198405173102006; FINKLER SA, 1982, ANN INTERN MED, V96, P102, DOI 10.7326/0003-4819-96-1-102; GOETZLER RM, 1991, ARCH INTERN MED, V151, P1537, DOI 10.1001/archinte.151.8.1537; GREENMAN RL, 1991, JAMA-J AM MED ASSOC, V266, P1097, DOI 10.1001/jama.266.8.1097; HARKONEN S, 1988, ANTIMICROB AGENTS CH, V32, P710, DOI 10.1128/AAC.32.5.710; HOLLENBERG J, 1985, SMLTREE ALL PURPOSE; JACOBS P, 1990, CRIT CARE MED, V18, P1282, DOI 10.1097/00003246-199011000-00020; KASSIRER JP, 1987, ANN INTERN MED, V106, P275, DOI 10.7326/0003-4819-106-2-275; LAFFEL GL, 1987, J AM COLL CARDIOL, V10, pB79, DOI 10.1016/S0735-1097(87)80432-1; MARTY AT, 1977, ANN THORAC SURG, V24, P409, DOI 10.1016/S0003-4975(10)63433-9; OYE RK, 1991, CHEST, V99, P6875; PARILLO J E, 1990, Annals of Internal Medicine, V113, P227; SCHULMAN KA, 1991, JAMA-J AM MED ASSOC, V266, P3466, DOI 10.1001/jama.266.24.3466; SCHWARTZ WB, 1991, NEW ENGL J MED, V324, P1037, DOI 10.1056/NEJM199104113241506; Shepherd M F, 1992, Clin Pharm, V11, P257; SLOAN FA, 1988, MED CARE, V26, P837, DOI 10.1097/00005650-198809000-00004; SOX HC, 1988, MED DECIS MAKING, P27; SPIVACK D, 1987, AM REV RESPIR DIS, V136, P1007, DOI 10.1164/ajrccm/136.4.1007; WARREN HS, 1992, NEW ENGL J MED, V326, P1153, DOI 10.1056/NEJM199204233261711; WEINSTEIN MC, 1977, NEW ENGL J MED, V296, P716, DOI 10.1056/NEJM197703312961304; WEINSTEIN MC, 1980, CLIN DECISION ANAL, P12; WENZEL RP, 1992, NEW ENGL J MED, V326, P1151, DOI 10.1056/NEJM199204233261710; WILKINSON L, 1989, SYSTAT SYSTEM STATIS; WILLARD KE, 1986, MED DECIS MAKING, V6, P85; ZIEGLER EJ, 1982, NEW ENGL J MED, V307, P1225, DOI 10.1056/NEJM198211113072001; ZIEGLER EJ, 1991, NEW ENGL J MED, V324, P429, DOI 10.1056/NEJM199102143240701; 1990, MMWR, V39, P31	43	58	59	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 13	1993	269	2					249	254		10.1001/jama.269.2.249	http://dx.doi.org/10.1001/jama.269.2.249			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF405	8417245				2022-12-24	WOS:A1993KF40500033
J	JANSSEN, HLA; BROUWER, JT; NEVENS, F; SANCHEZTAPIAS, JM; CRAXI, A; HADZIYANNIS, S				JANSSEN, HLA; BROUWER, JT; NEVENS, F; SANCHEZTAPIAS, JM; CRAXI, A; HADZIYANNIS, S			FATAL HEPATIC DECOMPENSATION ASSOCIATED WITH INTERFERON ALFA	BRITISH MEDICAL JOURNAL			English	Article							CONTROLLED TRIAL		UNIV HOSP LEUVEN,DEPT HEPATOGASTROENTEROL,LOUVAIN,BELGIUM; HOSP CLIN I PROVENCIAL,LIVEN UNIT,BARCELONA,SPAIN; UNIV PADUA,DIV MED INTERNA,I-35100 PADUA,ITALY; HIPPOKRAT GEN HOSP,ACAD DEPT MED,ATHENS,GREECE	KU Leuven; University Hospital Leuven; University of Padua	JANSSEN, HLA (corresponding author), UNIV HOSP DIJKZIGT,DEPT INTERNAL MED 2,3015 GD ROTTERDAM,NETHERLANDS.							DAVIS GL, 1989, NEW ENGL J MED, V321, P1501, DOI 10.1056/NEJM198911303212203; DURAND JM, 1991, LANCET, V338, P1268; KASSIANIDES C, 1988, VIRAL HEPATITIS LIVE, P840; PERRILLO RP, 1990, NEW ENGL J MED, V323, P295, DOI 10.1056/NEJM199008023230503; SHEEN IS, 1985, GASTROENTEROLOGY, V89, P732, DOI 10.1016/0016-5085(85)90566-9	5	51	52	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 9	1993	306	6870					107	108		10.1136/bmj.306.6870.107	http://dx.doi.org/10.1136/bmj.306.6870.107			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG465	8435602	Bronze, Green Published			2022-12-24	WOS:A1993KG46500020
J	ANDERSON, SJ; LEVIN, SD; PERLMUTTER, RM				ANDERSON, SJ; LEVIN, SD; PERLMUTTER, RM			PROTEIN-TYROSINE KINASE P56(LCK) CONTROLS ALLELIC EXCLUSION OF T-CELL RECEPTOR BETA-CHAIN GENES	NATURE			English	Article							ANTIGEN RECEPTOR; LYMPHOCYTES-T; THYMOCYTE DEVELOPMENT; SIGNAL TRANSDUCTION; TRANSGENIC MICE; EXPRESSION; P56LCK; ALPHA; LAMBDA-5; SURFACE	DURING T-cell development, site-specific DNA rearrangements mediating assembly of beta- and alpha-chain genes of the T-cell receptor (TCR) are developmentally ordered1,2. In particular, assembly and expression of a complete beta-chain gene blocks further rearrangements at the beta-locus (a process referred to as allelic exclusion)3 and drives the generation and expansion of CD4+8+ cells4,5. Although the mechanism used by TCRbeta chains to deliver such signals is unknown, studies in transgenic animals have suggested that the lymphocyte-specific protein tyrosine kinase p56lck may impinge on a similar signalling pathway6. The hypothesis that TCRbeta chains deliver intracellular signals via p56lck makes an explicit prediction: that interference with p56lck function will mitigate the effects of a simultaneously expressed TCRbeta chain. Here we confirm this prediction through examination of allelic exclusion in mice expressing both a functional TCRbeta chain transgene and a catalytically inactive form of p56lck.	UNIV WASHINGTON,SCH MED SL15,HOWARD HUGHES MED INST,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED SL15,DEPT IMMUNOL,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED SL15,DEPT BIOCHEM,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED SL15,DEPT MED MED GENET,SEATTLE,WA 98195	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle								ANDERSON SJ, 1992, EMBO J, V11, P4877, DOI 10.1002/j.1460-2075.1992.tb05594.x; CHOU HS, 1987, P NATL ACAD SCI USA, V84, P1992, DOI 10.1073/pnas.84.7.1992; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; GROETTRUP M, 1992, EMBO J, V11, P2735, DOI 10.1002/j.1460-2075.1992.tb05339.x; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; KARNITZ L, 1992, MOL CELL BIOL, V12, P4521, DOI 10.1128/MCB.12.10.4521; KITAMURA D, 1992, CELL, V69, P823, DOI 10.1016/0092-8674(92)90293-L; KRONENBERG M, 1986, ANNU REV IMMUNOL, V4, P529, DOI 10.1146/annurev.iy.04.040186.002525; KUDO A, 1987, EMBO J, V6, P2267, DOI 10.1002/j.1460-2075.1987.tb02500.x; LEVELT CN, 1993, J EXP MED, V177, P707, DOI 10.1084/jem.177.3.707; LEVIN SD, 1993, EMBO J, V12, P1671, DOI 10.1002/j.1460-2075.1993.tb05812.x; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; NUSSENZWEIG MC, 1987, SCIENCE, V236, P816, DOI 10.1126/science.3107126; OWEN JJT, 1988, IMMUNOLOGY, V63, P639; PERLMUTTER RM, 1988, J CELL BIOCHEM, V38, P117, DOI 10.1002/jcb.240380206; PUNT JA, 1991, J EXP MED, V174, P775, DOI 10.1084/jem.174.4.775; REYNOLDS PJ, 1990, MOL CELL BIOL, V10, P4266, DOI 10.1128/MCB.10.8.4266; SAKAGUCHI N, 1986, NATURE, V324, P579, DOI 10.1038/324579a0; SHINKAI Y, 1993, SCIENCE, V259, P822, DOI 10.1126/science.8430336; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; UEMATSU Y, 1988, CELL, V52, P831, DOI 10.1016/0092-8674(88)90425-4; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VONBOEHMER H, 1988, ANNU REV IMMUNOL, V6, P309, DOI 10.1146/annurev.iy.06.040188.001521; WILDIN RS, 1991, J EXP MED, V173, P383, DOI 10.1084/jem.173.2.383	28	138	138	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 7	1993	365	6446					552	554		10.1038/365552a0	http://dx.doi.org/10.1038/365552a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MA661	8413611				2022-12-24	WOS:A1993MA66100056
J	JOHNSSON, K; ALLEMANN, RK; WIDMER, H; BENNER, SA				JOHNSSON, K; ALLEMANN, RK; WIDMER, H; BENNER, SA			SYNTHESIS, STRUCTURE AND ACTIVITY OF ARTIFICIAL, RATIONALLY DESIGNED CATALYTIC POLYPEPTIDES	NATURE			English	Article							ALPHA-HELIX DIPOLE; BUNDLE PROTEIN; DECARBOXYLATION; ACID	BIOLOGICAL macromolecules with catalytic activity can be created artificially using two approaches. The first exploits a system that selects a few catalytically active biomolecules from a large pool of randomly generated (and largely inactive) molecules. Catalytic antibodies1 and many catalytic RNA molecules2 are obtained in this way. The second involves rational design of a biomolecule that folds in solution to present to the substrate an array of catalytic functional groups3-8. Here we report the synthesis of rationally designed polypeptides that catalyse the decarboxylation of oxaloacetate via an imine intermediate. We determine the secondary structures of the polypeptides by two-dimensional NMR spectroscopy. We are able to trap and identify intermediates in the catalytic cycle, and to explore the kinetics in detail. The formation of the imine by our artificial oxaloacetate decarboxylases is three to four orders of magnitude faster than can be achieved with simple amine catalysts: this performance rivals that of typical catalytic antibodies.	SWISS FED INST TECHNOL,ORGAN CHEM LAB,CH-8092 ZURICH,SWITZERLAND; UNIV CALIF BERKELEY,DEPT CHEM,BERKELEY,CA 94720; SANDOZ PHARMA LTD,PRECLIN RES,CH-4002 BASEL,SWITZERLAND	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of California System; University of California Berkeley; Novartis; Sandoz			johnsson, kai/P-4222-2014	johnsson, kai/0000-0002-8002-1981				ALLEMANN RK, 1989, THESIS EIDGENOSSISCH; BARTEL DP, 1993, SCIENCE, V261, P1411, DOI 10.1126/science.7690155; BENNER SA, 1989, TOP STEREOCHEM, P127; BRUICE PY, 1989, J AM CHEM SOC, V111, P962, DOI 10.1021/ja00185a028; CHAKRAVARTY PK, 1973, EXPERIENTIA, V29, P786, DOI 10.1007/BF01946284; EISENBERG D, 1986, Proteins Structure Function and Genetics, V1, P16, DOI 10.1002/prot.340010105; GHADIRI MR, 1992, J AM CHEM SOC, V114, P825, DOI 10.1021/ja00029a004; GORAJ K, 1990, PROTEIN ENG, V3, P259, DOI 10.1093/protein/3.4.259; GUTHRIE JP, 1972, J AM CHEM SOC, V94, P9136, DOI 10.1021/ja00781a025; GUTHRIE JP, 1972, J AM CHEM SOC, V94, P9132, DOI 10.1021/ja00781a024; GUTTE B, 1979, NATURE, V281, P650, DOI 10.1038/281650a0; HAHN KW, 1990, SCIENCE, V248, P1544, DOI 10.1126/science.2360048; HAY RW, 1965, AUST J CHEM, V18, P337, DOI 10.1071/CH9650337; HILL CP, 1990, SCIENCE, V249, P543, DOI 10.1126/science.2382133; HINE J, 1972, J AM CHEM SOC, V94, P190, DOI 10.1021/ja00756a033; HO SP, 1987, J AM CHEM SOC, V109, P6751, DOI 10.1021/ja00256a032; HOL WGJ, 1978, NATURE, V273, P443, DOI 10.1038/273443a0; JENCKS WP, 1975, ADV ENZYMOL RAMB, V43, P219; JENCKS WP, 1969, CATALYSIS CHEM ENZYM, V587; JOHNSSON K, 1990, MOLECULAR MECHANISMS IN BIOORGANIC PROCESSES, P166; JOHNSSON K, 1992, THESIS EIDGENOSISCHE; KAISER ET, 1988, REDESIGNING MOL LIFE, P25; KAPLAN H, 1971, BIOCHEM J, V124, P289, DOI 10.1042/bj1240289; KOEHLER K, 1964, J AM CHEM SOC, V86, P2413, DOI 10.1021/ja01066a024; LANGEN H, 1989, EUR J BIOCHEM, V182, P727, DOI 10.1111/j.1432-1033.1989.tb14885.x; LERNER RA, 1991, SCIENCE, V252, P659, DOI 10.1126/science.2024118; LEUSSING DL, 1980, J AM CHEM SOC, V102, P5635, DOI 10.1021/ja00537a039; MERRIFIELD RB, 1980, PEPTIDES ANAL SYNTHE, V2, P3; NELSON J W, 1986, Proteins Structure Function and Genetics, V1, P211, DOI 10.1002/prot.340010303; OLEARY MH, 1968, BIOCHEMISTRY-US, V7, P913, DOI 10.1021/bi00843a005; POLLACK SJ, 1986, SCIENCE, V234, P1570, DOI 10.1126/science.3787262; REIMANN JE, 1966, J AM CHEM SOC, V88, P3973, DOI 10.1021/ja00969a016; ROZZELL JD, 1987, METHOD ENZYMOL, V136, P479; ROZZELL JD, 1984, J AM CHEM SOC, V106, P4937, DOI 10.1021/ja00329a051; SALI D, 1988, NATURE, V335, P740, DOI 10.1038/335740a0; SASAKI T, 1989, J AM CHEM SOC, V111, P380, DOI 10.1021/ja00183a065; SELTZER S, 1959, J AM CHEM SOC, V81, P4018, DOI 10.1021/ja01524a051; SHEEHAN JC, 1966, J AM CHEM SOC, V88, P3455, DOI 10.1021/ja00966a065; SPETNAGEL WJ, 1976, J AM CHEM SOC, V98, P8199, DOI 10.1021/ja00441a052; Wada A, 1976, Adv Biophys, P1; WESETHEIMER FH, 1971, P R WELCH FDN C CHEM, V15, P7; Wuthrich K., 1986, NMR PROTEINS NUCL AC	42	200	202	6	41	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 7	1993	365	6446					530	532		10.1038/365530a0	http://dx.doi.org/10.1038/365530a0			3	Multidisciplinary Sciences	Index Chemicus (IC); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MA661	8413606				2022-12-24	WOS:A1993MA66100047
J	ROBERTS, CM; FOULCHER, E; ZAUNDERS, JJ; BRYANT, DH; FREUND, J; CAIRNS, D; PENNY, R; MORGAN, GW; BREIT, SN				ROBERTS, CM; FOULCHER, E; ZAUNDERS, JJ; BRYANT, DH; FREUND, J; CAIRNS, D; PENNY, R; MORGAN, GW; BREIT, SN			RADIATION PNEUMONITIS - A POSSIBLE LYMPHOCYTE-MEDIATED HYPERSENSITIVITY REACTION	ANNALS OF INTERNAL MEDICINE			English	Article						ALVEOLITIS, EXTRINSIC ALLERGIC; LYMPHOCYTES; RADIOTHERAPY; BREAST NEOPLASMS; LYMPHOCYTOSIS	BRONCHOALVEOLAR LAVAGE; LUNG-DISEASE; GA-67 UPTAKE; INJURY	Objective: To determine if unilateral thoracic irradiation results in a lymphoid alveolitis in both irradiated and unirradiated lung fields. Design: A prospective, nonrandomized study. Patients: Women receiving postoperative radiotherapy for carcinoma of the breast were evaluated both before and 4 to 6 weeks after radiotherapy. Findings after radiotherapy in 15 asymptomatic patients were compared with findings in a group of patients with clinical radiation pneumonitis. Measurements: History, physical examination, chest radiograph, quantitative gallium lung scanning, respiratory function tests, bronchoalveolar lavage, and lavage lymphocyte subset analysis. Results: After irradiation, lavage lymphocytes increased significantly (34.5% versus 46.8%; P = 0.01) in the 17 patients studied prospectively. There was an associated reduction in vital capacity (102.5% versus 95.5%; P = 0.04). Comparison of results in patients before treatment, after treatment without clinical pneumonitis, and after treatment with clinical pneumonitis showed a dramatic increase in total lymphocytes after irradiation (6.3 versus 9.4 versus 35.2 million, respectively; P = 0.005), particularly in those with clinical pneumonitis. Only in those with clinical pneumonitis was this accompanied by an increase in the gallium index (3.7 versus 3.4 versus 9.0, respectively; P < 0.001). Vital capacity was also progressively reduced (102.5% versus 96.9% versus 76.7%, respectively; P = 0.04), as was diffusing capacity (98.6% versus 91.4% versus 72.6%, respectively; P = 0.003). No statistical differences existed between irradiated and unirradiated sides of the chest in either lavage or gallium lung scan studies. Conclusion: In most patients, a lymphocytic alveolitis develops in both lung fields after strictly unilateral thoracic irradiation; this is more pronounced in patients developing clinical pneumonitis. These findings suggest that radiotherapy may cause a generalized lymphocyte-mediated hypersensitivity reaction.	ST VINCENTS HOSP, CTR IMMUNOL, SYDNEY, NSW 2010, AUSTRALIA; UNIV NEW S WALES, SYDNEY, NSW, AUSTRALIA; MACQUARIE UNIV, SCH BEHAV SCI, SYDNEY 2109, AUSTRALIA	St Vincents Hospital Sydney; University of New South Wales Sydney; Macquarie University			Zaunders, John/J-6553-2012	Zaunders, John/0000-0002-5912-5989; roberts, christopher/0000-0001-8212-1460				AKOUN GM, 1987, THORAX, V42, P652, DOI 10.1136/thx.42.9.652; BATE D, 1957, RADIOLOGY, V69, P372, DOI 10.1148/69.3.372; BENNETT DE, 1969, CANCER-AM CANCER SOC, V23, P1001, DOI 10.1002/1097-0142(196905)23:5<1001::AID-CNCR2820230505>3.0.CO;2-E; BISSON G, 1983, CHEST, V84, P513, DOI 10.1378/chest.84.5.513; CAIRNS D, 1991, AM REV RESPIR DIS, V143, P1235, DOI 10.1164/ajrccm/143.6.1235; COGGLE JE, 1986, ENVIRON HEALTH PERSP, V70, P261, DOI 10.2307/3430363; CORDIER JF, 1984, B EUR PHYSIOPATH RES, V20, P369; CORMIER Y, 1984, AM REV RESPIR DIS, V130, P1046; COSTABEL U, 1984, CHEST, V85, P514, DOI 10.1378/chest.85.4.514; COTES JE, 1979, LUNG FUNCTION ASSESS; FLEMING JAC, 1961, BRIT J RADIOL, V34, P713, DOI 10.1259/0007-1285-34-407-713; GIBSON PG, 1989, AUST NZ J MED, V19, P281, DOI 10.1111/j.1445-5994.1989.tb00263.x; GIBSON PG, 1988, ANN INTERN MED, V109, P288, DOI 10.7326/0003-4819-109-4-288; GROSS NJ, 1981, LUNG, V159, P115, DOI 10.1007/BF02713907; GROSS NJ, 1977, ANN INTERN MED, V86, P81, DOI 10.7326/0003-4819-86-1-81; Hammerschlag-Icaza B A, 1991, Bol Asoc Med P R, V83, P10; KATAOKA M, 1990, CLIN NUCL MED, V15, P707, DOI 10.1097/00003072-199015100-00012; Kataoka M, 1989, Ann Nucl Med, V3, P73; LAFITTE JJ, 1986, AM REV RESPIR DIS, V133, pA287; MARK EJ, 1984, LUNG BIOPSY INTERPRE, P73; RAMSAY SC, 1992, EUR J NUCL MED, V19, P80; ROTHWELL RI, 1985, RADIOTHER ONCOL, V4, P9, DOI 10.1016/S0167-8140(85)80056-6; SALTINI C, 1984, AM REV RESPIR DIS, V130, P650; SMITH JC, 1964, AM REV RESPIR DIS, V89, P264; WHITE DA, 1989, AM REV RESPIR DIS, V139, P18, DOI 10.1164/ajrccm/139.1.18	25	156	160	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1993	118	9					696	700		10.7326/0003-4819-118-9-199305010-00006	http://dx.doi.org/10.7326/0003-4819-118-9-199305010-00006			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY502	8460855				2022-12-24	WOS:A1993KY50200006
J	XU, ZS; CORK, LC; GRIFFIN, JW; CLEVELAND, DW				XU, ZS; CORK, LC; GRIFFIN, JW; CLEVELAND, DW			INCREASED EXPRESSION OF NEUROFILAMENT SUBUNIT-NF-L PRODUCES MORPHOLOGICAL ALTERATIONS THAT RESEMBLE THE PATHOLOGY OF HUMAN MOTOR-NEURON DISEASE	CELL			English	Article							AMYOTROPHIC LATERAL SCLEROSIS; PHOSPHORYLATED NEUROFILAMENTS; CALIBER; MICROTUBULES; ACCUMULATION; MOTONEURONS; TRANSPORT; PROTEINS; CELLS; MICE	Excessive accumulation of neurofilaments in the cell bodies and proximal axons of motor neurons is a major pathological hallmark during the early stages of many human motor neuron diseases. To test directly the consequence of overexpression of the major neurofilament subunit NF-L, we produced transgenic mice that accumulate NF-L to approximately 4-fold the normal level in the sciatic nerve. In young animals, the motor neurons of the ventral horn of the spinal cord have massive accumulations of neurofilaments, swollen perikarya, and eccentrically localized nuclei. NF-L accumulation is accompanied by an increased frequency of axonal degeneration, proximal axon swelling, and severe skeletal muscle atrophy. These data indicate that extensive accumulation of neurofilaments in motor neurons can trigger the neurodegenerative process.	JOHNS HOPKINS UNIV, SCH MED, DEPT COMPARAT MED, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT NEUROL, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT NEUROSCI, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	XU, ZS (corresponding author), JOHNS HOPKINS UNIV, SCH MED, DEPT BIOL CHEM, BALTIMORE, MD 21205 USA.		Cleveland, Don/AAN-9783-2021	Cleveland, Don/0000-0002-1934-3682				BANKER BQ, 1986, MYOLOGY 2, P2031; BYERS RK, 1961, ARCH NEUROL-CHICAGO, V5, P140, DOI 10.1001/archneur.1961.00450140022003; CARPENTER S, 1968, NEUROLOGY, V18, P841, DOI 10.1212/WNL.18.9.841; CHOU SM, 1971, J NEUROPATH EXP NEUR, V30, P368, DOI 10.1097/00005072-197107000-00005; Choudhary S. R., 1979, An economic classification and segregation of farms in order to examine the effect of "group" & "time" on the value of agricultural production in Belgium.; CLEVELAND DW, 1991, J CELL SCI, P85; CORK LC, 1982, LAB INVEST, V46, P89; CORK LC, 1988, J NEUROPATH EXP NEUR, V47, P420, DOI 10.1097/00005072-198807000-00003; FRIEDE RL, 1970, ANAT REC, V167, P379, DOI 10.1002/ar.1091670402; GOMEZ MR, 1986, MYOLOGY, P1993; GRIFFIN JW, 1978, SCIENCE, V202, P633, DOI 10.1126/science.81524; GRIFFIN JW, 1984, PERIPHERAL NEUROPATH, P621; HIRANO A, 1984, J NEUROPATH EXP NEUR, V43, P461, DOI 10.1097/00005072-198409000-00001; HIRANO A, 1984, J NEUROPATH EXP NEUR, V43, P471, DOI 10.1097/00005072-198409000-00002; HIRANO A, 1988, AMYOTROPHIC LATERAL, P193; HOFFMAN PN, 1987, P NATL ACAD SCI USA, V84, P3472, DOI 10.1073/pnas.84.10.3472; Inoue K, 1979, NEUROL MED CHIR TOKY, V11, P448; JONES SM, 1982, J BIOL CHEM, V257, P9902; JULIEN JP, 1982, J BIOL CHEM, V257, P467; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOPATA MA, 1987, J CELL BIOL, V105, P1707, DOI 10.1083/jcb.105.4.1707; MANETTO V, 1988, J NEUROPATH EXP NEUR, V47, P642, DOI 10.1097/00005072-198811000-00007; MONTEIRO MJ, 1990, J CELL BIOL, V111, P1543, DOI 10.1083/jcb.111.4.1543; MULDER DW, 1986, MYOLOGY, P2013; MULDER DW, 1984, PERIPHERAL NEUROPATH, P1525; MUNOZ DG, 1988, J NEUROPATH EXP NEUR, V47, P9, DOI 10.1097/00005072-198801000-00002; PRICE DL, 1972, J CELL BIOL, V53, P24, DOI 10.1083/jcb.53.1.24; SCHOCHET SS, 1969, ARCH NEUROL-CHICAGO, V20, P548, DOI 10.1001/archneur.1969.00480110112012; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SOBUE G, 1990, ACTA NEUROPATHOL, V79, P402, DOI 10.1007/BF00308716; STERNBERGER LA, 1983, P NATL ACAD SCI-BIOL, V80, P6126, DOI 10.1073/pnas.80.19.6126; Tower SS, 1939, PHYSIOL REV, V19, P1; TRONCOSO JC, 1985, BRAIN RES, V342, P172, DOI 10.1016/0006-8993(85)91369-1; WILEY CA, 1987, ACTA NEUROPATHOL, V72, P369, DOI 10.1007/BF00687269; WONG GL, 1984, J BIOL CHEM, V259, P4019; YAMASAKI H, 1992, LAB INVEST, V66, P734	36	491	503	1	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 9	1993	73	1					23	33		10.1016/0092-8674(93)90157-L	http://dx.doi.org/10.1016/0092-8674(93)90157-L			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KW753	8462100				2022-12-24	WOS:A1993KW75300005
J	POLLOCK, DA; ONEIL, JM; PARRISH, RG; COMBS, DL; ANNEST, JL				POLLOCK, DA; ONEIL, JM; PARRISH, RG; COMBS, DL; ANNEST, JL			TEMPORAL AND GEOGRAPHIC TRENDS IN THE AUTOPSY FREQUENCY OF BLUNT AND PENETRATING TRAUMA DEATHS IN THE UNITED-STATES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							QUALITY ASSURANCE	Objective.-To examine national trends in the percentage of blunt and penetrating trauma deaths autopsied. Design, Setting,and Participants.-For each year from 1980 through 1989, we used national mortality data files to determine the autopsy frequency (percentage of deaths autopsied) of all deaths in the United States. We analyzed variation in the autopsy frequency of blunt and penetrating trauma deaths by cause of injury and place of occurrence of death. Results.-The autopsy frequency of blunt and penetrating trauma deaths in the United States increased by 14.3% during the 1980s to 58.9% in 1989 (62 004 of 105 309 deaths autopsied), while the autopsy frequency of all deaths decreased by 23.6% during the same period to 11.5% in 1989 (248 272 of 2 153 859 deaths autopsied). Among trauma deaths, homicides remained far more likely to be autopsied than nonhomicides (deaths due to unintentional injuries, suicides, and injuries of undetermined intentionality). The autopsy frequency of homicidal trauma deaths in 1989 was 90.0% or higher in 44 states and ranged from 79.6% in Mississippi to 100.0% in six states. The autopsy frequency of nonhomicidal trauma deaths in 1989 was 90.0% or higher in two states and ranged from 10.3% in Oklahoma to 94.5% in Hawaii. Nationwide, we found significant differences in the autopsy frequency of trauma deaths in 1989 between metropolitan and nonmetropolitan counties, both for homicides (97.7% vs 89.3%; P<.001) and nonhomicides (58.2% vs 29.9%; P<.001). Conclusions.-The percentage of blunt and penetrating trauma deaths autopsied has increased recently in the United States, but extensive geographic variation in autopsy frequency suggests that the benefits of autopsy findings for trauma care quality improvement and public health surveillance of injuries are distributed unevenly throughout the nation.	CTR DIS CONTROL & PREVENT, NATL CTR ENVIRONM HLTH, ATLANTA, GA USA	Centers for Disease Control & Prevention - USA	POLLOCK, DA (corresponding author), CTR DIS CONTROL & PREVENT, NATL CTR INJURY PREVENT & CONTROL, 4770 BUFFORD HWY NE, MAIL STOP K-59, ATLANTA, GA 30341 USA.							ANGRIST A, 1962, JAMA-J AM MED ASSOC, V182, P929; BAKER SP, 1982, ACCIDENT ANAL PREV, V14, P199, DOI 10.1016/0001-4575(82)90030-6; BAKER SP, 1970, J AMER MED ASSOC, V214, P1079, DOI 10.1001/jama.214.6.1079; Combs D, 1990, DEATH INVESTIGATION; DIMAIO DJ, 1989, FORENSIC PATHOLOGY, P1; EASTMAN AB, 1992, ARCH SURG-CHICAGO, V127, P677; Fleiss JL, 1981, STATISTICAL METHODS, P19; FROEDE RC, 1990, HDB FORENSIC PATHOLO, P1; HANZLICK R, 1993, JAMA-J AM MED ASSOC, V269, P47; HILL RB, 1991, MILBANK Q, V69, P51, DOI 10.2307/3350121; HILL RB, 1988, AUTOPSY MED PRACTICE, P108; HIRSCH CS, 1984, ARCH PATHOL LAB MED, V108, P484; Jason D, 1980, Leg Med, P137; KIRCHER T, 1990, HUM PATHOL, V21, P166, DOI 10.1016/0046-8177(90)90125-O; KIRCHER T, 1985, NEW ENGL J MED, V313, P1263, DOI 10.1056/NEJM198511143132005; LUNDBERG GD, 1984, ARCH PATHOL LAB MED, V108, P449; LUNDBERG GD, 1988, JAMA-J AM MED ASSOC, V260, P3488; LUNDSTROM M, 1991, PUBLIC WELFARE   SUM, P18; MORITZ AR, 1956, AM J CLIN PATHOL, V26, P1383; NEMETZ PN, 1987, AM J PATHOL, V128, P362; PETTY CS, 1980, MODERN LEGAL MED PSY, P51; Reichert C M, 1985, Health Aff (Millwood), V4, P82, DOI 10.1377/hlthaff.4.2.82; RIVARA FP, 1989, PUBLIC HEALTH REP, V104, P293; ROSENBERG HM, 1990, REPORT WORKSHOP IMPR, P1; SALADINO AJ, 1984, CLIN LAB MED, V4, P165, DOI 10.1016/S0272-2712(18)30947-8; SCHMIDT S, 1983, JAMA-J AM MED ASSOC, V250, P1161, DOI 10.1001/jama.250.9.1161; STOTHERT JC, 1990, J TRAUMA, V30, P1021, DOI 10.1097/00005373-199008000-00012; SVENDSEN E, 1987, ARCH PATHOL LAB MED, V111, P846; THAL E, 1990, J TRAUMA, V30, P1021; Trunkey D D, 1990, Bull Am Coll Surg, V75, P10; Trunkey DD, 1991, CURRENT THERAPY TRAU, P3; WETLI CV, 1988, PRACTICAL FORENSIC P, P1; Wright R K, 1981, Pathol Annu, V16, P273; WRIGHT RK, 1980, AM J FOREN MED PATH, V1, P57, DOI 10.1097/00000433-198003000-00009; 1987, JAMA-J AM MED ASSOC, V258, P364; 1990, RESOURCES OPTIMAL CA, P68; 1990, STAT ABSTR US 1990; 1992, 3RD NAT INJ CONTR C, P377; [No title captured]; 1990, NATIONAL INPATIENT P, P1049; 1991, FATAL ACCIDENT REPOR; 1985, PHS851102 DEP HLTH H; 1987, MMWR, V37, P191; 1989, OTAH445 OFF TECHN AS, P45	44	24	24	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 24	1993	269	12					1525	1531		10.1001/jama.269.12.1525	http://dx.doi.org/10.1001/jama.269.12.1525			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KR803	8445815				2022-12-24	WOS:A1993KR80300025
J	BROMHAM, DR; CARTMILL, RSV				BROMHAM, DR; CARTMILL, RSV			KNOWLEDGE AND USE OF SECONDARY CONTRACEPTION AMONG PATIENTS REQUESTING TERMINATION OF PREGNANCY	BRITISH MEDICAL JOURNAL			English	Article											BROMHAM, DR (corresponding author), ST JAMES UNIV HOSP,FERTIL CONTROL UNIT,LEEDS LS9 7TF,W YORKSHIRE,ENGLAND.							BROOK SJ, 1991, BR J FAMILY PLANNING, V17, P18; DUNCAN G, 1990, BRIT J FAM PLANN, V15, P112; Griffiths M, 1990, BRIT J FAM PLANN, V16, P16; MELVILLE AWT, 1992, MED AUDIT NEWS, V2, P130; 1992, EMERGENCY POSTCOITAL	5	46	47	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 27	1993	306	6877					556	557		10.1136/bmj.306.6877.556	http://dx.doi.org/10.1136/bmj.306.6877.556			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP886	8461770	Bronze, Green Published			2022-12-24	WOS:A1993KP88600022
J	MOSER, E; MATHIESEN, I; ANDERSEN, P				MOSER, E; MATHIESEN, I; ANDERSEN, P			ASSOCIATION BETWEEN BRAIN TEMPERATURE AND DENTATE FIELD POTENTIALS IN EXPLORING AND SWIMMING RATS	SCIENCE			English	Article							EXPLORATION-DEPENDENT MODULATION; EVOKED-RESPONSES; FASCIA-DENTATA; SLICES; MOTOR	Attempts to correlate behavioral learning with cellular changes, such as increased synaptic efficacy, have often relied on increased extracellular potentials as an index of enhanced synaptic strength. A recent example is the enlarged excitatory field potentials in the dentate gyrus of rats that are learning spatial relations by exploration. The altered hippocampal field potentials do not reflect learning-specific cellular changes but result from a concomitant rise in brain temperature that is caused by the associated muscular effort. Enhanced dentate field excitatory potentials followed both passive and active heating and were linearly related to the brain temperature. These temperature-related effects may mask any learning-induced changes in field potential.	UNIV OSLO,INST BASIC MED SCI,DEPT NEUROPHYSIOL,POST BOX 1104 BLINDERN,N-0317 OSLO,NORWAY	University of Oslo				Mathiesen, Iacob/0000-0003-0397-0742				ABRAMS R, 1965, AM J PHYSIOL, V208, P698, DOI 10.1152/ajplegacy.1965.208.4.698; ABRAMS R, 1964, AM J PHYSIOL, V206, P641, DOI 10.1152/ajplegacy.1964.206.3.641; ABRAMS R. M., 1965, LIFE SCI, V4, P2399, DOI 10.1016/0024-3205(65)90295-X; ANDERSEN P, 1960, ACTA PHYSIOL SCAND, V48, P209, DOI 10.1111/j.1748-1716.1960.tb01857.x; BAKER MA, 1982, ANNU REV PHYSIOL, V44, P85, DOI 10.1146/annurev.ph.44.030182.000505; BARNES CA, 1988, TRENDS NEUROSCI, V11, P163, DOI 10.1016/0166-2236(88)90143-9; GORDON CJ, 1990, PHYSIOL BEHAV, V47, P963, DOI 10.1016/0031-9384(90)90025-Y; GREEN EJ, 1990, J NEUROSCI, V10, P1455; HARGREAVES EL, 1990, J NEUROSCI, V10, P1472; HODGKIN AL, 1949, J PHYSIOL-LONDON, V109, P240, DOI 10.1113/jphysiol.1949.sp004388; KATZ B, 1965, J PHYSIOL-LONDON, V181, P656, DOI 10.1113/jphysiol.1965.sp007790; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MORRIS R, 1984, NEUROPSYCHOLOGY MEMO, P521; O'Keefe J, 1979, HIPPOCAMPUS COGNITIV; SCHIFF SJ, 1985, BRAIN RES, V345, P279, DOI 10.1016/0006-8993(85)91004-2; Schoepfle GM, 1941, AM J PHYSIOL, V134, P0694, DOI 10.1152/ajplegacy.1941.134.4.694; SHARP PE, 1989, PSYCHOBIOLOGY, V17, P257, DOI 10.1007/BF03337777; SHEN KF, 1988, BRAIN RES, V475, P305, DOI 10.1016/0006-8993(88)90619-1; THOMPSON SM, 1985, J NEUROSCI, V5, P817	19	205	208	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 26	1993	259	5099					1324	1326		10.1126/science.8446900	http://dx.doi.org/10.1126/science.8446900			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KN883	8446900				2022-12-24	WOS:A1993KN88300031
J	DUNAWAY, M; OSTRANDER, EA				DUNAWAY, M; OSTRANDER, EA			LOCAL DOMAINS OF SUPERCOILING ACTIVATE A EUKARYOTIC PROMOTER INVIVO	NATURE			English	Article							TRANSCRIPTION FACTOR; XENOPUS-LAEVIS; DNA; GENE; ENHANCER; POLYMERASE; TEMPLATE; OOCYTES; PROTEIN	EXPERIMENTS Correlating template topology with transcriptional activity suggest that DNA topology plays a role in eukaryotic gene expression1-4. Linear templates transfected into cultured cells produce far fewer transcripts than do circular transcription templates3, and no transcripts can be detected from linear templates injected into Xenopus oocytes1,2. Further, when transcriptionally active circular templates in Xenopus oocytes are linearized by injection of a restriction enzyme, transcription dramatically decreases. Here we show that transcription by phage T7 RNA polymerase from a divergent promoter can partially replace the requirement for circular Xenopus ribosomal RNA transcription templates in Xenopus oocytes. Supercoiled domains can apparently be generated on short pieces of DNA having no known sequences that result in association with the nuclear architecture, suggesting that localized, transient domains of supercoiling fulfil the minimum topological needs for Xenopus rRNA transcription in vivo.	LAWRENCE BERKELEY LAB,CTR HUMAN GENOME,DEPT CELLULAR & MOLEC BIOL,BERKELEY,CA 94720	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory	DUNAWAY, M (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,DIV BIOCHEM & MOLEC BIOL,BERKELEY,CA 94720, USA.			Ostrander, Elaine/0000-0001-6075-9738				CARROLL D, 1986, MOL CELL BIOL, V6, P2053, DOI 10.1128/MCB.6.6.2053; DUNAWAY M, 1989, NATURE, V341, P657, DOI 10.1038/341657a0; DUNAWAY M, 1989, GENE DEV, V3, P1768, DOI 10.1101/gad.3.11.1768; GIAEVER GN, 1988, CELL, V55, P849, DOI 10.1016/0092-8674(88)90140-7; HARLAND R, 1983, NATURE, V301, P38; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; LABHART P, 1984, CELL, V37, P285, DOI 10.1016/0092-8674(84)90324-6; LABHART P, 1985, NUCLEIC ACIDS RES, V13, P8999, DOI 10.1093/nar/13.24.8999; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; LJUNGMAN M, 1992, P NATL ACAD SCI USA, V89, P6055, DOI 10.1073/pnas.89.13.6055; MIRKOVITCH J, 1984, CELL, V39, P223, DOI 10.1016/0092-8674(84)90208-3; OSTRANDER EA, 1990, SCIENCE, V249, P1261, DOI 10.1126/science.2399463; PAULSON JR, 1977, CELL, V12, P817, DOI 10.1016/0092-8674(77)90280-X; PIKAARD CS, 1989, GENE DEV, V3, P1779, DOI 10.1101/gad.3.11.1779; PRUITT SC, 1984, J MOL BIOL, V174, P121, DOI 10.1016/0022-2836(84)90368-1; SCHULTZ MC, 1992, GENE DEV, V6, P1332, DOI 10.1101/gad.6.7.1332; TSAO YP, 1989, CELL, V56, P111, DOI 10.1016/0092-8674(89)90989-6; WEINTRAUB H, 1986, CELL, V46, P115, DOI 10.1016/0092-8674(86)90865-2	18	85	85	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 25	1993	361	6414					746	748		10.1038/361746a0	http://dx.doi.org/10.1038/361746a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KN789	8441472				2022-12-24	WOS:A1993KN78900063
J	COHEN, IL; LAMBRINOS, J; FEIN, IA				COHEN, IL; LAMBRINOS, J; FEIN, IA			MECHANICAL VENTILATION FOR THE ELDERLY PATIENT IN INTENSIVE-CARE - INCREMENTAL CHARGES AND BENEFITS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LIFE; AGE; SURVIVAL; FAILURE; QUALITY; COSTS; UNIT	Objective.-To evaluate the cost-effectiveness of prolonged mechanical ventilation in patients 80 years of age and older in the intensive care unit (ICU). Design.-A retrospective review of consecutive ICU patients requiring 3 or more days of mechanical ventilation. Cost-effectiveness analysis was performed by assessing incremental hospital charges from hospital billing records; charges were then related to years of life saved. A telephone survey was used to follow up hospital survivors for a minimum of 4 years after discharge. Setting.-A 20-bed medical-surgical ICU in a 420-bed, tertiary-care community teaching hospital. Patients.-The study included all patients aged 80 years or older taken from a comprehensive database of all patients admitted to the ICU requiring mechanical ventilation from April 1, 1985, through October 31, 1987 (n=512). Of 59 potential candidates, 45 were found to have complete billing records and were the subject of further analysis. Results.-Of the 45 patients in the group under analysis, 10 survived to leave the hospital. Of these, two were alive and one could not be located at the time of follow-up. The charge per year of life saved is estimated to be between $51 854 and $75 090 in 1985-1987 dollars. Of 22 patients whose age in years plus duration of mechanical ventilation in days totaled 100 or greater, only two survived hospitalization and neither was alive at follow-up. The cost per year of life saved in this subset of patients was $181 308 in 1985-1987 dollars. One of these patients was discharged to a nursing home and died there 4.5 years later, after multiple hospital readmissions. The other patient died at home 2 months after hospital discharge Conclusion.-Based on hospital charges and life expectancy, the cost-effectiveness of prolonged mechanical ventilation in ICU patients age 80 years and over was poor in our population when the combination of age and duration ot mechanical ventilation exceeded 100. Further studies using this type of analysis may prove valuable in both clinical and administrative decision-making processes.	UNION UNIV, DEPT MED, ALBANY, NY 12208 USA; UNION COLL, INST GRAD MANAGEMENT, SCHENECTADY, NY 12308 USA	Union College; Union College	COHEN, IL (corresponding author), UNION UNIV, DEPT SURG, A-162, 47 NEW SCOTLAND AVE, ALBANY, NY 12208 USA.		Fein, I. Alan/J-2576-2019					BAKER R, 1991, ANESTHESIOL CLIN N A, V9, P437; BERMAN HJ, 1990, FINANC MANAGE, P109; BOUBJERG RR, 1987, IND L REV, V19, P857; CAMPION EW, 1981, JAMA-J AM MED ASSOC, V246, P2052, DOI 10.1001/jama.246.18.2052; CHELLURI L, 1992, CRIT CARE MED, V20, P757, DOI 10.1097/00003246-199206000-00010; CULLEN DJ, 1977, ANESTHESIOLOGY, V47, P203, DOI 10.1097/00000542-197708000-00011; DAVIS H, 1980, JAMA-J AM MED ASSOC, V243, P43; FEDULLO AJ, 1983, CRIT CARE MED, V11, P155, DOI 10.1097/00003246-198303000-00001; GIBBS J, 1982, HEW100790110 BLU CRO; GOLDBERG AI, 1988, CHEST, V94, P1277, DOI 10.1378/chest.94.6.1277; KNAUS W A, 1989, American Review of Respiratory Disease, V140, pS8; LAMBRINOS J, 1987, MANAGING CRITICAL CA, P358; LAPUMA J, 1990, JAMA-J AM MED ASSOC, V263, P2917, DOI 10.1001/jama.263.21.2917; LEAF A, 1977, NEW ENGL J MED, V297, P887, DOI 10.1056/NEJM197710202971612; LEAPE LL, 1990, JAMA-J AM MED ASSOC, V263, P669, DOI 10.1001/jama.263.5.669; LEGALL JR, 1982, CRIT CARE MED, V10, P575; MCLEAN RF, 1985, CRIT CARE MED, V13, P625, DOI 10.1097/00003246-198508000-00002; MOORE MJ, 1988, J POLICY ANAL MANAG, V7, P476, DOI 10.2307/3323726; NUNN JF, 1979, BRIT MED J, V1, P1525, DOI 10.1136/bmj.1.6177.1525; ODONNELL A, 1991, CHEST, V100, pS29; PESAU B, 1992, CRIT CARE MED, V20, P489, DOI 10.1097/00003246-199204000-00010; ROSEN RL, 1988, CLIN CHEST MED, V9, P163; SAGE WM, 1986, CRIT CARE MED, V14, P777, DOI 10.1097/00003246-198609000-00004; SCHMIDT CD, 1983, CRIT CARE MED, V11, P407, DOI 10.1097/00003246-198306000-00001; SCITOVSKY AA, 1988, MILBANK Q, V66, P640, DOI 10.2307/3349934; SWINBURNE AJ, 1991, CHEST, V100, pS79; TRAN DD, 1990, CRIT CARE MED, V18, P474, DOI 10.1097/00003246-199005000-00002; ZAREN B, 1987, CRIT CARE MED, V15, P743, DOI 10.1097/00003246-198708000-00006; 1981, FED REG         0219, V14, P13193; 1992, EC REPORT PRESIDENT, P361; 1986, GAOHRD8625 US GEN AC; 1992, NATIONAL ISSUES FORU	32	90	94	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 24	1993	269	8					1025	1029		10.1001/jama.269.8.1025	http://dx.doi.org/10.1001/jama.269.8.1025			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KM603	8429584				2022-12-24	WOS:A1993KM60300032
J	FEEST, TG; ROUND, A; HAMAD, S				FEEST, TG; ROUND, A; HAMAD, S			INCIDENCE OF SEVERE ACUTE-RENAL-FAILURE IN ADULTS - RESULTS OF A COMMUNITY BASED STUDY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							REFERRALS	Objective-To determine the age related incidence of severe acute renal failure Design-Prospective study of patients identified as having severe acute renal failure within a two year period; subsequent monitoring of outcome for a further two years. Setting-Two health districts in Devon. Subjects-Those adults in a population of 444971 who developed severe acute renal failure (serum creatinine concentration >500 mumol/l) for the first time during two years, with subsequent fall of the serum creatinine concentration below the index value. Main outcome measures and results-125 adults (140 per million total population yearly, 172 per million adults) developed severe acute renal failure, of whom 90 (72%) were over 70. Age related incidence rose from 17 per million yearly in adults under 50 to 949 per million yearly in the 80-89 age goups. In 31 patients (25%) the cause was prostatic disease, which was related to a good prognosis (84% (26) alive at three months). Overall survival was 54% (67) at three months and 34% (42) at two years and was not significantly age related. 18 per million total population yearly (22 per million adult population) received acute dialysis. Referral rate for specialised opinion was 51 per million total population yearly with an estimated appropriate referral rate of 70 per million per year. Conclusions-The incidence of severe acute renal failure in the community is at least twice as high as the incidence reported from renal unit based studies. Prostatic disease, a preventable and treatable problem, is the most common cause. Survival figures indicate that age alone should not be a bar to specialist referral or treatment.	PLYMOUTH HLTH AUTHOR, PLYMOUTH, ENGLAND; ROYAL DEVON & EXETER HOSP, EXETER EX2 9DW, ENGLAND	University of Exeter	FEEST, TG (corresponding author), SOUTHMEAD GEN HOSP, RICHARD BRIGHT RENAL UNIT, BRISTOL BS10 5NB, AVON, ENGLAND.							ABRAHAM G, 1989, J TROP MED HYG, V92, P325; Boardman A P, 1988, Int J Soc Psychiatry, V34, P172, DOI 10.1177/002076408803400302; BUKTUS ED, 1983, ARCH INTERN MED, V143, P209; KAUFMAN J, 1991, AM J KIDNEY DIS, V17, P191, DOI 10.1016/S0272-6386(12)81128-0; KENNEDY AC, 1973, Q J MED, V42, P73; KERSSENS JJ, 1990, SOC SCI MED, V30, P797, DOI 10.1016/0277-9536(90)90203-5; KJELLSTRAND CM, 1981, T AM SOC ART INT ORG, V27, P45; LAMIERE N, 1987, NEPHROL DIAL TRANSPL, V2, P316; LAZARUS JM, 1988, INTENSIVE CARD MED, V12, P61; LOHR JW, 1988, AM J KIDNEY DIS, V11, P254, DOI 10.1016/S0272-6386(88)80158-6; OLIVER DO, 1987, OXFORD TXB MED, P136; RASMUSSEN HH, 1982, AM J MED, V73, P211, DOI 10.1016/0002-9343(82)90181-4; REYNOLDS GA, 1991, BMJ-BRIT MED J, V302, P1250, DOI 10.1136/bmj.302.6787.1250; SACKS SH, 1989, BRIT MED J, V298, P156, DOI 10.1136/bmj.298.6667.156; SWANN RC, 1953, MEDICINE, V32, P215, DOI 10.1097/00005792-195305000-00002; TURNEY JH, 1990, Q J MED, V74, P83; 1988, REPORT	17	206	211	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 20	1993	306	6876					481	483		10.1136/bmj.306.6876.481	http://dx.doi.org/10.1136/bmj.306.6876.481			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KN786	8448456	Bronze, Green Published			2022-12-24	WOS:A1993KN78600015
J	PARKER, R; SILICIANO, PG				PARKER, R; SILICIANO, PG			EVIDENCE FOR AN ESSENTIAL NON-WATSON-CRICK INTERACTION BETWEEN THE 1ST AND LAST NUCLEOTIDES OF A NUCLEAR PREMESSENGER RNA INTRON	NATURE			English	Article							3' SPLICE-SITE; MAMMALIAN INTRONS; YEAST; U6; RIBONUCLEOPROTEIN; MUTATIONS; RECOGNITION; TETRAHYMENA; SEQUENCES; U2	NUCLEAR pre-messenger RNA splicing requires the action of five small nuclear (sn) RNAs, U1, U2, U4, U5 and U6, and more than 50 proteins1,2. The mechanistic similarity of nuclear pre-mRNA splicing and group II self-splicing suggests that many of the central processes of nuclear pre-mRNA splicing are based on RNA-RNA interactions3,4. To understand the mechanism of pre-mRNA splicing, the interactions, and their temporal relationships, that occur between the snRNAs and the pre-mRNA during splicing must be identified. Several snRNA-snRNA5-9 and snRNA-intron9-12 interactions have been demonstrated but the putative RNA-based interactions that recognize the AG dinucleotide at the 3' splice site during 3' cleavage and exon ligation are unknown. We report here the reciprocal suppression between 5' and 3' splice site mutations in the yeast actin intron, and propose that the 3' splice site is positioned for 3' cleavage and exon ligation, at least in part, through a non-Watson-Crick interaction between the guanosines at the 5' and 3' splice sites.	UNIV MINNESOTA, SCH MED, INST HUMAN GENET, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, SCH MED, DEPT BIOCHEM, MINNEAPOLIS, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	PARKER, R (corresponding author), UNIV ARIZONA, DEPT MOLEC & CELLULAR BIOL, LIFE SCI S, TUCSON, AZ 85721 USA.							AEBI M, 1986, CELL, V47, P555, DOI 10.1016/0092-8674(86)90620-3; BARTEL DP, 1991, CELL, V67, P529, DOI 10.1016/0092-8674(91)90527-6; BROW DA, 1988, NATURE, V334, P213, DOI 10.1038/334213a0; CECH TR, 1986, ANNU REV BIOCHEM, V55, P599, DOI 10.1146/annurev.bi.55.070186.003123; CECH TR, 1987, SCIENCE, V236, P1532, DOI 10.1126/science.2438771; FOUSER LA, 1986, CELL, V45, P81, DOI 10.1016/0092-8674(86)90540-4; GREEN MA, 1991, REV CELL BIOL, V7, P559; GUTHRIE C, 1989, AM ZOOL, V29, P557; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HASHIMOTO C, 1984, NUCLEIC ACIDS RES, V12, P3283, DOI 10.1093/nar/12.7.3283; HAUSNER TP, 1990, GENE DEV, V4, P2146, DOI 10.1101/gad.4.12a.2146; INOUE T, 1986, J MOL BIOL, V189, P143, DOI 10.1016/0022-2836(86)90387-6; JACKSON IJ, 1991, NUCLEIC ACIDS RES, V19, P3795; LESSER CF, IN PRESS GENETICS; MICHEL F, 1990, NATURE, V347, P578, DOI 10.1038/347578a0; MICHEL F, 1989, NATURE, V342, P391, DOI 10.1038/342391a0; MOORE MJ, 1992, SCIENCE, V256, P992, DOI 10.1126/science.1589782; NEWMAN AJ, 1985, CELL, V42, P335, DOI 10.1016/S0092-8674(85)80129-X; NEWMAN AJ, 1992, CELL, V68, P734; PARKER R, 1987, CELL, V49, P229, DOI 10.1016/0092-8674(87)90564-2; PYLE AM, 1992, NATURE, V358, P123, DOI 10.1038/358123a0; REED R, 1989, GENE DEV, V3, P2113, DOI 10.1101/gad.3.12b.2113; REICH CI, 1992, CELL, V69, P1159, DOI 10.1016/0092-8674(92)90637-R; SCHENA M, 1991, METHOD ENZYMOL, V194, P389; SMITH CWJ, 1989, NATURE, V342, P243, DOI 10.1038/342243a0; VIJAYRAGHAVAN U, 1986, EMBO J, V5, P1683, DOI 10.1002/j.1460-2075.1986.tb04412.x; WASSARMAN DA, 1992, SCIENCE, V257, P1918, DOI 10.1126/science.1411506; WU J, 1991, NATURE, V352, P818, DOI 10.1038/352818a0; ZHAUNG Y, 1986, CELL CAMBRIDGE, V46, P827	29	131	131	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 18	1993	361	6413					660	662		10.1038/361660a0	http://dx.doi.org/10.1038/361660a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KM776	8437627				2022-12-24	WOS:A1993KM77600071
J	EVANS, BG; CATCHPOLE, MA; HEPTONSTALL, J; MORTIMER, JY; MCCARRIGLE, CA; NICOLL, AG; WAIGHT, P; GILL, ON; SWAN, AV				EVANS, BG; CATCHPOLE, MA; HEPTONSTALL, J; MORTIMER, JY; MCCARRIGLE, CA; NICOLL, AG; WAIGHT, P; GILL, ON; SWAN, AV			SEXUALLY-TRANSMITTED DISEASES AND HIV-1 INFECTION AMONG HOMOSEXUAL MEN IN ENGLAND AND WALES	BRITISH MEDICAL JOURNAL			English	Article							RESURGENT GONORRHEA; RECTAL GONORRHEA; HEPATITIS-B; UNSAFE SEX; BEHAVIOR	Objective-To examine surveillance data for evidence of changing sexual behaviour and continuing transmission of HIV-1 among men who have sex with men. Design-Analytic study of surveillance data on sexually transmitted diseases. Setting-England and Wales. Main outcome measures-Number of cases of rectal gonorrhoea and newly diagnosed HIV infection in homosexual men. Results-New cases of gonorrhoea among men attending genitourinary medicine clinics increased by 7.7% in 1989 and by 4.2% in 1990. Reports of rectal isolates of Neisseria gonorrhoeae also rose and the male to female ratio for patients with rectal gonorrhoea changed from 0.3:1 during 1988-9 to 2.6:1 in 1990-1. Although the overall number of cases of acute hepatitis B fell during 1988-91, 81 and 82 homosexual men were infected in 1990 and 1991 respectively compared with 50 and 42 in 1988 and 1989. 1526 men had HIV-1 infection diagnosed in 1991, the largest number since 1987. Twenty eight of the 97 (29%) men who seroconverted between January 1989 and December 1991 were aged less than 25. The proportion of men aged 15-19 who were found to be infected with HIV-1 at their first test increased from an average of 2.4% up to 1990 to 4.7% in the first nine months of 1991. The prevalence of HIV infection in men under 25 attending genitourinary medicine clinics in London was 17% compared with 7.8% outside London. Conclusion-Unsafe sexual behaviour and HIV transmissions have increased among homosexual men after a period of decline. Recent HIV transmissions may disproportionately affect younger men.	COMMUNICABLE DIS SURVEILLANCE CTR,PUBL HLTH LAB SERV,STAT UNIT,LONDON NW9 5EQ,ENGLAND	Public Health England	EVANS, BG (corresponding author), COMMUNICABLE DIS SURVEILLANCE CTR,SERV AIDS CTR,DIV IMMUNISAT,PUBL HLTH LAB,LONDON NW9 5EQ,ENGLAND.		McGarrigle, Christine/J-8331-2017	McGarrigle, Christine/0000-0001-5814-5673				BHATTI N, 1991, BRIT MED J, V303, P97, DOI 10.1136/bmj.303.6794.97; FORSYTH JRL, 1990, LANCET, V336, P878, DOI 10.1016/0140-6736(90)92382-R; HANDSFIELD HH, 1989, MMWR-MORBID MORTAL W, V38, P762; HUNT AJ, 1991, BRIT MED J, V302, P505, DOI 10.1136/bmj.302.6775.505; JOHNSON AM, 1989, PHILOS T ROY SOC B, V325, P153, DOI 10.1098/rstb.1989.0080; LAWRENCE AG, 1987, LANCET, V1, P982; LOKE RHT, 1989, BRIT MED J, V298, P234, DOI 10.1136/bmj.298.6668.234; NICOLL A, 1992, 1992 P INT C AIDS II; RILEY VC, 1991, LANCET, V337, P183, DOI 10.1016/0140-6736(91)90853-H; ROSS JDC, 1991, COMMUNICABLE DISEASE, V25, P3; SINGARATNAM AE, 1991, BRIT MED J, V302, P469, DOI 10.1136/bmj.302.6774.469-b; TOMLINSON DR, 1991, LANCET, V337, P501, DOI 10.1016/0140-6736(91)93447-H; VANDELAAR MJW, 1990, GENITOURIN MED, V66, P148; VANDENHOEK JAR, 1990, LANCET, V336, P179, DOI 10.1016/0140-6736(90)91700-K; Waight P A, 1992, Commun Dis Rep CDR Rev, V2, pR85; WAIGHT PA, 1991, BMJ-BRIT MED J, V303, P311, DOI 10.1136/bmj.303.6797.311; WAUGH MA, 1991, LANCET, V337, P375, DOI 10.1016/0140-6736(91)91017-O; WINKELSTEIN W, 1987, AM J PUBLIC HEALTH, V76, P685; YOUNG H, 1991, LANCET, V337, P853, DOI 10.1016/0140-6736(91)92561-F; 1993, COMMUNICABLE DISEASE, V3, pR1; 1989, BMJ, V298, P422	21	60	60	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 13	1993	306	6875					426	428		10.1136/bmj.306.6875.426	http://dx.doi.org/10.1136/bmj.306.6875.426			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KM700	8461723	Bronze, Green Published			2022-12-24	WOS:A1993KM70000020
J	SCHMIDT, CF; SVOBODA, K; LEI, N; PETSCHE, IB; BERMAN, LE; SAFINYA, CR; GREST, GS				SCHMIDT, CF; SVOBODA, K; LEI, N; PETSCHE, IB; BERMAN, LE; SAFINYA, CR; GREST, GS			EXISTENCE OF A FLAT PHASE IN RED-CELL MEMBRANE SKELETONS	SCIENCE			English	Article							HUMAN-ERYTHROCYTE MEMBRANE; TETHERED MEMBRANES; MOLECULAR-DYNAMICS; X-RAY; FLUCTUATIONS; LAMELLAR; SURFACES; SPECTRIN; SYSTEM; SHAPE	Biomolecular membranes display rich statistical mechanical behavior. They are classified as liquid in the absence of shear elasticity in the plane of the membrane and tethered (solid) when the neighboring molecules or subunits are connected and the membranes exhibit solid-like elastic behavior in the plane of the membrane. The spectrin skeleton of red blood cells was studied as a model tethered membrane. The static structure factor of the skeletons, measured by small-angle x-ray and light scattering, was fitted with a structure factor predicted with a model calculation. The model describes tethered membrane sheets with free edges in a flat phase, which is a locally rough but globally flat membrane configuration. The fit was good for large scattering vectors. The membrane roughness exponent, zeta, defined through h is-proportional-to L(zeta), where h is the average amplitude of out-of-plane fluctuations and L is the linear membrane dimension, was determined to be 0.65 +/- 0.10. Computer simulations of model red blood cell skeletons also showed this flat phase. The value for the roughness exponent, which was determined from the scaling properties of membranes of different sizes, was consistent with that from the experiments.	HARVARD UNIV,DEPT CELLULAR & DEV BIOL,CAMBRIDGE,MA 02138; HARVARD UNIV,DEPT PHYS,CAMBRIDGE,MA 02138; EXXON RES & ENGN CO,ANNANDALE,NJ 08801; BROOKHAVEN NATL LAB,NATL SYNCHROTRON LIGHT SOURCE,UPTON,NY 11973; UNIV CALIF SANTA BARBARA,DEPT MAT & PHYS,SANTA BARBARA,CA 93106	Harvard University; Harvard University; Exxon Mobil Corporation; State University of New York (SUNY) System; United States Department of Energy (DOE); Brookhaven National Laboratory; University of California System; University of California Santa Barbara	SCHMIDT, CF (corresponding author), ROWLAND INST SCI INC,100 CAMBRIDGE PKWY,CAMBRIDGE,MA 02142, USA.		Schmidt, Christoph F/G-3787-2011	Schmidt, Christoph F/0000-0003-2864-6973				ABRAHAM FF, 1992, EUROPHYS LETT, V19, P293, DOI 10.1209/0295-5075/19/4/008; ABRAHAM FF, 1990, SCIENCE, V249, P393, DOI 10.1126/science.249.4967.393; ABRAHAM FF, 1989, PHYS REV LETT, V62, P1757, DOI 10.1103/PhysRevLett.62.1757; ARONOVITZ JA, 1988, PHYS REV LETT, V60, P2634, DOI 10.1103/PhysRevLett.60.2634; de Gennes P. G., 1979, SCALING CONCEPTS POL, P128; DODGE JT, 1963, ARCH BIOCHEM BIOPHYS, V100, P119, DOI 10.1016/0003-9861(63)90042-0; GOULIAN M, 1992, PHYS REV A, V46, pR6170, DOI 10.1103/PhysRevA.46.R6170; GREST GS, 1990, J PHYS-PARIS, V51, P1415, DOI 10.1051/jphys:0199000510130141500; HAEST CWM, 1982, BIOCHIM BIOPHYS ACTA, V694, P331, DOI 10.1016/0304-4157(82)90001-6; HELFRICH W, 1978, Z NATURFORSCH A, V33, P305; HO JS, 1989, PHYS REV LETT, V63, P1324, DOI 10.1103/PhysRevLett.63.1324; KANTOR Y, 1987, PHYS REV A, V36, P4020, DOI 10.1103/PhysRevA.36.4020; LANGE Y, 1982, J CELL BIOL, V92, P714, DOI 10.1083/jcb.92.3.714; LARCHE FC, 1986, PHYS REV LETT, V56, P1700, DOI 10.1103/PhysRevLett.56.1700; LEIBLER S, 1989, STATISTICAL MECHANIC, P45; LIPOWSKY R, 1990, PHYS REV LETT, V65, P2893, DOI 10.1103/PhysRevLett.65.2893; LIPOWSKY R, 1991, NATURE, V349, P475, DOI 10.1038/349475a0; LIU SC, 1987, J CELL BIOL, V104, P527, DOI 10.1083/jcb.104.3.527; NELSON DR, 1987, J PHYS-PARIS, V48, P1085, DOI 10.1051/jphys:019870048070108500; NELSON DR, 1989, STATISTICAL MECHANIC; NELSON DR, 1989, STATISTICAL MECHANIC, P137; Porod G., 1982, SMALL ANGLE XRAY SCA, P17, DOI DOI 10.1002/ACTP.1985.010360520; ROUX D, IN PRESS MODERN ATMO; SAFINYA CR, 1989, NATO ADV SCI I B-PHY, V211, P249; SAFINYA CR, 1986, PHYS REV LETT, V57, P2718, DOI 10.1103/PhysRevLett.57.2718; SAFINYA CR, 1989, PHYS REV LETT, V62, P1134, DOI 10.1103/PhysRevLett.62.1134; SHEETZ MP, 1978, J SUPRAMOL STR CELL, V8, P399, DOI 10.1002/jss.400080403; SHEN BW, 1984, J CELL BIOL, V99, P810, DOI 10.1083/jcb.99.3.810; SHOTTON DM, 1979, J MOL BIOL, V131, P303, DOI 10.1016/0022-2836(79)90078-0; SINHA SK, 1988, PHYS REV B, V38, P2297, DOI 10.1103/PhysRevB.38.2297; STOKKE BT, 1985, BIOCHIM BIOPHYS ACTA, V816, P102, DOI 10.1016/0005-2736(85)90398-0; STREY R, 1990, J CHEM SOC FARADAY T, V86, P2253, DOI 10.1039/ft9908602253; SVOBODA K, 1992, BIOPHYS J, V63, P784, DOI 10.1016/S0006-3495(92)81644-2; WEN X, 1992, NATURE, V355, P426, DOI 10.1038/355426a0	34	101	101	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 12	1993	259	5097					952	954		10.1126/science.8438153	http://dx.doi.org/10.1126/science.8438153			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL800	8438153				2022-12-24	WOS:A1993KL80000036
J	KURODA, Y; SUZUKI, N; KATAOKA, T				KURODA, Y; SUZUKI, N; KATAOKA, T			THE EFFECT OF POSTTRANSLATIONAL MODIFICATIONS ON THE INTERACTION OF RAS2 WITH ADENYLYL CYCLASE	SCIENCE			English	Article							INSECT BACULOVIRUS SYSTEM; GTP-BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE; POLYACRYLAMIDE GELS; CARBOXYL TERMINUS; FILM DETECTION; A-FACTOR; YEAST; P21RAS; GENES	Ras proteins undergo a series of posttranslational modifications that are critical for their cellular function. These modifications are necessary to anchor Ras proteins to the membrane. Yeast Ras2 proteins were purified with various degrees of modification and examined for their ability to activate their effector, adenylyl cyclase. The farnesylated intermediate form of Ras2 had more than 100 times higher affinity for adenylyl cyclase than for the unprocessed form. The subsequent palmitoylation reaction had little effect. In contrast, palmitoylation was required for efficient membrane localization of the Ras2 protein. These results indicate the importance of farnesylation in the interaction of Ras2 with its effector.	KOBE UNIV, SCH MED, DEPT PHYSIOL, 7-5-1 KUSUNOKI CHO, CHUO KU, KOBE 650, JAPAN	Kobe University								BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; Broach J R, 1990, Adv Cancer Res, V54, P79, DOI 10.1016/S0065-230X(08)60809-X; BROEK D, 1985, CELL, V41, P763, DOI 10.1016/S0092-8674(85)80057-X; BUSS JE, 1989, SCIENCE, V243, P1600, DOI 10.1126/science.2648572; BUSS JE, 1986, MOL CELL BIOL, V6, P116, DOI 10.1128/MCB.6.1.116; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CHEN ZQ, 1985, J VIROL, V56, P607, DOI 10.1128/JVI.56.2.607-612.1985; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; DEFEOJONES D, 1985, SCIENCE, V228, P179, DOI 10.1126/science.3883495; DESCHENES RJ, 1987, MOL CELL BIOL, V7, P2344, DOI 10.1128/MCB.7.7.2344; FIELD J, 1987, MOL CELL BIOL, V7, P2128, DOI 10.1128/MCB.7.6.2128; FUJIYAMA A, 1991, J BIOL CHEM, V266, P17926; FUJIYAMA A, 1987, EMBO J, V6, P223, DOI 10.1002/j.1460-2075.1987.tb04742.x; FUJIYAMA A, 1990, J BIOL CHEM, V265, P3362; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; GIBBS JB, 1989, MICROBIOL REV, V53, P171, DOI 10.1128/MMBR.53.2.171-185.1989; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HE B, 1991, P NATL ACAD SCI USA, V88, P11373, DOI 10.1073/pnas.88.24.11373; HIROYOSHI M, 1991, J BIOL CHEM, V266, P2962; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KATAOKA T, 1984, CELL, V37, P437, DOI 10.1016/0092-8674(84)90374-X; KATAOKA T, 1985, CELL, V40, P19, DOI 10.1016/0092-8674(85)90304-6; KIKUCHI A, 1988, J BIOL CHEM, V263, P2897; KRAMER W, 1987, METHOD ENZYMOL, V154, P350; KURODA Y, UNPUB; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; LOWE PN, 1990, ONCOGENE, V5, P1045; PAGE MJ, 1989, J BIOL CHEM, V264, P19147; POWERS S, 1986, CELL, V47, P413, DOI 10.1016/0092-8674(86)90598-2; QUI MS, 1991, J CELL BIOL, V115, P795; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STIMMEL JB, 1990, BIOCHEMISTRY-US, V29, P9651, DOI 10.1021/bi00493a021; SUMMERS MD, 1987, TEX AGR EXP STN B, V1555; SUZUKI N, 1990, P NATL ACAD SCI USA, V87, P8711, DOI 10.1073/pnas.87.22.8711; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VIALARD J, 1990, J VIROL, V64, P37, DOI 10.1128/JVI.64.1.37-50.1990; WANG JC, UNPUB; WILLUMSEN BM, 1984, EMBO J, V3, P2581, DOI 10.1002/j.1460-2075.1984.tb02177.x; YAMAWAKIKATAOKA Y, 1989, P NATL ACAD SCI USA, V86, P5693, DOI 10.1073/pnas.86.15.5693	44	132	135	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 29	1993	259	5095					683	686		10.1126/science.8430318	http://dx.doi.org/10.1126/science.8430318			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KJ688	8430318				2022-12-24	WOS:A1993KJ68800043
J	CAI, XD; GOLDE, TE; YOUNKIN, SG				CAI, XD; GOLDE, TE; YOUNKIN, SG			RELEASE OF EXCESS AMYLOID BETA-PROTEIN FROM A MUTANT AMYLOID BETA-PROTEIN PRECURSOR	SCIENCE			English	Article							FAMILIAL ALZHEIMERS-DISEASE; SOLUBLE DERIVATIVES; GENE; MUTATION; LOCALIZATION; PEPTIDE; BRAIN; CDNA	The 4-kilodalton amyloid beta protein (Abeta), which forms fibrillar deposits in Alzheimer's disease (AD), is derived from a large protein referred to as the amyloid beta protein precursor (betaAPP). Human neuroblastoma (M17) cells transfected with constructs expressing wild-type betaAPP or a mutant, betaAPP(DELTANL), recently linked to familial AD were compared. After continuous metabolic labeling for 8 hours, cells expressing betaAPP(DELTANL) had five times more of an Abeta-bearing, carboxyl terminal, betaAPP derivative than cells expressing wild-type betaAPP and they released six times more Abeta into the medium. Thus this mutant betaAPP may cause AD because its processing is altered in a way that releases increased amounts of Abeta.	CASE WESTERN RESERVE UNIV, INST PATHOL, DIV NEUROPATHOL, CLEVELAND, OH 44106 USA	Case Western Reserve University					NATIONAL INSTITUTE ON AGING [R01AG006656] Funding Source: NIH RePORTER; NIA NIH HHS [AG06656] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BURDICK D, 1992, J BIOL CHEM, V267, P546; CAI X, UNPUB; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P2252, DOI 10.1073/pnas.89.6.2252; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; COLE GM, 1990, INT CONGR SER, V884, P113; COLE GM, 1989, NEUROCHEM RES, V14, P933, DOI 10.1007/BF00965926; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; GLENNER G, 1983, BRANBURY REPORT, V15, P137; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V122, P1131, DOI 10.1016/0006-291X(84)91209-9; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; HAASS C, 1992, SCIENCE, V359, P322; HARDY J, 1991, LANCET, V337, P1342; HILBICH C, 1991, J MOL BIOL, V218, P149, DOI 10.1016/0022-2836(91)90881-6; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KIDD M, 1964, BRAIN, V87, P307, DOI 10.1093/brain/87.2.307; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; NARUSE S, 1991, LANCET, V337, P978, DOI 10.1016/0140-6736(91)91612-X; PALMERT MR, 1989, BIOCHEM BIOPH RES CO, V165, P182, DOI 10.1016/0006-291X(89)91052-8; PALMERT MR, 1989, P NATL ACAD SCI USA, V86, P6338, DOI 10.1073/pnas.86.16.6338; PRELLI F, 1988, J NEUROCHEM, V51, P648, DOI 10.1111/j.1471-4159.1988.tb01087.x; ROBAKIS NK, 1987, LANCET, V1, P384; SCHUBERT D, 1989, P NATL ACAD SCI USA, V86, P2066, DOI 10.1073/pnas.86.6.2066; SELKOE DJ, 1986, J NEUROCHEM, V46, P1820; SEUBERT P, 1992, SCIENCE, V359, P325; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; TERRY RD, 1963, BRAIN, V311, P528; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; YOSHIOKA K, 1991, BIOCHEM BIOPH RES CO, V178, P1141, DOI 10.1016/0006-291X(91)91011-Z	36	857	922	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 22	1993	259	5094					514	516		10.1126/science.8424174	http://dx.doi.org/10.1126/science.8424174			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KJ079	8424174				2022-12-24	WOS:A1993KJ07900034
J	CHANCE, PF; ALDERSON, MK; LEPPIG, KA; LENSCH, MW; MATSUNAMI, N; SMITH, B; SWANSON, PD; ODELBERG, SJ; DISTECHE, CM; BIRD, TD				CHANCE, PF; ALDERSON, MK; LEPPIG, KA; LENSCH, MW; MATSUNAMI, N; SMITH, B; SWANSON, PD; ODELBERG, SJ; DISTECHE, CM; BIRD, TD			DNA DELETION ASSOCIATED WITH HEREDITARY NEUROPATHY WITH LIABILITY TO PRESSURE PALSIES	CELL			English	Article							MARIE-TOOTH DISEASE; ARREST-SPECIFIC GENE; LINKAGE; TYPE-1A; MYELIN; LOCALIZATION; SEQUENCE; PROTEIN; MOUSE; MAP	Hereditary neuropathy with liability to pressure palsies (HNPP) is an autosomal dominant disorder that causes episodes of focal demyelinating neuropathy following minor trauma to peripheral nerves. We assign the HNPP locus to chromosome 17p11.2 and demonstrate the presence of a large interstitial deletion associated with this disorder in three unrelated pedigrees. De novo deletion is documented in one pedigree. The deleted region appears uniform in all pedigrees and includes the gene for peripheral myelin protein 22 (PMP-22), suggesting that underexpression of PMP-22 may cause HNPP. The deletion in HNPP spans approximately 1.5 Mb and includes all markers that are known to map within the Charcot-Marie-Tooth neuropathy type 1A (CMT1A) duplication. Furthermore, the breakpoints in HNPP and CMT1A map to the same intervals in 17p11.2, suggesting that these genetic disorders may be the result of reciprocal products of unequal crossover.	UNIV UTAH,MED CTR,DEPT NEUROL,SALT LAKE CITY,UT 84112; UNIV UTAH,MED CTR,DEPT HUMAN GENET,SALT LAKE CITY,UT 84112; UNIV UTAH,MED CTR,HOWARD HUGHES MED INST,SALT LAKE CITY,UT 84112; UNIV UTAH,MED CTR,MUSCULAR DYSTROPHY ASSOC,MUSCLE CLIN,SALT LAKE CITY,UT 84112; VET ADM MED CTR,SALT LAKE CITY,UT 84132; UNIV WASHINGTON,SCH MED,DEPT PATHOL,DIV GENET PATHOL,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED,DEPT MED,DIV NEUROL,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED,DEPT MED,DIV MED GENET,SEATTLE,WA 98195; VET ADM MED CTR,SEATTLE,WA 98195	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA)	CHANCE, PF (corresponding author), UNIV UTAH,MED CTR,DEPT PEDIAT,DIV MED GENET,SALT LAKE CITY,UT 84112, USA.		Chance, Phillip/AAX-5826-2020					AGUAYO AJ, 1977, NATURE, V265, P73, DOI 10.1038/265073a0; BEHSE F, 1972, BRAIN, V95, P777, DOI 10.1093/brain/95.4.777; BIRD TD, 1982, AM J HUM GENET, V34, P388; BRADLEY WG, 1975, BRAIN, V98, P381, DOI 10.1093/brain/98.3.381; BUCHBERG AM, 1989, GENETICS, V122, P153; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; CHANCE PF, 1992, NEUROLOGY, V42, P2295, DOI 10.1212/WNL.42.12.2295; CHANCE PF, 1990, AM J HUM GENET, V47, P915; CHANCE PF, 1992, NEUROLOGY, V42, P2037, DOI 10.1212/WNL.42.10.2037; DAVIES DM, 1954, LANCET, V2, P266; DAVISSON MT, 1978, CYTOGENET CELL GENET, V22, P552, DOI 10.1159/000131022; De Jong J, 1947, PSYCHIAT NEUROL BL A, V50, P60; DEBRUYNE J, 1980, J NEUROL SCI, V47, P385, DOI 10.1016/0022-510X(80)90091-X; DYCK PJ, 1981, ANN NEUROL, V10, P222, DOI 10.1002/ana.410100304; DYCK PJ, 1992, PERIPHERAL NEUROPATH, P1094; EARL CJ, 1964, Q J MED, V33, P481; FALCONER DS, 1951, J GENET, V50, P192, DOI 10.1007/BF02996215; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FISCHBECK KH, 1986, ANN NEUROL, V20, P527, DOI 10.1002/ana.410200414; GAL A, 1985, HUM GENET, V70, P38, DOI 10.1007/BF00389456; GREENBERG F, 1991, AM J HUM GENET, V49, P1207; HENRY EW, 1988, SCIENCE, V241, P344, DOI 10.1126/science.3388045; HOOGENDIJK JE, 1992, LANCET, V339, P1081, DOI 10.1016/0140-6736(92)90668-S; LEBO RV, 1992, AM J HUM GENET, V50, P42; LUPSKI JR, 1992, NAT GENET, V1, P29, DOI 10.1038/ng0492-29; LUPSKI JR, 1991, CELL, V66, P219, DOI 10.1016/0092-8674(91)90613-4; MADRID R, 1975, J NEUROL SCI, V25, P415, DOI 10.1016/0022-510X(75)90263-4; MANFIOLETTI G, 1990, MOL CELL BIOL, V10, P2924, DOI 10.1128/MCB.10.6.2924; MATSUNAMI N, 1992, NAT GENET, V1, P176, DOI 10.1038/ng0692-176; MOYZIS RK, 1987, CHROMOSOMA, V95, P375, DOI 10.1007/BF00333988; ODELBERG SJ, 1989, GENOMICS, V5, P915, DOI 10.1016/0888-7543(89)90134-1; PATEL PI, 1992, NAT GENET, V1, P157; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; RAEYMAEKER SP, 1991, NEUROMUSC DIS, V1, P93; RAEYMAEKERS P, 1992, J MED GENET, V29, P5, DOI 10.1136/jmg.29.1.5; Smith A.C.M.M.L., 1982, AM J HUM GENET, V34; SMITH PP, 1992, GENE CHROMOSOME CANC, V5, P150, DOI 10.1002/gcc.2870050209; SPREYER P, 1991, EMBO J, V10, P3661, DOI 10.1002/j.1460-2075.1991.tb04933.x; STAAL A, 1965, NEUROLOGY, V15, P1008, DOI 10.1212/WNL.15.11.1008; SUTER U, 1992, P NATL ACAD SCI USA, V89, P4382, DOI 10.1073/pnas.89.10.4382; SUTER U, 1992, NATURE, V356, P241, DOI 10.1038/356241a0; TIMMERMAN V, 1992, NAT GENET, V1, P171, DOI 10.1038/ng0692-171; VALENTIJN LJ, 1992, NAT GENET, V1, P166, DOI 10.1038/ng0692-166; VANCE JM, 1989, EXP NEUROL, V104, P186, DOI 10.1016/S0014-4886(89)80013-5; VANCE JM, 1991, GENOMICS, V9, P623, DOI 10.1016/0888-7543(91)90355-I; WELCHER AA, 1991, P NATL ACAD SCI USA, V88, P7195, DOI 10.1073/pnas.88.16.7195; WINDEBANK AJ, 1992, PERIPHERAL NEUROPATH, P1137; WRIGHT EC, 1990, GENOMICS, V7, P103, DOI 10.1016/0888-7543(90)90524-X	48	677	703	0	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 15	1993	72	1					143	151		10.1016/0092-8674(93)90058-X	http://dx.doi.org/10.1016/0092-8674(93)90058-X			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KG955	8422677				2022-12-24	WOS:A1993KG95500018
J	WEBSTER, A; HAY, RT; KEMP, G				WEBSTER, A; HAY, RT; KEMP, G			THE ADENOVIRUS PROTEASE IS ACTIVATED BY A VIRUS-CODED DISULFIDE-LINKED PEPTIDE	CELL			English	Article							INFECTED-CELLS; PROTEINASE; POLYPROTEIN; TYPE-2; CLEAVAGE; POLYPEPTIDE; SPECIFICITY; EXPRESSION; COMPONENT; ACIDS	In common with many other viruses, adenoviruses code for a protease essential for the development of infectivity. Recombinant adenovirus protease was active in crude in vitro complementation assays but was inactive with peptide or purified protein substrates. Activity was reconstituted by a component of adenovirus virions, which was identified as GVQSLKRRRCF, a peptide derived from the virus protein pVI. Synthetic peptides were used to demonstrate that the cysteine is essential and that the disulphide-linked dimer is required for activity. It is proposed that the adenovirus protease is a cysteine protease and that its activation by the peptide involves thiol-disulphide interchange, which serves to expose the active site cysteine. This represents a novel strategy for controlling the activity of a protease that is required for virus maturation.			WEBSTER, A (corresponding author), UNIV ST ANDREWS, SCH BIOL & MED SCI, DIV BIOCHEM & MOLEC BIOL, ST ANDREWS KY16 9ST, FIFE, SCOTLAND.		Hay, Ronald/S-3233-2019; Hay, Ronald T/F-9338-2011	Hay, Ronald/0000-0001-7113-9024; Hay, Ronald T/0000-0001-7113-9024				ANDERSON CW, 1990, VIROLOGY, V177, P259, DOI 10.1016/0042-6822(90)90479-B; ANDERSON CW, 1973, J VIROL, V12, P241, DOI 10.1128/JVI.12.2.241-252.1973; ATHERTON E, 1988, TETRAHEDRON, V44, P843, DOI 10.1016/S0040-4020(01)86121-4; BHATTI AR, 1978, BIOCHEM BIOPH RES CO, V81, P973, DOI 10.1016/0006-291X(78)91446-8; BOND JS, 1987, ANNU REV BIOCHEM, V56, P333, DOI 10.1146/annurev.bi.56.070187.002001; BOUDIN ML, 1980, VIROLOGY, V101, P144, DOI 10.1016/0042-6822(80)90491-2; BROCKLEHURST K, 1973, NATURE-NEW BIOL, V242, P167, DOI 10.1038/newbio242167a0; CAI F, 1992, BIOCHIM BIOPHYS ACTA, V1129, P339, DOI 10.1016/0167-4781(92)90514-Z; CHAMBERS TJ, 1991, J VIROL, V65, P6042, DOI 10.1128/JVI.65.11.6042-6050.1991; DEGROOT RJ, 1990, EMBO J, V9, P2631, DOI 10.1002/j.1460-2075.1990.tb07445.x; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; HELLEN CUT, 1992, EXPERIENTIA, V48, P201, DOI 10.1007/BF01923512; HIERHOLZER JC, 1991, ARCH VIROL, V121, P179, DOI 10.1007/BF01316753; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.biochem.54.1.237; HORWITZ MS, 1990, FIELDS VIROLOGY, V2, P1723; KITTS PA, 1990, NUCLEIC ACIDS RES, V18, P5667, DOI 10.1093/nar/18.19.5667; KRAUSSLICH HG, 1991, P NATL ACAD SCI USA, V88, P3213, DOI 10.1073/pnas.88.8.3213; LIANG YK, 1983, J MOL BIOL, V167, P217, DOI 10.1016/S0022-2836(83)80044-8; NAVIA MA, 1989, NATURE, V337, P615, DOI 10.1038/337615a0; NOIVA R, 1992, J BIOL CHEM, V267, P3553; RUSSELL WC, 1977, J GEN VIROL, V34, P19, DOI 10.1099/0022-1317-34-1-19; SCHEIDTMANN KH, 1989, PROTEIN STRUCTURE PR, P93; Summers MD, 1987, TEXAS AGR EXP STATIO, V1555; TEMPERLEY SM, 1992, EMBO J, V11, P761, DOI 10.1002/j.1460-2075.1992.tb05109.x; TEMPERLEY SM, 1991, NUCLEIC ACIDS RES, V19, P3243, DOI 10.1093/nar/19.12.3243; TREMBLAY ML, 1983, BIOCHIM BIOPHYS ACTA, V743, P239, DOI 10.1016/0167-4838(83)90220-0; UDENFRIEND S, 1972, SCIENCE, V178, P871, DOI 10.1126/science.178.4063.871; VANOOSTRUM J, 1985, J VIROL, V56, P439, DOI 10.1128/JVI.56.2.439-448.1985; WEBER J, 1976, J VIROL, V17, P462, DOI 10.1128/JVI.17.2.462-471.1976; WEBSTER A, 1989, J GEN VIROL, V70, P3225, DOI 10.1099/0022-1317-70-12-3225; WEBSTER A, 1989, J GEN VIROL, V70, P3215, DOI 10.1099/0022-1317-70-12-3215; WISKERCHEN M, 1991, VIROLOGY, V184, P341, DOI 10.1016/0042-6822(91)90850-B; WOLF DH, 1992, EXPERIENTIA, V48, P117, DOI 10.1007/BF01923505; WYCKOFF EE, 1990, P NATL ACAD SCI USA, V87, P9529, DOI 10.1073/pnas.87.24.9529	34	136	141	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 15	1993	72	1					97	104		10.1016/0092-8674(93)90053-S	http://dx.doi.org/10.1016/0092-8674(93)90053-S			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KG955	8422686				2022-12-24	WOS:A1993KG95500013
J	MAGGIONI, AP; MASERI, A; FRESCO, C; FRANZOSI, MG; MAURI, F; SANTORO, E; TOGNONI, G				MAGGIONI, AP; MASERI, A; FRESCO, C; FRANZOSI, MG; MAURI, F; SANTORO, E; TOGNONI, G			AGE-RELATED INCREASE IN MORTALITY AMONG PATIENTS WITH 1ST MYOCARDIAL INFARCTIONS TREATED WITH THROMBOLYSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background. The overall rate of mortality due to ischemic heart disease is known to increase progressively with age. We evaluated the relation between the mortality rate and age in patients with first myocardial infarctions treated with thrombolytic therapy. Methods. We studied 9720 patients with first infarctions who had been enrolled in the GISSI-2 trial. (This trial compared the efficacy of tissue plasminogen activator with that of streptokinase in patients with myocardial infarction.) Of these, only 35 percent had a history of angina. The relation between age and mortality during hospitalization and during the six months after discharge was determined by unadjusted and adjusted analyses. Results. The in-hospital mortality rate was 1.9 percent among patients 40 years old or younger, but it increased to 31.9 percent among those more than 80 years old; however, values for indicators of infarct size did not increase with age. Autopsies were performed in 20 percent of the 772 patients who died in the hospital; the findings showed that the frequency of cardiac rupture increased from 19 percent among patients 60 years old or younger to 86 percent among those more than 70 years old. The mortality rate for the first six months after hospital discharge also increased significantly with age. After adjustment for confounding variables, older age continued to be significantly associated with a higher risk of in-hospital and post-discharge death. When age was introduced into a multivariate model as a continuous variable, the risk of death was estimated to increase by about 6 percent per year for both in-hospital and six-month mortality rates. Conclusions. In patients with first myocardial infarctions who received thrombolytic therapy, age was a powerful independent predictor of both in-hospital and post-discharge mortality rates. The exponential, age-related increase in the mortality rate did not appear to be explained by larger infarcts.			MAGGIONI, AP (corresponding author), GISSI 2, COORDINATING CTR, VIA ERITREA 62, I-20157 MILAN, ITALY.		Fresco, Claudio/M-5203-2015; Maggioni, Aldo Pietro/AAL-5334-2020; santoro, eugenio/ABG-7901-2020	Fresco, Claudio/0000-0001-7123-8153; Maggioni, Aldo Pietro/0000-0003-2764-6779; santoro, eugenio/0000-0002-5719-9896				ACKERMAN RF, 1950, CIRCULATION, V1, P1345, DOI 10.1161/01.CIR.1.6.1345; [Anonymous], 1990, LANCET, V336, P65; [Anonymous], 1988, LANCET, V1, P921; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V1, P397; BATES RJ, 1977, AM J CARDIOL, V40, P429, DOI 10.1016/0002-9149(77)90167-9; BOGATY P, 1993, CIRCULATION, V87, P1938, DOI 10.1161/01.CIR.87.6.1938; CAPASSO JM, 1990, AM J PHYSIOL, V259, pH1086, DOI 10.1152/ajpheart.1990.259.4.H1086; DEVITA C, 1990, LANCET, V335, P289, DOI 10.1016/0140-6736(90)90104-D; FOLLAND ED, 1979, CIRCULATION, V60, P760, DOI 10.1161/01.CIR.60.4.760; GERSTENBLITH G, 1977, CIRCULATION, V56, P273, DOI 10.1161/01.CIR.56.2.273; GURWITZ JH, 1991, JAMA-J AM MED ASSOC, V265, P1720, DOI 10.1001/jama.265.13.1720; HACKETT D, 1988, EUR HEART J, V9, P1317, DOI 10.1093/oxfordjournals.eurheartj.a062449; HUNT D, 1992, LANCET, V339, P753; KILLIP T, 1967, AM J CARDIOL, V20, P457, DOI 10.1016/0002-9149(67)90023-9; OLIVETTI G, 1991, CIRC RES, V68, P1560, DOI 10.1161/01.RES.68.6.1560; Schlesselman JJ, 1982, CASE CONTROL STUDIES, P171; VESTAL RE, 1979, CLIN PHARMACOL THER, V26, P181; WAGNER GS, 1982, CIRCULATION, V65, P342, DOI 10.1161/01.CIR.65.2.342; WHITE NK, 1950, CIRCULATION, V1, P645, DOI 10.1161/01.CIR.1.4.645; 1988, LANCET, V2, P292; 1991, AM J CARDIOL S, V68, pD87; 1992, AM J CARDIOL S, V70, pC62	23	318	330	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 11	1993	329	20					1442	1448		10.1056/NEJM199311113292002	http://dx.doi.org/10.1056/NEJM199311113292002			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF292	8413454				2022-12-24	WOS:A1993MF29200002
J	SCHEDL, A; MONTOLIU, L; KELSEY, G; SCHUTZ, G				SCHEDL, A; MONTOLIU, L; KELSEY, G; SCHUTZ, G			A YEAST ARTIFICIAL CHROMOSOME COVERING THE TYROSINASE GENE CONFERS COPY NUMBER-DEPENDENT EXPRESSION IN TRANSGENIC MICE	NATURE			English	Article							MOUSE TYROSINASE; ALBINO MUTATION; LARGE INSERTS; HUMAN DNA; LIBRARIES; CLONING; CELLS	EXPRESSION of transgenes in mice often fails to follow the normal temporal and spatial pattern and to reach the same level as the endogenous copies1,2. Only in exceptional cases has position-independent and copy number-dependent expression been reproduced3. The size constraint of standard constructs may prevent the inclusion of important remote regulatory elements. Yeast artificial chromosomes (YACs)4 provide a means of cloning large DNA fragments and the transfer of YAC DNA into somatic cells has been reported5-9. We have previously produced transgenic mice carrying a 35 kilobase YAC construct10. Here we report the transfer of a 250 kilobase YAC covering the mouse tyrosinase gene into mice by pronuclear injection of gel-purified YAC DNA. The YAC was inserted into the mouse genome without major rearrangements and expression of the YAC-borne tyrosinase gene resulted in complete rescue of the albino phenotype of the recipient mice. Expression from the transgene reached levels comparable to that of the endogenous gene and showed copy number dependence and position independence.	GERMAN CANC RES CTR,DIV MOLEC BIOL CELL 1,NEUENHEIMER FELD 280,W-6900 HEIDELBERG,GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ)			Montoliu, Lluis/I-2039-2015; Schedl, Andreas/F-8823-2015; Schedl, Andreas/GOP-3427-2022	Montoliu, Lluis/0000-0003-3941-1176; Schedl, Andreas/0000-0001-9380-7396; Kelsey, Gavin/0000-0002-9762-5634				ANAND R, 1989, NUCLEIC ACIDS RES, V17, P3425, DOI 10.1093/nar/17.9.3425; BEERMANN F, 1990, EMBO J, V9, P2819, DOI 10.1002/j.1460-2075.1990.tb07470.x; BURKE DT, 1987, SCIENCE, V236, P806, DOI 10.1126/science.3033825; ELICEIRI B, 1991, P NATL ACAD SCI USA, V88, P2179, DOI 10.1073/pnas.88.6.2179; GAUDETTE MF, 1991, NUCLEIC ACIDS RES, V19, P1879, DOI 10.1093/nar/19.8.1879; GNIRKE A, 1991, EMBO J, V10, P1629, DOI 10.1002/j.1460-2075.1991.tb07685.x; GNIRKE A, 1991, SOMAT CELL MOLEC GEN, V17, P573, DOI 10.1007/BF01233622; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; Hogan B., 1986, MANIPULATING MOUSE E; JACKSON IJ, 1990, P NATL ACAD SCI USA, V87, P7010, DOI 10.1073/pnas.87.18.7010; JAENISCH R, 1988, SCIENCE, V240, P1468, DOI 10.1126/science.3287623; KELLUM R, 1991, CELL, V64, P941, DOI 10.1016/0092-8674(91)90318-S; KELSEY G, 1992, GENOMICS, V14, P275, DOI 10.1016/S0888-7543(05)80217-4; LARIN Z, 1991, P NATL ACAD SCI USA, V88, P4123, DOI 10.1073/pnas.88.10.4123; LOVELLBADGE RH, 1987, TERATOCARCINOMA EMBR; MUELLER G, 1988, EMBO (European Molecular Biology Organization) Journal, V7, P2723; PACHNIS V, 1990, P NATL ACAD SCI USA, V87, P5109, DOI 10.1073/pnas.87.13.5109; PALMITER RD, 1986, ANNU REV GENET, V20, P465, DOI 10.1146/annurev.ge.20.120186.002341; PORTER S, 1991, DEV GENET, V12, P393, DOI 10.1002/dvg.1020120604; REEVES RH, 1990, GENET ANAL TECHN APP, V5, P107; ROBINSON MO, 1991, NUCLEIC ACIDS RES, V19, P1557, DOI 10.1093/nar/19.7.1557; RUPPERT S, 1988, EMBO J, V7, P2715, DOI 10.1002/j.1460-2075.1988.tb03125.x; RUPPERT S, 1988, THESIS RUPRECHT KARL; SCHEDL A, 1992, NUCLEIC ACIDS RES, V20, P3073, DOI 10.1093/nar/20.12.3073; SHIBAHARA S, 1990, EUR J BIOCHEM, V189, P455, DOI 10.1111/j.1432-1033.1990.tb15510.x; SMITH DR, 1990, P NATL ACAD SCI USA, V87, P8242, DOI 10.1073/pnas.87.21.8242; STIEF A, 1989, NATURE, V345, P341; STRAUSS WM, 1992, EMBO J, V11, P417, DOI 10.1002/j.1460-2075.1992.tb05070.x; TANAKA S, 1990, DEVELOPMENT, V108, P223; WEIS JH, 1992, TRENDS GENET, V8, P263, DOI 10.1016/0168-9525(92)90242-V; YOKOYAMA T, 1990, NUCLEIC ACIDS RES, V18, P7293, DOI 10.1093/nar/18.24.7293	31	232	270	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 18	1993	362	6417					258	261		10.1038/362258a0	http://dx.doi.org/10.1038/362258a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KT026	8459851				2022-12-24	WOS:A1993KT02600060
J	LEVY, DN; FERNANDES, LS; WILLIAMS, WV; WEINER, DB				LEVY, DN; FERNANDES, LS; WILLIAMS, WV; WEINER, DB			INDUCTION OF CELL-DIFFERENTIATION BY HUMAN IMMUNODEFICIENCY VIRUS-1 VPR	CELL			English	Article							TRANS-ACTIVATOR GENE; VIRION-ASSOCIATED PROTEIN; OPEN READING FRAME; MUTATIONAL ANALYSIS; HTLV-III; LINE TE671; SOR GENE; INFECTION; TYPE-2; HIV-1	Cell lines from rhabdomyosarcomas, which are tumors of muscle origin, have been used as models of CD4-independent HIV infection. These cell lines can be induced to differentiate in vitro. We report here that the vpr gene of HIV1 is sufficient for the differentiation of the human rhabdomyosarcoma cell line TE671. Differentiated cells are characterized by great enlargement, altered morphology, lack of replication, and high level expression of the muscle-specific protein myosin. We have also observed the morphological differentiation and inhibition of proliferation of two other transformed cell lines. vpr-transfected cells remain fully viable in culture for extended periods. These observations elucidate a potential role for vpr in the virus life cycle and raise the possibility that some aspects of HIV-induced pathologies may be caused by a disturbance of cells by vpr.	WISTAR INST,PHILADELPHIA,PA 19104	The Wistar Institute	LEVY, DN (corresponding author), UNIV PENN,DEPT MED,INST BIOTECHNOL & ADV MOLEC MED,PHILADELPHIA,PA 19104, USA.		Weiner, David B/H-8579-2014	Williams, William/0000-0003-3611-9284				ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; AGUANNO S, 1990, CANCER RES, V50, P3377; ARYA SK, 1985, SCIENCE, V229, P69, DOI 10.1126/science.2990040; BRUNI C, 1979, MUSCLE REGENERATION, P265; CANN AJ, 1989, AIDS S1, V3, P19; CHEN TR, 1989, NATURE, V340, P106, DOI 10.1038/340106b0; CHERNOFF D, 1990, AIDS KNOWLEDGE BASE; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAPHAM PR, 1989, NATURE, V337, P368, DOI 10.1038/337368a0; CLAPHAM PR, 1991, VIROLOGY, V181, P703, DOI 10.1016/0042-6822(91)90904-P; COHEN EA, 1990, J ACQ IMMUN DEF SYND, V3, P11; COHEN EA, 1990, J VIROL, V64, P3097, DOI 10.1128/JVI.64.6.3097-3099.1990; COHEN PT, 1990, AIDS KNOWLEDGE BASE; DALAKAS M, 1991, PEDIATRIC AIDS CHALL, P420; DAYTON AI, 1986, CELL, V44, P941, DOI 10.1016/0092-8674(86)90017-6; DEDERA D, 1989, J VIROL, V63, P3205, DOI 10.1128/JVI.63.7.3205-3208.1989; FELIX CA, 1992, CANCER RES, V52, P2243; FISHER AG, 1986, NATURE, V320, P367, DOI 10.1038/320367a0; FISHER AG, 1987, SCIENCE, V237, P888, DOI 10.1126/science.3497453; FLORINI JR, 1991, ANNU REV PHYSIOL, V53, P201, DOI 10.1146/annurev.ph.53.030191.001221; GRODY WW, 1990, AM J CARDIOL, V66, P203, DOI 10.1016/0002-9149(90)90589-S; GUYADER M, 1989, EMBO J, V8, P1169, DOI 10.1002/j.1460-2075.1989.tb03488.x; HAGGERTY S, 1991, AIDS RES HUM RETROV, V7, P501, DOI 10.1089/aid.1991.7.501; HARADA S, 1986, VIROLOGY, V154, P249, DOI 10.1016/0042-6822(86)90451-4; HATTORI N, 1990, P NATL ACAD SCI USA, V87, P8080, DOI 10.1073/pnas.87.20.8080; HITI AL, 1989, MOL CELL BIOL, V9, P4722, DOI 10.1128/MCB.9.11.4722; KAPPES JC, 1991, VIROLOGY, V184, P197, DOI 10.1016/0042-6822(91)90836-Z; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LAMPERTH L, 1990, Neurology, V40, P121; LI L, 1992, ADV CANCER RES, V58, P95, DOI 10.1016/S0065-230X(08)60292-4; Ling L L, 1991, PCR Methods Appl, V1, P63; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MARCK C, 1988, NUCLEIC ACIDS RES, V16, P1829, DOI 10.1093/nar/16.5.1829; MCALLISTER RM, 1969, CANCER-AM CANCER SOC, V24, P520, DOI 10.1002/1097-0142(196909)24:3<520::AID-CNCR2820240313>3.0.CO;2-M; MCALLISTER RM, 1977, INT J CANCER, V20, P206, DOI 10.1002/ijc.2910200207; MILLER CW, 1990, CANCER RES, V50, P7950; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MULLIGAN LM, 1990, P NATL ACAD SCI USA, V87, P5863, DOI 10.1073/pnas.87.15.5863; OGAWA K, 1989, J VIROL, V63, P4110, DOI 10.1128/JVI.63.9.4110-4114.1989; ROULSTON A, 1992, J EXP MED, V175, P751, DOI 10.1084/jem.175.3.751; SCHNITTMAN SM, 1990, P NATL ACAD SCI USA, V87, P7727, DOI 10.1073/pnas.87.19.7727; SCHUITEMAKER H, 1992, J CLIN INVEST, V89, P1154, DOI 10.1172/JCI115697; SHIBATA R, 1990, J MED PRIMATOL, V19, P217; SHIBATA R, 1990, J VIROL, V64, P742, DOI 10.1128/JVI.64.2.742-747.1990; SIEGEL HN, 1988, DEV BRAIN RES, V44, P269, DOI 10.1016/0165-3806(88)90225-8; SODROSKI J, 1986, SCIENCE, V231, P1549, DOI 10.1126/science.3006244; SRINIVASAN A, 1988, ARCH VIROL, V99, P21, DOI 10.1007/BF01311020; STANLEY SK, 1992, J IMMUNOL, V149, P689; STRATTON MR, 1989, CARCINOGENESIS, V10, P899, DOI 10.1093/carcin/10.5.899; STREBEL K, 1988, SCIENCE, V241, P1221, DOI 10.1126/science.3261888; STREBEL K, 1987, NATURE, V328, P728, DOI 10.1038/328728a0; TAPSCOTT SJ, 1991, J CLIN INVEST, V87, P1133, DOI 10.1172/JCI115109; TATENO M, 1989, P NATL ACAD SCI USA, V86, P4287, DOI 10.1073/pnas.86.11.4287; TERWILLIGER EF, 1989, P NATL ACAD SCI USA, V86, P5163, DOI 10.1073/pnas.86.13.5163; TERWILLIGER EF, 1992, AIDS RES REV, V2, P3; TRISTEM M, 1992, EMBO J, V11, P3405, DOI 10.1002/j.1460-2075.1992.tb05419.x; TRISTEM M, 1990, NATURE, V347, P341, DOI 10.1038/347341b0; VOGEL J, 1988, NATURE, V335, P606, DOI 10.1038/335606a0; WEBER J, 1989, J GEN VIROL, V70, P2653, DOI 10.1099/0022-1317-70-10-2653; WEINER DB, 1991, PATHOBIOLOGY, V59, P361, DOI 10.1159/000163679; WEINER DB, 1989, ONCOGENE, V4, P1175; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WEISS RA, 1988, J ACQ IMMUN DEF SYND, V1, P536; WERNER A, 1990, AIDS, V4, P537, DOI 10.1097/00002030-199006000-00007; WONGSTAAL F, 1987, AIDS RES HUM RETROV, V3, P33, DOI 10.1089/aid.1987.3.33; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YU XF, 1990, J VIROL, V64, P5688, DOI 10.1128/JVI.64.11.5688-5693.1990; YUAN X, 1990, AIDS RES HUM RETROV, V6, P1265, DOI 10.1089/aid.1990.6.1265	69	212	228	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 26	1993	72	4					541	550		10.1016/0092-8674(93)90073-Y	http://dx.doi.org/10.1016/0092-8674(93)90073-Y			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KP165	8440020				2022-12-24	WOS:A1993KP16500009
J	FISHER, DE; PARENT, LA; SHARP, PA				FISHER, DE; PARENT, LA; SHARP, PA			HIGH-AFFINITY DNA-BINDING MYC ANALOGS - RECOGNITION BY AN ALPHA-HELIX	CELL			English	Article							LEUCINE-ZIPPER; SACCHAROMYCES-CEREVISIAE; DIMERIZATION SPECIFICITY; NEGATIVE REGULATOR; PROTEIN; FOS; JUN; TRANSCRIPTION; COMPLEX; DOMAINS	Myc and other basic-helix-loop-helix-leucine zipper (b-HLH-ZIP) proteins bind the sequence CACGTG. Exhaustive mutagenesis in the basic domain identified four amino acids critical for DNA binding with spacing suggestive of an alpha-helical face. Surprisingly, two highly conserved amino acids were nonessential for DNA binding. Circular dichroism demonstrated a DNA-induced alpha-helical transition. A series of analogs were constructed with multiple simultaneous alanine substitutions at nonessential positions and a critical lysine for arginine substitution. In this way 35-fold higher specific affinity for CACGTG was obtained as compared with the basic domain of c-Myc. These b-HLH-ZIP proteins appear to bind the same palindromic sequence and may compete for common sites in vivo. Additionally, a C-terminal basic region clamp motif was identified that was also identifiable in crystal structures from several different families of DNA-binding factors.	CHILDRENS HOSP MED CTR,DEPT PEDIAT HEMATOL & ONCOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT PEDIAT HEMATOL & ONCOL,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	FISHER, DE (corresponding author), MIT,CTR CANC RES,DEPT BIOL,CAMBRIDGE,MA 02139, USA.				NCI NIH HHS [P01-CA42063, P30-CA14051] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA042063, P30CA014051] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTHONYCAHILL SJ, 1992, SCIENCE, V255, P979, DOI 10.1126/science.1312255; BAKER RE, 1990, MOL CELL BIOL, V10, P2458, DOI 10.1128/MCB.10.6.2458; BECKMANN H, 1991, GENE DEV, V5, P1057, DOI 10.1101/gad.5.6.1057; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; CAI MJ, 1990, CELL, V61, P437, DOI 10.1016/0092-8674(90)90525-J; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; CHAKRABARTTY A, 1991, NATURE, V351, P586, DOI 10.1038/351586a0; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; DAVIS RL, 1992, SCIENCE, V256, P1027, DOI 10.1126/science.1317057; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DEPINHO RA, 1987, GENE DEV, V1, P1311, DOI 10.1101/gad.1.10.1311; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; ELLIS HM, 1990, CELL, V61, P27, DOI 10.1016/0092-8674(90)90212-W; FISHER DE, 1991, GENE DEV, V5, P2342, DOI 10.1101/gad.5.12a.2342; FISHER DE, 1992, IN PRESS P NATL ACAD; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HALEZONETIS TD, 1992, SCIENCE, V255, P464; HEGDE RS, 1992, NATURE, V359, P505, DOI 10.1038/359505a0; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KRISTIE TM, 1989, EMBO J, V8, P4229, DOI 10.1002/j.1460-2075.1989.tb08608.x; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LASSAR AB, 1986, CELL, V47, P649, DOI 10.1016/0092-8674(86)90507-6; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; MARQUSEE S, 1987, P NATL ACAD SCI USA, V84, P8898, DOI 10.1073/pnas.84.24.8898; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NICHOLSON H, 1988, NATURE, V336, P651, DOI 10.1038/336651a0; OGAWA N, 1990, MOL CELL BIOL, V10, P2224, DOI 10.1128/MCB.10.5.2224; ONEIL KT, 1990, SCIENCE, V249, P774, DOI 10.1126/science.2389143; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; OTTING G, 1990, EMBO J, V9, P3085, DOI 10.1002/j.1460-2075.1990.tb07505.x; PATEL L, 1990, NATURE, V347, P572, DOI 10.1038/347572a0; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; ROMAN C, 1991, SCIENCE, V254, P94, DOI 10.1126/science.1840705; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SELLERS JW, 1989, NATURE, V341, P74, DOI 10.1038/341074a0; TALANIAN RV, 1990, SCIENCE, V249, P769, DOI 10.1126/science.2389142; TALANIAN RV, 1992, BIOCHEMISTRY-US, V31, P6871, DOI 10.1021/bi00145a002; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722; WECHSLER DS, 1992, P NATL ACAD SCI USA, V89, P7635, DOI 10.1073/pnas.89.16.7635; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; WEISS MA, 1990, NATURE, V347, P545; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5	53	80	81	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 12	1993	72	3					467	476		10.1016/0092-8674(93)90122-7	http://dx.doi.org/10.1016/0092-8674(93)90122-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KM162	8431949				2022-12-24	WOS:A1993KM16200015
J	TOLLERVEY, D; LEHTONEN, H; JANSEN, R; KERN, H; HURT, EC				TOLLERVEY, D; LEHTONEN, H; JANSEN, R; KERN, H; HURT, EC			TEMPERATURE-SENSITIVE MUTATIONS DEMONSTRATE ROLES FOR YEAST FIBRILLARIN IN PRE-RIBOSOMAL-RNA PROCESSING, PRE-RIBOSOMAL-RNA METHYLATION, AND RIBOSOME ASSEMBLY	CELL			English	Article							SMALL NUCLEOLAR RNA; SMALL NUCLEAR-RNA; SACCHAROMYCES-CEREVISIAE; INVITRO SYNTHESIS; PROTEIN GENES; COILED BODY; U3 SNRNA; DEPLETION; SUBUNITS; CELLS	We have generated temperature-sensitive lethal point mutations in the small nucleolar RNA-associated protein fibrillarin (encoded by the NOP1 gene in yeast) and analyzed their effects on ribosome synthesis. The five alleles tested all prevent synthesis of normal ribosomes, but in dramatically different ways. At the non-permissive temperature, the nop1.2 and nop1.5 alleles prevent synthesis of both 18S and 25S rRNA and all pre-rRNA species except the 35S primary transcript. In contrast, the nop1.3, nop1.4, and nop1.7 alleles do not strongly impair processing. In nop1.3 strains, nucleolar methylation of pre-rRNA is strongly inhibited; late, cytoplasmic methylation of 18S rRNA and tRNA methylation continue. The nop1.4 and nop1.7 alleles result in the synthesis of cytoplasmic 60S ribosomal subunits with strongly aberrant mobilities on sucrose gradients even at the permissive temperature, owing to the impairment of a late step in ribosome assembly. Thus, all major posttranscriptional activities in ribosome synthesis, pre-rRNA processing, pre-rRNA modification, and ribosome assembly are dependent on fibrillarin.			TOLLERVEY, D (corresponding author), EUROPEAN MOLEC BIOL LAB, MEYERHOFSTR 1, W-6900 HEIDELBERG, GERMANY.		Ed Hurt, Dr./AAE-8874-2019; Tollervey, David/AAR-6662-2020	Ed Hurt, Dr./0000-0002-4535-8255; Tollervey, David/0000-0003-2894-2772				ALIX JH, 1982, MICROBIOL REV, V46, P281, DOI 10.1128/MMBR.46.3.281-295.1982; ARIS JP, 1991, P NATL ACAD SCI USA, V88, P931, DOI 10.1073/pnas.88.3.931; BASERGA SJ, 1992, IN PRESS GENES DEV, V6; BELTRAME M, 1992, EMBO J, V11, P1531, DOI 10.1002/j.1460-2075.1992.tb05198.x; BRAND RC, 1977, EUR J BIOCHEM, V75, P311, DOI 10.1111/j.1432-1033.1977.tb11531.x; CABOCHE M, 1977, EUR J BIOCHEM, V74, P19, DOI 10.1111/j.1432-1033.1977.tb11362.x; CARMOFONSECA M, 1991, EMBO J, V10, P195, DOI 10.1002/j.1460-2075.1991.tb07936.x; CARMOFONSECA M, 1992, J CELL BIOL, V117, P1, DOI 10.1083/jcb.117.1.1; CARMOFONSECA M, 1991, EUR J CELL BIOL, V55, P17; CHELBIALIX MK, 1981, EUR J BIOCHEM, V115, P627; CHRISTENSEN ME, 1977, BIOCHEM BIOPH RES CO, V74, P621, DOI 10.1016/0006-291X(77)90348-5; CLARKE MW, 1990, J CELL BIOL, V11, P1741; FABIAN GR, 1987, J BACTERIOL, V169, P1571, DOI 10.1128/jb.169.4.1571-1578.1987; GHISOLFI L, 1992, J BIOL CHEM, V267, P2955; GIRARD JP, 1992, EMBO J, V11, P673, DOI 10.1002/j.1460-2075.1992.tb05099.x; HENRIQUEZ R, 1990, J BIOL CHEM, V265, P2209; HUGHES JMX, 1987, EMBO J, V6, P2145, DOI 10.1002/j.1460-2075.1987.tb02482.x; HUGHES JMX, 1991, EMBO J, V10, P4231, DOI 10.1002/j.1460-2075.1991.tb05001.x; HURT EC, 1988, EUR J CELL BIOL, V46, P554; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JANSEN RP, 1991, J CELL BIOL, V113, P715, DOI 10.1083/jcb.113.4.715; JONG AYS, 1987, MOL CELL BIOL, V7, P2947, DOI 10.1128/MCB.7.8.2947; KASS S, 1990, MOL CELL BIOL, V10, P4920, DOI 10.1128/MCB.10.9.4920; KASS S, 1990, CELL, V60, P897, DOI 10.1016/0092-8674(90)90338-F; KLOOTWIJK J, 1972, FEBS LETT, V27, P102, DOI 10.1016/0014-5793(72)80419-8; KRUISWIJK T, 1978, BIOCHIM BIOPHYS ACTA, V517, P378, DOI 10.1016/0005-2787(78)90204-6; KRZYZOSIAK W, 1987, BIOCHEMISTRY-US, V26, P2353, DOI 10.1021/bi00382a042; LAPEYRE B, 1987, P NATL ACAD SCI USA, V84, P1472, DOI 10.1073/pnas.84.6.1472; LAPEYRE B, 1990, MOL CELL BIOL, V10, P430, DOI 10.1128/MCB.10.1.430; LEE WC, 1991, J CELL BIOL, V113, P1, DOI 10.1083/jcb.113.1.1; LEER RJ, 1984, NUCLEIC ACIDS RES, V12, P6685, DOI 10.1093/nar/12.17.6685; LI HV, 1990, MOL CELL BIOL, V10, P1145, DOI 10.1128/MCB.10.3.1145; LISCHWE MA, 1985, J BIOL CHEM, V260, P14304; Maden B E, 1990, Prog Nucleic Acid Res Mol Biol, V39, P241, DOI 10.1016/S0079-6603(08)60629-7; MADEN BEH, 1988, J MOL BIOL, V201, P289, DOI 10.1016/0022-2836(88)90139-8; Maniatis T., 1982, MOL CLONING; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MORITZ M, 1991, MOL CELL BIOL, V11, P5681, DOI 10.1128/MCB.11.11.5681; MORITZ M, 1990, J CELL BIOL, V111, P2261, DOI 10.1083/jcb.111.6.2261; NEHRBASS U, 1990, CELL, V61, P979, DOI 10.1016/0092-8674(90)90063-K; NIERHAUS KH, 1991, BIOCHIMIE, V73, P739, DOI 10.1016/0300-9084(91)90054-5; PUVIONDUTILLEUL F, 1991, EUR J CELL BIOL, V56, P178; RASKA I, 1990, J STRUCT BIOL, V104, P120, DOI 10.1016/1047-8477(90)90066-L; RASKA I, 1991, EXP CELL RES, V195, P27, DOI 10.1016/0014-4827(91)90496-H; ROSBASH M, 1981, CELL, V24, P679, DOI 10.1016/0092-8674(81)90094-5; RUSSELL ID, 1992, IN PRESS J CELL BIOL; SACHS AB, 1990, SCIENCE, V247, P1077, DOI 10.1126/science.2408148; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5466; SAVINO R, 1990, EMBO J, V9, P2299, DOI 10.1002/j.1460-2075.1990.tb07401.x; SCHIMMANG T, 1989, EMBO J, V8, P4015, DOI 10.1002/j.1460-2075.1989.tb08584.x; Sherman F., 1986, METHODS YEAST GENETI; STRATHERN JN, 1991, METHOD ENZYMOL, V194, P319; SWANN PF, 1975, BIOCHEM J, V150, P335, DOI 10.1042/bj1500335; TOLLERVEY D, 1987, EMBO J, V6, P4169, DOI 10.1002/j.1460-2075.1987.tb02763.x; TOLLERVEY D, 1991, EMBO J, V10, P573, DOI 10.1002/j.1460-2075.1991.tb07984.x; TRAPMAN J, 1975, EXP CELL RES, V90, P95, DOI 10.1016/0014-4827(75)90361-4; TYC K, 1989, EMBO J, V8, P3113, DOI 10.1002/j.1460-2075.1989.tb08463.x; UDEM SA, 1973, J BIOL CHEM, V248, P1412; VAUGHAN MH, 1967, P NATL ACAD SCI USA, V58, P1527, DOI 10.1073/pnas.58.4.1527; WARNER JR, 1972, J MOL BIOL, V65, P243, DOI 10.1016/0022-2836(72)90280-X; WOLF SF, 1977, BIOCHEMISTRY-US, V16, P2783, DOI 10.1021/bi00631a031; ZAGORSKI J, 1988, MOL CELL BIOL, V8, P3282, DOI 10.1128/MCB.8.8.3282	62	413	423	0	13	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 12	1993	72	3					443	457		10.1016/0092-8674(93)90120-F	http://dx.doi.org/10.1016/0092-8674(93)90120-F			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KM162	8431947				2022-12-24	WOS:A1993KM16200013
J	JALLEH, R; FITZPATRICK, MF; JAN, MA; MACNEE, W; DOUGLAS, NJ				JALLEH, R; FITZPATRICK, MF; JAN, MA; MACNEE, W; DOUGLAS, NJ			ALCOHOL AND COR-PULMONALE IN CHRONIC-BRONCHITIS AND EMPHYSEMA	BRITISH MEDICAL JOURNAL			English	Article									CITY HOSP EDINBURGH,DEPT MED RIE,RESP MED UNIT,EDINBURGH EH10 5SB,MIDLOTHIAN,SCOTLAND				Douglas, Neil/B-1491-2013	MacNee, William/0000-0002-3692-1448				CHAN CS, 1990, AM REV RESPIR DIS, V141, P861, DOI 10.1164/ajrccm/141.4_Pt_1.861; CHICK J, 1986, LANCET, V2, P1380; FRANCE AJ, 1988, THORAX, V43, P621, DOI 10.1136/thx.43.8.621; MUSABAYANE CT, 1985, ACTA ENDOCRINOL-COP, V110, P214, DOI 10.1530/acta.0.1100214; 1990, SPSS ADV STATISTICS, P64	5	8	8	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 6	1993	306	6874					374	374		10.1136/bmj.306.6874.374	http://dx.doi.org/10.1136/bmj.306.6874.374			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KL715	8461684	Green Published, Bronze			2022-12-24	WOS:A1993KL71500021
J	ADAM, D; DIMITRIJEVIC, N; SCHARTL, M				ADAM, D; DIMITRIJEVIC, N; SCHARTL, M			TUMOR SUPPRESSION IN XIPHOPHORUS BY AN ACCIDENTALLY ACQUIRED PROMOTER	SCIENCE			English	Article							MELANOMA; EXPRESSION; CELLS; ONCOGENE; ELEMENTS; FISH; GENE	Melanoma formation in the teleost Xiphophorus is caused by a dominant genetic locus, Tu. This locus includes the Xmrk oncogene, which encodes a receptor tyrosine kinase. Tumor induction is suppressed in wild-type fish by a tumor suppressor locus, R. Molecular genetic analyses revealed that the Tu locus emerged by nonhomologous recombination of the Xmrk proto-oncogene with a previously uncharacterized sequence, D. This event generated an additional copy of Xmrk with a new promoter. Suppression of the new Xmrk promoter by R in parental fish and its deregulation in hybrids explain the genetics of melanoma formation in Xiphophorus.	MAX PLANCK INST BIOCHEM, GENZENTRUM, W-8033 MARTINSRIED, GERMANY; UNIV WURZBURG, THEODOR BOVERI INST BIOWISSENSCH, W-8700 WURZBURG, GERMANY	Max Planck Society; University of Wurzburg			Adam, Dieter/E-9763-2010	Adam, Dieter/0000-0002-5668-5032; Schartl, Manfred/0000-0001-9882-5948				ADAM D, 1991, ONCOGENE, V6, P73; ADAM D, UNPUB; AHUJA MR, 1976, PROG EXP TUMOR RES, V20, P380; BELLAMY AW, 1922, ANAT REC, V23, P98; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRIEDENREICH H, 1990, NUCLEIC ACIDS RES, V18, P3299, DOI 10.1093/nar/18.11.3299; Gordon M, 1927, GENETICS, V12, P253; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; ISHII S, 1987, P NATL ACAD SCI USA, V84, P4374, DOI 10.1073/pnas.84.13.4374; KALLMAN KD, 1966, ZOOLOGICA-N Y, V51, P107; Kosswig C., 1928, Zeitschrift fuer Induktive Abstammungs- und Vererbungslehre, V47, P150; KUHN C, 1979, IN VITRO CELL DEV B, V15, P537, DOI 10.1007/BF02618156; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MAUELER W, 1988, ONCOGENE, V3, P113; MAUELER W, 1988, ONCOGENE, V2, P421; SCHARTL M, 1992, PIGM CELL RES, P173; SCHARTL M, 1990, GENETICS, V126, P1083; STEINER C, 1989, TRENDS GENET, V5, P138; SUEN TC, 1990, MOL CELL BIOL, V10, P6306, DOI 10.1128/MCB.10.12.6306; WAKAMATSU Y, 1981, CANCER RES, V41, P679; WITTBRODT J, 1989, NATURE, V341, P415, DOI 10.1038/341415a0	23	96	96	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 5	1993	259	5096					816	819		10.1126/science.8430335	http://dx.doi.org/10.1126/science.8430335			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL110	8430335	Green Submitted			2022-12-24	WOS:A1993KL11000034
J	GAYLIN, DS; HELD, PJ; PORT, FK; HUNSICKER, LG; WOLFE, RA; KAHAN, BD; JONES, CA; AGODOA, LYC				GAYLIN, DS; HELD, PJ; PORT, FK; HUNSICKER, LG; WOLFE, RA; KAHAN, BD; JONES, CA; AGODOA, LYC			THE IMPACT OF COMORBID AND SOCIODEMOGRAPHIC FACTORS ON ACCESS TO RENAL-TRANSPLANTATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DISEASE; AGE	Objective.-To assess the impact of sociodemographic factors and comorbid conditions on access to renal transplantation for adult US dialysis patients with end-stage renal disease (ESRD). Design.-Cohort analytic study. Data on comorbid conditions at onset of ESRD were abstracted from patients' medical records and matched to sociodemographic and ESRD data from the United States Renal Data System database. Setting.-United States Medicare dialysis population. Patients.-Random, national sample of ESRD patients starting dialysis in 1986 and 1987 (n=4118). Main Outcome Measure.-Time to first renal transplant (living or cadaver donor) since onset of ESRD regressed with two nested Cox proportional hazards models, first against sociodemographic factors alone, and then against sociodemographic factors and comorbid conditions. Results.-Cardiovascular diseases are most predictive of who receives a transplant; patients with coronary heart disease, congestive heart failure, or left ventricular hypertrophy showed lower transplantation rates relative to patients without the disease (relative rate [RR]=0.65 to 0.80, P<.05 each). Obese patients and patients with peripheral vascular disease also showed lower transplantation rates (RR=0.65 to 0.75, P<.05 each). Previously reported sociodemographic effects of lower transplantation rates for older patients, women, nonwhite patients, and lower income patients were confirmed (P<.01). Sociodemographic effects remained essentially unchanged when adjusted for comorbid conditions. Conclusions.-These findings indicate that sociodemographics have strong independent effects on access to transplantation that cannot be explained away as ''surrogate'' effects related to comorbid factors. Furthermore, the results suggest that lower mortality rates for transplant recipients relative to dialysis patients are due, in part, to a healthier case mix among patients receiving transplants.	UNIV MICHIGAN,SCH PUBL HLTH,DEPT EPIDEMIOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH PUBL HLTH,DEPT BIOSTAT,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT INTERNAL MED,ANN ARBOR,MI 48104; UNIV IOWA,DEPT INTERNAL MED,IOWA CITY,IA 52242; UNIV TEXAS,SCH MED,DIV IMMUNOL & ORGAN TRANSPLANTAT,HOUSTON,TX 77025; NIDDKD,DIV KIDNEY UROL & HEMATOL DIS,BETHESDA,MD	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Iowa; University of Texas System; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	GAYLIN, DS (corresponding author), URBAN INST,2100 M ST NW,SUITE 400 USRDS,WASHINGTON,DC 20037, USA.				NIDDK NIH HHS [N0 1-DK-8-2234] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [N01DK082234] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		COX DR, 1972, J R STAT SOC B, V34, P187; EGGERS PW, 1988, NEW ENGL J MED, V318, P223, DOI 10.1056/NEJM198801283180406; HELD P J, 1991, Journal of the American Society of Nephrology, V2, P328; HELD PJ, 1988, ARCH INTERN MED, V148, P2594, DOI 10.1001/archinte.148.12.2594; HELD PJ, 1992, CLIN TRANSPLANTS 199, P71; HUTCHINSON TA, 1982, ANN INTERN MED, V96, P417, DOI 10.7326/0003-4819-96-4-417; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KJELLSTRAND CM, 1988, ARCH INTERN MED, V148, P1305; MORRIS PI, 1983, KIDNEY TRANSPLANTATI, P547; WEBB RL, 1991, CLIN TRANSPLANTS 199, P75; 1991, DISTRIBUTION ORGANS; 1991, USRDS1991 NIH NAT I; 1992, SURGEON GENERALS WOR; 1991, USRDS1992 NIH NAT I	14	237	237	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 3	1993	269	5					603	608		10.1001/jama.269.5.603	http://dx.doi.org/10.1001/jama.269.5.603			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ444	8421364				2022-12-24	WOS:A1993KJ44400026
J	TAKASAWA, S; NATA, K; YONEKURA, H; OKAMOTO, H				TAKASAWA, S; NATA, K; YONEKURA, H; OKAMOTO, H			CYCLIC ADP-RIBOSE IN INSULIN-SECRETION FROM PANCREATIC BETA-CELLS	SCIENCE			English	Article							THYROTROPIN-RELEASING-HORMONE; DNA STRAND BREAKS; INOSITOL TRISPHOSPHATE; POLY(ADP-RIBOSE) SYNTHETASE; PROINSULIN SYNTHESIS; PITUITARY-CELLS; CALCIUM RELEASE; 2ND MESSENGER; GH4C1 CELLS; CA-2+	Inositol 1,4,5-trisphosphate (IP3) is thought to be a second messenger for intracellular calcium mobilization. However, in a cell-free system of islet microsomes, cyclic adenosine diphosphate-ribose (cADP-ribose), a nicotinamide adenine dinucleotide (NAD+) metabolite, but not IP3, induced calcium release. In digitonin-permeabilized islets, cADP-ribose and calcium, but not IP3, induced insulin secretion. Islet microsomes released calcium when combined with the extract from intact islets that had been incubated with high concentrations of glucose. Sequential additions of cADP-ribose inhibited the calcium release response to extracts from islets treated with high concentrations of glucose. Conversely, repeated additions of the islet extract inhibited the calcium release response to a subsequent addition of cADP-ribose. These results suggest that cADP-ribose is a mediator of calcium release from islet microsomes and may be generated in islets by glucose stimulation, serving as a second messenger for calcium mobilization in the endoplasmic reticulum.	TOHOKU UNIV, SCH MED, DEPT BIOCHEM, SENDAI, MIYAGI 980, JAPAN	Tohoku University								BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BERRIDGE MJ, 1989, NATURE, V341, P187; BIDEN TJ, 1984, BIOCHEM J, V223, P467, DOI 10.1042/bj2230467; CHIBA T, 1987, BIOCHEM BIOPH RES CO, V145, P263, DOI 10.1016/0006-291X(87)91315-5; CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; COLCA JR, 1985, BIOCHEM J, V228, P529, DOI 10.1042/bj2280529; DARGIE PJ, 1990, CELL REGUL, V1, P279, DOI 10.1091/mbc.1.3.279; GALIONE A, 1992, TRENDS PHARMACOL SCI, V13, P304, DOI 10.1016/0165-6147(92)90096-O; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; HEDESKOV CJ, 1980, PHYSIOL REV, V60, P442, DOI 10.1152/physrev.1980.60.2.442; HELLMICH MR, 1991, CELL REGUL, V2, P193, DOI 10.1091/mbc.2.3.193; ISLAM MS, 1992, FEBS LETT, V296, P287, DOI 10.1016/0014-5793(92)80306-2; ITOH N, 1980, NATURE, V283, P100, DOI 10.1038/283100a0; JOSEPH SK, 1984, J BIOL CHEM, V259, P2952; KAO JPY, 1989, J BIOL CHEM, V264, P8179; KOSHIYAMA H, 1991, J BIOL CHEM, V266, P16985; KOSHIYAMA H, 1991, ENDOCRINOLOGY, V128, P2715, DOI 10.1210/endo-128-6-2715; LEE HC, 1991, CELL REGUL, V2, P203, DOI 10.1091/mbc.2.3.203; LEE HC, 1989, J BIOL CHEM, V264, P1608; MASIELLO P, 1985, DIABETOLOGIA, V28, P683, DOI 10.1007/BF00291976; MOLLARD P, 1990, BIOCHEM J, V268, P345, DOI 10.1042/bj2680345; OKAMOTO H, 1981, MOL CELL BIOCHEM, V37, P43, DOI 10.1007/BF02355886; OKAMOTO H, 1985, BIOESSAYS, V2, P15, DOI 10.1002/bies.950020106; Okamoto H., 2008, MOL BIOL ISLETS LANG, P209; PRENTKI M, 1985, J BIOL CHEM, V260, P9185; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; PRENTKI M, 1984, NATURE, V309, P562, DOI 10.1038/309562a0; SALUJA AK, 1989, BIOCHEM BIOPH RES CO, V164, P8, DOI 10.1016/0006-291X(89)91675-6; SHIMA K, 1987, DIABETES RES CLIN PR, V3, P135, DOI 10.1016/S0168-8227(87)80019-0; TAKASAWA S, UNPUB; TASHJIAN AH, 1987, BIOCHEM J, V243, P305, DOI 10.1042/bj2430305; UCHIGATA Y, 1982, J BIOL CHEM, V257, P6084; WALSETH TF, 1991, BIOCHIM BIOPHYS ACTA, V1094, P113, DOI 10.1016/0167-4889(91)90032-S; WOLF BA, 1985, BIOCHEM J, V227, P965, DOI 10.1042/bj2270965; WOLLHEIM CB, 1986, J BIOL CHEM, V261, P8314; WORLEY PF, 1987, J BIOL CHEM, V262, P12132; YAMAMOTO H, 1981, NATURE, V294, P284, DOI 10.1038/294284a0	37	412	415	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 15	1993	259	5093					370	373		10.1126/science.8420005	http://dx.doi.org/10.1126/science.8420005			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KG624	8420005				2022-12-24	WOS:A1993KG62400035
J	JIMENEZGARCIA, LF; SPECTOR, DL				JIMENEZGARCIA, LF; SPECTOR, DL			INVIVO EVIDENCE THAT TRANSCRIPTION AND SPLICING ARE COORDINATED BY A RECRUITING MECHANISM	CELL			English	Article							DNA-BINDING-PROTEIN; INFECTED HELA-CELLS; PRE-MESSENGER-RNA; NUCLEAR RIBONUCLEOPROTEIN ANTIGENS; ADENOVIRUS TYPE-5 DNA; MONOCLONAL-ANTIBODIES; INSITU HYBRIDIZATION; LOCALIZATION; MATRIX; SITES	We describe the nuclear organization of pre-mRNA processing components in HeLa cells upon adenovirus 2 infection and their relationship to the localization of viral RNA sequences. We observe a redistribution of cellular splicing factors as well as RNA polymerase II and heterogeneous nuclear ribonucleoprotein particle proteins to sites of viral RNA transcription. Similar results were obtained in cells transiently transfected with a plasmid containing a portion of the beta-tropomyosin gene. Our findings demonstrate a very close association between RNA transcripts and transcription and pre-mRNA splicing factors, suggesting that these processes are both temporally and spatially linked in the cell nucleus. Furthermore, these data suggest a recruiting mechanism that regulates the localization of transcription and splicing factors in response to the initiation of active transcription.	COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA	Cold Spring Harbor Laboratory					NATIONAL CANCER INSTITUTE [P30CA045508] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042694] Funding Source: NIH RePORTER; NCI NIH HHS [5P30 CA45508-03] Funding Source: Medline; NIGMS NIH HHS [GM42694, R01 GM042694] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akusjarvi G, 1986, ADENOVIRUS DNA VIRAL, P53; BELTZ GA, 1979, J MOL BIOL, V131, P353, DOI 10.1016/0022-2836(79)90081-0; BEREZNEY R, 1984, CHROMOSOMAL NONHISTO, V4, P119; BEYER AL, 1988, GENE DEV, V2, P754, DOI 10.1101/gad.2.6.754; BOSHER J, 1992, J VIROL, V66, P3140, DOI 10.1128/JVI.66.5.3140-3150.1992; CARMOFONSECA M, 1992, J CELL BIOL, V117, P1, DOI 10.1083/jcb.117.1.1; CARTER KC, 1991, J CELL BIOL, V115, P1191, DOI 10.1083/jcb.115.5.1191; CIEJEK EM, 1982, BIOCHEMISTRY-US, V21, P4945, DOI 10.1021/bi00263a018; DARNELL JE, 1982, NATURE, V297, P365, DOI 10.1038/297365a0; DREYFUSS G, 1984, J CELL BIOL, V99, pA233, DOI 10.1083/jcb.99.6.1997; FAKAN S, 1976, EXP CELL RES, V99, P155, DOI 10.1016/0014-4827(76)90690-X; FAKAN S, 1986, J CELL BIOL, V103, P1153, DOI 10.1083/jcb.103.4.1153; FAKAN S, 1978, EXP CELL RES, V113, P327, DOI 10.1016/0014-4827(78)90373-7; FAKAN S, 1984, J CELL BIOL, V98, P358, DOI 10.1083/jcb.98.1.358; FLINT J, 1989, ANNU REV GENET, V23, P141, DOI 10.1146/annurev.genet.23.1.141; FLINT SJ, 1986, ADV VIRUS RES, V31, P169, DOI 10.1016/S0065-3527(08)60264-X; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GUO W, 1991, GENE DEV, V5, P2096, DOI 10.1101/gad.5.11.2096; HABETS WJ, 1989, J IMMUNOL, V143, P2560; HUANG S, 1992, P NATL ACAD SCI USA, V89, P305, DOI 10.1073/pnas.89.1.305; HUANG S, 1991, Genes and Development, V5, P2288, DOI 10.1101/gad.5.12a.2288; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LECHNER RL, 1977, CELL, V12, P1007, DOI 10.1016/0092-8674(77)90165-9; LERNER EA, 1981, P NATL ACAD SCI-BIOL, V78, P2737, DOI 10.1073/pnas.78.5.2737; MARIMAN ECM, 1982, J MOL BIOL, V154, P103, DOI 10.1016/0022-2836(82)90420-X; MARTIN TE, 1987, J CELL BIOL, V105, P2069, DOI 10.1083/jcb.105.5.2069; MARTINEZ-PALOMO A., 1967, J VIROL, V1, P817; MCGROGAN M, 1977, J VIROL, V23, P240, DOI 10.1128/JVI.23.2.240-249.1977; MCGROGAN M, 1978, P NATL ACAD SCI USA, V75, P625, DOI 10.1073/pnas.75.2.625; NEVINS JR, 1978, CELL, V15, P1477, DOI 10.1016/0092-8674(78)90071-5; NYMAN U, 1986, J CELL BIOL, V102, P137, DOI 10.1083/jcb.102.1.137; ORNELLES DA, 1991, J VIROL, V65, P424, DOI 10.1128/JVI.65.1.424-429.1991; Philipson L, 1979, Adv Virus Res, V25, P357, DOI 10.1016/S0065-3527(08)60573-4; PUVIONDUTILLEUL F, 1990, EUR J CELL BIOL, V52, P379; PUVIONDUTILLEUL F, 1992, J STRUCT BIOL, V108, P209, DOI 10.1016/1047-8477(92)90021-2; PUVIONDUTILLEUL F, 1990, J STRUCT BIOL, V103, P280, DOI 10.1016/1047-8477(90)90046-F; PUVIONDUTILLEUL F, 1991, BIOL CELL, V71, P135, DOI 10.1016/0248-4900(91)90060-Z; QUINLAN MP, 1984, CELL, V36, P857, DOI 10.1016/0092-8674(84)90035-7; REICH NC, 1983, VIROLOGY, V128, P480, DOI 10.1016/0042-6822(83)90274-X; REUTER R, 1984, EXP CELL RES, V154, P548, DOI 10.1016/0014-4827(84)90179-4; SASS H, 1984, J MOL BIOL, V180, P911, DOI 10.1016/0022-2836(84)90263-8; SCHAACK J, 1990, GENE DEV, V4, P1197, DOI 10.1101/gad.4.7.1197; SMITH HC, 1986, MOL CELL BIOCHEM, V70, P151; SPECTOR DL, 1983, BIOL CELL, V49, P1; SPECTOR DL, 1984, BIOL CELL, V51, P109, DOI 10.1111/j.1768-322X.1984.tb00289.x; SPECTOR DL, 1991, EMBO J, V10, P3467, DOI 10.1002/j.1460-2075.1991.tb04911.x; SPECTOR DL, 1990, P NATL ACAD SCI USA, V87, P147, DOI 10.1073/pnas.87.1.147; SPECTOR DL, 1986, EXP CELL RES, V163, P87, DOI 10.1016/0014-4827(86)90560-4; STEFANO JE, 1984, CELL, V36, P145, DOI 10.1016/0092-8674(84)90083-7; SUGAWARA K, 1977, J VIROL, V22, P527, DOI 10.1128/JVI.22.2.527-539.1977; THOMPSON NE, 1990, J BIOL CHEM, V265, P7069; TOOZE J, 1982, MOL BIOL TUMOR VIRUS, V2; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VERHEIJEN R, 1986, J CELL SCI, V86, P173; VOELKERDING K, 1986, J VIROL, V60, P353, DOI 10.1128/JVI.60.2.353-362.1986; VOGELSTEIN B, 1982, BIOCHEM BIOPH RES CO, V105, P1224, DOI 10.1016/0006-291X(82)91099-3; WANG J, 1991, P NATL ACAD SCI USA, V88, P7391, DOI 10.1073/pnas.88.16.7391; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; WU ZG, 1991, J CELL BIOL, V113, P465, DOI 10.1083/jcb.113.3.465; XING YG, 1991, J CELL BIOL, V112, P1055, DOI 10.1083/jcb.112.6.1055; ZEITLIN S, 1980, NATURE, V287, P491; [No title captured]	64	240	242	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 9	1993	73	1					47	59		10.1016/0092-8674(93)90159-N	http://dx.doi.org/10.1016/0092-8674(93)90159-N			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KW753	8462102				2022-12-24	WOS:A1993KW75300007
J	WEINZIERL, ROJ; DYNLACHT, BD; TJIAN, R				WEINZIERL, ROJ; DYNLACHT, BD; TJIAN, R			LARGEST SUBUNIT OF DROSOPHILA TRANSCRIPTION FACTOR-IID DIRECTS ASSEMBLY OF A COMPLEX CONTAINING TBP AND A COACTIVATOR	NATURE			English	Article							BINDING-PROTEIN; TFIID COMPLEX; ACTIVATION; GENE; MECHANISM; UPSTREAM	The TFIID complex consists of the TATA-binding protein (TBP) and associated factors (TAFs) serving to mediate transcriptional activation by promoter-specific regulators. Here we report the cloning of Drosophila TAF(II)250 and the assembly of a partial complex containing recombinant TBP, TAF(II)110 and the C-terminal domain of TAF(II)250. This triple complex supports Sp1 activation and reveals specific interactions between TAF(II)250, TBP and TAF(II)110.			WEINZIERL, ROJ (corresponding author), UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT MOLEC & CELL BIOL,401 BARKER HALL,BERKELEY,CA 94720, USA.			Weinzierl, Robert/0000-0003-4095-9921				COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; EISENMANN DM, 1992, GENE DEV, V6, P1319, DOI 10.1101/gad.6.7.1319; Gill G, 1992, CURR OPIN GENET DEV, V2, P236, DOI 10.1016/S0959-437X(05)80279-5; Gill Grace, 1992, Current Biology, V2, P565, DOI 10.1016/0960-9822(92)90046-D; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; HORIKOSHI M, 1988, CELL, V54, P665, DOI 10.1016/S0092-8674(88)80011-4; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; KOLESKE AJ, 1992, CELL, V69, P883, DOI 10.1016/0092-8674(92)90298-Q; LAELIN WG, 1992, CELL, V70, P351; LOBO SM, 1992, CELL, V71, P1029, DOI 10.1016/0092-8674(92)90397-U; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1992, J BIOL CHEM, V267, P679; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SEKIGUCHI T, 1991, MOL CELL BIOL, V11, P3317, DOI 10.1128/MCB.11.6.3317; STRATHMANN M, 1991, P NATL ACAD SCI USA, V88, P1247, DOI 10.1073/pnas.88.4.1247; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; TAGGART AKP, 1992, CELL, V71, P1015, DOI 10.1016/0092-8674(92)90396-T; TAKADA R, 1992, P NATL ACAD SCI USA, V89, P11809, DOI 10.1073/pnas.89.24.11809; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; WAMPLER SL, 1990, J BIOL CHEM, V265, P21223; WHITE RJ, 1992, CELL, V71, P1041, DOI 10.1016/0092-8674(92)90398-V; ZAWEL L, 1992, Current Opinion in Cell Biology, V4, P488, DOI 10.1016/0955-0674(92)90016-6; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964; ZHOU Q, 1993, GENE DEV, V7, P180, DOI 10.1101/gad.7.2.180; ZINN K, 1988, CELL, V53, P577, DOI 10.1016/0092-8674(88)90574-0	31	163	170	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 8	1993	362	6420					511	517		10.1038/362511a0	http://dx.doi.org/10.1038/362511a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KW453	8464492				2022-12-24	WOS:A1993KW45300044
J	PANTALEO, G; GRAZIOSI, C; DEMAREST, JF; BUTINI, L; MONTRONI, M; FOX, CH; ORENSTEIN, JM; KOTLER, DP; FAUCI, AS				PANTALEO, G; GRAZIOSI, C; DEMAREST, JF; BUTINI, L; MONTRONI, M; FOX, CH; ORENSTEIN, JM; KOTLER, DP; FAUCI, AS			HIV-INFECTION IS ACTIVE AND PROGRESSIVE IN LYMPHOID-TISSUE DURING THE CLINICALLY LATENT STAGE OF DISEASE	NATURE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CELLS; AIDS; LYMPHADENOPATHY; AMPLIFICATION; RESERVOIRS; EXPRESSION; NODES; RNA	PRIMARY infection with the human immunodeficiency virus (HIV) is generally followed by a burst of viraemia with or without clinical symptoms1-3. This in turn is followed by a prolonged period of clinical latency. During this period there is little, if any, detectable viraemia, the numbers of infected cells in the blood are very low, and it is extremely difficult to demonstrate virus expression in these cells4. We have analysed viral burden and levels of virus replication simultaneously in the blood and lymphoid organs of the same individuals at various stages of HIV disease. Here we report that in early-stage disease there is a dichotomy between the levels of viral burden and virus replication in peripheral blood versus lymphoid organs. HIV disease is active in the lymphoid tissue throughout the period of clinical latency, even at times when minimal viral activity is demonstrated in blood.	UNIV ANCONA,DEPT INTERNAL MED,I-60020 ANCONA,ITALY; YALE UNIV,SCH MED,DEPT NEUROPATHOL,NEW HAVEN,CT 06510; GEORGE WASHINGTON UNIV,DEPT PATHOL,WASHINGTON,DC 20037; ST LUKES ROOSEVELT HOSP,NEW YORK,NY 10025	Marche Polytechnic University; Yale University; George Washington University; Mount Sinai St. Luke's; Mount Sinai West	PANTALEO, G (corresponding author), NIAID,IMMUNOREGULAT LAB,BETHESDA,MD 20892, USA.		Pantaleo, Giuseppe/K-6163-2016; graziosi, cecilia/M-1882-2019					ARMSTRONG JA, 1985, IMMUNOL TODAY, V6, P121, DOI 10.1016/0167-5699(85)90076-3; ARMSTRONG JA, 1991, ACCESSORY CELLS IN HIV AND OTHER RETROVIRAL INFECTIONS, P69; BIBERFELD P, 1987, ACTA PATH MICRO IM A, V95, P47; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; CLOUSE KA, 1989, J IMMUNOL, V142, P431; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; EMILIE D, 1990, J CLIN INVEST, V86, P148, DOI 10.1172/JCI114678; FAUCI AS, 1991, ANN INTERN MED, V114, P678, DOI 10.7326/0003-4819-114-8-678; FOLKS TM, 1986, J EXP MED, V164, P280, DOI 10.1084/jem.164.1.280; FOX CH, 1991, J INFECT DIS, V164, P1051, DOI 10.1093/infdis/164.6.1051; GRAZIOSI C, IN PRESS CURR PROTOC; HAYNES BF, 1992, AIDS ETIOLOGY DIAGNO, P77; KWOK S, 1987, J VIROL, V61, P1690, DOI 10.1128/JVI.61.5.1690-1694.1987; MICHAEL NL, 1992, J VIROL, V66, P310, DOI 10.1128/JVI.66.1.310-316.1992; OU CY, 1988, SCIENCE, V239, P295, DOI 10.1126/science.3336784; PANTALEO G, 1991, P NATL ACAD SCI USA, V88, P9838, DOI 10.1073/pnas.88.21.9838; RACZ P, 1986, PROG ALLERGY, V37, P81; SCHNITTMAN SM, 1991, AIDS RES HUM RETROV, V7, P361, DOI 10.1089/aid.1991.7.361; SPIEGEL H, 1992, AM J PATHOL, V140, P15; TENNERRACZ K, 1985, LANCET, V1, P105; TINDALL B, 1991, AIDS, V5, P1, DOI 10.1097/00002030-199101000-00001; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401	23	1674	1705	0	70	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 25	1993	362	6418					355	358		10.1038/362355a0	http://dx.doi.org/10.1038/362355a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KU176	8455722				2022-12-24	WOS:A1993KU17600065
J	MILLER, R; DETITTA, GT; JONES, R; LANGS, DA; WEEKS, CM; HAUPTMAN, HA				MILLER, R; DETITTA, GT; JONES, R; LANGS, DA; WEEKS, CM; HAUPTMAN, HA			ON THE APPLICATION OF THE MINIMAL PRINCIPLE TO SOLVE UNKNOWN STRUCTURES	SCIENCE			English	Article							PHASE-RELATIONSHIPS; COMPLEX STRUCTURES	The Shake-and-Bake method of structure determination is a new direct methods phasing algorithm based on a minimum-variance, phase invariant residual, which is referred to as the minimal principle. Previously, the algorithm had been applied only to known structures. This algorithm has now been applied to two previously unknown structures that contain 105 and 110 non-hydrogen atoms, respectively. This report focuses on (i) algorithmic and parametric optimizations of Shake-and-Bake and (ii) the determination of two previously unknown structures. Traditional tangent formula phasing techniques were unable to unravel these two new structures.	SUNY BUFFALO,DEPT COMP SCI,BUFFALO,NY 14260; THINKING MACHINES CORP,CAMBRIDGE,MA 02142	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	MILLER, R (corresponding author), MED FDN BUFFALO INC,73 HIGH ST,BUFFALO,NY 14203, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019856] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM046733, R01GM032812] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-19856] Funding Source: Medline; NIGMS NIH HHS [GM-32812, GM-46733] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aarts E., 1988, SIMULATED ANNEALING; BASHIR N, 1990, 5TH P DISTR MEM COMP, P513; CHANG CS, IN PRESS INT J SUPER; DEBAERDEMAEKER T, 1988, ACTA CRYSTALLOGR A, V44, P353, DOI 10.1107/S0108767388000017; DETITTA GT, 1991, 6TH P DISTR MEM COMP, P587; HAUPTMAN HA, 1991, CRYSTALLOGRAPHIC COM, V5, P324; HAUPTMAN HA, 1988, ABSTR AM CRYST ASS, V16, P53; Holland. D.G.J., 1989, GENETIC ALGORITHMS S; Miller R, UNPUB; PLETNEV VZ, 1980, BIOPOLYMERS, V19, P1517, DOI 10.1002/bip.1980.360190808; PLETNEV VZ, 1992, BIOPOLYMERS, V32, P819, DOI 10.1002/bip.360320710; Rossmann M. G., 1972, MOL REPLACEMENT METH; SHELDRICK GM, 1990, ACTA CRYSTALLOGR A, V46, P467, DOI 10.1107/S0108767390000277; SHIONO M, 1992, ACTA CRYSTALLOGR A, V48, P451, DOI 10.1107/S010876739101471X; WEEKS CM, 1993, ACTA CRYSTALLOGR D, V49, P179, DOI 10.1107/S090744499200876X; WEEKS CM, 1976, ACTA CRYSTALLOGR B, V32, P261, DOI 10.1107/S0567740876002720; YAO JX, 1981, ACTA CRYSTALLOGR A, V37, P642, DOI 10.1107/S0567739481001460	17	159	159	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 5	1993	259	5100					1430	1433		10.1126/science.8451639	http://dx.doi.org/10.1126/science.8451639			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KP978	8451639				2022-12-24	WOS:A1993KP97800029
J	CZEIZEL, AE; INTODY, Z; MODELL, B				CZEIZEL, AE; INTODY, Z; MODELL, B			WHAT PROPORTION OF CONGENITAL-ABNORMALITIES CAN BE PREVENTED	BRITISH MEDICAL JOURNAL			English	Article								Objective-To estimate the proportion of preventable congenital abnormalities i Design-Analysis of available Hungarian databases and of the effectiveness of primary, secondary, and tertiary preventive methods. Setting-Databases of ad hoc epidemiological studies and of the Hungarian congenital abnormality registry. Main outcome measures-Prevalence at birth and prevalence after prevention in 73 congenital abnormality types or groups. Results-Preventive methods are available for 51 (70%) of the 73 congenital abnormality types or groups evaluated. The birth prevalence of all congenital abnormalities could be reduced from 65 to 26 per 1000; thus 39 per 1000 (60%) are preventable. Without congenital dislocation of the hip, which is unusually common in Hungary, the preventable proportion of congenital abnormalities is 52%. Conclusion-Many congenital abnormalities can be prevented, but as they do not represent a single pathological category there is no single strategy for their prevention.	UCL, UNIV COLL & MIDDLESEX, DEPT OBSTET & GYNAECOL, WHO, LONDON WC1E 6HX, ENGLAND	University of London; University College London; World Health Organization	CZEIZEL, AE (corresponding author), WHO, COLLABORATING CTR COMMUNITY CONTROL HEREDITARY DIS, NATL INST HYG, DEPT HUMAN GENET & TERATOL, BUDAPEST, HUNGARY.							[Anonymous], 1991, CONGENITAL MALFORMAT; BERES J, 1988, ORVOSI HETILAP, V129, P529; CZEIZEL A, 1985, Acta Paediatrica Hungarica, V26, P175; CZEIZEL A, 1988, World Health Statistics Quarterly, V41, P219; CZEIZEL A, 1981, J MED GENET, V18, P91, DOI 10.1136/jmg.18.2.91; CZEIZEL AE, 1992, NEW ENGL J MED, V327, P1832, DOI 10.1056/NEJM199212243272602; CZEIZEL AE, 1984, AETIOLOGICAL STUDIES; KALMAR Z, 1980, ORVOSI HETILAP, P1205; LUCK CA, 1992, BRIT MED J, V304, P1474, DOI 10.1136/bmj.304.6840.1474; Mehes K., 1983, MINOR MALFORMATIONS; SHELDON TA, 1991, BRIT MED J, V302, P1133, DOI 10.1136/bmj.302.6785.1133; SMITHELLS RW, 1989, LANCET, V2, P498; WALD N, 1991, LANCET, V338, P131; WALD NJ, 1992, BMJ-BRIT MED J, V305, P391, DOI 10.1136/bmj.305.6850.391; WOOLF CM, 1968, AM J HUM GENET, V20, P430	15	158	169	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 20	1993	306	6876					499	503		10.1136/bmj.306.6876.499	http://dx.doi.org/10.1136/bmj.306.6876.499			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KN786	8448464	Green Published, Bronze			2022-12-24	WOS:A1993KN78600023
J	RAGOT, T; VINCENT, N; CHAFEY, P; VIGNE, E; GILGENKRANTZ, H; COUTON, D; CARTAUD, J; BRIAND, P; KAPLAN, JC; PERRICAUDET, M; KAHN, A				RAGOT, T; VINCENT, N; CHAFEY, P; VIGNE, E; GILGENKRANTZ, H; COUTON, D; CARTAUD, J; BRIAND, P; KAPLAN, JC; PERRICAUDET, M; KAHN, A			EFFICIENT ADENOVIRUS-MEDIATED TRANSFER OF A HUMAN MINIDYSTROPHIN GENE TO SKELETAL-MUSCLE OF MDX MICE	NATURE			English	Article							DUCHENNE MUSCULAR-DYSTROPHY; MOUSE; INVIVO; EXPRESSION; INJECTION; DNA	DUCHENNE progressive muscular dystrophy is a lethal and common X-linked genetic disease1 caused by the absence of dystrophin2,3, a 427K protein encoded by a 14 kilobase transcript4. Two approaches have been proposed to correct the dystrophin deficiency in muscle. The first, myoblast transfer therapy, uses cells from normal donors5-7, whereas the second involves direct intramuscular injection of recombinant plasmids expressing dystrophin8. Adenovirus is an efficient vector for in vivo expression of various foreign genes9-13. It has recently been demonstrated that a recombinant adenovirus expressing the lac-Z reporter gene can infect stably many mouse tissues, particularly muscle and heart12,13. We have tested the ability of a recombinant adenovirus, containing a 6.3 kilobase pair Becker-like dystrophin complementary DNA14 driven by the Rous sarcoma virus promoter to direct the expression of a 'minidystrophin' in infected 293 cells and C2 myoblasts, and in the mdx mouse15,16, after intramuscular injection. We report here that in vivo, we have obtained a sarcolemmal immunostaining in up to 50% of fibres of the injected muscle.	INST COCHIN GENET MOLEC,INSERM,U129,F-75014 PARIS,FRANCE; ICGM,INSERM,CJF 9003,F-75014 PARIS,FRANCE; INST JACQUES MONOD,CNRS,UMR 3,F-75251 PARIS 05,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite	RAGOT, T (corresponding author), INST GUSTAVE ROUSSY,CNRS,URA 1301,PR2,39 RUE CAMILLE DESMOULINS,F-94805 VILLEJUIF,FRANCE.		Gilgenkrantz, Helene/G-5534-2017	gilgenkrantz, helene/0000-0001-6770-4561				ACSADI G, 1991, NATURE, V352, P815, DOI 10.1038/352815a0; BULFIELD G, 1984, P NATL ACAD SCI-BIOL, V81, P1189, DOI 10.1073/pnas.81.4.1189; CAMPBELL KP, 1989, NATURE, V338, P259, DOI 10.1038/338259a0; CARTAUD A, 1992, NEUROSCIENCE, V48, P995, DOI 10.1016/0306-4522(92)90288-D; Emery A, 1988, DUCHENNE MUSCULAR DY; ENGLAND SB, 1990, NATURE, V343, P180, DOI 10.1038/343180a0; GINJAAR HB, 1992, FEBS LETT, V308, P293, DOI 10.1016/0014-5793(92)81296-X; Gluzman Y., 1982, EUKARYOTIC VIRAL VEC, P187; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GUSSONI E, 1992, NATURE, V356, P435, DOI 10.1038/356435a0; HOFFMAN EP, 1989, NEURON, V2, P1019, DOI 10.1016/0896-6273(89)90226-2; HOFFMAN EP, 1990, J NEUROL SCI, V99, P9, DOI 10.1016/0022-510X(90)90195-S; HUARD J, 1992, MUSCLE NERVE, V15, P550, DOI 10.1002/mus.880150504; HUGNOT JP, 1992, P NATL ACAD SCI USA, V89, P7506, DOI 10.1073/pnas.89.16.7506; JIAO SS, 1992, HUM GENE THER, V3, P21, DOI 10.1089/hum.1992.3.1-21; KOENIG M, 1987, CELL, V50, P509, DOI 10.1016/0092-8674(87)90504-6; LEVRERO M, 1991, GENE, V101, P195, DOI 10.1016/0378-1119(91)90411-4; PARTRIDGE TA, 1989, NATURE, V337, P176, DOI 10.1038/337176a0; QUANTIN B, 1992, P NATL ACAD SCI USA, V89, P2581, DOI 10.1073/pnas.89.7.2581; RAGOT T, 1991, HUMAN GENE TRANSFER, P249; ROSENFELD MA, 1992, CELL, V68, P143, DOI 10.1016/0092-8674(92)90213-V; ROSENFELD MA, 1991, SCIENCE, V252, P431, DOI 10.1126/science.2017680; SHENK T, 1984, CURR TOP MICROBIOL, P1; SICINSKI P, 1989, SCIENCE, V244, P1578, DOI 10.1126/science.2662404; STEDMAN HH, 1991, NATURE, V352, P536, DOI 10.1038/352536a0; STRATFORDPERRICAUDET LD, 1990, HUM GENE THER, V1, P241, DOI 10.1089/hum.1990.1.3-241; STRATFORDPERRICAUDET LD, 1992, J CLIN INVEST, V90, P626, DOI 10.1172/JCI115902; ZUBRZYCKAGAARN EF, 1988, NATURE, V333, P466, DOI 10.1038/333466a0	28	394	449	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 18	1993	361	6413					647	650		10.1038/361647a0	http://dx.doi.org/10.1038/361647a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KM776	8437625				2022-12-24	WOS:A1993KM77600067
J	GURWITZ, JH; BOHN, RL; GLYNN, RJ; MONANE, M; MOGUN, H; AVORN, J				GURWITZ, JH; BOHN, RL; GLYNN, RJ; MONANE, M; MOGUN, H; AVORN, J			ANTIHYPERTENSIVE DRUG-THERAPY AND THE INITIATION OF TREATMENT FOR DIABETES-MELLITUS	ANNALS OF INTERNAL MEDICINE			English	Article						DIABETES-MELLITUS; DIURETICS, THIAZIDE; ANTIHYPERTENSIVE AGENTS; HYPOGLYCEMIC AGENTS; INSULIN	GLUCOSE-INTOLERANCE; BLOOD-PRESSURE; HYPERTENSION; TRIAL; HYPERINSULINEMIA; DIURETICS; INSULIN; OBESITY	Objective: To quantify the risk for the occurrence of hyperglycemia requiring initiation of therapy among patients taking various antihypertensive regimens. Design: Case-control study. Setting: New Jersey Medicaid program. Patients: The study included New Jersey Medicaid enrollees 35 years of age or older. The 11 855 case patients were newly started on a hypoglycemic agent (oral agent or insulin) between 1981 and 1990. The 11 855 controls were selected randomly from among other Medicaid enrollees. Measurements and Main Results: The frequency of initiation of hypoglycemic therapy was increased for users of virtually all antihypertensive agents relative to nonusers after adjustment for age, gender, race, nursing home residency, number of days hospitalized, total number of prescriptions, and selected medication exposures. The estimated relative risk for initiation of hypoglycemic therapy was 1.40 for patients receiving thiazide diuretics (95% CI, 1.26 to 1.58) and ranged from 1.56 to 1.77 for patients receiving other antihypertensive medications, depending on the medication category. A higher risk was associated with multiple-agent regimens, whether they excluded a thiazide diuretic (odds ratio, 1.76; CI, 1.49 to 2.07) or included one (odds ratio, 1.93; CI, 1.75 to 2.13). When the analysis was restricted to users of antihypertensive agents (n = 8005), the risk associated with other single-agent antihypertensive regimens was not significantly different from that associated with thiazide diuretics. However, patients receiving multiple-agent regimens continued to be at increased risk for hyperglycemia requiring hypoglycemic therapy relative to those who used thiazide diuretic therapy alone. Conclusion: The association between antihypertensive therapy and the initiation of treatment for diabetes mellitus is more closely related to the intensity of therapy than to the individual agent used. Our data do not support the hypothesis that thiazide diuretics are more strongly associated with the initiation of hypoglycemic therapy than are other antihypertensive agents.	HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; HEBREW REHABIL CTR AGED, BOSTON, MA USA	Harvard University; Harvard Medical School	GURWITZ, JH (corresponding author), BRIGHAM & WOMENS HOSP, PROGRAM ANAL CLIN STRATEGIES, 221 LONGWOOD AVE, SUITE 309, BOSTON, MA 02115 USA.				NIA NIH HHS [K08 AG00510, AG-08812] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P30AG008812, K08AG000510, P60AG008812] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALDERMAN MH, 1992, JAMA-J AM MED ASSOC, V267, P2786, DOI 10.1001/jama.267.20.2786; AMERY A, 1978, LANCET, V1, P681; [Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1981, LANCET, V2, P539; [Anonymous], 1985, Hypertension, V7, P1008; BARRETTCONNOR E, 1981, AM J EPIDEMIOL, V113, P276, DOI 10.1093/oxfordjournals.aje.a113097; BENGTSSON C, 1988, DIABETIC MED, V5, P261, DOI 10.1111/j.1464-5491.1988.tb00981.x; Cox DR., 1970, ANAL BINARY DATA; DONAHUE RP, 1990, AM J EPIDEMIOL, V132, P827, DOI 10.1093/oxfordjournals.aje.a115725; FERRANNINI E, 1987, NEW ENGL J MED, V317, P350, DOI 10.1056/NEJM198708063170605; FERRARI P, 1991, AM J MED, V91, P589, DOI 10.1016/0002-9343(91)90211-F; FLETCHER AE, 1991, AM J MED, V90, pS42, DOI 10.1016/0002-9343(91)90435-Z; FURMAN BL, 1981, PHARMACOL THERAPEUT, V12, P613, DOI 10.1016/0163-7258(81)90102-9; GOLDNER MG, 1960, NEW ENGL J MED, V262, P403, DOI 10.1056/NEJM196002252620807; HELGELAND A, 1980, AM J MED, V69, P725, DOI 10.1016/0002-9343(80)90438-6; KOHNER EM, 1971, LANCET, V1, P986; LANDSBERG L, 1987, NEW ENGL J MED, V317, P378, DOI 10.1056/NEJM198708063170609; MODAN M, 1985, J CLIN INVEST, V75, P809, DOI 10.1172/JCI111776; MOSER M, 1991, JAMA-J AM MED ASSOC, V265, P498, DOI 10.1001/jama.265.4.498; MURPHY MB, 1982, LANCET, V2, P1293; POLLARE T, 1989, NEW ENGL J MED, V321, P868, DOI 10.1056/NEJM198909283211305; RAY WA, 1986, AM J MED, V81, P9, DOI 10.1016/0002-9343(86)90522-X; SCHAPPERT SM, 1992, ADV DATA VITAL HLTH, V211; SHAPIRO AP, 1961, NEW ENGL J MED, V265, P1028, DOI 10.1056/NEJM196111232652102; SKARFORS ET, 1989, BRIT MED J, V298, P1147, DOI 10.1136/bmj.298.6681.1147; WOLFF FW, 1963, JAMA-J AM MED ASSOC, V185, P568, DOI 10.1001/jama.1963.03060070036019; 1985, SAS USERS GUIDE STAT	27	77	78	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1993	118	4					273	278		10.7326/0003-4819-118-4-199302150-00005	http://dx.doi.org/10.7326/0003-4819-118-4-199302150-00005			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KL457	8420444				2022-12-24	WOS:A1993KL45700005
J	KLEIN, RD; MEYER, BJ				KLEIN, RD; MEYER, BJ			INDEPENDENT DOMAINS OF THE SDC-3 PROTEIN CONTROL SEX DETERMINATION AND DOSAGE COMPENSATION IN C-ELEGANS	CELL			English	Article							X-CHROMOSOME DOSAGE; NEMATODE CAENORHABDITIS-ELEGANS; BINDING-PROTEINS; FINGER PROTEIN; ZINC FINGERS; GENE; SEQUENCE; MYOSIN; ATP; MUTANTS	sdc-3 is an early-acting regulatory gene that controls both sex determination and X chromosome dosage compensation in C. elegans. It is unique among sdc genes in that its sex determination and dosage compensation functions act independently. The molecular analysis reported here demonstrates that separate domains of the Sdc-3 protein control these two developmental processes. Sequence analysis of 16 sdc-3 alleles reveals that the dosage compensation mutations specifically eliminate a pair of zinc finger motifs at the carboxyl terminus of Sdc-3, while the sex determination mutations alter a region with limited homology to the ATP-binding domain of myosin. Null mutations, which disrupt both processes, abort translation of Sdc-3 prior to both domains. Analysis of site-directed changes confirms the functional significance of the two separate regions in sex determination and dosage compensation and reveals that an additional region, undetected by genetic analysis, is also required for proper dosage compensation.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT)	KLEIN, RD (corresponding author), UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA.			Meyer, Barbara/0000-0002-6530-4588	NIGMS NIH HHS [GM30702, R01 GM030702] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030702, R01GM030702] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BEJSOVEC A, 1990, CELL, V60, P133, DOI 10.1016/0092-8674(90)90723-R; BERG JM, 1986, SCIENCE, V232, P485, DOI 10.1126/science.2421409; COLLINS J, 1987, NATURE, V328, P726, DOI 10.1038/328726a0; COTTON RGH, 1988, P NATL ACAD SCI USA, V85, P5698; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; COULSON A, 1988, NATURE, V335, P184, DOI 10.1038/335184a0; DELONG LD, 1993, IN PRESS GENETICS, V133; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; FIELDS C, 1990, NUCLEIC ACIDS RES, V18, P1509, DOI 10.1093/nar/18.6.1509; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HODGKIN J, 1983, MOL GEN GENET, V192, P452, DOI 10.1007/BF00392190; HODGKIN J, 1980, GENETICS, V96, P649; HODGKIN J, 1979, GENETICS, V91, P67; HODGKIN J, 1990, NATURE, V344, P721, DOI 10.1038/344721a0; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KLUG A, 1987, TRENDS BIOCHEM SCI, V12, P464, DOI 10.1016/0968-0004(87)90231-3; KRAUSE M, 1989, J MOL BIOL, V208, P381, DOI 10.1016/0022-2836(89)90503-2; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; KUWABARA PE, 1992, TRENDS GENET, V8, P164, DOI 10.1016/0168-9525(92)90218-S; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MEYER BJ, 1986, CELL, V47, P871, DOI 10.1016/0092-8674(86)90802-0; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; MILLER LM, 1988, CELL, V55, P167, DOI 10.1016/0092-8674(88)90019-0; MOLINA MI, 1987, J BIOL CHEM, V262, P6478; MONTANDON AJ, 1989, NUCLEIC ACIDS RES, V17, P3347, DOI 10.1093/nar/17.9.3347; NONET ML, 1991, NATURE, V351, P65, DOI 10.1038/351065a0; NUSBAUM C, 1989, GENETICS, V122, P579; PAGE DC, 1987, CELL, V51, P1091, DOI 10.1016/0092-8674(87)90595-2; PLENEFISCH JD, 1989, GENETICS, V121, P57; Sambrook J., 1989, MOL CLONING LAB MANU; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SCHAUER IE, 1990, DEVELOPMENT, V110, P1303; Sulston J, 1988, NEMATODE CAENORHABDI, P587; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; TRENT C, 1991, MECH DEVELOP, V34, P43, DOI 10.1016/0925-4773(91)90090-S; Villeneuve A.M., 1990, Advances in Genetics, V27, P117; VILLENEUVE AM, 1987, CELL, V48, P25, DOI 10.1016/0092-8674(87)90352-7; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; [No title captured]; [No title captured]	42	58	78	0	2	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 12	1993	72	3					349	364		10.1016/0092-8674(93)90113-5	http://dx.doi.org/10.1016/0092-8674(93)90113-5			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KM162	8431944				2022-12-24	WOS:A1993KM16200006
J	TODO, T; TAKEMORI, H; RYO, H; IHARA, M; MATSUNAGA, T; NIKAIDO, O; SATO, K; NOMURA, T				TODO, T; TAKEMORI, H; RYO, H; IHARA, M; MATSUNAGA, T; NIKAIDO, O; SATO, K; NOMURA, T			A NEW PHOTOREACTIVATING ENZYME THAT SPECIFICALLY REPAIRS ULTRAVIOLET LIGHT-INDUCED (6-4)PHOTOPRODUCTS	NATURE			English	Article							ESCHERICHIA-COLI; PYRIMIDINE DIMER; BINDING-PROTEINS; HUMAN-CELLS; DNA; SEQUENCE; PHOTOPRODUCTS; ESTABLISHMENT; PURIFICATION; DAMAGE	CYCLOBUTANE pyrimidine dimers (CPDs) and pyrimidine (6-4) pyrimidone photoproducts ((6-4)photoproducts) are the two major classes of cytotoxic, mutagenic and carcinogenic DNA photoproducts produced by ultraviolet light irradiation of cells1-4. The phenomenon of photoreactivation, the reduction of the lethal and mutagenic effects of ultraviolet radiation by simultaneous or subsequent irradiation with near ultraviolet or visible light, has been identified in several organisms and in some cases the enzymes that catalyse this process have been characterized in sufficient detail5. CPDs are the only known substrate for the photoreactivating enzymes so far analysed and enzymatic photoreactivation of (6-4)photoproducts has not yet been reported4,5. We report here that an enzyme that catalyses the light-dependent repair of (6-4)photoproduct exists in Drosophila melanogaster. This is, to our knowledge, the first report of such photoreactivating activity specific for (6-4)photoproducts in any organism.	NARA MED UNIV,DEPT BIOL,KASHIHARA,NARA 634,JAPAN; KANAZAWA UNIV,FAC PHARMACEUT SCI,DIV RADIAT BIOL,KANAZAWA,ISHIKAWA 920,JAPAN; OSAKA UNIV,SCH MED,DEPT DERMATOL,OSAKA 553,JAPAN	Nara Medical University; Kanazawa University; Osaka University	TODO, T (corresponding author), OSAKA UNIV,FAC MED,DEPT RADIAT BIOL,YAMADA OKA 2-2,SUITA,OSAKA 565,JAPAN.							[Anonymous], 1985, DNA REPAIR; BRASH DE, 1988, PHOTOCHEM PHOTOBIOL, V48, P59; CHU G, 1988, SCIENCE, V242, P564, DOI 10.1126/science.3175673; Harm W, 1980, BIOL EFFECTS ULTRAVI; HASELTINE WA, 1980, NATURE, V285, P634, DOI 10.1038/285634a0; HIRSCHFELD S, 1990, MOL CELL BIOL, V10, P2041, DOI 10.1128/MCB.10.5.2041; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; LIPPKE JA, 1981, P NATL ACAD SCI-BIOL, V78, P3388, DOI 10.1073/pnas.78.6.3388; MATSUNAGA T, 1990, MUTAT RES, V235, P187, DOI 10.1016/0921-8777(90)90073-E; Maxam A M, 1980, Methods Enzymol, V65, P499; MITCHELL DL, 1990, NUCLEIC ACIDS RES, V18, P963, DOI 10.1093/nar/18.4.963; MITCHELL DL, 1989, PHOTOCHEM PHOTOBIOL, V49, P805, DOI 10.1111/j.1751-1097.1989.tb05578.x; MIZUNO T, 1991, MUTAT RES, V254, P175, DOI 10.1016/0921-8777(91)90009-E; MORI T, 1991, PHOTOCHEM PHOTOBIOL, V54, P225, DOI 10.1111/j.1751-1097.1991.tb02010.x; SANCAR A, 1984, J BIOL CHEM, V259, P6028; SANCAR GB, 1990, MUTAT RES, V236, P147, DOI 10.1016/0921-8777(90)90002-M; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SEIDMAN MM, 1985, GENE, V38, P233, DOI 10.1016/0378-1119(85)90222-7; TODO T, 1992, MUTAT RES, V273, P85, DOI 10.1016/0921-8777(92)90052-5; VARGHESE AJ, 1968, SCIENCE, V160, P186, DOI 10.1126/science.160.3824.186; WANG SY, 1967, BIOCHEM BIOPH RES CO, V29, P543, DOI 10.1016/0006-291X(67)90519-0	21	251	256	1	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 28	1993	361	6410					371	374		10.1038/361371a0	http://dx.doi.org/10.1038/361371a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KJ590	8426655				2022-12-24	WOS:A1993KJ59000064
J	HOGE, CW; SCHWARTZ, B; TALKINGTON, DF; BREIMAN, RF; MACNEILL, EM; ENGLENDER, SJ				HOGE, CW; SCHWARTZ, B; TALKINGTON, DF; BREIMAN, RF; MACNEILL, EM; ENGLENDER, SJ			THE CHANGING EPIDEMIOLOGY OF INVASIVE GROUP-A STREPTOCOCCAL INFECTIONS AND THE EMERGENCE OF STREPTOCOCCAL TOXIC SHOCK-LIKE SYNDROME - A RETROSPECTIVE POPULATION-BASED STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE RHEUMATIC-FEVER; 4-YEAR EXPERIENCE; UNITED-STATES; SCARLET FEVER; BACTEREMIA; DISEASE; MENINGITIS; CHILDREN; MORBIDITY; MORTALITY	Objective.-To determine disease incidence and changes in the epidemiology of invasive group A streptococcal infections in a community in Arizona. Design and Setting.-We retrospectively surveyed microbiology records from all 10 hospitals in Pima County, Arizona, to identify patients who had Streptococcus pyogenes isolated from blood, sterile body fluid, or tissue biopsy specimens between April 1985 and March 1990. Demographic and clinical information was abstracted from the medical records of these patients. Patients.-A total of 128 patients with a median age of 53.5 years (range, 6 months to 96 years). Outcome Measures.-Racial/ethnic differences in disease incidence; mortality and changes in the clinical spectrum of disease over the study period. Results.-The annual age-adjusted incidence was 4.3 per 100 000 but was 46.0 per 100 000 among Native Americans. Advanced age, age less than 5 years, hypotension, and multi-organ system involvement were significantly associated with increased mortality. From 1985 to 1990, the proportion of infections with hypotension, rash, desquamation, renal impairment, and gastrointestinal involvement increased significantly (chi2 for trend P less-than-or-equal-to .02 for each feature). A toxic shock-like syndrome occurred in 8% of infections since 1988, compared with none of the infections between 1985 and 1987 (P=.04). Patients with the syndrome were younger than patients with other invasive infections (median age 15 vs 54 years, P=02), and were less likely to have underlying medical conditions (P=.008). Conclusions.-Significant changes occurred in the spectrum of invasive group A streptococcal infections in Pima County, Arizona, between 1985 and 1990. Native Americans were at increased risk of acquiring these infections. Patients with the streptococcal toxic shock-like syndrome had epidemiologic features that distinguished them from patients with other invasive infections, including younger age and less underlying illness.	PIMA CTY HLTH DEPT,TUCSON,AZ; NATL CTR DIS CONTROL & PREVENT,CTR INFECT DIS,DIV BACTERIAL & MYCOT DIS,RESP DIS BRANCH,ATLANTA,GA; ARIZONA DEPT HLTH SERV,PHOENIX,AZ	Centers for Disease Control & Prevention - USA; Arizona Department of Health Services								BARTTER T, 1988, ARCH INTERN MED, V148, P1421, DOI 10.1001/archinte.148.6.1421; BEGOVAC J, 1990, PEDIATR INFECT DIS J, V9, P369, DOI 10.1097/00006454-199005000-00013; BIBLER MR, 1986, REV INFECT DIS, V8, P941; BISNO AL, 1985, JAMA-J AM MED ASSOC, V254, P538, DOI 10.1001/jama.254.4.538; BRAUNSTEIN H, 1991, REV INFECT DIS, V13, P8; BURKERT T, 1992, CLIN INFECT DIS, V14, P29, DOI 10.1093/clinids/14.1.29; CAMOSFILHO N, 1989, AM J EPIDEMIOL, V129, P439; CONE LA, 1987, NEW ENGL J MED, V317, P146, DOI 10.1056/NEJM198707163170305; COULEHAN J, 1980, PUBLIC HEALTH REP, V95, P62; COULEHAN JL, 1984, PUBLIC HEALTH REP, V99, P404; DAJANI AS, 1973, ARCH DERMATOL, V108, P517, DOI 10.1001/archderm.108.4.517; DAN M, 1990, REV INFECT DIS, V12, P537; DAVIS JP, 1982, J INFECT DIS, V145, P441, DOI 10.1093/infdis/145.4.441; DUMA RJ, 1969, MEDICINE, V48, P87, DOI 10.1097/00005792-196903000-00001; Facklam RR, 1985, MANUAL CLIN MICROBIO, V4th, P154; FRANCIS J, 1988, Q J MED, V68, P603; GIVNER LB, 1991, J PEDIATR-US, V118, P341, DOI 10.1016/S0022-3476(05)82144-4; HRIBALOVA V, 1988, ANN INTERN MED, V108, P772, DOI 10.7326/0003-4819-108-5-772_2; KOHLER W, 1987, ZBL BAKT-INT J MED M, V266, P104; LERSCH C, 1990, KLIN WOCHENSCHR, V68, P523, DOI 10.1007/BF01648248; LONGSTAFFE S, 1982, CAN MED ASSOC J, V127, P497; MARTIN PR, 1990, SCAND J INFECT DIS, V22, P421, DOI 10.3109/00365549009027073; MASSELL BF, 1988, NEW ENGL J MED, V318, P280, DOI 10.1056/NEJM198802043180504; MOODY M D, 1965, Health Lab Sci, V2, P149; QUINN RW, 1989, REV INFECT DIS, V11, P928; REDD SC, 1988, PEDIATRICS, V82, P576; SCHLIEVERT PM, 1981, J INFECT DIS, V143, P509, DOI 10.1093/infdis/143.4.509; STEVENS DL, 1989, NEW ENGL J MED, V321, P1, DOI 10.1056/NEJM198907063210101; STROMBERG A, 1991, J INFECT DIS, V164, P595, DOI 10.1093/infdis/164.3.595; TALKINGTON DF, 1991, 91ST AM SOC MICR ANN; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VEASY LG, 1987, NEW ENGL J MED, V316, P421, DOI 10.1056/NEJM198702193160801; WALLACE MR, 1989, JAMA-J AM MED ASSOC, V262, P2557, DOI 10.1001/jama.262.18.2557; WARD JI, 1981, LANCET, V1, P1281; WHEELER MC, 1991, JAMA-J AM MED ASSOC, V266, P533, DOI 10.1001/jama.266.4.533; WOTTON KA, 1981, CAN MED ASSOC J, V124, P887; YOST GC, 1986, AM J DIS CHILD, V140, P943, DOI 10.1001/archpedi.1986.02140230113047; 1990, COMMUNICAB DIS REP, V26, P3; 1990, MMWR, V39, P3; 1990, MMWR SRR13, V39, P1; 1990, CAN DIS WKLY REP, V16, P257; 1991, COLO DIS B, V18; 1989, TUCSON PROFILE	43	320	328	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 20	1993	269	3					384	389		10.1001/jama.269.3.384	http://dx.doi.org/10.1001/jama.269.3.384			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG381	8418346				2022-12-24	WOS:A1993KG38100031
J	CONSTINE, LS; WOOLF, PD; CANN, D; MICK, G; MCCORMICK, K; RAUBERTAS, RF; RUBIN, P				CONSTINE, LS; WOOLF, PD; CANN, D; MICK, G; MCCORMICK, K; RAUBERTAS, RF; RUBIN, P			HYPOTHALAMIC PITUITARY DYSFUNCTION AFTER RADIATION FOR BRAIN-TUMORS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GROWTH-HORMONE DEFICIENCY; CRANIAL IRRADIATION; THYROID-DYSFUNCTION; INTRACRANIAL TUMORS; ENDOCRINE SEQUELAE; LH-RH; CHILDREN; RADIOTHERAPY; CHILDHOOD; PUBERTY	Background. Patients with brain tumors who are treated with radiation frequently have growth hormone deficiency, but other neuroendocrine abnormalities are presumed to be uncommon. Methods. We studied endocrine function in 32 patients (age, 6 to 65 years) 2 to 13 years after they had received cranial radiotherapy for brain tumors. The doses of radiation to the hypothalamic-pituitary region ranged from 3960 to 7020 rad (39.6 to 70.2 Gy). Nine patients also received 1800 to 3960 rad (18.0 to 39.6 Gy) to the craniospinal axis. Serum concentrations of thyroid, gonadal, and pituitary hormones were measured at base line and after stimulation. Results. Nine patients (28 percent) had symptoms of thyroid deficiency, and 20 patients (62 percent) had low serum total or free thyroxine or total triiodothyronine concentrations. Of the 23 patients treated only with cranial radiation, 15 (65 percent) had hypothalamic or pituitary hypothyroidism. Of the nine patients who also received spinal (and thus direct thyroid) radiation, three (33 percent) had evidence of primary thyroid injury. Seven of the 10 postpubertal, premenopausal women (70 percent) had oligomenorrhea, and 5 (50 percent) had low serum estradiol concentrations. Three of the 10 men (30 percent) had low serum testosterone concentrations. Overall, 14 of the 23 postpubertal patients (61 percent) had evidence of hypogonadism. Mild hyperprolactinemia was present in 50 percent of the patients. Responses to stimulation with corticotropin-releasing hormone and corticotropin were normal in all patients except one, who had panhypothalamic dysfunction. However, serum 11-deoxycortisol responses to the administration of metyrapone were low in 11 of the 31 patients (35 percent) tested. Three of the 32 patients (9 percent) had no endocrine abnormalities, 9 (28 percent) had an abnormal result on tests of thyroid, gonadal, prolactin, or adrenal function, 8 (25 percent) had abnormalities in two axes, 8 (25 percent) in three axes, and 4 (12 percent) in all four axes. Conclusions. Cranial radiotherapy in children and adults with brain tumors frequently causes abnormal hypothalamic-pituitary function. The most frequent changes are hypothyroidism and gonadal dysfunction, although subtle abnormalities in adrenal function may also be present.	UNIV ROCHESTER, MED CTR, DEPT PEDIAT, DIV PEDIAT ONCOL, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, MED CTR, DEPT MED, DIV ENDOCRINOL, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, MED CTR, DEPT BIOSTAT, ROCHESTER, NY 14642 USA; DOVER GEN HOSP, DEPT RADIAT ONCOL, DOVER, NJ USA; SUNY HLTH SCI CTR, DEPT PEDIAT, DIV ENDOCRINOL, SYRACUSE, NY USA	University of Rochester; University of Rochester; University of Rochester; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	CONSTINE, LS (corresponding author), UNIV ROCHESTER, MED CTR, DEPT RADIAT ONCOL, ROCHESTER, NY 14642 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000044] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00044] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ABAYOMI OK, 1986, INT J RADIAT ONCOL, V12, P945, DOI 10.1016/0360-3016(86)90390-1; AGRESTI A, 1984, ANAL ORDINAL CATEGOR, P161; ALMQUIST S, 1964, ACTA RADIOL THER PHY, V2, P179, DOI 10.3109/02841866409134144; BAJORUNAS DR, 1980, J CLIN ENDOCR METAB, V50, P329, DOI 10.1210/jcem-50-2-329; BRAUNER R, 1989, J CLIN ENDOCR METAB, V68, P346, DOI 10.1210/jcem-68-2-346; BRUNNER H, 1920, ARCH KLIN CHIR, V114, P332; CLAYTON PE, 1991, J PEDIATR-US, V118, P226, DOI 10.1016/S0022-3476(05)80487-1; Conover WJ, 1980, PRACTICAL NONPARAMET, P215; CONSTINE LS, 1984, CANCER-AM CANCER SOC, V53, P878, DOI 10.1002/1097-0142(19840215)53:4<878::AID-CNCR2820530411>3.0.CO;2-J; CONSTINE LS, 1987, J CLIN ONCOL, V5, P1841, DOI 10.1200/JCO.1987.5.11.1841; CROMPTON MR, 1961, BRAIN, V84, P85, DOI 10.1093/brain/84.1.85; DANOFF BF, 1982, CANCER, V48, P1580, DOI 10.1002/1097-0142(19820415)49:8<1580::AID-CNCR2820490810>3.0.CO;2-7; DEUTSCH M, 1986, MEDULLOBLASTOMAS CHI, P213; DICKERMAN Z, 1976, AM J DIS CHILD, V130, P634, DOI 10.1001/archpedi.1976.02120070060011; DUFFNER PK, 1985, CANCER-AM CANCER SOC, V56, P2189, DOI 10.1002/1097-0142(19851101)56:9<2189::AID-CNCR2820560909>3.0.CO;2-I; Fleiss J. L, 1981, STATISTICAL METHODS, P24; GARNIER PE, 1974, ACTA ENDOCRINOL-COP, V77, P422; HAJJAR RA, 1973, ARCH INTERN MED, V132, P836, DOI 10.1001/archinte.132.6.836; HARROP JS, 1976, CLIN ENDOCRINOL, V5, P313, DOI 10.1111/j.1365-2265.1976.tb01960.x; KELLY KH, 1951, J NATL CANCER I, V11, P967; LAM KSL, 1991, Q J MED, V78, P165; LANNERING B, 1987, HORM RES, V27, P13, DOI 10.1159/000180772; LITTLEY MD, 1989, CLIN ENDOCRINOL, V31, P363, DOI 10.1111/j.1365-2265.1989.tb01260.x; LIVESEY EA, 1989, ARCH DIS CHILD, V64, P593, DOI 10.1136/adc.64.4.593; LIVESEY EA, 1988, ARCH DIS CHILD, V63, P495, DOI 10.1136/adc.63.5.495; OBERFIELD SE, 1986, J PEDIATR-US, V108, P219, DOI 10.1016/S0022-3476(86)80986-6; PERRYKEENE DA, 1976, CLIN ENDOCRINOL, V5, P373, DOI 10.1111/j.1365-2265.1976.tb01965.x; QUIGLEY C, 1989, NEW ENGL J MED, V321, P143, DOI 10.1056/NEJM198907203210303; RAMSAY N, 1978, P AM ASSOC CANC RES, V19, P389; RAPPAPORT R, 1989, PEDIATR RES, V25, P561, DOI 10.1203/00006450-198906000-00001; REITER EO, 1975, PEDIATR RES, V9, P111, DOI 10.1203/00006450-197509020-00011; Rubin P., 1968, CLIN RAD PATHOLOGY; SAMAAN NA, 1987, J LAB CLIN MED, V109, P364; SAMAAN NA, 1982, INT J RADIAT ONCOL, V8, P1857, DOI 10.1016/0360-3016(82)90442-4; SCHURMEYER TH, 1984, J CLIN ENDOCR METAB, V59, P1103, DOI 10.1210/jcem-59-6-1103; SHALET SM, 1976, CLIN ENDOCRINOL, V5, P287, DOI 10.1111/j.1365-2265.1976.tb01955.x; SHALET SM, 1975, LANCET, V2, P104; SKLAR C A, 1991, Pediatrician, V18, P53; SLANINA J, 1977, INT J RADIAT ONCOL, V2, P1, DOI 10.1016/0360-3016(77)90003-7; SLATSTEI.E, 1971, J CLIN ENDOCR METAB, V32, P833, DOI 10.1210/jcem-32-6-833; SNYDER PJ, 1974, ANN INTERN MED, V81, P751, DOI 10.7326/0003-4819-81-6-751; WARA WM, 1977, INT J RADIAT ONCOL, V2, P549, DOI 10.1016/0360-3016(77)90166-3; WIGG DR, 1982, ACTA RADIOL ONCOL, V21, P49, DOI 10.3109/02841868209133984	43	441	461	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 14	1993	328	2					87	94		10.1056/NEJM199301143280203	http://dx.doi.org/10.1056/NEJM199301143280203			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG467	8416438				2022-12-24	WOS:A1993KG46700003
J	BROADHURST, LE; ERICKSON, RL; KELLEY, PW				BROADHURST, LE; ERICKSON, RL; KELLEY, PW			DECREASES IN INVASIVE HAEMOPHILUS-INFLUENZAE DISEASES IN UNITED-STATES-ARMY CHILDREN, 1984 THROUGH 1991	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							B DISEASE; CONJUGATE VACCINE; EPIDEMIOLOGY; EFFICACY; MENINGITIS; INFECTIONS; POPULATION; POLYSACCHARIDE; COUNTY; YOUNG	Objective.-To document trends in the incidence of invasive Haemophilus influenzae diseases in young children of US Army active duty soldiers following the publication of H influenzae type b immunization recommendations for young children between 1985 and 1990. Design.-A population-based surveillance of hospital discharge diagnoses for H influenzae invasive diseases. Setting.-Military and civilian medical treatment facilities around the world. Patients.-There was a mean population of nearly 200 000 US Army health care beneficiaries younger than 5 years of age each year of the study. Outcome Measures.-Annual total and age-specific incidences of the six most common H influenzae invasive diseases in this population (meningitis, epiglottitis, septicemia, pneumonia, cellulitis, and septic arthritis). Results.-The annual number of cases of H influenzae invasive diseases decreased from a high of 188 in 1986 to 43 in 1991. The incidence in the age group at highest risk for H influenzae disease, those 6 to 11 months of age, decreased from 355 per 100 000 children in 1986 to 116 per 100 000 in 1991 (P<.0001, chi2 for trend). The incidence for H influenzae meningitis declined from 59 per 100 000 children in 1986 to 6 per 100 000 in 1991 (P<.0001, chi2 for trend). Conclusions.-The decrease in H influenzae invasive diseases closely follows the dates of H influenzae type b vaccine licensure for use in progressively younger age groups. Some age groups, however, experienced a decline in disease rates even before becoming eligible for vaccination.	WALTER REED ARMY INST RES,DIV PREVENT MED,DEPT ADV PREVENT MED STUDIES,WASHINGTON,DC 20307	United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR)								ADAMS W, 1992, APR CTR DIS CONTR EP; AHONKHAI VI, 1991, VACCINE, V9, pS38, DOI 10.1016/0264-410X(91)90180-E; BLACK SB, 1991, PEDIATR INFECT DIS J, V10, P97, DOI 10.1097/00006454-199102000-00004; BLACK SB, 1992, PEDIATR INFECT DIS J, V11, P610; BROOME CV, 1987, PEDIATR INFECT DIS J, V6, P779, DOI 10.1097/00006454-198708000-00036; COCHI SL, 1986, PEDIATR INFECT DIS J, V5, P12, DOI 10.1097/00006454-198601000-00003; ESKOLA J, 1991, VACCINE, V9, pS14, DOI 10.1016/0264-410X(91)90174-5; FERRECCIO C, 1990, PEDIATR INFECT DIS J, V9, P488, DOI 10.1097/00006454-199007000-00007; GERVAIX A, 1991, PEDIATR INFECT DIS J, V10, P370, DOI 10.1097/00006454-199105000-00005; GRANOFF DM, 1991, VACCINE, V9, pS30, DOI 10.1016/0264-410X(91)90178-9; GREENBERG DP, 1991, JAMA-J AM MED ASSOC, V265, P987, DOI 10.1001/jama.265.8.987; HALFONYANIV I, 1990, PEDIATR INFECT DIS J, V9, P321, DOI 10.1097/00006454-199005000-00004; HOWARD AJ, 1991, BRIT MED J, V303, P441, DOI 10.1136/bmj.303.6800.441; MARWICK C, 1991, JAMA-J AM MED ASSOC, V266, P3398, DOI 10.1001/jama.266.24.3398; MURPHY TV, 1987, PEDIATRICS, V79, P173; MURPHY TV, 1991, 31ST INT C ANT AG CH; NELSON JD, 1991, PEDIATR INFECT DIS J, V17, P23; PELTOLA H, 1990, REV INFECT DIS, V12, P708; PELTOLA H, 1992, LANCET, V340, P592, DOI 10.1016/0140-6736(92)92117-X; PELTOLA H, 1991, 31TH INT C ANT AG CH; RICE RB, 1990, AM J PUBLIC HEALTH, V80, P215, DOI 10.2105/AJPH.80.2.215; SHAPIRO ED, 1991, EPIDEMIOL REV, V13, P113, DOI 10.1093/oxfordjournals.epirev.a036066; SHAPIRO ED, 1992, MAY SOC PED RES BALT; SHERRY B, 1989, JAMA-J AM MED ASSOC, V261, P1924, DOI 10.1001/jama.261.13.1924; SMITH EWP, 1972, PEDIATRICS, V50, P723; TAKALA AK, 1989, PEDIATR INFECT DIS J, V8, P343, DOI 10.1097/00006454-198906000-00002; TAKALA AK, 1992, J INFECT DIS, V165, pS11, DOI 10.1093/infdis/165-Supplement_1-S11; TAKALA AK, 1989, PEDIATR INFECT DIS J, V8, P297; TAKALA AK, 1991, J INFECT DIS, V164, P982, DOI 10.1093/infdis/164.5.982; WENGER J, 1988, 28TH INT C ANT AG CH; WENGER JD, 1991, LANCET, V338, P395; WENGER JD, 1990, J INFECT DIS, V162, P1316, DOI 10.1093/infdis/162.6.1316; 1985, MMWR, V34, P201; 1990, MMWR, V39, P925; 1991, MMWR, V40, P1; 1990, MMWR, V39, P924; 1992, KY EPIDEMIOL NOT APR, P1; 1988, MMWR, V37, P13; 1990, MMWR, V39, P698	39	90	90	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 13	1993	269	2					227	231		10.1001/jama.269.2.227	http://dx.doi.org/10.1001/jama.269.2.227			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF405	8417240				2022-12-24	WOS:A1993KF40500028
J	NISWANDER, L; MARTIN, GR				NISWANDER, L; MARTIN, GR			FGF-4 AND BMP-2 HAVE OPPOSITE EFFECTS ON LIMB GROWTH	NATURE			English	Article							PATTERN-FORMATION; CONTAINING GENES; MOUSE; EXPRESSION; FAMILY; EMBRYOGENESIS; RECEPTORS; MULTIPLE; SUGGESTS; FETAL	LIMB development is dependent on epithelial-mesenchymal interactions. The apical ectodermal ridge (AER), a specialized epithelium at the limb tip, stimulates proliferation of underlying mesenchyme, causing directed limb outgrowth1 (for review see ref. 2). Several genes are expressed in the mouse AER3-10, including Fgf-4 (fibroblast growth factor-4)11,12 and Bmp-2 (bone morphogenetic protein-2)13, both of which encode secreted signalling molecules. Using a culture system developed to explore the function of molecules produced by the AER, we have shown that FGF-4 protein stimulates proliferation of mesenchyme in the early mouse limb-bud. This suggests that FGF-4 serves that major function of the AER. In contrast, BMP-2 inhibits limb growth, suggesting that as a result the AER may serve a hitherto unrecognized inhibitory function. Furthermore, the extent of limb outgrowth can be modulated by mixing the two signalling molecules, suggesting that limb growth is regulated by a combination of stimulatory and inhibitory signals from the AER.	UNIV CALIF SAN FRANCISCO,SCH MED,PROGRAM DEV BIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	NISWANDER, L (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,DEPT ANAT,SAN FRANCISCO,CA 94143, USA.		Niswander, Lee/D-3976-2013	Niswander, Lee/0000-0002-9959-0594				AONO H, 1988, DEV BIOL, V128, P136, DOI 10.1016/0012-1606(88)90275-8; DAVIS CA, 1991, DEVELOPMENT, V111, P287; DELLIBOVI P, 1988, MOL CELL BIOL, V8, P2933, DOI 10.1128/MCB.8.7.2933; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; DOLLE P, 1989, NATURE, V342, P702, DOI 10.1038/342702a0; DOLLE P, 1991, MECH DEVELOP, V36, P3, DOI 10.1016/0925-4773(91)90067-G; DOLLE P, 1989, NATURE, V342, P767, DOI 10.1038/342767a0; FROHMAN MA, 1990, DEVELOPMENT, V110, P589; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; HAUB O, 1991, DEVELOPMENT, V112, P397; HEBERT JM, 1990, DEV BIOL, V138, P454, DOI 10.1016/0012-1606(90)90211-Z; HILL RE, 1989, GENE DEV, V3, P26, DOI 10.1101/gad.3.1.26; Hinchliffe J. R., 1980, DEV VERTEBRATE LIMB; JACKSONGRUSBY L, 1992, GENE DEV, V6, P29, DOI 10.1101/gad.6.1.29; JONES CM, 1991, DEVELOPMENT, V111, P531; LYONS KM, 1990, DEVELOPMENT, V109, P833; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; MORGAN BA, 1992, NATURE, V358, P236, DOI 10.1038/358236a0; Neubert D., 1977, METHODS PRENATAL TOX, P241; NISWANDER L, 1992, DEVELOPMENT, V114, P755; ORRURTREGER A, 1991, DEVELOPMENT, V113, P1419; PETERS KG, 1992, DEVELOPMENT, V114, P233; ROBERT B, 1989, EMBO J, V8, P91, DOI 10.1002/j.1460-2075.1989.tb03352.x; RUBERTE E, 1992, DEVELOPMENT, V115, P973; SAUNDERS JW, 1948, J EXP ZOOL, V108, P363, DOI 10.1002/jez.1401080304; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUMMERBELL D, 1974, J EMBRYOL EXP MORPH, V32, P651; SUZUKI HR, 1992, DEV BIOL, V150, P219, DOI 10.1016/0012-1606(92)90020-H; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; TAKUWA Y, 1991, BIOCHEM BIOPH RES CO, V174, P96, DOI 10.1016/0006-291X(91)90490-X; WANEK N, 1989, J EXP ZOOL, V249, P41, DOI 10.1002/jez.1402490109; WILKINSON DG, 1989, DEVELOPMENT, V105, P131	32	365	380	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 7	1993	361	6407					68	71		10.1038/361068a0	http://dx.doi.org/10.1038/361068a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KF718	8421496				2022-12-24	WOS:A1993KF71800050
J	ANDERSON, DR; LENSING, AWA; WELLS, PS; LEVINE, MN; WEITZ, JI; HIRSH, J				ANDERSON, DR; LENSING, AWA; WELLS, PS; LEVINE, MN; WEITZ, JI; HIRSH, J			LIMITATIONS OF IMPEDANCE PLETHYSMOGRAPHY IN THE DIAGNOSIS OF CLINICALLY SUSPECTED DEEP-VEIN THROMBOSIS	ANNALS OF INTERNAL MEDICINE			English	Article						PLETHYSMOGRAPHY, IMPEDANCE; PHLEBOGRAPHY; THROMBOPHLEBITIS; ANTICOAGULANTS; THROMBOSIS	VENOUS-THROMBOSIS; OUTPATIENTS; MANAGEMENT; HIP; PHLEBOGRAPHY; REPLACEMENT; VENOGRAPHY; SURGERY	Objective: To re-evaluate the accuracy of impedance plethysmography (IPG) for the detection of proximal deep-vein thrombosis (DVT). Patients: A total of 384 of 390 consecutive outpatients referred with their first episode of clinically suspected deep-vein thrombosis. Setting: University-based tertiary care medical center associated with a cancer clinic. Design: A retrospective analysis of a cohort of patients whose data were recorded and stored prospectively on a computerized data base over a 22-month period. Measurements: Patients were evaluated by a physician and underwent IPG testing. Patients with abnormal IPG tests and those with normal IPG results in whom there was a high clinical suspicion of DVT or in whom follow-up IPG testing was not feasible were referred for venography. Venography and IPG results were interpreted by a panel of independent observers. Two models of the IPG instrument were used (Codman 200 and Electrodiagnostic Instruments 800). Results: Venography (or compression ultrasound) was done in 57 patients with an abnormal IPG test and in 85 patients with normal IPG results. Impedance plethysmography was abnormal in only 37 of 56 patients with confirmed proximal-vein thrombosis (sensitivity, 66%; 95% CI, 52% to 78%). Of the 57 patients with an abnormal IPG result, 37 had DVT (positive predictive value, 65%). The sensitivity for the detection of proximal DVT did not differ between the IPG 200 and 800 instruments (sensitivity, 63% and 71%, respectively; P > 0.2). Of the 19 proximal-vein thrombi not detected by IPG, 12 (63%) were occlusive and 11 (58%) involved at least the popliteal and superficial femoral veins. Conclusions: At our center, IPG has a far lower sensitivity for proximal-vein thrombosis than has been previously reported for symptomatic outpatients. The reason for this low sensitivity is unclear. Our findings indicate that centers using IPG as the initial diagnostic test for suspected DVT should be aware of this potential problem and should consider re-evaluating the sensitivity of their IPG machines by performing venography in a cohort of their patients with normal test results.	HAMILTON CIV HOSP, RES CTR, HAMILTON L8V 1C3, ON, CANADA; MCMASTER UNIV, HAMILTON L8S 4L8, ONTARIO, CANADA	McMaster University; McMaster University			Weitz, Jeffrey/AAD-1929-2019	Weitz, Jeffrey/0000-0002-1092-7550; Anderson, David/0000-0003-0845-1722				BETTMANN MA, 1977, RADIOLOGY, V122, P101, DOI 10.1148/122.1.101; BULLER HR, 1991, THROMB HAEMOSTASIS, V66, P133; COOPERMAN M, 1979, AM J SURG, V137, P252, DOI 10.1016/0002-9610(79)90157-0; CRUICKSHANK MK, 1989, THROMB HAEMOSTASIS, V62, P830; GINSBERG JS, 1991, RADIOLOGY, V181, P651, DOI 10.1148/radiology.181.3.1947076; HAEGER K, 1969, ANGIOLOGY, V20, P219, DOI 10.1177/000331976902000406; HUISMAN MV, 1986, NEW ENGL J MED, V314, P823, DOI 10.1056/NEJM198603273141305; HUISMAN MV, 1989, ARCH INTERN MED, V149, P511, DOI 10.1001/archinte.149.3.511; HULL R, 1981, CIRCULATION, V64, P622, DOI 10.1161/01.CIR.64.3.622; HULL R, 1976, CIRCULATION, V53, P696, DOI 10.1161/01.CIR.53.4.696; HULL R, 1981, ANN INTERN MED, V94, P12, DOI 10.7326/0003-4819-94-1-12; HULL RD, 1985, ANN INTERN MED, V102, P21, DOI 10.7326/0003-4819-102-1-21; KAKKAR VV, 1969, LANCET, V2, P230; LAGERSTEDT CI, 1985, LANCET, V2, P515; LENSING AWA, 1990, RADIOLOGY, V177, P503, DOI 10.1148/radiology.177.2.2217792; LENSING AWA, 1989, NEW ENGL J MED, V320, P342, DOI 10.1056/NEJM198902093200602; LENSING AWA, 1991, THROMB HAEMOSTASIS, V65, P1730; MCLACHLIN J, 1962, ARCH SURG-CHICAGO, V85, P738; PAIEMENT G, 1988, AM J SURG, V155, P400, DOI 10.1016/S0002-9610(88)80099-0; PETERS SHA, 1982, THROMB HAEMOSTASIS, V48, P297; PRANDONI P, 1991, THROMB HAEMOSTASIS, V65, P233; ROSENDAAL FR, 1991, THROMB HAEMOSTASIS, V65, P1043; SLUZEWSKI M, 1991, EUR J RADIOL, V13, P174, DOI 10.1016/0720-048X(91)90023-O; TAYLOR DW, 1980, THROMB RES, V17, P561, DOI 10.1016/0049-3848(80)90094-8; TOY PTCY, 1978, WESTERN J MED, V129, P89	25	83	84	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1993	118	1					25	30		10.7326/0003-4819-118-1-199301010-00005	http://dx.doi.org/10.7326/0003-4819-118-1-199301010-00005			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KE605	8416154				2022-12-24	WOS:A1993KE60500005
J	CHRIVIA, JC; KWOK, RPS; LAMB, N; HAGIWARA, M; MONTMINY, MR; GOODMAN, RH				CHRIVIA, JC; KWOK, RPS; LAMB, N; HAGIWARA, M; MONTMINY, MR; GOODMAN, RH			PHOSPHORYLATED CREB BINDS SPECIFICALLY TO THE NUCLEAR-PROTEIN CBP	NATURE			English	Article								CYCLIC AMP-regulated gene expression frequently involves a DNA element known as the cAMP-regulated enhancer (CRE)1-4. Many transcription factors bind to this element, including the protein CREB5,6, which is activated as a result of phosphorylation by protein kinase A7. This modification stimulates interaction with one or more of the general transcription factors or, alternatively, allows recruitment of a co-activator. Here we report that CREB phosphorylated by protein kinase A binds specifically to a nuclear protein of M(r) 265K which we term CBP (for CREB-binding protein). Fusion of a heterologous DNA-binding domain to the amino terminus of CBP enables the chimaeric protein to function as a protein kinase A-regulated transcriptional activator. We propose that CBP may participate in cAMP-regulated gene expression by interacting with the activated phosphorylated form of CREB.	CNRS,INSERM,CTR RECH BIOCHIM MACROMOLEC,F-34033 MONTPELLIER,FRANCE; OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201; SALK INST BIOL STUDIES,CLAYTON FDN LABS PEPTIDE BIOL,LA JOLLA,CA 92037	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Oregon Health & Science University; Salk Institute								BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; GONZALEZ GA, 1991, MOL CELL BIOL, V11, P1306, DOI 10.1128/MCB.11.3.1306; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GOODMAN RH, 1990, ANNU REV NEUROSCI, V13, P111, DOI 10.1146/annurev.neuro.13.1.111; HOEFFLER JP, 1988, SCIENCE, V242, P1428; LAMB NJC, 1990, CELL, V60, P151, DOI 10.1016/0092-8674(90)90725-T; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; Reichlin M, 1980, Methods Enzymol, V70, P159; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SHORT JM, 1986, J BIOL CHEM, V261, P9721; STOFKOHAHN RE, 1992, FEBS LETT, V302, P274, DOI 10.1016/0014-5793(92)80458-S; WALTON KM, 1992, MOL ENDOCRINOL, V6, P647, DOI 10.1210/me.6.4.647; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	18	1763	1810	4	75	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 28	1993	365	6449					855	859		10.1038/365855a0	http://dx.doi.org/10.1038/365855a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MD951	8413673				2022-12-24	WOS:A1993MD95100056
J	ZHAO, JJG; PICK, L				ZHAO, JJG; PICK, L			GENERATING LOSS-OF-FUNCTION PHENOTYPES OF THE FUSHI-TARAZU GENE WITH A TARGETED RIBOZYME IN DROSOPHILA	NATURE			English	Article							SEGMENTATION GENE; SELF-CLEAVAGE; MESSENGER-RNA; MELANOGASTER; EMBRYOGENESIS; NEUROGENESIS; EXPRESSION; REDUCTION; SEQUENCE; ENZYMES	THE ability to isolate gene sequences and analyse their expression patterns has generated demand for mutations created to assess their biological functions. In Drosophila melanogaster this can be achieved by traditional mutagenesis, but this is time-consuming, labour-intensive and not always successful. Moreover, the functions of genes that are expressed several times during development are often obscured in the later stages because of disruptions caused by the absence of early gene function. Here we propose a new strategy to create conditional knock-out mutations using a targeted heat-inducible ribozyme. Ribozymes are catalytic RNA molecules that specifically cleave RNAs1-11 and are potentially useful for studying gene function during animal development because the expression of critical regulatory genes is usually low and their function is often dosage-dependent. The ribozyme can be delivered to a specific region or at a particular developmental stage using a region-specific or inducible promoter. The Drosophila fushi tarazu (ftz) gene is a good candidate for testing this approach12-17. We generated transgenic flies carrying a ribozyme against the ftz gene. The two developmental phases of ftz function can be distinguished by timed induction of the ribozyme. Activation of the ribozyme in the blastoderm disrupts the ftz seven-stripe pattern and produces ftz-like pair-rule defects in larvae. The involvement of ftz in neurogenesis was verified by activation of the ribozyme during the early phase of formation of the central nervous system.	CUNY MT SINAI SCH MED,BROOKDALE CTR MOLEC BIOL,NEW YORK,NY 10029	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai								CAMERON FH, 1989, P NATL ACAD SCI USA, V86, P9139, DOI 10.1073/pnas.86.23.9139; CARROLL SB, 1985, CELL, V43, P47, DOI 10.1016/0092-8674(85)90011-X; CECH TR, 1987, SCIENCE, V236, P1532, DOI 10.1126/science.2438771; COTTEN M, 1989, EMBO J, V8, P3861, DOI 10.1002/j.1460-2075.1989.tb08564.x; DOE CQ, 1988, SCIENCE, V239, P170, DOI 10.1126/science.2892267; FORSTER AC, 1987, CELL, V49, P211, DOI 10.1016/0092-8674(87)90562-9; FURUKUBOTOKUNAGA K, 1992, GENE DEV, V6, P1082, DOI 10.1101/gad.6.6.1082; HAFEN E, 1984, CELL, V37, P833, DOI 10.1016/0092-8674(84)90418-5; HASELOFF J, 1988, NATURE, V334, P585, DOI 10.1038/334585a0; HIROMI Y, 1987, CELL, V50, P963, DOI 10.1016/0092-8674(87)90523-X; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; KARESS RE, 1984, CELL, V38, P135, DOI 10.1016/0092-8674(84)90534-8; KARR TL, 1989, DEVELOPMENT, V105, P95; LAUGHON A, 1984, NATURE, V310, P25, DOI 10.1038/310025a0; LHUILLIER PJ, 1992, EMBO J, V11, P4411, DOI 10.1002/j.1460-2075.1992.tb05541.x; PATEL NH, 1989, GENE DEV, V3, P890, DOI 10.1101/gad.3.6.890; PIROTTA V, 1988, VECTORS SURVEY MOL C, P437; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; RUFFNER DE, 1990, BIOCHEMISTRY-US, V29, P10695, DOI 10.1021/bi00499a018; SARVER N, 1990, SCIENCE, V247, P1222, DOI 10.1126/science.2107573; STEINECKE P, 1992, EMBO J, V11, P1525, DOI 10.1002/j.1460-2075.1992.tb05197.x; UHLENBECK OC, 1987, NATURE, V328, P596, DOI 10.1038/328596a0; WAKIMOTO BT, 1984, DEV BIOL, V102, P147, DOI 10.1016/0012-1606(84)90182-9; WEINER AJ, 1984, CELL, V37, P843, DOI 10.1016/0092-8674(84)90419-7; ZHAO JJ, 1993, GENE DEV, V7, P343, DOI 10.1101/gad.7.3.343; ZHENG X, 1992, J VIROL, V66, P1361	26	79	92	2	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 30	1993	365	6445					448	451		10.1038/365448a0	http://dx.doi.org/10.1038/365448a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LZ633	8413588				2022-12-24	WOS:A1993LZ63300058
J	HELLER, DA; DEFAIRE, U; PEDERSEN, NL; DAHLEN, G; MCCLEARN, GE				HELLER, DA; DEFAIRE, U; PEDERSEN, NL; DAHLEN, G; MCCLEARN, GE			GENETIC AND ENVIRONMENTAL-INFLUENCES ON SERUM-LIPID LEVELS IN TWINS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY HEART-DISEASE; HIGH-DENSITY LIPOPROTEIN; BODY-MASS INDEX; REARED APART; RISK-FACTORS; CHOLESTEROL CONCENTRATIONS; CARDIOVASCULAR-DISEASE; PLASMA-LIPIDS; A-II; DETERMINANTS	Background. The extent to which serum lipid levels are affected by genetic and environmental tactors remains a point ot controversy. We examined both genetic and environmental influences on serum lipid levels in twins reared either together or apart who participated in the Swedish Adoption/Twin Study of Aging. Methods. We studied 302 pairs ot twins (mean age, 65.6 years; range, 52 to 86); 146 pairs had been reared apart. We simultaneously compared the twins on the basis ot both zygosity and rearing status, which allowed joint estimation of genetic and environmental influences on serum lipid levels. Genetic influence was expressed in terms of heritability, the proportion of the population variation attributable to genetic variation (a value of 1.0 indicates that all of the population variation is attributable to genetic variation). The serum lipids and apolipoproteins measured included total cholesterol, high-density lipoprotein cholesterol, apolipoproteins A-I and B, and triglycerides. Results. Structural-equation analyses revealed substantial heritability for the serum levels of each lipid measured, ranging from 0.28 to 0.78. Comparisons of the twins reared together with those reared apart suggested that the environment of rearing had a substantial impact on the level of total cholesterol (accounting for 0.15 to 0.36 of the total variance). Sharing the same environment appeared to affect the other lipid measures much less, however, than did genetic factors and unique environmental factors not shared by twins. Comparisons of younger with older twins suggested that heritability for apolipoprotein B and triglyceride levels decreased with age. Conclusions. The effect of genetic factors on the serum levels of some but not all lipids appears to decrease with age. Early rearing environment appears to remain an important factor in relation to levels of total cholesterol later in life, but it has less effect on other serum lipids and apolipoproteins in the elderly.	PENN STATE UNIV,COLL HLTH & HUMAN DEV,CTR DEV & HLTH GENET,UNIV PK,PA 16802; KAROLINSKA HOSP,DEPT MED,DIV CARDIOVASC MED,S-10401 STOCKHOLM 60,SWEDEN; KAROLINSKA INST,INST ENVIRONM MED,DEPT EPIDEMIOL,S-10401 STOCKHOLM 60,SWEDEN; UMEA UNIV HOSP,DEPT AEROSP & MECH ENGN,S-90185 UMEA,SWEDEN	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Umea University	HELLER, DA (corresponding author), PENN STATE UNIV,COLL HLTH & HUMAN DEV,PROGRAM BIOBEHAV HLTH,210 E HLTH & HUMAN DEV,UNIV PK,PA 16802, USA.				NATIONAL INSTITUTE ON AGING [R01AG004563] Funding Source: NIH RePORTER; NIA NIH HHS [AG-04563] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AUSTIN MA, 1987, AM J EPIDEMIOL, V125, P308, DOI 10.1093/oxfordjournals.aje.a114531; BENFANTE R, 1990, JAMA-J AM MED ASSOC, V263, P393, DOI 10.1001/jama.263.3.393; BERG K, 1989, CLIN GENET, V36, P299; BOOMSMA DI, 1989, BEHAV GENET, V19, P3; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BUCHER KD, 1988, GENET EPIDEMIOL, V5, P17, DOI 10.1002/gepi.1370050103; CASTELLI WP, 1989, AM J CARDIOL, V63, pH12; CEDERLOF R, 1978, BIOL EPIDEMIOLOGY, V24, P189; DAHLEN G, 1983, INT J EPIDEMIOL, V12, P32, DOI 10.1093/ije/12.1.32; DALCOLLETTO GMD, 1981, HUM HERED, V31, P232; DAWSONSAUNDERS B, 1990, BASIC CLIN BIOSTATIS; Falconer D. S., 1989, Introduction to quantitative genetics.; FEINLEIB M, 1977, AM J EPIDEMIOL, V106, P284, DOI 10.1093/oxfordjournals.aje.a112464; GOLDSTEIN JL, 1973, J CLIN INVEST, V52, P1544, DOI 10.1172/JCI107332; HAMSTEN A, 1986, ATHEROSCLEROSIS, V60, P199, DOI 10.1016/0021-9150(86)90166-8; HASSTEDT SJ, 1984, ATHEROSCLEROSIS, V51, P21, DOI 10.1016/0021-9150(84)90141-2; HAYAKAWA K, 1987, ATHEROSCLEROSIS, V66, P1, DOI 10.1016/0021-9150(87)90173-0; HO HZ, 1989, DEV PSYCHOL, V16, P340; HOPKINS PN, 1989, ANNU REV NUTR, V9, P303; HUNT SC, 1989, AM J EPIDEMIOL, V129, P625, DOI 10.1093/oxfordjournals.aje.a115175; ISELIUS L, 1985, ACTA MED SCAND, V217, P161; JINKS JL, 1970, PSYCHOL BULL, V73, P311, DOI 10.1037/h0029135; Joreskog K. G., 1989, LISREL 7 GUIDE PROGR; KANNEL WB, 1978, B NEW YORK ACAD MED, V54, P573; KUUSI T, 1987, ARTERIOSCLEROSIS, V7, P421, DOI 10.1161/01.ATV.7.4.421; MAHLEY RW, 1991, JAMA-J AM MED ASSOC, V265, P78, DOI 10.1001/jama.265.1.78; MCDONOUGH JR, 1962, CIRCULATION, V25, P962, DOI 10.1161/01.CIR.25.6.962; MCGUE M, 1984, BEHAV GENET, V14, P325, DOI 10.1007/BF01080045; NAMBOODIRI K K, 1985, Genetic Epidemiology, V2, P227, DOI 10.1002/gepi.1370020302; NEALE MC, 1989, BEHAV GENET, V19, P63, DOI 10.1007/BF01065884; OCONNELL DL, 1988, GENET EPIDEMIOL, V5, P323, DOI 10.1002/gepi.1370050504; OSBORNE RH, 1959, AM J MED, V26, P54, DOI 10.1016/0002-9343(59)90326-2; PEDERSEN NL, 1984, ACTA GENET MED GEMEL, V33, P243, DOI 10.1017/S0001566000007285; PEDERSEN NL, 1991, ACTA GENET MED GEMEL, V40, P7, DOI 10.1017/S0001566000006681; PEDERSEN NL, 1989, PSYCHOSOM MED, V51, P428, DOI 10.1097/00006842-198907000-00006; PERUSSE L, 1989, ARTERIOSCLEROSIS, V9, P308, DOI 10.1161/01.ATV.9.3.308; PLOMIN R, 1988, PSYCHOL AGING, V3, P43, DOI 10.1037/0882-7974.3.1.43; RAO DC, 1982, AM J HUM GENET, V34, P888; RICE T, 1991, HUM HERED, V41, P107, DOI 10.1159/000153987; RIFAI N, 1988, ANN CLIN LAB SCI, V18, P429; ROBERTS WC, 1987, AM J CARDIOL, V60, pE33; ROSE RJ, 1988, J PERS SOC PSYCHOL, V54, P161, DOI 10.1037/0022-3514.54.1.161; SEIGLER L, 1981, CLIN CHEM, V27, P838; SING CF, 1989, INT J EPIDEMIOL, V18, pS183; SISTONEN P, 1989, AM J HUM GENET, V32, P1; STUNKARD AJ, 1990, NEW ENGL J MED, V322, P1483, DOI 10.1056/NEJM199005243222102; VOGEL F, 1989, HUMAN GENETICS; WEIDMANN P, 1988, DRUGS, V35, P118, DOI 10.2165/00003495-198800356-00017; WHITFIELD JB, 1983, ATHEROSCLEROSIS, V48, P265, DOI 10.1016/0021-9150(83)90044-8; ZIMETBAUM P, 1992, ARTERIOSCLER THROMB, V12, P416, DOI 10.1161/01.ATV.12.4.416; 1989, WORLD HLTH STATISTIC, P27; 1988, ARCH INTERN MED, V148, P36	52	382	392	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 22	1993	328	16					1150	1156		10.1056/NEJM199304223281603	http://dx.doi.org/10.1056/NEJM199304223281603			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KY447	8455681	Bronze			2022-12-24	WOS:A1993KY44700003
J	HUNT, LW; SILVERSTEIN, MD; REED, CE; OCONNELL, EJ; OFALLON, WM; YUNGINGER, JW				HUNT, LW; SILVERSTEIN, MD; REED, CE; OCONNELL, EJ; OFALLON, WM; YUNGINGER, JW			ACCURACY OF THE DEATH CERTIFICATE IN A POPULATION-BASED STUDY OF ASTHMATIC-PATIENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NEW-ZEALAND; MORTALITY; STATISTICS; AUTOPSY; INCREASE; ENGLAND; WALES	Objective.-To quantify the reliability of death certificate data concerning asthma. Design.-The complete medical records of decedents were reviewed by a physician certified in allergy and pulmonology who determined the cause of death without having access to the original death certificate. Disagreements between the death certificate and the reviewer were adjudicated by an expert panel. Setting.-The community of Rochester, Minn. Patients.-The mortality cohort included 339 deaths from a larger cohort of 5241 Rochester residents who received medical treatment for asthma between 1964 and 1983. Main Outcome Measures.-Kappa coefficients were used to measure agreement beyond that expected by chance between the reviewer and the death certificate. The sensitivity and specificity of the death certificate diagnosis of asthma were calculated against the standard of the reviewer/panel diagnosis. Results.-Death certificates reported asthma as an immediate or underlying cause of death in 22 instances (6%), whereas the reviewer/panel identified asthma in 53 cases (16%). In four cases, the death certificate listed asthma and the panel identified another cause of death. The death certificate had a sensitivity of 42% and a specificity of 99% compared with the reviewer/panel. Agreement between death certificates and the reviewer was not influenced by whether an autopsy was performed. Conclusions.-Death certificate diagnosis of asthma as an underlying cause of death had a low sensitivity but a high specificity. Increases in mortality due to asthma are not likely caused by false-positive diagnoses of asthma as an underlying cause of death. Asthma mortality rates, determined from death certificate data, may indeed underestimate actual asthma-related mortality.	MAYO CLIN & MAYO FDN,DEPT PEDIAT,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT HLTH SCI RES,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic	HUNT, LW (corresponding author), MAYO CLIN & MAYO FDN,DEPT INTERNAL MED,200 1ST ST SW,ROCHESTER,MN 55905, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025187] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR030582] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-25187] Funding Source: Medline; NIAMS NIH HHS [AR-30582] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		[Anonymous], 1984, Thorax, V39, P505; BARGER LW, 1988, AM REV RESPIR DIS, V137, pA147; BURNEY P, 1988, J EPIDEMIOL COMMUN H, V42, P316, DOI 10.1136/jech.42.4.316; BURNEY PGJ, 1987, J ALLERGY CLIN IMMUN, V80, P379, DOI 10.1016/0091-6749(87)90054-6; CAMERON HM, 1981, J PATHOL, V133, P273, DOI 10.1002/path.1711330402; CARTER JR, 1985, NEW ENGL J MED, V313, P1285, DOI 10.1056/NEJM198511143132009; CHAMBLEE RF, 1982, AM J PUBLIC HEALTH, V72, P1265, DOI 10.2105/AJPH.72.11.1265; CURB JD, 1983, AM J EPIDEMIOL, V118, P122, DOI 10.1093/oxfordjournals.aje.a113613; EVANS R, 1987, J ALLERGY CLIN IMMUN, V80, P377, DOI 10.1016/0091-6749(87)90053-4; Fleiss JL, 1981, STAT METHODS RATES P; GOODMAN RA, 1987, JAMA-J AM MED ASSOC, V258, P3758; ISRAEL RA, 1986, AM J EPIDEMIOL, V124, P161, DOI 10.1093/oxfordjournals.aje.a114375; JACKSON R, 1988, CHEST, V94, P914, DOI 10.1378/chest.94.5.914; Janssen TA, 1940, AM J PUBLIC HEALTH N, V30, P871, DOI 10.2105/AJPH.30.8.871; KIRCHER T, 1987, JAMA-J AM MED ASSOC, V258, P349, DOI 10.1001/jama.258.3.349; KIRCHER T, 1985, NEW ENGL J MED, V313, P1263, DOI 10.1056/NEJM198511143132005; KURLAND LT, 1981, SCI AM, V245, P54, DOI 10.1038/scientificamerican1081-54; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; LEITCH DGM, 1987, AUST NZ J MED, V17, P309, DOI 10.1111/j.1445-5994.1987.tb01234.x; LINDAHL BIB, 1985, J CHRON DIS, V38, P47, DOI 10.1016/0021-9681(85)90007-4; MODELMOG D, 1992, CANCER CAUSE CONTROL, V3, P541, DOI 10.1007/BF00052751; MORIYAMA IM, 1956, AM J PUBLIC HEALTH N, V46, P436, DOI 10.2105/AJPH.46.4.436; NEMETZ PN, 1989, MAYO CLIN PROC, V64, P1055, DOI 10.1016/S0025-6196(12)64974-X; ORMEROD LP, 1980, BRIT MED J, V280, P687, DOI 10.1136/bmj.280.6215.687; PAULOZZI LJ, 1986, ANN ALLERGY, V56, P392; ROBERTS WC, 1978, NEW ENGL J MED, V299, P332, DOI 10.1056/NEJM197808172990704; Schade B, 1987, Scand J Prim Health Care, V5, P109, DOI 10.3109/02813438709013985; SEARS MR, 1986, AM J EPIDEMIOL, V124, P1004, DOI 10.1093/oxfordjournals.aje.a114470; SEARS MR, 1987, J ALLERGY CLIN IMMUN, V80, P383, DOI 10.1016/0091-6749(87)90055-8; SIRKEN MG, 1987, AM J PUBLIC HEALTH, V77, P137, DOI 10.2105/AJPH.77.2.137; SLY RM, 1989, J ALLERGY CLIN IMMUN, V84, P421, DOI 10.1016/0091-6749(89)90351-5; YUNGINGER JW, 1992, AM REV RESPIR DIS, V146, P888, DOI 10.1164/ajrccm/146.4.888; ZUMWALT RE, 1987, POSTGRAD MED, V81, P245, DOI 10.1080/00325481.1987.11699876; ZUMWALT RE, 1987, POSTGRAD MED, V81, P253; ZUMWALT RE, 1987, POSTGRAD MED, V81, P250; 1987, PHYSICIANS HDB MED C; 1977, INT CLASSIFICATION D, P699	37	110	113	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 21	1993	269	15					1947	1952		10.1001/jama.269.15.1947	http://dx.doi.org/10.1001/jama.269.15.1947			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KX215	8464126				2022-12-24	WOS:A1993KX21500023
J	OLIVIER, JP; RAABE, T; HENKEMEYER, M; DICKSON, B; MBAMALU, G; MARGOLIS, B; SCHLESSINGER, J; HAFEN, E; PAWSON, T				OLIVIER, JP; RAABE, T; HENKEMEYER, M; DICKSON, B; MBAMALU, G; MARGOLIS, B; SCHLESSINGER, J; HAFEN, E; PAWSON, T			A DROSOPHILA SH2-SH3 ADAPTER PROTEIN IMPLICATED IN COUPLING THE SEVENLESS TYROSINE KINASE TO AN ACTIVATOR OF RAS GUANINE-NUCLEOTIDE EXCHANGE, SOS	CELL			English	Article							ELEGANS VULVAR INDUCTION; EPIDERMAL GROWTH-FACTOR; EGF RECEPTOR HOMOLOG; FAINT-LITTLE-BALL; NEURODEVELOPMENTAL PATHWAY; FUNCTIONS DOWNSTREAM; SIGNAL TRANSDUCTION; GENETIC DISSECTION; PHOSPHOLIPASE-C; VIRAL ONCOGENE	A Drosophila gene (drk) encodes a widely expressed protein with a single SH2 domain and two flanking SH3 domains, which is homologous to the Sem-5 protein of C. elegans and mammalian GRB2. Genetic analysis suggests that drk function is essential for signaling by the sevenless receptor tyrosine kinase. Drk biological activity correlates with binding of its SH2 domain to activated receptor tyrosine kinases and concomitant localization of drk to the plasma membrane. In vitro, drk also binds directly to the C-terminal tail of Sos, a Ras guanine nucleotide-releasing protein (GNRP), which, like Ras1 and drk, is required for sevenless signaling. These results suggest that drk binds autophosphorylated receptor tyrosine kinases with its SH2 domain and the Sos GNRP through its SH3 domains, thereby coupling receptor tyrosine kinases to Ras activation. The conservation of these signaling proteins during evolution indicates that this is a general mechanism for linking tyrosine kinases to Ras.	UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5S 1A8,ONTARIO,CANADA; UNIV ZURICH,INST ZOOL,CH-8057 ZURICH,SWITZERLAND; NYU MED CTR,KAPLAN CANC CTR,DEPT PHARMACOL,NEW YORK,NY 10016	University of Toronto; University of Zurich; New York University	OLIVIER, JP (corresponding author), MT SINAI HOSP,SAMUEL LUNENFELD RES INST,DIV MOLEC & DEV BIOL,TORONTO M5G 1X5,ONTARIO,CANADA.		Pawson, Tony J/E-4578-2013	Dickson, Barry/0000-0003-0715-892X; Henkemeyer, Mark/0000-0002-7525-1061				ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; ASHBURNER M, 1989, DROSOPHILA LABORATOR; BASLER K, 1988, CELL, V54, P299; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BOOKER GW, 1992, NATURE, V358, P684, DOI 10.1038/358684a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DICKSON B, 1992, GENE DEV, V6, P2327, DOI 10.1101/gad.6.12a.2327; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; DICKSON B, 1992, DEV DROSOPHILA; DOYLE HJ, 1993, IN PRESS GENES DEV; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; HAFEN E, 1987, SCIENCE, V236, P55, DOI 10.1126/science.2882603; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; HONEGGER AM, 1989, P NATL ACAD SCI USA, V86, P925, DOI 10.1073/pnas.86.3.925; HORVITZ HR, 1991, NATURE, V351, P535, DOI 10.1038/351535a0; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; KLEMENZ R, 1987, NUCLEIC ACIDS RES, V15, P3947, DOI 10.1093/nar/15.10.3947; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARENGERE LEM, 1992, J BIOL CHEM, V267, P22779; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; MUSACCHIO A, 1992, NATURE, V359, P851, DOI 10.1038/359851a0; MUSACCHIO A, 1992, FEBS LETT, V307, P55, DOI 10.1016/0014-5793(92)80901-R; OVERDUIN M, 1992, CELL, V70, P697, DOI 10.1016/0092-8674(92)90437-H; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; PRICE JV, 1989, CELL, V56, P1085, DOI 10.1016/0092-8674(89)90641-7; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROGGE R, 1992, P NATL ACAD SCI USA, V89, P5271, DOI 10.1073/pnas.89.12.5271; ROGGE RD, 1991, CELL, V64, P39, DOI 10.1016/0092-8674(91)90207-F; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SCHEJTER ED, 1989, CELL, V56, P1093, DOI 10.1016/0092-8674(89)90642-9; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SPRENGER F, 1992, CELL, V71, P987, DOI 10.1016/0092-8674(92)90394-R; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TOMLINSON A, 1986, SCIENCE, V231, P400, DOI 10.1126/science.231.4736.400; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VEGA QC, 1992, MOL CELL BIOL, V12, P128, DOI 10.1128/MCB.12.1.128; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858; ZHANG K, 1992, SCIENCE, V257, P671, DOI 10.1126/science.1496380	73	522	542	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 9	1993	73	1					179	191		10.1016/0092-8674(93)90170-U	http://dx.doi.org/10.1016/0092-8674(93)90170-U			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KW753	8462098	Green Submitted			2022-12-24	WOS:A1993KW75300018
J	ASHTON, CM; PETERSEN, NJ; WRAY, NP; KIEFE, CI; DUNN, JK; WU, L; THOMAS, JM				ASHTON, CM; PETERSEN, NJ; WRAY, NP; KIEFE, CI; DUNN, JK; WU, L; THOMAS, JM			THE INCIDENCE OF PERIOPERATIVE MYOCARDIAL-INFARCTION IN MEN UNDERGOING NONCARDIAC SURGERY	ANNALS OF INTERNAL MEDICINE			English	Article						MYOCARDIAL INFARCTION; CORONARY DISEASE; PERIPHERAL VASCULAR DISEASES; RISK FACTORS; ATHEROSCLEROSIS	PERIPHERAL VASCULAR-SURGERY; MB CREATINE-PHOSPHOKINASE; CORONARY-ARTERY DISEASE; CARDIAC RISK; SURGICAL PATIENTS; DIAGNOSIS; ANESTHESIA; MORTALITY; REINFARCTION; SPECIFICITY	Objectives: To determine the incidence of and risk factors for perioperative myocardial infarction with noncardiac surgery and to test the accuracy of a risk stratification system. Design: Prospective cohort study. Setting: A large urban Veterans Affairs hospital. Participants: A total of 1487 men older than 40 years undergoing major, nonemergent, noncardiac operations. Measurements: Infarction was established by at least two of the following: development of new Q waves, typical change in creatine kinase MB, and positive technetium pyrophosphate scintigraphy. Patients were stratified preoperatively into high-, intermediate-, low-, and negligible-risk strata based on clinical markers corresponding to different levels of coronary artery disease prevalence. Main Results: Patients with coronary disease (high-risk stratum) had a 4.1 % incidence of infarction (13 of 319; 95% Cl, 1.8% to 6.4%); patients with peripheral vascular disease but no evidence of coronary disease (intermediate-risk stratum) had a 0.8% incidence (2 of 260, upper bound of Cl, 2.0%); patients with high atherogenic risk factor profiles but no clinical atherosclerosis (low-risk stratum) had a 0% incidence (0 of 256, upper bound of Cl, 1.2%). No cardiac deaths occurred in 652 men who had no atherosclerosis and low atherogenic risk factor profiles (the negligible-risk stratum). Factors independently associated with infarction included age more than 75 years (adjusted odds ratio, 4.77; Cl, 1.17 to 19.41), signs of heart failure on the preoperative examination (adjusted odds ratio, 3.31; Cl, 0.96 to 11.38), coronary disease (adjusted odds ratio, 10.39; Cl, 2.27 to 47.46), and a planned vascular operation (adjusted odds ratio, 3.72; Cl, 1.12 to 12.37). Conclusions: Coronary artery disease is the major risk factor for perioperative infarction. The stratification scheme identifies subsets of patients with different risks, and finer within-stratum distinctions can be made using additional variables.			ASHTON, CM (corresponding author), VET AFFAIRS MED CTR, 2002 HOLCOMBE BLVD, HOUSTON, TX 77030 USA.							ASHTON CM, 1989, J AM GERIATR SOC, V37, P614, DOI 10.1111/j.1532-5415.1989.tb01251.x; BOUCHER CA, 1985, NEW ENGL J MED, V312, P389, DOI 10.1056/NEJM198502143120701; DETSKY AS, 1986, J GEN INTERN MED, V1, P211, DOI 10.1007/BF02596184; DIAMOND GA, 1979, NEW ENGL J MED, V300, P1350, DOI 10.1056/NEJM197906143002402; DRISCOLL AC, 1961, NEW ENGL J MED, V264, P633, DOI 10.1056/NEJM196103302641302; EAGLE KA, 1989, ANN INTERN MED, V110, P859, DOI 10.7326/0003-4819-110-11-859; FOSTER ED, 1986, ANN THORAC SURG, V41, P42, DOI 10.1016/S0003-4975(10)64494-3; GOLDMAN L, 1977, NEW ENGL J MED, V297, P845, DOI 10.1056/NEJM197710202971601; GORDON T, 1983, CORONARY RISK HDB ES; HERTZER NR, 1984, ANN SURG, V199, P223, DOI 10.1097/00000658-198402000-00016; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; IRVIN RG, 1980, ARCH INTERN MED, V140, P329, DOI 10.1001/archinte.140.3.329; KANNEL WB, 1976, AM J CARDIOL, V38, P46, DOI 10.1016/0002-9149(76)90061-8; Knapp RB, 1962, JAMA-J AM MED ASSOC, V182, P106; LEPPO J, 1987, J AM COLL CARDIOL, V9, P269, DOI 10.1016/S0735-1097(87)80374-1; MANGANO DT, 1990, NEW ENGL J MED, V323, P1781, DOI 10.1056/NEJM199012273232601; MAUNEY FM, 1970, ANN SURG, V172, P497, DOI 10.1097/00000658-197009000-00013; MORISE AP, 1987, AM J MED SCI, V293, P150, DOI 10.1097/00000441-198703000-00002; Prineas R., 1982, MINNESOTA CODE MANUA; RABY KE, 1989, NEW ENGL J MED, V321, P1296, DOI 10.1056/NEJM198911093211904; RAO TLK, 1983, ANESTHESIOLOGY, V59, P499, DOI 10.1097/00000542-198312000-00003; RIGHETTI A, 1977, AM J CARDIOL, V39, P43, DOI 10.1016/S0002-9149(77)80009-X; RILES TS, 1979, SURGERY, V85, P249; ROBERTS R, 1975, AM J CARDIOL, V36, P433, DOI 10.1016/0002-9149(75)90890-5; ROSE GA, 1982, CARDIOVASCULAR SURVE, P162; SALEL AF, 1977, NEW ENGL J MED, V296, P1447, DOI 10.1056/NEJM197706232962507; SECKINGER DL, 1983, AM J CLIN PATHOL, V80, P164, DOI 10.1093/ajcp/80.2.164; STEEN PA, 1978, JAMA-J AM MED ASSOC, V239, P2566, DOI 10.1001/jama.239.24.2566; TARHAN S, 1972, J AMER MED ASSOC, V220, P1451, DOI 10.1001/jama.220.11.1451; UUSITUPA M, 1983, AM HEART J, V106, P753, DOI 10.1016/0002-8703(83)90099-6; VONKNORRING J, 1981, SURGERY, V90, P55; WHITTEMORE AD, 1980, ANN SURG, V192, P414, DOI 10.1097/00000658-198009000-00017	32	225	238	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1993	118	7					504	510		10.7326/0003-4819-118-7-199304010-00004	http://dx.doi.org/10.7326/0003-4819-118-7-199304010-00004			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KU079	8442621				2022-12-24	WOS:A1993KU07900004
J	ROBBINS, LS; NADEAU, JH; JOHNSON, KR; KELLY, MA; ROSELLIREHFUSS, L; BAACK, E; MOUNTJOY, KG; CONE, RD				ROBBINS, LS; NADEAU, JH; JOHNSON, KR; KELLY, MA; ROSELLIREHFUSS, L; BAACK, E; MOUNTJOY, KG; CONE, RD			PIGMENTATION PHENOTYPES OF VARIANT EXTENSION LOCUS ALLELES RESULT FROM POINT MUTATIONS THAT ALTER MSH RECEPTOR FUNCTION	CELL			English	Article							MELANOCYTE-STIMULATING HORMONE; TYROSINASE ACTIVITY; ALPHA-MELANOTROPIN; CELLS; MOUSE; MICE; PEPTIDES; SEQUENCE; ASSAY; SITE	Coat colors in the chestnut horse, the yellow Labrador retriever, the red fox, and one type of yellow mouse are due to recessive alleles at the extension locus. Similarly, dominant alleles at this locus are often responsible for dark coat colors in mammals, such as the melanic form of the leopard, Panthera pardus. We show here that the murine extension locus encodes the melanocyte-stimulating hormone (MSH) receptor. In mice, the recessive yellow allele (e) results from a frameshift that produces a prematurely terminated, nonfunctioning receptor. The sombre (E(so) and E(so-3J)) and tobacco darkening (E(tob)) alleles, which both have dominant melanizing effects, result from point mutations that produce hyperactive MSH receptors. The E(so-3J) receptor is constitutively activated, while the E(tob) receptor remains hormone responsive and produces a greater activation of its effector, adenylyl cyclase, than does the wild-type allele.	OREGON HLTH SCI UNIV,DEPT CELL BIOL & ANAT,DEPT BIOCHEM & MOLEC BIOL,PORTLAND,OR 97201; JACKSON LAB,BAR HARBOR,ME 04609	Oregon Health & Science University; Jackson Laboratory	ROBBINS, LS (corresponding author), OREGON HLTH SCI UNIV,VOLLUM INST ADV BIOMED,PORTLAND,OR 97201, USA.		Mountjoy, Kathy/L-4473-2019	Kelly, Michele/0000-0003-1799-055X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043859, P01DK044239] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG00189] Funding Source: Medline; NIDDK NIH HHS [P01A DK44239, R01 DK43859] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADALSTEINSSON S, 1987, J HERED, V78, P235, DOI 10.1093/oxfordjournals.jhered.a110373; BATEMAN N, 1961, J HERED, V52, P186, DOI 10.1093/oxfordjournals.jhered.a107062; BULTMAN SJ, 1992, CELL, V71, P1195, DOI 10.1016/S0092-8674(05)80067-4; BURCHILL SA, 1986, J ENDOCRINOL, V109, P15, DOI 10.1677/joe.0.1090015; CANNON JG, 1986, J IMMUNOL, V137, P2232; Chase HB, 1939, GENETICS, V24, P610; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHHAJLANI V, 1992, FEBS LETT, V309, P417, DOI 10.1016/0014-5793(92)80820-7; CONE RD, 1993, IN PRESS NY ACAD SCI; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; DEWIED D, 1982, PHYSIOL REV, V62, P977; EBERLE AN, 1988, MELANOTROPINS CHEM P; ELLERKMANN E, 1992, ENDOCRINOLOGY, V130, P133, DOI 10.1210/en.130.1.133; Falconer D, 1962, MOUSE NEWS LETT, V27, P30; GERST JE, 1988, ENDOCRINOLOGY, V123, P1792, DOI 10.1210/endo-123-4-1792; Geschwind I.I., 1972, Recent Progress Hormone Res, V28, P91; GESCHWIND II, 1966, ENDOCRINOLOGY, V79, P1165, DOI 10.1210/endo-79-6-1165; GILMAN AG, 1970, P NATL ACAD SCI USA, V67, P305, DOI 10.1073/pnas.67.1.305; GRUBER KA, 1989, AM J PHYSIOL, V257, pR681, DOI 10.1152/ajpregu.1989.257.4.R681; HALABAN R, 1984, ARCH BIOCHEM BIOPHYS, V230, P383, DOI 10.1016/0003-9861(84)90121-8; HARRISON GA, 1973, J INVEST DERMATOL, V60, P418, DOI 10.1111/1523-1747.ep12702616; HAUSCHKA TS, 1968, J HERED, V59, P339, DOI 10.1093/oxfordjournals.jhered.a107738; HEARING VJ, 1991, FASEB J, V5, P2902, DOI 10.1096/fasebj.5.14.1752358; HOGANSON GE, 1989, SOMAT CELL MOLEC GEN, V15, P255, DOI 10.1007/BF01534876; HRUBY VJ, 1987, J MED CHEM, V30, P2126, DOI 10.1021/jm00394a033; Ibsen HL, 1919, GENETICS, V4, P597; JOHNSON RA, 1991, METHOD ENZYMOL, V195, P3; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KWON BS, 1988, BIOCHEM BIOPH RES CO, V153, P1301, DOI 10.1016/S0006-291X(88)81370-6; LAMOREUX ML, 1975, DEV BIOL, V46, P160, DOI 10.1016/0012-1606(75)90094-9; LERNER AB, 1961, NATURE, V189, P176, DOI 10.1038/189176a0; LIN SY, 1987, HYPERTENSION, V10, P619, DOI 10.1161/01.HYP.10.6.619; Little CC, 1957, INHERITANCE COAT COL, P49; MCGOVERN VJ, 1982, J CUTAN PATHOL, V9, P61, DOI 10.1111/j.1600-0560.1982.tb01044.x; MCGOVERN VJ, 1973, CANCER, V32, P1446, DOI 10.1002/1097-0142(197312)32:6<1446::AID-CNCR2820320623>3.0.CO;2-8; MEREDITH R, 1971, MOUSE NEWS LETT, V45, P31; MOUNTJOY KG, 1992, SCIENCE, V257, P1248, DOI 10.1126/science.1325670; PAWELEK JM, 1976, J INVEST DERMATOL, V66, P201, DOI 10.1111/1523-1747.ep12482134; PUNNETT RC, 1924, J GENET, V14, P230; REED TE, 1952, ANN EUGENIC, V17, P115; ROBINSON PR, 1992, NEURON, V9, P719, DOI 10.1016/0896-6273(92)90034-B; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SALOMON Y, 1991, METHOD ENZYMOL, V195, P22; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Searle A.G., 1968, COMP GENETICS COAT C; SEARLE AG, 1968, J HERED, V59, P341, DOI 10.1093/oxfordjournals.jhered.a107739; SEARLE AG, 1970, MOUSE NEWS LETT, V42, P27; SELSTED ME, 1985, J BIOL CHEM, V260, P4579; SILVERS WK, 1955, J EXP ZOOL, V130, P199, DOI 10.1002/jez.1401300203; SOLCA F, 1989, J BIOL CHEM, V264, P14277; SPONENBERG DP, 1987, J HERED, V78, P406, DOI 10.1093/oxfordjournals.jhered.a110430; STERN C, 1970, HUM HERED, V20, P165, DOI 10.1159/000152305; STRADER CD, 1987, J BIOL CHEM, V262, P16439; STRAND FL, 1980, PEPTIDES, V1, P135, DOI 10.1016/0196-9781(80)90077-7; TAKEUCHI T, 1989, SOC INVEST DERMATO S, V92, P239; TAMATE HB, 1984, SCIENCE, V224, P1241, DOI 10.1126/science.6328651; TAMATE HB, 1981, DEV GENET, V2, P349, DOI 10.1002/dvg.1020020404; TAMINAGA T, 1990, J ENDOCRINOL, V125, P287; TEMPLETON JW, 1977, J HERED, V68, P134, DOI 10.1093/oxfordjournals.jhered.a108792; VONLEHMANN E, 1973, MOUSE NEWS LETT, V48, P23; WONG G, 1975, NATURE, V255, P644, DOI 10.1038/255644a0; YASUMURA Y, 1966, SCIENCE, V154, P1186, DOI 10.1126/science.154.3753.1186; ZHU QZ, 1992, ENDOCRINOLOGY, V130, P1413, DOI 10.1210/en.130.3.1413	64	753	795	1	63	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 26	1993	72	6					827	834		10.1016/0092-8674(93)90572-8	http://dx.doi.org/10.1016/0092-8674(93)90572-8			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KU175	8458079				2022-12-24	WOS:A1993KU17500004
J	WHITEHEART, SW; GRIFF, IC; BRUNNER, M; CLARY, DO; MAYER, T; BUHROW, SA; ROTHMAN, JE				WHITEHEART, SW; GRIFF, IC; BRUNNER, M; CLARY, DO; MAYER, T; BUHROW, SA; ROTHMAN, JE			SNAP FAMILY OF NSF ATTACHMENT PROTEINS INCLUDES A BRAIN-SPECIFIC ISOFORM	NATURE			English	Article							SENSITIVE FUSION PROTEIN; VESICULAR TRANSPORT; REQUIRES; PURIFICATION; RECEPTOR	THE soluble NSF attachment proteins (SNAPs) enable N-ethyl-maleimide-sensitive fusion protein (NSF) to bind to target membranes1-3. Here we report the cloning and sequencing of complementary DNAs encoding alpha-, beta- and gamma-SNAPs. Two of these proteins, alpha and gamma, are found in a wide range of tissues, and act synergistically in intra-Golgi transport. The third, beta, is a brain-specific isoform of alpha-SNAP. Thus, NSF and SNAPs appear to be general components of the intracellular membrane fusion apparatus, and their action at specific sites of fusion must be controlled by SNAP receptors particular to the membranes being fused, as described in the accompanying article4.			WHITEHEART, SW (corresponding author), MEM SLOAN KETTERING CANC CTR,ROCKEFELLER RES LAB,1275 YORK AVE,NEW YORK,NY 10021, USA.			Whiteheart, Sidney/0000-0001-5577-0473; Mayer, Thomas/0000-0001-6954-2287; Brunner, Michael/0000-0001-9798-3047				BECKERS CJM, 1989, NATURE, V339, P397, DOI 10.1038/339397a0; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; CLARY DO, 1990, J BIOL CHEM, V265, P10109; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; DIAZ R, 1989, NATURE, V339, P398, DOI 10.1038/339398a0; GRIFF IC, 1992, J BIOL CHEM, V267, P12106; KATO K, 1990, EUR J NEUROSCI, V2, P704, DOI 10.1111/j.1460-9568.1990.tb00460.x; LUPAS A, 1991, SCIENCE, V252, P1163; SMITH TF, 1981, APPL MATH, V2, P488; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SZTUL E, 1993, J BIOL CHEM, V268, P1876; WEIDMAN PJ, 1989, J CELL BIOL, V108, P1589, DOI 10.1083/jcb.108.5.1589; WHITEHEART SW, 1992, J BIOL CHEM, V267, P12239; WILSON DW, 1992, J CELL BIOL, V117, P531, DOI 10.1083/jcb.117.3.531	14	236	244	1	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 25	1993	362	6418					353	355		10.1038/362353a0	http://dx.doi.org/10.1038/362353a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KU176	8455721				2022-12-24	WOS:A1993KU17600064
J	STIELL, IG; GREENBERG, GH; MCKNIGHT, RD; NAIR, RC; MCDOWELL, I; REARDON, M; STEWART, JP; MALONEY, J				STIELL, IG; GREENBERG, GH; MCKNIGHT, RD; NAIR, RC; MCDOWELL, I; REARDON, M; STEWART, JP; MALONEY, J			DECISION RULES FOR THE USE OF RADIOGRAPHY IN ACUTE ANKLE INJURIES - REFINEMENT AND PROSPECTIVE VALIDATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							X-RAY EXAMINATIONS; CLINICAL-ASSESSMENT; PREDICTION RULES; EMERGENCY; PROTOCOL; FRACTURE; PROGRAM; TRAUMA; SPRAIN	Objective.-To validate and refine previously derived clinical decision rules that aid the efficient use of radiography in acute ankle injuries. Design.-Survey prospectively administered in two stages: validation and refinement of the original rules (first stage) and validation of the refined rules (second stage). Setting.-Emergency departments of two university hospitals. Patients.-Convenience sample of adults with acute ankle injuries: 1032 of 1130 eligible patients in the first stage and 453 of 530 eligible patients in the second stage. Main Outcome Measures.-Attending emergency physicians assessed each patient for standardized clinical variables and classified the need for radiography according to the original (first stage) and the refined (second stage) decision rules. The decision rules were assessed for their ability to correctly identify the criterion standard of fractures on ankle and foot radiographic series. The original decision rules were refined by univariate and recursive partitioning analyses. Main Results.-In the first stage, the original decision rules were found to have sensitivities of 1.0 (95% confidence interval [Cl], 0.97 to 1.0) for detecting 121 malleolar zone fractures, and 0.98 (95% Cl, 0.88 to 1.0) for detecting 49 midfoot zone fractures. For interpretation of the rules in 116 patients, kappa values were 0.56 for the ankle series rule and 0.69 for the foot series rule. Recursive partitioning of 20 predictor variables yielded refined decision rules for ankle and foot radiographic series.In the second stage, the refined rules proved to have sensitivities of 1.0 (95% Cl, 0.93 to 1.0) for 50 malleolar zone fractures, and 1.0 (95% Cl, 0.83 to 1.0) for 19 midfoot zone fractures. The potential reduction in radiography is estimated to be 34% for the ankle series and 30% for the foot series. The probability of fracture, if the corresponding decision rule were ''negative,'' is estimated to be 0% (95% Cl, 0% to 0.8%) in the ankle series, and 0% (95% Cl, 0% to 0.4%) in the foot series. Conclusion.-Refinement and validation have shown the Ottawa ankle rules to be 100% sensitive for fractures, to be reliable, and to have the potential to allow physicians to safely reduce the number of radiographs ordered in patients with ankle injuries by one third. Field trials will assess the feasibility of implementing these rules into clinical practice.	ONTARIO MINIST HLTH,HLTH RES PERSONNEL DEV PROGRAM,TORONTO M5W 1R5,ONTARIO,CANADA; UNIV OTTAWA,FAC MED,DIV EMERGENCY MED,OTTAWA K1N 6N5,ONTARIO,CANADA; UNIV OTTAWA,FAC MED,DEPT EPIDEMIOL & COMMUNITY MED,OTTAWA K1N 6N5,ONTARIO,CANADA	University of Ottawa; University of Ottawa			Nair, Rama C/G-5674-2011; Reardon, Michael/ABF-8880-2021	Nair, Rama C/0000-0002-9101-0516; Stiell, Ian/0000-0002-2583-6408				ABRAMS HL, 1979, NEW ENGL J MED, V300, P1213, DOI 10.1056/NEJM197905243002110; ANGELL M, 1985, JAMA-J AM MED ASSOC, V254, P1203, DOI 10.1001/jama.254.9.1203; BATES DW, 1990, ANN INTERN MED, V113, P495, DOI 10.7326/0003-4819-113-7-495; BEAULIEU MD, 1986, CAN MED ASSOC J, V135, P1003; BELL RS, 1971, NEW ENGL J MED, V284, P236, DOI 10.1056/NEJM197102042840504; BRAND DA, 1982, NEW ENGL J MED, V306, P333, DOI 10.1056/NEJM198202113060604; BROOKS SC, 1981, BRIT MED J, V282, P607, DOI 10.1136/bmj.282.6264.607; CHARLSON ME, 1987, ARCH INTERN MED, V147, P2155, DOI 10.1001/archinte.147.12.2155; CIAMPI A, 1988, COMPUT METH PROG BIO, V26, P239, DOI 10.1016/0169-2607(88)90004-1; Ciampi A., 1987, TIME SERIES ECONOMET, P23; COCKSHOTT WP, 1983, CAN MED ASSOC J, V129, P129; DELACEY G, 1979, BRIT MED J, V1, P1597, DOI 10.1136/bmj.1.6178.1597; DIAMOND GA, 1989, AM J CARDIOL, V63, P99, DOI 10.1016/0002-9149(89)91084-9; DIEHR P, 1988, MED DECIS MAKING, V8, P40, DOI 10.1177/0272989X8800800106; DUNLOP MG, 1986, BRIT MED J, V293, P603, DOI 10.1136/bmj.293.6547.603; FEINSTEIN AR, 1985, ARCH INTERN MED, V145, P1257, DOI 10.1001/archinte.145.7.1257; Feinstein AR, 1987, CLINIMETRICS; Fleiss JL, 1981, STAT METHODS RATES P; GERVIN AS, 1991, AJR AM J ROENTGENOL, V157, P789; GLEADHILL DNS, 1987, BRIT MED J, V294, P943, DOI 10.1136/bmj.294.6577.943; GOLDMAN L, 1988, NEW ENGL J MED, V318, P797, DOI 10.1056/NEJM198803313181301; GRATTON MC, 1990, ANN EMERG MED, V19, P497, DOI 10.1016/S0196-0644(05)82175-4; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HECKERLING PS, 1990, ANN INTERN MED, V113, P664, DOI 10.7326/0003-4819-113-9-664; KOOPMAN PAR, 1984, BIOMETRICS, V40, P513, DOI 10.2307/2531405; LEE TH, 1990, J GEN INTERN MED, V5, P528, DOI 10.1007/BF02600886; LLOYD S, 1986, CAN MED ASSOC J, V135, P973; LLOYD S, 1988, CAN FAM PHYSICIAN, V34, P2261; Long A E, 1985, Emerg Med Clin North Am, V3, P437; MASTERS SJ, 1987, NEW ENGL J MED, V316, P84, DOI 10.1056/NEJM198701083160205; MATTHEWS MG, 1986, BRIT MED J, V293, P959; MCCONNOCHIE KM, 1990, PEDIATRICS, V86, P45; MOLONEY TW, 1979, NEW ENGL J MED, V301, P1413, DOI 10.1056/NEJM197912273012603; MONTAGUE AP, 1985, INJURY, V16, P545, DOI 10.1016/0020-1383(85)90082-8; POZEN MW, 1980, ANN INTERN MED, V92, P238, DOI 10.7326/0003-4819-92-2-238; Sackett D.L., 1985, CLIN EPIDEMIOLOGY BA; SIMON RR, 1987, EMERGENCY ORTHOPEDIC; Sox HC, 1988, MED DECISION MAKING; STIELL IG, 1992, CAN MED ASSOC J, V147, P1671; STIELL IG, 1992, ANN EMERG MED, V21, P384, DOI 10.1016/S0196-0644(05)82656-3; STIELL IG, 1992, AM J EMERG MED, V110, P14; SUJITKUMAR P, 1986, ARCH EMERG MED, V3, P101; SVENSON J, 1988, LANCET, V1, P244; VARGISH T, 1983, INJURY, V14, P507, DOI 10.1016/0020-1383(83)90053-0; WASSON JH, 1985, NEW ENGL J MED, V313, P793, DOI 10.1056/NEJM198509263131306; WEST A, 1988, BR J CLIN PRACT, V43, P360; 1990, ONTARIO STATISTICAL	47	355	356	0	20	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 3	1993	269	9					1127	1132		10.1001/jama.269.9.1127	http://dx.doi.org/10.1001/jama.269.9.1127			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KN611	8433468				2022-12-24	WOS:A1993KN61100029
J	ISEMAN, MD; COHN, DL; SBARBARO, JA				ISEMAN, MD; COHN, DL; SBARBARO, JA			DIRECTLY OBSERVED TREATMENT OF TUBERCULOSIS - WE CANT AFFORD NOT TO TRY IT	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									DENVER DEPT HLTH & HOSP,DENVER,CO 80204; UNIV COLORADO,HLTH SCI CTR,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	ISEMAN, MD (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED,DENVER,CO 80206, USA.							ALBERT RK, 1976, AM REV RESPIR DIS, V114, P1051; ANASTASATU C, 1982, B INT UNION TUBERC, V52, P1; [Anonymous], 1991, Am Rev Respir Dis, V143, P700; [Anonymous], 1987, Am Rev Respir Dis, V136, P1339; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; COHN DL, 1990, ANN INTERN MED, V112, P407, DOI 10.7326/0003-4819-76-3-112-6-407; COMBS DL, 1990, ANN INTERN MED, V112, P397, DOI 10.7326/0003-4819-76-3-112-6-397; CRAMER JA, 1989, JAMA-J AM MED ASSOC, V261, P3273, DOI 10.1001/jama.261.22.3273; DAVIS MS, 1967, J HEALTH SOC BEHAV, V8, P265, DOI 10.2307/2948420; HAYES RB, 1979, COMPLIANCE HLTH CARE; HUDSON LD, 1973, JAMA-J AM MED ASSOC, V223, P139, DOI 10.1001/jama.223.2.139; ISEMAN MD, 1985, AM REV RESPIR DIS, V132, P735; MCFADDEN RC, 1991, NY TIMES        1117, P20; PRABHAKER R, 1987, B INT UNION TUBERC L, V62, P21; SBARBARO JA, 1986, CHEST, V90, P754, DOI 10.1378/chest.90.5.754; SBARBARO JA, 1979, CHEST, V76, P750, DOI 10.1378/chest.76.6.750; 1990, MMWR MORB MORTAL WKL, V39, P369; 1991, MMWR MORB MORTAL WKL, V40, P585; 1985, CHEST S, V87, pS115; 1992, MMWR MORB MORTAL WKL, V41; [No title captured]; 1988, AM REV RESPIR DIS, V138, P1070; 1987, AM REV RESPIR DIS, V136, P92	23	176	176	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 25	1993	328	8					576	578		10.1056/NEJM199302253280811	http://dx.doi.org/10.1056/NEJM199302253280811			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP053	8426627				2022-12-24	WOS:A1993KP05300011
J	SOMMER, RJ; TAUTZ, D				SOMMER, RJ; TAUTZ, D			INVOLVEMENT OF AN ORTHOLOGUE OF THE DROSOPHILA PAIR-RULE GENE HAIRY IN SEGMENT FORMATION OF THE SHORT GERM-BAND EMBRYO OF TRIBOLIUM (COLEOPTERA)	NATURE			English	Article							MOLECULAR-GENETICS; KRUPPEL; EXPRESSION; REVEALS; HUNCHBACK; HOMOLOGY; PATTERN; GAP; DNA	THE segments in long germ-band insect embryos, like Drosophila, are all determined at syncytial blastoderm stage. This is in contrast to short germ-band embryos which show an early determination of only the anterior head segments, whereas the more posterior thoracic and abdominal segments are sequentially added after formation of a primary germ anlage (reviewed in ref. 1). Segment formation in Drosophila involves the pair-rule genes which define double segmental periodicities2,3 and which have been considered to represent a special adaptation to the long germ-band type development4,5 hairy belongs to the primary pair-rule genes in Drosophila which are directly regulated by the gap genes, such as Kruppel6-13. We have isolated the orthologues of hairy and Kruppel from the flour beetle Tribolium castaneum which has a short germ type development14. We show here that hairy is expressed in several stripes at blastoderm stage and later on in two stripes in the growth zone of the developing embryo. Kruppel expression overlaps hairy stripe three and four expression, very similar to Drosophila. This suggests that the segment patterning mechanism that acts in an open blastoderm in Drosophila works in a similar way in the cellularized Tribolium embryo.	UNIV MUNICH,INST ZOOL,W-8000 MUNICH 2,GERMANY	University of Munich			Tautz, Diethard/D-4304-2011; Tautz, Diethard/H-8436-2014	Tautz, Diethard/0000-0002-0460-5344				AKAM M, 1992, Current Biology, V2, P395, DOI 10.1016/0960-9822(92)90313-Y; BROWN SJ, 1990, INSECT BIOCHEM, V20, P185, DOI 10.1016/0020-1790(90)90011-I; COUNCE SJA, 1961, REV ENTOMOL, V6, P295; GAUL U, 1987, CELL, V50, P639, DOI 10.1016/0092-8674(87)90037-7; HOOPER KL, 1989, DEVELOPMENT, V107, P489; HOWARD KR, 1990, DEVELOPMENT, V110, P1223; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; INGHAM PW, 1985, NATURE, V318, P439, DOI 10.1038/318439a0; INGHAM PW, 1986, EMBO J, V5, P1659, DOI 10.1002/j.1460-2075.1986.tb04409.x; KRAUSE GERHARa, 1939, BIOL ZENTMLBI, V59, P495; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; PANKRATZ MJ, 1990, TRENDS GENET, V6, P287, DOI 10.1016/0168-9525(90)90234-W; PANKRATZ MJ, 1990, CELL, V61, P309, DOI 10.1016/0092-8674(90)90811-R; PATEL NH, 1992, NATURE, V357, P339, DOI 10.1038/357339a0; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; Patel Nipam H., 1992, P377; PREISS A, 1985, NATURE, V313, P27, DOI 10.1038/313027a0; RIDDIHOUGH G, 1991, GENE DEV, V5, P840, DOI 10.1101/gad.5.5.840; ROSENBERG UB, 1986, NATURE, V319, P336, DOI 10.1038/319336a0; RUSHLOW CA, 1989, EMBO J, V8, P3095, DOI 10.1002/j.1460-2075.1989.tb08461.x; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sander K., 1976, Advances in insect physiology. Volume 12., P125, DOI 10.1016/S0065-2806(08)60255-6; Sokoloff A, 1972, BIOL TRIBOLIUM; SOMMER RJ, 1992, P NATL ACAD SCI USA, V89, P10782, DOI 10.1073/pnas.89.22.10782; STANLEY MSM, 1970, ANN ENTOMOL SOC AM, V63, P1248, DOI 10.1093/aesa/63.5.1248; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TAUTZ D, 1986, NATURE, V322, P652, DOI 10.1038/322652a0; TREIER M, 1989, EMBO J, V8, P1517, DOI 10.1002/j.1460-2075.1989.tb03536.x	28	143	143	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 4	1993	361	6411					448	450		10.1038/361448a0	http://dx.doi.org/10.1038/361448a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KK713	8429884				2022-12-24	WOS:A1993KK71300060
J	LOUIS, JC; MAGAL, E; TAKAYAMA, S; VARON, S				LOUIS, JC; MAGAL, E; TAKAYAMA, S; VARON, S			CNTF PROTECTION OF OLIGODENDROCYTES AGAINST NATURAL AND TUMOR NECROSIS FACTOR-INDUCED DEATH	SCIENCE			English	Article							CILIARY NEUROTROPHIC FACTOR; CENTRAL-NERVOUS-SYSTEM; RAT OPTIC-NERVE; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; ASTROCYTE PROGENITOR CELLS; MULTIPLE-SCLEROSIS; REGIONAL DISTRIBUTION; NEURONAL SURVIVAL; FACTOR-ALPHA; BRAIN	A proportion of developing oligodendrocytes undergo natural cell death by apoptosis, and mature oligodendrocytes die, either by apoptosis or necrosis, in response to injurious signals such as cytotoxic cytokines and complement. Ciliary neurotrophic factor (CNTF), a trophic factor found in astrocytes in the central nervous system (CNS), promoted the survival and maturation of cultured oligodendrocytes. This trophic factor also protected oligodendrocytes from death induced by tumor necrosis factors (apoptosis) but not against complement (necrosis). These results suggest that CNTF functions in the survival of oligodendrocytes during development and may lead to therapeutic approaches for degenerative diseases of the CNS that involve oligodendrocyte destruction.			LOUIS, JC (corresponding author), UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093, USA.				NINDS NIH HHS [NS16349] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS016349] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABNEY ER, 1981, DEV BIOL, V83, P301, DOI 10.1016/0012-1606(81)90476-0; ARAKAWA Y, 1990, J NEUROSCI, V10, P3507; BARBIN G, 1984, J NEUROCHEM, V43, P146; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BARNES BA, 1992, CELL, V70, P31; COMPSTON DAS, 1991, TRENDS NEUROSCI, V14, P175; COWAN WM, 1984, SCIENCE, V225, P1258, DOI 10.1126/science.6474175; CUNNINGHAM TJ, 1982, INT REV CYTOL, V74, P163, DOI 10.1016/S0074-7696(08)61172-9; DUBOISDALCQ M, 1990, BIOESSAYS, V12, P569, DOI 10.1002/bies.950121203; DUBOISDALCQ M, 1987, EMBO J, V6, P2527; ELLISON MD, 1991, J NEUROIMMUNOL, V33, P245, DOI 10.1016/0165-5728(91)90112-K; FRANCIOTTA DM, 1989, ANN NEUROL, V26, P787, DOI 10.1002/ana.410260618; GERSCHENSON LE, 1992, FASEB J, V6, P2450, DOI 10.1096/fasebj.6.7.1563596; GLUCKSMANN A, 1951, BIOL REV, V26, P59, DOI 10.1111/j.1469-185X.1951.tb00774.x; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; GRIMALDI LME, 1991, ANN NEUROL, V29, P21, DOI 10.1002/ana.410290106; HAGG T, 1992, NEURON, V8, P145, DOI 10.1016/0896-6273(92)90116-U; HAMBURGER V, 1982, NEUROSCI COMMENT, V1, P39; HOFMAN FM, 1989, J EXP MED, V170, P607, DOI 10.1084/jem.170.2.607; HUGHES SM, 1988, NATURE, V335, P70, DOI 10.1038/335070a0; IP NY, 1991, J NEUROSCI, V11, P3124; JOHNSON EM, 1989, NEUROBIOL AGING, V10, P549, DOI 10.1016/0197-4580(89)90127-9; Kerr J. F., 1991, APOPTOSIS MOL BASIS, V3, P5; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; LAM A, 1991, GENE, V102, P271, DOI 10.1016/0378-1119(91)90089-T; LILLIE TH, 1988, J AM MOSQUITO CONTR, V4, P485; LOUIS JC, 1992, J NEUROSCI RES, V31, P193, DOI 10.1002/jnr.490310125; LOUIS JC, IN PRESS DEV BIOL; MAGAL E, 1991, J NEUROSCI RES, V30, P560, DOI 10.1002/jnr.490300314; MAGAL E, 1991, DEV BRAIN RES, V63, P141, DOI 10.1016/0165-3806(91)90074-S; MAIMONE D, 1991, NEUROIMMUNOL, V32, P67; MANTHORPE M, 1986, DEV BRAIN RES, V25, P191, DOI 10.1016/0165-3806(86)90208-7; McFarland H F, 1988, Ann N Y Acad Sci, V540, P99, DOI 10.1111/j.1749-6632.1988.tb27055.x; MCMORRIS FA, 1988, J NEUROSCI RES, V21, P199, DOI 10.1002/jnr.490210212; MCMORRIS FA, 1986, P NATL ACAD SCI USA, V83, P822, DOI 10.1073/pnas.83.3.822; MERRILL JE, 1990, ANN NY ACAD SCI, V594, P188; MERRILL JE, 1991, FASEB J, V5, P2391, DOI 10.1096/fasebj.5.10.2065887; MERRILL JE, 1989, J CLIN IMMUNOL, V9, P84, DOI 10.1007/BF00916935; MILLER RH, 1985, DEV BIOL, V111, P35, DOI 10.1016/0012-1606(85)90432-4; MOLINA JM, 1989, J CLIN INVEST, V84, P733, DOI 10.1172/JCI114230; MORGANTIKOSSMANN MC, 1992, TRENDS PHARMACOL SCI, V13, P286, DOI 10.1016/0165-6147(92)90087-M; OPPENHEIM RW, 1991, SCIENCE, V251, P1616, DOI 10.1126/science.2011743; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; PENDER MP, 1991, J NEUROL SCI, V104, P81, DOI 10.1016/0022-510X(91)90219-W; POSER CM, 1992, J NEUROL SCI, V107, P127, DOI 10.1016/0022-510X(92)90280-X; RAFF MC, 1989, SCIENCE, V243, P1450, DOI 10.1126/science.2648568; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RAINE CS, 1970, J NEUROPATH EXP NEUR, V29, P177, DOI 10.1097/00005072-197004000-00002; RAO MS, 1992, DEV BIOL, V150, P281, DOI 10.1016/0012-1606(92)90242-9; REYNOLDS R, 1988, DEVELOPMENT, V102, P409; ROBBINS DS, 1987, J IMMUNOL, V139, P2593; RUDDLE NH, 1990, J EXP MED, V172, P1193, DOI 10.1084/jem.172.4.1193; SAUNDERS JW, 1966, SCIENCE, V154, P604, DOI 10.1126/science.154.3749.604; SCOLDING NJ, 1992, NEUROSCI LETT, V135, P95, DOI 10.1016/0304-3940(92)90144-V; SCOLDING NJ, 1989, NATURE, V339, P620, DOI 10.1038/339620a0; SELMAJ K, 1991, J CLIN INVEST, V87, P949, DOI 10.1172/JCI115102; SELMAJ K, 1991, J IMMUNOL, V147, P1522; SELMAJ KW, 1988, ANN NEUROL, V23, P339, DOI 10.1002/ana.410230405; SHARIEF MK, 1991, NEW ENGL J MED, V325, P467, DOI 10.1056/NEJM199108153250704; SMALL RK, 1987, NATURE, V328, P155, DOI 10.1038/328155a0; STOCKLI KA, 1989, NATURE, V342, P920, DOI 10.1038/342920a0; STOCKLI KA, 1991, J CELL BIOL, V115, P447, DOI 10.1083/jcb.115.2.447; TSUKADA N, 1991, J NEUROL SCI, V102, P230; WAKSMAN BH, 1984, ANN NY ACAD SCI, V436, P125, DOI 10.1111/j.1749-6632.1984.tb14783.x; WREN DR, 1989, P NATL ACAD SCI USA, V86, P9025, DOI 10.1073/pnas.86.22.9025	65	450	463	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 29	1993	259	5095					689	692		10.1126/science.8430320	http://dx.doi.org/10.1126/science.8430320			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KJ688	8430320				2022-12-24	WOS:A1993KJ68800045
J	MAHAN, MJ; SLAUCH, JM; MEKALANOS, JJ				MAHAN, MJ; SLAUCH, JM; MEKALANOS, JJ			SELECTION OF BACTERIAL VIRULENCE GENES THAT ARE SPECIFICALLY INDUCED IN HOST TISSUES	SCIENCE			English	Article							CARBAMOYL-PHOSPHATE SYNTHETASE; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; SEQUENCE; DETERMINANTS; MUTATIONS; AVIRULENT; STRAINS	A genetic system was devised that positively selects for bacterial genes that are specifically induced when bacteria infect their host. With the pathogen Salmonella typhimurium, the genes identified by this selection show a marked induction in bacteria recovered from mouse spleen. Mutations in all ivi (in vivo-induced) genes that were tested conferred a defect in virulence. This genetic system was designed to be of general use in a wide variety of bacterial-host systems and has several applications in both vaccine and antimicrobial drug development.			MAHAN, MJ (corresponding author), HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOLEC GENET,BOSTON,MA 02115, USA.				NIAID NIH HHS [AI08245, AI26289] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026289] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BASELSKI VS, 1978, INFECT IMMUN, V22, P181, DOI 10.1128/IAI.22.1.181-188.1978; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DORMAN CJ, 1987, J BACTERIOL, V169, P3840, DOI 10.1128/jb.169.8.3840-3843.1987; FIELDS PI, 1986, P NATL ACAD SCI USA, V83, P5189, DOI 10.1073/pnas.83.14.5189; FRIEDMAN DI, 1988, CELL, V55, P545, DOI 10.1016/0092-8674(88)90213-9; GLANSDORFF N, 1987, ESCHERICHIA COLI SAL, P321; HUGHES KT, 1988, GENETICS, V119, P9; IVANOVICS G, 1968, J BACTERIOL, V85, P147; JIANG XM, 1991, MOL MICROBIOL, V5, P695, DOI 10.1111/j.1365-2958.1991.tb00741.x; LEUNK RD, 1982, INFECT IMMUN, V36, P1168, DOI 10.1128/IAI.36.3.1168-1174.1982; LEVINE HB, 1958, J IMMUNOL, V81, P433; LOCKMAN HA, 1992, INFECT IMMUN, V60, P491, DOI 10.1128/IAI.60.2.491-496.1992; Makela P. H., 1984, HDB ENDOTOXIN, P59; MCFARLAND WC, 1987, MICROB PATHOGENESIS, V3, P129, DOI 10.1016/0882-4010(87)90071-4; MECHULAM Y, 1985, J BACTERIOL, V163, P787, DOI 10.1128/JB.163.2.787-791.1985; MEKALANOS JJ, 1992, J BACTERIOL, V174, P1; MILLER VL, 1988, J BACTERIOL, V170, P2575, DOI 10.1128/JB.170.6.2575-2583.1988; NNALUE NA, 1990, INFECT IMMUN, V58, P2493, DOI 10.1128/IAI.58.8.2493-2501.1990; NYUNOYA H, 1983, P NATL ACAD SCI-BIOL, V80, P4629, DOI 10.1073/pnas.80.15.4629; PIETTE J, 1984, P NATL ACAD SCI-BIOL, V81, P4134, DOI 10.1073/pnas.81.13.4134; PLUMBRIDGE JA, 1980, J MOL BIOL, V144, P595, DOI 10.1016/0022-2836(80)90341-1; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; STOCKER BAD, 1988, VACCINE, V6, P141, DOI 10.1016/S0264-410X(88)80017-3; STRALEY SC, 1984, INFECT IMMUN, V45, P649, DOI 10.1128/IAI.45.3.649-654.1984	24	551	613	0	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 29	1993	259	5095					686	688		10.1126/science.8430319	http://dx.doi.org/10.1126/science.8430319			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KJ688	8430319				2022-12-24	WOS:A1993KJ68800044
J	PECHURA, CM				PECHURA, CM			THE HEALTH-EFFECTS OF MUSTARD GAS AND LEWISITE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											PECHURA, CM (corresponding author), INST MED,COMM SURVEY HLTH EFFECTS MUSTARD GAS & LEWISITE,ROOM FO-3036,2101 CONSTITUT AVE NW,WASHINGTON,DC 20418, USA.							1993, VETERANS RISK HLTH E; 1992, FED REG         0731; 1992, FED REG         0115	3	0	0	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 27	1993	269	4					453	453		10.1001/jama.269.4.453	http://dx.doi.org/10.1001/jama.269.4.453			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KH385	8419656				2022-12-24	WOS:A1993KH38500005
J	PRUMMEL, MF; WIERSINGA, WM				PRUMMEL, MF; WIERSINGA, WM			SMOKING AND RISK OF GRAVES-DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AUTOIMMUNE THYROID-DISEASE; CIGARETTE-SMOKING; OPHTHALMOPATHY; THYROGLOBULIN; ASSOCIATION; LYMPHOCYTES; GOITER	Objective.-To assess if smoking is associated with Graves' disease and, if so, to ascertain whether this association persists when controlling for confounding factors. Design.-Consecutive entry case-control study with two age- and sex-matched control subjects from two different populations per case patient. Setting.-University hospital. Patients.-Five groups were studied: (1) Graves' ophthalmopathy and Graves' hyperthyroidism (n=100; divided in four subgroups according to the severity of the eye disease); (2) Graves' hyperthyroidism without clinical eye involvement (n=100); (3) sporadic nontoxic goiter (n=100); (4) autoimmune hypothyroidism (n=75); and (5) toxic nodular goiter (n=75). The study comprised 200 subjects from a hospital-based population, and 200 from a population-based group served as control subjects. Main Outcome Measure.-Smoking status was determined from a questionnaire at the time of onset of the disease to exclude any effect of the disease itself on smoking. Results.-Smoking greatly increased the risk for Graves' ophthalmopathy (odds ratio, 7.7; 95% confidence interval, 4.3 to 13.7), but patients with Graves' hyperthyroidism alone were also more often smokers than control subjects (odds ratio, 1.9; 95% confidence interval, 1.1 to 3.2). Smoking was not associated with the other thyroid diseases studied. Essentially similar results were obtained after adjustment for differences in education between case patients and control subjects. Among the patients with Graves' ophthalmopathy, smokers had more severe eye disease than nonsmokers, but no association was found between the number of cigarettes smoked per day or the duration of smoking and the severity of the ophthalmopathy. However, there was a significant increase in the odds ratios in patients with more severe eye disease. Conclusions.-Smoking is associated with Graves' disease, and it especially increases the risk for the development of more severe ophthalmopathy. Thus, smoking appears to be one of the multiple factors inducing Graves' disease in genetically predisposed individuals.			PRUMMEL, MF (corresponding author), UNIV AMSTERDAM,ACAD MED CTR,DEPT ENDOCRINOL,F5-258,MEIBERGDREEF 9,1105 AZ AMSTERDAM,NETHERLANDS.							ANGELL M, 1990, NEW ENGL J MED, V323, P823, DOI 10.1056/NEJM199009203231209; BARTALENA L, 1989, J ENDOCRINOL INVEST, V12, P733, DOI 10.1007/BF03350047; BERGHOUT A, 1990, LANCET, V336, P193, DOI 10.1016/0140-6736(90)91730-X; CALKINS BM, 1989, DIGEST DIS SCI, V34, P1841, DOI 10.1007/BF01536701; CHRISTENSEN SB, 1984, J CLIN ENDOCR METAB, V58, P615, DOI 10.1210/jcem-58-4-615; DEGROOT LJ, 1989, ENDOCR REV, V10, P537, DOI 10.1210/edrv-10-4-537; FUNG HYM, 1988, BRIT MED J, V296, P241, DOI 10.1136/bmj.296.6617.241; GAMBLIN GT, 1983, NEW ENGL J MED, V308, P420, DOI 10.1056/NEJM198302243080803; HAGG E, 1987, BRIT MED J, V295, P634, DOI 10.1136/bmj.295.6599.634; HENNEKENS CH, 1987, EPIDEMIOLOGY MED, P132; Hernandez Avila M, 1990, EPIDEMIOLOGY, V1, P285; HUGHES DA, 1985, CLIN EXP IMMUNOL, V61, P459; KONISHI J, 1974, ENDOCRINOLOGY, V95, P434, DOI 10.1210/endo-95-2-434; LUDGATE M, 1986, LANCET, V2, P219; MCGREGOR AM, 1990, NEW ENGL J MED, V322, P1739, DOI 10.1056/NEJM199006143222409; PRUMMEL MF, 1989, NEW ENGL J MED, V321, P1353, DOI 10.1056/NEJM198911163212002; RATANACHAIYAVON.S, 1990, THYROID GLAND ENV AU, P167; REGIUS O, 1988, Z GERONTOL, V21, P161; Schlesselman JJ, 1982, CASE CONTROL STUDIES, P171; SHINE B, 1990, LANCET, V335, P1261, DOI 10.1016/0140-6736(90)91315-2; SHUKLA R, 1990, LANCET, V336, P184, DOI 10.1016/0140-6736(90)91711-I; THOMAS W, 1973, NATURE, V243, P240, DOI 10.1038/243240a0; VOLPE R, 1986, THYROID AUTOIMMUNITY, P283; WEETMAN AP, 1984, ENDOCR REV, V5, P309, DOI 10.1210/edrv-5-2-309; WERNER SC, 1974, NEW ENGL J MED, V290, P1447, DOI 10.1056/NEJM197406272902602; WERNER SC, 1977, J CLIN ENDOCR METAB, V44, P203, DOI 10.1210/jcem-44-1-203; 1990, STATISTISCH JB 1990, P425; 1990, LANCET, V335, P1561; 1990, LANCET, V335, P1127	29	327	344	0	13	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 27	1993	269	4					479	482		10.1001/jama.269.4.479	http://dx.doi.org/10.1001/jama.269.4.479			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KH385	8419666				2022-12-24	WOS:A1993KH38500030
J	RIVERA, GK; PINKEL, D; SIMONE, JV; HANCOCK, ML; CRIST, WM				RIVERA, GK; PINKEL, D; SIMONE, JV; HANCOCK, ML; CRIST, WM			TREATMENT OF ACUTE LYMPHOBLASTIC-LEUKEMIA - 30 YEARS EXPERIENCE AT ST-JUDE-CHILDRENS-RESEARCH-HOSPITAL	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE LYMPHOCYTIC-LEUKEMIA; CENTRAL NERVOUS-SYSTEM; HIGH-DOSE METHOTREXATE; LONG-TERM SURVIVORS; CLINICAL PHARMACODYNAMICS; COMBINATION CHEMOTHERAPY; CHILDHOOD LEUKEMIA; REMISSION DURATION; THERAPY; IRRADIATION	Background. Therapy for childhood lymphoblastic leukemia has evolved during the past three decades, but key questions about what are the least toxic, most effective forms of treatment remain unanswered because of the lack of comprehensive follow-up information. Methods. To assess long-term outcome in the series of clinical trials conducted at St. Jude Hospital, we compared the results of treatment typical of four eras: exploratory combination chemotherapy (era 1, 1962 to 1966; 91 patients), regimens for the control of meningeal leukemia (era 2, 1967 to 1979; 825 patients), limited intensification of therapy (era 3, 1979 to 1983; 428 patients), and extended intensification of therapy (era 4, 1984 to 1988; 358 patients). (''Intensification'' refers to strategies of systemic chemotherapy that are more aggressive than conventional ones.) The major end points were survival and event-free survival; we also calculated the relative risk of treatment failure and the rate of relapse or death after treatment ended (post-treatment failure rate). Results. The probability of event-free survival im proved significantly in each successive era (P<0.001 by the log-rank test), reaching 71 percent in era 4. There was a decrease of approximately 50 percent in the risk of treatment failure from one era to the next in each subgroup of patients defined according to different combinations of the leukocyte count, race, age, and sex. Leukemia appeared to be eradicated in patients who remained in complete remission for three years or more after treatment in era 4. The incidence of death due to nonleukemic causes remained 4 to 6 percent despite the trend toward more intensive treatment. An estimated 765 patients (45 percent) are long-term survivors; most of them (80 percent) have no health problems related to leukemia or its treatment. Conclusions. The development and successful application of preventive therapy for meningeal leukemia, followed by the intensification of systemic chemotherapy, has progressively improved the rate of cure of childhood lymphoblastic leukemia, with relatively few adverse sequelae.	ST JUDE CHILDRENS RES HOSP, DEPT HEMATOL ONCOL, MEMPHIS, TN 38101 USA; ST JUDE CHILDRENS RES HOSP, DEPT BIOSTAT, MEMPHIS, TN 38101 USA; UNIV TENNESSEE, CTR HLTH SCI, COLL MED, DEPT PEDIAT, MEMPHIS, TN 38163 USA; MD ANDERSON CANC CTR, NEW YORK, NY USA; MEM SLOAN KETTERING CANC CTR, NEW YORK, NY 10021 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; University of Texas System; UTMD Anderson Cancer Center; Memorial Sloan Kettering Cancer Center					NCI NIH HHS [CA 20180, CA 21765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA020180, P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUR RJA, 1978, CANCER, V42, P2123, DOI 10.1002/1097-0142(197811)42:5<2123::AID-CNCR2820420507>3.0.CO;2-5; AUR RJA, 1972, CANCER, V29, P381, DOI 10.1002/1097-0142(197202)29:2<381::AID-CNCR2820290219>3.0.CO;2-P; AUR RJA, 1971, BLOOD-J HEMATOL, V37, P272, DOI 10.1182/blood.V37.3.272.272; BLEYER WA, 1985, SEMIN ONCOL, V12, P131; CAMITTA BM, 1980, MED PEDIATR ONCOL, V8, P383, DOI 10.1002/mpo.2950080410; CAMPANA D, 1990, BLOOD, V76, P163, DOI 10.1182/blood.V76.1.163.163; CAMPANA D, 1990, BLOOD, V76, P1901; CHEN W, 1992, P NATL ACAD SCI USA, V89, P1468, DOI 10.1073/pnas.89.4.1468; CLAVELL LA, 1986, NEW ENGL J MED, V315, P657, DOI 10.1056/NEJM198609113151101; COX DR, 1972, J R STAT SOC B, V34, P187; DAHL GV, 1987, J CLIN ONCOL, V5, P1015, DOI 10.1200/JCO.1987.5.7.1015; EGUIGUREN JM, 1992, BLOOD, V79, P871; EVANS WE, 1988, BLUT, V56, P241, DOI 10.1007/BF00320282; EVANS WE, 1986, NEW ENGL J MED, V314, P471, DOI 10.1056/NEJM198602203140803; GAYNON PS, 1988, LANCET, V2, P921; GOLDIE JH, 1982, CANCER TREAT REP, V66, P439; HAMMOND D, 1986, MED PEDIATR ONCOL, V14, P124, DOI 10.1002/mpo.2950140305; HUGHES WT, 1977, NEW ENGL J MED, V297, P1419, DOI 10.1056/NEJM197712292972602; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; LIPSHULTZ SE, 1991, NEW ENGL J MED, V324, P808, DOI 10.1056/NEJM199103213241205; LOOK AT, 1987, NEW ENGL J MED, V317, P1666; MULHERN RK, 1988, J CLIN ONCOL, V6, P315, DOI 10.1200/JCO.1988.6.2.315; MURPHY SB, 1986, NEW ENGL J MED, V314, P188; NIEMEYER CM, 1991, ANN ONCOL, V2, P745, DOI 10.1093/oxfordjournals.annonc.a057856; NIEMEYER CM, 1991, BLOOD, V78, P2514, DOI 10.1182/blood.V78.10.2514.2514; OCHS J, 1991, J CLIN ONCOL, V9, P145, DOI 10.1200/JCO.1991.9.1.145; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PINKEL D, 1971, CANCER-AM CANCER SOC, V27, P247, DOI 10.1002/1097-0142(197102)27:2<247::AID-CNCR2820270202>3.0.CO;2-C; PINKEL D, 1971, J AMER MED ASSOC, V216, P648, DOI 10.1001/jama.216.4.648; PINKEL D, 1992, LEUKEMIA, V6, P127; PUI CH, 1988, MED PEDIATR ONCOL, V16, P21, DOI 10.1002/mpo.2950160106; PUI CH, 1984, CANCER RES, V44, P3593; PUI CH, 1991, NEW ENGL J MED, V325, P1682, DOI 10.1056/NEJM199112123252402; PULLEN J, 1993, J CLIN ONCOL, V11, P839, DOI 10.1200/JCO.1993.11.5.839; Riehm H, 1990, Haematol Blood Transfus, V33, P439; RIVERA G, 1979, BLOOD, V53, P1114; RIVERA GK, 1988, J CLIN ONCOL, V6, P191, DOI 10.1200/JCO.1988.6.2.191; RIVERA GK, 1991, LANCET, V337, P61, DOI 10.1016/0140-6736(91)90733-6; RIVERA GK, 1988, NEW ENGL J MED, V318, P1541; SCHRIOCK EA, 1991, J CLIN ONCOL, V9, P400, DOI 10.1200/JCO.1991.9.3.400; SIMONE JV, 1976, BRIT J HAEMATOL, V32, P465, DOI 10.1111/j.1365-2141.1976.tb00950.x; SKIPPER HOWARD E., 1965, CANCER CHEMOTHERAP REP, V45, P5; TRUEWORTHY R, 1992, J CLIN ONCOL, V10, P606, DOI 10.1200/JCO.1992.10.4.606	43	249	251	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 28	1993	329	18					1289	1295		10.1056/NEJM199310283291801	http://dx.doi.org/10.1056/NEJM199310283291801			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD557	8413409				2022-12-24	WOS:A1993MD55700001
J	DAMUTH, J				DAMUTH, J			COPES RULE, THE ISLAND RULE AND THE SCALING OF MAMMALIAN POPULATION-DENSITY	NATURE			English	Article							BODY SIZE; ABUNDANCE; BIRDS; EVOLUTION; ANIMALS	COPE'S rule-the generalization that animal taxa tend to evolve toward larger body size suggests that there are widespread net selective advantages to being large1-4. Size-abundance relationships within bird4-7 and desert rodent4 guilds show that larger species usually do control more energy locally, and thus maintain larger populations than expected for their body size, implying that larger individuals are relatively better at obtaining and using local resources. But we report here results that show that this is not generally the case among mammal species. Within dietary groups containing only small species, larger species usually do better, but within those that contain the largest mammals, small species tend to control more energy. This suggests that in mammals there is an optimum body size for energy acquisition at about 1 kg. Thus, net adaptive advantages of large individuals for resource control cannot be used as a general explanation for evolutionary size increase in mammals, although other proposed explanations for Cope's rule are unaffected8-10. Instead, these results suggest a partial explanation for another widespread ecotypic pattern, the 'island rule': that on islands, small mammal species evolve to larger size and large species to smaller size11-13. If on an island a species' usual competitors and predators are absent, it should often tend to evolve toward the optimum body size, and the adaptive advantages of doing so would be greatest for populations starting at body-size extremes.			DAMUTH, J (corresponding author), UNIV CALIF SANTA BARBARA,DEPT BIOL SCI,SANTA BARBARA,CA 93106, USA.			Damuth, John/0000-0002-1635-9726				BROWN JH, 1986, NATURE, V324, P248, DOI 10.1038/324248a0; Caughley G., 1977, ANAL VERTEBRATE POPU; COTGREAVE P, 1992, FUNCT ECOL, V6, P248, DOI 10.2307/2389514; DAMUTH J, 1981, NATURE, V290, P699, DOI 10.1038/290699a0; DAMUTH J, 1987, BIOL J LINN SOC, V31, P193, DOI 10.1111/j.1095-8312.1987.tb01990.x; DAMUTH J, 1991, NATURE, V351, P268, DOI 10.1038/351268a0; DUTOIT JT, 1989, AM NAT, V133, P736, DOI 10.1086/284949; Eisenberg J.F., 1981, MAMMALIAN RAD; FELSENSTEIN J, 1985, AM NAT, V125, P1, DOI 10.1086/284325; FOSTER JB, 1964, NATURE, V202, P234, DOI 10.1038/202234a0; GOULD SJ, 1988, J PALEONTOL, V62, P319, DOI 10.1017/S0022336000059126; GOULD SJ, 1966, BIOL REV, V41, P587, DOI 10.1111/j.1469-185X.1966.tb01624.x; HEANEY LR, 1978, EVOLUTION, V32, P29, DOI 10.1111/j.1558-5646.1978.tb01096.x; HOFMANN R R, 1972, Mammalia, V36, P226, DOI 10.1515/mamm.1972.36.2.226; JUANES F, 1986, AM NAT, V128, P921, DOI 10.1086/284613; Kleiber M., 1975, FIRE LIFE; KUHRY B, 1977, SYST ZOOL, V26, P201, DOI 10.2307/2412842; LAWTON JH, 1989, OIKOS, V55, P429, DOI 10.2307/3565606; LEWONTIN RC, 1989, AM NAT, V134, P513, DOI 10.1086/284994; LOMOLINO MV, 1985, AM NAT, V125, P310, DOI 10.1086/284343; Maiorana V.C., 1990, P69; MCARDLE BH, 1988, CAN J ZOOL, V66, P2329, DOI 10.1139/z88-348; NAGY KA, 1987, ECOL MONOGR, V57, P111, DOI 10.2307/1942620; NEE S, 1991, NATURE, V351, P312, DOI 10.1038/351312a0; NEWELL ND, 1949, EVOLUTION, V3, P103, DOI 10.2307/2405545; PAGEL MD, 1988, AM NAT, V132, P344, DOI 10.1086/284857; RIDLEY M, 1989, J THEOR BIOL, V136, P361, DOI 10.1016/S0022-5193(89)80171-7; RIGGS DS, 1978, LIFE SCI, V22, P1305, DOI 10.1016/0024-3205(78)90098-X; ROBINSON JG, 1986, AM NAT, V128, P665, DOI 10.1086/284596; Sondaar P.Y., 1977, MAJOR PATTERNS VERTE, P671, DOI DOI 10.1007/978-1-4684-8851-7; STANLEY SM, 1973, EVOLUTION, V27, P1, DOI 10.1111/j.1558-5646.1973.tb05912.x; Van Valen L, 1973, EVOL THEORY, V1, P31, DOI DOI 10.1007/S13398-014-0173-7.2; VANVALEN L, 1975, EVOLUTION, V29, P87, DOI 10.1111/j.1558-5646.1975.tb00816.x; Yablokov A.V, 1974, VARIABILITY MAMMALS	34	185	187	0	63	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 21	1993	365	6448					748	750		10.1038/365748a0	http://dx.doi.org/10.1038/365748a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MC812	8413651				2022-12-24	WOS:A1993MC81200061
J	SOLA, SM; KOHLER, M				SOLA, SM; KOHLER, M			RECENT DISCOVERIES OF DRYOPITHECUS SHED NEW LIGHT ON EVOLUTION OF GREAT APES	NATURE			English	Article							CLADE	THE origin and early evolution of the great ape/human clade (Hominidae) is currently a subject of debate1-3. The controversy is fuelled by the fragmentary nature of the fossils which renders it difficult to determine clearly derived features that permit the recognition of fossil members of this clade. We report here the recent discovery of a facial skeleton and a temporal fragment with the petrosal bone of Dryopithecus laietanus, which provides a way out of an impasse. The lack of the fossa subarcuata is a great ape and human clade synapomorphy, and proves unequivocally that Dryopithecus belongs to this clade. The zygomatic possesses derived characters which reveal that Dryopithecus is related to the Ponginae and not to the African apes/humans, as recently suggested1. The remaining morphological features are plesiomorphic and thus provide a good model of a common ancestor of all Hominidae.			SOLA, SM (corresponding author), ESCOLA IND 23,INST PALEONTOL M CRUSAFONT,E-08201 SABADELL,SPAIN.		Klein, Richard G/B-5910-2009	Kohler, Meike/0000-0002-6816-6651; Moya-Sola, Salvador/0000-0001-8506-1061; Kohler, Meike/0000-0001-9228-3164				Aiello L., 1990, P1; ANDREWS P, 1982, NATURE, V308, P541; ANDREWS P, 1992, SCIENCE, V360, P641; BEGUN DR, 1992, SCIENCE, V257, P1929, DOI 10.1126/science.1411507; BONIS L, 1990, NATURE, V345, P712; DEAN D, 1992, SCIENCE, V359, P676; GROVES CP, 1991, J HUM EVOL, V20, P167, DOI 10.1016/0047-2484(91)90056-2; Lartet E., 1856, CR HEBD ACAD SCI, V43, P219; Napier J. R., 1959, Fossil Mammals of Africa, V16, P1; PILBEAM D, 1990, NATURE, V348, P237, DOI 10.1038/348237a0; SABAN R, 1965, MEM MUS NAT HIST NAT, V29, P1; SCHWARTZ JH, 1990, J HUM EVOL, V19, P591, DOI 10.1016/0047-2484(90)90001-R; SIMONS EL, 1965, FOLIA PRIMATOL, V3, P81, DOI 10.1159/000155026	13	41	41	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 7	1993	365	6446					543	545		10.1038/365543a0	http://dx.doi.org/10.1038/365543a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MA661	8413607				2022-12-24	WOS:A1993MA66100052
J	FIGUEROA, M; GEHLSEN, J; HAMMOND, D; ONDREYCO, S; PIRO, L; POMEROY, T; WILLIAMS, F; MCMILLAN, R				FIGUEROA, M; GEHLSEN, J; HAMMOND, D; ONDREYCO, S; PIRO, L; POMEROY, T; WILLIAMS, F; MCMILLAN, R			COMBINATION CHEMOTHERAPY IN REFRACTORY IMMUNE THROMBOCYTOPENIC PURPURA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NON-HODGKINS-LYMPHOMA; THERAPY; LEUKEMIA; ITP	Background. Chronic idiopathic thrombocytopenic purpura is a destructive thrombocytopenia caused by an autoantibody. About 80 percent of patients with chronic idiopathic thrombocytopenic purpura have remissions after either corticosteroid therapy or splenectomy. Some patients with resistant disease respond to other agents, but a substantial group are refractory to therapy. Methods. We used combination chemotherapy to treat 10 patients with refractory immune thrombocytopenia. An average of 6.8 (range, 3 to 10) previous therapies, including corticosteroids and splenectomy, had been unsuccessful in these patients. The patients received from three to eight cycles of therapy consisting of cyclophosphamide and prednisone combined with either vincristine (one patient), vincristine and procarbazine (four patients), or etoposide (six patients, including one patient who received four cycles each containing procarbazine and etoposide) Results. Among the 10 patients, 6 had complete responses (platelet count, >180,000 per cubic millimeter); of these, 4 patients had responses that persisted for more than 11, 30, 54, or 126 months, 1 had a relapse 9 months after therapy but had a remission with further therapy and remained in remission for 48 months before dying of an unrelated illness, and another relapsed just before her fifth course of therapy. Two patients had partial responses (platelet count, >50,000 per cubic millimeter); the platelet counts in one remained stable for more than nine months after the end of therapy, and the other patient relapsed. The remaining two patients had no response. Complete responses were associated with a disappearance or marked decrease in the level of platelet-associated auto-antibody. Conclusions. Combination chemotherapy is beneficial in some patients in whom immune thrombocytopenia is refractory to corticosteroids and splenectomy.	SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, LA JOLLA, CA 92037 USA	Scripps Research Institute					NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037945] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00833] Funding Source: Medline; NHLBI NIH HHS [HL37945] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHN YS, 1977, ANNU REV MED, V28, P299, DOI 10.1146/annurev.me.28.020177.001503; ANDERSON T, 1977, CANCER TREAT REP, V61, P1057; BERCHTOLD P, 1989, BLOOD, V74, P2309; CHAO NJ, 1990, BLOOD, V76, P1293; COLEMAN CN, 1989, CANCER PRINCIPLES PR, V2, P2181; DENOTTOLANDER GJ, 1984, SCAND J HAEMATOL, V32, P101; DIFINO SM, 1980, AM J MED, V69, P430, DOI 10.1016/0002-9343(80)90016-9; FISHER RI, 1992, P AN M AM SOC CLIN, V11, P315; JACOBS P, 1986, Q J MED, V58, P153; JIJI RM, 1973, ARCH INTERN MED, V132, P380, DOI 10.1001/archinte.132.3.380; KALDOR JM, 1990, NEW ENGL J MED, V322, P1, DOI 10.1056/NEJM199001043220101; KALDOR JM, 1990, NEW ENGL J MED, V322, P7, DOI 10.1056/NEJM199001043220102; KELTON JG, 1982, SEMIN THROMB HEMOST, V8, P83, DOI 10.1055/s-2007-1005045; LIGHTSEY AL, 1975, JAMA-J AM MED ASSOC, V232, P734, DOI 10.1001/jama.232.7.734; MCMILLAN R, 1981, NEW ENGL J MED, V304, P1135, DOI 10.1056/NEJM198105073041904; MCMILLAN R, 1987, BLOOD, V70, P1040; PICOZZI VJ, 1980, AM J MED, V69, P690, DOI 10.1016/0002-9343(80)90419-2; PUI CH, 1991, NEW ENGL J MED, V325, P1682, DOI 10.1056/NEJM199112123252402; RODGERS GM, 1980, ANN INTERN MED, V92, P713; ROSSE WF, 1983, CLIN HAEMATOL, V12, P267	20	105	108	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 29	1993	328	17					1226	1229		10.1056/NEJM199304293281703	http://dx.doi.org/10.1056/NEJM199304293281703			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ061	8464433				2022-12-24	WOS:A1993KZ06100003
J	MIZUKAMI, T; CHANG, WI; GARKAVTSEV, I; KAPLAN, N; LOMBARDI, D; MATSUMOTO, T; NIWA, O; KOUNOSU, A; YANAGIDA, M; MARR, TG; BEACH, D				MIZUKAMI, T; CHANG, WI; GARKAVTSEV, I; KAPLAN, N; LOMBARDI, D; MATSUMOTO, T; NIWA, O; KOUNOSU, A; YANAGIDA, M; MARR, TG; BEACH, D			A 13-KB RESOLUTION COSMID MAP OF THE 14-MB FISSION YEAST GENOME BY NONRANDOM SEQUENCE-TAGGED SITE MAPPING	CELL			English	Article							SCHIZOSACCHAROMYCES-POMBE; GENE; IDENTIFICATION; INTEGRATION; CHROMOSOMES; FRAGMENTS	We present the application of a nonrandom sequence-tagged site (STS) content detection method in mapping an entire genome, that of fission yeast. The novelty of our strategy is in the use of STS probes made from both ends of cosmid clones, selected on the basis of ''sample without replacement'' (only library clones that show no previous positive hybridization are selected and made into probes). We developed powerful techniques, based on consistency analysis, for error detection and contig assembly. In addition, we probed our library with genetically mapped markers and NotI or SfiI linking clones, thereby anchoring contigs onto chromosomes. Our map contains more than 1000 sites, including genes (most were previously unmapped), occurrences of known repetitive elements, and NotI-SfiI restriction sites.	COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724; HOWARD HUGHES MED INST,COCONUT GROVE,FL 33133; KYOTO UNIV,FAC SCI,DEPT BIOPHYS,SAKYO KU,KYOTO 606,JAPAN	Cold Spring Harbor Laboratory; Howard Hughes Medical Institute; Kyoto University					NHGRI NIH HHS [5201 HG00017-02, 1R01 HG0020301A1] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000203] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		ARRATIA R, 1991, GENOMICS, V11, P806, DOI 10.1016/0888-7543(91)90004-X; BARILLOT E, 1991, P NATL ACAD SCI USA, V88, P3917, DOI 10.1073/pnas.88.9.3917; BEACH D, 1981, NATURE, V290, P140, DOI 10.1038/290140a0; CAERANOANOLLIS G, 1991, BIOTECHNOLOGY, V9, P553; CHIKASHIGE Y, 1989, CELL, V57, P739, DOI 10.1016/0092-8674(89)90789-7; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7826; DRAETTA G, 1987, CELL, V50, P319, DOI 10.1016/0092-8674(87)90227-3; EVANS GA, 1989, GENE, V79, P9, DOI 10.1016/0378-1119(89)90088-7; FAN JB, 1991, NUCLEIC ACIDS RES, V19, P6289, DOI 10.1093/nar/19.22.6289; FAN JB, 1988, NUCLEIC ACIDS RES, V17, P2801; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUKUI Y, 1985, EMBO J, V4, P687, DOI 10.1002/j.1460-2075.1985.tb03684.x; GREEN ED, 1990, SCIENCE, V250, P94, DOI 10.1126/science.2218515; Johnson B.F, 1989, MOL BIOL FISSION YEA, P243; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEVIN HL, 1990, MOL CELL BIOL, V10, P6791, DOI 10.1128/MCB.10.12.6791; MAIER E, 1992, NAT GENET, V1, P273, DOI 10.1038/ng0792-273; MARR TG, 1992, MAMM GENOME, V3, P644, DOI 10.1007/BF00352482; MATSUMOTO T, 1987, MOL CELL BIOL, V7, P4424, DOI 10.1128/MCB.7.12.4424; MATSUMOTO T, 1990, CURR GENET, V18, P323, DOI 10.1007/BF00318213; NAKASEKO Y, 1986, EMBO J, V5, P1011, DOI 10.1002/j.1460-2075.1986.tb04316.x; OLSON M, 1986, P NATL ACAD SCI USA, V83, P7821; PALAZZOLO MJ, 1991, P NATL ACAD SCI USA, V88, P8034, DOI 10.1073/pnas.88.18.8034; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Sambrook J., 1989, MOL CLONING LAB MANU; TODA T, 1984, CURR GENET, V8, P93, DOI 10.1007/BF00420224; YANAGIDA M, 1991, CONTROL CELL GROWTH, P255; ZHANG MQ, 1993, IN PRESS P NATL ACAD, V90	28	120	120	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 9	1993	73	1					121	132		10.1016/0092-8674(93)90165-M	http://dx.doi.org/10.1016/0092-8674(93)90165-M			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KW753	8462095				2022-12-24	WOS:A1993KW75300013
J	BOELENS, WC; JANSEN, EJR; VANVENROOIJ, WJ; STRIPECKE, R; MATTAJ, IW; GUNDERSON, SI				BOELENS, WC; JANSEN, EJR; VANVENROOIJ, WJ; STRIPECKE, R; MATTAJ, IW; GUNDERSON, SI			THE HUMAN U1 SNRNP-SPECIFIC U1A PROTEIN INHIBITS POLYADENYLATION OF ITS OWN PREMESSENGER RNA	CELL			English	Article							5' SPLICE SITE; A-PROTEIN; THYMIDYLATE SYNTHASE; BINDING DOMAIN; CHROMOSOMAL LOCALIZATION; RIBOSOMAL-PROTEINS; ESCHERICHIA-COLI; RIBONUCLEOPROTEIN; INVITRO; EXPRESSION	Human, mouse, and Xenopus mRNAs encoding the U1 snRNP-specific U1A protein contain a conserved 47 nt region in their 3' untranslated regions (UTRs). In vitro studies show that human U1A protein binds to two sites within the conserved region that resemble, in part, the previously characterized U1A-binding site on U1 snRNA. Overexpression of human U1A protein in mouse cells results in down-regulation of endogenous mouse U1A mRNA accumulation. In vitro and in vivo experiments demonstrate that excess U1A protein specifically inhibits polyadenylation of pre-mRNAs that contain the conserved 3' UTR from human U1A mRNA. Thus, U1A protein regulates the production of its own mRNA via a mechanism that involves pre-mRNA binding and inhibition of polyadenylation.	EUROPEAN MOLEC BIOL LAB,W-6900 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)	BOELENS, WC (corresponding author), CATHOLIC UNIV NIJMEGEN,DEPT BIOCHEM,6500 HB NIJMEGEN,NETHERLANDS.		Boelens, Wilbert/D-8877-2012; Jansen, Eric J.R./A-3158-2013	Mattaj, Iain/0000-0002-5537-8284				AMALDI F, 1989, TRENDS BIOCHEM SCI, V14, P175, DOI 10.1016/0968-0004(89)90269-7; BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BENTLEY RC, 1991, MOL CELL BIOL, V11, P1829, DOI 10.1128/MCB.11.4.1829; BINGHAM PM, 1988, TRENDS GENET, V4, P134, DOI 10.1016/0168-9525(88)90136-9; BOELENS W, 1991, NUCLEIC ACIDS RES, V19, P4611, DOI 10.1093/nar/19.17.4611; BOELENS W, 1991, NUCLEIC ACIDS RES, V19, P455, DOI 10.1093/nar/19.3.455; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHRISTOFORI G, 1988, CELL, V54, P875, DOI 10.1016/S0092-8674(88)91263-9; CHU E, 1991, P NATL ACAD SCI USA, V88, P8977, DOI 10.1073/pnas.88.20.8977; DRAPER DE, 1989, TRENDS BIOCHEM SCI, V14, P335, DOI 10.1016/0968-0004(89)90167-9; FEENEY RJ, 1989, J BIOL CHEM, V264, P5776; GALLI G, 1987, GENE DEV, V1, P471, DOI 10.1101/gad.1.5.471; GOLD L, 1988, ANNU REV BIOCHEM, V57, P199, DOI 10.1146/annurev.bi.57.070188.001215; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GUNDERSON SI, 1990, GENE DEV, V4, P2048, DOI 10.1101/gad.4.12a.2048; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HALL KB, 1992, NUCLEIC ACIDS RES, V20, P4283, DOI 10.1093/nar/20.16.4283; HAMM J, 1990, EMBO J, V9, P1237, DOI 10.1002/j.1460-2075.1990.tb08231.x; HEDLEY ML, 1991, CELL, V65, P579, DOI 10.1016/0092-8674(91)90090-L; HEINRICHS V, 1990, SCIENCE, V247, P69, DOI 10.1126/science.2136774; HENTZE MW, 1986, P NATL ACAD SCI USA, V83, P7226, DOI 10.1073/pnas.83.19.7226; HODGKIN J, 1989, CELL, V56, P905, DOI 10.1016/0092-8674(89)90619-3; HOFFMAN DW, 1991, P NATL ACAD SCI USA, V88, P2495, DOI 10.1073/pnas.88.6.2495; HSIEH SY, 1991, J VIROL, V65, P6438, DOI 10.1128/JVI.65.12.6438-6446.1991; HUMPHREY T, 1987, EMBO J, V6, P4159, DOI 10.1002/j.1460-2075.1987.tb02762.x; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; KAMBACH C, 1992, J CELL BIOL, V118, P11, DOI 10.1083/jcb.118.1.11; KANEDA S, 1987, NUCLEIC ACIDS RES, V15, P1259, DOI 10.1093/nar/15.3.1259; KANEDA S, 1990, J BIOL CHEM, V265, P20277; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; LUHRMANN R, 1990, BIOCHIM BIOPHYS ACTA, V1087, P265, DOI 10.1016/0167-4781(90)90001-I; LUTZFREYERMUTH C, 1990, P NATL ACAD SCI USA, V87, P6393, DOI 10.1073/pnas.87.16.6393; LUTZREYERMUTH C, 1989, MOL CELL BIOL, V9, P2975, DOI 10.1128/MCB.9.7.2975; MATTAJ IW, 1989, DEVELOPMENT, V105, P183; MATTAJ IW, 1989, CELL, V57, P1, DOI 10.1016/0092-8674(89)90164-5; MCCUE PA, 1984, J CELL BIOL, V98, P602, DOI 10.1083/jcb.98.2.602; MCKNIGHT SL, 1980, NUCLEIC ACIDS RES, V8, P5931, DOI 10.1093/nar/8.24.5931; MERMOUD JE, 1992, NUCLEIC ACIDS RES, V20, P5263, DOI 10.1093/nar/20.20.5263; MOORE CL, 1985, CELL, V41, P845, DOI 10.1016/S0092-8674(85)80065-9; MOUNT SM, 1983, CELL, V33, P509, DOI 10.1016/0092-8674(83)90432-4; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; NELISSEN RLH, 1991, GENE, V102, P189, DOI 10.1016/0378-1119(91)90077-O; PAPAVASSILIOU AG, 1992, P NATL ACAD SCI USA, V89, P11562, DOI 10.1073/pnas.89.23.11562; PETERSON ML, 1989, MOL CELL BIOL, V9, P726, DOI 10.1128/MCB.9.2.726; REICH CI, 1992, CELL, V69, P1159, DOI 10.1016/0092-8674(92)90637-R; ROSBASH M, 1991, TRENDS BIOCHEM SCI, V16, P187, DOI 10.1016/0968-0004(91)90073-5; SCHERLY D, 1989, EMBO J, V8, P4163, DOI 10.1002/j.1460-2075.1989.tb08601.x; SCHERLY D, 1991, J MOL BIOL, V219, P577, DOI 10.1016/0022-2836(91)90651-L; SCHERLY D, 1990, NATURE, V345, P502, DOI 10.1038/345502a0; SERAPHIN B, 1988, EMBO J, V7, P2533, DOI 10.1002/j.1460-2075.1988.tb03101.x; SILICIANO PG, 1988, GENE DEV, V2, P1258, DOI 10.1101/gad.2.10.1258; SILLEKENS PTG, 1987, EMBO J, V6, P3841, DOI 10.1002/j.1460-2075.1987.tb02721.x; SIMMEN KA, 1992, J MOL BIOL, V223, P873, DOI 10.1016/0022-2836(92)90249-J; SMITH V, 1991, EMBO J, V10, P2627, DOI 10.1002/j.1460-2075.1991.tb07805.x; SPRINGER M, 1989, EMBO J, V8, P2417, DOI 10.1002/j.1460-2075.1989.tb08372.x; TSAI DE, 1991, NUCLEIC ACIDS RES, V19, P4931, DOI 10.1093/nar/19.18.4931; WAHLE E, 1992, ANNU REV BIOCHEM, V61, P419; WELLINGTON C L, 1992, Current Biology, V2, P216, DOI 10.1016/0960-9822(92)90544-K; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F; ZHUANG Y, 1986, CELL, V46, P827, DOI 10.1016/0092-8674(86)90064-4	62	185	189	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 26	1993	72	6					881	892		10.1016/0092-8674(93)90577-D	http://dx.doi.org/10.1016/0092-8674(93)90577-D			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KU175	8458082				2022-12-24	WOS:A1993KU17500009
J	HESS, SD; DOROSHENKO, PA; AUGUSTINE, GJ				HESS, SD; DOROSHENKO, PA; AUGUSTINE, GJ			A FUNCTIONAL-ROLE FOR GTP-BINDING PROTEINS IN SYNAPTIC VESICLE CYCLING	SCIENCE			English	Article							SQUID GIANT SYNAPSE; TRANSMITTER RELEASE; NEUROTRANSMITTER RELEASE; CALCIUM ENTRY; MEMBRANE; TRANSMISSION; EXOCYTOSIS; INHIBITION; MODULATION; DROSOPHILA	The squid giant synapse was used to test the hypothesis that guanosine-5'-triphosphate (GTP)-binding proteins regulate the local distribution of synaptic vesicles within nerve terminals. Presynaptic injection of the nonhydrolyzable GTP analog GTPgammaS irreversibly inhibited neurotransmitter release without changing either the size of the calcium signals produced by presynaptic action potentials or the number of synaptic vesicles docked at presynaptic active zones. Neurotransmitter release was also inhibited by injection of the nonhydrolyzable guanosine diphosphate (GDP) analog GDPbetaS but not by injection of AlF4-. These results suggest that a small molecular weight GTP-binding protein directs the docking of synaptic vesicles that occurs before calcium-dependent neurotransmitter release. Depletion of undocked synaptic vesicles by GTPgammaS indicates that additional GTP-binding proteins function in the terminal at other steps responsible for synaptic vesicle replenishment.	DUKE UNIV, MED CTR, DEPT NEUROBIOL, POB 3209, DURHAM, NC 27710 USA; UNIV SO CALIF, DEPT BIOL SCI, LOS ANGELES, CA 90089 USA; MARINE BIOL LAB, WOODS HOLE, MA 02543 USA; KIEV PHYSIOL INST, KIEV, UKRAINE; MAX PLANCK INST BIOPHYS CHEM, W-3400 GOTTINGEN, GERMANY	Duke University; University of Southern California; Marine Biological Laboratory - Woods Hole; Max Planck Society			Augustine, George James/J-9228-2013		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021624] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-21624] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADLER EM, 1991, J NEUROSCI, V11, P1496; ARAKI S, 1990, J BIOL CHEM, V265, P13007; AUGUSTINE GJ, 1990, J PHYSIOL-LONDON, V431, P343, DOI 10.1113/jphysiol.1990.sp018333; AUGUSTINE GJ, 1985, J PHYSIOL-LONDON, V367, P143, DOI 10.1113/jphysiol.1985.sp015818; AUGUSTINE GJ, 1984, J PHYSIOL-LONDON, V346, P257, DOI 10.1113/jphysiol.1984.sp015020; AUGUSTINE GJ, 1985, J PHYSIOL-LONDON, V367, P163, DOI 10.1113/jphysiol.1985.sp015819; AUGUSTINE GJ, 1987, ANNU REV NEUROSCI, V10, P633, DOI 10.1146/annurev.ne.10.030187.003221; BALCH W E, 1992, Current Biology, V2, P157, DOI 10.1016/0960-9822(92)90276-G; BALCH WE, 1989, J BIOL CHEM, V264, P16965; BETZ WJ, 1992, SCIENCE, V255, P200, DOI 10.1126/science.1553547; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BROOKS JC, 1984, LIFE SCI, V35, P569, DOI 10.1016/0024-3205(84)90251-0; CHARLTON MP, 1982, J PHYSIOL-LONDON, V323, P173, DOI 10.1113/jphysiol.1982.sp014067; CHARLTON MP, 1988, J NEUROSCI METH, V22, P195, DOI 10.1016/0165-0270(88)90040-4; CHIN GJ, 1992, BRAIN RES, V571, P89, DOI 10.1016/0006-8993(92)90512-8; COLOMBO MI, 1992, SCIENCE, V255, P1695, DOI 10.1126/science.1348148; DOLPHIN AC, 1991, ANN NY ACAD SCI, V635, P139, DOI 10.1111/j.1749-6632.1991.tb36488.x; DOLPHIN AC, 1988, PFLUG ARCH EUR J PHY, V411, P628, DOI 10.1007/BF00580858; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOMPERTS BD, 1990, ANNU REV PHYSIOL, V52, P591; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HAYDON PG, 1991, J NEUROSCI, V11, P3851; HEUSER JE, 1973, J CELL BIOL, V57, P315, DOI 10.1083/jcb.57.2.315; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KATZ B, 1967, J PHYSIOL-LONDON, V192, P407, DOI 10.1113/jphysiol.1967.sp008307; Katz B., 1969, RELEASE NEURAL TRANS, P33; KOSAKA T, 1983, J NEUROBIOL, V14, P207, DOI 10.1002/neu.480140305; LIPSCOMBE D, 1989, NATURE, V340, P639, DOI 10.1038/340639a0; LLINAS R, 1982, P NATL ACAD SCI-BIOL, V79, P2415, DOI 10.1073/pnas.79.7.2415; LLINAS R, 1991, J PHYSIOL-LONDON, V436, P257, DOI 10.1113/jphysiol.1991.sp018549; MARTIN R, 1986, PHILOS T R SOC B, V312, P355, DOI 10.1098/rstb.1986.0013; MATSUI Y, 1988, J BIOL CHEM, V263, P11071; MATTEOLI M, 1991, J CELL BIOL, V115, P625, DOI 10.1083/jcb.115.3.625; NGSEE JK, 1990, J NEUROSCI, V10, P317; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; PUMPLIN DW, 1978, NEUROSCIENCE, V3, P685, DOI 10.1016/0306-4522(78)90065-9; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SANCHEZ ME, 1990, J EXP BIOL, V152, P369; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; SWANDULLA D, 1991, NEURON, V7, P915, DOI 10.1016/0896-6273(91)90337-Y; VALTORTA F, 1990, NEUROSCIENCE, V35, P477, DOI 10.1016/0306-4522(90)90323-V; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; VONMOLLARD GF, 1991, NATURE, V349, P79, DOI 10.1038/349079a0; ZIPSER K, 1991, Biophysical Journal, V59, p594A	47	112	113	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 19	1993	259	5098					1169	1172		10.1126/science.8438167	http://dx.doi.org/10.1126/science.8438167			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KM917	8438167				2022-12-24	WOS:A1993KM91700041
J	JUNG, S; RAJEWSKY, K; RADBRUCH, A				JUNG, S; RAJEWSKY, K; RADBRUCH, A			SHUTDOWN OF CLASS SWITCH RECOMBINATION BY DELETION OF A SWITCH REGION CONTROL ELEMENT	SCIENCE			English	Article							IMMUNOGLOBULIN HEAVY-CHAIN; MURINE B-CELLS; SACCHAROMYCES-CEREVISIAE; INITIATION SITE; STEM-CELLS; GENE; INTERLEUKIN-4; INDUCTION; MOUSE; TRANSCRIPTS	Upon activation, B lymphocytes can change the class of the antibody they express by immunoglobulin class switch recombination. Cytokines can direct this recombination to distinct classes by the specific activation of repetitive recombinogenic DNA sequences, the switch regions. Recombination to a particular switch region (s(gamma)1) was abolished in mice that were altered to lack sequences that are 5' to the s(gamma)1 region. This result directly implicates the functional importance of 5' switch region flanking sequences in the control of class switch recombination. Mutant mice exhibit a selective agammaglobulinemia and may be useful in the assessment of the biological importance of immunoglobulin G1.			JUNG, S (corresponding author), UNIV COLOGNE,INST GENET,W-5000 COLOGNE 41,GERMANY.		Jung, Steffen/K-1409-2012	Jung, Steffen/0000-0003-4290-5716; Radbruch, Andreas/0000-0001-5753-0000				BERGSTEDTLINDQVIST S, 1988, EUR J IMMUNOL, V18, P1073, DOI 10.1002/eji.1830180716; BERTON MT, 1989, P NATL ACAD SCI USA, V86, P2829, DOI 10.1073/pnas.86.8.2829; BROACH JR, 1980, CELL, V21, P501, DOI 10.1016/0092-8674(80)90487-0; BURGER C, 1990, EUR J IMMUNOL, V20, P2285, DOI 10.1002/eji.1830201018; ESSER C, 1989, EMBO J, V8, P483, DOI 10.1002/j.1460-2075.1989.tb03401.x; ESSER C, 1990, ANNU REV IMMUNOL, V8, P717, DOI 10.1146/annurev.iy.08.040190.003441; FERRIER P, 1990, EMBO J, V9, P117, DOI 10.1002/j.1460-2075.1990.tb08087.x; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; ILLGES H, 1992, MOL IMMUNOL, V29, P1265, DOI 10.1016/0161-5890(92)90063-4; ISAKSON PC, 1982, J EXP MED, V155, P734, DOI 10.1084/jem.155.3.734; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; LEBMAN DA, 1990, J IMMUNOL, V144, P952; LEUNG H, 1992, P NATL ACAD SCI USA, V89, P4154, DOI 10.1073/pnas.89.9.4154; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MILLS FC, 1992, J IMMUNOL, V149, P1075; MOWATT MR, 1986, J IMMUNOL, V136, P2674; NICOLAS A, 1989, NATURE, V338, P35, DOI 10.1038/338035a0; OGORMAN S, 1991, SCIENCE, V251, P1351, DOI 10.1126/science.1900642; RADBRUCH A, 1986, P NATL ACAD SCI USA, V83, P3954, DOI 10.1073/pnas.83.11.3954; ROTHMAN P, 1988, J EXP MED, V168, P2385, DOI 10.1084/jem.168.6.2385; ROTHMAN P, 1990, INT IMMUNOL, V2, P621, DOI 10.1093/intimm/2.7.621; Schmitz J, 1989, Int Immunol, V1, P570, DOI 10.1093/intimm/1.6.570; SCHULTES NP, 1991, MOL CELL BIOL, V11, P322, DOI 10.1128/MCB.11.1.322; SCHULTZ CL, 1992, J IMMUNOL, V149, P60; SEVERINSON E, 1990, EUR J IMMUNOL, V20, P1079, DOI 10.1002/eji.1830200520; SHIMIZU A, 1982, CELL, V28, P499, DOI 10.1016/0092-8674(82)90204-5; SIEBENKOTTEN G, 1992, EUR J IMMUNOL, V22, P1827, DOI 10.1002/eji.1830220723; STAVNEZERNORDGREN J, 1986, EMBO J, V5, P95, DOI 10.1002/j.1460-2075.1986.tb04182.x; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; VOELKELMEIMAN K, 1987, CELL, V48, P1071, DOI 10.1016/0092-8674(87)90714-8; WILLIAMS RL, 1988, NATURE, V336, P685; Xu M, 1990, Dev Immunol, V1, P11, DOI 10.1155/1990/47659; XU MZ, 1992, EMBO J, V11, P145, DOI 10.1002/j.1460-2075.1992.tb05037.x; YANCOPOULOS GD, 1986, EMBO J, V5, P3259, DOI 10.1002/j.1460-2075.1986.tb04637.x	35	312	334	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 12	1993	259	5097					984	987		10.1126/science.8438159	http://dx.doi.org/10.1126/science.8438159			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL800	8438159				2022-12-24	WOS:A1993KL80000047
J	NANAVATI, C; FERNANDEZ, JM				NANAVATI, C; FERNANDEZ, JM			THE SECRETORY GRANULE MATRIX - A FAST-ACTING SMART POLYMER	SCIENCE			English	Article							MAST-CELLS; FUSION PORE; GELS; EXOCYTOSIS; VESICLE	The secretory granule matrix is a miniature biopolymer that consists of a charged polymer network that traps peptides and transmitters when it condenses and releases them on exocytotic decondensation. Models of exocytotic fusion have treated this matrix as a short circuit and have neglected its electrical contributions. This matrix responded to negative voltages by swelling, which was accompanied by a large increase in conductance, and to positive voltages by condensing. Thus, the matrix resembled a diode. The swollen matrix exerted large pressures on the order of 12 bar. The responses took place within milliseconds of the application of the electric field. These findings suggest that matrix decondensation, and therefore product release, is controlled by potential gradients.	MAYO CLIN & MAYO FDN,DEPT PHYSIOL & BIOPHYS,ROCHESTER,MN 55905	Mayo Clinic								ALMERS W, 1990, ANNU REV PHYSIOL, V52, P607, DOI 10.1146/annurev.ph.52.030190.003135; BRECKENRIDGE LJ, 1987, P NATL ACAD SCI USA, V84, P1945, DOI 10.1073/pnas.84.7.1945; BRECKENRIDGE LJ, 1987, NATURE, V328, P814, DOI 10.1038/328814a0; CURRAN MJ, 1991, J GEN PHYSIOL, V98, P771, DOI 10.1085/jgp.98.4.771; FERNANDEZ JM, 1991, BIOPHYS J, V59, P1022, DOI 10.1016/S0006-3495(91)82317-7; FERNANDEZ JM, 1984, NATURE, V312, P453, DOI 10.1038/312453a0; KAJIWARA K, 1992, NATURE, V355, P208, DOI 10.1038/355208a0; KWON IC, 1991, NATURE, V354, P291, DOI 10.1038/354291a0; MONCK JR, 1991, BIOPHYS J, V59, P39, DOI 10.1016/S0006-3495(91)82196-8; NANAVATI C, 1992, BIOPHYS J, V63, P1118, DOI 10.1016/S0006-3495(92)81679-X; NIELSEN EH, 1990, J CELL SCI, V96, P43; OSADA Y, 1992, NATURE, V355, P242, DOI 10.1038/355242a0; Osada Y., 1991, POLYM GELS FUNDAMENT; STEINBERG IZ, 1966, NATURE, V210, P568, DOI 10.1038/210568a0; TAM PY, 1981, NATURE, V292, P340, DOI 10.1038/292340a0; TANAKA T, 1981, SCI AM, V244, P124, DOI 10.1038/scientificamerican0181-124; TANAKA T, 1982, SCIENCE, V218, P467, DOI 10.1126/science.218.4571.467; TANAKA T, 1979, J CHEM PHYS, V70, P1214, DOI 10.1063/1.437602; [No title captured]	19	111	117	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 12	1993	259	5097					963	965		10.1126/science.8438154	http://dx.doi.org/10.1126/science.8438154			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL800	8438154				2022-12-24	WOS:A1993KL80000040
J	GLANTZ, SA				GLANTZ, SA			REMOVING THE INCENTIVE TO SELL KIDS TOBACCO - A PROPOSAL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CHILDREN; CAMEL		UNIV CALIF SAN FRANCISCO,DEPT MED,DIV CARDIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,INST HLTH POLICY STUDIES,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	GLANTZ, SA (corresponding author), UNIV CALIF SAN FRANCISCO,MOFFITT HOSP,DEPT MED,DIV CARDIOL,ROOM 1186,SAN FRANCISCO,CA 94143, USA.							BEGAY M, 1991, U CALIFORNIA I HLTH; DIFRANZA JR, 1990, JAMA-J AM MED ASSOC, V263, P2784, DOI 10.1001/jama.263.20.2784; DIFRANZA JR, 1991, JAMA-J AM MED ASSOC, V266, P3149, DOI 10.1001/jama.266.22.3149; FISCHER PM, 1991, JAMA-J AM MED ASSOC, V266, P3145, DOI 10.1001/jama.266.22.3145; PIERCE J P, 1992, Morbidity and Mortality Weekly Report, V41, P485; PIERCE JP, 1991, JAMA-J AM MED ASSOC, V266, P3154, DOI 10.1001/jama.266.22.3154; Slade J, 1988, N J Med, V85, P102; SWEANOR DT, 1991, TAX BURDEN TOBACCO A; Tye J B, 1987, J Public Health Policy, V8, P492, DOI 10.2307/3342275; GAOHRD89119 US GEN A	10	12	12	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 10	1993	269	6					793	794		10.1001/jama.269.6.793	http://dx.doi.org/10.1001/jama.269.6.793			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK544	8423664				2022-12-24	WOS:A1993KK54400035
J	WELLINGER, RJ; WOLF, AJ; ZAKIAN, VA				WELLINGER, RJ; WOLF, AJ; ZAKIAN, VA			SACCHAROMYCES TELOMERES ACQUIRE SINGLE-STRAND TG(1-3) TAILS LATE IN S-PHASE	CELL			English	Article							DNA-SEQUENCES; YEAST CHROMOSOMES; REPLICATION ORIGINS; CEREVISIAE; GENE; PLASMID; TRANSFORMATION; CENTROMERES; EXPRESSION; ELEMENTS	Saccharomyces telomeres consist of approximately 300 bp of C1-3A/TG1-3 DNA. Nondenaturing Southern hybridization, capable of detecting approximately 60 to approximately 300 bases of TG1-3 DNA, revealed that yeast telomeres acquired and lost TG1-3 tails, the predicted intermediate in telomere replication, in a cell cycle-dependent manner. TG1-3 tails were also detected on the ends of a linear plasmid isolated from late S phase cells. In addition, a nonlinear form of this plasmid was detected: this structure migrated in two-dimensional agarose gels like a nicked circle of the same size as the linear plasmid, but had considerably more single-stranded character than a conventional nicked circle. The evidence indicates that these circles were formed by telomere-telomere interactions involving the TG1-3 tails. These data provide evidence for a cell cycle-dependent change in telomere structure and demonstrate that TG1-3 tails, generated during replication of a linear plasmid in vivo, are capable of mediating telomere-telomere interactions.	UNIV WASHINGTON,SEATTLE,WA 98104	University of Washington; University of Washington Seattle	WELLINGER, RJ (corresponding author), FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104, USA.		Wellinger, Raymund/K-3207-2019	Wellinger, Raymund/0000-0001-6670-2759	NIGMS NIH HHS [GM26938] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM026938, R01GM026938] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACEVEDO OL, 1991, NUCLEIC ACIDS RES, V19, P3409, DOI 10.1093/nar/19.12.3409; ANDREADIS A, 1984, J BIOL CHEM, V259, P8059; BERNARDS A, 1983, NATURE, V303, P592, DOI 10.1038/303592a0; BLAKCBURN EH, 1992, ANN REV BIOCH, V61, P113; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BREWER BJ, 1992, CELL, V71, P267, DOI 10.1016/0092-8674(92)90355-G; CASADABAN MJ, 1983, METHOD ENZYMOL, V100, P293; CHAN CSM, 1983, CELL, V33, P563, DOI 10.1016/0092-8674(83)90437-3; CONRAD MN, 1990, CELL, V63, P739, DOI 10.1016/0092-8674(90)90140-A; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FERGUSON BM, 1991, CELL, V65, P507, DOI 10.1016/0092-8674(91)90468-E; GREIDER CW, 1991, MOL CELL BIOL, V11, P4572, DOI 10.1128/MCB.11.9.4572; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HARRINGTON LA, 1991, NATURE, V353, P451, DOI 10.1038/353451a0; HARTLEY JL, 1980, NATURE, V286, P860, DOI 10.1038/286860a0; HENDERSON E, 1987, CELL, V51, P899, DOI 10.1016/0092-8674(87)90577-0; HENIKOFF S, 1987, GENETICS, V117, P711; HOROWITZ H, 1984, NUCLEIC ACIDS RES, V12, P7105, DOI 10.1093/nar/12.18.7105; HUBERMAN JA, 1987, CELL, V51, P473, DOI 10.1016/0092-8674(87)90643-X; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHNSTON RF, 1990, ELECTROPHORESIS, V11, P355, DOI 10.1002/elps.1150110503; KERR C, 1972, J BIOL CHEM, V247, P311; KROEKER WD, 1978, BIOCHEMISTRY-US, V17, P3236, DOI 10.1021/bi00609a010; LARSON DD, 1987, CELL, V50, P477, DOI 10.1016/0092-8674(87)90501-0; LEHMAN IR, 1964, J BIOL CHEM, V239, P2628; LIVINGSTON DM, 1977, J MOL BIOL, V116, P249, DOI 10.1016/0022-2836(77)90215-7; LOUIS EJ, 1990, GENETICS, V124, P533; LUSTIG AJ, 1992, NUCLEIC ACIDS RES, V20, P3021, DOI 10.1093/nar/20.12.3021; MCCARROLL RM, 1988, CELL, V54, P505, DOI 10.1016/0092-8674(88)90072-4; MCNEIL JB, 1981, MOL GEN GENET, V184, P386, DOI 10.1007/BF00352510; MURRAY AW, 1988, MOL CELL BIOL, V8, P4642, DOI 10.1128/MCB.8.11.4642; NEWLON CS, 1988, MICROBIOL REV, V52, P568, DOI 10.1128/MMBR.52.4.568-601.1988; NEWLON CS, 1974, NATURE, V247, P32, DOI 10.1038/247032a0; PLUTA AF, 1989, NATURE, V337, P429, DOI 10.1038/337429a0; REYNOLDS AE, 1989, MOL CELL BIOL, V9, P4488, DOI 10.1128/MCB.9.10.4488; RUNGE KW, 1991, MOL CELL BIOL, V11, P2919, DOI 10.1128/MCB.11.6.2919; RUNGE KW, 1989, MOL CELL BIOL, V9, P1488, DOI 10.1128/MCB.9.4.1488; Sambrook J., 1989, MOL CLONING LAB MANU; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SEN D, 1990, NATURE, V344, P410, DOI 10.1038/344410a0; SHAMPAY J, 1984, NATURE, V310, P154, DOI 10.1038/310154a0; STINCHCOMB DT, 1982, J MOL BIOL, V158, P157, DOI 10.1016/0022-2836(82)90427-2; STINCHCOMB DT, 1980, P NATL ACAD SCI-BIOL, V77, P4559, DOI 10.1073/pnas.77.8.4559; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; SUTCLIFFE JG, 1978, NUCLEIC ACIDS RES, V5, P2721, DOI 10.1093/nar/5.8.2721; WAHL GM, 1987, METHOD ENZYMOL, V152, P572; WALMSLEY RM, 1984, NATURE, V310, P157, DOI 10.1038/310157a0; WANG SS, 1990, MOL CELL BIOL, V10, P4415, DOI 10.1128/MCB.10.8.4415; WANG SS, 1990, NATURE, V345, P456, DOI 10.1038/345456a0; WELLINGER RJ, 1989, P NATL ACAD SCI USA, V86, P973, DOI 10.1073/pnas.86.3.973; WELLINGER RJ, 1992, IN PRESS CHROMOSOMA, V102; WELLINGER RJ, 1993, IN PRESS CHROMOSOME; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; ZAKIAN VA, 1982, MOL CELL BIOL, V2, P221, DOI 10.1128/MCB.2.3.221; ZAKIAN VA, 1989, ANNU REV GENET, V23, P579, DOI 10.1146/annurev.genet.23.1.579; ZAKIAN VA, 1990, TRENDS GENET, V6, P12, DOI 10.1016/0168-9525(90)90043-6	56	356	368	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 15	1993	72	1					51	60		10.1016/0092-8674(93)90049-V	http://dx.doi.org/10.1016/0092-8674(93)90049-V			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KG955	8422682				2022-12-24	WOS:A1993KG95500009
J	CARTER, NS; FAIRLAMB, AH				CARTER, NS; FAIRLAMB, AH			ARSENICAL-RESISTANT TRYPANOSOMES LACK AN UNUSUAL ADENOSINE TRANSPORTER	NATURE			English	Article							AFRICAN TRYPANOSOMES; NUCLEOSIDE TRANSPORTERS; LEISHMANIA-DONOVANI; BRUCEI; DRUGS; TRYPANOTHIONE; ALLOPURINOL; METABOLISM; PURINE; CELLS	THE melaminophenyl arsenical melarsoprol is still used to treat African sleeping sickness1-3, a disease caused by parasitic protozoa of the Trypanosoma brucei subgroup. Based on the observation that melamine antagonizes the trypanocidal activity of this class of drugs4, we investigated whether other physiological compounds could compete for the same receptor. Here we report that the in vitro trypanolytic effect of melarsen oxide can be specifically abrogated by adenine, adenosine and dipyridamole, all of which compete for uptake by an adenosine transporter. Melarsen-sensitive trypanosomes have two high-affinity adenosine transport systems: a P1 type, which also transports inosine; and a P2 type, which also transports adenine and the melaminophenyl arsenicals, Melarsen-resistant trypanosomes lack P2 adenosine transport, suggesting that resistance to these arsenicals is due to loss of uptake.	UNIV LONDON LONDON SCH HYG & TROP MED, DEPT MED PARASITOL, KEPPEL ST, LONDON WC1E 7HT, ENGLAND	University of London; London School of Hygiene & Tropical Medicine			Fairlamb, Alan/A-5272-2009	Fairlamb, Alan/0000-0001-5134-0329	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		APTED FIC, 1980, PHARMACOL THERAPEUT, V11, P391, DOI 10.1016/0163-7258(80)90035-2; ARONOW B, 1987, MOL BIOCHEM PARASIT, V22, P29, DOI 10.1016/0166-6851(87)90066-1; ARONOW B, 1985, J BIOL CHEM, V260, P6226; BAER HP, 1992, AM J TROP MED HYG, V47, P87, DOI 10.4269/ajtmh.1992.47.87; CLARKSON AB, 1976, SCIENCE, V194, P204, DOI 10.1126/science.986688; DANSON MJ, 1987, BIOCHEM J, V243, P661, DOI 10.1042/bj2430661; Ehrlich P., 1956, COLLECTED PAPERS P E, P596; Fairlamb A. H., 1986, Carbohydrate metabolism in cultured cells., P183; FAIRLAMB AH, 1989, PARASITOLOGY, V99, pS93, DOI 10.1017/S003118200008344X; FAIRLAMB AH, 1985, SCIENCE, V227, P1485, DOI 10.1126/science.3883489; FAIRLAMB AH, 1977, NATURE, V265, P270, DOI 10.1038/265270a0; FAIRLAMB AH, 1992, MOL BIOCHEM PARASIT, V53, P223, DOI 10.1016/0166-6851(92)90024-E; FAIRLAMB AH, 1992, MOL BIOCHEM PARASIT, V53, P213, DOI 10.1016/0166-6851(92)90023-D; FAIRLAMB AH, 1989, P NATL ACAD SCI USA, V86, P2607, DOI 10.1073/pnas.86.8.2607; FINLEY RW, 1988, MOL BIOCHEM PARASIT, V31, P133, DOI 10.1016/0166-6851(88)90164-8; FLYNN IW, 1974, COMP BIOCHEM PHYSIOL, V48, P261, DOI 10.1016/0305-0491(74)90203-X; FRIEDHEIM EAH, 1949, AM J TROP MED, V29, P173; HALLER L, 1986, AM J TROP MED HYG, V35, P94, DOI 10.4269/ajtmh.1986.35.94; HAMMOND DJ, 1984, MOL BIOCHEM PARASIT, V13, P243, DOI 10.1016/0166-6851(84)90117-8; Hawking F., 1938, Annals of Tropical Medicine and Parasitology, V32, P313; HAWKING F, 1966, EXPT CHEMOTHERAPY, V1, P129; HOEIJMAKERS JHJ, 1980, GENE, V8, P391, DOI 10.1016/0378-1119(80)90043-8; JAMES DM, 1980, PARASITOLOGY, V81, P383, DOI 10.1017/S0031182000056110; LANHAM SM, 1968, NATURE, V218, P1273, DOI 10.1038/2181273a0; MARR JJ, 1978, SCIENCE, V201, P1018, DOI 10.1126/science.356267; MESHNICK SR, 1978, J EXP MED, V148, P569, DOI 10.1084/jem.148.2.569; NELSON DJ, 1979, J BIOL CHEM, V254, P1544; OGBUNUDE POJ, 1991, EXP PARASITOL, V73, P369, DOI 10.1016/0014-4894(91)90109-A; OKOCHI VI, 1983, BIOCHEM INT, V6, P129; PLAGEMANN PGW, 1988, BIOCHIM BIOPHYS ACTA, V947, P405, DOI 10.1016/0304-4157(88)90002-0; RICHARME G, 1985, J BACTERIOL, V162, P286, DOI 10.1128/JB.162.1.286-293.1985; VANSCHAFTINGEN E, 1987, EUR J BIOCHEM, V166, P653; WERY M, 1991, CURR OPIN INFECT DIS, V4, P838, DOI 10.1097/00001432-199112000-00020; WILLIAMSON J, 1959, BRIT J PHARM CHEMOTH, V14, P431, DOI 10.1111/j.1476-5381.1959.tb00947.x	34	307	312	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 14	1993	361	6408					173	176		10.1038/361173a0	http://dx.doi.org/10.1038/361173a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KG466	8421523				2022-12-24	WOS:A1993KG46600066
J	MURPHY, TV; WHITE, KE; PASTOR, P; GABRIEL, L; MEDLEY, F; GRANOFF, DM; OSTERHOLM, MT				MURPHY, TV; WHITE, KE; PASTOR, P; GABRIEL, L; MEDLEY, F; GRANOFF, DM; OSTERHOLM, MT			DECLINING INCIDENCE OF HAEMOPHILUS-INFLUENZAE TYPE-B DISEASE SINCE INTRODUCTION OF VACCINATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							POLYSACCHARIDE VACCINE; HEMOPHILUS; CHILDREN; MINNESOTA; EFFICACY	Objective.-To determine the incidence of invasive Haemophilus influenzae type b disease in children living in Minnesota and Dallas County, Texas, before and since introduction of plain polysaccharide vaccine in 1985, and conjugate vaccine in 1988. Initially, use of these vaccines was limited to infants 18 months of age and older. Design.-Identification of culture-proven cases of H influenzae type b disease was through systems of active, laboratory-based surveillance. The mean incidence of disease (cases observed/100 000 child-years) for 1983 and 1984 served as a baseline for comparison with subsequent years through 1991. Participants.-Children less than 5 years of age in Minnesota and Dallas County, Texas. Overall, there were 2557 confirmed age-eligible cases of invasive H influenzae type b disease from 1983 through 1991. Results.-Between the 1983-1984 baseline and 1991, the incidence of H influenzae type b disease decreased 85% in Minnesota and 92% in Dallas. Notably, declines in incidence were observed in children in the age group being vaccinated as well as in infants younger than 18 months of age prior to introduction of vaccination. Conclusion.-In two widely separated areas of the United States, a profound decrease in the incidence of H influenzae type b disease has occurred. The data suggest that vaccination may be protecting against disease, as well as decreasing the spread of infection to unvaccinated infants.	MINNESOTA DEPT HLTH,ACUTE DIS EPIDEMIOL SECT,MINNEAPOLIS,MN; ST LOUIS CHILDRENS HOSP,ST LOUIS,MO 63178; WASHINGTON UNIV,SCH MED,DEPT PEDIAT,DIV INFECT DIS,ST LOUIS,MO 63110	Minnesota Department of Health (MHD); St. Louis Children's Hospital; Washington University (WUSTL); Washington University (WUSTL)	MURPHY, TV (corresponding author), UNIV TEXAS,SW MED CTR,DEPT PEDIAT,5323 HARRY HINES BLVD,DALLAS,TX 75235, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021842] Funding Source: NIH RePORTER; NIAID NIH HHS [R0 1 AI21842] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		FLEISCHER GR, 1992, PEDIATR RES, V31, P161; GRANOFF DM, 1989, J INFECT DIS, V159, P908, DOI 10.1093/infdis/159.5.908; GRANOFF DM, 1984, CURRENT CLIN TOPICS, V5, P290; HINMAN AR, 1979, PEDIATR RES, V13, P689, DOI 10.1203/00006450-197905001-00007; JAFFE DM, 1987, NEW ENGL J MED, V317, P1175, DOI 10.1056/NEJM198711053171902; LI KI, 1987, PEDIATR INFECT DIS J, V6, P303, DOI 10.1097/00006454-198703000-00028; MURPHY TV, 1987, PEDIATRICS, V79, P173; MURPHY TV, 1992, J INFECT DIS, V165, pS7, DOI 10.1093/infdis/165-Supplement_1-S7; MURPHY TV, 1991, 31ST INT C ANT AG CH; OSTERHOLM MT, 1988, JAMA-J AM MED ASSOC, V260, P1423, DOI 10.1001/jama.260.10.1423; PELTOLA H, 1977, PEDIATRICS, V60, P730; SHAPIRO ED, 1991, EPIDEMIOL REV, V13, P113, DOI 10.1093/oxfordjournals.epirev.a036066; SHAPIRO ED, 1988, JAMA-J AM MED ASSOC, V260, P1419, DOI 10.1001/jama.260.10.1419; TAKALA AK, 1991, J INFECT DIS, V164, P982, DOI 10.1093/infdis/164.5.982	14	177	178	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 13	1993	269	2					246	248		10.1001/jama.269.2.246	http://dx.doi.org/10.1001/jama.269.2.246			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF405	8417244				2022-12-24	WOS:A1993KF40500032
J	THERIAULT, Y; LOGAN, TM; MEADOWS, R; YU, LP; OLEJNICZAK, ET; HOLZMAN, TF; SIMMER, RL; FESIK, SW				THERIAULT, Y; LOGAN, TM; MEADOWS, R; YU, LP; OLEJNICZAK, ET; HOLZMAN, TF; SIMMER, RL; FESIK, SW			SOLUTION STRUCTURE OF THE CYCLOSPORINE-A CYCLOPHILIN COMPLEX BY NMR	NATURE			English	Article							CIS-TRANS ISOMERASE; BINDING-PROTEIN; CONFORMATION	CYCLOSPORIN A, a cyclic undecapeptide, is a potent immunosuppressant that binds to a peptidyl-prolyl cis-trans isomerase1,2 of 165 amino acids, cyclophilin3. The cyclosporin A/cyclophilin complex inhibits the calcium- and calmodulin-dependent phosphatase, calcineurin4, resulting in a failure to activate genes encoding interleukin-2 and other lymphokines5,6. The three-dimensional structures of uncomplexed cyclophilin7, a tetrapeptide/cyclophilin complex8,9, and cyclosporin A when bound to cyclophilin10,11 have been reported. However, the structure of the cyclosporin A/cyclophilin complex has not been determined. Here we present the solution structure of the cyclosporin A/cyclophilin complex obtained by heteronuclear three-dimensional NMR spectroscopy. The structure, one of the largest determined by NMR, differs from proposed models of the complex12-14 and is analysed in terms of the binding interactions and structure/activity relationships for CsA analogues15,16.	ABBOTT LABS,DIV PHARMACEUT DISCOVERY,ABBOTT PK,IL 60064	Abbott Laboratories				Yu, Liping/0000-0003-3536-6427				ALTSCHUH D, 1992, SCIENCE, V256, P92, DOI 10.1126/science.1566062; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; FESIK SW, 1991, BIOCHEMISTRY-US, V30, P6574, DOI 10.1021/bi00240a030; FESIK SW, 1992, J AM CHEM SOC, V114, P3165, DOI 10.1021/ja00034a087; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; GALLION S, 1992, PROTEIN ENG, V5, P391, DOI 10.1093/protein/5.5.391; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HARRISON RK, 1990, BIOCHEMISTRY-US, V29, P1684, DOI 10.1021/bi00459a003; JAMES MNG, 1982, P NATL ACAD SCI-BIOL, V79, P6137, DOI 10.1073/pnas.79.20.6137; KALLEN J, 1992, FEBS LETT, V300, P286, DOI 10.1016/0014-5793(92)80865-E; KALLEN J, 1991, NATURE, V353, P276, DOI 10.1038/353276a0; KE HM, 1991, P NATL ACAD SCI USA, V88, P9483, DOI 10.1073/pnas.88.21.9483; KESSLER H, 1990, HELV CHIM ACTA, V73, P1818, DOI 10.1002/hlca.19900730703; KOFRON JL, 1992, J AM CHEM SOC, V114, P2670, DOI 10.1021/ja00033a047; KUSZEWSKI J, 1992, J BIOMOL NMR, V2, P33, DOI 10.1007/BF02192799; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; LOOSLI HR, 1985, HELV CHIM ACTA, V68, P682, DOI 10.1002/hlca.19850680319; NERI D, 1989, BIOCHEMISTRY-US, V28, P7510, DOI 10.1021/bi00445a003; NERI P, 1991, FEBS LETT, V294, P81, DOI 10.1016/0014-5793(91)81348-C; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; QUESNIAUX VFJ, 1987, EUR J IMMUNOL, V17, P1359, DOI 10.1002/eji.1830170921; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SIGAL NH, 1991, J EXP MED, V173, P619, DOI 10.1084/jem.173.3.619; SPITZFADEN C, 1992, FEBS LETT, V300, P291, DOI 10.1016/0014-5793(92)80866-F; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; WEBER C, 1991, BIOCHEMISTRY-US, V30, P6563, DOI 10.1021/bi00240a029; WUTHRICH K, 1991, FEBS LETT, V285, P237, DOI 10.1016/0014-5793(91)80808-G	31	175	181	9	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 7	1993	361	6407					88	91		10.1038/361088a0	http://dx.doi.org/10.1038/361088a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KF718	8421500				2022-12-24	WOS:A1993KF71800056
J	SCHUTT, CE; MYSLIK, JC; ROZYCKI, MD; GOONESEKERE, NCW; LINDBERG, U				SCHUTT, CE; MYSLIK, JC; ROZYCKI, MD; GOONESEKERE, NCW; LINDBERG, U			THE STRUCTURE OF CRYSTALLINE PROFILIN BETA-ACTIN	NATURE			English	Article								The three-dimensional structure of bovine profilin-beta-actin has been solved to 2.55 angstrom resolution by X-ray crystallography. There are several significant local changes in the structure of beta-actin compared with alpha-actin as well as an overall 5-degrees rotation between its two major domains. Actin molecules in the crystal are organized into ribbons through intermolecular contacts like those found in oligomeric protein assemblies. Profilin forms two extensive contacts with the actin ribbon, one of which appears to correspond to the solution contact in vitro.	UNIV STOCKHOLM,ARRHENIUS LABS NAT SCI,WGI,DEPT ZOOL CELL BIOL,S-10691 STOCKHOLM,SWEDEN	Stockholm University	SCHUTT, CE (corresponding author), PRINCETON UNIV,HENRY H HOYT LAB,DEPT CHEM,PRINCETON,NJ 08544, USA.							AMPE C, 1988, FEBS LETT, V228, P17, DOI 10.1016/0014-5793(88)80575-1; ASPENSTROM P, 1993, FEBS LETT, V329, P163, DOI 10.1016/0014-5793(93)80215-G; BENNETT WS, 1980, J MOL BIOL, V140, P211, DOI 10.1016/0022-2836(80)90103-5; BJORKEGREN C, IN PRESS FEBS LETT; BRAY D, 1976, J MOL BIOL, V105, P527, DOI 10.1016/0022-2836(76)90233-3; BRUNGER AT, 1992, XPLOR V 30 MANUAL; CARLSSON L, 1976, J MOL BIOL, V105, P353, DOI 10.1016/0022-2836(76)90098-X; CARLSSON L, 1977, J MOL BIOL, V115, P465, DOI 10.1016/0022-2836(77)90166-8; CARLSSON L, 1979, THESIS UPPSALA U SWE; FINZEL BC, 1990, CRYSTALLOGRAPHIC MOD, P175; GOLDSCHMIDTCLERMONT PJ, 1991, J CELL BIOL, V113, P1081, DOI 10.1083/jcb.113.5.1081; GOLDSCHMIDTCLERMONT PJ, 1990, SCIENCE, V247, P1575, DOI 10.1126/science.2157283; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; JANIN J, 1990, J BIOL CHEM, V265, P16027; JANIN J, 1988, J MOL BIOL, V204, P155, DOI 10.1016/0022-2836(88)90606-7; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KOCKS C, 1992, CELL, V68, P521, DOI 10.1016/0092-8674(92)90188-I; LASSING I, 1988, J CELL BIOCHEM, V37, P255, DOI 10.1002/jcb.240370302; LASSING I, 1988, EXP CELL RES, V174, P1, DOI 10.1016/0014-4827(88)90136-X; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; LAZARIDES E, 1974, P NATL ACAD SCI USA, V71, P4742, DOI 10.1073/pnas.71.12.4742; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LINDBERG U, 1966, J BIOL CHEM, V241, P1246; MALM B, 1983, J MUSCLE RES CELL M, V4, P569, DOI 10.1007/BF00712116; MARKEY F, 1981, CELL, V23, P145, DOI 10.1016/0092-8674(81)90279-8; MILLIGAN RA, 1990, NATURE, V348, P217, DOI 10.1038/348217a0; MYSLIK JC, 1992, THESIS PRINCETON U U; NOBLE MEM, 1993, EMBO J, V12, P2617, DOI 10.1002/j.1460-2075.1993.tb05922.x; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; PROBST E, 1972, BIOCHIM BIOPHYS ACTA, V278, P577, DOI 10.1016/0005-2795(72)90017-7; RAGHUNATHAN V, 1992, FEBS LETT, V297, P46, DOI 10.1016/0014-5793(92)80324-A; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RODGERS DW, 1987, P NATL ACAD SCI USA, V84, P6157, DOI 10.1073/pnas.84.17.6157; SAFER D, 1990, P NATL ACAD SCI USA, V87, P2536, DOI 10.1073/pnas.87.7.2536; SCHUTT CE, 1989, J MOL BIOL, V209, P735, DOI 10.1016/0022-2836(89)90603-7; SEGURA M, 1984, J BIOL CHEM, V259, P3949; SOUTHWICK FS, 1990, J CELL BIOL, V110, P1965, DOI 10.1083/jcb.110.6.1965; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; STOSSEL TP, 1985, ANNU REV CELL BIOL, V1, P353, DOI 10.1146/annurev.cb.01.110185.002033; TANAKA M, 1985, EUR J BIOCHEM, V151, P291, DOI 10.1111/j.1432-1033.1985.tb09099.x; THERIOT JA, 1992, NATURE, V357, P257, DOI 10.1038/357257a0; TILNEY LG, 1983, J CELL BIOL, V97, P112, DOI 10.1083/jcb.97.1.112; TIRION MM, 1993, J MOL BIOL, V230, P186, DOI 10.1006/jmbi.1993.1135; Vandekerckhove J, 1990, CURR OPIN CELL BIOL, V2, P41, DOI 10.1016/S0955-0674(05)80029-8; VANDEKERCKHOVE J, 1978, EUR J BIOCHEM, V90, P451, DOI 10.1111/j.1432-1033.1978.tb12624.x; VANDEKERCKHOVE JS, 1989, J CELL BIOL, V109, P619, DOI 10.1083/jcb.109.2.619; WINKLER FK, 1979, ACTA CRYSTALLOGR A, V35, P901, DOI 10.1107/S0567739479002035; YU FX, 1992, J BIOL CHEM, V267, P14616; 1979, CCP4 DAR LAB PACK	51	612	627	1	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 28	1993	365	6449					810	816		10.1038/365810a0	http://dx.doi.org/10.1038/365810a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MD951	8413665				2022-12-24	WOS:A1993MD95100041
J	PLEASURE, IT; BLACK, MM; KEEN, JH				PLEASURE, IT; BLACK, MM; KEEN, JH			VALOSIN-CONTAINING PROTEIN, VCP, IS A UBIQUITOUS CLATHRIN-BINDING PROTEIN	NATURE			English	Article							YEAST; MEMBER; FAMILY; SECRETION; CDNA	CLATHRIN is the structural protein of coated membranes involved in receptor-mediated endocytosis and aspects of Golgi sorting in eukaryotic cells. We have now detected a stoichiometric complex of clathrin with a novel protein of M(r) approximately 100,000 (100K) in lysates of different mammalian cells. Formation of the complex, which also includes the 70K heat-shock protein Hsc70, occurs within 15 min of synthesis. The 100K protein has been identified as valosin-containing protein (VCP; ref. 1), an early substrate for tyrosine phosphorylation on T-cell receptor activation2. Further, VCP is the mammalian homologue of yeast Cdc48p (ref. 3) and is a member of a larger gene family that includes putative ATP-binding proteins involved in vesicle transport and fusion4,5, 26S proteasome function6, regulation of the expression of human immunodeficiency virus7,8, and assembly of peroxisomes9. The association with clathrin and the morphological and catalytic similarity to the chaperonin proteins indicate that VCP may modulate protein-protein interactions in membrane transport processes.	THOMAS JEFFERSON UNIV,DEPT PHARMACOL,233 S 10TH ST,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,PHILADELPHIA,PA 19107; TEMPLE UNIV,HLTH SCI CTR,SCH MED,DEPT ANAT & CELL BIOL,PHILADELPHIA,PA 19140	Jefferson University; Jefferson University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University								BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BLACK MM, 1991, J NEUROSCI, V11, P163; DUBIEL W, 1992, J BIOL CHEM, V267, P22699; EAKLE KA, 1988, MOL CELL BIOL, V8, P4098, DOI 10.1128/MCB.8.10.4098; EGERTON M, 1992, EMBO J, V11, P3533, DOI 10.1002/j.1460-2075.1992.tb05436.x; ERDMANN R, 1991, CELL, V64, P499, DOI 10.1016/0092-8674(91)90234-P; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FROHLICH KU, 1991, J CELL BIOL, V114, P443, DOI 10.1083/jcb.114.3.443; Georgopoulos C, 1990, Semin Cell Biol, V1, P19; GOUD B, 1985, J CELL BIOL, V100, P521, DOI 10.1083/jcb.100.2.521; KEEN JH, 1986, J CELL BIOL, V102, P1325, DOI 10.1083/jcb.102.4.1325; KEEN JH, 1987, J CELL BIOL, V105, P1989, DOI 10.1083/jcb.105.5.1989; KOLLER KJ, 1987, NATURE, V325, P542, DOI 10.1038/325542a0; MILARSKI KL, 1989, J CELL BIOL, V108, P413, DOI 10.1083/jcb.108.2.413; NELBOCK P, 1990, SCIENCE, V248, P1650, DOI 10.1126/science.2194290; PETERS JM, 1990, EMBO J, V9, P1757, DOI 10.1002/j.1460-2075.1990.tb08300.x; PETERS JM, 1992, J MOL BIOL, V223, P557, DOI 10.1016/0022-2836(92)90670-F; SHIBUYA H, 1992, NATURE, V357, P700, DOI 10.1038/357700a0; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0	19	117	119	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 30	1993	365	6445					459	462		10.1038/365459a0	http://dx.doi.org/10.1038/365459a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LZ633	8413590				2022-12-24	WOS:A1993LZ63300062
J	SEEMAN, P; GUAN, HC; VANTOL, HHM				SEEMAN, P; GUAN, HC; VANTOL, HHM			DOPAMINE D4 RECEPTORS ELEVATED IN SCHIZOPHRENIA	NATURE			English	Article							POSITRON EMISSION TOMOGRAPHY; HUMAN-BRAIN; ANTIPSYCHOTIC-DRUGS; HIGH-AFFINITY; BINDING; NEUROLEPTICS; D2-RECEPTORS; POPULATION; NUCLEOTIDE; CONVERSION	ALTHOUGH the biological basis of schizophrenia is not known, possible causes include genetic defects, viruses1, amines2, brain structure and metabolism3-5, neuroreceptors6-8, and G proteins9. The hypothesis of dopamine overactivity in schizophrenia is based on the fact that neuroleptics block dopamine D2 receptors in direct relation to their clinical antipsychotic potencies10,11. Moreover, dopamine D2 or D2-like receptors are elevated in postmortem schizophrenia brain tissue8,12,13. This elevation, however, is only found in vivo using [C-11]methylspiperone14 but not [C-11]raclopride15. The dopamine D4 receptor gene16 has not yet been excluded in schizophrenia because the 21 gene variants17 of D4 have not yet been tested. Because the link between D1 and D2 receptors is reduced in schizophrenia tissue9, we tested whether one component of this link was sensitive to guanine nucleotide. We report here that the binding of [H-3]raclopride to D2 receptors in schizophrenia was not sensitive to guanine nucleotide. This finding permitted analysis of data12,18 on the binding of [H-3]emonapride to the D2, D3 and D4 receptors. We conclude that the combined density of D2 and D3 receptors (labelled by [H-3]raclopride16,19) is increased by only 10% in schizophrenia brain, as found by Farde et al.15, but that it is the density of dopamine D4 receptors which is sixfold elevated in schizophrenia. These findings resolve the apparent discrepancy, mentioned above, wherein the density of [C-11]methylspiperone-labelled sites14 (D2, D3 and D4), but not that of [C-11]raclopride-labelled sites15 (D2 and D3), was found elevated in the schizophrenia striatum.	UNIV TORONTO,DEPT PSYCHIAT,TORONTO M5S 1A8,ONTARIO,CANADA; CLARKE INST PSYCHIAT,MOLEC NEUROBIOL LAB,TORONTO M5T 1R8,ONTARIO,CANADA	University of Toronto; University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada	SEEMAN, P (corresponding author), UNIV TORONTO,DEPT PHARMACOL,MED SCI BLDG,TORONTO M5S 1A8,ONTARIO,CANADA.							ANDREASEN NC, 1988, SCIENCE, V239, P1381, DOI 10.1126/science.3279509; BATTAGLIA G, 1984, J NEUROCHEM, V43, P1213, DOI 10.1111/j.1471-4159.1984.tb05375.x; BUCHSBAUM MS, 1992, ARCH GEN PSYCHIAT, V49, P935; CARTER GI, 1987, J NEUROL NEUROSUR PS, V50, P247, DOI 10.1136/jnnp.50.3.247; CROW TJ, 1980, ENZYMES NEUROTRANSMI, P559; EZRINWATERS C, 1981, J CLIN PSYCHIAT, V42, P16; FARDE L, 1990, ARCH GEN PSYCHIAT, V47, P213; GEORGE SR, 1985, J NEUROCHEM, V44, P1168, DOI 10.1111/j.1471-4159.1985.tb08740.x; HALL H, 1992, NEUROSCI LETT, V136, P79, DOI 10.1016/0304-3940(92)90652-N; LAZARENO S, 1983, J RECEPTOR RES, V3, P163, DOI 10.3109/10799898309041931; LEE T, 1978, NATURE, V274, P897, DOI 10.1038/274897a0; LICHTER JB, 1992, NATURE, V360, P424, DOI 10.1038/360424b0; MELTZER HY, 1991, SCHIZOPHRENIA BULL, V17, P263, DOI 10.1093/schbul/17.2.263; SEEMAN P, 1984, J NEUROCHEM, V43, P221, DOI 10.1111/j.1471-4159.1984.tb06700.x; SEEMAN P, 1992, EUR J PHARM-MOLEC PH, V227, P139, DOI 10.1016/0922-4106(92)90121-B; SEEMAN P, 1988, ISI ATLAS-PHARMACOL, V2, P161; SEEMAN P, 1989, P NATL ACAD SCI USA, V86, P10156, DOI 10.1073/pnas.86.24.10156; SEEMAN P, 1975, P NATL ACAD SCI USA, V72, P4376, DOI 10.1073/pnas.72.11.4376; SEEMAN P, 1991, EUR J PHARMACOL, V203, P105, DOI 10.1016/0014-2999(91)90796-S; SEEMAN P, 1974, FED PROC, V33, P246; SEEMAN P, 1989, SYNAPSE, V3, P96, DOI 10.1002/syn.890030113; SEEMAN P, 1985, BIOCHEM PHARMACOL, V34, P151, DOI 10.1016/0006-2952(85)90116-9; SEEMAN P, 1987, NEUROPSYCHOPHARMACOL, V1, P5, DOI 10.1016/0893-133X(87)90004-2; SEEMAN P, 1993, SYNAPSE, V14, P247, DOI 10.1002/syn.890140402; SEEMAN P, 1992, NEUROPSYCHOPHARMACOL, V7, P261; SOKOLOFF P, 1990, NATURE, V347, P146, DOI 10.1038/347146a0; SPOKES EGS, 1980, J NEUROL SCI, V48, P303, DOI 10.1016/0022-510X(80)90103-3; SUDDATH RL, 1990, NEW ENGL J MED, V322, P789, DOI 10.1056/NEJM199003223221201; VANTOL HHM, 1992, NATURE, V358, P149; VANTOL HHM, 1991, NATURE, V350, P610, DOI 10.1038/350610a0; WONG DF, 1986, SCIENCE, V234, P1558, DOI 10.1126/science.2878495; WREGGETT KA, 1984, MOL PHARMACOL, V25, P10	32	616	642	0	33	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 30	1993	365	6445					441	445		10.1038/365441a0	http://dx.doi.org/10.1038/365441a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LZ633	8413587				2022-12-24	WOS:A1993LZ63300056
J	HONIGMAN, B; THEIS, MK; KOZIOLMCLAIN, J; ROACH, R; YIP, R; HOUSTON, C; MOORE, LG				HONIGMAN, B; THEIS, MK; KOZIOLMCLAIN, J; ROACH, R; YIP, R; HOUSTON, C; MOORE, LG			ACUTE MOUNTAIN-SICKNESS IN A GENERAL TOURIST POPULATION AT MODERATE ALTITUDES	ANNALS OF INTERNAL MEDICINE			English	Article						ALTITUDE SICKNESS; LUNG DISEASES; ACETAZOLAMIDE; HEADACHE; PHYSICAL FITNESS	VENTILATION; DEXAMETHASONE; ACETAZOLAMIDE; PROPHYLAXIS; HYPOXIA	Objective: To determine the incidence of acute mountain sickness in a general population of visitors to moderate elevations, the characteristics associated with it, and its effect on physical activity. Design: A cross-sectional study. Setting: Resort communities located at 6300 to 9700 feet elevation in the Rocky Mountains of Colorado. Participants: Convenience sample of 3158 adult travelers, 16 to 87 years old (mean age [+/- SD], 43.8 +/- 11.8 years). Results: Twenty-five percent of the travelers to moderate elevations developed acute mountain sickness, which occurred in 65% of travelers within the first 12 hours of arrival. Fifty-six percent of those with symptoms reduced their physical activity. The odds favoring acute mountain sickness were 3.5 times as large for visitors whose permanent residence was below 3000 feet elevation as for those whose residence was above 3000 feet; 2.8 times as large for visitors with previous symptoms of acute mountain sickness; and twice as large in travelers younger than 60 years. Women, obese persons, those in poor or average physical condition, and those with underlying lung disease also had a higher occurrence of acute mountain sickness (P < 0.05). Conclusions: Acute mountain sickness occurs in 25% of visitors to moderate altitudes and affects activity in most symptomatic visitors. Persons who are younger, less physically fit, live at sea level, have a history of acute mountain sickness, or have underlying lung problems more often develop these symptoms.	CTR DIS CONTROL, DIV NUTR, ATLANTA, GA 30333 USA; UNIV COLORADO, DEPT ANTHROPOL, DENVER, CO 80202 USA; COLORADO ALTITUDE RES INST, KEYSTONE, CO USA; LOVELACE FDN MED EDUC & RES, ALBUQUERQUE, NM USA	Centers for Disease Control & Prevention - USA; University of Colorado System; University of Colorado Denver; Lovelace Respiratory Research Institute	HONIGMAN, B (corresponding author), UNIV COLORADO, HLTH SCI CTR, 4200 E 9TH AVE, B-215, DENVER, CO 80262 USA.		Roach, Robert/F-4729-2011	Roach, Robert/0000-0002-7998-8976; Koziol-McLain, Jane/0000-0003-3453-023X				ANHOLM JD, 1979, CHEST, V75, P33, DOI 10.1378/chest.75.1.33; CYMERMAN A, 1979, 1979 P HYP S CALG, P66; DAVIES CTM, 1972, CLIN SCI, V42, P1; DEAN AG, 1990, J WILDERNESS MED, V1, P86, DOI 10.1580/0953-9859-1.2.86; DILL DB, 1980, J APPL PHYSIOL, V48, P6, DOI 10.1152/jappl.1980.48.1.6; ELLSWORTH AJ, 1987, AM J MED, V83, P1024, DOI 10.1016/0002-9343(87)90937-5; EVANS WO, 1976, AVIAT SPACE ENVIR MD, V47, P512; FERRAZZINI G, 1987, BRIT MED J, V294, P1380, DOI 10.1136/bmj.294.6584.1380; GONG H, 1984, AM REV RESPIR DIS, V130, P980; HACKETT PH, 1982, RESPIRATION, V43, P321, DOI 10.1159/000194501; HACKETT PH, 1979, AM J MED, V67, P214, DOI 10.1016/0002-9343(79)90393-0; HACKETT PH, 1976, LANCET, V2, P1149; HACKETT PH, 1983, SEMIN RESPIR MED, V5, P132, DOI 10.1055/s-2007-1011443; Hackett PH, 1989, MANAGEMENT WILDERNES, P1; HARBER MJ, 1981, AVIAT SPACE ENVIR MD, V52, P38; HARRIS CW, 1966, AEROSPACE MED, V37, P1163; HEYES MP, 1983, SEMIN RESPIR MED, V5, P207, DOI 10.1055/s-2007-1011454; HOUSTON CS, 1985, AM ALPINE J, V59, P162; HOUSTON CS, 1987, GOING HIGHER STORY M; JOHNSON TS, 1988, NEW ENGL J MED, V319, P841, DOI 10.1056/NEJM198809293191306; KING AB, 1972, AEROSPACE MED, V43, P419; LARSON EB, 1982, JAMA-J AM MED ASSOC, V248, P328, DOI 10.1001/jama.248.3.328; LUPIHERRERA E, 1982, AM REV RESPIR DIS, V126, P509; MONTGOMERY AB, 1989, JAMA-J AM MED ASSOC, V261, P732, DOI 10.1001/jama.261.5.732; MOORE LG, 1986, J APPL PHYSIOL, V60, P1407, DOI 10.1152/jappl.1986.60.4.1407; MOORE LG, 1987, ANN EMERG MED, V16, P965, DOI 10.1016/S0196-0644(87)80742-4; ROBINSON SM, 1971, AEROSPACE MED, V42, P706; SINGH I, 1969, NEW ENGL J MED, V280, P175, DOI 10.1056/NEJM196901232800402; STAMPER DA, 1980, AVIAT SPACE ENVIR MD, V51, P379; Sutton JR, 1992, HYPOXIA MOUNTAIN MED, P327; VANITALLIE TB, 1985, ANN INTERN MED, V103, P983, DOI 10.7326/0003-4819-103-6-983; STATISTICAL ANAL SYS; 1991, COLORADO BOARD TOURI	33	326	334	2	33	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1993	118	8					587	592		10.7326/0003-4819-118-8-199304150-00003	http://dx.doi.org/10.7326/0003-4819-118-8-199304150-00003			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW470	8452324				2022-12-24	WOS:A1993KW47000003
J	LUBITZ, JD; RILEY, GF				LUBITZ, JD; RILEY, GF			TRENDS IN MEDICARE PAYMENTS IN THE LAST YEAR OF LIFE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							OLDER PERSONS; CARE; DEATH; ILL	Background. Increased attention is being paid to the amount and types of medical services rendered in the period before death. There is a popular impression that a greater share of resources is being devoted to dying patients than in the past. We examined trends in the proportion of Medicare expenditures for persons 65 years old or older in their last year of life to determine whether there were any changes from 1976 to 1988. Methods. Using Medicare program data for 1976, 1980, 1985, and 1988, we classified Medicare payments according to whether they were made for people in their last year of life (decedents) or for survivors. We also assigned expenses for care in the last year of life according to intervals of 30 days before the person's death and examined trends according to age. Results. Reflecting the large overall increase in Medicare spending, Medicare costs for decedents rose from $3,488 per person-year in 1976 to $13,316 in 1988. However, Medicare payments for decedents as a percentage of the total Medicare budget changed little, fluctuating between 27.2 and 30.6 percent during the study period. Payments for care during the last 60 days of life expressed as a percentage of payments for the last year also held steady at about 52 percent. Furthermore, the pattern of lower payments for older as compared with younger decedents also prevailed throughout the study period. Conclusions. The same forces that have acted to increase overall Medicare expenditures have affected care for both decedents and survivors. There is no evidence that persons in the last year of life account for a larger share of Medicare expenditures than in earlier years.			LUBITZ, JD (corresponding author), HLTH CARE FINANCING ADM,6325 SECUR BLVD,RM 2504,OAK MEADOWS BLDG,BALTIMORE,MD 21207, USA.							ANDERSON K, 1991, US TODAY        0311, pB3; BAYER R, 1983, NEW ENGL J MED, V309, P1490, DOI 10.1056/NEJM198312153092405; Brock Dwight B., 1992, P315; CLARK N, 1992, WALL STREET J   0226, pA12; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; FORSTER LE, 1988, ARCH INTERN MED, V148, P2540, DOI 10.1001/archinte.148.12.2540; FREUDENHEIM M, 1990, NY TIMES        0205, pA1; GURALNIK JM, 1991, AM J PUBLIC HEALTH, V81, P443, DOI 10.2105/AJPH.81.4.443; KIDDER D, 1992, HEALTH SERV RES, V27, P195; LAWTON MP, 1990, MILBANK Q, V68, P1, DOI 10.2307/3350075; Levit K R, 1991, Health Care Financ Rev, V13, P29; Lubitz J, 1984, Health Care Financ Rev, V5, P117; McMillan A, 1990, Health Care Financ Rev, V12, P1; MORALES P, 1990, COTTAGE GROVE S 1107, pA4; OLESKER M, 1992, BALTIMORE SUN   0114, pD1; ROOS NP, 1987, MILBANK Q, V65, P231, DOI 10.2307/3350021; SCITOVSKY AA, 1984, MILBANK Q, V62, P591, DOI 10.2307/3349838; SCITOVSKY AA, 1988, MILBANK Q, V66, P640, DOI 10.2307/3349934; SMEDIRA NG, 1990, NEW ENGL J MED, V322, P309, DOI 10.1056/NEJM199002013220506; SPECTOR WD, 1984, INQUIRY-J HEALTH CAR, V21, P328; Tukey J.W., 1977, EXPLORATORY DATA ANA; 1991, IMPACT MEDICARE HOSP; 1991, MEDICARE AM HLTH CAR; 1990, MON VITAL STAT REP S, V39	24	498	503	1	19	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 15	1993	328	15					1092	1096		10.1056/NEJM199304153281506	http://dx.doi.org/10.1056/NEJM199304153281506			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KX178	8455667				2022-12-24	WOS:A1993KX17800006
J	MULLERHILL, B				MULLERHILL, B			THE SHADOW OF GENETIC INJUSTICE	NATURE			English	Editorial Material											MULLERHILL, B (corresponding author), UNIV COLOGNE,INST GENET,WEYERTAL 121,W-5000 COLOGNE 41,GERMANY.							HALDANE JBS, 1924, SCI FUTURE	1	12	12	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 8	1993	362	6420					491	492		10.1038/362491a0	http://dx.doi.org/10.1038/362491a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KW453	8464485				2022-12-24	WOS:A1993KW45300022
J	POLDERMAN, KH; STEHOUWER, CDA; VANKAMP, GJ; DEKKER, GA; VERHEUGT, FWA; GOOREN, LJG				POLDERMAN, KH; STEHOUWER, CDA; VANKAMP, GJ; DEKKER, GA; VERHEUGT, FWA; GOOREN, LJG			INFLUENCE OF SEX-HORMONES ON PLASMA ENDOTHELIN LEVELS	ANNALS OF INTERNAL MEDICINE			English	Article						ENDOTHELINS; ATHEROSCLEROSIS; HYPERTENSION; SEX HORMONES; SEX FACTORS	CARDIOVASCULAR-DISEASE; ORAL-CONTRACEPTIVES; ANABOLIC-STEROIDS; ATHEROSCLEROSIS	Objective: To determine whether a sex-associated difference in endothelin levels exists and to assess whether this difference is mediated by sex hormones. Design: Initial survey in healthy persons, followed by a nonrandomized intervention. Setting: A university teaching hospital. Patients: Twenty-three healthy men, 29 healthy women, 20 pregnant women, and 12 male-to-female and 13 female-to-male transsexual patients. Measurements: Plasma levels of endothelin were first assessed in healthy men, healthy women, and pregnant women; subsequently, endothelin levels were determined in male-to-female and female-to-male transsexual patients both before and during cross-gender hormone treatment. This treatment involves administration of testosterone esters to women and of ethinylestradiol and cyproterone acetate to men. Results: Endothelin levels were higher in men than in women (5.9 +/- 1.2 compared with 4.17 +/- 0.67 pg/mL; P < 0.01). Endothelin levels were lower in pregnant women than in age- and sex-matched nonpregnant controls (2.19 +/- 0.73 compared with 4.17 +/- 0.67 pg/mL; P < 0.01). In 12 male-to-female transsexuals treated with estradiol and the progestational agent cyproterone acetate, endothelin levels decreased from 8.1 +/- 3.0 to 5.1 +/- 2.0 pg/mL (P < 0.01). In 13 female-to-male transsexuals treated with testosterone, endothelin levels increased from 6.2 +/- 1.1 to 7.8 +/- 1.2 pg/mL (P < 0.01). Conclusion: Sex hormones may modulate plasma endothelin levels, with male hormones raising levels and female hormones lowering them. This finding may be important in explaining sex-associated differences in susceptibility to atherosclerotic cardiovascular disease.			POLDERMAN, KH (corresponding author), FREE UNIV AMSTERDAM HOSP, DEPT INTERNAL MED, POB 7057, 1007 MB AMSTERDAM, NETHERLANDS.		Stehouwer, Coen/AAB-3435-2021; Polderman, Kees H/K-3623-2012; Verheugt, F.W.A./H-8105-2014					ASSCHEMAN H, 1989, METABOLISM, V38, P869, DOI 10.1016/0026-0495(89)90233-3; COHEN JC, 1987, J CLIN ENDOCR METAB, V64, P960, DOI 10.1210/jcem-64-5-960; Gooren LJG, 1990, TESTOSTERONE ACTION, P182; HIRATA Y, 1989, ATHEROSCLEROSIS, V78, P225, DOI 10.1016/0021-9150(89)90227-X; KNOPP RH, 1988, AM J OBSTET GYNECOL, V158, P1630, DOI 10.1016/0002-9378(88)90201-3; KOHNO M, 1990, AM J MED, V88, P614, DOI 10.1016/0002-9343(90)90527-K; LERMAN A, 1991, NEW ENGL J MED, V325, P997, DOI 10.1056/NEJM199110033251404; Lind T, 1979, Br J Obstet Gynaecol, V86 Suppl 3, P1, DOI 10.1111/j.1471-0528.1979.tb16232.x; MCNUTT RA, 1988, AM J CARDIOL, V62, P164, DOI 10.1016/0002-9149(88)91390-2; MOORADIAN AD, 1987, ENDOCR REV, V8, P1, DOI 10.1210/edrv-8-1-1; NAGELBERG SB, 1986, NEW ENGL J MED, V314, P649; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; STADEL BV, 1981, NEW ENGL J MED, V305, P612, DOI 10.1056/NEJM198109103051104; STADEL BV, 1981, NEW ENGL J MED, V305, P672, DOI 10.1056/NEJM198109173051205; VANE JR, 1990, NEW ENGL J MED, V323, P27; VIERHAPPER H, 1990, CIRCULATION, V81, P1415, DOI 10.1161/01.CIR.81.4.1415; VOERMAN HJ, 1992, CRIT CARE MED, V20, P1097, DOI 10.1097/00003246-199208000-00005; WREN BG, 1982, MED J AUSTRALIA, V2, P329, DOI 10.5694/j.1326-5377.1982.tb132453.x	18	286	288	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1993	118	6					429	432		10.7326/0003-4819-118-6-199303150-00006	http://dx.doi.org/10.7326/0003-4819-118-6-199303150-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KR817	8439117				2022-12-24	WOS:A1993KR81700006
J	HAND, R; FREMGEN, A; CHMIEL, JS; RECANT, W; BERK, R; SYLVESTER, J; SENER, S				HAND, R; FREMGEN, A; CHMIEL, JS; RECANT, W; BERK, R; SYLVESTER, J; SENER, S			STAGING PROCEDURES, CLINICAL MANAGEMENT, AND SURVIVAL OUTCOME FOR OVARIAN-CARCINOMA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COMMON EPITHELIAL CANCER; RANDOMIZED TRIAL; CYCLOPHOSPHAMIDE; CISPLATIN; REGIMENS; THERAPY	Objective.-To evaluate the relationship between survival and patterns of clinical management for ovarian carcinoma. Design.-Retrospective analysis of cancer registry data including follow-up, operative reports, and pathology reports. Setting.-Seventy-seven Illinois hospitals with active cancer registries. Patients.-A total of 2669 women with newly diagnosed ovarian carcinoma from 1983 through 1988. Main Outcome Measures.-Frequency of use of specific staging procedures and treatment options. Survival was estimated using the Kaplan-Meier product-limit method. Results.-Thirty percent of 632 stage I patients, 31% of 233 stage II patients, and 45% of 516 stage III patients underwent hysterectomy, bilateral salpingo-oophorectomy, omentectomy, sampled peritoneal washings, and node biopsy. Five year survival for those receiving this extensive surgery (who were therefore pathologically staged) was as follows: stage I, 80%; stage II, 63%; and stage III, 28%. For those not receiving this extensive surgery (who were therefore clinically staged), the 5-year survival at these stages was 76%, 62%, and 21%, respectively. The overall survival curves were not significantly different between those who were pathologically staged and those who were clinically staged for stage I patients (P=.27) or stage II patients (P=.47), but were for stage III patients (P=.01). Platinum-based combination chemotherapy was given to 76% of 221 patients with pathological stage III disease. Their 5-year survival-50% for the group with no residual disease and 20% for the group with residual disease-was better than for those receiving regimens without platinum-37% and 5%, respectively, for the two groups-and the overall survival curves were significantly better for those receiving platinum (P<.0005 for both groups). The groups receiving platinum had younger patients. Conclusions.-Extensive surgery for pathological staging was not usually done for management of ovarian cancer, while platinum-based chemotherapy was commonly used. Failure to undergo extensive surgery had little impact on survival for stage I and II patients. However, use of extensive surgery and platinum-based chemotherapy improved survival for stage III patients. The improved survival for this group receiving platinum-based chemotherapy may be explained in part by selection of younger patients for this treatment.	UNIV ILLINOIS, CHICAGO COLL MED, DEPT MED, CHICAGO, IL 60680 USA; NORTHWESTERN UNIV, SCH MED, CANC CTR BIOMETRY SECT, CHICAGO, IL 60611 USA; NORTHWESTERN UNIV, SCH MED, DEPT SURG, CHICAGO, IL 60611 USA; UNIV CHICAGO, DEPT PATHOL, CHICAGO, IL 60637 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Northwestern University; Northwestern University; University of Chicago	HAND, R (corresponding author), AMER CANC SOCIETY, CANC INCIDENCE & END RESULTS COMM, 77 E MONROE ST, CHICAGO, IL 60603 USA.		yang, xiao-jun/B-1927-2009					ALBERTS DS, 1984, ADJUVANT THERAPY CAN, V4, P507; AVERETTE HE, 1990, CANCER-AM CANCER SOC, V65, P703, DOI 10.1002/1097-0142(19900201)65:3+<703::AID-CNCR2820651314>3.0.CO;2-4; BEECHAM JB, 1983, CLIN ONCOLOGY MULTID, P435; BEREK JS, 1985, CANCER TREATMENT, P415; BRUCKNER HW, 1983, AM J OBSTET GYNECOL, V145, P653, DOI 10.1016/0002-9378(83)90569-0; BUCHSBAUM HJ, 1989, SURG GYNECOL OBSTET, V169, P226; COX DR, 1972, J R STAT SOC B, V34, P187; EDWARDS CL, 1983, GYNECOL ONCOL, V15, P261, DOI 10.1016/0090-8258(83)90082-3; GRIFFITHS CT, 1982, CANCER MED, P1965; GRILLI R, 1991, MED CARE, V29, P50, DOI 10.1097/00005650-199101000-00005; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LUCAS WE, 1983, PRINCIPLES PRACTICE, P885; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MCGOWAN L, 1985, OBSTET GYNECOL, V65, P568; MORROW CP, 1981, GYNECOL ONCOL, P655; NEIJT JP, 1987, J CLIN ONCOL, V5, P1157, DOI 10.1200/JCO.1987.5.8.1157; OMURA G, 1986, CANCER, V57, P1725, DOI 10.1002/1097-0142(19860501)57:9<1725::AID-CNCR2820570903>3.0.CO;2-J; OZOLS RF, 1982, PRINCIPLES CANCER TR, P482; PETTERSON F, 1985, ANN REPORT RESULTS T, P19; Pettersson F., 1988, ANN REPORT RESULTS T, VFIGO, P20; RICHARDSON GS, 1985, NEW ENGL J MED, V312, P415, DOI 10.1056/NEJM198502143120706; RICHARDSON GS, 1985, NEW ENGL J MED, V312, P474, DOI 10.1056/NEJM198502213120804; SCHWARTZ PE, 1982, CANCER THERAPY, P525; YOUNG RC, 1983, JAMA-J AM MED ASSOC, V250, P3072, DOI 10.1001/jama.250.22.3072; YOUNG RC, 1990, NEW ENGL J MED, V322, P1021, DOI 10.1056/NEJM199004123221501; YOUNG RC, 1987, CANCER, V60, P2042, DOI 10.1002/1097-0142(19901015)60:8+<2042::AID-CNCR2820601516>3.0.CO;2-D; YOUNG RC, 1982, CANCER PRINCIPLES PR, P884; 1983, CANCER ILLINOIS 1983; 1988, MANUAL STAGING CANCE; 1986, CANCER ILLINOIS 1986; 1988, CANCER ILLINOIS 1987; 1985, CANCER ILLINOIS 1985; 1984, CANCER ILLINOIS 1984	33	23	23	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 3	1993	269	9					1119	1122		10.1001/jama.269.9.1119	http://dx.doi.org/10.1001/jama.269.9.1119			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KN611	8433466				2022-12-24	WOS:A1993KN61100027
J	SHELTON, CA; WASSERMAN, SA				SHELTON, CA; WASSERMAN, SA			PELLE ENCODES A PROTEIN-KINASE REQUIRED TO ESTABLISH DORSOVENTRAL POLARITY IN THE DROSOPHILA EMBRYO	CELL			English	Article							NF-KAPPA-B; DORSAL-VENTRAL POLARITY; MATERNAL MESSENGER-RNA; TOLL GENE-PRODUCT; DNA-BINDING; TRANSMEMBRANE PROTEIN; NUCLEAR-LOCALIZATION; RETICULOENDOTHELIOSIS VIRUS; TRANSCRIPTION FACTOR; SIGNAL TRANSDUCTION	The pelle gene is required for the nuclear import of dorsal protein that establishes dorsoventral polarity in Drosophila embryos. We report here the genetic mapping and molecular characterization of pelle. DNA sequence analysis revealed that pelle encodes a protein of 501 amino acids, the last 292 of which comprise a protein kinase catalytic domain. Microinjection of in vitro synthesized transcripts containing site-directed mutations indicates that the kinase catalytic domain is required for biological activity. This domain is most similar to that of the raf and mos protein kinases and is predicted to have a serine and threonine specificity. These results provide direct evidence for the role of phosphorylation in the in vivo regulation of a rel-like transcription factor.			SHELTON, CA (corresponding author), UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235, USA.				NIGMS NIH HHS [GM07062] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007062] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMBROSIO L, 1989, NATURE, V342, P288, DOI 10.1038/342288a0; ANDERSON KV, 1987, TRENDS GENET, V3, P91, DOI 10.1016/0168-9525(87)90191-0; ANDERSON KV, 1985, CELL, V42, P791, DOI 10.1016/0092-8674(85)90275-2; ANDERSON KV, 1985, CELL, V42, P779, DOI 10.1016/0092-8674(85)90274-0; ANDERSON KV, 1984, NATURE, V311, P223, DOI 10.1038/311223a0; ANDERSON KV, 1986, GAMETOGENESIS EARLY, P177; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; BOOHER R, 1986, MOL CELL BIOL, V6, P3523, DOI 10.1128/MCB.6.10.3523; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CASANOVA J, 1991, MECH DEVELOP, V36, P41, DOI 10.1016/0925-4773(91)90070-M; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; CHIDA K, 1992, P NATL ACAD SCI USA, V89, P4290, DOI 10.1073/pnas.89.10.4290; COOLEY L, 1988, SCIENCE, V239, P1121, DOI 10.1126/science.2830671; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FLEMING RJ, 1990, GENE DEV, V4, P2188, DOI 10.1101/gad.4.12a.2188; GAY NJ, 1991, NATURE, V351, P355, DOI 10.1038/351355b0; GEISLER R, 1992, CELL, V71, P613, DOI 10.1016/0092-8674(92)90595-4; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; GIBBS CS, 1991, BIOCHEMISTRY-US, V30, P5329, DOI 10.1021/bi00236a001; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; GOVIND S, 1991, TRENDS GENET, V7, P119, DOI 10.1016/0168-9525(91)90456-Z; Hanks SK, 1991, CURR OPIN STRUC BIOL, V1, P369, DOI 10.1016/0959-440X(91)90035-R; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; HECHT P M, 1992, Trends in Cell Biology, V2, P197, DOI 10.1016/0962-8924(92)90246-J; HEGUY A, 1992, J BIOL CHEM, V267, P2605; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; HUNT T, 1989, CELL, V59, P949, DOI 10.1016/0092-8674(89)90747-2; IP YT, 1991, CELL, V64, P439; JOWETT T, 1986, PREPARATION NUCLEIC; KALFAYAN L, 1982, CELL, V29, P91, DOI 10.1016/0092-8674(82)90093-9; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; KIDD S, 1992, CELL, V71, P623, DOI 10.1016/0092-8674(92)90596-5; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LETSOU A, 1991, P NATL ACAD SCI USA, V88, P810, DOI 10.1073/pnas.88.3.810; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; LINDSLEY DL, 1972, GENETICS, V71, P157; LOHSSCHARDIN M, 1979, DEV BIOL, V73, P239, DOI 10.1016/0012-1606(79)90065-4; MARCK C, 1988, NUCLEIC ACIDS RES, V16, P1829, DOI 10.1093/nar/16.5.1829; MILLER M, 1991, DEVELOPMENT, V113, P569; MOSIALOS G, 1991, MOL CELL BIOL, V11, P5867, DOI 10.1128/MCB.11.12.5867; MULLERHOLTKAMP F, 1985, DEV BIOL, V110, P238, DOI 10.1016/0012-1606(85)90080-6; MULLERHOLTKAMP F, 1985, THESIS U TUBINGEN TU; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; NORRIS JL, 1992, GENE DEV, V6, P1654, DOI 10.1101/gad.6.9.1654; OHNO S, 1990, J BIOL CHEM, V265, P6296; PAN DJ, 1991, GENE DEV, V5, P1892, DOI 10.1101/gad.5.10.1892; PICARD D, 1990, CELL REGUL, V1, P291, DOI 10.1091/mbc.1.3.291; PIRROTTA V, 1986, DROSOPHILA PRACTICAL; RAY RP, 1991, DEVELOPMENT, V113, P35; ROBERTSON HM, 1988, GENETICS, V118, P461; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; ROTH S, 1991, DEVELOPMENT, V112, P371; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; SAMBROOK E, 1989, MOL CLONING LABORATO; SCHNEIDER DS, 1991, GENE DEV, V5, P797, DOI 10.1101/gad.5.5.797; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; SINGH B, 1986, J VIROL, V60, P1148, DOI 10.1128/JVI.60.3.1148-1152.1986; STEIN D, 1991, CELL, V65, P725, DOI 10.1016/0092-8674(91)90381-8; STEIN D, 1992, CELL, V68, P429, DOI 10.1016/0092-8674(92)90181-B; Stein DS, 1991, CURR OPIN GENET DEV, V1, P247, DOI 10.1016/S0959-437X(05)80078-4; STEIN JC, 1991, P NATL ACAD SCI USA, V88, P8816, DOI 10.1073/pnas.88.19.8816; STEPHENS RM, 1983, P NATL ACAD SCI-BIOL, V80, P6229, DOI 10.1073/pnas.80.20.6229; STEWARD R, 1989, CELL, V59, P1179, DOI 10.1016/0092-8674(89)90773-3; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; STJOHNSTON D, 1992, CELL, V68, P201; THISSE C, 1991, CELL, V65, P1191, DOI 10.1016/0092-8674(91)90014-P; WATSON R, 1982, P NATL ACAD SCI-BIOL, V79, P4078, DOI 10.1073/pnas.79.13.4078; WEISCHAUS E, 1986, DROSOPHILA PRACTICAL, P199; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984	80	197	202	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 26	1993	72	4					515	525		10.1016/0092-8674(93)90071-W	http://dx.doi.org/10.1016/0092-8674(93)90071-W			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KP165	8440018				2022-12-24	WOS:A1993KP16500007
J	ELDRED, GE; LASKY, MR				ELDRED, GE; LASKY, MR			RETINAL AGE PIGMENTS GENERATED BY SELF-ASSEMBLING LYSOSOMOTROPIC DETERGENTS	NATURE			English	Article							FAST ATOM BOMBARDMENT; MASS-SPECTROMETRY; EPITHELIUM	A UNIVERSAL biomarker of cellular ageing in eukaryotic post-mitotic cells is the appearance over time of autofluorescent lysosomal residual bodies called age pigments or lipofuscin granules1. Their role in the process of cellular ageing has been debated without resolution2. Neither the identity nor mechanism of formation of the fluorophores has been definitively determined. A post-mitotic cell type that accumulates large quantities of age pigments is the ocular retinal pigment epithelium2. We have now identified the major orange-emitting fluorophore of these pigments using fast-atom bombardment tandem mass spectrometry with collisional activation analysis4. It is an amphoteric quaternary amine that arises as a Schiff base reaction product of retinaldehyde and ethanolamine. This compound should display lysosomotropic detergent behaviour which would help explain many of the age-related changes shown in this cell. These results suggest a new role for Schiff base reaction products as lysosomotropic amines in the genesis of cellular age pigments.			ELDRED, GE (corresponding author), UNIV MISSOURI, SCH MED, MASON INST OPHTHALMOL, COLUMBIA, MO 65212 USA.							ELDRED GE, 1988, EXP EYE RES, V47, P71, DOI 10.1016/0014-4835(88)90025-5; FEENEY L, 1978, INVEST OPHTH VIS SCI, V17, P583; LYON PA, 1984, ANAL CHEM, V56, P2278, DOI 10.1021/ac00277a004; PORTA EA, 1991, ARCH GERONTOL GERIAT, V12, P303, DOI 10.1016/0167-4943(91)90036-P; SOHAL RS, 1989, ADV EXP MED BIOL, V266, P17; TOMER KB, 1989, MASS SPECTROM REV, V8, P445, DOI 10.1002/mas.1280080602	6	392	405	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 25	1993	361	6414					724	726		10.1038/361724a0	http://dx.doi.org/10.1038/361724a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KN789	8441466				2022-12-24	WOS:A1993KN78900056
J	PHILIPS, MR; PILLINGER, MH; STAUD, R; VOLKER, C; ROSENFELD, MG; WEISSMANN, G; STOCK, JB				PHILIPS, MR; PILLINGER, MH; STAUD, R; VOLKER, C; ROSENFELD, MG; WEISSMANN, G; STOCK, JB			CARBOXYL METHYLATION OF RAS-RELATED PROTEINS DURING SIGNAL TRANSDUCTION IN NEUTROPHILS	SCIENCE			English	Article							GTP-BINDING PROTEINS; SACCHAROMYCES-CEREVISIAE; NADPH OXIDASE; MEMBRANES; CYSTEINE; METHYLTRANSFERASE; CHEMOTAXIS; ACTIVATION; MECHANISMS; LEUKOCYTES	In human neutrophils, as in other cell types, Ras-related guanosine triphosphate binding proteins are directed toward their regulatory targets in membranes by a series of posttranslational modifications that include methyl esterification of a carboxyl-terminal prenylcysteine residue. In intact cells and in a reconstituted in vitro system, the amount of carboxyl methylation of Ras-related proteins increased in response to the chemoattractant N-formyl-methionyl-leucyl-phenylalanine (FMLP). Activation of Ras-related proteins by guanosine-5'-O-(3-thiotriphosphate) had a similar effect and induced translocation of p22rac2 from cytosol to plasma membrane. Inhibitors of prenylcysteine carboxyl methylation effectively blocked neutrophil responses to FMLP. These findings suggest a direct link between receptor-mediated signal transduction and the carboxyl methylation of Ras-related proteins.	PRINCETON UNIV, DEPT CHEM, PRINCETON, NJ 08544 USA; PRINCETON UNIV, DEPT MOLEC BIOL, PRINCETON, NJ 08544 USA; NYU MED CTR, DEPT CELL BIOL, NEW YORK, NY 10016 USA	Princeton University; Princeton University; New York University	PHILIPS, MR (corresponding author), NYU MED CTR, DEPT MED, DIV RHEUMATOL, NEW YORK, NY 10016 USA.		Weissmann, Gerald/N-5273-2015; Staud, Roland/A-8442-2008	Pillinger, Michael/0000-0003-3168-1542; Weissmann, Gerald/0000-0002-4285-4552; Mark, Philips/0000-0002-1179-8156	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007176] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020277, T32GM008309] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-07176-18] Funding Source: Medline; NIGMS NIH HHS [GM-8309, GM 20277] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; BACKLUND PS, 1992, J BIOL CHEM, V267, P18432; BACKLUND PS, 1988, J BIOL CHEM, V263, P15864; BINSTOCK J, 1984, METHOD ENZYMOL, V106, P310; BOKOCH GM, 1990, BIOCHEM J, V267, P407, DOI 10.1042/bj2670407; CHELSKY D, 1985, BIOCHEMISTRY-US, V24, P6651, DOI 10.1021/bi00344a053; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; EKLUND EA, 1991, J BIOL CHEM, V266, P13964; FARNSWORTH CC, 1991, P NATL ACAD SCI USA, V88, P6196, DOI 10.1073/pnas.88.14.6196; GOLDSTEIN IM, 1977, J CLIN INVEST, V59, P249, DOI 10.1172/JCI108635; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HANCOCK JF, 1991, EMBO J, V10, P641, DOI 10.1002/j.1460-2075.1991.tb07992.x; HORI Y, 1991, ONCOGENE, V6, P515; HRYCYNA CA, 1990, MOL CELL BIOL, V10, P5071, DOI 10.1128/MCB.10.10.5071; HRYCYNA CA, 1991, EMBO J, V10, P1699, DOI 10.1002/j.1460-2075.1991.tb07694.x; HUZOORAKBAR, 1991, J BIOL CHEM, V266, P4387; ISOMURA M, 1991, ONCOGENE, V6, P119; KAWATA M, 1990, P NATL ACAD SCI USA, V87, P8960, DOI 10.1073/pnas.87.22.8960; KINSELLA BT, 1991, J BIOL CHEM, V266, P9786; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KORCHAK HM, 1984, J BIOL CHEM, V259, P4070; MARIDONNEAUPARINI I, 1991, J CLIN INVEST, V87, P901, DOI 10.1172/JCI115096; ODEA RF, 1978, NATURE, V272, P462, DOI 10.1038/272462a0; PHILIPS MR, 1991, J BIOL CHEM, V266, P1289; PIKE MC, 1978, P NATL ACAD SCI USA, V75, P3928, DOI 10.1073/pnas.75.8.3928; REIBMAN J, 1988, J BIOL CHEM, V263, P6322; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; SNYDERMAN R, 1988, INFLAMMATION BASIC P, P309; SPRINGER MS, 1979, NATURE, V280, P279, DOI 10.1038/280279a0; STEPHENSON RC, 1992, J BIOL CHEM, V267, P13314; STEPHENSON RC, 1990, J BIOL CHEM, V265, P16248; STOCK JB, 1991, ANNU REV BIOPHYS BIO, V20, P109, DOI 10.1146/annurev.bb.20.060191.000545; VENKATASUBRAMANIAN K, 1980, MOL IMMUNOL, V17, P201, DOI 10.1016/0161-5890(80)90072-3; VOLKER C, 1990, Methods (Orlando), V1, P283, DOI 10.1016/S1046-2023(05)80329-9; VOLKER C, 1991, FEBS LETT, V295, P189, DOI 10.1016/0014-5793(91)81415-5; VOLKER C, 1991, J BIOL CHEM, V266, P21515; WEISSMANN G, 1989, SPRINGER SEMIN IMMUN, V11, P235	38	208	214	1	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 12	1993	259	5097					977	980		10.1126/science.8438158	http://dx.doi.org/10.1126/science.8438158			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL800	8438158				2022-12-24	WOS:A1993KL80000045
J	COOK, JTE; LEVY, JC; PAGE, RCL; SHAW, JAG; HATTERSLEY, AT; TURNER, RC				COOK, JTE; LEVY, JC; PAGE, RCL; SHAW, JAG; HATTERSLEY, AT; TURNER, RC			ASSOCIATION OF LOW-BIRTH-WEIGHT WITH BETA-CELL FUNCTION IN THE ADULT 1ST DEGREE RELATIVES OF NON-INSULIN-DEPENDENT DIABETIC SUBJECTS	BRITISH MEDICAL JOURNAL			English	Article							MODEL ASSESSMENT; GLUCOSE; RESISTANCE; INFUSION; FETAL	Objective-To examine the relation between birth weight and beta cell function in the first degree relatives of non-insulin dependent diabetic subjects. Design-Cross sectional study of 101 adults of known birth weight from 47 families which had at least one member with non-insulin dependent diabetes. Subjects-101 white adults aged mean 43 (SD 7) years. Setting-Oxfordshire, England. Main outcome measures-Glucose tolerance was measured by continuous infusion glucose tolerance test. Beta cell function and insulin sensitivity were calculated from the fasting plasma glucose and insulin concentrations with homeostasis model assessment. Beta cell function was standardised to allow for the confounding effects of age and obesity. Results-Twenty seven subjects had non-insulin dependent diabetes, 32 had impaired glucose tolerance, and 42 were normoglycaemic. Birth weight correlated with the beta cell function of the complete cohort (r(s)=0.29, p=0.005), the non-insulin dependent diabetic subjects (r(s)=0.50, p=0.023), and the non-diabetic subjects (r(s)=0.29, p=0.013). The non-insulin dependent diabetic (n=27) and the non-diabetic (n=74) subjects had similar mean (inter-quartile range) centile birth weight 50% (19%-91%), and 53% (30%-75%) respectively. Non-insulin dependent diabetic subjects had significantly lower beta function than the non-diabetic subjects: 69% (48%-83%) v 97% (86%-120%), p<0.001. Conclusions-The cause of the association between low birth weight and reduced beta cell function in adult life is uncertain. Impaired beta cell function in non-insulin dependent diabetic subjects was not accounted for by low birth weight, and genetic or environmental factors are likely to be necessary for development of diabetes.			COOK, JTE (corresponding author), RADCLIFFE INFIRM,DIABET RES LABS,OXFORD OX2 6HE,ENGLAND.			Hattersley, Andrew/0000-0001-5620-473X; Levy, Jonathan/0000-0002-9486-1885				BARKER DJP, 1989, LANCET, V2, P577; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; CLARK A, 1988, DIABETES RES CLIN EX, V9, P151; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; HAMMERSLEY MS, 1992, DIABETIC MED S1, V9, P17; HATTERSLEY AT, 1992, LANCET, V339, P1307, DOI 10.1016/0140-6736(92)91958-B; Hellerstrom C, 1988, PATHOLOGY ENDOCRINE, P141; HOSKER JP, 1985, DIABETOLOGIA, V28, P401, DOI 10.1007/BF00280882; HOSKER JP, 1985, DIABETOLOGIA, V28, P809, DOI 10.1007/BF00291069; LEVY JC, 1991, DIABETOLOGIA, V34, P488, DOI 10.1007/BF00403285; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; ORAHILLY SP, 1986, LANCET, V2, P360; PORTE D, 1991, DIABETES, V40, P166, DOI 10.2337/diabetes.40.2.166; SAAD MF, 1990, J CLIN ENDOCR METAB, V70, P1247, DOI 10.1210/jcem-70-5-1247; TANNER JM, 1970, ARCH DIS CHILD, V45, P566, DOI 10.1136/adc.45.242.566; TEMPLE RC, 1989, LANCET, V1, P293, DOI 10.1016/S0140-6736(89)91306-8; THOMSON A M, 1968, Journal of Obstetrics and Gynaecology of the British Commonwealth, V75, P903; van Assche F A, 1979, Contrib Gynecol Obstet, V5, P44; VELHO G, 1992, LANCET, V340, P444, DOI 10.1016/0140-6736(92)91768-4; WEIR GC, 1982, DIABETOLOGIA, V30, P123; 1985, WHO TECH REP SER, V727	21	79	81	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 30	1993	306	6873					302	306		10.1136/bmj.306.6873.302	http://dx.doi.org/10.1136/bmj.306.6873.302			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK718	8461648	Green Published, Bronze			2022-12-24	WOS:A1993KK71800020
J	FAIRLEY, CK; MCNEIL, JJ; DESMOND, P; SMALLWOOD, R; YOUNG, H; FORBES, A; PURCELL, P; BOYD, I				FAIRLEY, CK; MCNEIL, JJ; DESMOND, P; SMALLWOOD, R; YOUNG, H; FORBES, A; PURCELL, P; BOYD, I			RISK-FACTORS FOR DEVELOPMENT OF FLUCLOXACILLIN ASSOCIATED JAUNDICE	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To identify risk factors predisposing to the development of flucloxacillin associated jaundice. Design-Case-control study. Medical records of cases and controls were reviewed and information recorded on standard data collection forms. Setting-Alfred Hospital recruiting subjects from Melbourne, Sydney, and Brisbane. Subjects-Cases were defined as patients who had developed jaundice within eight weeks of stopping flucloxacillin, biochemical test results suggesting cholestasis, normal calibre bile ducts, and not been taking recognised hepatotoxic drugs. 51 of the 53 patients referred were included in the study. Four controls for each case were randomly selected from the patient register of the prescribing doctor. These were defined as patients who had been prescribed flucloxacillin without developing jaundice. Main outcome measures-Demographic characteristics, medical history, indication for flucloxacillin, dose, route and duration of treatment, other drugs, smoking, and previous drug allergies or use of flucloxacillin. Results-Increasing age and a prolonged duration of flucloxacillin treatment were found to be risk factors for the development of jaundice. Patients aged over 55 years had an odds ratio of 18.61 (95% confidence interval 5.16-67.17) compared with patients under 30. The odds ratio for patients prescribed flucloxacillin for over 14 days was 7.13 (2.90 to 17.58) compared with patients treated for 14 days or less. Dose and route of administration were not related to the risk of jaundice. Conclusions-Older patients and those receiving flucloxacillin for longer than two weeks are at a substantially greater risk of jaundice. Careful consideration of the risk-benefit ratio is required when flucloxacillin is used in these settings.	ST VINCENTS HOSP,DEPT GASTROENTEROL,MELBOURNE,VIC,AUSTRALIA; REPATRIAT GEN HOSP,DEPT MED,MELBOURNE,AUSTRALIA; THERAPEUT GOODS ADM,DRUG EVALUAT BRANCH,ADVERSE DRUG REACT SECT,CANBERRA,ACT 2601,AUSTRALIA	St Vincent's Hospital Melbourne	FAIRLEY, CK (corresponding author), MONASH UNIV,ALFRED HOSP,DEPT SOCIAL & PREVENT MED,MELBOURNE,VIC 3181,AUSTRALIA.		McNeil, John/L-6440-2019	McNeil, John/0000-0002-1049-5129; Forbes, Andrew/0000-0003-4269-914X; Christopher, Fairley/0000-0001-9081-1664				COULTER DM, 1990, LANCET, V336, P785, DOI 10.1016/0140-6736(90)93248-N; FAIRLEY CK, 1992, LANCET, V339, P679, DOI 10.1016/0140-6736(92)90837-S; LOBATTO S, 1982, NETH J MED, V25, P47; MIROS M, 1990, AUST NZ J MED, V20, P251, DOI 10.1111/j.1445-5994.1990.tb01032.x; OLSSON R, 1992, J HEPATOL, V15, P154, DOI 10.1016/0168-8278(92)90029-O; SUTHERLAND R, 1970, BMJ-BRIT MED J, V4, P455, DOI 10.1136/bmj.4.5733.455; TURNER IB, 1989, MED J AUSTRALIA, V151, P701, DOI 10.5694/j.1326-5377.1989.tb139652.x	7	68	68	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 23	1993	306	6872					233	235		10.1136/bmj.306.6872.233	http://dx.doi.org/10.1136/bmj.306.6872.233			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ591	8443520	Bronze, Green Published			2022-12-24	WOS:A1993KJ59100016
J	DAVIES, K				DAVIES, K			CLONING THE MENKES DISEASE GENE	NATURE			English	Article																		CHELLY J, 1993, NAT GENET, V3, P14, DOI 10.1038/ng0193-14; COLLINS FS, 1992, NAT GENET, V1, P3, DOI 10.1038/ng0492-3; DANKS DM, 1972, LANCET, V1, P1101; HAMER DH, 1993, NAT GENET, V3, P3, DOI 10.1038/ng0193-3; Kaler S. G., 1992, American Journal of Human Genetics, V51, pA170; LEVINSON D, 1993, NATURE GENET, V3, P6; MENKES JH, 1962, PEDIATRICS, V29, P764; MERCER JFB, 1993, NAT GENET, V3, P20, DOI 10.1038/ng0193-20; VULPE C, 1993, NAT GENET, V3, P7, DOI 10.1038/ng0193-7	9	12	12	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 7	1993	361	6407					98	98		10.1038/361098a0	http://dx.doi.org/10.1038/361098a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KF718	8421503	Bronze			2022-12-24	WOS:A1993KF71800059
J	GERBER, GS; THOMPSON, IM; THISTED, R; CHODAK, GW				GERBER, GS; THOMPSON, IM; THISTED, R; CHODAK, GW			DISEASE-SPECIFIC SURVIVAL FOLLOWING ROUTINE PROSTATE-CANCER SCREENING BY DIGITAL RECTAL EXAMINATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ADENOCARCINOMA; DIAGNOSIS; ANTIGEN	Objective.-To assess prostate cancer mortality in men undergoing routine screening by routine digital rectal examination. Design.-Cohort study with a median follow-up period of 75 months. Setting.-Population consisted of volunteers at a university clinic and men in an institutional health maintenance clinic. Patients.-Fifty-six men with a mean age of 65 years (range, 52 to 79 years) diagnosed with prostate cancer. Interventions.-Patients treated initially by observation, external or interstitial radiotherapy, radical prostatectomy, hormone therapy, or combination. Main Outcome Measures.-Kaplan-Meier analysis of time to local progression, distant metastases, death from all causes, and death from prostate cancer. Mantel-Haenszel log-rank statistic was used to compare outcome in men diagnosed on initial examination with those diagnosed on subsequent examinations. Results.-Clinically localized prostate cancer was diagnosed in 73% during an initial examination and in 33% (6/18) during subsequent examinations. Five- and 10-year disease-specific survival was 97% and 86%, respectively, for men diagnosed during the first rectal examination compared with only 81% and 57%, respectively, for men diagnosed on subsequent rectal examinations (P=.02). Conclusion.-Routine screening for prostate cancer by annual digital rectal examination alone may be insufficiently frequent and/or sensitive to prevent significant mortality from this disease.	UNIV CHICAGO HOSP & CLIN,DEPT SURG,DIV UROL,CHICAGO,IL 60637; UNIV CHICAGO HOSP & CLIN,DEPT STAT,CHICAGO,IL 60637; UNIV CHICAGO HOSP & CLIN,DEPT ANESTHESIA & CRIT CARE,CHICAGO,IL 60637; BROOKE ARMY MED CTR,DEPT SURG,UROL SERV,FT SAM HOUSTON,TX 78234	University of Chicago; University of Illinois System; University of Chicago; University of Illinois System; University of Chicago; University of Illinois System; San Antonio Military Medical Center; United States Department of Defense; United States Army			Thisted, Ronald A/B-1985-2008					AUBERT R, 1992, MMWR, V41, P401; BRAWER MK, 1992, J UROLOGY, V147, P841, DOI 10.1016/S0022-5347(17)37401-3; CATALONA WJ, 1991, NEW ENGL J MED, V324, P1156, DOI 10.1056/NEJM199104253241702; CHODAK GW, 1989, J UROLOGY, V141, P1136, DOI 10.1016/S0022-5347(17)41192-X; Cooner W H, 1987, Ala Med, V56, P13; GILBERTSON JA, 1976, JAMA-J AM MED ASSOC, V215, P81; GUINAN P, 1980, NEW ENGL J MED, V303, P499, DOI 10.1056/NEJM198008283030906; JENSON CB, 1960, JAMA-J AM MED ASSOC, V174, P1783, DOI 10.1001/jama.1960.03030140005002; LEE F, 1988, RADIOLOGY, V168, P389, DOI 10.1148/radiology.168.2.3293108; MURPHY GP, 1982, J UROLOGY, V127, P928, DOI 10.1016/S0022-5347(17)54135-X; SCHOENFELD DA, 1982, BIOMETRICS, V38, P163, DOI 10.2307/2530299; SHAPIRO S, 1982, JNCI-J NATL CANCER I, V69, P349; SILVERBERG E, 1987, CA-CANCER J CLIN, V37, P2; STAMEY TA, 1988, J UROLOGY, V139, P1235; STAMEY TA, 1989, J UROLOGY, V141, P1076, DOI 10.1016/S0022-5347(17)41175-X; THOMPSON IM, 1987, J UROLOGY, V137, P424, DOI 10.1016/S0022-5347(17)44055-9	16	68	69	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 6	1993	269	1					61	64		10.1001/jama.269.1.61	http://dx.doi.org/10.1001/jama.269.1.61			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF026	8416407				2022-12-24	WOS:A1993KF02600028
J	BERNHAGEN, J; CALANDRA, T; MITCHELL, RA; MARTIN, SB; TRACEY, KJ; VOELTER, W; MANOGUE, KR; CERAMI, A; BUCALA, R				BERNHAGEN, J; CALANDRA, T; MITCHELL, RA; MARTIN, SB; TRACEY, KJ; VOELTER, W; MANOGUE, KR; CERAMI, A; BUCALA, R			MIF IS A PITUITARY-DERIVED CYTOKINE THAT POTENTIATES LETHAL ENDOTOXEMIA	NATURE			English	Article							TUMOR-NECROSIS-FACTOR; MIGRATION-INHIBITORY FACTOR; ACTIVATES HUMAN MACROPHAGES; BINDING-PROTEIN; LIPOPOLYSACCHARIDE; CACHECTIN; INTERLEUKIN-1; HYPOTHALAMUS; CELLS; GENES	CYTOKINES are critical in the often fatal cascade of events that cause septic shock1-3. One regulatory system that is likely to be important in controlling inflammatory responses is the neuroendocrine axis. The pituitary, for example, is ideally situated to integrate central and peripheral stimuli4, and initiates the increase in systemic glucocorticoids that accompanies host stress responses6-8. To assess further the contribution of the pituitary to systemic inflammatory processes, we examined the secretory profile of cultured pituitary cells and whole pituitaries in vivo after stimulation with bacterial lipopolysaccharide (LPS). Here we identify macrophage migration inhibitory factor (MIF)9-11 as a major secreted protein released by anterior pituitary cells in response to LPS stimulation. Serum analysis of control, hypophysectomized and T-cell-deficient (nude) mice suggests that pituitary-derived MIF contributes to circulating MIF present in the post-acute phase of endotoxaemia. Recombinant murine MIF greatly enhances lethality when co-injected with LPS and anti-MIF antibody confers full protection against lethal endotoxaemia. We conclude that MIF plays a central role in the toxic response to endotoxaemia and possibly spetic shock.	PICOWER INST MED RES,350 COMMUNITY DR,MANHASSET,NY 11030; UNIV TUBINGEN,INST PHYSIOL CHEM,W-7400 TUBINGEN 1,GERMANY; CORNELL UNIV,MED CTR,NEW YORK HOSP,COLL MED,DIV NEUROSURG,NEW YORK,NY 10021; N SHORE UNIV HOSP,CORNELL UNIV MED COLL,COLL MED,DEPT SURG,MANHASSET,NY 11030	Northwell Health; Eberhard Karls University of Tubingen; Cornell University; NewYork-Presbyterian Hospital; Cornell University; Northwell Health; North Shore University Hospital			Calandra, Thierry/D-9017-2015	Calandra, Thierry/0000-0003-3051-1285; Tracey, Kevin J/0000-0003-1884-6314				ALONSO S, 1986, J MOL EVOL, V23, P11, DOI 10.1007/BF02100994; BESEDOVSKY H, 1986, SCIENCE, V233, P652, DOI 10.1126/science.3014662; BEUTLER B, 1986, NATURE, V320, P584, DOI 10.1038/320584a0; BLOOM BR, 1966, SCIENCE, V153, P80, DOI 10.1126/science.153.3731.80; BOYDEN S, 1962, J EXP MED, V115, P453, DOI 10.1084/jem.115.3.453; CUNHA FQ, 1993, J IMMUNOL, V150, P1908; DAVID JR, 1966, P NATL ACAD SCI USA, V65, P72; DINARELLO CA, 1991, J INFECT DIS, V163, P1177, DOI 10.1093/infdis/163.6.1177; FRAKER DL, 1988, J EXP MED, V168, P95, DOI 10.1084/jem.168.1.95; GILLILAND G, 1990, P NATL ACAD SCI USA, V87, P2725, DOI 10.1073/pnas.87.7.2725; HEUMANN D, 1991, J INFECT DIS, V163, P762, DOI 10.1093/infdis/163.4.762; KOENIG JI, 1990, ENDOCRINOLOGY, V126, P3053, DOI 10.1210/endo-126-6-3053; KRIEG M, 1990, TESTOSTERONE ACTION, P219; LI B, 1991, J EXP MED, V174, P1259, DOI 10.1084/jem.174.5.1259; MAKARA GB, 1971, ENDOCRINOLOGY, V88, P412, DOI 10.1210/endo-88-2-412; POZZI LAM, 1992, CELL IMMUNOL, V145, P372, DOI 10.1016/0008-8749(92)90339-Q; Reichlin S., 1992, WILLIAMS TXB ENDOCRI, P135; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; SILVERSTEIN R, 1991, J EXP MED, V173, P357, DOI 10.1084/jem.173.2.357; THORNER MO, 1992, WILLIAMS TXB ENDOCRI, P221; Tracey K J, 1990, Adv Surg, V23, P21; TRACEY KJ, 1989, LANCET, V1, P1122; WEISER WY, 1992, P NATL ACAD SCI USA, V89, P8049, DOI 10.1073/pnas.89.17.8049; WEISER WY, 1991, J IMMUNOL, V147, P2006; WEISER WY, 1989, P NATL ACAD SCI USA, V86, P7522, DOI 10.1073/pnas.86.19.7522; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; YASUDA N, 1978, ENDOCRINOLOGY, V102, P947, DOI 10.1210/endo-102-3-947	27	890	946	1	22	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 21	1993	365	6448					756	759		10.1038/365756a0	http://dx.doi.org/10.1038/365756a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MC812	8413654				2022-12-24	WOS:A1993MC81200064
J	FUNAHASHI, S; CHAFEE, MV; GOLDMANRAKIC, PS				FUNAHASHI, S; CHAFEE, MV; GOLDMANRAKIC, PS			PREFRONTAL NEURONAL-ACTIVITY IN RHESUS-MONKEYS PERFORMING A DELAYED ANTI-SACCADE TASK	NATURE			English	Article							POSTERIOR PARIETAL CORTEX; SUPERIOR COLLICULUS; EYE-MOVEMENTS; FRONTAL-LOBE; PROJECTIONS; RESPONSES; MACAQUE; AREAS; GOAL	PATIENTS with damage to the dorsolateral prefrontal cortex are impaired on cognitive tasks such as the Wisconsin Card Sort Test1, the Stroop Test2 and an anti-saccade paradigm3, in which sensory-guided habitual responses must be suppressed in favour of conceptually or memory-guided responses. We report here recordings from prefrontal neurons in rhesus monkeys trained to perform a delayed anti-saccade task based on tests that have been used with humans3. Activity in the same prefrontal neurons was recorded across conditions when saccades were made toward a remembered target, and also when this prepotent response was suppressed and a saccade in the opposite direction required. Our findings show that most prefrontal neurons code the location of the visual stimulus in working memory, and that this memory can be engaged to suppress as well as prescribe a response. These results establish, in a subset of prefrontal neurons, the iconic nature of the memory code, and suggest a role for visual memory in response suppression.	YALE UNIV,SCH MED,NEUROBIOL SECT,NEW HAVEN,CT 06510	Yale University								ALEXANDER GE, 1990, J NEUROPHYSIOL, V64, P164, DOI 10.1152/jn.1990.64.1.164; Baddeley A., 1974, PSYCHOL LEARNING MOT, V8; BARBAS H, 1987, J COMP NEUROL, V256, P211, DOI 10.1002/cne.902560203; BARBAS H, 1981, J COMP NEUROL, V200, P407, DOI 10.1002/cne.902000309; BOCH RA, 1989, J NEUROPHYSIOL, V61, P1064, DOI 10.1152/jn.1989.61.5.1064; BRUCE CJ, 1985, J NEUROPHYSIOL, V53, P603, DOI 10.1152/jn.1985.53.3.603; CAVADA C, 1989, J COMP NEUROL, V287, P422, DOI 10.1002/cne.902870403; FRIES W, 1984, J COMP NEUROL, V230, P55, DOI 10.1002/cne.902300106; FUKUSHIMA J, 1988, BIOL PSYCHIAT, V23, P670, DOI 10.1016/0006-3223(88)90050-9; FUNAHASHI S, 1990, J NEUROPHYSIOL, V63, P814, DOI 10.1152/jn.1990.63.4.814; FUNAHASHI S, 1991, J NEUROPHYSIOL, V65, P1464, DOI 10.1152/jn.1991.65.6.1464; FUNAHASHI S, 1989, J NEUROPHYSIOL, V61, P331, DOI 10.1152/jn.1989.61.2.331; GNADT JW, 1988, EXP BRAIN RES, V70, P216; GOLDMAN PS, 1976, BRAIN RES, V116, P145, DOI 10.1016/0006-8993(76)90256-0; GUITTON D, 1985, EXP BRAIN RES, V58, P455; MAYS LE, 1980, J NEUROPHYSIOL, V43, P207, DOI 10.1152/jn.1980.43.1.207; McGuire PK, 1991, CEREB CORTEX, V1, P390, DOI 10.1093/cercor/1.5.390; MILNER B, 1963, ARCH NEUROL-CHICAGO, V9, P90, DOI 10.1001/archneur.1963.00460070100010; NIKI H, 1976, BRAIN RES, V105, P79, DOI 10.1016/0006-8993(76)90924-0; PARK S, 1992, ARCH GEN PSYCHIAT, V49, P975; PERRET E, 1974, NEUROPSYCHOLOGIA, V12, P323, DOI 10.1016/0028-3932(74)90047-5; SELEMON LD, 1985, J NEUROSCI, V5, P776; THAKER G, 1989, PSYCHOPHARMACOL BULL, V25, P491	23	519	526	0	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 21	1993	365	6448					753	756		10.1038/365753a0	http://dx.doi.org/10.1038/365753a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MC812	8413653				2022-12-24	WOS:A1993MC81200063
J	BEGUN, DJ; AQUADRO, CF				BEGUN, DJ; AQUADRO, CF			AFRICAN AND NORTH-AMERICAN POPULATIONS OF DROSOPHILA-MELANOGASTER ARE VERY DIFFERENT AT THE DNA LEVEL	NATURE			English	Article							RESTRICTION-MAP VARIATION; NATURAL-POPULATIONS; PHENOTYPIC VARIATION; GENETIC-VARIATION; GENIC VARIATION; LOCUS REGION; POLYMORPHISM; ENDONUCLEASES; PATTERNS; FLOW	UNDERSTANDING genetic evolution within species requires an accurate description of variation within and between populations and the ability to distinguish between the potential causes of an observed distribution of variation. In the cosmopolitan species Drosophila melanogaster, previous studies suggested that gene flow within and between continents is extensive1 and that most of the nuclear gene variation is found within, rather than among, populations2,3. Here we present evidence that a population from Zimbabwe is more than twice as variable as those from the United States of America at the DNA sequence level, that most variants are not shared between the two geographic regions, and that there are nearly fixed differences between the Zimbabwe and USA samples in genomic regions experiencing low recombination rates. It appears that there is an unappreciated degree of population structure in D. melanogaster and that equilibrium models of molecular evolution are inappropriate for this species.			BEGUN, DJ (corresponding author), CORNELL UNIV, GENET & DEV SECT, BIOTECHNOL BLDG, ITHACA, NY 14853 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036431] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM036431] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEGUN DJ, 1992, NATURE, V356, P519, DOI 10.1038/356519a0; CHARLESWORTH B, 1993, GENETICS, V134, P1289; DAVID JR, 1988, TRENDS GENET, V4, P106, DOI 10.1016/0168-9525(88)90098-4; EANES WF, 1989, MOL BIOL EVOL, V6, P384; EANES WF, 1989, MOL BIOL EVOL, V6, P492; Hudson R.R., 1990, Oxford Surveys in Evolutionary Biology, V7, P1; HUDSON RR, 1992, MOL BIOL EVOL, V9, P138; HUDSON RR, 1987, GENETICS, V116, P153; HUDSON RR, 1992, GENETICS, V132, P583; HUDSON RR, 1982, GENETICS, V100, P711; KAPLAN NL, 1989, GENETICS, V123, P887; KREITMAN M, 1986, P NATL ACAD SCI USA, V83, P3562, DOI 10.1073/pnas.83.10.3562; KREITMAN M, 1983, NATURE, V304, P412, DOI 10.1038/304412a0; KREITMAN M, 1991, GENETICS, V127, P565; LANGLEY CH, 1993, P NATL ACAD SCI USA, V90, P1800, DOI 10.1073/pnas.90.5.1800; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; MARTINCAMPOS JM, 1992, GENETICS, V130, P805; Maynard-Smith J, 1974, GENET RES, V23, P23, DOI [10.1017/S0016672300014634, 10.1017/S0016672308009579]; MIYASHITA N, 1988, GENETICS, V120, P199; MIYASHITA NT, 1990, GENETICS, V125, P407; NEI M, 1979, P NATL ACAD SCI USA, V76, P5269, DOI 10.1073/pnas.76.10.5269; SINGH RS, 1987, GENETICS, V117, P255; SINGH RS, 1987, GENETICS, V115, P313; SINGH RS, 1982, GENETICS, V101, P235; STEPHAN W, 1992, GENETICS, V132, P1039, DOI 10.1093/genetics/132.4.1039; TAJIMA F, 1989, GENETICS, V123, P585	26	261	262	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 7	1993	365	6446					548	550		10.1038/365548a0	http://dx.doi.org/10.1038/365548a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MA661	8413609				2022-12-24	WOS:A1993MA66100054
J	DAY, ML; PICKERING, SJ; JOHNSON, MH; COOK, DI				DAY, ML; PICKERING, SJ; JOHNSON, MH; COOK, DI			CELL-CYCLE CONTROL OF A LARGE-CONDUCTANCE K+-CHANNEL IN MOUSE EARLY EMBRYOS	NATURE			English	Article							POTASSIUM CHANNELS; IMPROVED CULTURE; CALCIUM CURRENT; LYMPHOCYTE-T; PROLIFERATION; CLEAVAGE; PROTEINS; INVITRO	THERE have been few investigations into the role of ion channels in mammalian early embryonic development1-4, despite studies showing that changes in ion channel activity accompany the early embryonic development of non-mammalian species5-7 and the proliferation of mammalian cells8-12. Here we report that a large-conductance, voltage-activated K+ channel is active in unfertilized mouse oocytes but is rarely observed in later embryos. The channel activity is linked to the cell cycle, being active throughout M and G1 phases, and switching off during the G1-to-S transition. These changes in channel activity are accompanied by corresponding shifts in membrane potential. Inactivation of the channel during S/G2 can be prevented by exposing the oocytes to dibutyryl cyclic AMP or forskolin, an activator of adenylyl cyclase. Inhibition of protein synthesis with puromycin did not prevent inactivation of the channel at the end of G1 or its subsequent reactivation at the end of G2, indicating that the channel activity is not regulated by mitosis-promoting factor or cyclins.	UNIV SYDNEY, DEPT PHYSIOL, SYDNEY, NSW 2006, AUSTRALIA; UNIV CAMBRIDGE, DEPT ANAT, CAMBRIDGE CB2 3DY, ENGLAND	University of Sydney; University of Cambridge				Day, Margot/0000-0002-8689-7458; johnson, martin/0000-0002-5906-5883				AMIGORENA S, 1990, J IMMUNOL, V144, P2038; BLATZ AL, 1987, TRENDS NEUROSCI, V10, P463, DOI 10.1016/0166-2236(87)90101-9; BLOCK ML, 1990, SCIENCE, V247, P1090, DOI 10.1126/science.2309122; BOLTON VN, 1984, J EMBRYOL EXP MORPH, V79, P139; BOUNTRA C, 1987, Q J EXP PHYSIOL CMS, V72, P483, DOI 10.1113/expphysiol.1987.sp003090; BUBIEN JK, 1990, SCIENCE, V248, P1416, DOI 10.1126/science.2162561; CHATOT CL, 1989, J REPROD FERTIL, V86, P679, DOI 10.1530/jrf.0.0860679; CHIU SY, 1989, J PHYSIOL-LONDON, V408, P199, DOI 10.1113/jphysiol.1989.sp017455; DECOURSEY TE, 1984, NATURE, V307, P465, DOI 10.1038/307465a0; DEUTSCH C, 1990, PROG CLIN BIOL RES, V334, P251; GRANDIN N, 1991, J CELL BIOL, V112, P711, DOI 10.1083/jcb.112.4.711; HOWLETT SK, 1985, J EMBRYOL EXP MORPH, V87, P175; HOWLETT SK, 1986, CELL, V45, P387, DOI 10.1016/0092-8674(86)90324-7; KLINE D, 1991, DEV BIOL MEMBRANE TR, V39, P89; LEE SJ, 1987, IN VITRO FERT EMBRYO, V4, P331; MATTESON DR, 1984, NATURE, V307, P468, DOI 10.1038/307468a0; MEDINA I, 1991, P ROY SOC B-BIOL SCI, V245, P159, DOI 10.1098/rspb.1991.0103; MEDINA IR, 1988, PROC R SOC SER B-BIO, V235, P95, DOI 10.1098/rspb.1988.0064; MITANI S, 1985, J PHYSIOL-LONDON, V363, P71, DOI 10.1113/jphysiol.1985.sp015696; MOODY WJ, 1991, J NEUROBIOL, V22, P674, DOI 10.1002/neu.480220703; NASRESFAHANI M, 1990, HUM REPROD, V5, P997, DOI 10.1093/oxfordjournals.humrep.a137235; PERES A, 1987, J PHYSIOL-LONDON, V391, P573, DOI 10.1113/jphysiol.1987.sp016757; POENIE M, 1986, SCIENCE, V233, P886, DOI 10.1126/science.3755550; ROBINSON DH, 1991, DEV BIOL MEMBRANE TR, V39, P121; SABATH DE, 1986, P NATL ACAD SCI USA, V83, P4739, DOI 10.1073/pnas.83.13.4739; SMITH RKW, 1986, J REPROD FERTIL, V76, P393, DOI 10.1530/jrf.0.0760393; WAKSMUNDZKA M, 1984, J EMBRYOL EXP MORPH, V79, P77; WEGMAN EA, 1991, PFLUG ARCH EUR J PHY, V417, P562, DOI 10.1007/BF00372952; WHITAKER M, 1990, DEVELOPMENT, V108, P525; YOSHIDA S, 1990, PFLUG ARCH EUR J PHY, V415, P516, DOI 10.1007/BF00373637	30	119	122	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 7	1993	365	6446					560	562		10.1038/365560a0	http://dx.doi.org/10.1038/365560a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MA661	8413614				2022-12-24	WOS:A1993MA66100059
J	SIMON, MA; DODSON, GS; RUBIN, GM				SIMON, MA; DODSON, GS; RUBIN, GM			AN SH3-SH2-SH3 PROTEIN IS REQUIRED FOR P21(RAS1) ACTIVATION AND BINDS TO SEVENLESS AND SOS PROTEINS INVITRO	CELL			English	Article							DEVELOPING DROSOPHILA EYE; GLUTATHIONE-S-TRANSFERASE; ELEGANS VULVAR INDUCTION; SIGNAL TRANSDUCTION; TYROSINE KINASE; CELL FATES; CAENORHABDITIS-ELEGANS; ESCHERICHIA-COLI; GENE; PHOTORECEPTOR	Activation of the sevenless protein-tyrosine kinase is required for the proper specification of R7 photoreceptors in the Drosophila eye. The activation of a Ras protein, p21Ras1, is a crucial early event in the signaling pathway, and constitutive activation of p21Ras1 is sufficient to induce all of the effects of sevenless action. Here we report that another gene, E(sev)2B, required for proper signaling by sevenless encodes a protein of the structure SH3-SH2-SH3. We further provide evidence that the E(sev)2B protein is required for activation of p21Ras1 but not for any subsequent events, and that this protein can bind in vitro to sevenless and to Son of sevenless (Sos), a putative guanine nucleotide exchange factor for p21Ras1. These results suggest that the E(sev)2B protein may act to stimulate the ability of Sos to catalyze p21Ras1 activation by linking sevenless and Sos in a signaling complex. We have renamed the E(sev)2B locus downstream of receptor kinases (drk).	UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,BERKELEY,CA 94720; UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of California System; University of California Berkeley	SIMON, MA (corresponding author), STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305, USA.			Rubin, Gerald/0000-0001-8762-8703	NATIONAL EYE INSTITUTE [R01EY009845] Funding Source: NIH RePORTER; NEI NIH HHS [1RO1EY9845-01] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BANERJEE U, 1990, NEURON, V4, P177, DOI 10.1016/0896-6273(90)90093-U; BASLER K, 1989, EMBO J, V8, P2381, DOI 10.1002/j.1460-2075.1989.tb08367.x; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BOWTELL DDL, 1989, P NATL ACAD SCI USA, V86, P6245, DOI 10.1073/pnas.86.16.6245; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HAFEN E, 1987, SCIENCE, V236, P55, DOI 10.1126/science.2882603; HAN M, 1990, GENETICS, V126, P899; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; KARPEN GH, 1992, GENETICS, V132, P737; KIMMEL BE, 1990, GENE DEV, V4, P712, DOI 10.1101/gad.4.5.712; LI BQ, 1992, SCIENCE, V256, P1546; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; OLIVIER JP, 1993, IN PRESS CELL, V73; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PAZIN MJ, 1992, TRENDS BIOCHEM SCI, V17, P374, DOI 10.1016/0968-0004(92)90003-R; ROBERTSON HM, 1988, GENETICS, V118, P461; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; RUBIN GM, 1991, TRENDS GENET, V7, P372, DOI 10.1016/0168-9525(91)90258-R; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMON MA, 1989, P NATL ACAD SCI USA, V86, P8333, DOI 10.1073/pnas.86.21.8333; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STERNBERG PW, 1991, TRENDS GENET, V7, P366, DOI 10.1016/0168-9525(91)90257-Q; SZEBERENYI J, 1992, MOL CELL BIOL, V7, P2105; TOMLINSON A, 1988, DEVELOPMENT, V104, P183; TOMLINSON A, 1986, SCIENCE, V231, P400, DOI 10.1126/science.231.4736.400; XU T, 1993, IN PRESS DEVELOPMENT	35	443	452	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 9	1993	73	1					169	177		10.1016/0092-8674(93)90169-Q	http://dx.doi.org/10.1016/0092-8674(93)90169-Q			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KW753	8462097				2022-12-24	WOS:A1993KW75300017
J	GRAHAM, GG				GRAHAM, GG			STARVATION IN THE MODERN WORLD	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PROTEIN-CALORIE MALNUTRITION; CHILDREN		JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, BALTIMORE, MD 21205 USA; INST INVEST NUTR, LIMA, PERU	Johns Hopkins University								APPLETON J, 1987, DROUGHT RELIEF ETHIO, P48; AYKROYD WR, 1974, FAMINE IRELAND, P34; BRUNSER O, 1966, PEDIATRICS, V38, P605; CAHILL GF, 1978, ECOL FOOD NUTR, V6, P221, DOI 10.1080/03670244.1978.9990501; CHEEK DB, 1970, PEDIATR RES, V4, P135, DOI 10.1203/00006450-197003000-00004; DRENICK EJ, 1964, JAMA-J AM MED ASSOC, V187, P100; GRAHAM GG, 1986, J NUTR, V116, P978, DOI 10.1093/jn/116.6.978; GRAHAM GG, 1969, JOHNS HOPKINS MED J, V124, P139; GRAHAM GG, 1971, AM J CLIN NUTR, V24, P416; GRAHAM GG, 1973, AM J CLIN NUTR, V26, P491, DOI 10.1093/ajcn/26.5.491; HANSEN JDL, 1954, LANCET, V2, P477; HINTZ RL, 1978, J PEDIATR-US, V92, P153, DOI 10.1016/S0022-3476(78)80099-7; IFEKWUNIGWE AE, 1975, AM J CLIN NUTR, V28, P79, DOI 10.1093/ajcn/28.1.79; KEYS A, 1950, BIOL HUMAN STARVATIO, V2, P769; MAYER J, 1971, FAMINE S DEALING NUT, P178; MCLAREN DS, 1974, LANCET, V2, P93; RAMALINGASWAMI V, 1971, FAMINE S DEALING NUT, P94; SCRIMSHAW NS, 1972, P NUTR SOC, V31, P219; Stein Z., 1975, FAMINE HUM DEV DUTCH; TEPLY LJ, 1971, FAMINE S DEALING NUT, P165; TOOLE MJ, 1990, JAMA-J AM MED ASSOC, V263, P3296, DOI 10.1001/jama.263.24.3296; Viteri F E, 1968, Vitam Horm, V26, P573; VITERI FE, 1971, FAMINE S DEALING NUT, P25	24	15	15	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 8	1993	328	14					1058	1061		10.1056/NEJM199304083281429	http://dx.doi.org/10.1056/NEJM199304083281429			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW282	8450873				2022-12-24	WOS:A1993KW28200038
J	LEMASSON, G; MARDER, E; ABBOTT, LF				LEMASSON, G; MARDER, E; ABBOTT, LF			ACTIVITY-DEPENDENT REGULATION OF CONDUCTANCES IN MODEL NEURONS	SCIENCE			English	Article							IMMEDIATE EARLY GENES; CALCIUM; CHANNELS; SYSTEM	Neurons maintain their electrical activity patterns despite channel turnover, cell growth, and variable extracellular conditions. A model is presented in which maximal conductances of ionic currents depend on the intracellular concentration of calcium ions and so, indirectly, on activity. Model neurons with activity-dependent maximal conductances modify their conductances to maintain a given behavior when perturbed. Moreover, neurons that are described by identical sets of equations can develop different properties in response to different patterns of presynaptic activity.	BRANDEIS UNIV,DEPT PHYS,WALTHAM,MA 02254; BRANDEIS UNIV,DEPT BIOL,WALTHAM,MA 02254; BRANDEIS UNIV,CTR COMPLEX SYST,WALTHAM,MA 02254	Brandeis University; Brandeis University; Brandeis University					NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH046742, R37MH046742] Funding Source: NIH RePORTER; NIMH NIH HHS [MH46742] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ABBOTT LF, IN PRESS NEURAL COMP; BUCHHOLTZ F, 1992, J NEUROPHYSIOL, V67, P332, DOI 10.1152/jn.1992.67.2.332; Byrne J. H., 1989, NEURAL MODELS PLASTI; CHAD JE, 1986, J PHYSIOL-LONDON, V378, P31, DOI 10.1113/jphysiol.1986.sp016206; CONSTANTINEPATON M, 1990, ANNU REV NEUROSCI, V13, P129, DOI 10.1146/annurev.neuro.13.1.129; EPSTEIN IR, 1990, BIOL CYBERN, V63, P25, DOI 10.1007/BF00202450; FRANKLIN JL, 1992, J NEUROSCI, V12, P1726; Gluck M. A., 1990, NEUROSCIENCE CONNECT; GOLOWASCH J, 1992, J NEUROPHYSIOL, V67, P318, DOI 10.1152/jn.1992.67.2.318; GOLOWASCH J, 1992, J NEUROPHYSIOL, V67, P341, DOI 10.1152/jn.1992.67.2.341; HEMMICK LM, 1992, J NEUROSCI, V12, P2007; KACZMAREK LK, 1987, TRENDS NEUROSCI, V10, P30, DOI 10.1016/0166-2236(87)90122-6; Kaczmarek LK, 1987, NEUROMODULATION BIOC; KENNEDY MB, 1989, TRENDS NEUROSCI, V12, P417, DOI 10.1016/0166-2236(89)90089-1; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; MORRIS C, 1981, BIOPHYS J, V35, P193, DOI 10.1016/S0006-3495(81)84782-0; MURPHY TH, 1991, NEURON, V7, P625, DOI 10.1016/0896-6273(91)90375-A; PLANT RE, 1976, BIOPHYS J, V16, P227, DOI 10.1016/S0006-3495(76)85683-4; RASMUSSEN H, 1984, PHYSIOL REV, V64, P938, DOI 10.1152/physrev.1984.64.3.938; RINZEL J, 1987, J MATH BIOL, V25, P653, DOI 10.1007/BF00275501; ROSS WN, 1989, ANNU REV PHYSIOL, V51, P491, DOI 10.1146/annurev.physiol.51.1.491; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; TURRIGIANO GG, UNPUB	23	240	245	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 26	1993	259	5103					1915	1917		10.1126/science.8456317	http://dx.doi.org/10.1126/science.8456317			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KU172	8456317				2022-12-24	WOS:A1993KU17200037
J	FALLS, DL; ROSEN, KM; CORFAS, G; LANE, WS; FISCHBACH, GD				FALLS, DL; ROSEN, KM; CORFAS, G; LANE, WS; FISCHBACH, GD			ARIA, A PROTEIN THAT STIMULATES ACETYLCHOLINE-RECEPTOR SYNTHESIS, IS A MEMBER OF THE NEU LIGAND FAMILY	CELL			English	Article							EPIDERMAL GROWTH-FACTOR; SUBUNIT GENE-EXPRESSION; CULTURED MUSCLE-CELLS; AMINO-ACID-SEQUENCE; MESSENGER-RNA; NEUROMUSCULAR SYNAPSES; CHICK MYOTUBES; SPINAL-CORD; IMMUNOGLOBULIN SUPERFAMILY; DEVELOPMENTAL REGULATION	Motor neurons stimulate their postsynaptic muscle targets to synthesize neurotransmitter receptors. Polypeptide signaling molecules may mediate this inductive interaction. Here we report the purification of ARIA, a protein that stimulates the synthesis of muscle acetylcholine receptors, and the isolation of ARIA cDNA. Recombinant ARIA increases acetylcholine receptor synthesis greater than 3-fold, and it induces tyrosine phosphorylation of a 185 kd muscle protein. The ARIA cDNA hybridizes with mRNAs that are expressed in the spinal cord f rom E4, a time prior to the onset of neuromuscular synapse formation, through adulthood. By E7, hybridizing mRNAs are concentrated in motor neurons. Chicken ARIA is homologous to the rat Neu differentiation factor and human heregulin, ligands for the receptor tyrosine kinase encoded by the neu (c-erbB2, HER2) proto-oncogene. Our data suggest that members of the ARIA protein family promote the formation and maintenance of chemical synapses and, furthermore, that receptor tyrosine kinases play important roles in this process.	HARVARD UNIV, HARVARD MICROCHEM FACIL, CAMBRIDGE, MA 02138 USA	Harvard University	FALLS, DL (corresponding author), HARVARD UNIV, SCH MED, DEPT NEUROBIOL, BOSTON, MA 02115 USA.		Corfas, Gabriel/AAH-2378-2020	Corfas, Gabriel/0000-0001-5412-9473				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BAKER LP, 1992, J CELL SCI, V102, P543; BAKER LP, 1993, J CELL BIOL, V120, P185, DOI 10.1083/jcb.120.1.185; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BELL GI, 1981, P NATL ACAD SCI-BIOL, V78, P5759, DOI 10.1073/pnas.78.9.5759; BOSENBERG MW, 1992, CELL, V71, P1157, DOI 10.1016/S0092-8674(05)80064-9; BRENNER HR, 1992, P ROY SOC B-BIOL SCI, V250, P151, DOI 10.1098/rspb.1992.0143; BRENNER HR, 1978, NATURE, V271, P366, DOI 10.1038/271366a0; BRENNER HR, 1990, NATURE, V344, P544, DOI 10.1038/344544a0; BUCCARON MH, 1983, DEV BIOL, V95, P378, DOI 10.1016/0012-1606(83)90039-8; BURSZTAJN S, 1990, J NEUROBIOL, V21, P387, DOI 10.1002/neu.480210302; CAGAN RL, 1992, CELL, V69, P393, DOI 10.1016/0092-8674(92)90442-F; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CARPENTER G, 1990, PEPTIDE GROWTH FACTO, P69; CHANGEUX JP, 1991, NEW BIOL, V3, P413; CHAO MV, 1992, NEURON, V9, P583, DOI 10.1016/0896-6273(92)90023-7; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN JA, 1992, J NEUROSCI RES, V31, P622, DOI 10.1002/jnr.490310406; COHEN SA, 1977, DEV BIOL, V59, P24, DOI 10.1016/0012-1606(77)90237-8; CORFAS G, 1993, P NATL ACAD SCI USA, V90, P1624, DOI 10.1073/pnas.90.4.1624; CORFAS G, 1993, IN PRESS J NEUROSCI, V13; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DAHM LM, 1991, J NEUROSCI, V11, P238; DAVIS JG, 1991, BIOCHEM BIOPH RES CO, V179, P1536, DOI 10.1016/0006-291X(91)91747-Z; DEVREOTES PN, 1975, J CELL BIOL, V65, P335, DOI 10.1083/jcb.65.2.335; DOBASHI K, 1991, P NATL ACAD SCI USA, V88, P8582, DOI 10.1073/pnas.88.19.8582; FALLS DL, 1990, COLD SPRING HARB SYM, V55, P397; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; FONTAINE B, 1989, J CELL BIOL, V108, P1025, DOI 10.1083/jcb.108.3.1025; FURLEY AJ, 1990, CELL, V61, P157, DOI 10.1016/0092-8674(90)90223-2; Gall JG, 1971, METHOD ENZYMOL, V21, P470; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GODFREY EW, 1984, J CELL BIOL, V99, P615, DOI 10.1083/jcb.99.2.615; GOLDMAN D, 1991, NEURON, V7, P649, DOI 10.1016/0896-6273(91)90377-C; GOLDMAN D, 1989, NEURON, V3, P219, DOI 10.1016/0896-6273(89)90035-4; GORDON MY, 1991, CANCER CELL-MON REV, V3, P127; HALL ZW, 1993, CELL, V72, P99, DOI 10.1016/S0092-8674(05)80031-5; HARRIS DA, 1989, NATURE, V337, P173, DOI 10.1038/337173a0; HARRIS DA, 1988, P NATL ACAD SCI USA, V85, P1983, DOI 10.1073/pnas.85.6.1983; HARRIS DA, 1991, P NATL ACAD SCI USA, V88, P7664, DOI 10.1073/pnas.88.17.7664; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HOROVITZ O, 1989, J CELL BIOL, V108, P1823, DOI 10.1083/jcb.108.5.1823; HOROVITZ O, 1989, J CELL BIOL, V108, P1817, DOI 10.1083/jcb.108.5.1817; HUANG CF, 1992, NEURON, V9, P671, DOI 10.1016/0896-6273(92)90030-H; HUANG SS, 1992, J BIOL CHEM, V267, P11508; HUNKAPILLER T, 1989, ADV IMMUNOL, V44, P1; JESSELL TM, 1979, P NATL ACAD SCI USA, V76, P5397, DOI 10.1073/pnas.76.10.5397; JO SA, 1992, DEVELOPMENT, V115, P673; KANDEL J, 1991, CELL, V66, P1095, DOI 10.1016/0092-8674(91)90033-U; KIRILOVSKY J, 1989, NEUROSCIENCE, V32, P289, DOI 10.1016/0306-4522(89)90079-1; KLARSFELD A, 1989, NEURON, V2, P1229, DOI 10.1016/0896-6273(89)90307-3; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; LAUFER R, 1989, MOL NEUROBIOL, V3, P1, DOI 10.1007/BF02935587; LUPU R, 1990, SCIENCE, V249, P1552, DOI 10.1126/science.2218496; MARTINOU JC, 1991, J NEUROSCI, V11, P1291; MARTINOU JC, 1991, P NATL ACAD SCI USA, V88, P7669, DOI 10.1073/pnas.88.17.7669; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MCMAHAN UJ, 1990, COLD SPRING HARB SYM, V55, P407; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; MEEK RL, 1982, J BIOL CHEM, V257, P2245; MERLIE JP, 1985, NATURE, V317, P66, DOI 10.1038/317066a0; MISHINA M, 1986, NATURE, V321, P406, DOI 10.1038/321406a0; MORGAN MM, 1990, THESIS WASHINGTON U; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; PADHY LC, 1982, CELL, V28, P865, DOI 10.1016/0092-8674(82)90065-4; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PENG HB, 1991, NEURON, V6, P237; PENG HB, 1993, J CELL BIOL, V120, P197, DOI 10.1083/jcb.120.1.197; PERIN MS, 1991, J BIOL CHEM, V266, P623; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; PRIGENT S A, 1992, Progress in Growth Factor Research, V4, P1, DOI 10.1016/0955-2235(92)90002-Y; PRUSINER SB, 1992, BIOCHEMISTRY-US, V31, P12277, DOI 10.1021/bi00164a001; RANSCHT B, 1988, J CELL BIOL, V107, P1561, DOI 10.1083/jcb.107.4.1561; REIST NE, 1992, NEURON, V8, P865, DOI 10.1016/0896-6273(92)90200-W; ROLE LW, 1985, J NEUROSCI, V5, P2197; ROSEN KM, 1990, BIOTECHNIQUES, V8, P398; SALPETER M, 1987, VERTEBRATE NEUROMUSC; SANES JR, 1991, DEVELOPMENT, V113, P1181; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASSOON DA, 1988, DEVELOPMENT, V104, P155; SCHUETZE SM, 1987, ANNU REV NEUROSCI, V10, P403, DOI 10.1146/annurev.ne.10.030187.002155; SINGLETON TP, 1992, PATHOL ANNU, V27, P165; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STONE KL, 1989, TECHNIQUES PROTEIN C, P377; TAKAHASHI T, 1987, J NEUROSCI, V7, P473; TARAKHOVSKY A, 1991, ONCOGENE, V6, P2187; TUSZYNSKI GP, 1980, ANAL BIOCHEM, V106, P118, DOI 10.1016/0003-2697(80)90126-8; USDIN TB, 1986, J CELL BIOL, V103, P493, DOI 10.1083/jcb.103.2.493; VONHEIJNE G, 1988, BIOCHIM BIOPHYS ACTA, V947, P307, DOI 10.1016/0304-4157(88)90013-5; WALLACE BG, 1991, NEURON, V6, P869, DOI 10.1016/0896-6273(91)90227-Q; WALLACE BG, 1992, J NEUROBIOL, V23, P592, DOI 10.1002/neu.480230512; WANG GK, 1980, J BIOL CHEM, V255, P1156; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WITZEMANN V, 1989, FEBS LETT, V242, P419, DOI 10.1016/0014-5793(89)80514-9; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YARDEN Y, 1991, BIOCHEMISTRY-US, V30, P3543, DOI 10.1021/bi00228a027; YARDEN Y, 1989, P NATL ACAD SCI USA, V86, P3179, DOI 10.1073/pnas.86.9.3179	104	584	626	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 12	1993	72	5					801	815		10.1016/0092-8674(93)90407-H	http://dx.doi.org/10.1016/0092-8674(93)90407-H			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KR436	8453670				2022-12-24	WOS:A1993KR43600015
J	PONGUBALA, JMR; VANBEVEREN, C; NAGULAPALLI, S; KLEMSZ, MJ; MCKERCHER, SR; MAKI, RA; ATCHISON, ML				PONGUBALA, JMR; VANBEVEREN, C; NAGULAPALLI, S; KLEMSZ, MJ; MCKERCHER, SR; MAKI, RA; ATCHISON, ML			EFFECT OF PU.1 PHOSPHORYLATION ON INTERACTION WITH NF-EM5 AND TRANSCRIPTIONAL ACTIVATION	SCIENCE			English	Article							DNA-BINDING ACTIVITY; CASEIN KINASE-II; SERUM RESPONSE FACTOR; NF-KAPPA-B; PUTATIVE ONCOGENE; NUCLEAR FACTOR; FACTOR CREB; C-JUN; SEQUENCE; ERYTHROLEUKEMIAS	PU.1 recruits the binding of a second B cell-restricted nuclear factor, NF-EM5, to a DNA site in the immunoglobulin kappa 3' enhancer. DNA binding by NF-EM5 requires a protein-protein interaction with PU.1 'and specific DNA contacts. Dephosphorylated PU.1 bound to DNA but did not interact with NF-EM5. Analysis of serine-to-alanine mutations in PU.1 indicated that serine 148 (Ser148) is required for protein-protein interaction. PU.1 produced in bacteria did not interact with NF-EM5. Phosphorylation of bacterially produced PU.1 by purified casein kinase II modified it to a form that interacted with NF-EM5 and that recruited NF-EM5 to bind to DNA. Phosphopeptide analysis of bacterially produced PU.1 suggested that Ser148 is phosphorylated by casein kinase II. This site is also phosphorylated in vivo. Expression of wild-type PU.1 increased expression of a reporter construct containing the PU.1 and NF-EM5 binding sites nearly sixfold, whereas the Ser148 mutant form only weakly activated transcription. These results demonstrate that phosphorylation of PU.1 at Ser148 is necessary for interaction with NF-EM5 and suggest that this phosphorylation can regulate transcriptional activity.	UNIV PENN,SCH VET MED,DEPT ANIM BIOL,PHILADELPHIA,PA 19104; LA JOLLA CANC RES FDN,LA JOLLA,CA 92037	University of Pennsylvania; Sanford Burnham Prebys Medical Discovery Institute					NCI NIH HHS [CA 42909] Funding Source: Medline; NIAID NIH HHS [AI 30656] Funding Source: Medline; NIGMS NIH HHS [GM 42415] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042909] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030656] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042415] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GONZALEZ GA, 1991, MOL CELL BIOL, V11, P1306, DOI 10.1128/MCB.11.3.1306; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GROSSCHEDL R, 1985, CELL, V41, P885, DOI 10.1016/S0092-8674(85)80069-6; HATHAWAY GM, 1979, J BIOL CHEM, V254, P762; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; KLEMSZ M, UNPUB; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MANAK JR, 1990, GENE DEV, V4, P955, DOI 10.1101/gad.4.6.955; MANAK JR, 1991, MOL CELL BIOL, V11, P3652, DOI 10.1128/MCB.11.7.3652; MEYER KB, 1989, EMBO J, V8, P1959, DOI 10.1002/j.1460-2075.1989.tb03601.x; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; PONGUBALA JMR, UNPUB; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; Van Beveren C., UNPUB; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0	28	264	264	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 12	1993	259	5101					1622	1625		10.1126/science.8456286	http://dx.doi.org/10.1126/science.8456286			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KR543	8456286				2022-12-24	WOS:A1993KR54300043
J	FIDLER, HM; ROOK, GA; JOHNSON, NM; MCFADDEN, J				FIDLER, HM; ROOK, GA; JOHNSON, NM; MCFADDEN, J			MYCOBACTERIUM-TUBERCULOSIS DNA IN TISSUE AFFECTED BY SARCOIDOSIS	BRITISH MEDICAL JOURNAL			English	Article							EPIDEMIOLOGY; DIAGNOSIS; ANTIGEN; TOOL	Objective-To investigate the prevalence of Mycobacterium tuberculosis DNA in granulomatous tissues from patients with sarcoidosis and from controls matched for age, sex, and tissue by using the polymerase chain reaction. Design-Single blind control trial. Subjects-16 patients with sarcoidosis who had undergone diagnostic biopsy of lung, skin, or lymph node and 16 patients with squamous cell carcinoma or Hodgkin's disease to act as controls. In addition, four lung specimens infected with M tuberculosis were included as positive controls. Results-M tuberculosis DNA was present in sarcoid tissues containing granulomas from seven of the 16 patients and one of the 16 matched controls. Two of the four specimens known to be infected with M tuberculosis were positive in the controlled experiment. Conclusion-These figures suggest that M tuberculosis DNA is detected as readily in patients with sarcoidosis as in patients with frankly tuberculous tissues and imply that M tuberculosis may be linked to the cause of sarcoidosis.	WHITTINGTON HOSP, UNIV COLL & MIDDLESEX SCH MED, LONDON N19 5NF, ENGLAND; UNIV SURREY, SCH BIOL SCI, MOLEC BIOL GRP, GUILDFORD GU2 5XH, SURREY, ENGLAND	University of London; University College London; University of Surrey	FIDLER, HM (corresponding author), UCL, SCH MED, DEPT MED MICROBIOL, DIV BACTERIOL, LONDON W1P 7PP, ENGLAND.			Rook, Graham/0000-0002-8041-8110; McFadden, Johnjoe/0000-0003-2145-0046				BALBI B, 1990, J CLIN INVEST, V85, P1353, DOI 10.1172/JCI114579; BOCART D, 1992, AM REV RESPIR DIS, V145, P1142, DOI 10.1164/ajrccm/145.5.1142; BOOM R, 1990, J CLIN MICROBIOL, V28, P495, DOI 10.1128/JCM.28.3.495-503.1990; BRETT G. Z., 1965, Tubercle, V46, P412, DOI 10.1016/S0041-3879(65)80007-1; BRISSONNOEL A, 1991, LANCET, V338, P364, DOI 10.1016/0140-6736(91)90492-8; CALMETTE A., 1926, ANN MID, V19, P553; DEWIT D, 1990, J CLIN MICROBIOL, V28, P2347; FIDLER H, IN PRESS AM REV RESP; FOLEY N, 1988, CLIN SCI         S19, V75, pP2; GRAHAM DY, 1992, LANCET, V340, P52, DOI 10.1016/0140-6736(92)92465-R; GRAHAM DY, 1988, EXCERPTA MED SARCOID, V756, P16; Greer C E, 1991, PCR Methods Appl, V1, P46; Hanngren A, 1987, Sarcoidosis, V4, P101; HERMANS PWM, 1990, J CLIN MICROBIOL, V28, P2051, DOI 10.1128/JCM.28.9.2051-2058.1990; JAMES DG, 1959, LANCET, V1, P1057; KENT DC, 1970, AM REV RESPIR DIS, V101, P721; KHOMENKO AG, 1980, PROBL TUBERK, V2, P18; MANJUNATH N, 1991, TUBERCLE, V72, P21, DOI 10.1016/0041-3879(91)90020-S; MCFADDEN JJ, 1991, METHODS GENE TECHNOL, V1, P1; MCFADDEN JJ, 1991, GENETIC MANIPULATION, P97; MITCHELL DN, 1983, 9TH INT C SARC OTH G, P132; MITCHELL IC, 1992, LANCET, V339, P1015, DOI 10.1016/0140-6736(92)90536-C; PARKES SA, 1987, THORAX, V42, P420, DOI 10.1136/thx.42.6.420; ROOK GAW, 1992, IMMUNOL TODAY, V13, P160, DOI 10.1016/0167-5699(92)90119-R; SABOOR SA, 1992, LANCET, V339, P12; SCADDING JG, 1961, BRIT MED J, V2, P1165, DOI 10.1136/bmj.2.5261.1165; SHINNICK TM, 1987, J BACTERIOL, V169, P1080, DOI 10.1128/jb.169.3.1080-1088.1987; SIEGELE DA, 1992, J BACTERIOL, V174, P345, DOI 10.1128/jb.174.2.345-348.1992; VANEK J, 1970, AM REV RESPIR DIS, V101, P395; VANSOOLINGEN D, 1991, J CLIN MICROBIOL, V29, P2578, DOI 10.1128/JCM.29.11.2578-2586.1991	30	108	110	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 27	1993	306	6877					546	549		10.1136/bmj.306.6877.546	http://dx.doi.org/10.1136/bmj.306.6877.546			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP886	8461766	Green Published, Bronze			2022-12-24	WOS:A1993KP88600018
J	VANHOY, M; LEUTHER, KK; KODADEK, T; JOHNSTON, SA				VANHOY, M; LEUTHER, KK; KODADEK, T; JOHNSTON, SA			THE ACIDIC ACTIVATION DOMAINS OF THE GCN4 AND GAL4 PROTEINS ARE NOT ALPHA-HELICAL BUT FORM BETA-SHEETS	CELL			English	Article							TRANSCRIPTIONAL ACTIVATION; YEAST; BINDING; PURIFICATION; INVITRO; VP16; GENE; LAC9	The most common class of activation domains, the so-called acidic activators, has been proposed either to adopt an amphipathic alpha-helical structure or to exist as unstructured ''acid blobs.'' However, genetic analysis of an acidic activation domain in the yeast GAL4 protein has suggested that the structure of the activation region is a beta sheet. To distinguish between these models, we conducted a biophysical analysis of peptides corresponding to the yeast GAL4 and GCN4 acidic activation domains. Circular dichroism spectroscopy shows that the peptides are not alpha helical, but that they can undergo a transition to a structure that is almost 100% beta sheet in character in slightly acidic solution. We also show that the artificial acidic activator AH has structural properties that are markedly different from the natural GAL4 and GCN4 domains and does not adopt a beta-rich structure at reduced pH.	UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,GENET & DEV PROGRAM,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	VANHOY, M (corresponding author), UNIV TEXAS,DEPT CHEM & BIOCHEM,AUSTIN,TX 78712, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047140, R01GM040700] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-40700, GM-47140] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRANDL CJ, 1989, P NATL ACAD SCI USA, V86, P2652, DOI 10.1073/pnas.86.8.2652; CHASMAN DI, 1990, MOL CELL BIOL, V10, P2916, DOI 10.1128/MCB.10.6.2916; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; DEGRADO WF, 1981, J AM CHEM SOC, V103, P679, DOI 10.1021/ja00393a035; DONALDSON L, 1992, J BIOL CHEM, V267, P1411; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GINIGER E, 1987, NATURE, V330, P670, DOI 10.1038/330670a0; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; HOPE IA, 1988, NATURE, V333, P635, DOI 10.1038/333635a0; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; INNES MA, 1990, PCR PROTOCOLS GUIDE; JOHNSTON SA, 1987, CELL, V50, P143, DOI 10.1016/0092-8674(87)90671-4; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LEUTHER KK, 1993, CELL, V72, P575, DOI 10.1016/0092-8674(93)90076-3; LEUTHER KK, 1992, SCIENCE, V256, P1333, DOI 10.1126/science.1598579; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MA J, 1987, CELL, V50, P137, DOI 10.1016/0092-8674(87)90670-2; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; OHARE P, 1992, BIOCHEMISTRY-US, V31, P4150, DOI 10.1021/bi00131a035; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; REGIER JL, 1992, IN PRESS P NATL ACAD; SALMERON JM, 1986, NUCLEIC ACIDS RES, V14, P7767, DOI 10.1093/nar/14.19.7767; SALMERON JM, 1989, MOL CELL BIOL, V9, P2950, DOI 10.1128/MCB.9.7.2950; Sambrook J., 1989, MOL CLONING LAB MANU; SIGLER PB, 1988, NATURE, V333, P210, DOI 10.1038/333210a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SWAFFIELD JC, 1992, NATURE, V357, P698, DOI 10.1038/357698a0; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; VANHOY M, 1992, J AM CHEM SOC, V114, P362, DOI 10.1021/ja00027a057; WANG WD, 1992, GENE DEV, V6, P1716, DOI 10.1101/gad.6.9.1716; YOO Y, 1989, J BIOL CHEM, V264, P17078	37	136	138	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 26	1993	72	4					587	594		10.1016/0092-8674(93)90077-4	http://dx.doi.org/10.1016/0092-8674(93)90077-4			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KP165	8440022				2022-12-24	WOS:A1993KP16500013
J	FUSHIMI, K; UCHIDA, S; HARA, Y; HIRATA, Y; MARUMO, F; SASAKI, S				FUSHIMI, K; UCHIDA, S; HARA, Y; HIRATA, Y; MARUMO, F; SASAKI, S			CLONING AND EXPRESSION OF APICAL MEMBRANE WATER CHANNEL OF RAT-KIDNEY COLLECTING TUBULE	NATURE			English	Article							MAJOR INTRINSIC PROTEIN; XENOPUS OOCYTES; SEQUENCE; POLYMERASE; NUCLEOTIDE; FAMILY; LENS; MIP	CONCENTRATING urine is mandatory for most mammals to prevent water loss from the body. Concentrated urine is produced in response to vasopressin by the transepithelial recovery of water from the lumen of the kidney collecting tubule through highly water-permeable membranes1,2. In this nephron segment, vasopressin regulates water permeability by endo- and exocytosis of water channels from or to the apical membrane3,4. CHIP28 is a water channel in red blood cells and the kidney proximal tubule5, but it is not expressed in the collecting tubule6. Here we report the cloning of the complementary DNA for WCH-CD, a water channel of the apical membrane of the kidney collecting tubule. WCH-CD is 42% identical in amino-acid sequence to CHIP28. WCH-CD transcripts are detected only in the collecting tubule of the kidney. Immunohistochemically, WCH-CD is localized to the apical region of the kidney collecting tubule cells. Expression of WCH-CD in Xenopus oocytes markedly increases osmotic water permeability. The functional expression and the limited localization of WCH-CD to the apical region of the kidney collecting tubule suggest that WCH-CD is the vasopressin-regulated water channel.	TOKYO MED & DENT UNIV,DEPT BIOCHEM,TOKYO 113,JAPAN	Tokyo Medical & Dental University (TMDU)	FUSHIMI, K (corresponding author), TOKYO MED & DENT UNIV,DEPT INTERNAL MED 2,1-5-45 YUSHIMA,BUNKYO KU,TOKYO 113,JAPAN.		Uchida, Shinichi/D-1111-2013					DASCAL N, 1987, CRIT REV BIOCHEM MOL, V22, P317, DOI 10.3109/10409238709086960; DENKER BM, 1988, J BIOL CHEM, V263, P15634; HANDLER JS, 1988, AM J PHYSIOL, V255, pF375, DOI 10.1152/ajprenal.1988.255.3.F375; HARRIS HW, 1991, J CLIN INVEST, V88, P1, DOI 10.1172/JCI115263; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KENT NA, 1990, NUCLEIC ACIDS RES, V18, P4256, DOI 10.1093/nar/18.14.4256; KNEPPER MA, 1991, KIDNEY, P445; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KOXAK M, 1987, NUCLEIC ACIDS RES, V15, P8127; KUWAHARA M, 1988, BIOPHYS J, V54, P595, DOI 10.1016/S0006-3495(88)82994-1; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MORIYAMA T, 1990, AM J PHYSIOL, V258, pF1470, DOI 10.1152/ajprenal.1990.258.5.F1470; ORLOFF J, 1967, AM J MED, V42, P757, DOI 10.1016/0002-9343(67)90093-9; PAO GM, 1991, MOL MICROBIOL, V5, P33, DOI 10.1111/j.1365-2958.1991.tb01823.x; PISANO MM, 1991, GENOMICS, V11, P981; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; PRESTON GM, 1991, P NATL ACAD SCI USA, V88, P11110, DOI 10.1073/pnas.88.24.11110; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SIGEL E, 1990, J MEMBRANE BIOL, V117, P201, DOI 10.1007/BF01868451; SKOWSKY WR, 1972, J LAB CLIN MED, V80, P134; TERADA Y, 1991, AM J PHYSIOL, V261, pF1080, DOI 10.1152/ajprenal.1991.261.6.F1080; VERKMAN AS, 1992, ANNU REV PHYSIOL, V54, P97, DOI 10.1146/annurev.physiol.54.1.97; WISTOW GJ, 1991, TRENDS BIOCHEM SCI, V16, P170, DOI 10.1016/0968-0004(91)90065-4; ZHANG R, 1991, AM J PHYSIOL, V260, pC26, DOI 10.1152/ajpcell.1991.260.1.C26	24	891	913	0	30	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 11	1993	361	6412					549	552		10.1038/361549a0	http://dx.doi.org/10.1038/361549a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL714	8429910				2022-12-24	WOS:A1993KL71400065
J	KELLER, AS; LINK, RN; BICKELL, NA; CHARAP, MH; KALET, AL; SCHWARTZ, MD				KELLER, AS; LINK, RN; BICKELL, NA; CHARAP, MH; KALET, AL; SCHWARTZ, MD			DIABETIC-KETOACIDOSIS IN PRISONERS WITHOUT ACCESS TO INSULIN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note								Objective.-To assess the cause and clinical severity of diabetic ketoacidosis in male prisoners hospitalized in New York City. Design.-Retrospective chart review. Setting.-A municipal hospital in New York City. Patients.-Forty-nine adult male prisoners with a total of 54 hospital admissions for diabetic ketoacidosis between January 1, 1989, and June 30, 1991. Main Outcome Measures.-Charts were reviewed for diabetic and medical history, time from arrest until hospitalization, cause of diabetic ketoacidosis, admission laboratory data, and hospital course. Results.-Thirty-eight (70%) of the 54 admissions for diabetic ketoacidosis among prisoners occurred because prisoners had not received insulin during the period immediately following arrest (mean number of days from arrest until hospitalization was 2.5). All of these individuals had a history of insulin-dependent diabetes and were reportedly compliant with their insulin regimen at the time of arrest. Admission laboratory data for this group of prisoners included a mean serum glucose level of 27.4 mmol/L (495 mg/dL) and a mean serum bicarbonate level of 14.4 mmol/L. Mean number of days in the hospital was 3.4 including a mean of 1 day in an intensive care unit. Conclusions.-Inadequate access to medication results in serious sequelae for recently arrested prisoners in New York City with insulin-dependent diabetes. Access to health care for recently arrested prisoners needs to be improved.	NYU,SCH MED,DEPT MED,NEW YORK,NY 10003	New York University			Kalet, Adina/AAA-3440-2021	Kalet, Adina/0000-0003-4855-0223; Schwartz, Mark/0000-0002-7123-0060				Clements R S Jr, 1978, Diabetes Care, V1, P314; DUBLER NN, 1986, STANDARDS HLTH SERVI; FOSTER DW, 1983, NEW ENGL J MED, V309, P159; GANGI R, 1992, PRESENTATION TASK FO; HAMBLIN PS, 1989, MED J AUSTRALIA, V151, P439, DOI 10.5694/j.1326-5377.1989.tb101253.x; HAMBURG MA, 1992, FINAL REPORT NEW YOR; NAVARRO M, 1992, NY TIMES        0213, V13, pB3; RAAB S, 1992, NEW YORK TIMES  0305, pB1; Raab Selwyn, 1992, NY TIMES, P25; 1992, ANN INTERN MED, V117, P71; 1992, 1992 POLICY COMPENDI; 1992, DIABETES CARE S2, V15, P42	12	10	10	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 3	1993	269	5					619	621		10.1001/jama.269.5.619	http://dx.doi.org/10.1001/jama.269.5.619			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ444	8421367				2022-12-24	WOS:A1993KJ44400029
J	MANDEL, EM; ROCKETTE, HE; BLUESTONE, CD; PARADISE, JL; NOZZA, RJ				MANDEL, EM; ROCKETTE, HE; BLUESTONE, CD; PARADISE, JL; NOZZA, RJ			ANTIBIOTIC-THERAPY FOR OTITIS-MEDIA WITH EFFUSION - A RESPONSE FROM PITTSBURGH	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							DOUBLE-BLIND; DECONGESTANT-ANTIHISTAMINE; RANDOMIZED TRIAL; CHILDREN; MYRINGOTOMY; EFFICACY; AMOXICILLIN; COMBINATION; INFANTS; PLACEBO		CHILDRENS HOSP PITTSBURGH, OTTIS MEDIA RES CTR, PITTSBURGH, PA USA; CHILDRENS HOSP PITTSBURGH, DEPT PEDIAT OTOLARYNGOL, PITTSBURGH, PA USA; CHILDRENS HOSP PITTSBURGH, DEPT AUDIOL & COMMUN DISORDERS, PITTSBURGH, PA USA; CHILDRENS HOSP PITTSBURGH, DEPT PEDIAT, PITTSBURGH, PA USA; UNIV PITTSBURGH, SCH MED, DEPT OTOLARYNGOL, PITTSBURGH, PA 15261 USA; UNIV PITTSBURGH, SCH MED, DEPT PEDIAT, PITTSBURGH, PA 15261 USA; UNIV PITTSBURGH, SCH MED, DEPT CLIN EPIDEMIOL & PREVENT MED, PITTSBURGH, PA 15261 USA; UNIV PITTSBURGH, GRAD SCH PUBL HLTH, DEPT BIOSTAT, PITTSBURGH, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh								BROSTOFF LM, 1988, 4TH P INT S REC ADV, P47; BURKE P, 1991, BRIT MED J, V303, P558, DOI 10.1136/bmj.303.6802.558; CANTEKIN E I, 1991, Journal of the American Medical Association, V266, P3309, DOI 10.1001/jama.266.23.3309; CANTEKIN EI, 1980, ANN OTO RHINOL LARYN, V89, P190, DOI 10.1177/00034894800890S344; CANTEKIN EI, 1983, NEW ENGL J MED, V308, P297, DOI 10.1056/NEJM198302103080601; CANTEKIN EI, 1983, ANN OTOL RHINOL S107, V92, P6; ENGELHARD D, 1989, LANCET, V2, P141; FLETCHER RH, 1988, CLIN EPIDEMIOLOGY ES, P54; FROOM J, 1990, BRIT MED J, V300, P582, DOI 10.1136/bmj.300.6724.582; HALSTED C, 1968, AM J DIS CHILD, V115, P542, DOI 10.1001/archpedi.1968.02100010544003; HOWIE VM, 1972, CLIN PEDIATR, V11, P205, DOI 10.1177/000992287201100407; KALEIDA PH, 1991, PEDIATRICS, V87, P466; LAXDAL OE, 1970, CAN MED ASSOC J, V102, P263; LORENTZEN P, 1977, J LARYNGOL OTOL, V91, P331, DOI 10.1017/S0022215100083742; MANDEL EM, 1987, NEW ENGL J MED, V316, P432, DOI 10.1056/NEJM198702193160803; MYGIND N, 1981, CLIN OTOLARYNGOL, V6, P5, DOI 10.1111/j.1365-2273.1981.tb01781.x; OSTFELD E, 1988, 4TH P INT S REC ADV, P235; PARADISE JL, 1979, ANN OTO RHINOL LARYN, V88, P56, DOI 10.1177/000348947908800110; PARADISE JL, 1976, PEDIATRICS, V58, P198; PARADISE JL, 1977, NEW ENGL J MED, V296, P445, DOI 10.1056/NEJM197702242960809; SAAH AJ, 1982, JAMA-J AM MED ASSOC, V248, P1071, DOI 10.1001/jama.248.9.1071; SMITH CG, 1982, PEDIATRICS, V69, P351; Thalin A, 1986, P INT C AC SECR OT 1, P441; VAN DISHOECK H A, 1959, Acta Otolaryngol, V50, P250; VANBUCHEM FL, 1985, BRIT MED J, V290, P1033, DOI 10.1136/bmj.290.6474.1033; VANBUCHEM FL, 1981, LANCET, V2, P883	26	7	7	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 27	1993	269	4					516	517		10.1001/jama.269.4.516	http://dx.doi.org/10.1001/jama.269.4.516			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KH385	8419673				2022-12-24	WOS:A1993KH38500038
J	ROSENGREN, A; TIBBLIN, G; WILHELMSEN, L				ROSENGREN, A; TIBBLIN, G; WILHELMSEN, L			LOW SYSTOLIC BLOOD-PRESSURE AND SELF PERCEIVED WELLBEING IN MIDDLE-AGED MEN	BRITISH MEDICAL JOURNAL			English	Article							POPULATION; DISEASE	Objective-To examine the relation between systolic blood pressure and self perceived wellbeing in 50 year old men. Design-Cross sectional population study of data derived from questionnaires and physical examination as a part of a cardiovascular risk factor survey. Setting-City of Gothenburg, Sweden. Study population-776 men from a random population sample of 1016 men aged 50. Methods-Self perceived wellbeing according to the Gothenburg quality of life questionnaire, which is an assessment of social, physical, and mental wellbeing in 15 different areas. Main results-Low systolic blood pressure was significantly (p < 0.05) related to impaired social wellbeing in four areas: work, home and family, financial situation, and housing. Of the items dealing with physical wellbeing, health, memory, and appetite were significantly related to blood pressure. As regards mental wellbeing, energy and self confidence were significantly related to systolic blood pressure. Diastolic blood pressure was significantly related to housing, memory, energy, patience, and self confidence. In multiple regression analyses that controlled for smoking, stress, physical activity, social activity, and emotional support, poor social, physical, and mental wellbeing were all significantly related to low systolic blood pressure independently of other factors. Low diastolic blood pressure was independently associated with poor physical and mental, but not social, wellbeing. Conclusion-Low systolic blood pressure was associated with poor perception of wellbeing in several areas. The cause is unclear.	UNIV UPPSALA,DEPT FAMILY MED,S-75105 UPPSALA,SWEDEN	Uppsala University	ROSENGREN, A (corresponding author), GOTHENBURG UNIV,OSTRA HOSP,DEPT MED,PREVENT CARDIOL SECT,S-41685 GOTHENBURG,SWEDEN.							Bengtsson C, 1987, Scand J Prim Health Care, V5, P155, DOI 10.3109/02813438709013997; COTTINGTON EM, 1985, AM J EPIDEMIOL, V121, P515, DOI 10.1093/oxfordjournals.aje.a114029; GOODCHILD ME, 1985, BRIT J PSYCHIAT, V146, P55, DOI 10.1192/bjp.146.1.55; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; PEMBERTON J, 1989, BRIT MED J, V298, P660, DOI 10.1136/bmj.298.6674.660; PILGRIM JA, 1992, BRIT MED J, V304, P75, DOI 10.1136/bmj.304.6819.75; Rose G, 1982, CARDIOVASCULAR SURVE; ROSENGREN A, 1991, AM J CARDIOL, V68, P1171, DOI 10.1016/0002-9149(91)90189-R; Tibblin G, 1990, Scand J Prim Health Care Suppl, V1, P39; Tibblin G, 1990, Scand J Prim Health Care Suppl, V1, P33; TIBBLIN G, 1967, THESIS U GOTHENBURG; UNDEN AL, 1989, SOC SCI MED, V29, P1387, DOI 10.1016/0277-9536(89)90240-2; WELIN L, 1985, LANCET, V1, P915; WESSELY S, 1990, BRIT MED J, V301, P362, DOI 10.1136/bmj.301.6748.362	14	66	66	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 23	1993	306	6872					243	246		10.1136/bmj.306.6872.243	http://dx.doi.org/10.1136/bmj.306.6872.243			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ591	8443523	Bronze, Green Published			2022-12-24	WOS:A1993KJ59100019
J	LIAO, XS; BUTOW, RA				LIAO, XS; BUTOW, RA			RTG1 AND RTG2 - 2 YEAST GENES REQUIRED FOR A NOVEL PATH OF COMMUNICATION FROM MITOCHONDRIA TO THE NUCLEUS	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; CITRATE SYNTHASE; DNA-BINDING; MESSENGER-RNA; CYTOCHROME-B; CYC1 GENE; PROTEIN; EXPRESSION; SEQUENCE; TRANSCRIPTION	The expression of some nuclear genes is sensitive to the functional state of mitochondria, a process we term retrograde regulation. Here we show that retrograde regulation of the yeast ClT2 gene encoding peroxisomal citrate synthase depends on a new class of upstream activation site element (UAS(r)) and two previously unidentified genes, RTG1 and RTG2. RTG1 encodes a protein of 177 amino acids with similarity to basic helix-loop-helix transcription factors that likely functions at the ClT2 UAS(r). RTG2 encodes a protein of 394 amino acids of unknown function. Cells containing null alleles of RTG1 and RTG2 are viable and respiratory competent. However, they are auxotrophic for glutamic or aspartic acid and cannot use acetate as a sole carbon source, suggesting that both the tricarboxylic acid and glyoxylate cycles are compromised. Thus, RTG1 and RTG2 are pivotal genes in controlling interorganelle communication between mitochondria, peroxisomes, and the nucleus.			LIAO, XS (corresponding author), UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235, USA.				NIGMS NIH HHS [GM22525] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM022525, R01GM022525] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALMEIDA J, 1989, GENE DEV, V3, P1758, DOI 10.1101/gad.3.11.1758; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cb.04.110188.001445; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLONDEL A, 1991, NUCLEIC ACIDS RES, V19, P181, DOI 10.1093/nar/19.1.181; BOHMANN D, 1990, CANCER CELL-MON REV, V2, P337; BUTOW RA, 1927, PHILOS T ROY SOC B, V319, P1; CAI MJ, 1990, CELL, V61, P437, DOI 10.1016/0092-8674(90)90525-J; CONRADWEBB H, 1990, NUCLEIC ACIDS RES, V18, P1369, DOI 10.1093/nar/18.6.1369; COSTANZO MC, 1990, ANNU REV GENET, V24, P91; COSTANZO MC, 1988, P NATL ACAD SCI USA, V85, P2677, DOI 10.1073/pnas.85.8.2677; COSTANZO MC, 1986, MOL CELL BIOL, V6, P3694, DOI 10.1128/MCB.6.11.3694; CUPP JR, 1991, J BIOL CHEM, V266, P22199; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DIECKMANN CL, 1982, P NATL ACAD SCI-BIOL, V79, P1805, DOI 10.1073/pnas.79.6.1805; DIFFLEY JFX, 1991, P NATL ACAD SCI USA, V88, P7864, DOI 10.1073/pnas.88.17.7864; FOURY F, 1989, J BIOL CHEM, V264, P20552; GAMPEL A, 1987, MOL CELL BIOL, V7, P2545, DOI 10.1128/MCB.7.7.2545; GOODRICH J, 1992, CELL, V68, P955, DOI 10.1016/0092-8674(92)90038-E; GRIVELL LA, 1989, EUR J BIOCHEM, V182, P477, DOI 10.1111/j.1432-1033.1989.tb14854.x; GUARENTE L, 1984, P NATL ACAD SCI-BIOL, V81, P7860, DOI 10.1073/pnas.81.24.7860; GUARENTE L, 1981, P NATL ACAD SCI-BIOL, V78, P2199, DOI 10.1073/pnas.78.4.2199; GUARENTE L, 1984, CELL, V36, P503, DOI 10.1016/0092-8674(84)90243-5; JONES BA, 1992, GENE DEV, V6, P380, DOI 10.1101/gad.6.3.380; KIM KS, 1986, MOL CELL BIOL, V6, P1936, DOI 10.1128/MCB.6.6.1936; KISPAL G, 1989, J BIOL CHEM, V264, P11204; KUIPER MTR, 1988, J BIOL CHEM, V263, P2840; LABOUESSE M, 1990, MOL GEN GENET, V224, P209, DOI 10.1007/BF00271554; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LEWIN AS, 1990, MOL CELL BIOL, V10, P1399, DOI 10.1128/MCB.10.4.1399; LIAO XS, 1991, MOL CELL BIOL, V11, P38, DOI 10.1128/MCB.11.1.38; LISOWSKY T, 1988, MOL GEN GENET, V214, P218, DOI 10.1007/BF00337714; LUNARDI J, 1991, J BIOL CHEM, V266, P16534; LUNDIN M, 1991, J BIOL CHEM, V266, P12168; MCALISTERHENN L, 1987, J BACTERIOL, V169, P5157, DOI 10.1128/jb.169.11.5157-5166.1987; MCCONNELL SJ, 1990, J CELL BIOL, V111, P967, DOI 10.1083/jcb.111.3.967; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; PARIKH VS, 1989, MOL CELL BIOL, V9, P1897, DOI 10.1128/MCB.9.5.1897; PARIKH VS, 1987, SCIENCE, V235, P576, DOI 10.1126/science.3027892; PARTALEDIS JA, 1988, MOL CELL BIOL, V8, P3647, DOI 10.1128/MCB.8.9.3647; PFEIFER K, 1987, CELL, V49, P9, DOI 10.1016/0092-8674(87)90750-1; POUTRE CG, 1987, GENETICS, V115, P637; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROSE MD, 1988, METHODS YEAST GENETI; ROSENKRANTZ M, 1986, MOL CELL BIOL, V6, P4509, DOI 10.1128/MCB.6.12.4509; SERAPHIN B, 1989, NATURE, V337, P84, DOI 10.1038/337084a0; STEPIEN PP, 1992, P NATL ACAD SCI USA, V89, P6813, DOI 10.1073/pnas.89.15.6813; STEWART LC, 1991, J CELL BIOL, V115, P1249, DOI 10.1083/jcb.115.5.1249; SUISSA M, 1984, EMBO J, V3, P1773, DOI 10.1002/j.1460-2075.1984.tb02045.x; TAYLOR WE, 1990, P NATL ACAD SCI USA, V87, P4098, DOI 10.1073/pnas.87.11.4098; TZAGOLOFF A, 1986, ANNU REV BIOCHEM, V55, P249, DOI 10.1146/annurev.bi.55.070186.001341; WANG SS, 1987, MOL CELL BIOL, V7, P4431, DOI 10.1128/MCB.7.12.4431; WINKLER H, 1988, EMBO J, V7, P1799, DOI 10.1002/j.1460-2075.1988.tb03011.x	54	337	346	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 15	1993	72	1					61	71		10.1016/0092-8674(93)90050-Z	http://dx.doi.org/10.1016/0092-8674(93)90050-Z			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KG955	8422683				2022-12-24	WOS:A1993KG95500010
J	HWANG, KC; MAUZERALL, D				HWANG, KC; MAUZERALL, D			PHOTOINDUCED ELECTRON-TRANSPORT ACROSS A LIPID BILAYER MEDIATED BY C70	NATURE			English	Article							FULLERENES C60; MEMBRANES; CARBON	ELECTRON transport across a membrane is central to photosynthesis, to mitochondrial respiration and to the design of molecular systems for solar energy conversion. Relatively few synthetic molecules, however, have been shown to facilitate transport of electrons across a lipid bilayer1-3. We report here that C70 can act as both a photosensitizer for electron transfer from a donor molecule and a mediator for electron transport across a lipid bilayer membrane. The steady-state photocurrent density obtained from the C70-bilayer system is about 40 times higher, at comparable light intensities, than that of the carotene-porphyrin-quinone system2, previously the most efficient artificial system. The C70-bilayer system has a quantum yield of about 0.04, while the stability (tens of minutes) and turnover number (electrons transported per C70 before decay) of 10(3) are one to three orders of magnitude greater than those of other systems1-3. We anticipate that other higher fullerenes may also provide the basis for efficient transmembrane electron-transport systems.			HWANG, KC (corresponding author), ROCKEFELLER UNIV,1230 YORK AVE,NEW YORK,NY 10021, USA.		Hwang, Kuo Chu/AAG-8217-2021					AJIE H, 1990, J PHYS CHEM-US, V94, P8630, DOI 10.1021/j100387a004; ALLEMAND PM, 1991, J AM CHEM SOC, V113, P1050, DOI 10.1021/ja00003a053; ARBOGAST JW, 1992, J AM CHEM SOC, V114, P2277, DOI 10.1021/ja00032a063; BENESCH RE, 1953, SCIENCE, V11, P447; CLARK WM, 1960, OXIDATION REDUCTION, P470; DRAIN M, 1992, BIOPHYS J, V63, P1556; FELDBERG SW, 1981, BIOPHYS J, V34, P149, DOI 10.1016/S0006-3495(81)84842-4; HONG FT, 1976, J ELECTROCHEM SOC, V123, P1317, DOI 10.1149/1.2133068; HUNG RR, 1991, J PHYS CHEM-US, V95, P6073, DOI 10.1021/j100169a007; HWANG KC, 1992, J AM CHEM SOC, V114, P9705, DOI 10.1021/ja00050a086; IIJIMA S, 1991, NATURE, V354, P56, DOI 10.1038/354056a0; ILANI A, 1981, BIOPHYS J, V35, P79, DOI 10.1016/S0006-3495(81)84775-3; KAMAT PV, 1991, J AM CHEM SOC, V113, P9705, DOI 10.1021/ja00025a064; KIM DH, 1992, J AM CHEM SOC, V114, P4429, DOI 10.1021/ja00037a075; KRASNE S, 1971, SCIENCE, V174, P412, DOI 10.1126/science.174.4007.412; MILLER B, 1991, J AM CHEM SOC, V113, P6291, DOI 10.1021/ja00016a067; MOUNTZ JM, 1978, PHOTOCHEM PHOTOBIOL, V28, P395, DOI 10.1111/j.1751-1097.1978.tb07724.x; SCHUHANNK W, 1991, J AM CHEM SOC, V113, P394; SENSION RJ, 1991, CHEM PHYS LETT, V185, P179, DOI 10.1016/S0009-2614(91)85043-V; SETA P, 1989, PHOTOCHEM PHOTOBIOL, V49, P537, DOI 10.1111/j.1751-1097.1989.tb08422.x; SETA P, 1985, NATURE, V316, P651; WANG Y, 1992, NATURE, V356, P585, DOI 10.1038/356585a0; WASIELEWSKI MR, 1991, J AM CHEM SOC, V113, P2774, DOI 10.1021/ja00007a074	23	156	161	1	24	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 14	1993	361	6408					138	140		10.1038/361138a0	http://dx.doi.org/10.1038/361138a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KG466	8421519				2022-12-24	WOS:A1993KG46600053
J	SELBY, JV; FRIEDMAN, GD; QUESENBERRY, CP; WEISS, NS				SELBY, JV; FRIEDMAN, GD; QUESENBERRY, CP; WEISS, NS			EFFECT OF FECAL OCCULT BLOOD TESTING ON MORTALITY FROM COLORECTAL-CANCER - A CASE-CONTROL STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						OCCULT BLOOD; COLORECTAL NEOPLASMS; DIAGNOSTIC TESTS, ROUTINE; ADENOCARCINOMA; MORTALITY	CONTROLLED TRIAL; FOLLOW-UP; SENSITIVITY; EFFICACY; DEFINITION; PATTERNS	Objective: To estimate by case-control methods the effect of screening using the fecal occult blood test (FOBT) on mortality from colorectal cancer and to examine the relation of that effect to the interval since the most recent screening test. Design: A case-control study. Setting: The Kaiser Permanente Medical Care Program of Northern California. Patients: A total of 485 persons who developed fatal colorectal cancer after 50 years of age and 727 age- and sex-matched controls. Measurements: History of screening FOBTs during the 5 years before case diagnosis. Results: After adjustment for potentially confounding factors, an odds ratio of 0.69 (95% CI, 0.52 to 0.91) was observed for exposure to at least one screening FOBT during the 5-year interval. The odds ratio was lowest for the first year after the most recent FOBT and rose to 1.00 three years after the last screening examination. False-negative results among cases in the 1 to 2 years before diagnosis contributed substantially to lowering the estimate of efficacy. Conclusions: These data suggest that a program of annual or biennial screening using FOBTs might lower population risk for mortality from colorectal cancer sufficiently to have important public health implications. However, the confidence intervals around our odds ratio estimates were wide. We therefore believe that additional data will be needed before making recommendations that FOBT screening be expanded.	UNIV WASHINGTON, SCH PUBL HLTH & COMMUNITY MED, DEPT EPIDEMIOL, SEATTLE, WA 98125 USA	University of Washington; University of Washington Seattle	SELBY, JV (corresponding author), KAISER PERMANENTE MED CARE PROGRAM, DIV RES, 3451 PIEDMONT AVE, OAKLAND, CA 94611 USA.				NCI NIH HHS [R01 CA 46569, R35 CA 49761] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046569, R35CA049761] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHLQUIST DA, 1989, CANCER, V63, P1826; ALLISON JE, 1990, ANN INTERN MED, V112, P328, DOI 10.7326/0003-4819-112-5-328; ARELLANO MG, 1984, AM J PUBLIC HEALTH, V74, P1324, DOI 10.2105/AJPH.74.12.1324; BLACK SB, 1988, PEDIATR INFECT DIS J, V7, P149, DOI 10.1097/00006454-198803000-00003; CARLSSON U, 1986, DIS COLON RECTUM, V29, P553, DOI 10.1007/BF02554252; CLARKE EA, 1979, LANCET, V2, P1; CROWLEY ML, 1983, J CLIN GASTROENTEROL, V5, P127, DOI 10.1097/00004836-198304000-00007; EDDY DM, 1990, ANN INTERN MED, V113, P373, DOI 10.7326/0003-4819-113-5-373; FRIEDMAN GD, 1986, J CHRON DIS, V39, P453, DOI 10.1016/0021-9681(86)90112-8; GILBERTSEN VA, 1980, CANCER, V45, P2899, DOI 10.1002/1097-0142(19800601)45:11<2899::AID-CNCR2820451132>3.0.CO;2-M; HARDCASTLE JD, 1989, LANCET, V1, P1160; KEWENTER J, 1988, CANCER, V62, P645, DOI 10.1002/1097-0142(19880801)62:3<645::AID-CNCR2820620333>3.0.CO;2-#; KNIGHT KK, 1989, JAMA-J AM MED ASSOC, V261, P587; KRONBORG O, 1987, SCAND J GASTROENTERO, V22, P677, DOI 10.3109/00365528709011142; MACRAE FA, 1982, GASTROENTEROLOGY, V82, P891; MORRISON AS, 1982, AM J EPIDEMIOL, V115, P6; MORRISON AS, 1985, SCREENING CHRONIC DI, P108; RANSOHOFF DF, 1991, NEW ENGL J MED, V325, P37; SELBY JV, 1992, NEW ENGL J MED, V326, P653, DOI 10.1056/NEJM199203053261001; SIMON JB, 1985, GASTROENTEROLOGY, V88, P820, DOI 10.1016/0016-5085(85)90158-1; VERBEEK ALM, 1984, LANCET, V1, P1222; WEISS NS, 1983, AM J EPIDEMIOL, V118, P457; WINAWER SJ, 1991, JNCI-J NATL CANCER I, V83, P243, DOI 10.1093/jnci/83.4.243; WINAWER SJ, 1985, SCREENING CANCER, P347; 1990, CLIN EFFICACY ASSESS; 1989, SUMMARY CURRENT GUID; 1987, WORKING GUIDELINES E	27	215	217	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1993	118	1					1	6		10.7326/0003-4819-118-1-199301010-00001	http://dx.doi.org/10.7326/0003-4819-118-1-199301010-00001			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KE605	8416152				2022-12-24	WOS:A1993KE60500001
J	JIANG, J; LEVINE, M				JIANG, J; LEVINE, M			BINDING AFFINITIES AND COOPERATIVE INTERACTIONS WITH BHLH ACTIVATORS DELIMIT THRESHOLD RESPONSES TO THE DORSAL GRADIENT MORPHOGEN	CELL			English	Article							NF-KAPPA-B; DROSOPHILA EMBRYO; DNA-BINDING; DORSOVENTRAL PATTERN; GENE-EXPRESSION; SYNERGISTIC ACTIVATION; SEGMENTATION GENE; PROTEIN; MESODERM; SEQUENCE	The dorsal (dl) morphogen gradient initiates the formation of the mesoderm, neuroectoderm, and dorsal ectoderm by setting different limits of regulatory gene expression along the dorsoventral axis of the early Drosophila embryo. In this paper, we show that low affinity dl-binding sites restrict target gene expression to the ventralmost regions (presumptive mesoderm), where there are peak levels of dl, while high affinity sites permit expression in ventrolateral regions (mesoderm and mesectoderm) containing intermediate levels of the morphogen. Activation by low levels of dl in lateral regions (the presumptive neuroectoderm) depends on cooperative DNA binding interactions between dl and bHLH proteins. The snail repressor blocks this interaction and restricts expression to the neuroectoderm. We discuss how enhancers serve as templates to bring weakly interacting regulatory factors into close proximity so that they can function combinatorially to activate and repress transcription.	UNIV CALIF SAN DIEGO,CTR MOLEC GENET,DEPT BIOL,LA JOLLA,CA 92093	University of California System; University of California San Diego				Levine, Michael/0000-0001-7629-0081	NIGMS NIH HHS [GM46638] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM046638, R01GM046638] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERGA A, 1991, DEVELOPMENT, V111, P983; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BIER E, 1990, GENE DEV, V4, P190, DOI 10.1101/gad.4.2.190; BOULAY JL, 1987, NATURE, V330, P395, DOI 10.1038/330395a0; BRUGGEMEIER U, 1991, CELL, V64, P565, DOI 10.1016/0092-8674(91)90240-Y; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CREWS ST, 1988, CELL, V52, P143, DOI 10.1016/0092-8674(88)90538-7; DOYLE HJ, 1989, GENE DEV, V3, P1518, DOI 10.1101/gad.3.10.1518; DRIEVER W, 1989, NATURE, V340, P363, DOI 10.1038/340363a0; ERICKSON JW, 1991, SCIENCE, V251, P1071, DOI 10.1126/science.1900130; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GOVIND S, 1991, TRENDS GENET, V7, P119, DOI 10.1016/0168-9525(91)90456-Z; GREEN JBA, 1991, TRENDS GENET, V7, P245, DOI 10.1016/0168-9525(91)90323-I; HAN KH, 1989, CELL, V56, P573, DOI 10.1016/0092-8674(89)90580-1; IP YT, 1992, GENE DEV, V6, P1728, DOI 10.1101/gad.6.9.1728; IP YT, 1992, GENE DEV, V6, P1518, DOI 10.1101/gad.6.8.1518; IP YT, 1991, CELL, V64, P439; IP YT, 1992, SEM DEV BIOL, V3, P15; JIANG J, 1991, GENE DEV, V5, P1881, DOI 10.1101/gad.5.10.1881; JIANG J, 1992, EMBO J, V11, P3147, DOI 10.1002/j.1460-2075.1992.tb05387.x; JIANG J, 1991, GENE DEV, V5, P265, DOI 10.1101/gad.5.2.265; KAKIDANI H, 1988, CELL, V52, P161, DOI 10.1016/0092-8674(88)90504-1; KASAI Y, 1992, P NATL ACAD SCI USA, V89, P3414, DOI 10.1073/pnas.89.8.3414; KELLER AD, 1991, GENE DEV, V5, P868, DOI 10.1101/gad.5.5.868; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KOSMAN D, 1991, SCIENCE, V254, P118, DOI 10.1126/science.1925551; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; LEPTIN M, 1991, GENE DEV, V5, P1568, DOI 10.1101/gad.5.9.1568; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; LIN YS, 1990, NATURE, V345, P359, DOI 10.1038/345359a0; MELTON DA, 1991, SCIENCE, V252, P234, DOI 10.1126/science.1672778; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; PAN D, 1992, EMBO J, V11, P1837, DOI 10.1002/j.1460-2075.1992.tb05235.x; PAN D, 1991, GENE DEV, V5, P1592; RAO Y, 1991, GENE DEV, V5, P1577, DOI 10.1101/gad.5.9.1577; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; RUSHLOW C, 1987, NATURE, V330, P583, DOI 10.1038/330583a0; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; Sander K, 1975, Ciba Found Symp, V0, P241; SIMPSON P, 1983, GENETICS, V105, P615; SMALL S, 1991, GENE DEV, V5, P827, DOI 10.1101/gad.5.5.827; SMALL S, 1992, EMBO J, V11, P4047, DOI 10.1002/j.1460-2075.1992.tb05498.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STANOJEVIC D, 1991, SCIENCE, V254, P1385, DOI 10.1126/science.1683715; STEWARD R, 1989, CELL, V59, P1179, DOI 10.1016/0092-8674(89)90773-3; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; STJOHNSTON D, 1992, CELL, V68, P201; STJOHNSTON RD, 1987, EMBO J, V6, P2785, DOI 10.1002/j.1460-2075.1987.tb02574.x; STRUHL G, 1992, CELL, V69, P237, DOI 10.1016/0092-8674(92)90405-2; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THISSE B, 1987, GENE DEV, V1, P709, DOI 10.1101/gad.1.7.709; THISSE C, 1991, CELL, V65, P1191, DOI 10.1016/0092-8674(91)90014-P; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; VANDOREN M, 1991, DEVELOPMENT, V113, P245	57	273	281	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 12	1993	72	5					741	752		10.1016/0092-8674(93)90402-C	http://dx.doi.org/10.1016/0092-8674(93)90402-C			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KR436	8453668	Bronze			2022-12-24	WOS:A1993KR43600010
J	XUE, FY; COOLEY, L				XUE, FY; COOLEY, L			KELCH ENCODES A COMPONENT OF INTERCELLULAR BRIDGES IN DROSOPHILA EGG CHAMBERS	CELL			English	Article							SHOPE FIBROMA VIRUS; VACCINIA VIRUS; ESCHERICHIA-COLI; STRUCTURAL PROTEINS; ZINC FINGERS; UGA CODON; GENE; SELENOCYSTEINE; SEQUENCE; REGION	Oocyte maturation in Drosophila is supported by a cluster of 15 germline-derived nurse cells whose cytoplasm is transported into the oocyte through intercellular bridges called ring canals. kelch was isolated as a female sterile mutation affecting cytoplasm transport. We have cloned the kelch gene and found that it encodes an unusual transcript containing two open reading frames (ORF1 and ORF2) separated by a single UGA stop codon. At least two protein products are made from the kelch mRNA: a short protein from ORF1 and a longer protein from both ORF1 and ORF2 as a result of partial suppression of the UGA codon. The kelch ORF1 product is conserved, and antibodies directed against it are localized specifically to ring canals. Our results suggest that kelch produces a component of ring canals that regulates the flow of cytoplasm between cells.	YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06510	Yale University					NIGMS NIH HHS [GM43301] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043301] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENYAJATI C, 1992, NUCLEIC ACIDS RES, V20, P4481, DOI 10.1093/nar/20.17.4481; BERRY MJ, 1991, NATURE, V353, P273, DOI 10.1038/353273a0; BROWN EH, 1964, GROWTH, V28, P41; BROWN JL, 1991, EMBO J, V10, P665, DOI 10.1002/j.1460-2075.1991.tb07995.x; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; BURGOS MH, 1955, J BIOPHYS BIOCHEM CY, V1, P287, DOI 10.1083/jcb.1.4.287; CHANGYEH A, 1991, NUCLEIC ACIDS RES, V19, P3667, DOI 10.1093/nar/19.13.3667; CHARDIN P, 1991, NUCLEIC ACIDS RES, V19, P1431, DOI 10.1093/nar/19.7.1431; COOLEY L, 1988, SCIENCE, V239, P1121, DOI 10.1126/science.2830671; COOLEY L, 1992, CELL, V69, P173, DOI 10.1016/0092-8674(92)90128-Y; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIBELLO PR, 1991, GENETICS, V129, P385; FAWCETT DW, 1959, J BIOPHYS BIOCHEM CY, V5, P453, DOI 10.1083/jcb.5.3.453; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FENG YX, 1989, J VIROL, V63, P2870, DOI 10.1128/JVI.63.6.2870-2873.1989; FORCHHAMMER K, 1990, J BIOL CHEM, V265, P9346; GARDNER K, 1987, NATURE, V328, P359, DOI 10.1038/328359a0; GOEBEL SJ, 1990, VIROLOGY, V179, P247, DOI 10.1016/0042-6822(90)90294-2; GONDOS B, 1987, INT J GYNECOL PATHOL, V6, P114, DOI 10.1097/00004347-198706000-00003; GUTZEIT HO, 1986, J CELL SCI, V80, P159; GUTZEIT HO, 1989, ROUX ARCH DEV BIOL, V198, P185, DOI 10.1007/BF00375904; HARLOW E, 1988, ANTIBODIES LABORATOR; HARRISON SD, 1990, EMBO J, V9, P207, DOI 10.1002/j.1460-2075.1990.tb08097.x; HOFSTETTER H, 1974, BIOCHIM BIOPHYS ACTA, V374, P238, DOI 10.1016/0005-2787(74)90366-9; HOWARD ST, 1991, VIROLOGY, V180, P633, DOI 10.1016/0042-6822(91)90077-O; ITO S, 1960, J BIOPHYS BIOCHEM CY, V7, P433, DOI 10.1083/jcb.7.3.433; JALAJAKUMARI MB, 1989, MOL MICROBIOL, V3, P1685, DOI 10.1111/j.1365-2958.1989.tb00154.x; JONES DS, 1989, NUCLEIC ACIDS RES, V15, P5933; KAISER HW, 1989, J CELL BIOL, V109, P557, DOI 10.1083/jcb.109.2.557; King R. C., 1970, OVARIAN DEV DROSOPHI; KOTWAL GJ, 1988, VIROLOGY, V167, P524, DOI 10.1016/S0042-6822(88)90115-8; KOZAK M, 1986, ADV VIRUS RES, V31, P229, DOI 10.1016/S0065-3527(08)60265-1; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE BJ, 1990, MOL CELL BIOL, V10, P1940, DOI 10.1128/MCB.10.5.1940; Mahowald A.P., 1980, Genetics and Biology of Drosophila, V2d, P141; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PERKUS ME, 1991, VIROLOGY, V180, P406, DOI 10.1016/0042-6822(91)90047-F; QIAN S, 1987, NUCLEIC ACIDS RES, V15, P987, DOI 10.1093/nar/15.3.987; RUBY JR, 1969, J MORPHOL, V127, P307, DOI 10.1002/jmor.1051270304; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHON A, 1989, NUCLEIC ACIDS RES, V17, P7159, DOI 10.1093/nar/17.18.7159; SCHUPBACH T, 1991, GENETICS, V129, P1119; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Spradling Allan C., 1993, P1; STELLER H, 1985, EMBO J, V4, P167, DOI 10.1002/j.1460-2075.1985.tb02332.x; STEWARD R, 1986, GENETICS, V113, P665; STJOHNSTON D, 1989, DEVELOPMENT, V107, P13; STRAUSS EG, 1983, P NATL ACAD SCI-BIOL, V80, P5271, DOI 10.1073/pnas.80.17.5271; THEURKAUF WE, 1992, DEVELOPMENT, V115, P923; UPTON C, 1990, VIROLOGY, V179, P618, DOI 10.1016/0042-6822(90)90129-F; UPTON C, 1986, VIROLOGY, V152, P308, DOI 10.1016/0042-6822(86)90134-0; WARN RM, 1985, EXP CELL RES, V157, P355, DOI 10.1016/0014-4827(85)90120-X; WEINER AM, 1973, J MOL BIOL, V80, P837, DOI 10.1016/0022-2836(73)90213-1; WRIGHT TRF, 1976, GENETICS, V84, P267; YUE L, 1992, GENE DEV, V6, P2443, DOI 10.1101/gad.6.12b.2443; ZAMBONI L, 1968, J CELL BIOL, V36, P276, DOI 10.1083/jcb.36.1.276; ZINONI F, 1990, P NATL ACAD SCI USA, V87, P4660, DOI 10.1073/pnas.87.12.4660	59	377	395	1	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 12	1993	72	5					681	693		10.1016/0092-8674(93)90397-9	http://dx.doi.org/10.1016/0092-8674(93)90397-9			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KR436	8453663	Bronze			2022-12-24	WOS:A1993KR43600005
J	ANDERSON, G; JENKINSON, EJ; MOORE, NC; OWEN, JJT				ANDERSON, G; JENKINSON, EJ; MOORE, NC; OWEN, JJT			MHC CLASS-II-POSITIVE EPITHELIUM AND MESENCHYME CELLS ARE BOTH REQUIRED FOR T-CELL DEVELOPMENT IN THE THYMUS	NATURE			English	Article							LYMPHOCYTE-T; DIFFERENTIATION; MICE	T LYMPHOCYTES are produced in the thymus from precursors originating in the haemopoietic tissues. On entering the thymus, they undergo a programme of proliferation, T-cell receptor (TCR) gene rearrangement, differentiation and repertoire selection1. Although the thymus provides a unique environment for these events, the role of the thymic stroma in regulating specific developmental stages is not well understood2. We therefore devised an in vitro system to study the role of individual thymic stromal components in T-cell development. We report here that the development of TCR-CD4-CD8- T-cell precursors into TCR+ cells expressing CD4 and/or CD8 requires the presence of both major histocompatibility complex class II+ epithelial cells and fetal mesenchyme. The requirement for mesenchymal support can be mapped to the initial stages of intrathymic development because the later stages of maturation, from double-positive CD4+CD8+ thymocytes into single-positive CD4+ or CD8+ cells, can be supported by epithelial cells alone. We also show that the requirement for mesenchymal cells can be met by cells of the fibroblast line 3T3 (but not by supernatants from these cells). To our knowledge, these findings provide the first direct evidence that mesenchymal as well as epithelial cells are involved in T-cell development, and suggest that their involvement is stage-specific and likely to be dependent on short-range or contact-mediated interactions.			ANDERSON, G (corresponding author), UNIV BIRMINGHAM,SCH MED,DEPT ANAT,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND.			anderson, graham/0000-0002-2917-4085	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AUERBACH R, 1960, DEV BIOL, V2, P271, DOI 10.1016/0012-1606(60)90009-9; AUSTYN JM, 1981, EUR J IMMUNOL, V11, P805, DOI 10.1002/eji.1830111013; CARDING SR, 1991, IMMUNOL TODAY, V12, P239, DOI 10.1016/0167-5699(91)90037-T; DEXTER TM, 1990, PHILOS T ROY SOC B, V327, P85, DOI 10.1098/rstb.1990.0045; HAYNES BF, 1983, J CLIN INVEST, V71, P9, DOI 10.1172/JCI110755; Jenkinson E J, 1990, Semin Immunol, V2, P51; JENKINSON EJ, 1992, J EXP MED, V176, P845, DOI 10.1084/jem.176.3.845; JENKINSON EJ, 1982, EUR J IMMUNOL, V12, P583, DOI 10.1002/eji.1830120710; KANARIOU M, 1989, CLIN EXP IMMUNOL, V78, P263; KINGSTON R, 1984, EUR J IMMUNOL, V14, P1052, DOI 10.1002/eji.1830141117; LARSSON L, 1991, INT IMMUN, V1, P279; MIZUTANI S, 1987, P NATL ACAD SCI USA, V84, P4999, DOI 10.1073/pnas.84.14.4999; MOORE NC, IN PRESS EUR J IMMUN; MURDOCH A, 1990, J IMMUNOL METHODS, V132, P45, DOI 10.1016/0022-1759(90)90396-D; NAGAMINE J, 1991, J IMMUNOL, V147, P1147; Shortman K, 1990, Semin Immunol, V2, P3; SIDERAS P, 1987, EUR J IMMUNOL, V17, P217, DOI 10.1002/eji.1830170211; VANEWIJK W, 1991, ANNU REV IMMUNOL, V9, P591, DOI 10.1146/annurev.iy.09.040191.003111; VANVLIET E, 1985, EUR J IMMUNOL, V15, P675, DOI 10.1002/eji.1830150707; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531	20	288	297	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 4	1993	362	6415					70	73		10.1038/362070a0	http://dx.doi.org/10.1038/362070a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KP976	8446171	Bronze			2022-12-24	WOS:A1993KP97600063
J	DAVIES, K				DAVIES, K			PERIPHERIN AND THE VISION THING	NATURE			English	Editorial Material							RETINITIS-PIGMENTOSA; GENE; FAMILY											AHMAD NN, 1991, P NATL ACAD SCI USA, V88, P6624, DOI 10.1073/pnas.88.15.6624; BARR FG, 1993, NAT GENET, V3, P113, DOI 10.1038/ng0293-113; FARRAR GJ, 1991, NATURE, V354, P478, DOI 10.1038/354478a0; FORSMAN K, 1992, CLIN GENET, V42, P156; KAJIWARA K, 1991, NATURE, V354, P480, DOI 10.1038/354480a0; KAJIWARA K, 1993, NAT GENET, V3, P208, DOI 10.1038/ng0393-208; LEE B, 1989, SCIENCE, V244, P978, DOI 10.1126/science.2543071; MCINNES RR, 1992, NAT GENET, V1, P155, DOI 10.1038/ng0692-155; NICHOLS BE, 1993, NAT GENET, V3, P202, DOI 10.1038/ng0393-202; SMALL KW, 1992, GENOMICS, V13, P681, DOI 10.1016/0888-7543(92)90141-E; STONE EM, 1992, NAT GENET, V1, P246, DOI 10.1038/ng0792-246; WELLS J, 1993, NAT GENET, V3, P213, DOI 10.1038/ng0393-213	12	9	10	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 4	1993	362	6415					92	92						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KP976	8446174				2022-12-24	WOS:A1993KP97600070
J	TAPPERO, JW; KOEHLER, JE; BERGER, TG; COCKERELL, CJ; LEE, TH; BUSCH, MP; STITES, DP; MOHLEBOETANI, J; REINGOLD, AL; LEBOIT, PE				TAPPERO, JW; KOEHLER, JE; BERGER, TG; COCKERELL, CJ; LEE, TH; BUSCH, MP; STITES, DP; MOHLEBOETANI, J; REINGOLD, AL; LEBOIT, PE			BACILLARY ANGIOMATOSIS AND BACILLARY SPLENITIS IN IMMUNOCOMPETENT ADULTS	ANNALS OF INTERNAL MEDICINE			English	Note						ANGIOMATOSIS, BACILLARY; SPLENITIS, BACILLARY; IMMUNOCOMPETENCE; ROCHALIMAEA-HENSELAE; ERYTHROMYCIN	INFECTION; DNA	Bacillary angiomatosis and bacillary peliosis have been described in patients with human immunodeficiency virus (HIV) infection and drug-induced immunosuppression. Patients with these vascular lesions in the absence of profound immunodeficiency have not been well characterized. We studied five patients with histologically confirmed bacillary angiomatosis or bacillary splenitis without clinical immunodeficiency. Studies to detect HIV infection, immunologic defects, and presence of Rochalimaea species DNA in infected tissues were done. Cell cultures were negative for HIV-1 replication, and HIV-1 DNA was not detected. Results of lymphocyte subsets and activation, neutrophil oxidative burst, skin testing to mumps antigen, and assays for quantitative immunoglobulins and complement were normal. DNA amplification and sequencing confirmed infection by Rochalimaea henselae, even in tissue showing bacillary splenitis without peliosis. Bacillary angiomatosis and bacillary splenitis may occur in the absence of demonstrable immunodeficiency. On the basis of the therapeutic response of these five patients, we recommend treatment with erythromycin or doxycycline for a minimum of 6 weeks.	UNIV CALIF SAN FRANCISCO, SAN FRANCISCO, CA 94143 USA; IRWIN MEM BLOOD CTR, SAN FRANCISCO, CA USA; UNIV CALIF BERKELEY, BERKELEY, CA 94720 USA; UNIV TEXAS, SW MED CTR, DALLAS, TX 75235 USA	University of California System; University of California San Francisco; University of California System; University of California Berkeley; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	TAPPERO, JW (corresponding author), CTR DIS CONTROL & PREVENT, MAIL STOP C09, 1600 CLIFTON RD NE, ATLANTA, GA 30333 USA.		Mohle-Boetani, Janet/AAH-4221-2019		NIAMS NIH HHS [AR07175-15] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007175] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALKASSAB AS, 1990, CLIN EXP IMMUNOL, V81, P267; BUSCH MP, 1991, NEW ENGL J MED, V325, P1, DOI 10.1056/NEJM199107043250101; DESOUSA M, 1989, CLIN EXP IMMUNOL, V75, P1; EPLING CL, 1992, CYTOMETRY, V13, P615, DOI 10.1002/cyto.990130609; KOEHLER JE, 1992, NEW ENGL J MED, V327, P1625, DOI 10.1056/NEJM199212033272303; LEBOIT PE, 1988, LANCET, V1, P960; LEE TH, 1991, AIDS, V5, P1201, DOI 10.1097/00002030-199110000-00008; MALIUSH AE, 1986, MANUAL CLIN LABORATO, P274; REGNERY RL, 1992, J CLIN MICROBIOL, V30, P265, DOI 10.1128/JCM.30.2.265-274.1992; RELMAN DA, 1990, NEW ENGL J MED, V323, P1573, DOI 10.1056/NEJM199012063232301; STEVENS P, 1978, INFECT IMMUN, V22, P41, DOI 10.1128/IAI.22.1.41-51.1978; STITES DP, 1991, BASIC CLIN IMMUNOL, P263; TAPPERO JW, 1993, IN PRESS JAMA; TCHORZEWSKI H, 1989, EXP CLIN IMMUNOGENET, V6, P185; WELCH DF, 1992, J CLIN MICROBIOL, V30, P275, DOI 10.1128/JCM.30.2.275-280.1992	15	109	112	1	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1993	118	5					363	365		10.7326/0003-4819-118-5-199303010-00007	http://dx.doi.org/10.7326/0003-4819-118-5-199303010-00007			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KN688	8430982				2022-12-24	WOS:A1993KN68800007
J	PATTERSON, DR; MILLERPERRIN, C; MCCORMICK, TR; HUDSON, LD				PATTERSON, DR; MILLERPERRIN, C; MCCORMICK, TR; HUDSON, LD			WHEN LIFE-SUPPORT IS QUESTIONED EARLY IN THE CARE OF PATIENTS WITH CERVICAL-LEVEL QUADRIPLEGIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							SPINAL-CORD INJURY; DEPRESSION				PATTERSON, DR (corresponding author), UNIV WASHINGTON,SCH MED,SEATTLE,WA 98104, USA.							ABRAMS KS, 1981, PARAPLEGIA, V19, P253, DOI 10.1038/sc.1981.49; CHARLIFUE SW, 1991, ARCH PHYS MED REHAB, V72, P488; CREWE N M, 1979, Archives of Physical Medicine and Rehabilitation, V60, P252; CUSHMAN LA, 1990, ARCH PHYS MED REHAB, V71, P191; DUCHARME SH, 1980, SCI DIG, V2, P29; ELGHATIT AZ, 1975, J CHRON DIS, V28, P383, DOI 10.1016/0021-9681(75)90034-X; FINK SL, 1968, J MARRIAGE FAM, V30, P64, DOI 10.2307/350223; Fleetwood J, 1989, Nursing, V19, P62; FRANK RG, 1987, CLIN PSYCHOL REV, V7, P611, DOI 10.1016/0272-7358(87)90009-2; GARDNER BP, 1985, BRIT MED J, V291, P1620, DOI 10.1136/bmj.291.6509.1620; GEISLER WO, 1983, PARAPLEGIA, V21, P364, DOI 10.1038/sc.1983.60; MAYNARD FM, 1987, ARCH PHYS MED REHAB, V68, P862; Morris J, 1986, J HEAD TRAUMA REHAB, V1, P31; Nyquist R H, 1967, Paraplegia, V5, P22; PALMER JB, 1985, ARCH PHYS MED REHAB, V66, P253, DOI 10.1016/0003-9993(85)90164-9; PATTERSON DR, IN PRESS PSYCHOL B; Ridley B, 1989, Rehabil Nurs, V14, P250; SIEGEL M, 1969, 17TH P VET ADM SPIN, V18, P230; SIEGEL M, 1970, PSYCHOL ASPECTS DISA, V17, P9; SIEGEL M, 1971, RES UTILIZATION REHA; SIEGEL MS, 1969, MED CLIN N AM, V53, P713, DOI 10.1016/S0025-7125(16)32767-5; SKIPPER JK, 1968, J REHABIL, V34, P16; SOMERVILLE J, 1990, AM MED NEWS     0202, P6; STOVER SL, 1986, SPINAL CORD INJURY F; Trieschmann RB, 1988, SPINAL CORD INJURIES; Vargo F.A., 1984, J APPL REHABIL COUNS, V15, P28, DOI 10.1891/0047-2220.15.1.28; VARGO FA, 1984, INT J ADV COUNS, V7, P253, DOI 10.1007/BF00379147; WESTBROOK MT, 1986, REHABIL PSYCHOL, V31, P79, DOI 10.1037//0090-5550.31.2.79; WHITENECK GG, 1985, COLLABORATIVE STUDY; YORKSTON KM, 1992, AUGMENTATIVE COMMUNI; 1991, AM REV RESPIR DIS, V144, P726	31	42	42	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 18	1993	328	7					506	509		10.1056/NEJM199302183280712	http://dx.doi.org/10.1056/NEJM199302183280712			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KM417	8421482				2022-12-24	WOS:A1993KM41700012
J	KHAN, AS; HENEINE, WM; CHAPMAN, LE; GARY, HE; WOODS, TC; FOLKS, TM; SCHONBERGER, LB				KHAN, AS; HENEINE, WM; CHAPMAN, LE; GARY, HE; WOODS, TC; FOLKS, TM; SCHONBERGER, LB			ASSESSMENT OF A RETROVIRUS SEQUENCE AND OTHER POSSIBLE RISK-FACTORS FOR THE CHRONIC FATIGUE SYNDROME IN ADULTS	ANNALS OF INTERNAL MEDICINE			English	Article						FATIGUE SYNDROME, CHRONIC; HTLV-II; GENE PRODUCTS, GAG; RETROVIRUS INFECTIONS; RISK FACTORS	EPSTEIN-BARR VIRUS; BLOOD MONONUCLEAR-CELLS; COMMON ODDS RATIO; INFECTION; AMPLIFICATION; INTERVAL; TABLES	Objective: To assess whether the human T-lymphotropic virus type II (HTLV-II) gag gene sequence, a purportedly new laboratory marker of the chronic fatigue syndrome (CFS), and other possible risk factors for CFS, particularly those associated with retroviral transmission, are associated with well-characterized CFS. Design: Two matched case-control studies. Setting. The metropolitan Atlanta area. Patients: Twenty-one patients with CFS who were identified by the Centers for Disease Control and Prevention CFS surveillance system; 21 CDC employee controls (laboratory study) and 42 neighborhood controls (risk-factor study) who were matched to patients by age, race, and gender. Measurements: Peripheral blood lymphocytes and leukocytes were assayed for the HTLV-II gag gene sequence by polymerase chain reaction and specific Southern blot hybridization. Questionnaires elicited demographic and clinical information and a history of exposures associated with retrovirus transmission (for example, blood transfusions, sexual practices, intravenous drug use). Results: All patients were white and 86% were female. The median age at illness onset was 34 years (range, 16 to 51 years). The HTLV-II gag gene sequence was not identified in the blood of any patient or control under conditions in which the appropriate assay controls were positive. No statistical differences were observed between patients and controls in frequency of blood transfusions (10% compared with 7%), median number of sex partners before illness (3 compared with 3), bisexual or homosexual behavior (14% compared with 7%), intravenous drug use (0% compared with 0%), and other factors associated with retroviral infection. Conclusions: The HTLV-II gag gene sequence was not a marker for CFS in this small study of well-defined patients, nor did other characteristics of the patients and controls support the hypothesis that a retrovirus, transmitted by usual modes, was a cause of CFS.			KHAN, AS (corresponding author), CTR DIS CONTROL & PREVENT, NATL CTR INFECT DIS, DIV VIRAL & RICKETTSIAL DIS, OFF DIRECTOR, ATLANTA, GA 30333 USA.							BELL KM, 1991, REV INFECT DIS, V13, pS32; BUCHWALD D, 1990, J CLIN IMMUNOL, V10, P335, DOI 10.1007/BF00917479; BUCKNER C, 1992, J INFECT DIS, V166, P1160, DOI 10.1093/infdis/166.5.1160; Cox DR., 1970, ANAL BINARY DATA; CROOK WG, 1983, YEAST CONNECTION MED; DEFREITAS E, 1991, P NATL ACAD SCI USA, V88, P2922, DOI 10.1073/pnas.88.7.2922; DUBOIS RE, 1984, SOUTHERN MED J, V77, P1376, DOI 10.1097/00007611-198411000-00007; FLUGEL RM, 1992, CLIN INFECT DIS, V14, P623, DOI 10.1093/clinids/14.2.623; FOLKS TM, 1993, CIBA F SYMP, V173, P160; GART JJ, 1970, BIOMETRIKA, V57, P471, DOI 10.1093/biomet/57.3.471; GOLD D, 1990, JAMA-J AM MED ASSOC, V264, P48, DOI 10.1001/jama.264.1.48; GOW J, IN PRESS J CLIN PATH; GOW JW, 1991, BRIT MED J, V302, P692, DOI 10.1136/bmj.302.6778.692; GUNN WJ, 1993, CIBA F S, V173; HASHINAKA K, 1988, BIOCHEMISTRY-US, V27, P5906, DOI 10.1021/bi00416a013; HOLMES GP, 1987, JAMA-J AM MED ASSOC, V257, P2297, DOI 10.1001/jama.257.17.2297; HOLMES GP, 1988, ANN INTERN MED, V108, P387, DOI 10.7326/0003-4819-108-3-387; JONES JF, 1985, ANN INTERN MED, V102, P1, DOI 10.7326/0003-4819-102-1; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; KWOK S, 1988, BLOOD, V72, P1117; LAL RB, 1991, J CLIN MICROBIOL, V29, P2253, DOI 10.1128/JCM.29.10.2253-2258.1991; LANE TJ, 1991, AM J MED, V91, P335, DOI 10.1016/0002-9343(91)90150-V; LEHMANN EL, 1975, NONPARAMETRICS; Maniatis T., 1982, MOL CLONING; MEHTA CR, 1985, J AM STAT ASSOC, V80, P969, DOI 10.2307/2288562; OU CY, 1988, SCIENCE, V239, P295, DOI 10.1126/science.3336784; STRAUS SE, 1985, ANN INTERN MED, V102, P7, DOI 10.7326/0003-4819-102-1-7; YOUSEF GE, 1988, LANCET, V1, P146	28	41	42	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1993	118	4					241	245		10.7326/0003-4819-118-4-199302150-00001	http://dx.doi.org/10.7326/0003-4819-118-4-199302150-00001			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KL457	8420441				2022-12-24	WOS:A1993KL45700001
J	LELIEVER, WC				LELIEVER, WC			EUSTACHIAN-TUBE DYSFUNCTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											LELIEVER, WC (corresponding author), UNIV N CAROLINA, CHAPEL HILL, NC 27514 USA.								0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 10	1993	269	6					809	809						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK544	8423666				2022-12-24	WOS:A1993KK54400037
J	SCHAPIRA, DV; STUDNICKI, J; BRADHAM, DD; WOLFF, P; JARRETT, A				SCHAPIRA, DV; STUDNICKI, J; BRADHAM, DD; WOLFF, P; JARRETT, A			INTENSIVE-CARE, SURVIVAL, AND EXPENSE OF TREATING CRITICALLY ILL CANCER-PATIENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COST-EFFECTIVENESS; HEMATOLOGIC MALIGNANCY; RESPIRATORY-FAILURE; PROGNOSIS	Objective.-To determine the survival and factors affecting the survival of patients with solid tumors and hematologic cancers who were admitted to the intensive care unit, the time these patients spent at home (meaningful survival) before they died, and the cost per year of life gained and per year of life gained at home Design.-Survival and cost-effectiveness analysis. Setting.-A tertiary-care cancer center at a university medical center. Patients.-Every patient admitted to the intensive care unit between July 1, 1988, and June 30,1990, was entered into the study. This group comprised 83 patients with solid tumors and 64 patients with hematologic cancers. Main Outcome Measures.-Factors affecting survival, such as age, sex, malignancy, length of stay in the intensive care unit, and necessity for mechanical ventilator assistance, as well as cost per year of life gained and cost per year of life gained at home. Results.-The only factor that significantly affected survival was the requirement for mechanically assisted ventilation for patients with hematologic cancers. More than three fourths of the patients in either group spent less than 3 months at home before dying. The cost per year of life gained for patients with solid tumors was $82 845 and for patients with hematologic cancers was $189 339. The cost per year of life gained at home was $95 142 for patients with solid tumors and $449 544 for patients with hematologic cancers. Conclusion.-The majority of patients with solid tumors and hematologic cancers admitted to the intensive care unit die before discharge, or, if they survive the hospital admission, they spend a minimal amount of time at home before dying. This limited survival is achieved at considerable cost. Physicians who treat patients with neoplastic disease should discuss potential outcomes and the possibility of withdrawing life-supportive therapy if appropriate with the patient and family, so that a reasonable strategy can be agreed on before the initiation of therapy.	UNIV S FLORIDA,COLL MED,TAMPA,FL 33612; UNIV S FLORIDA,SCH PUBL HLTH,TAMPA,FL 33620	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	SCHAPIRA, DV (corresponding author), H LEE MOFFITT CANC CTR & RES INST,CANC PREVENT SECT,12902 MAGNOLIA DR,TAMPA,FL 33612, USA.							ANDERSON G, 1990, JAMA-J AM MED ASSOC, V263, P967, DOI 10.1001/jama.263.7.967; EDDY DM, 1989, ANN INTERN MED, V111, P389, DOI 10.7326/0003-4819-111-5-389; EDELSON JT, 1990, JAMA-J AM MED ASSOC, V263, P407, DOI 10.1001/jama.263.3.407; ESTOPA R, 1984, CRIT CARE MED, V12, P26, DOI 10.1097/00003246-198401000-00007; GAUMER GL, 1992, HEALTH SERV RES, V26, P725; GOODWIN PJ, 1988, J CLIN ONCOL, V6, P1537, DOI 10.1200/JCO.1988.6.10.1537; HELLINGER FJ, 1991, INQUIRY-J HEALTH CAR, V28, P213; JOHNSON MH, 1986, CRIT CARE MED, V14, P693, DOI 10.1097/00003246-198608000-00006; LLOYDTHOMAS AR, 1988, BRIT MED J, V296, P1025, DOI 10.1136/bmj.296.6628.1025; MCCUSKER J, 1983, PUBLIC HEALTH REP, V98, P170; OYE RK, 1991, CHEST, V99, P685, DOI 10.1378/chest.99.3.685; PETERS SG, 1988, CHEST, V94, P99, DOI 10.1378/chest.94.1.99; RIZZO JA, 1992, HEALTH SERV RES, V26, P705; SCHUSTER DP, 1983, AM J MED, V75, P402, DOI 10.1016/0002-9343(83)90340-6; Sonnefeld S T, 1991, Health Care Financ Rev, V13, P1; WELCH HG, 1989, NEW ENGL J MED, V321, P807, DOI 10.1056/NEJM198909213211207; WELCH HG, 1991, MED CARE, V29, P578, DOI 10.1097/00005650-199106000-00016; 1984, Y3T2222C822CASE28 PU, P3; 1992, CANCER FACTS FIGURES	19	165	169	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 10	1993	269	6					783	786		10.1001/jama.269.6.783	http://dx.doi.org/10.1001/jama.269.6.783			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK544	8423662				2022-12-24	WOS:A1993KK54400033
J	KLAG, MJ; FORD, DE; MEAD, LA; HE, J; WHELTON, PK; LIANG, KY; LEVINE, DM				KLAG, MJ; FORD, DE; MEAD, LA; HE, J; WHELTON, PK; LIANG, KY; LEVINE, DM			SERUM-CHOLESTEROL IN YOUNG MEN AND SUBSEQUENT CARDIOVASCULAR-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ISCHEMIC HEART-DISEASE	Background. The increased risk of cardiovascular disease associated with higher serum cholesterol levels in middle-aged persons has been clearly established, but there have been few opportunities to examine a potential link between serum cholesterol levels measured in young men and clinically evident premature cardiovascular disease later in life. Methods. We performed a prospective study of 1017 young men (mean age, 22 years) followed for 27 to 42 years to quantify the risk of cardiovascular disease and total mortality associated with serum cholesterol levels during early adult life. The mean serum cholesterol level at entry was 192 mg per deciliter (5.0 mmol per liter). Results. During a median follow-up of 30.5 years, there were 125 cardiovascular-disease events, 97 of which were due to coronary heart disease. The serum cholesterol level at base line was strongly associated with the incidence of events related to coronary heart disease and cardiovascular disease, as well as to total mortality and mortality due to cardiovascular disease. The risks were similar whether the events occurred before or after the age of 50. In a proportional-hazards analysis adjusted for age, body-mass index (the weight in kilograms divided by the square of the height in meters), the level of physical activity, coffee intake, change in smoking status, and the incidence of diabetes and hypertension during follow-up, a difference in the serum cholesterol level at base line of 36 mg per deciliter (0.9 mmol per liter) - the difference between the 25th and 75th percentiles of cholesterol level in the study population at base line - was associated with an increased risk of cardiovascular disease (relative risk, 1.72; 95 percent confidence interval, 1.39 to 2.14), coronary heart disease (relative risk, 2.01; 95 percent confidence interval, 1.59 to 2.53), and mortality due to cardiovascular disease (relative risk, 2.02; 95 percent confidence interval, 1.23 to 3.32). A difference in the base-line serum cholesterol level of 36 mg per deciliter was significantly associated with an increased risk of death before the age of 50 (relative risk, 1.64; 95 percent confidence interval, 1.03 to 2.61), but not with the overall risk of death (relative risk, 1.21; 95 percent confidence interval, 0.93 to 1.58). Conclusions. These findings indicate a strong association between the serum cholesterol level measured early in adult life in men and cardiovascular disease in midlife.	JOHNS HOPKINS UNIV, SCH MED, DEPT MED, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT EPIDEMIOL, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT HLTH POLICY & MANAGEMENT, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT BIOSTAT, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, BALTIMORE, MD 21218 USA; BEIJING UNION MED COLL, BEIJING, PEOPLES R CHINA; CHINESE ACAD MED SCI, BEIJING, PEOPLES R CHINA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College			Liang, Kung-Yee/F-8299-2011		NCRR NIH HHS [RR00035] Funding Source: Medline; NHLBI NIH HHS [HL42734] Funding Source: Medline; NIA NIH HHS [AG01760] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042734] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG001760] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		USA Pooling Project Research Group, 1978, Journal of Chronic Diseases, V31, P201; CLEEMAN JI, 1988, ARCH INTERN MED, V148, P36, DOI 10.1001/archinte.148.1.36; COLLINS RA, 1970, AM J CLIN PATHOL, V54, P219; CORESH J, 1992, HYPERTENSION, V19, P218; COX DR, 1972, J R STAT SOC B, V34, P187; DECKERS JW, 1990, CIRCULATION, V82, P259; ENOS WF, 1953, JAMA-J AM MED ASSOC, V152, P1090, DOI 10.1001/jama.1953.03690120006002; HOLMAN RL, 1958, AM J PATHOL, V34, P209; JUDSON JJ, 1971, J AMER MED ASSOC, V216, P1185; KANNEL W B, 1981, Progress in Lipid Research, V20, P339, DOI 10.1016/0163-7827(81)90067-9; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KLAG MJ, 1991, CIRCULATION, V83, P14; LACROIX AZ, 1986, NEW ENGL J MED, V315, P977, DOI 10.1056/NEJM198610163151601; LIU K, 1978, J CHRON DIS, V31, P399, DOI 10.1016/0021-9681(78)90004-8; MCGILL HC, 1990, JAMA-J AM MED ASSOC, V264, P3018; NEATON JD, 1992, ARCH INTERN MED, V152, P56, DOI 10.1001/archinte.152.1.56; NEWMAN WP, 1986, NEW ENGL J MED, V314, P138, DOI 10.1056/NEJM198601163140302; OBERMAN A, 1967, CIRCULATION, V36, P812, DOI 10.1161/01.CIR.36.6.812; PAFFENBARGER RS, 1966, AM J PUBLIC HEALTH N, V56, P962, DOI 10.2105/AJPH.56.6.962; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; RABKIN SW, 1977, AM J CARDIOL, V39, P452, DOI 10.1016/S0002-9149(77)80104-5; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P365; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; SHEKELLE RB, 1989, LANCET, V1, P1177; SMITH GD, 1992, JAMA-J AM MED ASSOC, V267, P70, DOI 10.1001/jama.267.1.70; THOMAS C B, 1957, J Chronic Dis, V6, P1, DOI 10.1016/0021-9681(57)90059-0; THOMAS CB, 1951, B JOHNS HOPKINS HOSP, V89, P419; THOMAS CB, 1965, B JOHNS HOPKINS HOSP, V116, P348; THOMAS CB, 1956, AM J MED SCI, V232, P389, DOI 10.1097/00000441-195610000-00003; [No title captured]; 1980, DHHS PHS801260 PUBL; 1987, JAMA-J AM MED ASSOC, V257, P937	32	407	417	1	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 4	1993	328	5					313	318		10.1056/NEJM199302043280504	http://dx.doi.org/10.1056/NEJM199302043280504			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK247	8419817				2022-12-24	WOS:A1993KK24700004
J	MILINKOVITCH, MC; ORTI, G; MEYER, A				MILINKOVITCH, MC; ORTI, G; MEYER, A			REVISED PHYLOGENY OF WHALES SUGGESTED BY MITOCHONDRIAL RIBOSOMAL DNA-SEQUENCES	NATURE			English	Article							EVOLUTION; RNA; MAMMALS; ORIGIN; EOCENE	LIVING cetaceans are subdivided into two highly distinct suborders, Odontoceti (the echolocating toothed whales) and Mysticeti (the filter-feeding baleen whales), which are believed to have had a long independent history. Here we report the determination of DNA sequences from two mitochondrial ribosomal gene segments (930 base pairs per species) for 16 species of cetaceans, a perissodactyl and a sloth, and construct the first phylogeny for whales and dolphins based on explicit cladistic methods. Our data (and earlier published myoglobin sequences) confirmed that cetaceans are closely related to artiodactyls and that all families and superfamilies of cetaceans are monophyletic. A surprising finding was that one group of toothed whales, the sperm whales, is more closely related to the baleen whales than to other odontocetes. The common ancestor of baleen whales and sperm whales might have lived only 10-15 million years ago. The suggested paraphyly of toothed whales has many implications for classification, phylogeny and our understanding of the evolutionary history of cetaceans.	SUNY STONY BROOK,DEPT ECOL & EVOLUT,STONY BROOK,NY 11794; UNIV LIBRE BRUXELLES,INST RECH INTERDISCIPLINAIRE BIOL HUMAINE & NUCL,B-1070 BRUSSELS,BELGIUM	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Universite Libre de Bruxelles			Meyer, Axel/C-9826-2009	Meyer, Axel/0000-0002-0888-8193; Orti, Guillermo/0000-0002-6886-2323; Milinkovitch, Michel/0000-0002-2553-0724				ALLARD MW, 1992, P NATL ACAD SCI USA, V89, P3972, DOI 10.1073/pnas.89.9.3972; ANDERSON S, 1982, J MOL BIOL, V156, P683, DOI 10.1016/0022-2836(82)90137-1; ARNASON U, 1991, J MOL EVOL, V33, P556, DOI 10.1007/BF02102808; Barnes L.G., 1978, P582; BARNES LG, 1985, MAR MAMMAL SCI, V1, P15, DOI 10.1111/j.1748-7692.1985.tb00530.x; Czelusniak J., 1990, Current Mammalogy, V2, P545; EPERON IC, 1980, NATURE, V286, P460, DOI 10.1038/286460a0; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; FELSENSTEIN J, 1991, PHYLIP VERSION 341; Flower W. H., 1883, P ZOOL SOC LOND, V1883, P466; GATSEY J, 1992, MOL BIOL EVOL, V9, P433; GINGERICH PD, 1990, SCIENCE, V249, P154, DOI 10.1126/science.249.4965.154; GINGERICH PD, 1983, SCIENCE, V220, P403, DOI 10.1126/science.220.4595.403; GOODMAN M, 1985, Cladistics, V1, P171, DOI 10.1111/j.1096-0031.1985.tb00420.x; Grabowski, 1991, SIMPLE FOOLS GUIDE P; GUTELL RR, 1988, NUCLEIC ACIDS RES, V16, pR175, DOI 10.1093/nar/16.suppl.r175; GUTELL RR, 1985, PROG NUCLEIC ACID RE, V32, P155, DOI 10.1016/S0079-6603(08)60348-7; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; IRWIN DM, 1991, J MOL EVOL, V32, P128, DOI 10.1007/BF02515385; KOCHER TD, 1989, P NATL ACAD SCI USA, V86, P6196, DOI 10.1073/pnas.86.16.6196; KRAUS F, 1991, SYST ZOOL, V40, P117, DOI 10.2307/2992252; MEYER A, 1990, NATURE, V347, P550, DOI 10.1038/347550a0; MILINKOVITCH MC, 1992, J EVOLUTION BIOL, V5, P149, DOI 10.1046/j.1420-9101.1992.5010149.x; MINDELL DP, 1990, ANNU REV ECOL SYST, V21, P541, DOI 10.1146/annurev.es.21.110190.002545; MIYAMOTO MM, 1990, P NATL ACAD SCI USA, V87, P6127, DOI 10.1073/pnas.87.16.6127; NOVACEK MJ, 1992, NATURE, V356, P121, DOI 10.1038/356121a0; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SCHLOTTERER C, 1991, NATURE, V354, P63, DOI 10.1038/354063a0; Szalay F. S., 1969, American Museum Novitates, VNo. 2361, P1; VAN VALEN LEIGH, 1966, BULL AMER MUS NATUR HIST, V132, P1; [No title captured]	31	145	154	1	41	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 28	1993	361	6410					346	348		10.1038/361346a0	http://dx.doi.org/10.1038/361346a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KJ590	8426652	Green Submitted			2022-12-24	WOS:A1993KJ59000055
J	WEINSTOCK, HS; BOLAN, G; REINGOLD, AL; POLISH, LB				WEINSTOCK, HS; BOLAN, G; REINGOLD, AL; POLISH, LB			HEPATITIS-C VIRUS-INFECTION AMONG PATIENTS ATTENDING A CLINIC FOR SEXUALLY-TRANSMITTED DISEASES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							NON-B-HEPATITIS; NON-A-HEPATITIS; POSTTRANSFUSION HEPATITIS; HEMODIALYSIS-PATIENTS; ANTIBODIES; RISK; TRANSMISSION; PREVALENCE; HIV	Objective.-To evaluate the association between hepatitis C virus (HCV) infection and sexual behavior in a sexually active population. Design.-Cross-sectional study. Setting.-Inner-city clinic for sexually transmitted diseases. Subjects.-The study included 1292 patients attending the clinic for care during a 1-month period and having syphilis serologic tests performed. Outcome Measures.-Antibody to HCV (anti-HCV) positivity as defined by a repeatedly reactive enzyme immunoassay and a positive neutralization enzyme immunoassay (Abbott Laboratories, Chicago, III). Results.-Of 1292 patients screened for anti-HCV, 99 (7.7%) were positive. Logistic regression analysis found that patients who reported intravenous drug use, were positive for antibody to hepatitis B core antigen, reported a history of a blood transfusion, were black, or reported crack cocaine use were more likely to be anti-HCV-positive. Forty-five percent of patients who were anti-HCV-positive reported intravenous drug use. Sex with an intravenous drug user and a history of gonorrhea and syphilis were associated with anti-HCV positivity in a univariate analysis, but after controlling for confounding variables, no such associations remained. While having multiple sexual partners in the previous 3 months, being homosexual or bisexual, and engaging in receptive anal intercourse were associated with being positive for antibody to hepatitis B core antigen, those behaviors were not associated with anti-HCV positivity. Conclusions.-While these results cannot exclude a role for the sexual transmission of HCV, they do suggest that, in this sexually active population, the sexual transmission of HCV occurs infrequently and that HCV is largely associated with intravenous drug use.	CTR DIS CONTROL & PREVENT,DIV STD HIV PREVENT,ATLANTA,GA 30333; CTR DIS CONTROL & PREVENT,DIV VIRAL & RICKETTSIAL DIS,HEPATITIS BRANCH,ATLANTA,GA 30333; SAN FRANCISCO,DEPT PUBL HLTH,SAN FRANCISCO,CA; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF BERKELEY,SCH PUBL HLTH,BERKELEY,CA 94720	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; University of California System; University of California San Francisco; University of California System; University of California Berkeley					PHS HHS [H-25CCH904371-01-2] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AACH RD, 1991, NEW ENGL J MED, V325, P1325, DOI 10.1056/NEJM199111073251901; ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; ALTER MJ, 1990, JAMA-J AM MED ASSOC, V264, P2231, DOI 10.1001/jama.264.17.2231; ALTER MJ, 1989, JAMA-J AM MED ASSOC, V262, P1201, DOI 10.1001/jama.262.9.1201; ESTEBAN JI, 1990, NEW ENGL J MED, V323, P1107, DOI 10.1056/NEJM199010183231605; ESTEBAN JI, 1989, LANCET, V2, P294; EVERHART JE, 1990, ANN INTERN MED, V112, P544, DOI 10.7326/0003-4819-112-7-544; EYSTER ME, 1991, ANN INTERN MED, V115, P764, DOI 10.7326/0003-4819-115-10-764; HAYASHI J, 1991, AM J EPIDEMIOL, V134, P651, DOI 10.1093/oxfordjournals.aje.a116137; KALLINOWSKI B, 1991, NEPHRON, V59, P236, DOI 10.1159/000186557; KELEN GD, 1992, NEW ENGL J MED, V326, P1399, DOI 10.1056/NEJM199205213262105; KLEIN RS, 1991, LANCET, V338, P1539, DOI 10.1016/0140-6736(91)92369-D; RAKELA J, 1979, GASTROENTEROLOGY, V77, P1200; REALDI G, 1982, GUT, V23, P270, DOI 10.1136/gut.23.4.270; TOR J, 1990, BRIT MED J, V301, P1130, DOI 10.1136/bmj.301.6761.1130; TREMOLADA F, 1991, ANN INTERN MED, V114, P277, DOI 10.7326/0003-4819-114-4-277; WEINER AJ, 1990, LANCET, V335, P1, DOI 10.1016/0140-6736(90)90134-Q; 1987, HEPATITIS SURVEILLAN, P19	18	118	117	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 20	1993	269	3					392	394						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG381	8418348				2022-12-24	WOS:A1993KG38100033
J	BERRILL, WT				BERRILL, WT			FOR DEBATE - IS THE DEATH RATE FROM ASTHMA EXAGGERATED - EVIDENCE FROM WEST CUMBRIA	BRITISH MEDICAL JOURNAL			English	Article							MORTALITY; INCREASE; ENGLAND; WALES	Although the death rate from asthma in England and Wales is reported to be about 2000 a year, clinical experience suggests that it is much rarer. Doctors in West Cumbria health district could recall only seven cases in 14 years. Examination of case notes of patients officially recorded as dying of asthma showed that many were aged over 60 and cigarette smokers. An alternative cause of death was evident in over half the patients. If the picture is representative of that in the whole of Britain the reported mortality from asthma may be much too high.			BERRILL, WT (corresponding author), W CUMBERLAND DIST GEN HOSP,WHITEHAVEN CA28 8JG,CUMBRIA,ENGLAND.							[Anonymous], 1984, Thorax, V39, P505; BURNEY P, 1988, J EPIDEMIOL COMMUN H, V42, P316, DOI 10.1136/jech.42.4.316; BURNEY PGJ, 1986, LANCET, V2, P323; COCHRANE AL, 1981, LANCET, V2, P742; EASON J, 1987, BRIT MED J, V294, P1255, DOI 10.1136/bmj.294.6582.1255; REA HH, 1986, THORAX, V41, P83; 1982, BMJ, V285, P1251	7	19	19	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 16	1993	306	6871					193	194		10.1136/bmj.306.6871.193	http://dx.doi.org/10.1136/bmj.306.6871.193			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KH513	8443487	Bronze, Green Published			2022-12-24	WOS:A1993KH51300029
J	SINGH, R; GREEN, MR				SINGH, R; GREEN, MR			SEQUENCE-SPECIFIC BINDING OF TRANSFER-RNA BY GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE	SCIENCE			English	Article							URACIL DNA GLYCOSYLASE; NUCLEAR TRANSPORT; IMMUNOCYTOCHEMICAL LOCALIZATION; SKELETAL-MUSCLE; PROTEIN; EXPORT; SYNTHETASE; CELLS; IDENTIFICATION; TRANSCRIPTION	A transfer RNA (tRNA) binding protein present in HeLa cell nuclear extracts was purified and identified as the glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Studies with mutant tRNAs indicated that GAPDH recognizes both sequence and structural features in the RNA. GAPDH discriminated between wild-type tRNA and two tRNA mutants that are defective in nuclear export, which suggests that the protein may participate in RNA export. The cofactor nicotinamide adenine dinucleotide disrupted complex formation between tRNA and GAPDH and thus may share a common binding site with the RNA. Indirect immunofluorescence experiments showed that GAPDH is present in the nucleus as well as in the cytoplasm.			SINGH, R (corresponding author), UNIV MASSACHUSETTS,MED CTR,PROGRAM MOLEC MED,WORCESTER,MA 01605, USA.				NIGMS NIH HHS [GM35490] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035490] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKINS RA, 1987, CELL, V50, P331, DOI 10.1016/0092-8674(87)90488-0; ALLEN RW, 1987, J BIOL CHEM, V262, P649; BENTLEY RC, 1991, MOL CELL BIOL, V11, P1829, DOI 10.1128/MCB.11.4.1829; BODE J, 1975, BIOCHEMISTRY-US, V14, P1146, DOI 10.1021/bi00677a008; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; CASWELL AH, 1985, J BIOL CHEM, V260, P6892; COOL BL, 1989, CANCER RES, V49, P3029; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; FOLK WR, 1983, CELL, V33, P585, DOI 10.1016/0092-8674(83)90439-7; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; GUDDAT U, 1990, CELL, V60, P619, DOI 10.1016/0092-8674(90)90665-2; HAMM J, 1990, CELL, V63, P109, DOI 10.1016/0092-8674(90)90292-M; HANAUER A, 1984, EMBO J, V3, P2627, DOI 10.1002/j.1460-2075.1984.tb02185.x; HODOR P, 1989, MICROCIRC ENDOTH LYM, V5, P485; HUITOREL P, 1985, EUR J BIOCHEM, V150, P265, DOI 10.1111/j.1432-1033.1985.tb09016.x; KAPTAIN S, 1991, P NATL ACAD SCI USA, V88, P10109, DOI 10.1073/pnas.88.22.10109; KARPEL RL, 1981, BIOCHIM BIOPHYS ACTA, V654, P256, DOI 10.1016/0005-2787(81)90180-5; KAWAMOTO RM, 1986, BIOCHEMISTRY-US, V25, P656, DOI 10.1021/bi00351a022; LIN T, 1986, J BIOL CHEM, V261, P4594; MARTIN K, 1991, CELL, V67, P117, DOI 10.1016/0092-8674(91)90576-K; MCALISTER L, 1985, J BIOL CHEM, V260, P5013; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MEYERSIEGLER K, 1991, P NATL ACAD SCI USA, V88, P8460, DOI 10.1073/pnas.88.19.8460; MORGENEGG G, 1986, J NEUROCHEM, V47, P54; NIGG EA, 1991, CELL, V66, P15, DOI 10.1016/0092-8674(91)90135-L; PERUCHO M, 1977, EUR J BIOCHEM, V81, P557, DOI 10.1111/j.1432-1033.1977.tb11982.x; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; ROSSMANN MG, 1976, ENZYMES, P62; ROUAULT TA, 1991, CELL, V64, P881, DOI 10.1016/0092-8674(91)90312-M; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; RYAZANOV AG, 1985, FEBS LETT, V192, P131, DOI 10.1016/0014-5793(85)80058-2; SAMPSON JR, 1990, BIOCHEMISTRY-US, V29, P2523, DOI 10.1021/bi00462a014; SANTOS T, 1981, CELL, V23, P699, DOI 10.1016/0092-8674(81)90433-5; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; Singh R., UNPUB; TOBIAN JA, 1985, CELL, V43, P415, DOI 10.1016/0092-8674(85)90171-0; TUNG KS, 1992, MOL CELL BIOL, V12, P2673, DOI 10.1128/MCB.12.6.2673; VANTUINEN E, 1987, J HISTOCHEM CYTOCHEM, V35, P327, DOI 10.1177/35.3.3546482; ZAMORE PD, 1990, NATURE, V348, P485, DOI 10.1038/348485a0; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; ZASLOFF M, 1982, NATURE, V295, P533, DOI 10.1038/295533a0; ZASLOFF M, 1982, NATURE, V300, P81, DOI 10.1038/300081a0; ZASLOFF M, 1983, P NATL ACAD SCI-BIOL, V80, P6436, DOI 10.1073/pnas.80.21.6436	44	404	425	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 15	1993	259	5093					365	368		10.1126/science.8420004	http://dx.doi.org/10.1126/science.8420004			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KG624	8420004				2022-12-24	WOS:A1993KG62400033
J	KAWACHI, I; COLDITZ, GA; STAMPFER, MJ; WILLETT, WC; MANSON, JE; ROSNER, B; SPEIZER, FE; HENNEKENS, CH				KAWACHI, I; COLDITZ, GA; STAMPFER, MJ; WILLETT, WC; MANSON, JE; ROSNER, B; SPEIZER, FE; HENNEKENS, CH			SMOKING CESSATION AND DECREASED RISK OF STROKE IN WOMEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CIGARETTE-SMOKING; SUBARACHNOID HEMORRHAGE; QUESTIONNAIRE; DISEASE	Objective.-To prospectively examine the relationship of time since stopping smoking with risk of stroke in middle-aged women. Design.-An ongoing prospective cohort of women with 12 years' follow-up data (1976 to 1988), in which information on smoking habits was updated every 2 years by postal questionnaire. Population Studied.-A total of 117 006 female registered nurses aged 30 to 55 years in 1976 and free of coronary heart disease, stroke, and cancer at baseline. Main Outcome Measures.-Incident strokes (fatal and nonfatal), further subdivided into ischemic stroke, subarachnoid hemorrhage, and cerebral hemorrhage. Results.-The age-adjusted relative risk of total stroke among current smokers compared with never smokers was 2.58 (95% confidence interval, 2.08 to 3.19). The corresponding relative risk among former smokers was 1.34 (95% confidence interval, 1.04 to 1.73). For total and ischemic stroke, the excess risks among former smokers largely disappeared from 2 to 4 years after cessation. The same patterns of decline were observed regardless of number of cigarettes smoked, the age at starting, or the presence of other risk factors for stroke. Conclusions.-The risk of suffering a stroke among cigarette smokers declines soon after cessation and the benefits are independent of the age at starting and the number of cigarettes smoked per day.	HARVARD UNIV, SCH PUBL HLTH, DEPT HLTH & SOCIAL BEHAV, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, CHANNING LAB, DEPT PREVENT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT BIOSTAT, BOSTON, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	KAWACHI, I (corresponding author), HARVARD UNIV, SCH MED, CHANNING LAB, DEPT MED, 180 LONGWOOD AVE, BOSTON, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NATIONAL CANCER INSTITUTE [R37CA040356, R01CA040356] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034594] Funding Source: NIH RePORTER; NCI NIH HHS [CA 40356] Funding Source: Medline; NHLBI NIH HHS [HL 34594] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALLANTYNE D, 1978, CLIN SCI MOL MED, V55, P333; BELL BA, 1979, BRIT MED J, V1, P577, DOI 10.1136/bmj.1.6163.577; CELLINA GU, 1975, AM HEART J, V89, P18, DOI 10.1016/0002-8703(75)90004-6; COLDITZ GA, 1988, NEW ENGL J MED, V318, P937, DOI 10.1056/NEJM198804143181501; COLDITZ GA, 1987, INT J EPIDEMIOL, V16, P392, DOI 10.1093/ije/16.3.392; DONNAN GA, 1989, LANCET, V2, P643; GILL JS, 1989, ARCH INTERN MED, V149, P2053, DOI 10.1001/archinte.149.9.2053; GIOVANNUCCI E, 1991, AM J EPIDEMIOL, V133, P810; HENNEKENS CH, 1979, LANCET, V1, P1390; KANNEL WB, 1987, AM HEART J, V113, P1006, DOI 10.1016/0002-8703(87)90063-9; KUBOTA K, 1983, STROKE, V14, P720, DOI 10.1161/01.STR.14.5.720; LACROIX AZ, 1991, NEW ENGL J MED, V324, P1619, DOI 10.1056/NEJM199106063242303; LEVINE PH, 1973, CIRCULATION, V48, P619, DOI 10.1161/01.CIR.48.3.619; LONGSTRETH WT, 1985, STROKE, V16, P377, DOI 10.1161/01.STR.16.3.377; MIETTINEN O, 1976, AM J EPIDEMIOL, V103, P226, DOI 10.1093/oxfordjournals.aje.a112220; MYERS AH, 1987, AM J PUBLIC HEALTH, V77, P628, DOI 10.2105/AJPH.77.5.628; ROGERS RL, 1985, JAMA-J AM MED ASSOC, V253, P2970, DOI 10.1001/jama.253.20.2970; SHINTON R, 1989, BMJ-BRIT MED J, V298, P789, DOI 10.1136/bmj.298.6676.789; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; STAMPFER MJ, 1985, NEW ENGL J MED, V313, P1044, DOI 10.1056/NEJM198510243131703; TAHA A, 1982, J ROY SOC MED, V75, P332; Walker A E, 1981, Stroke, V12, pI13; WOLF PA, 1988, JAMA-J AM MED ASSOC, V259, P1025, DOI 10.1001/jama.259.7.1025; 1990, PHS CDC908416 US DEP	24	302	312	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 13	1993	269	2					232	236		10.1001/jama.269.2.232	http://dx.doi.org/10.1001/jama.269.2.232			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF405	8417241				2022-12-24	WOS:A1993KF40500029
J	GALETTO, G; LEVINE, A				GALETTO, G; LEVINE, A			AIDS-ASSOCIATED PRIMARY CENTRAL-NERVOUS-SYSTEM LYMPHOMA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS; RADIATION-THERAPY; CHEMOTHERAPY; RISK		NIAID,DIV AIDS,AIDS CLIN TRIALS GRP,ONCOL CORE COMM,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	GALETTO, G (corresponding author), UNIV SO CALIF,SCH MED,1441 EASTLAKE AVE,LOS ANGELES,CA 90033, USA.							BAUMGARTNER JE, 1990, J NEUROSURG, V73, P206, DOI 10.3171/jns.1990.73.2.0206; CORN BW, 1992, P ASCO, V11, P44; DEANGELIS LM, 1990, NEUROLOGY, V40, P80, DOI 10.1212/WNL.40.1.80; EBY NL, 1988, CANCER, V62, P2461, DOI 10.1002/1097-0142(19881201)62:11<2461::AID-CNCR2820621135>3.0.CO;2-M; FORMENTI SC, 1989, CANCER, V63, P1101, DOI 10.1002/1097-0142(19890315)63:6<1101::AID-CNCR2820630611>3.0.CO;2-R; GAIL MH, 1991, JNCI-J NATL CANCER I, V83, P695, DOI 10.1093/jnci/83.10.695; GERBERDING JL, 1987, J INFECT DIS, V156, P1, DOI 10.1093/infdis/156.1.1; HENDERSON DK, 1990, ANN INTERN MED, V113, P740, DOI 10.7326/0003-4819-113-10-740; LEVINE AM, 1991, JAMA-J AM MED ASSOC, V266, P84, DOI 10.1001/jama.266.1.84; LEVY RM, 1992, NEUROSURGERY, V30, P186, DOI 10.1227/00006123-199202000-00006; MARCUS R, 1988, NEW ENGL J MED, V319, P1118, DOI 10.1056/NEJM198810273191703; PLUDA JM, 1990, ANN INTERN MED, V113, P276, DOI 10.7326/0003-4819-113-4-276; SHETTER AG, 1977, SURG NEUROL, V8, P341; SOCIE G, 1990, CANCER, V65, P322, DOI 10.1002/1097-0142(19900115)65:2<322::AID-CNCR2820650223>3.0.CO;2-D	14	20	20	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 6	1993	269	1					92	93		10.1001/jama.269.1.92	http://dx.doi.org/10.1001/jama.269.1.92			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF026	8416414				2022-12-24	WOS:A1993KF02600035
J	JARRETT, RJ				JARRETT, RJ			GESTATIONAL DIABETES - A NONENTITY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							GLUCOSE-INTOLERANCE; TOLERANCE	Screening for gestational diabetes is commonly recommended despite the absence of a common definition of gestational diabetes. Furthermore, there is no consensus about management or treatment. Those who recommend screening do so largely on the basis of fetal morbidity, which seems to be predominantly ''macrosomia''-another term without an agreed definition. The implications of macrosomia in terms of actual morbidity are also not clear. R J Jarrett reviews the history of the subject and concludes that gestational diabetes is simply impaired glucose tolerance temporally associated with pregnancy. Its main importance is as a predictor of subsequent non-insulin dependent diabetes, but it fails the major tests for a condition suitable for a screening programme.			JARRETT, RJ (corresponding author), UNITED MED & DENT SCH GUYS & ST THOMAS HOSP, GUYS CAMPUS, LONDON SE1 9RT, ENGLAND.							ALES KL, 1989, LANCET, V1, P1187; COUSTAN DR, 1978, OBSTET GYNECOL, V51, P306, DOI 10.1097/00006250-197803000-00010; Diabetes mellitus, 1985, WHO TECHNICAL REPORT, V727; FURMAN GI, 1987, DIABETES S1, V36, P90; GABBE SG, 1989, CARBOHYD METABOL, P309; GILBERT JAL, 1949, BRIT MED J, V1, P48, DOI 10.1136/bmj.1.4592.48; GREEN JR, 1991, OBSTET GYNECOL, V78, P235; HADDEN DR, 1980, DIABETES CARE, V3, P440, DOI 10.2337/diacare.3.3.440; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; HARRIS MI, 1988, DIABETES CARE, V11, P402, DOI 10.2337/diacare.11.5.402; O'Sullivan J.B., 1975, CARBOHYD METABOL, P195; OSULLIVAN JB, 1964, DIABETES, V13, P278; OSULLIVAN JB, 1966, DIABETES, V15, P466, DOI 10.2337/diab.15.7.466; OSULLIVAN JB, 1971, J REPROD MED, V7, P45; PARKER DJP, 1992, J EPIDEMIOL COMMUN H, V46, P8, DOI 10.1136/jech.46.1.8; 1986, MANAGEMENT DIABETES, V92, P1; 1980, WHO TECHNICAL REPORT, V646; 1985, DIABETES S2, V34, P123; 1991, DIABETES CARE, V14, P5; 1979, DIABETES, V28, P1038	20	94	95	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 2	1993	306	6869					37	38		10.1136/bmj.306.6869.37	http://dx.doi.org/10.1136/bmj.306.6869.37			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KE984	8435576	Bronze, Green Published			2022-12-24	WOS:A1993KE98400026
J	CLOZEL, M; BREU, V; BURRI, K; CASSAL, JM; FISCHLI, W; GRAY, GA; HIRTH, G; LOFFLER, BM; MULLER, M; NEIDHART, W; RAMUZ, H				CLOZEL, M; BREU, V; BURRI, K; CASSAL, JM; FISCHLI, W; GRAY, GA; HIRTH, G; LOFFLER, BM; MULLER, M; NEIDHART, W; RAMUZ, H			PATHOPHYSIOLOGICAL ROLE OF ENDOTHELIN REVEALED BY THE 1ST ORALLY-ACTIVE ENDOTHELIN RECEPTOR ANTAGONIST	NATURE			English	Article							SUBARACHNOID HEMORRHAGE; CORONARY-ARTERY; SMOOTH-MUSCLE; BLOOD-FLOW; RATS; CELLS; VASODILATION; MECHANISM; CLONING; SUBTYPE	SINCE its discovery1, endothelin-1 has attracted considerable scientific interest because of its extremely potent and long-lasting vaso-constrictor effect and its binding to G-protein-coupled receptors2. Plasma concentrations of endothelin-1 are low3 and its release by endothelial cells is polarized towards the basolateral side4,5, suggesting that it is a paracrine factor and not a hormone. Consequently, the effect of injected endothelin-1 may not reflect the effect of endogenous endothelin-1. In contrast, blockade of the action of endogenous endothelin-1 using receptor antagonists should be a valuable means of investigating its physiological and pathological effects. We report here evidence for the pathophysiological role of endothelin-1 as brought by the first synthetic orally active non-peptide antagonist of endothelin receptors, Ro 46-2005.			CLOZEL, M (corresponding author), F HOFFMANN LA ROCHE & CO LTD,PRECLIN RES,DIV PHARMA,GRENZACHERSTR 124,CH-4002 BASEL,SWITZERLAND.		Gray, Gillian A/B-4058-2014	Gray, Gillian A/0000-0003-3104-3305				ANDO K, 1989, FEBS LETT, V245, P164, DOI 10.1016/0014-5793(89)80213-3; ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; ARUNLAKSHANA O, 1959, BRIT J PHARM CHEMOTH, V14, P48, DOI 10.1111/j.1476-5381.1959.tb00928.x; CLOZEL JP, 1993, HYPERTENSION, V11, P75; CLOZEL M, 1989, J HYPERTENS, V7, P913, DOI 10.1097/00004872-198911000-00011; CLOZEL M, 1991, J CARDIOVASC PHARM, V17, pS313, DOI 10.1097/00005344-199100177-00089; CLOZEL M, 1992, BIOCHEM BIOPH RES CO, V186, P867, DOI 10.1016/0006-291X(92)90826-7; CLOZEL M, 1993, LIFE SCI, V52, P825, DOI 10.1016/0024-3205(93)90081-D; DOHI Y, 1991, HYPERTENSION, V18, P543, DOI 10.1161/01.HYP.18.4.543; EMORI T, 1990, FEBS LETT, V263, P261, DOI 10.1016/0014-5793(90)81388-5; FISCHLI W, 1989, LIFE SCI, V44, P1429, DOI 10.1016/0024-3205(89)90321-4; HARRISON VJ, 1992, BRIT J PHARMACOL, V105, P511, DOI 10.1111/j.1476-5381.1992.tb09009.x; HEYMANN MA, 1977, PROG CARDIOVASC DIS, V20, P55, DOI 10.1016/S0033-0620(77)80005-4; IHARA M, 1992, LIFE SCI, V50, P247, DOI 10.1016/0024-3205(92)90331-I; KASUYA Y, 1992, BRIT J PHARMACOL, V107, P456, DOI 10.1111/j.1476-5381.1992.tb12767.x; LERMAN A, 1991, NEW ENGL J MED, V325, P997, DOI 10.1056/NEJM199110033251404; MCMURDO L, 1993, BRIT J PHARMACOL, V108, P557, DOI 10.1111/j.1476-5381.1993.tb12840.x; MCMURRAY JJ, 1992, CIRCULATION, V85, P1374, DOI 10.1161/01.CIR.85.4.1374; MINO N, 1992, EUR J PHARMACOL, V221, P77; MORELAND S, 1992, BIOCHEM BIOPH RES CO, V184, P100, DOI 10.1016/0006-291X(92)91163-K; MULVANY MJ, 1977, CIRC RES, V41, P19, DOI 10.1161/01.RES.41.1.19; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SOKOLOVSKY M, 1992, J BIOL CHEM, V267, P20551; SOLOMON RA, 1985, STROKE, V16, P58, DOI 10.1161/01.STR.16.1.58; SUZUKI R, 1992, J NEUROSURG, V77, P96, DOI 10.3171/jns.1992.77.1.0096; TAKAYANAGI R, 1991, FEBS LETT, V282, P103, DOI 10.1016/0014-5793(91)80454-B; WAGNER OF, 1992, J BIOL CHEM, V267, P16066; WEBB ML, 1992, BIOCHEM BIOPH RES CO, V185, P887, DOI 10.1016/0006-291X(92)91710-8; WILLIAMS DL, 1991, BIOCHEM BIOPH RES CO, V175, P556, DOI 10.1016/0006-291X(91)91601-8; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; YOSHIMOTO S, 1991, J CARDIOVASC PHARM, V17, pS260, DOI 10.1097/00005344-199100177-00074	31	499	536	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 21	1993	365	6448					759	761		10.1038/365759a0	http://dx.doi.org/10.1038/365759a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MC812	8413655				2022-12-24	WOS:A1993MC81200065
J	PALLEROS, DR; REID, KL; SHI, L; WELCH, WJ; FINK, AL				PALLEROS, DR; REID, KL; SHI, L; WELCH, WJ; FINK, AL			ATP-INDUCED PROTEIN HSP70 COMPLEX DISSOCIATION REQUIRES K+ BUT NOT ATP HYDROLYSIS	NATURE			English	Article							HEAT-SHOCK PROTEINS; UNFOLDED PROTEINS; DNAK; CHAPERONE; BINDING; GROEL	THE molecular chaperone proteins, particularly Hsp60 and Hsp70, have been implicated in essential cell functions under both normal and stress conditions (reviewed in refs 1-5). Members of the family of heat-shock proteins of M(r) 70K, Hsp70, bind to unfolded proteins and short peptides6-13. Addition of Mg-ATP results in the dissociation of the substrate polypeptides from the chaperone7-11, but as ATP-gammaS (an ATP analogue that is only slowly hydrolysable) cannot substitute for ATP in this reaction7,9,11, it has been concluded that ATP hydrolysis is necessary to dissociate Hsp70-substrate protein complexes. By independently measuring the rates of ATP hydrolysis and substrate protein dissociation, we show here that Mg-ATP binding but not Mg-ATP hydrolysis is essential for substrate dissociation. We also show that there is an absolute requirement for K+ for the effect of Mg-ATP: only the combination of K+ and Mg-ATP will cause the conformational change in Hsp70 that is necessary for substrate dissociation. Moreover, in the absence of K+, Mg-ATP favours complex formation. We consider these results in terms of a G-protein-like model.	UNIV CALIF SANTA CRUZ,DEPT CHEM & BIOCHEM,SANTA CRUZ,CA 95064; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143	University of California System; University of California Santa Cruz; University of California System; University of California San Francisco; University of California System; University of California San Francisco								ANG D, 1991, J BIOL CHEM, V266, P24233; ANTONINO LC, 1991, P NATL ACAD SCI USA, V88, P7715, DOI 10.1073/pnas.88.17.7715; BARDWELL JCA, 1984, P NATL ACAD SCI-BIOL, V81, P848, DOI 10.1073/pnas.81.3.848; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BROWN CR, 1993, J CELL BIOL, V120, P1101, DOI 10.1083/jcb.120.5.1101; ELLIS RJ, 1991, SEMIN CELL BIOL, V1, P1; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; GETHING MJ, 1992, NATURE, V355, P35; HARTL FU, 1992, REV BIOPHYS BIOMED S, V21, P293; HIGHTOWER LE, 1991, CELL, V66, P191, DOI 10.1016/0092-8674(91)90611-2; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LIBEREK K, 1991, J BIOL CHEM, V266, P14491; MCCARTY JS, 1991, P NATL ACAD SCI USA, V88, P9513, DOI 10.1073/pnas.88.21.9513; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; PALLEROS DR, 1992, J BIOL CHEM, V267, P5279; SADIS S, 1992, BIOCHEMISTRY-US, V31, P9406, DOI 10.1021/bi00154a012; SCHMID SL, 1985, J BIOL CHEM, V260, P57	20	372	376	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 14	1993	365	6447					664	666		10.1038/365664a0	http://dx.doi.org/10.1038/365664a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MB846	8413631				2022-12-24	WOS:A1993MB84600064
J	MULLAART, E; DEVOS, GJ; MEERMAN, GJT; UITTERLINDEN, AG; VIJG, J				MULLAART, E; DEVOS, GJ; MEERMAN, GJT; UITTERLINDEN, AG; VIJG, J			PARALLEL GENOME ANALYSIS BY 2-DIMENSIONAL DNA TYPING	NATURE			English	Article							ELECTROPHORESIS; PROTEINS		UNIV GRONINGEN,DEPT MED GENET,9713 AW GRONINGEN,NETHERLANDS	University of Groningen	MULLAART, E (corresponding author), INGENY BV,POB 685,2300 AR LEIDEN,NETHERLANDS.							FISCHER SG, 1979, CELL, V16, P191, DOI 10.1016/0092-8674(79)90200-9; HOVIG E, 1993, GENOMICS, V17, P66, DOI 10.1006/geno.1993.1284; JEFFREYS AJ, 1985, NATURE, V314, P67, DOI 10.1038/314067a0; MEERMAN GJT, IN PRESS AM J HUM GE; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; SCHAAP GH, 1983, CYTOMETRY, V3, P408, DOI 10.1002/cyto.990030604; SCHEELE GA, 1975, J BIOL CHEM, V250, P5375; UITTERLINDEN AG, 1989, P NATL ACAD SCI USA, V86, P2742, DOI 10.1073/pnas.86.8.2742; UITTERLINDEN AG, 1993, 2 DIMENSIONAL DNA TY; VERWEST AM, IN PRESS BR J CANCER	10	23	23	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 30	1993	365	6445					469	471		10.1038/365469a0	http://dx.doi.org/10.1038/365469a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LZ633	8413593				2022-12-24	WOS:A1993LZ63300068
J	KING, MC; ROWELL, S; LOVE, SM				KING, MC; ROWELL, S; LOVE, SM			INHERITED BREAST AND OVARIAN-CANCER - WHAT ARE THE RISKS - WHAT ARE THE CHOICES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PROPHYLACTIC MASTECTOMY; P53 MUTATIONS; ONCOGENE; PREVENTION; LINKAGE		UNIV CALIF BERKELEY, SCH PUBL HLTH, BERKELEY, CA 94720 USA; UNIV CALIF LOS ANGELES, CTR HLTH SCI, DEPT SURG, LOS ANGELES, CA USA; UNIV CALIF LOS ANGELES, CTR BREAST, LOS ANGELES, CA USA	University of California System; University of California Berkeley; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	KING, MC (corresponding author), UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, 140 WARREN HALL, BERKELEY, CA 94720 USA.			King, Mary-Claire/0000-0001-9426-1743	NCI NIH HHS [R01 CA27632] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA027632] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON LA, IN PRESS GENOMICS; BAKER LH, 1982, CA-CANCER J CLIN, V32, P194, DOI 10.3322/canjclin.32.4.194; BEVILACQUA G, 1989, CANCER RES, V49, P5185; BOICE JD, 1977, J NATL CANCER I, V59, P823, DOI 10.1093/jnci/59.3.823; BOWCOCK AM, IN PRESS AM J HUM GE; Broca P., 1866, TRAITE TUMERURS; CALLAHAN R, 1992, CANCER, V69, P1582, DOI 10.1002/1097-0142(19920315)69:6+<1582::AID-CNCR2820691313>3.0.CO;2-Y; CLAUS EB, 1991, AM J HUM GENET, V48, P232; CLAUS EB, IN PRESS AM J HUM GE; COLES C, 1992, CANCER RES, V52, P5291; COLLINS FS, 1992, NAT GENET, V1, P3, DOI 10.1038/ng0492-3; CRUICKSHANK DJ, 1992, BRIT J OBSTET GYNAEC, V99, P226, DOI 10.1111/j.1471-0528.1992.tb14504.x; EASTON DF, IN PRESS AM J HUM GE; GOODNIGHT JE, 1984, J SURG ONCOL, V26, P198, DOI 10.1002/jso.2930260313; HALL JM, 1992, AM J HUM GENET, V50, P1235; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HENDERSON BE, 1991, SCIENCE, V254, P1131, DOI 10.1126/science.1957166; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; IRWIN KL, 1988, AM J EPIDEMIOL, V127, P1192, DOI 10.1093/oxfordjournals.aje.a114912; KING MC, 1992, NAT GENET, V2, P89, DOI 10.1038/ng1092-89; KING MC, 1990, CANCER SURV, V9, P417; La Francis I E, 1992, Conn Med, V56, P411; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MCGREGOR DH, 1977, J NATL CANCER I, V59, P799, DOI 10.1093/jnci/59.3.799; MILLER AB, 1992, CAN MED ASSOC J, V147, P1459; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; NAYFIELD SG, 1991, J NATL CANCER I, V83, P1450, DOI 10.1093/jnci/83.20.1450; NELSON H, 1989, PLAST RECONSTR SURG, V83, P662, DOI 10.1097/00006534-198904000-00011; NEWMAN B, 1988, P NATL ACAD SCI USA, V85, P3044, DOI 10.1073/pnas.85.9.3044; PIKE MC, 1983, NATURE, V303, P767, DOI 10.1038/303767a0; RIES LA, 1990, CANCER STATISTICS RE; RUNOWICZ CD, 1992, CA-CANCER J CLIN, V42, P327, DOI 10.3322/canjclin.42.6.327; SCHILDKRAUT JM, 1988, AM J EPIDEMIOL, V128, P456, DOI 10.1093/oxfordjournals.aje.a114994; SIDRANSKY D, 1992, CANCER RES, V52, P2984; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SMITH SA, 1992, NAT GENET, V2, P128, DOI 10.1038/ng1092-128; TEMPLE WJ, 1991, AM J SURG, V161, P413, DOI 10.1016/0002-9610(91)91100-W; TSUDA H, 1989, CANCER RES, V49, P3104; VANDEVIJVER MJ, 1991, BIOCHIM BIOPHYS ACTA, V1072, P33, DOI 10.1016/0304-419X(91)90005-6; WEBER AM, 1992, OBSTET GYNECOL, V80, P558; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZIEGLER LD, 1991, AM J CLIN ONCOL-CANC, V14, P451, DOI 10.1097/00000421-199110000-00018; ZUPPAN P, 1991, AM J HUM GENET, V48, P1065	44	227	228	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 21	1993	269	15					1975	1980		10.1001/jama.269.15.1975	http://dx.doi.org/10.1001/jama.269.15.1975			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KX215	8464130				2022-12-24	WOS:A1993KX21500029
J	COTE, F; COLLARD, JF; JULIEN, JP				COTE, F; COLLARD, JF; JULIEN, JP			PROGRESSIVE NEURONOPATHY IN TRANSGENIC MICE EXPRESSING THE HUMAN NEUROFILAMENT HEAVY GENE - A MOUSE MODEL OF AMYOTROPHIC-LATERAL-SCLEROSIS	CELL			English	Article							SLOW AXONAL-TRANSPORT; MOTOR-NEURON; MAMMALIAN NEUROFILAMENTS; INTERMEDIATE FILAMENTS; PHOSPHORYLATION SITES; NEUROLOGICAL DISEASE; TRIPLET PROTEINS; NF-H; INVITRO; POLYPEPTIDES	We generated four transgenic mice with a 34 kb genomic fragment including the complete human neurofilament heavy (NF-H) gene. This human NF-H fragment contained all regulatory elements for tissue-specific expression, and in two transgenic lines, human NF-H proteins were produced at levels up to 2-fold the levels of endogenous mouse NF-H protein. By 3-4 months of age, these NF-H transgenics progressively develop neurological defects and abnormal neurofilamentous swellings that are highly reminiscent of those found in amyotrophic lateral sclerosis (ALS). We propose that a modest up-regulation of NF-H cross-linkers can result in an impairment of neurofilament transport, causing neuronal swellings with ensuing axonopathy and muscle atrophy, a mechanism of pathogenesis pertinent to the possible etiology of ALS.			COTE, F (corresponding author), MCGILL UNIV,MONTREAL GEN HOSP,RES INST,CTR RES NEUROSCI,MONTREAL H3G 1A4,QUEBEC,CANADA.							ANDREWS JM, 1975, J NEUROPATH EXP NEUR, V34, P12, DOI 10.1097/00005072-197501000-00002; ARMON C, 1992, HDB AMYOTROPHIC LATE, P93; ASBURY AK, 1978, PATHOLOGY PERIPHERAL, V9; AUBRY M, 1992, GENOMICS, V13, P641, DOI 10.1016/0888-7543(92)90135-F; AVERBACK P, 1982, ARCH NEUROL-CHICAGO, V39, P155, DOI 10.1001/archneur.1982.00510150025006; BIZZI A, 1984, J NEUROSCI, V4, P722; BREUER AC, 1992, HDB AMYOTROPHIC LATE, P503; BRINSTER RL, 1981, CELL, V27, P223, DOI 10.1016/0092-8674(81)90376-7; CALLAHAN LM, 1991, J NEUROPATH EXP NEUR, V50, P491, DOI 10.1097/00005072-199107000-00009; CARDEN MJ, 1985, J BIOL CHEM, V260, P9805; CARDEN MJ, 1987, J NEUROSCI, V7, P3489; CARPENTE.S, 1974, ARCH NEUROL-CHICAGO, V31, P312, DOI 10.1001/archneur.1974.00490410060005; CARPENTER S, 1968, NEUROLOGY, V18, P841, DOI 10.1212/WNL.18.9.841; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Chou SM., 1992, HDB AMYOTROPHIC LATE, P133; DEWAEGH SM, 1992, CELL, V68, P451, DOI 10.1016/0092-8674(92)90183-D; FIGLEWICZ DA, 1992, HDB AMYOTROPHIC LATE, P687; FRANKE WW, 1987, CELL, V48, P3, DOI 10.1016/0092-8674(87)90345-X; GAJDUSEK DC, 1985, NEW ENGL J MED, V312, P714, DOI 10.1056/NEJM198503143121110; GARDNER EE, 1984, J NEUROSCI RES, V11, P145, DOI 10.1002/jnr.490110204; GEISLER N, 1984, EMBO J, V3, P2701, DOI 10.1002/j.1460-2075.1984.tb02196.x; GEISLER N, 1981, J MOL BIOL, V151, P565, DOI 10.1016/0022-2836(81)90011-5; GOLDMAN JE, 1986, ANN NEUROL, V19, P209, DOI 10.1002/ana.410190302; GRAHAM DG, 1984, P NATL ACAD SCI-BIOL, V81, P4979, DOI 10.1073/pnas.81.15.4979; GRIFFIN JW, 1978, SCIENCE, V202, P633, DOI 10.1126/science.81524; GRIFFIN JW, 1988, ANN NEUROL, V23, P3, DOI 10.1002/ana.410230103; HIRANO A, 1984, J NEUROPATH EXP NEUR, V43, P461, DOI 10.1097/00005072-198409000-00001; HIRANO A, 1992, HDB AMYOTROPHIC LATE, P183; HIROKAWA N, 1984, J CELL BIOL, V98, P1523, DOI 10.1083/jcb.98.4.1523; HIROKAWA N, 1991, NEURONAL CYTOSKELETO, P5; HISANAGA S, 1990, J MOL BIOL, V211, P871, DOI 10.1016/0022-2836(90)90080-6; HOFFMAN PN, 1975, J CELL BIOL, V66, P351, DOI 10.1083/jcb.66.2.351; HOFFMAN PN, 1984, J CELL BIOL, V99, P705, DOI 10.1083/jcb.99.2.705; HOFFMAN PN, 1987, P NATL ACAD SCI USA, V84, P3472, DOI 10.1073/pnas.84.10.3472; HOFFMAN PN, 1985, J CELL BIOL, V101, P1332, DOI 10.1083/jcb.101.4.1332; JULIEN JP, 1982, J BIOL CHEM, V257, P467; JULIEN JP, 1983, J BIOL CHEM, V258, P4019; JULIEN JP, 1988, GENE, V68, P307, DOI 10.1016/0378-1119(88)90033-9; JULIEN JP, 1987, GENE DEV, V1, P1085, DOI 10.1101/gad.1.10.1085; JULIEN JP, 1986, MOL BRAIN RES, V1, P243, DOI 10.1016/0169-328X(86)90030-6; Julien JP, 1991, NEURONAL CYTOSKELETO, P215; KAUPMANN K, 1992, GENOMICS, V13, P39, DOI 10.1016/0888-7543(92)90199-3; KAWAMURA Y, 1981, J NEUROPATH EXP NEUR, V40, P667, DOI 10.1097/00005072-198111000-00008; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE VMY, 1988, P NATL ACAD SCI USA, V85, P1998, DOI 10.1073/pnas.85.6.1998; LEES JF, 1988, EMBO J, V7, P1947, DOI 10.1002/j.1460-2075.1988.tb03032.x; LIEM RKH, 1978, J CELL BIOL, V79, P637, DOI 10.1083/jcb.79.3.637; LIEM RKH, 1982, BIOCHEMISTRY-US, V21, P3221, DOI 10.1021/bi00256a029; LUTSEP HL, 1989, J NEUROPATH EXP NEUR, V48, P519, DOI 10.1097/00005072-198909000-00003; MACK K, 1988, J NEUROSCI RES, V20, P129, DOI 10.1002/jnr.490200118; MESSER A, 1992, HDB AMYOTROPHIC LATE, P433; MITSUMOTO H, 1982, BRAIN, V105, P811, DOI 10.1093/brain/105.4.811; MONTEIRO MJ, 1990, J CELL BIOL, V111, P1543, DOI 10.1083/jcb.111.4.1543; NORRIS FH, 1992, HDB AMYOTROPHIC LATE, P3; RADTKE RA, 1986, NEUROLOGY, V36, P796, DOI 10.1212/WNL.36.6.796; SACHER MG, 1992, BIOCHEM BIOPH RES CO, V186, P524, DOI 10.1016/S0006-291X(05)80839-3; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SASAKI S, 1989, ANN NEUROL, V25, P520, DOI 10.1002/ana.410250520; SCHMIDT ML, 1987, LAB INVEST, V56, P282; SENDTNER M, 1992, NATURE, V358, P502, DOI 10.1038/358502a0; SHAW G, 1982, NATURE, V298, P277, DOI 10.1038/298277a0; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; STERNBERGER LA, 1983, P NATL ACAD SCI-BIOL, V80, P6126, DOI 10.1073/pnas.80.19.6126; TRONCOSO JC, 1990, J STRUCT BIOL, V103, P2, DOI 10.1016/1047-8477(90)90080-V; TRONCOSO JC, 1985, BRAIN RES, V342, P172, DOI 10.1016/0006-8993(85)91369-1; TRONCOSO JC, 1992, HDB AMYOTROPHIC LATE, P543; WILLARD M, 1983, CELL, V35, P551, DOI 10.1016/0092-8674(83)90189-7; ZIMMERMAN UJP, 1986, BIOCHEMISTRY-US, V25, P3533, DOI 10.1021/bi00360a009	69	496	509	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 9	1993	73	1					35	46		10.1016/0092-8674(93)90158-M	http://dx.doi.org/10.1016/0092-8674(93)90158-M			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KW753	8462101				2022-12-24	WOS:A1993KW75300006
J	RUFF, HA; BIJUR, PE; MARKOWITZ, M; MA, YC; ROSEN, JF				RUFF, HA; BIJUR, PE; MARKOWITZ, M; MA, YC; ROSEN, JF			DECLINING BLOOD LEAD LEVELS AND COGNITIVE CHANGES IN MODERATELY LEAD-POISONED CHILDREN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PORT-PIRIE COHORT; EXPOSURE; MONKEYS; DEFICITS; REVERSAL; CHILDHOOD; INFANCY; BIRTH; IRON	Objective.-To determine whether chelation therapy or biochemical changes during a lead-lowering intervention was associated with changes in cognitive functioning of moderately lead-poisoned children. It was hypothesized that cognitive performance would improve as blood lead level declined over time. Design.-Short-term intervention study with measures obtained before and after intervention. Setting.-Hospital specialty clinic and university research center. Patients.-A total of 154 previously untreated children referred to clinic with blood lead levels between 1.21 and 2.66 mumol/L (25 and 55 mug/dL) at time of enrollment. Ages ranged from 13 to 87 months. Intervention.-Enrolled children were treated with edetate calcium disodium (EDTA) if eligible and/or with orally administered iron supplement if iron deficient. For all children, housing inspections and abatement procedures were performed as necessary. Main Outcome Measures.-Score on Bayley Mental Development Scale or Stanford-Binet Intelligence Scale (4th edition). Results.-There was no effect of edetate calcium disodium treatment per se. In the short term (7 weeks), changes in blood lead levels were not related to changes in cognitive scores. In the long term (6 months), however, changes in performance were significantly related to changes in blood lead level, even after controlling for confounding variables. The standardized score increased 1 point for every decrease of 0.14 mumol/L (3 mug/dL) in blood lead level. Conclusion.-The results suggest an association between decreases in blood lead level and cognitive improvements in moderately lead-poisoned children.			RUFF, HA (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED, MONTEFIORE MED CTR, DEPT PEDIAT, ROOM 222, KENNEDY CTR, BRONX, NY 10461 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004039] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [K02MH000652] Funding Source: NIH RePORTER; NICHD NIH HHS [HD07199] Funding Source: Medline; NIEHS NIH HHS [ES04039] Funding Source: Medline; NIMH NIH HHS [MH00652] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BAGHURST PA, 1987, NEUROTOXICOLOGY, V8, P395; Bayley N., 1993, BAYLEY SCALES INFANT, Vsecond; BELLINGER D, 1991, PEDIATRICS, V87, P219; BELLINGER D, 1987, NEW ENGL J MED, V316, P1037, DOI 10.1056/NEJM198704233161701; BUSHNELL PJ, 1979, PHARMACOL BIOCHEM BE, V10, P733, DOI 10.1016/0091-3057(79)90326-5; BUSHNELL PJ, 1979, J TOXICOL ENV HEALTH, V5, P1015, DOI 10.1080/15287397909529810; COHEN J, 1983, APPLIED MULTIPLE REG, P145; DAVID OJ, 1985, ARCH ENVIRON HEALTH, V40, P109, DOI 10.1080/00039896.1985.10545899; DAVID OJ, 1976, AM J PSYCHIAT, V133, P1155; DIETRICH KN, 1990, ENVIRON HEALTH PERSP, V89, P13, DOI 10.2307/3430891; DIETRICH KN, 1987, PEDIATRICS, V80, P721; ERNHART CB, 1987, NEUROTOXICOL TERATOL, V9, P259, DOI 10.1016/0892-0362(87)90011-0; ESCALONA SK, 1982, PEDIATRICS, V70, P670; FULTON M, 1987, LANCET, V1, P1221; LEVIN ED, 1983, NEUROBEH TOXICOL TER, V5, P391; LOZOFF B, 1989, B NEW YORK ACAD MED, V65, P1050; MARKOWITZ ME, 1984, J PEDIATR-US, V104, P337, DOI 10.1016/S0022-3476(84)81091-4; MARKOWITZ ME, 1990, J PEDIATR-US, V116, P360, DOI 10.1016/S0022-3476(05)82821-5; MARKOWITZ ME, 1991, J PEDIATR-US, V119, P305, DOI 10.1016/S0022-3476(05)80750-4; MARKOWITZ ME, IN PRESS PEDIATRICS; MCMICHAEL AJ, 1988, NEW ENGL J MED, V319, P468, DOI 10.1056/NEJM198808253190803; NEEDLEMAN HL, 1990, JAMA-J AM MED ASSOC, V263, P673, DOI 10.1001/jama.263.5.673; NEEDLEMAN HL, 1979, NEW ENGL J MED, V300, P689, DOI 10.1056/NEJM197903293001301; PIOMELLI S, 1977, CLIN CHEM, V23, P264; RICE DC, 1985, TOXICOL APPL PHARM, V77, P201, DOI 10.1016/0041-008X(85)90319-9; RICE DC, 1984, TOXICOL APPL PHARM, V75, P337, DOI 10.1016/0041-008X(84)90216-3; RUFF HA, 1989, J DEV BEHAV PEDIATR, V10, P103; SCHWARTZ J, IN PRESS NEUROTOXICO; SILVERSTEIN AB, 1982, J CONSULT CLIN PSYCH, V50, P415, DOI 10.1037/0022-006X.50.3.415; THORNDIKE RL, 1986, STANFORDBINET INTELL	30	90	91	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 7	1993	269	13					1641	1646		10.1001/jama.269.13.1641	http://dx.doi.org/10.1001/jama.269.13.1641			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KV349	8455297				2022-12-24	WOS:A1993KV34900027
J	FERRIS, FL				FERRIS, FL			HOW EFFECTIVE ARE TREATMENTS FOR DIABETIC-RETINOPATHY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											FERRIS, FL (corresponding author), NEI, CLIN TRIALS BRANCH, BLDG 31, ROOM 6A24, 9000 ROCKVILLE PIKE, BETHESDA, MD 20892 USA.							[Anonymous], 1988, OPHTHALMOLOGY, V95, P1307; [Anonymous], 1981, OPHTHALMOLOGY, V88, P583; [Anonymous], 1976, Am J Ophthalmol, V81, P383; BEETHAM W P, 1963, Br J Ophthalmol, V47, P611, DOI 10.1136/bjo.47.10.611; BLANKENSHIP GW, 1991, OPHTHALMOLOGY, V98, P125; CAIRD FI, 1968, DIABETES, V17, P121, DOI 10.2337/diab.17.3.121; DECKERT T, 1967, DIABETES, V16, P728, DOI 10.2337/diab.16.10.728; DRUMMOND MF, 1992, SOC SCI MED, V34, P973, DOI 10.1016/0277-9536(92)90128-D; JAVITT JC, 1989, OPHTHALMOLOGY, V96, P255; 1991, OPHTHALMOLOGY S, V98, P767; 1990, ARCH OPHTHALMOL-CHIC, V108, P958; 1989, DIABETIC RETINOPATHY	12	271	276	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 10	1993	269	10					1290	1291		10.1001/jama.269.10.1290	http://dx.doi.org/10.1001/jama.269.10.1290			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP885	8437309				2022-12-24	WOS:A1993KP88500030
J	ROMAN, E; WATSON, A; BERAL, V; BUCKLE, S; BULL, D; BAKER, K; RYDER, H; BARTON, C				ROMAN, E; WATSON, A; BERAL, V; BUCKLE, S; BULL, D; BAKER, K; RYDER, H; BARTON, C			CASE-CONTROL STUDY OF LEUKEMIA AND NON-HODGKINS-LYMPHOMA AMONG CHILDREN AGED 0-4 YEARS LIVING IN WEST-BERKSHIRE AND NORTH-HAMPSHIRE HEALTH DISTRICTS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; CHILDHOOD LEUKEMIA; OCCUPATIONS; AUTHORITY; MORTALITY; CUMBRIA; CANCER	Objective-To investigate the relation between parental employment in the nuclear industry and childhood leukaemia and non-Hodgkin's lymphoma. Design-Case-control study. Setting-West Berkshire and Basingstoke and North Hampshire District Health Authorities. Subjects-54 children aged 0-4 years who had leukaemia or non-Hodgkin's lymphoma diagnosed during 1972-89, who were born in the study area and were resident there when cancer was diagnosed. Six controls were selected for each case: four from hospital delivery registers and two from livebirth registers maintained by the NHS central register. Controls were matched for sex, date of birth (within six months), and area of residence at birth and time of diagnosis. Main outcome measures-Parents' employment by the nuclear industry and exposure to ionising radiation at work. Results-Five (9%) of the 54 cases and 14 (4%) of the 324 controls had fathers or mothers, or both, who had been employed by the nuclear industry (relative risk 2.2, 95% confidence interval 0.6 to 6.9). Nuclear industry employees who work in areas where exposure to radiation is possible are given film badges to monitor their exposure to external penetrating ionising radiation. Three fathers of cases and two fathers of controls (and no mothers of either) had been monitored in this way before their child was conceived (relative risk 9.0, 95% confidence interval 1.0 to 107.8). No father (of a case or control) had accumulated a recorded dose of more than 5 mSv before his child was conceived, and no father had been monitored at any time in the four years before his child was conceived. A dose-response relation was not evident among fathers who had been monitored. Conclusions-These results suggest that the children of fathers who had been monitored for exposure to external penetrating ionising radiation in the nuclear industry may be at increased risk of developing leukaemia before their fifth birthday. The finding is based on small numbers and could be due to chance. If the relationship is real the mechanisms are far from clear, except that the effect is unlikely to be due to external radiation; the possibility that it could be due to internal contamination by radioactive substances or some other exposure at work should be pursued. The above average rates of leukaemia in the study area cannot be accounted for by these findings.	STOKE MANDEVILLE HOSP, AYLESBURY HP21 8AL, BUCKS, ENGLAND; ROYAL BERKSHIRE HOSP, READING RG1 5AN, BERKS, ENGLAND	Royal Berkshire Hospital	ROMAN, E (corresponding author), RADCLIFFE INFIRM, IMPERIAL CANC RES FUND, CANC EPIDEMIOL UNIT, GIBSON UNIT, OXFORD OX2 6HE, ENGLAND.			Roman, Eve/0000-0001-7603-3704				[Anonymous], 1980, CLASSIFICATION OCCUP; BERAL V, 1990, BRIT MED J, V300, P411, DOI 10.1136/bmj.300.6722.411; BERAL V, 1988, BRIT MED J, V297, P757, DOI 10.1136/bmj.297.6651.757; Breslow N, 1980, STATISTICAL METHODS, V32; DOLL R, 1989, J R STAT SOC A STAT, V152, P1; FRASER P, 1985, BRIT MED J, V291, P435, DOI 10.1136/bmj.291.6493.435; GARDNER MJ, 1992, BRIT MED J, V305, P715, DOI 10.1136/bmj.305.6855.715; GARDNER MJ, 1990, BRIT MED J, V300, P423, DOI 10.1136/bmj.300.6722.423; GREAVES MF, 1988, LEUKEMIA, V2, P120; KAYE SA, 1991, CANCER-AM CANCER SOC, V68, P1351, DOI 10.1002/1097-0142(19910915)68:6<1351::AID-CNCR2820680627>3.0.CO;2-J; KENDALL GM, 1992, BRIT MED J, V304, P220, DOI 10.1136/bmj.304.6821.220; MCKINNEY PA, 1991, BRIT MED J, V302, P681, DOI 10.1136/bmj.302.6778.681; MCLAUGHLIN JR, 1992, OCCUPATIONAL EXPOSUR; NAROD SA, 1991, BRIT J CANCER, V63, P993, DOI 10.1038/bjc.1991.216; OLEARY LM, 1991, AM J IND MED, V20, P17, DOI 10.1002/ajim.4700200103; ROMAN E, 1987, BRIT MED J, V294, P597, DOI 10.1136/bmj.294.6572.597; SANDERS BM, 1981, J EPIDEMIOL COMMUN H, V35, P245, DOI 10.1136/jech.35.4.245; STILLER CA, 1991, STUDIES MED POPULATI, V53, P7; URQUHART JD, 1991, BRIT MED J, V302, P687, DOI 10.1136/bmj.302.6778.687; VANSTEENSELMOLL HA, 1985, INT J EPIDEMIOL, V14, P555, DOI 10.1093/ije/14.4.555; YOSHIMOTO Y, 1991, J RADIAT RES, P294; 1989, EGRET USERS GUIDE; 1989, STATISTICAL PACKAGE; 1988, 2ND COMM MED ASP RAD; 1989, 3RD COMM MED ASP RAD; 1991, FOXPRO USERS GUIDE	26	86	86	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 6	1993	306	6878					615	621		10.1136/bmj.306.6878.615	http://dx.doi.org/10.1136/bmj.306.6878.615			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KQ859	8461811	Bronze, Green Published			2022-12-24	WOS:A1993KQ85900019
J	YOSHIHISA, T; BARLOWE, C; SCHEKMAN, R				YOSHIHISA, T; BARLOWE, C; SCHEKMAN, R			REQUIREMENT FOR A GTPASE-ACTIVATING PROTEIN IN VESICLE BUDDING FROM THE ENDOPLASMIC-RETICULUM	SCIENCE			English	Article							ADP-RIBOSYLATION FACTOR; TRANSPORT VESICLES; BINDING PROTEIN; RAS PROTEINS; FUSION; YEAST; ER; CYTOPLASM; MECHANISM; CLONING	The binding and hydrolysis of guanosine triphosphate (GTP) by the small GTP-binding protein Sar1p is required to form transport vesicles from the endoplasmic reticulum (ER) in Saccharomyces cerevisiae. Experiments revealed that an interaction between Sar1p and the Sec23p subunit of an oligomeric protein is also required for vesicle budding. The isolated Sec23p subunit and the oligomeric complex stimulated guanosine triphosphatase (GTPase) activity of Sar1p 10- to 15-fold but did not activate two other small GTP-binding proteins involved in vesicle traffic (Ypt1p and ARF). Activation of GTPase was inhibited by an antibody to Sec23p but not by an antibody that inhibits the budding activity of the other subunit of the Sec23p complex. Also, activation was thermolabile in pure samples of Sec23p that were isolated from two independent sec23 mutant strains. It appears that Sec23p represents a new class of GTPase-activating protein because its sequence shows no similarity to any known member of this family.			YOSHIHISA, T (corresponding author), UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT MOLEC & CELL BIOL,BARKER HALL,BERKELEY,CA 94720, USA.							BARLOWE C, 1993, J BIOL CHEM, V268, P873; BOBAK DA, 1990, BIOCHEMISTRY-US, V29, P855, DOI 10.1021/bi00456a600; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CRECHET JB, 1990, SCIENCE, V248, P866, DOI 10.1126/science.2188363; DENFERT C, 1991, J CELL BIOL, V114, P663, DOI 10.1083/jcb.114.4.663; HARIHARAN IK, 1987, EMBO J, V6, P115, DOI 10.1002/j.1460-2075.1987.tb04727.x; HICKE L, 1992, MOL BIOL CELL, V3, P667, DOI 10.1091/mbc.3.6.667; HICKE L, 1989, EMBO J, V8, P1677, DOI 10.1002/j.1460-2075.1989.tb03559.x; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; NAKANO A, 1989, J CELL BIOL, V109, P2677, DOI 10.1083/jcb.109.6.2677; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; OKA T, 1991, J CELL BIOL, V114, P671, DOI 10.1083/jcb.114.4.671; ORCI L, 1991, P NATL ACAD SCI USA, V88, P8611, DOI 10.1073/pnas.88.19.8611; ORRWEAVER TL, 1983, METHOD ENZYMOL, V101, P228; Pfeffer S R, 1992, Trends Cell Biol, V2, P41, DOI 10.1016/0962-8924(92)90161-F; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; SEGEV N, 1991, SCIENCE, V252, P1553, DOI 10.1126/science.1904626; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WAGNER P, 1987, EMBO J, V6, P2373, DOI 10.1002/j.1460-2075.1987.tb02514.x; WEISS O, 1989, J BIOL CHEM, V264, P21066; YOSHIHISA T, UNPUB; YU G, 1990, CELL, V62, P599	27	285	289	1	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 5	1993	259	5100					1466	1468		10.1126/science.8451644	http://dx.doi.org/10.1126/science.8451644			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KP978	8451644				2022-12-24	WOS:A1993KP97800040
J	LOWENBERG, B; VANPUTTEN, WLJ; TOUW, IP; DELWEL, R; SANTINI, V				LOWENBERG, B; VANPUTTEN, WLJ; TOUW, IP; DELWEL, R; SANTINI, V			AUTONOMOUS PROLIFERATION OF LEUKEMIC-CELLS INVITRO AS A DETERMINANT OF PROGNOSIS IN ADULT ACUTE MYELOID-LEUKEMIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background and Methods. A characteristic of acute myeloid leukemia is the frequent ability of the leukemic cells to sustain their own proliferation in vitro. To determine the clinical importance of this property, we measured the uptake of tritiated thymidine by leukemic cells in serum-free and cytokine-free cultures as a means of determining the rate of spontaneous proliferation in 114 patients with newly diagnosed acute myeloid leukemia. Proliferation was then classified according to three quantitative levels of activity and related to overall survival and to treatment outcome (the response to treatment, the actuarial probability of relapse, and disease-free survival) in 91 patients who were treated with chemotherapy to induce remission. Results. Of the 114 patients, 37 had low, 39 had intermediate, and 38 had high levels of proliferation. The probability of survival at three years was 36 percent among patients with low levels of proliferative activity and 3 percent among those with high levels (P<0.001). Among the patients treated with chemotherapy, those with low rates of proliferative activity had a 68 percent rate of complete remission and a 49 percent probability of remaining free of relapse, whereas those with high rates of proliferative activity had only a 39 percent rate of complete remission (P = 0.04) and an 11 percent probability of remaining in complete remission (P = 0.009). The probability of disease-free survival at three years among the patients in complete remission after chemotherapy was 49 percent among those with low rates of proliferative activity and 9 percent among those with high rates (P = 0.004). Accordingly, patients with low rates of proliferative activity also had a significantly higher rate of overall survival (44 percent vs. 4 percent; P = 0.002). Patients whose cells had intermediate levels of proliferation in vitro had intermediate rates of survival, relapse, and disease-free survival. Conclusions. The capacity of leukemic blasts for autonomous proliferation is associated with highly aggressive acute myeloid leukemia.	ERASMUS UNIV, 3000 DR ROTTERDAM, NETHERLANDS	Erasmus University Rotterdam	LOWENBERG, B (corresponding author), DR DANIEL DEN HOED CANC CTR, GROENE HILLEDIJK 301, 3075 EA ROTTERDAM, NETHERLANDS.		SANTINI, VALERIA/AAL-3135-2020	SANTINI, VALERIA/0000-0002-5439-2172				ADKINS B, 1984, CELL, V39, P439, DOI 10.1016/0092-8674(84)90451-3; BEGLEY CG, 1988, EXP HEMATOL, V16, P71; BENNETT JM, 1985, ANN INTERN MED, V103, P620, DOI 10.7326/0003-4819-103-4-620; BUDEL LM, 1989, BLOOD, V74, P565; COX DR, 1972, J R STAT SOC B, V34, P187; COZZOLINO F, 1989, P NATL ACAD SCI USA, V86, P2369, DOI 10.1073/pnas.86.7.2369; DELWEL R, 1989, BLOOD, V74, P586; DELWEL R, 1988, BLOOD, V72, P1944; ELBAZ O, 1991, BLOOD, V77, P989; GOLDIE JH, 1984, CANCER RES, V44, P3643; GRAF T, 1986, CELL, V45, P357, DOI 10.1016/0092-8674(86)90321-1; GRIFFIN JD, 1987, BLOOD, V70, P1218; HAGEMEIJER A, 1979, CYTOGENET CELL GENET, V23, P208, DOI 10.1159/000131327; Harnden DG, 1985, INT SYSTEM HUMAN CYT; HOANG T, 1989, J EXP MED, V170, P15, DOI 10.1084/jem.170.1.15; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LOWENBERG B, 1989, J CLIN ONCOL, V7, P1268; LOWENBERG B, 1990, J CLIN ONCOL, V8, P287; METZ T, 1991, EMBO J, V10, P837, DOI 10.1002/j.1460-2075.1991.tb08016.x; OSTER W, 1989, J CLIN INVEST, V84, P451, DOI 10.1172/JCI114186; PARK LS, 1989, BLOOD, V74, P56; REES JKH, 1987, SEMIN ONCOL, V14, P32; SALEM M, 1990, LEUKEMIA, V4, P37; SALEM M, 1989, BRIT J HAEMATOL, V71, P363; SCHIFFER CA, 1989, BLOOD, V73, P263; SHERR CJ, 1990, BLOOD, V75, P1; SOUYRI M, 1990, CELL, V63, P1137, DOI 10.1016/0092-8674(90)90410-G; VANDERSCHOOT CE, 1989, BLOOD, V74, P2081; YOUNG DC, 1987, J CLIN INVEST, V79, P100, DOI 10.1172/JCI112769; YOUNG DC, 1986, BLOOD, V68, P1178; ZITTOUN R, 1989, BLOOD, V73, P896	31	175	177	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 4	1993	328	9					614	619		10.1056/NEJM199303043280904	http://dx.doi.org/10.1056/NEJM199303043280904			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP680	8429853				2022-12-24	WOS:A1993KP68000004
J	TAFT, KL; PAPAEFTHYMIOU, GC; LIPPARD, SJ				TAFT, KL; PAPAEFTHYMIOU, GC; LIPPARD, SJ			A MIXED-VALENT POLYIRON OXO COMPLEX THAT MODELS THE BIOMINERALIZATION OF THE FERRITIN CORE	SCIENCE			English	Article							HORSE SPLEEN APOFERRITIN; MAMMALIAN FERRITIN; IRON-OXO; CHEMISTRY; BIOLOGY	A novel polyiron oxo complex, [FeIII4FeII8(O)2(OCH3)18(O2CCH3)6(CH3OH)4.67] (1), has been prepared from ferrous acetate and lithium methoxide in methanol by slow addition of dioxygen. The three-dimensional close-packed layered structure found in 1 closely mimics that proposed for the inorganic core in the iron storage protein ferritin. The Mossbauer spectra of 1 reveal superparamagnetic relaxation at temperatures below 15 K, a property characteristic of the ferritin core. The small size and mixed-valent nature of 1 suggest that it is a reasonable model for intermediates formed in the biomineralization of iron during ferritin core formation. A related compound, with the same iron-oxygen framework found in 1 but containing only two ferric ions, has also been structurally characterized. Because the clusters exhibit properties of both discrete molecules and extended solids, they are representative of a new class of nanometer-sized compounds that bridge the molecular solid-state boundary.	MIT, DEPT CHEM, CAMBRIDGE, MA 02139 USA; MIT, FRANCIS BITTER NATL MAGNET LAB, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)								ARTYMIUK PJ, 1991, IRON BIOMINERALS, P269; BAUMINGER ER, 1991, BIOCHIM BIOPHYS ACTA, V1118, P48, DOI 10.1016/0167-4838(91)90440-B; BURNS RG, 1991, NATO ADV SCI I C-MAT, V343, P175; Crichton R. R., 1991, INORGANIC BIOCH IRON; DAY VW, 1985, SCIENCE, V228, P533, DOI 10.1126/science.228.4699.533; FISCHER RX, 1985, J APPL CRYSTALLOGR, V18, P258, DOI 10.1107/S002188988501024X; FORD GC, 1984, PHILOS T R SOC B, V304, P551, DOI 10.1098/rstb.1984.0046; GORUN SM, 1987, J AM CHEM SOC, V109, P3337, DOI 10.1021/ja00245a025; HAGEN SL, 1992, ANGEW CHEM INT ED EN, V31; HANNA PM, 1991, J BIOL CHEM, V266, P886; HARRISON PM, 1991, ADV INORG CHEM, V36, P449; HEATH SL, 1992, ANGEW CHEM INT EDIT, V31, P191, DOI 10.1002/anie.199201911; HEGETSCHWEILER K, 1992, INORG CHEM, V31, P1299, DOI 10.1021/ic00033a032; HEGETSCHWEILER K, 1990, INORG CHEM, V29, P3625, DOI 10.1021/ic00343a066; JACOBS D, 1989, BIOCHEMISTRY-US, V28, P9216, DOI 10.1021/bi00449a038; KURTZ DM, 1990, CHEM REV, V90, P585, DOI 10.1021/cr00102a002; LAWSON DM, 1991, NATURE, V349, P541, DOI 10.1038/349541a0; LIPPARD SJ, 1988, ANGEW CHEM INT EDIT, V27, P344, DOI 10.1002/anie.198803441; Mann S., 1989, BIOMINERALIZATION CH; MELDRUM FC, 1992, SCIENCE, V257, P522, DOI 10.1126/science.1636086; MICKLITZ W, 1989, J AM CHEM SOC, V111, P6856, DOI 10.1021/ja00199a064; MICKLITZ W, UNPUB; Murad E., 1987, MOSSBAUER SPECTROSCO, V2, P507; PAPAEFTHYMIOU GC, 1992, PHYS REV B, V46, P10366, DOI 10.1103/PhysRevB.46.10366; Pope M. T., 1983, HETEROPOLY ISOPOLY O; QUE L, 1990, PROG INORG CHEM, V38, P97; Robin M.B., 1967, ADV INORGANIC CHEM R, V10, P247, DOI [10.1016/S0065-2792(08)60179-X, DOI 10.1016/S0065-2792(08)60179-X]; STPIERRE TG, 1986, BIOCHIM BIOPHYS ACTA, V870, P127, DOI 10.1016/0167-4838(86)90015-4; TAFT KL, UNPUB; TOWE KM, 1967, J COLLOID INTERF SCI, V24, P384, DOI 10.1016/0021-9797(67)90266-4; TREFFRY A, 1992, FEBS LETT, V302, P108, DOI 10.1016/0014-5793(92)80417-F; WADE VJ, 1991, J MOL BIOL, V221, P1443, DOI 10.1016/0022-2836(91)80137-J; WATT GD, 1985, P NATL ACAD SCI USA, V82, P3640, DOI 10.1073/pnas.82.11.3640; YANG CY, 1987, BIOCHEMISTRY-US, V26, P497, DOI 10.1021/bi00376a023; YOU JF, 1992, J AM CHEM SOC, V114, P2697, DOI 10.1021/ja00033a050; ZIOLO RF, 1992, SCIENCE, V257, P219, DOI 10.1126/science.257.5067.219; [No title captured]	37	173	174	0	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 26	1993	259	5099					1302	1305		10.1126/science.8446898	http://dx.doi.org/10.1126/science.8446898			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KN883	8446898				2022-12-24	WOS:A1993KN88300024
J	JOHNSTON, J; PATERSON, KR; OREILLY, DS				JOHNSTON, J; PATERSON, KR; OREILLY, DS			ESTIMATING URINARY ALBUMIN EXCRETION RATE OF DIABETIC-PATIENTS IN CLINICAL-PRACTICE	BRITISH MEDICAL JOURNAL			English	Article							SLIGHT ALBUMINURIA		GLASGOW ROYAL INFIRM,CTR DIABET,GLASGOW G4 0SF,SCOTLAND	University of Glasgow	JOHNSTON, J (corresponding author), GLASGOW ROYAL INFIRM,DEPT PATHOL BIOCHEM,GLASGOW G4 0SF,SCOTLAND.							COHEN DL, 1987, DIABETIC MED, V4, P437, DOI 10.1111/j.1464-5491.1987.tb00905.x; HOWEY JEA, 1987, CLIN CHEM, V33, P2034; HUTCHISON AS, 1988, CLIN CHEM, V34, P2019; WINOCOUR PH, 1992, BRIT MED J, V304, P1196, DOI 10.1136/bmj.304.6836.1196; WOOD P, 1985, ANN CLIN BIOCHEM, V22, P1	5	23	24	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 20	1993	306	6876					493	494		10.1136/bmj.306.6876.493-a	http://dx.doi.org/10.1136/bmj.306.6876.493-a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KN786	8448461	Green Published, Bronze			2022-12-24	WOS:A1993KN78600020
J	CAGLIOTI, A; ESPOSITO, C; FUIANO, G; BUZIO, C; POSTORINO, M; RAMPINO, T; CONTE, G; DALCANTON, A				CAGLIOTI, A; ESPOSITO, C; FUIANO, G; BUZIO, C; POSTORINO, M; RAMPINO, T; CONTE, G; DALCANTON, A			PREVALENCE OF SYMPTOMS IN PATIENTS WITH SIMPLE RENAL CYSTS	BRITISH MEDICAL JOURNAL			English	Article							KIDNEYS		UNIV CATANZARO, CATTEDRA NEFROL, CATANZARO, ITALY; UNIV PARMA, IST MED INTERNA & NEFROL, I-43100 PARMA, ITALY; CNR, CTR FISIOL CLIN, REGGIO DI CALALBRIA, ITALY; UNITA DIALISI, SANT ANGELO LOMBARDI, ITALY; UNIV NAPLES, PRIMA FAC, CATTEDRA NEFROL, I-80138 NAPLES, ITALY; UNIV PAVIA, CATTEDRA NEFROL, I-27100 PAVIA, ITALY	Magna Graecia University of Catanzaro; University of Parma; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; University of Pavia			dal canton, antonio/G-4388-2013; esposito, ciro/AAC-8023-2020; Rampino, Teresa/AAF-3988-2022; Rampino, Teresa/AFI-8315-2022	esposito, ciro/0000-0002-7906-1097; Rampino, Teresa/0000-0002-5311-9174; Rampino, Teresa/0000-0002-5311-9174; DAL CANTON, ANTONIO/0000-0002-2189-6315				DALTON D, 1986, J UROLOGY, V135, P905, DOI 10.1016/S0022-5347(17)45919-2; GARDNER KD, 1984, AM J KIDNEY DIS, V3, P403, DOI 10.1016/S0272-6386(84)80002-5; GARDNER KD, 1988, KIDNEY INT, V33, P610, DOI 10.1038/ki.1988.41; LUSCHER TF, 1986, CLIN NEPHROL, V26, P91; NORUSIS MJ, 1986, STATISTICAL PACKAGE	5	30	31	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 13	1993	306	6875					430	431		10.1136/bmj.306.6875.430	http://dx.doi.org/10.1136/bmj.306.6875.430			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KM700	8461726	Bronze, Green Published			2022-12-24	WOS:A1993KM70000023
J	WRIGHT, CDP; MANSELL, RE; GAZET, JC; COMPSTON, JE				WRIGHT, CDP; MANSELL, RE; GAZET, JC; COMPSTON, JE			EFFECT OF LONG-TERM TAMOXIFEN TREATMENT ON BONE TURNOVER IN WOMEN WITH BREAST-CANCER	BRITISH MEDICAL JOURNAL			English	Article									UNIV CAMBRIDGE,ADDENBROOKES HOSP,SCH CLIN,DEPT MED,CAMBRIDGE CB2 2QQ,ENGLAND; UNIV WALES COLL MED,DEPT SURG,CARDIFF CF4 4XN,S GLAM,WALES; ST GEORGE HOSP,DEPT SURG,LONDON SW17,ENGLAND	Addenbrooke's Hospital; University of Cambridge; Cardiff University; St Georges University London					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		FORNANDER T, 1989, LANCET, V1, P117; GOTFREDSEN A, 1984, CANCER, V53, P853, DOI 10.1002/1097-0142(19840215)53:4<853::AID-CNCR2820530406>3.0.CO;2-M; LOVE RR, 1992, NEW ENGL J MED, V326, P852, DOI 10.1056/NEJM199203263261302; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; RECKER RR, 1988, J BONE MINER RES, V3, P133	5	31	32	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 13	1993	306	6875					429	430		10.1136/bmj.306.6875.429-a	http://dx.doi.org/10.1136/bmj.306.6875.429-a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KM700	8461725	Green Published, Bronze			2022-12-24	WOS:A1993KM70000022
J	HEINZ, DW; BAASE, WA; DAHLQUIST, FW; MATTHEWS, BW				HEINZ, DW; BAASE, WA; DAHLQUIST, FW; MATTHEWS, BW			HOW AMINO-ACID INSERTIONS ARE ALLOWED IN AN ALPHA-HELIX OF T4-LYSOZYME	NATURE			English	Article							PROTEIN STABILITY CURVES; BACTERIOPHAGE-T4 LYSOZYME; T4 LYSOZYME; SEQUENCES; ACCESSIBILITY; ENZYME	STUDIES of extant protein sequences indicate that amino-acid insertions and deletions are preferentially located in loop regions1, which has traditionally been explained as the result of selection removing deleterious mutations within secondary structural elements from the population. But there is no a priori reason to discount the possibility that insertions within secondary structure could either be tolerated until compensatory mutations arise, or have effects that are propagated away from secondary structure into loops. Earlier studies have indicated that insertions are generally tolerated, although much less well within secondary structure elements than in loop regions2-8. Here we show that amino-acid insertions in an alpha-helix of T4 lysozyme can be accepted in two different ways. In some cases the inserted amino acids are accommodated within the helix, leading to the translocation of wild-type residues from the helix to the preceding loop. In other cases the insertion causes a 'looping-out' in the first or last turn of the helix. The individual structural responses seem to be dominated by the maintenance of the interface between the helix and the rest of the protein.	UNIV OREGON,INST MOLEC BIOL,EUGENE,OR 97403; UNIV OREGON,HOWARD HUGHES MED INST,EUGENE,OR 97403; UNIV OREGON,DEPT PHYS,EUGENE,OR 97403; UNIV OREGON,DEPT CHEM,EUGENE,OR 97403	University of Oregon; Howard Hughes Medical Institute; University of Oregon; University of Oregon; University of Oregon								ALBER T, 1987, BIOCHEMISTRY-US, V26, P3754, DOI 10.1021/bi00387a002; BARANY F, 1985, P NATL ACAD SCI USA, V82, P4202, DOI 10.1073/pnas.82.12.4202; BASHFORD D, 1987, J MOL BIOL, V196, P199, DOI 10.1016/0022-2836(87)90521-3; BECKTEL WJ, 1987, BIOPOLYMERS, V26, P1859, DOI 10.1002/bip.360261104; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; DAOPIN S, 1990, PROTEINS, V7, P198, DOI 10.1002/prot.340070208; ERIKSSON AE, 1992, SCIENCE, V255, P178, DOI 10.1126/science.1553543; FREIMUTH PI, 1990, J BIOL CHEM, V265, P896; GRAY TM, 1984, J MOL BIOL, V175, P75, DOI 10.1016/0022-2836(84)90446-7; HEINZ DW, 1992, P NATL ACAD SCI USA, V89, P3751, DOI 10.1073/pnas.89.9.3751; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; KURKEL TA, 1987, METHOD ENZYMOL, V154, P367; LADANT D, 1992, J BIOL CHEM, V267, P2244; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LESK AM, 1980, J MOL BIOL, V136, P225, DOI 10.1016/0022-2836(80)90373-3; MARTI T, 1992, P NATL ACAD SCI USA, V89, P1219, DOI 10.1073/pnas.89.4.1219; MATSUMURA M, 1989, SCIENCE, V243, P792, DOI 10.1126/science.2916125; MCINTOSH LP, 1990, BIOCHEMISTRY-US, V29, P6341, DOI 10.1021/bi00479a003; MILNERWHITE EJ, 1987, TRENDS BIOCHEM SCI, V12, P189; PASCARELLA S, 1992, J MOL BIOL, V224, P461, DOI 10.1016/0022-2836(92)91008-D; POTEETE AR, 1991, BIOCHEMISTRY-US, V30, P1425, DOI 10.1021/bi00219a037; PRESTA LG, 1988, SCIENCE, V240, P1632, DOI 10.1126/science.2837824; SONDEK J, 1990, PROTEINS, V7, P299, DOI 10.1002/prot.340070402; SONDEK J, 1992, PROTEINS, V13, P132, DOI 10.1002/prot.340130206; STARZYK RM, 1989, BIOCHEMISTRY-US, V28, P8479, DOI 10.1021/bi00447a031; STREISINGER G, 1961, COLD SPRING HARB SYM, V26, P25, DOI 10.1101/SQB.1961.026.01.007; WEAVER LH, 1987, J MOL BIOL, V193, P189, DOI 10.1016/0022-2836(87)90636-X; ZHANG XJ, 1991, BIOCHEMISTRY-US, V30, P2012, DOI 10.1021/bi00222a001	28	112	112	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 11	1993	361	6412					561	564		10.1038/361561a0	http://dx.doi.org/10.1038/361561a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL714	8429913				2022-12-24	WOS:A1993KL71400069
J	MENDENHALL, MD				MENDENHALL, MD			AN INHIBITOR OF P34(CDC28) PROTEIN-KINASE ACTIVITY FROM SACCHAROMYCES-CEREVISIAE	SCIENCE			English	Article							XENOPUS CDC2 PROTEIN; CELL-DIVISION CYCLE; FISSION YEAST; M-PHASE; ACTIVATION; MITOSIS; P34CDC2; COMPLEX; GENE; DEPHOSPHORYLATION	The p34CDC28 protein from Saccharomyces cerevisiae is a homolog of the p34cdc2 protein kinase, a fundamental regulator of cell division in all eukaryotic cells. Once activated it initiates the visible events of mitosis (chromosome condensation, nuclear envelope breakdown, and spindle formation). The p34CDC28 protein also has a critical role in the initiation of DNA synthesis. The protein kinase activity is regulated by cycles of phosphorylation and dephosphorylation and by periodic association with cyclins. An endogenous 40-kilodalton protein (p40) originally identified as a substrate of the p34CDC28 protein kinase was purified. The p40 protein bound tightly to p34CDC28 and inhibited the activity of the kinase. The p40 protein may provide another mechanism to regulate p34CDC28 protein kinase activity.	UNIV KENTUCKY,DEPT BIOCHEM,LEXINGTON,KY 40536	University of Kentucky	MENDENHALL, MD (corresponding author), UNIV KENTUCKY,LUCILLE P MARKEY CANC CTR,LEXINGTON,KY 40536, USA.							DUCOMMUN B, 1990, ANAL BIOCHEM, V187, P94, DOI 10.1016/0003-2697(90)90422-6; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; HADWIGER JA, 1989, MOL CELL BIOL, V9, P2034, DOI 10.1128/MCB.9.5.2034; HARLOW E, 1988, ANTIBODIES LABORATOR, P304; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LUCA FC, 1989, J CELL BIOL, V109, P1895, DOI 10.1083/jcb.109.5.1895; MCGOWAN CH, 1990, MOL CELL BIOL, V10, P3847, DOI 10.1128/MCB.10.7.3847; MEIKRANTZ W, 1991, FEBS LETT, V291, P192, DOI 10.1016/0014-5793(91)81281-C; MENDENHALL MD, 1987, CELL, V50, P927, DOI 10.1016/0092-8674(87)90519-8; MENDENHALL MD, UNPUB; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; REED SI, 1985, P NATL ACAD SCI USA, V82, P4055, DOI 10.1073/pnas.82.12.4055; REED SI, 1990, P NATL ACAD SCI USA, V87, P5697, DOI 10.1073/pnas.87.15.5697; ROY LM, 1991, J CELL BIOL, V113, P507, DOI 10.1083/jcb.113.3.507; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; WELCH PJ, 1992, P NATL ACAD SCI USA, V89, P3093, DOI 10.1073/pnas.89.7.3093; WITTENBERG C, 1988, CELL, V54, P1061, DOI 10.1016/0092-8674(88)90121-3; YAMASHITA M, 1992, DEV BIOL, V149, P8, DOI 10.1016/0012-1606(92)90259-J	28	173	178	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 8	1993	259	5092					216	219		10.1126/science.8421781	http://dx.doi.org/10.1126/science.8421781			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KF719	8421781				2022-12-24	WOS:A1993KF71900027
J	BURROWS, RF; KELTON, JG				BURROWS, RF; KELTON, JG			FETAL THROMBOCYTOPENIA AND ITS RELATION TO MATERNAL THROMBOCYTOPENIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NEONATAL THROMBOCYTOPENIA; PURPURA; PREGNANCY; MANAGEMENT; WOMEN	Background. Neonates with severe thrombocytopenia can have bleeding leading to death or lifelong residual defects. The predictors, frequency, and consequences of fetal thrombocytopenia are not known, nor is it known if there are maternal clinical features that could predict fetal thrombocytopenia. Methods. We conducted a seven-year cross-sectional study in which platelet counts were determined in newborns' umbilical-cord blood and blood obtained from their mothers at consecutive deliveries in one obstetrical unit. The relations of the umbilical-cord platelet count to maternal risk factors were determined. Results. Platelet counts were determined in blood samples from 15,471 mothers and 15,932 newborn infants. The cord-blood platelet count was less than 50,000 per cubic millimeter in 19 infants (0.12 percent; 95 percent confidence interval, 0.07 to 0.19 percent), whereas the platelet count was less than 150,000 per cubic millimeter in 6.6 percent of the mothers (95 percent confidence interval, 6.2 to 7.0 percent). One infant among those born to 756 mothers with incidental thrombocytopenia, 5 infants among those born to 1414 mothers with hypertension, and 4 infants among those born to 46 mothers with idiopathic thrombocytopenic purpura had cord-blood platelet counts between 20,000 and 50,000 per cubic millimeter. Only 6 infants (0.04 percent; 95 percent confidence interval, 0.01 to 0.08 percent) had cord-blood platelet counts of less than 20,000 per cubic millimeter; all their mothers were among the 18 whose 19 fetuses were at risk for neonatal alloimmune thrombocytopenia. Two of these infants had in utero intracranial hemorrhage. In addition, 3 infants born to these 18 women had cord-blood platelet counts between 20,000 and 50,000 per cubic millimeter; there was 1 stillbirth due to intracranial hemorrhage. Conclusions. Moderate-to-severe fetal thrombocytopenia is a rare event. The only severely affected neonates with morbidity or mortality due to this condition are those born to mothers with antiplatelet alloantibodies.	CANADIAN RED CROSS,BLOOD TRANSFUS SERV,HAMILTON CTR,HAMILTON,ON,CANADA; MCMASTER UNIV,MED CTR,DEPT MED,HAMILTON L8N 3Z5,ONTARIO,CANADA; MCMASTER UNIV,MED CTR,DEPT PATHOL,HAMILTON L8N 3Z5,ONTARIO,CANADA	McMaster University; McMaster University	BURROWS, RF (corresponding author), MCMASTER UNIV,MED CTR,DEPT OBSTET & GYNECOL,1200 MAIN ST W,HAMILTON L8N 3Z5,ONTARIO,CANADA.							ANDREW M, 1987, J PEDIATR-US, V110, P457, DOI 10.1016/S0022-3476(87)80517-6; BLANCHETTE VS, 1988, CURR STUD HEMATOL BL, V54, P112; BURROWS RF, 1990, AM J OBSTET GYNECOL, V163, P1147, DOI 10.1016/0002-9378(90)90675-W; BURROWS RF, 1990, AM J OBSTET GYNECOL, V162, P731, DOI 10.1016/0002-9378(90)90996-K; BURROWS RF, 1988, NEW ENGL J MED, V319, P142, DOI 10.1056/NEJM198807213190304; BURROWS RF, 1990, OBSTET GYNECOL, V76, P234; BUSEL JB, 1991, HEMATOLOGY BASIC PRI, P1485; CHRISTIAENS GCML, 1990, BRIT J OBSTET GYNAEC, V97, P893, DOI 10.1111/j.1471-0528.1990.tb02443.x; CINES DB, 1984, MED GRAND ROUNDS, V3, P344; COOK RL, 1991, OBSTET GYNECOL, V78, P578; HATHAWAY WE, 1978, PERINATAL COAGULATIO, P115; KELTON JG, 1983, ANN INTERN MED, V99, P796, DOI 10.7326/0003-4819-99-6-796; MCCRAE KR, 1992, BLOOD, V80, P2697; MOUTET A, 1990, ARCH INTERN MED, V150, P2141, DOI 10.1001/archinte.150.10.2141; MUELLERECKHARDT C, 1989, LANCET, V1, P363; PEARSON HA, 1964, BLOOD, V23, P154, DOI 10.1182/blood.V23.2.154.154; SAMUELS P, 1990, NEW ENGL J MED, V323, P229, DOI 10.1056/NEJM199007263230404; SHULMAN NR, 1964, PROG HEMATOL, V4, P222; Taaning E, 1990, Obstet Gynecol Surv, V45, P521, DOI 10.1097/00006254-199008000-00004; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101	20	323	339	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 11	1993	329	20					1463	1466		10.1056/NEJM199311113292005	http://dx.doi.org/10.1056/NEJM199311113292005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF292	8413457	Bronze			2022-12-24	WOS:A1993MF29200005
J	SUNG, P; BAILLY, V; WEBER, C; THOMPSON, LH; PRAKASH, L; PRAKASH, S				SUNG, P; BAILLY, V; WEBER, C; THOMPSON, LH; PRAKASH, L; PRAKASH, S			HUMAN XERODERMA-PIGMENTOSUM GROUP-D GENE ENCODES A DNA HELICASE	NATURE			English	Article								XERODERMA pigmentosum (XP), a genetically heterogeneous human disease, results from a defect in nucleotide excision repair of ultraviolet-damaged DNA. XP patients are extremely sensitive to sunlight and suffer from a high incidence of skin cancers. Cell fusion studies have identified seven XP complementation groups, A-G1-3. Group D is of particular interest as mutations in this gene can also cause Cockayne's syndrome and trichothiodystrophy4. The XPD gene was initially named ERCC2 (excision repair cross complementing) as it was cloned using human DNA to complement the ultraviolet sensitivity of a rodent cell line5. We have purified the XPD protein to near homogeneity and show that it possesses single-stranded DNA-dependent ATPase and DNA helicase activities. We tested whether XPD can substitute for its yeast counterpart RAD3, which is essential for excision repair and for cell viability6. Expression of the XPD gene in Saccharomyces cerevisiae can complement the lethality defect of a mutation in the RAD3 gene6, suggesting that XPD is an essential gene in humans.	UNIV ROCHESTER,DEPT BIOL,ROCHESTER,NY 14627; UNIV ROCHESTER,SCH MED,DEPT BIOPHYS,ROCHESTER,NY 14642; LAWRENCE LIVERMORE NATL LAB,BIOL & TECHNOL RES PROGRAM,LIVERMORE,CA 94550	University of Rochester; University of Rochester; United States Department of Energy (DOE); Lawrence Livermore National Laboratory			Prakash, Louise/C-7891-2012; Prakash, Satya/C-6420-2013	Prakash, Satya/0000-0001-7228-1444; Prakash, Louise/0000-0001-9143-6261				BUNICK D, 1982, CELL, V29, P877, DOI 10.1016/0092-8674(82)90449-4; Cleaver JE, 1989, METABOLIC BASIS INHE, V6th, P2949; CONAWAY RC, 1989, P NATL ACAD SCI USA, V86, P7356, DOI 10.1073/pnas.86.19.7356; DEWEERDK.EA, 1972, NATURE-NEW BIOL, V238, P80, DOI 10.1038/newbio238080a0; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; GULYAS KD, 1992, CELL, V69, P1031, DOI 10.1016/0092-8674(92)90621-I; JOHNSON RT, 1992, MUTAT RES, V273, P97, DOI 10.1016/0921-8777(92)90072-B; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; PARK E, 1992, P NATL ACAD SCI USA, V89, P11416, DOI 10.1073/pnas.89.23.11416; Prakash S, 1990, EUKARYOTIC NUCLEUS, P275; SAWADOGO M, 1984, J BIOL CHEM, V259, P5321; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SUNG P, 1987, P NATL ACAD SCI USA, V84, P8951, DOI 10.1073/pnas.84.24.8951; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x; VERMEULEN W, 1991, MUTAT RES, V255, P201, DOI 10.1016/0921-8777(91)90054-S; WEBER CA, 1990, EMBO J, V9, P1437, DOI 10.1002/j.1460-2075.1990.tb08260.x; WILCOX DR, 1981, J BACTERIOL, V148, P618, DOI 10.1128/JB.148.2.618-623.1981	17	289	299	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 28	1993	365	6449					852	855		10.1038/365852a0	http://dx.doi.org/10.1038/365852a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MD951	8413672				2022-12-24	WOS:A1993MD95100055
J	GROSOF, DH; SHAPLEY, RM; HAWKEN, MJ				GROSOF, DH; SHAPLEY, RM; HAWKEN, MJ			MACAQUE-V1 NEURONS CAN SIGNAL ILLUSORY CONTOURS	NATURE			English	Article							MONKEY VISUAL-CORTEX; SUBJECTIVE CONTOURS; PERCEPTION; SENSITIVITY; ORGANIZATION; MECHANISMS; ELEMENTS; CONTRAST; MOTION; CUES	WE describe here a new view of primary visual cortex (V1) based on measurements of neural responses in V1 to patterns called 'illusory contours' (Fig. 1a, b). Detection of an object's boundary contours is a fundamental visual task. Boundary contours are defined by discontinuities not only in luminance and colour, but also in texture1-3, disparity4 and motion5-7. Two theoretical approaches can account for illusory contour perception. The cognitive approach emphasizes top-down processes8,9. An alternative emphasizes bottom-up processing. This latter view is supported by (1) stimulus constraints for illusory contour perception10-14 and (2) the discovery by von der Heydt and Peterhans15-17 of neurons in extrastriate visual area V2 (but not in V1) of macaque monkeys that respond to illusory contours. Using stimuli different from those used previously15,16, we found illusory contour responses in about half the neurons studied in V1 of macaque monkeys. Therefore, there are neurons as early as V1 with the computational power to detect illusory contours and to help distinguish figure from ground.	NYU,CTR NEURAL SCI,4 WASHINGTON PL,NEW YORK,NY 10003	New York University								BECK J, 1983, BIOL CYBERN, V48, P125, DOI 10.1007/BF00344396; GREGORY RL, 1972, NATURE, V238, P51, DOI 10.1038/238051a0; GREGORY RL, 1977, PERCEPTION, V6, P113, DOI 10.1068/p060113; GROSSBERG S, 1985, PSYCHOL REV, V92, P173, DOI 10.1037/0033-295X.92.2.173; HAWKEN MJ, 1988, J NEUROSCI, V8, P3541; HOCHSTEIN S, 1976, J PHYSIOL-LONDON, V262, P237, DOI 10.1113/jphysiol.1976.sp011594; JULESZ B, 1981, NATURE, V290, P91, DOI 10.1038/290091a0; JULESZ B, 1971, F CYCLOPEAN PERCEPTI; Julesz B., 1962, IRE T INFORM THEOR, V8, P84, DOI DOI 10.1109/TIT.1962.1057698; LAMME VAF, 1993, NATURE, V363, P541, DOI 10.1038/363541a0; MERRILL EG, 1972, MED BIOL ENG, V10, P662, DOI 10.1007/BF02476084; MILKMAN N, 1980, BEHAV RES METH INSTR, V12, P283, DOI 10.3758/BF03201667; NAKAYAMA K, 1985, PERCEPTION, V14, P225, DOI 10.1068/p140225; NAKAYAMA K, 1981, VISION RES, V21, P427, DOI 10.1016/0042-6989(81)90089-4; PARADISO MA, 1989, VISION RES, V29, P1205, DOI 10.1016/0042-6989(89)90066-7; PETERHANS E, 1989, J NEUROSCI, V9, P1749; ROCK I, 1979, PERCEPTION, V8, P665, DOI 10.1068/p080665; SHAPLEY R, 1985, PERCEPT PSYCHOPHYS, V37, P84, DOI 10.3758/BF03207143; SHAPLEY R, 1988, PERCEPTION ILLUSORY, P109; SMITH AT, 1979, PERCEPT PSYCHOPHYS, V25, P95, DOI 10.3758/BF03198792; SMITH AT, 1977, PERCEPTION, V6, P441, DOI 10.1068/p060441; SPITZER H, 1985, J NEUROPHYSIOL, V53, P1266, DOI 10.1152/jn.1985.53.5.1266; TAKAHASHI S, 1992, VISION RES, V32, P1709, DOI 10.1016/0042-6989(92)90163-D; VANDOORN AJ, 1982, EXP BRAIN RES, V45, P179, DOI 10.1007/BF00235777; VONDERHEYDT R, 1984, SCIENCE, V224, P1260, DOI 10.1126/science.6539501; VONDERHEYDT R, 1989, J NEUROSCI, V9, P1731; WONGRILEY M, 1979, BRAIN RES, V171, P11, DOI 10.1016/0006-8993(79)90728-5	27	305	308	1	28	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 7	1993	365	6446					550	552		10.1038/365550a0	http://dx.doi.org/10.1038/365550a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	MA661	8413610				2022-12-24	WOS:A1993MA66100055
J	OLIVERA, A; SPIEGEL, S				OLIVERA, A; SPIEGEL, S			SPHINGOSINE-1-PHOSPHATE AS 2ND MESSENGER IN CELL-PROLIFERATION INDUCED BY PDGF AND FCS MITOGENS	NATURE			English	Article							PROTEIN-KINASE-C; ENDOGENOUS GANGLIOSIDE; SIGNAL TRANSDUCTION; PHOSPHATIDIC-ACID; FREE SPHINGOSINE; ACTIVATION; HYDROLYSIS; RECEPTOR; LIVER	GROWTH signalling networks that use glycerophospholipid metabolites as second messengers have been well characterized1,2, but less is known of the second messengers derived from sphingolipids3,4, another major class of membrane lipids. A tantalizing fink between sphingolipids and cellular proliferation has emerged from the discovery that the sphingolipid metabolites sphingosine and sphingosine-1-phosphate stimulate growth of quiescent Swiss 3T3 fibroblasts by a pathway that is independent of protein kinase C5,6. Sphingosine-1-phosphate is rapidly produced from sphingosine and may mediate its biological effects6. Furthermore, sphingosine-1-phosphate triggers the dual signal transduction pathways of calcium mobilization6,7 and activation of phospholipase D8, prominent events in the control of cellular proliferation. Here we report that activation of sphingosine kinase and the formation of sphingosine-1-phosphate are important in the signal transduction pathways activated by the potent mitogens platelet-derived growth factor (PDGF) and fetal calf serum (FCS).	GEORGETOWN UNIV,MED CTR,DEPT BIOCHEM & MOLEC BIOL,WASHINGTON,DC 20007	Georgetown University								AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BUEHRER BM, 1992, J BIOL CHEM, V267, P3154; Christie W.W., 2003, LIPID ANAL; DESAI NN, 1992, J BIOL CHEM, V267, P23122; FUKAMI K, 1992, J BIOL CHEM, V267, P10988; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HILL TD, 1990, SCIENCE, V248, P1660, DOI 10.1126/science.2163545; LOPEZRIVAS A, 1987, P NATL ACAD SCI USA, V84, P5768, DOI 10.1073/pnas.84.16.5768; MARGOLIS B, 1990, SCIENCE, V248, P607, DOI 10.1126/science.2333512; MERRILL AH, 1988, ANAL BIOCHEM, V171, P373, DOI 10.1016/0003-2697(88)90500-3; MERRILL AH, 1988, BIOCHEMISTRY-US, V227, P340; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; SADAHIRA Y, 1992, P NATL ACAD SCI USA, V89, P9686, DOI 10.1073/pnas.89.20.9686; SPIEGEL S, 1989, J BIOL CHEM, V264, P6766; SPIEGEL S, 1988, EXP CELL RES, V177, P414, DOI 10.1016/0014-4827(88)90474-0; STOFFEL W, 1973, H-S Z PHYSIOL CHEM, V354, P1311, DOI 10.1515/bchm2.1973.354.2.1311; STOFFEL W, 1970, H-S Z PHYSIOL CHEM, V351, P1041, DOI 10.1515/bchm2.1970.351.2.1041; TSAI MH, 1989, SCIENCE, V243, P522, DOI 10.1126/science.2536192; VANVELDHOVEN PP, 1991, J BIOL CHEM, V266, P12502; VANVELDHOVEN PP, 1989, ANAL BIOCHEM, V183, P177, DOI 10.1016/0003-2697(89)90186-3; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; WILSON E, 1988, J BIOL CHEM, V263, P9304; ZHANG H, 1990, J BIOL CHEM, V265, P76; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155	29	802	835	2	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 7	1993	365	6446					557	560		10.1038/365557a0	http://dx.doi.org/10.1038/365557a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MA661	8413613				2022-12-24	WOS:A1993MA66100058
J	LANDRY, DW; ZHAO, K; YANG, GXQ; GLICKMAN, M; GEORGIADIS, TM				LANDRY, DW; ZHAO, K; YANG, GXQ; GLICKMAN, M; GEORGIADIS, TM			ANTIBODY-CATALYZED DEGRADATION OF COCAINE	SCIENCE			English	Article							DOPAMINE TRANSPORTER; NONHUMAN-PRIMATES; EXPRESSION; HYDROLYSIS; CHEMISTRY; SUBSTRATE; CLONING; PLASMA; DRUGS	Immunization with a phosphonate monoester transition-state analog of cocaine provided monoclonal antibodies capable of catalyzing the hydrolysis of the cocaine benzoyl ester group. An assay for the degradation of radiolabeled cocaine identified active enzymes. Benzoyl esterolysis yields ecgonine methyl ester and benzoic acid, fragments devoid of cocaine's stimulant activity. Passive immunization with such an artificial enzyme could provide a treatment for dependence by blunting reinforcement.			LANDRY, DW (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032, USA.		Zhao, Kang/K-3777-2015	Zhao, Kang/0000-0002-0213-2854	NINDS NIH HHS [T32 NS07258] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS007258] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BENDER ML, 1960, CHEM REV, V60, P53, DOI 10.1021/cr60203a005; BERGMAN J, 1989, J PHARMACOL EXP THER, V251, P150; BONESE KF, 1974, NATURE, V252, P708, DOI 10.1038/252708a0; CORRIU RJP, 1980, TETRAHEDRON, V36, P1617, DOI 10.1016/S0040-4020(01)83131-8; FISCHMAN MW, 1990, J PHARMACOL EXP THER, V253, P760; FISCHMAN MW, 1988, J CLIN PSYCHIAT, V49, P7; FOWLER JS, 1989, SYNAPSE, V4, P371, DOI 10.1002/syn.890040412; FUJII I, 1991, J AM CHEM SOC, V113, P8528, DOI 10.1021/ja00022a054; GATLEY SJ, 1991, BIOCHEM PHARMACOL, V41, P1249, DOI 10.1016/0006-2952(91)90665-R; GAWIN FH, 1989, ARCH GEN PSYCHIAT, V46, P117; GAWIN FH, 1988, NEW ENGL J MED, V318, P1173, DOI 10.1056/NEJM198805053181806; GOEDERS NE, 1983, SCIENCE, V221, P773, DOI 10.1126/science.6879176; HORN AS, 1990, PROG NEUROBIOL, V34, P387, DOI 10.1016/0301-0082(90)90033-D; IKEDA S, 1991, J AM CHEM SOC, V113, P7763, DOI 10.1021/ja00020a049; JANDA KD, 1989, SCIENCE, V244, P437, DOI 10.1126/science.2717936; JANDA KD, 1991, J AM CHEM SOC, V113, P5427, DOI 10.1021/ja00014a039; JANDA KD, 1991, TETRAHEDRON, V47, P2503, DOI 10.1016/S0040-4020(01)81784-1; Johanson C E, 1984, NIDA Res Monogr, V50, P54; KILTY JE, 1991, SCIENCE, V254, P578, DOI 10.1126/science.1948035; KUHAR MJ, 1978, J NEUROCHEM, V31, P251, DOI 10.1111/j.1471-4159.1978.tb12456.x; KUHAR MJ, 1991, TRENDS NEUROSCI, V14, P299, DOI 10.1016/0166-2236(91)90141-G; LANDRY D, UNPUB; LERNER RA, 1992, SCIENCE, V258, P1313, DOI 10.1126/science.1455226; LERNER RA, 1991, SCIENCE, V252, P659, DOI 10.1126/science.2024118; POLLACK SJ, 1989, J AM CHEM SOC, V111, P5961, DOI 10.1021/ja00197a078; POLLACK SJ, 1986, SCIENCE, V234, P1570, DOI 10.1126/science.3787262; RITZ MC, 1987, SCIENCE, V237, P1219, DOI 10.1126/science.2820058; SCHULTZ PG, 1988, SCIENCE, V240, P426, DOI 10.1126/science.2833815; SHIMADA S, 1991, SCIENCE, V254, P576, DOI 10.1126/science.1948034; SPEALMAN RD, 1989, J PHARMACOL EXP THER, V251, P142; STEWART DJ, 1977, LIFE SCI, V20, P1557, DOI 10.1016/0024-3205(77)90448-9; STEWART DJ, 1979, CLIN PHARMACOL THER, V25, P464; TRAMONTANO A, 1988, J AM CHEM SOC, V110, P2282, DOI 10.1021/ja00215a045; TRAMONTANO A, 1986, SCIENCE, V234, P1566, DOI 10.1126/science.3787261; ZHAO K, 1993, TETRAHEDRON, V49, P363, DOI 10.1016/S0040-4020(01)80305-7	35	224	236	2	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 26	1993	259	5103					1899	1901		10.1126/science.8456315	http://dx.doi.org/10.1126/science.8456315			3	Multidisciplinary Sciences	Index Chemicus (IC); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KU172	8456315				2022-12-24	WOS:A1993KU17200032
J	LOVEJOY, B; CHOE, S; CASCIO, D; MCRORIE, DK; DEGRADO, WF; EISENBERG, D				LOVEJOY, B; CHOE, S; CASCIO, D; MCRORIE, DK; DEGRADO, WF; EISENBERG, D			CRYSTAL-STRUCTURE OF A SYNTHETIC TRIPLE-STRANDED ALPHA-HELICAL BUNDLE	SCIENCE			English	Article							COILED-COILS; SECONDARY-STRUCTURE; PROTEIN; DESIGN; REFINEMENT; TROPOMYOSIN; REPEATS; MODEL; STABILIZATION; PREDICTION	The x-ray crystal structure of a peptide designed to form a double-stranded parallel coiled coil shows that it is actually a triple-stranded coiled coil formed by three alpha-helices. Unlike the designed parallel coiled coil, the helices run up-up-down. The structure is stabilized by a distinctive hydrophobic interface consisting of eight layers. As in the design, each alpha-helix in the coiled coil contributes one leucine side chain to each layer. The structure suggests that hydrophobic interactions are a dominant factor in the stabilization of coiled coils. The stoichiometry and geometry of coiled coils are primarily determined by side chain packing in the solvent-inaccessible interior, but electrostatic interactions also contribute.	UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024; BECKMAN INSTRUMENTS INC,DEPT RES & APPLICAT,PALO ALTO,CA 94304; DUPONT MERCK PHARMACEUT CO,DEPT BIOTECHNOL,WILMINGTON,DE 19880; UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; DuPont; University of California System; University of California Los Angeles					PHS HHS [31299] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; CHOTHIA C, 1984, ANNU REV BIOCHEM, V53, P537; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; CONWAY JF, 1990, INT J BIOL MACROMOL, V12, P328, DOI 10.1016/0141-8130(90)90023-4; CONWAY JF, 1991, INT J BIOL MACROMOL, V13, P15; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; DAVISON MD, 1988, CELL, V52, P159, DOI 10.1016/0092-8674(88)90503-X; DEGRADO WF, 1987, COLD SPRING HARB SYM, V52, P521, DOI 10.1101/SQB.1987.052.01.059; DEGRADO WF, UNPUB; DEISENHOFER J, 1978, H-S Z PHYSIOL CHEM, V359, P975, DOI 10.1515/bchm2.1978.359.2.975; EALICK SE, 1991, SCIENCE, V252, P698, DOI 10.1126/science.1902591; EISENBERG D, 1986, Proteins Structure Function and Genetics, V1, P16, DOI 10.1002/prot.340010105; EISENBERG D, 1986, NATURE, V319, P199, DOI 10.1038/319199a0; EISENBERG D, 1989, CHEM SCRIPTA, V29A, P217; ELLENBERGER TE, 1993, CELL, V71, P1224; HILL CP, 1990, SCIENCE, V249, P543, DOI 10.1126/science.2382133; HODGES RS, 1981, J BIOL CHEM, V256, P1214; HOL WGJ, 1978, NATURE, V273, P443, DOI 10.1038/273443a0; HOL WGJ, 1985, PROG BIOPHYS MOL BIO, V45, P149, DOI 10.1016/0079-6107(85)90001-X; HUBER R, 1990, EMBO J, V9, P3867, DOI 10.1002/j.1460-2075.1990.tb07605.x; JONES TA, 1985, METHOD ENZYMOL, V115, P157; LAU SYM, 1984, J BIOL CHEM, V259, P3253; LOVEJOY B, 1992, PROTEIN SCI, V1, P956, DOI 10.1002/pro.5560010714; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MARQUSEE S, 1987, P NATL ACAD SCI USA, V84, P8898, DOI 10.1073/pnas.84.24.8898; MCGREGOR MJ, 1987, J MOL BIOL, V198, P295, DOI 10.1016/0022-2836(87)90314-7; MCLACHLAN AD, 1975, J MOL BIOL, V98, P293, DOI 10.1016/S0022-2836(75)80119-7; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; PARRY DAD, 1982, BIOSCIENCE REP, V2, P1017, DOI 10.1007/BF01122170; PERISIC O, 1989, CELL, V59, P797, DOI 10.1016/0092-8674(89)90603-X; POLLET RJ, 1979, J BIOL CHEM, V254, P30; SKOLNICK J, 1985, MACROMOLECULES, V18, P1549, DOI 10.1021/ma00150a005; SORGER PK, 1989, CELL, V59, P807, DOI 10.1016/0092-8674(89)90604-1; SPEICHER DW, 1984, NATURE, V311, P177, DOI 10.1038/311177a0; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; TERWILLIGER TC, 1982, J BIOL CHEM, V257, P6016; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; WEBER PC, 1980, NATURE, V287, P81; Zhang K. Y. J., 1990, ACTA CRYST A, VA46, P41; ZHANG KYJ, 1990, ACTA CRYSTALLOGR A, V46, P377, DOI 10.1107/S0108767389012158	43	275	297	0	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 26	1993	259	5099					1288	1293		10.1126/science.8446897	http://dx.doi.org/10.1126/science.8446897			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KN883	8446897				2022-12-24	WOS:A1993KN88300020
J	ZAADSTRA, BM; SEIDELL, JC; VANNOORD, PAH; TEVELDE, ER; HABBEMA, JDF; VRIESWIJK, B; KARBAAT, J				ZAADSTRA, BM; SEIDELL, JC; VANNOORD, PAH; TEVELDE, ER; HABBEMA, JDF; VRIESWIJK, B; KARBAAT, J			FAT AND FEMALE FECUNDITY - PROSPECTIVE-STUDY OF EFFECT OF BODY-FAT DISTRIBUTION ON CONCEPTION RATES	BRITISH MEDICAL JOURNAL			English	Article							WOMEN; ASSOCIATION; INFERTILITY; OBESITY; WEIGHT	Objectives-To study the effect of body fat distribution in women of reproducti Design-Prospective cohort study of all women who had entered a donor insemination programme. Setting-One fertility clinic serving a large part of the midwest of the Netherlands. Subjects-Of 542 women attending the clinic for artificial insemination for the first time, 500 women were eligible for study. Main outcome measures-Probability of conception per cycle and number of insemination cycles before pregnancy or stopping treatment. Results-A 0.1 unit increase in waist-hip ratio led to a 30% decrease in probability of conception per cycle (hazard ratio 0.706; 95% confidence interval 0.562 to 0.887) after adjustment for age, fatness, reasons for artificial insemination, cycle length and regularity, smoking, and parity. Increasing age was significantly related to lower fecundity (p<0.05); very lean and obese women were less likely to conceive (p<0.10) as were women with subfertile partners (p<0.10). All other exposure variables were not significantly related to fecundity. Conclusions-Increasing waist-hip ratio is negatively associated with the probability of conception per cycle, before and after adjustment for confounding factors. Body fat distribution in women of reproductive age seems to have more impact on fertility than age or obesity.	AGR UNIV WAGENINGEN, DEPT HUMAN NUTR, 6700 HB WAGENINGEN, NETHERLANDS; UNIV UTRECHT, SCH MED, DEPT EPIDEMIOL, UTRECHT, NETHERLANDS; UNIV HOSP UTRECHT, DEPT OBSTET & GYNAECOL, UTRECHT, NETHERLANDS; ERASMUS UNIV, SCH MED, DEPT PUBL HLTH & SOCIAL MED, 3000 DR ROTTERDAM, NETHERLANDS; CRYO BIOL LABS BIJDORP, BARENDRECHT, NETHERLANDS	Wageningen University & Research; Utrecht University; Utrecht University; Utrecht University Medical Center; Erasmus University Rotterdam	ZAADSTRA, BM (corresponding author), TNO, INST PREVENT HLTH CARE, DIV CHILD HLTH, POSTBOX 124, 2300 AC LEIDEN, NETHERLANDS.		seidell, jacob/AAF-5362-2019; seidell, jacob c/N-7427-2013	seidell, jacob/0000-0002-9262-9062; 				AITKIN M, 1989, STATISTICAL MODELLIN; BAIRD DD, 1985, JAMA-J AM MED ASSOC, V253, P2979, DOI 10.1001/jama.253.20.2979; COX DR, 1972, J R STAT SOC B, V34, P187; EMPERAIRE JC, 1982, FERTIL STERIL, V37, P90; EVANS DJ, 1983, J CLIN ENDOCR METAB, V57, P304, DOI 10.1210/jcem-57-2-304; FRIEDL KE, 1985, J OBESITY WEIGHT REG, V4, P129; FRISCH RE, 1988, SCI AM, V3, P70; GRENMAN S, 1986, J CLIN ENDOCR METAB, V63, P1257, DOI 10.1210/jcem-63-6-1257; HARTZ AJ, 1979, INT J OBESITY, V3, P57; HARTZ AJ, 1984, AM J EPIDEMIOL, V119, P71, DOI 10.1093/oxfordjournals.aje.a113727; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; MITCHELL GW, 1953, NEW ENGL J MED, V249, P835, DOI 10.1056/NEJM195311192492102; NEWCOMBE RG, 1982, J EPIDEMIOL COMMUN H, V36, P306, DOI 10.1136/jech.36.4.306; PASQUALI R, 1987, J ENDOCRINOL INVEST, V10, P575, DOI 10.1007/BF03346997; REGAN L, 1990, LANCET, V336, P1141, DOI 10.1016/0140-6736(90)92765-A; ROGERS J, 1952, NEW ENGL J MED, V247, P53, DOI 10.1056/NEJM195207102470204; ROOKUS MA, 1987, HUM BIOL, V59, P617; SEIDELL JC, 1990, J CLIN EPIDEMIOL, V43, P21, DOI 10.1016/0895-4356(90)90052-Q; SELLERS TA, 1992, NEW ENGL J MED, V326, P1323, DOI 10.1056/NEJM199205143262004; SHIMOKATA H, 1989, INT J OBESITY, V13, P455; van Noord-Zaadstra B M, 1980, Ned Tijdschr Geneeskd, V124, P581; van Noord-Zaadstra B M, 1989, Paediatr Perinat Epidemiol, V3, P11; VANNOORDZAADSTRA BM, 1991, BMJ-BRIT MED J, V302, P1361, DOI 10.1136/bmj.302.6789.1361	23	402	405	0	33	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 20	1993	306	6876					484	487		10.1136/bmj.306.6876.484	http://dx.doi.org/10.1136/bmj.306.6876.484			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KN786	8448457	Green Accepted, Bronze, Green Published			2022-12-24	WOS:A1993KN78600016
J	ADLER, AI; ALTMAN, J				ADLER, AI; ALTMAN, J			AN OUTBREAK OF MUD-WRESTLING INDUCED PUSTULAR DERMATITIS IN COLLEGE-STUDENTS - DERMATITIS-PALAESTRAE-LIMOSAE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							GRAM-NEGATIVE FOLLICULITIS; PSEUDOMONAS-AERUGINOSA; CITROBACTER	Objective.-To investigate an outbreak of gram-negative folliculitis in relation to a common exposure, mud wrestling, and identify risk factors for dermatitis among those who mud wrestled. Design.-Case-control study. Setting.-University of Washington, Seattle. Participants.-Two college-residence groups of students. Results.-Cultures from affected students and from mud similar to that used for wrestling yielded Enterobacteriaceae. The odds ratio associated with mud wrestling was 79.5 (95% confidence interval, 13.9 to 895.4). Increased time spent wrestling was associated with increased risk. Skin trauma during wrestling or immersion in the mud increased the risk of infection (odds ratio, 23.1; 95% confidence interval, 1.7 to 1440.4). Conclusions.-Mud wrestling is one cause of pustular follicular dermatitis. Trauma to the skin may be a necessary cofactor for the development of infection.	UNIV WASHINGTON, CTR STUDENT HLTH, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT EPIDEMIOL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT FAMILY MED, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle								ARNOLD HA, 1990, ANDREWS DISEASES SKI; BELONGIA EA, 1991, NEW ENGL J MED, V325, P906, DOI 10.1056/NEJM199109263251302; BERGER RS, 1990, CUTIS, V45, P97; BLANKENSHIP ML, 1984, ARCH DERMATOL, V120, P1301, DOI 10.1001/archderm.120.10.1301; Braun Julius, 1875, CURATIVE EFFECTS BAT; CHANDRASEKAR PH, 1984, ARCH DERMATOL, V120, P1337, DOI 10.1001/archderm.120.10.1337; FOX AB, 1984, ARCH DERMATOL, V120, P1304, DOI 10.1001/archderm.120.10.1304; FREEMAN MJ, 1977, CUTIS, V20, P333; KELLY MT, 1985, MANUAL CLIN MICROBIO, P00263; LIPSKY BA, 1980, REV INFECT DIS, V2, P746; MOSTAFA WZ, 1989, J AM ACAD DERMATOL, V20, P504, DOI 10.1016/S0190-9622(89)80090-8; Seefelder A, 1991, Offentl Gesundheitswes, V53, P338; Tscharntke D, 1987, Offentl Gesundheitswes, V49, P589	13	6	7	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 27	1993	269	4					502	504		10.1001/jama.269.4.502	http://dx.doi.org/10.1001/jama.269.4.502			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KH385	8419670				2022-12-24	WOS:A1993KH38500035
J	NISHIZAKA, T; YAGI, T; TANAKA, Y; ISHIWATA, S				NISHIZAKA, T; YAGI, T; TANAKA, Y; ISHIWATA, S			RIGHT-HANDED ROTATION OF AN ACTIN FILAMENT IN AN INVITRO MOTILE SYSTEM	NATURE			English	Article							MYOSIN; MOVEMENT; MUSCLE	MUSCLE contraction occurs by mutual sliding between thick (myosin) and thin (actin) filaments1,2. But the physical and chemical properties of the sliding force are not clear; even the precise direction of sliding force generated at each cross-bridge is not known. We report here the use of a recently developed in vitro motile assay system3-5 to show supercoiling of an actin filament in which the front part of the filament was fixed to a glass surface through cross-linked heavy-meromyosin and the rear part was able to slide on a track of heavy-meromyosin. A left-handed single turn of superhelix formed just before supercoiling, suggesting that the sliding force has a right-handed torque component that induces the right-handed rotation of an actin filament around its long axis. The presence of the torque component in the sliding force will explain several properties of the contractile system of muscle.	WASEDA UNIV,SCH SCI & ENGN,DEPT PHYS,3-4-1 OKUBO,SHINJUKU KU,TOKYO 169,JAPAN; HONDA RES & DEV CO LTD,WAKO RES CTR,SAITAMA 35101,JAPAN	Waseda University; Honda Motor Company								ANDO T, 1989, J BIOCHEM-TOKYO, V105, P818, DOI 10.1093/oxfordjournals.jbchem.a122751; CECCHI G, 1990, SCIENCE, V250, P1409, DOI 10.1126/science.2255911; GOLDSTEIN MA, 1987, FASEB J, V1, P133, DOI 10.1096/fasebj.1.2.3609610; HARADA Y, 1990, J MOL BIOL, V216, P49, DOI 10.1016/S0022-2836(05)80060-9; HARADA Y, 1987, NATURE, V326, P805, DOI 10.1038/326805a0; HUXLEY AF, 1954, NATURE, V173, P971, DOI 10.1038/173971a0; HUXLEY H, 1954, NATURE, V173, P973, DOI 10.1038/173973a0; JAROSCH R, 1987, NATURE FUNCTION CYTO, P231; KONDO H, 1976, J BIOCHEM-TOKYO, V79, P159, DOI 10.1093/oxfordjournals.jbchem.a131043; KRON SJ, 1986, P NATL ACAD SCI USA, V83, P6272, DOI 10.1073/pnas.83.17.6272; SELLERS JR, 1990, SCIENCE, V249, P406, DOI 10.1126/science.2377894; SHIMADA K, 1975, NATURE, V254, P332, DOI 10.1038/254332a0; TANAKA Y, 1992, BIOCHIM BIOPHYS ACTA, V1159, P94, DOI 10.1016/0167-4838(92)90079-S; TOYOSHIMA YY, 1989, NATURE, V341, P154, DOI 10.1038/341154a0; TOYOSHIMA YY, 1987, NATURE, V328, P536, DOI 10.1038/328536a0; VALE RD, 1988, CELL, V52, P459, DOI 10.1016/S0092-8674(88)80038-2; WEEDS AG, 1977, J MOL BIOL, V111, P129, DOI 10.1016/S0022-2836(77)80119-8; YAMAGUCHI M, 1985, J MOL BIOL, V184, P621, DOI 10.1016/0022-2836(85)90308-0	18	109	110	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 21	1993	361	6409					269	271		10.1038/361269a0	http://dx.doi.org/10.1038/361269a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KH614	8423853				2022-12-24	WOS:A1993KH61400063
J	FRIDEN, PM; WALUS, LR; WATSON, P; DOCTROW, SR; KOZARICH, JW; BACKMAN, C; BERGMAN, H; HOFFER, B; BLOOM, F; GRANHOLM, AC				FRIDEN, PM; WALUS, LR; WATSON, P; DOCTROW, SR; KOZARICH, JW; BACKMAN, C; BERGMAN, H; HOFFER, B; BLOOM, F; GRANHOLM, AC			BLOOD-BRAIN-BARRIER PENETRATION AND INVIVO ACTIVITY OF AN NGF CONJUGATE	SCIENCE			English	Article							NERVE GROWTH-FACTOR; ANTITRANSFERRIN RECEPTOR ANTIBODY; SEPTAL CHOLINERGIC NEURONS; BASAL FOREBRAIN NEURONS; PROMOTES DEVELOPMENT; ALZHEIMERS-DISEASE; ANTERIOR-CHAMBER; ADULT-RATS; TRANSPORT; INFUSION	Nerve growth factor (NGF) is essential for the survival of both peripheral ganglion cells and central cholinergic neurons of the basal forebrain. The accelerated loss of central cholinergic neurons during Alzheimer's disease may be a determinant of dementia in these patients and may therefore suggest a therapeutic role for NGF. However, NGF does not significantly penetrate the blood-brain barrier, which makes its clinical utility dependent on invasive neurosurgical procedures. When conjugated to an antibody to the transferrin receptor, however, NGF crossed the blood-brain barrier after peripheral injection. This conjugated NGF increased the survival of both cholinergic and noncholinergic neurons of the medial septal nucleus that had been transplanted into the anterior chamber of the rat eye. This approach may prove useful for the treatment of Alzheimer's disease and other neurological disorders that are amenable to treatment by proteins that do not readily cross the blood-brain barrier.	UNIV COLORADO,SCH DENT,DEPT BASIC SCI,DENVER,CO 80262; UNIV LINKOPING,HLTH SCI CTR,DEPT CELL BIOL,LINKOPING,SWEDEN; SCRIPPS CLIN & RES FDN,DEPT NEUROPHARMACOL,LA JOLLA,CA 92037; UNIV COLORADO,SCH MED,DEPT PHARMACOL,DENVER,CO 80262	University of Colorado System; University of Colorado Denver; Linkoping University; Scripps Research Institute; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	FRIDEN, PM (corresponding author), ALKERMES INC,64 SIDNEY ST,CAMBRIDGE,MA 02139, USA.		backman, cristina/C-1276-2013	Doctrow, Susan/0000-0003-0628-9960	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R44NS029601, R43NS029601] Funding Source: NIH RePORTER; NINDS NIH HHS [NS29601-01] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARTUS RT, 1982, SCIENCE, V217, P408, DOI 10.1126/science.7046051; BJORKLUND H, 1990, ENVIRON RES, V22, P229; BLAIR AH, 1983, J IMMUNOL METHODS, V59, P129; BRIGHTMAN MW, 1977, EXP EYE RES, V25, P1, DOI 10.1016/S0014-4835(77)80008-0; BUXSER S, 1991, J NEUROCHEM, V56, P1012, DOI 10.1111/j.1471-4159.1991.tb02022.x; CARLSSON J, 1978, BIOCHEM J, V173, P723, DOI 10.1042/bj1730723; DRACHMAN DA, 1974, ARCH NEUROL-CHICAGO, V30, P113, DOI 10.1001/archneur.1974.00490320001001; ERIKSDOTTERNILSSON M, 1989, EXP BRAIN RES, V74, P89; ERIKSDOTTERNILSSON M, 1989, NEUROSCIENCE, V30, P755, DOI 10.1016/0306-4522(89)90167-X; FISCHER W, 1987, NATURE, V329, P65, DOI 10.1038/329065a0; FRIDEN PM, 1991, P NATL ACAD SCI USA, V88, P4771, DOI 10.1073/pnas.88.11.4771; GAHWILER BH, 1987, NEUROSCI LETT, V75, P6, DOI 10.1016/0304-3940(87)90066-8; GOLDSTEIN GW, 1986, SCI AM, V255, P74, DOI 10.1038/scientificamerican0986-74; GREENE LA, 1980, ANNU REV NEUROSCI, V3, P353, DOI 10.1146/annurev.ne.03.030180.002033; HAGG T, 1990, J NEUROSCI, V10, P3087; HAGG T, 1988, EXP NEUROL, V101, P303, DOI 10.1016/0014-4886(88)90013-1; Haigler HJ, 1985, BRAIN RES, V362, P157; HARIK SI, 1990, P NATL ACAD SCI USA, V87, P4261, DOI 10.1073/pnas.87.11.4261; HARLOW E, 1988, ANTIBODIES LABORATOR; HARTIKKA J, 1988, J NEUROSCI, V8, P2967; HEFTI F, 1986, J NEUROSCI, V6, P2155; HOFFMAN D, 1990, EXP NEUROL, V110, P39, DOI 10.1016/0014-4886(90)90049-X; JEFFERIES WA, 1984, NATURE, V312, P162, DOI 10.1038/312162a0; JUNARD EO, 1990, EXP NEUROL, V110, P25, DOI 10.1016/0014-4886(90)90048-W; KNOBLER RL, 1992, J NEUROPATH EXP NEUR, V51, P36, DOI 10.1097/00005072-199201000-00005; KOTTLER M, 1970, INVEST OPHTH VISUAL, V9, P758; KROMER LF, 1987, SCIENCE, V235, P214, DOI 10.1126/science.3798108; KUPERSMITH M, 1989, IMPLICATIONS BLOOD B, P369; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACRI FJ, 1970, ARCH OPHTHALMOL-CHIC, V83, P741; MOBLEY WC, 1986, MOL BRAIN RES, V1, P53, DOI 10.1016/0169-328X(86)90020-3; OLSON L, 1991, ARCH NEUROL-CHICAGO, V48, P373, DOI 10.1001/archneur.1991.00530160037011; OLSON L, 1992, J NEURAL TRANSM-PARK, V4, P79, DOI 10.1007/BF02257624; OLSON L, 1977, BRAIN RES, V119, P87, DOI 10.1016/0006-8993(77)90093-2; PARDRIDGE WM, 1991, J PHARMACOL EXP THER, V259, P66; PRICE DL, 1986, ANNU REV NEUROSCI, V9, P489; RAVIOLA G, 1977, EXP EYE RES, V25, P27, DOI 10.1016/S0014-4835(77)80009-2; RAVIOLA G, 1984, INVEST OPHTH VIS SCI, V25, P827; REESE TS, 1967, J CELL BIOL, V34, P207, DOI 10.1083/jcb.34.1.207; ROSSIER J, 1984, NEUROCHEM INT, V6, P183, DOI 10.1016/0197-0186(84)90090-1; SAFFRAN BN, 1989, BRAIN RES, V492, P245, DOI 10.1016/0006-8993(89)90907-4; SCHWAB ME, 1979, BRAIN RES, V168, P473, DOI 10.1016/0006-8993(79)90303-2; TRIGUERO D, 1990, J NEUROCHEM, V54, P1882, DOI 10.1111/j.1471-4159.1990.tb04886.x; WAINER BH, 1984, NEUROCHEM INT, V6, P163, DOI 10.1016/0197-0186(84)90089-5; WALUS LR, UNPUB; Wawrzyaczak E. J., 1987, IMMUNOCONJUGATES ANT, P28; WHITEHOUSE PJ, 1982, SCIENCE, V215, P1237, DOI 10.1126/science.7058341; WHITTEMORE SR, 1987, BRAIN RES REV, V12, P439, DOI 10.1016/0165-0173(87)90008-7; WILL B, 1985, BEHAV BRAIN RES, V17, P17, DOI 10.1016/0166-4328(85)90004-X; WILLIAMS LR, 1986, P NATL ACAD SCI USA, V83, P9231, DOI 10.1073/pnas.83.23.9231	50	262	310	1	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 15	1993	259	5093					373	377		10.1126/science.8420006	http://dx.doi.org/10.1126/science.8420006			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KG624	8420006				2022-12-24	WOS:A1993KG62400036
J	HAAS, JS; UDVARHELYI, IS; MORRIS, CN; EPSTEIN, AM				HAAS, JS; UDVARHELYI, IS; MORRIS, CN; EPSTEIN, AM			THE EFFECT OF PROVIDING HEALTH COVERAGE TO POOR UNINSURED PREGNANT-WOMEN IN MASSACHUSETTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRENATAL-CARE; EXPANSION	Objectives.-There has been substantial policy interest in whether the provision of health coverage to poor uninsured pregnant women affects access to prenatal care and birth outcomes. We therefore examined whether the statewide provision of health coverage to uninsured low-income pregnant women affects access to prenatal care and infant birth outcomes. Design.-Natural experiment. Patients.-All inhospital, single-gestation live births in 1984 (N=57257) and 1987 (N=64 346). Intervention.-In 1985, Massachusetts instituted Healthy Start, a program providing health coverage to uninsured pregnant women with incomes below 185% of the federal poverty level. Main Outcome Measures.-Rates of satisfactory prenatal care, care initiated before the third trimester, and adverse infant outcome for uninsured women and for two concurrent control groups, women with Medicaid, and women with private insurance. We calculated the difference in rates between the uninsured and each concurrent control. To assess the effect of the program, we examined the change in these interpayer differences in rates between 1984 and 1987. Main Results.-Between 1984 and 1987, the rate of satisfactory prenatal care declined from 96.4% to 93.8% for all women in Massachusetts (P<.001). There was no statewide change in the overall incidence of adverse birth outcome (6.6% in both years). In 1984, uninsured women were less likely than privately insured women to receive satisfactory prenatal care (90.5% and 98.1 %, respectively; interpayer difference, -7.6%) and to initiate care before the third trimester (94.2% and 99.1 %; interpayer difference, -4.9%), and were more likely to suffer an adverse birth outcome (7.1 % and 5.8%; interpayer difference, 1.3%). Between 1984 and 1987, there were no statistically significant changes in the interpayer differences in rates for any of the outcome measures relative to either control group. Conclusions.-Our findings suggest that access to prenatal care may have declined for all women in Massachusetts between 1984 and 1987. In the setting of this statewide decline in access, the expansion of health coverage to uninsured low-income pregnant women was not associated with an improvement in access to prenatal care or birth outcomes.	HARVARD UNIV, SCH MED,DEPT HLTH CARE POLICY,25 SHATTUCK ST, PARCEL B,1ST FLOOR, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT MED, DIV GEN MED, HLTH SERV & POLICY RES SECT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT HLTH POLICY & MANAGEMENT, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health				HAAS, JENNIFER/0000-0001-7227-851X				ALEXANDER GR, 1991, AM J PUBLIC HEALTH, V81, P1013, DOI 10.2105/AJPH.81.8.1013; AZZARA CV, 1988, HLTH START PROGRAM E; BRAVEMAN P, 1989, NEW ENGL J MED, V321, P508, DOI 10.1056/NEJM198908243210805; GOLD LB, 1987, BLESSED EVENTS BOTTO; GORTMAKER SL, 1979, AM J PUBLIC HEALTH, V69, P653, DOI 10.2105/AJPH.69.7.653; GUYER B, 1990, CHILDREN CHANGING HL, P297; HILL IT, 1989, COORDINATING PRENATA; Kessner DM, 1973, CONTRASTS HLTH STATU; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; MILLER CL, 1989, AM J PUBLIC HEALTH, V79, P62, DOI 10.2105/AJPH.79.1.62; PIPER JM, 1990, JAMA-J AM MED ASSOC, V264, P2219, DOI 10.1001/jama.264.17.2219; ROSENBAUM S, 1988, MED CARE, V26, P315, DOI 10.1097/00005650-198804000-00002; ROSENBAUM S, 1991, HLTH AM CHILDREN; SHOWSTACK JA, 1984, AM J PUBLIC HEALTH, V74, P1003, DOI 10.2105/AJPH.74.9.1003; TAFFEL S, 1980, VITAL HLTH STATIS 21, V37; TORRES A, 1989, FAM PLANN PERSPECT, V21, P19, DOI 10.2307/2135414; WEGMAN ME, 1990, PEDIATRICS, V86, P835; 1987, GAOHRD87137 US GEN A; 1980, PHS801260 US DEP HLT; 1988, OBSTETRIC GYNECOLOGI	20	98	98	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 6	1993	269	1					87	91		10.1001/jama.269.1.87	http://dx.doi.org/10.1001/jama.269.1.87			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF026	8416413				2022-12-24	WOS:A1993KF02600034
J	LAW, CM; DESWIET, M; OSMOND, C; FAYERS, PM; BARKER, DJP; CRUDDAS, AM; FALL, CHD				LAW, CM; DESWIET, M; OSMOND, C; FAYERS, PM; BARKER, DJP; CRUDDAS, AM; FALL, CHD			INITIATION OF HYPERTENSION INUTERO AND ITS AMPLIFICATION THROUGHOUT LIFE	BRITISH MEDICAL JOURNAL			English	Article							BLOOD-PRESSURE; ADULT LIFE; FETAL; GROWTH; AGE	Objective-To determine whether the relation between high blood pressure and low birth weight is initiated in utero or during infancy, and whether it changes with age. Design-A longitudinal study of children and three follow up studies of adults. Setting-Farnborough, Preston, and Hertfordshire, England, and a national sample in Britain. Subjects-1895 children aged 0-10 years, 3240 men and women aged 36 years, 459 men and women aged 46-54 years, and 1231 men and women aged 59-71 years. The birth weight of all subjects had been recorded. Main outcome measure-Systolic blood pressure. Results-At all ages beyond infancy people who had lower birth weight had higher systolic blood pressure. Systolic blood pressure was not related to growth during infancy independently of birth weight. The relation between systolic pressure and birth weight became larger with increasing age so that, after current body mass was allowed for, systolic pressure at ages 64-71 years decreased by 5.2 mm Hg (95% confidence interval 1.8 to 8.6) for every kg increase in birth weight. Conclusions-Essential hypertension is initiated in fetal life. A raised blood pressure is then amplified from infancy to old age, perhaps by a positive feedback mechanism.	QUEEN CHARLOTTES & CHELSEA HOSP,INST OBSTET & GYNAECOL,LONDON W6 0XG,ENGLAND; MRC,CANC TRIALS OFF,CAMBRIDGE CB2 2BB,ENGLAND	Imperial College London	LAW, CM (corresponding author), SOUTHAMPTON GEN HOSP,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND.		Fayers, Peter M/A-5999-2010; Law, Catherine/A-1353-2009	Osmond, Clive/0000-0002-9054-4655; Fayers, Peter/0000-0003-4778-1513; Law, Catherine/0000-0002-1777-9386				Barker D J, 1992, Paediatr Perinat Epidemiol, V6, P35, DOI 10.1111/j.1365-3016.1992.tb00741.x; BARKER DJP, 1989, BRIT MED J, V298, P564, DOI 10.1136/bmj.298.6673.564; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; BERRY CL, 1978, BRIT HEART J, V40, P709; CRUISE M, 1973, PEDIATRICS, V51, P322; DESWIET M, 1992, BRIT MED J, V304, P23, DOI 10.1136/bmj.304.6818.23; FERRISS JB, 1975, BMJ-BRIT MED J, V1, P135, DOI 10.1136/bmj.1.5950.135; FOLKOW B, 1978, CLIN SCI MOL MED, V55, pS3, DOI 10.1042/cs055003s; FOLKOW B, 1982, PHYSIOL REV, V62, P347, DOI 10.1152/physrev.1982.62.2.347; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; LAW CM, 1991, ARCH DIS CHILD, V66, P1291, DOI 10.1136/adc.66.11.1291; LEVER AF, 1992, J HYPERTENS, V10, P101, DOI 10.1097/00004872-199202000-00001; OUNSTED MK, 1985, ARCH DIS CHILD, V60, P631, DOI 10.1136/adc.60.7.631; Owens J.A., 1989, ADV FETAL PHYSL, P263; SCOTT A, 1982, EARLY HUM DEV, V7, P17, DOI 10.1016/0378-3782(82)90004-4; WADSWORTH MEJ, 1985, BRIT MED J, V291, P1534, DOI 10.1136/bmj.291.6508.1534	16	508	515	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 2	1993	306	6869					24	27		10.1136/bmj.306.6869.24	http://dx.doi.org/10.1136/bmj.306.6869.24			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KE984	8435572	Green Published, Bronze			2022-12-24	WOS:A1993KE98400021
J	GALLANT, JL; BRAUN, J; VANESSEN, DC				GALLANT, JL; BRAUN, J; VANESSEN, DC			SELECTIVITY FOR POLAR, HYPERBOLIC, AND CARTESIAN GRATINGS IN MACAQUE VISUAL-CORTEX	SCIENCE			English	Article							INFERIOR TEMPORAL NEURONS; MONKEY; FIELD; AREA; PATTERNS; SENSITIVITY; PERCEPTION; DIRECTION; SULCUS; MOTION	The neural basis of pattern recognition is a central problem in visual neuroscience. Responses of single cells were recorded in area V4 of macaque monkey to three classes of periodic stimuli that are based on spatial derivative operators: polar (concentric and radial), hyperbolic, and conventional sinusoidal (Cartesian) gratings. Of 118 cells tested, 16 percent responded significantly more to polar or hyperbolic (non-Cartesian) gratings than to Cartesian gratings and only 8 percent showed a significant preference for Cartesian gratings. Among cells selective for non-Cartesian gratings, those that preferred concentric gratings were most common. Cells selective for non-Cartesian gratings may constitute an important intermediate stage in pattern recognition and the representation of surface shape.	CALTECH,DIV BIOL,PASADENA,CA 91125	California Institute of Technology			Braun, Jochen/F-1370-2013; Gallant, Jack L/C-4426-2011	Braun, Jochen/0000-0002-8886-078X; 	NATIONAL EYE INSTITUTE [R01EY002091] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS007251] Funding Source: NIH RePORTER; NEI NIH HHS [EY02091] Funding Source: Medline; NINDS NIH HHS [T32NS07251] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		CAELLI TM, 1976, MATH BIOSCI, V30, P191, DOI 10.1016/0025-5564(76)90065-1; Cavanagh P., 1984, FIGURAL SYNTHESIS, P185; DESIMONE R, 1985, VISION RES, V25, P441, DOI 10.1016/0042-6989(85)90069-0; DESIMONE R, 1984, J NEUROSCI, V4, P2051; DESIMONE R, 1987, J NEUROPHYSIOL, V57, P835, DOI 10.1152/jn.1987.57.3.835; DeValois RL, 1990, SPATIAL VISION; DEYOE EA, 1988, TRENDS NEUROSCI, V11, P219, DOI 10.1016/0166-2236(88)90130-0; DODWELL PC, 1987, VISION RES, V27, P569, DOI 10.1016/0042-6989(87)90043-5; DODWELL PC, 1990, PSYCHOL REV, V97, P78, DOI 10.1037/0033-295X.97.1.78; DODWELL PC, 1983, PERCEPT PSYCHOPHYS, V34, P1, DOI 10.3758/BF03205890; DUFFY CJ, 1991, J NEUROPHYSIOL, V65, P1346, DOI 10.1152/jn.1991.65.6.1346; Eagleson Roy, 1992, Spatial Vision, V6, P183, DOI 10.1163/156856892X00073; EMERSON VF, 1985, PERCEPT PSYCHOPHYS, V37, P155, DOI 10.3758/BF03202851; EMERSON VF, 1984, CAN J PSYCHOL, V38, P551, DOI 10.1037/h0080866; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; FELLEMAN DJ, 1987, J NEUROPHYSIOL, V57, P889, DOI 10.1152/jn.1987.57.4.889; FERRARO M, 1988, J OPT SOC AM A, V5, P738, DOI 10.1364/JOSAA.5.000738; GASKA JP, 1987, VISION RES, V27, P1687, DOI 10.1016/0042-6989(87)90098-8; HOFFMAN W C, 1970, Mathematical Biosciences, V6, P437, DOI 10.1016/0025-5564(70)90079-9; HOFFMAN WC, 1985, CAN J PSYCHOL, V39, P491, DOI 10.1037/h0080077; Horn BKP, 1989, SHAPE SHADING; HUBEL DH, 1968, J PHYSIOL-LONDON, V195, P215, DOI 10.1113/jphysiol.1968.sp008455; KOBATAKE E, 1991, SOC NEUR ABSTR, V21, P443; KOENDERINK JJ, 1990, BIOL CYBERN, V63, P291, DOI 10.1007/BF00203452; LEYTON M, 1984, BIOL CYBERN, V51, P141, DOI 10.1007/BF00346136; OLAVARRIA JF, 1992, J NEUROPHYSIOL, V68, P164, DOI 10.1152/jn.1992.68.1.164; ORBAN GA, 1992, P NATL ACAD SCI USA, V89, P2595, DOI 10.1073/pnas.89.7.2595; PALMER SE, 1985, ACTA PSYCHOL, V59, P67, DOI 10.1016/0001-6918(85)90042-3; RICHMOND BJ, 1987, J NEUROPHYSIOL, V57, P132, DOI 10.1152/jn.1987.57.1.132; ROLLS ET, 1987, VISION RES, V27, P311, DOI 10.1016/0042-6989(87)90081-2; SAITO H, 1986, J NEUROSCI, V6, P145; SCHWARTZ EL, 1983, P NATL ACAD SCI-BIOL, V80, P5776, DOI 10.1073/pnas.80.18.5776; TANAKA K, 1989, J NEUROPHYSIOL, V62, P626, DOI 10.1152/jn.1989.62.3.626; TANAKA K, 1991, J NEUROPHYSIOL, V66, P170, DOI 10.1152/jn.1991.66.1.170	34	417	424	0	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 1	1993	259	5091					100	103		10.1126/science.8418487	http://dx.doi.org/10.1126/science.8418487			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	KE601	8418487				2022-12-24	WOS:A1993KE60100039
J	ATTALI, B; GUILLEMARE, E; LESAGE, F; HONORE, E; ROMEY, G; LAZDUNSKI, M; BARHANIN, J				ATTALI, B; GUILLEMARE, E; LESAGE, F; HONORE, E; ROMEY, G; LAZDUNSKI, M; BARHANIN, J			THE PROTEIN ISK IS A DUAL ACTIVATOR OF K+ AND CL- CHANNELS	NATURE			English	Article								THE protein IsK (M(r) 14,500) is present in epithelial cells1, heart2,3, uterus4 and lymphocytes5 and induces slowly activating K+ currents when expressed in Xenopus oocytes1. The finding that mutations of its single transmembrane segment altered channel gating6 or selectivity7 has suggested that IsK is a channel-forming protein. But IsK does not exhibit the K+ channel hallmarks8 (a conserved K+ selective pore (H5) flanked by either six9-11 or two 12,13 membrane-spanning regions). Here we report that IsK expression in Xenopus oocytes also induces a Cl- selective current very similar to the Cl- current produced by phospholemman expression14 and wit h biophysical, pharmacological and regulation characteristics very different from those of the IsK-induced K+ channel activity. IsK mutagenesis identifies amino- and carboxy-terminal domains as critical for the induction of Cl- and K+ channel activities, respectively. Our data lead to a model in which the IsK protein (now called IsK, Cl) acts as a potent activator of endogenous and otherwise silent K+ or Cl- channels.	SOPHIA ANTIPOLIS,CNRS,INST PHARMACOL MOLEC & CELLULAIRE,660 ROUTE LUCIOLES,F-06560 VALBONNE,FRANCE	Centre National de la Recherche Scientifique (CNRS)			Lesage, Florian/P-9780-2019; Lesage, Florian/D-5097-2011	Lesage, Florian/0000-0002-4406-7106; Lesage, Florian/0000-0002-4406-7106; HONORE, Eric/0000-0002-8007-0919				ALDRICH R, 1993, NATURE, V362, P107, DOI 10.1038/362107a0; ATTALI B, 1992, J BIOL CHEM, V267, P8650; BUSCH AE, 1992, SCIENCE, V255, P1705, DOI 10.1126/science.1553557; BUSCH AE, 1992, BIOCHEM BIOPH RES CO, V184, P804, DOI 10.1016/0006-291X(92)90661-4; FOLANDER K, 1990, P NATL ACAD SCI USA, V87, P2975, DOI 10.1073/pnas.87.8.2975; GOLDSTEIN SAN, 1991, NEURON, V7, P403, DOI 10.1016/0896-6273(91)90292-8; GUILLEMARE E, 1992, BIOCHEMISTRY-US, V31, P12463, DOI 10.1021/bi00164a024; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; HONORE E, 1991, EMBO J, V10, P2805, DOI 10.1002/j.1460-2075.1991.tb07829.x; HONORE E, 1992, BIOCHEM BIOPH RES CO, V184, P1135, DOI 10.1016/S0006-291X(05)80001-4; JAN LY, 1992, ANNU REV PHYSIOL, V54, P535, DOI 10.1146/annurev.physiol.54.1.535; KREIG PA, 1984, NUCLEIC ACIDS RES, V12, P7057; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; LESAGE F, 1993, RECEPTOR CHANNEL, V1, P143; MOORMAN JR, 1992, J BIOL CHEM, V267, P14551; MURAI T, 1989, BIOCHEM BIOPH RES CO, V161, P176, DOI 10.1016/0006-291X(89)91577-5; PALMER CJ, 1991, J BIOL CHEM, V266, P11126; PONGS O, 1992, PHYSIOL REV, V72, pS69, DOI 10.1152/physrev.1992.72.suppl_4.S69; PRAGNELL M, 1990, NEURON, V4, P807, DOI 10.1016/0896-6273(90)90207-V; RUDY B, 1991, Molecular and Cellular Neuroscience, V2, P89, DOI 10.1016/1044-7431(91)90001-5; TAKUMI T, 1991, J BIOL CHEM, V266, P22192; TAKUMI T, 1988, SCIENCE, V242, P1042, DOI 10.1126/science.3194754	22	126	128	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 28	1993	365	6449					850	852		10.1038/365850a0	http://dx.doi.org/10.1038/365850a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MD951	8413671				2022-12-24	WOS:A1993MD95100054
J	MAMMANO, F; ASHMORE, JF				MAMMANO, F; ASHMORE, JF			REVERSE TRANSDUCTION MEASURED IN THE ISOLATED COCHLEA BY LASER MICHELSON INTERFEROMETRY	NATURE			English	Article								IT is thought that the sensitivity of mammalian hearing depends on amplification of the incoming sound within the cochlea by a select population of sensory cells, the outer hair cells. It has been suggested that these cells sense displacements and feedback forces which enhance the basilar membrane motion by reducing the inherent damping of the cochlear partition1-7. In support of this hypothesis, outer hair cells show membrane-potential-induced length changes1-3 at acoustic rates. This process has been termed 'reverse transduction'. For amplification, the forces should be large enough to move the basilar membrane. Using a displacement-sensitive interferometer8, we tested this hypothesis in an isolated cochlea while stimulating the outer hair cells with current passed across the partition. We show here that the cochlear partition distorts under the action of electrically driven hair cell length changes and produces place-specific vibration of the basilar membrane of a magnitude comparable to that observed near auditory threshold (about 1 nm). Such measurements supply direct evidence that cochlear amplification arises from the properties of the outer hair cell population.	SCH MED SCI,DEPT PHYSIOL,UNIV WALK,BRISTOL BS8 1TD,ENGLAND	University of Bristol			Mammano, Fabio/I-5064-2012; Mammano, Fabio/AAM-3902-2020	Mammano, Fabio/0000-0003-3751-1691; Mammano, Fabio/0000-0003-3751-1691	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ASHMORE JF, 1987, J PHYSIOL-LONDON, V388, P323, DOI 10.1113/jphysiol.1987.sp016617; ASHMORE JF, 1986, NATURE, V322, P368, DOI 10.1038/322368a0; BROWNELL WE, 1985, SCIENCE, V227, P194, DOI 10.1126/science.3966153; DALLOS P, 1991, NATURE, V350, P155, DOI 10.1038/350155a0; DALLOS P, 1984, HEARING RES, V14, P281, DOI 10.1016/0378-5955(84)90055-8; DALLOS P, 1988, AUDITORY FUNCTION NE, P153; DAVIS H, 1983, HEARING RES, V9, P79, DOI 10.1016/0378-5955(83)90136-3; DAVIS H, 1958, Laryngoscope, V68, P359; EVANS B N, 1988, Society for Neuroscience Abstracts, V14, P800; Evans E F, 1981, Ciba Found Symp, V85, P108; GREENWOOD DD, 1990, J ACOUST SOC AM, V87, P2592, DOI 10.1121/1.399052; HUBBARD A, 1993, SCIENCE, V259, P68, DOI 10.1126/science.8418496; HUBBARD AE, 1983, SCIENCE, V222, P510, DOI 10.1126/science.6623090; KOLSTON PJ, 1989, J ACOUST SOC AM, V86, P133, DOI 10.1121/1.398332; MAMMANO F, 1993, J ACOUST SOC AM, V93, P3320, DOI 10.1121/1.405716; MAMMANO F, 1992, J PHYSIOL-LONDON, V452, pP169; MCFADDEN D, 1984, J ACOUST SOC AM, V76, P443, DOI 10.1121/1.391585; NEELY ST, 1986, J ACOUST SOC AM, V79, P1472, DOI 10.1121/1.393674; NUTTALL AL, 1991, HEARING RES, V51, P203, DOI 10.1016/0378-5955(91)90037-A; REUTER G, 1992, HEARING RES, V60, P236, DOI 10.1016/0378-5955(92)90025-I; REUTER G, 1990, HEARING RES, V43, P219, DOI 10.1016/0378-5955(90)90230-M; RUGGERO MA, 1991, J NEUROSCI, V11, P1057; SANTOS-SACCHI J, 1989, J NEUROSCI, V9, P2954; SANTOS-SACCHI J, 1991, J NEUROSCI, V11, P3096, DOI 10.1523/jneurosci.11-10-03096.1991; SELLICK PM, 1982, J ACOUST SOC AM, V72, P131, DOI 10.1121/1.387996; SHEHATA WE, 1991, ACTA OTO-LARYNGOL, V111, P707, DOI 10.3109/00016489109138403; STYPULKOWSKI PH, 1990, HEARING RES, V46, P113, DOI 10.1016/0378-5955(90)90144-E; ULFENDAHL M, 1989, HEARING RES, V40, P55, DOI 10.1016/0378-5955(89)90099-3	28	170	175	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 28	1993	365	6449					838	841		10.1038/365838a0	http://dx.doi.org/10.1038/365838a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MD951	8413667				2022-12-24	WOS:A1993MD95100050
J	ESTEVEZ, M; ATTISANO, L; WRANA, JL; ALBERT, PS; MASSAGUE, J; RIDDLE, DL				ESTEVEZ, M; ATTISANO, L; WRANA, JL; ALBERT, PS; MASSAGUE, J; RIDDLE, DL			THE DAF-4 GENE ENCODES A BONE MORPHOGENETIC PROTEIN-RECEPTOR CONTROLLING C-ELEGANS DAUER LARVA DEVELOPMENT	NATURE			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; TRANSFORMING GROWTH-FACTOR; SERINE THREONINE KINASE; VENTRALIZING FACTOR; MESSENGER-RNA; FAMILY; DIFFERENTIATION; TEMPERATURE; EXPRESSION; PHEROMONE	THE bone morphogenetic protein (BMP) family is a conserved group of signalling molecules within the transforming growth factor-beta (TGF-beta) superfamily1,2. This group, including the Drosophila decapentaplegic (dpp) protein and the mammalian BMPs, mediates cellular interactions and tissue differentiation during development3,4 . Here we show that a homologue of human BMPs controls a developmental switch in the life cycle of the free-living soil nematode Caenorhabditis elegans. Starvation and overcrowding induce C elegans to form a developmentally arrested, third-stage dauer larva5. The daf-4 gene, which acts to inhibit dauer larva formation and promote growth, encodes a receptor protein kinase similar to the daf-1, activin and TGF-beta receptor serine/threonine kinases. When expressed in monkey COS cells, the daf-4 receptor binds human BMP-2 and BMP-4. The daf-4 receptor is the first to be identified for any growth factor in the BMP family.	UNIV MISSOURI,DIV BIOL SCI,COLUMBIA,MO 65211; MEM SLOAN KETTERING CANC CTR,HOWARD HUGHES MED INST,CELL BIOL & GENET PROGRAM,NEW YORK,NY 10021	University of Missouri System; University of Missouri Columbia; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center	ESTEVEZ, M (corresponding author), UNIV MISSOURI,MOLEC BIOL PROGRAM,311 TUCKER HALL,COLUMBIA,MO 65211, USA.		Wrana, Jeffrey/F-8857-2013	Massague, Joan/0000-0001-9324-8408				ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; BARGMANN CI, 1991, SCIENCE, V251, P1243, DOI 10.1126/science.2006412; BARSTEAD RJ, 1989, J BIOL CHEM, V264, P10177; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; DALE L, 1992, DEVELOPMENT, V115, P573; GEORGI LL, 1990, CELL, V61, P635, DOI 10.1016/0092-8674(90)90475-T; GOLDEN JW, 1984, P NATL ACAD SCI-BIOL, V81, P819, DOI 10.1073/pnas.81.3.819; GOLDEN JW, 1984, DEV BIOL, V102, P368, DOI 10.1016/0012-1606(84)90201-X; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; IRISH VF, 1987, GENE DEV, V1, P868, DOI 10.1101/gad.1.8.868; JONES CM, 1992, DEVELOPMENT, V115, P639; JONES D, 1986, J BIOL CHEM, V261, P2006; KINGSLEY DM, 1992, CELL, V71, P399, DOI 10.1016/0092-8674(92)90510-J; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LIN HY, 1992, CELL, V70, P1069; LYONS KM, 1991, TRENDS GENET, V7, P408, DOI 10.1016/0168-9525(91)90265-R; MASSAGUE J, 1987, METHOD ENZYMOL, V146, P174; MATTHEWS LS, 1991, CELL, V65, P973; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MONTANDON AJ, 1989, NUCLEIC ACIDS RES, V17, P3347, DOI 10.1093/nar/17.9.3347; NISWANDER L, 1993, NATURE, V361, P68, DOI 10.1038/361068a0; PANGANIBAN GEF, 1990, MOL CELL BIOL, V10, P2669, DOI 10.1128/MCB.10.6.2669; PARALKAR VM, 1992, J CELL BIOL, V119, P1721, DOI 10.1083/jcb.119.6.1721; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RIDDLE DL, 1981, NATURE, V290, P668, DOI 10.1038/290668a0; ROSEN V, 1992, TRENDS GENET, V8, P97, DOI 10.1016/0168-9525(92)90063-A; Sulston J, 1988, NEMATODE CAENORHABDI, P587; TRENT C, 1983, GENETICS, V104, P619; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; YAMAGUCHI A, 1991, J CELL BIOL, V113, P681, DOI 10.1083/jcb.113.3.681	31	333	357	0	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 14	1993	365	6447					644	649		10.1038/365644a0	http://dx.doi.org/10.1038/365644a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MB846	8413626				2022-12-24	WOS:A1993MB84600058
J	PESSI, A; BIANCHI, E; CRAMERI, A; VENTURINI, S; TRAMONTANO, A; SOLLAZZO, M				PESSI, A; BIANCHI, E; CRAMERI, A; VENTURINI, S; TRAMONTANO, A; SOLLAZZO, M			A DESIGNED METAL-BINDING PROTEIN WITH A NOVEL FOLD	NATURE			English	Article							3-DIMENSIONAL STRUCTURE; CRYSTAL-STRUCTURE; DENOVO DESIGN; LIGHT CHAIN; SITE; CONFORMATION; EXPRESSION	A MAJOR challenge in protein design is to create stable scaffolds into which tailored functions can be introduced. Here we present the design, synthesis and characterization of a 61-residue all-beta protein: the minibody. We used a portion of the heavy chain variable domain of an immunoglobulin as a template, obtaining a molecule with a novel beta-sheet scaffold and two regions corresponding to the hypervariable loops H1 and H2. To exploit the potential for creating functional centres in the minibody, we engineered a metal-binding site into it. This site is formed by one histidine in H1 and two in H2. The protein is folded, compact and able to bind metal, thus representing the first designed beta-protein with a novel fold and a tailored function. By randomizing the sequence of the hypervariable loops, we are using the minibody scaffold to construct a conformationally constrained peptide library displayed on phage.	IST RIC BIOL MOLEC P ANGELETTI, DEPT GENET, VIA PONTINA KM 306, I-00040 POMEZIA, ITALY; IST RIC BIOL MOLEC P ANGELETTI, DEPT BIOCHEM, I-00040 POMEZIA, ITALY; IST RIC BIOL MOLEC P ANGELETTI, DEPT BIOCOMP, I-00040 POMEZIA, ITALY				Tramontano, anna/D-5378-2009	Tramontano, anna/0000-0002-5610-3338; Bianchi, Elisabetta/0000-0002-5302-6912				ARNOLD FH, 1991, SCIENCE, V252, P1796, DOI 10.1126/science.1648261; BIANCHI E, IN PRESS INT J PEPTI; BRUCCOLERI RE, 1988, NATURE, V335, P564, DOI 10.1038/335564a0; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; CHOTHIA C, 1987, J MOL BIOL, V196, P901, DOI 10.1016/0022-2836(87)90412-8; CREIGHTON TE, 1990, BIOCHEM J, V270, P1; FEDOROV AN, 1992, J MOL BIOL, V225, P927, DOI 10.1016/0022-2836(92)90092-X; GOTO Y, 1979, J BIOCHEM-TOKYO, V86, P1433, DOI 10.1093/oxfordjournals.jbchem.a132661; HECHT MH, 1990, SCIENCE, V249, P884, DOI 10.1126/science.2392678; HIGAKI JN, 1990, BIOCHEMISTRY-US, V29, P8582, DOI 10.1021/bi00489a012; HILL CP, 1990, SCIENCE, V249, P543, DOI 10.1126/science.2382133; IVERSON BL, 1990, SCIENCE, V249, P659, DOI 10.1126/science.2116666; KANNAN KK, 1975, P NATL ACAD SCI USA, V72, P51, DOI 10.1073/pnas.72.1.51; KUBIAK T, 1987, BIOCHEMISTRY-US, V26, P7849, DOI 10.1021/bi00398a047; LEVITT M, 1977, J MOL BIOL, V114, P181, DOI 10.1016/0022-2836(77)90207-8; LINDSKOG S, 1964, BIOCHIM BIOPHYS ACTA, V85, P462, DOI 10.1016/0926-6569(64)90310-4; MARTIN ACR, 1991, METHOD ENZYMOL, V203, P121; Pace C N, 1986, Methods Enzymol, V131, P266; REGAN L, 1990, BIOCHEMISTRY-US, V29, P10878, DOI 10.1021/bi00501a003; RICHARDSON JS, 1989, TRENDS BIOCHEM SCI, V14, P304, DOI 10.1016/0968-0004(89)90070-4; SARAGOVI HU, 1992, BIO-TECHNOL, V10, P773, DOI 10.1038/nbt0792-773; SEGAL DM, 1974, P NATL ACAD SCI USA, V71, P4298, DOI 10.1073/pnas.71.11.4298; Smith G P, 1991, Curr Opin Biotechnol, V2, P668, DOI 10.1016/0958-1669(91)90032-Z; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001	24	190	212	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 25	1993	362	6418					367	369		10.1038/362367a0	http://dx.doi.org/10.1038/362367a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KU176	8455724				2022-12-24	WOS:A1993KU17600069
J	TSAY, YF; SCHROEDER, JI; FELDMANN, KA; CRAWFORD, NM				TSAY, YF; SCHROEDER, JI; FELDMANN, KA; CRAWFORD, NM			THE HERBICIDE SENSITIVITY GENE CHL1 OF ARABIDOPSIS ENCODES A NITRATE-INDUCIBLE NITRATE TRANSPORTER	CELL			English	Article							MAIZE ROOTS; H+-ATPASE; THALIANA; REDUCTASE; SEEDLINGS; SEQUENCE; KINETICS; EXPRESSION; INDUCTION; MUTANTS	This paper reports the identification and functional expression of a gene that is involved in nitrate uptake in plants, a process essential for the assimilation of nitrate and the biological removal of nitrate from the soil solution. The CHL1 gene of Arabidopsis, which when mutated confers resistance to the herbicide chlorate and a decrease in nitrate uptake, was isolated and found to encode a protein with 12 putative membrane-spanning segments. Injection of CHL1 mRNA into Xenopus oocytes produces a nitrate- and pH-dependent membrane depolarization, inward current, and nitrate uptake. These data show that the CHL1 gene encodes an electrogenic nitrate transporter. CHL1 mRNA is found predominantly in roots and displays nitrate- and pH-dependent regulation.	UNIV CALIF SAN DIEGO, CTR MOLEC GENET, LA JOLLA, CA 92093 USA; UNIV ARIZONA, DEPT PLANT SCI, TUCSON, AZ 85721 USA	University of California System; University of California San Diego; University of Arizona	TSAY, YF (corresponding author), UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA.		Tsay, Yi-Fang/ABB-3662-2021; Geenen, Rinie/G-3408-2012	Tsay, Yi-Fang/0000-0003-4271-0687; 	NIGMS NIH HHS [GM40672] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040672, R29GM040672] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABERG B, 1947, ANN R AGR COLL SWEDE, V15, P37; ANDERSON JA, 1992, P NATL ACAD SCI USA, V89, P3736, DOI 10.1073/pnas.89.9.3736; BEVAN M, 1984, NUCLEIC ACIDS RES, V12, P8711, DOI 10.1093/nar/12.22.8711; BRAAKSMA FJ, 1982, THEOR APPL GENET, V64, P83, DOI 10.1007/BF00303657; CABOCHE M, 1990, TRENDS GENET, V6, P187, DOI 10.1016/0168-9525(90)90175-6; CAO YW, 1992, PLANT CELL, V4, P961, DOI 10.1105/tpc.4.8.961; CHASAN R, 1992, PLANT CELL, V4, P1180; Crawford N. M., 1992, Genetic engineering: principles and methods. Volume 14., P89; CRAWFORD NM, 1990, PLANT CELL, V2, P829; CRAWFORD NM, 1988, P NATL ACAD SCI USA, V85, P5006, DOI 10.1073/pnas.85.14.5006; DEWITT ND, 1991, PLANT J, V1, P121, DOI 10.1111/j.1365-313X.1991.00121.x; DODDEMA H, 1979, PHYSIOL PLANTARUM, V45, P332, DOI 10.1111/j.1399-3054.1979.tb02593.x; DODDEMA H, 1978, PHYSIOL PLANTARUM, V43, P343, DOI 10.1111/j.1399-3054.1978.tb01592.x; ELLEDGE SJ, 1991, P NATL ACAD SCI USA, V88, P1731, DOI 10.1073/pnas.88.5.1731; FELDMANN KA, 1989, SCIENCE, V243, P1351, DOI 10.1126/science.243.4896.1351; FELDMANN KA, 1991, PLANT J, V1, P71, DOI 10.1111/j.1365-313X.1991.00071.x; GLASS ADM, 1992, PLANT PHYSIOL, V99, P456, DOI 10.1104/pp.99.2.456; GOYAL SS, 1986, PLANT CELL ENVIRON, V9, P209, DOI 10.1111/1365-3040.ep11611654; HARPER JF, 1990, J BIOL CHEM, V265, P13601; HARPER JF, 1989, P NATL ACAD SCI USA, V86, P1234, DOI 10.1073/pnas.86.4.1234; Haynes R., 1986, MINERAL NITROGEN PLA; HOLE DJ, 1990, PLANT PHYSIOL, V93, P642, DOI 10.1104/pp.93.2.642; HUMBURG NE, 1909, HERBICIDE HDB WEED S; JACKSON WA, 1973, PLANT PHYSIOL, V51, P120, DOI 10.1104/pp.51.1.120; Kleinhofs A., 1990, BIOCH PLANTS, P89, DOI [DOI 10.1016/B978-0-08-092616-2.50009-7, 10.1016/B978-0-08-092616-2.50009-7]; KOORNNEEF M, 1983, J HERED, V74, P265, DOI 10.1093/oxfordjournals.jhered.a109781; KOPITO RR, 1985, NATURE, V316, P234, DOI 10.1038/316234a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LABRIE ST, 1992, MOL GEN GENET, V233, P169, DOI 10.1007/BF00587576; Larsson C. M., 1989, Molecular and genetic aspects of nitrate assimilation., P3; MACKOWN CT, 1988, PLANT PHYSIOL, V87, P162, DOI 10.1104/pp.87.1.162; MARKS MD, 1987, PLANT MOL BIOL, V10, P91, DOI 10.1007/BF00016147; MCCLURE PR, 1990, PLANT PHYSIOL, V93, P281, DOI 10.1104/pp.93.1.281; NEHER E, 1992, SCIENCE, V256, P498, DOI 10.1126/science.1373906; NOJI S, 1989, FEBS LETT, V252, P139, DOI 10.1016/0014-5793(89)80906-8; OOSTINDI.FJ, 1973, MUTAT RES, V19, P175, DOI 10.1016/0027-5107(73)90076-6; REDINBAUGH MG, 1991, PHYSIOL PLANTARUM, V82, P640, DOI 10.1111/j.1399-3054.1991.tb02958.x; Saier MH, 1991, CURR OPIN STRUC BIOL, V1, P362, DOI 10.1016/0959-440X(91)90034-Q; SAKMANN B, 1992, SCIENCE, V256, P503, DOI 10.1126/science.1373907; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUER N, 1990, EMBO J, V9, P3045, DOI 10.1002/j.1460-2075.1990.tb07500.x; SCHACHTMAN DP, 1992, IN PRESS SCIENCE; SCHOLTEN HJ, 1986, PHYSIOL PLANTARUM, V66, P265, DOI 10.1111/j.1399-3054.1986.tb02418.x; SCHROEDER JI, 1989, TRENDS BIOCHEM SCI, V14, P187, DOI 10.1016/0968-0004(89)90272-7; SENTENAC H, 1992, SCIENCE, V256, P663, DOI 10.1126/science.1585180; SHACKLOCK PS, 1992, NATURE, V358, P753, DOI 10.1038/358753a0; SHEPHERD GM, 1991, CELL, V67, P845, DOI 10.1016/0092-8674(91)90358-6; SIDDIQI MY, 1990, PLANT PHYSIOL, V93, P1426, DOI 10.1104/pp.93.4.1426; SIDDIQI MY, 1989, PLANT PHYSIOL, V90, P806, DOI 10.1104/pp.90.3.806; STIMMANN M W, 1990, California Agriculture, V44, P12; SUSSMAN MR, 1992, SCIENCE, V256, P619, DOI 10.1126/science.256.5057.619; TEYKER RH, 1988, PLANT PHYSIOL, V86, P778, DOI 10.1104/pp.86.3.778; THAYER JR, 1980, ANAL BIOCHEM, V102, P110, DOI 10.1016/0003-2697(80)90325-5; THOMAS RC, 1989, NATURE, V337, P601, DOI 10.1038/337601a0; ULLRICH WR, 1981, PLANT SCI LETT, V22, P211, DOI 10.1016/0304-4211(81)90233-9; UNKLES SE, 1991, P NATL ACAD SCI USA, V88, P204, DOI 10.1073/pnas.88.1.204; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536; WILKINSON JQ, 1991, PLANT CELL, V3, P461, DOI 10.1105/tpc.3.5.461; Wray J.L., 1989, MOL GENETIC ASPECTS; WRIGHT EM, 1991, J CLIN INVEST, V88, P1435, DOI 10.1172/JCI115451	60	572	626	8	131	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 12	1993	72	5					705	713		10.1016/0092-8674(93)90399-B	http://dx.doi.org/10.1016/0092-8674(93)90399-B			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KR436	8453665	Bronze			2022-12-24	WOS:A1993KR43600007
J	RICE, WG; SCHAEFFER, CA; HARTEN, B; VILLINGER, F; SOUTH, TL; SUMMERS, MF; HENDERSON, LE; BESS, JW; ARTHUR, LO; MCDOUGAL, JS; ORLOFF, SL; MENDELEYEV, J; KUN, E				RICE, WG; SCHAEFFER, CA; HARTEN, B; VILLINGER, F; SOUTH, TL; SUMMERS, MF; HENDERSON, LE; BESS, JW; ARTHUR, LO; MCDOUGAL, JS; ORLOFF, SL; MENDELEYEV, J; KUN, E			INHIBITION OF HIV-1 INFECTIVITY BY ZINC-EJECTING AROMATIC C-NITROSO COMPOUNDS	NATURE			English	Article							MURINE LEUKEMIA-VIRUS; STRANDED NUCLEIC-ACIDS; NUCLEOCAPSID PROTEIN; DIMER FORMATION; FINGER DOMAIN; METAL-IONS; VIRAL-RNA; BINDING; POLYMERASE; SEQUENCE	RETROVIRAL nucleocapsid and gag-precursor proteins from all known strains of retroviruses contain one or two copies of an invariant sequence, Cys-X2-Cys-X4-His-X4-Cys1,2, that is populated with zinc in mature particles3. Modification of cysteine or histidine residues results in defective packaging of genomic viral RNA and formation of non-infectious particles4-8, making these structures potentially attractive targets for antiviral therapy3,8. We recently reported that aromatic C-nitroso ligands of poly(ADP-ribose) polymerase preferentially destabilize one of the two (CYS-X2-CYS-X28-His-X2-Cys) zinc-fingers with concomitant loss of enzymatic activity9,10, coincidental with selective cytocidal action of the C-nitroso substituted ligands on cancer cells11. Based on the occurrence of (3Cys, 1His) zinc-binding sites in both retroviral nucleocapsid and gag proteins and in poly(ADP-ribose) polymerase12, we reasoned that the C-nitroso compounds may also have antiretroviral effects. We show here that two such compounds, 3-nitrosobenzamide and 6-nitroso-1,2-benzopyrone, inhibit infection of human immunodeficiency virus HIV-1 in human lymphocytes and also eject zinc from isolated HIV-1 nucleocapsid zinc fingers and from intact HIV-1 virions. Thus the design of zinc-ejecting agents that target retroviral zinc fingers represents a new approach to the chemotherapy of AIDS.	NCI,FREDERICK CANC RES & DEV CTR,PROGRAM RESOURCES INC DYNCORP,AIDS VACCINE PROGRAM,FREDERICK,MD 21702; EMORY UNIV,SCH MED,DEPT PATHOL & LAB MED,ATLANTA,GA 30322; CTR DIS CONTROL,NCID,DHA,IMMUNOL BRANCH,ATLANTA,GA 30333; OCTAMER INC,TIBURON,CA 94920; SAN FRANCISCO STATE UNIV,ROMBERG TIBURON CTR,ENVIRONM TOXICOL & CHEM LAB,TIBURON,CA 94920	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Emory University; Centers for Disease Control & Prevention - USA; California State University System; San Francisco State University	RICE, WG (corresponding author), NCI,FREDERICK CANC RES & DEV CTR,ANTIVIRAL DRUG MECHANISMS LAB,FREDERICK,MD 21702, USA.		Bess, Jr., Julian/B-5343-2012					ALDOVINI A, 1990, J VIROL, V64, P1920, DOI 10.1128/JVI.64.5.1920-1926.1990; BESS JW, 1992, J VIROL, V66, P840, DOI 10.1128/JVI.66.2.840-847.1992; BIETH E, 1990, NUCLEIC ACIDS RES, V18, P119, DOI 10.1093/nar/18.1.119; BUKI KG, 1991, FEBS LETT, V290, P181, DOI 10.1016/0014-5793(91)81255-7; CHANCE MR, 1992, P NATL ACAD SCI USA, V89, P10041, DOI 10.1073/pnas.89.21.10041; CHEN MJ, 1980, P NATL ACAD SCI USA, V77, P4961; COLE GA, 1991, BIOCHEM BIOPH RES CO, V180, P504, DOI 10.1016/S0006-291X(05)81093-9; CORNILLE F, 1990, INT J PEPT PROT RES, V36, P551; DUPRAZ P, 1990, J VIROL, V64, P4978, DOI 10.1128/JVI.64.10.4978-4987.1990; FITZGERALD DW, 1991, BIOCHEMISTRY-US, V30, P5195, DOI 10.1021/bi00235a012; GORELICK RJ, 1988, P NATL ACAD SCI USA, V85, P8420, DOI 10.1073/pnas.85.22.8420; GRADWOHL G, 1990, P NATL ACAD SCI USA, V87, P2990, DOI 10.1073/pnas.87.8.2990; GREEN LM, 1990, P NATL ACAD SCI USA, V87, P6403, DOI 10.1073/pnas.87.16.6403; GREEN LM, 1989, P NATL ACAD SCI USA, V86, P4047, DOI 10.1073/pnas.86.11.4047; HENDERSON LE, 1981, J BIOL CHEM, V256, P8400; KARPEL RL, 1987, J BIOL CHEM, V262, P4961; KUN E, 1836, Patent No. 780809; LEVER A, 1989, J VIROL, V63, P4085, DOI 10.1128/JVI.63.9.4085-4087.1989; MCDOUGAL JS, 1985, J IMMUNOL METHODS, V76, P171, DOI 10.1016/0022-1759(85)90489-2; MERIC C, 1986, J VIROL, V60, P450; MERIC C, 1984, J MOL BIOL, V173, P531, DOI 10.1016/0022-2836(84)90396-6; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MYERS G, 1991, HUMAN RETROVIRUSES A; PRATS AC, 1991, NUCLEIC ACIDS RES, V19, P3533, DOI 10.1093/nar/19.13.3533; PRATS AC, 1988, EMBO J, V7, P1777, DOI 10.1002/j.1460-2075.1988.tb03008.x; RICE WG, 1992, P NATL ACAD SCI USA, V89, P7703, DOI 10.1073/pnas.89.16.7703; SMITH BJ, 1979, NUCLEIC ACIDS RES, V7, P2055; SOUTH TL, 1990, BIOCHEMISTRY-US, V29, P7786, DOI 10.1021/bi00486a002; SOUTH TL, 1991, BIOCHEMISTRY-US, V30, P6342, DOI 10.1021/bi00239a036; SOUTH TL, 1993, PROTEIN SCI, V2, P3; SOUTH TL, 1989, J AM CHEM SOC, V111, P295; SUMMERS MF, 1990, BIOCHEMISTRY-US, V29, P329, DOI 10.1021/bi00454a005; SUMMERS MF, 1992, PROTEIN SCI, V1, P563, DOI 10.1002/pro.5560010502; SUMMERS MF, 1991, J CELL BIOCHEM, V45, P41, DOI 10.1002/jcb.240450110	34	206	222	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 4	1993	361	6411					473	475		10.1038/361473a0	http://dx.doi.org/10.1038/361473a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KK713	8429889				2022-12-24	WOS:A1993KK71300068
J	MEIEREWERT, S; MAIER, E; AHMADI, A; CURTIS, J; LEHRACH, H				MEIEREWERT, S; MAIER, E; AHMADI, A; CURTIS, J; LEHRACH, H			AN AUTOMATED APPROACH TO GENERATING EXPRESSED SEQUENCE CATALOGS	NATURE			English	Article							DNA; HYBRIDIZATION				MEIEREWERT, S (corresponding author), IMPERIAL CANC RES FUND,GENOME ANAL LAB,44 LINCOLNS INN FIELDS,POB 123,LONDON WC2A 3PX,ENGLAND.							ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; BELLANNECHANTELOT C, 1992, CELL, V70, P1059, DOI 10.1016/0092-8674(92)90254-A; DRMANAC R, 1989, GENOMICS, V4, P114; DRMANAC R, 1990, ELECTROPHORESIS SUPE, P60; ENDO I, 1991, NATURE, V352, P89, DOI 10.1038/352089a0; HOHEISEL JD, IN PRESS CELL; JONES P, 1992, NUCLEIC ACIDS RES, V20, P4599, DOI 10.1093/nar/20.17.4599; KAHN AS, 1992, NAT GENET, V2, P180; LEHRACH H, 1990, GENOME ANAL GENETIC, P36; MAIER E, 1992, NAT GENET, V1, P273, DOI 10.1038/ng0792-273; OKUBO K, 1992, NAT GENET, V2, P173, DOI 10.1038/ng1192-173; STREZOSKA Z, 1991, P NATL ACAD SCI USA, V88, P10089, DOI 10.1073/pnas.88.22.10089; UBER DC, 1991, BIOTECHNIQUES, V5, P642	14	96	106	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 28	1993	361	6410					375	376		10.1038/361375a0	http://dx.doi.org/10.1038/361375a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KJ590	8426656				2022-12-24	WOS:A1993KJ59000068
J	RAO, DS; SHIH, MS; MOHINI, R				RAO, DS; SHIH, MS; MOHINI, R			EFFECT OF SERUM PARATHYROID-HORMONE AND BONE-MARROW FIBROSIS ON THE RESPONSE TO ERYTHROPOIETIN IN UREMIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RECOMBINANT-HUMAN-ERYTHROPOIETIN; CHRONIC RENAL-FAILURE; SECONDARY HYPER-PARATHYROIDISM; PRIMARY HYPERPARATHYROIDISM; ILIAC BONE; ANEMIA; ALUMINUM; OSTEODYSTROPHY; THERAPY; DISEASE	Background and Methods. Anemia is common in patients with chronic renal insufficiency and secondary hyperparathyroidism. Erythropoietin therapy is effective, but the dose required varies greatly. One possible determinant of the efficacy of erythropoietin therapy is the extent of marrow fibrosis caused by hyperparathyroidism. We examined the relation between the erythropoietic response to erythropoietin and hyperparathyroidism in a cross-sectional study of 18 patients undergoing hemodialysis who had received erythropoietin therapy for one to three years. In 7 patients (the poor-response group) the dose of intravenous erythropoietin needed to maintain a mean (+/-SD) target hematocrit of 35+/-3 percent was >100 units per kilogram of body weight three times a week, and in 11 patients (the good-response group) it was less-than-or-equal-to 100 units per kilogram. In all patients, indexes of the adequacy of dialysis and the extent of hyperparathyroidism and aluminum toxicity were determined monthly, and bone histomorphometry was performed. Results. The mean (+/-SD) dose of erythropoietin required to maintain the target hematocrit was 174+/-33 units per kilogram three times a week in the poor-response group and 56+/-18 units per kilogram in the good-response group. The mean ages, duration and adequacy of dialysis, increment in hematocrit, iron requirements, and serum concentrations of calcium, phosphate, and aluminum were similar in the two groups. The percentages of osteoid volume and surface, the osteoid thickness, and the stainable aluminum content of bone were similar in the two groups. In contrast, the mean serum parathyroid hormone concentration, the percentages of osteoclastic and eroded bone surfaces, and the degree of marrow fibrosis were greater in the poor-response group than in the good-response group (P = 0.03, P = 0.04, P = 0.009, and P = 0.009, respectively). Conclusions. In patients with uremia, the dose of erythropoietin needed to achieve an adequate hematocrit response may depend on the severity of secondary hyperparathyroidism and the extent of bone marrow fibrosis.	HENRY FORD HOSP, DEPT MED, DIV NEPHROL, DETROIT, MI 48202 USA	Henry Ford Health System; Henry Ford Hospital	RAO, DS (corresponding author), HENRY FORD HOSP, DEPT MED, DIV BONE & MINERAL METAB, 2799 W GRAND BLVD, DETROIT, MI 48202 USA.		Rao, Sudhaker/ABG-8204-2021					Albright F, 1934, J AMER MED ASSOC, V102, P1276, DOI 10.1001/jama.1934.02750160010003; ANDRESS DL, 1986, J BONE MINER RES, V1, P391; BARBOUR GL, 1979, ARCH INTERN MED, V139, P889, DOI 10.1001/archinte.139.8.889; BIA MJ, 1989, KIDNEY INT, V36, P852, DOI 10.1038/ki.1989.271; BOXER M, 1977, ARCH INTERN MED, V137, P588, DOI 10.1001/archinte.137.5.588; CHAN YL, 1985, MEDICINE, V64, P296, DOI 10.1097/00005792-198509000-00002; DELWICHE F, 1983, J LAB CLIN MED, V102, P613; ERSLEV AJ, 1991, NEW ENGL J MED, V324, P1339, DOI 10.1056/NEJM199105093241907; ESCHBACH JW, 1989, ANN INTERN MED, V111, P992, DOI 10.7326/0003-4819-111-12-992; FALKO JM, 1976, ARCH INTERN MED, V136, P887, DOI 10.1001/archinte.136.8.887; MALLETTE LE, 1974, MEDICINE, V53, P127, DOI 10.1097/00005792-197403000-00002; MALONEY NA, 1982, J LAB CLIN MED, V99, P206; MCGONIGLE RJS, 1984, J LAB CLIN MED, V104, P1016; MEYTES D, 1981, J CLIN INVEST, V67, P1263, DOI 10.1172/JCI110154; MURPHY G, 1989, J AM SOC NEPHROL, pA262; NISSENSON AR, 1991, ANN INTERN MED, V114, P402, DOI 10.7326/0003-4819-114-5-402; PARFITT AM, 1985, J CLIN INVEST, V76, P2403, DOI 10.1172/JCI112253; RAO DS, 1991, VITAMIN D, P881; Rao DS., 1983, BONE HISTOMORPHOMETR, P3; ROGER SD, 1991, NEPHRON, V58, P33, DOI 10.1159/000186374; SCHOBER HC, 1991, CONTRIB NEPHROL, V88, P127; SHASHA SM, 1978, ISRAEL J MED SCI, V14, P328; STIVELMAN JC, 1989, SEMIN NEPHROL, V9, P8; URENA P, 1991, NEPHRON, V59, P384, DOI 10.1159/000186596; VANWYCK DB, 1989, KIDNEY INT, V35, P712, DOI 10.1038/ki.1989.43; WEINBERG SG, 1977, AM J MED, V63, P755, DOI 10.1016/0002-9343(77)90162-0; ZINGRAFF J, 1978, ARCH INTERN MED, V138, P1650, DOI 10.1001/archinte.138.11.1650	27	317	330	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 21	1993	328	3					171	175		10.1056/NEJM199301213280304	http://dx.doi.org/10.1056/NEJM199301213280304			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG625	8417383				2022-12-24	WOS:A1993KG62500004
J	NIGHTINGALE, SL				NIGHTINGALE, SL			INSTRUCTIONAL VIDEOS ON FOOD SAFETY IN NURSING-HOMES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1991, JAMA-J AM MED ASSOC, V266, P2105	1	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 20	1993	269	3					328	328						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG381	8418328				2022-12-24	WOS:A1993KG38100006
J	DURAND, ML; CALDERWOOD, SB; WEBER, DJ; MILLER, SI; SOUTHWICK, FS; CAVINESS, VS; SWARTZ, MN				DURAND, ML; CALDERWOOD, SB; WEBER, DJ; MILLER, SI; SOUTHWICK, FS; CAVINESS, VS; SWARTZ, MN			ACUTE BACTERIAL-MENINGITIS IN ADULTS - A REVIEW OF 493 EPISODES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SEVERE CHILDHOOD MENINGITIS; LUMBAR PUNCTURE; COMPUTED-TOMOGRAPHY; PURULENT-MENINGITIS; UNITED-STATES; COUNTY; SURVEILLANCE; PROGNOSIS; LISTERIA; CITY	Background and Methods. To characterize acute bacterial meningitis in adults, we reviewed the charts of all persons 16 years of age or older in whom acute bacterial meningitis was diagnosed at Massachusetts General Hospital from 1962 through 1988. We included patients who were admitted after initial treatment at other hospitals. Results. During the 27-year period, 445 adults were treated for 493 episodes of acute bacterial meningitis, of which 197 (40 percent) were nosocomial. Gram-negative bacilli (other than Haemophilus influenzae) caused 33 percent of the nosocomial episodes but only 3 percent of the community-acquired episodes. In the 296 episodes of community-acquired meningitis, the most common pathogens were Streptococcus pneumoniae (37 percent), Neisseria meningitidis (13 percent), and Listeria monocytogenes (10 percent); these organisms accounted for only 8 percent of the nosocomial episodes. Only 19 of the 493 episodes of meningitis (4 percent) were due to H. influenzae. Nine percent of all patients had recurrent meningitis; many had a cerebrospinal fluid leak. Seizures occurred in 23 percent of patients with community-acquired meningitis, and 28 percent had focal central nervous system findings. Risk factors for death among those with single episodes of community-acquired meningitis included older age (greater-than-or-equal-to 60 years), obtunded mental state on admission, and seizures within the first 24 hours. Among those with single episodes, the in-hospital mortality rate was 25 percent for community-acquired and 35 percent for nosocomial meningitis. The overall case fatality rate was 25 percent and did not vary significantly over the 27 years. Conclusions. In our large urban hospital, a major proportion of cases of acute bacterial meningitis in adults were nosocomial. Recurrent episodes of meningitis were frequent. The overall mortality rate remained high.	MASSACHUSETTS GEN HOSP, DEPT NEUROL, BOSTON, MA 02114 USA	Harvard University; Massachusetts General Hospital	DURAND, ML (corresponding author), MASSACHUSETTS GEN HOSP, FAC INFECT DIS, FRUIT ST, BOSTON, MA 02114 USA.							ADDY DP, 1987, ARCH DIS CHILD, V62, P873, DOI 10.1136/adc.62.9.873; ADDY DP, 1987, ARCH DIS CHILD, V62, P1293; BODINO J, 1982, AM J DIS CHILD, V136, P495, DOI 10.1001/archpedi.1982.03970420019003; BOHR V, 1983, J INFECTION, V7, P21, DOI 10.1016/S0163-4453(83)90894-0; BOHR V, 1983, J INFECTION, V7, P102, DOI 10.1016/S0163-4453(83)90443-7; BOHR V, 1983, J INFECTION, V7, P193, DOI 10.1016/S0163-4453(83)96980-3; CABRAL DA, 1987, J PEDIATR-US, V111, P201, DOI 10.1016/S0022-3476(87)80067-7; CARPENTER R R, 1962, Am J Med, V33, P262, DOI 10.1016/0002-9343(62)90024-4; CHERUBIN CE, 1981, AM J MED, V71, P199, DOI 10.1016/0002-9343(81)90106-6; DODGE PR, 1965, NEW ENGL J MED, V272, P954, DOI 10.1056/NEJM196505062721806; DODGE PR, 1965, NEW ENGL J MED, V272, P1003, DOI 10.1056/NEJM196505132721906; FEIGIN RD, 1987, TXB PEDIATRIC INFECT, V1, P439; FINLAND M, 1977, J INFECT DIS, V136, P400, DOI 10.1093/infdis/136.3.400; FRASER DW, 1973, J INFECT DIS, V128, P300, DOI 10.1093/infdis/128.3.300; FRASER DW, 1974, AM J EPIDEMIOL, V100, P29, DOI 10.1093/oxfordjournals.aje.a112005; FRASER DW, 1973, J INFECT DIS, V127, P271, DOI 10.1093/infdis/127.3.271; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; GEISELER PJ, 1980, REV INFECT DIS, V2, P725; Genton B, 1988, Rev Med Suisse Romande, V108, P795; GORSE GJ, 1984, ARCH INTERN MED, V144, P1603, DOI 10.1001/archinte.144.8.1603; GORSE GJ, 1985, ARCH INTERN MED, V145, P957, DOI 10.1001/archinte.1985.00360050227058; HAND WL, 1970, ANN INTERN MED, V73, P862, DOI 10.7326/0003-4819-73-5-862; HARPER JR, 1985, BRIT MED J, V291, P651, DOI 10.1136/bmj.291.6496.651; Harris L F, 1988, Ala Med, V58, P20; HO JL, 1986, ARCH INTERN MED, V146, P520, DOI 10.1001/archinte.146.3.520; HODGES GR, 1975, AM J MED SCI, V270, P427, DOI 10.1097/00000441-197511000-00003; HORWITZ SJ, 1980, ANN NEUROL, V7, P524, DOI 10.1002/ana.410070605; KAPLAN SL, 1985, BACTERIAL MENINGITIS, V3, P83; KARANDANIS D, 1976, SOUTHERN MED J, V69, P449, DOI 10.1097/00007611-197604000-00021; KLINE MW, 1989, PEDIATR INFECT DIS J, V8, P630, DOI 10.1097/00006454-198909000-00013; KLINE MW, 1988, PEDIATR INFECT DIS J, V7, P855; LEVIN S, 1972, AM J MED SCI, V264, P319, DOI 10.1097/00000441-197210000-00010; LORBER J, 1980, LANCET, V1, P785; Magnussen C R, 1980, N Y State J Med, V80, P901; MCGEE ZA, 1990, PRINCIPLES PRACTICE, P741; QUAGLIARELLO V, 1992, NEW ENGL J MED, V327, P864, DOI 10.1056/NEJM199209173271208; RISCHBIETH R. H., 1960, Medical Journal of Australia, V1, P578; SCHLECH WF, 1985, JAMA-J AM MED ASSOC, V253, P1749, DOI 10.1001/jama.253.12.1749; SILBERSTEIN P, 1986, MED J AUSTRALIA, V144, P110, DOI 10.5694/j.1326-5377.1986.tb113682.x; SLACK J, 1980, LANCET, V2, P474; SNYDER RD, 1984, NEUROPEDIATRICS, V15, P136, DOI 10.1055/s-2008-1052356; SNYDER RD, 1981, J NEUROL NEUROSUR PS, V44, P581, DOI 10.1136/jnnp.44.7.581; SPENDER Q, 1985, BRIT MED J, V291, P898, DOI 10.1136/bmj.291.6499.898; STEPHENSON JBP, 1985, BRIT MED J, V291, P1123, DOI 10.1136/bmj.291.6502.1123-b; STOVRING J, 1980, J PEDIATR-US, V96, P820, DOI 10.1016/S0022-3476(80)80549-X; SWARTZ MN, 1965, NEW ENGL J MED, V272, P779, DOI [10.1056/NEJM196504152721506, 10.1056/NEJM196504222721607]; SWARTZ MN, 1965, NEW ENGL J MED, V272, P725, DOI 10.1056/NEJM196504082721406; TALAN DA, 1989, ANN EMERG MED, V18, P856, DOI 10.1016/S0196-0644(89)80213-6; TUNKEL AR, 1990, ANN INTERN MED, V112, P610, DOI 10.7326/0003-4819-112-8-610; WENGER JD, 1990, J INFECT DIS, V162, P1316, DOI 10.1093/infdis/162.6.1316; WILLIAMS CP, 1964, PEDIATRICS, V34, P220; 1992, MED LETT DRUGS THER, V34, P49	52	955	985	0	37	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 7	1993	328	1					21	28		10.1056/NEJM199301073280104	http://dx.doi.org/10.1056/NEJM199301073280104			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF507	8416268	Green Published			2022-12-24	WOS:A1993KF50700004
J	ORHOLM, M; ISELIUS, L; SORENSEN, TIA; MUNKHOLM, P; LANGHOLZ, E; BINDER, V				ORHOLM, M; ISELIUS, L; SORENSEN, TIA; MUNKHOLM, P; LANGHOLZ, E; BINDER, V			INVESTIGATION OF INHERITANCE OF CHRONIC INFLAMMATORY BOWEL DISEASES BY COMPLEX SEGREGATION ANALYSIS	BRITISH MEDICAL JOURNAL			English	Article							REGIONAL PATIENT GROUP; ULCERATIVE-COLITIS; CROHNS-DISEASE; PREVALENCE; COPENHAGEN; COUNTY; FAMILY; RELATIVES; PROGNOSIS	Objective-To investigate the mode of inheritance of ulcerative colitis and Crohn's disease by complex segregation analysis. Design-Cross sectional population based survey of familial occurrence of chronic inflammatory bowel disease. Setting-Population of the Copenhagen county in 1987. Subjects-662 patients in whom inflammatory bowel disease had been diagnosed before 1979, of whom 637 (96%) provided adequate information. Of 504 patients with ulcerative colitis, 54 had 77 relatives with ulcerative colitis and of 133 patients with Crohn's disease, five had seven relatives with Crohn's disease. Main outcome measures-Patterns of segregation of either disease as assessed by complex segregation analysis performed with the computer program POINTER. Results-The analysis suggested that a major dominant gene with a penetrance of 0.20-0.26 is present in 9-13% of adult patients with ulcerative colitis. The analysis did not allow for other components in the familial aggregation. For Crohn's disease the best fitting model included a major recessive gene with complete penetrance, for which 7% of the patients are homozygous. However, this model was not significantly different from a multifactorial model. Conclusions-The segregation pattern indicates that a major dominant gene has a role in ulcerative colitis, and suggests that a major recessive gene has a role in Crohn's disease.	UNIV COPENHAGEN,HERLEV HOSP,DEPT MED GASTROENTEROL C,DK-2730 HERLEV,DENMARK; KAROLINSKA HOSP,DEPT SURG,S-10401 STOCKHOLM 60,SWEDEN; KOMMUNE HOSP COPENHAGEN,COPENHAGEN HLTH SERV,INST PREVENT MED,COPENHAGEN,DENMARK	University of Copenhagen; Herlev & Gentofte Hospital; Karolinska Institutet; Karolinska University Hospital			Munkholm, Pia/ABD-2432-2021					BINDER V, 1985, GUT, V26, P146, DOI 10.1136/gut.26.2.146; BINDER V, 1982, GASTROENTEROLOGY, V83, P563; FARMER RG, 1980, CLIN GASTROENTEROL, V9, P271; HENDRIKSEN C, 1985, GUT, V26, P158, DOI 10.1136/gut.26.2.158; KHOURY MJ, 1988, AM J EPIDEMIOL, V127, P674, DOI 10.1093/oxfordjournals.aje.a114842; KUSTER W, 1989, AM J MED GENET, V32, P105, DOI 10.1002/ajmg.1320320122; LALOUEL JM, 1981, HUM HERED, V31, P312, DOI 10.1159/000153231; LANGHOLZ E, 1991, SCAND J GASTROENTERO, V26, P1247, DOI 10.3109/00365529108998621; LASHNER BA, 1986, GASTROENTEROLOGY, V91, P1396, DOI 10.1016/0016-5085(86)90193-9; MCCONNELL RB, 1986, GENETICS EPIDEMIOLOG, V11, P1; MCCONNELL RB, 1980, DEV DIGESTIVE DISEAS, P129; MONSEN U, 1989, CLIN GENET, V36, P411; MONSEN U, 1991, SCAND J GASTROENTERO, V26, P302, DOI 10.3109/00365529109025046; MONSEN U, 1987, SCAND J GASTROENTERO, V22, P214, DOI 10.3109/00365528708991882; MONSEN U, 1990, THESIS CAROLINSKA ME; MUNKHOLM P, 1992, SCAND J GASTROENTERO, V27, P609, DOI 10.3109/00365529209000127; ORHOLM M, 1991, NEW ENGL J MED, V324, P84, DOI 10.1056/NEJM199101103240203; TYSK C, 1988, GUT, V29, P990, DOI 10.1136/gut.29.7.990	18	99	101	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 2	1993	306	6869					20	24		10.1136/bmj.306.6869.20	http://dx.doi.org/10.1136/bmj.306.6869.20			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KE984	8435571	Green Published, Bronze			2022-12-24	WOS:A1993KE98400020
J	KEAVENEY, M; BERKENSTAM, A; FEIGENBUTZ, M; VRIEND, G; STUNNENBERG, HG				KEAVENEY, M; BERKENSTAM, A; FEIGENBUTZ, M; VRIEND, G; STUNNENBERG, HG			RESIDUES IN THE TATA-BINDING PROTEIN REQUIRED TO MEDIATE A TRANSCRIPTIONAL RESPONSE TO RETINOIC ACID IN EC CELLS	NATURE			English	Article							ACTIVATION DOMAIN; STEM-CELLS; GENE; E1A; COACTIVATORS; SPECIFICITY; PROMOTER; RECEPTOR; INVIVO; YEAST	THE eukaryotic TATA-binding protein TBP, which is required for transcription by RNA polymerase II, is tightly associated with a particular set of factors in the TFIID complex1-5, and as such provides a target for transcriptional regulation exerted by upstream factors. An embryonic carcinoma (EC) cell-specific activity like that of the viral factor E1A has been implicated in the mediation of transactivation from the retinoic acid receptor to human TBP, but yeast TBP cannot perform this function6. Using TBP mutants with an altered TATA-box-binding specificity7, we show here that yeast TBP can mediate transcriptional activation in mammalian cells and that its inability to convey retinoic acid-dependent transactivation in EC cells is due to specific residues in its core region. These residues preclude a functional association with the cellular E1A-like activity. TBP is thus a target for retinoic acid-dependent transactivation in EC cells by providing a surface for interaction with the EC cell-specific E1A-like activity.	EMBL,GENE EXPRESS PROGRAM,MEYERHOFSTR 1,W-6900 HEIDELBERG,GERMANY; EMBL,BIOL STRUCT PROGRAM,W-6900 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL); European Molecular Biology Laboratory (EMBL)			Vriend, G./H-8112-2014; Vriend, Gert/D-6730-2011; Berkenstam, Anders/E-7136-2012; Stunnenberg, Hendrik G./D-6875-2012	Stunnenberg, Hendrik G./0000-0002-0066-1576				BERKENSTAM A, 1992, CELL, V69, P401, DOI 10.1016/0092-8674(92)90443-G; BROU C, 1993, EMBO J, V12, P489, DOI 10.1002/j.1460-2075.1993.tb05681.x; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; EISENMANN DM, 1992, GENE DEV, V6, P1319, DOI 10.1101/gad.6.7.1319; GILL G, 1991, CELL, V65, P333, DOI 10.1016/0092-8674(91)90166-V; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HAHN S, 1989, CELL, V58, P1173, DOI 10.1016/0092-8674(89)90515-1; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; IMPERIALE MJ, 1984, MOL CELL BIOL, V4, P867, DOI 10.1128/MCB.4.5.867; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; INOSTROZA JA, 1992, CELL, V70, P477; LATHANGUE NB, 1987, CELL, V49, P507, DOI 10.1016/0092-8674(87)90453-3; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; PRATT MAC, 1990, MOL CELL BIOL, V10, P6445, DOI 10.1128/MCB.10.12.6445; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SCHOLER HR, 1991, CELL, V66, P291, DOI 10.1016/0092-8674(91)90619-A; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; STRUBIN M, 1992, CELL, V68, P721, DOI 10.1016/0092-8674(92)90147-5; STUNNENBERG HG, 1993, BIOESSAYS, V15, P309, DOI 10.1002/bies.950150504; TAKADA R, 1992, P NATL ACAD SCI USA, V89, P11809, DOI 10.1073/pnas.89.24.11809; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; WHITE J, 1992, EMBO J, V11, P2229, DOI 10.1002/j.1460-2075.1992.tb05282.x; ZAWEL L, 1992, Current Opinion in Cell Biology, V4, P488, DOI 10.1016/0955-0674(92)90016-6; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	31	59	59	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 7	1993	365	6446					562	566		10.1038/365562a0	http://dx.doi.org/10.1038/365562a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MA661	8413615				2022-12-24	WOS:A1993MA66100060
J	DURANT, RH; RICKERT, VI; ASHWORTH, CS; NEWMAN, C; SLAVENS, G				DURANT, RH; RICKERT, VI; ASHWORTH, CS; NEWMAN, C; SLAVENS, G			USE OF MULTIPLE-DRUGS AMONG ADOLESCENTS WHO USE ANABOLIC-STEROIDS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HIGH-SCHOOL-STUDENTS; SEXUAL-BEHAVIOR; FEMALE ADOLESCENTS; KNOWLEDGE; PREVALENCE; PREDICTORS; EDUCATION	Background. Because adolescent users of anabolic steroids are concerned with increasing muscle size and strength, they may be unique among substance users and unlikely to use other drugs. Alternatively, if the factors that cause the use of anabolic steroids are similar to those associated with the use of other substances, adolescents who use anabolic steroids would be expected to report use of other drugs as well. Methods. We administered a questionnaire based on the 1989 Secondary School Health Risk Survey and the 1990 Youth Risk Behavior Survey of the Centers for Disease Control and Prevention to 1881 students enrolled in compulsory health-science classes (mean [+/-SD] age, 14.9 +/- 1.0 years) in the Richmond County, Georgia, school system. Results. A higher percentage of boys (6.5 percent) than girls (1.9 percent, P less-than-or-equal-to 0.001) reported using anabolic steroids without a doctor's prescription. Among ninth-grade students, 5.4 percent of boys and 1.5 percent of girls reported using anabolic steroids (P less-than-or-equal-to 0.001). Among users of anabolic steroids, 25 percent reported sharing needles to inject drugs. The frequency of anabolic-steroid use was significantly (P<0.001) associated with the frequency of use in the previous 30 days of cocaine (r = 0.44), injectable drugs, alcohol (r = 0.23), marijuana (r = 0.42), cigarettes (r = 0.25), and smokeless tobacco (r = 0.40). On the basis of multiple regression analysis, the use of marijuana, shared needles, smokeless tobacco, and cocaine accounted for 33 percent of the variation in anabolic-steroid use among the ninth-grade students. Conclusions. In our study, adolescent users of anabolic steroids were likely to use other drugs as well, and many were sharing needles.	MED COLL GEORGIA, DEPT INTERNAL MED, AUGUSTA, GA 30912 USA; UNIV ALABAMA, DEPT PEDIAT, BIRMINGHAM, AL 35294 USA; UNIV ARKANSAS MED SCI HOSP, ARKANSAS CHILDRENS HOSP, DEPT PEDIAT, LITTLE ROCK, AR 72205 USA	University System of Georgia; Augusta University; University of Alabama System; University of Alabama Birmingham; Arkansas Children's Hospital; University of Arkansas System; University of Arkansas Medical Sciences	DURANT, RH (corresponding author), MED COLL GEORGIA, DEPT PEDIAT, GEN PEDIAT & ADOLESCENT MED SECT, CE-112, AUGUSTA, GA 30912 USA.							ANDERSON JE, 1990, FAM PLANN PERSPECT, V22, P252, DOI 10.2307/2135681; [Anonymous], 1984, BEHAV HLTH HDB HLTH; ASHWORTH CS, 1992, J ADOLESCENT HEALTH, V13, P582, DOI 10.1016/1054-139X(92)90372-I; BOTVIN GJ, 1989, J DEV BEHAV PEDIATR, V10, P181; BUCKLEY W E, 1988, Journal of the American Medical Association, V260, P3441, DOI 10.1001/jama.260.23.3441; BURKETT LN, 1984, PHYSICIAN SPORTSMED, V12, P69; DICLEMENTE RJ, 1991, J ADOLESCENT HEALTH, V12, P385, DOI 10.1016/0197-0070(91)90052-N; DURANT RH, 1992, J ADOLESCENT HEALTH, V13, P499, DOI 10.1016/1054-139X(92)90014-3; DURANT RH, 1992, J SCHOOL HEALTH, V62, P59, DOI 10.1111/j.1746-1561.1992.tb07886.x; DURANT RH, 1990, PEDIATRICS, V85, P1051; GIANNINI AJ, 1991, CLIN PEDIATR, V30, P538, DOI 10.1177/000992289103000903; GOLDBERG L, 1990, NEW ENGL J MED, V322, P775; GOLDBERG L, 1991, PEDIATRICS, V87, P283; GOLDBERG L, 1990, J ADOLESCENT HEALTH, V11, P210, DOI 10.1016/0197-0070(90)90350-B; HALLAGAN JB, 1990, NEW ENGL J MED, V322, P776; HALLAGAN JB, 1989, NEW ENGL J MED, V321, P1042, DOI 10.1056/NEJM198910123211510; JOHNSON MD, 1990, PEDIATR CLIN N AM, V37, P1111; JOHNSON MD, 1989, PEDIATRICS, V83, P921; KANN L, 1989, J SCHOOL HEALTH, V59, P55, DOI 10.1111/j.1746-1561.1989.tb05392.x; KASHKIN KB, 1989, JAMA-J AM MED ASSOC, V262, P3166, DOI 10.1001/jama.262.22.3166; KOLBE LJ, 1990, HLTH ED, V21, P44; KOMOROSKI EM, 1992, AM J DIS CHILD, V146, P823, DOI 10.1001/archpedi.1992.02160190055019; NEMECHEK PM, 1991, NEW ENGL J MED, V325, P357; NEWMAN C, IN PRESS J AIDS ED; PENDERGRAST RA, 1992, J ADOLESCENT HEALTH, V13, P133, DOI 10.1016/1054-139X(92)90080-U; POPE HG, 1988, PHYSICIAN SPORTSMED, V16, P75, DOI 10.1080/00913847.1988.11709554; RICKERT VI, 1990, MED CLIN N AM, V74, P1135, DOI 10.1016/S0025-7125(16)30507-7; SKLAREK HM, 1984, NEW ENGL J MED, V311, P1701; TAYLOR W N, 1987, Annals of Sports Medicine, V3, P155; TERNEY R, 1990, AM J DIS CHILD, V144, P99, DOI 10.1001/archpedi.1990.02150250111046; WINDSOR R, 1989, MED SCI SPORT EXER, V21, P494; YESALIS CE, 1989, J DRUG EDUC, V19, P103, DOI 10.2190/NG9C-0WEA-8AU8-GUA4; 1989, GAOHRD89109 PUBL; 1986, SPSSX USERS GUIDE, P663	34	197	199	1	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 1	1993	328	13					922	926		10.1056/NEJM199304013281304	http://dx.doi.org/10.1056/NEJM199304013281304			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KU177	8446139	Bronze			2022-12-24	WOS:A1993KU17700004
J	HONIG, PK; WORTHAM, DC; ZAMANI, K; CONNER, DP; MULLIN, JC; CANTILENA, LR				HONIG, PK; WORTHAM, DC; ZAMANI, K; CONNER, DP; MULLIN, JC; CANTILENA, LR			TERFENADINE-KETOCONAZOLE INTERACTION - PHARMACOKINETIC AND ELECTROCARDIOGRAPHIC CONSEQUENCES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ERYTHROMYCIN; METABOLITE	Objective.-To examine prospectively the effects of ketoconazole on the pharmacokinetics and electrocardiographic repolarization pharmacodynamics (corrected QT intervals) of terfenadine in men and women. Design.-Prospective cohort study with each subject serving as his or her own control. Setting.-Outpatient cardiology clinic and inpatient telemetry unit for monitoring period. Participants.-Six healthy volunteers (four men and two women, aged 24 to 35 years) not taking any prescription or over-the-counter medications. Intervention.-After achieving a steady state while taking terfenadine (60 mg every 12 hours for 7 days), daily concomitant oral ketoconazole (200 mg every 12 hours) was added to the subjects' regimen. Pharmacokinetic profiles were obtained while subjects were taking terfenadine alone and after the addition of ketoconazole. Electrocardiograms were obtained at baseline, after 1 week of taking terfenadine alone, and at the time of the second pharmacokinetic profile after the addition of ketoconazole to the regimen. Main Outcome Measures.-Terfenadine and its acid metabolite serum concentrations and corrected QT intervals. Results.-All subjects had detectable levels of unmetabolized terfenadine after the addition of ketoconazole, which was associated with QT prolongation. Only two of the six subjects could complete the entire course of ketoconazole coadministration. Four subjects received a shortened duration of ketoconazole therapy because of significant electrocardiographic repolarization abnormalities. There was a significant change in the area under the curve of the acid metabolite of terfenadine after the addition of ketoconazole administration. Conclusions.-Ketoconazole alters the metabolism of terfenadine in normal men and women and results in the accumulation of unmetabolized parent drug, which is associated with significant prolongation of the corrected QT interval. This drug combination should be avoided.	UNIFORMED SERV UNIV HLTH SCI,DEPT PHARMACOL,DIV CLIN PHARMACOL,4301 JONES BRIDGE RD,BETHESDA,MD 20814; WALTER REED ARMY MED CTR,DIV CARDIOL,WASHINGTON,DC 20307; US FDA,ROCKVILLE,MD 20857	Uniformed Services University of the Health Sciences - USA; United States Department of Defense; United States Army; Walter Reed National Military Medical Center; US Food & Drug Administration (FDA)			Zamani, Kaveh/A-9182-2011					ALGRA A, 1991, CIRCULATION, V83, P1888, DOI 10.1161/01.CIR.83.6.1888; ALVAREZ J, 1992, J BIOL CHEM, V267, P11789; [Anonymous], 1992, Med Lett Drugs Ther, V34, P9; Bazett HC, 1920, HEART-J STUD CIRC, V7, P353; BENNETT JE, 1990, GOODMAN GILMANS PHAR; BETHEA RM, 1985, STATISTICAL METHODS; CHEN Y, 1991, J AM COLL CARDIOL, V17, P140; COUTANT JE, 1991, J CHROMATOGR-BIOMED, V570, P139, DOI 10.1016/0378-4347(91)80208-T; DANAN G, 1981, J PHARMACOL EXP THER, V218, P509; GARTEIZ DA, 1982, ARZNEIMITTEL-FORSCH, V32-2, P1185; GUTTENDORF RJ, 1992, J CLIN PHARMACOL, V32, P107, DOI 10.1002/j.1552-4604.1992.tb03814.x; HONIG PK, 1992, CLIN PHARMACOL THER, V52, P231, DOI 10.1038/clpt.1992.135; HUME AL, 1983, DRUG INTEL CLIN PHAR, V17, P169, DOI 10.1177/106002808301700301; HUNT CM, 1992, CLIN PHARMACOL THER, V51, P18, DOI 10.1038/clpt.1992.3; LOOSE DS, 1983, J CLIN INVEST, V71, P1495, DOI 10.1172/JCI110903; MCBRIDE G, 1991, JAMA-J AM MED ASSOC, V266, P2375; MONAHAN BP, 1990, JAMA-J AM MED ASSOC, V264, P2788, DOI 10.1001/jama.264.21.2788; NATTEL S, 1990, AM J MED, V89, P235, DOI 10.1016/0002-9343(90)90305-W; SANFORD JP, 1992, J CRIT ILLNESS, V7, P605; SIMONSEN L, 1991, PHARM TIMES      APR, P57; 1992, IMPORTANT DRUG WARNI; 1992, 1992 NATIONAL PRESCR; 1984, FDA DRUG B, V14, P2; 1992, HLTH INFORMATION DES; 1990, IMPORTANT DRUG WARNI; 1992, ADVERSE REACTION REP; 1992, MED GRAM IMPORTANT D; 1990, P PULMONARY ALLERGY	28	606	623	0	19	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 24	1993	269	12					1513	1518		10.1001/jama.269.12.1513	http://dx.doi.org/10.1001/jama.269.12.1513			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KR803	8445813				2022-12-24	WOS:A1993KR80300023
J	LANDRIGAN, PJ				LANDRIGAN, PJ			HEALTH RISKS OF CREOSOTES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											LANDRIGAN, PJ (corresponding author), CUNY MT SINAI SCH MED,NEW YORK,NY 10029, USA.							1990, TP9009 US DEP HLTH H; 1987, UPDATING IARC MON S7, V1	2	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 10	1993	269	10					1309	1309		10.1001/jama.1993.03500100109042	http://dx.doi.org/10.1001/jama.1993.03500100109042			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP885	8437314				2022-12-24	WOS:A1993KP88500036
J	NEVILLE, RG; CLARK, RC; HOSKINS, G; SMITH, B				NEVILLE, RG; CLARK, RC; HOSKINS, G; SMITH, B			NATIONAL ASTHMA ATTACK AUDIT 1991-2	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE; HOSPITAL-CARE; MANAGEMENT	Objective-To describe the frequency and characteristics of asthma attacks in the United Kingdom and to compare actual management with recommended guidelines for the management of attacks. Design-Correspondence survey. Setting-218 general practices in the United Kingdom. Subjects-1775 patients of all ages who had a total of 1805 asthma attacks over three months. Main outcome measures-Patient characteristics, place of management of attacks, comparison of actual management with recommended guidelines. Results-Of the 1805 attacks, 300 occurred in boys aged 0-9, 144 in girls aged 0-9, and 118 in women aged 20-29. The estimated frequency of attacks in the community was 14.3 per 1000 patients per year. 1546 (86%) patients with attacks were managed within general practice, 225 (12%) were admitted to hospital, and 34 (2%) were discharged from an accident and emergency department. Two patients died. On initial presentation, 248 (14%) patients were ''not breathless,'' 900 (50%) were ''moderately breathless,'' 535 (30%) were ''breathless and distressed,'' 68 (4%) were ''too breathless to talk,'' and 2 were ''moribund.'' Recording of clinical data was variable. Underuse of nebulised bronchodilators and systemic steroids was apparent in all grades of clinical severity. Contrary to current guidelines for asthma management, ''step up'' in maintainance therapy after an attack was often not practised. Conclusion-Reported management was at variance with recommended guidelines. This has major implications for the design and distribution of future guidelines.			NEVILLE, RG (corresponding author), UNIV DUNDEE,WESTGATE HLTH CTR,DEPT GEN PRACTICE,GEN PRACTITIONERS ASTHMA GRP,RES UNIT,DUNDEE DD2 4AD,SCOTLAND.							ALDERSON M, 1987, TRENDS MORBIDITY MOR; ANDERSON HR, 1990, THORAX, V45, P431, DOI 10.1136/thx.45.6.431; [Anonymous], 1990, BMJ, V301, P651; ARNOLD AG, 1983, BRIT J DIS CHEST, V77, P51, DOI 10.1016/0007-0971(83)90005-0; BELL D, 1991, BRIT MED J, V302, P1440, DOI 10.1136/bmj.302.6790.1440; BUCKNALL CE, 1988, BRIT MED J, V296, P1637, DOI 10.1136/bmj.296.6637.1637; CHIDLEY KE, 1991, RESP MED, V85, P373, DOI 10.1016/S0954-6111(06)80180-0; HAINES A, 1992, BMJ, V305, P705; JOBANPUTRA P, 1991, BRIT J GEN PRACT, V41, P410; JONES K, 1991, BRIT J GEN PRACT, V41, P224; LIM KL, 1991, THORAX, V46, P316; STRACHAN DP, 1992, BRIT MED J, V304, P819, DOI 10.1136/bmj.304.6830.819; WARNER JO, 1989, ARCH DIS CHILD, V64, P1065, DOI 10.1136/adc.64.7.1065; WARNER JO, 1992, ARCH DIS CHILD, V67, P240; 1986, 3RD ANN STUDY MORBID; 1982, BMJ, V285, P1251; 1990, OCCURRENCE COST ASTH; 1990, BMJ, V301, P797	18	64	65	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 27	1993	306	6877					559	562		10.1136/bmj.306.6877.559	http://dx.doi.org/10.1136/bmj.306.6877.559			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP886	8461773	Green Published, Bronze			2022-12-24	WOS:A1993KP88600025
J	MAGEE, MS; WALDEN, CE; BENEDETTI, TJ; KNOPP, RH				MAGEE, MS; WALDEN, CE; BENEDETTI, TJ; KNOPP, RH			INFLUENCE OF DIAGNOSTIC-CRITERIA ON THE INCIDENCE OF GESTATIONAL DIABETES AND PERINATAL MORBIDITY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GLUCOSE-TOLERANCE; SCREENING-TESTS; PREGNANCY; POPULATION; MELLITUS; WOMEN; MANAGEMENT; THERAPY; AGE	Objective.-To determine the incidence of gestational diabetes and its associated maternal and infant morbidity by two sets of 3-hour glucose tolerance test criteria, those recommended by the National Diabetes Data G roup or the lower, modified criteria of Carpenter and Coustan. Design.-Prospective, observational outcome cohort study. Setting.-Prepaid health maintenance organization. Subjects.-A total of 2019 pregnant women preregistered in a health maintenance organization were screened for a plasma glucose of 7.77 mmol/L (140 mg/dL) or greater, 1 hour after ingestion of a 50-g glucose drink administered after an overnight fast. Positive subjects received a 3-hour glucose tolerance test interpreted by the two criteria. Data are presented for 521 randomly selected negative screenees; 264 positive screen, negative glucose tolerance test subjects; and 101 subjects with gestational diabetes mellitus. Outcome Measures.-Maternal risk factors for diabetes, infant birth weight corrected for gestational age (birth-weight ratio), umbilical cord serum insulin levels, and 33 maternal and infant perinatal morbidities assessed from chart review. Results.-Gestational diabetes incidence was 5.0% overall based on the modified criteria and 3.2% by the recommended criteria. Maternal age and family history of diabetes were higher in both modified and recommended groups. Birth-weight ratio was 1.05 in negative screenees, 1.09 in gestational diabetes overall (P<.05 when only diet-treated subjects were considered), and 1.11 in modified and 1.08 in recommended criteria groups. Cord serum insulin levels in infants of gestational diabetic mothers by both criteria were 40% above those of negative screenees (P<.001). The average percentage incidence of 33 possible perinatal morbidities was 41 % higher in gestational diabetic pregnancies by the modified criteria. The cumulative number of morbidities was higher in both modified and recommended criteria groups (P<.01 in both instances). In contrast, subjects having a positive glucose screening test but a negative glucose tolerance test by modified criteria had none of the characteristics of gestational diabetes with the single exception of greater age. Conclusions.-Fifty percent more cases of gestational diabetes were identified using the more inclusive, modified criteria. These cases had as much excess in maternal diabetes risk factors, infant macrosomia, and cord hyperinsulinemia and nearly as much increase in perinatal morbidity as subjects diagnosed by the recommended criteria. The incidence and perinatal impact of gestational diabetes may be greater than previously appreciated. The modified criteria deserve wider verification and use.	UNIV WASHINGTON, SCH MED, DEPT MED, SEATTLE, WA 98195 USA; UNIV WASHINGTON, SCH MED, DEPT OBSTET & GYNECOL, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK035816] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-35816, DK-28130] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BABSON SG, 1970, PEDIATRICS, V45, P937; CARPENTER MW, 1982, AM J OBSTET GYNECOL, V144, P768, DOI 10.1016/0002-9378(82)90349-0; CATALANO PM, 1986, AM J OBSTET GYNECOL, V155, P1255, DOI 10.1016/0002-9378(86)90155-9; CLEEMAN JI, 1988, ARCH INTERN MED, V148, P36, DOI 10.1001/archinte.148.1.36; COUSTAN DR, 1986, AM J OBSTET GYNECOL, V154, P1031, DOI 10.1016/0002-9378(86)90744-1; COUSTAN DR, 1989, OBSTET GYNECOL, V73, P557; COUSTAN DR, 1978, OBSTET GYNECOL, V51, P306, DOI 10.1097/00006250-197803000-00010; DANDROW RV, 1966, AM J OBSTET GYNECOL, V96, P1144, DOI 10.1016/0002-9378(66)90525-4; DOOLEY SL, 1991, INT J GYNECOL OBSTET, V35, P13, DOI 10.1016/0020-7292(91)90057-C; DUNN OJ, 1964, TECHNOMETRICS, V6, P241, DOI 10.2307/1266041; EFENDIC S, 1987, DIABETES, V36, P413, DOI 10.2337/diabetes.36.4.413; GABBE SG, 1977, AM J OBSTET GYNECOL, V127, P465, DOI 10.1016/0002-9378(77)90436-7; GREEN JR, 1990, AM J OBSTET GYNECOL, V163, P86, DOI 10.1016/S0002-9378(11)90675-9; Gribble R K, 1988, Wis Med J, V87, P19; HARRIS M, 1979, DIABETES, V28, P1039; HOET JP, 1954, DIABETES, V3, P1; JACOBSON JD, 1989, AM J OBSTET GYNECOL, V161, P981, DOI 10.1016/0002-9378(89)90767-9; JOVANOVIC L, 1986, DIABETES, V35, pA216, DOI 10.2337/diab.34.2.S21; KNOPP RH, 1978, LABORATORY INDICES N, P35; LANGER O, 1989, AM J OBSTET GYNECOL, V161, P593, DOI 10.1016/0002-9378(89)90361-X; LEIKIN EL, 1987, OBSTET GYNECOL, V69, P570; MAIN DM, 1985, AM J OBSTET GYNECOL, V152, P1031, DOI 10.1016/0002-9378(85)90553-8; MORGAN CR, 1963, DIABETES, V12, P115, DOI 10.2337/diab.12.2.115; OSULLIVAN JB, 1964, DIABETES, V13, P278; OSULLIVAN JB, 1975, EARLY DIABETES EARLY, P503; OSULLIVAN JB, 1975, EARLY DIABETES EARLY, P447; PEARSON DC, 1987, PREV MED, V16, P783, DOI 10.1016/0091-7435(87)90018-1; Philipson E H, 1985, Diabetes, V34 Suppl 2, P55; ROMANO AT, 1973, CLIN CHEM, V19, P1152; SACKS DA, 1987, OBSTET GYNECOL, V70, P89; SACKS DA, 1989, AM J OBSTET GYNECOL, V161, P638, DOI 10.1016/0002-9378(89)90369-4; SIEGEL S, 1988, NONPARAMETRIC STAT, P206; Snedecor G.W., 1967, STAT METHODS, V6th, P1; TALLARIGO L, 1986, NEW ENGL J MED, V315, P989, DOI 10.1056/NEJM198610163151603; WARD WK, 1985, J CLIN ENDOCR METAB, V61, P1039, DOI 10.1210/jcem-61-6-1039; WATSON WJ, 1989, OBSTET GYNECOL, V74, P40; Zoller D P, 1988, J Am Board Fam Pract, V1, P98; 1985, DIABETES S2, V34, P123	38	155	160	0	24	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 3	1993	269	5					609	615		10.1001/jama.269.5.609	http://dx.doi.org/10.1001/jama.269.5.609			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ444	8421365				2022-12-24	WOS:A1993KJ44400027
J	DEFRANCHIS, R; MEUCCI, G; VECCHI, M; TATARELLA, M; COLOMBO, M; DELNINNO, E; RUMI, MG; DONATO, MF; RONCHI, G				DEFRANCHIS, R; MEUCCI, G; VECCHI, M; TATARELLA, M; COLOMBO, M; DELNINNO, E; RUMI, MG; DONATO, MF; RONCHI, G			THE NATURAL-HISTORY OF ASYMPTOMATIC HEPATITIS-B SURFACE-ANTIGEN CARRIERS	ANNALS OF INTERNAL MEDICINE			English	Article						CARRIER STATE; HEPATITIS-B SURFACE ANTIGENS; HEPATOMA; LIVER NEOPLASMS; HEPATITIS	HEPATOCELLULAR-CARCINOMA; VIRUS-INFECTION; HBSAG-CARRIERS; FOLLOW-UP; REACTIVATION; STATE; THERAPY	Objective: To assess the long-term outcome in hepatitis B surface antigen (HBsAg) carriers who have normal liver function tests, focusing on survival and the development of severe liver disease and hepatocellular carcinoma. Design: Cohort study with a mean follow-up of 130 months. Setting: Liver clinic of a referral center. Patients: Ninety-two HBsAg-positive blood donors with normal liver function tests. Measurements: Histologic evaluation of liver specimens at baseline; clinical, biochemical, and serologic follow-up; and repeat liver biopsy if clinically indicated or after 10 years of follow-up. Results: At baseline, 69 subjects had normal histologic findings or only minor abnormalities, 18 had chronic persistent hepatitis, and 5 had mild chronic active hepatitis. Serum enzyme levels remained normal in 58 of 68 patients who had regular follow-up. Three patients had biochemical changes consistent with hepatitis B virus (HBV) infection; in one of these patients, a later histologic evaluation showed progression to chronic active hepatitis. One patient developed alcoholic cirrhosis. Six other patients had mild or transient transaminase elevations, with no evidence of HBV replication, hepatitis D virus infection, hepatitis C virus (HCV) infection, or histologic deterioration. Liver histologic findings also remained unchanged in 21 patients who showed no biochemical changes during 10 years of follow-up and consented to have repeated liver biopsy. Ten patients showed loss of HBsAg; 2 of these patients acquired antibody to hepatitis B surface antigen (anti-HBs). All patients who did not have regular follow-up, except 1, were interviewed by telephone during 1990: All denied having liver disease. No patients developed hepatocellular carcinoma. Conclusions: Italian HBsAg carriers with initially normal liver function tests have an excellent prognosis: Delta superinfection is infrequent and the risk for developing hepatocellular carcinoma is low.			DEFRANCHIS, R (corresponding author), UNIV MILAN,IST MED INTERNA,VIA PACE 9,I-20122 MILAN,ITALY.		Donato, Maria francesca/AAC-2372-2019; Meucci, Gianmichele/AFJ-8527-2022	RUMI, MARIAGRAZIA/0000-0002-5876-8528; Meucci, Gianmichele/0000-0001-9004-8195				BEASLEY RP, 1988, CANCER, V61, P1942, DOI 10.1002/1097-0142(19880515)61:10<1942::AID-CNCR2820611003>3.0.CO;2-J; BIANCHI L, 1987, PATHOLOGY LIVER DISE, P310; COLOMBO M, 1991, NEW ENGL J MED, V325, P675, DOI 10.1056/NEJM199109053251002; DAVIS GL, 1987, GASTROENTEROLOGY, V92, P2028, DOI 10.1016/0016-5085(87)90641-X; DAVIS GL, 1984, GASTROENTEROLOGY, V86, P230; DEFRANCHIS R, 1980, GASTROENTEROLOGY, V79, P521, DOI 10.1016/0016-5085(80)90378-9; DRAGOSICS B, 1987, HEPATOLOGY, V7, P302, DOI 10.1002/hep.1840070215; FEINMAN SV, 1975, GASTROENTEROLOGY, V68, P113; FEINMAN SV, 1992, HEPATOGASTROENTEROLO, V29, P58; FLOWERS MA, 1990, ANN INTERN MED, V112, P381, DOI 10.7326/0003-4819-112-5-381; GIUSTI G, 1981, HEPATO-GASTROENTEROL, V28, P96; HOFFNAGLE JH, 1983, GASTROENTEROLOGY, V84, P422; HOOFNAGLE JH, 1987, HEPATOLOGY, V7, P758, DOI 10.1002/hep.1840070424; HOWDLE PD, 1987, VOX SANG, V52, P200, DOI 10.1111/j.1423-0410.1987.tb03027.x; KORETZ RL, 1978, GASTROENTEROLOGY, V75, P860; LOK ASF, 1991, GASTROENTEROLOGY, V100, P182, DOI 10.1016/0016-5085(91)90599-G; PICCININO F, 1991, PROG CLIN BIOL RES, V364, P33; PICCININO F, 1978, ACTA HEPATO-GASTRO, V25, P171; POPPER H, 1987, HEPATOLOGY, V7, P764, DOI 10.1002/hep.1840070425; RICCI G, 1973, J INFECT DIS, V128, P125, DOI 10.1093/infdis/128.1.125; RIZZETTO M, 1991, PROG CLIN BIOL RES, V364, P1; SAKUMA K, 1982, GASTROENTEROLOGY, V83, P114; SHRAGO SS, 1977, ARCH PATHOL LAB MED, V101, P648; TAPP E, 1976, J CLIN PATHOL, V29, P884, DOI 10.1136/jcp.29.10.884; VILLA E, 1982, LANCET, V2, P1243	25	217	222	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572	0003-4819			ANN INTERN MED	Ann. Intern. Med.	FEB 1	1993	118	3					191	194		10.7326/0003-4819-118-3-199302010-00006	http://dx.doi.org/10.7326/0003-4819-118-3-199302010-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ439	8417636				2022-12-24	WOS:A1993KJ43900006
J	CHAPARRO, A; STROMEYER, CF; HUANG, EP; KRONAUER, RE; ESKEW, RT				CHAPARRO, A; STROMEYER, CF; HUANG, EP; KRONAUER, RE; ESKEW, RT			COLOR IS WHAT THE EYE SEES BEST	NATURE			English	Article							RETINAL GANGLION-CELLS; LATERAL GENICULATE-NUCLEUS; RED-GREEN; CHROMATIC STIMULI; MACAQUE; LUMINANCE; CONTRAST; SENSITIVITY; INTEGRATION; ADAPTATION	IT has been argued by Watson, Barlow and Robson1 that the visual stimulus that humans detect best specifies the spatial-temporal structure of the receptive field of the most sensitive visual neurons. To investigate 'what the eye sees best' they used stimuli that varied in luminance alone. Because the most abundant primate retinal ganglion cells, the P cells, are colour-opponent2-4, we might expect that a coloured pattern would also be detected well. We generalized Watson et al.'s study1 to include variations in colour as well as luminance. We report here that our best detected coloured stimulus was seen 5-9-fold better than our best luminance spot and 3-8-fold better than Watson's best luminance stimulus. The high sensitivity to colour is consistent with the prevalence and high colour contrast-gain of retinal P cells, and may compensate for the low chromatic contrasts typically found in natural scenes.	HARVARD UNIV,DEPT PSYCHOL,CAMBRIDGE,MA 02138; NORTHEASTERN UNIV,DEPT PSYCHOL,BOSTON,MA 02115	Harvard University; Northeastern University	CHAPARRO, A (corresponding author), HARVARD UNIV,DIV APPL SCI,CAMBRIDGE,MA 02138, USA.							COLE GR, 1990, J OPT SOC AM A, V7, P128, DOI 10.1364/JOSAA.7.000128; CROOK JM, 1988, J PHYSIOL-LONDON, V396, P205, DOI 10.1113/jphysiol.1988.sp016959; DERRINGTON AM, 1984, J PHYSIOL-LONDON, V357, P219, DOI 10.1113/jphysiol.1984.sp015498; DERRINGTON AM, 1984, J PHYSIOL-LONDON, V357, P241, DOI 10.1113/jphysiol.1984.sp015499; GOURAS P, 1968, J PHYSIOL-LONDON, V199, P533, DOI 10.1113/jphysiol.1968.sp008667; HIRSCH J, 1989, VISION RES, V29, P1095, DOI 10.1016/0042-6989(89)90058-8; KAPLAN E, 1990, PROGR RETINAL RES, V9; KELLY DH, 1977, J OPT SOC AM, V67, P1081, DOI 10.1364/JOSA.67.001081; KINGSMITH PE, 1976, J OPT SOC AM, V66, P709, DOI 10.1364/JOSA.66.000709; LEE BB, 1989, J PHYSIOL-LONDON, V414, P223, DOI 10.1113/jphysiol.1989.sp017685; MULLEN KT, 1985, J PHYSIOL-LONDON, V359, P381, DOI 10.1113/jphysiol.1985.sp015591; NOORLANDER C, 1981, J OPT SOC AM, V71, P453, DOI 10.1364/JOSA.71.000453; Pelli D. G., 1990, VISION CODING EFFICI; PERRY VH, 1985, VISION RES, V25, P1795, DOI 10.1016/0042-6989(85)90004-5; PERRY VH, 1984, NEUROSCIENCE, V12, P1101, DOI 10.1016/0306-4522(84)90006-X; PURPURA K, 1988, P NATL ACAD SCI USA, V85, P4534, DOI 10.1073/pnas.85.12.4534; REID RC, 1992, NATURE, V356, P716, DOI 10.1038/356716a0; SCHEIN SJ, 1988, J COMP NEUROL, V269, P479, DOI 10.1002/cne.902690403; SHAPLEY RM, 1991, INVEST OPHTHALMOL S, V32, P115; SMITH VC, 1984, VISION RES, V24, P653, DOI 10.1016/0042-6989(84)90206-2; STROMEYER CF, 1985, VISION RES, V25, P219, DOI 10.1016/0042-6989(85)90116-6; STROMEYER CF, 1987, VISION RES, V27, P1113, DOI 10.1016/0042-6989(87)90026-5; THORNTON JE, 1983, SCIENCE, V219, P191, DOI 10.1126/science.6849131; TROY JB, 1991, INVEST OPHTH VIS SCI, V32, P905; Van Trees HL, 1968, DETECTION ESTIMATION; WATSON AB, 1983, PERCEPT PSYCHOPHYS, V33, P113, DOI 10.3758/BF03202828; WATSON AB, 1983, NATURE, V302, P419, DOI 10.1038/302419a0; WILLIAMS DR, 1981, VISION RES, V21, P1341, DOI 10.1016/0042-6989(81)90241-8	28	124	125	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 28	1993	361	6410					348	350		10.1038/361348a0	http://dx.doi.org/10.1038/361348a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KJ590	8426653				2022-12-24	WOS:A1993KJ59000056
J	NIGHTINGALE, SL				NIGHTINGALE, SL			AGENCY POLICY ON INDUSTRY-SUPPORTED CME	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1992, FED REGISTER, V57, P56412	1	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 20	1993	269	3					328	328						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG381	8418328				2022-12-24	WOS:A1993KG38100005
J	AGOFF, SN; HOU, J; LINZER, DIH; WU, B				AGOFF, SN; HOU, J; LINZER, DIH; WU, B			REGULATION OF THE HUMAN HSP70 PROMOTER BY P53	SCIENCE			English	Article							WILD-TYPE P53; CELLULAR TUMOR-ANTIGEN; DNA-BINDING PROTEIN; E1A GENE-PRODUCTS; GLUCOCORTICOID RECEPTOR; SV40-TRANSFORMED CELLS; TRANSFORMED-CELLS; MAMMALIAN-CELLS; MUTANT P53; T-ANTIGEN	The tumor suppressor p53 is a nuclear phosphoprotein with characteristics of a transcription factor. It displays sequence-specific DNA binding, contains a potent transactivation domain, and has been implicated as both a transcriptional activator and a repressor. Transcription of the human hsp70 gene is stimulated by adenovirus E1a protein. This E1a transactivation of the hsp70 promoter is mediated by CCAAT binding factor (CBF). It is demonstrated here that p53 both represses transcription from the human hsp70 promoter and also interacts with CBF. Thus, the repression of the hsp70 promoter by p53 may be mediated by direct protein-protein interaction with CBF. These results suggest that protein-protein interaction between p53 and specific transcription factors may be an additional mechanism by which p53 regulates gene expression.	NORTHWESTERN UNIV,DEPT BIOCHEM MOLEC BIOL & CELL BIOL,EVANSTON,IL 60208	Northwestern University								AGOFF SN, UNPUB; BENBROOK DM, 1990, ONCOGENE, V5, P295; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BONTHRON DT, 1986, NATURE, V324, P270, DOI 10.1038/324270a0; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1089; GANNON JV, 1987, NATURE, V329, P429; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HALEY KP, 1984, P NATL ACAD SCI-BIOL, V81, P5734, DOI 10.1073/pnas.81.18.5734; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JONAT G, 1990, CELL, V62, P1189; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KAKIDANI H, 1988, CELL, V52, P161, DOI 10.1016/0092-8674(88)90504-1; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LUM LSY, 1990, MOL CELL BIOL, V10, P6709, DOI 10.1128/MCB.10.12.6709; LUM SYL, 1992, MOL CELL BIOL, V12, P2599; LUND H, 1983, NATURE, V304, P596; MERCER WE, 1982, P NATL ACAD SCI-BIOL, V79, P6309, DOI 10.1073/pnas.79.20.6309; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILARSKI KL, 1986, P NATL ACAD SCI USA, V83, P9517, DOI 10.1073/pnas.83.24.9517; MILARSKI KL, 1989, J CELL BIOL, V109, P1947, DOI 10.1083/jcb.109.5.1947; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1990, ONCOGENE, V5, P1683; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SIMON MC, 1987, MOL CELL BIOL, V7, P2884, DOI 10.1128/MCB.7.8.2884; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WU BJ, 1986, MOL CELL BIOL, V6, P2994, DOI 10.1128/MCB.6.8.2994; WU BJ, 1985, P NATL ACAD SCI USA, V82, P6070, DOI 10.1073/pnas.82.18.6070; WU BJ, 1986, P NATL ACAD SCI USA, V83, P629, DOI 10.1073/pnas.83.3.629; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0	55	310	317	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 1	1993	259	5091					84	87		10.1126/science.8418500	http://dx.doi.org/10.1126/science.8418500			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KE601	8418500				2022-12-24	WOS:A1993KE60100034
J	SCHULTZ, JR; VERSTUYFT, JG; GONG, EL; NICHOLS, AV; RUBIN, EM				SCHULTZ, JR; VERSTUYFT, JG; GONG, EL; NICHOLS, AV; RUBIN, EM			PROTEIN-COMPOSITION DETERMINES THE ANTI-ATHEROGENIC PROPERTIES OF HDL IN TRANSGENIC MICE	NATURE			English	Article							HIGH-DENSITY-LIPOPROTEIN; APOLIPOPROTEIN-A-I; CORONARY-ARTERY DISEASE; CHOLESTEROL EFFLUX; PARTICLES; ATHEROSCLEROSIS; SIZE; SUSCEPTIBILITY; EXPRESSION; CELLS	HIGH-DENSITY lipoprotein (HDL) contains two major proteins, apolipoprotein A-I (apoA-I) and apolipoprotein A-II (apoA-II), comprising about 70% and 20% of the total HDL protein mass, respectively. HDL exists in human plasma in two main forms, one containing apoA-I with apoA-II (AI/AII-HDL) and another containing apoA-I without apoA-II (AI-HDL). A strong inverse relationship exists between total plasma HDL concentration and atherosclerosis, but the results of studies examining the relationship between AI-HDL and AI/AII-HDL and atherosclerosis have been conflicting1-9. To determine whether these two HDL populations have different effects on atherogenesis, human apoA-I (AI) and human apoA-I and apoA-II (AI/AII) transgenic mice were produced in an atherosclerosis-susceptible strain10-12. Following an atherogenic diet, despite similar total cholesterol and HDL cholesterol concentrations, the area of atherogenic lesions in the AI/AII mice was 15-fold greater than in the AI animals. These studies show that the protein composition of HDL significantly affects its role in atherogenesis and that AI-HDL is more anti-atherogenic than AI/AII-HDL.	LAWRENCE BERKELEY LAB,DIV LIFE SCI,BERKELEY,CA 94720	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory								BARBARAS R, 1987, BIOCHEM BIOPH RES CO, V142, P63, DOI 10.1016/0006-291X(87)90451-7; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BREWER HB, 1972, P NATL ACAD SCI USA, V69, P1304, DOI 10.1073/pnas.69.5.1304; CASTRO GR, 1988, BIOCHEMISTRY-US, V27, P25, DOI 10.1021/bi00401a005; CHEUNG MC, 1984, J BIOL CHEM, V259, P2201; CHEUNG MC, 1991, J LIPID RES, V32, P383; CIVEIRA F, 1992, ATHEROSCLEROSIS, V92, P165, DOI 10.1016/0021-9150(92)90275-L; COSTEBUREL M, 1990, CLIN CHEM, V36, P1889; DOOLITTLE MH, 1990, J BIOL CHEM, V265, P16380; FRUCHART JC, 1992, CLIN CHEM, V38, P793; GENEST JJ, 1990, CIRCULATION, V82, P621; GLOMSET JA, 1968, J LIPID RES, V9, P155; IZZO C, 1981, CLIN CHEM, V27, P371; JOHNSON WJ, 1991, J LIPID RES, V32, P1993; KNOTT TJ, 1984, BIOCHEM BIOPH RES CO, V120, P734, DOI 10.1016/S0006-291X(84)80168-0; LEBOEUF RC, 1990, J LIPID RES, V31, P91; LUC G, 1991, METABOLISM, V40, P1238, DOI 10.1016/0026-0495(91)90022-O; LUSSIERCACAN S, 1989, ATHEROSCLEROSIS, V78, P167, DOI 10.1016/0021-9150(89)90221-9; MEHRABIAN M, 1993, ARTERIOSCLER THROMB, V13, P1, DOI 10.1161/01.ATV.13.1.1; MILLER NE, 1985, NATURE, V314, P109, DOI 10.1038/314109a0; NICHOLS AV, 1986, METHOD ENZYMOL, V128, P417; PAIGEN B, 1990, ARTERIOSCLEROSIS, V10, P316, DOI 10.1161/01.ATV.10.2.316; PUCHOIS P, 1987, ATHEROSCLEROSIS, V68, P35, DOI 10.1016/0021-9150(87)90091-8; RUBIN EM, 1991, NATURE, V353, P265, DOI 10.1038/353265a0; RUBIN EM, 1991, P NATL ACAD SCI USA, V88, P434, DOI 10.1073/pnas.88.2.434; SCHAEFER EJ, 1982, ARTERIOSCLEROSIS, V2, P16, DOI 10.1161/01.ATV.2.1.16; SCHULTZ JR, 1992, J BIOL CHEM, V267, P21630; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P375; STEWARTPHILLIPS JL, 1991, ATHEROSCLEROSIS, V90, P211, DOI 10.1016/0021-9150(91)90117-L; VALIMAKI M, 1991, METABOLISM, V40, P1168, DOI 10.1016/0026-0495(91)90211-E	30	256	269	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 21	1993	365	6448					762	764		10.1038/365762a0	http://dx.doi.org/10.1038/365762a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MC812	8413656				2022-12-24	WOS:A1993MC81200066
J	CRIQUI, MH; HEISS, G; COHN, R; COWAN, LD; SUCHINDRAN, CM; BANGDIWALA, S; KRITCHEVSKY, S; JACOBS, DR; OGRADY, HK; DAVIS, CE				CRIQUI, MH; HEISS, G; COHN, R; COWAN, LD; SUCHINDRAN, CM; BANGDIWALA, S; KRITCHEVSKY, S; JACOBS, DR; OGRADY, HK; DAVIS, CE			PLASMA TRIGLYCERIDE LEVEL AND MORTALITY FROM CORONARY HEART-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DENSITY LIPOPROTEIN CHOLESTEROL; CLINICS PROGRAM PREVALENCE; INDEPENDENT RISK FACTOR; MYOCARDIAL-INFARCTION; FOLLOW-UP; CARDIOVASCULAR MORTALITY; PLASMINOGEN-ACTIVATOR; SERUM TRIGLYCERIDES; MEN; DEATH	Background. Whether the plasma triglyceride level is a risk factor for coronary heart disease has been controversial, and evaluation of the triglyceride level as a risk factor is fraught with methodologic difficulties. Methods. We studied the association between plasma triglyceride levels and the 12-year incidence of death from coronary heart disease in 10 North American populations participating in the Lipid Research Clinics Follow-up Study, while adjusting for the potential confounding effects of other risk factors for cardiovascular disease, including the level of high-density lipoprotein (HDL) cholesterol. All analyses were sex-specific, and separate analyses were performed in high and low strata of HDL cholesterol, low-density lipoprotein (LDL) cholesterol, fasting plasma glucose, and age. Results. The rates of coronary death in both men and women increased with the triglyceride level. In Cox proportional-hazards models adjusted for age, in which the natural log of the triglyceride levels was used to give a normal distribution, the relative risk per natural-log unit of triglyceride (e.g., a triglyceride level of 150 mg per deciliter vs. a level of 55 mg per deciliter) was 1.54 (95 percent confidence interval, 1.19 to 1.98; P<0.001) in men and 1.88 (95 percent confidence interval, 1.19 to 2.98; P = 0.007) in women. After an adjustment for potential covariates, however, these relative risks were not statistically significant. Analyses based on lipoprotein cholesterol levels revealed a positive association between the triglyceride level and coronary mortality in the lower stratum of both HDL and LDL cholesterol, but not in the higher stratum. Conversely, the HDL cholesterol level was unrelated to coronary mortality in the lower stratum of LDL cholesterol, but was strongly inversely associated with coronary death in the higher stratum of LDL cholesterol. The relative risk of coronary death associated with triglyceride level was higher at younger ages. The associations between the triglyceride level and coronary mortality in the lower HDL cholesterol, LDL cholesterol, and age strata were small and were further reduced by an adjustment for the fasting plasma glucose level. Conclusions. Overall, the plasma triglyceride level showed no independent association with coronary mortality. However, in subgroups of subjects with lower HDL and LDL cholesterol levels and in younger subjects, defined a priori, an association between the triglyceride level and coronary mortality was observed, although this association was small and was not statistically significant after an adjustment for the plasma glucose level.	UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT COMMUNITY & FAMILY MED, LA JOLLA, CA 92093 USA; UNIV OKLAHOMA HLTH SCI CTR, COLL PUBL HLTH, DEPT BIOSTAT & EPIDEMIOL, OKLAHOMA CITY, OK USA; UNIV MINNESOTA, SCH PUBL HLTH, DEPT EPIDEMIOL, MINNEAPOLIS, MN 55455 USA; UNIV TENNESSEE CTR HLTH SCI, DEPT BIOSTAT & EPIDEMIOL, MEMPHIS, TN 38163 USA; UNIV N CAROLINA, DEPT EPIDEMIOL, CHAPEL HILL, NC 27514 USA; UNIV N CAROLINA, DEPT BIOSTAT, CHAPEL HILL, NC 27514 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Minnesota System; University of Minnesota Twin Cities; University of Tennessee System; University of Tennessee Health Science Center; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill				Jacobs, David/0000-0002-7232-0543	NHLBI NIH HHS [N01-HV32961, N01-HV12159, N01-HV12156] Funding Source: Medline; DIVISION OF HEART AND VASCULAR DISEASES [N01HV012156] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF HEART AND VASCULAR DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABBOTT RD, 1988, ARTERIOSCLEROSIS, V8, P207, DOI 10.1161/01.ATV.8.3.207; ABERG H, 1985, ATHEROSCLEROSIS, V54, P89, DOI 10.1016/0021-9150(85)90156-X; ASSMANN G, 1992, AM J CARDIOL, V70, P733, DOI 10.1016/0002-9149(92)90550-I; AUSTIN MA, 1988, JAMA-J AM MED ASSOC, V260, P1917; AUSTIN MA, 1989, AM J EPIDEMIOL, V129, P249, DOI 10.1093/oxfordjournals.aje.a115130; AVINS AL, 1993, CIRCULATION, V87, P300, DOI 10.1161/circ.87.1.8419022; BAINTON D, 1992, BRIT HEART J, V68, P60; BENFANTE RJ, 1989, J CLIN EPIDEMIOL, V42, P95, DOI 10.1016/0895-4356(89)90082-6; CAMBIEN F, 1986, AM J EPIDEMIOL, V124, P624, DOI 10.1093/oxfordjournals.aje.a114435; CARLSON LA, 1985, ACTA MED SCAND, V218, P207; CARLSON LA, 1988, ACTA MED SCAND, V223, P405; CASTELLI WP, 1986, AM HEART J, V112, P432, DOI 10.1016/0002-8703(86)90296-6; COWAN LD, 1985, ARTERIOSCLEROSIS, V5, P466, DOI 10.1161/01.ATV.5.5.466; COX DR, 1972, J R STAT SOC B, V34, P187; CRIQUI MH, 1986, CIRCULATION, V73, P40; CRIQUI MH, 1987, AM J EPIDEMIOL, V126, P629, DOI 10.1093/oxfordjournals.aje.a114702; CRIQUI MH, 1990, PROG CARDIOL, V3, P3; DAVIS CE, 1990, CIRCULATION, V81, P725; DAVIS CE, 1980, CIRCULATION, V62, P24; FONTBONNE A, 1989, DIABETOLOGIA, V32, P300, DOI 10.1007/BF00265546; GLYNN RJ, 1982, CIRCULATION, V66, P724, DOI 10.1161/01.CIR.66.4.724; HAMSTEN A, 1987, LANCET, V2, P3; HAMSTEN A, 1985, NEW ENGL J MED, V313, P1557, DOI 10.1056/NEJM198512193132501; HEYDEN S, 1980, J CHRON DIS, V33, P275, DOI 10.1016/0021-9681(80)90022-3; HULLEY SB, 1980, NEW ENGL J MED, V302, P1383, DOI 10.1056/NEJM198006193022503; JACOBS DR, 1990, AM J EPIDEMIOL, V131, P32, DOI 10.1093/oxfordjournals.aje.a115483; JACOBS DR, 1982, AM J EPIDEMIOL, V116, P878, DOI 10.1093/oxfordjournals.aje.a113490; JANKA HU, 1985, HORM METAB RES, V15, P15; LAMONFAVA S, 1988, CLIN RES, V36, pA787; LAPIDUS L, 1985, ACTA MED SCAND, V217, P481; LAROSA JC, 1986, CIRCULATION, V73, P12; MANNINEN V, 1992, CIRCULATION, V85, P37, DOI 10.1161/01.CIR.85.1.37; NESTEL PJ, 1987, PRACT CARDIOL, V13, P96; PATSCH JR, 1987, J CLIN INVEST, V80, P341, DOI 10.1172/JCI113078; PELKONEN R, 1977, BRIT MED J, V2, P1185, DOI 10.1136/bmj.2.6096.1185; PETERSSON B, 1984, AM J MED, V77, P418, DOI 10.1016/0002-9343(84)90096-2; POCOCK SJ, 1989, BMJ-BRIT MED J, V298, P998, DOI 10.1136/bmj.298.6679.998; SALONEN JT, 1983, INT J EPIDEMIOL, V12, P26, DOI 10.1093/ije/12.1.26; SIMPSON HCR, 1983, LANCET, V1, P786; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P373, DOI 10.1056/NEJM199108083250601; TVERDAL A, 1989, AM J EPIDEMIOL, V129, P458, DOI 10.1093/oxfordjournals.aje.a115157; WALSH BW, 1991, NEW ENGL J MED, V325, P1196, DOI 10.1056/NEJM199110243251702; WEST KM, 1983, DIABETES CARE, V6, P361, DOI 10.2337/diacare.6.4.361; WILHELMSEN L, 1973, CIRCULATION, V48, P950, DOI 10.1161/01.CIR.48.5.950; WILLIAMS OD, 1986, CIRCULATION, V73, P4; WU LL, 1988, CIRCULATION S2, V78, P481; 1974, DHEW NIH75628 PUBL	47	316	326	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 29	1993	328	17					1220	1225		10.1056/NEJM199304293281702	http://dx.doi.org/10.1056/NEJM199304293281702			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ061	8464432				2022-12-24	WOS:A1993KZ06100002
J	SHIN, J; LEE, S; STROMINGER, JL				SHIN, J; LEE, S; STROMINGER, JL			TRANSLOCATION OF TCR-ALPHA CHAINS INTO THE LUMEN OF THE ENDOPLASMIC-RETICULUM AND THEIR DEGRADATION	SCIENCE			English	Article							CELL RECEPTOR COMPLEX; PROTEINS; RETENTION; MEMBRANE; CD4; ER	After synthesis, the alpha chain of the T cell antigen receptor (TCRalpha) can form a complex with other TCR chains and move to the cell surface, or TCRalpha can undergo degradation in the endoplasmic reticulum (ER) if it remains unassembled. The mechanism of translocation and degradation in the ER is unclear. It was found that the putative transmembrane region of TCRalpha (alpha(tm)) was incompetent on its own to act as a transmembrane region. Molecules that contained alpha(tm) were translocated into the ER lumen and then underwent either rapid degradation or secretion, depending on the sequence of the cytoplasmic domain. A specific signal for ER degradation within alpha(tm) does not appear to be present.			SHIN, J (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV TUMOR VIROL,BOSTON,MA 02115, USA.				NATIONAL CANCER INSTITUTE [R35CA047554] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020182] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM048961] Funding Source: NIH RePORTER; NCI NIH HHS [CA47554] Funding Source: Medline; NIAID NIH HHS [AI20182] Funding Source: Medline; NIGMS NIH HHS [GM48961] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALARCON B, 1988, J BIOL CHEM, V263, P2953; BANIYASH M, 1988, J BIOL CHEM, V263, P9874; BONIFACINO JS, 1991, EMBO J, V10, P2783, DOI 10.1002/j.1460-2075.1991.tb07827.x; BONIFACINO JS, 1990, SCIENCE, V247, P79, DOI 10.1126/science.2294595; BONIFACINO JS, 1990, CELL, V63, P503, DOI 10.1016/0092-8674(90)90447-M; BORDIER C, 1981, J BIOL CHEM, V256, P1604; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213; CREIGHTON TE, 1984, PROTEINS STRUCTURES, P142; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; GOVERMAN J, 1990, CELL, V60, P929, DOI 10.1016/0092-8674(90)90341-B; KUCHROO VK, 1991, P NATL ACAD SCI USA, V88, P8700, DOI 10.1073/pnas.88.19.8700; LEIDEN JM, 1986, IMMUNOGENETICS, V24, P17, DOI 10.1007/BF00372293; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; MANOLIOS N, 1990, SCIENCE, V249, P274, DOI 10.1126/science.2142801; SHIN J, 1990, EMBO J, V9, P425, DOI 10.1002/j.1460-2075.1990.tb08127.x; SHIN J, 1991, P NATL ACAD SCI USA, V88, P1918, DOI 10.1073/pnas.88.5.1918; Shin J., UNPUB; SHIN JY, 1991, J BIOL CHEM, V266, P10658; SITIA R, 1987, EMBO J, V6, P3969, DOI 10.1002/j.1460-2075.1987.tb02739.x; SITIA R, 1990, CELL, V60, P781, DOI 10.1016/0092-8674(90)90092-S; WILEMAN T, 1990, J CELL BIOL, V110, P973, DOI 10.1083/jcb.110.4.973	23	73	75	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 26	1993	259	5103					1901	1904		10.1126/science.8456316	http://dx.doi.org/10.1126/science.8456316			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KU172	8456316				2022-12-24	WOS:A1993KU17200033
J	LIAW, YF; HUANG, MJ; FAN, KD; LI, KL; WU, SS; CHEN, TJ				LIAW, YF; HUANG, MJ; FAN, KD; LI, KL; WU, SS; CHEN, TJ			HEPATIC-INJURY DURING PROPYLTHIOURACIL THERAPY IN PATIENTS WITH HYPERTHYROIDISM - A COHORT STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						HYPOTHYROIDISM; PROPYLTHIOURACIL; LIVER DISEASES; HYPERBILIRUBINEMIA; HEPATITIS, TOXIC	LIVER	Objective: To evaluate the incidence, severity, and course of propylthiouracil-induced hepatic injury in patients with hyperthyroidism. Design: Cohort study. Setting: Outpatient clinic of a university-based hospital. Patients: Fifty-four patients with normal aspartate aminotransferase (AST) and alanine aminotransferase (ALT) values and a definite diagnosis of hyperthyroidism. Intervention: Treatment,with propylthiouracil, 300 mg/d for 2 months followed by 100 to 150 mg/d for 3 months and a subsequent maintenance dose of 100 mg/d. Measurements: Liver biochemical tests were studied before therapy and 2 months and 5 months after starting propylthiouracil therapy. The patients were monitored with clinical evaluation and weekly liver biochemical tests after AST or ALT levels became abnormal. Serologic markers of hepatitis A, B, C, and delta virus infection were also studied when appropriate. Results: Fifteen (28%; 95% CI, 16% to 42%) of the 54 patients showed ALT elevations 2 months after propylthiouracil therapy. The mean peak ALT level for these patients was 1.35 mukat/L (range, 0.65 3.85 mukat/L). None of these patients had symptoms or hyperbilirubinemia. Liver biopsy in three patients showed mild perivenular focal necrosis or ill-defined granuloma composed of foamy histiocytes with ceroid pigment and mild fatty metamorphosis. Despite continued propylthiouracil therapy at a reduced dose, ALT levels returned to normal in 13 of 15 patients in the following 3 months. None of these ALT elevations resulted from hepatitis A, B, C, or delta virus infection. No statistical difference was seen in the pretreatment characteristics between patients with and those without ALT elevation, except that the former had a higher pretreatment T4 level (270 +/- 12.9 compared with 237 +/- 7.72 nmol/L, P = 0.027) and T3 level (7.22 +/- 0.72 compared with 5.85 +/- 0.39 nmol/L, P = 0.048). Conclusions: Propylthiouracil-induced subclinical liver injury is common and is usually transient and asymptomatic. Therapy with propylthiouracil may be continued with caution in the absence of symptoms and hyperbilirubinemia.	CHANG GUNG MED COLL, TAIPEI, TAIWAN	Chang Gung University	LIAW, YF (corresponding author), CHANG GUNG MEM HOSP, 199 TUNG HWA N RD, TAIPEI 105, TAIWAN.		Liaw, Yun-Fan/B-4305-2009					BENICHOU C, 1990, J HEPATOL, V11, P272; COOPER DS, 1979, ANN INTERN MED, V90, P164, DOI 10.7326/0003-4819-90-2-164; EISEN MJ, 1953, NEW ENGL J MED, V249, P814, DOI 10.1056/NEJM195311122492007; FEDOTIN MS, 1975, ARCH INTERN MED, V135, P319, DOI 10.1001/archinte.135.2.319; GARTY BZ, 1985, DRUG INTEL CLIN PHAR, V19, P740, DOI 10.1177/106002808501901009; GEUBEL AP, 1987, PHARMACOL THERAPEUT, V33, P193, DOI 10.1016/0163-7258(87)90050-7; HANSON JS, 1984, ARCH INTERN MED, V144, P994, DOI 10.1001/archinte.144.5.994; HAYASHIDA CY, 1990, J ENDOCRINOL INVEST, V13, P937, DOI 10.1007/BF03349663; HUNTER AL, 1975, BIOCHEM PHARMACOL, V24, P2199, DOI 10.1016/0006-2952(75)90052-0; JONAS MM, 1988, J PEDIATR GASTR NUTR, V7, P776, DOI 10.1097/00005176-198809000-00027; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; LIMAYE A, 1987, AM J GASTROENTEROL, V82, P152; MADDREY WC, 1977, GASTROENTEROLOGY, V72, P1348; MIHAS AA, 1976, GASTROENTEROLOGY, V70, P770; PARKER LN, 1975, ANN INTERN MED, V82, P228, DOI 10.7326/0003-4819-82-2-228_2; PARKER W A, 1982, Clinical Pharmacy, V1, P471; PETER SA, 1991, J NATL MED ASSOC, V83, P75; SAFANI MM, 1982, ARCH INTERN MED, V142, P838, DOI 10.1001/archinte.1982.00340170198033; SALATA R, 1985, SEMIN LIVER DIS, V5, P29, DOI 10.1055/s-2008-1041755; VITUG AC, 1985, HORM RES, V21, P229, DOI 10.1159/000180054; WEISS M, 1980, ARCH INTERN MED, V140, P1184, DOI 10.1001/archinte.140.9.1184; ZIMMERMAN HJ, 1978, HEPATOTOXICITY, P487; ZIMMERMAN HJ, 1978, HEPATOTOXICITY ADVER, P459	23	93	96	1	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1993	118	6					424	428		10.7326/0003-4819-118-6-199303150-00005	http://dx.doi.org/10.7326/0003-4819-118-6-199303150-00005			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KR817	8439116				2022-12-24	WOS:A1993KR81700005
J	MACDESSI, J; OATES, RK				MACDESSI, J; OATES, RK			CLINICAL-DIAGNOSIS OF PYLORIC-STENOSIS - A DECLINING ART	BRITISH MEDICAL JOURNAL			English	Article							ULTRASOUND	Objective-To assess whether diagnostic imaging of pyloric stenosis has made a difference in rapidity of diagnosis, duration of pre-operative hydration, and length of stay in hospital. Design-Chart review of infants with confirmed diagnosis of pyloric stenosis. Setting-Paediatric teaching hospital. Subjects-215 infants with a confirmed diagnosis of pyloric stenosis seen during 1974-7 and 187 infants with pyloric stenosis seen during 1988-91. Main outcome measures-State of hydration on admission, time between presentation to hospital and a definite diagnosis, techniques used to make the diagnosis, whether a pyloric mass was felt before or after an imaging procedure, time between presentation and surgery, and length of stay in hospital. Results-The average age at presentation was 40 days in both groups. A pyloric mass was palpated either without or before an imaging study in 87% (187/215) of cases during 1974-7 but in only 49% (91/187) during 1988-91. The use of barium meal examination and ultrasonography increased from 20% (42/215) of cases during 1974-7 to 61% (114/187) during 1988-91. There were no significant differences between the two groups in the time taken to establish a diagnosis, the mean duration of preoperative treatment, or the length of stay in hospital (after allowance for the decline in average length of stay of all hospital patients between the two periods). Conclusions-An increased use of diagnostic imaging for pyloric stenosis did not lead to earlier diagnosis or better management. While imaging is important in identifying pyloric stenosis in difficult cases, increasing reliance on imaging has reduced doctors' skills in diagnosing pyloric stenosis clinically.	SYDNEY UNIV,CHILDRENS HOSP,DEPT PAEDIAT & CHILD HLTH,CAMPERDOWN,NSW 2050,AUSTRALIA	University of Sydney								BEASELY S, 1991, J PAEDIATR CHILD HLT, V27, P231; BREAUX CW, 1988, PEDIATRICS, V81, P213; FORMAN HP, 1990, J PEDIATR SURG, V25, P262, DOI 10.1016/0022-3468(90)90436-D; Garcia V F, 1990, Pediatr Rev, V11, P292, DOI 10.1542/pir.11-10-292; LEAHY PF, 1986, IRISH MED J, V79, P114; MENUSSEN T, 1934, AM J DIS CHILD, V48, P1304; PERRY EP, 1988, LANCET, V2, P391; SCHARLI A, 1969, J PEDIATR SURG, V4, P108, DOI 10.1016/0022-3468(69)90190-0; SCHUMAN FL, 1967, J PEDIATR, V71, P70; STUNDEN RJ, 1986, PEDIATR RADIOL, V16, P200, DOI 10.1007/BF02456287; TEELE RL, 1977, NEW ENGL J MED, V296, P1149, DOI 10.1056/NEJM197705192962006; 1984, LANCET, V1, P888; 1988, LANCET, V1, P1146	13	61	61	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 27	1993	306	6877					553	555		10.1136/bmj.306.6877.553	http://dx.doi.org/10.1136/bmj.306.6877.553			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP886	8461768	Bronze, Green Published			2022-12-24	WOS:A1993KP88600020
J	WEIJLAND, A; PARMEGGIANI, A				WEIJLAND, A; PARMEGGIANI, A			TOWARD A MODEL FOR THE INTERACTION BETWEEN ELONGATION FACTOR-TU AND THE RIBOSOME	SCIENCE			English	Article							AMINOACYL-TRANSFER-RNA; EF-TU; MOLECULES PARTICIPATE; ESCHERICHIA-COLI; BINDING DOMAIN; MUTATION; SPECIFICITY; P21	In the elongation cycle of bacterial protein synthesis the interaction between elongation factor-Tu (EF-Tu).guanosine triphosphate (GTP), aminoacyl-transfer RNA (aa-tRNA), and messenger RNA-programmed ribosomes is associated with the hydrolysis of GTP. This interaction determines the selection of the proper aa-tRNA for incorporation into the polypeptide. In the canonical scheme, one molecule of GTP is hydrolyzed in the EF-Tu-dependent binding of aa-tRNA to the ribosome, and a second molecule is hydrolyzed in the elongation factor-G (EF-G)-mediated translocation of the polypeptide from the ribosomal A site to the P site. Substitution of Asp138 with Asn in EF-Tu changed the substrate specificity from GTP to xanthosine triphosphate and demonstrated that the EF-Tu-mediated reactions involved the hydrolysis of two nucleotide triphosphates for each Phe incorporated. This stoichiometry of two is associated with the binding of the correct aa-tRNA to the ribosome.			WEIJLAND, A (corresponding author), ECOLE POLYTECH,BIOCHIM LAB,CNRS,SDI 61840,F-91128 PALAISEAU,FRANCE.							ANBORGH PH, 1991, FEBS LETT, V292, P232, DOI 10.1016/0014-5793(91)80874-3; BENSCH K, 1991, BIOCHIMIE, V73, P1045, DOI 10.1016/0300-9084(91)90146-R; BILGIN N, 1992, J MOL BIOL, V224, P1011, DOI 10.1016/0022-2836(92)90466-W; CABRER B, 1976, J BIOL CHEM, V251, P1718; CHINALI G, 1980, J BIOL CHEM, V255, P7455; EHRENBERG M, 1990, J MOL BIOL, V211, P739, DOI 10.1016/0022-2836(90)90074-V; GLYNN IM, 1964, BIOCHEM J, V90, P147, DOI 10.1042/bj0900147; GROSJEAN HJ, 1978, P NATL ACAD SCI USA, V75, P610, DOI 10.1073/pnas.75.2.610; HOPFIELD JJ, 1974, P NATL ACAD SCI USA, V71, P4135, DOI 10.1073/pnas.71.10.4135; HUGHES D, 1987, EMBO J, V6, P4235, DOI 10.1002/j.1460-2075.1987.tb02772.x; HWANG YW, 1987, J BIOL CHEM, V262, P13081; JACQUET E, 1988, EMBO J, V7, P2861, DOI 10.1002/j.1460-2075.1988.tb03142.x; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; KAKHNIASHVILI DG, 1986, FEBS LETT, V196, P103, DOI 10.1016/0014-5793(86)80222-8; KAZIRO Y, 1978, BIOCHIM BIOPHYS ACTA, V505, P95, DOI 10.1016/0304-4173(78)90009-5; KJELDGAARD M, 1992, J MOL BIOL, V223, P721, DOI 10.1016/0022-2836(92)90986-T; LACOUR TFM, 1985, EMBO J, V4, P2385, DOI 10.1002/j.1460-2075.1985.tb03943.x; Miller DL, 1977, MOL MECH PROTEIN BIO, P323; NINIO J, 1975, BIOCHIMIE, V57, P587, DOI 10.1016/S0300-9084(75)80139-8; NISHIZUKA Y, 1966, ARCH BIOCHEM BIOPHYS, V116, P344, DOI 10.1016/0003-9861(66)90040-3; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; RICHTER AA, 1990, J MOL BIOL, V216, P311; RUUSALA T, 1982, EMBO J, V1, P741, DOI 10.1002/j.1460-2075.1982.tb01240.x; SWART GWM, 1987, BIOCHEMISTRY-US, V26, P2047, DOI 10.1021/bi00381a038; THOMAS LK, 1988, P NATL ACAD SCI USA, V85, P4242, DOI 10.1073/pnas.85.12.4242; THOMAS LK, 1989, P NATL ACAD SCI USA, V86, P6888; THOMPSON RC, 1981, J BIOL CHEM, V256, P81; THOMPSON RC, 1981, ARCH BIOCHEM BIOPHYS, V258, P6676; UHLENBECK OC, 1971, J MOL BIOL, V57, P221; VIGENBOOM E, 1989, J BIOL CHEM, V264, P1302; VIGENBOOM E, 1985, EMBO J, V4, P1049; WEIJLAND A, 1992, MOL MICROBIOL, V6, P683, DOI 10.1111/j.1365-2958.1992.tb01516.x; WEIJLAND A, UNPUB	33	114	117	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 26	1993	259	5099					1311	1314		10.1126/science.8446899	http://dx.doi.org/10.1126/science.8446899			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KN883	8446899				2022-12-24	WOS:A1993KN88300027
J	LEVINE, B; HUANG, Q; ISAACS, JT; REED, JC; GRIFFIN, DE; HARDWICK, JM				LEVINE, B; HUANG, Q; ISAACS, JT; REED, JC; GRIFFIN, DE; HARDWICK, JM			CONVERSION OF LYTIC TO PERSISTENT ALPHAVIRUS INFECTION BY THE BCL-2 CELLULAR ONCOGENE	NATURE			English	Article							FOLLICULAR LYMPHOMA; B-CELLS; DEATH; APOPTOSIS; GENE; EXPRESSION; VIRUS; PROTEIN; LINES	LITTLE is known about virus-host cell interactions that regulate the lytic potential of viruses during productive replication. Sindbis virus (SV), a single-stranded positive-sense RNA virus in the alphavirus genus (family Togaviridae), results in lytic infection in most vertebrate cell lines, but persistent productive infection in post-mitotic neurons1. The cellular oncogene bcl-2, which encodes an inner mitochondrial membrane protein of M(r) 26,000 (ref. 2), blocks programmed cell death (apoptosis) in neurons3. We therefore investigated whether SV infection induces programmed cell death in non-neuronal cells, and if so, whether virus-induced programmed cell death can be blocked by transfection with bcl-2. We demonstrate that SV infection of baby hamster kidney (BHK-2), mouse neuroblastoma (N18), and rat prostatic adenocarcinoma (AT-3) cells results in programmed cell death, whereas SV infection of bcl-2-transfected AT-3 cells results in long-term persistent productive infection. Thus cellular bcl-2 oncogene expression plays a role in the establishment of persistent viral infection by blocking virus-induced programmed cell death.	JOHNS HOPKINS UNIV, SCH MED, DEPT PHARMACOL & MOLEC SCI, BALTIMORE, MD 21287 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT MED, BALTIMORE, MD 21287 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT ONCOL, BALTIMORE, MD 21287 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT UROL, BALTIMORE, MD 21287 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT NEUROL, BALTIMORE, MD 21287 USA; LA JOLLA CANC RES FDN, CANC RES INST, LA JOLLA, CA 92037 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Sanford Burnham Prebys Medical Discovery Institute								ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; Buchmeier M J, 1980, Adv Immunol, V30, P275, DOI 10.1016/S0065-2776(08)60197-2; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHOU J, 1992, P NATL ACAD SCI USA, V89, P3266, DOI 10.1073/pnas.89.8.3266; CLEM RJ, 1991, SCIENCE, V254, P1388, DOI 10.1126/science.1962198; FROSHAUER S, 1988, J CELL BIOL, V107, P2075, DOI 10.1083/jcb.107.6.2075; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; GREGORY CD, 1991, NATURE, V349, P612, DOI 10.1038/349612a0; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; JOHNSON RT, 1972, J INFECT DIS, V125, P257, DOI 10.1093/infdis/125.3.257; LAURENTCRAWFORD AG, 1991, VIROLOGY, V185, P829, DOI 10.1016/0042-6822(91)90554-O; LEVINE B, 1992, J VIROL, V66, P6429, DOI 10.1128/JVI.66.11.6429-6435.1992; LEVINE B, 1991, SCIENCE, V254, P856, DOI 10.1126/science.1658936; MARTIKAINEN P, 1991, CANCER RES, V51, P4693; NEGRINI M, 1987, CELL, V49, P455, DOI 10.1016/0092-8674(87)90448-X; NUNEZ G, 1990, J IMMUNOL, V144, P3602; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; REED JC, 1991, CANCER RES, V51, P6529; REED JC, 1988, NATURE, V336, P259, DOI 10.1038/336259a0; SORENSON CM, 1990, JNCI-J NATL CANCER I, V82, P749, DOI 10.1093/jnci/82.9.749; TERAI C, 1991, J CLIN INVEST, V87, P1710, DOI 10.1172/JCI115188; TREIGER B, 1988, J UROLOGY, V140, P1580, DOI 10.1016/S0022-5347(17)42131-8; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; Wyllie A H, 1980, Int Rev Cytol, V68, P251; [No title captured]; [No title captured]	28	447	470	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 25	1993	361	6414					739	742		10.1038/361739a0	http://dx.doi.org/10.1038/361739a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KN789	8441470				2022-12-24	WOS:A1993KN78900061
J	SHINKAI, Y; KOYASU, S; NAKAYAMA, K; MURPHY, KM; LOH, DY; REINHERZ, EL; ALT, FW				SHINKAI, Y; KOYASU, S; NAKAYAMA, K; MURPHY, KM; LOH, DY; REINHERZ, EL; ALT, FW			RESTORATION OF T-CELL DEVELOPMENT IN RAG-2 DEFICIENT MICE BY FUNCTIONAL TCR TRANSGENES	SCIENCE			English	Article							ANTIGEN RECEPTOR; MONOCLONAL-ANTIBODY; SCID MUTATION; V(D)J RECOMBINATION; EXPRESSION; REPAIR; CHAIN; DIFFERENTIATION; THYMOCYTES; BIOLOGY	Introduction of TCRalpha transgene, TCRbeta transgene, or both into RAG-2-/- mice differentially rescues T cell development. RAG-2-/- mice have small numbers of TCR-CD4-CD8- (double negative, DN) thymocytes that express CD3gammadeltaepsilon and zeta proteins intracellularly. Introduction of a TCRbeta transgene, but not a TCRalpha transgene, into the RAG-2-/- background restored normal numbers of thymocytes. These cells were CD4+CD8+ (double positive, DP) and expressed small amounts of surface TCRbeta chain dimers in association with CD3gammadeltaepsilon but not zeta. RAG-2-/- mice that expressed alpha and beta TCR transgenes developed both DP and single positive thymocytes. Thus, the TCRbeta subunit, possibly in association with a novel CD3 complex, participates in the DN to the DP transition.	CHILDRENS HOSP MED CTR, HOWARD HUGHES MED INST, BOSTON, MA 02115 USA; CHILDRENS HOSP MED CTR, DEPT GENET, BOSTON, MA 02115 USA; CHILDRENS HOSP MED CTR, DEPT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, IMMUNOL LAB, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA; WASHINGTON UNIV, SCH MED, HOWARD HUGHES MED INST, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT MED, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT GENET, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT MOLEC MICROBIOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT PATHOL, ST LOUIS, MO 63110 USA	Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)			Koyasu, Shigeo/J-5583-2015; Shinkai, Yoichi/N-3909-2014	Koyasu, Shigeo/0000-0001-9585-3038; Shinkai, Yoichi/0000-0002-6051-2484	NIAID NIH HHS [AI19807, AI20047] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI019807, R37AI020047, R37AI019807, R01AI020047, R01AI019807] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASHWELL JD, 1990, ANNU REV IMMUNOL, V8, P139, DOI 10.1146/annurev.immunol.8.1.139; BIEDERMANN KA, 1991, P NATL ACAD SCI USA, V88, P1394, DOI 10.1073/pnas.88.4.1394; BLACKWELL TK, 1989, J BIOL CHEM, V264, P10327; BOSMA MJ, 1991, ANNU REV IMMUNOL, V9, P323, DOI 10.1146/annurev.iy.09.040191.001543; CLAYTON LK, 1990, J EXP MED, V172, P1243, DOI 10.1084/jem.172.4.1243; DIALYNAS DP, 1983, IMMUNOL REV, V74, P29, DOI 10.1111/j.1600-065X.1983.tb01083.x; FOWLKES BJ, 1989, ADV IMMUNOL, V44, P207; FULOP GM, 1990, NATURE, V347, P479, DOI 10.1038/347479a0; GROETTRUP M, 1992, EMBO J, V11, P2735, DOI 10.1002/j.1460-2075.1992.tb05339.x; HAVRAN WL, 1987, NATURE, V330, P170, DOI 10.1038/330170a0; HENDRICKSON EA, 1991, P NATL ACAD SCI USA, V88, P4061, DOI 10.1073/pnas.88.10.4061; HUSSEY RE, IN PRESS J IMMUNOL; ITOHARA S, 1989, P NATL ACAD SCI USA, V86, P5094, DOI 10.1073/pnas.86.13.5094; KISHI H, 1991, EMBO J, V10, P93, DOI 10.1002/j.1460-2075.1991.tb07924.x; KLAUSNER RD, 1990, ANNU REV CELL BIOL, V6, P403, DOI 10.1146/annurev.cb.06.110190.002155; KOSUGI A, 1992, P NATL ACAD SCI USA, V89, P9494, DOI 10.1073/pnas.89.20.9494; KOYASU S, 1992, J EXP MED, V175, P203, DOI 10.1084/jem.175.1.203; KUBO RT, 1989, J IMMUNOL, V142, P2736; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LOH DY, 1991, NEW BIOL, V3, P924; MALISSEN M, 1992, IMMUNOL TODAY, V13, P315, DOI 10.1016/0167-5699(92)90044-8; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; PHILPOTT KL, 1992, SCIENCE, V256, P1448, DOI 10.1126/science.1604321; REINHERZ EL, 1980, CELL, V19, P821, DOI 10.1016/0092-8674(80)90072-0; RETH M, 1992, ANNU REV IMMUNOL, V10, P97, DOI 10.1146/annurev.iy.10.040192.000525; ROLINK A, 1991, CELL, V66, P1081, DOI 10.1016/0092-8674(91)90032-T; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; SUSSMAN JJ, 1988, CELL, V52, P85, DOI 10.1016/0092-8674(88)90533-8; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; WEISSMAN AM, 1989, EMBO J, V8, P3651, DOI 10.1002/j.1460-2075.1989.tb08539.x	33	369	371	1	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 5	1993	259	5096					822	825		10.1126/science.8430336	http://dx.doi.org/10.1126/science.8430336			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL110	8430336				2022-12-24	WOS:A1993KL11000036
J	JONES, RVH; HANSFORD, J; FISKE, J				JONES, RVH; HANSFORD, J; FISKE, J			DEATH FROM CANCER AT HOME - THE CARERS PERSPECTIVE	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To collect information from principal carers of people who had died at home with cancer; to identify areas of support which need improvement. Design-Semistructured interviews with carers two to four months after the death. Setting-38 general practices in the Exeter, Torbay, and Plymouth health districts. Subjects-207 carers. Main outcome measures-Services received by carers and quality of support. Results-161 of 207 patients were aged 60 or over. 88 carers were aged under 60, 110 were 60-80, and 9 were > 80. Carers had difficulty in getting urgent professional help in only 15 out of 177 cases. 124 carers were not given advice on financial help and 174 were not told of support available from local charities. Although pain was well controlled, 25% of patients had no relief of other symptoms. Overall, 150 carers considered the support excellent, 45 good, 8 moderate, 2 poor, and 2 had no comment. Conclusions-Although care has improved in recent years, health professionals need to give carers more advice about help available outside health services. Domestic help was often needed earlier. Better appreciation of carers' problems is needed.			JONES, RVH (corresponding author), UNIV EXETER,POSTGRAD MED SCH,DEPT GEN PRACTICE,EXETER EX2 5DW,ENGLAND.							CARTWRIGHT A, 1973, LIFE DEATH; HERD EB, 1990, BRIT J GEN PRACT, V40, P248; HIGGINSON I, 1990, BRIT MED J, V301, P277, DOI 10.1136/bmj.301.6746.277; HIGGINSON I, 1989, J R SOC MED, V82, P2264; JONES R, 1992, EUR J CANCER CARE, V1, P9; JONES RVH, 1992, BRIT J GEN PRACT, V42, P419; Parkes C M, 1978, J R Coll Gen Pract, V28, P19; SYKES N P, 1992, Palliative Medicine, V6, P227, DOI 10.1177/026921639200600307; WILKES E, 1984, LANCET, V1, P950; 1987, CARE DYING GUIDE HLT; 1989, MORTALITY UK; 1980, TERMINAL CARE REPORT	12	86	87	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 23	1993	306	6872					249	251		10.1136/bmj.306.6872.249	http://dx.doi.org/10.1136/bmj.306.6872.249			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ591	8443527	Green Published, Bronze			2022-12-24	WOS:A1993KJ59100024
J	LARSON, SB; KOSZELAK, S; DAY, J; GREENWOOD, A; DODDS, JA; MCPHERSON, A				LARSON, SB; KOSZELAK, S; DAY, J; GREENWOOD, A; DODDS, JA; MCPHERSON, A			DOUBLE-HELICAL RNA IN SATELLITE TOBACCO MOSAIC-VIRUS	NATURE			English	Article							PHENYLALANINE TRANSFER-RNA; HUMAN RHINOVIRUS-14; ICOSAHEDRAL VIRUS; NECROSIS VIRUS; RESOLUTION; REFINEMENT; SEQUENCE; CRYSTALS; STRATEGY; PROGRAMS	SATELLITE tobacco mosaic virus (STMV) is the spherical satellite to an obligatory rod-shaped helper tobacco mosaic virus (TMV), which is required for replication1,2. STMV has 60 protein subunits of M(r) 17,500 on a T = 1 icosahedral capsid3 containing a single-stranded RNA genome of 1,059 bases4-6. STMV appears similar to another virus, STNV7,8, but is approximately 20 per cent smaller. It shows no amino-acid homology or immunological cross-reactivity with either STNV or its host TMV4,9. Here we report the X-ray crystal structure of STMV, which shows that the coat protein of STMV contains a 'Swiss roll' beta-barrel. An amino-terminal strand extends more than 60angstrom and is primarily responsible for quaternary interactions. Each capsid dimer is associated with a segment of genomic RNA double helix comprising seven base pairs. The dyad of each protein dimer is coincident with that of the central base pair of the associated RNA segment whose helix axis is directed along an icosahedral edge. Protein-nucleic acid interactions are extensive. The RNA helices, which have additional stacked bases at their 3' termini, differ significantly from canonical nucleic acid helical forms.	UNIV CALIF RIVERSIDE, DEPT PLANT PATHOL, RIVERSIDE, CA 92521 USA	University of California System; University of California Riverside	LARSON, SB (corresponding author), UNIV CALIF RIVERSIDE, DEPT BIOCHEM, RIVERSIDE, CA 92521 USA.							ABADZAPATERO C, 1981, ACTA CRYSTALLOGR B, V37, P2002, DOI 10.1107/S0567740881007863; ARNOLD E, 1987, ACTA CRYSTALLOGR A, V43, P346, DOI 10.1107/S0108767387099306; ARNOLD E, 1988, ACTA CRYSTALLOGR A, V44, P270, DOI 10.1107/S0108767387011875; BENEVIDES JM, 1991, BIOCHEMISTRY-US, V30, P4855, DOI 10.1021/bi00234a004; BENTLEY GA, 1987, J MOL BIOL, V194, P129, DOI 10.1016/0022-2836(87)90722-4; BRANDEN C, 1991, INTRO PROTEIN STRUCT, pCH11; BRANDEN CI, 1991, INTRO PROTEIN STRUCT, P70; BRICOGNE G, 1974, ACTA CRYSTALLOGR A, VA 30, P395, DOI 10.1107/S0567739474010722; BRICOGNE G, 1976, ACTA CRYSTALLOGR A, V32, P832, DOI 10.1107/S0567739476001691; BRUNGER AT, 1991, ANNU REV PHYS CHEM, V42, P197, DOI 10.1146/annurev.pc.42.100191.001213; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CASPAR DLD, 1962, COLD SPRING HARB SYM, V27, P1, DOI 10.1101/sqb.1962.027.001.005; CHEN ZG, 1989, SCIENCE, V245, P154, DOI 10.1126/science.2749253; DAY J, 1992, PROTEIN SCI, V1, P1254, DOI 10.1002/pro.5560011004; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DICKERSON RE, 1985, BIOL MACROMOLECULES, V2; DODDS JA, 1991, CAN J PLANT PATHOL, V13, P192, DOI 10.1080/07060669109500954; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; JONES TA, 1984, J MOL BIOL, V177, P735, DOI 10.1016/0022-2836(84)90047-0; JONES TA, 1982, COMPUTATIONAL CRYSTA, P307; KIM KS, 1989, J ULTRA MOL STRUCT R, V102, P196, DOI 10.1016/0889-1605(89)90014-1; KIM SH, 1974, SCIENCE, V185, P435, DOI 10.1126/science.185.4149.435; KOSZELAK S, 1989, J MOL BIOL, V209, P323, DOI 10.1016/0022-2836(89)90281-7; LILJAS L, 1982, J MOL BIOL, V159, P93, DOI 10.1016/0022-2836(82)90033-X; MCKENNA R, 1992, NATURE, V355, P137, DOI 10.1038/355137a0; MIRKOV TE, 1989, VIROLOGY, V170, P139, DOI 10.1016/0042-6822(89)90361-9; RAYMENT I, 1983, ACTA CRYSTALLOGR A, V39, P102, DOI 10.1107/S0108767383000197; ROBERTUS JD, 1974, NATURE, V250, P546, DOI 10.1038/250546a0; ROSSMANN MG, 1989, ANNU REV BIOCHEM, V58, P533, DOI 10.1146/annurev.bi.58.070189.002533; ROSSMANN MG, 1962, ACTA CRYSTALLOGR, V15, P24, DOI 10.1107/S0365110X62000067; TERWILLIGER T, 1964, ACTA CRYSTALLOGR A, V39, P813; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; TSAO J, 1991, SCIENCE, V251, P1456, DOI 10.1126/science.2006420; VALVERDE RA, 1986, J GEN VIROL, V67, P1875, DOI 10.1099/0022-1317-67-9-1875; VALVERDE RA, 1987, J GEN VIROL, V68, P965, DOI 10.1099/0022-1317-68-4-965; XUONG NH, 1985, J APPL CRYSTALLOGR, V18, P342, DOI 10.1107/S0021889885010433; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	38	97	97	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 14	1993	361	6408					179	182		10.1038/361179a0	http://dx.doi.org/10.1038/361179a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KG466	8421525				2022-12-24	WOS:A1993KG46600068
J	QIAN, HH; DOWLING, JE				QIAN, HH; DOWLING, JE			NOVEL GABA RESPONSES FROM ROD-DRIVEN RETINAL HORIZONTAL CELLS	NATURE			English	Article							GAMMA-AMINOBUTYRIC-ACID; RECEPTOR SUBTYPES; MOLECULAR-BIOLOGY; XENOPUS-OOCYTES; RAT-BRAIN; PHARMACOLOGY; NEURONS; EXPRESSION; INVITRO; CAT	Gamma-AMINOBUTYRIC acid (GABA) is the main inhibitory neurotransmitter in the central nervous system. Two classes of GABA receptors (GABA(A) and GABA(B)) have been identified. GABA(A) receptors are ligand-gated chloride channels that are competitively antagonized by bicuculline, noncompetitively blocked by picrotoxin, and often allosterically modulated by barbiturates and benzodiazepines1-3. GABA(B) receptors regulate potassium and calcium channels through G-protein and intracellular second-messenger pathways2,3, are selectively activated by baclofen, and are antagonized by phaclofen and 2-hydroxysaclofen4,5. For some years, evidence has accumulated that there are GABA receptors, especially prominent along visual pathways, which are neither antagonized by bicuculline nor activated by baclofen, but are activated by certain conformationally restricted analogues of GABA, including cis-4-aminocrotonic acid (CACA)6-9. These receptors have been designated GABA(C) receptors9. As yet, membrane current responses from isolated neurons that reflect this novel pharmacology have not been reported, although such responses have been recorded from oocytes injected with retinal messenger RNA10-13. Here we describe a chloride-mediated current response from isolated rod-driven horizontal cells (H4) of the white perch retina that has this novel pharmacology.			QIAN, HH (corresponding author), HARVARD UNIV,DEPT CELLULAR & DEV BIOL,16 DIV AVE,CAMBRIDGE,MA 02138, USA.							AKAIKE N, 1985, J PHYSIOL-LONDON, V360, P367, DOI 10.1113/jphysiol.1985.sp015622; ARAKAWA T, 1988, EUR J PHARMACOL, V158, P217, DOI 10.1016/0014-2999(88)90070-2; BORMANN J, 1988, TRENDS NEUROSCI, V11, P112, DOI 10.1016/0166-2236(88)90156-7; BURT DR, 1991, FASEB J, V5, P2916, DOI 10.1096/fasebj.5.14.1661244; CURTIS DR, 1980, BRAIN RES, V194, P255, DOI 10.1016/0006-8993(80)91339-6; CUTTING GR, 1991, P NATL ACAD SCI USA, V88, P2673, DOI 10.1073/pnas.88.7.2673; Dowling J. E., 1987, RETINA APPROACHABLE; DOWLING JE, 1985, BRAIN RES, V360, P331, DOI 10.1016/0006-8993(85)91250-8; DREW CA, 1984, NEUROSCI LETT, V52, P317, DOI 10.1016/0304-3940(84)90181-2; GALLAGHER JP, 1978, J PHYSIOL-LONDON, V275, P263, DOI 10.1113/jphysiol.1978.sp012189; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HILL DR, 1981, NATURE, V290, P149, DOI 10.1038/290149a0; HOUAMED KM, 1984, NATURE, V310, P318, DOI 10.1038/310318a0; ITABASHI S, 1992, J NEUROPHYSIOL, V67, P1367, DOI 10.1152/jn.1992.67.5.1367; JOHNSTON GA, 1975, J NEUROCHEM, V24, P157, DOI 10.1111/j.1471-4159.1975.tb07642.x; Johnston GA, 1986, RECEPTOR BIOCH METHO, V5, P57; KERR DIB, 1988, NEUROSCI LETT, V92, P92, DOI 10.1016/0304-3940(88)90748-3; MATHISON RD, 1980, BRAIN RES, V187, P476, DOI 10.1016/0006-8993(80)90219-X; NAKAGAWA T, 1991, AM J PHYSIOL, V260, pC745, DOI 10.1152/ajpcell.1991.260.4.C745; OLSEN RW, 1990, FASEB J, V4, P1469, DOI 10.1096/fasebj.4.5.2155149; OLSEN RW, 1982, ANNU REV PHARMACOL, V22, P245, DOI 10.1146/annurev.pa.22.040182.001333; POLENZANI L, 1991, P NATL ACAD SCI USA, V88, P4318, DOI 10.1073/pnas.88.10.4318; SEEBURG PH, 1990, COLD SH Q B, V55, P29; SHIMADA S, 1992, MOL PHARMACOL, V41, P683; SIVILOTTI L, 1989, EUR J PHARMACOL, V164, P205, DOI 10.1016/0014-2999(89)90460-3; SIVILOTTI L, 1991, PROG NEUROBIOL, V36, P35, DOI 10.1016/0301-0082(91)90036-Z; WOODWARD RM, 1992, MOL PHARMACOL, V42, P165	27	255	261	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 14	1993	361	6408					162	164		10.1038/361162a0	http://dx.doi.org/10.1038/361162a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KG466	8421521				2022-12-24	WOS:A1993KG46600062
J	CHAPMAN, S; WOODWARD, S				CHAPMAN, S; WOODWARD, S			AUSTRALIAN COURT DECISION ON PASSIVE SMOKING UPHELD ON APPEAL	BRITISH MEDICAL JOURNAL			English	Article							INDUSTRY		ACT SMOKING & HLTH LTD,WOOLLOOMOOLOO 2011,AUSTRALIA		CHAPMAN, S (corresponding author), UNIV SYDNEY,WESTMEAD HOSP,WESTMEAD 2145,AUSTRALIA.							CHAPMAN S, 1987, COMMUNITY HEALTH ST, V11, P139; CHAPMAN S, 1991, BRIT MED J, V302, P943, DOI 10.1136/bmj.302.6782.943; CHAPMAN S, 1990, INT J HEALTH SERV, V20, P417, DOI 10.2190/YYKC-PGTC-VUMM-3A5P; DOYLE AE, 1988, MED J AUSTRALIA, V148, P152, DOI 10.5694/j.1326-5377.1988.tb112788.x; MACASKILL P, 1992, AM J PUBLIC HEALTH, V82, P96, DOI 10.2105/AJPH.82.1.96; WARNER KE, 1991, AM J PUBLIC HEALTH, V81, P839, DOI 10.2105/AJPH.81.7.839; 1990, TOBACCO AUSTR SUMMAR, P12	7	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 9	1993	306	6870					120	122		10.1136/bmj.306.6870.120	http://dx.doi.org/10.1136/bmj.306.6870.120			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KG465	8435609	Bronze, Green Published			2022-12-24	WOS:A1993KG46500027
J	GROOP, LC; KANKURI, M; SCHALINJANTTI, C; EKSTRAND, A; NIKULAIJAS, P; WIDEN, E; KUISMANEN, E; ERIKSSON, J; FRANSSILAKALLUNKI, A; SALORANTA, C; KOSKIMIES, S				GROOP, LC; KANKURI, M; SCHALINJANTTI, C; EKSTRAND, A; NIKULAIJAS, P; WIDEN, E; KUISMANEN, E; ERIKSSON, J; FRANSSILAKALLUNKI, A; SALORANTA, C; KOSKIMIES, S			ASSOCIATION BETWEEN POLYMORPHISM OF THE GLYCOGEN-SYNTHASE GENE AND NON-INSULIN-DEPENDENT DIABETES-MELLITUS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MUSCLE; RESISTANCE; DEFECTS; NIDDM; DNA	Background. The storage of glucose as glycogen in skeletal muscle is frequently impaired in patients with non-insulin-dependent diabetes mellitus (NIDDM) and their nondiabetic relatives. Despite an intensive search for candidate genes associated with NIDDM, no data have been available on the gene coding for the key enzyme of this pathway, glycogen synthase. Methods and Results. Using a human complementary DNA probe, the restriction enzyme XbaI, and Southern blot analysis, we identified two polymorphic alleles, A1 and A2, in the glycogen synthase gene. The gene was localized to chromosome 19. The A1A2 or A2A2 genotype was found in 30 percent of 107 patients with NIDDM but in only 8 percent of 164 nondiabetic subjects without a family history of NIDDM (P<0.001). The diabetic patients with the A2 allele had a stronger family history of N IDDM (P = 0.019), a higher prevalence of hypertension (P = 0.008), ard a more severe defect in insulin-stimulated glucose storage (P = 0.001) than the diabetic patients with the A1 allele. The concentration of the glycogen synthase protein in biopsy specimens of skeletal muscle from the patients with the A2 allele was normal, however, suggesting that expression of the gene was unaltered. The XbaI polymorphism was due to a change of a single base in an intron. Conclusions. The XbaI polymorphism of the glycogen synthase gene identifies a subgroup of patients with NIDDM characterized by a strong family history of NIDDM, a high prevalence of hypertension, and marked insulin resistance.	UNIV HELSINKI,DEPT MED 4,SF-00100 HELSINKI 10,FINLAND; UNIV HELSINKI,DEPT BIOCHEM,SF-00100 HELSINKI 10,FINLAND; FINNISH RED CROSS & BLOOD TRANSFUS SERV,BLOOD TRANSFUS SERV,HELSINKI,FINLAND	University of Helsinki; Finland National Institute for Health & Welfare; University of Helsinki								BARNETT AH, 1981, DIABETOLOGIA, V20, P87, DOI 10.1007/BF00262007; BROWNER MF, 1989, P NATL ACAD SCI USA, V86, P1443, DOI 10.1073/pnas.86.5.1443; DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667; ERIKSSON J, 1992, DIABETOLOGIA, V35, P143, DOI 10.1007/BF00402546; ERIKSSON J, 1989, NEW ENGL J MED, V321, P337, DOI 10.1056/NEJM198908103210601; FERRANNINI E, 1987, NEW ENGL J MED, V317, P350, DOI 10.1056/NEJM198708063170605; FERRANNINI E, 1988, METABOLISM, V37, P287, DOI 10.1016/0026-0495(88)90110-2; GROOP LC, 1989, J CLIN INVEST, V84, P205, DOI 10.1172/JCI114142; HITMAN GA, 1991, BAILLIERE CLIN ENDOC, V5, P455, DOI 10.1016/S0950-351X(05)80142-9; K÷bberling J., 1982, GENETICS DIABETES ME, P201; PERMUTT MA, 1991, BAILLIERE CLIN ENDOC, V5, P495, DOI 10.1016/S0950-351X(05)80144-2; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; SCHALINJANTTI C, 1992, DIABETES, V41, P598, DOI 10.2337/diabetes.41.5.598; THORBURN AW, 1991, J CLIN INVEST, V87, P489, DOI 10.1172/JCI115022; VAAG A, 1992, J CLIN INVEST, V89, P782, DOI 10.1172/JCI115656; VANDENPLAS S, 1984, J MED GENET, V21, P164, DOI 10.1136/jmg.21.3.164; VESTERGAARD H, 1991, DIABETES, V40, P1740, DOI 10.2337/diabetes.40.12.1740	17	176	181	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 7	1993	328	1					10	14		10.1056/NEJM199301073280102	http://dx.doi.org/10.1056/NEJM199301073280102			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF507	8416266				2022-12-24	WOS:A1993KF50700002
J	MARZUK, PM; TARDIFF, K; HIRSCH, CS; LEON, AC; STAJIC, M; HARTWELL, N; PORTERA, L				MARZUK, PM; TARDIFF, K; HIRSCH, CS; LEON, AC; STAJIC, M; HARTWELL, N; PORTERA, L			INCREASE IN SUICIDE BY ASPHYXIATION IN NEW-YORK-CITY AFTER THE PUBLICATION OF FINAL EXIT	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							TELEVISION-NEWS STORIES		OFF CHIEF MED EXAMINER,NEW YORK,NY 10016		MARZUK, PM (corresponding author), CORNELL UNIV,MED CTR,COLL MED,DEPT PSYCHIAT,1300 YORK AVE,NEW YORK,NY 10021, USA.				NIDA NIH HHS [DA-06534] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA006534] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ALTMAN LK, 1991, NY TIMES        0724, pA10; CARD JJ, 1974, OMEGA-J DEATH DYING, V5, P37, DOI 10.2190/K59M-Y0KN-PAKV-JFUV; COX M, 1991, WALL STREET J   0527, pB1; Gould M.S., 1990, SUICIDE LIFE CYCLE R, P517; Humphry Derek, 1991, FINAL EXIT PRACTICAL; KESSLER RC, 1989, J NERV MENT DIS, V177, P551, DOI 10.1097/00005053-198909000-00006; LAVIN MR, 1992, NEW ENGL J MED, V326, P890; MARZUK PM, 1992, ARCH GEN PSYCHIAT, V49, P451; MEHTA CR, 1990, STATABLE ELECTORNIC; OLKIN I, 1980, PROBABILITY MODELS A, P253; PHILLIPS DP, 1986, NEW ENGL J MED, V315, P685, DOI 10.1056/NEJM198609113151106; RICH CL, 1986, ARCH GEN PSYCHIAT, V43, P577; RODIN G, 1986, AM J PSYCHIAT, V143, P696; SACKS MH, 1992, AM J PSYCHIAT, V149, P842; WEISSMAN MM, 1974, ARCH GEN PSYCHIAT, V30, P737; 1991, DHHS PHS911101 NAT C, V2	16	56	57	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 11	1993	329	20					1508	1510		10.1056/NEJM199311113292022	http://dx.doi.org/10.1056/NEJM199311113292022			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MF292	8413474				2022-12-24	WOS:A1993MF29200035
J	AREVALO, JH; TAUSSIG, MJ; WILSON, IA				AREVALO, JH; TAUSSIG, MJ; WILSON, IA			MOLECULAR-BASIS OF CROSS-REACTIVITY AND THE LIMITS OF ANTIBODY-ANTIGEN COMPLEMENTARITY	NATURE			English	Article								TWO major unanswered questions concerning the specificity of antibodies are: how do structurally different antigens bind with high affinity to the same antibody, and what are the limits of the antibody combining site complementarity and flexibility that contribute to such crossreactivity? We report here a comparative analysis of the X-ray structures of five conformationally different steroids in complex with the Fab' fragment of an anti-progesterone antibody DB3 at 2.7 angstrom. This antibody is unable to complement completely the shape of the hydrophobic antigen so that crossreactivity occurs with other ligands without major structural rearrangements of the binding site. Antigen specificity can be explained through conserved interactions of DB3 with the steroid D-ring, whereas some of the crossreactivity is realized through different binding orientations of the steroid skeleton that place the A-ring into alternative pockets on the antibody surface. The restricted gene usage of the VGAM3.8 family in the generation of anti-progesterone monoclonal antibodies1,2 may be explained by the specific interaction Of V(H) hallmark residues with the steroid D-ring. This first detailed structure of steroid interactions with a protein could be applied to the understanding of general mechanisms of steroid recognition as well as in the design of specific binding sites for small hydrophobic ligands.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; AFRC, BABRAHAM INST, DEPT IMMUNOL, STRUCT STUDIES LAB, CAMBRIDGE CB2 4AT, ENGLAND	Scripps Research Institute; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute								ALZARI PM, 1990, EMBO J, V9, P3807, DOI 10.1002/j.1460-2075.1990.tb07598.x; AREVALO JH, 1993, J MOL BIOL, V231, P103, DOI 10.1006/jmbi.1993.1260; BAULIEU EE, 1989, SCIENCE, V245, P1351, DOI 10.1126/science.2781282; BEREK C, 1987, IMMUNOL REV, V96, P23, DOI 10.1111/j.1600-065X.1987.tb00507.x; BOHACEK RS, 1992, J MED CHEM, V35, P1671, DOI 10.1021/jm00088a002; BRUNGER AT, 1990, XPLOR VERSION 21; BURLEY SK, 1985, SCIENCE, V229, P23, DOI 10.1126/science.3892686; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; DEVERSON E, 1987, EUR J IMMUNOL, V17, P9, DOI 10.1002/eji.1830170103; Duax W.L., 1975, ATLAS STEROID STRUCT, V1; ELLIS ST, 1988, J ENDOCRINOL, V118, P69, DOI 10.1677/joe.0.1180069; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; GELIN BR, 1979, BIOCHEMISTRY-US, V18, P1256, DOI 10.1021/bi00574a022; GRIFFIN JF, 1984, ATLAS STEROID STRUCT, V2; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KABAT EA, 1991, J IMMUNOL, V147, P1709; Kabat EA, 1991, SEQUENCES PROTEINS I; Landsteiner K., 1962, SPECIFICITY SEROLOGI; LASCOMBE MB, 1992, P NATL ACAD SCI USA, V89, P9429, DOI 10.1073/pnas.89.20.9429; LEE B, 1971, J MOL BIOL, V55, P376; LUUTHE V, 1991, BIOCHEMISTRY-US, V30, P8861; MUDGETTHUNTER M, 1985, MOL IMMUNOL, V22, P477, DOI 10.1016/0161-5890(85)90132-4; PARHAMISEREN B, 1993, J IMMUNOL, V150, P1829; RINI JM, 1992, SCIENCE, V255, P959, DOI 10.1126/science.1546293; SIMS MJ, 1992, J IMMUNOL, V149, P1642; STANFIELD RL, IN PRESS STRUCTURE; STRICKLER RC, 1980, BIOCHEMISTRY-US, V19, P4950, DOI 10.1021/bi00563a002; STURA EA, 1987, IMMUNOLOGY, V62, P511; TAUSSIG MJ, 1991, IMMUNOLOGY, V72, P471; UPSON C, 1989, IEEE COMPUT GRAPH, V9, P30, DOI 10.1109/38.31462; VANREGENMORTEL MHV, 1989, IMMUNOL TODAY, V10, P266, DOI 10.1016/0167-5699(89)90140-0; WILSON IA, 1993, CURR OPIN STRUC BIOL, V3, P113, DOI 10.1016/0959-440X(93)90210-C; WRIGHT LJ, 1982, NATURE, V295, P415, DOI 10.1038/295415a0	34	153	156	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 28	1993	365	6449					859	863		10.1038/365859a0	http://dx.doi.org/10.1038/365859a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MD951	8413674				2022-12-24	WOS:A1993MD95100057
J	WINSLOW, JT; HASTINGS, N; CARTER, CS; HARBAUGH, CR; INSEL, TR				WINSLOW, JT; HASTINGS, N; CARTER, CS; HARBAUGH, CR; INSEL, TR			A ROLE FOR CENTRAL VASOPRESSIN IN PAIR BONDING IN MONOGAMOUS PRAIRIE VOLES	NATURE			English	Article							NEUROHYPOPHYSEAL PEPTIDES; MICROTUS-OCHROGASTER; SEXUAL-BEHAVIOR; MALE-RATS; OXYTOCIN; RECEPTOR; ANTAGONISTS; SYSTEM	MONOGAMOUS social organization is characterized by selective affiliation with a partner, high levels of paternal behaviour and, in many species, intense aggression towards strangers for defence of territory, nest and mate1,2. Although much has been written about the evolutionary causes of monogamy, little is known about the proximate mechanisms for pair bonding in monogamous mammals2,3. The prairie vole, Microtus ochrogaster, is a monogamous, biparental rodent which exhibits long-term pair bonds characterized by selective affiliation (partner preference) and aggression4,5. Here we describe the rapid development of both selective aggression and partner preferences following mating in the male of this species. We hypothesized that either arginine-vasopressin (AVP) or oxytocin (OT), two nine-amino-acid neuropeptides with diverse forebrain projections, could mediate the development of selective aggression and affiliation. This hypothesis was based on the following observations: (1) monogamous and polygamous voles differ specifically in the distribution of forebrain AVP and OT receptors6,7; (2) AVP innervation in the prairie vole brain is sexually dimorphic and important for paternal behaviour8; (3) central AVP pathways have been previously implicated in territorial displays and social memory9,10; and (4) central OT pathways have been previously implicated in affiliative behaviours11. We now demonstrate that central AVP is both necessary and sufficient for selective aggression and partner preference formation, two critical features of pair bonding in the monogamous prairie vole.	NIMH,NEUROPHYSIOL LAB,POB 608,POOLESVILLE,MD 20837; UNIV MARYLAND,DEPT ZOOL,COLL PK,MD 20742	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); University System of Maryland; University of Maryland College Park								BAMSHAD M, 1993, J NEUROENDOCRINOL, V5, P247, DOI 10.1111/j.1365-2826.1993.tb00480.x; BAMSHAD M, 1992, SOC NEUR ABSTR, V18; CAMPAAN JC, 1993, BRAIN RES B, V30, P1; CARTER CS, 1986, ADV STUD BEHAV, P109; CLUTTONBROCK TH, 1989, PROC R SOC SER B-BIO, V236, P339, DOI 10.1098/rspb.1989.0027; DANTZER R, 1987, PSYCHOPHARMACOLOGY, V91, P363, DOI 10.1007/BF00518192; DEWIED D, 1991, P NATL ACAD SCI USA, V88, P1494, DOI 10.1073/pnas.88.4.1494; DEWSBURY DA, 1988, AM ZOOL NEBR S MOT, P1; ELANDS J, 1987, EUR J PHARMACOL, V147, P197; FERRIS CF, 1984, SCIENCE, V224, P521, DOI 10.1126/science.6538700; FERRIS CF, 1988, EUR J PHARMACOL, V154, P153, DOI 10.1016/0014-2999(88)90092-1; GETZ LL, 1981, BEHAV ECOL SOCIOBIOL, V8, P189, DOI 10.1007/BF00299829; HUGHES AM, 1987, BRAIN RES, V414, P133, DOI 10.1016/0006-8993(87)91333-3; INSEL TR, 1992, P NATL ACAD SCI USA, V89, P5981, DOI 10.1073/pnas.89.13.5981; INSEL TR, 1992, PSYCHONEUROENDOCRINO, V17, P3, DOI 10.1016/0306-4530(92)90073-G; INSEL TR, 1993, REGUL PEPTIDES, V45, P127, DOI 10.1016/0167-0115(93)90194-D; JANNETT F J JR, 1980, Biologist (Charleston), V62, P3; JONES PM, 1982, NEUROENDOCRINOLOGY, V34, P297, DOI 10.1159/000123316; KLEIMAN DG, 1977, Q REV BIOL, V52, P39, DOI 10.1086/409721; KRUSZYNSKI M, 1980, J MED CHEM, V23, P364, DOI 10.1021/jm00178a003; Miczek K. A., 1987, EXPT PSYCHOPHARMACOL, P27; MURPHY MR, 1987, J CLIN ENDOCR METAB, V65, P738, DOI 10.1210/jcem-65-4-738; PIERCE JD, 1991, AGGRESSIVE BEHAV, V17, P337, DOI 10.1002/1098-2337(1991)17:6<337::AID-AB2480170605>3.0.CO;2-F; POPICK FE, 1975, LIFE SCI, V18, P197; ROCHE KE, 1979, SCIENCE, V204, P1343, DOI 10.1126/science.221973; WILLIAMS JR, 1992, HORM BEHAV, V26, P339, DOI 10.1016/0018-506X(92)90004-F; WITT DM, 1991, ENDOCRINOLOGY, V128, P3269, DOI 10.1210/endo-128-6-3269	27	691	704	1	145	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 7	1993	365	6446					545	548		10.1038/365545a0	http://dx.doi.org/10.1038/365545a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MA661	8413608				2022-12-24	WOS:A1993MA66100053
J	LEVY, SB				LEVY, SB			CONFRONTING MULTIDRUG RESISTANCE - A ROLE FOR EACH OF US	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ANTIMICROBIAL RESISTANCE; ESCHERICHIA-COLI; ENTEROCOCCUS		TULANE UNIV,SCH MED,DEPT MED,NEW ORLEANS,LA 70112; NEW ENGLAND MED CTR,BOSTON,MA 02111	Tulane University; Tufts Medical Center	LEVY, SB (corresponding author), TULANE UNIV,SCH MED,DEPT MOLEC BIOL & MICROBIOL,CTR ADAPTAT GENET & DRUG RESISTANCE,NEW ORLEANS,LA 70112, USA.							BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; BLUMBERG HM, 1991, J INFECT DIS, V163, P1279, DOI 10.1093/infdis/163.6.1279; DATTA N, 1971, LANCET, V1, P312; DOVER MJ, 1986, BIOSCIENCE, V36, P78, DOI 10.2307/1310107; FORNASINI M, 1992, J INFECT DIS, V166, P326, DOI 10.1093/infdis/166.2.326; HOLMBERG SD, 1987, REV INFECT DIS, V9, P1065; KLOOS WE, 1986, MICROBIOLOGY 1986, P132; KUNIN CM, 1990, PRINCIPLES PRACTICE, P427; LECLERCQ R, 1988, NEW ENGL J MED, V319, P157, DOI 10.1056/NEJM198807213190307; Lederberg J., 1992, EMERGING INFECTIONS; Levy S. B., 1986, BANBURY REPORT, P17; Levy Stuart B., 1992, ANTIBIOTIC PARADOX M; MOELLERING RC, 1991, J ANTIMICROB CHEMOTH, V28, P1, DOI 10.1093/jac/28.1.1; MORTON A, 1991, J INFECT DIS, V163, P542; MURRAY BE, 1982, NEW ENGL J MED, V306, P130, DOI 10.1056/NEJM198201213060302; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; PHELPS CE, 1989, MED CARE, V27, P194, DOI 10.1097/00005650-198902000-00009; REICHLER MR, 1992, J INFECT DIS, V166, P1346, DOI 10.1093/infdis/166.6.1346; Shlaes D, 1991, ASM NEWS, V57, P455; STAMM WE, 1992, INFECT DIS, P792; TAUXE RV, 1990, J INFECT DIS, V162, P1107, DOI 10.1093/infdis/162.5.1107; WONGSRICHANALAI C, 1992, AM J TROP MED HYG, V47, P112, DOI 10.4269/ajtmh.1992.47.112	22	47	47	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 14	1993	269	14					1840	1842		10.1001/jama.269.14.1840	http://dx.doi.org/10.1001/jama.269.14.1840			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW250	8459518				2022-12-24	WOS:A1993KW25000041
J	HOHEISEL, JD; MAIER, E; MOTT, R; MCCARTHY, L; GRIGORIEV, AV; SCHALKWYK, LC; NIZETIC, D; FRANCIS, F; LEHRACH, H				HOHEISEL, JD; MAIER, E; MOTT, R; MCCARTHY, L; GRIGORIEV, AV; SCHALKWYK, LC; NIZETIC, D; FRANCIS, F; LEHRACH, H			HIGH-RESOLUTION COSMID AND P1-MAPS SPANNING THE 14-MB GENOME OF THE FISSION YEAST S-POMBE	CELL			English	Article							SCHIZOSACCHAROMYCES-POMBE; REFERENCE LIBRARIES; DNA; CONSTRUCTION; PHOSPHATASE; CHROMOSOMES; DEPENDENCE; ELEGANS; TYPE-1; REPEAT	Gridded on high density filters, a P1 genomic library of 17-fold coverage and a cosmid library of 8 genome equivalents, both made from S. pombe strain 972h-, were ordered by hybridizing genetic markers and individual clones from the two libraries. Yeast artificial chromosome (YAC) clones covering the entire genome were used to subdivide the libraries, and hybridization of short oligonucleotides and DNA pools made from randomly selected cosmids provided further mapping information. Restriction digests were generated as an independent confirmation of the clone order. The high resolution clone map was aligned to the genetic map and the physical NotI and YAC maps. The usefulness of the various mapping techniques and cloning procedures could be assessed upon the different data sets.			HOHEISEL, JD (corresponding author), IMPERIAL CANC RES FUND,LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND.		Nizetic, Dean/F-9509-2015; Schalkwyk, Leonard C/A-2150-2010; Francis, Fiona/B-5854-2016	Schalkwyk, Leonard C/0000-0001-7030-5756; Mott, Richard/0000-0002-1022-9330; Nizetic, Dean/0000-0001-5486-5761; Francis, Fiona/0000-0001-8542-7537; Grigoriev, Andrey/0000-0002-3227-532X				BOOHER R, 1989, CELL, V57, P1009, DOI 10.1016/0092-8674(89)90339-5; CHIKASHIGE Y, 1989, CELL, V57, P739, DOI 10.1016/0092-8674(89)90789-7; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; COULSON A, 1991, BIOESSAYS, V13, P413, DOI 10.1002/bies.950130809; COX DR, 1990, SCIENCE, V250, P245, DOI 10.1126/science.2218528; CRAIG AG, 1990, NUCLEIC ACIDS RES, V18, P2653; ELLIOTT S, 1986, J BIOL CHEM, V261, P2936; ENOCH T, 1991, CELL, V65, P921, DOI 10.1016/0092-8674(91)90542-7; EVANS GA, 1989, P NATL ACAD SCI USA, V86, P5030, DOI 10.1073/pnas.86.13.5030; FAN JB, 1988, NUCLEIC ACIDS RES, V17, P2801; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FOOTE S, 1992, SCIENCE, V258, P60, DOI 10.1126/science.1359640; FORSBURG SL, 1991, ANNU REV CELL BIOL, V7, P227, DOI 10.1146/annurev.cb.07.110191.001303; HAYLES J, 1992, ANNU REV GENET, V26, P373, DOI 10.1146/annurev.ge.26.120192.002105; HERRMANN BG, 1987, METHOD ENZYMOL, V152, P180; HOHEISEL JD, 1990, J BIOL CHEM, V265, P16656; HOHEISEL JD, 1991, J MOL BIOL, V220, P903, DOI 10.1016/0022-2836(91)90362-A; KINOSHITA N, 1990, CELL, V63, P405, DOI 10.1016/0092-8674(90)90173-C; LARIN Z, 1990, GENET RES, V56, P203, DOI 10.1017/S0016672300035308; LARIN Z, 1991, P NATL ACAD SCI USA, V88, P4123, DOI 10.1073/pnas.88.10.4123; LEHRACH H., 1990, GENOME ANAL, P39; LENNON GG, 1992, CURR GENET, V21, P1, DOI 10.1007/BF00318646; LEVIN HL, 1990, MOL CELL BIOL, V10, P6791, DOI 10.1128/MCB.10.12.6791; MAIER E, 1992, NAT GENET, V1, P273, DOI 10.1038/ng0792-273; MEIEREWERT S, 1993, NATURE, V361, P375, DOI 10.1038/361375a0; NIZETIC D, 1991, P NATL ACAD SCI USA, V88, P3233, DOI 10.1073/pnas.88.8.3233; OLIVER SG, 1992, NATURE, V357, P38, DOI 10.1038/357038a0; OLSON M, 1989, SCIENCE, V245, P1434, DOI 10.1126/science.2781285; PIERCE JC, 1992, P NATL ACAD SCI USA, V89, P2056, DOI 10.1073/pnas.89.6.2056; POHL FM, 1982, EUR J BIOCHEM, V123, P141, DOI 10.1111/j.1432-1033.1982.tb06510.x; Ross M. T., 1992, Techniques for the analysis of complex genomes., P137; Sambrook J., 1989, MOL CLONING LAB MANU; SCHAAK J, 1982, NUCLEIC ACIDS RES, V10, P2851, DOI 10.1093/nar/10.9.2851; STERNBERG N, 1990, New Biologist, V2, P151; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0	35	236	239	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 9	1993	73	1					109	120		10.1016/0092-8674(93)90164-L	http://dx.doi.org/10.1016/0092-8674(93)90164-L			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KW753	8462094				2022-12-24	WOS:A1993KW75300012
J	KIM, CWA; BERG, JM				KIM, CWA; BERG, JM			THERMODYNAMIC BETA-SHEET PROPENSITIES MEASURED USING A ZINC-FINGER HOST PEPTIDE	NATURE			English	Article							HELIX-FORMING TENDENCIES; OCCURRING AMINO-ACIDS; GLOBULAR-PROTEINS; SECONDARY STRUCTURE; DEPENDENT STRUCTURE; PREFERENCES; STABILITY	THE three-dimensional structures of proteins reveal that the distribution of amino acids within the major classes of secondary structure is not random but that each amino acid has its own preferred secondary structural arrangements1-5. Propensity scales for residues in alpha-helices have been generated through the use of various host-guest systems6-9. Here we measure the thermodynamic beta-sheet propensities of each of the twenty commonly occurring amino acids. A previously studied zinc-finger peptide10 was used as the host system in which amino acids were substituted into a guest site, a solvent-exposed position in an antiparallel beta-sheet. As these peptides are unfolded in the absence of bound metal but are folded in their presence, it is assumed that the thermodynamics of metal binding fully reflect peptide-folding energy. A competitive cobalt(II)-binding assay was used to determine these energies with high precision. The relative free energies correlate well with previously derived potential values based on statistical analysis of protein structures. We are therefore able to present a thermodynamic beta-sheet propensity scale for all the commonly occurring amino acids in aqueous solution.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOPHYS & BIOPHYS CHEM,BALTIMORE,MD 21205	Johns Hopkins University	KIM, CWA (corresponding author), JOHNS HOPKINS UNIV,DEPT CHEM,34TH & CHARLES ST,BALTIMORE,MD 21218, USA.		Berg, Jeremy/GRY-6706-2022	Berg, Jeremy/0000-0002-2444-8139; Berg, Jeremy/0000-0003-3022-0963				CHOU PY, 1974, BIOCHEMISTRY-US, V13, P211, DOI 10.1021/bi00699a001; CREAMER TP, 1992, P NATL ACAD SCI USA, V89, P5937, DOI 10.1073/pnas.89.13.5937; FRANKEL AD, 1987, P NATL ACAD SCI USA, V84, P4841, DOI 10.1073/pnas.84.14.4841; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; HARPER LV, IN PRESS J AM CHEM S; KRIZEK BA, 1991, J AM CHEM SOC, V113, P4518, DOI 10.1021/ja00012a021; KRIZEK BA, IN PRESS INORG CHEM; LEVITT M, 1978, BIOCHEMISTRY-US, V17, P4277, DOI 10.1021/bi00613a026; LIFSON S, 1979, NATURE, V282, P109, DOI 10.1038/282109a0; LYU PC, 1990, SCIENCE, V250, P669, DOI 10.1126/science.2237416; MCGREGOR MJ, 1987, J MOL BIOL, V198, P295, DOI 10.1016/0022-2836(87)90314-7; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; PADMANABHAN S, 1990, NATURE, V344, P268, DOI 10.1038/344268a0; PARRAGA G, 1988, SCIENCE, V241, P1489, DOI 10.1126/science.3047872; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; Richardson J. S., 1989, PREDICTION PROTEIN S, P1; RICHARDSON JS, 1977, NATURE, V268, P495, DOI 10.1038/268495a0; WOJCIK J, 1990, BIOPOLYMERS, V30, P121, DOI 10.1002/bip.360300113; ZAWADZKE LE, 1992, J AM CHEM SOC, V114, P4002, DOI 10.1021/ja00036a073	19	334	349	0	32	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 18	1993	362	6417					267	270		10.1038/362267a0	http://dx.doi.org/10.1038/362267a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KT026	8459852				2022-12-24	WOS:A1993KT02600063
J	OLSSON, T; BAKHIET, M; HOJEBERG, B; LJUNGDAHL, A; EDLUND, C; ANDERSSON, G; EKRE, HP; FUNGLEUNG, WP; MAK, T; WIGZELL, H; FISZER, U; KRISTENSSON, K				OLSSON, T; BAKHIET, M; HOJEBERG, B; LJUNGDAHL, A; EDLUND, C; ANDERSSON, G; EKRE, HP; FUNGLEUNG, WP; MAK, T; WIGZELL, H; FISZER, U; KRISTENSSON, K			CD8 IS CRITICALLY INVOLVED IN LYMPHOCYTE-ACTIVATION BY A TRYPANOSOMA-BRUCEI BRUCEI-RELEASED MOLECULE	CELL			English	Article							GROWTH-FACTOR-BETA; TRYPANOSOMA-CRUZI INFECTIONS; ATHYMIC NUDE-MICE; INTERFERON-GAMMA; MONOCLONAL-ANTIBODIES; RAT LYMPHOCYTES; IFN-GAMMA; CYTOKINE PRODUCTION; INVIVO TREATMENT; ALPHA-3 DOMAIN	T. brucei brucei released a lymphocyte triggering factor (TLTF), which triggered purified CD8+, but not CD4+, T cells to interferon gamma (IFN-gamma) mRNA expression and secretion and to [H-3]thymidine incorporation. TLTF also induced mRNA for transforming growth factor beta, but not for interleukin-4. The action of this TLTF on mononuclear cell (MNC) cultures was blocked by anti-CD8 antibodies and by soluble CD8. MNCs from a mutant mouse strain lacking CD8 expression were not triggered by TLTF. IFN-gamma provides a growth stimulus for T. brucei brucei, and infected CD8- mice had much lower parasitemia and survived longer than CD8+ mice. The host-parasite interaction in experimental African trypanosomiasis thus involves parasite release of TLTF, which by binding to CD8 triggers CD8+ cells to produce the parasite growth-promoting cytokine IFN-gamma.	KAROLINSKA INST,HUDDINGE HOSP,CLIN RES CTR,S-14186 HUDDINGE,SWEDEN; UNIV LUND,DEPT MED MICROBIOL & CLIN IMMUNOL,S-22007 LUND 7,SWEDEN; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO M4X 1K9,ONTARIO,CANADA; UNIV TORONTO,DEPT IMMUNOL,TORONTO M4X 1K9,ONTARIO,CANADA; KAROLINSKA INST,DEPT IMMUNOL,S-10401 STOCKHOLM 60,SWEDEN	Karolinska Institutet; Lund University; University of Toronto; University of Toronto; Karolinska Institutet	OLSSON, T (corresponding author), KAROLINSKA INST,HUDDINGE HOSP,DEPT NEUROL,S-14186 HUDDINGE,SWEDEN.			Fiszer, Urszula/0000-0002-9286-2454; Fung-Leung, Wai-Ping/0000-0001-7013-8855				AMIRI P, 1992, NATURE, V356, P604, DOI 10.1038/356604a0; ANDERSSON G, 1989, J IMMUNOL METHODS, V125, P89, DOI 10.1016/0022-1759(89)90081-1; ANDERSSON U, 1988, EUR J IMMUNOL, V18, P2081, DOI 10.1002/eji.1830181232; ASKONAS BA, 1984, PARASITOLOGY, V88, P633, DOI 10.1017/S0031182000085553; BAKHIET M, 1990, CLIN EXP IMMUNOL, V81, P195, DOI 10.1111/j.1365-2249.1990.tb03317.x; BAKHIET M, 1993, IN PRESS SCAND J IMM; BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; BARCLAY AN, 1981, IMMUNOLOGY, V42, P593; BLACK SJ, 1985, CURR TOP MICROBIOL, V117, P93; BRIDEAU RJ, 1980, EUR J IMMUNOL, V10, P609, DOI 10.1002/eji.1830100807; CARDELL S, 1991, EUR J IMMUNOL, V21, P2495, DOI 10.1002/eji.1830211028; CONNOLLY JM, 1988, J EXP MED, V168, P325, DOI 10.1084/jem.168.1.325; CZERKINSKY C, 1988, J IMMUNOL METHODS, V110, P29, DOI 10.1016/0022-1759(88)90079-8; DAGERLIND A, 1992, HISTOCHEMISTRY, V98, P39, DOI 10.1007/BF00716936; DALLMAN MJ, 1984, EUR J IMMUNOL, V14, P260, DOI 10.1002/eji.1830140311; DOHLSTEN M, 1991, IMMUNOL TODAY, V12, P147, DOI 10.1016/0167-5699(91)90078-8; EMMRICH F, 1986, P NATL ACAD SCI USA, V83, P8298, DOI 10.1073/pnas.83.21.8298; ENEROTH A, 1992, J NEUROCYTOL, V21, P846, DOI 10.1007/BF01191682; ESPEVIK T, 1987, J EXP MED, V166, P571, DOI 10.1084/jem.166.2.571; FUNGLEUNG WP, 1991, CELL, V65, P443, DOI 10.1016/0092-8674(91)90462-8; GOLDSTEIN SAN, 1988, J IMMUNOL, V140, P3707; HECHT TT, 1983, J IMMUNOL, V131, P1049; HEINZEL FP, 1989, J EXP MED, V169, P59, DOI 10.1084/jem.169.1.59; HIDE G, 1989, MOL BIOCHEM PARASIT, V36, P51, DOI 10.1016/0166-6851(89)90199-0; HOLMDAHL R, 1985, SCAND J IMMUNOL, V22, P157, DOI 10.1111/j.1365-3083.1985.tb01868.x; JACOB CO, 1987, J EXP MED, V166, P798, DOI 10.1084/jem.166.3.798; JOHNSON P, 1985, EMBO J, V4, P2539, DOI 10.1002/j.1460-2075.1985.tb03968.x; KABILAN L, 1990, EUR J IMMUNOL, V20, P1085, DOI 10.1002/eji.1830200521; KANE KP, 1989, J IMMUNOL, V142, P4153; KAPLOW LS, 1974, AM J CLIN PATHOL, V63, P451; KARPUS WJ, 1991, J IMMUNOL, V146, P1163; KARUPIAH G, 1990, J EXP MED, V172, P1495, DOI 10.1084/jem.172.5.1495; KORNFELD H, 1988, NATURE, V335, P445, DOI 10.1038/335445a0; LAKE JP, 1991, J IMMUNOL, V147, P1121; LANHAM SM, 1970, EXP PARASITOL, V28, P521, DOI 10.1016/0014-4894(70)90120-7; LJUNGDAHL A, 1989, J NEUROSCI RES, V24, P451, DOI 10.1002/jnr.490240316; MILLER A, 1992, P NATL ACAD SCI USA, V89, P421, DOI 10.1073/pnas.89.1.421; MIX E, 1990, SCAND J IMMUNOL, V31, P493, DOI 10.1111/j.1365-3083.1990.tb02797.x; MIZUOCHI T, 1988, J IMMUNOL, V141, P1571; MOLLER G, 1989, IMMUNOL REV, V112; MUSTAFA MI, 1991, J NEUROIMMUNOL, V31, P165, DOI 10.1016/0165-5728(91)90022-Y; OLSSON T, 1989, J NEUROSCI, V9, P3870; OLSSON T, 1991, EUR J IMMUNOL, V21, P2447, DOI 10.1002/eji.1830211022; OROURKE AM, 1990, NATURE, V346, P187, DOI 10.1038/346187a0; PALIARD X, 1988, J IMMUNOL, V141, P849; PORAT R, 1991, SCIENCE, V254, P430, DOI 10.1126/science.1833820; RAHEMTULLA A, 1991, NATURE, V353, P180, DOI 10.1038/353180a0; REED SG, 1988, J IMMUNOL, V140, P4342; ROOSNEK EE, 1985, EUR J IMMUNOL, V15, P652, DOI 10.1002/eji.1830150703; SALGAME P, 1991, SCIENCE, V254, P279, DOI 10.1126/science.1681588; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; SANDVIG S, 1987, IMMUNOL REV, V97, P51, DOI 10.1111/j.1600-065X.1987.tb00516.x; SCHLUESENER HJ, 1989, J NEUROIMMUNOL, V24, P249, DOI 10.1016/0165-5728(89)90123-9; SILVA JS, 1991, J EXP MED, V174, P539, DOI 10.1084/jem.174.3.539; SILVA JS, 1992, J EXP MED, V175, P169, DOI 10.1084/jem.175.1.169; STREET NE, 1991, FASEB J, V5, P171, DOI 10.1096/fasebj.5.2.1825981; TARLETON RL, 1992, NATURE, V356, P338, DOI 10.1038/356338a0; TERRY LA, 1990, TISSUE ANTIGENS, V35, P82, DOI 10.1111/j.1399-0039.1990.tb01761.x; TODD RF, 1984, LEUCOCYTE TYPING, P424; VANDERMEIDE PH, 1986, J GEN VIROL, V67, P1059, DOI 10.1099/0022-1317-67-6-1059; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VYAKARNAM A, 1990, AIDS, V4, P21, DOI 10.1097/00002030-199001000-00003; WILLIAMS AF, 1977, CELL, V12, P663, DOI 10.1016/0092-8674(77)90266-5	63	127	129	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 12	1993	72	5					715	727		10.1016/0092-8674(93)90400-K	http://dx.doi.org/10.1016/0092-8674(93)90400-K			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KR436	8453666	Bronze			2022-12-24	WOS:A1993KR43600008
J	TROFATTER, JA; MACCOLLIN, MM; RUTTER, JL; MURRELL, JR; DUYAO, MP; PARRY, DM; ELDRIDGE, R; KLEY, N; MENON, AG; PULASKI, K; HAASE, VH; AMBROSE, CM; MUNROE, D; BOVE, C; HAINES, JL; MARTUZA, RL; MACDONALD, ME; SEIZINGER, BR; SHORT, MP; BUCKLER, AJ; GUSELLA, JF				TROFATTER, JA; MACCOLLIN, MM; RUTTER, JL; MURRELL, JR; DUYAO, MP; PARRY, DM; ELDRIDGE, R; KLEY, N; MENON, AG; PULASKI, K; HAASE, VH; AMBROSE, CM; MUNROE, D; BOVE, C; HAINES, JL; MARTUZA, RL; MACDONALD, ME; SEIZINGER, BR; SHORT, MP; BUCKLER, AJ; GUSELLA, JF			A NOVEL MOESIN-LIKE, EZRIN-LIKE, RADIXIN-LIKE GENE IS A CANDIDATE FOR THE NEUROFIBROMATOSIS-2 TUMOR SUPPRESSOR	CELL			English	Article							BILATERAL ACOUSTIC NEUROFIBROMATOSIS; PROTEIN-TYROSINE-PHOSPHATASE; TYPE-1 GENE; SEQUENCE HOMOLOGY; CDNA SEQUENCE; DNA MARKER; CHROMOSOME-22; CELLS; ASSOCIATION; CLONING	Neurofibromatosis 2 (NF2) is a dominantly inherited disorder characterized by the occurrence of bilateral vestibular schwannomas and other central nervous system tumors including multiple meningiomas. Genetic linkage studies and investigations of both sporadic and familial tumors suggest that NF2 is caused by inactivation of a tumor suppressor gene in chromosome 22q12. We have identified a candidate gene for the NF2 tumor suppressor that has suffered nonoverlapping deletions in DNA from two independent NF2 families and alterations in meningiomas from two unrelated NF2 patients. The candidate gene encodes a 587 amino acid protein with striking similarity to several members of a family of proteins proposed to link cytoskeletal components with proteins in the cell membrane. The NF2 gene may therefore constitute a novel class of tumor suppressor gene.	HARVARD UNIV,SCH MED,BOSTON,MA 02129; NCI,CLIN EPIDEMIOL BRANCH,BETHESDA,MD 20892; US PHS,BETHESDA,MD 20892; BRISTOL MYERS SQUIBB,PHARMACEUT RES INST,ONCOL DRUG DISCOVERY,PRINCETON,NJ 08543; UNIV CINCINNATI,MED CTR,DEPT MOLEC GENET,CINCINNATI,OH 45267; MIT,CTR CANC RES,CAMBRIDGE,MA 02139; GEORGETOWN UNIV,MED CTR,DEPT NEUROSURG,WASHINGTON,DC 20007	Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); United States Public Health Service; Bristol-Myers Squibb; University System of Ohio; University of Cincinnati; Massachusetts Institute of Technology (MIT); Georgetown University	TROFATTER, JA (corresponding author), MASSACHUSETTS GEN HOSP,MOLEC NEUROGENET UNIT,BOSTON,MA 02129, USA.		Haase, Volker Hans/AAJ-5061-2021; Haase, Volker Hans/A-6758-2013; Haines, Jonathan/C-3374-2012	Haase, Volker Hans/0000-0002-7051-8994; Haines, Jonathan/0000-0002-4351-4728; Rutter, Joni/0000-0002-6502-2361	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000317, R01HG000672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS024279] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG00672, HG00317] Funding Source: Medline; NINDS NIH HHS [NS24279] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Ambrose Christine, 1992, Human Molecular Genetics, V1, P697, DOI 10.1093/hmg/1.9.697; ANDERSON MA, 1984, IN VITRO CELL DEV B, V20, P856; ATHWAL RS, 1977, P NATL ACAD SCI USA, V74, P2943, DOI 10.1073/pnas.74.7.2943; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; BERNAL SD, 1985, CRC CR REV ONCOL-HEM, V3, P191, DOI 10.1016/S1040-8428(85)80026-3; BIJLSMA EK, 1992, GENE CHROMOSOME CANC, V5, P201, DOI 10.1002/gcc.2870050305; BIRGBAUER E, 1991, J NEUROSCI RES, V30, P232; BRETSCHER A, 1989, J CELL BIOL, V108, P921, DOI 10.1083/jcb.108.3.921; BUCAN M, 1990, GENOMICS, V6, P1; BUCHBERG AM, 1990, NATURE, V347, P291, DOI 10.1038/347291a0; BUCKLER AJ, 1991, P NATL ACAD SCI USA, V88, P4005, DOI 10.1073/pnas.88.9.4005; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; CONBOY J, 1986, P NATL ACAD SCI USA, V83, P9512, DOI 10.1073/pnas.83.24.9512; CORREAS I, 1986, J BIOL CHEM, V261, P3310; COUTURIER J, 1990, CANCER GENET CYTOGEN, V45, P55, DOI 10.1016/0165-4608(90)90066-J; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; DELAUNAY J, 1991, NOUV REV FR HEMATOL, V33, P63; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DRYJA TP, 1986, P NATL ACAD SCI USA, V83, P7391, DOI 10.1073/pnas.83.19.7391; EVANS DGR, 1992, J MED GENET, V29, P841, DOI 10.1136/jmg.29.12.841; FIEDLER W, 1991, GENOMICS, V10, P786, DOI 10.1016/0888-7543(91)90464-P; FONTAINE B, 1991, ANN NEUROL, V29, P183, DOI 10.1002/ana.410290211; FONTAINE B, 1991, GENOMICS, V10, P280, DOI 10.1016/0888-7543(91)90513-E; FRANCKE U, 1979, CYTOGENET CELL GENET, V24, P185, DOI 10.1159/000131375; FRAZER KA, 1992, GENOMICS, V14, P574, DOI 10.1016/S0888-7543(05)80154-5; FROSCH PM, 1991, MOL BIOCHEM PARASIT, V48, P121, DOI 10.1016/0166-6851(91)90108-I; FUNAYAMA N, 1991, J CELL BIOL, V115, P1039, DOI 10.1083/jcb.115.4.1039; FURTHMAYR H, 1992, KIDNEY INT, V41, P665, DOI 10.1038/ki.1992.102; GOULD KL, 1989, EMBO J, V8, P4133, DOI 10.1002/j.1460-2075.1989.tb08598.x; GU MX, 1991, P NATL ACAD SCI USA, V88, P5867, DOI 10.1073/pnas.88.13.5867; GUSELLA J, 1979, P NATL ACAD SCI USA, V76, P5239, DOI 10.1073/pnas.76.10.5239; GUSELLA JF, 1983, NATURE, V306, P234, DOI 10.1038/306234a0; HANZEL D, 1991, EMBO J, V10, P2363, DOI 10.1002/j.1460-2075.1991.tb07775.x; KAISERKUPFER MI, 1989, ARCH OPHTHALMOL-CHIC, V107, P541, DOI 10.1001/archopht.1989.01070010555030; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KRIEG J, 1992, J BIOL CHEM, V267, P19258; LANKES WT, 1991, P NATL ACAD SCI USA, V88, P5297; LEES JF, 1988, EMBO J, V7, P1947, DOI 10.1002/j.1460-2075.1988.tb03032.x; LETO TL, 1984, J BIOL CHEM, V259, P4603; LETO TL, 1986, MEMBRANE SKELETONS C, P201; LOGAN JA, 1990, CANCER GENET CYTOGEN, V45, P41, DOI 10.1016/0165-4608(90)90064-H; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; MARTUZA RL, 1988, NEW ENGL J MED, V318, P684, DOI 10.1056/NEJM198803173181106; MCCLATCHEY AI, 1992, HUM MOL GENET, V1, P521; MCCLATCHEY AI, 1992, CELL, V68, P769, DOI 10.1016/0092-8674(92)90151-2; MULVIHILL JJ, 1990, ANN INTERN MED, V113, P39, DOI 10.7326/0003-4819-113-1-39; NAROD SA, 1992, AM J HUM GENET, V51, P486; PAKKANEN R, 1988, J CELL BIOCHEM, V38, P65, DOI 10.1002/jcb.240380107; REES DJG, 1990, NATURE, V347, P685, DOI 10.1038/347685a0; RICCARDI VM, 1978, PEDIATRICS, V61, P604; RICCARDI VM, 1981, NEW ENGL J MED, V305, P1617, DOI 10.1056/NEJM198112313052704; Riccardi VM., 1993, PLASTIC RECONST SURG, V91, P561, DOI [10.1097/00006534-199303000-00029, DOI 10.1097/00006534-199303000-00029]; ROULEAU GA, 1990, AM J HUM GENET, V46, P323; ROULEAU GA, 1987, NATURE, V329, P246, DOI 10.1038/329246a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO N, 1991, J CELL BIOL, V113, P321, DOI 10.1083/jcb.113.2.321; SATO N, 1992, J CELL SCI, V103, P131; SEIZINGER BR, 1986, NATURE, V322, P644, DOI 10.1038/322644a0; SEIZINGER BR, 1987, SCIENCE, V236, P317, DOI 10.1126/science.3105060; SEIZINGER BR, 1987, P NATL ACAD SCI USA, V84, P5419, DOI 10.1073/pnas.84.15.5419; TCHERNIA G, 1981, J CLIN INVEST, V68, P454, DOI 10.1172/JCI110275; Trofatter J. A., 1992, Human Molecular Genetics, V1, P455, DOI 10.1093/hmg/1.6.455-a; TSUKITA S, 1989, J CELL BIOL, V108, P2369, DOI 10.1083/jcb.108.6.2369; TURUNEN O, 1989, J BIOL CHEM, V264, P16727; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WATERSTON R, 1992, NAT GENET, V1, P114, DOI 10.1038/ng0592-114; WERTELECKI W, 1988, NEW ENGL J MED, V319, P278, DOI 10.1056/NEJM198808043190505; WOLFF RK, 1992, AM J HUM GENET, V51, P478; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949	73	1089	1126	0	35	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 12	1993	72	5					791	800		10.1016/0092-8674(93)90406-G	http://dx.doi.org/10.1016/0092-8674(93)90406-G			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KR436	8453669	Bronze			2022-12-24	WOS:A1993KR43600014
J	BONINI, NM; LEISERSON, WM; BENZER, S				BONINI, NM; LEISERSON, WM; BENZER, S			THE EYES ABSENT GENE - GENETIC-CONTROL OF CELL-SURVIVAL AND DIFFERENTIATION IN THE DEVELOPING DROSOPHILA EYE	CELL			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; T-CELLS; CAENORHABDITIS-ELEGANS; NERVOUS-SYSTEM; VISUAL-SYSTEM; C-ELEGANS; MELANOGASTER; DEATH; APOPTOSIS; SEQUENCE	The eyes absent (eya) gene is required at an early stage in development of the D. melanogaster compound eye. In eya mutants, progenitor cells in the eye disc undergo programmed cell death anterior to the morphogenetic furrow, rather than proceeding into the pathway of retinal differentiation. A low level of cell death normally occurs at this stage, suggesting that eya activity influences the distribution of cells between differentiation and death. Molecular analysis identifies a nuclear protein expressed in progenitor cells prior to differentiation. Transformation with the cDNA prevents progenitor cell death and allows the events that generate the eye to proceed. eya activity is required for the survival of eye progenitor cells at a critical stage in morphogenesis.			BONINI, NM (corresponding author), CALTECH, DIV BIOL, PASADENA, CA 91125 USA.		Leiserson, William/A-5721-2013	Leiserson, William/0000-0001-5477-0674; Bonini, Nancy/0000-0003-0226-5291	NATIONAL EYE INSTITUTE [R01EY009278] Funding Source: NIH RePORTER; NEI NIH HHS [EY09278] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALPHEY L, 1992, CELL, V69, P977, DOI 10.1016/0092-8674(92)90616-K; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AMEISEN JC, 1991, IMMUNOL TODAY, V12, P102; APPLE DJ, 1991, OCULAR PATHOLOGY CLI; ASKEW DS, 1991, ONCOGENE, V6, P1915; BANERJEE U, 1990, NEURON, V4, P177, DOI 10.1016/0896-6273(90)90093-U; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; BASLER K, 1989, SCIENCE, V243, P931, DOI 10.1126/science.2493159; BODENSTEIN D, 1953, INSECT PHYSL, P822; BOLWIG N, 1946, VIDENSK MEDD FRA DAN, V109, P80; BOWTELL DDL, 1989, CELL, V56, P931, DOI 10.1016/0092-8674(89)90626-0; BRENDEL V, 1992, P NATL ACAD SCI USA, V89, P2002, DOI 10.1073/pnas.89.6.2002; BRENDEL V, 1989, P NATL ACAD SCI USA, V86, P5698, DOI 10.1073/pnas.86.15.5698; BROWN NL, 1991, DEVELOPMENT, V113, P1245; Bryant PJ., 1978, GENET BIOL DROSOPHIL, P229; CARR VM, 1981, DEV BRAIN RES, V2, P157, DOI 10.1016/0165-3806(81)90066-3; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; CHELSKY D, 1989, MOL CELL BIOL, V9, P2487, DOI 10.1128/MCB.9.6.2487; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOE CQ, 1985, DEV BIOL, V111, P193, DOI 10.1016/0012-1606(85)90445-2; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; EISENBERG JC, 1991, DROS INF SERV, V70, P266; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ELLIS RE, 1991, DEVELOPMENT, V112, P591; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FESUS L, 1991, IMMUNOL LETT, V30, P277, DOI 10.1016/0165-2478(91)90038-C; FISCHBACH KF, 1983, DEV BIOL, V95, P1, DOI 10.1016/0012-1606(83)90002-7; FRISTROM D, 1969, MOL GEN GENET, V103, P363, DOI 10.1007/BF00383486; GARZA D, 1989, SCIENCE, V246, P641, DOI 10.1126/science.2510296; GATEFF EA, 1975, ROUX ARCH DEV BIOL, V176, P171, DOI 10.1007/BF00576800; GELBART WM, 1982, P NATL ACAD SCI-BIOL, V79, P2636, DOI 10.1073/pnas.79.8.2636; GLASER T, 1990, SCIENCE, V250, P823, DOI 10.1126/science.2173141; GLUCKSMANN A, 1951, BIOL REV, V26, P59, DOI 10.1111/j.1469-185X.1951.tb00774.x; GOLDSTEIN P, 1991, IMMUNOL REV, V121, P29; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; HAMBURGER V, 1981, J NEUROSCI, V1, P60, DOI 10.1523/JNEUROSCI.01-01-00060.1981; HAMBURGER V, 1949, J EXP ZOOL, V111, P457, DOI 10.1002/jez.1401110308; HARRIS WA, 1976, J PHYSIOL-LONDON, V256, P415; HARTE PJ, 1982, GENETICS, V101, P477; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; ITOH N, 1986, P NATL ACAD SCI USA, V83, P4081, DOI 10.1073/pnas.83.11.4081; JIMENEZ F, 1990, NEURON, V5, P81, DOI 10.1016/0896-6273(90)90036-F; JORDAN T, 1992, NAT GENET, V1, P328, DOI 10.1038/ng0892-328; KAPPLER JW, 1988, NATURE, V332, P35, DOI 10.1038/332035a0; KARLIN S, 1990, ONCOGENE, V5, P85; Kerr J.F.R., 1987, P93; LASKI FA, 1986, CELL, V44, P7, DOI 10.1016/0092-8674(86)90480-0; LAWRENCE PA, 1979, DEV BIOL, V71, P142, DOI 10.1016/0012-1606(79)90088-5; LEWIS EB, 1968, DROSOPHILA INFORM SE, V43, P193; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; MCCONKEY DJ, 1990, IMMUNOL TODAY, V11, P120, DOI 10.1016/0167-5699(90)90048-E; MEYAARD L, 1992, SCIENCE, V257, P217, DOI 10.1126/science.1352911; MEYEROWITZ EM, 1978, DEV BIOL, V62, P112, DOI 10.1016/0012-1606(78)90096-9; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; Ochman H., 1990, PCR PROTOCOLS GUIDE, P219; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; PANNESE E, 1976, NEUROPATH APPL NEURO, V2, P247, DOI 10.1111/j.1365-2990.1976.tb00501.x; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Power ME, 1943, J EXP ZOOL, V94, P33, DOI 10.1002/jez.1400940103; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; READY DF, 1989, TRENDS NEUROSCI, V12, P102, DOI 10.1016/0166-2236(89)90166-5; READY DF, 1976, DEV BIOL, V53, P217, DOI 10.1016/0012-1606(76)90225-6; RECHSTEINER M, 1988, ADV ENZYME REGUL, V27, P135; Rechsteiner M, 1990, Semin Cell Biol, V1, P433; RENFRANZ PJ, 1989, DEV BIOL, V136, P411, DOI 10.1016/0012-1606(89)90267-4; ROBERTSON HM, 1988, GENETICS, V118, P461; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; RUBIN GM, 1991, TRENDS GENET, V7, P372, DOI 10.1016/0168-9525(91)90258-R; Sambrook J., 1989, MOL CLONING LAB MANU; SAMPEDRO J, 1991, NATURE, V353, P187, DOI 10.1038/353187a0; SARGENT TD, 1986, DEV BIOL, V114, P238, DOI 10.1016/0012-1606(86)90399-4; SAUNDERS JW, 1966, SCIENCE, V154, P604, DOI 10.1126/science.154.3749.604; SCHNEUWLY S, 1987, NATURE, V325, P816, DOI 10.1038/325816a0; SELLECK SB, 1991, NEURON, V6, P83, DOI 10.1016/0896-6273(91)90124-I; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPREIJ T E, 1971, Netherlands Journal of Zoology, V21, P221; STELLER H, 1985, EMBO J, V4, P3765, DOI 10.1002/j.1460-2075.1985.tb04146.x; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; Sved J, 1986, DROSOPH INF SERV, V63, P169; TATA JR, 1966, DEV BIOL, V13, P77, DOI 10.1016/0012-1606(66)90050-9; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; TON CCT, 1991, CELL, V67, P1059, DOI 10.1016/0092-8674(91)90284-6; TRENT C, 1983, GENETICS, V104, P619; TRUMAN JW, 1988, DEV BIOL, V125, P145, DOI 10.1016/0012-1606(88)90067-X; VANDERMEERDEJONG R, 1990, GENOMICS, V7, P270, DOI 10.1016/0888-7543(90)90550-E; VANVACTOR DL, 1991, CELL, V67, P1145, DOI 10.1016/0092-8674(91)90291-6; WADDINGTON CH, 1960, PROC R SOC SER B-BIO, V153, P155, DOI 10.1098/rspb.1960.0094; WHARTON KA, 1985, CELL, V40, P55, DOI 10.1016/0092-8674(85)90308-3; WHITE RH, 1961, J EXP ZOOL, V148, P223, DOI 10.1002/jez.1401480305; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; WOLFF T, 1991, DEVELOPMENT, V113, P825; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZINSMAIER KE, 1990, J NEUROGENET, V7, P15, DOI 10.3109/01677069009084150; ZIPURSKY SL, 1984, CELL, V36, P15, DOI 10.1016/0092-8674(84)90069-2	106	442	453	0	18	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 12	1993	72	3					379	395		10.1016/0092-8674(93)90115-7	http://dx.doi.org/10.1016/0092-8674(93)90115-7			17	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KM162	8431945				2022-12-24	WOS:A1993KM16200008
J	HARADA, H; KITAGAWA, M; TANAKA, N; YAMAMOTO, H; HARADA, K; ISHIHARA, M; TANIGUCHI, T				HARADA, H; KITAGAWA, M; TANAKA, N; YAMAMOTO, H; HARADA, K; ISHIHARA, M; TANIGUCHI, T			ANTI-ONCOGENIC AND ONCOGENIC POTENTIALS OF INTERFERON REGULATORY FACTOR-I AND FACTOR-II	SCIENCE			English	Article							BETA-GENE; FACTOR-I; TRANSCRIPTIONAL ACTIVATOR; INDUCIBLE ENHANCER; GROWTH-INHIBITION; NUDE-MICE; IRF-1; EXPRESSION; IFN; INDUCTION	Interferon regulatory factor-1 (IRF-1), a transcriptional activator, and IRF-2, its antagonistic repressor, have been identified as regulators of type I interferon and interferon-inducible genes. The IRF-1 gene is itself interferon-inducible and hence may be one of the target genes critical for interferon action. When the IRF-2 gene was overexpressed in NIH 3T3 cells, the cells became transformed and displayed enhanced tumorigenicity in nude mice. This transformed phenotype was reversed by concomitant overexpression of the IRF-1 gene. Thus, restrained cell growth depends on a balance between these two mutually antagonistic transcription factors.			HARADA, H (corresponding author), OSAKA UNIV,INST MOLEC & CELLULAR BIOL,YAMADAOKA 1-3,SUITA,OSAKA 565,JAPAN.		Kitagawa, Motoo/W-8468-2019; Harada, Hisashi/H-2815-2019	Kitagawa, Motoo/0000-0003-1036-840X; Harada, Hisashi/0000-0001-5993-1289; Tanaka, Nobuyuki/0000-0002-6373-2220				ABDOLLAHI A, 1991, CELL GROWTH DIFFER, V2, P401; AU WC, 1992, NUCLEIC ACIDS RES, V20, P2877, DOI 10.1093/nar/20.11.2877; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Demaeyer E., 1988, INTERFERONS OTHER RE; DRIGGERS PH, 1990, P NATL ACAD SCI USA, V87, P3743, DOI 10.1073/pnas.87.10.3743; DYSON N, 1989, MOL DIAGNOSTICS HUMA, P235; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; FUJITA T, 1987, CELL, V49, P357, DOI 10.1016/0092-8674(87)90288-1; FUJITA T, 1988, EMBO J, V7, P3397, DOI 10.1002/j.1460-2075.1988.tb03213.x; FUJITA T, 1985, CELL, V41, P489, DOI 10.1016/S0092-8674(85)80022-2; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; GRESSER I, 1989, ACTA ONCOL, V28, P347, DOI 10.3109/02841868909111205; HABER DA, 1992, ADV CANCER RES, V59, P41, DOI 10.1016/S0065-230X(08)60302-4; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HARADA H, UNPUB; HARADA K, UNPUB; HARLOW E, 1988, ANTIBODIES; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HORI T, UNPUB; ITOH S, 1991, GENOMICS, V10, P1097, DOI 10.1016/0888-7543(91)90208-V; ITOH S, UNPUB; ITOH S, 1990, THESIS OSAKA U; JACOBSEN H, 1983, P NATL ACAD SCI-BIOL, V80, P4954, DOI 10.1073/pnas.80.16.4954; KATO K, 1990, MOL CELL BIOL, V10, P486, DOI 10.1128/MCB.10.2.486; KATOH K, 1987, CELL STRUCT FUNCT, V12, P575, DOI 10.1247/csf.12.575; KEATH EJ, 1984, CELL, V39, P339, DOI 10.1016/0092-8674(84)90012-6; KIMURA T, UNPUB; Kirchhoff S., 1992, Journal of Interferon Research, V12, pS102; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MEURS EF, IN PRESS P NATL ACAD; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MIYASHITA K, 1975, CELL, V5, P131, DOI 10.1016/0092-8674(75)90021-5; NAF D, 1991, P NATL ACAD SCI USA, V88, P1369, DOI 10.1073/pnas.88.4.1369; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; REIS LFL, 1992, EMBO J, V11, P185, DOI 10.1002/j.1460-2075.1992.tb05041.x; REVEL M, 1986, TRENDS BIOCHEM SCI, V11, P166, DOI 10.1016/0968-0004(86)90134-9; Shin S, 1979, Methods Enzymol, V58, P370; STARK GR, 1992, J INTERFERON RES, V12, P147, DOI 10.1089/jir.1992.12.147; TANAKA N, 1992, ADV IMMUNOL, V52, P263, DOI 10.1016/S0065-2776(08)60877-9; Tanaka N., UNPUB; TANIGUCHI T, 1991, ORIGINS OF HUMAN CANCER, P501; VANHEYNINGEN V, 1992, TRENDS GENET, V8, P16, DOI 10.1016/0168-9525(92)90019-Z; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; VILCEK J, 1990, HDB EXPT PHARM, P3; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WATANABE N, 1991, NUCLEIC ACIDS RES, V19, P4421, DOI 10.1093/nar/19.16.4421; Watanabe N., UNPUB; WELLS V, 1985, EXP CELL RES, V159, P27, DOI 10.1016/S0014-4827(85)80034-3; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; YAMADA G, 1991, P NATL ACAD SCI USA, V88, P532, DOI 10.1073/pnas.88.2.532; YONEMA M, UNPUB; YULEE LY, 1990, MOL CELL BIOL, V10, P3087, DOI 10.1128/MCB.10.6.3087	56	439	452	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 12	1993	259	5097					971	974		10.1126/science.8438157	http://dx.doi.org/10.1126/science.8438157			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL800	8438157				2022-12-24	WOS:A1993KL80000043
J	GAMBLE, AR; BELL, JA; RONAN, JE; PEARSON, D; ELLIS, IO				GAMBLE, AR; BELL, JA; RONAN, JE; PEARSON, D; ELLIS, IO			USE OF TUMOR-MARKER IMMUNOREACTIVITY TO IDENTIFY PRIMARY SITE OF METASTATIC CANCER	BRITISH MEDICAL JOURNAL			English	Article							UNKNOWN PRIMARY SITE; MONOCLONAL-ANTIBODIES; CARCINOMA; ADENOCARCINOMA; ANTIGEN; BREAST; CA-125	Objectives-To determine whether variations in the expression of tumour related antigens can predict the origin of tumours. Design-Immunohistological study of tumour marker expression in primary adenocarcinomas and respective metastatic deposits. Antibodies to the following tumour markers were used: polymorphic epithelial mucin (NCRC-11 and SM3), carcinoembryonic antigen, carcinoembryonic antigen with non-specific antigen cospecificity, CA125, CA19.9, prostate specific antigens, and thyroglobulin. Setting-Histopathology department of teaching hospital. Subjects-100 pathology sections of metastatic adenocarcinoma and their related primary tumours. Main outcome measures-Concordance of reactivity between primary and metastatic tumours. Reactivity profiles of tumour sites. Results-The correct primary site of origin was predicted in 70% (33/47) of tumours in men and 54% (27/43) tumours in women with antibodies SM3, 288, CA19.9, CA125, and PSA (men only). Specificities ranged from 68% for breast tumour to 98% for prostate tumour. Conclusion-Use of tumour markers in patients presenting with metastatic adenocarcinoma of unknown origin can help localise the probable primary sites and reduce the need for extensive and expensive imaging techniques.	CITY HOSP NOTTINGHAM,DEPT HISTOPATHOL,NOTTINGHAM NG5 1PB,ENGLAND; CITY HOSP NOTTINGHAM,DEPT MED PHYS,NOTTINGHAM NG5 1PB,ENGLAND	Nottingham University Hospital NHS Trust; Nottingham City Hospital; Nottingham University Hospital NHS Trust; Nottingham City Hospital				Ellis, Ian/0000-0001-5292-8474				BERCHUCK A, 1989, CANCER RES, V49, P2091; COGGI G, 1966, IMMUNOHISTOCHEMISTRY; ELLIS IO, 1984, HISTOPATHOLOGY, V8, P501, DOI 10.1111/j.1365-2559.1984.tb02360.x; GENDLER S, 1988, J BIOL CHEM, V263, P12820; Gorich J, 1988, Rofo, V149, P277, DOI 10.1055/s-2008-1048341; GRECO FA, 1989, SEMIN ONCOL, V16, P116; Hamaya K, 1988, Gan No Rinsho, V34, P1956; HAMMOND ME, 1989, CANCER-AM CANCER SOC, V63, P461, DOI 10.1002/1097-0142(19890201)63:3<461::AID-CNCR2820630312>3.0.CO;2-J; HEYDERMAN E, 1990, J CLIN PATHOL, V43, P448, DOI 10.1136/jcp.43.6.448; HITCHCOCK A, 1987, J OBSTET GYNAECOL, V8, P173, DOI 10.3109/01443618709008792; KEEP JC, 1989, TUMOR BIOL, V10, P153, DOI 10.1159/000217612; MA WX, 1989, CHUNG HUA PING LI HS, V18, P37; NYSTROM JS, 1979, JAMA-J AM MED ASSOC, V241, P381, DOI 10.1001/jama.241.4.381; REID WA, 1990, J PATHOL, V160, P203, DOI 10.1002/path.1711600304; ROSEN A, 1990, ARCH GYNECOL OBSTET, V247, P125, DOI 10.1007/BF02390860; SHEAHAN K, 1990, LAB INVEST, V62, pA112; STERNS EE, 1989, SURG GYNECOL OBSTET, V169, P81; STURM U, 1989, Zentralblatt fuer Allgemeine Pathologie und Pathologische Anatomie, V135, P281	18	39	39	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 30	1993	306	6873					295	298		10.1136/bmj.306.6873.295	http://dx.doi.org/10.1136/bmj.306.6873.295			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK718	8461645	Bronze, Green Published			2022-12-24	WOS:A1993KK71800017
J	FISHER, AJ; JOHNSON, JE				FISHER, AJ; JOHNSON, JE			ORDERED DUPLEX RNA CONTROLS CAPSID ARCHITECTURE IN AN ICOSAHEDRAL ANIMAL VIRUS	NATURE			English	Article							BUSHY STUNT VIRUS; 3.0-A RESOLUTION	SMALL spherical viruses are among the simplest replicating systems in biology, yet the factors affecting their assembly, stability and disassembly are still poorly understood. A molecular switch is required for the assembly of icosahedral virus particles containing more than 60 identical subunits because strict symmetry cannot be maintained in subunit packing1. All previously reported viruses with this type of structure use a portion of the capsid protein to regulate interactions between chemically equivalent but structurally distinct interfaces2-4. We have investigated the T = 3 quasi-equivalent5 nodaviruses, which are small non-enveloped viruses with a single-stranded RNA genome that infect insects6, mice7 and fish8. They undergo a well-characterized series of steps in assembly and maturation9,10, which in some respects are similar to the picornaviruses11, despite their different capsid architecture. Here we report the X-ray structure of Flock House virus at 3.0 angstrom resolution, which reveals an ordered RNA duplex of 20 nucleotides and a protein segment that control the subunit interactions in this animal virus. The RNA interacts with a helical protein domain of the subunit that lies inside the capsid shell. One of the helices that binds the RNA is part of a 44-amino-acid polypeptide which is autocatalytically cleaved from the initial subunit translation product after virion assembly. The structure indicates that RNA associated with the cleaved polypeptide may be important in the infection process.	UNIV WISCONSIN,DEPT BIOL SCI,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison				Fisher, Andrew/0000-0003-3488-6594				ABADZAPATERO C, 1980, NATURE, V286, P33, DOI 10.1038/286033a0; ARNOLD E, 1987, ACTA CRYSTALLOGR A, V43, P346, DOI 10.1107/S0108767387099306; CASPAR DLD, 1962, COLD SPRING HARB SYM, V27, P1, DOI 10.1101/sqb.1962.027.001.005; CASPAR DLD, 1980, BIOPHYS J, V32, P103, DOI 10.1016/S0006-3495(80)84929-0; CHEN ZG, 1989, SCIENCE, V245, P154, DOI 10.1126/science.2749253; FERNANDEZTOMAS CB, 1973, J VIROL, V12, P1122, DOI 10.1128/JVI.12.5.1122-1130.1973; FISHER AJ, 1992, ACTA CRYSTALLOGR B, V48, P515, DOI 10.1107/S0108768192000053; GALLAGHER TM, 1988, J VIROL, V62, P3399, DOI 10.1128/JVI.62.9.3399-3406.1988; HARRISON SC, 1978, NATURE, V276, P368, DOI 10.1038/276368a0; HENDRY DA, 1991, VIRUSES INVERTEBRATE, P227; HOGLE J, 1983, J MOL BIOL, V171, P95, DOI 10.1016/S0022-2836(83)80315-5; HOGLE JM, 1986, J MOL BIOL, V191, P625, DOI 10.1016/0022-2836(86)90450-X; HOSUR MV, 1987, PROTEINS, V2, P167, DOI 10.1002/prot.340020302; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KAESBERG P, 1990, J MOL BIOL, V214, P423, DOI 10.1016/0022-2836(90)90191-N; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LI TS, 1990, BIOCHEMISTRY-US, V29, P5018, DOI 10.1021/bi00473a004; MCKENNA R, 1992, NATURE, V355, P137, DOI 10.1038/355137a0; MORI KI, 1992, VIROLOGY, V187, P368, DOI 10.1016/0042-6822(92)90329-N; NEWMAN JFE, 1973, J GEN VIROL, V21, P371, DOI 10.1099/0022-1317-21-2-371; ROSSMANN MG, 1989, ANNU REV BIOCHEM, V58, P533, DOI 10.1146/annurev.bi.58.070189.002533; SILVA AM, 1987, J MOL BIOL, V197, P69, DOI 10.1016/0022-2836(87)90610-3; SMITH TJ, 1990, J APPL CRYSTALLOGR, V23, P141; TSAO J, 1991, SCIENCE, V251, P1456, DOI 10.1126/science.2006420	24	226	231	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 14	1993	361	6408					176	179		10.1038/361176a0	http://dx.doi.org/10.1038/361176a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KG466	8421524				2022-12-24	WOS:A1993KG46600067
J	DUMENCO, LL; ALLAY, E; NORTON, K; GERSON, SL				DUMENCO, LL; ALLAY, E; NORTON, K; GERSON, SL			THE PREVENTION OF THYMIC LYMPHOMAS IN TRANSGENIC MICE BY HUMAN O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE	SCIENCE			English	Article							METHYL-N-NITROSOUREA; MAMMALIAN O-6-ALKYLGUANINE-DNA ALKYLTRANSFERASE; DNA ALKYLTRANSFERASE; ALKYLATING-AGENTS; MAMMARY CARCINOGENESIS; HUMAN-LYMPHOCYTES; HUMAN-FIBROBLASTS; CELL-LINES; REPAIR; O-6-METHYLGUANINE	Nitrosoureas form O6-alkylguanine-DNA adducts that are converted to G to A transitions, the mutation found in the activated ras oncogenes of nitrosourea-induced mouse lymphomas and rat mammary tumors. These adducts are removed by the DNA repair protein O6-alkylguanine-DNA alkyltransferase. Transgenic mice that express the human homolog of this protein in the thymus were found to be protected from developing thymic lymphomas after exposure to N-methyl-N-nitrosourea. Thus, transgenic expression of a single human DNA repair gene is sufficient to block chemical carcinogenesis. The transduction of DNA repair genes in vivo may unravel mechanisms of carcinogenesis and provide therapeutic protection from known carcinogens.	UNIV HOSP CLEVELAND,IRELAND CANC CTR,CLEVELAND,OH 44106; UNIV HOSP CLEVELAND,DEPT MED,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,CLEVELAND,OH 44106	University Hospitals of Cleveland; University Hospitals of Cleveland; Case Western Reserve University					NATIONAL CANCER INSTITUTE [P30CA043703, P01CA051183] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006288] Funding Source: NIH RePORTER; NCI NIH HHS [P01CA51183, P30CA43703] Funding Source: Medline; NIEHS NIH HHS [R01ES06288] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BOGDEN JM, 1981, NUCLEIC ACIDS RES, V9, P3089; BOICE JD, 1983, NEW ENGL J MED, V309, P1079, DOI 10.1056/NEJM198311033091802; BRONSTEIN SM, 1991, CANCER RES, V51, P5188; COHEN SM, 1990, SCIENCE, V249, P1007, DOI 10.1126/science.2204108; CRADDOCK VM, 1987, CHEM-BIOL INTERACT, V53, P283; DEROSSI A, 1981, J NATL CANCER I, V67, P1241; DEVEREUX S, 1990, BRIT MED J, V301, P1077, DOI 10.1136/bmj.301.6760.1077; DEVITA VT, 1965, CANCER RES, V25, P1876; DOLAN ME, 1991, P NATL ACAD SCI USA, V12, P2305; DOMORADZKI J, 1985, CARCINOGENESIS, V6, P1823, DOI 10.1093/carcin/6.12.1823; DUMENCO LL, 1991, CANCER RES, V51, P3391; EADIE JS, 1984, NATURE, V308, P201, DOI 10.1038/308201a0; ELLISON KS, 1989, P NATL ACAD SCI USA, V86, P8620, DOI 10.1073/pnas.86.22.8620; ERICKSON LC, 1978, CANCER RES, V38, P3379; FONG LYY, 1990, CARCINOGENESIS, V11, P411, DOI 10.1093/carcin/11.3.411; FREI JV, 1975, CHEM-BIOL INTERACT, V10, P413, DOI 10.1016/0009-2797(75)90072-1; FREI JV, 1978, BIOCHEM J, V174, P1031, DOI 10.1042/bj1741031; FREI JV, 1980, J NATL CANCER I, V64, P845; GERSON SL, 1985, J CLIN INVEST, V76, P2106, DOI 10.1172/JCI112215; GERSON SL, 1992, BIOCHEM PHARMACOL, V43, P1101, DOI 10.1016/0006-2952(92)90618-S; GERSON SL, 1986, CARCINOGENESIS, V7, P745, DOI 10.1093/carcin/7.5.745; GERSON SL, 1987, CANCER RES, V47, P89; GERSON SL, 1970, CANCER RES, V30, P11; GONZAGA PE, 1989, NUCLEIC ACIDS RES, V17, P6581, DOI 10.1093/nar/17.16.6581; GRESON SL, UNPUB; HANSEN MF, 1987, CANCER RES, V47, P5518; HARRIS CC, 1991, CANCER RES, V51, pS5023; HATZOGLOU M, 1988, J BIOL CHEM, V263, P17798; HAYAKAWA H, 1990, J MOL BIOL, V213, P739, DOI 10.1016/S0022-2836(05)80260-8; HITTELMAN WN, 1988, CANCER RES, V48, P276; KAINA B, 1991, CARCINOGENESIS, V12, P1857; LOEB LA, 1991, CANCER RES, V51, P3075; LUKASH LL, 1991, MUTAT RES, V250, P397, DOI 10.1016/0027-5107(91)90196-U; NEWCOMB EW, 1988, CANCER RES, V48, P5514; PEGG AE, 1984, CANCER INVEST, V2, P223, DOI 10.3109/07357908409104376; PEGG AE, 1990, CANCER RES, V50, P6119; PETERSON LA, 1991, CANCER RES, V51, P5557; PIEPER RO, 1990, CANCER COMMUN, V2, P13, DOI 10.3727/095535490820874812; QUITSCHKE WW, 1989, J BIOL CHEM, V264, P9539; SHIRAISHI A, 1992, CARCINOGENESIS, V13, P289, DOI 10.1093/carcin/13.2.289; SINGER B, 1979, J NATL CANCER I, V62, P1329; TANO K, 1990, P NATL ACAD SCI USA, V87, P686, DOI 10.1073/pnas.87.2.686; TERRACINI B, 1967, European Journal of Cancer, V3, P435, DOI 10.1016/0014-2964(67)90028-X; TIMME TL, 1988, AM J MED SCI, V295, P40, DOI 10.1097/00000441-198801000-00009; TOPAL MD, 1988, CARCINOGENESIS, V9, P691, DOI 10.1093/carcin/9.5.691; TREY JE, 1989, CANCER RES, V49, P1899; TSUJIMURA T, 1987, JPN J CANCER RES, V78, P1207; WEINSTEIN IB, 1988, CANCER RES, V48, P4135; WIENCKE JK, 1985, CANCER RES, V45, P4798; WOYCHIK RP, 1984, P NATL ACAD SCI-BIOL, V81, P3944, DOI 10.1073/pnas.81.13.3944; ZARBL H, 1985, NATURE, V315, P382, DOI 10.1038/315382a0	51	262	269	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 8	1993	259	5092					219	222		10.1126/science.8421782	http://dx.doi.org/10.1126/science.8421782			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KF719	8421782				2022-12-24	WOS:A1993KF71900028
J	IGARASHI, M; STRITTMATTER, SM; VARTANIAN, T; FISHMAN, MC				IGARASHI, M; STRITTMATTER, SM; VARTANIAN, T; FISHMAN, MC			MEDIATION BY G-PROTEINS OF SIGNALS THAT CAUSE COLLAPSE OF GROWTH CONES	SCIENCE			English	Article							NEURITE GROWTH; MYELIN; MEMBRANES; GUIDANCE; SYSTEM; REGENERATION; INHIBITION; MECHANISM; CHANNELS; BRAIN	During development, motion of nerve growth cones ceases on contact with particular targets. The signaling mechanism is unknown. In culture, growth cone collapse can be caused by solubilized embryonic brain membranes, central nervous system myelin, a 35-kilodalton protein isolated from myelin, and mastoparan. Collapse induced by each of these is blocked by pertussis toxin. Thus, collapse of growth cones is mediated by G protein-coupled receptors, which may be activated by proteins associated with the cell surface as well as by soluble ligands.	MASSACHUSETTS GEN HOSP E,DEV BIOL LAB,BOSTON,MA 02129; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Harvard Medical School			Strittmatter, Stephen/F-5739-2011	Strittmatter, Stephen/0000-0001-8188-3092				AVELDANO MI, 1991, J NEUROCHEM, V57, P250, DOI 10.1111/j.1471-4159.1991.tb02122.x; BANDTLOW C, 1990, J NEUROSCI, V10, P3837, DOI 10.1523/JNEUROSCI.10-12-03837.1990; BANDTLOW CE, 1993, SCIENCE, V259; BIRNBAUMER L, 1990, CRIT REV BIOCHEM MOL, V25, P225, DOI 10.3109/10409239009090610; BIXBY JL, 1991, ANNU REV CELL BIOL, V7, P117, DOI 10.1146/annurev.cellbio.7.1.117; CARONI P, 1988, J CELL BIOL, V106, P1281, DOI 10.1083/jcb.106.4.1281; COX EC, 1990, NEURON, V4, P31, DOI 10.1016/0896-6273(90)90441-H; DAVID S, 1981, SCIENCE, V214, P931, DOI 10.1126/science.6171034; DAVIES JA, 1991, BIOESSAYS, V13, P11, DOI 10.1002/bies.950130103; DAVIES JA, 1990, NEURON, V4, P11, DOI 10.1016/0896-6273(90)90439-M; DOHERTY P, 1991, CELL, V67, P21, DOI 10.1016/0092-8674(91)90569-K; DOHERTY P, 1992, DEVELOPMENT, V115, P892; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; EDMONDS BT, 1990, DEV BRAIN RES, V56, P131, DOI 10.1016/0165-3806(90)90172-U; HAYDON PG, 1984, SCIENCE, V226, P561, DOI 10.1126/science.6093252; HIGASHIJIMA T, 1990, J BIOL CHEM, V265, P14176; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; Keynes R J, 1992, Curr Opin Neurobiol, V2, P55, DOI 10.1016/0959-4388(92)90162-E; LANKFORD KL, 1988, P NATL ACAD SCI USA, V85, P4567, DOI 10.1073/pnas.85.12.4567-a; MENDELL L M, 1992, Current Biology, V2, P259, DOI 10.1016/0960-9822(92)90378-N; NORTON WT, 1973, J NEUROCHEM, V21, P749, DOI 10.1111/j.1471-4159.1973.tb07519.x; RAPER JA, 1990, NEURON, V4, P21, DOI 10.1016/0896-6273(90)90440-Q; SCHMIDT M F, 1991, Society for Neuroscience Abstracts, V17, P927; SCHNELL L, 1990, NATURE, V343, P269, DOI 10.1038/343269a0; SCHUCH U, 1989, NEURON, V3, P13, DOI 10.1016/0896-6273(89)90111-6; SCHWAB ME, 1990, TRENDS NEUROSCI, V13, P452, DOI 10.1016/0166-2236(90)90098-U; STRITTMATTER SM, 1991, BIOESSAYS, V13, P127, DOI 10.1002/bies.950130306; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; SUIDAN HS, 1992, NEURON, V8, P363, DOI 10.1016/0896-6273(92)90302-T; WALTER J, 1990, TRENDS NEUROSCI, V13, P447, DOI 10.1016/0166-2236(90)90097-T	30	179	186	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 1	1993	259	5091					77	79		10.1126/science.8418498	http://dx.doi.org/10.1126/science.8418498			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KE601	8418498				2022-12-24	WOS:A1993KE60100032
J	KORETZ, RL				KORETZ, RL			MALIGNANT POLYPS - ARE THEY SHEEP IN WOLVES CLOTHING	ANNALS OF INTERNAL MEDICINE			English	Editorial Material						COLONIC POLYPS; COLONIC NEOPLASMS; ADENOMA; AUTOPSY; COLONOSCOPY	COLORECTAL-CANCER; OCCULT BLOOD; LARGE-INTESTINE; CONTROLLED TRIAL; LARGE BOWEL; COLONIC POLYPS; COLONOSCOPY; RISK; DIVERTICULOSIS; NECROPSY	One of the arguments supporting the concept that benign adenomatous polyps of the colon degenerate into cancer is the observation of malignancy in polypoid growths known to have been present for years. Although a latent phase-the duration of time between the initial development of a malignancy and the subsequent occurrence of a clinical problem-must exist, this argument implies that this time span is not many years. If both the prevalence of malignant polyps and the incidence of consequent symptomatic colon cancer were known, the average latent phase could be calculated. In order to estimate this prevalence, I used autopsy data; the estimate was validated using independent data from three colonoscopic screening studies. The annual incidence of all colon cancer in the United States is approximately 150 000 cases. I estimate that 725 000 people in the United States harbor at least one malignant polyp. Even if all 150 000 cases of colon cancer were associated with symptoms and began as malignant polyps, the average latent phase is 4.8 years. Because some colon cancers are removed while the patient is still asymptomatic (discovered on screening examination) and because at least some colon cancers arise de novo from the mucosa, the average latent phase must be even longer. These estimates suggest that it cannot be assumed that the histologic finding of cancer in a polyp that has been observed for many years represents ''malignant degeneration'' of a previously benign neoplasm; such a malignancy may have had that histologic characteristic from the start. Further, histologically ominous lesions (malignant polyps) may often have prolonged benign clinical courses.			KORETZ, RL (corresponding author), OLIVE VIEW MED CTR, DEPT MED, 14445 OLIVE VIEW DR, SYLMAR, CA 91342 USA.							ACHKAR E, 1988, ANN INTERN MED, V109, P880, DOI 10.7326/0003-4819-109-11-880; ALSTEAD E M, 1990, Gastroenterology, V98, pA269; ARMINSKI T. C., 1964, DIS COLON RECTUM, V7, P249, DOI 10.1007/BF02630528; BALDRIDGE M, 1987, STATISTICAL ABSTRACT; BELLENCANI S, 1990, Gastroenterology, V98, pA273; Blatt LJ., 1961, DIS COLON RECTUM, V4, P277; BUNTAIN WL, 1972, SURG GYNECOL OBSTETR, V134, P499; BUSSEY HJR, 1985, BRIT J SURG, V72, pS29, DOI 10.1002/bjs.1800721318; CARLSSON G, 1987, ARCH SURG-CHICAGO, V122, P1261; CHAPMAN I, 1963, ANN SURG, V157, P223, DOI 10.1097/00000658-196302000-00007; COLARIAN J, 1990, Gastroenterology, V98, pA276; COLVERT JR, 1948, AM J MED SCI, V215, P24, DOI 10.1097/00000441-194801000-00004; DISARIO JA, 1991, AM J GASTROENTEROL, V86, P941; EIDE TJ, 1978, CANCER, V42, P2839, DOI 10.1002/1097-0142(197812)42:6<2839::AID-CNCR2820420645>3.0.CO;2-Y; ENQUIST IF, 1952, SURGERY, V32, P696; GABRIELSSON N, 1978, ACTA RADIOL DIAGN, V19, P479, DOI 10.1177/028418517801900309; GILBERTS.VA, 1974, CANCER, V34, P936, DOI 10.1002/1097-0142(197409)34:3+<936::AID-CNCR2820340722>3.0.CO;2-5; GILBERTSEN VA, 1978, CANCER, V41, P1137, DOI 10.1002/1097-0142(197803)41:3<1137::AID-CNCR2820410350>3.0.CO;2-G; GILBERTSEN VA, 1980, CANCER, V45, P2899, DOI 10.1002/1097-0142(19800601)45:11<2899::AID-CNCR2820451132>3.0.CO;2-M; GILBERTSON VA, 1963, SURG GYNECOL OBSTET, V116, P413; GILLESPIE PE, 1979, GUT, V20, P240, DOI 10.1136/gut.20.3.240; HARDCASTLE JD, 1989, LANCET, V1, P1160; HELWIG EB, 1947, SURG GYNECOL OBSTET, V84, P36; Hughes L E, 1968, Aust N Z J Surg, V38, P30; IKEGAMI M, 1987, ACTA PATHOL JAPON, V37, P21; KEWENTER J, 1988, CANCER, V62, P645, DOI 10.1002/1097-0142(19880801)62:3<645::AID-CNCR2820620333>3.0.CO;2-#; KRONBORG O, 1987, SCAND J GASTROENTERO, V22, P677, DOI 10.3109/00365528709011142; KURAMOTO S, 1988, CANCER, V61, P829, DOI 10.1002/1097-0142(19880215)61:4<829::AID-CNCR2820610431>3.0.CO;2-P; KURZON RM, 1974, AM J CLIN PATHOL, V62, P447; LAWRENCE JC, 1936, AM J SURG, V32, P499; Lee Y S, 1987, Ann Acad Med Singap, V16, P412; LESCHER TC, 1967, DIS COLON RECTUM, V10, P118, DOI 10.1007/BF02617358; LEUCHTENBERGER C, 1954, LAB INVEST, V3, P132; LIEBERMAN DA, 1991, AM J GASTROENTEROL, V86, P946; LOFTI AM, 1986, MAYO CLIN P, V61, P337; MOERTEL CG, 1966, MAYO CLIN PROC, V41, P368; MUTO T, 1975, CANCER, V36, P2251, DOI 10.1002/cncr.2820360944; PAGTALUN.RJ, 1965, SURG GYNECOL OBSTETR, V120, P1259; REX DK, 1991, GASTROENTEROLOGY, V100, P64, DOI 10.1016/0016-5085(91)90583-7; RICKERT RR, 1979, CANCER-AM CANCER SOC, V43, P1847, DOI 10.1002/1097-0142(197905)43:5<1847::AID-CNCR2820430538>3.0.CO;2-L; RIDER JA, 1954, AM J MED, V16, P555, DOI 10.1016/0002-9343(54)90372-1; ROSEVELT J, 1984, DIGEST DIS SCI, V29, P161, DOI 10.1007/BF01317059; SATO E, 1976, CANCER, V37, P1316, DOI 10.1002/1097-0142(197603)37:3<1316::AID-CNCR2820370312>3.0.CO;2-#; SCARBOROUGH R A, 1960, Dis Colon Rectum, V3, P336, DOI 10.1007/BF02623800; SHINYA H, 1979, ANN SURG, V190, P679, DOI 10.1097/00000658-197912000-00001; SILVERBERG E, 1990, CA-CANCER J CLIN, V40, P9, DOI 10.3322/canjclin.40.1.9; SIMON JB, 1985, GASTROENTEROLOGY, V88, P820, DOI 10.1016/0016-5085(85)90158-1; SPRATT JS, 1962, JAMA-J AM MED ASSOC, V179, P337, DOI 10.1001/jama.1962.03050050027005; STEMMERMANN GN, 1973, CANCER-AM CANCER SOC, V31, P1260, DOI 10.1002/1097-0142(197305)31:5<1260::AID-CNCR2820310535>3.0.CO;2-N; Stewart MJ, 1931, LANCET, V2, P669; STRYKER SJ, 1987, GASTROENTEROLOGY, V93, P1009, DOI 10.1016/0016-5085(87)90563-4; SWINTON N W, 1947, Lahey Clin Bull, V5, P84; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WEBB WA, 1985, ANN SURG, V201, P626, DOI 10.1097/00000658-198505000-00012; WELCH CE, 1952, NEW ENGL J MED, V247, P959, DOI 10.1056/NEJM195212182472501; WILLIAMS AR, 1982, GUT, V23, P835, DOI 10.1136/gut.23.10.835; WILSON GS, 1955, AM J SURG, V90, P834, DOI 10.1016/0002-9610(55)90707-8; WINAWER SJ, 1980, CANCER, V45, P2959, DOI 10.1002/1097-0142(19800615)45:12<2959::AID-CNCR2820451212>3.0.CO;2-E; WYCHULIS AR, 1967, SURG GYNECOL OBSTETR, V124, P87; 1988, ANN CANCER STATISTIC; 1988, GASTROENTEROLOGY OBS, V7, P7; 1988, GASTROENTEROLOGY OBS, V7, P1	62	68	71	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1993	118	1					63	68		10.7326/0003-4819-118-1-199301010-00011	http://dx.doi.org/10.7326/0003-4819-118-1-199301010-00011			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KE605	8416159				2022-12-24	WOS:A1993KE60500010
J	KERR, LD; RANSONE, LJ; WAMSLEY, P; SCHMITT, MJ; BOYER, TG; ZHOU, Q; BERK, AJ; VERMA, IM				KERR, LD; RANSONE, LJ; WAMSLEY, P; SCHMITT, MJ; BOYER, TG; ZHOU, Q; BERK, AJ; VERMA, IM			ASSOCIATION BETWEEN PROTO-ONCOPROTEIN REL AND TATA-BINDING PROTEIN MEDIATES TRANSCRIPTIONAL ACTIVATION BY NF-KAPPA-B	NATURE			English	Article							RNA POLYMERASE-II; DNA-BINDING; C-REL; BASIC REPEAT; P65 SUBUNIT; GENE; BOX; DOMAIN; YEAST; INVITRO	The c-Rel protein is able to associate in vitro and in vivo with the TATA-binding protein (TBP) of the TFIID complex. Coexpression of TBP with c-Rel augments transactivation from the kappaB site in Drosophila Schneider cells. DNA-binding mutants of TBP not only fall to cooperate, but they repress transactivation by c-Rel. There may be a direct communication between kappaB enhancer binding proteins and basal transcription factors which leads to enhanced transcription.	SALK INST BIOL STUDIES,MOLEC BIOL & VIROL LAB,SAN DIEGO,CA 92138; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,DEPT MICROBIOL & MOLEC GENET,LOS ANGELES,CA 90024	Salk Institute; University of California System; University of California Los Angeles			BERK, ARNOLD/AAF-7052-2020					BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BULL P, 1990, MOL CELL BIOL, V10, P5473, DOI 10.1128/MCB.10.10.5473; COLGAN J, 1992, GENE DEV, V6, P304, DOI 10.1101/gad.6.2.304; CORTES P, 1992, MOL CELL BIOL, V12, P413, DOI 10.1128/MCB.12.1.413; Coulombe Benoit, 1992, Gene Expression, V2, P99; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMORE TD, 1992, CANCER SURV, V15, P69; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GREENBLATT J, 1992, NATURE, V360, P16, DOI 10.1038/360016a0; HAHN S, 1989, CELL, V58, P1173, DOI 10.1016/0092-8674(89)90515-1; HEINTZ N, 1984, P NATL ACAD SCI-BIOL, V81, P2713, DOI 10.1073/pnas.81.9.2713; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; HORIKOSHI M, 1988, CELL, V54, P655; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; INOSTROZA JA, 1992, CELL, V70, P477; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; INOUE JI, 1992, P NATL ACAD SCI USA, V89, P4333, DOI 10.1073/pnas.89.10.4333; IP YT, 1991, CELL, V64, P439; KAO KR, 1991, P NATL ACAD SCI USA, V88, P2697, DOI 10.1073/pnas.88.7.2697; KELLEHER RJ, 1992, GENE DEV, V6, P296, DOI 10.1101/gad.6.2.296; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KUMAR S, 1992, MOL CELL BIOL, V12, P3094, DOI 10.1128/MCB.12.7.3094; LEE DK, 1992, MOL CELL BIOL, V12, P5189, DOI 10.1128/MCB.12.11.5189; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LIEBERMAN PM, 1991, GENE DEV, V5, P2441, DOI 10.1101/gad.5.12b.2441; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MEISTERERNST M, 1991, CELL, V6, P557; NILOLOV DB, 1992, NATURE, V360, P40; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; PAN D, 1991, DEVELOPMENT, V5, P1892; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; REDDY P, 1991, CELL, V65, P349, DOI 10.1016/0092-8674(91)90168-X; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; SUZUKI Y, 1986, P NATL ACAD SCI USA, V83, P9522, DOI 10.1073/pnas.83.24.9522; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; TOPOL J, 1985, CELL, V42, P527, DOI 10.1016/0092-8674(85)90110-2; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; YAMAMOTO T, 1992, P NATL ACAD SCI USA, V89, P2844, DOI 10.1073/pnas.89.7.2844; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964; ZHU H, 1991, NEW BIOL, V3, P455	50	154	157	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 30	1993	365	6445					412	419		10.1038/365412a0	http://dx.doi.org/10.1038/365412a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LZ633	8413585				2022-12-24	WOS:A1993LZ63300047
J	YOUNG, T; PALTA, M; DEMPSEY, J; SKATRUD, J; WEBER, S; BADR, S				YOUNG, T; PALTA, M; DEMPSEY, J; SKATRUD, J; WEBER, S; BADR, S			THE OCCURRENCE OF SLEEP-DISORDERED BREATHING AMONG MIDDLE-AGED ADULTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DAYTIME SLEEPINESS; MYOCARDIAL-INFARCTION; APNEA SYNDROME; RISK FACTOR; NIGHT; MEN; ASSOCIATION; POPULATION; PREVALENCE; MORBIDITY	Background. Limited data have suggested that sleep-disordered breathing, a condition of repeated episodes of apnea and hypopnea during sleep, is prevalent among adults. Data from the Wisconsin Sleep Cohort Study, a longitudinal study of the natural history of cardiopulmonary disorders of sleep, were used to estimate the prevalence of undiagnosed sleep-disordered breathing among adults and address its importance to the public health. Methods. A random sample of 602 employed men and women 30 to 60 years old were studied by overnight polysomnography to determine the frequency of episodes of apnea and hypopnea per hour of sleep (the apnea-hypopnea score). We measured the age- and sex-specific prevalence of sleep-disordered breathing in this group using three cutoff points for the apnea-hypopnea score (greater-than-or-equal-to 5, greater-than-or-equal-to 10, and greater-than-or-equal-to 15); we used logistic regression to investigate risk factors. Results. The estimated prevalence of sleep-disordered breathing, defined as an apnea-hypopnea score of 5 or higher, was 9 percent for women and 24 percent for men We estimated that 2 percent of women and 4 percent of men in the middle-aged work force meet the minimal diagnostic criteria for the sleep apnea syndrome (an apnea-hypopnea score of 5 or higher and daytime hypersomnolence). Male sex and obesity were strongly associated with the presence of sleep-disordered breathing. Habitual snorers, both men and women, tended to have a higher prevalence of apnea-hypopnea scores of 15 or higher. Conclusions. The prevalence of undiagnosed sleep-disordered breathing is high among men and is much higher than previously suspected among women. Undiagnosed sleep-disordered breathing is associated with daytime hypersomnolence.	UNIV WISCONSIN,SCH MED,DEPT MED,MADISON,WI 53705; UNIV WISCONSIN,SCH MED,DEPT NEUROL,MADISON,WI 53705	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	YOUNG, T (corresponding author), UNIV WISCONSIN,SCH MED,DEPT PREVENT MED,504 N WALNUT ST,MADISON,WI 53705, USA.				NCRR NIH HHS [RR 03186] Funding Source: Medline; NHLBI NIH HHS [P01 HL 42242, HL 02588] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL002588, P01HL042242] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agnew H W Jr, 1966, Psychophysiology, V2, P263, DOI 10.1111/j.1469-8986.1966.tb02650.x; ANCOLIISRAEL S, 1991, SLEEP, V14, P486, DOI 10.1093/sleep/14.6.486; BLOCK AJ, 1979, NEW ENGL J MED, V300, P513, DOI 10.1056/NEJM197903083001001; CARSKADON MA, 1989, PRINCIPLES PRACTICE, P3; COCHRAN WG, 1977, SAMPLING TECHNIQUES, P107; DALESSANDRO R, 1990, BRIT MED J, V300, P1557, DOI 10.1136/bmj.300.6739.1557-a; DEMPSEY JA, 1991, LUNG SCI F, V2, P1615; GISLASON T, 1988, J CLIN EPIDEMIOL, V41, P571, DOI 10.1016/0895-4356(88)90061-3; GOULD GA, 1988, AM REV RESPIR DIS, V137, P895, DOI 10.1164/ajrccm/137.4.895; GUILLEMINAULT C, 1991, CHEST, V99, P40, DOI 10.1378/chest.99.1.40; GUILLEMINAULT C, 1988, CHEST, V93, P104, DOI 10.1378/chest.93.1.104; Guilleminault C., 1989, PRINCIPLES PRACTICE, P552; HE J, 1988, CHEST, V94, P9, DOI 10.1378/chest.94.1.9; HUNG J, 1990, LANCET, V336, P261, DOI 10.1016/0140-6736(90)91799-G; IBER C, 1991, SLEEP, V14, P383; KNIGHT H, 1987, AM REV RESPIR DIS, V136, P845, DOI 10.1164/ajrccm/136.4.845; KOSKENVUO M, 1987, BRIT MED J, V294, P16, DOI 10.1136/bmj.294.6563.16; LAVIE P, 1983, SLEEP, V6, P312, DOI 10.1093/sleep/6.4.312; LORD S, 1991, SLEEP, V14, P252; LUGARESI E, 1990, OBSTRUCTIVE SLEEP APNEA SYNDROME : CLINICAL RESEARCH AND TREATMENT, P25; MARTIN RJ, 1985, SLEEP, V8, P371, DOI 10.1093/sleep/8.4.371; PARTINEN M, 1990, CHEST, V97, P27, DOI 10.1378/chest.97.1.27; PHILLIPS BA, 1992, CHEST, V101, P345, DOI 10.1378/chest.101.2.345; RECHTSCHAFFEN A, 1968, NIH204 PUBL; REDLINE S, 1991, CHEST, V100, P1281, DOI 10.1378/chest.100.5.1281; SANDERS MH, 1991, AM REV RESPIR DIS, V144, P1256, DOI 10.1164/ajrccm/144.6.1256; SCHMIDTNOWARA WW, 1990, OBSTRUCTIVE SLEEP APNEA SYNDROME : CLINICAL RESEARCH AND TREATMENT, P1; SCHMIDTNOWARA WW, 1990, ARCH INTERN MED, V150, P597, DOI 10.1001/archinte.150.3.597; SEPPALA T, 1991, J INTERN MED, V229, P23, DOI 10.1111/j.1365-2796.1991.tb00301.x; STRADLING JR, 1991, THORAX, V46, P85, DOI 10.1136/thx.46.2.85; SULLIVAN CE, 1981, LANCET, V1, P862; THORPY MJ, 1992, SLEEP, V15, P268; THORPY MJ, 1992, SLEEP, V15, P381; Thorpy MJ, 1990, DIAGNOSTIC CODING MA; VINER S, 1991, ANN INTERN MED, V115, P356, DOI 10.7326/0003-4819-115-5-356; WITTIG RM, 1984, AM REV RESPIR DIS, V129, P244; 1985, SAS USERS GUIDE STAT; 1988, ANTHROPOMETRIC STAND, P1; 1993, NATIONAL COMMISSION, V1; 1989, AM REV RESPIR DIS, V139, P559; 1991, SLEEP, V14, P169	41	7173	7556	12	527	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 29	1993	328	17					1230	1235		10.1056/NEJM199304293281704	http://dx.doi.org/10.1056/NEJM199304293281704			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ061	8464434	Bronze			2022-12-24	WOS:A1993KZ06100004
J	STEERE, AC; TAYLOR, E; MCHUGH, GL; LOGIGIAN, EL				STEERE, AC; TAYLOR, E; MCHUGH, GL; LOGIGIAN, EL			THE OVERDIAGNOSIS OF LYME-DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LINKED IMMUNOSORBENT-ASSAY; BORRELIA-BURGDORFERI; NEUROLOGIC MANIFESTATIONS; FIBROMYALGIA; ANTIBODY; NEUROBORRELIOSIS; ABNORMALITIES; PENICILLIN; DIAGNOSIS	Objective.-To analyze the diagnoses, serological test results, and treatment results of the patients evaluated in a Lyme disease clinic, both prior to referral and from current evaluation. Design.-Retrospective case survey of prescreened patients. Setting.-Research and diagnostic Lyme disease clinic in a university hospital. Patients.-All 788 patients referred to the clinic during a 4.5-year period who were thought by the referring physician or the patient to have a diagnosis of Lyme disease. Main Outcome Measurements.-Symptoms and signs of disease, immunodiagnostic tests of Lyme disease, and tests of neurological function. Results.-Of the 788 patients, 180 (23%) had active Lyme disease, usually arthritis, encephalopathy, or polyneuropathy. One hundred fifty-six patients (20%) had previous Lyme disease and another current illness, most commonly chronic fatigue syndrome or fibromyalgia; and in 49 patients, these symptoms began soon after objective manifestations of Lyme disease. The remaining 452 patients (57%) did not have Lyme disease. The majority of these patients also had the chronic fatigue syndrome or fibromyalgia; the others usually had rheumatic or neurological diseases. Of the patients who did not have Lyme disease, 45% had had positive serological test results for Lyme disease in other laboratories, but all were seronegative in our laboratory. Prior to referral, 409 of the 788 patients had been treated with antibiotic therapy. In 322 (79%) of these patients, the reason for lack of response was incorrect diagnosis. Conclusions.-Only a minority of the patients referred to the clinic met diagnostic criteria for Lyme disease. The most common reason for lack of response to antibiotic therapy was misdiagnosis.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT NEUROL,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard Medical School	STEERE, AC (corresponding author), TUFTS UNIV,NEW ENGLAND MED CTR,SCH MED,DIV RHEUMATOL IMMUNOL,BOX 406,750 WASHINGTON AVE,BOSTON,MA 02111, USA.			Steere, Allen/0000-0002-5268-9853	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR020358] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-20358] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BAKKEN LL, 1992, JAMA-J AM MED ASSOC, V268, P891, DOI 10.1001/jama.268.7.891; BUCHWALD D, 1991, REV INFECT DIS, V13, pS12; DATTWYLER RJ, 1988, NEW ENGL J MED, V319, P1441, DOI 10.1056/NEJM198812013192203; DATTWYLER RJ, 1988, LANCET, V1, P1191; DATTWYLER RJ, 1990, LANCET, V336, P1404, DOI 10.1016/0140-6736(90)93103-V; DINERMAN H, 1992, ANN INTERN MED, V117, P281, DOI 10.7326/0003-4819-117-4-281; DRESSLER F, 1991, ANN INTERN MED, V115, P533, DOI 10.7326/0003-4819-115-7-533; DRESSLER F, 1993, J INFECT DIS, V167, P392, DOI 10.1093/infdis/167.2.392; GOLDENBERG DL, 1986, ARTHRITIS RHEUM, V29, P1371, DOI 10.1002/art.1780291110; GOLDENBERG DL, 1987, JAMA-J AM MED ASSOC, V257, P2782, DOI 10.1001/jama.257.20.2782; HALPERIN JJ, 1989, NEUROLOGY, V39, P753, DOI 10.1212/WNL.39.6.753; HALPERIN JJ, 1987, NEUROLOGY, V37, P1700, DOI 10.1212/WNL.37.11.1700; HANRAHAN JP, 1984, J INFECT DIS, V150, P489, DOI 10.1093/infdis/150.4.489; HEDBERG CW, 1987, J INFECT DIS, V155, P1325, DOI 10.1093/infdis/155.6.1325; HOLMES GP, 1988, ANN INTERN MED, V108, P387, DOI 10.7326/0003-4819-108-3-387; KALISH RA, IN PRESS INFECT IMMU; KAPLAN RF, 1992, NEUROLOGY, V42, P1263, DOI 10.1212/WNL.42.7.1263; KOMAROFF AL, 1991, REV INFECT DIS, V13, pS8; LANE TJ, 1991, AM J MED, V91, P334; LIU N Y, 1989, Arthritis and Rheumatism, V32, pS46; LOGIGIAN EL, 1990, NEW ENGL J MED, V323, P1438, DOI 10.1056/NEJM199011223232102; LOGIGIAN EL, 1992, NEUROLOGY, V42, P303, DOI 10.1212/WNL.42.2.303; MAGNARELLI LA, 1984, J CLIN MICROBIOL, V20, P181, DOI 10.1128/JCM.20.2.181-184.1984; MASSAROTTI EM, 1992, AM J MED, V92, P396, DOI 10.1016/0002-9343(92)90270-L; MCCAIN GA, 1988, ARTHRITIS RHEUM, V31, P1135, DOI 10.1002/art.1780310908; PACHNER AR, 1985, NEUROLOGY, V35, P47, DOI 10.1212/WNL.35.1.47; RAHN DW, 1991, ANN INTERN MED, V114, P472, DOI 10.7326/0003-4819-114-6-472; REILLY P A, 1990, Current Opinion in Rheumatology, V2, P282; RUSSELL H, 1984, J INFECT DIS, V149, P465, DOI 10.1093/infdis/149.3.465; SHRESTHA M, 1985, AM J MED, V78, P235, DOI 10.1016/0002-9343(85)90432-2; SIGAL LH, 1990, AM J MED, V88, P577, DOI 10.1016/0002-9343(90)90520-N; STEER AC, 1983, ANN INTERN MED, V99, P767, DOI 10.7326/0003-4819-99-6-767; STEERE AC, 1990, NEW ENGL J MED, V323, P219, DOI 10.1056/NEJM199007263230402; STEERE AC, 1983, ANN INTERN MED, V99, P76, DOI 10.7326/0003-4819-99-1-76; STEERE AC, 1990, J INFECT DIS, V161, P1203, DOI 10.1093/infdis/161.6.1203; STEERE AC, 1980, ANN INTERN MED, V93, P8, DOI 10.7326/0003-4819-93-1-8; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; STEERE AC, 1986, J INFECT DIS, V154, P295, DOI 10.1093/infdis/154.2.295; STEERE AC, 1987, ANN INTERN MED, V107, P725, DOI 10.7326/0003-4819-107-5-725; 1992, MED LETT, V34, P95	40	300	304	0	17	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 14	1993	269	14					1812	1816		10.1001/jama.269.14.1812	http://dx.doi.org/10.1001/jama.269.14.1812			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW250	8459513				2022-12-24	WOS:A1993KW25000036
J	HEALY, B				HEALY, B			MUCOSAL IMMUNITY, VACCINE DEVELOPMENTS NEW FRONTIER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA								LAMM M, 1991, P NATL ACAD SCI USA, V88, P8796; LAMM M, 1992, P NATL ACAD SCI USA, V89, P6901	2	3	3	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 7	1993	269	13					1612	1612						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KV349	8455284				2022-12-24	WOS:A1993KV34900006
J	HUANG, S; HENDRIKS, W; ALTHAGE, A; HEMMI, S; BLUETHMANN, H; KAMIJO, R; VILCEK, J; ZINKERNAGEL, RM; AGUET, M				HUANG, S; HENDRIKS, W; ALTHAGE, A; HEMMI, S; BLUETHMANN, H; KAMIJO, R; VILCEK, J; ZINKERNAGEL, RM; AGUET, M			IMMUNE-RESPONSE IN MICE THAT LACK THE INTERFERON-GAMMA RECEPTOR	SCIENCE			English	Article							LYMPHOCYTIC CHORIOMENINGITIS VIRUS; CD4+ T-CELLS; MONOCLONAL-ANTIBODY; EXPRESSION; INVIVO; CD8+; INFECTION; CLONING; BINDING; DISEASE	Interferon-gamma (IFN-gamma) exerts pleiotropic effects, including antiviral activity, stimulation of macrophages and natural killer cells, and increased expression of major histocompatibility complex antigens. Mice without the IFN-gamma receptor had no overt anomalies, and their immune system appeared to develop normally. However, mutant mice had a defective natural resistance; they had increased susceptibility to infection by Listeria monocytogenes and vaccinia virus despite normal cytotoxic and T helper cell responses. Immunoglobulin isotype analysis revealed that IFN-gamma is necessary for a normal antigen-specific immunoglobulin G2a response. These mutant mice offer the possibility for the further elucidation of IFN-gamma-mediated functions by transgenic cell- or tissue-specific reconstitution of a functional receptor.	UNIV ZURICH,INST MOLEC BIOL 1,CH-8093 ZURICH,SWITZERLAND; F HOFFMANN LA ROCHE & CO LTD,DEPT PHARMACEUT RES NEW TECHNOL,CH-4002 BASEL,SWITZERLAND; UNIV ZURICH,INST EXPTL IMMUNOL,CH-8057 ZURICH,SWITZERLAND; NYU MED CTR,DEPT MICROBIOL,NEW YORK,NY 10016	University of Zurich; Roche Holding; University of Zurich; New York University			Hendriks, Wiljan J.A.J./A-5214-2013; Hendriks, Wiljan/Q-4325-2019	Hendriks, Wiljan J.A.J./0000-0001-9481-8281; Hendriks, Wiljan/0000-0001-9481-8281; Lee-Huang, Sylvia/0000-0003-3302-241X	NATIONAL CANCER INSTITUTE [R35CA049731] Funding Source: NIH RePORTER; NCI NIH HHS [CA 49731] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGUET M, 1988, CELL, V55, P273, DOI 10.1016/0092-8674(88)90050-5; BAENZIGER J, 1986, EUR J IMMUNOL, V16, P387, DOI 10.1002/eji.1830160413; BINDER D, 1991, J IMMUNOL, V146, P4301; Blanden R V, 1972, Scand J Immunol, V1, P379, DOI 10.1111/j.1365-3083.1972.tb03304.x; BUCHMEIER NA, 1985, P NATL ACAD SCI USA, V82, P7407; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; CAMPBELL IL, 1991, J CLIN INVEST, V87, P739, DOI 10.1172/JCI115055; DING AH, 1988, J IMMUNOL, V141, P2407; FARRAR MA, 1991, J BIOL CHEM, V266, P19626; FINKELMAN FD, 1990, ANNU REV IMMUNOL, V8, P303, DOI 10.1146/annurev.iy.08.040190.001511; FOUNTOULAKIS M, 1991, J BIOL CHEM, V266, P14970; FUNGLEUNG WP, 1991, CELL, V65, P443, DOI 10.1016/0092-8674(91)90462-8; HEINZEL FP, 1989, J EXP MED, V169, P59, DOI 10.1084/jem.169.1.59; HEMMI S, 1989, P NATL ACAD SCI USA, V86, P9901, DOI 10.1073/pnas.86.24.9901; Huang S. H., UNPUB; JACOB CO, 1987, J EXP MED, V166, P798, DOI 10.1084/jem.166.3.798; KLAVINSKIS LS, 1989, J GEN VIROL, V70, P3317, DOI 10.1099/0022-1317-70-12-3317; LEFEVRE F, 1990, EUR J IMMUNOL, V20, P2485, DOI 10.1002/eji.1830201119; LEIST TP, 1989, J VIROL, V63, P2813, DOI 10.1128/JVI.63.6.2813-2819.1989; LEIST TP, 1987, J IMMUNOL, V138, P2278; LEVY DE, 1990, EMBO J, V9, P1105, DOI 10.1002/j.1460-2075.1990.tb08216.x; LOH JE, 1992, EMBO J, V11, P1351, DOI 10.1002/j.1460-2075.1992.tb05180.x; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MOSKOPHIDIS D, 1989, P NATL ACAD SCI USA, V86, P3291, DOI 10.1073/pnas.86.9.3291; MOSMANN TR, 1991, IMMUNOL REV, V123, P209, DOI 10.1111/j.1600-065X.1991.tb00612.x; PORTNOY DA, 1992, CURR OPIN IMMUNOL, V4, P20, DOI 10.1016/0952-7915(92)90118-X; RAHEMTULLA A, 1991, NATURE, V353, P180, DOI 10.1038/353180a0; SARVETNICK N, 1990, NATURE, V346, P844, DOI 10.1038/346844a0; SCHIJNS V, COMMUNICATION; SNAPPER CM, 1987, SCIENCE, V236, P944, DOI 10.1126/science.3107127; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; VALENTE G, 1992, EUR J IMMUNOL, V22, P2403, DOI 10.1002/eji.1830220933; WILLE A, 1989, EUR J IMMUNOL, V19, P1283, DOI 10.1002/eji.1830190720; YANG Y, 1992, P NATL ACAD SCI USA, V89, P4928, DOI 10.1073/pnas.89.11.4928	34	1421	1446	1	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 19	1993	259	5102					1742	1745		10.1126/science.8456301	http://dx.doi.org/10.1126/science.8456301			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KT810	8456301				2022-12-24	WOS:A1993KT81000034
J	COSMAN, F; SHEN, V; XIE, F; SEIBEL, M; RATCLIFFE, A; LINDSAY, R				COSMAN, F; SHEN, V; XIE, F; SEIBEL, M; RATCLIFFE, A; LINDSAY, R			ESTROGEN PROTECTION AGAINST BONE RESORBING EFFECTS OF PARATHYROID-HORMONE INFUSION - ASSESSMENT BY USE OF BIOCHEMICAL MARKERS	ANNALS OF INTERNAL MEDICINE			English	Article						ESTROGEN REPLACEMENT THERAPY; SKELETON; OSTEOPOROSIS, POSTMENOPAUSAL; BONE RESORPTION; PARATHYROID HORMONES	OSTEOBLAST-LIKE CELLS; POSTMENOPAUSAL OSTEOPOROSIS; PYRIDINIUM CROSSLINKS; CIRCADIAN-RHYTHM; MESSENGER-RNA; HUMAN-SERUM; CYCLIC-AMP; WOMEN; OSTEOCALCIN; OSTEOCLASTS	Objective: Because parathyroid hormone (PTH) stimulates bone resorption, resistance to its actions might help maintain bone mass. We tested the hypothesis that the effects of estrogen on bone are accomplished in part by decreasing the sensitivity of the skeleton to the resorbing effects of PTH. Study Design: Comparison of response to PTH infusion in untreated and estrogen-treated postmenopausal women with osteoporosis. Intervention: (1-34) human PTH, 0.55 U/(kg.h), was infused intravenously over 20 hours. Setting: The inpatient clinical research unit of a referral hospital. Patients: Women with primary postmenopausal osteoporosis who were untreated (n = 15) or treated with estrogen (n = 17). Main Outcome Measures: Skeletal turnover indices including hydroxyproline, deoxypyridinoline, pyridinoline, tartrate-resistant acid phosphatase, alkaline phosphatase, bone Gla protein, and insulin-like growth factor-1. Results: All basal indices were higher in untreated than in estrogen-treated women, but statistical differences were seen only for deoxypyridinoline and pyridinoline. During the 20-hour infusion, hydroxyproline/creatinine increased 0.023 mumol/mumol in untreated women but only 0.010 mumol/mumol in estrogen-treated women (P < 0.05). Corresponding changes for deoxypyridinoline/creatinine were 14.6 mumol/mumol and 3.5 mumol/mumol (P = 0.06). Tartrate-resistant acid phosphatase and pyridinoline increased only in the untreated group. A circadian rhythm in circulating bone Gla protein was seen in both groups without clear PTH-induced effects or differences between groups. Alkaline phosphatase levels and insulin-like growth factor-1 decreased in both groups with no distinction between untreated and estrogen-treated women. Conclusion: The estrogenized postmenopausal osteoporotic skeleton is less sensitive to the bone resorbing effects of acutely administered PTH. There are no differential effects on bone formation.	COLUMBIA UNIV, NEW YORK, NY 10027 USA	Columbia University	COSMAN, F (corresponding author), HELEN HAYES HOSP, REG BONE CTR, ROUTE 9W, W HAVERSTRAW, NY 10993 USA.			Seibel, Markus J/0000-0002-2701-378X	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000645] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P50AR039191] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042892] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00645] Funding Source: Medline; NIAMS NIH HHS [AR-39191] Funding Source: Medline; NIDDK NIH HHS [R01-DK-42892] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARNETT TR, 1986, J BONE MINER RES, V1, pA99; BARON R, 1981, METAB BONE DIS RELAT, V2, P339, DOI 10.1016/0221-8747(81)90020-5; BLACK D, 1988, ANAL BIOCHEM, V169, P197, DOI 10.1016/0003-2697(88)90274-6; CANALIS E, 1989, ENDOCRIN METAB CLIN, V18, P903, DOI 10.1016/S0889-8529(18)30348-7; COSMAN F, 1991, J CLIN ENDOCR METAB, V73, P1345, DOI 10.1210/jcem-73-6-1345; DAUGHADAY WH, 1980, J CLIN ENDOCR METAB, V51, P781, DOI 10.1210/jcem-51-4-781; DELMAS PD, 1990, ENDOCRIN METAB CLIN, V19, P1; DELMAS PD, 1990, J BONE MINER RES, V5, P5, DOI 10.1002/jbmr.5650050104; DELMAS PD, 1983, J CLIN INVEST, V71, P1316, DOI 10.1172/JCI110882; DELMAS PD, 1991, J BONE MINER RES, V6, P639; EASTELL R, 1988, OSTEOPOROSIS ETIOLOG, P373; ERIKSEN EF, 1988, SCIENCE, V241, P84, DOI 10.1126/science.3388021; ERNST M, 1991, MOL ENDOCRINOL, V5, P1081, DOI 10.1210/mend-5-8-1081; ETTINGER B, 1985, ANN INTERN MED, V102, P319, DOI 10.7326/0003-4819-102-3-319; GARCIACARRASCO M, 1988, CALCIFIED TISSUE INT, V42, P13, DOI 10.1007/BF02555833; GREENBERG C, 1986, ENDOCRINOLOGY, V118, P2594, DOI 10.1210/endo-118-6-2594; GRIFFIN JE, 1985, TXB ENDOCRINOLOGY, P147; GUNDBERG CM, 1985, J CLIN ENDOCR METAB, V60, P736, DOI 10.1210/jcem-60-4-736; HEANEY RP, 1965, AM J MED, V39, P877, DOI 10.1016/0002-9343(65)90109-9; JOBORN C, 1991, CLIN ENDOCRINOL, V34, P335, DOI 10.1111/j.1365-2265.1991.tb00302.x; KIVIRIKKO KI, 1967, ANAL BIOCHEM, V19, P249, DOI 10.1016/0003-2697(67)90160-1; KOMM BS, 1988, SCIENCE, V241, P81, DOI 10.1126/science.3164526; KRAENZLIN ME, 1990, J CLIN ENDOCR METAB, V71, P442, DOI 10.1210/jcem-71-2-442; KUMEGAWA M, 1984, CALCIFIED TISSUE INT, V36, P72, DOI 10.1007/BF02405296; LEGGATE J, 1984, CLIN ENDOCRINOL, V20, P85, DOI 10.1111/j.1365-2265.1984.tb00062.x; LINDSAY R, 1986, J BONE MINER RES, V1, P121; LINDSAY R, 1990, OBSTET GYNECOL, V76, P290; LINDSAY R, 1988, OSTEOPOROSIS ETIOLOG, P333; LINKHART TA, 1989, ENDOCRINOLOGY, V125, P1484, DOI 10.1210/endo-125-3-1484; MAJESKA RJ, 1982, CALCIFIED TISSUE INT, V34, P59, DOI 10.1007/BF02411210; MARCUS R, 1984, ANN INTERN MED, V100, P633, DOI 10.7326/0003-4819-100-5-633; MURRILLS RJ, 1990, ENDOCRINOLOGY, V127, P2648, DOI 10.1210/endo-127-6-2648; NODA M, 1988, J BIOL CHEM, V263, P18574; ORIMO H, 1972, ENDOCRINOLOGY, V90, P760, DOI 10.1210/endo-90-3-760; OURSLER MJ, 1991, P NATL ACAD SCI USA, V88, P6613, DOI 10.1073/pnas.88.15.6613; Parfitt A.M., 1988, OSTEOPOROSIS ETIOLOG, P45; PIETSCHMANN P, 1990, EUR J CLIN INVEST, V20, P310, DOI 10.1111/j.1365-2362.1990.tb01861.x; PILBEAM CC, 1989, BIOCHEM BIOPH RES CO, V163, P1319, DOI 10.1016/0006-291X(89)91122-4; QUIGLEY MET, 1987, AM J OBSTET GYNECOL, V156, P1516; RECKER RR, 1977, ANN INTERN MED, V87, P649, DOI 10.7326/0003-4819-87-6-649; RIGGS BL, 1972, J CLIN INVEST, V51, P1659, DOI 10.1172/JCI106967; ROTH GS, 1990, ENDOCRINE FUNCTION AND AGING, P26; SEIBEL MJ, 1989, J RHEUMATOL, V16, P964; SELBY PL, 1986, NEW ENGL J MED, V314, P1481, DOI 10.1056/NEJM198606053142304; STEINICHE T, 1989, BONE, V10, P313, DOI 10.1016/8756-3282(89)90126-9; STEVENSON JC, 1983, EUR J CLIN INVEST, V13, P481, DOI 10.1111/j.1365-2362.1983.tb00133.x; TOBIAS JH, 1991, ACTA ENDOCRINOL-COP, V124, P121, DOI 10.1530/acta.0.1240121; TSAI KS, 1989, J CLIN ENDOCR METAB, V69, P1024, DOI 10.1210/jcem-69-5-1024; TSAI KS, 1984, J CLIN INVEST, V73, P1668, DOI 10.1172/JCI111373	49	106	109	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1993	118	5					337	343		10.7326/0003-4819-118-5-199303010-00003	http://dx.doi.org/10.7326/0003-4819-118-5-199303010-00003			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KN688	8430979				2022-12-24	WOS:A1993KN68800003
J	GIOVANNUCCI, E; ASCHERIO, A; RIMM, EB; COLDITZ, GA; STAMPFER, MJ; WILLETT, WC				GIOVANNUCCI, E; ASCHERIO, A; RIMM, EB; COLDITZ, GA; STAMPFER, MJ; WILLETT, WC			A PROSPECTIVE COHORT STUDY OF VASECTOMY AND PROSTATE-CANCER IN UNITED-STATES MEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN SEMINAL PLASMA; RISK; ETIOLOGY; ANTIGENS; SPERM; MOUSE	Objective.-To examine prospectively the relationship between vasectomy and prostate cancer. Design.-Cohort study. Setting.-Health professionals (dentists, veterinarians, osteopaths, optometrists, pharmacists, and podiatrists) in the United States. Participants.-There were 10055 male members of the Health Professionals Follow-up Study, aged 40 to 75 years, who had had a vasectomy, and 37 800 members who had not had a vasectomy at the time of study entry in 1986. These participants had provided detailed information on various life-style variables including diet. Main Outcome Measure.-Diagnosis of prostate cancer. Results.-Between 1986 and 1990, 300 new cases of prostate cancer were diagnosed in participants who were initially free of diagnosed cancer. Vasectomy was associated with an elevated risk of prostate cancer (age-adjusted relative risk, 1.66; 95% confidence interval, 1.25 to 2.21; P=.0004). This elevated risk persisted after excluding 21 stage A1 cases (age-adjusted relative risk, 1.56; 95% confidence interval, 1.15 to 2.11; P=.004). Among men who had their vasectomy at least 22 years in the past (before 1965), the risk of prostate cancer was even higher (relative risk, 1.85; 95% confidence interval, 1.26 to 2.72; P=.002). This elevated risk among men with vasectomy did not appear to be caused by detection bias and persisted when we controlled for diet, level of physical activity, smoking, alcohol consumption, educational level, body mass index, and geographical area of residence. Conclusions.-These results support evidence from other epidemiologic studies that vasectomy increases risk of prostate cancer. The consistency of results among various epidemiologic studies, the increase of risk over time following vasectomy, the apparent lack of confounding or bias, and the existence of physiological changes in the prostate following vasectomy suggest that the association may be causal.	HARVARD UNIV,SCH PUBL HLTH,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital	GIOVANNUCCI, E (corresponding author), HARVARD UNIV,SCH MED,CHANNING LAB,DEPT MED,180 LONGWOOD AVE,BOSTON,MA 02115, USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035464] Funding Source: NIH RePORTER; NCI NIH HHS [CA55075] Funding Source: Medline; NHLBI NIH HHS [HL35464] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adamopoulos D A, 1976, Acta Eur Fertil, V7, P219; BORING CC, 1991, CA-CANCER J CLIN, V41, P19, DOI 10.3322/canjclin.41.1.19; FRANKS LM, 1954, J PATHOL BACTERIOL, V68, P603, DOI 10.1002/path.1700680233; FREUND M, 1969, FERTIL STERIL, V20, P163; GACHELIN G, 1977, DEV BIOL, V57, P199, DOI 10.1016/0012-1606(77)90365-7; GIOVANNUCCI E, 1993, JAMA-J AM MED ASSOC, V269, P878, DOI 10.1001/jama.269.7.878; GIOVANNUCCI E, 1992, NEW ENGL J MED, V326, P1392, DOI 10.1056/NEJM199205213262104; GOLDBERG EH, 1977, TRANSPLANT P, V9, P1363; GUESS HA, 1990, AM J EPIDEMIOL, V132, P1062, DOI 10.1093/oxfordjournals.aje.a115748; HONDA GD, 1988, BRIT J CANCER, V57, P326, DOI 10.1038/bjc.1988.74; ISAACS JT, 1983, PROSTATE, V4, P351, DOI 10.1002/pros.2990040405; JAKOBSEN H, 1988, PROSTATE, V13, P57, DOI 10.1002/pros.2990130107; JAKOBSEN H, 1989, J REPROD FERTIL, V87, P39; JOSHI UM, 1981, ARCH ANDROLOGY, V7, P187, DOI 10.3109/01485018108999306; JOUANNET P, 1978, FERTIL STERIL, V29, P435; KINSON GA, 1977, RES COMMUN CHEM PATH, V18, P561; LELANNOU D, 1980, INT J ANDROL, V3, P502; LOHIYA N K, 1987, Acta Europaea Fertilitatis, V18, P207; MENDIRATTA R, 1980, INDIAN J EXP BIOL, V18, P409; MENGE AC, 1978, DEV BIOL, V63, P111, DOI 10.1016/0012-1606(78)90117-3; METTLIN C, 1990, AM J EPIDEMIOL, V132, P1056, DOI 10.1093/oxfordjournals.aje.a115747; NAG DSK, 1984, ANDROLOGIA, V16, P451; NAIK VK, 1980, J REPROD FERTIL, V58, P289; NIENHUIS H, 1992, BRIT MED J, V304, P743, DOI 10.1136/bmj.304.6829.743; NOMURA AMY, 1991, AM J EPIDEMIOL, V13, P200; PERLMAN JA, 1991, AM J EPIDEMIOL, V134, P107, DOI 10.1093/oxfordjournals.aje.a115985; PIERREPOINT CG, 1975, J REPROD FERTIL, V44, P395; PURVIS K, 1976, CLIN ENDOCRINOL, V5, P263, DOI 10.1111/j.1365-2265.1976.tb01952.x; RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211; RIMM EB, 1991, LANCET, V338, P464, DOI 10.1016/0140-6736(91)90542-W; ROSENBERG L, 1990, AM J EPIDEMIOL, V132, P1051, DOI 10.1093/oxfordjournals.aje.a115746; ROSS RK, 1983, PROSTATE, V4, P333, DOI 10.1002/pros.2990040403; Rothman K, 1986, MODERN EPIDEMIOLOGY; SHETH AR, 1982, MED HYPOTHESES, V8, P237, DOI 10.1016/0306-9877(82)90118-9; SIDNEY S, 1991, CANCER CAUSE CONTROL, V2, P113, DOI 10.1007/BF00053130; SIDNEY S, 1987, J UROLOGY, V138, P795, DOI 10.1016/S0022-5347(17)43377-5; SKINNER JD, 1968, J ENDOCRINOL, V42, P355, DOI 10.1677/joe.0.0420355; SOLTER D, 1977, DEV BIOL, V57, P199; SPITZ MR, 1991, AM J EPIDEMIOL, V134, P108, DOI 10.1093/oxfordjournals.aje.a115986; SRIVASTAVA A, 1986, ACTA ENDOCRINOL-COP, V113, P440, DOI 10.1530/acta.0.1130440; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; YING W, 1983, INT J ANDROL, V6, P116, DOI 10.1111/j.1365-2605.1983.tb00330.x	42	165	168	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 17	1993	269	7					873	877		10.1001/jama.269.7.873	http://dx.doi.org/10.1001/jama.269.7.873			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KL474	8426446				2022-12-24	WOS:A1993KL47400024
J	MILLER, HI				MILLER, HI			FOODS OF THE FUTURE - THE NEW BIOTECHNOLOGY AND FDA REGULATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											MILLER, HI (corresponding author), US FDA,OFF BIOTECHNOL,ROCKVILLE,MD 20857, USA.							1992, FED REG         0529, V57, P22984; 1989, FIELD TESTING GENETI	2	5	5	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 17	1993	269	7					910	912						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KL474	8426451				2022-12-24	WOS:A1993KL47400031
J	BLOOM, BS; HILLMAN, AL; FENDRICK, AM; SCHWARTZ, JS				BLOOM, BS; HILLMAN, AL; FENDRICK, AM; SCHWARTZ, JS			A REAPPRAISAL OF HEPATITIS-B VIRUS VACCINATION STRATEGIES USING COST-EFFECTIVENESS ANALYSIS	ANNALS OF INTERNAL MEDICINE			English	Article						HEPATITIS-B; VIRAL HEPATITIS VACCINES; HEPATITIS-B VIRUS; COST-BENEFIT ANALYSIS; VACCINATION	POSITIVE CARRIER MOTHERS; LONG-TERM IMMUNOGENICITY; YUPIK ESKIMO POPULATION; HOMOSEXUAL MEN; HEPATOCELLULAR-CARCINOMA; VIRAL-HEPATITIS; IMMUNE GLOBULIN; PREGNANT-WOMEN; UNITED-STATES; INFANTS BORN	Objective: To determine clinical and economic consequences of alternative vaccination strategies for preventing hepatitis B virus infection (HBV). Methods: Decision analysis was used to evaluate costs, outcomes, and cost-effectiveness of three HBV management strategies (''no vaccination,'' ''universal vaccination,'' and ''screen and vaccinate'') in four populations (newborns, 10-year-old adolescents, a high-risk adult population, and the general adult U.S. population). Information on HBV incidence and prevalence, clinical course, and management of acute illness and chronic sequelae was obtained from the literature and a panel of experts. Actual payments (costs) were obtained from Blue Cross/Blue Shield and local pharmacies. Incremental cost-effectiveness was calculated from the perspective of the payer of medical care and subjected to sensitivity analysis. Results: Vaccination (with or without screening) prevents more disease at somewhat increased cost than no vaccination for the neonatal, adolescent, and adult populations. Vaccination (with or without screening) is a dominant strategy in adult high-risk populations (lower cost and greater benefit than no vaccination). Optimal cost-effectiveness, with nonmonetary benefits not discounted, results if all pregnant women are screened for active HBV infection, and HBV vaccine and hepatitis B immune globulin are administered to babies born to mothers with positive screening tests. Then HBV vaccine is administered to all children at age 10 and again 10 years later (incremental cost-per-year-of-life-saved relative to the ''no vaccination'' strategy is $375). A strategy of universal newborn vaccination alone leads to an incremental cost-per-year-of-life saved of $3332. If adolescents are vaccinated at age 10, incremental cost-per-year-of-life saved is $13 938; for the general adult population, the incremental cost-per-year-of-life saved of universal vaccination is $54 524. Discounting benefits will increase cost-per-year-of-life saved 7 to 12 times for all strategies. Conclusions: HBV vaccine is most cost-effective when a strategy of screening newborns is combined with routine administration to 10-year-old children. The means to achieve substantial improvements in the health of the public in a cost-effective fashion are now available and should be pursued aggressively.	UNIV PENN, SCH MED, PHILADELPHIA, PA 19104 USA; UNIV PENN, WHARTON SCH, PHILADELPHIA, PA 19104 USA; UNIV PENN, LEONARD DAVIS INST HLTH ECON, PHILADELPHIA, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	BLOOM, BS (corresponding author), UNIV PENN, SCH DENT MED, 2L NURSING EDUC BLDG, PHILADELPHIA, PA 19104 USA.							ALTER MJ, 1987, AM J EPIDEMIOL, V125, P133, DOI 10.1093/oxfordjournals.aje.a114496; ALTER MJ, 1990, JAMA-J AM MED ASSOC, V263, P1218, DOI 10.1001/jama.263.9.1218; ANDRE FE, 1987, POSTGRAD MED J, V63, P169; ANDRE FE, 1989, AM J MED, V87, pS14, DOI 10.1016/0002-9343(89)90525-1; AREVALO JA, 1988, JAMA-J AM MED ASSOC, V259, P365, DOI 10.1001/jama.259.3.365; Beasley R.P., 1984, VIRAL HEPATITIS LIVE, P209; BEASLEY RP, 1983, LANCET, V2, P1099; BEASLEY RP, 1988, CANCER, V61, P1942, DOI 10.1002/1097-0142(19880515)61:10<1942::AID-CNCR2820611003>3.0.CO;2-J; BOYLE MH, 1983, NEW ENGL J MED, V308, P1330, DOI 10.1056/NEJM198306023082206; CADRANEL S, 1987, POSTGRAD MED J, V63, P159; DELAPLANE D, 1983, PEDIATRICS, V72, P176; GOILAV C, 1989, AM J MED, V87, pS21, DOI 10.1016/0002-9343(89)90526-3; HADLER SC, 1986, NEW ENGL J MED, V315, P209, DOI 10.1056/NEJM198607243150401; HILLMAN AL, 1991, NEW ENGL J MED, V324, P1362, DOI 10.1056/NEJM199105093241911; Hoofnagle J H, 1981, Semin Liver Dis, V1, P7, DOI 10.1055/s-2008-1063925; KINOSIAN BP, 1988, JAMA-J AM MED ASSOC, V259, P2249, DOI 10.1001/jama.259.15.2249; KUMAR ML, 1987, ANN INTERN MED, V107, P273, DOI 10.7326/0003-4819-107-2-273; LAUKAMMJOSTEN U, 1987, POSTGRAD MED J, V63, P143; LO KJ, 1988, HEPATOLOGY, V8, P1647, DOI 10.1002/hep.1840080629; MARGOLIS HS, 1990, VACCINE, V8, pS81, DOI 10.1016/0264-410X(90)90224-A; MCQUILLAN GM, 1989, AM J MED, V87, pS5; MEHEUS A, 1987, POSTGRAD MED J, V63, P139; MULLEY AG, 1982, NEW ENGL J MED, V307, P644, DOI 10.1056/NEJM198209093071103; ODAKA N, 1988, JAMA-J AM MED ASSOC, V260, P3635, DOI 10.1001/jama.260.24.3635; PERILLO RP, 1981, SEMIN LIVER DIS, V1, P15; PIAZZA M, 1988, LANCET, V2, P1132; POOVORAWAN Y, 1989, JAMA-J AM MED ASSOC, V261, P3278, DOI 10.1001/jama.261.22.3278; PRINSEN H, 1987, POSTGRAD MED J, V63, P147; REDEKER AG, 1975, AM J MED SCI, V270, P9, DOI 10.1097/00000441-197507000-00003; ROBERTS SD, 1980, ANN INTERN MED, V92, P243, DOI 10.7326/0003-4819-92-2-243; SAMPLINER RE, 1979, ARCH INTERN MED, V139, P145, DOI 10.1001/archinte.139.2.145; SHERLOCK S, 1987, POSTGRAD MED J, V63, P7; SINATRA FR, 1982, PEDIATRICS, V70, P557; SISK JE, 1986, ANN INTERN MED, V104, P79, DOI 10.7326/0003-4819-104-1-79; STEVENS CE, 1987, JAMA-J AM MED ASSOC, V257, P2612, DOI 10.1001/jama.257.19.2612; STEVENS CE, 1975, NEW ENGL J MED, V292, P771, DOI 10.1056/NEJM197504102921503; Szmuness W, 1978, Prog Med Virol, V24, P40; SZMUNESS W, 1973, J INFECT DIS, V127, P17, DOI 10.1093/infdis/127.1.17; WAINWRIGHT RB, 1989, JAMA-J AM MED ASSOC, V261, P2362, DOI 10.1001/jama.261.16.2362; WAINWRIGHT RB, 1991, ARCH INTERN MED, V151, P1634, DOI 10.1001/archinte.151.8.1634; WEINSTEIN MC, 1985, ANNU REV PUBL HEALTH, V6, P41; Weinstein MC, 1980, CLIN DECISION ANAL; WEISSBERG JI, 1984, ANN INTERN MED, V101, P613, DOI 10.7326/0003-4819-101-5-613; 1990, MMWR MORBID MORTAL W, V39, P1; 1989, MMWR MORBID MORTAL W, V36, P353; 1989, PHS52 CTR DIS CONTR; 1989, MMWR MORBID MORTAL W, V38, P818; 1991, MMWR MORBID MORTAL W, V40, P1; 1987, WHOHEP871 PUB; 1991, USDL91618 US DEP LAB	50	152	152	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1993	118	4					298	306		10.7326/0003-4819-118-4-199302150-00009	http://dx.doi.org/10.7326/0003-4819-118-4-199302150-00009			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KL457	8420448				2022-12-24	WOS:A1993KL45700008
J	BORKMAN, M; STORLIEN, LH; PAN, DA; JENKINS, AB; CHISHOLM, DJ; CAMPBELL, LV				BORKMAN, M; STORLIEN, LH; PAN, DA; JENKINS, AB; CHISHOLM, DJ; CAMPBELL, LV			THE RELATION BETWEEN INSULIN SENSITIVITY AND THE FATTY-ACID COMPOSITION OF SKELETAL-MUSCLE PHOSPHOLIPIDS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NORMAL GLUCOSE-TOLERANCE; DIETARY-FAT; RESISTANCE; MEMBRANE; SERUM; CELLS; HYPERINSULINEMIA; DISEASE; BINDING; HYPERTENSION	Background. Insulin resistance and hyperinsulinemia are features of obesity, non-insulin-dependent diabetes mellitus, and other disorders. Skeletal muscle is a major site of insulin action, and insulin sensitivity may be related to the fatty-acid composition of the phospholipids within the muscle membranes involved in the action of insulin. Methods. We determined the relation between the fatty-acid composition of skeletal-muscle phospholipids and insulin sensitivity in two groups of subjects. In one study, we obtained samples of the rectus abdominis muscle from 27 patients undergoing coronary artery surgery; fasting serum insulin levels provided an index of insulin sensitivity. In the second study, a biopsy of the vastus lateralis muscle was performed in 13 normal men, and insulin sensitivity was assessed by euglycemic-clamp studies. Results. In the patients undergoing surgery, the fasting serum insulin concentration (a measure of insulin resistance) was negatively correlated with the percentage of individual long-chain polyunsaturated fatty acids in the phospholipid fraction of muscle, particularly arachidonic acid (r = -0.63, P<0.001); the total percentage of C20-22 polyunsaturated fatty acids (r = -0.68, P<0.001); the average degree of fatty-acid unsaturation (r = -0.61, P<0.001); and the ratio of the percentage of C20:4 n-6 fatty acids to the percentage of C20:3 n-6 fatty acids (r = -0.55, P<0.01), an index of fatty-acid desaturase activity. In the normal men, insulin sensitivity was positively correlated with the percentage of arachidonic acid in muscle (r = 0.76, P<0.01), the total percentage of C20-22 polyunsaturated fatty acids (r = 0.76, P<0.01), the average degree of fatty-acid unsaturation (r = 0.62, P<0.05), and the ratio of C20:4 n-6 to C20:3 n-6 (rho = 0.78, P = 0.007). Conclusions. Decreased insulin sensitivity is associated with decreased concentrations of polyunsaturated fatty acids in skeletal-muscle phospholipids, raising the possibility that changes in the fatty-acid composition of muscles modulate the action of insulin.	ST VINCENTS HOSP,GARVAN INST MED RES,DARLINGHURST,NSW 2010,AUSTRALIA	Garvan Institute of Medical Research; St Vincents Hospital Sydney			Jenkins, Arthur B/D-4533-2012; Campbell, Lesley V/B-2271-2008; Chisholm, Donald J/J-9332-2013	Jenkins, Arthur B/0000-0003-1310-264X; Chisholm, Donald J/0000-0002-5349-5735				ALLAIN CC, 1974, CLIN CHEM, V20, P470; BUCOLO G, 1973, CLIN CHEM, V19, P476; BURSTEIN M, 1970, J LIPID RES, V11, P583; DEFRONZO RA, 1991, DIABETES CARE, V14, P173, DOI 10.2337/diacare.14.3.173; DEFRONZO RA, 1979, AM J PHYSIOL, V237, pE214; DEFRONZO RA, 1981, DIABETES, V30, P1000, DOI 10.2337/diab.30.12.1000; ELBOUSTANI S, 1989, METABOLISM, V38, P315, DOI 10.1016/0026-0495(89)90117-0; ERIKSSON J, 1989, NEW ENGL J MED, V321, P337, DOI 10.1056/NEJM198908103210601; FAAS FH, 1980, LIPIDS, V15, P953, DOI 10.1007/BF02534421; FERRANNINI E, 1987, NEW ENGL J MED, V317, P350, DOI 10.1056/NEJM198708063170605; FIELD CJ, 1988, BIOCHEM J, V253, P417, DOI 10.1042/bj2530417; FOLCH J, 1957, J BIOL CHEM, V226, P497; GINSBERG BH, 1982, BIOCHIM BIOPHYS ACTA, V690, P157, DOI 10.1016/0005-2736(82)90318-2; Ginsberg BH, 1987, DIABETES S1, V36, p51A; GRUNFELD C, 1981, BIOCHEM BIOPH RES CO, V103, P219, DOI 10.1016/0006-291X(81)91682-X; HAGVE TA, 1988, SCAND J CLIN LAB INV, V48, P381, DOI 10.3109/00365518809085746; HOLLENBECK C, 1987, J CLIN ENDOCR METAB, V64, P1169, DOI 10.1210/jcem-64-6-1169; KLIP A, 1990, DIABETES CARE, V13, P228, DOI 10.2337/diacare.13.3.228; LILLIOJA S, 1986, J CLIN ENDOCR METAB, V62, P922, DOI 10.1210/jcem-62-5-922; LITHELL HOL, 1991, DIABETES CARE, V14, P203, DOI 10.2337/diacare.14.3.203; MOLLER DE, 1991, NEW ENGL J MED, V325, P938; MORGAN CR, 1963, DIABETES, V12, P115, DOI 10.2337/diab.12.2.115; NANKERVIS A, 1985, DIABETOLOGIA, V28, P427, DOI 10.1007/BF00280885; PELIKANOVA T, 1989, METABOLISM, V38, P188, DOI 10.1016/0026-0495(89)90261-8; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; RIZZA RA, 1985, DIABETOLOGIA, V28, P70; ROWE JW, 1983, J CLIN INVEST, V71, P1581, DOI 10.1172/JCI110914; SAAD MF, 1991, NEW ENGL J MED, V324, P733, DOI 10.1056/NEJM199103143241105; SALTIEL AR, 1990, DIABETES CARE, V13, P244, DOI 10.2337/diacare.13.3.244; SHULMAN GI, 1990, NEW ENGL J MED, V322, P223, DOI 10.1056/NEJM199001253220403; STORLIEN LH, 1991, DIABETES, V40, P280, DOI 10.2337/diabetes.40.2.280; STRALFORS P, 1988, NATURE, V335, P554, DOI 10.1038/335554a0; STUBBS CD, 1984, BIOCHIM BIOPHYS ACTA, V779, P89, DOI 10.1016/0304-4157(84)90005-4; TILVIS RS, 1985, J CLIN ENDOCR METAB, V61, P741, DOI 10.1210/jcem-61-4-741; VOELKER DR, 1991, MICROBIOL REV, V55, P543, DOI 10.1128/MMBR.55.4.543-560.1991; WAHLE KWJ, 1991, LIPIDS, V26, P16, DOI 10.1007/BF02544018; WHITCOMB RW, 1988, J CLIN INVEST, V81, P185, DOI 10.1172/JCI113292; WILLIS AL, 1984, NUTR REV PRESENT KNO, P90; YKIJARVINEN H, 1984, METABOLISM, V33, P1011, DOI 10.1016/0026-0495(84)90229-4; YOREK M, 1989, INVEST OPHTH VIS SCI, V30, P2087; ZAVARONI I, 1985, ATHEROSCLEROSIS, V55, P259, DOI 10.1016/0021-9150(85)90105-4; ZAVARONI I, 1989, NEW ENGL J MED, V320, P702, DOI 10.1056/NEJM198903163201105	42	727	746	1	26	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 28	1993	328	4					238	244		10.1056/NEJM199301283280404	http://dx.doi.org/10.1056/NEJM199301283280404			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ442	8418404				2022-12-24	WOS:A1993KJ44200004
J	MICHAELS, MG; FRADER, J; ARMITAGE, J				MICHAELS, MG; FRADER, J; ARMITAGE, J			ETHICAL CONSIDERATIONS IN LISTING FETUSES AS CANDIDATES FOR NEONATAL HEART-TRANSPLANTATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ORTHOTOPIC CARDIAC TRANSPLANTATION; PATIENTS EVER; RECIPIENTS; DIAGNOSIS; ISSUES; LIFE		CHILDRENS HOSP PITTSBURGH,PITTSBURGH,PA; UNIV PITTSBURGH,SCH MED,CTR MED ETH,PITTSBURGH,PA 15261; UNIV PITTSBURGH,SCH MED,DEPT SURG,PITTSBURGH,PA 15261	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	MICHAELS, MG (corresponding author), UNIV PITTSBURGH,SCH MED,DEPT PEDIAT,PITTSBURGH,PA 15261, USA.		Frader, Joel/A-8610-2010	Frader, Joel/0000-0001-5620-2400				ADDONIZIO LJ, 1989, CIRCULATION, V80, P84; BACKER CL, 1991, J THORAC CARDIOV SUR, V101, P826; BAILEY LL, 1989, ARCH SURG-CHICAGO, V124, P1221; Beauchamp TL, 1989, PRINCIPLES BIOMEDICA, P290; Bernstein D, 1990, Adv Pediatr, V37, P413; BOUCEK MM, 1990, J PEDIATR-US, V116, P171, DOI 10.1016/S0022-3476(05)82870-7; CAPLAN AL, 1987, CIRCULATION, V75, P10, DOI 10.1161/01.CIR.75.1.10; Cooley D A, 1969, Ann Thorac Surg, V8, P30; Field M A, 1989, Law Med Health Care, V17, P114; JOHNSTON J, 1990, WESTERN J MED, V152, P70; JONASSON O, 1989, TRANSPLANT P, V21, P3390; KANTROWITZ A, 1968, AM J CARDIOL, V22, P782, DOI 10.1016/0002-9149(68)90173-2; KAYE M, 1991, INFANT HEART TRANSPL; KOLDER VEB, 1987, NEW ENGL J MED, V316, P1192, DOI 10.1056/NEJM198705073161905; MACKLIN R, 1989, TRANSPLANT P, V21, P3395; MAVROUDIS C, 1988, J THORAC CARDIOV SUR, V96, P912; NELSON LJ, 1988, JAMA-J AM MED ASSOC, V259, P1060, DOI 10.1001/jama.259.7.1060; Rhoden N K, 1987, Law Med Health Care, V15, P118; ROBERTSON JA, 1987, CIRCULATION, V75, P77, DOI 10.1161/01.CIR.75.1.77; STRONG C, 1987, CLIN PERINATOL, V14, P313, DOI 10.1016/S0095-5108(18)30767-X; WERTZ DC, 1989, PEDIATR ANN, V18, P739, DOI 10.3928/0090-4481-19891101-09; 1990, JAMA-J AM MED ASSOC, V264, P2663	22	11	11	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 20	1993	269	3					401	403		10.1001/jama.269.3.401	http://dx.doi.org/10.1001/jama.269.3.401			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG381	8418350				2022-12-24	WOS:A1993KG38100035
J	GOTTLIEB, TM; JACKSON, SP				GOTTLIEB, TM; JACKSON, SP			THE DNA-DEPENDENT PROTEIN-KINASE - REQUIREMENT FOR DNA ENDS AND ASSOCIATION WITH KU ANTIGEN	CELL			English	Article							RNA POLYMERASE-II; VIRUS-40 T-ANTIGEN; HELA-CELL NUCLEI; BINDING PROTEIN; TRANSCRIPTIONAL ACTIVATION; AUTOANTIGEN-KU; AUTO-ANTIGEN; PHOSPHORYLATION; PURIFICATION; INITIATION	The DNA-dependent protein kinase (DNA-PK) phosphorylates Sp1 and several other nuclear proteins. Here, we show that Sp1 and the DNA-PK must be colocalized on the same DNA molecule for efficient phosphorylation to occur. Interestingly, we find that the DNA-PK binds to and is activated by the ends of DNA molecules. Furthermore, we show that the DNA binding properties of the DNA-PK are identical to those of Ku, a well-characterized human autoimmune antigen. We demonstrate that the DNA-PK can be fractionated into two components, one of which is Ku and the other of which is a polypeptide of approximately 350 kd. DNA cross-linking and coimmunoprecipitation studies indicate that the catalytic 350 kd DNA-PK component is directed to DNA by protein-protein interactions with Ku. The implications of the unusual DNA binding mode and multicomponent nature of the DNA-PK are discussed.			GOTTLIEB, TM (corresponding author), WELLCOME CRC INST,TENNIS COURT RD,CAMBRIDGE CB2 1QR,ENGLAND.		Jackson, Stephen Philip/R-4548-2019; Dry, Kate/I-2328-2014	Jackson, Stephen Philip/0000-0001-9317-7937; 	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALLAWAY GP, 1990, BIOCHEM BIOPH RES CO, V168, P747, DOI 10.1016/0006-291X(90)92385-D; ANDERSON CW, 1992, IN PRESS CRIT REV EU; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; CHAN JYC, 1989, J BIOL CHEM, V264, P3651; CHEN YR, 1991, J VIROL, V65, P5131, DOI 10.1128/JVI.65.10.5131-5140.1991; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; COUREY AJ, 1992, IN PRESS TRANSCRIPTI; DEVRIES E, 1989, J MOL BIOL, V208, P65, DOI 10.1016/0022-2836(89)90088-0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; FRANCOEUR AM, 1986, J IMMUNOL, V136, P1648; GRIFFITH AJ, 1992, J BIOL CHEM, V267, P331; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; IIJIMA S, 1992, EUR J BIOCHEM, V205, P595; Jackson S P, 1992, Trends Cell Biol, V2, P104, DOI 10.1016/0962-8924(92)90014-E; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1989, P NATL ACAD SCI USA, V86, P1781, DOI 10.1073/pnas.86.6.1781; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; KNUTH MW, 1990, J BIOL CHEM, V265, P17911; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; MATSUI T, 1980, J BIOL CHEM, V255, P1992; MAY G, 1991, J BIOL CHEM, V266, P3052; MIMORI T, 1990, P NATL ACAD SCI USA, V87, P1777, DOI 10.1073/pnas.87.5.1777; MIMORI T, 1986, J BIOL CHEM, V261, P2274; MIMORI T, 1981, J CLIN INVEST, V68, P611, DOI 10.1172/JCI110295; MIMORI T, 1986, J BIOL CHEM, V261, P375; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MYLIN LM, 1990, MOL CELL BIOL, V10, P4623, DOI 10.1128/MCB.10.9.4623; PAILLARD S, 1991, NUCLEIC ACIDS RES, V19, P5619, DOI 10.1093/nar/19.20.5619; PAYNE JM, 1989, J BIOL CHEM, V264, P19621; PETERSON SR, 1992, GENE DEV, V6, P426, DOI 10.1101/gad.6.3.426; PORGES AJ, 1990, J IMMUNOL, V145, P4222; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REEVES WH, 1989, J BIOL CHEM, V264, P5047; REEVES WH, 1985, J EXP MED, V161, P18, DOI 10.1084/jem.161.1.18; ROBERTS MR, 1989, CELL REGUL, V1, P151, DOI 10.1091/mbc.1.1.151; SENTENAC A, 1985, CRC CR REV BIOCH MOL, V18, P31, DOI 10.3109/10409238509082539; SLATTERY E, 1983, J BIOL CHEM, V258, P5955; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; STUIVER MH, 1990, J EXP MED, V172, P1049, DOI 10.1084/jem.172.4.1049; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; WALKER AI, 1985, EMBO J, V4, P139, DOI 10.1002/j.1460-2075.1985.tb02328.x; WANG TSF, 1980, BIOCHEMISTRY-US, V19, P1782, DOI 10.1021/bi00550a009; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; YANEVA M, 1985, BIOCHIM BIOPHYS ACTA, V841, P22, DOI 10.1016/0304-4165(85)90270-3; YANEVA M, 1986, BIOCHEMISTRY-US, V25, P5057, DOI 10.1021/bi00366a013; YANEVA M, 1989, J BIOL CHEM, V264, P13407; ZHANG WW, 1992, BIOCHEM BIOPH RES CO, V186, P574, DOI 10.1016/S0006-291X(05)80847-2	48	1031	1047	1	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 15	1993	72	1					131	142		10.1016/0092-8674(93)90057-W	http://dx.doi.org/10.1016/0092-8674(93)90057-W			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KG955	8422676				2022-12-24	WOS:A1993KG95500017
J	MARSDEN, PD				MARSDEN, PD			LETTER FROM BRASILIA - OBSTRUCTIVE LYMPHATIC FILARIASIS	BRITISH MEDICAL JOURNAL			English	Article											MARSDEN, PD (corresponding author), UNIV BRASILIA,CP 102382,BR-70840 BRASILIA,DF,BRAZIL.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 9	1993	306	6870					136	136		10.1136/bmj.306.6870.136	http://dx.doi.org/10.1136/bmj.306.6870.136			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG465	8435614	Bronze, Green Published			2022-12-24	WOS:A1993KG46500033
J	HEALY, DL; BURGER, HG; MAMERS, P; JOBLING, T; BANGAH, M; QUINN, M; GRANT, P; DAY, AJ; ROME, R; CAMPBELL, JJ				HEALY, DL; BURGER, HG; MAMERS, P; JOBLING, T; BANGAH, M; QUINN, M; GRANT, P; DAY, AJ; ROME, R; CAMPBELL, JJ			ELEVATED SERUM INHIBIN CONCENTRATIONS IN POSTMENOPAUSAL WOMEN WITH OVARIAN-TUMORS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CANCER	Background. Inhibin is an ovarian hormone that inhibits the secretion of follicle-stimulating hormone (FSH) by the anterior pituitary gland. Women with granulosa-cell tumors of the ovary have elevated serum inhibin concentrations, but whether the concentrations are increased in women with other ovarian tumors is unknown. Methods. We measured serum inhibin and FSH concentrations before surgery in 212 postmenopausal women with suspected ovarian cancer and after surgery in 210 of them. Results. Eighteen of the 22 women (82 percent) with mucinous carcinomas (mucinous cystadenocarcinomas and mucinous borderline cystic tumors) of the ovary had elevated serum inhibin concentrations, whereas only 9 of the 53 women (17 percent) with serous carcinomas (serous cystadenocarcinomas and serous borderline cystic tumors) had elevated levels. Serum inhibin concentrations were also elevated in 2 of 12 women (17 percent) with clear-cell carcinomas, 4 of 26 women (15 percent) with undifferentiated carcinomas, 3 of 3 women (100 percent) with granulosa-cell tumors, and 5 of 27 women (19 percent) with other ovarian cancers. The serum concentrations of inhibin were increased in 2 of 28 women (7 percent) with nonovarian pelvic cancers and 11 of 41 women (27 percent) with benign ovarian diseases. All women but one with initially elevated serum inhibin concentrations had low values one week after surgery. Serum inhibin concentrations correlated negatively with serum FSH concentrations (P = 0.05) in women with granulosa-cell tumors but not in women with other tumors, suggesting that the inhibin secreted by tumors in the latter group has decreased biologic activity. Conclusions. Serum inhibin concentrations are elevated in most postmenopausal women with mucinous carcinomas of the ovary and in some women with other types of epithelial ovarian tumors. The concentrations fall after tumor removal.	MONASH UNIV,DEPT OBSTET & GYNECOL,MELBOURNE,VIC 3004,AUSTRALIA; MERCY HOSP WOMEN,MELBOURNE,AUSTRALIA; PRINCE HENRY INST MED RES,MELBOURNE,AUSTRALIA; ROYAL WOMENS HOSP,MELBOURNE,AUSTRALIA; PETER MACCALLUM INST,MELBOURNE,AUSTRALIA	Monash University; Prince Henry's Institute of Medical Research; Peter Maccallum Cancer Center				Burger, Henry/0000-0002-5333-6144; Quinn, Michael/0000-0003-0694-3870				BAST RC, 1983, NEW ENGL J MED, V309, P883, DOI 10.1056/NEJM198310133091503; CREASMAN WT, 1991, AM J OBSTET GYNECOL, V165, P7, DOI 10.1016/0002-9378(91)90213-B; KAUPPILA A, 1992, GYNECOL ENDOCRINOL, V6, P271, DOI 10.3109/09513599209024990; LAPPOHN RE, 1989, NEW ENGL J MED, V321, P790, DOI 10.1056/NEJM198909213211204; LONGCOPE C, 1986, MATURITAS, V8, P189, DOI 10.1016/0378-5122(86)90025-3; MCLACHLAN RI, 1987, J CLIN ENDOCR METAB, V65, P954, DOI 10.1210/jcem-65-5-954; Montag T W, 1990, Obstet Gynecol Surv, V45, P94, DOI 10.1097/00006254-199002000-00003; OKAMOTO SH, 1987, BRIT MED J, V294, P667, DOI 10.1136/bmj.294.6573.667; PIVER MS, 1983, CURRENT REV OBSTETRI, V4, P1; SEROV SF, 1973, HISTOLOGICAL TYPING, P37; SHEPHERD JH, 1989, BRIT J OBSTET GYNAEC, V96, P889, DOI 10.1111/j.1471-0528.1989.tb03341.x; WESTHOFF C, 1991, AM J OBSTET GYNECOL, V165, P502, DOI 10.1016/0002-9378(91)90275-V	12	202	210	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 18	1993	329	21					1539	1542		10.1056/NEJM199311183292104	http://dx.doi.org/10.1056/NEJM199311183292104			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MG188	8413476				2022-12-24	WOS:A1993MG18800004
J	ROBERTSON, D; HOLLISTER, AS; BIAGGIONI, I; NETTERVILLE, JL; MOSQUEDAGARCIA, R; ROBERTSON, RM				ROBERTSON, D; HOLLISTER, AS; BIAGGIONI, I; NETTERVILLE, JL; MOSQUEDAGARCIA, R; ROBERTSON, RM			THE DIAGNOSIS AND TREATMENT OF BAROREFLEX FAILURE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SINOAORTIC BARORECEPTOR DENERVATION; NEUROGENIC HYPERTENSION; CAROTID ENDARTERECTOMY; ORTHOSTATIC HYPOTENSION; BLOOD-PRESSURE; HUMANS; DYSFUNCTION	Background. Baroreflexes originate in the great vessels of the neck and thorax and prevent arterial pressure from rising or failing excessively. Methods. This study was undertaken to clarify the cause, clinical spectrum, and therapy of this disorder. We studied 11 patients with baroreflex failure presenting as severe, labile hypertension and hypotension, often with headache, diaphoresis, and emotional instability, and characterized by the failure of exogenous vasoactive substances to alter heart rate. Each underwent hemodynamic monitoring and biochemical, physiologic, and pharmacologic testing. Results. The patients' maximal systolic blood pressures ranged from 164 to 280 mm Hg, and their minimal systolic pressures ranged from 58 to 96 mm Hg. Plasma norepinephrine and epinephrine concentrations were sometimes many times normal during blood-pressure surges. All the patients had excessive pressor and tachycardic responses to the mental-arithmetic and cold pressor tests and marked hypersensitivity to clonidine. The underlying causes of baroreflex failure included the familial paraganglioma syndrome, neck surgery or radiation therapy for pharyngeal carcinoma, bilateral lesions of the nucleus tractus solitarii, and surgical section of the glossopharyngeal nerves; in two patients the cause was unknown. Therapy with clonidine reduced the frequency of attacks by 81 percent and attenuated the elevated blood pressure and heart rate in the attacks that occurred. Conclusions. The syndrome of baroreflex failure should be considered in patients with otherwise unexplained labile hypertension. Clonidine attenuates the pressor and tachycardic surges in baroreflex failure.	VANDERBILT UNIV,CTR AUTON DYSFUNCT,DEPT PHARMACOL,NASHVILLE,TN 37232; VANDERBILT UNIV,CTR AUTON DYSFUNCT,DEPT NEUROL,NASHVILLE,TN 37232; VANDERBILT UNIV,CTR AUTON DYSFUNCT,DEPT OTOLARYNGOL,NASHVILLE,TN 37232; UNIV COLORADO,HLTH SCI CTR,DIV CLIN PHARMACOL,DENVER,CO 80262	Vanderbilt University; Vanderbilt University; Vanderbilt University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	ROBERTSON, D (corresponding author), VANDERBILT UNIV,CTR AUTON DYSFUNCT,DEPT MED,AA3228 MCN,NASHVILLE,TN 37232, USA.			Netterville, James/0000-0002-7282-8769	NCRR NIH HHS [RR00095] Funding Source: Medline; NHLBI NIH HHS [HL44589, HL37961] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044589, R01HL037961] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABBOUD FM, 1979, J PHYSIOL-LONDON, V286, P173, DOI 10.1113/jphysiol.1979.sp012612; AKSAMIT TR, 1987, HYPERTENSION, V9, P309, DOI 10.1161/01.HYP.9.3.309; ATUK NO, 1972, NEW ENGL J MED, V287, P1356; BOVE EL, 1979, SURGERY, V85, P633; BRAVO EL, 1981, NEW ENGL J MED, V305, P623, DOI 10.1056/NEJM198109103051107; BRAVO EL, 1990, HYPERTENSION S1, V15, P128; BRODAL A, 1957, HJERNENERVENE, P1; CHAMONTIN B, 1989, ARCH MAL COEUR VAISS, V82, P1143; COWLEY AW, 1973, CIRC RES, V32, P564, DOI 10.1161/01.RES.32.5.564; DOBA N, 1974, CIRC RES, V34, P293, DOI 10.1161/01.RES.34.3.293; Eckberg D, 1992, HUMAN BAROREFLEXES H; FAGIUS J, 1985, BRAIN, V108, P423, DOI 10.1093/brain/108.2.423; FERGUSON DW, 1985, J CLIN INVEST, V76, P2265, DOI 10.1172/JCI112236; FORD FR, 1957, J HOPKINS MED J, V100, P14; FUNCKBRENTANO C, 1987, BRIT HEART J, V57, P487; GUZ A, 1966, CLIN SCI, V30, P161; HOLTON P, 1965, J PHYSIOL-LONDON, V181, P365, DOI 10.1113/jphysiol.1965.sp007767; HSU CY, 1984, AM J MED, V76, pA49, DOI 10.1016/0002-9343(84)90839-8; JANNETTA PJ, 1985, ANN SURG, V201, P391, DOI 10.1097/00000658-198503000-00023; KEZDI P, 1953, ARCH INTERN MED, V91, P26, DOI 10.1001/archinte.1953.00240130034003; KUCHEL O, 1987, J HYPERTENS, V5, P277, DOI 10.1097/00004872-198706000-00003; LAMPEN HEINRICH, 1949, ZEITSCHR KREISLAUFFORSCH, V38, P726; Langford HG, 1987, J HYPERTENS       S5, V5, pS467; Magnus O, 1977, Prog Brain Res, V47, P199; Manger WM, 1977, PHEOCHROMOCYTOMA; Page IH, 1935, AM J MED SCI, V190, P9, DOI 10.1097/00000441-193507000-00002; PAGE IH, 1987, HYPERTENSION MECH, P707; PERSSON PB, 1991, BAROREFLEXES INTEGRA; REIS DJ, 1972, NEW ENGL J MED, V287, P1355; ROBERTSON D, 1983, AM J MED, V74, P193, DOI 10.1016/0002-9343(83)90607-1; ROBERTSON D, 1984, AM J MED, V76, pA58, DOI 10.1016/0002-9343(84)90844-1; ROBERTSON D, 1979, CIRCULATION, V59, P637, DOI 10.1161/01.CIR.59.4.637; Robertson D, 1981, CLIN DIAGNOSTIC MANU, P86; ROBERTSON D, 1992, CLIN PHARM, P84; SANDERS JS, 1989, CIRCULATION, V79, P83, DOI 10.1161/01.CIR.79.1.83; TOWNE JB, 1980, SURGERY, V88, P575; VANBAARS FM, 1981, ACTA OTO-LARYNGOL, V91, P589, DOI 10.3109/00016488109138545; WADE JG, 1970, NEW ENGL J MED, V282, P823, DOI 10.1056/NEJM197004092821501; [No title captured]	39	223	230	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 11	1993	329	20					1449	1455		10.1056/NEJM199311113292003	http://dx.doi.org/10.1056/NEJM199311113292003			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF292	8413455				2022-12-24	WOS:A1993MF29200003
J	ZEHENDER, M; KASPER, W; KAUDER, E; SCHONTHALER, M; GEIBEL, A; OLSCHEWSKI, M; JUST, H				ZEHENDER, M; KASPER, W; KAUDER, E; SCHONTHALER, M; GEIBEL, A; OLSCHEWSKI, M; JUST, H			RIGHT VENTRICULAR INFARCTION AS AN INDEPENDENT PREDICTOR OF PROGNOSIS AFTER ACUTE INFERIOR MYOCARDIAL-INFARCTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ST-SEGMENT DEPRESSION; CHEST LEADS V3R; PRECORDIAL ST; ELECTROCARDIOGRAPHIC ALTERATIONS; THROMBOLYTIC THERAPY; DIAGNOSTIC-ACCURACY; RANDOMIZED TRIAL; WALL INFARCTION; ELEVATION; V7R	Background. Acute inferior myocardial infarction frequently involves the right ventricle. We hypothesized that right ventricular involvement, as diagnosed by ST-segment elevation in the right precordial lead V4R, may affect the prognosis of patients with inferior myocardial infarctions. Methods. In 200 consecutive patients admitted to the hospital with acute inferior myocardial infarctions, we assessed the prevalence and diagnostic accuracy of ST-segment elevation in lead V4R (as compared with four other diagnostic procedures) to identify right ventricular involvement and its prognostic implications for in-hospital and long-term outcomes. Results. The in-hospital mortality after inferior myocardial infarction was 19 percent, and major complications occurred in 47 percent of the patients. The presence of ST-segment elevation in lead V4R in 107 patients (54 percent) was highly predictive of right ventricular infarction (sensitivity, 88 percent; specificity, 78 percent; diagnostic accuracy, 83 percent), as compared with the other diagnostic procedures. The patients with ST-segment elevation in lead V4R had a higher in-hospital mortality rate (31 percent vs. 6 percent, P<0.001) and a higher incidence of major in-hospital complications (64 percent vs. 28 percent, P<0.001) than did those without ST elevation in V4R. Multiple logistic-regression analysis showed ST elevation in V4R to be independent of and superior to all other clinical variables available on admission for the prediction of in-hospital mortality (relative risk, 7.7; 95 percent confidence interval, 2.6 to 23) and major complications (relative risk, 4.7; 95 percent confidence interval, 2.4 to 9). The post-hospital course (follow-up, at least 1 year; mean follow-up, 37 months) was similar in patients with and in those without electrocardiographic evidence of right ventricular infarction. Conclusions. Right ventricular involvement during acute inferior myocardial infarction can be accurately diagnosed by the presence of ST-segment elevation in lead V4R, a finding that is a strong, independent predictor of major complications and in-hospital mortality. Electrocardiographic assessment of right ventricular infarction should be routinely performed in all patients with acute inferior myocardial infarctions.	UNIV KLIN FREIBURG, MED BIOMETRIE & INFORMAT ABT, W-7800 FREIBURG, GERMANY	University of Freiburg	ZEHENDER, M (corresponding author), UNIV KLIN FREIBURG, KARDIOL ABT, HUGSTETTERSTR 55, W-7800 FREIBURG, GERMANY.							Altman DG, 1991, PRACTICAL STATISTICS; ANDERSEN HR, 1989, AM HEART J, V117, P82, DOI 10.1016/0002-8703(89)90659-5; ANDERSEN HR, 1989, BRIT HEART J, V61, P514; ANDERSEN HR, 1989, INT J CARDIOL, V23, P349, DOI 10.1016/0167-5273(89)90195-2; ANDERSEN HR, 1989, BRIT HEART J, V62, P328; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V1, P397; BAR FW, 1987, AM J CARDIOL, V59, P6, DOI 10.1016/S0002-9149(87)80060-7; BATES ER, 1990, J AM COLL CARDIOL, V16, P1538, DOI 10.1016/0735-1097(90)90297-3; BERGER PB, 1990, CIRCULATION, V81, P401, DOI 10.1161/01.CIR.81.2.401; BOUGH EW, 1986, J AM COLL CARDIOL, V7, P990, DOI 10.1016/S0735-1097(86)80216-9; BRAAT SH, 1983, BRIT HEART J, V49, P368; BRAAT SH, 1984, J AM COLL CARDIOL, V4, P940, DOI 10.1016/S0735-1097(84)80054-6; CANDELLRIERA J, 1981, AM HEART J, V101, P281, DOI 10.1016/0002-8703(81)90191-5; CHOU TC, 1981, AM J MED, V70, P1175, DOI 10.1016/0002-9343(81)90824-X; COHN JN, 1979, AM J CARDIOL, V43, P666, DOI 10.1016/0002-9149(79)90030-4; COHN JN, 1974, AM J CARDIOL, V33, P209, DOI 10.1016/0002-9149(74)90276-8; COMACANELLA I, 1986, AM HEART J, V112, P940, DOI 10.1016/0002-8703(86)90304-2; CRAGG DR, 1989, CIRCULATION S2, V80, P552; CROFT CH, 1982, AM J CARDIOL, V50, P421, DOI 10.1016/0002-9149(82)90305-8; DELLITALIA LJ, 1984, J AM COLL CARDIOL, V4, P931, DOI 10.1016/S0735-1097(84)80053-4; FORMAN MB, 1984, J AM COLL CARDIOL, V4, P640, DOI 10.1016/S0735-1097(84)80115-1; GIBSON RS, 1982, CIRCULATION, V66, P732, DOI 10.1161/01.CIR.66.4.732; GREENBERG H, 1987, AM J CARDIOL, V59, P1057, DOI 10.1016/0002-9149(87)90848-4; GRINES CL, 1990, J AM COLL CARDIOL, V16, P223, DOI 10.1016/0735-1097(90)90482-5; ISNER JM, 1978, AM J CARDIOL, V42, P885, DOI 10.1016/0002-9149(78)90672-0; ISNER JM, 1988, RIGHT VENTRICLE, P87; KENNEDY, 1988, CIRCULATION, V77, P1037; KENNEDY JW, 1988, CIRCULATION, V77, P345, DOI 10.1161/01.CIR.77.2.345; KLEIN HO, 1983, CIRCULATION, V67, P558, DOI 10.1161/01.CIR.67.3.558; LEMBO NJ, 1986, CIRCULATION, V74, P56, DOI 10.1161/01.CIR.74.1.56; LOPEZSENDON J, 1981, CIRCULATION, V64, P515, DOI 10.1161/01.CIR.64.3.515; LOPEZSENDON J, 1985, J AM COLL CARDIOL, V6, P1273, DOI 10.1016/S0735-1097(85)80213-8; MORGERA T, 1984, AM HEART J, V108, P13, DOI 10.1016/0002-8703(84)90538-6; NASMITH J, 1982, ANN INTERN MED, V96, P22, DOI 10.7326/0003-4819-96-1-22; PIERARD LA, 1986, AM J CARDIOL, V57, P82, DOI 10.1016/0002-9149(86)90956-2; Pocock SJ, 1983, CLIN TRIALS PRACTICA; RATLIFF NB, 1980, AM J CARDIOL, V45, P217, DOI 10.1016/0002-9149(80)90638-4; REDUTO LA, 1978, ANN INTERN MED, V89, P441, DOI 10.7326/0003-4819-89-4-441; ROBALINO BD, 1989, AM HEART J, V118, P138, DOI 10.1016/0002-8703(89)90084-7; RODRIGUES EA, 1986, BRIT HEART J, V56, P19; SHAH PK, 1985, J AM COLL CARDIOL, V6, P1264, DOI 10.1016/S0735-1097(85)80212-6; SHARPE DN, 1978, CIRCULATION, V57, P483, DOI 10.1161/01.CIR.57.3.483; STARLING MR, 1984, J AM COLL CARDIOL, V4, P923, DOI 10.1016/S0735-1097(84)80052-2; WACKERS FJT, 1978, AM J CARDIOL, V42, P358, DOI 10.1016/0002-9149(78)90928-1; WARTMAN WB, 1948, ANN INTERN MED, V28, P41, DOI 10.7326/0003-4819-28-1-41; WEAVER W D, 1989, Journal of the American College of Cardiology, V13, p152A; WILCOX RG, 1988, LANCET, V2, P525	48	446	473	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 8	1993	328	14					981	988		10.1056/NEJM199304083281401	http://dx.doi.org/10.1056/NEJM199304083281401			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW282	8450875				2022-12-24	WOS:A1993KW28200001
J	NAKAGAWARA, A; ARIMANAKAGAWARA, M; SCAVARDA, NJ; AZAR, CG; CANTOR, AB; BRODEUR, GM				NAKAGAWARA, A; ARIMANAKAGAWARA, M; SCAVARDA, NJ; AZAR, CG; CANTOR, AB; BRODEUR, GM			ASSOCIATION BETWEEN HIGH-LEVELS OF EXPRESSION OF THE TRK GENE AND FAVORABLE OUTCOME IN HUMAN NEUROBLASTOMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NERVE GROWTH-FACTOR; HUMAN NEURO-BLASTOMA; PEDIATRIC-ONCOLOGY-GROUP; N-MYC ONCOGENE; FACTOR RECEPTOR; NGF RECEPTOR; CELL-LINES; DEVELOPMENTAL EXPRESSION; PHEOCHROMOCYTOMA CELLS; PROTOONCOGENE PRODUCT	Background and Methods. The nerve growth factor receptor is expressed in some neuroblastomas, in which its primary component is encoded by the TRK proto-oncogene. To determine the relation of the expression of TRK messenger RNA in neuroblastomas to other clinical and laboratory variables, we studied frozen tumor samples from 77 patients. In addition, we tested two primary neuroblastomas that expressed TRK for responsiveness to nerve growth factor. Results. TRK expression strongly correlated with favorable tumor stage (I, II, and IVS vs. III and IV), younger age (<1 year vs. greater-than-or-equal-to 1 year), normal N-myc copy number, and low level of N-myc expression. N-myc amplification (indicated by a high copy number) correlated with advanced tumor stage, older age, an adrenal site of the primary tumor, low level of expression of TRK, and high level of expression of N-myc. Analysis of five-year cumulative-survival rates demonstrated an association of a very favorable outcome with a high level of TRK expression (86 percent vs. 14 percent) and with normal N-myc copy number (84 percent vs. 0 percent). Univariate analysis showed that these two variables were the most powerful predictors of outcome (chi-square = 51.30, P<0.001; and chi-square = 93.61, P<0.001, respectively). TRK expression still had significant prognostic value when the analysis was restricted to tumors without N-myc amplification. In primary cultures of neuroblastoma cells expressing TRK, exposure to nerve growth factor induced early gene expression and neurite outgrowth, but deprivation of nerve growth factor led to neuronal cell death. Conclusions. A high level of expression of the TRK proto-oncogene in a neuroblastoma is strongly predictive of a favorable outcome. A tumor with a functional nerve growth factor receptor may be dependent on the neurotrophin nerve growth factor for survival and may regress in its absence, allowing a new approach to the treatment of certain patients with neuroblastoma.	WASHINGTON UNIV, SCH MED, DEPT PEDIAT, 1 CHILDRENS PL, ST LOUIS, MO 63110 USA; PEDIAT ONCOL GRP, STAT OFF, GAINESVILLE, FL USA; PEDIAT ONCOL GRP, ST LOUIS, MO USA	Washington University (WUSTL)					NCI NIH HHS [CA-05587, CA-39771, CA-49712] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039771, U10CA005587, P01CA049712] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AZAR CG, 1990, CELL GROWTH DIFFER, V1, P421; BAKER DL, 1991, AM J PATHOL, V139, P115; BARTRAM CR, 1987, EUR J PEDIATR, V146, P162, DOI 10.1007/BF02343225; BILL AH, 1969, J NATL CANCER I, V43, P1221; BIRREN SJ, 1990, NEURON, V4, P189, DOI 10.1016/0896-6273(90)90094-V; BOLANDE RP, 1974, HUM PATHOL, V5, P409, DOI 10.1016/S0046-8177(74)80021-3; BOTHWELL M, 1991, CELL, V65, P915, DOI 10.1016/0092-8674(91)90540-F; BOWMAN LC, 1990, MED PEDIATR ONCOL, V18, P364; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; CASTLEBERRY RP, 1991, J CLIN ONCOL, V9, P789, DOI 10.1200/JCO.1991.9.5.789; CHAO MV, 1986, SCIENCE, V232, P518, DOI 10.1126/science.3008331; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOPER MJ, 1990, CELL GROWTH DIFFER, V1, P149; COX DR, 1972, J R STAT SOC B, V34, P187; CURRAN T, 1985, SCIENCE, V229, P1265, DOI 10.1126/science.4035354; EICHLER ME, 1989, BRAIN RES, V482, P340, DOI 10.1016/0006-8993(89)91197-9; EVANS AE, 1971, CANCER, V27, P374, DOI 10.1002/1097-0142(197102)27:2<374::AID-CNCR2820270221>3.0.CO;2-G; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GODFREY EW, 1986, J NEUROSCI, V6, P2543; GOLDSTEIN MN, 1964, JNCI-J NATL CANCER I, V32, P165; GRAHAMPOLE J, 1991, J CLIN ONCOL, V9, P152; GREEN AA, 1981, CANCER, V48, P2310, DOI 10.1002/1097-0142(19811115)48:10<2310::AID-CNCR2820481029>3.0.CO;2-W; GREEN SH, 1986, J BIOL CHEM, V261, P5316; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HASKELL BE, 1987, CELL TISSUE RES, V247, P67, DOI 10.1007/BF00216548; HAYASHI Y, 1987, CANCER GENET CYTOGEN, V29, P175, DOI 10.1016/0165-4608(87)90047-1; HEMPSTEAD B, 1988, COLD SPRING HARB SYM, V53, P477, DOI 10.1101/SQB.1988.053.01.055; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HEUER JG, 1990, DEV BIOL, V137, P287, DOI 10.1016/0012-1606(90)90255-H; IKEDA K, 1989, J PEDIATR SURG, V24, P189, DOI 10.1016/S0022-3468(89)80247-7; KANEKO Y, 1987, CANCER RES, V47, P311; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOIKE T, 1991, P NATL ACAD SCI USA, V88, P3892, DOI 10.1073/pnas.88.9.3892; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LOOK AT, 1984, NEW ENGL J MED, V311, P231, DOI 10.1056/NEJM198407263110405; LOOK AT, 1991, J CLIN ONCOL, V9, P581, DOI 10.1200/JCO.1991.9.4.581; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MARCHETTI D, 1987, J NEUROCHEM, V49, P475, DOI 10.1111/j.1471-4159.1987.tb02889.x; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; MARTINZANCA D, 1990, GENE DEV, V4, P683, DOI 10.1101/gad.4.5.683; MATSUSHIMA H, 1990, MOL CELL BIOL, V10, P5015, DOI 10.1128/MCB.10.9.5015; MILBRANDT J, 1986, P NATL ACAD SCI USA, V83, P4789, DOI 10.1073/pnas.83.13.4789; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; NAKAGAWARA A, 1987, J PEDIATR SURG, V22, P895, DOI 10.1016/S0022-3468(87)80583-3; NAKAGAWARA A, 1990, CANCER, V65, P1960, DOI 10.1002/1097-0142(19900501)65:9<1960::AID-CNCR2820650914>3.0.CO;2-4; NAKAGAWARA A, 1991, CANCER, V68, P2037, DOI 10.1002/1097-0142(19911101)68:9<2037::AID-CNCR2820680932>3.0.CO;2-C; NAKAGAWARA A, 1992, CANCER RES, V52, P1364; NITSCHKE R, 1991, J CLIN ONCOL, V9, P1181, DOI 10.1200/JCO.1991.9.7.1181; OTA K, 1980, HISTOLOGICAL CLASSIF; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; RAGSDALE C, 1991, NATURE, V350, P660, DOI 10.1038/350660a0; REDDY UR, 1991, J NEUROCHEM, V56, P67, DOI 10.1111/j.1471-4159.1991.tb02563.x; Reynolds C P, 1988, Prog Clin Biol Res, V271, P291; RUIT KG, 1992, NEURON, V8, P573, DOI 10.1016/0896-6273(92)90284-K; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SHIMADA H, 1985, HUM PATHOL, V16, P471, DOI 10.1016/S0046-8177(85)80085-X; SLAVC I, 1990, CANCER RES, V50, P1459; SONNENFELD KH, 1985, J NEUROSCI, V5, P1717; SONNENFELD KH, 1982, J NEUROSCI RES, V8, P375, DOI 10.1002/jnr.490080226; STEMPLE DL, 1988, NEURON, V1, P517, DOI 10.1016/0896-6273(88)90182-1; SUTTER A, 1979, J BIOL CHEM, V254, P5972; TAKEDA T, 1989, MED PEDIATR ONCOL, V17, P361; TAYLOR SR, 1988, CANCER, V62, P749, DOI 10.1002/1097-0142(19880815)62:4<749::AID-CNCR2820620418>3.0.CO;2-W; TISCHLER AS, 1984, CANCER, V54, P1344, DOI 10.1002/1097-0142(19841001)54:7<1344::AID-CNCR2820540718>3.0.CO;2-J; TSOKOS M, 1987, AM J PATHOL, V128, P484; WARIS T, 1973, EXPERIENTIA, V29, P1128, DOI 10.1007/BF01946760; YAN Q, 1987, DEV BIOL, V121, P139, DOI 10.1016/0012-1606(87)90147-3; YAN Q, 1988, J NEUROSCI, V8, P3481	73	590	608	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 25	1993	328	12					847	854		10.1056/NEJM199303253281205	http://dx.doi.org/10.1056/NEJM199303253281205			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KT814	8441429				2022-12-24	WOS:A1993KT81400005
J	SOLLNER, T; WHITEHART, SW; BRUNNER, M; ERDJUMENTBROMAGE, H; GEROMANOS, S; TEMPST, P; ROTHMAN, JE				SOLLNER, T; WHITEHART, SW; BRUNNER, M; ERDJUMENTBROMAGE, H; GEROMANOS, S; TEMPST, P; ROTHMAN, JE			SNAP RECEPTORS IMPLICATED IN VESICLE TARGETING AND FUSION	NATURE			English	Article							CENTRAL NERVOUS-SYSTEM; VESICULAR TRANSPORT; MEMBRANE-PROTEIN; SECRETORY PATHWAY; SYNAPTIC VESICLES; GOLGI STACK; YEAST; GENES; FAMILY; PURIFICATION	The N-ethylmaleimide-sensitive fusion protein (NSF) and the soluble NSF attachment proteins (SNAPs) appear to be essential components of the intracellular membrane fusion apparatus. An affinity purification procedure based on the natural binding of these proteins to their targets was used to isolate SNAP receptors (SNAREs) from bovine brain. Remarkably, the four principal proteins isolated were all proteins associated with the synapse, with one type located in the synaptic vesicle and another in the plasma membrane, suggesting a simple mechanism for vesicle docking. The existence of numerous SNARE-related proteins, each apparently specific for a single kind of vesicle or target membrane, indicates that NSF and SNAPs may be universal components of a vesicle fusion apparatus common to both constitutive and regulated fusion (including neurotransmitter release), in which the SNAREs may help to ensure vesicle-to-target specificity.			SOLLNER, T (corresponding author), MEM SLOAN KETTERING CANC CTR,ROCKEFELLER RES LAB,1275 YORK AVE,NEW YORK,NY 10021, USA.			Brunner, Michael/0000-0001-9798-3047; Erdjument-Bromage, Hediye/0000-0003-0224-3594; Whiteheart, Sidney/0000-0001-5577-0473				ARCHER BT, 1990, J BIOL CHEM, V265, P17267; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; Beavis R C, 1989, Rapid Commun Mass Spectrom, V3, P432, DOI 10.1002/rcm.1290031207; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BENNETT MK, INPRESS P NATN ACAD; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; CHAPPELL TG, 1986, CELL, V45, P3, DOI 10.1016/0092-8674(86)90532-5; CLARY DO, 1990, J BIOL CHEM, V265, P10109; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; ELFERINK LA, 1989, J BIOL CHEM, V264, P11061; ERDJUMENTBROMAG.H, IN PRESS TECHNIQUES, V4; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FRIES E, 1980, P NATL ACAD SCI-BIOL, V77, P3870, DOI 10.1073/pnas.77.7.3870; GLICK BS, 1987, NATURE, V326, P309, DOI 10.1038/326309a0; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; GRIFF IC, 1992, J BIOL CHEM, V267, P12106; HARDWICK KG, 1992, J CELL BIOL, V119, P513, DOI 10.1083/jcb.119.3.513; HARLOW E, 1988, ANTIBODIES LABORATOR; HESS DT, 1992, J NEUROSCI, V12, P4634; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; KELLY RB, 1985, SCIENCE, V230, P25, DOI 10.1126/science.2994224; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDIS DMD, 1988, NEURON, V1, P201, DOI 10.1016/0896-6273(88)90140-7; LLINAS R, 1981, BIOPHYS J, V33, P323, DOI 10.1016/S0006-3495(81)84899-0; MALHOTRA V, 1988, CELL, V54, P221, DOI 10.1016/0092-8674(88)90554-5; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NEWMAN AP, 1992, EMBO J, V11, P3609, DOI 10.1002/j.1460-2075.1992.tb05445.x; NEWMAN AP, 1992, MOL CELL BIOL, V12, P3663, DOI 10.1128/MCB.12.8.3663; NOVICK P, 1981, CELL, V25, P461, DOI 10.1016/0092-8674(81)90064-7; ORCI L, 1989, CELL, V56, P357, DOI 10.1016/0092-8674(89)90239-0; OYLER GA, 1989, J CELL BIOL, V109, P3030; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; PFANNER N, 1990, J CELL BIOL, V110, P955, DOI 10.1083/jcb.110.4.955; PRESTON RA, 1991, MOL CELL BIOL, V11, P5801, DOI 10.1128/MCB.11.12.5801; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SCHLENSTEDT G, 1990, J BIOL CHEM, V265, P13960; SHIM J, 1991, J CELL BIOL, V113, P55, DOI 10.1083/jcb.113.1.55; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; SUDHOF TC, 1989, NEURON, V2, P1475, DOI 10.1016/0896-6273(89)90193-1; TAGAYA M, 1993, J BIOL CHEM, V269, P2662; TEMPST P, 1989, ANAL BIOCHEM, V183, P290, DOI 10.1016/0003-2697(89)90482-X; TEMPST P, 1990, ELECTROPHORESIS, V11, P537, DOI 10.1002/elps.1150110704; TRIMBLE WS, 1991, ANNU REV NEUROSCI, V14, P93, DOI 10.1146/annurev.ne.14.030191.000521; VONMOLLARD GF, 1991, NATURE, V349, P79, DOI 10.1038/349079a0; WATERS RG, 1992, J CELL BIOL, V118, P1015; WEIDMAN PJ, 1989, J CELL BIOL, V108, P1589, DOI 10.1083/jcb.108.5.1589; WENDLAND B, 1991, NEURON, V6, P993, DOI 10.1016/0896-6273(91)90239-V; WHITEHEART SW, 1992, J BIOL CHEM, V267, P12239; WHITEHEART SW, 1993, NATURE, V362, P353, DOI 10.1038/362353a0; WILSON DW, 1992, METHOD ENZYMOL, V219, P309; WILSON DW, 1992, J CELL BIOL, V117, P531, DOI 10.1083/jcb.117.3.531; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0	56	2656	2728	7	319	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 25	1993	362	6418					318	324		10.1038/362318a0	http://dx.doi.org/10.1038/362318a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KU176	8455717				2022-12-24	WOS:A1993KU17600051
J	TODD, KH; SAMAROO, N; HOFFMAN, JR				TODD, KH; SAMAROO, N; HOFFMAN, JR			ETHNICITY AS A RISK FACTOR FOR INADEQUATE EMERGENCY DEPARTMENT ANALGESIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							PAIN	Objective.-To determine whether Hispanic patients with isolated long-bone fractures are less likely to receive emergency department (ED) analgesics than similar non-Hispanic white patients. Design.-Retrospective cohort study. Setting.-The UCLA Emergency Medicine Center, a level I trauma center. Participants.-All Hispanic and non-Hispanic white ED patients aged 15 to 55 years, seen between January 1, 1990, and December 31, 1991, with isolated long-bone fractures, identified by ICD-9 codes 812, 813, 821, and 823, were eligible for inclusion. Exclusion criteria included injury more than 6 hours prior to presentation, ''possible'' or chip fractures only, altered mentation, or ethanol intoxication. Main Outcome Measures.-Emergency department administration of analgesic or no analgesic. Results.-The study group consisted of 139 patients meeting inclusion criteria, of whom 31 were Hispanic and 108 non-Hispanic white. Non-Hispanic whites were significantly more likely to speak English, be insured, and suffer nonoccupational injuries, Hispanics were twice as likely as non-Hispanic whites to receive no ED pain medication (crude relative risk [RR], 2.12; 95% confidence interval [CI], 1.35 to 3.32; P=.003). The RR for ethnicity was similar and significant (P<.05) after controlling by stratification for covariates related to patient, injury, or physician characteristics. After controlling for several covariates simultaneously through multiple logistic regression, ethnicity remained the strongest predictor of ED analgesic administration (odds ratio [OR], 7.46; 95% CI, 2.22 to 25.04; P<.01). Conclusions.-Hispanics with isolated long-bone fractures are twice as likely as non-Hispanic whites to receive no pain medication in the UCLA Emergency Medicine Center. No covariate measured in this study could account for this effect. An ethnic basis for variability in analgesic practice needs to be further characterized.			TODD, KH (corresponding author), UNIV CALIF LOS ANGELES, CTR EMERGENCY MED, 924 WESTWOOD BLVD, SUITE 300, LOS ANGELES, CA 90024 USA.							Dean A. G., 1990, EPI INFO VERSION 5 W; GREENLAND S, 1985, BIOMETRICS, V41, P55, DOI 10.2307/2530643; GREENWALD HP, 1991, PAIN, V44, P157, DOI 10.1016/0304-3959(91)90130-P; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; KIRKMANLIFF B, 1991, AM J PUBLIC HEALTH, V81, P1399, DOI 10.2105/AJPH.81.11.1399; PFEFFERBAUM B, 1990, J AM ACAD CHILD PSY, V29, P642, DOI 10.1097/00004583-199007000-00020; SELBST SM, 1990, ANN EMERG MED, V19, P1010, DOI 10.1016/S0196-0644(05)82565-X; WILSON JE, 1989, AM J EMERG MED, V7, P620, DOI 10.1016/0735-6757(89)90286-6; ZATZICK DF, 1990, PSYCHOSOM MED, V52, P544, DOI 10.1097/00006842-199009000-00007; 1992, STATE REFERENCE MANU	10	588	592	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 24	1993	269	12					1537	1539		10.1001/jama.269.12.1537	http://dx.doi.org/10.1001/jama.269.12.1537			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KR803	8445817				2022-12-24	WOS:A1993KR80300027
J	BRAVEMAN, P; BENNETT, T; LEWIS, C; EGERTER, S; SHOWSTACK, J				BRAVEMAN, P; BENNETT, T; LEWIS, C; EGERTER, S; SHOWSTACK, J			ACCESS TO PRENATAL-CARE FOLLOWING MAJOR MEDICAID ELIGIBILITY EXPANSIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BIRTH-WEIGHT; INSURANCE; HEALTH; WOMEN	Objective.-To determine whether lack of financial access was a significant barrier to prenatal care following major expansions of Medicaid eligibility in California. Design.-Retrospective analysis of birth certificates, assessing risks of inadequate prenatal care by insurance, controlling for maternal race/ethnicity, birthplace, age, parity, education, and marital status. Sample.-Singleton live births to California residents occurring in-state in 1990 (N=593510). Outcome Measures.-Untimely initiation of care, too few visits, and no prenatal care. Results.-Despite major Medicaid expansions, nearly 11% of live births were uninsured for prenatal care. Being uninsured and having Medi-Cal were both risk factors of sizable magnitude, controlling for,maternal characteristics. Compared with women who had private fee-for-service coverage, uninsured women were at elevated risk of untimely initiation (odds ratio [OR], 2.54; 95% confidence interval [Cl], 2.47 to 2.60) and too few visits (OR, 2.49; 95% Cl, 2.44 to 2.55). Women with Medi-Cal had a high risk of untimely care (OR, 3.33; 95% Cl, 3.26 to 3.40); their risk of too few visits was also elevated (OR, 1.63; 95% Cl, 1.60 to 1.66) but less than for the uninsured. Lack of private insurance was a strong risk factor for no care (OR, 6.70; 95% Cl, 6.00 to 7.47). Conclusions.-In spite of major Medicaid expansions, access to prenatal care was limited for women without private insurance. Medicaid was associated with untimely entry but with improved continuity. The findings suggest that financial barriers were salient even when controlling for many factors related to care-seeking behavior. Policy initiatives need to address continuing financial barriers along with other obstacles.	UNIV CALIF SAN FRANCISCO,SCH MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,INST HLTH POLICY STUDIES,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	BRAVEMAN, P (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT FAMILY & COMMUNITY MED,BOX 0900,SAN FRANCISCO,CA 94143, USA.		Showstack, Jonathan/L-6556-2013	Showstack, Jonathan/0000-0002-1367-419X				BRAVEMAN P, 1988, WESTERN J MED, V149, P708; BROWN ER, 1988, CHANGES HLTH INSURAN; BROWN SS, 1989, FAM PLANN PERSPECT, V21, P73, DOI 10.2307/2135557; COONEY JP, 1985, MED CARE, V23, P986, DOI 10.1097/00005650-198508000-00006; DAVID RJ, 1980, AM J PUBLIC HEALTH, V70, P964, DOI 10.2105/AJPH.70.9.964; GREENBERG RS, 1983, AM J OBSTET GYNECOL, V145, P797, DOI 10.1016/0002-9378(83)90681-6; HAAS JS, 1993, JAMA-J AM MED ASSOC, V269, P87, DOI 10.1001/jama.269.1.87; HUGHES D, 1988, HLTH AM CHILDREN MAT; JAMISON H, UNPUB BIRTH CERTIFIC; KOTELCHUCK M, 1987, 115TH ANN M AM PUBL; MURRAY JL, 1988, NEW ENGL J MED, V319, P1385, DOI 10.1056/NEJM198811243192105; Oberg C N, 1991, J Health Care Poor Underserved, V2, P270; PIPER JM, 1990, JAMA-J AM MED ASSOC, V264, P2219, DOI 10.1001/jama.264.17.2219; SCHWETHELM B, 1989, AM J PREV MED, V5, P157, DOI 10.1016/S0749-3797(18)31097-3; WILLIAMS RL, 1982, OBSTET GYNECOL, V59, P624; [No title captured]; 1985, SAS USERS GUIDE STAT; 1987, PRENATAL CARE MEDICA; [No title captured]; 1988, PRENATAL CARE REACHI	20	105	105	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 10	1993	269	10					1285	1289		10.1001/jama.269.10.1285	http://dx.doi.org/10.1001/jama.269.10.1285			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP885	8437308				2022-12-24	WOS:A1993KP88500029
J	HELZLSOUER, KJ; BUSH, TL; ALBERG, AJ; BASS, KM; ZACUR, H; COMSTOCK, GW				HELZLSOUER, KJ; BUSH, TL; ALBERG, AJ; BASS, KM; ZACUR, H; COMSTOCK, GW			PROSPECTIVE-STUDY OF SERUM CA-125 LEVELS AS MARKERS OF OVARIAN-CANCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MONOCLONAL-ANTIBODY; RISK	Objective.-To evaluate prospectively the sensitivity and specificity of serum CA-125 levels for the detection of ovarian cancer. Design.-Case-control study nested within a cohort of women who donated blood to a community-based serum bank established in 1974. Setting.-Washington County, Maryland. Population.-Cases consisted of 37 women who developed ovarian cancer from 1975 through 1989. Controls consisted of 73 women, matched on age and time since last menstrual period, and free of cancer until the cases' diagnoses. Study Variable.-Serum CA-125 levels. Outcome Measure.-Histologically confirmed ovarian cancer. Results.-Levels of serum CA-1 25 among cases were higher than among controls for each 3-year interval up to 12 years prior to the time of the cases' diagnoses. The median level for cases diagnosed within the first 3 years of follow-up was 35.4 U/mL compared with 9.0 U/mL for controls (P=.002). The sensitivity of a serum CA-1 25 level greater than 35 U/mL within the first 3 years was 57% (95% confidence interval, 20% to 88%) and the specificity was 100% (95% confidence interval lower limit, 73%). Sensitivity and specificity decreased with increasing time to diagnosis. Conclusions.-Measurement of serum CA-125 levels, particularly at a reference value of 35 U/mL, is not sufficiently sensitive to be used alone as a screening test for the detection of ovarian cancer. Lower CA-125 reference values could identify women at higher risk of developing ovarian cancer, but CA-125 measurement cannot be recommended for this purpose because of the high proportion of women who would be falsely classified as being at high risk for developing ovarian cancer.	FRANCIS SCOTT KEY MED CTR,DEPT GYNECOL,BALTIMORE,MD; JOHNS HOPKINS UNIV,DEPT GYNECOL & OBSTET,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV HOSP,CTR ONCOL,SCH HYG & PUBL HLTH,DEPT IMMUNOL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine			zacur, howard/W-2170-2019		NCI NIH HHS [CA36390] Funding Source: Medline; NICHD NIH HHS [HD-06268] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD006268] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA036390, R55CA036390] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAST RC, 1983, NEW ENGL J MED, V309, P883, DOI 10.1056/NEJM198310133091503; BAST RC, 1981, J CLIN INVEST, V68, P1331, DOI 10.1172/JCI110380; BORING CC, 1992, CA-CANCER J CLIN, V42, P19, DOI 10.3322/canjclin.42.1.19; CRAMER DW, 1983, JNCI-J NATL CANCER I, V71, P711; EINHORN N, 1992, OBSTET GYNECOL, V80, P14; GLATTRE E, 1989, INT J EPIDEMIOL, V18, P45, DOI 10.1093/ije/18.1.45; HAGA Y, 1986, AM J MED SCI, V292, P25, DOI 10.1097/00000441-198607000-00005; HELZLSOUER KJ, 1992, OCT NAT CANC I WORKS; JACOBS I, 1988, LANCET, V1, P268; JACOBS I, 1989, HUM REPROD, V4, P1; KLUG TL, 1984, CANCER RES, V44, P1048; KWA HG, 1981, INT J CANCER, V28, P673, DOI 10.1002/ijc.2910280603; MILLER AB, 1985, SCREENING CANCER, P3; NILOFF JM, 1984, OBSTET GYNECOL, V64, P703; RIES LAG, 1991, NCI NIH912789 PUBL; SZKLO M, 1990, Journal of General Internal Medicine, V5, pS47, DOI 10.1007/BF02600841; ZURAWSKI VR, 1988, INT J CANCER, V42, P677, DOI 10.1002/ijc.2910420507; 1988, NCI NIH882789 PUBL	18	71	73	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 3	1993	269	9					1123	1126		10.1001/jama.269.9.1123	http://dx.doi.org/10.1001/jama.269.9.1123			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KN611	8433467				2022-12-24	WOS:A1993KN61100028
J	LEUTHER, KK; SALMERON, JM; JOHNSTON, SA				LEUTHER, KK; SALMERON, JM; JOHNSTON, SA			GENETIC-EVIDENCE THAT AN ACTIVATION DOMAIN OF GAL4 DOES NOT REQUIRE ACIDITY AND MAY FORM A BETA-SHEET	CELL			English	Article							YEAST TRANSCRIPTIONAL ACTIVATORS; NEGATIVE REGULATORY PROTEIN; DNA-BINDING PROTEINS; NF-KAPPA-B; SACCHAROMYCES-CEREVISIAE; FUNCTIONAL DOMAINS; MAMMALIAN-CELLS; POLYMERASE-II; AMINO-ACIDS; INVITRO	Regulation of gene expression in eukaryotes relies on intricate protein-protein interactions. Transcription of the galactose genes in yeast has been a productive model for this type of interaction. The positive activator in this system, GAL4, has a bifunctional C-terminus. It contains both a prototypic acidic activation domain and a region that binds the negative regulator, GAL80. We have taken advantage of this colocalization of functions to subject the region to a constrained mutagenesis analysis: one function was maintained, while the other one was altered. This analysis and the experiments it suggested have led us to two conclusions: first, the acidic amino acids are not, as commonly thought, required for activation; second, this region is not unstructured or alpha helical, but its function may require a beta sheet.	UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	LEUTHER, KK (corresponding author), UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235, USA.							BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAICHWAL VR, 1991, NATURE, V352, P165, DOI 10.1038/352165a0; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; BOSTIAN K, 1980, P NATL ACAD SCI USA, V77, P4505; CAREY M, 1990, SCIENCE, V247, P710, DOI 10.1126/science.2405489; CHAN AML, 1991, SCIENCE, V254, P1382, DOI 10.1126/science.1720571; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CHRIST C, 1991, GENE DEV, V5, P751, DOI 10.1101/gad.5.5.751; COUSENS DJ, 1989, EMBO J, V8, P2337, DOI 10.1002/j.1460-2075.1989.tb08361.x; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; DONALDSON L, 1992, J BIOL CHEM, V267, P1411; DOSTATNI N, 1991, GENE DEV, V5, P1657, DOI 10.1101/gad.5.9.1657; DOUGLAS HC, 1966, GENETICS, V54, P911; FLANAGAN JR, 1992, MOL CELL BIOL, V12, P38, DOI 10.1128/MCB.12.1.38; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GILL G, 1990, P NATL ACAD SCI USA, V87, P2127, DOI 10.1073/pnas.87.6.2127; GILL G, 1987, CELL, V51, P121, DOI 10.1016/0092-8674(87)90016-X; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GINIGER E, 1987, NATURE, V330, P670, DOI 10.1038/330670a0; GINIGER E, 1985, CELL, V40, P767, DOI 10.1016/0092-8674(85)90336-8; HARDWICK JM, 1992, J VIROL, V66, P5500, DOI 10.1128/JVI.66.9.5500-5508.1992; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; HERMES JD, 1989, GENE, V84, P143, DOI 10.1016/0378-1119(89)90148-0; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; HOPE IA, 1988, NATURE, V333, P635, DOI 10.1038/333635a0; INOSTROZA JA, 1992, CELL, V70, P477; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHNSTON M, 1987, MICROBIOL REV, V51, P458, DOI 10.1128/MMBR.51.4.458-476.1987; JOHNSTON SA, 1982, P NATL ACAD SCI-BIOL, V79, P6971, DOI 10.1073/pnas.79.22.6971; JOHNSTON SA, 1987, CELL, V50, P143, DOI 10.1016/0092-8674(87)90671-4; KELLER AD, 1991, GENE DEV, V5, P868, DOI 10.1101/gad.5.5.868; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; LAUGHON A, 1984, MOL CELL BIOL, V4, P260, DOI 10.1128/MCB.4.2.260; LEUTHER KK, 1992, SCIENCE, V256, P1333, DOI 10.1126/science.1598579; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LUCHE RM, 1992, P NATL ACAD SCI USA, V89, P7412, DOI 10.1073/pnas.89.16.7412; LUE NF, 1987, MOL CELL BIOL, V7, P3446, DOI 10.1128/MCB.7.10.3446; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MA J, 1987, CELL, V50, P137, DOI 10.1016/0092-8674(87)90670-2; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MATSUMOTO K, 1980, J BACTERIOL, V141, P508, DOI 10.1128/JB.141.2.508-527.1980; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NOGI Y, 1989, MOL CELL BIOL, V9, P3009, DOI 10.1128/MCB.9.7.3009; OHARE P, 1992, BIOCHEMISTRY-US, V31, P4150, DOI 10.1021/bi00131a035; PARTHUN MR, 1992, MOL CELL BIOL, V12, P4981, DOI 10.1128/MCB.12.11.4981; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; PETERSON CL, 1991, CELL, V64, P1135, DOI 10.1016/0092-8674(91)90268-4; PLATT T, 1984, MOL CELL BIOL, V4, P994, DOI 10.1128/MCB.4.5.994; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; REGIER JL, 1993, IN PRESS P NATL ACAD; Richardson J. S., 1989, PREDICTION PROTEIN S, P1; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; RUDEN DM, 1991, NATURE, V350, P250, DOI 10.1038/350250a0; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SALMERON JM, 1990, GENETICS, V125, P21; SALMERON JM, 1986, NUCLEIC ACIDS RES, V14, P7767, DOI 10.1093/nar/14.19.7767; SALMERON JM, 1989, MOL CELL BIOL, V9, P2950, DOI 10.1128/MCB.9.7.2950; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SELLECK SB, 1987, MOL CELL BIOL, V7, P3260, DOI 10.1128/MCB.7.9.3260; SHERMAN F, 1986, LABORATORY COURSE MA; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SIGLER PB, 1988, NATURE, V333, P210, DOI 10.1038/333210a0; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; SWAFFIELD JC, 1992, NATURE, V357, P698, DOI 10.1038/357698a0; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; TREACY MN, 1992, CELL, V68, P491, DOI 10.1016/0092-8674(92)90186-G; TREACY MN, 1991, NATURE, V350, P577, DOI 10.1038/350577a0; TREACY MN, 1992, NATURE, V68, P491; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; VANHOY M, 1993, CELL, V72, P587, DOI 10.1016/0092-8674(93)90077-4; VANHOY M, 1992, J AM CHEM SOC, V114, P362, DOI 10.1021/ja00027a057; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WILLIAMS TM, 1991, SCIENCE, V254, P1791, DOI 10.1126/science.1840704; YOCUM RR, 1984, MOL CELL BIOL, V4, P1985, DOI 10.1128/MCB.4.10.1985; ZAKIAN VA, 1982, MOL CELL BIOL, V2, P21	79	130	130	1	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 26	1993	72	4					575	585		10.1016/0092-8674(93)90076-3	http://dx.doi.org/10.1016/0092-8674(93)90076-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KP165	8440021				2022-12-24	WOS:A1993KP16500012
J	SANDVIK, L; ERIKSSEN, J; THAULOW, E; ERIKSSEN, G; MUNDAL, R; RODAHL, K				SANDVIK, L; ERIKSSEN, J; THAULOW, E; ERIKSSEN, G; MUNDAL, R; RODAHL, K			PHYSICAL-FITNESS AS A PREDICTOR OF MORTALITY AMONG HEALTHY, MIDDLE-AGED NORWEGIAN MEN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY HEART-DISEASE; RISK-FACTORS; EXERCISE; TRIAL; ATHEROSCLEROSIS; LIPOPROTEINS; INFARCTION; SMOKING; DEATH; LIFE	Background. Despite many studies suggesting that poor physical fitness is an independent risk factor for death from cardiovascular causes, the matter has remained controversial. We studied this question in a 16-year follow-up investigation of Norwegian men that began in 1972. Methods. Our study included 1960 healthy men 40 to 59 years of age (84 percent of those invited to participate). Conventional coronary risk factors and physical fitness were assessed at base line, with physical fitness measured as the total work performed on a bicycle ergometer during a symptom-limited exercise-tolerance test. Results. After an average follow-up time of 16 years, 271 men had died, 53 percent of them from cardiovascular disease. The relative risk of death from any cause in fitness quartile 4 (highest) as compared with quartile 1 (lowest) was 0.54 (95 percent confidence interval, 0.32 to 0.89; P = 0.015) after adjustment for age, smoking status, serum lipids, blood pressure, resting heart rate, vital capacity, body-mass index, level of physical activity, and glucose tolerance. Total mortality was similar among the subjects in fitness quartiles 1, 2, and 3 when the data were adjusted for these same variables. The adjusted relative risk of death from cardiovascular causes in fitness quartile 4 as compared with quartile 1 was 0.41 (95 percent confidence interval, 0.20 to 0.84; P = 0.013). The corresponding relative risks for quartiles 3 and 2 (as compared with quartile 1) were 0.45 (95 percent confidence interval, 0.22 to 0.92; P = 0.026) and 0.59 (95 percent confidence interval, 0.28 to 1.22; P = 0.15), respectively. Conclusions. Physical fitness appears to be a graded, independent, long-term predictor of mortality from cardiovascular causes in healthy, middle-aged men. A high level of fitness was also associated with lower mortality from any cause.	CENT HOSP AKERSHUS,DEPT MED,N-1474 NORDBYHAGEN,NORWAY; NATL UNIV OSLO HOSP,OSLO,NORWAY; ULLEVAL HOSP,OSLO 1,NORWAY; UNIV OSLO,DEPT WORK PHYSIOL,OSLO 3,NORWAY	University of Oslo; University of Oslo; University of Oslo								ASTRAND PO, 1986, TSB WORK PHYSL PHYSL; BEERE PA, 1984, SCIENCE, V226, P180, DOI 10.1126/science.6484569; BERKSON DM, 1970, ATHEROSCLEROSIS, P382; BILLMAN GE, 1984, CIRCULATION, V69, P1182, DOI 10.1161/01.CIR.69.6.1182; BLAIR S N, 1985, Physician and Sportsmedicine, V13, P153; BLAIR SN, 1989, JAMA-J AM MED ASSOC, V262, P2395, DOI 10.1001/jama.262.17.2395; BONJER FH, 1966, FED PROC, V5, P1363; BOUCHARD C, 1986, MED SCI SPORT EXER, V18, P639; BOVE AA, 1985, CIRCULATION, V71, P620, DOI 10.1161/01.CIR.71.3.620; BRUCE RA, 1983, J AM COLL CARDIOL, V2, P565, DOI 10.1016/S0735-1097(83)80286-1; COX DR, 1972, J R STAT SOC B, V34, P187; CROW RS, 1986, AM J CARDIOL, V57, P1075, DOI 10.1016/0002-9149(86)90677-6; DYER AR, 1980, AM J EPIDEMIOL, V112, P736, DOI 10.1093/oxfordjournals.aje.a113046; EKELUND LG, 1988, NEW ENGL J MED, V319, P1379, DOI 10.1056/NEJM198811243192104; ENGER SC, 1977, SCAND J CLIN LAB INV, V37, P251, DOI 10.3109/00365517709091490; ERIKSSEN J, 1977, SCAND J CLIN LAB INV, V37, P243, DOI 10.3109/00365517709091489; ERIKSSEN J, 1982, ANN NY ACAD SCI, V382, P438, DOI 10.1111/j.1749-6632.1982.tb55236.x; ERIKSSEN J, 1977, ACTA MED SCAND, V202, P357; ERIKSSEN J, 1978, THESIS U HOSPITAL OS; FEARNLEY GR, 1955, BRIT J HAEMATOL, V1, P189, DOI 10.1111/j.1365-2141.1955.tb05500.x; GORDON DJ, 1987, AM J EPIDEMIOL, V125, P587, DOI 10.1093/oxfordjournals.aje.a114572; KEMMER FW, 1983, INT J SPORTS MED, V4, P77, DOI 10.1055/s-2008-1026017; KENNEY WL, 1985, MED SCI SPORT EXER, V17, P451, DOI 10.1249/00005768-198508000-00008; KRAMSCH DM, 1981, NEW ENGL J MED, V305, P1483, DOI 10.1056/NEJM198112173052501; LIE H, 1985, EUR HEART J, V6, P147, DOI 10.1093/oxfordjournals.eurheartj.a061829; MUNDAL R, 1987, EUR J APPL PHYSIOL O, V56, P245, DOI 10.1007/BF00690888; NOAKES TD, 1983, CIRCULATION, V67, P24, DOI 10.1161/01.CIR.67.1.24; PETERS RK, 1983, JAMA-J AM MED ASSOC, V249, P3052, DOI 10.1001/jama.249.22.3052; POWELL KE, 1987, ANNU REV PUBL HEALTH, V8, P253, DOI 10.1146/annurev.publhealth.8.1.253; RAURAMAA R, 1984, BRIT MED J, V288, P603, DOI 10.1136/bmj.288.6417.603; RAURAMAA R, 1986, CIRCULATION, V74, P939, DOI 10.1161/01.CIR.74.5.939; ROSE GA, 1968, WHO MONOGRAPH SERIES, V56; ROSING DR, 1970, CIRC RES, V27, P171, DOI 10.1161/01.RES.27.2.171; SCHWANE JA, 1979, METABOLISM, V28, P771, DOI 10.1016/0026-0495(79)90184-7; SLATTERY ML, 1988, AM J EPIDEMIOL, V127, P571, DOI 10.1093/oxfordjournals.aje.a114832; SOBOLSKI J, 1987, AM J EPIDEMIOL, V125, P601, DOI 10.1093/oxfordjournals.aje.a114573; TAYLOR HL, 1962, AM J PUBLIC HEALTH N, V52, P1697, DOI 10.2105/AJPH.52.10.1697; WILHELMSEN L, 1981, CARDIOLOGY, V68, P1, DOI 10.1159/000173310; WYATT HL, 1978, J APPL PHYSIOL, V45, P619, DOI 10.1152/jappl.1978.45.4.619; 1971, PRINCIPLES MED STATI, P309; 1986, SUGI SUPPLEMENTAL LI	41	580	590	1	40	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 25	1993	328	8					533	537		10.1056/NEJM199302253280803	http://dx.doi.org/10.1056/NEJM199302253280803			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP053	8426620	Bronze			2022-12-24	WOS:A1993KP05300003
J	MUTTON, DE; IDE, R; ALBERMAN, E; BOBROW, M				MUTTON, DE; IDE, R; ALBERMAN, E; BOBROW, M			ANALYSIS OF NATIONAL REGISTER OF DOWNS-SYNDROME IN ENGLAND AND WALES - TRENDS IN PRENATAL-DIAGNOSIS, 1989-91	BRITISH MEDICAL JOURNAL			English	Article									ST BARTHOLOMEWS HOSP,COLL MED,WOLFSON INST PREVENT MED,LONDON EC1M 6BQ,ENGLAND; UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,DIV MED & MOLEC GENET,PAEDIAT RES UNIT,LONDON SE1 9RT,ENGLAND	University of London; Queen Mary University London; University of London; King's College London	MUTTON, DE (corresponding author), LONDON HOSP,COLL MED QMW,DEPT EPIDEMIOL & MED STAT,LONDON E1 4NS,ENGLAND.							BOYD PA, 1992, J MED GENET, V29, P91, DOI 10.1136/jmg.29.2.91; CULLEN S, 1992, ARCH DIS CHILD-FETAL, V67, P775, DOI 10.1136/adc.67.7_Spec_No.775; MUTTON DE, 1991, BRIT MED J, V303, P1295, DOI 10.1136/bmj.303.6813.1295; WALD N, 1992, LANCET, V340, P494, DOI 10.1016/0140-6736(92)91822-P	4	21	21	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 13	1993	306	6875					431	432		10.1136/bmj.306.6875.431	http://dx.doi.org/10.1136/bmj.306.6875.431			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KM700	8461727	Green Published, Bronze			2022-12-24	WOS:A1993KM70000024
J	WILLMAN, CL; SEVER, CE; PALLAVICINI, MG; HARADA, H; TANAKA, N; SLOVAK, ML; YAMAMOTO, H; HARADA, K; MEEKER, TC; LIST, AF; TANIGUCHI, T				WILLMAN, CL; SEVER, CE; PALLAVICINI, MG; HARADA, H; TANAKA, N; SLOVAK, ML; YAMAMOTO, H; HARADA, K; MEEKER, TC; LIST, AF; TANIGUCHI, T			DELETION OF IRF-1, MAPPING TO CHROMOSOME 5Q31.1 IN HUMAN LEUKEMIA AND PRELEUKEMIC MYELODYSPLASIA	SCIENCE			English	Article							FLUORESCENCE INSITU HYBRIDIZATION; ACUTE NONLYMPHOCYTIC LEUKEMIA; REGULATORY FACTOR-I; TRANSCRIPTION FACTOR; LONG ARM; GM-CSF; GENE; 5Q; IDENTIFICATION; EXPRESSION	One of the most frequent cytogenetic abnormalities in human leukemia and myelodysplasia is an interstitial deletion within chromosome 5q. A tumor suppressor gene has been hypothesized to lie in 5q31, the smallest commonly deleted region. IRF-1, a gene whose product manifests anti-oncogenic activity, was mapped to 5q31.1. IRF-1 lies between IL-5 and CDC25C and is centromeric to IL-3 and GM-CSF. Among these genes, only IRF-1 was consistently deleted at one or both alleles in 13 cases of leukemia or myelodysplasia with aberrations of 5q31. Inactivating rearrangements of one IRF-1 allele, accompanied by deletion of the second allele, were also identified in one case of acute leukemia. Thus, IRF-1 may be a critically deleted gene in human leukemia and myelodysplasia.	OSAKA UNIV,INST MOLEC & CELLULAR BIOL,SUITA,OSAKA 565,JAPAN; CITY HOPE NATL MED CTR,DEPT PATHOL,DUARTE,CA 91010; UNIV NEW MEXICO,SCH MED,DEPT CELL BIOL,ALBUQUERQUE,NM 87131; UNIV CALIF SAN FRANCISCO,DEPT LAB MED,DIV MOLEC CYTOMETRY,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV ARIZONA,CTR CANC,TUCSON,AZ 85724	Osaka University; City of Hope; University of New Mexico; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Arizona	WILLMAN, CL (corresponding author), UNIV NEW MEXICO,SCH MED,DEPT PATHOL,900 CAMINO SALUD NE,ALBUQUERQUE,NM 87131, USA.		Harada, Hisashi/H-2815-2019	Harada, Hisashi/0000-0001-5993-1289; Tanaka, Nobuyuki/0000-0002-6373-2220; LIST, ALAN/0000-0002-1647-2972	NATIONAL CANCER INSTITUTE [U10CA032102, U10CA032734] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043042] Funding Source: NIH RePORTER; NCI NIH HHS [CA-32102, CA-32734] Funding Source: Medline; NIDDK NIH HHS [DK-43042] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABBOTT C, 1989, GENOMICS, V4, P606, DOI 10.1016/0888-7543(89)90286-3; ABDOLLAHI A, 1991, CELL GROWTH DIFFER, V2, P401; DEWALD GW, 1985, BLOOD, V66, P189; DISCIPIO RG, 1984, P NATL ACAD SCI-BIOL, V81, P7298, DOI 10.1073/pnas.81.23.7298; FUJITA T, 1989, P NATL ACAD SCI USA, V86, P9936, DOI 10.1073/pnas.86.24.9936; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HARADA H, UNPUB; HUEBNER K, 1985, SCIENCE, V230, P1282, DOI 10.1126/science.2999978; KERIM S, 1990, LEUKEMIA, V4, P12; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KUO WL, 1991, AM J HUM GENET, V49, P112; LEBEAU MM, 1987, P NATL ACAD SCI USA, V84, P5913; LEBEAU MM, 1986, SCIENCE, V231, P984, DOI 10.1126/science.3484837; LEBEAU MM, 1986, J CLIN ONCOL, V4, P325, DOI 10.1200/JCO.1986.4.3.325; LI Y, 1992, CELL, V69, P275, DOI 10.1016/0092-8674(92)90408-5; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MARUYAMA M, 1989, NUCLEIC ACIDS RES, V17, P3292, DOI 10.1093/nar/17.8.3292; MEEKER TR, UNPUB; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; NIENHUIS AW, 1985, CELL, V42, P421, DOI 10.1016/0092-8674(85)90099-6; NIMER SD, 1987, BLOOD, V70, P1705; PEDERSEN B, 1991, LEUKEMIA, V5, P566; PEDERSENBJERGAARD J, 1990, BLOOD, V76, P1083; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; PINKEL D, 1988, P NATL ACAD SCI USA, V85, P9138, DOI 10.1073/pnas.85.23.9138; Sambrook J., 1989, MOL CLONING LAB MANU; SARTOR H, 1992, GENOMICS, V13, P911, DOI 10.1016/0888-7543(92)90190-4; SUTHERLAND GR, 1988, BLOOD, V71, P1150; Tanaka N., UNPUB; VANDENBERGHE H, 1974, NATURE, V251, P437, DOI 10.1038/251437a0; VANDENBERGHE H, 1985, CANCER GENET CYTOGEN, V17, P189, DOI 10.1016/0165-4608(85)90016-0; WARRINGTON JA, 1992, GENOMICS, V13, P803, DOI 10.1016/0888-7543(92)90156-M; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; YAMADA G, 1991, P NATL ACAD SCI USA, V88, P532, DOI 10.1073/pnas.88.2.532; 1982, CANCER GENET CYTOGEN, V11, P296	40	363	374	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 12	1993	259	5097					968	971		10.1126/science.8438156	http://dx.doi.org/10.1126/science.8438156			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL800	8438156				2022-12-24	WOS:A1993KL80000042
J	MANDEL, LJ; BACALLAO, R; ZAMPIGHI, G				MANDEL, LJ; BACALLAO, R; ZAMPIGHI, G			UNCOUPLING OF THE MOLECULAR FENCE AND PARACELLULAR GATE FUNCTIONS IN EPITHELIAL TIGHT JUNCTIONS	NATURE			English	Article							MDCK CELLS; POLARITY; PERMEABILITY; RESISTANCE; MEMBRANE	DURING epithelial morphogenesis, the establishment of tight junctions precedes the development of both the asymmetry in protein and lipid composition between apical and basolateral cell surfaces (the 'fence' function) and the restriction in the transport of ions and nonelectrolytes through the extracellular clefts between cells (the 'gate' function)1,2. Molecular models that explain both functions envision strands of particles extending as rings in the cell's perimeter that interact with similar strands located at the apposing cell2-5. This model accounts for the 'fence' function, because the strands prevent diffusion of protein and lipids, and also for the 'gate' function, because the interaction between strands minimizes the width of the extracellular clefts, increasing transepithelial resistance to ions and decreasing non-electrolyte permeability. Here we describe the results of energy depletion, which for the first time separates both functions: it abolishes the gate function, as determined by the dramatic decrease in transepithelial resistance, but it leaves the fence function intact, as determined by the maintenance of lipid polarity.	NORTHWESTERN UNIV,DEPT MOLEC CELLULAR & STRUCT BIOL,DIV NEPHROL & HYPERTENS,CHICAGO,IL 60611; UNIV CALIF LOS ANGELES,DEPT ANAT & CELL BIOL,LOS ANGELES,CA 90024	Northwestern University; University of California System; University of California Los Angeles	MANDEL, LJ (corresponding author), DUKE UNIV,MED CTR,DEPT CELL BIOL,DIV PHYSIOL,DURHAM,NC 27710, USA.			Bacallao, Robert/0000-0002-5703-5701				BACALLAO R, 1990, HDB BIOL CONFOCAL MI, P197; BENNETT V, 1991, J CLIN INVEST, V87, P1483, DOI 10.1172/JCI115157; CEREIJIDO M, 1989, J MEMBRANE BIOL, V110, P1, DOI 10.1007/BF01870987; CLAUDE P, 1978, J MEMBRANE BIOL, V39, P219, DOI 10.1007/BF01870332; CLAUDE P, 1973, J CELL BIOL, V58, P390, DOI 10.1083/jcb.58.2.390; Diamond J M, 1977, Physiologist, V20, P10; DRAGSTEN PR, 1981, NATURE, V294, P718, DOI 10.1038/294718a0; GUMBINER B, 1987, AM J PHYSIOL, V253, pC749, DOI 10.1152/ajpcell.1987.253.6.C749; LADINO C, 1991, EUR J CELL BIOL, V55, P217; MADARA JL, 1989, J CLIN INVEST, V83, P1089, DOI 10.1172/JCI113987; MADARA JL, 1985, J CELL BIOL, V101, P2124, DOI 10.1083/jcb.101.6.2124; MANDEL LJ, 1988, J CLIN INVEST, V81, P1255, DOI 10.1172/JCI113443; MOLITORIS BA, 1989, J CLIN INVEST, V84, P1334, DOI 10.1172/JCI114302; MUCKTER H, 1987, EUR J CELL BIOL, V44, P258; MULLIN JM, 1986, AM J PHYSIOL, V251, pC597, DOI 10.1152/ajpcell.1986.251.4.C597; NELSON WJ, 1989, J CELL BIOL, V108, P893, DOI 10.1083/jcb.108.3.893; NIGAM SK, 1991, BIOCHEM BIOPH RES CO, V181, P548, DOI 10.1016/0006-291X(91)91224-Z; OJAKIAN GK, 1981, CELL, V23, P95, DOI 10.1016/0092-8674(81)90274-9; PAGANO RE, 1988, BIOCHEMISTRY-US, V27, P4439, DOI 10.1021/bi00412a034; STEVENSON BR, 1988, MOL CELL BIOCHEM, V83, P129; STEVENSON BR, 1988, J CELL BIOL, V107, P2401, DOI 10.1083/jcb.107.6.2401; VAN MEER G, 1986, EMBO J, V5, P1455, DOI 10.1002/j.1460-2075.1986.tb04382.x; ZAMPIGHI G, 1988, J CELL BIOL, V106, P1667, DOI 10.1083/jcb.106.5.1667	23	236	237	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 11	1993	361	6412					552	555		10.1038/361552a0	http://dx.doi.org/10.1038/361552a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL714	8429911				2022-12-24	WOS:A1993KL71400066
J	MANGEL, WF; MCGRATH, WJ; TOLEDO, DL; ANDERSON, CW				MANGEL, WF; MCGRATH, WJ; TOLEDO, DL; ANDERSON, CW			VIRAL-DNA AND A VIRAL PEPTIDE CAN ACT AS COFACTORS OF ADENOVIRUS VIRION PROTEINASE ACTIVITY	NATURE			English	Article							TYPE-2	HUMAN adenovirus (Ad2), like many other viruses1, contains a virion-associated proteinase essential for the synthesis of infectious virus particles2-4. We observed proteinase activity in wild-type virus but not in the ts-1 virus2, which contains a mutation in the Ad2 L3 endoprotease gene5 that confers temperature-sensitive processing of virion precursor proteins. Unexpectedly, we did not observe proteinase activity with purified recombinant6,7 endoprotease protein (M(r) 23 K). Purified recombinant endoprotease protein, however, complemented the mutation in ts-1 virions, restoring proteinase activity when mixed together. This implied that cofactors may be required. Here we reconstitute proteinase activity in vitro with three purified viral components: (1) the recombinant endoprotease protein; (2) an 11-amino-acid peptide that originates from the carboxy terminus of pVI, the precursor to virion component VI; and (3) adenovirus DNA. The use of DNA for a proteinase activity is unprecedented.			MANGEL, WF (corresponding author), BROOKHAVEN NATL LAB, DEPT BIOL, UPTON, NY 11973 USA.			McGrath, William/0000-0002-9375-624X				AKUSJARVI G, 1981, J VIROL, V38, P469; ANDERSON CW, 1993, PROTEIN EXPRES PURIF, V4, P8, DOI 10.1006/prep.1993.1002; ANDERSON CW, 1990, VIROLOGY, V177, P259, DOI 10.1016/0042-6822(90)90479-B; HANNAN C, 1983, INTERVIROLOGY, V19, P213, DOI 10.1159/000149363; KRAUSSLICH HG, 1988, ANNU REV BIOCHEM, V57, P701, DOI 10.1146/annurev.bi.57.070188.003413; LEYTUS SP, 1983, BIOCHEM J, V215, P253, DOI 10.1042/bj2150253; LIANG YK, 1983, J MOL BIOL, V167, P217, DOI 10.1016/S0022-2836(83)80044-8; MIRZA A, 1980, INTERVIROLOGY, V13, P307, DOI 10.1159/000149139; WEBER J, 1976, J VIROL, V17, P462, DOI 10.1128/JVI.17.2.462-471.1976; WEBSTER A, 1989, J GEN VIROL, V70, P3225, DOI 10.1099/0022-1317-70-12-3225; WEBSTER A, 1989, J GEN VIROL, V70, P3215, DOI 10.1099/0022-1317-70-12-3215	11	148	151	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 21	1993	361	6409					274	275		10.1038/361274a0	http://dx.doi.org/10.1038/361274a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KH614	8423855				2022-12-24	WOS:A1993KH61400065
J	SUKEGAWA, J; BLOBEL, G				SUKEGAWA, J; BLOBEL, G			A NUCLEAR-PORE COMPLEX PROTEIN THAT CONTAINS ZINC FINGER MOTIFS, BINDS DNA, AND FACES THE NUCLEOPLASM	CELL			English	Article							LINKED N-ACETYLGLUCOSAMINE; GLUCOCORTICOID RECEPTOR; ENVELOPE PROTEIN; STRUCTURAL MOTIF; DOMAIN; GLYCOPROTEINS; IDENTIFICATION; EXPRESSION; CDNA; P62	We have molecularly cloned and sequenced a cDNA for a rat liver nucleoporin with a molecular mass of 152.8 kd, termed nup153, that shares a repetitive degenerate pentapeptide motif with a subgroup of nucleoporins of yeast and vertebrates. However, its most striking feature is a novel 4-fold repeat of a Cys2-Cys2-type zinc finger motif. When expressed in E. coli, the zinc finger domain of nupl53 binds DNA in a zinc-dependent fashion. Immunoelectron microscopy localized nup153 exclusively to the nucleoplasmic side of the nuclear pore complex. We suggest that nup153 recognizes a specific DNA sequence to organize the genome three-dimensionally and to gate transcribable genes to nuclear pore complexes.			SUKEGAWA, J (corresponding author), ROCKEFELLER UNIV,HOWARD HUGHES MED INST,CELL BIOL LAB,NEW YORK,NY 10021, USA.							Akey C W, 1991, Semin Cell Biol, V2, P167; BERG JM, 1990, J BIOL CHEM, V265, P6513; BLOBEL G, 1966, SCIENCE, V154, P1662, DOI 10.1126/science.154.3757.1662; BLOBEL G, 1985, P NATL ACAD SCI USA, V82, P8527, DOI 10.1073/pnas.82.24.8527; CARMOFONSECA M, 1991, EUR J CELL BIOL, V55, P17; COLEMAN JE, 1992, ANNU REV BIOCHEM, V61, P897, DOI 10.1146/annurev.bi.61.070192.004341; CORDES V, 1991, EUR J CELL BIOL, V55, P31; DAHLMAN K, 1989, J BIOL CHEM, V264, P804; DAVIS LI, 1987, P NATL ACAD SCI USA, V84, P7552, DOI 10.1073/pnas.84.21.7552; DAVIS LI, 1990, CELL, V61, P965, DOI 10.1016/0092-8674(90)90062-J; DAVIS LI, 1986, CELL, V45, P699, DOI 10.1016/0092-8674(86)90784-1; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; DWYER N, 1976, J CELL BIOL, V70, P581, DOI 10.1083/jcb.70.3.581; GRIFFITHS G, 1983, METHOD ENZYMOL, V96, P466; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HALTIWANGER RS, 1992, BIOCHEM SOC T, V20, P264, DOI 10.1042/bst0200264; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; HINSHAW JE, 1992, CELL, V69, P1133, DOI 10.1016/0092-8674(92)90635-P; HOLT GD, 1987, J CELL BIOL, V104, P1157, DOI 10.1083/jcb.104.5.1157; HURT EC, 1988, EMBO J, V7, P4323, DOI 10.1002/j.1460-2075.1988.tb03331.x; JARNIK M, 1991, J STRUCT BIOL, V107, P291, DOI 10.1016/1047-8477(91)90054-Z; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; Marston F. A. O., 1987, DNA CLONING, P59; NEHRBASS U, 1990, CELL, V61, P979, DOI 10.1016/0092-8674(90)90063-K; NIGG EA, 1991, CELL, V66, P15, DOI 10.1016/0092-8674(91)90135-L; OKAYAMA H, 1987, METHOD ENZYMOL, V154, P3; PARK MK, 1987, P NATL ACAD SCI USA, V84, P6462, DOI 10.1073/pnas.84.18.6462; REICHELT R, 1990, J CELL BIOL, V110, P883, DOI 10.1083/jcb.110.4.883; RIS H, 1989, SEM I PHYS C SER, V98, P657; RIS H, 1991, EMSA B, V21, P54; Sambrook J., 1989, MOL CLONING LAB MANU; SCHWABE JWR, 1990, NATURE, V348, P458, DOI 10.1038/348458a0; SCHWABE JWR, 1991, TRENDS BIOCHEM SCI, V16, P291, DOI 10.1016/0968-0004(91)90121-B; SMITH DE, 1984, J CELL BIOL, V99, P20, DOI 10.1083/jcb.99.1.20; SNOW CM, 1987, J CELL BIOL, V104, P1143, DOI 10.1083/jcb.104.5.1143; STARR CM, 1991, BIOESSAYS, V13, P145, DOI 10.1002/bies.950130309; STARR CM, 1990, J CELL BIOL, V110, P1861, DOI 10.1083/jcb.110.6.1861; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; THOMAS PS, 1983, METHOD ENZYMOL, V100, P255; TOKUYASU KT, 1973, J CELL BIOL, V57, P551, DOI 10.1083/jcb.57.2.551; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; WENTE SR, 1992, J CELL BIOL, V119, P705, DOI 10.1083/jcb.119.4.705; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4	45	280	286	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 15	1993	72	1					29	38		10.1016/0092-8674(93)90047-T	http://dx.doi.org/10.1016/0092-8674(93)90047-T			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KG955	8422679				2022-12-24	WOS:A1993KG95500007
J	POL, S; ROMANA, CA; RICHARD, S; AMOUYAL, P; DESPORTESLIVAGE, I; CARNOT, F; PAYS, JF; BERTHELOT, P				POL, S; ROMANA, CA; RICHARD, S; AMOUYAL, P; DESPORTESLIVAGE, I; CARNOT, F; PAYS, JF; BERTHELOT, P			MICROSPORIDIA INFECTION IN PATIENTS WITH THE HUMAN-IMMUNODEFICIENCY-VIRUS AND UNEXPLAINED CHOLANGITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BOWEL BACTERIAL OVERGROWTH; INTESTINAL MICROSPORIDIOSIS; SCLEROSING CHOLANGITIS; AIDS; DIAGNOSIS; DISEASE; RATS	Background. Cholangitis in patients with the acquired immunodeficiency syndrome (AIDS) is usually associated with opportunistic infections by cryptosporidium species or cytomegalovirus, but in about a third of cases no opportunistic agent is identified. We suspected some of these cases of biliary disease might be explained by infection with the microsporidia species Enterocytozoon bieneusi, an obligate intracellular protozoan that causes chronic diarrhea in patients infected with the human immunodeficiency virus (HIV). Methods. We studied eight HIV-infected homosexual men (in either group IV of the classification of the Centers for Disease Control and Prevention or group II, with a CD4 cell count of less-than-or-equal-to 10 per cubic millimeter) who were referred because of cholangitis for which no causative agent had been found by standard tests. All the patients underwent abdominal ultrasonography and endoscopic ultrasonography or endoscopic retrograde cholangiopancreatography with collection of bile from the common bile duct. One patient had transhepatic biliary catheterization, and two others had cholecystectomy. Bile samples, duodenal- and liver-biopsy specimens, and gallbladder tissue were studied by light and electron microscopy. Results. All eight patients with unexplained AIDS-related cholangitis had biliary microsporidiosis. Intraepithelial E bieneusi spores (1 to 2 mum) and supranuclear plasmodia (3 to 8 mum) were identified in the six duodenal-biopsy specimens. May-Grunwald-Giemsa staining of bile samples revealed free forms of microsporidia in all eight patients, and the presence of E. bieneusi was confirmed by electron microscopy. E. bieneusi was also identified in ductal biliary cells on a liver biopsy, in one common-bile-duct smear, and in gallbladder epithelium (in two patients). Four patients were found to have associated but previously undetected biliary or duodenal cryptosporidiosis, whereas another had biliary infection associated with cytomegalovirus. Conclusions. Infection of the biliary tract with E. bieneusi is associated with and may be a cause of AIDS-related cholangitis.	HOP LA PITIE SALPETRIERE,SERV NEUROHISTOL,PARIS,FRANCE; INSERM,U313,F-75005 PARIS,FRANCE; INSERM,U99,F-75005 PARIS,FRANCE; HOP NECKER LAENNEC,HEPATOL UNIT,PARIS,FRANCE; HOP NECKER LAENNEC,PARASITOL UNIT,PARIS,FRANCE; HOP NECKER LAENNEC,ANAT & PATHOL UNIT,PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm)			RICHARD, Stéphane/O-1005-2017	RICHARD, Stéphane/0000-0002-9859-9773; desportes, isabelle/0000-0002-8472-449X				BERAL V, 1992, LANCET, V339, P632, DOI 10.1016/0140-6736(92)90793-3; BOUCHE H, IN PRESS J HEPATOL; CANNING EU, 1990, T ROY SOC TROP MED H, V84, P181, DOI 10.1016/0035-9203(90)90247-C; CELLO JP, 1989, AM J MED, V86, P539, DOI 10.1016/0002-9343(89)90381-1; Centers for Disease Control (CDC), 1986, MMWR Morb Mortal Wkly Rep, V35, P334; DESPORTES I, 1985, J PROTOZOOL, V32, P250; DOWSETT JF, 1988, SCAND J GASTROENTERO, V23, P1267, DOI 10.3109/00365528809090203; KORNFELD H, 1982, NEW ENGL J MED, V307, P729, DOI 10.1056/NEJM198209163071206; LICHTMAN SN, 1991, GASTROENTEROLOGY, V100, P513, DOI 10.1016/0016-5085(91)90224-9; LICHTMAN SN, 1991, HEPATOLOGY, V13, P766, DOI 10.1002/hep.1840130425; MARGULIS SJ, 1986, ANN INTERN MED, V105, P207, DOI 10.7326/0003-4819-105-2-207; MCWHINNEY PHM, 1991, AIDS, V5, P1394, DOI 10.1097/00002030-199111000-00024; ORENSTEIN JM, 1990, HUM PATHOL, V21, P475; PEACOCK CS, 1991, J CLIN PATHOL, V44, P558, DOI 10.1136/jcp.44.7.558; PITLIK SD, 1983, NEW ENGL J MED, V308, P967; POL S, 1992, GASTROENTEROLOGY, V102, P1778, DOI 10.1016/0016-5085(92)91743-N; RIJPSTRA AC, 1988, J INFECT DIS, V157, P827, DOI 10.1093/infdis/157.4.827; SCHATTENKERK JKME, 1991, LANCET, V337, P895, DOI 10.1016/0140-6736(91)90215-B; SHADDUCK JA, 1989, REV INFECT DIS, V11, P203; SIMON D, 1991, GASTROENTEROLOGY, V100, P271, DOI 10.1016/0016-5085(91)90613-P; SUNG JY, 1991, HEPATOLOGY, V14, P313, DOI 10.1016/0270-9139(91)91421-V; WEBER R, 1992, NEW ENGL J MED, V326, P161, DOI 10.1056/NEJM199201163260304	22	165	168	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 14	1993	328	2					95	99		10.1056/NEJM199301143280204	http://dx.doi.org/10.1056/NEJM199301143280204			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG467	8416439				2022-12-24	WOS:A1993KG46700004
J	PICCIRILLI, JA; VYLE, JS; CARUTHERS, MH; CECH, TR				PICCIRILLI, JA; VYLE, JS; CARUTHERS, MH; CECH, TR			METAL-ION CATALYSIS IN THE TETRAHYMENA RIBOZYME REACTION	NATURE			English	Article							PHOSPHORYL-TRANSFER-REACTIONS; RNA CLEAVAGE; ENDORIBONUCLEASE ACTIVITY; THERMOPHILA RIBOZYME; KINETIC DESCRIPTION; ESCHERICHIA-COLI; DNA; SUBSTRATE; BINDING; SITE	ALL catalytic RNAs (ribozymes) require or are stimulated by divalent metal ions, but it has been difficult to separate the contribution of these metal ions to formation of the RNA tertiary structure1 from a more direct role in catalysis. The Tetrahymena ribozyme catalyses cleavage of exogenous RNA2,3 or DNA4,5 substrates with an absolute requirement for Mg2+ or Mn2+ (ref. 6). A DNA substrate, in which the bridging 3' oxygen atom at the cleavage site is replaced by sulphur, is cleaved by the ribozyme about 1,000 times more slowly than the corresponding unmodified DNA substrate when Mg2+ is present as the only divalent metal ion. But addition of Mn2+ or Zn2+ to the reaction relieves this negative effect, with the 3' S-P bond being cleaved nearly as fast as the 3' O-P bond. Considering that Mn2+ and Zn2+ coordinate sulphur more strongly than Mg2+ does7,8, these results indicate that the metal ion contributes directly to catalysis by coordination to the 3' oxygen atom in the transition state, presumably stabilizing the developing negative charge on the leaving group. We conclude that the Tetrahymena ribozyme is a metalloenzyme, with mechanistic similarities to several protein enzymes9-12.	UNIV COLORADO, HOWARD HUGHES MED INST, BOULDER, CO 80309 USA; UNIV COLORADO, DEPT CHEM & BIOCHEM, BOULDER, CO 80309 USA	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder			Vyle, Joseph S/A-6077-2013					BASS BL, 1984, NATURE, V308, P820, DOI 10.1038/308820a0; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BEVILACQUA PC, 1991, BIOCHEMISTRY-US, V30, P10632, DOI 10.1021/bi00108a005; BROWNE KA, 1992, J AM CHEM SOC, V114, P4951, DOI 10.1021/ja00039a001; CECH TR, 1992, J BIOL CHEM, V267, P17479; CELANDER DW, 1991, SCIENCE, V251, P401, DOI 10.1126/science.1989074; COSSTICK R, 1990, NUCLEIC ACIDS RES, V8, P2295; DAHM SC, 1991, BIOCHEMISTRY-US, V30, P9464, DOI 10.1021/bi00103a011; DAVIES RW, 1982, NATURE, V300, P719, DOI 10.1038/300719a0; ECKSTEIN F, 1985, ANNU REV BIOCHEM, V54, P367, DOI 10.1146/annurev.bi.54.070185.002055; FREEMONT PS, 1988, P NATL ACAD SCI USA, V85, P8924, DOI 10.1073/pnas.85.23.8924; FREY PA, 1989, ADV ENZYMOL RAMB, V62, P119; GROSSHANS CA, 1989, BIOCHEMISTRY-US, V28, P6888, DOI 10.1021/bi00443a017; GUERRIERTAKADA C, 1986, BIOCHEMISTRY-US, V25, P1509, DOI 10.1021/bi00355a006; HERSCHLAG D, 1991, BIOCHEMISTRY-US, V30, P4844, DOI 10.1021/bi00234a003; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10172, DOI 10.1021/bi00496a004; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10159, DOI 10.1021/bi00496a003; HERSCHLAG D, 1990, NATURE, V344, P405, DOI 10.1038/344405a0; HERSCHLAG D, 1987, J AM CHEM SOC, V109, P4665, DOI 10.1021/ja00249a033; HOUGH E, 1989, NATURE, V338, P357, DOI 10.1038/338357a0; JAFFE EK, 1978, J BIOL CHEM, V253, P4823; KIM EE, 1991, J MOL BIOL, V218, P449, DOI 10.1016/0022-2836(91)90724-K; KNOWLES JR, 1980, ANNU REV BIOCHEM, V49, P877, DOI 10.1146/annurev.bi.49.070180.004305; KOIZUMI M, 1991, BIOCHEMISTRY-US, V30, P5145, DOI 10.1021/bi00235a005; MCSWIGGEN JA, 1989, SCIENCE, V244, P679, DOI 10.1126/science.2470150; MICHEL F, 1989, NATURE, V342, P391, DOI 10.1038/342391a0; MILSTIEN S, 1967, J AM CHEM SOC, V89, P5820, DOI 10.1021/ja00999a016; NAKAMAYE KL, 1988, NUCLEIC ACIDS RES, V16, P9947, DOI 10.1093/nar/16.21.9947; PECORARO VL, 1984, BIOCHEMISTRY-US, V23, P5262, DOI 10.1021/bi00317a026; PERREAULT JP, 1991, BIOCHEMISTRY-US, V30, P4020, DOI 10.1021/bi00230a029; PYLE AM, 1990, P NATL ACAD SCI USA, V87, P8187, DOI 10.1073/pnas.87.21.8187; PYLE AM, 1991, NATURE, V350, P628, DOI 10.1038/350628a0; PYLE AM, 1992, NATURE, V358, P123, DOI 10.1038/358123a0; RAJAGOPAL J, 1989, SCIENCE, V244, P692, DOI 10.1126/science.2470151; ROBERTSON DL, 1990, NATURE, V344, P467, DOI 10.1038/344467a0; VYLE JS, 1992, BIOCHEMISTRY-US, V31, P3012, DOI 10.1021/bi00126a024; YARUS M, 1991, J MOL BIOL, V222, P995, DOI 10.1016/0022-2836(91)90590-3; ZAUG AJ, 1986, NATURE, V324, P429, DOI 10.1038/324429a0; ZAUG AJ, 1988, BIOCHEMISTRY-US, V27, P8924, DOI 10.1021/bi00425a008	39	377	382	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 7	1993	361	6407					85	88		10.1038/361085a0	http://dx.doi.org/10.1038/361085a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KF718	8421499				2022-12-24	WOS:A1993KF71800055
J	MITCHELL, EA; STEWART, AW; SCRAGG, R; FORD, RPK; TAYLOR, BJ; BECROFT, DMO; THOMPSON, JMD; HASSALL, IB; BARRY, DMJ; ALLEN, EM; ROBERTS, AP				MITCHELL, EA; STEWART, AW; SCRAGG, R; FORD, RPK; TAYLOR, BJ; BECROFT, DMO; THOMPSON, JMD; HASSALL, IB; BARRY, DMJ; ALLEN, EM; ROBERTS, AP			ETHNIC-DIFFERENCES IN MORTALITY FROM SUDDEN-INFANT-DEATH-SYNDROME IN NEW-ZEALAND	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objectives-To examine the factors which might explain the higher mortality from sudden infant death syndrome in Maori infants (7.4/1000 live births in 1986 compared with 3.6 in non-Maori children). Design-A large nationwide case control study. Setting-New Zealand. 485 infants who died of sudden infant death syndrome were compared with 1800 control infants. There were 229 Maori and 240 non-Maori cases of sudden infant death syndrome (16 cases unassigned) and 353 Maori and 1410 non-Maori controls (37 unassigned). Results-Maori infants had 3.81 times the risk (95% confidence interval 3.06 to 4.76) of sudden infant death syndrome compared with non-Maori infants. The risk factors for sudden infant death syndrome within groups were remarkably similar. When Maori and non-Maori controls were compared the prevalence of many of the known risk factors was higher in Maori infants. In particular, mothers were socioeconomically disadvantaged, younger, and more likely to smoke and their infants were of lower birth weight and more likely to share a bed with another person. Multivariate analysis controlling for potential confounders found that simply being Maori increased the risk of sudden infant death syndrome by only 1.37 (95% CI=0.95 to 2.01), not statistically significantly different from 1. Population attributable risk was calculated for prone sleeping position, maternal smoking, not breast feeding, and infants sharing a bed with another person. In total these four risk factors for accounted for 89% of deaths from sudden infant death syndrome in Maori infants and 79% in non-Maori infants. Conclusion-The high rate of sudden infant death syndrome among Maori infants is based largely on the high prevalence in the Maori population of the major risk factors. Other risk factors, not related to ethnicity, probably explain remaining differences between Maori and non-Maori children.	UNIV OTAGO, DUNEDIN, NEW ZEALAND; PRINCESS MARY HOSP CHILDREN, AUCKLAND, NEW ZEALAND	University of Otago	MITCHELL, EA (corresponding author), UNIV AUCKLAND, DEPT PAEDIAT, AUCKLAND 1, NEW ZEALAND.		Taylor, Barry j/G-1410-2010	Taylor, Barry/0000-0002-6450-8677; Scragg, Robert/0000-0003-0013-2620				BALARAJAN R, 1989, BRIT MED J, V298, P716, DOI 10.1136/bmj.298.6675.716; BEAL SM, 1986, AUST PAEDIATR J, V22, P13; BLACK L, 1986, J PEDIATR-US, V108, P209, DOI 10.1016/S0022-3476(86)80984-2; BORMAN B, 1988, NEW ZEAL MED J, V101, P413; BRESLOW NE, 1980, STAT METHODS CANC RE, V1, P74; KRAUS JF, 1989, INT J EPIDEMIOL, V18, P113, DOI 10.1093/ije/18.1.113; KYLE D, 1990, ARCH DIS CHILD, V65, P830, DOI 10.1136/adc.65.8.830; LEE NNY, 1989, BRIT MED J, V298, P721, DOI 10.1136/bmj.298.6675.721; MITCHELL EA, 1991, NEW ZEAL MED J, V104, P71; MITCHELL EA, 1992, J PAEDIATR CHILD H, V28, pS3, DOI 10.1111/j.1440-1754.1992.tb02729.x; Mitchison TJ, 1989, CURR OPIN CELL BIOL, V1, P67, DOI 10.1016/S0955-0674(89)80039-0; TANGERMANN R, 1987, MONATSSCHR KINDERH, V135, P679; 1988, FETAL INFANT DEATHS	13	72	73	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 2	1993	306	6869					13	16		10.1136/bmj.306.6869.13	http://dx.doi.org/10.1136/bmj.306.6869.13			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KE984	8435568	Bronze, Green Published			2022-12-24	WOS:A1993KE98400018
J	SUCHYNA, TM; XU, LX; GAO, F; FOURTNER, CR; NICHOLSON, BJ				SUCHYNA, TM; XU, LX; GAO, F; FOURTNER, CR; NICHOLSON, BJ			IDENTIFICATION OF A PROLINE RESIDUE AS A TRANSDUCTION ELEMENT INVOLVED IN VOLTAGE GATING OF GAP-JUNCTIONS	NATURE			English	Article								GAP junction channels are structurally distinct from other ion channels in that they comprise two hemichannels which interact head-to-head to form an aqueous channel between cells. Intercellular voltage differences together with increased intracellular concentrations of H+ and Ca2+ cause closure of these normally patent channels1. The relative sensitivity to voltage varies with the subunit (connexin) composition of the channels2. The third of four transmembrane-spanning regions (M3) in connexins has been proposed to form the channel lining3, and a global 'tilting' of the hemichannel subunits has been correlated with channel closure4. But specific components involved in transduction of channel gating events have not been identified in either gap junctions or other ion channel classes (however, see model in ref. 5). We have examined a strictly conserved proline centrally located in M2 of connexin proteins. Mutation of this proline (Pro 87) in connexin 26 causes a reversal in the voltage-gating response when the mutant hemichannel is paired with wild-type connexin 26 in the Xenopus oocyte system. This suggests that the unique properties associated with this residue are critical to the transduction of voltage gating in these channels.	SUNY BUFFALO,DEPT BIOL SCI,BUFFALO,NY 14260	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo				Nicholson, Bruce/0000-0003-1649-7173				BARLOW DJ, 1988, J MOL BIOL, V201, P601, DOI 10.1016/0022-2836(88)90641-9; BARRIO LC, 1991, P NATL ACAD SCI USA, V88, P8410, DOI 10.1073/pnas.88.19.8410; BENNETT MVL, 1988, GAP JUNCTIONS, P287; BRANDL CJ, 1986, P NATL ACAD SCI USA, V83, P917, DOI 10.1073/pnas.83.4.917; CONNOLLY JG, 1989, COMP BIOCHEM PHYS A, V93, P221, DOI 10.1016/0300-9629(89)90210-7; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; FIMMEL AL, 1983, BIOCHEM J, V213, P451, DOI 10.1042/bj2130451; GRENNINGLOH G, 1987, NATURE, V328, P215, DOI 10.1038/328215a0; GUY RH, 1990, TRENDS NEUROSCI, V13, P201; HAEFLIGER JA, 1992, J BIOL CHEM, V267, P2057; HENDERSON R, 1990, J MOL BIOL, V213, P899, DOI 10.1016/S0022-2836(05)80271-2; HENNEMANN H, 1992, J CELL BIOL, V117, P1299, DOI 10.1083/jcb.117.6.1299; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LOLKEMA JS, 1988, BIOCHEMISTRY-US, V27, P8307, DOI 10.1021/bi00422a003; MILKS LC, 1988, EMBO J, V7, P2967, DOI 10.1002/j.1460-2075.1988.tb03159.x; MOGI T, 1989, J BIOL CHEM, V264, P14192; REED KE, 1993, J CLIN INVEST, V91, P997, DOI 10.1172/JCI116321; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; Schulz G. E., 1979, PRINCIPLES PROTEIN S; SPRAY DC, 1985, ANNU REV PHYSIOL, V47, P281, DOI 10.1146/annurev.ph.47.030185.001433; UNWIN PNT, 1984, NATURE, V307, P609, DOI 10.1038/307609a0; VEENSTRA RD, 1990, AM J PHYSIOL, V258, pC662, DOI 10.1152/ajpcell.1990.258.4.C662; VERSELIS VK, 1992, 22ND NEUR ANN M AN; WERNER R, 1989, P NATL ACAD SCI USA, V86, P5380, DOI 10.1073/pnas.86.14.5380; WILLECKE K, 1991, J CELL BIOL, V114, P1049, DOI 10.1083/jcb.114.5.1049; YUN RH, 1991, PROTEINS, V10, P219, DOI 10.1002/prot.340100306	26	136	139	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 28	1993	365	6449					847	849		10.1038/365847a0	http://dx.doi.org/10.1038/365847a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MD951	8413670				2022-12-24	WOS:A1993MD95100053
J	DILL, M; WOLF, R; HEISENBERG, M				DILL, M; WOLF, R; HEISENBERG, M			VISUAL-PATTERN RECOGNITION IN DROSOPHILA INVOLVES RETINOTOPIC MATCHING	NATURE			English	Article							BEES; DISCRIMINATION; ORIENTATION	HONEYBEES remember the shapes of flowers and are guided by visual landmarks on their foraging trips1,2. How insects recognize visual patterns is poorly understood. Experiments suggest that they try to match retinotopically the incoming visual pattern with a previously stored memory image2-7. But bees can be conditioned to individual pattern parameters such as orientation of contours, colour or size2,8-11. These and other results are difficult to reconcile with simple template matching. In such investigations, freely moving animals are observed; their behaviour and visual input, therefore, are not well known. Mostly, processing strategies are inferred from stimulus design. We have studied visual pattern recognition with tethered flies (Drosophila melanogaster) in a flight simulator and report here that flies store visual images at, or together with, fixed retinal positions and can retrieve them from there only5. Position invariance, an acknowledged property of human pattern recognition, may no exist as a primary mechanism in insects.	THEODOR BOVERI INST BIOWISSENSCH, BIOZENTRUM, LEHRSTUHL GENET, HUBLAND, D-97074 WURZBURG, GERMANY									BUCHNER E, 1976, BIOL CYBERN, V24, P85, DOI 10.1007/BF00360648; CARTWRIGHT BA, 1983, J COMP PHYSIOL, V151, P521, DOI 10.1007/BF00605469; CARTWRIGHT BA, 1982, NATURE, V295, P560, DOI 10.1038/295560a0; COLLETT TS, 1992, PHILOS T R SOC B, V337, P295, DOI 10.1098/rstb.1992.0107; CRONLYDILLON JR, 1966, EXP NEUROL, V15, P455, DOI 10.1016/0014-4886(66)90142-7; GOTZ KG, 1965, KYBERNETIK, V2, P215, DOI 10.1007/BF00306417; GOULD JL, 1985, SCIENCE, V227, P1492, DOI 10.1126/science.227.4693.1492; HEISENBERG M, 1988, J COMP PHYSIOL A, V163, P373, DOI 10.1007/BF00604013; HEISENBERG M, 1993, VISUAL MOTION ITS RO, P265; HORRIDGE GA, 1992, PHILOS T R SOC B, V337, P49, DOI 10.1098/rstb.1992.0082; KARNI A, 1991, P NATL ACAD SCI USA, V88, P4966, DOI 10.1073/pnas.88.11.4966; MYERS RE, 1955, J COMP PHYSIOL PSYCH, V48, P470, DOI 10.1037/h0044224; OCARROLL D, 1993, NATURE, V362, P541, DOI 10.1038/362541a0; RAMACHANDRAN VS, 1976, NATURE, V262, P382, DOI 10.1038/262382a0; RONACHER B, 1979, BIOL CYBERN, V32, P63, DOI 10.1007/BF00337437; SRINIVASAN MV, 1993, NATURE, V362, P539, DOI 10.1038/362539a0; TINBERGEN N, 1932, Z VERGL PHYSIOL, V15, P305; VANHATEREN JH, 1990, J COMP PHYSIOL A, V167, P649, DOI 10.1007/BF00192658; WEHNER R, 1972, J COMP PHYSIOL PSYCH, V77, P256, DOI 10.1007/BF00696429; WEHNER R, 1981, HDB SENSORY PHYSL, V7; WOLF R, 1991, J COMP PHYSIOL A, V169, P699; ZHANG SW, 1992, P ROY SOC B-BIOL SCI, V248, P55, DOI 10.1098/rspb.1992.0042	22	104	105	0	18	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	OCT 21	1993	365	6448					751	753		10.1038/365751a0	http://dx.doi.org/10.1038/365751a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MC812	8413652				2022-12-24	WOS:A1993MC81200062
J	KIM, YC; GEIGER, JH; HAHN, S; SIGLER, PB				KIM, YC; GEIGER, JH; HAHN, S; SIGLER, PB			CRYSTAL-STRUCTURE OF A YEAST TBP TATA-BOX COMPLEX	NATURE			English	Article							TRANSCRIPTION FACTOR; BINDING-PROTEIN; DNA; DOMAIN; INVIVO; SPECIFICITY; INITIATION; RESOLUTION; REFINEMENT; HYDRATION	The 2.5 angstrom crystal structure of a TATA-box complex with yeast TBP shows that the eight base pairs of the TATA box bind to the concave surface of TBP by bending towards the major groove with unprecedented severity. This produces a wide open, underwound, shallow minor groove which forms a primarily hydrophobic interface with the entire under-surface of the TBP saddle. The severe bend and a positive writhe radically alter the trajectory of the flanking B-form DNA.	YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06510; YALE UNIV,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510; FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104	Yale University; Howard Hughes Medical Institute; Yale University; Fred Hutchinson Cancer Center				Kim, Youngchang/0000-0002-1610-4889; Geiger, James/0000-0002-9443-4488				ARNDT KM, 1992, MOL CELL BIOL, V12, P2372, DOI 10.1128/MCB.12.5.2372; AUBLE DT, 1993, GENE DEV, V7, P844, DOI 10.1101/gad.7.5.844; BRICOGNE G, 1976, ACTA CRYSTALLOGR A, V32, P832, DOI 10.1107/S0567739476001691; BRUNGER AT, 1993, XPLOR VERSION 31 MAN; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CHASMAN DI, 1993, P NATL ACAD SCI USA, V90, P8174, DOI 10.1073/pnas.90.17.8174; CONNER BN, 1982, NATURE, V295, P294, DOI 10.1038/295294a0; CORMACK BP, 1991, CELL, V65, P341, DOI 10.1016/0092-8674(91)90167-W; DREW HR, 1981, J MOL BIOL, V151, P535, DOI 10.1016/0022-2836(81)90009-7; EISENMANN DM, 1989, CELL, V58, P1183, DOI 10.1016/0092-8674(89)90516-3; EISENSTEIN M, 1990, NUCLEIC ACIDS RES, V18, P3185, DOI 10.1093/nar/18.11.3185; FINZEL BC, 1987, J APPL CRYSTALLOGR, V20, P53, DOI 10.1107/S0021889887087144; GILL G, 1991, CELL, V65, P333, DOI 10.1016/0092-8674(91)90166-V; HAHN S, 1989, P NATL ACAD SCI USA, V86, P5718, DOI 10.1073/pnas.86.15.5718; HAHN S, 1989, EMBO J, V8, P3379, DOI 10.1002/j.1460-2075.1989.tb08501.x; HAHN S, 1989, CELL, V58, P1173, DOI 10.1016/0092-8674(89)90515-1; HAWLEY DK, 1991, CELL, V67, P1231; HEGDE RS, 1992, NATURE, V359, P505, DOI 10.1038/359505a0; Hendrickson W. A., 1981, BIOMOLECULAR STRUCTU, V1, P43; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; HORIKOSHI M, 1992, P NATL ACAD SCI USA, V89, P1060, DOI 10.1073/pnas.89.3.1060; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P67, DOI 10.1107/S0021889887009737; LAVERY R, 1989, J BIOMOL STRUCT DYN, V6, P655, DOI 10.1080/07391102.1989.10507728; LEE DK, 1992, MOL CELL BIOL, V12, P5189, DOI 10.1128/MCB.12.11.5189; LEE DK, 1991, CELL, V67, P1241, DOI 10.1016/0092-8674(91)90300-N; LORCH Y, 1993, MOL CELL BIOL, V13, P1872, DOI 10.1128/MCB.13.3.1872; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; Patel D J, 1983, Cold Spring Harb Symp Quant Biol, V47 Pt 1, P197; POON D, 1993, J BIOL CHEM, V268, P5005; RANISH JA, 1992, SCIENCE, V255, P1127, DOI 10.1126/science.1546313; REDDY P, 1991, CELL, V65, P349, DOI 10.1016/0092-8674(91)90168-X; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SHAKKED Z, 1983, J MOL BIOL, V166, P183, DOI 10.1016/S0022-2836(83)80005-9; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; STRUBIN M, 1992, CELL, V68, P721, DOI 10.1016/0092-8674(92)90147-5; Travers A. A., 1990, DNA TOPOLOGY ITS BIO, P57; Travers AA, 1991, CURR OPIN STRUC BIOL, V1, P114, DOI 10.1016/0959-440X(91)90019-P; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WESTHOF E, 1985, J MOL BIOL, V184, P119, DOI 10.1016/0022-2836(85)90048-8; WOBBE CR, 1990, MOL CELL BIOL, V10, P3859, DOI 10.1128/MCB.10.8.3859; YAMAMOTO T, 1992, P NATL ACAD SCI USA, V89, P2844, DOI 10.1073/pnas.89.7.2844; ZHANG KYJ, 1993, ACTA CRYSTALLOGR D, V49, P213, DOI 10.1107/S0907444992007911	47	957	969	0	35	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 7	1993	365	6446					512	520		10.1038/365512a0	http://dx.doi.org/10.1038/365512a0			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MA661	8413604				2022-12-24	WOS:A1993MA66100044
J	MORROW, K; MORRIS, CK; FROELICHER, VF; HIDEG, A; HUNTER, D; JOHNSON, E; KAWAGUCHI, T; LEHMANN, K; RIBISL, PM; THOMAS, R; UESHIMA, K; FROELICHER, E; WALLIS, J				MORROW, K; MORRIS, CK; FROELICHER, VF; HIDEG, A; HUNTER, D; JOHNSON, E; KAWAGUCHI, T; LEHMANN, K; RIBISL, PM; THOMAS, R; UESHIMA, K; FROELICHER, E; WALLIS, J			PREDICTION OF CARDIOVASCULAR DEATH IN MEN UNDERGOING NONINVASIVE EVALUATION FOR CORONARY-ARTERY DISEASE	ANNALS OF INTERNAL MEDICINE			English	Article						CORONARY DISEASE; EXERCISE TEST; OUTCOME ASSESSMENT (HEALTH CARE); DEATH, SUDDEN, CARDIAC; HEART FAILURE, CONGESTIVE	MEDICALLY TREATED PATIENTS; PROGNOSTIC VALUE; EXERCISE TEST; STANDARDS; SURVIVAL; SCORE	Objective: To develop prediction rules from clinical and exercise test data identifying patients at high and low risk for cardiovascular events among a group of male veterans. Design: Prognostic study with prospective gathering of data and routine follow-up of consecutive patients referred for exercise testing. Patients only underwent noninvasive evaluation for coronary artery disease. No validation cohort is yet available. Setting: A 1200-bed Veterans Affairs Medical Center. Patients: Of 3609 men referred for exercise testing between 1984 and 1990, 2546 patients remained evaluable after exclusion of those who underwent subsequent cardiac catheterization, those with significant valvular heart disease, and those who had previous coronary artery bypass surgery. Measurements: Evaluation included recording of clinical data on a standardized form and a standard treadmill test followed by assessment of cardiovascular events. Results: During a mean follow-up period (+/- SD) of 2.75 (+/- 1.8) years, 119 cardiovascular deaths and 44 nonfatal myocardial infarctions occurred in 2546 patients. The Cox proportional hazards model showed the following characteristics to be statistically independent predictors of time until cardiovascular death: history of congestive heart failure or digoxin use, exercise-induced ST depression, change in systolic blood pressure during exercise, and exercise capacity. Using a simple score based on one item of clinical information (history of congestive heart failure or digoxin use) and three exercise test responses (ST depression, exercise capacity, and change in systolic blood pressure), 77% of patients were categorized as low risk (annual cardiac mortality rate, less than 2%), 18% as moderate risk (annual cardiac mortality rate, 7%), and 6% as high risk (annual cardiac mortality rate, 15%; hazard ratio, 10; 95% confidence interval, 6 to 17). This model has not yet been validated. Conclusions: Variables available from the usual noninvasive work-up of patients with known or suspected coronary artery disease can be used to predict future risk for cardiovascular death.	PALO ALTO VET AFFAIRS MED CTR, DEPT CARDIOL 111C, 3801 MIRANDA AVE, PALO ALTO, CA 94304 USA; LONG BEACH VET AFFAIRS MED CTR, LONG BEACH, CA USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Long Beach Healthcare System				Froelicher, Victor/0000-0001-8831-4853				BRUNELLI C, 1989, EUR HEART J, V10, P292, DOI 10.1093/oxfordjournals.eurheartj.a059486; DANS PE, 1988, ARCH INTERN MED, V148, P2633, DOI 10.1001/archinte.148.12.2633; DODGE HT, 1960, AM HEART J, V60, P762, DOI 10.1016/0002-8703(60)90359-8; DUBACH P, 1988, CIRCULATION, V78, P1380, DOI 10.1161/01.CIR.78.6.1380; FLETCHER GF, 1990, CIRCULATION, V82, P2286, DOI 10.1161/01.CIR.82.6.2286; GOHLKE H, 1983, CIRCULATION, V68, P979, DOI 10.1161/01.CIR.68.5.979; GRABOYS TB, 1992, JAMA-J AM MED ASSOC, V268, P2537, DOI 10.1001/jama.268.18.2537; HAMMERMEISTER KE, 1979, CIRCULATION, V59, P421, DOI 10.1161/01.CIR.59.3.421; LACHTERMAN B, 1990, ANN INTERN MED, V112, P11, DOI 10.7326/0003-4819-112-1-11; LERMAN J, 1986, MEDICINA-BUENOS AIRE, V46, P201; MARK DB, 1987, ANN INTERN MED, V106, P793, DOI 10.7326/0003-4819-106-6-793; MARK DB, 1991, NEW ENGL J MED, V325, P849, DOI 10.1056/NEJM199109193251204; MORRIS CK, 1993, IN PRESS AM HEART J; MORRIS CK, 1993, IN PRESS J AM COLL C; OBERMAN A, 1972, B NEW YORK ACAD MED, V48, P1109; PEDUZZI P, 1986, PROG CARDIOVASC DIS, V28, P285, DOI 10.1016/0033-0620(86)90006-X; PHILBRICK JT, 1982, JAMA-J AM MED ASSOC, V248, P2467, DOI 10.1001/jama.248.19.2467; REEVES TJ, 1974, AM J CARDIOL, V33, P423, DOI 10.1016/0002-9149(74)90327-0; ROMHILT DW, 1968, AM HEART J, V75, P752, DOI 10.1016/0002-8703(68)90035-5; SCHLANT RC, 1986, J AM COLL CARDIOL, V8, P725; WASSON JH, 1985, NEW ENGL J MED, V313, P793, DOI 10.1056/NEJM198509263131306; WEINER DA, 1984, J AM COLL CARDIOL, V3, P772, DOI 10.1016/S0735-1097(84)80254-5; WOLTHUIS RA, 1977, AM J CARDIOL, V39, P697, DOI 10.1016/S0002-9149(77)80131-8; WYNS W, 1985, EUR HEART J, V6, P939, DOI 10.1093/oxfordjournals.eurheartj.a061791	24	128	138	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1993	118	9					689	695		10.7326/0003-4819-118-9-199305010-00005	http://dx.doi.org/10.7326/0003-4819-118-9-199305010-00005			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY502	8460854				2022-12-24	WOS:A1993KY50200005
J	REDMAN, JB; FENWICK, RG; FU, YH; PIZZUTI, A; CASKEY, CT				REDMAN, JB; FENWICK, RG; FU, YH; PIZZUTI, A; CASKEY, CT			RELATIONSHIP BETWEEN PARENTAL TRINUCLEOTIDE GCT REPEAT LENGTH AND SEVERITY OF MYOTONIC-DYSTROPHY IN OFFSPRING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To assess the relationship between the GCT repeat number in the myotonic dystrophy gene and the clinical phenotype and examine its predictive utility in prenatal testing. Design.-DNA from patients was examined for the length of the myotonic dystrophy GCT repeat region, using both Southern blot analysis and polymerase chain reaction. The results were compared with the clinical onset of disease, as well as with pregnancy outcomes. Setting.-Patient samples were referred to the Kleberg DNA Diagnostic Laboratory at the Baylor College of Medicine for DNA analysis by geneticists and genetic counselors (84%), neurologists (10%), and obstetricians and other specialists (6%). Clinical features including onset of disease and family pedigrees were determined by the referring centers. Patients.-A total of 241 patient samples from 118 families referred from primarily genetic or neurological centers for genetic linkage analysis or mutation analysis for myotonic dystrophy. This included 44 families referred for prenatal diagnosis. Main Outcome Measures.-A relationship between myotonic dystrophy disease onset and length of the GCT repeat allele, parental origin of the disease allele, and results of prenatal diagnosis predictions of disease status were measured. Results.-There is a relationship between increasing repeat length and earlier clinical onset of disease. Essentially all (>99%) myotonic mutations causing myotonic dystrophy are accounted for by GCT repeat amplification. Congenital myotonic dystrophy occurs with as few as 730 GCT repeats but only with alleles of maternal origin. Maternal GCT repeats were found as low as 75 (asymptomatic) that were amplified to result in a child with congenital myotonic dystrophy. Application of DNA diagnosis to 32 pregnancies provided an accurate method for identification of at-risk fetuses and allele enlargement. Conclusions.-The GCT repeat in myotonic dystrophy is highly mutable. The triplet repeat amplification is highly specific for mutations involving the myotonin protein kinase gene accounting for myotonic dystrophy. The quantitation of triplet repeats can be more sensitive than physical, ophthalmologic, and electromyography examinations since the mutation can be detected in patients without evidence of myotonic dystrophy clinical findings. The length of the triplet expansion is influenced by the sex of the transmitting parent and is related to the clinical onset of disease features. Prenatal measurement of the GCT triplet repeat has utility for families with myotonic dystrophy risk since mutant and normal repeats are distinguishable and the length of mutant repeat alleles is associated with clinical severity. Thus, GCT triplet measurement provides a highly accurate means of detecting the myotonic dystrophy mutation in patients and offers a new reproductive option for families at risk for myotonic dystrophy.	BAYLOR COLL MED,INST MOLEC GENET,1 BAYLOR PLAZA,HOUSTON,TX 77030; BAYLOR COLL MED,HOWARD HUGHES MED INST,HOUSTON,TX 77030; COLLABORAT RES LABS,WALTHAM,MA	Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute				PIZZUTI, Antonio/0000-0003-3245-1925	NHGRI NIH HHS [5P30-HG00210] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P30HG000210] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		ASHIZAWA T, 1992, NEUROLOGY, V42, P1877; ASHIZAWA T, 1989, CURRENT NEUROLOGY, V11, P27; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; BRUNNER HG, 1992, J MED GENET, V29, P780, DOI 10.1136/jmg.29.11.780; DAVIES J, 1992, J MED GENET, V29, P766, DOI 10.1136/jmg.29.11.766; EIBERG H, 1983, CLIN GENET, V24, P159; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; HARLEY HG, 1992, LANCET, V339, P1125, DOI 10.1016/0140-6736(92)90729-M; Harper P.S., 1989, MYOTONIC DYSTROPHY; HARPER PS, 1975, ARCH DIS CHILD, V50, P514, DOI 10.1136/adc.50.7.514; HARPER PS, 1990, PRINCIPLES PRACTICE, P579; HOWELER CJ, 1989, BRAIN, V112, P779, DOI 10.1093/brain/112.3.779; HUNTER A, 1992, J MED GENET, V29, P774, DOI 10.1136/jmg.29.11.774; KOCH MC, 1991, AM J HUM GENET, V48, P1084; MAHADEVAN M, 1992, SCIENCE, V255, P1253, DOI 10.1126/science.1546325; OBRIEN T, 1983, ANN HUM GENET, V47, P117, DOI 10.1111/j.1469-1809.1983.tb00978.x; PENROSE LS, 1948, ANN EUGENIC, V14, P125; TSILFIDIS C, 1992, NAT GENET, V1, P192, DOI 10.1038/ng0692-192; WHITEHEAD AS, 1982, P NATL ACAD SCI-BIOL, V79, P5021, DOI 10.1073/pnas.79.16.5021	19	168	170	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 21	1993	269	15					1960	1965		10.1001/jama.269.15.1960	http://dx.doi.org/10.1001/jama.269.15.1960			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KX215	8464127				2022-12-24	WOS:A1993KX21500025
J	NOGUCHI, M; YI, HF; ROSENBLATT, HM; FILIPOVICH, AH; ADELSTEIN, S; MODI, WS; MCBRIDE, OW; LEONARD, WJ				NOGUCHI, M; YI, HF; ROSENBLATT, HM; FILIPOVICH, AH; ADELSTEIN, S; MODI, WS; MCBRIDE, OW; LEONARD, WJ			INTERLEUKIN-2 RECEPTOR GAMMA CHAIN MUTATION RESULTS IN X-LINKED SEVERE COMBINED IMMUNODEFICIENCY IN HUMANS	CELL			English	Article							B-CELLS; MOLECULAR-CLONING; ALPHA-CHAIN; CHROMOSOME INACTIVATION; IMMATURE THYMOCYTES; IL-2 RECEPTOR; HUMAN GENOME; LINKAGE MAP; BONE-MARROW; T-CELLS	The interleukin-2 (IL-2) receptor gamma chain (IL-2Rgamma) is a component of high and intermediate affinity IL-2 receptors that is required to achieve full ligand binding affinity and internalization. We have localized the IL-2Rgamma gene to human chromosome Xq13. Genetic linkage analysis indicates that the IL-2Rgamma gene and the locus for X-linked severe combined immunodeficiency (XSCID) appear to be at the same position. Moreover, we demonstrate that each of three unrelated patients with XSCID has a different mutation in his IL-2Rgamma gene resulting in a different premature stop codon and predicted C-terminal truncation. These data establish that XSCID is associated with mutations of the IL-2Rgamma gene product. Since XSCID is characterized by absent or markedly reduced numbers of T cells, our findings imply that IL-2Rgamma plays a vital role in thymic maturation of T cells. These results also have important implications for prenatal and postnatal diagnosis, carrier female detection, and gene therapy for XSCID.	NCI,DIV CANC BIOL & DIAG,BIOCHEM LAB,BETHESDA,MD 20892; BAYLOR COLL MED,DEPT PEDIAT,DIV ALLERGY & IMMUNOL,HOUSTON,TX 77030; UNIV MINNESOTA HOSP & CLIN,DEPT PEDIAT,DIV IMMUNOL,MINNEAPOLIS,MN 55455; NCI,FREDERICK CANC RES & DEV CTR,PROGRAM RESOURCES INC DYNCORP,FREDERICK,MD 21701	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Baylor College of Medicine; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	NOGUCHI, M (corresponding author), NHLBI,INTRAMURAL RES PROGRAM,OFF DIRECTOR,PULM & MOLEC IMMUNOL SECT,BETHESDA,MD 20892, USA.			Adelstein, Stephen/0000-0001-7221-6298	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000188] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR00188] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ARIMA N, 1992, J EXP MED, V176, P1265, DOI 10.1084/jem.176.5.1265; CEREDIG R, 1985, NATURE, V314, P98, DOI 10.1038/314098a0; CHATILA T, 1990, P NATL ACAD SCI USA, V87, P10033, DOI 10.1073/pnas.87.24.10033; CONLEY ME, 1988, P NATL ACAD SCI USA, V85, P3090, DOI 10.1073/pnas.85.9.3090; CONLEY ME, 1992, ANNU REV IMMUNOL, V10, P215; CONLEY ME, 1990, J CLIN INVEST, V85, P1548, DOI 10.1172/JCI114603; COOPER MD, 1989, FUNDAMENTAL IMMUNOLO, P1034; CREMERS FPM, 1988, AM J HUM GENET, V43, P452; DAUSSET J, 1990, GENOMICS, V6, P575, DOI 10.1016/0888-7543(90)90491-C; DESAINTBASILE G, 1987, P NATL ACAD SCI USA, V84, P7576; DONISKELLER H, 1987, CELL, V51, P319, DOI 10.1016/0092-8674(87)90158-9; DUKOVICH M, 1987, NATURE, V327, P518, DOI 10.1038/327518a0; FANEN P, 1992, GENOMICS, V13, P770, DOI 10.1016/0888-7543(92)90152-I; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; Gelfand E W, 1983, Birth Defects Orig Artic Ser, V19, P65; GNARRA JR, 1990, P NATL ACAD SCI USA, V87, P3440, DOI 10.1073/pnas.87.9.3440; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; ISHIDA N, 1985, NUCLEIC ACIDS RES, V13, P7579, DOI 10.1093/nar/13.21.7579; JENKINSON EJ, 1987, NATURE, V329, P160, DOI 10.1038/329160a0; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; LAFRENIERE RG, 1991, GENOMICS, V11, P352, DOI 10.1016/0888-7543(91)90143-3; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; LEONARD WJ, 1985, SCIENCE, V228, P1547, DOI 10.1126/science.3925551; LEONARD WJ, 1985, SCIENCE, V230, P633, DOI 10.1126/science.2996141; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; LEONARD WJ, 1992, INTERLEUKIN, V2, P29; LOUGHNAN MS, 1989, NATURE, V340, P76, DOI 10.1038/340076a0; MAHTANI MM, 1991, GENOMICS, V10, P849, DOI 10.1016/0888-7543(91)90172-B; MCBRIDE OW, 1982, J EXP MED, V155, P1480, DOI 10.1084/jem.155.5.1480; MCBRIDE OW, 1982, NUCLEIC ACIDS RES, V10, P8155, DOI 10.1093/nar/10.24.8155; MICHELSON AM, 1985, J BIOL CHEM, V260, P6982; MINGARI MC, 1984, NATURE, V312, P641, DOI 10.1038/312641a0; Nezelof C, 1986, Curr Top Pathol, V75, P151; NIKAIDO T, 1984, NATURE, V311, P631, DOI 10.1038/311631a0; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PAHWA R, 1989, P NATL ACAD SCI USA, V86, P5069, DOI 10.1073/pnas.86.13.5069; PETRIE HT, 1990, EUR J IMMUNOL, V20, P2813, DOI 10.1002/eji.1830201243; PUCK JM, 1991, CYTOGENET CELL GENET, V58, P2082; PUCK JM, 1987, J CLIN INVEST, V79, P1395, DOI 10.1172/JCI112967; PUCK JM, 1989, AM J HUM GENET, V44, P724; RAULET DH, 1985, NATURE, V314, P101, DOI 10.1038/314101a0; ROSENBLATT HM, 1987, PEDIATR RES, V21, P331, DOI 10.1203/00006450-198704000-00003; SCHORLE H, 1991, NATURE, V352, P621, DOI 10.1038/352621a0; SHARON M, 1988, J EXP MED, V167, P1265, DOI 10.1084/jem.167.3.1265; SHARON M, 1986, SCIENCE, V234, P859, DOI 10.1126/science.3095922; SHEARER WT, 1985, NEW ENGL J MED, V312, P1151, DOI 10.1056/NEJM198505023121804; SHIBUYA H, 1990, NUCLEIC ACIDS RES, V18, P3697, DOI 10.1093/nar/18.13.3697; SIEGEL JP, 1987, SCIENCE, V238, P75, DOI 10.1126/science.3116668; SMITH KA, 1989, ANNU REV CELL BIOL, V5, P397; SOUTH MA, 1977, PEDIATR RES, V11, P71, DOI 10.1203/00006450-197701000-00005; TAGA T, 1992, P NATL ACAD SCI USA, V89, P10998, DOI 10.1073/pnas.89.22.10998; TAKESHITA T, 1992, J IMMUNOL, V148, P2154; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TAKESHITA T, 1990, INT IMMUNOL, V2, P477, DOI 10.1093/intimm/2.5.477; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; TENTORI L, 1988, J EXP MED, V168, P1741, DOI 10.1084/jem.168.5.1741; TESHIGAWARA K, 1987, J EXP MED, V165, P223, DOI 10.1084/jem.165.1.223; TORY K, 1992, GENOMICS, V13, P275, DOI 10.1016/0888-7543(92)90243-L; Tosato G., 1991, CURRENT PROTOCOLS IM; TSUDO M, 1986, P NATL ACAD SCI USA, V83, P9694, DOI 10.1073/pnas.83.24.9694; VONBOEHMER H, 1985, NATURE, V314, P539, DOI 10.1038/314539a0; VOSS SD, 1992, J EXP MED, V176, P531, DOI 10.1084/jem.176.2.531; WALDMANN TA, 1989, ANNU REV BIOCHEM, V58, P875, DOI 10.1146/annurev.bi.58.070189.004303; WALDMANN TA, 1984, J EXP MED, V160, P1450, DOI 10.1084/jem.160.5.1450; WEINBERG K, 1990, NEW ENGL J MED, V322, P1718, DOI 10.1056/NEJM199006143222406	65	1111	1170	0	37	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 9	1993	73	1					147	157		10.1016/0092-8674(93)90167-O	http://dx.doi.org/10.1016/0092-8674(93)90167-O			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KW753	8462096				2022-12-24	WOS:A1993KW75300015
J	JANDA, M; AHLQUIST, P				JANDA, M; AHLQUIST, P			RNA-DEPENDENT REPLICATION, TRANSCRIPTION, AND PERSISTENCE OF BROME MOSAIC-VIRUS RNA REPLICONS IN SACCHAROMYCES-CEREVISIAE	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; NONSTRUCTURAL PROTEINS; ESCHERICHIA-COLI; SUBGENOMIC RNA; SINDBIS VIRUS; MESSENGER-RNA; YEAST; GENE; DNA; SEQUENCES	This paper shows that yeast can be a host for the replication of a higher eukaryotic viral genome. Brome mosaic virus (BMV) is a member of the alphavirus-like superfamily of animal and plant positive strand RNA viruses. Yeast expressing BMV RNA replication genes 1a and 2a support RNA-dependent replication and transcription of BMV RNA3 derivatives. RNA3 derivatives with the coat gene replaced by a reporter gene expressed that gene in a fashion dependent on la and 2a expression in trans and on BMV RNA replication and transcription signals in cis. RNA3 derivatives carrying the yeast URA3 gene complemented ura3- yeast to prototrophy and were maintained as persistent RNA episomes. Thus, all cellular factors essential for BMV RNA replication and transcription must be present in yeast, and yeast genetics should facilitate their identification.	UNIV WISCONSIN, DEPT PLANT PATHOL, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	JANDA, M (corresponding author), UNIV WISCONSIN, INST MOLEC VIROL, MADISON, WI 53706 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035072, R37GM035072] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35072] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHLQUIST P, 1984, P NATL ACAD SCI-BIOL, V81, P7066, DOI 10.1073/pnas.81.22.7066; AHLQUIST P, 1985, J VIROL, V53, P536, DOI 10.1128/JVI.53.2.536-542.1985; AHLQUIST P, 1984, PLANT MOL BIOL, V3, P37, DOI 10.1007/BF00023414; Ahlquist P, 1992, CURR OPIN GENET DEV, V2, P71, DOI 10.1016/S0959-437X(05)80325-9; ALLISON R, 1990, P NATL ACAD SCI USA, V87, P1820, DOI 10.1073/pnas.87.5.1820; AMMERER G, 1983, METHOD ENZYMOL, V101, P192; Ausubel F, 1989, MOL REPROD DEV, V1, P146; BARIC RS, 1983, J VIROL, V45, P200, DOI 10.1128/JVI.45.1.200-205.1983; BOTSTEIN D, 1979, GENE, V8, P17, DOI 10.1016/0378-1119(79)90004-0; BOTSTEIN D, 1988, SCIENCE, V240, P1439, DOI 10.1126/science.3287619; DEJONG W, 1992, P NATL ACAD SCI USA, V89, P6808, DOI 10.1073/pnas.89.15.6808; DERR LK, 1991, J MOL BIOL, V67, P355; FARABAUGH PJ, 1980, NATURE, V286, P352, DOI 10.1038/286352a0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FRENCH R, 1986, SCIENCE, V231, P1294, DOI 10.1126/science.231.4743.1294; FRENCH R, 1988, J VIROL, V62, P2411, DOI 10.1128/JVI.62.7.2411-2420.1988; FRENCH R, 1987, J VIROL, V61, P1457, DOI 10.1128/JVI.61.5.1457-1465.1987; Goldbach R., 1991, Seminars in Virology, V2, P19; HARTWELL LH, 1969, P NATL ACAD SCI USA, V62, P468, DOI 10.1073/pnas.62.2.468; HASELOFF J, 1984, P NATL ACAD SCI-BIOL, V81, P4358, DOI 10.1073/pnas.81.14.4358; HAYES RJ, 1990, CELL, V63, P363, DOI 10.1016/0092-8674(90)90169-F; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; ISHIKAWA M, 1991, MOL GEN GENET, V230, P33, DOI 10.1007/BF00290647; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JANDA M, 1987, VIROLOGY, V158, P259, DOI 10.1016/0042-6822(87)90265-0; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; JONES MD, 1989, NUCLEIC ACIDS RES, V17, P8387, DOI 10.1093/nar/17.20.8387; KAJITANI M, 1991, NUCLEIC ACIDS RES, V19, P1063, DOI 10.1093/nar/19.5.1063; KAO CC, 1992, J VIROL, V66, P7293, DOI 10.1128/JVI.66.12.7293-7302.1992; KAO CC, 1992, J VIROL, V66, P6322, DOI 10.1128/JVI.66.11.6322-6329.1992; KRONER P, 1989, J VIROL, V63, P5302, DOI 10.1128/JVI.63.12.5302-5309.1989; KRONER PA, 1990, J VIROL, V64, P6110, DOI 10.1128/JVI.64.12.6110-6120.1990; LEEDS P, 1991, GENE DEV, V5, P2303, DOI 10.1101/gad.5.12a.2303; LUYTJES W, 1989, CELL, V59, P1107, DOI 10.1016/0092-8674(89)90766-6; MARSH LE, 1988, NUCLEIC ACIDS RES, V16, P981, DOI 10.1093/nar/16.3.981; MAYER SA, 1991, MOL CELL BIOL, V11, P813, DOI 10.1128/MCB.11.2.813; MEYERHANS A, 1990, NUCLEIC ACIDS RES, V18, P1687, DOI 10.1093/nar/18.7.1687; MILLER WA, 1985, NATURE, V313, P68, DOI 10.1038/313068a0; MOLLA A, 1991, SCIENCE, V254, P1647, DOI 10.1126/science.1661029; PACHA RF, 1990, VIROLOGY, V174, P436, DOI 10.1016/0042-6822(90)90097-B; PARDIGON N, 1992, J VIROL, V66, P1007, DOI 10.1128/JVI.66.2.1007-1015.1992; QUADT R, 1993, P NATL ACAD SCI USA, V90, P1498, DOI 10.1073/pnas.90.4.1498; QUADT R, 1990, VIROLOGY, V178, P189, DOI 10.1016/0042-6822(90)90393-6; RACANIELLO VR, 1981, SCIENCE, V214, P916, DOI 10.1126/science.6272391; RODRIGUEZCOUSINO N, 1992, NUCLEIC ACIDS RES, V20, P2761, DOI 10.1093/nar/20.11.2761; RONER MR, 1990, VIROLOGY, V179, P845, DOI 10.1016/0042-6822(90)90153-I; ROSE M, 1984, MOL GEN GENET, V193, P557, DOI 10.1007/BF00382100; RUSSELL PJ, 1991, NUCLEIC ACIDS RES, V19, P4949, DOI 10.1093/nar/19.18.4949; STONE DE, 1990, MOL CELL BIOL, V10, P1622, DOI 10.1128/MCB.10.4.1622; TRAYNOR P, 1990, J VIROL, V64, P69, DOI 10.1128/JVI.64.1.69-77.1990; TRAYNOR P, 1991, J VIROL, V65, P2807, DOI 10.1128/JVI.65.6.2807-2815.1991; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WICKNER RB, 1989, FASEB J, V3, P2257, DOI 10.1096/fasebj.3.11.2550303; WIDNER WR, 1991, MOL CELL BIOL, V11, P2905, DOI 10.1128/MCB.11.5.2905; WU SX, 1992, P NATL ACAD SCI USA, V89, P11136, DOI 10.1073/pnas.89.23.11136	56	170	178	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 26	1993	72	6					961	970		10.1016/0092-8674(93)90584-D	http://dx.doi.org/10.1016/0092-8674(93)90584-D			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KU175	8458084				2022-12-24	WOS:A1993KU17500016
J	JAKOBOVITS, A; MOORE, AL; GREEN, LL; VERGARA, GJ; MAYNARDCURRIE, CE; AUSTIN, HA; KLAPHOLZ, S				JAKOBOVITS, A; MOORE, AL; GREEN, LL; VERGARA, GJ; MAYNARDCURRIE, CE; AUSTIN, HA; KLAPHOLZ, S			GERM-LINE TRANSMISSION AND EXPRESSION OF A HUMAN-DERIVED YEAST ARTIFICIAL CHROMOSOME	NATURE			English	Article							CELLS; RECOMBINATION; LIBRARIES; SEQUENCES; CLONING; GENE; CDNA; DNA	INTRODUCTION of DNA fragments, hundreds of kilobases in size, into mouse embryonic stem (ES) cells would greatly advance the ability to manipulate the mouse genome. Mice generated from such modified cells would permit investigation of the function and expression of very large or crudely mapped genes. Large DNA molecules cloned into yeast artificial chromosomes (YACs) are stable and genetically manipulable within yeast1, suggesting yeast-cell fusion as an ideal method for transferring large DNA segments into mammalian cells. Introduction of YACs into different cell types by this technique has been reported2-8; however, the incorporation of yeast DNA along with the YAC has raised doubts as to whether ES cells, modified in this way. would be able to recolonize the mouse germ line5. Here we provide, to our knowledge, the first demonstration of germ-line transmission and expression of a large human DNA fragment, introduced into ES cells by fusion with yeast spheroplasts. Proper development was not impaired by the cointegration of a large portion of the yeast genome with the YAC.			JAKOBOVITS, A (corresponding author), CELL GENESYS INC, 322 LAKESIDE DR, FOSTER CITY, CA 94404 USA.							Bradley A, 1987, TERATOCARCINOMAS EMB, P113; BURKE DT, 1991, METHOD ENZYMOL, V194, P251; CHAN CSM, 1983, CELL, V33, P563, DOI 10.1016/0092-8674(83)90437-3; DAVIES NP, 1992, NUCLEIC ACIDS RES, V20, P2693, DOI 10.1093/nar/20.11.2693; GAFNER J, 1983, EMBO J, V2, P583, DOI 10.1002/j.1460-2075.1983.tb01467.x; GNIRKE A, 1991, EMBO J, V10, P1629, DOI 10.1002/j.1460-2075.1991.tb07685.x; GRAY PW, 1989, P NATL ACAD SCI USA, V86, P8497, DOI 10.1073/pnas.86.21.8497; HERMANSON GG, 1991, NUCLEIC ACIDS RES, V19, P4943, DOI 10.1093/nar/19.18.4943; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; HUXLEY C, 1991, GENOMICS, V9, P742, DOI 10.1016/0888-7543(91)90369-P; IMAI T, 1990, GENOMICS, V8, P297, DOI 10.1016/0888-7543(90)90285-3; JOLLY DJ, 1983, P NATL ACAD SCI-BIOL, V80, P477, DOI 10.1073/pnas.80.2.477; KEIL RL, 1984, CELL, V39, P377, DOI 10.1016/0092-8674(84)90016-3; MARTIN GR, 1975, CELL, V6, P467, DOI 10.1016/0092-8674(75)90035-5; PANCHNIS V, 1990, P NATL ACAD SCI USA, V87, P5109; PAVAN WJ, 1990, P NATL ACAD SCI USA, V87, P1300, DOI 10.1073/pnas.87.4.1300; PAVAN WJ, 1990, MOL CELL BIOL, V10, P4163, DOI 10.1128/MCB.10.8.4163; PHILIPPSEN P, 1983, GENE EXPRESSION YEAS, V1, P189; RILEY JH, 1992, NUCLEIC ACIDS RES, V20, P2971, DOI 10.1093/nar/20.12.2971; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; Trask B, 1990, Methods Cell Biol, V33, P383; TRAVER CN, 1989, P NATL ACAD SCI USA, V86, P5698	22	115	566	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 18	1993	362	6417					255	258		10.1038/362255a0	http://dx.doi.org/10.1038/362255a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KT026	8459850				2022-12-24	WOS:A1993KT02600059
J	STEWART, PM; MAHESHWARAN, S; GRIFFITH, J; LI, J; SHEPPARD, MC; OLLIFF, J; FRANKLYN, JA				STEWART, PM; MAHESHWARAN, S; GRIFFITH, J; LI, J; SHEPPARD, MC; OLLIFF, J; FRANKLYN, JA			PITUITARY IMAGING IS ESSENTIAL FOR WOMEN WITH MODERATE HYPERPROLACTINEMIA	BRITISH MEDICAL JOURNAL			English	Article							PROLACTIN		GEN HOSP,DEPT RADIOL,BIRMINGHAM B6 4NH,ENGLAND; GEN HOSP,ENDOCRINE CLIN,BIRMINGHAM B6 4NH,ENGLAND				Griffith, James/C-3186-2011	Griffith, James/0000-0001-5206-9382				BEVAN JS, 1987, AM J MED, V82, P29, DOI 10.1016/0002-9343(87)90373-1; HARTOG M, 1988, BRIT MED J, V297, P701, DOI 10.1136/bmj.297.6650.701; NABARRO JDN, 1982, CLIN ENDOCRINOL, V17, P129, DOI 10.1111/j.1365-2265.1982.tb01573.x; ROSS RJM, 1985, CLIN ENDOCRINOL, V23, P227, DOI 10.1111/j.1365-2265.1985.tb00218.x; TEASDALE E, 1986, CLIN RADIOL, V37, P227, DOI 10.1016/S0009-9260(86)80322-1	5	6	6	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 20	1993	306	6876					507	508		10.1136/bmj.306.6876.507	http://dx.doi.org/10.1136/bmj.306.6876.507			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KN786	8448466	Green Published, Bronze			2022-12-24	WOS:A1993KN78600026
J	HART, JT; EDWARDS, C; HART, M; JONES, J; JONES, M; HAINES, A; WATT, G				HART, JT; EDWARDS, C; HART, M; JONES, J; JONES, M; HAINES, A; WATT, G			SCREEN DETECTED HIGH BLOOD-PRESSURE UNDER 40 - A GENERAL-PRACTICE POPULATION FOLLOWED UP FOR 21 YEARS	BRITISH MEDICAL JOURNAL			English	Article							HEALTH CHECK; NON-ATTENDERS; HYPERTENSION; MANAGEMENT; INVITATION; COMMUNITY; DISEASE; COHORT; RISK; CARE	Objective-To assess hypertension detected under 40 in a general practice population. Design-Prospective case-control study. Setting and subjects-Former coal mining community in south Wales. Systematic case finding for hypertension and associated risk factors applied to a mean total population of 1945 from age 20 on a five year cycle through 21 years. Mean population aged 20-39, 227 men and 213 women. Case criteria: age < 40 and mean systolic pressure greater-than-or-equal-to 160 mm Hg or diastolic pressure greater-than-or-equal-to 100 mm Hg. Age and sex matched controls randomly sampled from the same population. Main outcome measures-Mean initial pressures and pressures at follow up in 1989 or preceding death, and all cardiovascular events. Results-25 men and 16 women met criteria. Estimated five yearly inceptions were 26/1000 for men and 18/1000 for women. Male group mean initial blood pressure was 164/110 mm Hg for cases, falling to 148/89 mm Hg at follow up. Five male cases died at mean age 47.8, compared with two controls at 49.5. Female group mean initial pressure was 172/107 mm Hg for cases, falling to 145/86 mm Hg at follow up. One female case died aged 50, no controls. 10 male cases had non-fatal cardiovascular events at mean age 40.2, compared with two controls at mean age 50.5. Four female cases had non-fatal events at mean age 47.2, compared with one control aged 58. Male differences were statistically significant. Conclusions-Hypertension under 40 is dangerous, commoner in men than women, rarely secondary to classic causes, and may be controlled in general practice on a whole community basis.	GLYNCORRWG HLTH CTR,GLYNCORRWYG SA13 3BL,W GLAM,WALES; UNIV LONDON UNIV COLL,SCH MED,LONDON WC1E 6BT,ENGLAND; UNIV GLASGOW,DEPT PUBL HLTH,GLASGOW G12 8QQ,SCOTLAND	University of London; University College London; UCL Medical School; University of Glasgow	HART, JT (corresponding author), NORTHWICK PK & GLYNCORRWG HLTH CTR,MRC,EPIDEMIOL & MED CARE UNIT,GLYNCORRWYG SA13 3BL,W GLAM,WALES.			Haines, Andy/0000-0002-8053-4605				ARKWRIGHT PD, 1982, CIRCULATION, V66, P60, DOI 10.1161/01.CIR.66.1.60; BEEVERS DG, 1977, LANCET, V2, P111; BJORNTORP P, 1985, ANN CLIN RES, V17, P3; FOWLER G, 1990, BMJ-BRIT MED J, V300, P1318, DOI 10.1136/bmj.300.6735.1318; Hart J T, 1974, J R Coll Physicians Lond, V8, P299; Hart J T, 1970, J R Coll Gen Pract, V19, P258; HART JT, 1970, LANCET, V2, P223; HART JT, 1990, FAM PRACT, V7, P288, DOI 10.1093/fampra/7.4.288; HART JT, 1991, BMJ-BRIT MED J, V302, P1509, DOI 10.1136/bmj.302.6791.1509; HART JT, 1975, J R COLL GEN PRACT, V4, P326; HELLER RF, 1977, BRIT MED J, V1, P1442, DOI 10.1136/bmj.1.6074.1442; KURJI KH, 1984, BMJ-BRIT MED J, V288, P903, DOI 10.1136/bmj.288.6421.903; MAIN J, 1990, RCGP CONNECTION  SEP, P4; Miall W E, 1973, Clin Sci Mol Med Suppl, V45 Suppl 1, p23s; MORRELL DC, 1991, BMJ-BRIT MED J, V302, P1313, DOI 10.1136/bmj.302.6788.1313; PILL R, 1988, J ROY COLL GEN PRACT, V38, P53; PILL R, 1988, J ROY COLL GEN PRACT, V38, P57; SHAPER AG, 1981, BRIT MED J, V283, P179, DOI 10.1136/bmj.283.6285.179; SMITH WCS, 1990, BRIT MED J, V300, P981, DOI 10.1136/bmj.300.6730.981; THOMPSON NF, 1990, BRIT J GEN PRACT, V40, P16; WADSWORTH MEJ, 1985, BRIT MED J, V291, P1534, DOI 10.1136/bmj.291.6508.1534; WALLER D, 1990, BRIT MED J, V300, P1115, DOI 10.1136/bmj.300.6732.1115; WEINBERGER MH, 1983, HDB HYPERTENSION, V2, P196; WIDIMSKY J, 1980, CAS LEK CESK, V119, P1185	24	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 13	1993	306	6875					437	440		10.1136/bmj.306.6875.437	http://dx.doi.org/10.1136/bmj.306.6875.437			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KM700	8461729	Green Published, Bronze			2022-12-24	WOS:A1993KM70000026
J	ZHOU, XL; SASAKI, H; LOWE, L; HOGAN, BLM; KUEHN, MR				ZHOU, XL; SASAKI, H; LOWE, L; HOGAN, BLM; KUEHN, MR			NODAL IS A NOVEL TGF-BETA-LIKE GENE EXPRESSED IN THE MOUSE NODE DURING GASTRULATION	NATURE			English	Article							CPG ISLANDS; FATE	DURING gastrulation, the three germ layers of the embryo are formed and organized along the anterior-posterior body axis. In the mouse, gastrulation involves the delamination of ectodermal cells through the primitive streak and their differentiation into mesoderm1. These processes do not occur in embryos homozygous for a retrovirally induced recessive prenatal lethal mutation, the strain 413-d insertional mutation2,3. Instead of giving rise to mesoderm, embryonic ectoderm in 413-d mutants overproliferates and then rapidly degenerates, although extraembryonic lineages remain viable2. Here we isolate a candidate for the mutated gene which encodes a new member of the transforming growth factor-beta (TGF-beta) superfamily4 . Expression is first detected in primitive streak-stage embryos at about the time of mesoderm formation. It then becomes highly localized in the node at the anterior of the primitive streak. This region is analogous to chick Hensen's node and Xenopus dorsal lip (Spemann's organizer), which can induce secondary body axes when grafted into host embryos (reviewed in refs 5 and 6). Our findings suggest that this gene, named nodal, encodes a signalling molecule essential for mesoderm formation and subsequent organization of axial structures in early mouse development.	NCI,EXPTL IMMUNOL BRANCH,BETHESDA,MD 20892; VANDERBILT UNIV,MED CTR,SCH MED,DEPT CELL BIOL,NASHVILLE,TN 37232	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Vanderbilt University			Kuehn, Michael R/A-4573-2014	Kuehn, Michael R/0000-0002-7703-9160; Sasaki, Hiroshi/0000-0001-8752-6846				BELLAIRS R, 1986, ANAT EMBRYOL, V174, P1, DOI 10.1007/BF00318331; BIRD AP, 1987, TRENDS GENET, V3, P342, DOI 10.1016/0168-9525(87)90294-0; BLUM M, 1992, CELL, V69, P1097, DOI 10.1016/0092-8674(92)90632-M; CONLON FL, 1991, DEVELOPMENT, V111, P969; CONLON RA, 1992, DEVELOPMENT, V116, P357; EVANS GA, 1989, GENE, V79, P9, DOI 10.1016/0378-1119(89)90088-7; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; HERRMANN BG, 1987, GUIDE MOL CLONING TE, P180; HOGAN BLM, 1992, NATURE, V359, P237, DOI 10.1038/359237a0; IANNACCONE PM, 1992, DEV DYNAM, V194, P198, DOI 10.1002/aja.1001940305; JESSELL TM, 1992, CELL, V68, P257, DOI 10.1016/0092-8674(92)90469-S; LAWSON KA, 1991, DEVELOPMENT, V113, P891; LAWSON KA, 1992, POSTIMPLANTATION DEV, P3; LYONS KM, 1991, TRENDS GENET, V7, P408, DOI 10.1016/0168-9525(91)90265-R; Massague J., 1990, REV CELL BIOL, V6, P597; NAKAMURA O, 1978, ORG MILESTONE HALF C; SELIGER B, 1986, MOL CELL BIOL, V6, P286, DOI 10.1128/MCB.6.1.286; Slack J. M. W, 1991, EGG EMBRYON REGIONAL; SMITH JC, 1989, DEVELOPMENT, V105, P665; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; TAM PPL, 1992, POSTIMPLANTATION DEV, P27; [No title captured]	22	522	568	0	25	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 11	1993	361	6412					543	547		10.1038/361543a0	http://dx.doi.org/10.1038/361543a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL714	8429908	Green Published			2022-12-24	WOS:A1993KL71400063
J	CAVALLISFORZA, LL; MENOZZI, P; PIAZZA, A				CAVALLISFORZA, LL; MENOZZI, P; PIAZZA, A			DEMIC EXPANSIONS AND HUMAN-EVOLUTION	SCIENCE			English	Article							INDO-EUROPEAN LANGUAGES; MITOCHONDRIAL-DNA; GENETIC-VARIATION; CLIMATE; POPULATIONS; FREQUENCIES; DIFFUSION; HISTORY; MAPS	Geographic expansions are caused by successful innovations, biological or cultural, that favor local growth and movement. They have had a powerful effect in determining the present patterns of human genetic geography. Modern human populations expanded rapidly across the Earth in the last 100,000 years. At the end of the Paleolithic (10,000 years ago) only a few islands and other areas were unoccupied. The number of inhabitants was then about one thousand times smaller than it is now. Population densities were low throughout the Paleolithic, and random genetic drift was therefore especially effective. Major genetic differences between living human groups must have evolved at that time. Population growths that began afterward, especially with the spread of agriculture, progressively reduced the drift in population and the resulting genetic differentiation. Genetic traces of the expansions that these growths determined are still recognizable.	UNIV PARMA, IST ECOL, I-43100 PARMA, ITALY; UNIV TURIN, CNR, CTR IMMUNOGENET & ISTOCOMPATIBIL, I-10124 TURIN, ITALY	University of Parma; Consiglio Nazionale delle Ricerche (CNR); University of Turin	CAVALLISFORZA, LL (corresponding author), STANFORD UNIV, DEPT GENET, STANFORD, CA 94305 USA.		MENOZZI, PAOLO/A-6234-2012	MENOZZI, PAOLO/0000-0001-8638-7370; Piazza, Alberto/0000-0002-2355-4183	NIGMS NIH HHS [GM 10452, GM 20467] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM010452, R01GM020467] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ammerman A.J., 1973, EXPLANATION CULTURE, P343; AMMERMAN AJ, 1984, NEOLITHIC TRANSITION; BARINAGA M, 1992, SCIENCE, V255, P686, DOI 10.1126/science.1738842; BIRABEN JN, 1980, POPULATION, V4, P1; BIRDSELL JB, 1957, COLD SPRING HARB SYM, V22, P47, DOI 10.1101/SQB.1957.022.01.008; BOWCOCK AM, 1991, P NATL ACAD SCI USA, V88, P839, DOI 10.1073/pnas.88.3.839; BRAUER G, 1989, HUMAN REVOLUTION, P123; CANN RL, 1987, NATURE, V325, P31, DOI 10.1038/325031a0; Cavalli-Sforza L.L., 1971, GENETICS HUMAN POPUL; Cavalli-Sforza LL, 1988, MUNIBE S, V6, P129; Cavalli-Sforza LL., 1981, CULTURAL TRANSMISSIO; CAVALLISFORZA LL, 1988, P NATL ACAD SCI USA, V85, P6002, DOI 10.1073/pnas.85.16.6002; CAVALLISFORZA LL, 1993, EUR J HUM GENET, V1, P3; CAVALLISFORZA LL, 1991, SCI AM, V265, P72, DOI 10.1038/scientificamerican1191-104; CAVALLISFORZA LL, IN PRESS HIST GEOGRA; CULBERT TP, 1983, ANCIENT S AM, pCH2; DIAMOND JM, 1991, NATURE, V350, P275, DOI 10.1038/350275a0; Dolgopolsky A, 1988, MEDITERR LANG REV, V3, P7; Eldredge N., 1972, P82; Fisher RA, 1937, ANN EUGENIC, V7, P355, DOI 10.1111/j.1469-1809.1937.tb02153.x; GAMKRELIDZE TV, 1990, SCI AM, V262, P110, DOI 10.1038/scientificamerican0390-110; GIMBUTAS M, 1991, CIVILIZATION GODDESS, pCH10; GREENBERG JH, 1986, CURR ANTHROPOL, V27, P477, DOI 10.1086/203472; GREENBERG JH, 1963, LANGUAGES AFRICA; GUGLIELMINO CR, 1990, AM J PHYS ANTHROPOL, V83, P57, DOI 10.1002/ajpa.1330830107; GUGLIELMINOMATESSI CR, 1979, AM J PHYS ANTHROPOL, V50, P549, DOI 10.1002/ajpa.1330500407; HASSAN FA, 1981, DEMOGRAPHIC ARCHAEOL; HEDGES SB, 1992, SCIENCE, V255, P737, DOI 10.1126/science.1738849; HEWLETT BS, 1986, AM ANTHROPOL, V88, P922; Howells W. W., 1973, PAPERS PEABODY MUSEU, V67; Howells W. W., 1989, PAP PEABODY MUS, V79, P1; ISAAC GL, 1976, ANN NY ACAD SCI, V280, P275, DOI 10.1111/j.1749-6632.1976.tb25494.x; JONES R, 1989, HUMAN REVOLUTION, P743; Jones R., 1977, SUNDA SAHUL PREHISTO, P113; KAISER M, 1988, ANNU REV ANTHROPOL, V17, P309; Khazanov Anatoly M., 1984, NOMADS OUTSIDE WORLD; KLEIN RG, 1989, HUMAN REVOLUTION, P529; Koyama S., 1978, SENRI ETHNOL STUD, V2, P1; Lathrap DW., 1977, ORIGINS AGR, P713, DOI [10.1515/9783110813487.713, DOI 10.1515/9783110813487.713]; Livingstone FB, 1967, ABNORMAL HEMOGLOBINS; Mallory J. P., 1989, SEARCH INDOEUROPEANS; MATESSI CRG, 1983, MONOGR CONSIGLIO NAZ, V383; MENOZZI P, 1978, SCIENCE, V201, P786, DOI 10.1126/science.356262; MOUNTAIN JL, 1992, PHILOS T ROY SOC B, V337, P159, DOI 10.1098/rstb.1992.0093; OROURKE DH, 1985, AM J PHYS ANTHROPOL, V67, P241, DOI 10.1002/ajpa.1330670309; OROURKE DH, 1986, ANN HUM BIOL, V13, P13, DOI 10.1080/03014468600008171; PIAZZA A, 1988, ANN HUM GENET, V52, P203, DOI 10.1111/j.1469-1809.1988.tb01098.x; PIAZZA A, 1981, P NATL ACAD SCI-BIOL, V78, P2638, DOI 10.1073/pnas.78.4.2638; PIAZZA A, UNPUB; RENDINE S, 1986, AM NAT, V128, P681, DOI 10.1086/284597; RENFREW C, 1989, SCI AM, V261, P106, DOI 10.1038/scientificamerican1089-106; RENFREW C, 1987, ARCHAEOLOGY LANGUAGE; RIGHTMIRE PG, 1989, HUMAN REVOLUTION BEH, P109; SAITOU N, 1991, ISOLATION MIGRATION; Salzano FM, 1988, S AM INDIANS CASE ST; SGARAMELLAZONTA L, 1973, GENETIC STRUCTURE PO, P128; SOKAL RR, 1982, AM NAT, V119, P1, DOI 10.1086/283886; SOKAL RR, 1991, NATURE, V351, P143, DOI 10.1038/351143a0; SOKAL RR, 1992, NATURE, V355, P214, DOI 10.1038/355214b0; STRINGER CB, 1989, HUMAN REVOLUTION, P232; TEMPLETON AR, 1992, SCIENCE, V255, P737, DOI 10.1126/science.1590849; VIGILANT L, 1991, SCIENCE, V253, P1503, DOI 10.1126/science.1840702; WEIDENREICH F, 1965, LIVING RACES MAN; WOLPOFF MH, 1989, HUMAN REVOLUTION, P62; ZVELEBIL M, 1980, CAMBRIDGE ENCY ARCHA, pCH38; [No title captured]	66	308	311	1	41	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 29	1993	259	5095					639	646		10.1126/science.8430313	http://dx.doi.org/10.1126/science.8430313			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KJ688	8430313				2022-12-24	WOS:A1993KJ68800032
J	BROADIE, K; BATE, M				BROADIE, K; BATE, M			INNERVATION DIRECTS RECEPTOR SYNTHESIS AND LOCALIZATION IN DROSOPHILA EMBRYO SYNAPTOGENESIS	NATURE			English	Article							ACETYLCHOLINE-RECEPTORS; CELL; PROSPERO; PROTEIN; AGRIN	IN the Drosophila embryo, motor neurons form stereotyped synapses (neuromuscular junctions) on identified muscles1-3. We have used a mutant (prospero) that removes or delays innervation4,5 to assay the role of the presynaptic motor neuron in the development of the receptive field of the postsynaptic muscle. prospero (pros) is not expressed in the muscles or their precursors. Here we find that the muscle defines the correct synaptic zone in the absence of the motor neuron by restricting putative guidance molecules to this specialized membrane region. Furthermore, the muscle expresses functional transmitter receptors at the correct developmental time without innervation. On the other hand, the muscle does not localize receptors to the synapse without instruction from the motor neuron, nor does a second, much larger, synthesis of receptors occur in muscles deprived of innervation. In muscles receiving delayed innervation, or muscles innervated at aberrant synaptic sites, both receptor clustering and receptor synthesis are delayed or redirected, consistent with the new pattern of innervation. We conclude that the muscle autonomously defines the synaptic site, whereas the motor neuron directs the development of the muscle's receptive field by stimulating the synthesis and localization of transmitter receptors.			BROADIE, K (corresponding author), UNIV CAMBRIDGE,DEPT ZOOL,DOWNING ST,CAMBRIDGE CB2 3EJ,ENGLAND.							ANDERSON MJ, 1977, J PHYSIOL-LONDON, V268, P757, DOI 10.1113/jphysiol.1977.sp011880; BROADIE KS, 1993, J NEUROSCI, V13, P144; CAMPANELLI JT, 1991, CELL, V67, P909, DOI 10.1016/0092-8674(91)90364-5; CAMPOSORTEGA JA, 1992, ROUX ARCH DEV BIOL, V201, P1, DOI 10.1007/BF00188770; DAHM LM, 1991, J NEUROSCI, V11, P238; DENNIS MJ, 1981, ANNU REV NEUROSCI, V4, P43, DOI 10.1146/annurev.ne.04.030181.000355; DOE CQ, 1991, CELL, V65, P451, DOI 10.1016/0092-8674(91)90463-9; HALPERN ME, 1991, J NEUROSCI, V11, P3227; HORTSCH M, 1991, ANNU REV CELL BIOL, V7, P505, DOI 10.1146/annurev.cellbio.7.1.505; JAN LY, 1992, CELL, V69, P715, DOI 10.1016/0092-8674(92)90280-P; JAN LY, 1982, P NATL ACAD SCI-BIOL, V79, P2700, DOI 10.1073/pnas.79.8.2700; JOHANSEN J, 1989, J NEUROSCI, V9, P4318; LANDMESSER L, 1990, NEURON, V4, P655, DOI 10.1016/0896-6273(90)90193-J; LIU DWC, 1992, J NEUROSCI, V12, P1859; MARTINOU JC, 1991, J NEUROSCI, V11, P1291; NITKIN RM, 1987, J CELL BIOL, V105, P2471, DOI 10.1083/jcb.105.6.2471; NOSE A, 1992, CELL, V70, P553, DOI 10.1016/0092-8674(92)90426-D; REIST NE, 1992, NEURON, V8, P865, DOI 10.1016/0896-6273(92)90200-W; SALKOFF L, 1992, TRENDS NEUROSCI, V15, P161, DOI 10.1016/0166-2236(92)90165-5; SANES JR, 1991, DEVELOPMENT, V113, P1181; SCHUETZE SM, 1987, ANNU REV NEUROSCI, V10, P403, DOI 10.1146/annurev.ne.10.030187.002155; SIMON AM, 1992, DEVELOPMENT, V114, P545; SINK H, 1991, J NEUROBIOL, V22, P298, DOI 10.1002/neu.480220309; TOSNEY K, 1988, DEV BIOL, V114, P427; VAESSIN H, 1991, CELL, V67, P941, DOI 10.1016/0092-8674(91)90367-8	25	105	105	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 28	1993	361	6410					350	353		10.1038/361350a0	http://dx.doi.org/10.1038/361350a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KJ590	8426654				2022-12-24	WOS:A1993KJ59000057
J	ELFERINK, LA; PETERSON, MR; SCHELLER, RH				ELFERINK, LA; PETERSON, MR; SCHELLER, RH			A ROLE FOR SYNAPTOTAGMIN (P65) IN REGULATED EXOCYTOSIS	CELL			English	Article							SYNAPTIC VESICLE; SECRETORY GRANULE; ENDOCRINE-CELLS; PROTEINS; IDENTIFICATION; SYNAPTOPHYSIN; BIOGENESIS; BINDING	Proteins that are specifically localized to synaptic vesicles in the nervous system have been proposed to mediate aspects of synaptic transmission. Antibodies raised against the cytoplasmic domains of five of these proteins, vamp, rab3A, synaptophysin, synaptotagmin, and SV2, were used to investigate their function. Microinjection of monoclonal and polyclonal antibodies raised against synaptotagmin (p65), but not the other vesicle proteins, decreases K+/Ca2+-mediated dopamine beta-hydroxylase surface staining, a measure of regulated secretion in PC12 cells. Microinjection of a soluble fragment of synaptotagmin encompassing one of the domains homologous to the C2 regulatory region of protein kinase C, but lacking the membrane anchor, also inhibits evoked dopamine beta-hydroxylase surface staining. These results provide support for the hypothesis that synaptotagmin, a Ca2+- and phospholipid-binding protein, is important for regulated exocytosis in neurons.			ELFERINK, LA (corresponding author), STANFORD UNIV,HOWARD HUGHES MED INST,DEPT MOLEC & CELLULAR PHYSIOL,STANFORD,CA 94305, USA.							BENNETT MK, 1992, J CELL BIOL, V116, P761, DOI 10.1083/jcb.116.3.761; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BENNETT MK, 1993, IN PRESS J NEUROSCI; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; BUCKLEY K, 1985, J CELL BIOL, V100, P1284, DOI 10.1083/jcb.100.4.1284; CLIFTOGRADY L, 1990, J CELL BIOL, V110, P1693, DOI 10.1083/jcb.110.5.1693; CUTLER DF, 1990, J CELL BIOL, V110, P721, DOI 10.1083/jcb.110.3.721; GRAESSMANN A, 1980, METHOD ENZYMOL, V65, P817; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; JOHNSTON PA, 1989, EMBO J, V8, P2863, DOI 10.1002/j.1460-2075.1989.tb08434.x; KELLY RB, 1988, NEURON, V1, P431, DOI 10.1016/0896-6273(88)90174-2; MATTHEW WD, 1981, J CELL BIOL, V91, P257, DOI 10.1083/jcb.91.1.257; MOCHLYROSEN D, 1992, BIOCHEMISTRY-US, V31, P8120, DOI 10.1021/bi00150a003; PERIN MS, 1991, J BIOL CHEM, V266, P623; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; PETRENKO AG, 1991, NATURE, V353, P65, DOI 10.1038/353065a0; SCHEUNER D, 1992, J CELL BIOL, V116, P359, DOI 10.1083/jcb.116.2.359; SHOJIKASAI Y, 1992, SCIENCE, V256, P1820, DOI 10.1126/science.256.5065.1820; STEWART LC, 1988, ANNU REV BIOCHEM, V57, P551; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; TOOZE SA, 1991, J CELL BIOL, V115, P1491, DOI 10.1083/jcb.115.6.1491; TRIMBLE WS, 1991, ANNU REV NEUROSCI, V14, P93, DOI 10.1146/annurev.ne.14.030191.000521; WENDLAND B, 1991, NEURON, V6, P993, DOI 10.1016/0896-6273(91)90239-V; WIEDENMANN B, 1986, P NATL ACAD SCI USA, V83, P3500, DOI 10.1073/pnas.83.10.3500	24	234	235	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 15	1993	72	1					153	159		10.1016/0092-8674(93)90059-Y	http://dx.doi.org/10.1016/0092-8674(93)90059-Y			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KG955	8422678				2022-12-24	WOS:A1993KG95500019
J	VERSHON, AK; JOHNSON, AD				VERSHON, AK; JOHNSON, AD			A SHORT, DISORDERED PROTEIN REGION MEDIATES INTERACTIONS BETWEEN THE HOMEODOMAIN OF THE YEAST ALPHA-2 PROTEIN AND THE MCM1 PROTEIN	CELL			English	Article							DNA-BINDING; REPRESSOR ALPHA-2; TRANSCRIPTION FACTORS; REGULATORY PROTEINS; DROSOPHILA EMBRYOS; CRYSTAL-STRUCTURE; HOMEO DOMAIN; GENE; EXPRESSION; OPERATOR	Homeodomains are folded into a characteristic three-dimensional structure capable of recognizing DNA in a sequence-specific manner. We show that correct target site selection by the yeast alpha2 protein requires, as well as its homeodomain, an adjacent short and apparently unstructured region of the protein. This flexible homeodomain extension is responsible for specifying an interaction with a second regulatory protein, MCM1, which permits the cooperative binding of the two proteins to an operator. Two additional experiments suggest that this extension-homeodomain arrangement is likely to have some generality. First, when the extension of alpha2 is grafted onto the Drosophila engrailed homeodomain, it yields a protein with the DNA binding specificity of engrailed and the ability to bind cooperatively to DNA with MCM1. Second, the alpha2 extension specifies interaction not only with the yeast MCM1 protein, but also with the related human protein SRF.	UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco					NIGMS NIH HHS [GM37049] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037049] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alberts B., 2017, MOL BIOL CELL; AMMERER G, 1990, GENE DEV, V4, P299, DOI 10.1101/gad.4.2.299; CHRIST C, 1991, GENE DEV, V5, P751, DOI 10.1101/gad.5.5.751; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DESPLAN C, 1988, CELL, V54, P1081, DOI 10.1016/0092-8674(88)90123-7; FRANKEL AD, 1991, CELL, V65, P717, DOI 10.1016/0092-8674(91)90378-C; GEHRING WJ, 1987, SCIENCE, V236, P1245, DOI 10.1126/science.2884726; GOUTTE C, 1988, CELL, V52, P875, DOI 10.1016/0092-8674(88)90429-1; HALL MN, 1987, SCIENCE, V237, P1007, DOI 10.1126/science.2887035; HAYES TE, 1988, GENE DEV, V2, P1713, DOI 10.1101/gad.2.12b.1713; HOVLAND P, 1989, GENE, V83, P57, DOI 10.1016/0378-1119(89)90403-4; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KARCH F, 1990, GENE DEV, V4, P1573, DOI 10.1101/gad.4.9.1573; KELEHER CA, 1988, CELL, V53, P927, DOI 10.1016/S0092-8674(88)90449-7; KELEHER CA, 1989, MOL CELL BIOL, V9, P5228, DOI 10.1128/MCB.9.11.5228; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; MA H, 1991, GENE DEV, V5, P484, DOI 10.1101/gad.5.3.484; MAVILIO F, 1986, NATURE, V324, P664, DOI 10.1038/324664a0; MCGINNIS N, 1990, CELL, V63, P969, DOI 10.1016/0092-8674(90)90500-E; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; PASSMORE S, 1989, GENE DEV, V3, P921, DOI 10.1101/gad.3.7.921; PASSMORE S, 1988, J MOL BIOL, V204, P593, DOI 10.1016/0022-2836(88)90358-0; PHILLIPS CL, 1991, GENE DEV, V5, P764, DOI 10.1101/gad.5.5.764; PRIMIG M, 1991, EMBO J, V10, P4209, DOI 10.1002/j.1460-2075.1991.tb04999.x; QIAN YQ, IN PRESS P NATL ACAD; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SAUER RT, 1988, GENE DEV, V2, P807, DOI 10.1101/gad.2.7.807; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; SMITH DL, 1992, CELL, V68, P133, DOI 10.1016/0092-8674(92)90212-U; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; WILDE CD, 1987, EMBO J, V6, P1393, DOI 10.1002/j.1460-2075.1987.tb02380.x; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; YANOFSKY MF, 1990, NATURE, V346, P35, DOI 10.1038/346035a0	34	117	118	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 15	1993	72	1					105	112		10.1016/0092-8674(93)90054-T	http://dx.doi.org/10.1016/0092-8674(93)90054-T			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KG955	8422672				2022-12-24	WOS:A1993KG95500014
J	MARSHALL, CJ				MARSHALL, CJ			PROTEIN PRENYLATION - A MEDIATOR OF PROTEIN-PROTEIN INTERACTIONS	SCIENCE			English	Editorial Material							GDP DISSOCIATION INHIBITOR; GTP-BINDING-PROTEINS; C-TERMINAL REGION; REGULATORY PROTEIN; EXCHANGE PROTEIN; PLASMA-MEMBRANE; ALPHA-SUBUNIT; SMG P25A; MOTIF; CAAX				MARSHALL, CJ (corresponding author), INST CANC RES,CHESTER BEATTY LABS,237 FULHAM RD,LONDON SW3 6JB,ENGLAND.							ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; ARAKI S, 1991, MOL CELL BIOL, V11, P1438, DOI 10.1128/MCB.11.3.1438; ARAKI S, 1990, J BIOL CHEM, V265, P13007; BERANGER F, 1991, P NATL ACAD SCI USA, V88, P1606, DOI 10.1073/pnas.88.5.1606; BLACK SD, 1992, BIOCHEM BIOPH RES CO, V186, P1437, DOI 10.1016/S0006-291X(05)81567-0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; COX AD, 1992, MOL CELL BIOL, V12, P606; GIBBS JB, 1991, CELL, V65, P1, DOI 10.1016/0092-8674(91)90352-Y; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; HORI Y, 1991, ONCOGENE, V6, P515; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; ISOMURA M, 1991, ONCOGENE, V6, P119; ITOH T, IN PRESS J BIOL CHEM; KURODA Y, 1993, SCIENCE, V259, P683, DOI 10.1126/science.8430318; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; OHGURO H, 1990, BIOCHEM BIOPH RES CO, V167, P1235, DOI 10.1016/0006-291X(90)90656-8; PHILIPS MR, 1993, SCIENCE, V259, P977, DOI 10.1126/science.8438158; REESE JH, 1991, MOL CELL BIOCHEM, V104, P109; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SEABRA MC, 1993, SCIENCE, V259, P377, DOI 10.1126/science.8380507	24	315	318	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 26	1993	259	5103					1865	1866		10.1126/science.8456312	http://dx.doi.org/10.1126/science.8456312			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KU172	8456312				2022-12-24	WOS:A1993KU17200022
J	WARCHOL, ME; LAMBERT, PR; GOLDSTEIN, BJ; FORGE, A; CORWIN, JT				WARCHOL, ME; LAMBERT, PR; GOLDSTEIN, BJ; FORGE, A; CORWIN, JT			REGENERATIVE PROLIFERATION IN INNER-EAR SENSORY EPITHELIA FROM ADULT GUINEA-PIGS AND HUMANS	SCIENCE			English	Article							HAIR CELL REGENERATION; ACOUSTIC TRAUMA; CHICK COCHLEA	Supporting cells in the vestibular sensory epithelia from the ears of mature guinea pigs and adult humans proliferate in vitro after treatments with aminoglycoside antibiotics that cause sensory hair cells to die. After 4 weeks in culture, the epithelia contained new cells with some characteristics of immature hair cells. These findings are in contrast to expectations based on previous studies, which had suggested that hair cell loss is irreversible in mammals. The loss of hair cells is responsible for hearing and balance deficits that affect millions of people.	UCL, INST LARYNGOL & OTOL, LONDON WC1X 8EE, ENGLAND; UNIV VIRGINIA, SCH MED, DEPT NEUROSCI, CHARLOTTESVILLE, VA 22908 USA	University of London; University College London; University of Virginia	WARCHOL, ME (corresponding author), UNIV VIRGINIA, SCH MED, DEPT OTOLARYNGOL HEAD & NECK SURG, CHARLOTTESVILLE, VA 22908 USA.			Forge, Andrew/0000-0002-0995-0219; Goldstein, Bradley/0000-0002-9612-1696				BALAK KJ, 1990, J NEUROSCI, V10, P2502; CORWIN JT, 1988, SCIENCE, V240, P1772, DOI 10.1126/science.3381100; CORWIN JT, 1991, ANNU REV NEUROSCI, V14, P301, DOI 10.1146/annurev.neuro.14.1.301; CORWIN JT, 1991, CIBA F SYMP, V160, P103; CORWIN JT, 1986, BIOL CHANGE OTOLARYN, P291; COTANCHE DA, 1987, HEARING RES, V30, P181, DOI 10.1016/0378-5955(87)90135-3; CRUZ RM, 1987, ARCH OTOLARYNGOL, V113, P1058; FORGE A, 1993, SCIENCE, V259, P1616, DOI 10.1126/science.8456284; GLASSCOCK ME, 1989, OTOLARYNG HEAD NECK, V100, P237, DOI 10.1177/019459988910000312; JONES JE, 1991, THESIS U VIRGINIA; LAMBERT PR, UNPUB; Ruben R.J., 1967, ACTA OTO-LARYNGOL, DOI DOI 10.3109/00016486709127790; RYALS BM, 1988, SCIENCE, V240, P1774, DOI 10.1126/science.3381101; WAGNER JE, 1976, BIOL GUINEA PIG, P9; WEISLEDER P, 1992, EXP NEUROL, V115, P2, DOI 10.1016/0014-4886(92)90211-8	15	408	433	3	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 12	1993	259	5101					1619	1622		10.1126/science.8456285	http://dx.doi.org/10.1126/science.8456285			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KR543	8456285				2022-12-24	WOS:A1993KR54300042
J	REINER, SL; WANG, ZE; HATAM, F; SCOTT, P; LOCKSLEY, RM				REINER, SL; WANG, ZE; HATAM, F; SCOTT, P; LOCKSLEY, RM			T(H)1 AND T(H)2 CELL ANTIGEN RECEPTORS IN EXPERIMENTAL LEISHMANIASIS	SCIENCE			English	Article							HUMAN T-CELLS; MURINE LEISHMANIASIS; INTERFERON-GAMMA; IFN-GAMMA; HELPER; MICE; INTERLEUKIN-10; SUBSETS; LINES; EXPRESSION	The complexity and chronicity of parasitic infections have obscured the identification of biologically relevant antigens. Analysis of the T cell receptor repertoire used by mice infected with Leishmania major revealed the expansion of a restricted population of CD4+ cells. These cells expressed the V(alpha)8-J(alpha)TA72,V(beta)4 heterodimer in both progressive infection and protective immunity and across several major histocompatibility haplotypes. Thus, the same immunodominant parasite epitope drives the disparate outcomes of this infectious process, suggesting that candidate vaccine antigens selected by screening of immune individuals may be capable of exacerbating disease in genetically susceptible individuals.	UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143; UNIV PENN,SCH VET MED,DEPT PATHOBIOL,PHILADELPHIA,PA 19104	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Pennsylvania					NIAID NIH HHS [AI30663] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030663] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS S, 1991, P NATL ACAD SCI USA, V88, P11271, DOI 10.1073/pnas.88.24.11271; BELOSEVIC M, 1989, J IMMUNOL, V143, P266; BOGDAN C, 1991, J EXP MED, V174, P1549, DOI 10.1084/jem.174.6.1549; BOITEL B, 1992, J EXP MED, V175, P765, DOI 10.1084/jem.175.3.765; BOITEL B, 1991, J EXP MED, V174, P1371; CANDEIAS S, 1991, J EXP MED, V174, P989, DOI 10.1084/jem.174.5.989; CHATELAIN R, 1992, J IMMUNOL, V148, P1182; CHOI YW, 1989, P NATL ACAD SCI USA, V86, P8941, DOI 10.1073/pnas.86.22.8941; CHOU HS, 1986, EMBO J, V5, P2149, DOI 10.1002/j.1460-2075.1986.tb04478.x; DELPRETE GF, 1991, J CLIN INVEST, V88, P346, DOI 10.1172/JCI115300; EVAVOLD BD, 1992, J IMMUNOL, V148, P347; HAANEN JBAG, 1991, J EXP MED, V174, P583, DOI 10.1084/jem.174.3.583; HEINZEL FP, 1989, J EXP MED, V169, P59, DOI 10.1084/jem.169.1.59; HEINZEL FP, 1991, P NATL ACAD SCI USA, V88, P7011, DOI 10.1073/pnas.88.16.7011; HOLADAY BJ, 1991, J IMMUNOL, V147, P1653; JORGENSEN JL, 1992, ANNU REV IMMUNOL, V10, P835, DOI 10.1146/annurev.iy.10.040192.004155; JORGENSEN JL, 1992, NATURE, V355, P224, DOI 10.1038/355224a0; LEHN M, 1989, J IMMUNOL, V143, P3020; MALEFYT RD, 1991, J EXP MED, V174, P915; REINER SL, UNPUB; ROCKEN M, 1992, J IMMUNOL, V148, P1031; ROMANI L, 1992, J EXP MED, V176, P19, DOI 10.1084/jem.176.1.19; SADICK MD, 1990, J EXP MED, V171, P115, DOI 10.1084/jem.171.1.115; SALGAME P, 1991, SCIENCE, V254, P279, DOI 10.1126/science.1681588; SCOTT P, 1990, J IMMUNOL, V144, P1075; SCOTT P, 1988, J EXP MED, V168, P1675, DOI 10.1084/jem.168.5.1675; SEDER RA, 1992, J EXP MED, V176, P1091, DOI 10.1084/jem.176.4.1091; SHER A, 1992, ANNU REV IMMUNOL, V10, P385, DOI 10.1146/annurev.iy.10.040192.002125; STREET NE, 1991, FASEB J, V5, P171, DOI 10.1096/fasebj.5.2.1825981; TAYLOR AH, 1990, J EXP MED, V172, P1643, DOI 10.1084/jem.172.6.1643; TITUS RG, 1985, J IMMUNOL, V135, P2108; TOMONARI K, 1990, IMMUNOGENETICS, V31, P333, DOI 10.1007/BF02115007; TOMONARI K, 1989, EUR J IMMUNOL, V19, P1131, DOI 10.1002/eji.1830190625; WHITE J, 1989, J IMMUNOL, V143, P1822; YAMAMURA M, 1991, SCIENCE, V254, P277, DOI 10.1126/science.1925582; YSSEL H, 1991, J EXP MED, V174, P593, DOI 10.1084/jem.174.3.593	36	214	216	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 5	1993	259	5100					1457	1460		10.1126/science.8451641	http://dx.doi.org/10.1126/science.8451641			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KP978	8451641				2022-12-24	WOS:A1993KP97800037
J	SIMONS, M; LECLERC, G; SAFIAN, RD; ISNER, JM; WEIR, L; BAIM, DS				SIMONS, M; LECLERC, G; SAFIAN, RD; ISNER, JM; WEIR, L; BAIM, DS			RELATION BETWEEN ACTIVATED SMOOTH-MUSCLE CELLS IN CORONARY-ARTERY LESIONS AND RESTENOSIS AFTER ATHERECTOMY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MYOSIN HEAVY-CHAINS; VASCULAR-DISEASE; EXPRESSION; PROLIFERATION; ANGIOPLASTY; MECHANISMS; STENOSIS; ISOFORM; GRAFTS; KINASE	Background. Neointimal proliferation leading to restenosis frequently develops after coronary angioplasty. This process is associated with a change in vascular smooth-muscle cells from a contractile (quiescent) phenotype to a synthetic or proliferating (activated) one. We investigated whether the presence of activated smooth-muscle cells in coronary lesions at the time of coronary atherectomy predisposes patients to subsequent restenosis. Methods. We used in situ hybridization to study the expression of messenger RNA in coronary-atherectomy specimens from 20 patients. Plaque material was hybridized with a probe for the B isoform of human non-muscle myosin heavy chain, a major nonmuscle myosin isoform in activated, but not quiescent, smooth-muscle cells. Angiographic follow-up data were obtained a mean (+/-SD) of 174+/-54 days after atherectomy in 16 of the 20 patients, and the extent of recurrent luminal narrowing was analyzed quantitatively. The presence of restenosis was assessed by exercise thallium scintigraphy in the other four patients. Results. Atherectomy specimens from 10 of the 20 patients showed hybridization with the probe, defined as the clustering of more than 20 silver grains per cell nucleus in more than 10 nuclei in five high-power fields (x250); specimens from the other 10 patients showed no such hybridization. At follow-up, restenosis had developed in 8 of the 10 patients with positive hybridization results, but was absent in 9 of the 1 0 patients with negative results (P = 0.007). The degree of late loss in luminal diameter was significantly higher in patients with positive hybridization results than in those with negative results (ratio of late loss to immediate gain after atherectomy, 0.76+/-0.3 vs. 0.36+/-0.3; P<0.001). Conclusions. We conclude that the expression of the B isoform of nonmuscle myosin heavy chain is increased in some coronary atherosclerotic plaques and that this increase in expression identifies a group of lesions at high risk for restenosis after atherectomy.	CHARLES A DANA RES INST,BOSTON,MA; HARVARD UNIV,SCH MED,BOSTON,MA 02115; ST ELIZABETH HOSP,DIV CARDIOL,BOSTON,MA	Harvard University; Harvard University; Harvard Medical School	SIMONS, M (corresponding author), HARVARD UNIV,BETH ISRAEL HOSP,DEPT MED,DIV CARDIOVASC,THORNDIKE LAB,330 BROOKLINE AVE,BOSTON,MA 02215, USA.		Simons, Michael/G-8553-2014	Simons, Michael/0000-0003-0348-7734	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032747, R01HL040518] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-40518, HL-32747] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUSTIN GE, 1985, J AM COLL CARDIOL, V6, P369, DOI 10.1016/S0735-1097(85)80174-1; CALIFF RM, 1990, TXB INTERVENTIONAL C, P333; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; DILLEY RJ, 1988, ARCH SURG-CHICAGO, V123, P691; FANELLI C, 1990, AM HEART J, V119, P357, DOI 10.1016/S0002-8703(05)80028-6; FISHMAN RF, 1992, J AM COLL CARDIOL, V20, P1101, DOI 10.1016/0735-1097(92)90365-T; GARRATT KN, 1991, J AM COLL CARDIOL, V17, P442, DOI 10.1016/S0735-1097(10)80113-5; GORDON D, 1990, P NATL ACAD SCI USA, V87, P4600, DOI 10.1073/pnas.87.12.4600; HIRSHFELD JW, 1991, J AM COLL CARDIOL, V18, P647, DOI 10.1016/0735-1097(91)90783-6; KAWAMOTO S, 1991, J CELL BIOL, V112, P915, DOI 10.1083/jcb.112.5.915; KAWAMOTO S, 1987, J BIOL CHEM, V262, P7282; KERRICK WGL, 1984, P NATL ACAD SCI-BIOL, V81, P165, DOI 10.1073/pnas.81.1.165; KNECHT DA, 1987, SCIENCE, V236, P1081, DOI 10.1126/science.3576221; KOCHER O, 1991, LAB INVEST, V65, P459; KUNTZ RE, 1993, J AM COLL CARDIOL, V21, P15, DOI 10.1016/0735-1097(93)90712-A; KUROO M, 1991, J BIOL CHEM, V266, P3768; LECLERC G, 1992, CIRCULATION, V85, P543, DOI 10.1161/01.CIR.85.2.543; LUDOWYKE RI, 1989, J BIOL CHEM, V264, P12492; SAFIAN RD, 1990, CIRCULATION, V82, P69, DOI 10.1161/01.CIR.82.1.69; SCHWARTZ SM, 1986, CIRC RES, V58, P427, DOI 10.1161/01.RES.58.4.427; SCHWARTZ SM, 1987, HUM PATHOL, V18, P240, DOI 10.1016/S0046-8177(87)80006-0; SCOBLIONKO DP, 1984, AM J CARDIOL, V53, P689, DOI 10.1016/0002-9149(84)90387-4; SIMONS M, 1992, CIRC RES, V70, P835, DOI 10.1161/01.RES.70.4.835; SIMONS M, 1991, CIRC RES, V69, P530, DOI 10.1161/01.RES.69.2.530; SIMPSON JB, 1988, AM J CARDIOL, V61, pG96, DOI 10.1016/S0002-9149(88)80040-7; ZANELLATO AMC, 1990, ARTERIOSCLEROSIS, V10, P996, DOI 10.1161/01.ATV.10.6.996	26	104	109	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 4	1993	328	9					608	613		10.1056/NEJM199303043280903	http://dx.doi.org/10.1056/NEJM199303043280903			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP680	8429852				2022-12-24	WOS:A1993KP68000003
J	LESKO, SM; ROSENBERG, L; SHAPIRO, S				LESKO, SM; ROSENBERG, L; SHAPIRO, S			A CASE-CONTROL STUDY OF BALDNESS IN RELATION TO MYOCARDIAL-INFARCTION IN MEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; DIHYDROTESTOSTERONE; TESTOSTERONE; LIPOPROTEINS; ANDROGENS	Objective.-To examine the relationship between male pattern baldness and the risk of myocardial infarction in men under the age of 55 years. Design and Participants.-A hospital-based, case-control study was conducted in eastern Massachusetts and Rhode Island. Cases were men admitted to a hospital for a first nonfatal myocardial infarction (n=665); controls were men admitted to the same hospitals with noncardiac diagnoses (n=772). Extent of baldness was assessed using the 12-point modified Hamilton Baldness Scale; other information was obtained by personal interview. Among the controls, the prevalence of any baldness was 34%, while the prevalence of baldness involving the vertex scalp was 23%. Results.-After allowing for age, the relative risk estimate for frontal baldness compared with no hair loss was 0.9 (95% confidence interval, 0.6 to 1.3), for baldness involving the vertex scalp it was 1.4 (95% confidence interval, 1.2 to 1.9). Risk of myocardial infarction increased as the degree of vertex baldness increased (P<.01); for severe vertex baldness the relative risk was 3.4 (95% confidence interval, 1.7 to 7.0). The relationship between vertex baldness and myocardial infarction was consistent within strata defined by age and other risk factors for coronary artery disease. Conclusion.-These data support the hypothesis that male pattern baldness involving the vertex scalp is associated with coronary artery disease in men under the age of 55 years.			LESKO, SM (corresponding author), BOSTON UNIV,SCH MED,SCH PUBL HLTH,SLONE EPIDEMIOL UNIT,1371 BEACON ST,BROOKLINE,MA 02146, USA.			Rosenberg, Lynn/0000-0003-2760-2987				ARMITAGE P, 1971, STATISTICAL METHODS, P319; BALAZS T, 1971, TOXICOL APPL PHARM, V20, P442, DOI 10.1016/0041-008X(71)90287-0; BUECHNER HOWARD A., 1964, J LOUISIANA STATE MED SOC, V116, P329; COOKE NT, 1979, BRIT J DERMATOL, V101, P455, DOI 10.1111/j.1365-2133.1979.tb00026.x; COTTON SG, 1972, BRIT HEART J, V34, P458, DOI 10.1136/hrt.34.5.458; GORMLEY GJ, 1990, J CLIN ENDOCR METAB, V70, P1136, DOI 10.1210/jcem-70-4-1136; GREGER NG, 1990, METABOLISM, V39, P919, DOI 10.1016/0026-0495(90)90301-R; Halim M M, 1978, Br J Dermatol, V98, P63, DOI 10.1111/j.1365-2133.1978.tb07334.x; HAMALAINEN E, 1986, METABOLISM, V35, P535, DOI 10.1016/0026-0495(86)90011-9; Hamilton JB, 1942, AM J ANAT, V71, P451, DOI 10.1002/aja.1000710306; HAYNES SG, 1978, AM J EPIDEMIOL, V107, P362, DOI 10.1093/oxfordjournals.aje.a112556; HELLER RF, 1981, BRIT MED J, V282, P438, DOI 10.1136/bmj.282.6262.438; HERMAN EH, 1979, TOXICOL APPL PHARM, V47, P493, DOI 10.1016/0041-008X(79)90520-9; MANTEL N, 1959, J NATL CANCER I, V22, P719; MCGILL HC, 1980, SCIENCE, V207, P775, DOI 10.1126/science.6766222; MIETTINEN O, 1976, AM J EPIDEMIOL, V103, P226, DOI 10.1093/oxfordjournals.aje.a112220; NORWOOD OT, 1975, SOUTHERN MED J, V68, P1359, DOI 10.1097/00007611-197511000-00009; PERSSON B, 1984, ACTA MED SCAND, V216, P485; PHILLIPS GB, 1976, LANCET, V2, P14; REYNOLDS JEF, 1989, MARTINDALE EXTRA PHA, P491; SHERIDAN PJ, 1989, ANAT REC, V223, P414, DOI 10.1002/ar.1092230410; TENOVER JS, 1991, ENDOCRIN METAB CLIN, V20, P893, DOI 10.1016/S0889-8529(18)30249-4; TREVISON M, 1990, CIRCULATION, V81, P18; VERMEULEN A, 1985, MATURITAS, V7, P281, DOI 10.1016/0378-5122(85)90051-9; 1972, BMJ, V4, P3; 1971, ISCHEMIC HEART DISEA	26	89	90	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 24	1993	269	8					998	1003		10.1001/jama.269.8.998	http://dx.doi.org/10.1001/jama.269.8.998			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KM603	8429606				2022-12-24	WOS:A1993KM60300027
J	LEE, JM				LEE, JM			SCREENING AND INFORMED CONSENT	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CANCER				LEE, JM (corresponding author), MERRITHEW MEM HOSP,MARTINEZ,CA 94553, USA.							BARSKY AJ, 1988, NEW ENGL J MED, V318, P414, DOI 10.1056/NEJM198802183180705; BLAKESLEE S, 1992, NY TIMES        0315, V4, P1; CAIRNS J, 1985, SCI AM, V253, P51, DOI 10.1038/scientificamerican1185-51; EDDY DM, 1989, ANN INTERN MED, V111, P389, DOI 10.7326/0003-4819-111-5-389; EDDY DM, 1988, JAMA-J AM MED ASSOC, V259, P1512, DOI 10.1001/jama.259.10.1512; Kaplan R.M., 1982, HEALTH PSYCHOL, V1, P61, DOI [DOI 10.1037/0278-6133.1.1.61, 10.1037/0278-6133.1.1.61]; KELLY PT, 1991, UNDERSTANDING BREAST, P30; MUSHLIN AI, 1992, CANCER, V69, P1957, DOI 10.1002/1097-0142(19920401)69:7+<1957::AID-CNCR2820691716>3.0.CO;2-T; PAULOS JA, 1990, INNUMERACY MATH ILLI, P162; STANGE KC, 1992, J FAM PRACTICE, V34, P409	10	42	42	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 11	1993	328	6					438	440		10.1056/NEJM199302113280613	http://dx.doi.org/10.1056/NEJM199302113280613			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KL584	8421464				2022-12-24	WOS:A1993KL58400013
J	ORR, HA				ORR, HA			HALDANE RULE HAS MULTIPLE GENETIC CAUSES	NATURE			English	Article								HALDANE'S rule states that ''When in the F1 offspring of two different animal races one sex is absent, rare, or sterile, that sex is the heterozygous [heterogametic or XY] sex''1. This rule represents one of the few patterns characterizing animal speciation2,3. Traditional explanations of Haldane's rule1,4-6 claim that heterogametic hybrids are unfit because they lack an X chromosome that is 'compatible' with the autosomes of one species. Recent work2,7 shows that this explanation is incorrect for hybrid sterility: contrary to prediction, homogametic hybrids carrying both X chromosomes from the same species remain fertile. Until now, similar tests have not been performed for hybrid inviability. Here I show that homogametic hybrids who carry both X chromosomes from the same species are inviable. These results show that the genetic causes of Haldane's rule differ for hybrid sterility versus inviability. Haldane's rule does not, therefore, have a single genetic basis.			ORR, HA (corresponding author), UNIV CALIF DAVIS,CTR POPULAT BIOL,DAVIS,CA 95616, USA.							Ashburner M, 1989, DROSOPHILA LAB HDB, P1; Biddle RL, 1932, GENETICS, V17, P0153; Coyne J.A., 1989, P180; COYNE JA, 1985, NATURE, V314, P736, DOI 10.1038/314736a0; COYNE JA, 1992, NATURE, V355, P511, DOI 10.1038/355511a0; Dobzhansky T., 1937, GENETICS ORIGIN SPEC; Haldane JBS, 1922, J GENET, V12, P101, DOI 10.1007/BF02983075; HUTTER P, 1990, GENETICS, V124, P909; LEE WH, 1987, JPN J GENET, V62, P225, DOI 10.1266/jjg.62.225; Muller H., 1942, BIOL S, V6, P71; Muller HJ., 1940, NEW SYSTEMATICS, P185; ORR HA, 1992, GENET RES, V59, P73, DOI 10.1017/S0016672300030275; Sturtevant AH, 1920, GENETICS, V5, P488; STURTEVANT AH, 1929, PUBL CARNEG I WASH, V399, P1; WU CI, 1992, EVOLUTION, V46, P1584, DOI 10.1111/j.1558-5646.1992.tb01152.x	15	90	90	0	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 11	1993	361	6412					532	533		10.1038/361532a0	http://dx.doi.org/10.1038/361532a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL714	8429905				2022-12-24	WOS:A1993KL71400058
J	NEUGUT, AI; GARBOWSKI, GC; LEE, WC; MURRAY, T; NIEVES, JW; FORDE, KA; TREAT, MR; WAYE, JD; FENOGLIOPREISER, C				NEUGUT, AI; GARBOWSKI, GC; LEE, WC; MURRAY, T; NIEVES, JW; FORDE, KA; TREAT, MR; WAYE, JD; FENOGLIOPREISER, C			DIETARY RISK-FACTORS FOR THE INCIDENCE AND RECURRENCE OF COLORECTAL ADENOMATOUS POLYPS - A CASE-CONTROL STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						COLORECTAL NEOPLASM; POLYPS; COLONOSCOPY; FOOD HABITS; DIET	LARGE-BOWEL CANCER; RANDOMIZED TRIAL; COLON CANCER; VITAMIN-E; ENERGY-INTAKE; RECTUM; EPIDEMIOLOGY; PREVENTION; FIBER; ETIOLOGY	Objective: To investigate the association of dietary factors with the incidence and recurrence of colorectal adenomatous polyps. Design: Two case-control studies. Setting: Three university-based colonoscopy practices in New York City. Patients: For the incidence study, 286 patients with pathologically confirmed incident adenomatous polyps (162 men and 124 women) were compared with 480 controls (210 men and 270 women) with no current or previous neoplasia. For the recurrence study, 186 patients with recurrent polyps (130 men and 56 women) were compared with 330 controls (187 men and 143 women). These patients had a history of polyps but no current neoplasia. Measurements: Structured interviews using the Block food frequency questionnaire were conducted on all participants and were compared over quartiles of crude nutrient intake of total and saturated fat; fiber; protein; carbohydrates; carotene; vitamins A, C, and E; and various food groups. Data were adjusted for age, Quetelet index, and caloric intake by multiple logistic regression for men and women separately. Results: For incident polyps, elevated adjusted odds ratios (high to low quartile) for women were found for saturated fat (odds ratio, 2.3; 95% CI, 0.9 to 5.8) and the ratio of red meat to chicken and fish intake (odds ratio, 1.9; CI, 1.0 to 3.6). Protective associations were observed for fish and chicken (odds ratio, 0.6; CI, 0.3 to 1.2) and vitamin A intake (odds ratio, 0.4; CI, 0.2 to 0.9). Among women, recurrent polyps showed an association with total dietary fat (odds ratio, 4.4; CI, 1.0 to 19.5), saturated fat (odds ratio, 3.8; CI, 1.0 to 14.9; P = 0.15 for the trend), and total fiber (odds ratio, 0.2; CI, 0.1 to 0.5; P = 0.01) and a borderline association with carbohydrates (odds ratio, 0.3; CI, 0.1 to 1.3; P = 0.10). No consistent relations were observed for men, although increased caloric intake increased the risk for incidence and recurrence in both men and women. Conclusions: These findings are consistent with previously described relations between diet and the incidence of colon cancer and suggest that, at least in women, dietary modification may be warranted in patients diagnosed with polyps.	UNIV CINCINNATI, MED CTR, CINCINNATI, OH 45267 USA; CUNY MT SINAI SCH MED, NEW YORK, NY 10029 USA	University System of Ohio; University of Cincinnati; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	NEUGUT, AI (corresponding author), COLUMBIA UNIV COLL PHYS & SURG, DIV ONCOL, 630 W 168TH ST, NEW YORK, NY 10032 USA.			Nieves, Jeri/0000-0001-8593-343X	NATIONAL CANCER INSTITUTE [R01CA037196, K07CA001211] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA37196, KO7-CA01211] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLOCK G, 1986, AM J EPIDEMIOL, V124, P453, DOI 10.1093/oxfordjournals.aje.a114416; CROWTHER JS, 1976, BRIT J CANCER, V34, P191, DOI 10.1038/bjc.1976.142; DALES LG, 1979, AM J EPIDEMIOL, V109, P132, DOI 10.1093/oxfordjournals.aje.a112668; DAY DW, 1984, SCAND J GASTROENTERO, V19, P99; DIXON WJ, 1985, BMDP STATISTICAL SOF; GARLAND C, 1985, LANCET, V1, P307, DOI 10.1016/S0140-6736(85)91082-7; GILBERTSEN VA, 1978, CANCER, V41, P1137, DOI 10.1002/1097-0142(197803)41:3<1137::AID-CNCR2820410350>3.0.CO;2-G; GIOVANNUCCI E, 1992, JNCI-J NATL CANCER I, V84, P91, DOI 10.1093/jnci/84.2.91; GRAHAM S, 1978, JNCI-J NATL CANCER I, V61, P709; HAENSZEL W, 1973, J NATL CANCER I, V51, P1765, DOI 10.1093/jnci/51.6.1765; HILL MJ, 1978, LANCET, V1, P245, DOI 10.1016/S0140-6736(78)90487-7; HILL MJ, 1974, CANCER, V34, P815, DOI 10.1002/1097-0142(197409)34:3+<815::AID-CNCR2820340705>3.0.CO;2-6; HOFF G, 1986, SCAND J GASTROENTERO, V21, P199, DOI 10.3109/00365528609034647; HOWE GR, 1986, AM J EPIDEMIOL, V124, P157, DOI 10.1093/oxfordjournals.aje.a114365; JOHNSEN CM, 1987, REV ENDOCRINE RELATE, V25, P25; Kune S, 1987, Nutr Cancer, V9, P21; KUSHI LH, 1985, NEW ENGL J MED, V313, P119; LEIGHTON J, 1988, AM J EPIDEMIOL, V128, P891; Lev R, 1990, ADENOMATOUS POLYPS C; LIPKIN M, 1985, NEW ENGL J MED, V313, P1381, DOI 10.1056/NEJM198511283132203; LYON JL, 1987, JNCI-J NATL CANCER I, V78, P853; MACOUARTMOULIN G, 1987, INT J CANCER, V40, P179, DOI 10.1002/ijc.2910400209; MACQUARTMOULIN G, 1986, INT J CANCER, V38, P183, DOI 10.1002/ijc.2910380207; MCKEOWNEYSSEN G, 1988, CANCER RES, V48, P4701; MCKEOWNEYSSEN G, 1991, AM J EPIDEMIOL, V134, P746; MCMICHAEL AJ, 1983, AM J EPIDEMIOL, V118, P620, DOI 10.1093/oxfordjournals.aje.a113672; MILLER AB, 1983, INT J CANCER, V32, P155, DOI 10.1002/ijc.2910320204; NEUGUT AI, 1985, CANCER, V55, P1586, DOI 10.1002/1097-0142(19850401)55:7<1586::AID-CNCR2820550729>3.0.CO;2-I; NEUGUT AI, 1991, J NATL CANCER I, V83, P359, DOI 10.1093/jnci/83.5.359; NEUGUT AI, 1988, AM J GASTROENTEROL, V83, P295; NEUGUT AI, 1988, DIS COLON RECTUM, V31, P430, DOI 10.1007/BF02552611; NEUGUT AI, 1991, FRONT GASTR RES, V18, P157; NOMURA AMY, 1985, CANCER RES, V45, P2369; PETO R, 1981, NATURE, V290, P201, DOI 10.1038/290201a0; PHILLIPS RL, 1975, CANCER RES, V35, P3513; POTTER JD, 1986, JNCI-J NATL CANCER I, V76, P557, DOI 10.1093/jnci/76.4.557; SILVERBERG E, 1990, CA-CANCER J CLIN, V40, P9, DOI 10.3322/canjclin.40.1.9; STEMMERMANN GN, 1988, AM J CLIN NUTR, V47, P312, DOI 10.1093/ajcn/47.2.312; STRYKER SJ, 1987, GASTROENTEROLOGY, V93, P1009, DOI 10.1016/0016-5085(87)90563-4; TROCK B, 1990, JNCI-J NATL CANCER I, V82, P650, DOI 10.1093/jnci/82.8.650; TUYNS AJ, 1988, NUTR CANCER, V11, P189, DOI 10.1080/01635588809513986; VANDERWERE SDJ, 1982, LANCET, V1, P759; WILLETT WC, 1990, NEW ENGL J MED, V323, P1664, DOI 10.1056/NEJM199012133232404; WILLETT WC, 1984, NEW ENGL J MED, V310, P430, DOI 10.1056/NEJM198402163100705; WYNDER EL, 1974, CANCER, V34, P801, DOI 10.1002/1097-0142(197409)34:3+<801::AID-CNCR2820340703>3.0.CO;2-P	45	121	121	0	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1993	118	2					91	95		10.7326/0003-4819-118-2-199301150-00002	http://dx.doi.org/10.7326/0003-4819-118-2-199301150-00002			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF918	8416323				2022-12-24	WOS:A1993KF91800002
J	DOBERSTEIN, SK; BAINES, IC; WIEGAND, G; KORN, ED; POLLARD, TD				DOBERSTEIN, SK; BAINES, IC; WIEGAND, G; KORN, ED; POLLARD, TD			INHIBITION OF CONTRACTILE VACUOLE FUNCTION IN-VIVO BY ANTIBODIES AGAINST MYOSIN-I	NATURE			English	Article								MYOSIN-I is thought to supply the force for movement of cell membranes relative to actin filaments (reviewed in refs 1, 2), but confirmation of this hypothesis has been difficult because of the presence of multiple isoforms of myosin-I and other unconventional myosins in most cells3. We report here the first evidence that a myosin-I isoform is essential for a specific class of intracellular membrane movements in vivo. In Acanthamoeba, the contractile vacuole is an autonomous structure which fuses with the plasma membrane to control the water content of the cell. Because myosin-IC is the only myosin-I isoform concentrated in the contractile vacuole complex4,5 and a protein antigenically related to myosin-IC is located on or near the Dictyostelium (slime mould) contractile vacuole6, we thought this organelle might provide the best opportunity to demonstrate a relationship between myosin-I and membrane motility. Antibodies that inhibit the activity of Acanthamoeba myosin-IC in vitro interfere with expulsion of excess water by the contractile vacuole in vivo, leading to overfilling of this organelle and cell lysis. Myosin-IC may generate the force required to contract the vacuole and may also be involved in transfer of water to the contractile vacuole during refilling.	JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21225; NHLBI,CELL BIOL LAB,BETHESDA,MD 20892	Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	DOBERSTEIN, SK (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT CELL BIOL & ANAT,BALTIMORE,MD 21225, USA.		Korn, Edward D/F-9929-2012	Korn, Edward/0000-0003-3867-6295				ALBANESI JP, 1986, J BIOL CHEM, V261, P445; ALBANESI JP, 1985, J BIOL CHEM, V260, P8649; BAINES IC, 1990, J CELL BIOL, V111, P1895, DOI 10.1083/jcb.111.5.1895; BAINES IC, 1992, J CELL BIOL, V119, P1193, DOI 10.1083/jcb.119.5.1193; BRZESKA H, 1990, J BIOL CHEM, V265, P3591; CHENEY R E, 1992, Current Opinion in Cell Biology, V4, P27, DOI 10.1016/0955-0674(92)90055-H; CLARKE MSF, 1992, J CELL SCI, V102, P533; COX D, 1992, J CELL BIOL, V116, P943, DOI 10.1083/jcb.116.4.943; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; FURUKAWA R, 1992, PROTOPLASMA, V169, P18; Hammer J A, 1991, Trends Cell Biol, V1, P50, DOI 10.1016/0962-8924(91)90089-R; JUNG G, 1990, J CELL BIOL, V110, P1955, DOI 10.1083/jcb.110.6.1955; KNECHT DA, 1987, SCIENCE, V236, P1081, DOI 10.1126/science.3576221; LYNCH TJ, 1989, J BIOL CHEM, V264, P19333; LYNCH TJ, 1990, METHOD ENZYMOL, V196, P12; MARUTA H, 1977, J BIOL CHEM, V252, P8329; POLLARD TD, 1973, J BIOL CHEM, V248, P4682; POLLARD TD, 1991, REV PHYSL, V53, P653; SINARD JH, 1989, CELL MOTIL CYTOSKEL, V12, P42, DOI 10.1002/cm.970120106; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; TITUS MA, 1993, MOL BIOL CELL, V4, P233, DOI 10.1091/mbc.4.2.233; WESSELS D, 1988, DEV BIOL, V128, P164, DOI 10.1016/0012-1606(88)90279-5; WESSELS D, 1991, CELL MOTIL CYTOSKEL, V20, P301, DOI 10.1002/cm.970200406; WIGG D, 1967, J PROTOZOOL, V14, P104, DOI 10.1111/j.1550-7408.1967.tb01453.x; WITKE W, 1992, CELL, V68, P53, DOI 10.1016/0092-8674(92)90205-Q; ZHU QL, 1992, J CELL BIOL, V118, P347, DOI 10.1083/jcb.118.2.347; ZOT HG, 1992, J CELL BIOL, V116, P367, DOI 10.1083/jcb.116.2.367	27	110	111	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 28	1993	365	6449					841	843		10.1038/365841a0	http://dx.doi.org/10.1038/365841a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MD951	8413668				2022-12-24	WOS:A1993MD95100051
J	OBEID, LM; LINARDIC, CM; KAROLAK, LA; HANNUN, YA				OBEID, LM; LINARDIC, CM; KAROLAK, LA; HANNUN, YA			PROGRAMMED CELL-DEATH INDUCED BY CERAMIDE	SCIENCE			English	Article							TUMOR-NECROSIS-FACTOR; PROTEIN KINASE-C; DNA FRAGMENTATION; FACTOR-ALPHA; SPHINGOMYELIN TURNOVER; HL-60 CELLS; DIFFERENTIATION; ACTIVATION; INHIBITION; APOPTOSIS	Sphingomyelin hydrolysis and ceramide generation have been implicated in a signal transduction pathway that mediates the effects of tumor necrosis factor-alpha (TNF-alpha) and other agents on cell growth and differentiation. In many leukemic cells, TNF-alpha causes DNA fragmentation, which leads to programmed cell death (apoptosis). C2-ceramide (0.6 to 5 muM), a synthetic cell-permeable ceramide analog, induced internucleosomal DNA fragmentation, which was inhibited by zinc ion. Other amphiphilic lipids failed to induce apoptosis. The closely related C2-dihydroceramide was also ineffective, which suggests a critical role for the sphingolipid double bond. The effects of C2-ceramide on DNA fragmentation were- prevented by the protein kinase C activator phorbol 12-myristate 13-acetate, which suggests the existence of two opposing intracellular pathways in the regulation of apoptosis.	DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710	Duke University; Duke University				obeid, lina/0000-0002-0734-0847				ALNEMRI ES, 1990, J BIOL CHEM, V265, P17323; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; ELIAS L, 1991, LEUKEMIA, V5, P879; FLIEGER D, 1989, INT J CANCER, V44, P315, DOI 10.1002/ijc.2910440221; GERSCHENSON LE, 1992, FASEB J, V6, P2450, DOI 10.1096/fasebj.6.7.1563596; GOLDKORN T, 1991, J BIOL CHEM, V266, P16092; GUNJI H, 1992, J CLIN INVEST, V89, P954, DOI 10.1172/JCI115677; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; KELER T, 1992, P NATL ACAD SCI USA, V89, P4830, DOI 10.1073/pnas.89.11.4830; KERR JFR, 1972, J PATHOL, V107, P41, DOI 10.1002/path.1711070107; KIM MY, 1991, J BIOL CHEM, V266, P484; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; MCCONKEY DJ, 1989, J BIOL CHEM, V264, P13399; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; MERRILL AH, 1992, NUTR REV, V50, P78; MERRILL AH, 1992, METHOD ENZYMOL, V209, P427; MEYAARD L, 1992, SCIENCE, V257, P217, DOI 10.1126/science.1352911; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; RUBIN BY, 1988, CANCER RES, V48, P6006; SCHMID DS, 1987, LYMPHOKINE RES, V6, P195; SCHUTZE S, 1990, J IMMUNOL, V144, P2604; STRAUSS WM, 1992, CURRENT PROTOCOLS MO, P1; TOMEI LD, 1988, BIOCHEM BIOPH RES CO, V155, P324, DOI 10.1016/S0006-291X(88)81088-X; TURINSKY J, 1991, AM J PHYSIOL, V261, pE620, DOI 10.1152/ajpendo.1991.261.5.E620; VANVELDHOVEN PP, 1992, BIOCHEM BIOPH RES CO, V187, P209, DOI 10.1016/S0006-291X(05)81480-9; WRIGHT SC, 1992, J CELL BIOCHEM, V48, P344, DOI 10.1002/jcb.240480403; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0	29	1632	1681	3	93	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 19	1993	259	5102					1769	1771		10.1126/science.8456305	http://dx.doi.org/10.1126/science.8456305			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KT810	8456305				2022-12-24	WOS:A1993KT81000042
J	FRENKEL, LM; GARRATTY, EM; SHEN, JP; WHEELER, N; CLARK, O; BRYSON, YJ				FRENKEL, LM; GARRATTY, EM; SHEN, JP; WHEELER, N; CLARK, O; BRYSON, YJ			CLINICAL REACTIVATION OF HERPES-SIMPLEX VIRUS TYPE-2 INFECTION IN SEROPOSITIVE PREGNANT-WOMEN WITH NO HISTORY OF GENITAL HERPES	ANNALS OF INTERNAL MEDICINE			English	Article						HERPES GENITALIS; PREGNANCY COMPLICATIONS, INFECTIONS; VIRUS SHEDDING; INFANT, NEWBORN, DISEASES	UNITED-STATES; EPIDEMIOLOGY; VIDARABINE; DELIVERY; RISK; TIME	Objective: To determine the risk for genital herpes and asymptomatic herpes simplex virus (HSV) shedding in late pregnancy and delivery in a population of HSV type 2 (HSV-2)-seropositive but previously asymptomatic pregnant women. Design: A prospective inception cohort study. Participants: A total of 1355 pregnant women with no history of genital herpes referred from three private obstetrics practices between November 1985 and June 1988. Main Outcome Measures: Confidential questionnaires evaluated sexual risk factors in relation to HSV-2 serologic status as determined by Western blot analysis. Herpes simplex virus shedding was determined by viral culture of the cervix and vulva and of any suspicious lesions. Results: Antibody to HSV-2 was detected in 439 of 1355 pregnant women (32%) with no history of genital herpes. Asymptomatic HSV shedding was detected in 5 of 1160 cultures (0.43%) obtained in late pregnancy and during delivery. A first episode of clinical genital herpes was recognized by 43 of 264 HSV-2-seropositive women (16%) during their pregnancy. Conclusions: Serologic evidence of unknown HSV-2 infection was common in pregnant women without a history of genital herpes. Asymptomatic viral shedding in these women occurred at a rate similar to that seen in women with symptomatic genital HSV-2 infection. To improve recognition of genital herpes near term, obstetricians should counsel pregnant women about the high prevalence and mild and diverse symptoms of genital HSV-2 infection.	UNIV CALIF LOS ANGELES, DEPT PEDIAT, DIV INFECT DIS & BIOMATH, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles								ASHLEY R, 1991, ANN INTERN MED, V115, P520, DOI 10.7326/0003-4819-115-7-520; BECKER TM, 1986, J REPROD MED, V31, P359; BERNSTEIN DI, 1985, J MED VIROL, V15, P223, DOI 10.1002/jmv.1890150303; BOLOGNESE RJ, 1976, OBSTET GYNECOL, V48, P507; BREINIG MK, 1990, J INFECT DIS, V162, P299, DOI 10.1093/infdis/162.2.299; BROWN ZA, 1991, NEW ENGL J MED, V324, P1247, DOI 10.1056/NEJM199105023241804; CORY L, 1990, SEXUALLY TRANSMITTED, P391; FIFE KH, 1990, SEXUALLY TRANSMITTED, P941; FLEISS JL, 1981, STATISTICAL METHODS, P64; GIBBS RS, 1988, OBSTET GYNECOL, V71, P779; GIBSON JJ, 1990, J INFECT DIS, V162, P306, DOI 10.1093/infdis/162.2.306; GOLDSMITH MF, 1989, JAMA-J AM MED ASSOC, V261, P678, DOI 10.1001/jama.1989.03420050020007; HARDY DA, 1990, J INFECT DIS, V162, P1031, DOI 10.1093/infdis/162.5.1031; JOHNSON RE, 1989, NEW ENGL J MED, V321, P7, DOI 10.1056/NEJM198907063210102; KOUTSKY LA, 1992, NEW ENGL J MED, V326, P1533, DOI 10.1056/NEJM199206043262305; KULHANJIAN JA, 1992, NEW ENGL J MED, V326, P916, DOI 10.1056/NEJM199204023261403; LANGENBERG A, 1989, ANN INTERN MED, V110, P882, DOI 10.7326/0003-4819-110-11-882; PROBER CG, 1987, NEW ENGL J MED, V316, P240, DOI 10.1056/NEJM198701293160503; RAWLS WE, 1971, AM J OBSTET GYNECOL, V110, P682, DOI 10.1016/0002-9378(71)90254-7; STAVRAKY KM, 1983, AM J EPIDEMIOL, V118, P109, DOI 10.1093/oxfordjournals.aje.a113612; WHITLEY R, 1991, NEW ENGL J MED, V324, P450, DOI 10.1056/NEJM199102143240704; WHITLEY R, 1991, NEW ENGL J MED, V324, P444, DOI 10.1056/NEJM199102143240703; WHITLEY RJ, 1988, J INFECT DIS, V158, P109, DOI 10.1093/infdis/158.1.109; WHITLEY RJ, 1983, PEDIATRICS, V72, P778	24	73	76	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1993	118	6					414	418		10.7326/0003-4819-118-6-199303150-00003	http://dx.doi.org/10.7326/0003-4819-118-6-199303150-00003			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KR817	8439114				2022-12-24	WOS:A1993KR81700003
J	NGAI, J; CHESS, A; DOWLING, MM; NECLES, N; MACAGNO, ER; AXEL, R				NGAI, J; CHESS, A; DOWLING, MM; NECLES, N; MACAGNO, ER; AXEL, R			CODING OF OLFACTORY INFORMATION - TOPOGRAPHY OF ODORANT RECEPTOR EXPRESSION IN THE CATFISH OLFACTORY EPITHELIUM	CELL			English	Article							ELECTRICAL-STIMULATION; 2-DEOXYGLUCOSE METHOD; SPATIAL-DISTRIBUTION; SALMONID FISHES; RAINBOW-TROUT; BULB; RAT; PROJECTION; NEURONS; CELLS	Discrimination among the vast array of odors requires that the brain discern which of the numerous odorant receptors have been activated. If individual olfactory neurons express only a subset of the odorant receptor repertoire, then the nature of a given odorant can be discerned by identifying which cells have been activated. We performed in situ hybridization experiments demonstrating that individual olfactory neurons express different complements of odorant receptors and are therefore functionally distinct. Thus, a topographic map, defining either the positions of specific neurons in the epithelium or the positions of their projections, may be employed to determine the quality of an olfactory stimulus. Neurons expressing specific receptors appear to be randomly distributed within the olfactory epithelium. These data are consistent with a model in which randomly dispersed olfactory neurons with common receptor specificities project to common glomeruli in the olfactory bulb.	COLUMBIA UNIV COLL PHYS & SURG, HOWARD HUGHES MED INST, DEPT BIOCHEM & MOLEC BIOPHYS, NEW YORK, NY 10032 USA; COLUMBIA UNIV, DEPT BIOL SCI, NEW YORK, NY 10027 USA	Columbia University; Howard Hughes Medical Institute; Columbia University			Dowling, Michael M./AAE-5263-2020	Dowling, Michael M./0000-0001-5058-6589; Axel, Richard/0000-0002-3141-4076	NIGMS NIH HHS [T-32 GM07367] Funding Source: Medline; PHS HHS [R01-20336] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007367] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADRIAN ED, 1950, BRIT MED BULL, V6, P330, DOI 10.1093/oxfordjournals.bmb.a073625; ALLEN BA, 1990, COMPUT MED IMAG GRAP, V14, P319, DOI 10.1016/0895-6111(90)90106-L; ASTIC L, 1986, BRAIN RES BULL, V16, P445, DOI 10.1016/0361-9230(86)90172-3; ASTIC L, 1988, DEV BRAIN RES, V42, P297, DOI 10.1016/0165-3806(88)90248-9; ASTIC L, 1987, BRAIN RES, V424, P144, DOI 10.1016/0006-8993(87)91204-2; BOWER JM, 1991, OLFACTION, P265; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; CANCALON P, 1982, TISSUE CELL, V14, P717, DOI 10.1016/0040-8166(82)90061-1; CAPRIO J, 1978, TISSUE CELL, V10, P1, DOI 10.1016/0040-8166(78)90002-2; CLARK WEL, 1951, J NEUROL NEUROSUR PS, V14, P1, DOI 10.1136/jnnp.14.1.1; COSTANZO RM, 1976, J GEN PHYSIOL, V68, P297, DOI 10.1085/jgp.68.3.297; DEMSKI LS, 1984, BRAIN RES, V291, P241, DOI 10.1016/0006-8993(84)91256-3; DOVING KB, 1980, ACTA PHYSIOL SCAND, V108, P123, DOI 10.1111/j.1748-1716.1980.tb06509.x; DUBOISDAUPHIN M, 1980, CHEM SENSES, V5, P159, DOI 10.1093/chemse/5.2.159; DUBOISDAUPHIN M, 1981, BRAIN RES, V219, P269, DOI 10.1016/0006-8993(81)90291-2; DUNCAN HJ, 1990, J COMP NEUROL, V299, P299, DOI 10.1002/cne.902990304; FREEMAN WJ, 1991, OLFACTION, P225; FUJITA SC, 1985, BRAIN RES, V326, P192, DOI 10.1016/0006-8993(85)91403-9; GOULDING EH, 1992, NEURON, V8, P45, DOI 10.1016/0896-6273(92)90107-O; GREER CA, 1981, BRAIN RES, V217, P279, DOI 10.1016/0006-8993(81)90004-4; HARA T J, 1975, Progress in Neurobiology (Oxford), V5, P271, DOI 10.1016/0301-0082(75)90014-3; Iwamura Y, 1985, DEV ORG PROCESSING S, P239; JAKUBOWSKI M, 1979, Z MIKROSK ANAT FORSC, V93, P728; JASTREBOFF PJ, 1984, P NATL ACAD SCI-BIOL, V81, P5250, DOI 10.1073/pnas.81.16.5250; JOURDAN F, 1982, BRAIN RES, V240, P341, DOI 10.1016/0006-8993(82)90232-3; JOURDAN F, 1980, BRAIN RES, V188, P139, DOI 10.1016/0006-8993(80)90563-6; KAAS JH, 1979, SCIENCE, V204, P521, DOI 10.1126/science.107591; KAUER JS, 1991, TRENDS NEUROSCI, V14, P79, DOI 10.1016/0166-2236(91)90025-P; KAUER JS, 1991, OLFACTION, P43; KAUER JS, 1974, J PHYSIOL-LONDON, V243, P717, DOI 10.1113/jphysiol.1974.sp010773; LANCET D, 1986, ANNU REV NEUROSCI, V9, P329, DOI 10.1146/annurev.ne.09.030186.001553; LANCET D, 1982, P NATL ACAD SCI-BIOL, V79, P670, DOI 10.1073/pnas.79.2.670; LAND LJ, 1973, BRAIN RES, V63, P153, DOI 10.1016/0006-8993(73)90084-X; LAND LJ, 1974, BRAIN RES, V70, P506, DOI 10.1016/0006-8993(74)90259-5; LEVY NS, 1991, J STEROID BIOCHEM, V39, P633, DOI 10.1016/0960-0760(91)90262-4; MACAGNO ER, 1979, ANNU REV BIOPHYS BIO, V8, P323, DOI 10.1146/annurev.bb.08.060179.001543; MACKAYSIM A, 1984, ANAT EMBRYOL, V170, P93, DOI 10.1007/BF00319463; MACKAYSIM A, 1982, J NEUROPHYSIOL, V48, P584, DOI 10.1152/jn.1982.48.2.584; MACLEOD NK, 1976, EXP BRAIN RES, V25, P267; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MORI K, 1985, J COMP NEUROL, V242, P214, DOI 10.1002/cne.902420205; MORI K, 1987, PROG NEUROBIOL, V29, P275, DOI 10.1016/0301-0082(87)90024-4; MORI K, 1992, J NEUROPHYSIOL, V67, P786, DOI 10.1152/jn.1992.67.3.786; NGAI J, 1993, CELL, V72; PARMENTIER M, 1992, NATURE, V355, P453, DOI 10.1038/355453a0; PINCHING AJ, 1974, BRAIN RES, V82, P195, DOI 10.1016/0006-8993(74)90598-8; POWELL TPS, 1959, B JOHNS HOPKINS HOSP, V105, P133; REED RR, 1992, NEURON, V8, P205, DOI 10.1016/0896-6273(92)90287-N; RIDDLE DR, 1991, J NEUROSCI, V11, P3752; ROWE MJ, 1985, DEV ORG PROCESSING S, P247; ROYET JP, 1987, BRAIN RES, V417, P1, DOI 10.1016/0006-8993(87)90173-9; SATOU M, 1983, J COMP PHYSIOL, V152, P319, DOI 10.1007/BF00606238; SATOU M, 1990, PROG NEUROBIOL, V34, P115, DOI 10.1016/0301-0082(90)90004-Z; SATOU M, 1979, BRAIN RES, V173, P142, DOI 10.1016/0006-8993(79)91102-8; SAUCIER D, 1986, BRAIN RES BULL, V16, P455, DOI 10.1016/0361-9230(86)90173-5; SCHWARTING GA, 1991, BRAIN RES, V547, P239, DOI 10.1016/0006-8993(91)90967-Z; Sheldon RE, 1912, J COMP NEUROL, V22, P177, DOI 10.1002/cne.900220301; SHEPHERD GM, 1991, OLFACTION, P3; STACEY NE, 1983, PHYSIOL BEHAV, V30, P621, DOI 10.1016/0031-9384(83)90231-7; STEWART WB, 1979, J COMP NEUROL, V185, P715, DOI 10.1002/cne.901850407; TEICHER MH, 1980, BRAIN RES, V194, P530, DOI 10.1016/0006-8993(80)91237-8; THOMMESEN G, 1983, ACTA PHYSIOL SCAND, V117, P241, DOI 10.1111/j.1748-1716.1983.tb07203.x; THOMMESEN G, 1977, ACTA PHYSIOL SCAND, V99, P270, DOI 10.1111/j.1748-1716.1977.tb10380.x; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; WILKINSON DG, 1987, DEVELOPMENT, V99, P493	65	214	217	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 12	1993	72	5					667	680		10.1016/0092-8674(93)90396-8	http://dx.doi.org/10.1016/0092-8674(93)90396-8			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KR436	8453662	Bronze			2022-12-24	WOS:A1993KR43600004
J	TAKAHASHI, H; NAKADA, T; PUISIEUX, I				TAKAHASHI, H; NAKADA, T; PUISIEUX, I			INHIBITION OF HUMAN COLON CANCER GROWTH BY ANTIBODY-DIRECTED HUMAN LAK CELLS IN SCID MICE	SCIENCE			English	Article							TUMOR-INFILTRATING LYMPHOCYTES; SEVERE COMBINED IMMUNODEFICIENCY; PERIPHERAL-BLOOD LYMPHOCYTES; ACTIVATED KILLER CELLS; MONOCLONAL-ANTIBODIES; RECOMBINANT INTERLEUKIN-2; METASTATIC MELANOMA; CYTO-TOXICITY; FC-RECEPTORS; MOUSE	Advanced human colon cancer does not respond to lymphokine-activated killer (LAK) cells. In order to direct cytotoxic cells to the tumor, human LAK cells linked with antibodies to a tumor cell surface antigen were tested with established hepatic metastases in severe combined immunodeficient (SCID) mice. These cells had increased uptake into the tumor and suppression of tumor growth as compared with LAK cells alone, thereby improving the survival of tumor-bearing mice. Thus, tumor growth can be inhibited by targeted LAK cells, and SCID mice can be used to test the antitumor properties of human effector cells.	HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School	TAKAHASHI, H (corresponding author), MASSACHUSETTS GEN HOSP, CTR CANC, MOLEC HEPATOL LAB, BOSTON, MA 02129 USA.				NCI NIH HHS [CA-35711, CA-57584] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA035711, R29CA057584, R01CA057584, R37CA035711] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BANCROFT GJ, 1991, IMMUNOL REV, V124, P5, DOI 10.1111/j.1600-065X.1991.tb00613.x; BANKERT RB, 1989, CURR TOP MICROBIOL, V152, P201; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; BOSMA MJ, 1991, ANNU REV IMMUNOL, V9, P323, DOI 10.1146/annurev.iy.09.040191.001543; DEARMAN RJ, 1988, BLOOD, V72, P1985; DORSHKIND K, 1985, J IMMUNOL, V134, P3798; FIDLER IJ, 1990, CANCER RES, V50, P6130; FISHER B, 1989, J CLIN ONCOL, V7, P250, DOI 10.1200/JCO.1989.7.2.250; FRIEDMANN T, 1991, CANCER CELL-MON REV, V3, P271; GRIFFITH KD, 1989, J NATL CANCER I, V81, P1709, DOI 10.1093/jnci/81.22.1709; GRIMM EA, 1982, J EXP MED, V155, P1823, DOI 10.1084/jem.155.6.1823; HERLYN D, 1982, P NATL ACAD SCI-BIOL, V79, P4761, DOI 10.1073/pnas.79.15.4761; JOHNSON WJ, 1986, J IMMUNOL, V136, P4704; JONES JF, 1980, J IMMUNOL, V125, P926; KAWASE I, 1988, CANCER RES, V48, P1173; KURNICK JT, 1986, CLIN IMMUNOL IMMUNOP, V38, P367, DOI 10.1016/0090-1229(86)90247-3; MCCUNE JM, 1988, SCIENCE, V241, P1632, DOI 10.1126/science.2971269; MOSIER DE, 1988, NATURE, V335, P256, DOI 10.1038/335256a0; MUKHERJI B, 1988, NUCL MED BIOL, V15, P419, DOI 10.1016/0883-2897(88)90012-8; MUUL LM, 1987, J IMMUNOL, V138, P989; NELSON H, 1991, CANCER CELL-MON REV, V3, P163; NISHIHARA K, 1988, CANCER RES, V48, P4730; ORTALDO JR, 1986, J EXP MED, V164, P1193, DOI 10.1084/jem.164.4.1193; PFEFFER K, 1989, CURR TOP MICROBIOL, V152, P211; PHILLIPS JH, 1986, J EXP MED, V164, P814, DOI 10.1084/jem.164.3.814; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; ROBERTS K, 1987, CANCER RES, V47, P4366; ROSENBERG SA, 1990, NEW ENGL J MED, V323, P570, DOI 10.1056/NEJM199008303230904; ROSENBERG SA, 1985, NEW ENGL J MED, V313, P1485, DOI 10.1056/NEJM198512053132327; ROSENBERG SA, 1988, NEW ENGL J MED, V319, P1676, DOI 10.1056/NEJM198812223192527; SCHMIDTWOLF IGH, 1991, J EXP MED, V174, P139, DOI 10.1084/jem.174.1.139; SIMPSON E, 1991, IMMUNOL REV, V124, P97, DOI 10.1111/j.1600-065X.1991.tb00618.x; STEPLEWSKI Z, 1988, P NATL ACAD SCI USA, V85, P4852, DOI 10.1073/pnas.85.13.4852; TAKAHASHI H, 1988, CANCER RES, V48, P6573; TAKAHASHI H, 1989, GASTROENTEROLOGY, V96, P1317, DOI 10.1016/S0016-5085(89)80019-8; Takahashi H., UNPUB; TONG AW, 1989, CANCER RES, V49, P4103; UNKELESS JC, 1989, J CLIN INVEST, V83, P355, DOI 10.1172/JCI113891; VIVIER E, 1991, J IMMUNOL, V146, P206; WEST WH, 1987, NEW ENGL J MED, V316, P898, DOI 10.1056/NEJM198704093161502; WILSON B, 1988, P NATL ACAD SCI USA, V85, P3140, DOI 10.1073/pnas.85.9.3140	41	89	90	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 5	1993	259	5100					1460	1463		10.1126/science.8451642	http://dx.doi.org/10.1126/science.8451642			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KP978	8451642				2022-12-24	WOS:A1993KP97800038
J	RANSICK, A; DAVIDSON, EH				RANSICK, A; DAVIDSON, EH			A COMPLETE 2ND GUT INDUCED BY TRANSPLANTED MICROMERES IN THE SEA-URCHIN EMBRYO	SCIENCE			English	Article							CELL FATE; GASTRULATION; MESOMERES; LINEAGE; ARCHENTERON; MECHANISMS; PROTEIN	Founder cells for most early lineages of the sea urchin embryo are probably specified through inductive intercellular interactions. It is shown here that a complete respecification of cell fate occurs when 16-cell stage micromeres from the vegetal pole of a donor embryo are implanted into the animal pole of an intact recipient embryo. Animal pole cells adjacent to the transplanted micromeres are respecified from presumptive ectoderm into vegetal plate founder cells. These induced vegetal plate cells express the entire battery of genes characteristic of the endogenous vegetal plate cells. The ectopic vegetal plate invaginates during gastrulation to form a second archenteron which differentiates properly into a tripartite gut, as shown by the spatial pattern of expression of an endoderm-specific marker gene. Thus, transplanted micromeres can signal neighboring cells to induce them to change their fate.	CALTECH,DIV BIOL,PASADENA,CA 91125	California Institute of Technology					NICHD NIH HHS [HD-07257, HD-05753] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD005753, R37HD005753] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		CAMERON RA, 1991, DEVELOPMENT, V113, P1085; CAMERON RA, 1987, GENE DEV, V1, P75, DOI 10.1101/gad.1.1.75; DAVIDSON EH, 1990, DEVELOPMENT, V108, P365; DAVIDSON EH, 1989, DEVELOPMENT, V105, P421; DAVIDSON EH, 1991, DEVELOPMENT, V113, P1; DAVIDSON EH, 1986, GENE ACTIVITY EARLY, pCH4; Driesch H, 1891, Z WISS ZOOL ABT A, V53, P160; ETTENSOHN CA, 1990, SCIENCE, V248, P1115, DOI 10.1126/science.2188366; ETTENSOHN CA, 1984, AM ZOOL, V24, P571; ETTENSOHN CA, 1986, DEV BIOL, V117, P380, DOI 10.1016/0012-1606(86)90307-6; HARDIN J, 1990, DEV BIOL, V142, P86, DOI 10.1016/0012-1606(90)90153-A; HARDIN JD, 1986, DEV BIOL, V115, P490, DOI 10.1016/0012-1606(86)90269-1; HARKEY MA, 1983, DEV BIOL, V100, P12, DOI 10.1016/0012-1606(83)90196-3; HARKEY MA, 1992, MECH DEVELOP, V37, P173, DOI 10.1016/0925-4773(92)90079-Y; HENRY JJ, 1989, DEV BIOL, V136, P140, DOI 10.1016/0012-1606(89)90137-1; Horstadius S, 1939, BIOL REV CAMB PHILOS, V14, P132, DOI 10.1111/j.1469-185X.1939.tb00929.x; HORSTADIUS S, 1973, EXPT EMBRYOLOGY ECHI, pCH6; HORSTADIUS S, 1935, PUBBL STN ZOOL NAPOL, V14, P1; KHANER O, 1991, DEVELOPMENT, V112, P881; KHANER O, 1990, DEVELOPMENT, V109, P625; LIVINGSTON BT, 1990, DEVELOPMENT, V108, P403; NOCENTEMCGRATH C, 1989, DEV BIOL, V136, P264, DOI 10.1016/0012-1606(89)90147-4; NOCENTEMCGRATH C, 1991, DEV BIOL, V147, P445, DOI 10.1016/0012-1606(91)90302-J; OKAZAKI K, 1975, AM ZOOL, V15, P567; PEHRSON JR, 1986, DEV BIOL, V113, P522, DOI 10.1016/0012-1606(86)90188-0; RANSICK A, IN PRES MECH DEV; WILT FH, 1987, DEVELOPMENT, V100, P559	27	170	171	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 19	1993	259	5098					1134	1138		10.1126/science.8438164	http://dx.doi.org/10.1126/science.8438164			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KM917	8438164				2022-12-24	WOS:A1993KM91700031
J	LANZER, M; DEBRUIN, D; RAVETCH, JV				LANZER, M; DEBRUIN, D; RAVETCH, JV			TRANSCRIPTIONAL DIFFERENCES IN POLYMORPHIC AND CONSERVED DOMAINS OF A COMPLETE CLONED PLASMODIUM-FALCIPARUM CHROMOSOME	NATURE			English	Article							PARASITE PLASMODIUM-FALCIPARUM; HISTIDINE-RICH PROTEIN; INVOLVE DELETIONS; GENE; SEQUENCE; REARRANGEMENT; EXPRESSION; CROSS	CLASSICAL genetic studies on the human malaria parasite Plasmodium falciparum have been hampered by a complex life cycle which alternates between vertebrate and invertebrate hosts. Consequently, only a few genetic crosses have been performed so far1-4. In addition, molecular genetics has provided only limited access to the genes of this pathogen, a consequence of an unusually high A + T content5,6. To overcome these limitations we have constructed an ordered telomere-to-telomere contig map of P. falciparum chromosome 2 by isolating overlapping yeast artificial chromosome clones. This approach was used to examine the strain-dependent polymorphisms commonly observed for P. falciparum chromosomes7,8. Our analysis reveals that polymorphisms of chromosome 2 are restricted to regions at either end, representing 20% of the chromosome. Transcription mapping of the entire chromosome suggests a compartmentalization of chromosome 2 into a transcribed central domain and silent polymorphic ends.			LANZER, M (corresponding author), SLOAN KETTERING INST CANC RES,DEWITT WALLACE RES LAB,DIV MOLEC BIOL,1275 YORK AVE,NEW YORK,NY 10021, USA.		Ravetch, Jeffrey/Z-1596-2019; Lanzer, Michael/E-9752-2013	Ravetch, Jeffrey/0000-0003-2024-9041; Lanzer, Michael/0000-0002-0220-6526				BIGGS BA, 1989, P NATL ACAD SCI USA, V86, P2428, DOI 10.1073/pnas.86.7.2428; BLACKWELL TK, 1989, ANNU REV GENET, V23, P605, DOI 10.1146/annurev.ge.23.120189.003133; BORST P, 1987, SCIENCE, V235, P658, DOI 10.1126/science.3544215; BZIK DJ, 1988, MOL BIOCHEM PARASIT, V30, P279, DOI 10.1016/0166-6851(88)90097-7; CORCORAN LM, 1986, CELL, V44, P87, DOI 10.1016/0092-8674(86)90487-3; DEBRUIN D, 1992, GENOMICS, V14, P332, DOI 10.1016/S0888-7543(05)80223-X; FENTON B, 1991, MOL CELL BIOL, V11, P963, DOI 10.1128/MCB.11.2.963; GOMAN M, 1982, MOL BIOCHEM PARASIT, V5, P391, DOI 10.1016/0166-6851(82)90012-3; KEMP DJ, 1985, NATURE, V315, P347, DOI 10.1038/315347a0; LANZER M, 1992, EMBO J, V11, P1949, DOI 10.1002/j.1460-2075.1992.tb05248.x; LUTZKER S, 1988, CELL, V53, P177, DOI 10.1016/0092-8674(88)90379-0; PATARAPOTIKUL J, 1988, NUCLEIC ACIDS RES, V16, P4331, DOI 10.1093/nar/16.10.4331; PETERSON DS, 1988, P NATL ACAD SCI USA, V85, P9115; POLLACK Y, 1982, NUCLEIC ACIDS RES, V10, P539, DOI 10.1093/nar/10.2.539; POLOGE LG, 1986, NATURE, V322, P474, DOI 10.1038/322474a0; POLOGE LG, 1988, CELL, V55, P869, DOI 10.1016/0092-8674(88)90142-0; SMYTHE JA, 1988, P NATL ACAD SCI USA, V85, P5159; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; TRIGLIA T, 1987, EMBO J, V6, P1413, DOI 10.1002/j.1460-2075.1987.tb02382.x; VANDERPLOEG LHT, 1985, SCIENCE, V229, P658, DOI 10.1126/science.3895435; WALKERJONAH A, 1992, MOL BIOCHEM PARASIT, V51, P313, DOI 10.1016/0166-6851(92)90081-T; WALLIKER D, 1987, SCIENCE, V236, P1661, DOI 10.1126/science.3299700; WELLEMS TE, 1987, CELL, V49, P633, DOI 10.1016/0092-8674(87)90539-3; WELLEMS TE, 1990, NATURE, V345, P253, DOI 10.1038/345253a0	24	61	62	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 18	1993	361	6413					654	657		10.1038/361654a0	http://dx.doi.org/10.1038/361654a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KM776	8437626				2022-12-24	WOS:A1993KM77600069
J	LALLIER, T; BRONNERFRASER, M				LALLIER, T; BRONNERFRASER, M			INHIBITION OF NEURAL CREST CELL ATTACHMENT BY INTEGRIN ANTISENSE OLIGONUCLEOTIDES	SCIENCE			English	Article							AMINO-ACID SEQUENCE; ACETYLTRANSFERASE GENE-EXPRESSION; ADHESION MOLECULE-1 EXPRESSION; H INDEPENDENT MECHANISM; 2 DISTINCT MECHANISMS; HUMAN BREAST-CANCER; C-MYC EXPRESSION; PHOSPHOROTHIOATE OLIGONUCLEOTIDES; TRANSLATION INITIATION; ALKYL PHOSPHOTRIESTER	Neural crest cell interactions with extracellular matrix molecules were analyzed with the use of antisense oligonucleotides to block synthesis of integrin subunits. When added to the culture medium of quail neural crest cells, selected antisense phosphorothiol oligonucleotides reduced the amounts of cell surface alpha1 or beta1, integrin subunits by up to 95 percent and inhibited neural crest cell attachment to laminin or fibronectin substrata. Differential effects on specific alpha integrins were noted after treatment with alpha-specific oligonucleotides. Cells recovered the ability to bind to substrata 8 to 16 hours after treatment with inhibitory oligonucleotides. The operation of at least three distinct alpha integrin subunits is indicated by substratum-selective inhibition of cell attachment.	UNIV CALIF IRVINE,CTR DEV BIOL,IRVINE,CA 92717	University of California System; University of California Irvine			Lallier, Thomas E/K-5977-2015	Lallier, Thomas/0000-0001-6577-6676; Bronner, Marianne/0000-0003-4274-1862	PHS HHS [15527] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AGRAWAL S, 1989, P NATL ACAD SCI USA, V86, P7790, DOI 10.1073/pnas.86.20.7790; AKHTAR S, 1991, LIFE SCI, V49, P1793, DOI 10.1016/0024-3205(91)90480-Y; ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; BOIZIAU C, 1991, NUCLEIC ACIDS RES, V19, P1113, DOI 10.1093/nar/19.5.1113; BOSSY B, 1991, EMBO J, V10, P2375, DOI 10.1002/j.1460-2075.1991.tb07776.x; BOSSY B, 1990, BIOCHEMISTRY-US, V29, P10191, DOI 10.1021/bi00496a006; BRONNERFRASER M, 1986, DEV BIOL, V117, P528, DOI 10.1016/0012-1606(86)90320-9; BRONNERFRASER M, 1988, J CELL BIOL, V106, P1321, DOI 10.1083/jcb.106.4.1321; BRONNERFRASER M, 1985, J CELL BIOL, V101, P610, DOI 10.1083/jcb.101.2.610; BRONNERFRASER M, 1988, J NEUROSCI RES, V21, P135, DOI 10.1002/jnr.490210206; BUCK CA, 1986, J CELL BIOL, V103, P2421, DOI 10.1083/jcb.103.6.2421; BURCH RM, 1991, J CLIN INVEST, V88, P1190, DOI 10.1172/JCI115421; CACERES A, 1990, NATURE, V343, P461, DOI 10.1038/343461a0; CHIANG MY, 1991, J BIOL CHEM, V266, P18162; CORBI AL, 1987, EMBO J, V6, P4023, DOI 10.1002/j.1460-2075.1987.tb02746.x; COTTEN M, 1991, NUCLEIC ACIDS RES, V19, P2629, DOI 10.1093/nar/19.10.2629; DECURTIS I, 1991, J CELL BIOL, V113, P405, DOI 10.1083/jcb.113.2.405; HAYASHI Y, 1991, CELL STRUCT FUNCT, V16, P241, DOI 10.1247/csf.16.241; HEINO J, 1989, J BIOL CHEM, V264, P380; HICKSTEIN DD, 1989, P NATL ACAD SCI USA, V86, P257, DOI 10.1073/pnas.86.1.257; HOKE GD, 1991, NUCLEIC ACIDS RES, V19, P5743, DOI 10.1093/nar/19.20.5743; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; IGNATIUS MJ, 1990, J CELL BIOL, V111, P709, DOI 10.1083/jcb.111.2.709; LALLIER T, 1991, DEVELOPMENT, V113, P1069; LALLIER T, 1992, J CELL BIOL, V119, P1335, DOI 10.1083/jcb.119.5.1335; Lallier T., 1990, Seminars in Developmental Biology, V1, P35; LAPIDOTLIESON Y, 1992, P NATL ACAD SCI USA, V89, P579, DOI 10.1073/pnas.89.2.579; LEONETTI JP, 1991, P NATL ACAD SCI USA, V88, P2702, DOI 10.1073/pnas.88.7.2702; LISTERUD M, 1991, SCIENCE, V254, P1518, DOI 10.1126/science.1720573; MANSON J, 1990, LYMPHOKINE RES, V9, P35; MARCUSSEKURA CJ, 1987, NUCLEIC ACIDS RES, V15, P5749, DOI 10.1093/nar/15.14.5749; MCCLAY DR, 1981, P NATL ACAD SCI-BIOL, V78, P4975, DOI 10.1073/pnas.78.8.4975; NEUHAUS H, 1991, J CELL BIOL, V115, P1149, DOI 10.1083/jcb.115.4.1149; PYTELA R, 1988, EMBO J, V7, P1371, DOI 10.1002/j.1460-2075.1988.tb02953.x; SUZUKI S, 1987, J BIOL CHEM, V262, P14080; SYFRIG J, 1991, EXP CELL RES, V194, P165, DOI 10.1016/0014-4827(91)90349-Y; TAKADA Y, 1991, J CELL BIOL, V115, P257, DOI 10.1083/jcb.115.1.257; TAKADA Y, 1989, EMBO J, V8, P1361, DOI 10.1002/j.1460-2075.1989.tb03516.x; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; TAMKUN JW, 1986, CELL, V46, P271, DOI 10.1016/0092-8674(86)90744-0; TAMURA RN, 1990, J CELL BIOL, V111, P1593, DOI 10.1083/jcb.111.4.1593; TEICHMANWEINBERG A, 1988, GENE, V72, P297, DOI 10.1016/0378-1119(88)90155-2; WATSON PH, 1991, CANCER RES, V51, P3996; WOOLF TM, 1990, NUCLEIC ACIDS RES, V18, P1743	44	94	101	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 29	1993	259	5095					692	695		10.1126/science.8430321	http://dx.doi.org/10.1126/science.8430321			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KJ688	8430321				2022-12-24	WOS:A1993KJ68800046
J	COULTER, A; KLASSEN, A; MACKENZIE, IZ; MCPHERSON, K				COULTER, A; KLASSEN, A; MACKENZIE, IZ; MCPHERSON, K			DIAGNOSTIC DILATATION AND CURETTAGE - IS IT USED APPROPRIATELY	BRITISH MEDICAL JOURNAL			English	Article							HYSTEROSCOPY; WOMEN; ASPIRATION; HYSTERECTOMY; MENORRHAGIA; PIPELLE	Objective-To determine patterns of use of dilatation and curettage in Britain as compared with those in the United States; to examine variations in utilisation rates within one regional health authority. Design-Analysis of routinely collected hospital inpatient statistics. Setting-Statistics for England, Scotland, and the United States; local statistics for Oxford region. Subjects-All inpatient episodes in which dilatation and curettage was performed but excluding those related to pregnancy. Results-Dilatation and curettage rates remained stable in Britain between 1977 and 1990, whereas in the United States they declined dramatically. In 1989-90 the rate was 71.1 per 10000 women in England as compared with only 10.8 per 10000 in America. In 1989, 6936 women underwent diagnostic dilatation and curettage in the Oxford region, making it the most common elective operation. A total of 2726 (39%) of these women were under 40. There was a more than twofold variation in usage of the procedure among district health authorities within the region and even greater variation in rates in women under 40. The proportion of patients treated as day cases in the district general hospitals ranged from 22% to 82%. Conclusions-Dilatation and curettage may frequently be used inappropriately. The considerable variations in usage of dilatation and curettage internationally and nationally indicate differences in clinical perception of its appropriateness. This makes it suitable for audit. In developing guidelines it will be important to agree on the most appropriate patients and the relative merits of alternative methods of endometrial sampling. Probably this, could result in considerable cost savings at no risk and possibly some benefit to patients.	UNIV OXFORD,JOHN RADCLIFFE HOSP,NUFFIELD DEPT OBSTET & GYNAECOL,OXFORD OX3 9DU,ENGLAND; UNIV LONDON LONDON SCH HYG & TROP MED,DEPT PUBL HLTH & POLICY,LONDON WC1E 7HT,ENGLAND	University of Oxford; University of London; London School of Hygiene & Tropical Medicine	COULTER, A (corresponding author), UNIV OXFORD,RADCLIFFE INFIRM,DEPT PUBL HLTH & PRIMARY CARE,HLTH SERV RES UNIT,OXFORD OX2 6HE,ENGLAND.		Coulter, Angela/N-6998-2019; Klassen, Anne F/AAS-3211-2021	Coulter, Angela/0000-0002-6308-8375; Klassen, Anne F/0000-0003-4720-0096				[Anonymous], 1990, TABULAR LIST CLASSIF, V4th; [Anonymous], 1978, INT CLASSIFICATION D; [Anonymous], 1990, SHORT CUT BETTER SER; BROOKS PG, 1988, AM J OBSTET GYNECOL, V158, P1354, DOI 10.1016/0002-9378(88)90367-5; COULTER A, 1990, BMJ-BRIT MED J, V301, P273, DOI 10.1136/bmj.301.6746.273; COULTER A, 1988, SOC SCI MED, V27, P987, DOI 10.1016/0277-9536(88)90289-4; COULTER A, 1991, BRIT J OBSTET GYNAEC, V98, P789, DOI 10.1111/j.1471-0528.1991.tb13484.x; DANERO S, 1986, European Journal of Gynaecological Oncology, V7, P162; DEJONG P, 1990, BRIT J OBSTET GYNAEC, V97, P299; EDDOWES HA, 1990, BRIT J OBSTET GYNAEC, V97, P961, DOI 10.1111/j.1471-0528.1990.tb02458.x; FINIKIOTIS G, 1989, AUST NZ J OBSTET GYN, V29, P253, DOI 10.1111/j.1479-828X.1989.tb01731.x; FRASER IS, 1990, AM J OBSTET GYNECOL, V162, P1264, DOI 10.1016/0002-9378(90)90032-3; GIMPELSON RJ, 1988, AM J OBSTET GYNECOL, V158, P489, DOI 10.1016/0002-9378(88)90011-7; GOLDRATH MH, 1985, AM J OBSTET GYNECOL, V152, P220, DOI 10.1016/S0002-9378(85)80026-0; GREGG RH, 1981, AM J OBSTET GYNECOL, V140, P179, DOI 10.1016/0002-9378(81)90106-X; GRIMES DA, 1986, OBSTET GYNECOL, V67, P760, DOI 10.1097/00006250-198606000-00002; GRIMES DA, 1982, AM J OBSTET GYNECOL, V142, P1; HAMMOND RH, 1989, BRIT J OBSTET GYNAEC, V96, P496, DOI 10.1111/j.1471-0528.1989.tb02433.x; HAYNES PJ, 1977, BRIT J OBSTET GYNAEC, V84, P763, DOI 10.1111/j.1471-0528.1977.tb12490.x; LEWIS BV, 1990, BRIT J OBSTET GYNAEC, V97, P283, DOI 10.1111/j.1471-0528.1990.tb01803.x; LOFFER FD, 1989, OBSTET GYNECOL, V73, P16; LOFGREN O, 1988, ACTA OBSTET GYN SCAN, V67, P401, DOI 10.3109/00016348809004248; LUTZ MH, 1977, SOUTHERN MED J, V70, P393, DOI 10.1097/00007611-197704000-00003; MACKENZIE IZ, 1985, BRIT J OBSTET GYNAEC, V92, P1291, DOI 10.1111/j.1471-0528.1985.tb04878.x; MACKENZIE IZ, 1978, LANCET, V2, P566; MCPHERSON K, 1981, SOC SCI MED-MED SOC, V15, P273, DOI 10.1016/0271-7123(81)90011-0; MENCAGLIA L, 1987, J REPROD MED, V32, P577; SMITH JJ, 1985, OBSTET GYNECOL, V65, P516; STOCK RJ, 1975, OBSTET GYNECOL, V45, P537; STOVALL TG, 1989, OBSTET GYNECOL, V73, P405; STOVALL TG, 1991, AM J OBSTET GYNECOL, V165, P1287; SUAREZ RA, 1983, J REPROD MED, V28, P41; VALLE RF, 1981, SURG GYNECOL OBSTET, V153, P521; VESSEY M, 1979, HLTH B, V39, P59; VESSEY MP, 1992, BRIT J OBSTET GYNAEC, V99, P402, DOI 10.1111/j.1471-0528.1992.tb13758.x; WEBB MJ, 1976, OBSTET GYNECOL, V47, P239; 1982, NATIONAL HOSPITAL 13; 1990, SCOTTISH HLTH STATIS; 1991, HLTH US 1990; 1975, CLASSIFICATION SURGI; 1987, VITAL HLTH STATIS 13, V92; 1987, HOSPITAL INPATIE MB4	42	54	54	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 23	1993	306	6872					236	239		10.1136/bmj.306.6872.236	http://dx.doi.org/10.1136/bmj.306.6872.236			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ591	8443521	Bronze, Green Published			2022-12-24	WOS:A1993KJ59100017
J	CUENOUD, B; SCHEPARTZ, A				CUENOUD, B; SCHEPARTZ, A			ALTERED SPECIFICITY OF DNA-BINDING PROTEINS WITH TRANSITION-METAL DIMERIZATION DOMAINS	SCIENCE			English	Article							TRANSCRIPTIONAL ACTIVATOR PROTEIN; LEUCINE ZIPPER PROTEINS; YEAST GCN4; GEL-ELECTROPHORESIS; COILED COIL; FOS; JUN; DESIGN; C/EBP; MOTIF	The bZIP motif is characterized by a leucine zipper domain that mediates dimerization and a basic domain that contacts DNA. A series of transition metal dimerization domains were used to alter systematically the relative orientation of basic domain peptides. Both the affinity and the specificity of the peptide-DNA interaction depend on domain orientation. These results indicate that the precise configuration linking the domains is important; dimerization is not always sufficient for DNA binding. This approach to studying the effect of orientation on protein function complements mutagenesis and could be used in many systems.	YALE UNIV,DEPT CHEM,NEW HAVEN,CT 06511	Yale University								AGRE P, 1989, SCIENCE, V246, P922, DOI 10.1126/science.2530632; BLATTER EE, 1992, NATURE, V359, P650, DOI 10.1038/359650a0; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; CUENOUD B, 1991, TETRAHEDRON LETT, V28, P3325; CUENOUD B, IN PRESS P NATL ACAD; CUENOUD B, UNPUB; DEGRADO WF, 1989, SCIENCE, V243, P622, DOI 10.1126/science.2464850; DEVORE JL, 1987, PROBABILITY STATISTI; Fasman G. D., 1975, HDB BIOCH MOL BIOL, V1; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GARTENBERG MR, 1990, P NATL ACAD SCI USA, V87, P6034, DOI 10.1073/pnas.87.16.6034; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GHADIRI MR, 1992, J AM CHEM SOC, V114, P825, DOI 10.1021/ja00029a004; GUTTE B, 1979, NATURE, V281, P650, DOI 10.1038/281650a0; HAI T, 1988, GENE DEV, V2, P1216, DOI 10.1101/gad.2.10.1216; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HILL DE, 1986, SCIENCE, V234, P451, DOI 10.1126/science.3532321; HOPE IA, 1985, CELL, V43, P177, DOI 10.1016/0092-8674(85)90022-4; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; HOPE IA, 1987, EMBO J, V6, P2781, DOI 10.1002/j.1460-2075.1987.tb02573.x; HU JC, 1990, SCIENCE, V250, P1400, DOI 10.1126/science.2147779; JONES MW, 1992, INORG CHEM, V31, P1308, DOI 10.1021/ic00033a036; KAISER ET, 1987, TRENDS BIOCHEM SCI, V12, P305, DOI 10.1016/0968-0004(87)90147-2; KERPPOLA TK, 1991, SCIENCE, V254, P1210, DOI 10.1126/science.1957173; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; KOUZARIDES T, 1989, NATURE, V340, P568, DOI 10.1038/340568a0; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LIEBERMAN M, 1991, J AM CHEM SOC, V113, P1470, DOI 10.1021/ja00004a090; MANIATIS T, 1987, MOL CLONING; MAVROTHALASSITIS G, 1990, DNA CELL BIOL, V9, P783, DOI 10.1089/dna.1990.9.783; MORGAN GT, 1932, J CHEM SOC, V134, P20; MUTTER M, 1989, ANGEW CHEM INT EDIT, V28, P535, DOI 10.1002/anie.198905353; OAKLEY MG, 1990, SCIENCE, V248, P847, DOI 10.1126/science.2111578; OAS TG, 1990, BIOCHEMISTRY-US, V29, P2891, DOI 10.1021/bi00464a001; OLIPHANT AR, 1989, MOL CELL BIOL, V9, P2944, DOI 10.1128/MCB.9.7.2944; ONEIL KT, 1990, SCIENCE, V249, P774, DOI 10.1126/science.2389143; ONEIL KT, 1991, BIOCHEMISTRY-US, V30, P9030, DOI 10.1021/bi00101a017; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; PU WT, 1991, P NATL ACAD SCI USA, V88, P6901, DOI 10.1073/pnas.88.16.6901; PU WT, 1991, MOL CELL BIOL, V11, P4918, DOI 10.1128/MCB.11.10.4918; RANSONE LJ, 1989, GENE DEV, V3, P770, DOI 10.1101/gad.3.6.770; RASMUSSEN R, 1991, P NATL ACAD SCI USA, V88, P561, DOI 10.1073/pnas.88.2.561; RICHARDSON JS, 1989, TRENDS BIOCHEM SCI, V14, P304, DOI 10.1016/0968-0004(89)90070-4; SAUDEK V, 1991, PROTEIN ENG, V4, P519, DOI 10.1093/protein/4.5.519; SCHEPARTZ A, 1989, J AM CHEM SOC, V111, P5976, DOI 10.1021/ja00197a088; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SELLERS JW, 1990, MOL CELL BIOL, V10, P5077, DOI 10.1128/MCB.10.10.5077; SELLERS JW, 1989, NATURE, V341, P74, DOI 10.1038/341074a0; SHUMAN JD, 1990, SCIENCE, V249, P771, DOI 10.1126/science.2202050; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; TALANIAN RV, 1990, SCIENCE, V249, P769, DOI 10.1126/science.2389142; TALANIAN RV, 1992, BIOCHEMISTRY-US, V31, P6871, DOI 10.1021/bi00145a002; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; TZAMARIAS D, 1992, P NATL ACAD SCI USA, V89, P2007, DOI 10.1073/pnas.89.6.2007; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; WEISS MA, 1990, BIOCHEMISTRY-US, V29, P8020, DOI 10.1021/bi00487a004	60	126	126	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 22	1993	259	5094					510	513		10.1126/science.8424173	http://dx.doi.org/10.1126/science.8424173			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KJ079	8424173				2022-12-24	WOS:A1993KJ07900033
J	LEE, DY; HAYES, JJ; PRUSS, D; WOLFFE, AP				LEE, DY; HAYES, JJ; PRUSS, D; WOLFFE, AP			A POSITIVE ROLE FOR HISTONE ACETYLATION IN TRANSCRIPTION FACTOR ACCESS TO NUCLEOSOMAL DNA	CELL			English	Article							5S RNA GENE; CHROMATIN CORE PARTICLES; LINKING NUMBER CHANGE; TUMOR VIRUS PROMOTER; SILENT MATING LOCI; FACTOR-IIIA; 5S-RNA GENE; C-FOS; BINDING; REPRESSION	Acetylation of the N-terminal tails of the core histones directly facilitates the recognition by TFIIIA of the 5S RNA gene within model chromatin templates. This effect is independent of a reduction in the extent of histone-DNA interactions or a change in DNA helical repeat; it is also independent of whether a histone tetramer or octamer inhibits TFIIIA binding. Removal of the N-terminal tails from the core histones also facilitates the association of TFIIIA with nucleosomal templates. We suggest that the histone tails have a major role in restricting transcription factor access to DNA and that their acetylation releases this restriction by directing dissociation of the tails from DNA and/or inducing a change in DNA configuration on the histone core to allow transcription factor binding. Acetylation of core histones might be expected to exert a major influence on the accessibility of chromatin to regulatory molecules.			LEE, DY (corresponding author), NICHHD, MOLEC EMBRYOL LAB, BETHESDA, MD 20892 USA.							ALLFREY VG, 1964, P NATL ACAD SCI USA, V51, P786, DOI 10.1073/pnas.51.5.786; ALMOUZNI G, 1991, MOL CELL BIOL, V11, P655, DOI 10.1128/MCB.11.2.655; ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; AUSIO J, 1986, BIOCHEMISTRY-US, V25, P1421, DOI 10.1021/bi00354a035; AUSIO J, 1989, J MOL BIOL, V206, P451, DOI 10.1016/0022-2836(89)90493-2; BAER BW, 1983, NATURE, V301, P482, DOI 10.1038/301482a0; BOHM L, 1984, BIOSCIENCE REP, V4, P365, DOI 10.1007/BF01122502; BOLUND LA, 1973, EUR J BIOCHEM, V35, P546, DOI 10.1111/j.1432-1033.1973.tb02871.x; CAMERINIOTERO RD, 1976, CELL, V8, P333, DOI 10.1016/0092-8674(76)90145-8; CARY PD, 1982, EUR J BIOCHEM, V127, P137, DOI 10.1111/j.1432-1033.1982.tb06847.x; CARY PD, 1978, EUR J BIOCHEM, V89, P475, DOI 10.1111/j.1432-1033.1978.tb12551.x; CHEN TA, 1990, J MOL BIOL, V212, P481, DOI 10.1016/0022-2836(90)90327-I; CHEN TA, 1987, P NATL ACAD SCI USA, V84, P5252, DOI 10.1073/pnas.84.15.5252; CHRISTENSEN ME, 1984, NUCLEIC ACIDS RES, V12, P4575, DOI 10.1093/nar/12.11.4575; CLARK DJ, 1991, EMBO J, V10, P3419, DOI 10.1002/j.1460-2075.1991.tb04906.x; DABAN JR, 1982, J MOL BIOL, V156, P749, DOI 10.1016/0022-2836(82)90140-1; DELCUVE GP, 1992, ANAL BIOCHEM, V200, P339, DOI 10.1016/0003-2697(92)90475-M; DELRIO S, 1991, NUCLEIC ACIDS RES, V19, P6197; DONG F, 1991, P NATL ACAD SCI USA, V88, P10596, DOI 10.1073/pnas.88.23.10596; DONG F, 1990, P NATL ACAD SCI USA, V87, P5724, DOI 10.1073/pnas.87.15.5724; DURRIN LK, 1991, CELL, V65, P1023, DOI 10.1016/0092-8674(91)90554-C; FAIRALL L, 1986, J MOL BIOL, V192, P577, DOI 10.1016/0022-2836(86)90278-0; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FITZGERALD PC, 1985, J BIOL CHEM, V260, P5318; GOLDBLATT D, 1975, BIOCHEMISTRY-US, V14, P1689, DOI 10.1021/bi00679a022; GOTTESFELD JM, 1987, MOL CELL BIOL, V7, P1612, DOI 10.1128/MCB.7.5.1612; GRIGORYEV SA, 1982, EUR J BIOCHEM, V129, P119, DOI 10.1111/j.1432-1033.1982.tb07029.x; HANSEN JC, 1991, J BIOL CHEM, V266, P4276; HAYES JJ, 1990, P NATL ACAD SCI USA, V87, P7405, DOI 10.1073/pnas.87.19.7405; HAYES JJ, 1991, P NATL ACAD SCI USA, V88, P6829, DOI 10.1073/pnas.88.15.6829; HAYES JJ, 1992, P NATL ACAD SCI USA, V89, P1229, DOI 10.1073/pnas.89.4.1229; HAYES JJ, 1992, J MOL BIOL, V227, P407, DOI 10.1016/0022-2836(92)90897-S; JOHNSON LM, 1990, P NATL ACAD SCI USA, V87, P6286, DOI 10.1073/pnas.87.16.6286; KAYNE PS, 1988, CELL, V55, P27, DOI 10.1016/0092-8674(88)90006-2; KLUG A, 1981, NUCLEIC ACIDS RES, V9, P4267, DOI 10.1093/nar/9.17.4267; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIAO XB, 1992, J MOL BIOL, V223, P857, DOI 10.1016/0022-2836(92)90248-I; LIN R, 1989, J CELL BIOL, V108, P1577, DOI 10.1083/jcb.108.5.1577; MARVIN KW, 1990, J BIOL CHEM, V265, P19839; MEERSSEMAN G, 1992, EMBO J, V11, P2951, DOI 10.1002/j.1460-2075.1992.tb05365.x; NORTON VG, 1989, CELL, V57, P449, DOI 10.1016/0092-8674(89)90920-3; NORTON VG, 1990, J BIOL CHEM, V265, P19848; OLIVA R, 1990, NUCLEIC ACIDS RES, V18, P2739, DOI 10.1093/nar/18.9.2739; PERLMANN T, 1992, P NATL ACAD SCI USA, V89, P3884, DOI 10.1073/pnas.89.9.3884; PERLMANN T, 1988, EMBO J, V7, P3073, DOI 10.1002/j.1460-2075.1988.tb03172.x; PERRY CA, 1989, NUCLEIC ACIDS RES, V17, P4275, DOI 10.1093/nar/17.11.4275; PERRY M, 1981, J BIOL CHEM, V256, P3313; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; RHODES D, 1985, EMBO J, V4, P3473, DOI 10.1002/j.1460-2075.1985.tb04106.x; RICHMOND TJ, 1984, NATURE, V311, P532, DOI 10.1038/311532a0; ROBERGE M, 1991, FEBS LETT, V288, P215, DOI 10.1016/0014-5793(91)81037-9; ROTH SY, 1992, GENE DEV, V6, P411, DOI 10.1101/gad.6.3.411; SAKONJU S, 1982, CELL, V31, P395, DOI 10.1016/0092-8674(82)90133-7; SIMON RH, 1979, NUCLEIC ACIDS RES, V6, P689, DOI 10.1093/nar/6.2.689; SIMPSON RT, 1991, PROG NUCLEIC ACID RE, V40, P143; SMITH DR, 1984, CELL, V37, P645, DOI 10.1016/0092-8674(84)90396-9; SUNG MT, 1970, P NATL ACAD SCI USA, V67, P1616, DOI 10.1073/pnas.67.3.1616; TATCHELL K, 1977, BIOCHEMISTRY-US, V16, P5295, DOI 10.1021/bi00643a021; TAYLOR ICA, 1991, GENE DEV, V5, P1285, DOI 10.1101/gad.5.7.1285; THOMA F, 1979, J CELL BIOL, V83, P403, DOI 10.1083/jcb.83.2.403; TREMETHICK D, 1990, J BIOL CHEM, V265, P5014; TURNER BM, 1992, CELL, V69, P375, DOI 10.1016/0092-8674(92)90417-B; VRANA KE, 1988, MOL CELL BIOL, V8, P1684, DOI 10.1128/MCB.8.4.1684; WALKER IO, 1984, BIOCHEMISTRY-US, V23, P5622, DOI 10.1021/bi00318a037; WALKER J, 1990, J BIOL CHEM, V265, P5736; WATERBORG JH, 1984, EUR J BIOCHEM, V142, P329, DOI 10.1111/j.1432-1033.1984.tb08290.x; WHITE JH, 1989, J MOL BIOL, V207, P193, DOI 10.1016/0022-2836(89)90450-6; WHITEWAY M, 1985, CELL, V43, P483, DOI 10.1016/0092-8674(85)90178-3; WHITLOCK JP, 1977, J BIOL CHEM, V252, P6516; WINSOR WT, 1988, J BIOL CHEM, V263, P10272; WOLFFE AP, 1986, CELL, V44, P381, DOI 10.1016/0092-8674(86)90459-9; WOLFFE AP, 1988, SCIENCE, V241, P1626, DOI 10.1126/science.3420414; WOLFFE AP, 1987, CELL, V51, P732, DOI 10.1016/0092-8674(87)90096-1; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; Zweidler A, 1978, Methods Cell Biol, V17, P223, DOI 10.1016/S0091-679X(08)61145-0	75	967	1000	0	37	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 15	1993	72	1					73	84		10.1016/0092-8674(93)90051-Q	http://dx.doi.org/10.1016/0092-8674(93)90051-Q			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KG955	8422685				2022-12-24	WOS:A1993KG95500011
J	SCHRENK, F; BROMAGE, TG; BETZLER, CG; RING, U; JUWAYEYI, YM				SCHRENK, F; BROMAGE, TG; BETZLER, CG; RING, U; JUWAYEYI, YM			OLDEST HOMO AND PLIOCENE BIOGEOGRAPHY OF THE MALAWI RIFT	NATURE			English	Article								THE Malawi Rift and Pliocene palaeofaunas, which include a hominid mandible attributed to Homo rudolfensis, provide a biogeographical link between the better known Plio-Pleistocene faunal records of East and Southern Africa. The Malawi Rift is in a latitudinal position suitable for recording any hominid and faunal dispersion towards the Equator that was brought on by increased aridity of the Late Pliocene African landscape. The evidence suggests that Pliocene hominids originated in the eastern African tropical domain and dispersed to southern Africa only during more favourable ecological circumstances.	UNIV FRANKFURT,INST GEOL PALAONTOL,D-60325 FRANKFURT,GERMANY; UNIV MAINZ,INST GEOWISSENSCH,D-55099 MAINZ,GERMANY; DEPT ANTIQUITIES,LILONGWE,MALAWI; CUNY HUNTER COLL,DEPT ANTHROPOL,NEW YORK,NY 10021	Goethe University Frankfurt; Johannes Gutenberg University of Mainz; City University of New York (CUNY) System; Hunter College (CUNY)	SCHRENK, F (corresponding author), HESS LANDESMUSEUM,DEPT PALAEONTOL,FRIEDENSPL 1,D-64283 DARMSTADT,GERMANY.		Klein, Richard G/B-5910-2009; bromage, timothy/H-8621-2015	bromage, timothy/0000-0002-9843-7993; Betzler, Christian/0000-0002-5757-4553				BETZLER C, IN PRESS J HUM EVOL; BONNEFILLE R, 1976, EARLIEST MAN ENV LAK, P421; Bromage T. G., 1987, J HUM EVOL, V15, P497; BROMAGE TG, IN PRESS J HUM EVOL; Brown F.H., 1988, P325; BROWN FH, 1976, EARLIEST MAN ENV LAK, P50; CLARK JD, 1966, AM ANTHROPOL, V68, P46; Clark JD, 1970, QUATERNARIA, V13, P305; CROSSLEY R, 1980, ACCAD NAZ LINCEI, V47, P77; Delson E., 1984, Courier Forschungsinstitut Senckenberg, V69, P199; DIXEY FQ, 1927, J GEOL SOC LONDON, V83, P432; EBINGER CJ, 1989, GEOL SOC AM BULL, V101, P885, DOI 10.1130/0016-7606(1989)101<0885:TDOTWB>2.3.CO;2; HARRIS J, 1991, KOOBI FORA RES PROJE, V3, P215; HILL A, 1992, NATURE, V355, P719, DOI 10.1038/355719a0; KAUFULU Z, 1981, Annals of the Transvaal Museum, V33, P1; RING U, IN PRESS J HUM EVOL; SCHRENK F, IN PRESS J HUM EVOL; STRECKER MR, 1990, GEOLOGY, V18, P299, DOI 10.1130/0091-7613(1990)018<0299:ROEDIT>2.3.CO;2; TURNER A, 1993, J HUM EVOL, V24, P147, DOI 10.1006/jhev.1993.1011; Vrba E.S., 1988, P405; VRBA ES, 1985, S AFR J SCI, V81, P224; VRBA ES, 1992, J MAMMAL, V73, P1, DOI 10.2307/1381862; VRBA ES, 1982, PRETIRAGE; WOOD B, 1992, NATURE, V355, P678, DOI 10.1038/355678a0; WOOD B, 1992, NATURE, V355, P783, DOI 10.1038/355783a0; Wood B., 1991, HOMINID CRANIAL REMA, V4	26	106	108	0	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 28	1993	365	6449					833	836		10.1038/365833a0	http://dx.doi.org/10.1038/365833a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MD951	8413666				2022-12-24	WOS:A1993MD95100048
J	YOU, GF; SMITH, CP; KANAI, Y; LEE, WS; STELZNER, M; HEDIGER, MA				YOU, GF; SMITH, CP; KANAI, Y; LEE, WS; STELZNER, M; HEDIGER, MA			CLONING AND CHARACTERIZATION OF THE VASOPRESSIN-REGULATED UREA TRANSPORTER	NATURE			English	Article								UREA is the principal end product of nitrogen metabolism in mammals1. Movement of urea across cell membranes was originally thought to occur by lipid-phase permeation, but recent studies have revealed the existence of specialized transporters with a low affinity for urea (K(m) > 200 mM)2. Here we report the isolation of a complementary DNA from rabbit renal medulla that encodes a 397-amino-acid membrane glycoprotein, UT2, with the functional characteristics of the vasopressin-sensitive urea transporter previously described in in vitro-perfused inner medullary collecting ducts3,4. UT2 is not homologous to any known protein and displays a unique pattern of hydrophobicity. Because of the central role of this transporter in fluid balance1,3-7 and nitrogen metabolism8, the study of this protein will provide important insights into the urinary concentrating mechanism and nitrogen balance.	BRIGHAM & WOMENS HOSP,DEPT MED,DIV RENAL,75 FRANCIS ST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School				Hediger, Matthias/0000-0003-1946-027X				BRAHM J, 1983, J GEN PHYSIOL, V82, P1, DOI 10.1085/jgp.82.1.1; CHOU CL, 1989, AM J PHYSIOL, V257, pF359, DOI 10.1152/ajprenal.1989.257.3.F359; CHOU CL, 1990, AM J PHYSIOL, V258, pF486, DOI 10.1152/ajprenal.1990.258.3.F486; EFFROS RM, 1992, AM J PHYSIOL, V263, pL619, DOI 10.1152/ajplung.1992.263.6.L619; EFFROS RM, 1992, FASEB J, V6, pA2073; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FUSHIMI K, 1993, NATURE, V361, P549, DOI 10.1038/361549a0; HEDIGER MA, 1987, P NATL ACAD SCI USA, V84, P2634, DOI 10.1073/pnas.84.9.2634; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; HEDIGER MA, 1991, BIOCHIM BIOPHYS ACTA, V1064, P360, DOI 10.1016/0005-2736(91)90323-Z; IMAI M, 1984, PFLUG ARCH EUR J PHY, V402, P385, DOI 10.1007/BF00583939; KANAI Y, 1992, AM J PHYSIOL, V263, pF1087, DOI 10.1152/ajprenal.1992.263.6.F1087; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KAWAMURA S, 1976, J CLIN INVEST, V58, P604, DOI 10.1172/JCI108507; KNEPPER MA, 1990, AM J PHYSIOL, V259, pF393, DOI 10.1152/ajprenal.1990.259.3.F393; KNEPPER MA, 1989, AM J PHYSIOL, V256, pF610, DOI 10.1152/ajprenal.1989.256.4.F610; KNEPPER MA, 1987, KIDNEY INT, V31, P629, DOI 10.1038/ki.1987.44; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANGRAN M, 1992, CLIN SCI, V82, P191, DOI 10.1042/cs0820191; MARSH DJ, 1992, HDB PHYSL 8, V2, P1317; MAYRAND RR, 1983, J GEN PHYSIOL, V81, P221, DOI 10.1085/jgp.81.2.221; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; PALLONE TL, IN PRESS J CLIN INVE; SANDS JM, 1990, KIDNEY INT, V38, P695, DOI 10.1038/ki.1990.261; SANDS JM, 1987, J CLIN INVEST, V79, P138, DOI 10.1172/JCI112774; SANDS JM, 1987, AM J PHYSIOL, V253, pF823, DOI 10.1152/ajprenal.1987.253.5.F823; SANDS JM, 1988, VASOPRESSIN CELLULAR, P137; SNUTCH TP, 1990, P NATL ACAD SCI USA, V87, P3391, DOI 10.1073/pnas.87.9.3391; STAR RA, 1988, J CLIN INVEST, V81, P1879, DOI 10.1172/JCI113534; TOON MR, 1988, BIOCHIM BIOPHYS ACTA, V940, P266, DOI 10.1016/0005-2736(88)90201-5; UEZONO Y, 1991, RECEPT CHANNELS, V1, P233; ZHANG R, 1990, J MEMBRANE BIOL, V117, P253, DOI 10.1007/BF01868455	33	274	281	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 28	1993	365	6449					844	847		10.1038/365844a0	http://dx.doi.org/10.1038/365844a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MD951	8413669				2022-12-24	WOS:A1993MD95100052
J	LEHMKUHLE, S; GARZIA, RP; TURNER, L; HASH, T; BARO, JA				LEHMKUHLE, S; GARZIA, RP; TURNER, L; HASH, T; BARO, JA			A DEFECTIVE VISUAL PATHWAY IN CHILDREN WITH READING-DISABILITY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LATERAL GENICULATE-NUCLEUS; SPECIFICALLY DISABLED READERS; DEPENDENT VISIBLE PERSISTENCE; CONTRAST SENSITIVITY; SPATIAL-FREQUENCY; X-CELL; Y-CELL; LUMINANCE; DYSLEXIA; MASKING	Background. The possibility that reading disability in children is associated with visual problems is in dispute. We sought to test the existence of this association by using electrophysiologic techniques to measure the processing of visual information in the magnicellular and parvicellular visual pathways of the brain. Methods. Visual evoked potentials were measured with scalp electrodes in children 8 to 11 years old who were normal readers and in those with reading disability. The potentials were measured for targets with low (0.5 cycle per degree of visual angle) and high (4.5 cycles per degree) spatial frequency, surrounded by either a steady background or a uniform-field flickering 12 times per second. A flickering field normally reduces the amplitude and increases the latency of a transient potential evoked by a low-spatial-frequency target, which preferentially excites the magnicellular visual pathway, but has little effect on the response to a high-spatial-frequency target. Results. With a steady background, the latencies of the early components (N1 and P1) of the visual evoked potentials were longer in the reading-disabled children than in the normal readers when the low-spatial-frequency target was used, but not when the high-spatial-frequency target was used. In normal readers, the flickering background increased the latency and reduced the amplitude of the early components, whereas in the reading-disabled children only the amplitude was affected. No differences were observed in either group with the high-spatial-frequency target. Conclusions. The pattern of results suggests that the response of the magnicellular visual pathway is slowed in reading-disabled children, who do not, however, have a general slowing of the visual response. The possibility that there is a cause-and-effect relation between these findings and reading disability will require further study.			LEHMKUHLE, S (corresponding author), UNIV MISSOURI,SCH OPTOMETRY,8001 NAT BRIDGE RD,ST LOUIS,MO 63121, USA.							BADCOCK D, 1981, J EXP PSYCHOL HUMAN, V7, P495, DOI 10.1037/0096-1523.7.3.495; BARO JA, 1988, BEHAV RES METH INSTR, V20, P515, DOI 10.3758/BF03202709; BARO JA, 1989, VISUAL NEUROSCI, V3, P563, DOI 10.1017/S0952523800009895; BARO JA, 1990, CLIN VISION SCI, V5, P265; Bassi C J, 1990, J Am Optom Assoc, V61, P98; BRANNAN JR, 1988, CLIN VISION SCI, V3, P137; BREITMEYER BG, 1976, PSYCHOL REV, V83, P1, DOI 10.1037/0033-295X.83.1.1; BREITMEYER BG, 1983, EYE MOVEMENTS READIN, P3; DERRINGTON AM, 1984, J PHYSIOL-LONDON, V357, P219, DOI 10.1113/jphysiol.1984.sp015498; KAPLAN E, 1982, J PHYSIOL-LONDON, V330, P125, DOI 10.1113/jphysiol.1982.sp014333; LIVINGSTONE M, 1988, SCIENCE, V240, P740, DOI 10.1126/science.3283936; LIVINGSTONE MS, 1991, P NATL ACAD SCI USA, V88, P7943, DOI 10.1073/pnas.88.18.7943; LOVEGROVE W, 1982, NEUROPSYCHOLOGIA, V20, P309, DOI 10.1016/0028-3932(82)90105-1; LOVEGROVE W, 1986, COGN NEUROPSYCHOL, V3, P225, DOI 10.1080/02643298608252677; Lovegrove W J, 1990, J Am Optom Assoc, V61, P137; LOVEGROVE WJ, 1980, SCIENCE, V210, P439, DOI 10.1126/science.7433985; LOVEGROVE WJ, 1980, NEUROPSYCHOLOGIA, V18, P111, DOI 10.1016/0028-3932(80)90093-7; MARTIN F, 1984, NEUROPSYCHOLOGIA, V22, P73, DOI 10.1016/0028-3932(84)90009-5; MARTIN F, 1987, PERCEPTION, V16, P215, DOI 10.1068/p160215; MARTIN F, 1988, PERCEPTION, V17, P203, DOI 10.1068/p170203; MAY JG, 1992, CLIN VISION SCI, V7, P67; MAY JG, 1988, NEUROPSYCHOLOGIA, V26, P917, DOI 10.1016/0028-3932(88)90059-0; MCCORMICK S, 1987, REMEDIAL CLIN READIN; SHAPIRO KL, 1990, J LEARN DISABIL, V23, P99, DOI 10.1177/002221949002300205; SHAPLEY R, 1981, NATURE, V292, P543, DOI 10.1038/292543a0; SHAYWITZ SE, 1990, JAMA-J AM MED ASSOC, V264, P998, DOI 10.1001/jama.264.8.998; SLAGHUIS WL, 1985, BRAIN COGNITION, V4, P219, DOI 10.1016/0278-2626(85)90071-5; SLAGHUIS WL, 1984, PERCEPTION, V13, P527, DOI 10.1068/p130527; STEDMAN LC, 1987, READ RES QUART, V22, P8, DOI 10.2307/747719; VELLUTINO FR, 1977, J LEARN DISABIL, V10, P375, DOI 10.1177/002221947701000614; Williams M C, 1990, J Am Optom Assoc, V61, P111; WILLIAMS MC, 1989, CLIN VISION SCI, V4, P137; WINTERS RL, 1989, J LEARN DISABIL-US, V22, P641, DOI 10.1177/002221948902201010; YULE W, 1974, BRIT J EDUC PSYCHOL, V44, P1, DOI 10.1111/j.2044-8279.1974.tb00760.x	34	110	111	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 8	1993	328	14					989	996		10.1056/NEJM199304083281402	http://dx.doi.org/10.1056/NEJM199304083281402			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KW282	8450876				2022-12-24	WOS:A1993KW28200002
J	CURHAN, GC; WILLETT, WC; RIMM, EB; STAMPFER, MJ				CURHAN, GC; WILLETT, WC; RIMM, EB; STAMPFER, MJ			A PROSPECTIVE-STUDY OF DIETARY CALCIUM AND OTHER NUTRIENTS AND THE RISK OF SYMPTOMATIC KIDNEY-STONES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEALTHY-SUBJECTS; EXCRETION; OXALATE; UROLITHIASIS; FREQUENCY; FORMERS; NEPHROLITHIASIS; HYPERCALCIURIA; HYPEROXALURIA; EPIDEMIOLOGY	Background. A high dietary calcium intake is strongly suspected of increasing the risk of kidney stones. However, a high intake of calcium can reduce the urinary excretion of oxalate, which is thought to lower the risk. The concept that a higher dietary calcium intake increases the risk of kidney stones therefore requires examination. Methods. We conducted a prospective study of the relation between dietary calcium intake and the risk of symptomatic kidney stones in a cohort of 45,619 men, 40 to 75 years of age, who had no history of kidney stones. Dietary calcium was measured by means of a semiquantitative food-frequency questionnaire in 1986. During four years of follow-up, 505 cases of kidney stones were documented. Results. After adjustment for age, dietary calcium intake was inversely associated with the risk of kidney stones; the relative risk of kidney stones for men in the highest as compared with the lowest quintile group for calcium intake was 0.56 (95 percent confidence interval, 0.43 to 0.73; P for trend, <0.001). This reduction in risk decreased only slightly (relative risk, 0.66; 95 percent confidence interval, 0.49 to 0.90) after further adjustment for other potential risk factors, including alcohol consumption and dietary intake of animal protein, potassium, and fluid. intake of animal protein was directly associated with the risk of stone formation (relative risk for men with the highest intake as compared with those with the lowest, 1.33; 95 percent confidence interval, 1.00 to 1.77); potassium intake (relative risk, 0.49; 95 percent confidence interval, 0.35 to 0.68) and fluid intake (relative risk, 0.71; 95 percent confidence interval, 0.52 to 0.97) were inversely related to the risk of kidney stones. Conclusions. A high dietary calcium intake decreases the risk of symptomatic kidney stones.	HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA; BROCKTON W ROXBURY VET AFFAIRS MED CTR, DIV RENAL, MED SERV, BOSTON, MA USA; HARVARD UNIV, SCH MED, CHANNING LAB, DEPT MED, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	CURHAN, GC (corresponding author), HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, 677 HUNTINGTON AVE, BOSTON, MA 02115 USA.				NATIONAL CANCER INSTITUTE [P01CA055075] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035464] Funding Source: NIH RePORTER; NCI NIH HHS [CA55075] Funding Source: Medline; NHLBI NIH HHS [HL35464] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARILLA DE, 1978, AM J MED, V64, P579, DOI 10.1016/0002-9343(78)90576-4; BATAILLE P, 1983, J UROLOGY, V130, P218, DOI 10.1016/S0022-5347(17)51073-3; BORSATTI A, 1991, KIDNEY INT, V39, P1283, DOI 10.1038/ki.1991.162; BRESLAU NA, 1988, J CLIN ENDOCR METAB, V66, P140, DOI 10.1210/jcem-66-1-140; COE FL, 1982, AM J MED, V72, P25, DOI 10.1016/0002-9343(82)90567-8; COE FL, 1976, J CHRON DIS, V29, P793, DOI 10.1016/0021-9681(76)90053-9; COE FL, 1988, NEPHROLITHIASIS PATH; Drach GW, 1986, CAMPBELLS UROLOGY, VII, P1094; EARNEST DL, 1974, GASTROENTEROLOGY, V66, P1114; FELLSTROM B, 1989, BRIT J UROL, V63, P575, DOI 10.1111/j.1464-410X.1989.tb05248.x; GOLDFARB S, 1988, KIDNEY INT, V34, P544, DOI 10.1038/ki.1988.216; GRIFFITH HM, 1981, BRIT J UROL, V53, P416, DOI 10.1111/j.1464-410X.1981.tb03220.x; HIATT RA, 1982, AM J EPIDEMIOL, V115, P255, DOI 10.1093/oxfordjournals.aje.a113297; JOHANSSON G, 1980, J UROLOGY, V124, P770, DOI 10.1016/S0022-5347(17)55655-4; JOHNSON CM, 1979, KIDNEY INT, V16, P624, DOI 10.1038/ki.1979.173; KASIDAS GP, 1980, J HUM NUTR, V34, P255; Kleinbaum D.G, 1988, APPL REGRESSION ANAL; LARSSON L, 1987, MINER ELECTROL METAB, V13, P242; LEMANN J, 1991, KIDNEY INT, V39, P973, DOI 10.1038/ki.1991.123; LEMANN J, 1979, NEW ENGL J MED, V301, P535, DOI 10.1056/NEJM197909063011008; LEMANN J, 1969, NEW ENGL J MED, V280, P232, DOI 10.1056/NEJM196901302800502; LINGEMAN JE, 1986, MED CARE, V24, P1151, DOI 10.1097/00005650-198612000-00007; Lingeman JE, 1989, URINARY CALCULI ESWL; MARSHALL RW, 1972, CLIN SCI, V43, P91, DOI 10.1042/cs0430091; MULDOWNEY FP, 1982, KIDNEY INT, V22, P292, DOI 10.1038/ki.1982.168; NORLIN A, 1976, SCAND J UROL NEPHROL, V10, P150, DOI 10.3109/00365597609179677; PAK CYC, 1988, J UROLOGY, V140, P461, DOI 10.1016/S0022-5347(17)41692-2; POWER C, 1984, BRIT J UROL, V56, P456; RAO PN, 1982, BRIT J UROL, V54, P578, DOI 10.1111/j.1464-410X.1982.tb13600.x; RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211; RIMM EB, 1990, AM J EPIDEMIOL, V131, P1068, DOI 10.1093/oxfordjournals.aje.a115598; ROBERTSON WG, 1979, J CHRON DIS, V32, P469, DOI 10.1016/0021-9681(79)90107-3; Rothman K, 1986, MODERN EPIDEMIOLOGY; SIERAKOWSKI R, 1978, INVEST UROL, V15, P438; TRINCHIERI A, 1991, BRIT J UROL, V67, P230, DOI 10.1111/j.1464-410X.1991.tb15124.x; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366; Willett W, 1990, NUTRITIONAL EPIDEMIO; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; YOSHIDA O, 1990, UROL INT, V45, P104, DOI 10.1159/000281680; ZAREMBSK.PM, 1969, CLIN CHIM ACTA, V25, P1, DOI 10.1016/0009-8981(69)90218-6	40	799	832	0	68	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 25	1993	328	12					833	838		10.1056/NEJM199303253281203	http://dx.doi.org/10.1056/NEJM199303253281203			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KT814	8441427				2022-12-24	WOS:A1993KT81400003
J	OLSEN, B; JAENSON, TGT; NOPPA, L; BUNIKIS, J; BERGSTROM, S				OLSEN, B; JAENSON, TGT; NOPPA, L; BUNIKIS, J; BERGSTROM, S			A LYME BORRELIOSIS CYCLE IN SEABIRDS AND IXODES-URIAE TICKS	NATURE			English	Article							MONOCLONAL-ANTIBODY; BURGDORFERI	THE Lyme disease spirochaete, Borrelia burgdorferi s.l., is the only Borrelia known to infect both mammals and birds1. The main vertebrate reservoirs of B. burgdorferi are thought to be various small and intermediate size mammals2, but the importance of birds as a reservoir has not been thoroughly explored. In the Northern and Southern Hemispheres the seabird tick, Ixodes uriae, is prevalent and closely associated with many species of colony-nesting marine birds3. Here we report the presence of spirochaetes, demonstrated by immunofluorescent assay, by polymerase chain reaction and in culture. in I. uriae infesting razorbills on an island in the Baltic Sea. This island is free from mammals. The protein profile of the spirochaetes and the sequences of their flagellin and ospA genes are identical to those of the Lyme disease spirochaete, Borrelia burgdorferi s.l., previously isolated from I. ricinus on a nearby island. In biopsies from the foot web of razorbills, B. burgdorferi-specific DNA was detected after amplification by polymerase chain reaction. Our results suggest that birds play an important part in the maintenance of B. burgdorferi and that mammals may not be a prerequisite for its life cycle.	UMEA UNIV,DEPT MICROBIOL,S-90187 UMEA,SWEDEN; UMEA UNIV,DEPT INFECT DIS,S-90187 UMEA,SWEDEN; UNIV UPPSALA,DEPT ZOOL,S-75122 UPPSALA,SWEDEN	Umea University; Umea University; Uppsala University				Olsen, Bjorn/0000-0002-4646-691X; Jaenson, Thomas/0000-0003-0780-7475				ANDERSON JF, 1986, INFECT IMMUN, V51, P394, DOI 10.1128/IAI.51.2.394-396.1986; ANDERSON JF, 1989, REV INFECT DIS, V11, pS1451; BARBOUR AG, 1984, YALE J BIOL MED, V57, P521; BARBOUR AG, 1986, INFECT IMMUN, V52, P549, DOI 10.1128/IAI.52.2.549-554.1986; BARBOUR AG, 1983, INFECT IMMUN, V41, P795, DOI 10.1128/IAI.41.2.795-804.1983; BERGSTROM S, 1989, MOL MICROBIOL, V3, P479, DOI 10.1111/j.1365-2958.1989.tb00194.x; BERGSTROM S, 1992, SCAND J INFECT DIS, V24, P181, DOI 10.3109/00365549209052610; Clifford C. M., 1979, Arctic and tropical arboviruses., P83; FILIPPOVA NA, 1977, IXODID TICKS SUBFAMI, V114; GASSMANN GS, 1989, NUCLEIC ACIDS RES, V17, P3590, DOI 10.1093/nar/17.9.3590; Kolonin G.V., 1981, WORLD DISTRIBUTION I; OLSEN B, 1992, VAR FAGELVARD, V3, P11; PICKEN RN, 1992, J CLIN MICROBIOL, V30, P99, DOI 10.1128/JCM.30.1.99-114.1992; POKKI J, 1981, ACTA ZOOL FENN, V164, P13; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Southwood TRE, 1978, ECOLOGICAL METHODS P, P170	16	168	176	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 25	1993	362	6418					340	342		10.1038/362340a0	http://dx.doi.org/10.1038/362340a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KU176	8455718				2022-12-24	WOS:A1993KU17600059
J	BRIGGS, H; ILETT, S				BRIGGS, H; ILETT, S			WEAK LINK IN VACCINE COLD CHAIN	BRITISH MEDICAL JOURNAL			English	Article							STORAGE		CTR COMMUNITY HLTH,BIRMINGHAM B12 0YA,ENGLAND; UNIV BIRMINGHAM,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND	University of Birmingham								HUNTER S, 1989, BRIT MED J, V299, P661, DOI 10.1136/bmj.299.6700.661; LUGOSI L, 1990, B WORLD HEALTH ORGAN, V68, P431; MALONELEE MC, 1992, PURCHASE SUPPLY VACC; THAKKER Y, 1992, BRIT MED J, V304, P756, DOI 10.1136/bmj.304.6829.756	4	18	18	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 27	1993	306	6877					557	558		10.1136/bmj.306.6877.557	http://dx.doi.org/10.1136/bmj.306.6877.557			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP886	8461771	Bronze, Green Published			2022-12-24	WOS:A1993KP88600023
J	MOYA, M; ROBERTS, D; NOVICK, P				MOYA, M; ROBERTS, D; NOVICK, P			DSS4-1 IS A DOMINANT SUPPRESSOR OF SEC4-8 THAT ENCODES A NUCLEOTIDE EXCHANGE PROTEIN THAT AIDS SEC4P FUNCTION	NATURE			English	Article							PLASMA-MEMBRANE; RAS PROTEINS; YEAST; DNA; SECRETION; SEQUENCES; BINDING	THE protein Sec4p plays an essential role at the final stage of the yeast secretory pathway and belongs to the ras superfamily of GTP-binding proteins1, more specifically to a branch that includes Ypt1p in Saccharomyces cerevisiae and rab proteins in mammalian cells. GTP-binding proteins change conformation depending on whether GTP or GDP is bound2 and can thus act as a regulatory switch. The protein remains in its inactive, GDP-bound form until exchange of GTP for GDP allows it to stimulate a downstream effector. This interaction is curtailed by GTP hydrolysis. The rates of nucleotide exchange and GTP hydrolysis can be regulated by interaction with accessory proteins3. Although GDP dissociation stimulators (GDS) have been identified that act on members of the ras and rho branches of the superfamily, less is known regarding GDSs that act on members of the Sec4/Ypt1/Rab subgroup. A preliminary characterization of a Rab3A GDP dissociation stimulating activity has been presented4. We report here the use of suppressor analysis to clone a gene, dss4, encoding a 17K protein that aids Sec4p action in vivo by functioning as a GDP dissociation stimulator.	YALE UNIV, SCH MED, DEPT CELL BIOL, 333 CEDAR ST, NEW HAVEN, CT 06510 USA	Yale University								BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BOWSER R, 1991, J CELL BIOL, V112, P1117, DOI 10.1083/jcb.112.6.1117; BURNSTEIN ES, 1992, P NATL ACAD SCI USA, V89, P1154; BURTON J, IN PRESS NATURE; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; EMANUEL JR, 1986, MOL CELL BIOL, V6, P2476, DOI 10.1128/MCB.6.7.2476; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; GUESDON JL, 1976, J IMMUNOL METHODS, V11, P129, DOI 10.1016/0022-1759(76)90140-X; HOLM C, 1986, GENE, V42, P169, DOI 10.1016/0378-1119(86)90293-3; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P227; KABCENELL AK, 1990, J BIOL CHEM, V265, P9366; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; NAIR J, 1990, J CELL BIOL, V110, P1897, DOI 10.1083/jcb.110.6.1897; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; NOVICK P, 1992, METHOD ENZYMOL, V219, P352; PHILIPPSEN P, 1991, METHOD ENZYMOL, V194, P169; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WALWORTH NC, 1992, MOL CELL BIOL, V12, P2017, DOI 10.1128/MCB.12.5.2017	25	103	104	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 4	1993	361	6411					460	463		10.1038/361460a0	http://dx.doi.org/10.1038/361460a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KK713	8429886				2022-12-24	WOS:A1993KK71300064
J	EISENBERG, DM; KESSLER, RC; FOSTER, C; NORLOCK, FE; CALKINS, DR; DELBANCO, TL				EISENBERG, DM; KESSLER, RC; FOSTER, C; NORLOCK, FE; CALKINS, DR; DELBANCO, TL			UNCONVENTIONAL MEDICINE IN THE UNITED-STATES - PREVALENCE, COSTS, AND PATTERNS OF USE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ALTERNATIVE MEDICINE; PRIMARY CARE; PRACTITIONERS; THERAPIES; REMEDIES; PATIENT	Background. Many people use unconventional therapies for health problems, but the extent of this use and the costs are not known. We conducted a national survey to determine the prevalence, costs, and patterns of use of unconventional therapies, such as acupuncture and chiropractic. Methods. We limited the therapies studied to 16 commonly used interventions neither taught widely in U.S. medical schools nor generally available in U.S. hospitals. We completed telephone interviews with 1539 adults (response rate, 67 percent) in a national sample of adults 18 years of age or older in 1990. We asked respondents to report any serious or bothersome medical conditions and details of their use of conventional medical services; we then inquired about their use of unconventional therapy. Results. One in three respondents (34 percent) reported using at least one unconventional therapy in the past year, and a third of these saw providers for unconventional therapy. The latter group had made an average of 19 visits to such providers during the preceding year, with an average charge per visit of $27.60. The frequency of use of unconventional therapy varied somewhat among sociodemographic groups, with the highest use reported by nonblack persons from 25 to 49 years of age who had relatively more education and higher incomes. The majority used unconventional therapy for chronic, as opposed to life-threatening, medical conditions. Among those who used unconventional therapy for serious medical conditions, the vast majority (83 percent) also sought treatment for the same condition from a medical doctor; however, 72 percent of the respondents who used unconventional therapy did not inform their medical doctor that they had done so. Extrapolation to the U.S. population suggests that in 1990 Americans made an estimated 425 million visits to providers of unconventional therapy. This number exceeds the number of visits to all U.S. primary care physicians (388 million). Expenditures associated with use of unconventional therapy in 1990 amounted to approximately $13.7 billion, three quarters of which ($10.3 billion) was paid out of pocket. This figure is comparable to the $12.8 billion spent out of pocket annually for all hospitalizations in the United States. Conclusions. The frequency of use of unconventional therapy in the United States is far higher than previously reported. Medical doctors should ask about their patients' use of unconventional therapy whenever they obtain a medical history.	HARVARD UNIV,SCH MED,BOSTON,MA 02115; UNIV MICHIGAN,INST SOCIAL RES,ANN ARBOR,MI 48109; NEW ENGLAND DEACONESS HOSP,DEPT MED,DIV GEN MED,BOSTON,MA 02215; CHICAGO COLL OSTEOPATH MED,CHICAGO,IL 60615	Harvard University; Harvard Medical School; University of Michigan System; University of Michigan; Midwestern University; Midwestern University - Chicago College of Osteopathic Medicine	EISENBERG, DM (corresponding author), BETH ISRAEL HOSP,DEPT MED,DIV GEN MED & PRIMARY CARE,330 BROOKLINE AVE,BOSTON,MA 02215, USA.		Fahimifar, Sepideh/M-5303-2019					BRIGDEN ML, 1987, POSTGRAD MED, V81, P271, DOI 10.1080/00325481.1987.11699682; CASSILETH BR, 1989, CANCER, V63, P1247, DOI 10.1002/1097-0142(19890401)63:7<1247::AID-CNCR2820630703>3.0.CO;2-3; CASSILETH BR, 1984, ANN INTERN MED, V101, P105, DOI 10.7326/0003-4819-101-1-105; CHERKIN DC, 1989, WESTERN J MED, V150, P351; CLEARY PD, 1982, AM J PUBLIC HEALTH, V72, P727, DOI 10.2105/AJPH.72.7.727; COHEN CJ, 1990, CLIN RES, V38, pA692; COOK C, 1986, SOUTH MED J, V79, P1098, DOI 10.1097/00007611-198609000-00014; CRONAN TA, 1989, ARTHRITIS RHEUM, V32, P1604, DOI 10.1002/anr.1780321217; Gevitz N, 1988, OTHER HEALERS UNORTH, P1; GILLICK MR, 1985, NEW ENGL J MED, V313, P700, DOI 10.1056/NEJM198509123131120; KLEINMAN A, 1978, ANN INTERN MED, V88, P251, DOI 10.7326/0003-4819-88-2-251; KRONENFELD JJ, 1982, SOC SCI MED, V16, P1119, DOI 10.1016/0277-9536(82)90114-9; LEPKOWSKI JM, 1988, TELEPHONE SURVEY MET, P73; Levit K R, 1991, Health Care Financ Rev, V13, P29; McGuire Meredith, 1988, RITUAL HEALING SUBUR; MURRAY RH, 1992, NEW ENGL J MED, V326, P61, DOI 10.1056/NEJM199201023260113; Schappert SM, 1992, ADV DATA VITAL HLTH, V213; SMART HL, 1986, GUT, V27, P826, DOI 10.1136/gut.27.7.826; SNYDER P, 1983, CULT MED PSYCHIAT, V7, P57, DOI 10.1007/BF00249999; VERHOEF MJ, 1990, CAN MED ASSOC J, V142, P121; YAGER J, 1989, J NERV MENT DIS, V177, P632, DOI 10.1097/00005053-198910000-00006; 1984, SUBCOMMITTEE HLTH LO; 1987, NZ MED J, V100, P110; 1989, SUDAAN PROFESSIONAL; 1987, HLTH INFORMATION USE; 1990, OTAH405 US C OFF TEC; 1984, HLTH NUTRITION EXAMI; 1980, PATIENTS HEALERS CON, P50; 1989, NATIONAL HLTH INTERV	29	2925	2975	6	201	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 28	1993	328	4					246	252		10.1056/NEJM199301283280406	http://dx.doi.org/10.1056/NEJM199301283280406			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ442	8418405	Bronze			2022-12-24	WOS:A1993KJ44200006
J	GOULD, MM; MOHAMEDALI, V; GOUBET, SA; YUDKIN, JS; HAINES, AP				GOULD, MM; MOHAMEDALI, V; GOUBET, SA; YUDKIN, JS; HAINES, AP			MICROALBUMINURIA - ASSOCIATIONS WITH HEIGHT AND SEX IN NONDIABETIC SUBJECTS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							NEPHROPATHY; PREDICTOR; DISEASE; ALBUMIN; HEART	Objectives-To study the association(s) between microalbuminuria and cardiovascular risk factors in non-diabetic subjects. Design-Patients aged 40-75 years were randomly selected from a general practice list and invited to participate. Setting-Health centre in inner city London. Subjects-Of those invited, 1046 out of 1671 (62.6%) attended. Subjects were excluded for the following reasons: not being white (44); urinary albumin excretion rate > 200 mug/min (3); having a urinary infection (5); taking penicillamine or angiotensin converting enzyme inhibitors (7); older than 75 (2); having diabetes (25); missing data on glucose concentration (1). Main outcome measures-Glucose tolerance test results, albumin excretion rate from overnight and timed morning collections of urine; blood pressure; height. Results-Mean albumin excretion rate was significantly lower in women than men (mean ratio 0.8, 95% confidence interval (0.69 to 0.91)). Mean albumin excretion rate was significantly associated with age, blood pressure, and blood glucose concentration (fasting, 1 hour, and 2 hour) in men and inversely with height. Men who had microalbuminuria in both samples were significantly shorter (by 5 cm (1.3 to 9.3 cm)) than those who had no microalbuminuria in either sample when age was taken into account. In the case of women only systolic pressure was significantly associated with albumin excretion rate. Conclusions-Microalbuminuria and short stature in men are associated. Cardiovascular risk has been associated with both of these factors and with lower birth weight. The inverse association of microalbuminuria with height is compatible with the suggestion that factors operating in utero or early childhood are implicated in cardiovascular disease. The higher prevalence of microalbuminuria in men compared with women may indicate that sex differences in cardiovascular risk are reflected in differences in albumin excretion rate.	UNIV COLL & MIDDLESEX SCH MED, WHITTINGTON HOSP, DEPT MED, LONDON N19 5NF, ENGLAND	University of London; University College London	GOULD, MM (corresponding author), UNIV COLL & MIDDLESEX SCH MED, WHITTINGTON HOSP, DEPT PRIMARY HLTH CARE, LONDON N19 5NF, ENGLAND.		Yudkin, John S/C-1988-2008	Haines, Andy/0000-0002-8053-4605				CHESHAM J, 1986, CLIN CHEM, V32, P669; Diabetes mellitus, 1985, WHO TECHNICAL REPORT, V727; HAFFNER SM, 1990, ARTERIOSCLEROSIS, V10, P727, DOI 10.1161/01.ATV.10.5.727; ISLES CG, 1992, LANCET, V339, P702, DOI 10.1016/0140-6736(92)90599-X; KUH D, 1989, INT J EPIDEMIOL, V18, P663, DOI 10.1093/ije/18.3.663; MARMOT MG, 1984, LANCET, V1, P1003; MATTOCK MB, 1988, DIABETOLOGIA, V31, P82, DOI 10.1007/BF00395552; MOGENSEN CE, 1984, NEW ENGL J MED, V311, P89, DOI 10.1056/NEJM198407123110204; MORRIS JN, 1977, BMJ-BRIT MED J, V2, P1307, DOI 10.1136/bmj.2.6098.1307; PARKER DJP, 1992, J EPIDEMIOL COMMUN H, V46, P8, DOI 10.1136/jech.46.1.8; THOMSON A M, 1968, Journal of Obstetrics and Gynaecology of the British Commonwealth, V75, P903; VIBERTI GC, 1982, LANCET, V1, P1430; WINOCOUR PH, 1992, ATHEROSCLEROSIS, V93, P71, DOI 10.1016/0021-9150(92)90201-Q; YUDKIN JS, 1988, LANCET, V2, P530	14	108	110	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 23	1993	306	6872					240	242		10.1136/bmj.306.6872.240	http://dx.doi.org/10.1136/bmj.306.6872.240			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ591	8443522	Green Published, Bronze			2022-12-24	WOS:A1993KJ59100018
J	RINCHIK, EM; BULTMAN, SJ; HORSTHEMKE, B; LEE, ST; STRUNK, KM; SPRITZ, RA; AVIDANO, KM; JONG, MTC; NICHOLLS, RD				RINCHIK, EM; BULTMAN, SJ; HORSTHEMKE, B; LEE, ST; STRUNK, KM; SPRITZ, RA; AVIDANO, KM; JONG, MTC; NICHOLLS, RD			A GENE FOR THE MOUSE PINK-EYED DILUTION LOCUS AND FOR HUMAN TYPE-II OCULOCUTANEOUS ALBINISM	NATURE			English	Article							PRADER-WILLI SYNDROME; RECEPTOR; PROTEINS	THE mouse pink-eyed dilution (p) locus on chromosome 7 is associated with defects of skin, eye and coat pigmentation1. Mutations at p cause a reduction of eumelanin (black-brown) pigment and altered morphology of black pigment granules (eumelanosomes), but have little effect on pheomelanin (yellow-red) pigment2. We show here that the human complementary DNA DN10, linked to the p locus in mice3-5, identifies the human homologue (P) of the mouse p gene, and appears to encode an integral membrane transporter protein. The expression pattern of this gene in various p mutant mice correlates with the pigmentation phenotype; moreover, an abnormally sized messenger RNA is detected in one mutant, p(un), which reverts to the normal size in p(un) revertants. The human P gene corresponds to the D15S12 locus within the chromosome segment 15q11-q13, which is typically deleted in patients with Prader-Willi and Angelman syndrome (see ref. 5 for review). These disorders are phenotypically distinct, depending on the parent of origin of the deleted chromosome5-7, but both syndromes are often associated with hypopigmentation of the skin, hair and eyes (see ref. 8 for review), and deletion of the P gene may be responsible for this hypopigmentation. In addition, we report a mutation in both copies of the human P gene in one case of tyrosinase-positive (type II) oculocutaneous albinism, recently linked to 15q11-q13 (ref. 9).	UNIV FLORIDA,COLL MED,DEPT NEUROSCI,BOX 100244 JHMHC,GAINESVILLE,FL 32610; OAK RIDGE NATL LAB,DIV BIOL,OAK RIDGE,TN 37831; UNIV TENNESSEE,OAK RIDGE NATL LAB,OAK RIDGE GRAD SCH BIOMED SCI,OAK RIDGE,TN 37831; UNIV ESSEN GESAMTHSCH KLINIKUM,INST HUMANGENET,W-4300 ESSEN 1,GERMANY; UNIV WISCONSIN,DEPT MED GENET,MADISON,WI 53706	State University System of Florida; University of Florida; United States Department of Energy (DOE); Oak Ridge National Laboratory; United States Department of Energy (DOE); Oak Ridge National Laboratory; University of Tennessee System; University of Tennessee Knoxville; University of Duisburg Essen; University of Wisconsin System; University of Wisconsin Madison				Lee, Seung-Taek/0000-0001-7300-9784				BRILLIANT MH, 1991, SCIENCE, V252, P566, DOI 10.1126/science.1673574; Cassidy S B, 1984, Curr Probl Pediatr, V14, P1; CLAYTONSMITH J, 1992, J MED GENET, V29, P412, DOI 10.1136/jmg.29.6.412; DAUMER C, 1991, MED GENETIK, V3, P27; DAYHOFF MO, 1983, METHOD ENZYMOL, V91, P524; FRYBURG JS, 1991, AM J MED GENET, V38, P58, DOI 10.1002/ajmg.1320380114; GARDNER JM, 1992, SCIENCE, V257, P1121, DOI 10.1126/science.257.5073.1121; HEARING VJ, 1991, FASEB J, V5, P2902, DOI 10.1096/fasebj.5.14.1752358; KLEIN P, 1985, BIOCHIM BIOPHYS ACTA, V815, P468, DOI 10.1016/0005-2736(85)90375-X; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LODISH HF, 1988, TRENDS BIOCHEM SCI, V13, P332, DOI 10.1016/0968-0004(88)90101-6; MELVOLD RW, 1971, MUTAT RES, V12, P171, DOI 10.1016/0027-5107(71)90138-2; NAKATSU Y, 1992, MAMM GENOME, V2, P69, DOI 10.1007/BF00570442; NICHOLLS RD, IN PRESS AM J MED GE; NICHOLLS RD, 1989, MOUSE NEWS LETT, V84, P87; NICHOLLS RD, 1992, GENOMIC IMPRINTING M, V3, P139; RAMSAY M, 1992, AM J HUM GENET, V51, P879; Rinchik E.M., 1990, GENOME ANAL, P121; RINCHIK EM, 1989, GENOMICS, V4, P251, DOI 10.1016/0888-7543(89)90328-5; RUSSELL ES, 1949, GENETICS, V34, P146; Russell L. B., 1983, Cytogenetics of the mammalian X chromosome. Part A. Basic mechanisms of X chromosome behavior., P205; Sambrook J., 1989, MOL CLONING LAB MANU; SCRABLE HJ, 1990, P NATL ACAD SCI USA, V87, P2182, DOI 10.1073/pnas.87.6.2182; SHIBAHARA S, 1991, J BIOL CHEM, V266, P15895; SIDMAN RL, 1965, DEV BIOL, V12, P93, DOI 10.1016/0012-1606(65)90023-0; Silvers WK., 1979, COAT COLORS MICE, DOI [10.1007/978-1-4612-6164-3, DOI 10.1007/978-1-4612-6164-3]; TANTRAVAHI U, 1989, AM J MED GENET, V33, P78, DOI 10.1002/ajmg.1320330110; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; WALLIS CE, 1989, J MED GENET, V26, P337, DOI 10.1136/jmg.26.5.337; WANG H, 1991, NATURE, V352, P729, DOI 10.1038/352729a0; WOOKEY PJ, 1988, J BACTERIOL, V170, P4946, DOI 10.1128/jb.170.10.4946-4949.1988; [No title captured]	32	316	327	0	24	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 7	1993	361	6407					72	76		10.1038/361072a0	http://dx.doi.org/10.1038/361072a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KF718	8421497				2022-12-24	WOS:A1993KF71800051
